0001193125-14-094593.txt : 20140312 0001193125-14-094593.hdr.sgml : 20140312 20140312061044 ACCESSION NUMBER: 0001193125-14-094593 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 25 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140312 DATE AS OF CHANGE: 20140312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPECTRUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000831547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930979187 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35006 FILM NUMBER: 14686104 BUSINESS ADDRESS: STREET 1: 11500 S. EASTERN AVE., SUITE 240 CITY: HENDERSON STATE: NV ZIP: 89052 BUSINESS PHONE: 702-835-6300 MAIL ADDRESS: STREET 1: 11500 S. EASTERN AVE., SUITE 240 CITY: HENDERSON STATE: NV ZIP: 89052 FORMER COMPANY: FORMER CONFORMED NAME: NEOTHERAPEUTICS INC DATE OF NAME CHANGE: 19960819 FORMER COMPANY: FORMER CONFORMED NAME: AMERICUS FUNDING CORP DATE OF NAME CHANGE: 19920703 10-K 1 d640093d10k.htm 10-K 10-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 10-K

 

 

 

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-35006

 

LOGO

 

 

SPECTRUM PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   93-0979187

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

11500 South Eastern Avenue, Suite 240

Henderson, Nevada 89052

(Address of principal executive offices)

(702) 835-6300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Name of Each Exchange on Which Registered

Common Stock, $0.001 par value

Rights to Purchase Series B Junior Participating Preferred Stock

  The NASDAQ Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act:

None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K  x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of June 30, 2013, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant was $449,722,900 (based upon the $7.46 closing sale price for shares of the Registrant’s Common Stock as reported by the NASDAQ Global Select Market on June 28, 2013, the last trading date of the Registrant’s most recently completed second fiscal quarter).

As of February 28, 2014, approximately 65,287,782 shares of the Registrant’s Common Stock, $0.001 par value, were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for the registrant’s 2014 Annual Meeting of Shareholders, to be filed on or before April 30, 2014, are incorporated by reference into Part III, Items 10-14 of this Annual Report on Form 10-K.

 

 

 


TABLE OF CONTENTS

 

          Page  
   PART I   
Item 1.    Business      3   
Item 1A.    Risk Factors      20   
Item 1B.    Unresolved Staff Comments      41   
Item 2.    Properties      41   
Item 3.    Legal Proceedings      41   
Item 4.    Mine Safety Disclosures      43   
   PART II   
Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities      43   
Item 6.    Selected Financial Data      45   
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations      47   
Item 7A.    Quantitative and Qualitative Disclosures About Market Risk      59   
Item 8.    Financial Statements and Supplementary Data      F-1   
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure      61   
Item 9A.    Controls and Procedures      61   
Item 9B.    Other Information      62   
   PART III   
Item 10.    Directors, Executive Officers and Corporate Governance      62   
Item 11.    Executive Compensation      62   
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters      62   
Item 13.    Certain Relationships and Related Transactions, and Director Independence      63   
Item 14.    Principal Accountant Fees and Services      63   
   PART IV   
Item 15.    Exhibits and Financial Statement Schedules      63   
Signatures      60   

 

1


Cautionary Note Concerning Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). These forward looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995 and speak only as of the time this Annual Report on Form 10-K was filed with the Securities and Exchange Commission, or SEC. You can identify forward-looking statements by the use of forward-looking terminology such as, “believes,” “expects,” “may,” “will,” “intends,” “plans,” “should,” “could,” “seeks,” “pro forma,” “anticipates,” “estimates,” “continues,” or other variations thereof, including their use in the negative, or by discussions of strategies, opportunities, plans or intentions. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. We have based these forward-looking statements largely on our current expectations based on information currently available to us and projections about future events and trends affecting the financial condition of our business. These Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.’s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to:

 

   

our ability to successfully develop, obtain regulatory approval for and market our products;

 

   

our ability to continue to grow sales revenue of our marketed products;

 

   

risks associated with doing business internationally;

 

   

our ability to generate and maintain sufficient cash resources to fund our business;

 

   

our ability to enter into strategic alliances with partners for manufacturing, development and commercialization;

 

   

efforts of our development partners;

 

   

the ability of our manufacturing partners to meet our timelines;

 

   

the ability to timely deliver product supplies to our customers;

 

   

our ability to identify new product candidates and to successfully integrate those product candidates into our operations;

 

   

the timing and/or results of pending or future clinical trials, and our reliance on contract research organizations;

 

   

our ability to protect our intellectual property rights;

 

   

competition in the marketplace for our drugs;

 

   

delay in approval of our products or new indications for our products by the U.S. Food and Drug Administration, or the FDA;

 

   

actions by the FDA and other regulatory agencies, including international agencies;

 

   

securing positive reimbursement for our products;

 

   

the impact of any product liability, or other litigation to which we are, or may become a party;

 

   

the impact of legislative or regulatory reform of the healthcare industry and the impact of recently enacted healthcare reform legislation;

 

   

the availability and price of acceptable raw materials and components from third-party suppliers, and their ability to meet our demands;

 

   

our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards, and the application and interpretation of those laws, regulations and standards, that govern or affect the pharmaceutical and biotechnology industries, the non-compliance with which may delay or prevent the development, manufacturing, regulatory approvals and sale of our products;

 

   

defending against claims relating to improper handling, storage or disposal of hazardous chemical, radioactive or biological materials which could be time consuming and expensive;

 

2


   

our ability to maintain the services of our key executives and technical and sales and marketing personnel;

 

   

the difficulty in predicting the timing or outcome of product development efforts and regulatory approvals; and

 

   

demand and market acceptance for our approved products.

In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate results or future period trends. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. Except as required by law, we do not undertake to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this Annual Report on Form 10-K.

Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the “Company”, “we,” “us,” “our,” “Spectrum” and “Spectrum Pharmaceuticals” refer to Spectrum Pharmaceuticals, Inc. and its subsidiaries and other consolidated entities, as a consolidated entity. We primarily conduct our business activities as Spectrum Pharmaceuticals.

***

Spectrum Pharmaceuticals, Inc.®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, EOquin®, and RenaZorb® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its subsidiaries. Redefining Cancer CareTM, Turning Insights Into HopeTM, RIT Oncology, LLCTM, RITTM, RRZTM, and our logos are trademarks owned by Spectrum Pharmaceuticals, Inc. and its subsidiaries. All other trademarks and trade names are the property of their respective owners.

PART I

 

ITEM 1. BUSINESS

Company Overview

Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. Our strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.

We currently market four oncology drugs:

 

   

FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain side effects of methotrexate therapy;

 

   

ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

 

   

FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

 

   

MARQIBO injection for patients in the U.S. with relapsed Philadelphia chromosome–negative acute lymphoblastic leukemia.

We also have ongoing indication expansion studies with several of our marketed products, and a diversified pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical affairs, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategy described in detail below.

Business Strategy

Our business strategy is comprised of the following three initiatives:

 

   

Maximizing the revenue potential of our four currently-marketed drugs for the treatment of cancer.

 

3


Our near-term outlook largely depends on sales and marketing successes for our four marketed drugs. It is this base business, along with potential additional indications for these drugs, that provides the working capital needed to operate our daily business and provides the necessary capital for opportunistic acquisitions.

 

   

Developing and commercializing the drugs for the treatment of cancer within our pipeline.

Our strategy for our development portfolio is to focus on late-stage development drugs. We strive to complete clinical studies to demonstrate the safety and efficacy of these drugs in order to obtain regulatory approval in a timely manner. Upon obtaining approval, our sales and marketing function educates physicians on the safety of the drug and its effectiveness in treating patients for the approved indication, with the goal of achieving maximum commercial success.

 

   

Expanding our pipeline of development-stage and commercial-stage drugs through business development activities.

It is our goal to identify new strategic opportunities that are synergistic with our currently-marketed drugs. We will continue to (i) explore strategic collaborations as they relate to drugs that are either in clinical trials or are currently on the market, and (ii) identify and secure drugs that have significant growth potential – through enhanced marketing and sales efforts and/or through pursuit of additional clinical development. We may also identify and pursue partnerships for out-licensing certain of our drugs in development.

Cancer Background and Market Size

Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can result in death. The development of cancer is multi-factorial and includes both external factors (tobacco, infectious organisms, chemicals, and radiation) and internal factors (inherited mutations, hormones, immune conditions, and mutations that occur from exposure to environmental factors or errors in making DNA (deoxyribonucleic acid) during normal cell division). These causal factors may act together or in sequence to initiate or promote the development of cancer. Ten or more years often pass between exposure to these factors and the development of detectable cancer. Cancer is treated through surgery, radiation, chemotherapy, hormone therapy, immune therapy, and/or targeted drug therapy.

According to the American Cancer Society’s publication Cancer Facts & Figures 2014, cancer is the second leading cause of death in the U.S. (only behind heart disease). In the U.S., approximately 1.7 million new cancer cases are expected to be diagnosed in 2014 and over 585,000 persons are expected to die from the disease in 2014. Anyone can develop cancer. Since the risk of being diagnosed with cancer increases with age, most cases occur in adults who are middle aged or older. About 77% of all cancers are diagnosed in people 55 years of age and older. In the U.S., men have slightly less than a 1 in 2 lifetime risk of developing cancer; for women, the risk is a little more than 1 in 3. These probabilities are estimated based on the overall experience of the general population. Individuals within the population may have higher or lower risk because of differences in exposures (e.g., smoking), and/or genetic susceptibility. In addition, currently available treatments are variably effective in the different cancers and individual patients. Together these patients’ risks and the treatment limitations suggest a significant current and long-term demand for improved and novel cancer treatments.

All cancers involve the malfunction of genes that control cell growth and division. Only a small proportion of cancers are strongly hereditary, in that an inherited genetic alteration confers a very high risk for developing cancer. Inherited factors play a larger role in determining risk for some cancers (e.g., colorectal, breast, and prostate) than for others. It is now thought that many familial cancers arise from the interplay between common gene variations and lifestyle/environmental risk factors. However, most cancers do not result from inherited genes but rather from damage to genes occurring during a person’s lifetime. Genetic damage may result from internal factors, such as hormones or the metabolism of nutrients within cells, or external factors, such as tobacco, or excessive exposure to chemicals, sunlight, or ionizing radiation.

Cancer cell growth is different from normal cell growth. Instead of being regulated and stopping to grow in a controlled manner, cancer cells continue to grow and form new, abnormal cells. Cancer cells can also invade (grow into) other tissues, something that normal cells do not do. Cells become cancer cells because of DNA damage. DNA is in every cell and it directs all of the cell’s actions. In a normal cell, when DNA is damaged, the cell either repairs the damage, or the cell dies. In cancer cells, the damaged DNA is not repaired, and the cell doesn’t die. Instead, it continues to make new cells in an uncontrolled manner that the body doesn’t require. People can inherit abnormal DNA, but most DNA damage is caused by abnormal cellular reproduction, usually triggered by environmental causes. In most cases, the cancer cells form a tumor, though some cancers, like leukemia, involve the blood and blood-forming organs and circulate through other tissues where they grow.

 

4


Cancer cells often travel to other parts of the body where they begin to grow and form new tumors. This happens when the cancer cells get into the body’s bloodstream or lymph vessels; this process of cancer spreading is called metastasis. No matter where a cancer may spread, it is always named for the place where it originated. For example, breast cancer that has spread to the liver is called metastatic breast cancer, not liver cancer. Likewise, prostate cancer that has spread to the bone is called metastatic prostate cancer, not bone cancer. Different types of cancer can behave very differently. For instance, lung cancer and skin cancer are very different diseases. They grow at different rates and respond to different treatments.

Product Portfolio

We have a product portfolio consisting of both commercial stage and development stage products that address various cancer types (see “Research & Development” section below for our pipeline of cancer therapeutics that are in various development stages). We remain committed to growing the sales of our currently marketed products, as we strive to maintain a robust development pipeline.

Commercialized Products

Our commercialized drug products, and their approved indications, are summarized in the following table:

 

LOGO

FUSILEV

FUSILEV (levoleucovorin), a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. Leucovorin is a mixture of equal part of both isomers: the pharmacologically active levo-isomer and the inactive dextro-isomer. Preclinical studies have demonstrated that the inactive dextro-isomer may compete with the active levo-isomer for uptake at the cellular level. By removing the inactive dextro form, the dosage of FUSILEV is one-half that of leucovorin and patients are spared the administration of an inactive substance. FUSILEV is approved as a ready-to-use solution, and as freeze-dried powder.

FUSILEV has the following indications for use:

 

   

in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

 

   

for rescue after high-dose methotrexate therapy in osteosarcoma.

 

   

to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.

The product similar to FUSILEV is marketed outside the U.S. by Pfizer, Sanofi-Aventis, and Takeda.

 

5


FOLOTYN

FOLOTYN, (pralatrexate injection), a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. (“Allos”). In September 2009, the FDA granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (“PTCL”). FOLOTYN was the first chemotherapy approved by the FDA for the treatment of relapsed or refractory PTCL and has been available to patients in the U.S. since October 2009.

According to the Lymphoma Research Foundation, lymphoma is the most common blood cancer. Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL) are the two main forms of lymphoma. Lymphoma occurs when lymphocytes, a type of white blood cell, grow abnormally and accumulate in one or more lymph nodes or lymphoid tissues. The body has two main types of lymphocytes that can develop into lymphomas: B-lymphocytes (B-cells) and T-lymphocytes (T-cells). PTCL comprises a group of rare and aggressive NHLs that develop from mature T-cells. PTCL accounts for approximately 10 to 15% of all NHL cases in the United States.

Based on preclinical studies, we believe that FOLOTYN selectively enters cells expressing RFC, a protein that is frequently over expressed on cancer cells compared to normal cells. Once inside cancer cells, FOLOTYN is efficiently polyglutamylated, which makes it less susceptible to efflux-based drug resistance and leads to high intracellular drug retention compared to other antifolates. Inside the cell, FOLOTYN targets the inhibition of DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death.

We are exploring additional settings for FOLOTYN where methotrexate (“MTX”), a drug in the same category as FOLOTYN, has been successfully used for decades in the treatment of breast cancer, bladder cancer, and lung cancer. We will be testing FOLOTYN’s benefits in these settings because FOLOTYN is designed to provide greater activity than MTX. In addition to its use alone as a single agent, we are evaluating FOLOTYN as part of different chemotherapy combinations.

ZEVALIN

ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. Rituximab is used to reduce the number of B-cells in the blood and Y-90 ZEVALIN is then given to treat non-Hodgkin’s lymphoma. It is currently approved in the U.S. and more than 40 countries outside the U.S. including countries in Europe, Latin America and Asia for the treatment of patients with:

 

   

Recurring, low-grade or follicular B-cell NHL, after other anticancer drugs are no longer working.

 

   

Newly diagnosed follicular NHL following a response to initial anticancer therapy.

We are currently working towards a new indication for ZEVALIN for diffuse large B-cell lymphoma (“DLBCL”). An estimated 40,000 new cases of DLBCL were diagnosed in major markets in 2010. The need for improved treatments for DLBCL is high because the two-year progression-free survival rate is only approximately 55% and the estimated two-year overall survival rate is 71%.

ZEVALIN would be used as an add-on to frontline therapy in which there is currently no competitor. A number of Phase 2 studies have been completed by investigators with high response rates in this indication. We plan to complete our Phase 3 study enrollment in early 2016 and file a supplemental Biologics License Application (“sBLA”) in 2018.

MARQIBO

MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. MARQIBO’s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (“ALL”) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. In the U.S., approximately 6,000 patients per year are diagnosed with ALL, of which approximately 1,600 can be categorized as ALL in second or greater relapse.

MARQIBO is also currently being explored for the treatment of the broader ALL indication as well as in NHL in addition to its approved treatment for Philadelphia chromosome-negative ALL. During 2014, we also intend to conduct an additional Phase 2 study for MARQIBO in patients with NHL.

 

6


Product Pipeline

BELEODAQ

BELEODAQ (belinostat) is a histone deacytelase, (“HDAC”) inhibitor that is being studied in multiple clinical trials, both as a single drug and in combination with chemotherapeutic drugs for the treatment of various hematological and solid tumors. Its anticancer effect is thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis (programmed cell death), inhibition of angiogenesis, induction of differentiation, and the activity in tumors that had become resistant to anticancer agents such as the platinums, taxanes and topoisomerase II inhibitors. We are currently seeking FDA approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

BELEODAQ is differentiated from other HDAC inhibitors that selectively inhibit a single class of HDAC enzymes because it inhibits all 3 classes of the zinc-dependent HDAC enzymes (Class I, Class II and Class IV); this leads to different alterations in histone and non-histone protein acetylation that, in turn, could importantly influence chromatin accessibility, gene transcription, and activity in different cancer patients, including those who develop drug resistant disease.

Based on the data from the clinical studies, we believe there are many potential attributes associated with BELEODAQ that separate it from other currently marketed HDACs, including efficacy when used alone and in combination, less toxicities (when compared to the reported rates of some adverse events with the other currently-marketed HDACs), including less bone marrow toxicity, and a lack of other severe side effects, such as mucositis, that may enable full dose combinations of this drug with several other cytotoxic agents. Hence, BELEODAQ is currently being investigated in multiple indications, both as monotherapy and in combination with other treatment regimens. Numerous studies have been conducted, or are ongoing, through the National Cancer Institute (the “NCI”) and other well-known oncologic academic institutions. Additionally, we have a comprehensive development plan for BELEODAQ, which includes both hematologic indications, such as PTCL, and solid tumor indications, such as ovarian cancer, colorectal cancer and non-small cell lung cancer. Based upon the foregoing, we believe BELEODAQ potentially has broad applicability and hence, commercial potential beyond that of its currently targeted indication.

BELEODAQ is currently the only HDAC inhibitor in clinical development with multiple potential routes of administration, including intravenous administration, continuous intravenous infusion and oral administration, which we believe may afford BELEODAQ a significant competitive advantage.

In December 2013, we filed our NDA with the FDA. Our application was subsequently accepted by the FDA with Priority Review in February 2014.

Captisol-Enabled® MELPHALAN

Captisol-enabled MELPHALAN (“C-E MELPHALAN”) is a novel intravenous formulation of MELPHALAN that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting. Multiple myeloma is a cancer of plasma cells, a type of white blood cell present mainly in the bone marrow that produces antibodies. In multiple myeloma, a group of plasma cells (myeloma cells) become cancerous and multiply, raising the number of plasma cells to a higher-than-normal level, which can crowd out normal blood cells and lead to abnormally high proteins in the blood or urine. Per NCI and the ACS, there were an estimated 22,000 new cases of multiple myeloma in the U.S. in 2013, with the incidence of new cases increasing by approximately 1.7% per year. The current intravenous MELPHALAN market is approximately $130 million annually, with predominant use in stem cell transplants. The rate of autologous stem cell transplantation for patients with multiple myeloma is growing by approximately 3.3% annually.

The C-E MELPHALAN formulation avoids the use of propylene glycol (“PG”), which is required as a co-solvent in the current MELPHALAN formulation; PG has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. The use of Captisol technology to reformulate MELPHALAN is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity for pre-transplant chemotherapy.

C-E MELPHALAN was granted Orphan Drug status by the FDA for use as a high-dose conditioning regimen prior to hematopoietic progenitor (stem) cell transplantation. If approved, the propylene glycol-free formulation of MELPHALAN will be the first product approved for this indication.

Currently, C-E MELPHALAN is a Phase 2B drug (Pivotal Trial) with an NDA filing anticipated in 2014.

 

7


APAZIQUONE

APAZIQUONE is an anti-cancer agent that becomes activated by certain enzymes often present in higher amounts in cancer cells than in normal cells. It is currently being investigated for the treatment of Non- muscle Invasive Bladder Cancer (“NMIBC”), which is a cancer that is only in the innermost layer of the bladder and has not spread to deeper layers of the bladder.

The ACS estimated that the 2013 incidence and prevalence of bladder cancer in the U.S. was approximately 74,690 and over 500,000 respectively. According to Botteman et al., (PharmacoEconomics 2003), bladder cancer is the most expensive cancer to treat on a lifetime basis.

The initial treatment of this cancer is to attempt a complete surgical removal of the tumor. However, bladder cancer is a highly recurrent disease with approximately 75% of patients recurring within 5 years, and a majority of patients recurring within 2 years. This high recurrence rate is attributed to:

 

  (1) the highly implantable nature of cancer cells that are dispersed during surgery,

 

  (2) incomplete tumor resection, and

 

  (3) tumors present in multiple locations in the bladder which may be missed or too small to visualize at the time of resection.

Despite evidence in the published literature and guidance from the American and European Urology Associations, instillation of a chemotherapeutic agent immediately following surgery is not a standard clinical practice. Currently, there are no FDA approved drugs for this indication which may, in part, explain the difference between the literature and urology guidelines and actual clinical management of this disease. For more than 30 years, no new drugs have been introduced in the market for treatment of NMIBC.

APAZIQUONE is a bio-reductive alkylating indoloquinone that is enzymatically activated by enzymes that are over expressed by bladder tumors that is being tested in NMIBC. Pharmacokinetic studies have verified that APAZIQUONE is rarely detectable in the bloodstream of patients when it is administered either after surgical resection or as a part of a delayed multi-instillation protocol. APAZIQUONE is inactivated in the systemic circulation by the red blood cell fraction. The proposed dose therefore carries a minimal risk of systemic toxicity that could arise from absorption of a drug through the bladder wall into the bloodstream. These features of APAZIQUONE are distinct from other intravesical agents currently in use for the treatment of recurrent bladder cancer. An immediate instillation of APAZIQUONE may help by:

 

  (1) reducing tumor recurrence by destroying dispersed cancer cells that would otherwise re-implant onto the inner lining of the bladder,

 

  (2) by destroying remaining cancer cells at the site of tumor resection (also known as chemo-resection), and

 

  (3) by destroying tumors not observed during resection (also known as chemo-ablation).

We expect to commence a confirmatory Phase 3 study for APAZIQUONE in 2014 and expect to prepare and submit a NDA at the end of 2014.

SPI-2012

SPI-2012, our third biologic drug, is used for the treatment of chemotherapy-induced neutropenia. In January 2012, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Company, for SPI-2012 based on Hanmi’s proprietary LAPSCOVERY™ Technology. Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections, hospitalizations, and interruption of additional chemotherapy treatments.

Granulocyte colony-stimulating factor, or GCSF, stimulates the production of white blood cells by the bone marrow. A recombinant form of GCSF is used in appropriate cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens to be given at full-dose and on schedule. We believe the worldwide market for GCSF-related drugs was over $5.0 billion in 2013.

We are currently enrolling a Phase 2 study with clinical trial results expected in the second half of 2014.

 

8


Manufacturing

We currently do not have internal manufacturing capabilities; therefore, all of our products are manufactured on a contract basis. We expect to continue to contract with third-party providers for manufacturing and packaging services, including active pharmaceutical ingredients (“API”) and finished-dosage products. We believe that our current agreements with third-party manufacturers provide for sufficient operating capacity to support the anticipated commercial demand for our products. However, we have only one approved contract manufacturer for each aspect of the manufacturing process for ZEVALIN and MARQIBO. We have multiple drug product contract manufacturers for FUSILEV and FOLOTYN.

We believe these third-party manufacturers have the capability to meet our projected worldwide clinical trial and commercial requirements for our products. We attempt to prevent disruption of supplies through supply agreements, appropriate forecasting, maintaining stock levels and other strategies. We believe that the market for such manufacturers and suppliers is such that we could quickly enter into another supply or manufacturing agreement on substantially similar terms if we were required to do so.

Sales and Marketing

We market and sell our drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. We divide the U.S. market between “corporate accounts” and “oncology accounts.” The primary decision makers for our products are oncologists and hematologists. As of December 31, 2013, our U.S. sales force (management, representatives, and direct support) numbered 81 employees.

Our corporate accounts are divided among four regions and 20 territories, led by our Vice President of Corporate Accounts and Executive Director of Corporate Accounts Sales. Each region is managed by an Associate Director of Corporate Accounts who oversees four Regional Business Managers.

Our oncology accounts are divided among six regions and 40 territories, led by our Vice President of Sales. Each region is managed by a Regional Sales Director who oversees six or seven Oncology Account Managers (sales representatives), an Oncology Nurse Specialist (sales support), and a Clinical Logistical Specialist (sales support).

Customers

Our product sales are concentrated to large pharmaceutical distributors (that ship and bill to hospitals and clinics). The customers that represent 10% or more of our total product sales in 2013, 2012, and 2011 are as follows:

 

     2013     2012     2011  

Oncology Supply

     35.4     26.5     57.0

McKesson Specialty

     19.8     23.2     19.1

ICS

     15.8     19.4     *   

Cardinal Health

     *        15.7     *   

 

* Less than 10%

We are exposed to credit risk associated with trade receivables that result from these product sales. We do not require collateral or deposits from our customers due to our assessment of their creditworthiness and our long-standing relationship with them. We maintain reserves for potential bad debt, though credit losses have historically been nominal and within management’s expectations. A summary of our customers that represent 10% or more of our accounts receivables, net, as of December 31, 2013 and 2012 are as follows:

 

     December 31,
2013
    December 31,
2012
 

Oncology Supply

     37.7     37.7

McKesson Specialty

     30.7     26.0

ICS

     10.3     19.1

Competition

The pharmaceutical industry is characterized by rapidly-evolving biotechnology and intense competition, which we expect will continue. Many companies are engaged in research and development of compounds that are similar to ours – both commercialized and in development. In the event that one or more of our competitor’s programs are successful, the market for some of our drug products could be reduced or eliminated. Any product for which we obtain FDA approval must also compete for market acceptance and market share.

 

9


Successful marketing of branded products depends primarily on the ability to communicate the effectiveness, safety, and value of the products to healthcare professionals in private practice, group practices, hospitals, academic institutions, and managed care organizations. Competition for branded drugs is less driven by price and is more focused on innovation in treatment of disease, advanced drug delivery, and specific clinical benefits over competitive drug therapies. Unless our products are shown to be differentiated, i.e., have a better safety profile, efficacy, and cost-effectiveness, as compared to other alternatives, they may not gain acceptance by medical professionals and may therefore never be commercially successful.

Companies that have products on the market or in research and development that target the same indications as our product targets include, among others, Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson.

Each of the aforementioned companies may be more advanced in development of competing drug products. Many of these competitors are large and well-capitalized companies focusing on a wide range of cancers and drug indications, and have substantially greater resources and expertise than we do.

The general competitive landscape for each of our commercialized products is summarized below:

 

  (a) FUSILEV is the levo-isomeric form of the racemic compound calcium, leucovorin, a product already approved for the same indication as FUSILEV. As there are currently three generic companies approved by the FDA to sell the leucovorin product, we are competing with a low-cost alternative.

 

  (b) ZEVALIN has three competitive products for its currently approved indications:

 

   

Rituxan® (rituximab), marketed by Genentech and Biogen, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP (cyclophosphamide, vincristine and prednisone combination) chemotherapy; and non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy. Rituxan is administered as a part of various chemotherapy regimens and schedules, the vast majority of which, could be used in concert with other therapeutic agents, such as ZEVALIN, as part of a treatment plan.

 

   

Treanda® (bendamustine hydrochloride) for Injection, for Intravenous Infusion, marketed by Cephalon, is indicated for the treatment of patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

 

   

Bexxar® therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab), a radiopharmaceutical marketed by GlaxoSmithKline, is indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade, follicular, or transformed NHL, including patients with Rituximab-refractory NHL. In August 2013, the manufacturer of this product announced the discontinuation of both the manufacture and sale of Bexxar as of February 20, 2014.

 

  (c) FOLOTYN, the first agent approved by the FDA for treatment of patients with relapsed or refractory PTCL, has two competitive products for its currently approved indications:

 

   

Romidepsin, marketed by Celgene, Inc., was granted accelerated approval by the FDA in June 2011 for the treatment of patients with PTCL who have received at least one prior therapy. This was the second indication approved for romidepsin, which was initially approved by the FDA in November 2009 for the treatment of patients with CTCL who have received at least one prior systemic therapy.

 

   

Brentuximab vedotin, marketed by Seattle Genetics, Inc., was also granted accelerated approval by the FDA in August 2011 for two indications, one of which was for the treatment of patients with systemic anaplastic large cell lymphoma (“ALCL”) after failure of at least one prior multi-agent chemotherapy regimen. ALCL is one of the subtypes of PTCL included in the labels of both FOLOTYN and romidepsin.

We are aware of multiple investigational agents that are currently being studied in clinical trials for PTCL, including BELEODAQ and alisertib, which, if approved, may compete with FOLOTYN in the United States. Because of the natural history of PTCL with repeated treatment failures, it is likely that many patients would receive treatment with more than one agent, e.g., BELEODAQ and FOLOTYN. In addition, there are many existing approaches used in the treatment of relapsed or refractory PTCL, including combination chemotherapy and single agent regimens, which represent competition for FOLOTYN.

 

10


  (d) MARQIBO is a next generation liposomal form of standard vincristine. In its current indication, MARQIBO is approved for adult patients with relapsed or refractory Ph-ALL who have not responded or relapsed after two prior treatments. Currently, standard vincristine is not approved for the same indication as MARQIBO.

Research and Development

New drug development is the process whereby drug product candidates are tested for the purpose of filing a new drug application (“NDA”) or a Biologistics License Application (“BLA”) in the U.S. (or similar filing in other countries). Obtaining marketing approval from the FDA or similar regulatory authorities outside of the U.S., is an inherently uncertain, lengthy and expensive process that requires several phases of clinical trials to demonstrate to the satisfaction of the appropriate regulatory authorities that the products are both safe and effective for their respective indications. Our development focus is primarily based on acquiring and developing late-stage development drugs as compared to new drug discovery, which is particularly uncertain and lengthy.

Our in-development products are summarized below:

 

LOGO

 

LOGO

 

11


Our research and development expenses for drug development are comprised of personnel expenses, contract services, license fees and milestone payments, clinical trials, laboratory supplies and drug products, and certain allocations of corporate costs. The below table summarizes our research and development expenses by project in 2013, 2012, and 2011:

 

     Research and Development Expenses for the Year Ended
December  31,

(in thousands)
 
     2013     2012     2011  

APAZIQUONE

   $ 1,078      $ 6,642      $ 7,695   

BELEODAQ

     6,733        3,742        7,207   

FUSILEV

     4,517        1,416        1,239   

FOLOTYN

     2,992        1,586        —    

ZEVALIN

     8,572        5,040        167   

SPI-2012

     1,403        1,049        —    

LUCANTHONE

     795        792        —    

MARQIBO

     4,099        —         —    

MELPHALAN

     3,400        —          —     

OZARELIX

     247        724        740   

ORTATAXEL

     421        554        107   

RenaZorb

     346        1,299        476   

Other development drugs

     1,823        4,695        1,417   
  

 

 

   

 

 

   

 

 

 

Total — Direct costs

     36,426        27,539        19,048   

Add: Indirect costs (including stock-based compensation of $2,000, $1,800, and $1,600, respectively)

     13,335        21,404        16,502   

(Less): Reimbursements from development partners

     (804     (7,383     (8,888

(Less): Mundipharma deferred payment contingency

     (2,287     —          —     
  

 

 

   

 

 

   

 

 

 

Total – Research and development expenses

   $ 46,670      $ 41,560      $ 26,662   
  

 

 

   

 

 

   

 

 

 

Patents and Proprietary Rights

Our Patents and Proprietary Rights

We in-license from third parties certain patent and related intellectual property rights related to our proprietary drug products. Under most of these license arrangements, we are generally responsible for all development, patent filing and maintenance costs, sales, marketing and liability insurance costs related to the drug products.

In addition, these licenses and agreements may require us to make royalty and other payments and to reasonably exploit the underlying technology of applicable patents. If we fail to comply with these and other terms in these licenses and agreements, we could lose the underlying rights to one or more of our potential products, which would adversely affect our product development and harm our business.

The protection, preservation and infringement-free commercial exploitation of these patents and related intellectual property rights are very important to the successful execution of our strategy. However, the issuance of a patent is neither conclusive as to its validity nor as to the enforceable scope of the claims of the patent. Accordingly, our patents and the patents we have licensed may not prevent other companies from developing similar or functionally equivalent products or from successfully challenging the validity of our patents. If our patent applications are not allowed or, even if allowed and issued as patents, if such patents or the patents we have in-licensed are circumvented or not upheld by the courts, our ability to competitively exploit our patented products and technologies may be significantly reduced. Also, such patents may or may not provide competitive advantages for their respective products or they may be challenged or circumvented by competitors, in which case our ability to commercially exploit these products may be diminished.

 

12


From time-to-time, we may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market our products. If we are unable to timely obtain these licenses on commercially reasonable terms, our ability to commercially exploit such products may be inhibited or prevented.

We believe that our patents and licenses are critical to operating our business, as summarized below by commercialized and in-development drugs products.

FUSILEV: We have one U.S. composition of matter patent that expires in March 2022.

ZEVALIN: We have sublicensed U.S. patents that cover the processes and tools for making monoclonal anti-bodies or MABs, in general, licensed U.S. patents that cover the CD-20 MAB in ZEVALIN as well as the use of ZEVALIN to treat NHL, and acquired patents covering the ZEVALIN compounding process (i.e., process of linking the CD-20 MAB to a radioactive isotope to make the patient-ready dosage form of ZEVALIN). These patents expire over a wide range of dates, but the licensed patents covering the CD-20 MAB itself do not begin to expire until 2015. Additionally, we have U.S. patents covering the compounding process expiring in 2019, and will consider filing more patent applications, if the opportunity arises.

FOLOTYN: We have a composition of matter patent due to expire in 2022 following a five-year patent term extension in U.S. The composition of matter patent is due to expire in Europe in 2017 but is eligible for a similar patent term extension following regulatory approval in Europe. We also have patents covering the use of FOLOTYN for PTCL that will not expire until 2025. Additionally, we have issued patents and pending patent applications in U.S. and many other countries claiming different uses of FOLOTYN, and we may consider filing new patent applications if the opportunity arises.

MARQIBO: We have patents covering the use of MARQIBO for leukemia, lymphoma and melanoma and a patent claiming Marqibo kit in US that expire in 2020. We have filed an application for patent term extension through December 2024 for one of the patents covering the use of MARQIBO for relapsed leukemia and lymphoma in the U.S. However, it is not certain if the patent term extension will be granted by the USPTO. We also have issued patents covering the use of MARQIBO in Europe and other countries that expire in 2020. We have recently filed a PCT application claiming a method of encapsulating vincristine sulphate into liposomes

BELEODAQ: The composition of matter patents that cover BELEODAQ and related compounds do not begin to expire until 2021. Currently, there are multiple U.S. and foreign patent applications pending that cover BELEODAQ formulations, uses and manufacturing and synthesis processes. We plan to file additional U.S. and foreign patent applications covering new formulations, uses and manufacturing and synthesis processes, where appropriate.

APAZIQUONE: The U.S. formulation patent does not expire until 2022, and method of treatment of bladder cancer using a stabilized formulation that does not expire until 2024. Formulation patents outside U.S. are due to expire in 2022. We have filed and plan to file additional U.S. and foreign patent applications covering new formulations and/or uses for this product.

OZARELIX: In the U.S. as well as outside the U.S., a composition of matter patent expires in 2020, and a formulation patent expires in 2023. We also have method of use patent applications on file.

ORTAXTEL: Two U.S. composition patents expired in 2013. Corresponding European patents expire in 2014, while multiple manufacturing and synthesis patents in U.S. and Europe do not begin to expire until 2021. We anticipate filing new method of use and formulation patent applications in the future.

LUCANTHONE: Our U.S. method of use patent expires in 2019.

RENAZORB: We have one method of use patent that is expiring in 2024, and pending U.S. and foreign patent applications covering compositions of matter, manufacturing process, and methods directed to treating hyperphosphatemia.

SPI-1620: We have filed method of use patent applications in the U.S. and Europe. We also have multiple U.S. method of use patents that expire in 2024, and there is ongoing prosecution for their European counterparts. We have also filed another method of use patent applications in the U.S. and Europe, and anticipate filing future patent applications pending the continued development of new methods of use and new formulations.

SPI-2012: Composition of matter patents covering SPI-2012 are due to expire in 2025 in the U.S. and in 2024 outside the U.S. SPI-2012 is also covered by additional patents claiming various aspects of the technology that are due to expire between 2024 and 2030 and recently-filed patent applications for its formulation.

 

13


C-E MELPHALAN: Melphalan is covered by issued patents claiming improved Captisol ® technology that are due to expire between 2025 and 2029 in the U.S. Outside the U.S., we have issued patents that cover improved Captisol technology that are due to expire in 2025 and pending applications with anticipated expiry in 2029, if issued. We also have a recently filed patent application covering Captisol-based formulation of melphalan in the U.S. and a number of other countries.

***

We are constantly evaluating our patent portfolio and are currently prosecuting patent applications for our drug products and are considering new patent applications in order to maximize the life cycle of each of our products.

While the U.S. and the European Union are currently the largest potential markets for most of our products, we also have patents issued and patent applications pending outside of the U.S. and Europe. Limitations on patent protection in these countries, and the differences in what constitutes patentable subject matter in countries outside the U.S., may limit the protection we have on patents issued or licensed to us outside of the U.S. In addition, laws of foreign countries may not protect our intellectual property to the same extent as would laws in the U.S.

To minimize our costs and expenses and to maintain effective protection, we usually focus our patent and licensing activities within the U.S., the European Union, Canada and Japan. In determining whether or not to seek a patent or to license any patent in a certain foreign country, we weigh the relevant costs and benefits, and consider, among other things, the market potential and profitability, the scope of patent protection afforded by the law of the jurisdiction and its enforceability, and the nature of terms with any potential licensees. Failure to obtain adequate patent protection for our proprietary drugs and technology would impair our ability to be commercially competitive in these markets.

In conducting our business generally, we rely upon trade secrets, know-how, and licensing arrangements and use customary practices for the protection of our confidential and proprietary information such as confidentiality agreements and trade secret protection measures. It is possible that these agreements will be breached or will not be enforceable in every instance, and that we will not have adequate remedies for any such breach. It is also possible that our trade secrets or know-how will otherwise become known or independently developed by competitors. The protection of know-how is particularly important because the know-how is often the necessary or useful information that allows us to practice the claims in the patents related to our proprietary drug products.

In addition to the specific intellectual property subjects discussed above, we have trademark protection in the U.S. for Spectrum Pharmaceuticals, Inc.®, FUSILEV®, MARQIBO®, EOquin®, Spectrum Therapy Access Resources, STAR, ZEVALIN®, FOLOTYN flower design associated with FOLOTYN and RenaZorb®. We also have the FOLOTYN trademark and the associated flower design registered in Europe and other countries. Additionally, for some other of these and other works related to our business, we have pending U.S. and ex-U.S. trademark applications.

The Patent Process

The U.S. Constitution provides Congress with the authority to provide inventors the exclusive right to their discoveries. Congress codified this right in U.S. Code Title 35, which gave the U.S. Patent and Trademark Office, or USPTO, the right to grant patents to inventors and defined the process for securing a U.S. patent. This process involves the filing of a patent application that instructs a person having ordinary skill in the respective art how to make and use the invention in clear and concise terms. The invention must be novel (not previously known) and non-obvious (not an obvious extension of what is already known). The patent application concludes with a series of claims that specifically describe the subject matter that the patent applicant considers his invention.

The USPTO undertakes an examination process that can take from one to seven years, or more, depending on the complexity of the patent and the problems encountered during examination.

In exchange for disclosing the invention to the public, for all U.S. patent applications filed after 1995, the successful patent applicant is currently provided a right to exclude others from making, using or selling the claimed invention for a period of 20 years from the effective filing date of the patent application.

Under certain circumstances, a patent term may be extended. Patent extensions are most frequently granted in the pharmaceutical and medical device industries under the Drug Price Competition and Pricing Term Restoration Act of 1984, or Hatch 1984, or Hatch-Waxman Act, to recover some of the time lost during the FDA regulatory process, subject to a number of limitations and exceptions. The patent term may be extended up to a maximum of five years; however, as a general rule, the average extension period granted for a new drug is approximately three years. Only one patent can be extended per FDA approved product, and a patent can only be extended once.

 

14


Product Exclusivity

Under the Hatch-Waxman Act, drug products are provided exclusivity whereby the FDA will not accept applications to market a generic form of an innovator reference listed drug product until the end of the prescribed period. A product is granted a five-year period of exclusivity if it contains a chemical entity never previously approved by the FDA either alone or in combination, although generic applications may be submitted after four years if they contain a certification of patent invalidity or non-infringement as further discussed below. A three-year period of exclusivity is granted to a previously approved product based on certain changes, e.g., in strength, dosage form, route of administration or conditions of use, where the application is supported by new clinical investigations that are essential to approval. In addition, in 1997 Congress amended the law to provide an additional six months of exclusivity as a reward for studying drugs in children. This pediatric exclusivity, which can be obtained during the approval process or after approval, effectively delays the approval of a generic application until six months after the expiration of any patent or other exclusivity that would otherwise delay approval, thus providing an additional six months free of generic competition. In order to qualify for pediatric exclusivity, the FDA must make a written request for pediatric studies, the application holder must agree to the request and complete the studies with required timeframe, and the studies must be accepted by the FDA based on a determination that the studies fairly respond to the request. The provisions were enacted with a five-year sunset date, and have been reauthorized in 2002, 2007 and 2012.

Generic Approval and Patent Certification

The Hatch-Waxman Act also created the abbreviated new drug application, or ANDA, approval process, which permits the approval of a generic version of a previously approved branded drug without the submission of a full new drug application, or NDA, and based in part on the FDA’s finding of safety and effectiveness for the reference listed drug. Applicants submitting an NDA are required to list patents associated with the drug product, which are published in the FDA Orange Book, and the timing of an ANDA approval depends in part on patent protection for the branded drug. When an ANDA is filed, the applicant must file a certification for each of the listed patents for the branded drug, stating one of the following: (1) that there is no patent information listed; (2) that such patent has expired; (3) that the patent will expire on a particular date (indicating that the ANDA may be approved on that date); or (4) that the drug for which approval is sought either does not infringe the patent or the patent is invalid, otherwise known as paragraph IV certification. If an ANDA applicant files a paragraph 4 certification, it is required to provide the patent holder with notice of that certification. If the patent holder brings suit against the ANDA applicant for patent infringement within 45 days of receiving notice, the FDA may not approve the ANDA until the earlier of (i) 30 months from the patent holder’s receipt of the notice (the 30-month stay) or (ii) the issuance of a final, non-appealed, or non-appealable court decision finding the patent invalid, unenforceable or not infringed.

The Hatch-Waxman Act also provided an incentive for generic manufacturers to file paragraph 4 certifications challenging patents that may be invalid unenforceable, or not infringed, whereby the first company to successfully challenge a listed patent and receive ANDA approval is protected from competition from subsequent generic versions of the same drug product for 180 days after the earlier of (1) the date of the first commercial marketing of the first-filed ANDA applicant’s generic drug or (2) the date of a decision of a court in an action holding the relevant patent invalid, unenforceable, or not infringed. These 180-day exclusivity provisions have been the subject of litigation and administrative review, and the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, amended the provisions in several ways, including by providing that an ANDA applicant entitled to 180-day exclusivity may lose such exclusivity if any of the following events occur: (1) failure to market; (2) withdrawal of the ANDA; (3) change in patent certification; (4) failure to obtain tentative approval; (5) illegal settlement agreement; and (6) patent expiration.

With respect to the illegal settlement prong, the MMA amendments require that certain types of settlement agreements entered into between branded and generic pharmaceutical companies related to the manufacture, marketing and sale of generic versions of branded drugs are required to be filed with the Federal Trade Commission and the Department of Justice for review of potential anti-competitive practices. This requirement could affect the manner in which generic drug manufacturers resolve intellectual property litigation and other disputes with branded pharmaceutical companies, and could result generally in an increase in private-party litigation against pharmaceutical companies. The impact of this requirement, and the potential governmental investigations and private-party lawsuits associated with arrangements between brand name and generic drug manufacturers, remains uncertain and could adversely affect our business. In addition, Congress has considered enacting legislation that would prohibit such settlements between brand name and generic drug manufacturers. Such a provision was considered as part of the Patient Protection and Affordable Care Act, or PPACA, signed into law on March 23, 2010. However, Congress removed the provision prior to passage. It is possible that Congress will again consider a ban on such settlements between brand name and generic drug manufacturers in the future.

 

15


The PPACA provides exclusivity protections for certain innovator biological products and a framework for FDA review and approval of biosimilar and interchangeable versions of innovator biologic products. The PPACA provides that no application for a biosimilar product may be approved until 12 years after the date on which the innovator product was first licensed, and no application may be submitted until four years after the date of first licensure. Products deemed interchangeable (as opposed to biosimilar) are also eligible for certain exclusivity.

Orphan Drug Designation

Some jurisdictions, including Europe and the U.S., may designate drugs for relatively small patient populations as “orphan” drugs. The FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the U.S., and a drug may also be considered an orphan even if the drug treats a disease or condition affecting more than 200,000 individuals in the U.S. where the drug has no expected profitability. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and process for marketing approval. If a product with an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to seven years of orphan drug exclusivity, during which time FDA will not approve any other application to market the same drug for the same indication except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Also, competitors are not prohibited from receiving approval to market the same drug or biologic for a different indication than that which received orphan approval.

Under European Union medicines laws, the criteria for designating an “orphan medicinal product” are similar in principle to those in the U.S. Criteria for orphan designation are set out in Article 3 of Regulation (EC) 141/2000 on the basis of two alternative conditions. A medicinal product may be designated as orphan if it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand persons in the European Union, or EU, when the application is made. This is commonly known as the “disease prevalence criterion” Alternatively, a product may be so designated if it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and if without incentives it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment. This is commonly known as the “insufficient return criterion.”

These two alternative criteria must cumulatively meet the second condition that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. “Significant benefit” is defined in Regulation (EC) 847/2000 as a clinically relevant advantage or a major contribution to patient care.

Upon grant of a marketing authorization, orphan medicinal products are entitled to ten years of market exclusivity in respect of the approved therapeutic indication. Within the period of market exclusivity, no competent authority in the EU is permitted to accept an application for marketing authorization, a variation or a line-extension for the same approved therapeutic indication in respect of a similar medicinal product pursuant to Article 8.1 of Regulation 141/2000 unless one of derogations set out in Article 8.3 of the same Regulation applies. In order to determine whether two products are considered similar, Regulation 847/2000 requires an assessment of the principal molecular structure and the underlying mode of action. Any minor variation or modification of the principal molecular structure would not ordinarily render the second product dissimilar to the first authorized product.

In order for the second applicant to break the market exclusivity granted to the first authorized similar medicinal product in respect of the same therapeutic indication, the second applicant would principally rely upon data to demonstrate that his product is safer, more efficacious or clinically superior to the first product pursuant to Article 8.3I of Regulation 141/2000. Ordinarily, such an assessment will require a head-to-head comparative clinical trial for the purpose of demonstrating clinical superiority.

The 10-year market exclusivity may be reduced to 6 years if at the end of the fifth year it is established that the product no longer meets the criteria for orphan designation on the basis of available evidence.

FUSILEV has been granted orphan drug designations for its use in conjunction with high dose methotrexate in the treatment of osteosarcoma and for its use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum (colorectal cancer). In addition, FOLOTYN has been granted an orphan drug designation for PTCL and CTCL and BELEODAQ has been granted an orphan drug designation for PTCL. As discussed above, a drug with orphan designation status may obtain orphan exclusivity upon marketing approval under specified conditions set out in the applicable laws and regulations.

 

16


Governmental Regulation

The development, production and marketing of our proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries. In the U.S., drugs and biologics are subject to rigorous regulation. The Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated there under, as well as other federal and state statutes and regulations, govern, among other things, the development, approval, manufacture, safety, labeling, storage, record keeping, distribution, promotion, and advertising of our products. Product development and approval within this regulatory framework, including for drugs already at a clinical stage of development, can take many years and require the expenditure of substantial resources, and to obtain FDA approval, a product must satisfy mandatory quality, safety and efficacy requirements. In addition, each drug-manufacturing establishment must be registered with the FDA. Domestic manufacturing establishments must comply with the FDA’s current good manufacturing practice (“GMP”), regulations and are subject to inspections by the FDA. To supply drug ingredients or products for use in the U.S., foreign manufacturing establishments must also comply with GMP and are subject to inspections by the FDA or by other regulatory authorities in certain countries under reciprocal agreements with the FDA.

General Information about the Drug Approval Process and Post-Marketing Requirements

The U.S. system of new drug and biologics approval is a rigorous process. Only a small percentage of compounds that enter the pre-clinical testing stage are ever approved for commercialization. Our strategy focuses on in-licensing clinical stage drug products that are already in or about to enter human clinical trials. A late-stage focus helps us to effectively manage the high cost of drug development by focusing on compounds that have already passed the many hurdles in the pre-clinical and early clinical process.

The following general comments about the drug approval process are relevant to the development activities we are undertaking with our proprietary products.

Pre-clinical Testing: During the pre-clinical testing stage, laboratory and animal studies are conducted to show biological activity of a drug or biologic compound against the targeted disease. The compound is evaluated for safety. While all of our compounds are currently in clinical trials, it is possible that additional pre-clinical testing could be requested by a regulatory authority for any of our compounds.

Investigational New Drug Application: After certain pre-clinical studies are completed, an Investigational New Drug (“IND”) application is submitted to the FDA to request the ability to begin human testing of the drug or biologic. An IND becomes effective thirty days after the FDA receives the application (unless the FDA notifies the sponsor of a clinical hold), or upon prior notification by the FDA.

Phase 1 Clinical Trials: These trials, typically involving small numbers of healthy volunteers or patients and usually define a drug candidate’s safety profile, including the safe dosage range.

Phase 2 Clinical Trials: In Phase 2 clinical trials, controlled studies of human patients with the targeted disease are conducted to assess the drug’s effectiveness. These studies are designed primarily to determine the appropriate dose levels, dose schedules and route(s) of administration, and to evaluate the effectiveness of the drug or biologic on humans, as well as to determine if there are any side effects on humans to expand the safety profile following Phase 1. These clinical trials, and Phase 3 trials discussed below, are designed to evaluate the product’s overall benefit-risk profile, and to provide information for physician labeling.

Phase 3 Clinical Trials: This phase usually involves larger number of patients with the targeted disease. Investigators (typically physicians) monitor the patients to determine the drug candidate’s efficacy and to observe and report any adverse reactions that may result from long-term use of the drug on a large, more widespread, patient population. During the Phase 3 clinical trials, typically the drug candidate is compared to either a placebo or a standard treatment for the target disease.

New Drug Application or Biologic License Application: After completion of all three clinical trial Phases, if the data indicates that the drug is safe and effective, a NDA or BLA is filed with the FDA requesting FDA approval to market the new drug as a treatment for the target disease.

 

17


Fast Track and Priority Review: The FDA has established procedures for accelerating the approval of drugs to be marketed for serious or life threatening diseases for which the manufacturer can demonstrate the potential to address unmet medical needs. BELEODAQ has received both Fast Track status and its NDA as a Priority Review.

Abbreviated New Drug Application: An ANDA is an abbreviated new drug application for generic drugs created by the Hatch-Waxman Act. When a company files an ANDA, it must make a patent certification regarding the patents covering the branded product listed in the FDA’s Orange Book. The ANDA drug development process generally takes less time than the NDA drug development process since the ANDA process usually does not require new clinical trials establishing the safety and efficacy of the drug product.

NDA/BLA and ANDA Approval: The FDA approves drugs and biologics that are subject to NDA and BLA review based on data in the application demonstrating the product is safe and effective in its proposed use(s) and that the product’s benefits outweigh its risks. The FDA will also review the NDA or BLA applicant’s manufacturing process and controls to ensure they are adequate to preserve the drug’s identity, strength, quality, and purity. Finally, the FDA will review and approve the product’s proposed labeling. As for the ANDA approval process, these “abbreviated” applications are generally not required to include preclinical or clinical data to establish safety and effectiveness. Rather, an ANDA must demonstrate both chemical equivalence and bio-equivalence (the rate and extent of absorption in the body) to the innovator drug — unless a bio-equivalence waiver is granted by the FDA.

Phase 4 Clinical Trials: After a drug has been approved by the FDA, Phase 4 studies may be conducted to explore additional patient populations, compare the drug to a competitor, or to further study the risks, benefits and optimal use of a drug. These studies may be a requirement as a condition of the initial approval of the NDA or BLA.

Post-Approval Studies Requirements under FDAAA: The Food and Drug Administration Amendments Act of 2007, or FDAAA significantly added to the FDA’s authority to require post-approval studies. Under the FDAAA, if the FDA becomes aware of new safety information after approval of a product, they may require us to conduct further clinical trials to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. If required to conduct a post-approval study, periodic status reports must be submitted to the FDA. Failure to conduct such post-approval studies in a timely manner may result in administrative action being taken by FDA, including substantial civil fines.

Risk Evaluation and Mitigation Strategy Authority under FDAAA: The FDAAA also gave the FDA new authority to require the implementation of a Risk Evaluation and Mitigation Strategy, or REMS, for a product when necessary to minimize known and preventable safety risks associated with the product. The FDA may require the submission of a REMS before a product is approved, or after approval based on “new safety information,” including new analyses of existing safety information. A REMS may include a medication guide, patient package insert, a plan for communication with healthcare providers, or other elements as the FDA deems are necessary to assure safe use of the product, which could include imposing certain restrictions on distribution or use of a product. A REMS must include a timetable for submission of assessments of the strategy at specified time intervals. Failure to comply with a REMS, including the submission of a required assessment, may result in substantial civil or criminal penalties.

Other Issues Related to Product Safety: Adverse events that are reported after marketing approval also can result in additional limitations being placed on a product’s use and, potentially, withdrawal of the product from the market. In addition, under the FDAAA, the FDA has authority to mandate labeling changes to products at any point in a product’s lifecycle based on new safety information derived from clinical trials, post-approval studies, peer-reviewed medical literature, or post-market risk identification and analysis systems data.

FDA Enforcement

The development of drug and biologic products, as well as the marketing of approved drugs and biologics, is subject to substantial continuing regulation by the FDA, including regulation of adverse event reporting, manufacturing practices and the advertising and promotion of the product. Failure to comply with the FDA and other governmental regulations can result in fines, unanticipated compliance expenditures, recall or seizure of products, total or partial suspension of production and/or distribution, suspension of the FDA’s review of NDAs, BLAs, ANDAs or other product applications, enforcement actions, injunctions and criminal prosecution. Under certain circumstances, the FDA also has the authority to revoke previously granted drug approvals. Although we have internal compliance programs, if these programs do not meet regulatory agency standards or if our compliance is deemed deficient in any significant way, it could have a material adverse effect on our business.

 

18


With respect specifically to information submitted to FDA in support of marketing applications, the FDA, under its Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities Policy, can significantly delay the approval of a marketing application, or seek to withdraw an approved application where it identifies fraud or discrepancies in regulatory submissions. Such actions by the FDA may significantly delay or suspend substantive scientific review of a pending application during validity assessment or remove approved products from the market until the assessment is complete and questions regarding reliability of the data are resolved. In addition, the Generic Drug Enforcement Act of 1992 established penalties for wrongdoing in connection with the development or submission of an ANDA. Under this Act, the FDA has the authority to permanently or temporarily bar companies or individuals from submitting or assisting in the submission of an ANDA, and to temporarily deny approval and suspend applications to market generic drugs. The FDA may also suspend the distribution of all drugs approved or developed in connection with certain wrongful conduct and/or withdraw approval of an ANDA and seek civil penalties.

Healthcare Reform

Continuing studies of the proper utilization, safety and efficacy of pharmaceuticals and other health care products are being conducted by industry, government agencies and others. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety and efficacy of previously marketed products and in some cases have resulted, and may in the future result, in the discontinuance of their marketing.

The Patient Centered Outcomes Research Institute, a private, non-profit corporation created as a result of the PPACA, is tasked with assisting patients, clinician, purchasers, and policy-makers in making informed health decisions. One of the Institute’s initiatives will be to conduct comparative clinical effectiveness research, which is defined as “research evaluating and comparing health outcomes and the clinical effectiveness, risks, and benefits of 2 or more medical treatments, services, and items.” It is important to note that the Institute would not be permitted to mandate coverage, reimbursement, or other policies for any public or private payer, however the outcome of the Institute’s initiatives could influence prescriber behavior.

Foreign Regulation

Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country/region to country/region, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement also may vary, sometimes significantly, from country/region to country/region.

Under the EU regulatory systems, we may submit marketing authorization applications either under a centralized procedure or decentralized procedure or the mutual recognition procedure. The centralized procedure is mandatory for medicines produced by a biotechnological process. The procedure is also mandatory for new active substances which are indicated for treatment of several diseases or conditions, including cancer and orphan conditions. Companies may apply for centralized assessment if the product contains a new active substance or the product constitutes significant therapeutic, scientific or technical innovation or the granting of authorization under the centralized procedure is in the interests of the EU patients. A centralized marketing authorization is valid in all European Union member states. This marketing authorization is issued in the form of a European Commission decision which is legally binding in its entirety to which it is addressed.

Directive 2004/27/EC introduced two parallel procedures to the centralized procedure to allow a product to be progressively authorized in each of the member states of the EU. They are the decentralized procedure and the mutual recognition procedure. The mutual recognition procedure applies where the product has already been authorized in a member state of the EU that will act as reference member state. The national marketing authorization granted by the reference member state forms the basis for mutual recognition in the member states chosen by the applicant. In the decentralized procedure, the product in question is not authorized in any one the EU member states. In such a situation, the applicant company will request a member state to act as the reference member state to lead the scientific assessment for the benefit/risk balance for agreement by the concerned member states. In both cases, the concerned member states have up to 90 days to accept or raise reasoned objections to the assessment made by the reference member state.

In addition, pricing and reimbursement is subject to negotiation and regulation in most countries outside the U.S. Increasingly, adoption of a new product for use in national health services is subject to health technology assessment under the national rules and regulations to establish the clinical effectiveness and cost-effectiveness of a new treatment. In some countries, in order to contain health care expenditures, reference price is introduced in order for the national healthcare providers to achieve a price comparable to the reference price in the same therapeutic category. We may therefore face the risk that the resulting prices would be insufficient to generate an acceptable return to us.

 

19


Third Party Reimbursement and Pricing Controls

In the U.S. and elsewhere, sales of pharmaceutical products depend in significant part on the availability of reimbursement to the consumer from third-party payers, such as government and private insurance plans. Third-party payers are increasingly challenging the prices charged for medical products and services. It is time-consuming and expensive for us to go through the process of seeking reimbursement from Medicare and private payers. Our products may not be considered cost effective, and coverage and reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.

The PPACA enacted significant reforms, including revising the definition of “average manufacturer price” for reporting purposes, increasing Medicaid rebates, expanding the 340B drug discount program, and making changes to affect the Medicare Part D coverage gap, or “donut hole.” In the coming years, additional significant changes could be made to governmental healthcare programs, and the U.S. healthcare system as a whole, that may result in significantly increased rebates, decreased pricing flexibility, diminished negotiating flexibility, coverage and reimbursement limitations based upon comparative and cost-effectiveness reviews, and other measures that could significantly impact the success of our products.

In many foreign markets, including the countries in the EU, pricing of pharmaceutical products is subject to governmental control. In the U.S., there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental pricing control. While we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business, financial condition and profitability.

Employees

As of December 31, 2013, we had 226 employees (as compared to 193 employees as of December 31, 2012), 13 of whom hold an M.D. degree, and eight of whom hold a Ph.D. degree. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel. Our employees are not subject to any collective bargaining agreements. We believe that we have good relations with our employees.

General Information

We are a Delaware corporation. We originally incorporated in Colorado in December 1987 as Americus Funding Corporation. We changed our corporate name in August 1996 to NeoTherapeutics, Inc., and reincorporated in Delaware in June 1997. We changed our corporate name in December 2002 to Spectrum Pharmaceuticals, Inc.

Our principal executive office is located at 11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052. Our telephone number is (702) 835-6300. Our website is located at www.sppirx.com and www.spectrumpharm.com. The information on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part hereof.

We make our proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K (and related amendments to these reports, as applicable) available on our website free of charge as soon as practicable after filing or furnishing with the SEC.

All such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov. In addition, the public may read and copy materials filed by us with the SEC at the SEC’s public reference room located at 100 F Street, NE, Washington, D.C., 20549. Information regarding operation of the SEC’s public reference room can be obtained by calling the SEC at 1-800-SEC-0330.

 

ITEM 1A. RISK FACTORS

Before deciding to invest in our company, or to maintain or increase your investment, you should carefully consider the risks described below, in addition to the other information contained in this Annual Report on Form 10-K and other reports we have filed with the SEC. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us, or that we currently deem immaterial, may also affect our business operations. If any of these risks are realized, our business, financial condition, or results of operations could be seriously harmed and in that event, the market price for our common stock could decline, and you may lose all or part of your investment.

 

20


These risk factors should be considered in connection with evaluating the forward-looking statements contained in this Annual Report on Form 10-K. These factors could cause actual results and conditions to differ materially from those projected in our forward-looking statements.

Risks Related to Our Business

Our drug product FUSILEV may not be more cost-effective than competing drugs and otherwise may not have any competitive advantage, which could adversely affect sales performance.

FUSILEV is a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound calcium leucovorin, a product already approved for the same indications for which FUSILEV is approved. Leucovorin has been sold as a generic product on the market for a number of years. There are generic companies currently selling the product and therefore, FUSILEV competes against a low-cost alternative. Also, FUSILEV is offered as part of a treatment regimen, and that regimen may change to exclude FUSILEV. Accordingly, it may not continue to be accepted by the medical field or remain commercially successful.

Our revenue may not be sustainable and our customer concentration for FUSILEV AND FOLOTYN is significant. The loss of, or significant reduction or cancellation in sales to, any one of these customers could adversely affect our results of operations.

There is no assurance that FUSILEV sales will be sustainable at their current levels. Our customer concentration of FUSILEV is high. A summary of our FUSILEV customers that represent 10% or more of our total consolidated gross product sales in 2013, 2012, and 2011 is as follows:

 

     2013     2012     2011  

Oncology Supply

     32.0     25.8     57.0

McKesson Specialty

     19.8     23.2     19.1

ICS

     *        16.1     *   

Cardinal Health

     *        15.7     *   

 

* Less than 10%

For the years ended December 31, 2013, 2012 and 2011, three companies affiliated with AmerisourceBergen Corporation accounted for substantially all of Allos Therapeutics’ FOLOTYN sales. We expect significant customer concentration to continue for the foreseeable future. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us or any failure to pay for the products we have shipped to them could materially and adversely affect our results of operations, as it would likely take time for those sales to transition to another customer.

If the distributors that we rely upon to sell our products fail to perform, our business may be adversely affected.

Our success depends on the continued customer support efforts of our network of distributors. In the United States, we sell our products to a small number of distributors who in turn sell-through to patient health care providers. These distributors also provide multiple logistics services relating to the distribution of our products, including transportation, warehousing, cross-docking, inventory management, packaging and freight-forwarding. We do not promote products to these distributors and they do not set or determine demand for products. The use of distributors involves certain risks, including, but not limited to, risks that these distributors will:

 

   

not provide us with accurate or timely information regarding their inventories, the number of patients who are using our products or complaints about our products;

 

   

not purchase sufficient inventory on hand to fulfill end user orders in a timely manner;

 

   

be unable to satisfy financial obligations to us or others; and

 

   

cease operations.

Any such actions may result in decreased sales of our products, which would harm our business.

 

21


Wholesaler actions could increase competitive and pricing pressures on pharmaceutical manufacturers, including us.

We sell certain of our products primarily through wholesalers. These wholesale customers comprise a significant part of the distribution network for pharmaceutical products in the U.S. A small number of large wholesale distributors control a significant share of the market, which can increase competitive and pricing pressures on pharmaceutical manufacturers, including us. In addition, wholesalers may apply pricing pressure through fee-for-service arrangements, and their purchases may exceed customer demand, resulting in reduced wholesaler purchases in later quarters. We cannot assure you that we can manage these pressures or that wholesaler purchases will not decrease as a result of this potential excess buying.

Even though we have obtained accelerated approval to market FOLOTYN for the treatment of patients with relapsed or refractory PTCL, we are subject to ongoing regulatory obligations and review, including post-approval requirements.

FOLOTYN was approved for the treatment of patients with relapsed or refractory PTCL under the FDA’s accelerated approval regulations, which allow the FDA to approve products for cancer or other serious or life threatening diseases based on initial positive data from clinical trials. Under these provisions, we are subject to certain post-approval requirements pursuant to which we are required to conduct two randomized Phase 3 trials to confirm FOLOTYN’s clinical benefit in patients with T-cell lymphoma. The FDA has also required that we conduct two Phase 1 trials to assess whether FOLOTYN poses a serious risk of altered drug levels resulting from organ impairment. Failure to complete the studies or adhere to the timelines established by the FDA could result in penalties, including fines or withdrawal of FOLOTYN from the market. The FDA may also initiate proceedings to withdraw approval or request that we voluntarily withdraw FOLOTYN from the market if our Phase 3 studies fail to confirm FOLOTYN’s clinical benefit. Further, the FDA may require us to amend the FOLOTYN package insert, including by strengthening the warnings and precautions section or institute a risk evaluation and mitigation strategy based on the results of these studies or clinical experience. We are also subject to additional, continuing post-approval regulatory obligations, including the possibility of additional clinical studies required by the FDA, safety reporting requirements and regulatory oversight of the promotion and marketing of FOLOTYN. In addition, we or our third-party manufacturers are required to adhere to the FDA’s current Good Manufacturing Practices, or cGMP. The cGMP regulations cover all aspects of the manufacturing, storage, testing, quality control and record keeping relating to FOLOTYN. Furthermore, we or our third-party manufacturers are subject to periodic inspection by the FDA and foreign regulatory authorities to ensure compliance with cGMP or other applicable government regulations and corresponding foreign standards. We have limited control over a third-party manufacturer’s compliance with these regulations and standards. If we or our third-party manufacturers fail to comply with applicable regulatory requirements, we may be subject to fines, suspension, modification or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Our collaboration partner, Mundipharma, may not be successful in obtaining regulatory approval for FOLOTYN in a number of countries and FOLOTYN is subject to numerous complex regulatory requirements.

Our collaboration partner, Mundipharma, may not be successful in obtaining regulatory approval for FOLOTYN in a number of countries and FOLOTYN is subject to numerous complex regulatory requirements. Failure to comply with, or changes to, the regulatory requirements that are applicable to FOLOTYN outside the United States may result in a variety of consequences, including the following:

 

   

restrictions on FOLOTYN or our manufacturing processes;

 

   

warning letters;

 

   

withdrawal of FOLOTYN from the market;

 

   

voluntary or mandatory recall of FOLOTYN;

 

   

fines against us;

 

   

suspension or withdrawal of regulatory approvals for FOLOTYN;

 

   

suspension or termination of any of our ongoing clinical trials of FOLOTYN;

 

   

refusal to permit import or export of FOLOTYN;

 

   

refusal to approve pending applications or supplements to approved applications that we submit;

 

   

denial of permission to file an application or supplement in a jurisdiction;

 

   

product seizure;

 

   

injunctions, consent decrees, or the imposition of civil or criminal penalties against us.

 

22


If actual future payments for allowances, discounts, returns, rebates and chargebacks exceed the estimates we made at the time of the sale of our products, including, without limitation, due to a change in the composition of our sales over time, our financial position, results of operations and cash flows may be materially and negatively impacted.

We recognize product revenue net of estimated allowances for discounts, returns, rebates and chargebacks. Such estimates require our most subjective and complex judgment due to the need to make estimates about matters that are inherently uncertain. Based on industry practice, pharmaceutical companies, including us, have liberal return policies. Generally, we are obligated to accept from customers the return of pharmaceuticals that have reached their expiration date up to twelve months after their expiration. We authorize returns for damaged products and exchanges for expired products in accordance with our return goods policy and procedures. In addition, like our competitors, we also give credits for chargebacks to wholesale customers that have contracts with us for their sales to hospitals, group purchasing organizations, pharmacies or other retail customers. A chargeback is the difference between the price the wholesale customer (in our case, the GPOs) pays (wholesale acquisition cost) and the price that the GPO’s end-customer pays for a product (contracted customer). For instance, our products are subject to certain programs with federal government qualified entities whereby pricing on products is discounted to such entities and results in a chargeback claim to us. To the extent that our sales to discount purchasers, such as federal government qualified entities, increases, our chargebacks will also increase. We do not have significant historical data on returns and allowances given our limited commercial distribution history. Although we believe that we have estimated the allowances very conservatively, actual results may differ significantly from our estimated allowances for discounts, returns, rebates and chargebacks. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operations and/or financial condition. Such changes to estimates will be made to the financial statements in the year in which the estimate is charged. In addition, our financial position, results of operations and cash flows may be materially and negatively impacted if actual future payments for allowances, discounts, returns, rebates and chargebacks exceed the estimates we made at the time of the sale of our products.

Reports of adverse events or safety concerns involving our products or similar agents could delay or prevent us from obtaining or maintaining regulatory approval or negatively impact sales.

Certain of our products may cause serious adverse events. Discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, could interrupt, delay or halt clinical trials of such products, including the FDA-required post-approval studies, and could result in the FDA or other regulatory authorities denying or withdrawing approval of our products for any or all indications. The FDA, other regulatory authorities or we may suspend or terminate clinical trials at any time. We may also be required to update the package inserts based on reports of adverse events or safety concerns or implement a risk evaluation and mitigation strategy, which could adversely affect such products acceptance in the market. In addition, the public perception of our products might be adversely affected, which could harm our business and results of operations and cause the market price of our common stock to decline, even if the concern relates to another company’s product or product candidate. Our planned trials to demonstrate efficacy in a variety of indications and to better manage side effect profiles of certain of our products may not be successful.

The marketing and sale of our products may be adversely affected by the marketing and sales efforts of third parties who sell our products or similar products outside of our territories.

We have only licensed the rights to develop, market and our products in limited territories. Other companies market and sell the same products in other parts of the world. If, as a result of other companies’ actions, negative publicity is associated with our products or similar products, our own efforts to successfully market and sell our products in our markets may be adversely impacted.

Our sales depend on coverage and reimbursement from third-party payors and a reduction in the coverage and/or reimbursement for our products could have a material adverse effect on our product sales, business and results of operations.

Sales of our products are dependent on the availability and extent of coverage and reimbursement from third-party payors, including government programs and private insurance plans. Governments and private payors may regulate prices, reimbursement levels and/or access to our products to contain costs or to affect levels of use. We rely in large part on the reimbursement of our products through government programs such as Medicare and Medicaid in the United States, and a reduction in the coverage and/or reimbursement for our products could have a material adverse effect on our product sales, business and results of operations.

 

23


A substantial portion of our U.S. business relies on reimbursement from the U.S. federal government under Medicare Part B coverage. Most of our products furnished to Medicare beneficiaries in both a physician office setting and hospital outpatient setting are reimbursed under the Medicare Part B Average Sales Price, or ASP, payment methodology. ASP-based reimbursement of our products under Medicare may be below or could fall below the cost that some medical providers pay for such products, which could materially and adversely affect sales of our products. We also face risks relating to the reporting of pricing data that affect the U.S. reimbursement of and discounts for our products. ASP data are calculated by the manufacturer based on a formula defined by statute and regulation and are then submitted to the Centers for Medicare & Medicaid Services, the agency responsible for administering the Medicare program, or CMS, on a quarterly basis. CMS uses those ASP data to determine the applicable reimbursement rates for our products under Medicare Part B. However, the statute, regulations and CMS guidance do not define specific methodologies for all aspects of the reporting of ASP data. For example, CMS has not provided specific guidance regarding administrative fees paid to group purchasing organizations, or GPOs, in the ASP calculation. CMS directs that manufacturers make “reasonable assumptions” in their calculation of ASP data in the absence of specific CMS guidance on a topic. As a result, we are required to apply our reasonable judgment to certain aspects of calculating ASP data. If our submitted ASP data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse impact on our business and results of operations.

We are aware of several competitors attempting to develop and market products competitive to our products, which may reduce or eliminate our commercial opportunities.

The pharmaceutical and biotechnology industries are intensely competitive and subject to rapid and significant technological changes, and a number of companies are pursuing the development of pharmaceuticals and products that target the same diseases and conditions that our products target. We cannot predict with accuracy the timing or impact of the introduction of potentially competitive products or their possible effect on our sales. Certain potentially competitive products to our products are in various stages of development, some of which have pending applications for approval with the FDA or have been approved by regulatory authorities in other countries. Also, there are many ongoing studies with currently marketed products and other developmental products, which may yield new data that could adversely impact the use of our products in their current and potential future indications. The introduction of competitive products could significantly reduce our sales, which, in turn would adversely impact our financial and operating results.

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

We had $120 million of long term debt as of December 31, 2013. Any such indebtedness will require the dedication of a portion of our expected cash flow from operations to service our indebtedness, thereby reducing the amount of our cash flow available for other purposes. In addition, our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including our convertible notes, depends on our future performance, which is subject to regulatory, economic, financial, competitive and other factors beyond our control, and our ability to raise equity capital. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

Clinical trials may fail to demonstrate the safety and efficacy of our drug products, which could prevent or significantly delay obtaining regulatory approval.

Prior to receiving approval to commercialize any of our drug products, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, and other regulatory authorities in the U.S. and other countries, that each of the products is both safe and effective. For each drug product, we will need to demonstrate its efficacy and monitor its safety throughout the process. If such development is unsuccessful, our business and reputation would be harmed and our stock price would be adversely affected.

All of our drug products are prone to the risks of failure inherent in drug development. Clinical trials of new drug products sufficient to obtain regulatory marketing approval are expensive, uncertain, and take years to complete. We may not be able to successfully complete clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent us from receiving regulatory approval or commercializing our drug products. In addition, the results of pre-clinical studies and early-stage

 

24


clinical trials of our drug products do not necessarily predict the results of later-stage clinical trials. Later-stage clinical trials may fail to demonstrate that a drug product is safe and effective despite having progressed through initial clinical testing. Even if we believe the data collected from clinical trials of our drug products is promising, data are susceptible to varying interpretations, and such data may not be sufficient to support approval by the FDA or any other U.S. or foreign regulatory approval. Pre-clinical and clinical data can be interpreted in different ways.

Accordingly, FDA officials could interpret such data in different ways than we or our partners do which could delay, limit or prevent regulatory approval. The FDA, other regulatory authorities, our institutional review boards, our contract research organizations, or we may suspend or terminate our clinical trials for our drug products. Any failure or significant delay in completing clinical trials for our drug products, or in receiving regulatory approval for the sale of any drugs resulting from our drug products, may severely harm our business and reputation. Even if we receive FDA and other regulatory approvals, our drug products may later exhibit adverse effects that may limit or prevent their widespread use, may cause the FDA to revoke, suspend or limit their approval, or may force us to withdraw products derived from those drug products from the market.

Moreover, the commencement and completion of clinical trials may be delayed by many factors that are beyond our control, including:

 

   

delays obtaining regulatory approval to commence a trial;

 

   

reaching agreement on acceptable terms with contract research organizations, or CROs, and clinical trial sites;

 

   

obtaining institutional review board, or IRB, approval at each site;

 

   

slower than anticipated patient enrollment;

 

   

scheduling conflicts with participating clinicians and clinical institutions;

 

   

lack of funding;

 

   

negative or inconclusive results;

 

   

patient noncompliance with the protocol;

 

   

adverse medical events or side effects among patients during the clinical trials;

 

   

negative or problematic FDA inspections of our clinical operations or manufacturing operations; and

 

   

real or perceived lack of effectiveness or safety of mifepristone.

We could encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the clinical trial sites in which such trials are being conducted, or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, any delay in final data results in the second quarter of 2014 in the pivotal trial of our Captisol-enabled MELPHALAN product candidate for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma could delay a new drug application filing with respect to that product candidate.

Our supply of active pharmaceutical ingredients, or APIs, and drug products will be dependent upon the production capabilities of contract manufacturing organizations, or CMOs, component and packaging supply sources, other third-party suppliers, and other providers of logistical services, some of whom are based overseas and, if these parties are not able to meet our demands and FDA scrutiny, we may be limited in our ability to meet demand for our products, ensure regulatory compliance or maximize profit on the sale of our products.

We have no internal manufacturing capacity for APIs or our drug products, and, therefore, we have entered into agreements with CMOs and other suppliers to supply us with APIs and our finished dose drug products. Success in the development and marketing of our drug products depends, in part, upon our ability to maintain, expand and enhance our

 

25


existing relationships and establish new sources of supply. Some of the third-party manufacturing facilities used in the production of APIs and our drug products are located outside the U.S. The manufacture of APIs and finished drug products, including the acquisition of compounds used in the manufacture of the finished drug product, may require considerable lead times. We have little or no control over the production processes of third-party manufacturers, CMOs or other suppliers. Our ability to source APIs and drug products is also dependent on providers of logistical services who may be subject to disruptions that we cannot predict or sufficiently plan around. Accordingly, while we do not currently anticipate shortages of supply, circumstances could arise in which we will not have adequate supplies to timely meet our requirements or market demand for a particular drug product could outstrip the ability of our supply source to timely manufacture and deliver the product, thereby causing us to lose sales. In addition, our ability to make a profit on the sale of our drug products depends on our ability to obtain price arrangements that ensure a supply of product at favorable prices.

Additionally, we are in the process of transitioning to a new supplier for ZEVALIN cold kits, and currently no qualified alternative suppliers exist. Furthermore, we have multiple but a limited number of suppliers of FUSILEV. If problems arise during the production of a batch of our drug products, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. To the extent that one of our suppliers experiences significant manufacturing problems, this could have a material adverse effect on our revenues and profitability.

Finally, reliance on CMOs entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the third party for regulatory compliance and adherence to the FDA’s current Good Manufacturing Practice, or cGMP, requirements, the possible breach of the manufacturing agreement by the CMO and the possibility of termination or non-renewal of the agreement by the CMO, based on its own business priorities, at a time that is costly or inconvenient for us. Before we can obtain marketing approval for our drug products, our CMO facilities must pass an FDA pre-approval inspection. In order to obtain approval, all of the facility’s manufacturing methods, equipment and processes must comply with cGMP requirements. The cGMP requirements govern all areas of record keeping, production processes and controls, personnel and quality control. In addition, our CMOs will be subject to on-going periodic inspection by the FDA and corresponding state and foreign agencies for compliance with cGMP regulations, similar foreign regulations and other regulatory standards. We do not have control over our CMOs’ compliance with these regulations and standards. Any failure of our third party manufacturers or us to comply with applicable regulations, including an FDA pre-approval inspection and cGMP requirements, could result in sanctions being imposed on them or us, including warning letters, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delay, suspension or withdrawal of approvals, license revocation, seizures or recalls of product, operation restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.

Adverse economic conditions may have material adverse consequences on our business, results of operations and financial condition.

Unpredictable and unstable changes in economic conditions, including recession, inflation, increased government intervention, or other changes, may adversely affect our general business strategy. We rely upon our ability to generate positive cash flow from operations to fund our business. If we are not able to generate positive cash flow from operations, we may need to utilize sources of financing or other sources of cash. We may need to raise additional funds through public or private debt or equity financings in order to fund existing operations or to take advantage of opportunities, including acquisitions of complementary businesses or technologies. In addition, if our business deteriorates, we may not be able to maintain compliance with any covenants or representations and warranties in any such financings which could result in reduced availability of such financings, an event of default under such financings, or could make other sources of financing unavailable to us. Any such event would have a material adverse impact on our business, results of operations and financial condition.

While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, an economic downturn or an increase in our expenses could require additional financing on less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans or plans to acquire additional technology.

Volatile economic conditions may not only limit our access to capital, but may also make it difficult for our customers and us to accurately forecast and plan future business activities, and they could cause businesses to slow spending on our products, which would delay and lengthen sales cycles. Furthermore, during challenging economic times, our customers may face issues gaining timely access to sufficient credit, which could result in an impairment of their ability to make timely payments to us. In addition, adverse economic conditions could also adversely impact our suppliers’ ability to provide us with materials which would negatively impact on our business, financial condition and results of operations.

 

26


Our dependence on key executives, scientists and sales and marketing personnel could impact the development and management of our business.

We are highly dependent upon our ability to attract and retain qualified scientific, technical sales and marketing and managerial personnel. There is intense competition for qualified personnel in the pharmaceutical and biotechnology industries, and we cannot be sure that we will be able to continue to attract and retain the qualified personnel necessary for the development and management of our business. Although we do not believe the loss of one individual would materially harm our business, our business might be harmed by the loss of the services of multiple existing personnel, as well as the failure to recruit additional key scientific, technical and managerial personnel in a timely manner. Much of the know-how we have developed resides in our scientific and technical personnel and is not readily transferable to other personnel. While we have employment agreements with each of our Chief Executive Officer and our Chief Operating Officer, we do not have employment agreements with any of our other key scientific, technical and managerial employees.

As we evolve from a company primarily involved in development to a company also involved in commercialization, we may encounter difficulties in managing our growth and expanding our operations successfully.

Our commercial sales history is limited and we have had to increase our personnel to accommodate such sales, including establishing a direct sales force and complete commercial team. In addition, as we advance our drug products through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with such third parties, as well as additional collaborators and suppliers. Maintaining these relationships and managing our future growth will impose significant added responsibilities on members of our management. We must be able to: manage our development efforts effectively; manage our clinical trials effectively; hire, train and integrate additional management, development, administrative and sales and marketing personnel; improve our managerial, development, operational and finance systems and expand our facilities, all of which may impose a strain on our administrative and operational infrastructure. If we are not able to effectively manage our growth, our product sales and resulting revenues will be negatively impacted.

Expansion into international markets is important to our long-term success, and our inexperience in international operations increases the risk that our international expansion efforts will not be successful.

We currently maintain offices outside of the United States and have sales personnel or independent consultants in several countries. Additionally, we conduct clinical trials and manufacture our drug products internationally. We have limited experience operating in foreign jurisdictions and are rapidly building our international operations. Managing a global organization is difficult, time consuming and expensive. Our inexperience in operating our business outside of the United States increases the risk that any international expansion efforts that we may undertake will not be successful. In addition, conducting international operations subjects us to new risks that we have not generally faced in the United States, many of which are beyond our control. These risks include, among other things:

 

   

challenges caused by distance, language and cultural differences;

 

   

maintaining compliance with foreign legal requirements, including employment law;

 

   

unexpected changes in foreign regulatory requirements, including quality standards and other certification requirements;

 

   

potentially adverse tax consequences, including the complexities of foreign value added tax systems and restrictions on the repatriation of earnings;

 

   

tariffs, customs, duties and other trade barriers;

 

   

increased financial accounting and reporting burdens and complexities;

 

   

changing economic conditions in countries where our products are manufactured;

 

   

exchange rate risks;

 

   

product liability, intellectual property and other claims;

 

   

reduced or varied protection for intellectual property rights in some countries;

 

   

political and social instability;

 

   

new export license requirements; and

 

   

difficulties in managing and staffing foreign operations.

 

27


Operating in international markets also requires significant management attention and financial resources. The investment and additional resources required to establish operations and manage growth in other countries may not produce the desired levels of revenue or profitability, which could have an adverse effect on our business, financial condition and results of operations.

We may not be able to successfully integrate our recent acquisitions and any additional businesses we may acquire.

We regularly evaluate and, as appropriate, may make selective acquisitions of businesses that we believe complement or augment our existing business. In September 2012, we acquired Allos Therapeutics, pursuant to which we obtained FOLOTYN, and in July 2013, we acquired Talon, pursuant to which we obtained MARQIBO. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Issues that could delay or prevent integration of the acquired business into our own include:

 

   

conforming standards, controls, procedures and policies, business cultures and compensation structures;

 

   

conforming information technology and accounting systems;

 

   

consolidating corporate and administrative infrastructures;

 

   

consolidating sales and marketing operations;

 

   

retaining existing customers and attracting new customers;

 

   

retaining key employees;

 

   

identifying and eliminating redundant and underperforming operations and assets;

 

   

minimizing the diversion of management’s attention from ongoing business concerns;

 

   

coordinating geographically dispersed organizations;

 

   

managing tax costs or inefficiencies associated with integrating operations; and

 

   

making any necessary modifications to operating control standards to comply with the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.

If we are unable to successfully integrate our acquisitions with our existing business, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely affect our business, results of operations, financial condition and cash flows, our ability to develop and introduce new products and the market price of our stock. Actual costs and sales synergies, if achieved at all, may be lower than we expect and may take longer to achieve than we anticipate. Furthermore, the products of companies we acquire may overlap with our products or those of our customers, creating conflicts with existing relationships or with other commitments that are detrimental to the integrated businesses.

Our collaborations with outside scientists may be subject to change, which could limit our access to their expertise.

We work with scientific advisors and collaborators at research institutions. These scientists are not our employees and may have other commitments that would limit their availability to us. If a conflict of interest between their work for us and their work for another entity arises, we may lose their services, which could negatively impact our research and development activities.

We may rely on contract research organizations and other third parties to conduct clinical trials and, in such cases, we are unable to directly control the timing, conduct and expense of our clinical trials.

We may rely, in full or in part, on third parties to conduct our clinical trials. In such situations, we have less control over the conduct of our clinical trials, the timing and completion of the trials, the required reporting of adverse events and the management of data developed through the trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay our trials, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable cost.

 

28


We may have conflicts with our partners that could delay or prevent the development or commercialization of our drug products.

We may have conflicts with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our drug product, and in turn prevent us from generating revenues from such drug product:

 

   

unwillingness on the part of a partner to pay us milestone payments or royalties that we believe are due to us under a collaboration;

 

   

uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations;

 

   

unwillingness by the partner to cooperate in the development or manufacture of the product, including providing us with product data or materials;

 

   

unwillingness on the part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities;

 

   

initiation of litigation or alternative dispute resolution options by either party to resolve the dispute;

 

   

attempts by either party to terminate the collaboration;

 

   

our ability to maintain or defend our intellectual property rights may be compromised by our partner’s acts or omissions;

 

   

a partner may utilize our intellectual property rights in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential liability;

 

   

a partner may change the focus of its development and commercialization efforts due to internal reorganizations, mergers, consolidations and otherwise;

 

   

unwillingness of a partner to fully fund or commit sufficient resources to the testing, marketing, distribution or development of our products;

 

   

unwillingness or ability of a partner to fulfill their obligations to us due to the pursuit of alternative products, conflicts of interest that arise or changes in business strategy or other business issues; and/or

 

   

we may not be able to guarantee supplies of development or marketed products.

Given these risks, it is possible that any collaborative arrangements which we have or may enter into may not be successful.

Our efforts to acquire or in-license and develop additional drug products may fail, which might limit our ability to grow our business.

To remain competitive and grow our business, our long-term strategy includes the acquisition or in-license of additional drug products. We are actively seeking to acquire, or in-license, additional commercial drug products as well as drug products that have demonstrated positive pre-clinical and/or clinical data. We have certain criteria that we are looking for in any drug product acquisition and in-license and we may not be successful in locating and acquiring, or in-licensing, additional desirable drug products on acceptable terms.

To accomplish our acquisition and in-license strategy, we intend to commit efforts, funds and other resources to research and development and business development. Even with acquired and in-licensed drug products, a high rate of failure is inherent in the development of such products. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. For example, promising new drug product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights or infringement of the intellectual property rights of others.

 

29


In addition, many other large and small companies within the pharmaceutical and biotechnology industry seek to establish collaborative arrangements for product research and development, or otherwise acquire products in late-stage clinical development, in competition with us. We face additional competition from public and private research organizations, academic institutions and governmental agencies in establishing collaborative arrangements for drug products in late-stage clinical development. Many of the companies and institutions that compete against us have substantially greater capital resources, research and development staffs and facilities than we have, and greater experience in conducting business development activities. These entities represent significant competition to us as we seek to expand our portfolio through the in-license or acquisition of compounds. Finally, while it is not feasible to predict the actual cost of acquiring and developing additional drug products, that cost could be substantial and we may need to raise additional financing for such purpose, which may further dilute existing stockholders.

From time to time we may need to license patents, intellectual property and proprietary technologies from third parties, which may be difficult or expensive to obtain.

We may need to obtain licenses to patents and other proprietary rights held by third parties to successfully develop, manufacture and market our drug products. As an example, it may be necessary to use a third party’s proprietary technology to reformulate one of our drug products in order to improve upon the capabilities of the drug product. If we are unable to timely obtain these licenses on reasonable terms, our ability to commercially exploit our drug products may be inhibited or prevented.

We are a small company relative to our principal competitors, and our limited financial resources may limit our ability to develop and market our drug products.

Many companies, both public and private, including well-known pharmaceutical companies and smaller niche-focused companies, are developing products to treat many, if not all, of the diseases we are pursuing or are currently distributing drug products that directly compete with the drugs that we sell or that we intend to develop, market and distribute. Many of these companies have substantially greater financial, research and development, manufacturing, marketing and sales experience and resources than us. As a result, our competitors may be more successful than us in developing their products, obtaining regulatory approvals and marketing their products to consumers.

Competition for branded or proprietary drugs is less driven by price and is more focused on innovation in the treatment of disease, advanced drug delivery and specific clinical benefits over competitive drug therapies. We may not be successful in any or all of our current clinical studies; or if successful, and if one or more of our drug products is approved by the FDA, we may encounter direct competition from other companies who may be developing products for similar or the same indications as our drug products. Companies that have products on the market or in research and development that target the same indications as our products target include, among others, Abraxis Bioscience, Inc., Astra Zeneca LP, Bayer AG, Endo Pharmaceuticals, Eli Lilly and Co., Novartis Pharmaceuticals Corporation, Genentech, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., Cephalon, Inc., Sanofi-aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., Roche Pharmaceuticals and Johnson & Johnson who may be more advanced in the development of competing drug products or are more established. Many of our competitors are large and well-capitalized companies focusing on a wide range of diseases and drug indications, and have substantially greater financial, research and development, marketing, human and other resources than we do. Furthermore, large pharmaceutical companies have significantly more experience than we do in pre-clinical testing, human clinical trials and regulatory approval procedures, among other things.

The potential size of the market for our drug products is uncertain.

We often provide estimates of the number of people who suffer from the diseases that our drugs are targeting. However, there is limited information available regarding the actual size of these patient populations. In addition, it is uncertain whether the results from previous or future clinical trials of drug products will be observed in broader patient populations, and the number of patients who may benefit from our drug products may be significantly smaller than the estimated patient populations.

 

30


Changes in our effective income tax rate could adversely affect our profitability.

We are subject to federal and state income taxes in the U.S. and our tax liabilities are dependent upon the distribution of income among these different jurisdictions. Various factors may have favorable or unfavorable effects on our effective income tax rate. These factors include, but are not limited to:

 

   

interpretations of existing tax laws;

 

   

the accounting for stock options and other share-based compensation;

 

   

changes in tax laws and rates;

 

   

future levels of research and development spending;

 

   

changes in accounting standards;

 

   

changes in the mix of earnings in the various tax jurisdictions in which we operate;

 

   

the outcome of examinations by the Internal Revenue Service and other jurisdictions;

 

   

the accuracy of our estimates for unrecognized tax benefits;

 

   

realization of deferred tax assets; and

 

   

changes in overall levels of pre-tax earnings.

The impact on our income tax provision resulting from the above-mentioned factors may be significant and could have an impact on our profitability.

Earthquakes or other natural or man-made disasters and business interruptions could adversely affect our business.

Our operations are vulnerable to interruption by fire, power loss, floods, telecommunications failure and other events beyond our control. In addition, our operations are susceptible to disruption as a result of natural disasters such as earthquakes. So far we have never experienced any significant disruption of our operations as a result of earthquakes or other natural or man-made disasters. Although we have a contingency recovery plan, any significant business interruption could cause delays in our drug development and future sales and harm our business.

Risks Related to Our Industry

If we are unable to adequately protect our technology or enforce our patent rights, our business could suffer.

Our success with the drug products that we develop will depend, in part, on our ability and the ability of our licensors to obtain and maintain patent protection for these products. We currently have a number of U.S. and foreign patents issued and pending, however, we primarily rely on patent rights licensed from others. Our license agreements generally give us the right and/or obligation to maintain and enforce the subject patents. We may not receive patents for any of our pending patent applications or any patent applications we may file in the future. If our pending and future patent applications are not allowed or, if allowed and issued into patents, if such patents and the patents we have licensed are not upheld in a court of law, our ability to competitively exploit our drug products would be substantially harmed. Also, such patents may or may not provide competitive advantages for their respective products or they may be challenged or circumvented by our competitors, in which case our ability to commercially exploit these products may be diminished.

The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in pharmaceutical and biotechnology patents has emerged to date in the U.S. The laws of many countries may not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. Filing, prosecuting and defending patents on all our products or product candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions and may not be covered by any of our patent claims or other intellectual property rights.

Changes in either patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property. We do not know whether any of our patent applications will result in the issuance of any patents, and we cannot predict the breadth of claims that may be allowed in our patent applications or in the patent applications we license from others.

 

31


The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

 

   

in certain jurisdictions, we or our licensors might not have been the first to make the inventions covered by each of our or our licensors’ pending patent applications and issued patents, and we may have to participate in expensive and protracted interference proceedings to determine priority of invention;

 

   

we or our licensors might not have been the first to file patent applications for these inventions;

 

   

others may independently develop similar or alternative product candidates or duplicate any of our or our licensors’ product candidates;

 

   

our or our licensors’ pending patent applications may not result in issued patents;

 

   

our or our licensors’ issued patents may not provide a basis for commercially viable products or may not provide us with any competitive advantages or may be challenged by third parties;

 

   

others may design around our or our licensors’ patent claims to produce competitive products that fall outside the scope of our or our licensors’ patents;

 

   

we may not develop or in-license additional patentable proprietary technologies related to our product candidates; or

 

   

the patents of others may prevent us from marketing one or more of our product candidates for one or more indications that may be valuable to our business strategy.

Moreover, an issued patent does not guarantee us the right to practice the patented technology or commercialize the patented product. Third parties may have blocking patents that could be used to prevent us from commercializing our patented products and practicing our patented technology. Our issued patents and those that may be issued in the future may be challenged, invalidated or circumvented, which could limit our ability to prevent competitors from marketing related product candidates or could limit the length of the term of patent protection of our product candidates. For example, on January 20, 2012 and February 17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate Abbreviated New Drug Applications, or ANDAs, to manufacture a generic version of FUSILEV. On December 9, 2013, three parties collaborating with Innopharma were joined to Innopharma case: Mylan Teoranta, Mylan Institutional LLC; and Mylan Institutional, Inc. (collectively “Mylan”). While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain, and if we do not prevail in the litigation, Sandoz Inc. and Innopharma Inc.,/Mylan, subject to fulfilling the applicable regulatory requirements, may be able to launch a generic version that would compete with FUSILEV, which could result in an immediate and substantial decrease in our revenues. In addition, our competitors may independently develop similar technologies. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.

We also rely on trade secret protection and contractual protections for our unpatented, confidential and proprietary technology. Trade secrets are difficult to protect. While we enter into confidentiality agreements with our employees, consultants and others, these agreements may not successfully protect our trade secrets or other confidential and proprietary information. It is possible that these agreements will be breached, or that they will not be enforceable in every instance, and that we will not have adequate remedies for any such breach. Likewise, although we conduct periodic trade secret audits of certain partners, vendors and contract manufacturers, these trade secret audits may not protect our trade secrets or other confidential and proprietary information. It is possible that despite having certain trade secret audited security measures in place, trade secrets or other confidential and proprietary information may still be leaked or disclosed to a third party. It is also possible that our trade secrets will become known or independently developed by our competitors.

We also rely on trademarks to protect the names of our products. These trademarks may be challenged by others. If we enforce our trademarks against third parties, such enforcement proceedings may be expensive. Some of our trademarks, including ZEVALIN are owned by, or assignable to, our licensors and, upon expiration or termination of the applicable license agreements, we may no longer be able to use these trademarks.

If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our patents and trademarks, our business, financial condition and prospects could suffer.

Intellectual property rights are complex and uncertain and therefore may subject us to infringement claims.

The patent positions related to our drug products are inherently uncertain and involve complex legal and factual issues. We believe that there is significant litigation in the pharmaceutical and biotechnology industry regarding patent and other intellectual property rights. A patent does not provide the patent holder with freedom to operate in a way that infringes the

 

32


patent rights of others. We may be accused of patent infringement at any time. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents in the U.S.

Although we are not aware of any infringement by any of our drug products on the rights of any third party, there may be third party patents or other intellectual property rights, including trademarks and copyrights, relevant to our drug products of which we are not aware. Third parties may assert patent or other intellectual property infringement claims against us, or our licensors and collaborators, with products. Any claims that might be brought against us relating to infringement of patents may cause us to incur significant expenses and, if successfully asserted against us, may cause us to pay substantial damages and result in the loss of our use of the intellectual property that is critical to our business strategy.

In the event that we or our partners are found to infringe any valid claim of a patent held by a third party, we may, among other things, be required to:

 

   

pay damages, including up to treble damages and the other party’s attorneys’ fees, which may be substantial;

 

   

cease the development, manufacture, use and sale of our products that infringe the patent rights of others through a court-imposed sanction such as an injunction;

 

   

expend significant resources to redesign our products so they do not infringe others’ patent rights, which may not be possible;

 

   

discontinue manufacturing or other processes incorporating infringing technology; or

 

   

obtain licenses to the infringed intellectual property, which may not be available to us on acceptable terms, or at all.

Rapid bio-technological advancement may render our drug products obsolete before we are able to recover expenses incurred in connection with their development. As a result, some of our drug products may never become profitable.

The pharmaceutical industry is characterized by rapidly evolving biotechnology. Biotechnologies under development by other pharmaceutical companies could result in treatments for diseases and disorders for which we are developing our own treatments. Several other companies are engaged in research and development of compounds that are similar to our research. A competitor could develop a new biotechnology, product or therapy that has better efficacy, a more favorable side-effect profile or is more cost-effective than one or more of our drug products and thereby cause our drug products to become commercially obsolete. Some of our drug products may become obsolete before we recover the expenses incurred in their development. As a result, such products may never become profitable.

Failure to obtain regulatory approval outside the U.S. will prevent us from marketing our product candidates abroad.

We intend to market certain of our existing and future product candidates in outside of the U.S. In order to market our existing and future product candidates in the European Union and many other foreign jurisdictions, we must obtain separate regulatory approvals according to the applicable domestic laws and regulations. We have had limited interactions with foreign regulatory authorities, and the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not guarantee approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not necessarily ensure approval by regulatory authorities in other countries or by the FDA. A failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval as well as other risks specific to the jurisdictions in which we may seek approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for foreign regulatory approvals and may not receive necessary approvals to commercialize our existing and future product candidates in any market.

 

33


Competition for patients in conducting clinical trials may prevent or delay product development and strain our limited financial resources.

Many pharmaceutical companies are conducting clinical trials involving patients with the disease indications that our drug products target. As a result, we must compete with them for clinical sites, physicians and the limited number of patients who fulfill the stringent requirements for participation in clinical trials. Also, due to the confidential nature of clinical trials, we do not know how many of the eligible patients may be enrolled in competing studies and who are consequently not available to us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. Patient enrollment depends on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites and the eligibility criteria for the study. The delay or inability to meet planned patient enrollment may result in increased costs and delays or termination of the trial, which could have a harmful effect on our ability to develop products.

Even after we receive regulatory approval to market our drug products, the market may not be receptive to our drug products upon their commercial introduction, which would negatively impact our ability to achieve profitability.

Our drug products may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved drug products will depend on a number of factors, including:

 

   

the effectiveness of the drug product;

 

   

the prevalence and severity of any side effects;

 

   

potential advantages or disadvantages over alternative treatments;

 

   

relative convenience and ease of administration;

 

   

the strength of marketing and distribution support;

 

   

the price of the drug product, both in absolute terms and relative to alternative treatments; and

 

   

sufficient third-party coverage and reimbursement.

If our drug products receive regulatory approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate drug product revenues sufficient to attain profitability.

Guidelines and recommendations published by various organizations can reduce the use of our products.

Government agencies such as the Centers for Medicare & Medicaid Services promulgate regulations, and issue guidelines, directly applicable to us and to our products. In addition, third parties such as professional societies, practice management groups, insurance carriers, physicians, private health/science foundations and organizations involved in various diseases from time to time may publish guidelines or recommendations to healthcare providers, administrators and payors, and patient communities. Recommendations may relate to such matters as utilization, dosage, route of administration and use of related therapies and coverage and reimbursement of our products by government and private payors. Third-party organizations like the above have in the past made recommendations about our products. Recommendations or guidelines that are followed by patients and healthcare providers could result in decreased utilization and/or dosage of our products, any of which could adversely affect our product sales and operating results materially.

The sale of our products is subject to regulatory approvals, and our business is subject to extensive regulatory requirements, and if we are unable to obtain regulatory approval for our product candidates, or if we fail to comply with governmental regulations we will be limited in our ability to commercialize our products and product candidates and/or subject us to penalties.

We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Obtaining regulatory approval of a new drug is an uncertain, lengthy and expensive process, and success is never guaranteed. Despite the time, resources and effort expended, failure can occur at any stage. In order to receive approval from the FDA for each product candidate, we must demonstrate that the new drug product is safe and effective for its intended use and that the manufacturing processes for the product candidate comply with the FDA’s cGMPs. cGMPs include requirements related to production processes, quality control and assurance, and recordkeeping. The FDA has substantial discretion in the approval process for human medicines.

The FDA and comparable agencies in foreign countries impose many requirements related to the drug development process through lengthy and rigorous clinical testing and data collection procedures, and other costly and time consuming compliance procedures. While we believe that we are currently in compliance with applicable FDA regulations, if our partners, the contract research organizations or contract manufacturers with which we have relationships, or we fail to comply with the regulations applicable to our clinical testing, the FDA may delay, suspend or cancel our clinical trials, or the FDA might not accept the test results. The FDA, an institutional review board, third party investigators, any comparable regulatory agency in another country, or we, may suspend clinical trials at any time if the trials expose subjects participating in such

 

34


trials to unacceptable health risks. Further, human clinical testing may not show any current or future drug product to be safe and effective to the satisfaction of the FDA or comparable regulatory agencies, or the data derived from the clinical tests may be unsuitable for submission to the FDA or other regulatory agencies. Once we submit an application seeking approval to market a drug product, the FDA or other regulatory agencies may not issue their approvals on a timely basis, if at all. If we are delayed or fail to obtain these approvals, our business and prospects may be significantly damaged. In addition, any regulatory approvals that we receive for our future product candidates may also be subject to limitations on the indicated uses for which they may be marketed or contain requirements for potentially costly post-marketing follow-up studies and surveillance to monitor the safety and efficacy of the product.

If we obtain regulatory approval for our drug products, we, our partners, our manufacturers, and other contract entities will continue to be subject to extensive requirements by a number of national, foreign, state and local agencies. These regulations will impact many aspects of our operations, including testing, research and development, manufacturing, safety, effectiveness, labeling, storage, quality control, adverse event reporting, record keeping, approval, advertising and promotion of our future products. FDA and foreign regulatory authorities strictly regulate the promotional claims that may be made about prescription products and our product labeling, advertising and promotion is subject to continuing regulatory review. Physicians may nevertheless prescribe our product to their patients in a manner that is inconsistent with the approved label, or that is off-label. The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and if we are found to have improperly promoted off-label uses we may be subject to significant sanctions, civil and criminal fines and injunctions prohibiting us from engaging in specified promotional conduct. Moreover, our failure to comply with any applicable regulatory requirements could, among other things, result in:

 

   

warning letters;

 

   

fines;

 

   

changes in advertising;

 

   

revocation or suspension of regulatory approvals of products;

 

   

product recalls or seizures;

 

   

delays, interruption, or suspension of product distribution, marketing and sales;

 

   

civil or criminal sanctions;

 

   

suspension or termination of ongoing clinical trials;

 

   

imposition of restrictions on our operations;

 

   

close the facilities of our contract manufacturers; and

 

   

refusals to approve new products.

The discovery of previously unknown safety risks with drug products approved to go to market may raise costs or prevent us from marketing such products or change the labeling of our products or take other potentially limiting or costly actions if we or others identify safety risks after our products are on the market.

The later discovery of previously unknown safety risks with our products may result in the imposition of restrictions on distribution or use of the drug product, including withdrawal from the market. The FDA may revisit and change its prior determinations with regard to the safety and efficacy of our products. If the FDA’s position changes, we may be required to change our labeling or to cease manufacture and marketing of the products at issue. Even prior to any formal regulatory action, we could voluntarily decide to cease the distribution and sale or recall any of our products if concerns about their safety or effectiveness develop.

The FDA has significant authority to take regulatory actions in the event previously unknown safety risks are identified or if data suggest that our products may present a risk to safety. For example, the FDA may:

 

   

require sponsors of marketed products to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk;

 

   

mandate labeling changes to products, at any point in a product’s lifecycle, based on new safety information; and

 

   

require sponsors to implement a Risk Evaluation and Mitigation Strategy, or REMS, for a product which could include a medication guide, patient package insert, a communication plan to healthcare providers, or other elements as the FDA deems are necessary to assure safe use of the drug (either prior to approval or post-approval as necessary).

 

35


Failure to comply with a REMS could result in significant civil monetary penalties or other administrative actions by FDA. Further, regulatory agencies could change existing, or promulgate new, regulations at any time which may affect our ability to obtain or maintain approval of our existing or future products or require significant additional costs to obtain or maintain such approvals.

Legislative or regulatory reform of the healthcare system and pharmaceutical industry related to pricing, coverage or reimbursement may hurt our ability to sell our products profitably or at all.

Our ability to commercialize any products successfully will depend in part on the availability of coverage and reimbursement from third-party payors such as government authorities, private health insurers, health maintenance organizations including pharmacy benefit managers and other health care-related organizations, both in the U.S. and foreign markets. Even if we succeed in bringing one or more products to the market, the amount reimbursed for our products may be insufficient to allow us to compete effectively and could adversely affect our profitability. Coverage and reimbursement by governmental and other third-party payors may depend upon a number of factors, including a governmental or other third-party payor’s determination that use of a product is:

 

   

a covered benefit under its health plan;

 

   

safe, effective and medically necessary;

 

   

appropriate for the specific patient;

 

   

cost-effective; and

 

   

neither experimental nor investigational.

Obtaining coverage and reimbursement approval for a product from each third-party and governmental payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each payor. We may not be able to provide data sufficient to obtain coverage and adequate reimbursement.

In both the U.S. and certain foreign jurisdictions, there have been and may continue to be a number of legislative and regulatory proposals related to coverage and reimbursement that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively referred to as the Healthcare Reform Law, was signed into law on March 30, 2010. The Healthcare Reform Law substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacted the pharmaceutical industry. The Healthcare Reform Law included, among other things, an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, revisions to the definition of “average manufacturer price” for reporting purposes, increases in the amount of rebates owed by drug manufacturers under the Medicaid Drug Rebate Program, expansion of the 340B drug discount program that mandates discounts to certain hospitals, community centers and other qualifying providers, and changes to affect the Medicare Part D coverage gap, or “donut hole.” The full effects of these provisions will become apparent as these laws are implemented and the Centers for Medicare & Medicaid Services and other agencies issue applicable regulations or guidance as required by the Healthcare Reform Law. Moreover, in the coming years, additional changes could be made to governmental healthcare programs that could significantly impact the success of our products.

The high cost of pharmaceuticals continues to generate substantial government interest. It is possible that proposals will be adopted, or existing regulations that affect the coverage and reimbursement of pharmaceutical and other medical products may change, that may impact our products currently on the market and any of our products approved for marketing in the future. Cost control initiatives could decrease the price that we receive for any of our products or product candidates. In addition, third-party payors are increasingly challenging the price and cost-effectiveness of medical products and services. Significant uncertainty exists as to the coverage and reimbursement status of newly-approved pharmaceutical products. Future developments may require us to decrease the price that we charge for our products, thereby negatively affecting our financial results.

In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. Drug pricing may be made against a reference price set by the healthcare providers as a measure for healthcare cost containment. Pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. If coverage and reimbursement of our products are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels for the purpose of adoption of these products in the national health services in these jurisdictions, our profitability will likely be negatively affected.

 

36


If we market products in a manner that violates health care fraud and abuse laws, we may be subject to civil or criminal penalties, including exclusion from participation in government health care programs.

As a pharmaceutical company, even though we do not provide healthcare services or receive payments directly from or bill directly to Medicare, Medicaid or other third-party payors for our products, certain federal and state healthcare laws and regulations pertaining to fraud and abuse are and will be applicable to our business. We are subject to healthcare fraud and abuse by both the federal government and the states in which we conduct our business.

The laws that may affect our ability to operate include the federal health care program Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid or other federally financed health care programs. This statute applies to arrangements between pharmaceutical manufacturers and prescribers, purchasers and formulary managers. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.

Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicaid for non-covered off-label uses; and submitting inflated best price information to the Medicaid Drug Rebate Program.

The Health Insurance Portability and Accountability Act of 1996 also created prohibitions against health care fraud and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.

In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians. The Healthcare Reform Law imposed new requirements on manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined above) and their immediate family members and payments or other “transfers of value” to such physician owners and their immediate family members. Manufacturers were required to begin data collection on August 1, 2013 and will be required to report such data to the government by March 31, 2014 and by the 90th calendar day of each year thereafter.

The majority of states also have statutes or regulations similar to these federal laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In addition, some states have laws that require pharmaceutical companies to adopt comprehensive compliance programs. For example, under California law, pharmaceutical companies must comply with both the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and the PhRMA Code on Interactions with Healthcare Professionals, as amended. Certain states also mandate the tracking and reporting of gifts, compensation, and other remuneration paid by us to physicians and other health care providers. We have adopted and implemented a compliance program designed to comply with applicable federal, state and local requirements wherever we operate, including but not limited to the laws of the states of California and Nevada.

Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state laws may prove costly.

 

37


Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The Healthcare Reform Law also make several important changes to the federal Anti-Kickback Statute, false claims laws, and health care fraud statute by weakening the intent requirement under the anti-kickback and health care fraud statutes that may make it easier for the government, or whistleblowers to charge such fraud and abuse violations. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes. In addition, the Healthcare Reform Law increases penalties for fraud and abuse violations. If our past, present or future operations are found to be in violation of any of the laws described above or other similar governmental regulations to which we are subject, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and negatively impact our financial results.

We may be subject to product liability claims, and may not have sufficient product liability insurance to cover any such claims, which may expose us to substantial liabilities.

We may be held liable if any product we or our partners develop causes injury or is found otherwise unsuitable during product testing, manufacturing, clinical trials, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our product candidates, injury to our reputation, withdrawal of patients from our clinical trials, substantial monetary awards to trial participants and the inability to commercialize any products that we may develop. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. Although we currently carry product liability insurance in the amount of at least $15.0 million in the aggregate, it is possible that this coverage will be insufficient to protect us from future claims. Additionally, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. Failure to maintain sufficient insurance coverage could have a material adverse effect on our business, prospects and results of operations if claims are made that exceed our coverage.

On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and financial condition.

The use of hazardous materials, including radioactive and biological materials, in our research and development and commercial efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials.

Our research and development, manufacturing (including a radiolabeling step for ZEVALIN) and administration of our drugs involves the controlled use of hazardous materials, including chemicals, radioactive and biological materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the risk of contamination or injury from these materials and we could be held liable for any damages that result, which could exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research, development, production and commercialization efforts.

Risks Related to Our Common Stock

There are a substantial number of shares of our common stock eligible for future sale in the public market. The sale of these shares could cause the market price of our common stock to fall. Any future equity issuances by us may have dilutive and other effects on our existing stockholders.

As of December 31, 2013, there were 64,104,173 shares of our common stock outstanding. Security holders held outstanding options, warrants, preferred stock and convertible notes which, if vested, exercised or converted, would obligate us to issue up to approximately 11.9 million additional shares of common stock. A substantial number of those shares, when

 

38


we issue them upon vesting, conversion or exercise, will be available for immediate resale in the public market. In addition, we have reserved an aggregate of 16.2 million shares of our common stock for future issuance under our equity compensation plans. We may also sell additional shares of common stock or securities convertible or exercisable into common stock in public or private offerings, which would be available for resale in the market. Certain issuances by us of equity securities may be at or below the prevailing market price of our common stock and may have a dilutive impact on our existing stockholders. These issuances or other dilutive issuances would also cause our net income, if any, per share to decrease in future periods. The market price of our common stock could fall as a result of sales of any of these shares of common stock due to the increased number of shares available for sale in the market.

The convertible note hedge and warrant transactions that we entered into in December 2013 may affect the value of our common stock.

In connection with the pricing of our convertible notes in December 2013, we entered into convertible note hedge transactions and separate warrant transactions with RBC Capital Markets, LLC, or RBC. The convertible note hedge transactions are expected generally to reduce the potential dilution upon any conversion of the notes and/or offset any cash payments we are required to make in excess of the principal amount of converted notes, as the case may be. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of our common stock exceeds the strike price of the warrants. RBC and/or its affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock in secondary market transactions prior to the maturity of the convertible notes (and is likely to do so during any observation period related to a conversion of notes). This activity could cause or avoid an increase or a decrease in the market price of our common stock.

In addition, if the convertible note hedge and warrant transactions fail to become effective, through the failure of counterparties to perform or otherwise, RBC and/or its affiliates may unwind its hedge positions with respect to our common stock, which could adversely affect the value of our common stock. The potential effect, if any, of these transactions and activities on the market price of our common stock will depend in part on market conditions and cannot be ascertained at this time. Any of these activities could adversely affect the value of our common stock.

The market price and trading volume of our common stock fluctuate significantly and could result in substantial losses for individual investors.

The stock market from time to time experiences significant price and trading volume fluctuations that are unrelated to the operating performance of particular companies. These broad market fluctuations may cause the market price and trading volume of our common stock to decrease. In addition, the market price and trading volume of our common stock is often highly volatile.

Factors that may cause the market price and volume of our common stock to decrease include:

 

   

recognition on up-front licensing or other fees or revenues;

 

   

payments of non-refundable up-front or license fees, or payment for cost-sharing expenses, to third parties;

 

   

adverse results or delays in our clinical trials;

 

   

fluctuations in our results of operations;

 

   

timing and announcements of our technological innovations or new products or those of our competitors;

 

   

developments concerning any strategic alliances or acquisitions we may enter into;

 

   

announcements of FDA non-approval of our drug products, or delays in the FDA or other foreign regulatory review process or actions;

 

   

changes in recommendations or guidelines of government agencies or other third parties regarding the use of our drug products;

 

   

adverse actions taken by regulatory agencies with respect to our drug products, clinical trials, manufacturing processes or sales and marketing activities;

 

   

concerns about our products being reimbursed;

 

   

any lawsuit involving us or our drug products;

 

   

developments with respect to our patents and proprietary rights;

 

   

public concern as to the safety of products developed by us or others;

 

39


   

regulatory developments in the U.S. and in foreign countries;

 

   

changes in stock market analyst recommendations regarding our common stock or lack of analyst coverage;

 

   

the pharmaceutical industry generally and general market conditions;

 

   

failure of our results of operations to meet the expectations of stock market analysts and investors;

 

   

sales of our common stock by our executive officers, directors and five percent stockholders or sales of substantial amounts of our common stock;

 

   

hedging or arbitrage transactions by holders of our convertible notes;

 

   

changes in accounting principles; and

 

   

loss of any of our key scientific or management personnel.

Also, certain dilutive securities such as warrants can be used as hedging tools which may increase volatility in our stock and cause a price decline. While a decrease in market price could result in direct economic loss for an individual investor, low trading volume could limit an individual investor’s ability to sell our common stock, which could result in substantial economic loss as well. Since January 2, 2013 through February 28, 2014, the closing price of our common stock ranged between $7.00 and $13.01, and the daily trading volume was as high as 22,555,500 shares and as low as 143,200 shares.

Following periods of volatility in the market price of a company’s securities, securities class action litigation may be instituted against that company. Regardless of their merit, these types of lawsuits generally result in substantial legal fees and management’s attention and resources being diverted from the operations of a business.

Provisions of our charter, bylaws and stockholder rights plan may make it more difficult for someone to acquire control of us or replace current management even if doing so would benefit our stockholders, which may lower the price an acquirer or investor would pay for our stock.

Provisions of our certificate of incorporation and bylaws, both as amended, may make it more difficult for someone to acquire control of us or replace our current management. These provisions include:

 

   

the ability of our board of directors to amend our bylaws without stockholder approval;

 

   

the inability of stockholders to call special meetings;

 

   

the ability of members of the board of directors to fill vacancies on the board of directors;

 

   

the inability of stockholders to act by written consent, unless such consent is unanimous; and

 

   

the establishment of advance notice requirements for nomination for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.

These provisions may make it more difficult for stockholders to take certain corporate actions and could delay, discourage or prevent someone from acquiring our business or replacing our current management, even if doing so would benefit our stockholders. These provisions could limit the price that certain investors might be willing to pay for shares of our common stock.

We have a stockholder rights plan pursuant to which we distributed rights to purchase units of our series B junior participating preferred stock. The rights become exercisable upon the earlier of ten days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or ten business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our business, even if doing so would benefit our stockholders. We currently have no stockholders who own 15% or more of the outstanding shares of our common stock.

We have identified a material weakness in our internal control over financial reporting as of December 31, 2013, which also existed as of December 31, 2012, and has not yet been adequately remediated. The continuation of this material weakness, or any others, could impact our ability to produce accurate and timely financial statements. As a result, our stock price could be adversely impacted and investors’ views of us could be harmed.

We have determined that we have a material weakness in our internal control over financial reporting which also existed as of December 31, 2012. See Item 9A, Controls and Procedures for a complete discussion of this material weakness in our internal control over financial reporting. Although we are undertaking steps to address this material weakness, the

 

40


existence of a material weakness is an indication that there is more than a remote likelihood that a material misstatement of our financial statements will not be prevented or detected in the current or any future period. There can be no assurance that we will be able to fully implement our plans and controls, as described in Item 9A, to address this material weakness, or that the plans and controls, if implemented, will be successful in fully remediating this material weakness. In addition, we may in the future identify further material weaknesses in our internal control over financial reporting that we have not discovered to date. If we fail to successfully remediate the identified material weakness, or we identify further material weaknesses in our internal controls, the market’s confidence in our financial statements could decline and the market price of our common stock could be adversely impacted.

Our publicly-filed SEC reports are reviewed by the SEC from time to time and any significant changes required as a result of any such review may result in material liability to us and have a material adverse impact on the trading price of our common stock.

The reports of publicly-traded companies are subject to review by the SEC from time to time for the purpose of assisting companies in complying with applicable disclosure requirements and to enhance the overall effectiveness of companies’ public filings, and reviews of such reports are now required at least every three years under the Sarbanes-Oxley Act of 2002. SEC reviews may be initiated at any time, and we could be required to modify or reformulate information contained in prior filings as a result of an SEC review. Any modification or reformulation of information contained in such reports could be significant and could result in material liability to us and have a material adverse impact on the trading price of our common stock.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

 

ITEM 2. PROPERTIES

We lease our principal executive office in Henderson, Nevada under a lease agreement expiring April 30, 2014. We are in process of negotiating an extension to this lease, while also evaluating alternative locations in Henderson for our corporate headquarters.

In addition, we lease our research and development and administrative facility in Irvine, California, and lease administrative space in Colorado, New Jersey, California, Japan, the Netherlands, and India.

We believe that these leased facilities, and our planned facility alternatives/additions, are adequate to meet our current and future business needs.

 

ITEM 3. LEGAL PROCEEDINGS

We are involved with various legal matters arising in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows or financial condition.

FUSILEV ANDA Litigation

On January 20, 2012 and February 17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate Abbreviated New Drug Applications (“ANDAs”), to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our fees and costs incurred in such matters. On December 9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain.

Allos Transaction Class Action Lawsuits

On April 9, 2012, a putative class action lawsuit captioned Radmore, et al. v. Allos Therapeutics, Inc., et al., No. 1:12-cv-00948-PAB, was filed in the United States District Court for the District of Colorado, (“the Radmore Complaint”). The Radmore Complaint named as defendants Allos Therapeutics, the members of the Allos board of directors, as well as Spectrum. The plaintiffs alleged that Allos directors breached their fiduciary duties to their stockholders in connection with

 

41


the proposed merger between Allos and Spectrum, and were aided and abetted by Allos and Spectrum. The Radmore Complaint alleged that the merger involves an unfair price, an inadequate sales process, unreasonable deal protection devices, and that the defendants entered into the transaction to benefit themselves personally. The Radmore Complaint sought injunctive relief, including to enjoin the merger, attorneys’ and other fees and costs, and other relief. On April 12, 2012, a putative class action lawsuit captioned Keucher v. Berns, et al., C.A. No. 7419, was filed in the Delaware Court of Chancery, alleging similar violations. On April 20, 2012, an Amended Class Action Complaint was filed in the Delaware Court of Chancery in the matter captioned Keucher v. Berns, et al., C.A. No. 7419-VCN, adding allegations that the Solicitation/Recommendation Statement on Schedule 14D-9, or the Schedule 14D-9, filed by us with the SEC on April 13, 2012, contains inadequate, incomplete and/or misleading disclosures.

On May 7, 2012, the parties to all three actions executed a memorandum of understanding, or MOU, containing the terms for an agreement-in-principle to resolve all litigation. The MOU provided that the defendants would agree to make certain supplemental disclosures in an amended Schedule 14D-9 and that the parties would use their best efforts to agree upon, enter, and present to the Delaware Chancery court a formal stipulation of settlement. The MOU provides for an award to plaintiffs’ counsel of $850,000 for their fees and expenses but did not include any payment to stockholders. The parties completed confirmatory discovery on July 18, 2012 and filed a stipulation and agreement of compromise and settlement in the Delaware court on November 8, 2012. On February 11, 2013, the Delaware court approved the settlement, including the payment of $850,000 to counsel for the stockholders, entered final judgment and dismissed the cases.

Shareholder Litigation

John Perry v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH); Junqian Carroll v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00498-RBJ-CF); Gary Santi v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00502-LDG-CWH); William Skene v. Spectrum Pharmaceuticals, Inc. et al. (Filed April 10, 2013 in United States District Court, District of Nevada; Case Number 3:2013-cv-00175-RBJ-VPC); and Rubin v. Spectrum Pharmaceuticals, Inc. et al. (Filed April 24, 2013 in the United States District Court, District of Nevada; Case Number 3:2013-cv-00212-RCJ-VPC). These putative class actions raise substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr. Rajesh C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August 8, 2012 to March 12, 2013. The lawsuits allege a violation of Section 10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section 20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company’s March 12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate. The court entered a consolidation order on April 29, 2013, designating the Perry action as the consolidated action.

Timothy Fik v. Rajesh C. Shrotriya, et al. (Filed April 11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May 28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against defendants Krishan K. Arora, Gilles Gagnon, Anton Gueth, Joseph Kenneth Keller, Stuart M Krassner, Luigi Lenaz, Anthony E. Maida, Brett L. Scott, and Dr. Rajesh C. Shrotriya. The Fik and Watkins complaints allege six counts against all defendants: breach of fiduciary duty for disseminating false and misleading information; breach of fiduciary duty for failing to properly oversee and manage the company; unjust enrichment; abuse of control; gross mismanagement; and waste of corporate assets. The Fik and Watkins complaints also allege a seventh count for breach of fiduciary duties for insider selling and misappropriation of information against defendants Dr. Raj Shrotriya, Brett Scott, and Anthony Maida. The Muenchhagen complaint alleges five counts against all defendants: breach of fiduciary duty for disseminating false and misleading information; breach of fiduciary duty for failing to properly oversee and manage the company; abuse of control; gross mismanagement; and waste of corporate assets. The Muenchhagen complaint also alleges two counts against defendants Dr. Raj Shrotriya, Brett Scott, and Anthony Maida for unjust enrichment and for breach of fiduciary duties for insider selling and misappropriation of information. These substantially identical complaints allege that defendants knew or should have known that the Company’s statements about future FUSILEV sales were misleadingly optimistic and that these statements inflated the trading price of Company stock. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, and costs and fees. On May 15, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.

 

42


Hardik Kakadia v. Rajesh C. Shrotriya, et al. (Filed April 23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May 31, 2013; Case Number A-13-682668-C) (collectively the “State Derivative Actions”). The State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. against defendants Krishan K. Arora, Gilles Gagnon, Anton Gueth, Joseph Kenneth Keller, Stuart M Krassner, Luigi Lenaz, Anthony E. Maida, Brett L. Scott and Dr. Rajesh C. Shrotriya. The Kakadia complaint alleges three counts against all defendants: breach of fiduciary duty; waste of corporate assets; and unjust enrichment. The Besner complaint alleges five counts against all defendants: breach of fiduciary duty for disseminating false and misleading information; breach of fiduciary duty for failing to properly oversee and manage the company; abuse of control; gross mismanagement; and waste of corporate assets. The Besner complaint also alleges two counts against defendants Dr. Raj Shrotriya, Brett Scott, and Anthony Maida for unjust enrichment and for breach of fiduciary duties for insider selling and misappropriation. The complaints similarly allege that defendants knew or should have known that the Company’s statements about future FUSILEV sales were misleadingly optimistic and that these statements inflated the trading price of Company stock. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, equitable and/or injunctive relief, and costs and fees. On July 10, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.

Mark J. Sherwin v. Spectrum Pharmaceuticals, Inc. (Filed September 3, 2013 in the Court of Chancery of the State of Delaware; Case Number 8858). The complaint seeks inspection of Spectrum’s books and records under Delaware Code section 220. Specifically, the complaint seeks inspection of books and records concerning whether Spectrum’s officers and directors breached their fiduciary duties by causing the Company to make false statements concerning the performance of FUSILEV. The complaint also seeks fees and costs. On December 27, 2013, plaintiff filed a notice of dismissal of the books and records action. On January 7, 2014, the court granted plaintiff’s dismissal of the action.

SEC Subpoena

On April 1, 2013, the Company received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed the Company’s March 12, 2013 announcement that it anticipated a change in ordering patterns of FUSILEV. The Company is cooperating with the SEC investigation. The Company cannot predict when the SEC will conclude its investigation or the outcome of the investigation.

 

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is traded on the NASDAQ Global Market under the symbol “SPPI.” The high and low closing sale prices of our common stock reported by NASDAQ during each quarter ended in 2013 and 2012 were as follows:

 

     High      Low  

Year Ended December 31, 2013:

     

First Quarter

   $ 13.01       $ 7.01   

Second Quarter

   $ 8.55       $ 7.00   

Third Quarter

   $ 8.89       $ 7.29   

Fourth Quarter

   $ 9.82       $ 8.11   

Year Ended December 31, 2012:

     

First Quarter

   $ 15.87       $ 12.63   

Second Quarter

   $ 15.56       $ 9.51   

Third Quarter

   $ 17.05       $ 11.51   

Fourth Quarter

   $ 12.31       $ 10.64   

 

43


On February 28, 2014, the closing price of our common stock on the NASDAQ Global Select Market was $8.35 per share, and there were 325 holders of record of our common stock.

Stock Performance Graph (1)

The graph below compares the cumulative total stockholder return on $100 invested, assuming the reinvestment of all dividends, on December 31, 2008, the last trading day before our 2009 fiscal year, through the end of fiscal 2013 with the cumulative total return on $100 invested for the same period in the Russell 2000 index and a Peer Group.

 

LOGO

The Peer Group consists of the following publicly-traded companies:

 

   

Alkermes PLC

 

   

Amarin Corporation PLC

 

   

BioMarin Pharmaceutical, Inc.

 

   

Celgene Corporation

 

   

Dendreon Corporation

 

   

Jazz Pharmaceuticals PLC

 

   

Regeneron Pharmaceuticals, Inc.

 

   

Vertex Pharmaceuticals, Inc.

 

     12/31/08      12/31/09      12/31/10      12/31/11      12/31/12      12/31/13  

Spectrum Pharmaceuticals, Inc.

     100.00         297.99         461.07         981.88         760.69         601.83   

Russell 2000

     100.00         127.17         161.32         154.59         179.86         249.69   

Peer Group

     100.00         113.83         123.34         132.04         181.13         341.09   

 

(1) The information in this section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

 

44


Dividend Policy

We currently intend to retain all earnings, if any, for use in the expansion of our business and therefore do not anticipate paying any dividends in the foreseeable future. However, the payment of dividends, if any will be at the discretion of the Board of Directors and subject to compliance with any applicable restrictions contained in our agreements.

 

ITEM 6. SELECTED FINANCIAL DATA

The following selected consolidated financial data has been derived from our audited Consolidated Financial Statements. The audited Consolidated Financial Statements for the fiscal years ended December 31, 2013, 2012, and 2011 are included elsewhere in this Annual Report on Form 10-K. The information set forth below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and the Consolidated Financial Statements and Notes thereto in Item 8. The information set forth below is not necessarily indicative of our future financial condition or results of operations.

 

     Year ended December 31,  
Selected Statement of Operations Data:    2013     2012     2011     2010     2009  
     (In thousands, except per share data)  

Total revenues

   $ 155,854      $ 267,707      $ 192,963      $ 74,113      $ 38,025   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating costs and expenses:

          

Cost of product sales (excludes amortization of intangible assets)

     28,580        46,633        33,838        17,439        8,148   

Selling, general and administrative

     99,315        89,922        72,197        47,411        33,607   

Research and development

     46,670        41,560        26,662        56,660        20,379   

Amortization and impairment of intangible assets

     20,074        8,818        3,720        3,720        3,720   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from operations

     (38,785     80,774        56,546        (51,117     (27,829

Change in fair value of common stock warrant liability

     —         —         (3,488     2,731        8,075   

Change in fair value of contingent consideration related to acquisition

     2,871       —         —         —         —    

Other (expense) income, net

     (722     (844     577        1,279        662   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before provision for income taxes

     (36,636     79,930        53,635        (47,107     (19,092

(Provision) benefit for income taxes

     (25,498     14,271        (3,704     43        (421

Net income attributable to non-controlling interest

     —         —         —         —         1,146   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income attributable to Spectrum Pharmaceuticals, Inc. stockholders

   $ (62,134   $ 94,201      $ 49,931      $ (47,064   $ (18,367
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income per share—basic

   $ (1.02   $ 1.61      $ 0.94      $ (0.95   $ (0.47
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income per share—diluted

   $ (1.02   $ 1.46      $ 0.86      $ (0.95   $ (0.47
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Cash dividend declared per common share

   $ —       $ 0.15      $ —       $ —       $ —    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

45


     As of December 31,  
Selected Balance Sheet Data:    2013      2012      2011      2010      2009  
     (In thousands)  

Working capital (current assets minus total current liabilities)

   $ 145,206       $ 141,630       $ 151,443       $ 61,308       $ 87,743   

Total assets

   $ 499,155       $ 504,955       $ 280,780       $ 163,631       $ 173,133   

Long term obligations, less current portion

   $ 127,565       $ 93,031       $ 14,336       $ 25,833       $ 25,310   

Total stockholders’ equity (including non-controlling interest in 2009)

   $ 281,606       $ 288,681       $ 192,086       $ 77,241       $ 109,309   

 

46


ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with “Selected Financial Data” and our consolidated financial statements and the related notes included in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors including the risks we discuss in Item 1A of Part I, “Risk Factors” and elsewhere in this Annual Report on Form 10-K.

OVERVIEW

Our Business

We are a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products. We currently market four drugs:

 

   

FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

 

   

ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

 

   

FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

 

   

MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.

We also have a diversified pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.

Our business strategy is comprised of the following three initiatives:

 

   

Maximizing the revenue potential of our four currently-marketed drugs for the treatment of cancer.

Our near-term outlook largely depends on sales and marketing successes for our four marketed drugs. It is this base business, along with potential additional indications for these drugs, that provides the working capital needed to operate our daily business and provides the necessary capital for opportunistic acquisitions.

 

   

Developing and Commercializing the drugs for the treatment of cancer within our pipeline.

Our strategy for our development portfolio is to focus on late-stage development drugs. We strive to complete clinical studies to demonstrate the safety and efficacy of these drugs in order to obtain regulatory approval in a timely manner. Upon obtaining approval, our sales and marketing function educates physicians on the safety of the drug and its effectiveness in treating patients for the approved indication, with the goal of achieving maximum commercial success.

 

   

Expanding our pipeline of development-stage and commercial-stage drugs through business development activities.

It is our goal to identify new strategic opportunities that will create strong synergies with our currently-marketed drugs, and to identify and pursue partnerships for out-licensing certain of our drugs in development. We will continue to (i) explore strategic collaborations as they relate to drugs that are either in clinical trials or are currently on the market, and (ii) identify and secure drugs that have significant growth potential – through enhanced marketing and sales efforts and/or through pursuit of additional clinical development.

 

47


See Item 1, “Business,” for a discussion of:

 

   

Company Overview

 

   

Cancer Background & Market Size

 

   

Product Portfolio

 

   

Manufacturing

 

   

Sales and Marketing

 

   

Customers

 

   

Competition

 

   

Research and Development

2013 Overview

During 2013 we accomplished various critical objectives for our business, which included:

 

   

Acquisitions: We completed two strategic acquisitions, including a FDA-approved, patented, proprietary, oncology drug, MARQIBO through the acquisition of a NASDAQ-listed company, Talon Therapeutics, Inc. and we licensed-in a late-stage oncology drug, Captisol-enabled MELPHALAN, from Ligand Pharmaceuticals, Inc.

 

   

Commercial: We executed the launch of MARQIBO in less than seven weeks after acquisition, and we continued to focus on the growth of our marketed drugs.

 

   

Medical: We filed the NDA for BELEODAQ, for which the FDA has granted a Priority Review and has established an action date of August 9, 2014. We also completed the enrollment in the pivotal study for Captisol-enabled MELPHALAN and initiated a Phase 2 study for SPI-2012.

 

   

Corporate: We strengthened our management team with the additions of our new Chief Financial Officer and new Chief Medical Officer. We also continued to invest in our infrastructure for long-term growth and success.

 

   

Financial: We maintained fiscal discipline during the year, and ended 2013 with nearly $160 million in aggregate cash and equivalents and marketable securities.

CHARACTERISTICS OF OUR REVENUE AND EXPENSES

The below summarizes the nature of our revenue and operating expense line items within our Consolidated Statements of Operations:

Revenue

The majority of our revenue is derived from sales of our drug products to large pharmaceutical wholesalers and distributors upon title transfer (which is typically at time of shipment), provided our other revenue recognition criteria have been met. To a lesser extent we also derive revenue from license fees (i.e., royalties) and service revenue for our research and development activities conducted for the benefit of third parties.

Cost of Goods Sold

Cost of goods sold includes production materials and supplies expense, third party manufacturing and packaging service expenses, and royalty expenses.

 

48


Selling, General and Administrative

Selling, general and administrative expenses primarily consist of compensation (including stock-based compensation) and benefits for our sales force and personnel that support our sales and marketing operations, and our general operations such as information technology, executive management, financial accounting, and human resources. It also includes costs attributable to marketing our products to our customers and prospective customers, patent and legal fees, financial audit fees, insurance, bad debt expense, recruiting fees, and other professional services.

Research and Development

Research and development expenses consist of compensation (including stock-based compensation) and benefits for research and development and clinical and regulatory personnel, materials and supplies, research and development consultants, and regulatory and clinical payments related to studies. Our research and development activities primarily relate to the development and testing of new drugs, and conducting studies in order to gain regulatory approval for the commercialization of our drug products.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation and presentation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to establish policies and make estimates and assumptions that affect (i) the amounts of assets and liabilities as of the date presented on the accompanying Consolidated Balance Sheets and (ii) the amounts of revenue and expenses for each year presented in the accompanying Consolidated Statements of Operations.

Our management believes its estimates and assumptions are supportable, reasonable, and consistently applied. Nonetheless, estimates are by nature inherently uncertain. As a result, our financial position and operating results could materially differ from the amounts reported within the accompanying Consolidated Financial Statements if management’s estimates require prospective adjustment. Our critical accounting policies and estimates arise in conjunction with the following accounts:

 

   

Revenue recognition

 

   

Inventories – lower of cost or market

 

   

Fair value of acquired assets and assumed liabilities

 

   

Goodwill and intangible assets – impairment evaluations

 

   

Income taxes

 

   

Stock-based compensation

 

   

Litigation accruals

Revenue Recognition

Product Sales: We recognize revenue from product sales when all of the following criteria are met:

 

  (i) Appropriate evidence of a binding arrangement exists with our customer;

 

  (ii) Price is substantially fixed and determinable;

 

  (iii) Collection from our customer is reasonably assured;

 

  (iv) Our customer’s obligation to pay us is not contingent on resale of the product;

 

  (v) We do not have significant obligations for future performance to directly bring about the resale of our product; and

 

  (vi) We have a reasonable basis to estimate future returns.

Our product sales are reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.

 

49


Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:

 

  (i) Product Returns Allowances

 

  (ii) Government Chargebacks

 

  (iii) Discounts

 

  (iv) Rebates

 

  (v) Medicaid Rebates

 

  (vi) Distribution and Data Fees

Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.

Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.

Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.

Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.

Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.

License Fees: We recognize license fees (i.e., royalties) based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum fee in which revenue is recognized in that period.

Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.

 

50


Inventories – Lower of Cost or Market

We adjust our inventory value for estimated amounts of excess, obsolete, or unmarketable items. Such assumptions involve projections of future customer demand, as driven by economic and market conditions, and the product’s shelf life. If actual demand, or economic or market conditions are less favorable than those projected by us, incremental inventory write-downs may be required.

Fair Value of Acquired Assets and Assumed Liabilities

The accounting for business combination and asset acquisitions requires extensive use of estimates and judgments to measure the fair value of the identifiable tangible and intangible assets acquired, including in-process research and development, and liabilities assumed. Additionally, we must determine whether the acquisition meets the criteria for business combination accounting (rather than an asset acquisition), because the excess of the purchase price over the fair value of net assets acquired can only be recognized as “goodwill” in a business combination.

The fair value of acquired tangible and identifiable intangible assets and liabilities assumed, are based on their estimated fair values at the acquisition date and requires extensive use of accounting estimates, judgments, and assumptions, including but not limited to: likelihood, timing, and costs to complete the in-process projects, probability of achieving regulatory approvals, cash flows to be derived from the acquired assets, and the application of appropriate discount rates. For each acquisition, we engage an independent third-party valuation specialist to assist management in determining the fair value of in-process research and development, identifiable intangible assets, and any contingent consideration.

In connection with certain of our acquisitions, we must record a contingent consideration liability for cash or stock payments upon the completion of certain future performance milestones. In these cases, a liability is recorded on the acquisition date for an estimate of the acquisition date fair value of the contingent consideration by applying the income approach utilizing variable inputs such as probability of achievement and risk-free adjusted discount rates. Any change in the fair value of the contingent consideration subsequent to the acquisition date is recognized in earnings.

Goodwill and Intangible Assets – Impairment Evaluations

Goodwill and other intangible assets with indefinite lives are not subject to amortization, but are evaluated for impairment annually as of October 1, or whenever events or changes in circumstance indicate that the asset might be impaired. We evaluate the possible impairment (i) if/when events or changes in circumstances occur that indicate that the carrying value of assets may not be recoverable; or (ii) in the case of goodwill and indefinite lived intangible assets, our annual impairment assessment date of October 1. These evaluations require significant judgment by our management in forecasting net cash flows to be derived by these intangible assets in our on-going operations. The discounted value of such cash flows (or our market capitalization in the case of goodwill) are compared to each asset’s carrying value to assess whether there is an indication of impairment and related charges to record.

Income Taxes

Our consolidated balance sheets reflect net deferred tax assets (net of a valuation allowance) that primarily represent the tax benefit of net operating loss and tax credit carryforwards, and credits and timing differences between book and tax. When it is more likely than not that all or some portion of deferred tax assets may not be realized, we establish a valuation allowance for the amount that may not be realized. Each quarter, we evaluate the need to retain all or a portion of the valuation allowance on our net deferred tax assets. Our evaluation considers historical earnings, estimated future taxable income and ongoing prudent and feasible tax planning strategies. Adjustments to the valuation allowance increase or decrease net income or loss in the period such adjustments are made. If our estimates require adjustments, it could have a significant impact on our consolidated financial statements.

Stock-Based Compensation

We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.

We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.

 

51


Litigation Accruals

From time-to-time we are involved in various claims and legal proceedings of a nature considered normal and incidental to our business. These matters may include product liability, intellectual property, employment, and other general claims. We accrue for contingent liabilities when it is probably that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.

RESULTS OF OPERATIONS

Operations Overview – 2013, 2012, and 2011

 

     Year Ended December 31,  
     2013     2012     2011  
     ($ in thousands)  

Total revenues

   $ 155,854        100.0   $ 267,707        100.0   $ 192,963        100.0
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating costs and expenses:

            

Cost of product sales (excludes amortization of intangible assets)

     28,580        18.3     46,633        17.4     33,838        17.5

Selling, general and administrative

     99,315        63.7     89,922        33.6     72,197        37.4

Research and development

     46,670        29.9     41,560        15.5     26,662        13.8

Amortization and impairment of intangible assets

     20,074        12.9     8,818        3.3     3,720        1.9
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

     194,639        124.9     186,933        69.8     136,417        70.7
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income from operations

     (38,785     (24.9 )%      80,774        30.2     56,546        29.3
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Change in fair value of common stock warrant liability

     —          —          —          —          (3,488     (1.8 %) 

Change in fair value of contingent consideration from acquisition

     2,871        1.8     —          —          —          —     

Other (expense) income, net

     (722     (0.5 )%      (844     (0.3 )%      577        0.3
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before income tax

     (36,636     (23.5 )%      79,930        29.9     53,655        27.8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Income tax (expense) benefit

     (25,498     (16.4 )%      14,271        5.3     (3,704     (1.9 )% 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (62,134     (39.9 )%    $ 94,201        35.2   $ 49,931        25.9
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

YEAR ENDED DECEMBER 31, 2013 VERSUS DECEMBER 31, 2012

Total Revenues

 

     Year Ended December 31,               
     2013      2012      $ Change     % Change  
     ($ in millions)               

Product sales, net:

          

FUSILEV

   $ 68.4       $ 204.3       $ (135.9     (66.5 )% 

FOLOTYN

     44.4         20.4         24.0        >100.0

ZEVALIN

     29.4         30.3         (0.9     (3.0 )% 

MARQIBO

     1.3         —          1.3        >100.0
  

 

 

    

 

 

    

 

 

   

 

 

 
   $ 143.5       $ 255.0       $ (111.5     (43.7 )% 

License fees and service revenue

     12.4         12.7         (0.3     (2.4 )% 
  

 

 

    

 

 

    

 

 

   

 

 

 

Total revenues

   $ 155.9       $ 267.7       $ (111.8     (41.8 )% 
  

 

 

    

 

 

    

 

 

   

 

 

 

Product sales, net: Gross product revenues are reduced by estimated provisions for product returns, sales discounts and rebates, distribution and data fees, and estimates for chargebacks established at the time revenues are recognized to arrive at product sales, net. Management considers various factors in determination of such provisions, which are described more in detail within “Critical Accounting Policies and Estimates” above.

 

52


FUSILEV revenue decrease is primarily due to a change in buying patterns of wholesalers, a lower average net sales price, and a decrease in underlying demand by end-users, as the shortage in generic leucovorin abated in late 2012. In addition, government rebates as a percentage of gross sales increased by 17% as compared to the same period in 2012, driven primarily by a change in customer mix, and to a lesser extent, a refinement to our methodology to estimate rebate claims remaining in channel inventory. This revenue decrease was partially offset by a refinement in our estimate of future products returns. As compared to 2012, this refinement reduced our percentage of 2013 sales that we expect will be subject to reversal for future product returns.

FOLOTYN revenue increase is due to a full year of recognition of product sales in 2013, as compared to the prior year. We acquired this drug through our acquisition of Allos in September 2012.

ZEVALIN revenue decreased slightly in 2013. The slight decrease is attributable to less U.S. product demand and a minor decrease in our average net sales price per unit, which was not fully offset by an increase in European product demand. Beginning in the second quarter of 2013, we terminated our ZEVALIN services agreement with Bayer, and transitioned to a sales distribution model in Europe. This transition has had a favorable impact on 2013 unit sales in Europe.

MARQIBO revenue derived in 2013 is a result of our acquisition of Talon in July 2013.

License fees and service revenue: In 2013 and 2012, we recognized $12.4 million and $12.7 million, respectively, from the amortization of deferred revenue that corresponded with our contracted research and development services. This revenue is associated with a $41.5 million upfront payment we received from Allergan in 2008, and an aggregate of $16.0 million in upfront payments we received from Nippon Kayaku and Handok in 2010. As of December 31, 2013, these upfront payments have been recognized through “license fees and service revenue” in full.

Operating Expenses

 

     Year Ended December 31,              
     2013      2012     $ Change     % Change  
     ($ in millions)              

Operating expenses:

         

Cost of product sales (excludes amortization of intangibles)

   $ 28.6       $ 46.6      $ (18.0     (38.6 %) 

Selling, general and administrative

     99.3         89.9        9.4        10.5

Research and development

     46.6         41.6        5.0        12.0

Amortization and impairment of intangible assets

     20.1         8.8        11.3        > 100.0
  

 

 

    

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

   $ 194.6       $ 186.9      $ 7.7        4.1
  

 

 

    

 

 

   

 

 

   

 

 

 

Other (expense) income, net

   $ 2.1       $ (0.8   $ 2.9        > 100.0
  

 

 

    

 

 

   

 

 

   

 

 

 

Cost of Product Sales. The decrease in the cost of product sales is primarily driven by an overall 44% decrease in product sales. Gross margins in 2013 and 2012 remained largely consistent.

Selling, General and Administrative. Selling, general and administrative expenses increased due to:

 

   

$1.3 million increase in professional fees which include legal costs for patent and trademark matters, audit fees, and tax consulting services.

 

   

$3.0 million increase in legal and professional fees related to our Talon acquisition.

 

   

$3.1 million increase in marketing expenses and commercial costs related to our sales outside the U.S.

 

   

$2.7 million increase in employee severance costs related to the Talon acquisition.

 

   

$5.7 million increase in legal and professional fees related to ongoing shareholder and patent litigation.

 

   

$1.0 million increase in consulting, compensation and associated benefits, which is mainly attributable to the addition of senior management positions, and the inclusion of personnel in Japan and Netherlands, and also includes a $0.5 million increase in recruitment fees.

 

53


   

$0.8 million increase in other expenses consisting of computer software and services, as well as rent and utilities for new facilities in Japan, Colorado, and the Netherlands.

These increases were partially offset by 2012 expenses that did not recur in 2013, including:

 

   

$5.5 million in legal and professional fees related to our 2012 acquisitions of Allos and rights to market ZEVALIN outside of the U.S.

 

   

$1.9 million for Allos employee severance costs.

Research and Development. Research and development expenses increased due to:

 

   

$0.9 million increase in continuing medical education grants.

 

   

$1.3 million increase in consulting, compensation and associated benefits.

 

   

$7.1 million increase in expenses incurred following the amendment of our agreement with Allergan in the first quarter of 2013. This resulted in a decrease in the reimbursement of expenses compared to 2012.

These increases were partially offset by:

 

   

$2.4 million decrease in 2013 of our “drug development liability” as a result of our amendment to the Mundipharma agreement, which had the corresponding effect of reducing 2013 research and development expenses.

 

   

$0.6 million reduction in licensing, quality, and regulatory fees.

 

   

$0.6 million reduction in depreciation.

Amortization and Impairment of Intangible Assets. The amortization and impairment of intangible assets increased $11.3 million in 2013, of which $1.0 million is due to the impairment of our FOLOTYN distribution rights as a result of our Mundipharma contract amendment in May 2013. The remaining amount is due to the amortization of definite-lived intangible assets from our acquisitions of ZEVALIN Rights, Allos, and Talon.

Other Income (Expense), net. Other income (expense), net increased by $2.9 million and was primarily due to the $2.9 million decrease to our “acquisition-related contingent obligations” liability, which resulted in an equal credit to our “change in fair value of contingent consideration related to acquisition.” This change in value corresponds to our acquisition of Talon and rights to C-E MELPHALAN. This amount is partially offset by an increase in “interest expense” from our convertible senior notes issued in December 2013.

 

     Year Ended December 31,               
     2013     2012      $ Change     % Change  
     ($ in millions)               

Benefit (provision) for income taxes

   $ (25.5   $ 14.3       $ (39.8     >(100.0 %) 
  

 

 

   

 

 

    

 

 

   

 

 

 

Benefit (Provision) for Income Taxes. In 2013 we recognized an income tax provision of $25.5 million. This provision was due to the recording of a full valuation allowance against our deferred tax assets. As of December 31, 2013, we determined that there are uncertainties regarding the realization of our deferred tax assets (which were primarily generated by our cumulative net operating losses and from the tax attributes of acquired entities) due to multiple quarterly consecutive net losses.

In 2012, we recorded a $14.3 million tax benefit. The tax benefit in 2012 was the result of a change in judgment in the first quarter of 2012 regarding the realizability of our deferred tax assets due to positive earnings trends and operating income realized in 2011 and 2012. These positive factors resulted in a $44.5 million tax benefit from the release of our valuation allowance on deferred tax assets.

 

54


YEAR ENDED DECEMBER 31, 2012 VERSUS DECEMBER 31, 2011

Revenue

 

     Year Ended December 31,                
     2012      2011      $ Change      % Change  
     ($ in millions)                

Product sales, net

           

FUSILEV

   $ 204.3       $ 153.1       $ 51.2         33.4

FOLOTYN

     20.4         —          20.4         n/a   

ZEVALIN

     30.3         27.6         2.7         9.8
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 255.0       $ 180.7       $ 74.3         41.1

License fees and service revenue

     12.7         12.3         0.4         3.3
  

 

 

    

 

 

    

 

 

    

 

 

 

Total revenues

   $ 267.7       $ 193.0       $ 74.7         38.7
  

 

 

    

 

 

    

 

 

    

 

 

 

Product sales, net:

FUSILEV revenues increased due to FDA approval of FUSILEV for use in the treatment of advanced metastatic colorectal cancer received on April 29, 2011 and a supply disruption of generic leucovorin which abated in late 2012.

FOLOTYN revenues increased due to acquiring the drug through the acquisition of Allos on September 5, 2012.

ZEVALIN revenues increased between the 2012 and 2011 periods due to an increase in product demand.

License fees and service revenue: During 2012 and 2011, we recognized $12.7 million and 12.3 million, respectively, of service revenue from the amortization of a $41.5 million upfront payment we received from Allergan in 2008, and a $16.0 million upfront payment we received from Nippon Kayaku and Handok in the first quarter of 2010.

Operating Expenses

Our operating expenses are summarized in the following table:

 

     Year Ended December 31,              
     2012     2011     $ Change     % Change  
     ($ in millions)              

Operating expenses:

        

Cost of product sales (excludes amortization of purchased intangibles)

   $ 46.6      $ 33.8      $ 12.8        37.9

Selling, general and administrative

     89.9        72.2        17.7        24.5

Research and development

     41.6        26.7        14.9        55.8

Amortization of purchased intangible assets

     8.8        3.7        5.1        >100.0
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating costs and expenses

   $ 186.9      $ 136.4      $ 50.5        37.0

Change in the fair value of common stock warrant liability

     —         (3.5     (3.5     (100.0 %) 

Other (expense) income, net

   $ (0.8   $ 0.6      $ (1.4     > (100.0 %) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Cost of Product Sales. The increase in total cost of product sales relates to an increase in product revenues for all products and an increase in inventory reserves of approximately $3.0 million, primarily relating to the ZEVALIN inventory estimated to be in excess of anticipated usage.

Selling, General and Administrative. Selling, general and administrative expenses increased as a result of the inclusion of Allos and is primarily due to:

 

   

$7.0 million increase in compensation and associated benefits, of which $4.3 million is attributable to sales and marketing expenses as a result of the expansion of our sales force, and the inclusion of Allos personnel.

 

   

$4.8 million increase in advertising, branding, printing, marketing and promotion.

 

   

$5.6 million in legal and professional fees related to the Allos acquisition and $0.7 million in transaction costs related to the acquisition of ZEVALIN Rights.

 

55


   

$2.0 million increase for transitional services related to sales of ZEVALIN outside the U.S.

 

   

$1.7 million severance and related expenses in connection with the Allos acquisition.

 

   

$1.6 million increase in sales force travel and expenses.

These increases were partially offset by a $7.6 million decrease in stock compensation expense.

Research and Development. Research and development expenses increased is primarily due to:

 

   

$5.0 million increase for drug product and a payment related to the co-development and commercialization agreement with Hamni Pharmaceutical Company for SPI-2012.

 

   

$2.7 million increase in compensation and associated benefits.

 

   

$2.2 million increase in on-going clinical trials.

 

   

$1.2 million increase in continuing medical education grants and symposiums.

Amortization and Impairment of Intangible Assets. We incurred a non-cash charge of $8.8 million and $3.7 million in 2012 and 2011, respectively, due to the amortization of intangibles recognized in the acquisition of ZEVALIN Rights and the amortization of intangibles recognized as part of the acquisition of Allos.

Change in Fair Value of Common Stock Warrant Liability. We recorded a loss of $3.5 million for the change in the fair value of the outstanding warrants to non-employees during 2011, which were not outstanding in 2012.

Other Income (Expense), net. The principal components of other income (expense) consisted primarily of a $0.7 million increase in interest expense in connection with the revolving line of credit, an increase of $0.1 million for the sale of property and equipment due to the downsizing of the Allos facilities, and a decrease of $0.1 million of interest income due to the sale of marketable securities at the end of the second quarter of 2012.

 

     Year Ended December 31,               
     2012      2011     $ Change      % Change  
     ($ in millions)               

Benefit (provision) for income taxes

   $ 14.3       $ (3.7   $ 18.0         >(100.0 %) 
  

 

 

    

 

 

   

 

 

    

 

 

 

Benefit (Provision) for Income Taxes. As of December 31, 2011, we maintained a $44.6 million valuation allowance against our domestic deferred tax assets and a $1.0 valuation allowance against our foreign deferred tax assets. Based on the weight of both positive and negative evidence, we concluded that it was more likely than not that the domestic net deferred tax assets would be realized, and therefore, we released $23.5 million of our domestic valuation allowance as a discrete tax benefit through December 31, 2012 with the remaining $21.1 million domestic valuation allowance being released through our annual effective tax rate based upon projected current year earnings.

The annual effective rate for fiscal 2012 is below the statutory rate principally as a result of tax benefits realized from the release of our valuation allowance against domestic deferred tax assets. The year-to-date tax benefit of $14.3 million in 2012 is primarily the result of $44.6 million in tax benefits recognized through December 31, 2012 related to the release of our valuation allowance on domestic deferred tax assets.

LIQUIDITY AND CAPITAL RESOURCES

 

     December 31,  
     2013      2012  
     (in thousands, except financial
metrics data)
 

Cash and cash equivalents

   $ 156,306       $ 139,698   

Marketable securities

   $ 3,471       $ 3,310   

Accounts receivable, net

   $ 49,483       $ 92,169   

Total current assets

   $ 235,190       $ 264,873   

Total current liabilities

   $ 89,984       $ 123,243   

Working capital surplus (a)

   $ 145,206       $ 141,630   

Days sales outstanding (“DSO”) (b)

     110         121   

Current ratio (c)

     2.6         2.1   

 

(a) Total current assets at period end minus total current liabilities at period end.
(b) Net accounts receivable at period end divided by revenue, net for the fourth quarter multiplied by 92 days.
(c) Total current assets at period end divided by total current liabilities at period end.

 

56


Net Cash (Used In) Provided By Operating Activities

Cash used in operating activities was $2.1 million for 2013, as compared to cash provided by operating activities of $72.0 million in the prior year. The decrease in cash provided by operating activities during the current year, as compared to the prior year is primarily a function of the working capital drivers of (i) decreased revenue and related collections and (ii) increased payments to our vendors to reduce trade payables between these periods.

For the years ended December 31, 2013 and 2012, our cash collections from customers totaled $239.7 million and $301.9 million, respectively, representing 154% and 113% of reported net revenue for the same years.

For the years ended December 31, 2013 and 2012, cash payments to our employees and vendors for products, services, and rebates totaled $249.7 million and $231.3 million, respectively.

Net Cash (Used In) Investing Activities

Net cash used in investing activities of $14.3 million in 2013 was due to (i) our acquisition of Talon for $11.2 million (see Note 10(a) to the accompanying Consolidated Financial Statements), (ii) our $3.0 million purchase of C-E MELPHALAN rights (see Note 10(b)), and (iii) $0.2 million in purchases of property and equipment.

Net Cash Provided By Financing Activities

Net cash provided by financing activities of $35.3 million in 2013 is due to (i) $115.4 million in net proceeds from our 2018 Convertible Notes (see below) issuance in December 2013, (ii) proceeds of $7.0 million from Mundipharma towards our continued development of FOLOTYN (see Note 13), and (iii) $3.6 million in proceeds from the exercise of employee stock options.

These cash proceeds are partially offset by (i) $75.0 million net repayment of our terminated credit facility, (ii) $13.1 million of net costs for derivative instrument purchases to hedge the conversion feature of our 2018 Convertible Notes, and (iii) $1.7 million purchase of treasury stock, which was subsequently retired.

Convertible Senior Notes Due 2018

On December 17, 2013, we entered into an agreement for the sale of $120.0 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price are subject to adjustment under certain limited circumstances. Initially, we may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval in accordance with applicable NASDAQ rules (which is expected at our Annual Meeting of Shareholders in June 2014), we may then settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of our common stock, or a combination of cash and shares, at our election.

The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2014. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option.

Our December 23, 2013 net proceeds were $115.4 million from the sale of the 2018 Convertible Notes, after deducting banker and professional fees of $4.6 million. We used a portion of these proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to “additional paid-in capital” in our accompanying Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reporting periods.

 

57


Retired Credit Facility

On September 5, 2012, we entered into a credit agreement with Bank of America, N.A., as the administrative agent and an initial lender and Wells Fargo Bank, National Association, as an initial lender, as amended July 16, 2013 (the “Credit Agreement”). The Credit Agreement provided us with a committed $50.0 million revolving line of credit facility (the “Credit Facility”). The Credit Facility was to expire on September 5, 2014, but was repaid in full and cancelled by us on December 20, 2013.

The Credit Facility bore interest, at our election, at a rate equal to the London Interbank Offer Rate (LIBOR), plus an applicable margin (2.75% to 4.25%, dependent on a defined liquidity ratio).

Future Capital Requirements

We believe that the future growth of our business will depend on our ability to successfully develop and acquire new drugs for the treatment of cancer and successfully bring these drugs to market.

The timing and amount of our future capital requirements will depend on many factors, including:

 

   

the need for additional capital to fund future development programs;

 

   

the need for additional capital to fund strategic acquisitions;

 

   

the need for additional capital to fund licensing arrangements;

 

   

our requirement for additional information technology infrastructure and systems; and

 

   

adverse outcomes from potential litigation and the cost to defend such litigation.

We believe that our $159.8 million in aggregate cash and equivalents, and marketable securities as of December 31, 2013, will allow us to fund our current and planned operations for at least the next twelve to eighteen months. We may seek to obtain additional capital through the sale of debt or equity securities, if necessary, especially in conjunction with opportunistic acquisitions or licensing arrangements.

We may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.

Contractual Obligations

The following table summarizes our contractual and other commitments, including obligations under facility and equipment leases, as of December 31, 2013:

 

     Total      Less than
1 Year
     2-3 Years      4-5 Years      After
5 Years
 
     (in thousands)  

Operating lease obligations (1)

   $ 4,693       $ 849       $ 1,842       $ 1,711       $ 291   

Purchase obligations (2)

     42,925         37,404         4,295         1,226         —     

Contingent milestone obligations (3)

     428,438         35,630         21,295         25,729         345,784   

Drug development liability (4)

     17,742         3,119         2,413         2,267         9,943   

Debt obligations (5)

     136,666         3,273         6,701         126,692         —    
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 630,464       $ 80,275       $ 36,546       $ 157,625       $ 356,018   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(1) The operating lease obligations are primarily related to the facility lease for our corporate headquarters in Henderson, Nevada, expiring April 30, 2014; and our research and development and administrative facility in Irvine, California, expiring May 31, 2019.
(2) Purchase obligations represent the amount of open purchase orders and contractual commitments to vendors for products and services that have not been delivered, or rendered, as of December 31, 2013.
(3)

Milestone obligations are payable contingent upon successfully reaching certain development and regulatory milestones (see Note 14 to the accompanying Consolidated Financial Statements). Given the unpredictability of the drug development process, and the impossibility of predicting the success of current and future clinical trials, the

 

58


  timelines estimated above do not represent a forecast of when payment milestones will actually be reached, if at all. Rather, they assume that all development and regulatory milestones under all of our license agreements are successfully met, and represent our best estimates of the timelines. In the event that the milestones are met, we believe it is likely that the increase in the potential value of the related drug product will exceed the amount of the milestone obligation.
(4) Research and development services under the Mundipharma Collaboration Agreement (see Note 13 to the accompanying Consolidated Financial Statements) over the period required to complete the jointly agreed-upon clinical development activities.
(5) Debt obligations represent amount due under our 2018 Convertible Notes issued in December 2013, inclusive of interest payments over its full term (see Note 12 to the accompanying Consolidated Financial Statements).

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (except for operating leases) that provide financing, liquidity, market or credit risk support, or involve derivatives. In addition, we have no arrangements that may expose us to liability that are not expressly reflected in the accompanying Consolidated Financial Statements.

As of December 31, 2013, we did not have any relationships with unconsolidated entities or financial partnerships, often referred to as “structured finance” or “special purpose entities,” established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not subject to any material financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

In the normal course of business, our operations are exposed to risks associated with fluctuations in interest rates and foreign currency exchange rates.

The primary objective of our investment activities is to preserve principal, while at the same time maximizing yields without significantly increasing risk. We do not utilize hedging contracts or similar instruments. Because of our ability to generally redeem these investments at par at short notice and without penalty, changes in interest rates would have an immaterial effect on the fair value of these investments. If a 10% change in interest rates were to have occurred on December 31, 2013, any decline in the fair value of our investments would not be material in the context of our accompanying Consolidated Financial Statements. In addition, we are exposed to certain market risks associated with credit ratings of corporations whose corporate bonds we may purchase from time to time. If these companies were to experience a significant detrimental change in their credit ratings, the fair market value of such corporate bonds may significantly decrease. If these companies were to default on these corporate bonds, we may lose part or all of our principal. We believe that we effectively manage this market risk by diversifying our investments, and investing in highly rated securities.

We are exposed to foreign currency exchange rate fluctuations relating to payments we make to vendors, suppliers and license partners using foreign currencies. In particular, some of our obligations are incurred in Euros. We mitigate such risk by maintaining a limited portion of our cash in Euros and other currencies.

 

59


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Spectrum Pharmaceuticals, Inc.

By:

  /s/ RAJESH C. SHROTRIYA, M.D.
 

Rajesh C. Shrotriya, M.D.

Chief Executive Officer and President

Date: March 12, 2014

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints each of Rajesh C. Shrotriya and Kurt A. Gustafson as his attorney-in-fact, with full power of substitution, for him in any and all capacities, to sign any amendments to this Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each attorney-in-fact, or his substitute, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

Signature

  

Title

 

Date

/s/ RAJESH C. SHROTRIYA, M.D.

Rajesh C. Shrotriya, M.D.

  

Chairman of the Board, Chief Executive

Officer, and President

(Principal Executive Officer)

  March 12, 2014

/s/ KURT A. GUSTAFSON

Kurt A. Gustafson

  

Executive Vice President and Chief

Financial Officer

(Principal Financial and Accounting Officer)

  March 12, 2014

/s/ DOLOTRAI M. VYAS, PH.D.

Dolatrai M. Vyas, Ph.D.

  

Director

  March 12, 2014

/s/ LUIGI LENAZ, M.D.

Luigi Lenaz, M.D.

  

Director

  March 12, 2014

/s/ STUART M. KRASSNER, SC.D., PSY.D.

Stuart M. Krassner, Sc.D., Psy.D.

  

Director

  March 12, 2014

/s/ ANTHONY E. MAIDA, III, M.A., M.B.A., PH.D.

Anthony E. Maida, III, M.A., M.B.A., Ph.D.

  

Director

  March 12, 2014

/s/ RAYMOND W. COHEN

Raymond W. Cohen

  

Director

  March 12, 2014

/s/ GILLES GAGNON

Gilles Gagnon, M.Sc., M.B.A

  

Director

  March 12, 2014

 

60


ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

SPECTRUM PHARMACEUTICALS, INC.

FORM 10-K ANNUAL REPORT

For the Fiscal Year Ended December 31, 2013

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

     Page  

Report of Independent Registered Public Accounting Firm

     F-2   

Consolidated Balance Sheets as of December 31, 2013 and 2012

     F-5   

Consolidated Statements of Operations for each of the years ended December 31, 2013, 2012, and 2011

     F-6   

Consolidated Statements of Comprehensive Income (Loss) for each of the years ended December  31, 2013, 2012, and 2011

     F-7   

Consolidated Statements of Stockholders’ Equity for each of the years ended December  31, 2013, 2012, and 2011

     F-8   

Consolidated Statements of Cash Flows for each of the years ended December 31, 2013, 2012, and 2011

     F-9   

Notes to Consolidated Financial Statements

     F-10   

 

F-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders

Spectrum Pharmaceuticals, Inc.

We have audited Spectrum Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) (the COSO criteria). Spectrum Pharmaceuticals, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment. Management has identified a material weakness in internal control over financial reporting related to the accurate and timely accounting for accruals. Specifically, (i) ineffective design of controls over the process of estimating the required period-end accruals for services performed under open purchase orders, which resulted in overstated operating expenses and accrued liabilities in multiple reporting periods in, and prior to, 2013; and (ii) the ineffective design and operating effectiveness of controls over the process for identifying and recording liabilities for vendor invoices received subsequent to year end that related to 2013 activities, which would have resulted in understated operating expenses and accrued liabilities, if left uncorrected.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Spectrum Pharmaceuticals, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2013. This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of those consolidated financial statements, and this report does not affect our report dated March 12, 2014, which expressed an unqualified opinion on those consolidated financial statements.

 

F-2


In our opinion, because of the effect of the material weakness described above on the achievement of the objectives of the control criteria, Spectrum Pharmaceuticals, Inc. has not maintained effective internal control over financial reporting as of December 31, 2013, based on the COSO criteria.

 

/s/ Ernst & Young LLP
Irvine, California
March 12, 2014

 

F-3


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders

Spectrum Pharmaceuticals, Inc.

We have audited the accompanying consolidated balance sheets of Spectrum Pharmaceuticals, Inc. as of December 31, 2013 and 2012, and the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2013. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Spectrum Pharmaceuticals, Inc. at December 31, 2013 and 2012, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2013, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Spectrum Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) and our report dated March 12, 2014 expressed an adverse opinion thereon.

 

/s/ Ernst & Young LLP
Irvine, California
March 12, 2014

 

F-4


SPECTRUM PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and par value amounts)

 

     December 31,  
     2013     2012  
ASSETS   

Current assets:

    

Cash and equivalents

   $ 156,306      $ 139,698   

Marketable securities

     3,471        3,310   

Accounts receivable, net of allowance for doubtful accounts of $206 and $228, respectively

     49,483        92,169   

Other receivables

     7,539        —    

Inventories

     13,519        14,478   

Prepaid expenses and other current assets

     3,213        2,745   

Deferred tax assets

     1,659        12,473   
  

 

 

   

 

 

 

Total current assets

     235,190        264,873   

Property and equipment, net

     1,535        2,548   

Intangible assets, net

     231,352        200,234   

Goodwill

     18,501        7,279   

Deferred tax assets

     —          23,276   

Other assets

     12,577        6,745   
  

 

 

   

 

 

 

Total assets

   $ 499,155      $ 504,955   
  

 

 

   

 

 

 
LIABILITIES AND STOCKHOLDERS’ EQUITY   

Current liabilities:

    

Accounts payable and other accrued liabilities

   $ 79,837      $ 105,252   

Accrued payroll and related expenses

     6,872        4,835   

Deferred revenue

     156        12,300   

Drug development liability

     3,119        856   
  

 

 

   

 

 

 

Total current liabilities

     89,984        123,243   

Drug development liability, less current portion

     14,623        11,377   

Deferred payment contingency

     —          2,287   

Acquisition-related contingent obligations

     8,329        —     

Deferred tax liability

     7,168        —     

Other long-term liabilities

     5,965        4,367   

Revolving line of credit

     —          75,000   

Convertible senior notes

     91,480        —     
  

 

 

   

 

 

 

Total liabilities

     217,549        216,274   

Commitments and contingencies

    

Stockholders’ equity:

    

Preferred stock, $0.001 par value; 5,000,000 shares authorized

    

Series B Junior Participating Preferred Stock, $0.001 par value; 1,500,000 shares authorized: no shares issued and outstanding

     —          —     

Series E Convertible Voting Preferred Stock, $0.001 par value and $10,000 stated value; 2,000 shares authorized; 20 shares issued and outstanding at December 31, 2013 and 2012, respectively (convertible into 40,000 shares of common stock, with aggregate liquidation value of $240)

     123        123   

Common stock, $0.001 par value; 175,000,000 shares authorized; 64,104,173 and 60,026,675 issued and outstanding at December 31, 2013 and 2012, respectively

     64        60   

Additional paid-in capital

     518,144        463,710   

Accumulated other comprehensive income

     894        273   

Accumulated deficit

     (237,619     (175,485
  

 

 

   

 

 

 

Total stockholders’ equity

     281,606        288,681   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 499,155      $ 504,955   
  

 

 

   

 

 

 

See accompanying notes to these consolidated financial statements.

 

F-5


SPECTRUM PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

 

     Year Ended December 31,  
     2013     2012     2011  

Revenues:

      

Product sales, net

   $ 143,475      $ 254,992      $ 180,663   

License fees and service revenue

     12,379        12,715        12,300   
  

 

 

   

 

 

   

 

 

 

Total revenues

   $ 155,854      $ 267,707      $ 192,963   
  

 

 

   

 

 

   

 

 

 

Operating costs and expenses:

      

Cost of product sales (excludes amortization of purchased intangible assets)

     28,580        46,633        33,838   

Selling, general and administrative

     99,315        89,922        72,197   

Research and development

     46,670        41,560        26,662   

Amortization and impairment of intangible assets

     20,074        8,818        3,720   
  

 

 

   

 

 

   

 

 

 

Total costs and operating expenses

     194,639        186,933        136,417   
  

 

 

   

 

 

   

 

 

 

(Loss) income from operations

     (38,785     80,774        56,546   
  

 

 

   

 

 

   

 

 

 

Other income (expense):

      

Interest expense, net

     (2,192     (485     297   

Change in fair value of contingent consideration related to acquisition

     2,871        —          —     

Change in fair value of common stock warrant liability

     —          —          (3,488

Other income (expense), net

     1,470        (359     280   
  

 

 

   

 

 

   

 

 

 

Total other income (expense)

     2,149        (844     (2,911
  

 

 

   

 

 

   

 

 

 

(Loss) income before income taxes

     (36,636     79,930        53,635   

(Provision) benefit for income taxes

     (25,498     14,271        (3,704
  

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (62,134   $ 94,201      $ 49,931   
  

 

 

   

 

 

   

 

 

 

Net (loss) income per share:

      

Basic

   $ (1.02   $ 1.61      $ 0.94   
  

 

 

   

 

 

   

 

 

 

Diluted

   $ (1.02   $ 1.46      $ 0.86   
  

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding:

      

Basic

     60,729,128        58,588,916        53,272,767   
  

 

 

   

 

 

   

 

 

 

Diluted

     60,729,128        64,637,256        57,959,714   
  

 

 

   

 

 

   

 

 

 

See accompanying notes to these consolidated financial statements.

 

F-6


SPECTRUM PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

 

     Year Ended December 31,  
     2013     2012     2011  

Net (loss) income

   $ (62,134   $ 94,201      $ 49,931   

Other comprehensive (loss) income, net of tax:

      

Unrealized gain (loss) on available-for-sale securities

     1,110        797        (135

Income tax on unrealized gain on available-for-sale securities

     (420     (213     —     

Foreign currency translation adjustments

     (69     (84     —     
  

 

 

   

 

 

   

 

 

 

Other comprehensive income (loss), net

     621        500        (135
  

 

 

   

 

 

   

 

 

 

Total comprehensive (loss) income

   $ (61,513   $ 94,701      $ 49,796   
  

 

 

   

 

 

   

 

 

 

See accompanying notes to these consolidated financial statements.

 

F-7


SPECTRUM PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)

 

                                   Accumulated
Other
Comprehensive
Income (Loss)
                         
     Preferred Stock     Common Stock     Additional       Accumulated     Treasury Stock    

Total

Stockholders

 
     Shares     Amount     Shares     Amount     Paid-In Capital       Deficit     Shares     Amount     Equity  

Balance at December 31, 2010

     26      $ 160        51,459,284      $ 51      $ 384,757      $ (92   $ (307,635     —        $ —        $ 77,241   

Net income

     —          —          —          —          —          —          49,931        —          —          49,931   

Other comprehensive income, net

     —          —          —          —          —          (135     —          —          —          (135

Conversion of Series E preferred stock to common stock

     (6     (37     12,000        —          37        —          —          —          —          —     

Issuance of common stock to 401(k) plan

     —          —          65,889        —          593        —          —          —          —          593   

Issuance of common stock for ESPP

     —          —          100,386        —          655        —          —          —          —          655   

Adjustments resulting from change in value of warrants recognized in equity

     —          —          —          —          7,392        —          —          —          —          7,392   

Issuance of common stock upon exercise of stock options

     —          —          1,126,257        1        5,136        —          —          —          —          5,137   

Issuance of common stock upon exercise of warrants

     —          —          3,747,312        4        24,804        —          —          —          —          24,808   

Share-based compensation expense and common stock issued (net of forfeitures)

     —          —          998,711        1        21,643        —          —          —          —          21,644   

Purchase of treasury stock

     —          —          —          —          —          —          —          363,055        (2,926     (2,926

Issuance of restricted stock for management incentive plan, net of shares repurchased/retired for employee tax withholding

     —          —          426,562        1        (4,033     —          —          —          —          (4,032

Fair value of common stock issued to Targent for milestone

     —          —          1,311,082        1        11,777        —          —          —          —          11,778   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2011

     20      $ 123        59,247,483      $ 59      $ 452,761      $ (227   $ (257,704     363,055      $ (2,926   $ 192,086   

Net income

     —          —          —          —          —          —          94,201        —          —          94,201   

Other comprehensive income, net

     —          —          —          —          —          500        —          —          —          500   

Issuance of common stock to 401(k) plan

     —          —          56,254        —          691        —          —          —          —          691   

Issuance of common stock for ESPP

     —          —          54,521        —          606        —          —          —          —          606   

Issuance of common stock upon exercise of stock options

     —          —          1,287,430        2        5,815        —          —          —          —          5,817   

Issuance of common stock upon exercise of warrant

     —          —          50,000        —          89        —          —          —          —          89   

Share-based compensation expense and common stock issued (net of forfeitures)

     —          —          554,239        —          14,193        —          —          —          —          14,193   

Repurchase of shares to satisfy employee tax withholding

     —          —          (120,197     —          (1,434     —          —          —          —          (1,434

Dividends paid

     —          —          —          —          (9,011     —          —          —          —          (9,011

Purchase of treasury stock

     —          —          —          —          —          —          —          740,000        (9,057     (9,057

Retirement of treasury stock

     —          —          (1,103,055     (1     —          —          (11,982     (1,103,055     11,983        —     
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2012

     20      $ 123        60,026,675      $ 60      $ 463,710      $ 273      $ (175,485     —        $ —        $ 288,681   

Net loss

     —          —          —          —          —          —          (62,134     —          —          (62,134

Other comprehensive loss, net

     —          —          —          —          —          621        —          —          —          621   

Issuance of common stock to 401(k) plan

     —          —          99,359        —          860        —          —          —          —          860   

Issuance of common stock for ESPP

     —          —          74,925        —          495        —          —          —          —          495   

Issuance of common stock upon exercise of stock options

     —          —          825,884        1        3,576        —          —          —          —          3,577   

Share-based compensation expense and common stock issued (net of forfeitures)

     —          —          471,875        —          11,913        —          —          —          —          11,913   

Repurchase of shares to satisfy employee tax withholding

     —          —          (159,545     —          (1,509     —          —          —          —          (1,509

Purchase of treasury stock

     —          —          —          —          —          —          —          235,000       (1,651     (1,651

Retirement of treasury stock

     —          —          (235,000     —          (1,651     —          —          (235,000     1,651        —     

Issuance of common stock for Talon acquisition

     —          —          3,000,000        3        26,307        —          —          —          —          26,310   

Issuance of 2018 Convertible Notes

     —          —          —          —          14,443        —          —          —          —          14,443   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

     20      $ 123        64,104,173      $ 64      $ 518,144      $ 894      $ (237,619     —        $ —        $ 281,606   

See accompanying notes to these consolidated financial statements.

 

F-8


SPECTRUM PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

     Year Ended December 31,  
     2013     2012     2011  

Cash Flows From Operating Activities:

      

Net (loss) income

   $ (62,134   $ 94,201      $ 49,931   

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

      

Amortization of deferred service revenue

     (12,400     (12,300     (12,300

Depreciation and amortization

     22,096        12,243        5,650   

Stock-based compensation

     12,423        14,884        22,237   

Change in fair value of common stock warrants issued to non-employees

     356        —          3,488   

Accretion of debt discount to interest expense on 2018 Convertible Notes

     43        —          —     

Amortization of deferred financing costs to interest expense on 2018 Convertible Notes

     101        —          —     

Bad debt expense (recovery)

     127        (128     245   

Loss on disposal of fixed assets

     —          132        38   

Non-cash foreign currency exchange loss

     1,222        107        —     

Impairment of FOLOTYN distribution rights

     1,023        —          —     

Change in fair value of contingent consideration related to acquisition

     (2,871     20        —     

Change in fair value of Allos deferred development costs and deferred payment contingency

     (2,869     —          —     

Changes in operating assets and liabilities:

      

Accounts receivable

     42,559        (33,504     (30,897

Inventories

     1,570        3,530        (6,528

Prepaid expenses and other current assets

     (359     9,483        (7,115

Deferred tax assets

     33,252        (34,605     —     

Other assets

     (8,989     —          —     

Accounts payable and other accrued obligations

     (23,897     24,038        15,711   

Accrued payroll and related expenses

     425        (9,726     (1,525

Drug development liability

     (5,917     2,376        3,519   

Other long-term liabilities

     2,153        1,208       834  
  

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by operating activities

     (2,086     71,959        43,288   
  

 

 

   

 

 

   

 

 

 

Cash Flows From Investing Activities:

      

Sales and maturities of marketable securities

     —          72,463        18,255   

Purchases of marketable securities

     —          (26,430     (17,027

Purchases of property and equipment

     (161     (312     (475

Purchases of available-for-sale securities

     —          (1,712     (164

Proceeds from sale of available-for-sale securities

     —          —          157   

Purchase of ZEVALIN Ex-U.S. rights

     —          (25,435     —     

Purchase of C-E MELPHALAN rights

     (3,000     —          —     

Acquisition of Talon, net of cash acquired

     (11,169     —          —     

Acquisition of Allos, net of cash acquired

     —          (133,264     —     
  

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by investing activities

     (14,330     (114,690     746   
  

 

 

   

 

 

   

 

 

 

Cash Flows From Financing Activities:

      

Proceeds from Mundipharma for FOLOTYN development

     7,000        —          —     

Proceeds from exercise of stock options

     3,576        5,817        5,137   

Proceeds from exercise of common stock warrants

     —          89        24,808   

Proceeds from sale of common stock under employee stock purchase plan

     495        606        655   

Payments to acquire treasury stock

     (1,651     (9,057     (2,926

Repurchase of restricted stock to satisfy employee tax withholdings at vesting

     (1,509     (1,434     (4,032

Payment of stock dividend

     —          (9,011     —     

Repayment of capital leases

     —          (9     (31

Proceeds from revolving line of credit

     100,000        125,000        —     

Repayment of revolving line of credit

     (175,000     (50,000     —     

Proceeds from 2018 Convertible Notes

     120,000        —          —     

Deferred financing costs

     (4,573     —          —     

Proceeds from sale of common stock warrants related to 2018 Convertible Notes issuance

     12,612        —          —     

Payment of debt issuance costs

     —          (976     —     

Purchase of common stock call options related to 2018 Convertible Notes issuance

     (25,692     —          —     
  

 

 

   

 

 

   

 

 

 

Net cash provided by financing activities

     35,258        61,025        23,611   
  

 

 

   

 

 

   

 

 

 

Effect of exchange rates on cash and equivalents

     (2,235     202        —     

Net increase (decrease) in cash and equivalents

     16,608        18,496        67,645   

Cash and equivalents — beginning of year

     139,698        121,202        53,557   
  

 

 

   

 

 

   

 

 

 

Cash and equivalents — end of year

   $ 156,306      $ 139,698      $ 121,202   
  

 

 

   

 

 

   

 

 

 

Supplemental Disclosure of Cash Flow Information:

      

Cash paid for income taxes

   $ —        $ 17,157      $ 2,042   
  

 

 

   

 

 

   

 

 

 

Cash paid for interest

   $ 1,200      $ 495      $ 14   
  

 

 

   

 

 

   

 

 

 

Retirement of treasury shares

   $ 1,652      $ 11,983      $ —     
  

 

 

   

 

 

   

 

 

 

Inventory liability assumed in acquisitions

   $ —        $ 580      $ —     
  

 

 

   

 

 

   

 

 

 

Inventory included in accounts payable

   $ —        $ 5,000      $ —     
  

 

 

   

 

 

   

 

 

 

Conversion of preferred stock to common stock

   $ —        $ —        $ 37   
  

 

 

   

 

 

   

 

 

 

Common stock issued for Targent milestones

   $ —        $ —        $ 11,778   
  

 

 

   

 

 

   

 

 

 

Common stock issued for Talon acquisition

   $ 26,310        —          —     
  

 

 

   

 

 

   

 

 

 

See accompanying notes to consolidated financial statements.

 

F-9


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

1. DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT

(a) Description of Business

Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.

We currently market four drugs:

 

   

FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

 

   

ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

 

   

FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

 

   

MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.

We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.

(b) Basis of Presentation

Principles of Consolidation

The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.

On April 1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the “ZEVALIN Rights”); on September 5, 2012, we acquired Allos Therapeutics, Inc. (“Allos”); and on July 17, 2013, we acquired Talon Therapeutics, Inc. (“Talon”). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.

Variable Interest Entity

We own fifty-percent of Spectrum Pharma Canada (a “variable interest entity,” as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its “primary beneficiary”. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.

(c) Operating Segment

We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.

 

F-10


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, our management evaluates its estimates, including those related to (i) revenue adjustments; (ii) the collectability of customer accounts; (iii) whether the cost of inventories can be recovered; (iv) the value of goodwill and intangible assets; (v) the realization of tax assets and estimates of tax liabilities; (vi) the likelihood of payment and value of contingent liabilities; (vii) the fair value of investments; (viii) assumptions used in reporting stock-based compensation; and (ix) the potential outcome of litigation.

Such estimates are based on our management’s judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may materially differ from management’s estimates. In our judgment, the accounting policies, estimates, and assumptions described below have the potential to significantly impact our preparation of the accompanying Consolidated Financial Statements:

(i) Revenue Recognition

(a) Product Sales: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:

 

  (1) appropriate evidence of a binding arrangement exists with our customer;

 

  (2) price is substantially fixed and determinable;

 

  (3) collection from our customer is reasonably assured;

 

  (4) our customer’s obligation to pay us is not contingent on resale of the product;

 

  (5) we do not have significant obligations for future performance to directly bring about the resale of our product; and

 

  (6) we have a reasonable basis to estimate returns.

Our gross revenue is reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.

Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:

Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.

Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.

Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.

Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

 

F-11


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.

Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.

(b) License Fees: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.

(c) Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.

(ii) Cash and Equivalents

Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.

(iii) Marketable Securities

Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive Income (Loss).

(iv) Accounts Receivable

Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.

(v) Inventories

We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.

(vi) Property and Equipment

Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.

 

F-12


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

(vii) Goodwill and Intangible Assets

Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October 1 each year.

We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

 

  (a) a significant decrease in the market value of an asset;

 

  (b) a significant adverse change in the extent or manner in which an asset is used; or

 

  (c) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.

(viii) Stock-Based Compensation

We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.

We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.

(ix) Foreign Currency Translation

We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).

We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.

(x) Comprehensive Income (Loss)

Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.

(xi) Basic and Diluted Net (Loss) Income per Share

We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.

(xii) Income Taxes

Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax

 

F-13


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in “income tax expense” within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.

(xiii) Research and Development Costs

Research and development costs are expensed as incurred.

(xiv) Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

“Cash and equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.

The fair value of our “drug development liability” and our “deferred payment contingency” within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) internal estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.

“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See Note 10(a) for a discussion of CVRs granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

 

3. BALANCE SHEET ACCOUNT DETAIL

(a) Cash and Equivalents and Marketable Securities

As of December 31, 2013, we held substantially all of our cash and equivalents, and marketable securities at major financial institutions.

Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, with limitations on investing in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation (FDIC) and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks on our portfolio by investing in highly liquid, highly rated instruments and do not invest in long-term maturity instruments.

 

F-14


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Cash and equivalents and marketable securities, including long term bank certificates of deposits, and investments totaled $159.8 million and $143.0 million as of December 31, 2013 and 2012, respectively. The carrying amount of our money market funds and bank certificate of deposits (“Bank CDs”) approximates its fair value (utilizing Level 2 inputs – see Note 2(x)) because of our ability to immediately convert these instruments into cash with minimal change in value.

The following is a summary of our cash and equivalents and marketable securities:

 

     Cost      Gross
Unrealized
Gains
     Gross
Unrealized
Losses
     Estimated
fair
Value
     Cash and
equivalents
     Marketable Securities  
                  Current      Long
Term
 

December 31, 2013

                    

Bank deposits

   $ 55,911       $ —         $ —         $ 55,911       $ 55,911       $ —         $ —     

Money market funds

     100,395               100,395         100,395         

Bank CDs

     410         —           —           410         —           410         —     

Mutual funds

     3,061         —           —           3,061         —           3,061         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 159,777       $ —         $ —         $ 159,777       $ 156,306       $ 3,471       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

December 31, 2012

                    

Bank deposits

   $ 128,000       $ —         $ —         $ 128,000       $ 128,000       $ —         $ —     

Money market funds

     11,698               11,698         11,698         

Bank CDs

     987         —           —           987         —           987         —     

Mutual funds

     2,323         —           —           2,323         —           2,323         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 143,008       $ —         $ —         $ 143,008       $ 139,698       $ 3,310       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

As of December 31, 2013, none of these securities had been in a continuous unrealized loss position longer than one year.

(b) Property and Equipment

Property and equipment consist of the following:

 

     December 31,  
     2013     2012  

Computers and software

   $ 5,154      $ 4,540   

Lab and media equipment

     1,063        886   

Office furniture and equipment

     1,575        1,492   

Leasehold improvements

     2,813        2,799   

Assets held under capital lease obligations

     —          146   
  

 

 

   

 

 

 

Property and equipment, at cost

     10,605        9,863   

(Less): accumulated depreciation and amortization

     (9,070     (7,315
  

 

 

   

 

 

 

Property and equipment, net

   $ 1,535      $ 2,548   
  

 

 

   

 

 

 

Depreciation and amortization expense for property and equipment (including leasehold improvements) for the years ended December 31, 2013, 2012, and 2011 was $1.2 million, $1.2 million, and $0.9 million, respectively.

 

F-15


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

(c) Inventories

Inventories, net consist of the following:

 

     December 31,  
     2013      2012  

Raw materials

   $ 1,794       $ 887   

Work in process

     3,312         7,302   

Finished goods

     8,413         6,289   
  

 

 

    

 

 

 

Inventories

   $ 13,519       $ 14,478   
  

 

 

    

 

 

 

(d) Intangible Assets and Goodwill

Intangible assets consist of the following:

 

            December 31, 2013  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
     Impairment     Net Amount      Full
Amortization

Period  (years)
     Remaining
Amortization
Period (years)
 

MARQIBO IPR&D

   $ 17,600       $ —        $ —         $ —        $ 17,600         n/a         n/a   

MELPHALAN IPR&D

     7,700         —          —           —          7,700         n/a         n/a   

MARQIBO developed technology

     26,900         (1,107     —           —          25,793         11         11   

ZEVALIN marketing rights – U.S.

     41,900         (23,455     —           —          18,445         10         5   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (5,343     682         —          18,829         8         6   

FUSILEV developed technology

     16,778         (4,821     —           —          11,957         11         8   

FOLOTYN distribution rights*

     27,900         (3,662     —           (1,023     23,215         10         9   

FOLOTYN developed technology

     118,400         (10,587     —           —          107,813         13         12   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

Total intangible assets

   $ 280,668       $ (48,975   $ 682       $ (1,023   $ 231,352         
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

 

* On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the “amortization and impairment of intangible assets” in the accompanying Consolidated Statement of Operations for the year ended December 31, 2013.

 

     December 31, 2012  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
    Net
Amount
 

ZEVALIN marketing rights – U.S.

   $ 41,900       $ (19,735   $ —        $ 22,165   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (2,192     (355     20,943   

FUSILEV developed technology

     16,778         (2,980     —          13,798   

FOLOTYN distribution rights

     27,900         (895     —          27,005   

FOLOTYN developed technology

     118,400         (2,077     —          116,323   
  

 

 

    

 

 

   

 

 

   

 

 

 

Total intangible assets

   $ 228,468       $ (27,879   $ (355   $ 200,234   
  

 

 

    

 

 

   

 

 

   

 

 

 

 

F-16


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Intangible asset amortization expense recognized in 2013, and 2012, and 2011 was $21.2 million, $8.8 million, and $4.7 million, respectively. Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:

 

Years Ending December 31

      

2014

   $ 22,468   

2015

     22,468   

2016

     22,468   

2017

     22,468   

2018

     22,313   

2019 and thereafter

     93,867   
  

 

 

 
   $ 206,052   
  

 

 

 

Goodwill is comprised of the following (by source):

 

     December 31,
2013
     December 31,
2012
 

Acquisition of Talon

   $ 10,526         —     

Acquisition of ZEVALIN Rights

     2,525       $ 2,525   

Acquisition of Allos

     5,346         4,791   

Foreign exchange translation effects

     104         (37
  

 

 

    

 

 

 
   $ 18,501       $ 7,279   
  

 

 

    

 

 

 

(e) Other assets

Other assets are comprised of the following:

 

     December 31,
2013
     December 31,
2012
 

Investments in equity securities

   $ 3,593       $ 2,476   

Deposits

     190         304   

Debt issuance cost

     3,432         814   

Life insurance cash surrender value

     5,361         2,881   
  

 

 

    

 

 

 
   $ 12,576       $ 6,475   
  

 

 

    

 

 

 

(f) Accounts payable and other accrued obligations

Accounts payable and other accrued obligations are comprised of the following:

 

     December 31,  
     2013      2012  

Trade payables

   $ 12,796       $ 30,814   

Accrued rebates

     28,893         11,023   

Accrued product royalty

     9,498         12,275   

Allowance for returns

     2,900         5,056   

Accrued data and distribution fees

     2,430         8,449   

Accrued GPO administrative fees

     2,327         2,650   

Inventory management fee

     616         3,050   

Accrued income taxes

     3         2,522   

Allowance for chargebacks

     5,074         15,153   

Accrued drug development costs

     6,433         11,441   

Other accrued obligations

     8,867         2,819   
  

 

 

    

 

 

 
   $ 79,837       $ 105,252   
  

 

 

    

 

 

 

 

F-17


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

 

Description

   Rebates and
Chargebacks
    Data and
Distribution,
GPO Fees, and
Inventory
Management
Fees
    Prompt
Pay
Discount
    Returns  

Balance as of December 31, 2011

   $ 9,064      $ 9,808      $ 992      $ 4,000   

Allos accruals assumed

     2,371        182        —          941   

Add: provisions (recovery)

     91,059        32,793        4,814        159   

Less: credits or actual allowances

     (76,318     (28,634     (4,355     (44
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2012

     26,176        14,149        1,451        5,056   

Add: provisions (recovery)

     63,609        19,067        183        (2,034

Less: credits or actual allowances

     (55,818     (27,843     (1,317     (122
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2013

   $ 33,967      $ 5,373      $ 317      $ 2,900   
  

 

 

   

 

 

   

 

 

   

 

 

 

(g) Other long-term liabilities

Other long-term liabilities are comprised of the following:

 

     December 31,  
     2013      2012  

Accrued executive deferred compensation

   $ 3,949       $ 2,366   

Deferred rent (non-current portion)

     366         571   

Business acquisition liability

     298         298   

Other tax liabilities

     1,352         1,132   
  

 

 

    

 

 

 
   $ 5,965       $ 4,367   
  

 

 

    

 

 

 

 

4. GROSS-TO-NET PRODUCT SALES

The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:

 

     2013     2012     2011  

Gross product sales

   $ 224,301      $ 383,817      $ 220,670   

Rebates and government chargebacks

     (63,610     (91,059     (22,190

Distribution and data fees and group purchasing organizations fees

     (19,067     (32,793     (11,637

Prompt pay discounts

     (183     (4,814     (4,086

Product returns allowance

     2,034        (159     (2,094
  

 

 

   

 

 

   

 

 

 

Product sales, net

   $ 143,475      $ 254,992      $ 180,663   
  

 

 

   

 

 

   

 

 

 

 

F-18


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

5. PRODUCT SALES, NET BY GEOGRAPHIC REGION AND PRODUCT LINE

The below table presents product sales, net by geography for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

United States

   $ 133,462         93.0   $ 245,697         96.4   $ 180,663         —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

International:

               

Europe

     3,953         2.8     3,113         1.2     —           —  

Asia Pacific

     6,060         4.2     6,182         2.4     —           —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total International

     10,013         7.0     9,295         3.6     —           —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         100.0
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

The below table presents product sales, net by product line for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

FUSILEV

   $ 68,397         47.7   $ 204,253         80.1   $ 153,110         84.7

FOLOTYN

     44,370         30.9     20,412         8.0     —           —  

ZEVALIN

     29,393         20.5     30,327         11.9     27,553      

MARQIBO

     1,315         0.9     —           —       —           —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         15.3
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

6. STOCK-BASED COMPENSATION

2009 Stock Incentive Plan

We have one active stockholder-approved stock-based compensation plan, the 2009 Incentive Award Plan (the “2009 Plan”), which replaced our former stockholder-approved plans. We may grant incentive stock options, non-qualified options, restricted stock awards, and stock appreciation rights under the 2009 Plan.

The maximum number of our common stock available for issuance under the 2009 Plan is 10.0 million shares. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the 2009 Plan increases by the greater of (i) 2.5 million shares or (ii) a number of shares such that the total number of shares of common stock available for issuance under the 2009 Plan shall equal 30% of the then number of shares of common stock issued and outstanding. As of December 31, 2013, 5.7 million shares were available for grant. It is our policy that before stock is issued through the exercise of stock options, we must first receive all required cash payment for such shares (whether through an upfront cash exercise or net-settlement exercise).

Stock-based awards are governed by agreements between us and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2009 Plan at an exercise price of not less than 100% of the closing fair market value of our common stock on the respective date of grant. The grant date is generally the date the award is approved by the Compensation Committee of the Board of Directors, though for aggregate awards of 50,000 or less in each quarter, the grant date is the date the award is approved by our Chief Executive Officer.

Stock-based awards generally vest 25% on the first anniversary of the date of grant, or for new hires, the first anniversary of their initial date of employment. Awards vest monthly thereafter on a straight-line basis over three years. Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 90 days from the last date of employment. In the event of an optionee’s death, disability, or retirement, the exercise period is 365 days from the last date of employment.

Employee Stock Purchase Plan

Under the terms of our 2009 Employee Stock Purchase Plan (the “ESPP”), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of our common stock on the first or last day of the offering period (whichever is less), minus a 15% discount. We use the Black-Scholes option-pricing model, in combination with the

 

F-19


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

discounted employee price, in determining the value of ESPP expense to be recognized during each offering period. A participant may purchase a maximum of 50,000 shares of common stock during a six-month offering period, not to exceed $25,000 worth of stock on the offering date during each plan year.

A total of 5.0 million shares of common stock are authorized for issuance under the ESPP. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the ESPP shall increase by an amount equal to the lesser of (i) 1 million shares or (ii) an amount determined by the ESPP administrator. However, in no event shall the number of shares of common stock available for future sale under the ESPP exceed 10.0 million shares, subject to capitalization adjustments occurring due to dividends, splits, dissolution, liquidation, mergers, or changes in control.

Stock-Based Compensation Expense Summary

We classify our stock-based compensation expense (inclusive of our 2009 Plan, ESPP, and 401(k) matching) in the accompanying Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within operating expenses for years ended December 31, 2013, 2012, and 2011 was as follows:

 

     Year Ended December 31,  
     2013      2012      2011  

Selling, general and administrative

   $ 10,762       $ 13,041       $ 20,609   

Research and development

     2,017         1,843         1,628   
  

 

 

    

 

 

    

 

 

 

Total

   $ 12,779       $ 14,884       $ 22,237   
  

 

 

    

 

 

    

 

 

 

Employee stock-based compensation expense for the years ended December 31, 2013, 2012, and 2011 was recognized (reduced for estimated forfeitures) on a straight-line basis over the vesting period. Forfeitures are estimated at the time of grant and prospectively revised if actual forfeitures differ from those estimates. We estimate forfeitures of stock options using the historical exercise behavior of our employees. For purposes of this estimate, we have applied an estimated forfeiture rate of 8%, 5%, and 5% for the years ended December 31, 2013, 2012, and 2011.

Valuation Assumptions – Restricted Stock and Stock Options

The grant-date fair value per share for restricted stock awards was based upon the closing market price of our common stock on the award grant-date.

The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:

 

     Year Ended December 31,
     2013    2012    2011

Expected option life (in years) (a)

   4.95    4.50    4.93

Risk-free interest rate (b)

   0.35% - 0.78%    0.34% - 0.51%    0.82% - 2.4%

Volatility (c)

   58.3% - 71.5%    64.2% -73.6%    55.8%

Dividend yield (d)

   0%    0%    0%

Weighted-average grant-date fair value per stock option

   $4.66    $6.20    $2.65

 

(a) Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
(b) Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
(c) Measured using our historical stock price for a period equal to stock options’ expected term.
(d) We do not expect to declare any cash dividends in the foreseeable future.

 

F-20


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Stock Option Activity

Stock option activity during the years ended December 31, 2013, 2012, and 2011 is as follows:

 

     Number  of
Shares
    Weighted-
Average

Exercise
Price/Share
     Weighted-
Average
Remaining
Contractual
Term (Years)
     Aggregate
Intrinsic
Value
 

Outstanding — December 31, 2010

     8,397,094      $ 4.17         

Granted

     3,622,150        7.92         

Exercised

     (1,126,257     4.07          $ 8,255 (1) 

Forfeited

     (547,479     4.81         

Expired

     (159,987     5.17         
  

 

 

   

 

 

       

Outstanding — December 31, 2011

     10,185,521      $ 5.46         

Granted

     1,821,915        11.57         

Exercised

     (1,287,430     4.52          $ 11,500 (1) 

Forfeited

     (316,825     7.93         

Expired

     (3,916     7.69         
  

 

 

   

 

 

       

Outstanding — December 31, 2012

     10,399,265      $ 6.57         

Granted

     2,041,300        8.92         

Exercised

     (825,884     4.40          $ 3,435 (1) 

Forfeited

     (202,882     8.22         

Expired

     (82,581     8.91         
  

 

 

   

 

 

       

Outstanding — December 31, 2013

     11,329,218      $ 7.10         7.0       $ 25,849 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Vested (exercisable) — December 31, 2013

     7,876,025      $ 6.11         6.2       $ 24,080 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Unvested (unexercisable) — December 31, 2013

     3,453,193      $ 9.38         8.9       $ 1,770 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

 

(1) Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2) Represents the total difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.

The following table summarizes information with respect to stock option grants as of December 31, 2013:

 

     Outstanding      Exercisable  

Exercise Price

   Granted Stock
Options
Outstanding
     Weighted-
Average

Remaining
Contractual
Life (Years)
     Weighted-
Average

Exercise
Price
     Granted
Stock
Options
Exercisable
     Weighted-
Average

Exercise
Price
 

$0.92 –   3.15

     1,192,794         4.5       $ 2.16         1,192,794       $ 2.16   

$3.55 –   4.95

     1,924,904         5.9         4.23         1,865,794         4.23   

$5.05 –   6.90

     2,862,699         5.5         6.26         2,565,220         6.19   

$7.00 –   8.99

     2,329,167         8.2         8.17         1,147,138         8.26   

$9.00 – 16.32

     3,019,654         9.2         10.86         1,105,079         11.09   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
     11,329,218         7.0       $ 7.10         7,876,025       $ 6.11   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

As of December 31, 2013, there was unrecognized compensation expense of $12.4 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.54 years.

 

F-21


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Restricted Stock Activity

A summary of restricted stock activity is as follows:

 

     Number of
Restricted  Stock
Awards
    Weighted Average
Fair Value per
Share at Grant
Date
 

Unvested as of December 31, 2010

     359,500      $ 3.96   

Granted

     1,781,000        12.48   

Vested

     (1,104,025     12.33   

Forfeited

     (83,950     4.78   
  

 

 

   

Unvested — December 31, 2011

     952,525        10.11   

Granted

     586,639        11.76   

Vested

     (472,160     10.26   

Forfeited

     (32,400     9.57   
  

 

 

   

Unvested — December 31, 2012

     1,034,604        11.00   

Granted

     523,800        8.74   

Vested

     (501,660     9.72   

Forfeited

     (49,625     10.60   
  

 

 

   

Unvested — December 31, 2013

     1,007,119      $ 10.09   
  

 

 

   

 

 

 

 

* Represents our stock price on the vesting date multiplied by the number of vested shares.

 

     2013      2012      2011  

Restricted stock expense

   $ 4,202      $ 6,500       $ 4,100   

As of December 31, 2013, there was approximately $6.5 million of unrecorded expense related to issued restricted stock that will be recognized over an estimated weighted average period of 2.4 years.

401(k) Plan – Stock Matching Contribution

We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:

 

     2013      2012      2011  

Shares of common stock issued

     99,359         56,254         65,889   

Match contribution value**

   $ 860       $ 691       $ 593   

 

** Represents our stock price on the date of the stock match multiplied by the number of shares of common stock issued.

 

7. STOCKHOLDERS’ EQUITY

Authorized Stock

On December 13, 2010, we filed the Certificate of Designation of Rights, Preferences and Privileges of Series B Junior Participating Preferred Stock with the Delaware Secretary of State which authorized 1.5 million shares to be designated as Series B Junior Participating Preferred Stock. On June 13, 2011, our stockholders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of our common stock from 100.0 million shares to 175.0 million shares. The amendment was filed with the Delaware Secretary of State on June 24, 2011. As of December 31, 2013, we also had 5.0 million shares of preferred stock authorized, of which 1.5 million shares were designated as Series B Junior Participating Preferred Stock and 2,000 shares were designated as Series E Convertible Voting Preferred Stock.

Stockholder Rights Agreement

On November 29, 2010, our Board of Directors approved a replacement rights agreement, effective December 13, 2010, that replaced the stockholder rights agreement which was originally adopted in 2000. This replacement rights agreement will extend until December 13, 2020. A stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive

 

F-22


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

tactics that might be used in an attempt to gain control of the Company. A stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire the Company to first negotiate with our Board of Directors.

Under the terms of the new Stockholder Rights Agreement, the rights become exercisable upon the earlier of 10 days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or 10 business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our business, even if doing so would benefit our stockholders. We currently have no stockholders who own 15% or more of the outstanding shares of our common stock. Five days after the rights become exercisable, each right, other than rights held by the person or group of affiliated persons whose acquisition of more than 15% of our outstanding common stock caused the rights to become exercisable, will entitle its holder to buy, in lieu of shares of Series B Preferred Stock, a number of shares of our common stock having a market value of twice the exercise price of the rights. After the rights become exercisable, if we are a party to certain merger or business combination transactions or transfers 50% or more of our assets or earnings power (as defined), each right will entitle its holder to buy a number of shares of common stock of the acquiring or surviving entity having a market value of twice the exercise price of the right.

Series E Preferred Stock

In September 2003, we received gross cash proceeds of $20.0 million in exchange for the issuance of 2,000 shares of our Series E Convertible Voting Preferred Stock, convertible into 4.0 million shares of common stock. As of December 31, 2013 and 2012, 20 shares of Series E Preferred Stock were outstanding. No dividends are payable on the Series E Preferred Stock. Pursuant to certain provisions of the Certificate of Designation, Rights and Preferences of the Series E Preferred Stock, we have the option to redeem all of the unconverted Series E Preferred Stock outstanding at the end of a 20-day trading period if, among other things, in that period our common stock trades above $12.00 per share.

In the event we are the subject of any voluntary or involuntary liquidation, dissolution or winding up, before any distribution of our assets shall be made to the common stockholders, the holders of the Series E Preferred Stock shall be entitled to receive a liquidation preference in an amount equal to 120% of the stated value per share plus any declared and unpaid dividends thereon.

Common Stock Reserved for Future Issuance

As of December 31, 2013, approximately 28.1 million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:

 

Conversion of Series E Preferred Stock

     40,000   

2018 Convertible Notes

     11,400,000   

Exercise of issued employee stock options

     11,329,218   

Exercise of issued warrants

     445,000   

ESPP shares reserved

     4,540,986   

Long-term retention and management incentive plan shares

     346,500   
  

 

 

 

Total shares of common stock reserved for future issuances

     28,101,704   
  

 

 

 

Warrant Activity

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through December 2015. A summary of warrant activity is as follows:

 

     Number of
Shares
    Weighted
Average
Exercise Price
 

Outstanding — December 31, 2010

     4,192,312      $ 6.45   

Expired

     (3,747,312     6.62   
  

 

 

   

 

 

 

Outstanding — December 31, 2011

     445,000      $ 5.04   

Exercised

     (50,000     1.79   
  

 

 

   

 

 

 

Outstanding — December 31, 2012

     395,000      $ 5.45   

Granted

     50,000        7.51   
  

 

 

   

 

 

 

Outstanding — December 31, 2013

     445,000      $ 6.39   
  

 

 

   

 

 

 

Exercisable — December 31, 2013

     407,500      $ 6.29   
  

 

 

   

 

 

 

 

F-23


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

8. NET (LOSS) INCOME PER SHARE

Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012      2011  

Net (loss) income

   $ (62,134   $ 94,201       $ 49,931   

Weighted average shares - basic

     60,729,128        58,588,916         53,272,767   

Net (loss) income per share - basic

   $ (1.02   $ 1.61       $ 0.94   

Weighted average shares - diluted

     60,729,128        64,637,256         57,959,714   

Net (loss) income per share - diluted

   $ (1.02   $ 1.46       $ 0.86   

The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2012

        

Basic net income per share:

   $ 94,201         58,588,916       $ 1.61   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,749,299      

Incremental common stock assumed issued on exercise of in-the-money warrants

        224,437      

Unvested restrictive stock awards

        1,034,604      
  

 

 

    

 

 

    

Diluted net income per share

   $ 94,201         64,637,256       $ 1.46   
  

 

 

    

 

 

    

 

 

 

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2011

        

Basic net income per share:

   $ 49,931         53,272,767       $ 0.94   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,185,224      

Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned

        248,193      

Incremental common stock assumed issued on exercise of in-the-money warrants

        200,656      

Unvested restrictive stock awards

        12,874      
  

 

 

    

 

 

    

Diluted net income per share

   $ 49,931         57,959,714       $ 0.86   
  

 

 

    

 

 

    

 

 

 

 

F-24


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:

 

     Year Ended December 31,  
     2013      2012      2011  

2018 Convertible Notes

     343,600         —           —     

Common stock options

     2,934,625         —           —     

Restricted stock awards

     1,007,119         —           —     

Common stock warrants

     160,816         —           —     

Preferred stock

     40,000         —           —     
  

 

 

    

 

 

    

 

 

 

Total

     4,486,160         —           —     
  

 

 

    

 

 

    

 

 

 

 

9. FAIR VALUE MEASUREMENTS

The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2 (x)):

 

     December 31, 2013
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 410       $ —        $ 410   

Money market currency funds

     —           100,395         —          100,395   

Mutual funds

     —          3,061         —          3,061   

Deferred compensation investments, including life insurance cash surrender value

     —          5,361         —          5,361   

Equity securities

     3,593         —           —          3,593   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,593       $ 109,227       $ —         $ 112,820   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          3,949         —          3,949   

Deferred development costs

     —          —           17,742         17,742   

Ligand Contingent Consideration

     —          —           4,000         4,000   

Talon CVR

     —          —           4,329         4,329   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 3,949       $ 26,071       $ 30,020   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

F-25


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

     December 31, 2012
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 987       $ —        $ 987   

Money market currency funds

        11,698         —          11,698   

Mutual funds

     —          2,323         —          2,323   

Deferred compensation investments, including life insurance cash surrender value

     —          2,881         —          2,881   

Equity securities

     2,480         —          —          2,480   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 2,480       $ 17,889       $ —        $ 20,369   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          2,365         —          2,365   

Deferred development costs

     —          —          12,233         12,233   

Deferred payment contingency

     —          —          2,287         2,287   

Ligand Contingent Consideration

     —          —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 2,365       $ 14,520       $ 16,885   
  

 

 

    

 

 

    

 

 

    

 

 

 

We did not have any transfers between Levels 1 and 2 for all periods presented. The following presents a roll forward of our liabilities for which we utilize Level 3 inputs (see Note 2(x)) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “accrued and deferred development costs, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.

Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration liabilities, approximate their related fair values due to their short-term nature.

 

     Fair Value Measurements  of
Unobservable Inputs (Level 3)
 

Balance at December 31, 2011

   $ —    

Transfers in (out)

     —    

Deferred development costs

     12,233   

Deferred payment contingency

     2,287   
  

 

 

 

Balance at December 31, 2012

     14,520   

Transfers in (out)

     —    

Deferred development costs (see Note 13)

     5,509   

Deferred payment contingency (see Note 13)

     (2,287

Ligand Contingent Consideration (see Note 10(b))

     4,000   

Talon CVR (see Note 10(a))

     4,329   
  

 

 

 

Balance at December 31, 2013

   $ 26,071   
  

 

 

 

 

F-26


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

10. BUSINESS COMBINATIONS

(a) Acquisition of Talon Therapeutics, Inc.

Talon Acquisition Overview

On July 16, 2013, we entered into a Securities Purchase Agreement with Talon Therapeutics, Inc. (“Talon”), whereby, on July 17, 2013, we purchased all of its then outstanding shares of common stock. Through the acquisition of Talon, we gained worldwide rights to MARQIBO, an FDA-approved drug that we believe complements our other hematology and oncology products.

Since July 17, 2013, the results of operations of the former Talon business have been included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2013. From July 17, 2013 through December 31, 2013, our revenue derived from the former Talon business was approximately $1.3 million. We had nominal earnings from the Talon business during this period.

The Talon purchase consideration comprised of (i) an aggregate upfront cash amount of $11.3 million, (ii) issuance of 3.0 million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July 17, 2013), and (iii) the issuance of contingent value rights (“CVR”) initially valued by us at $6.5 million.

The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 3 (x)). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:

 

   

$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year

 

   

$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year

 

   

$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year

 

   

$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year

 

   

$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year

 

   

$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion

Direct Costs of the Talon Acquisition

Our direct costs of the Talon acquisition included employee severance, banker, legal, and accounting fees which aggregated to $5.7 million. This amount is included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

Consideration Transferred

The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:

 

Cash consideration

   $ 11,300   

CVR

     6,500   

Spectrum shares of common stock

     26,300   
  

 

 

 

Total purchase consideration

   $ 44,100   
  

 

 

 

 

F-27


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Fair Value Estimate of Assets Acquired and Liabilities Assumed

Under the purchase method of accounting, the total purchase consideration is allocated to Talon net tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date. The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:

 

Cash and equivalents

   $ 131   

Inventory

     611   

Prepaid expenses and other current assets

     109   

Property and equipment

     30   

Identifiable intangible assets

     44,500   
  

 

 

 

Total assets acquired

     45,381   
  

 

 

 

Accounts payable & accrued liabilities

     5,231   

Deferred tax liability

     6,576   
  

 

 

 

Total liabilities assumed

     11,807   
  

 

 

 

Net assets acquired

   $ 33,574   
  

 

 

 
  
  

 

 

 

Goodwill

   $ 10,526   
  

 

 

 

The acquired intangible assets consisted of developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) as follows in the table below:

 

     Value of
Intangible
Assets
Acquired
     Amortization
Period*
 

Developed technology —MARQIBO for ALL

   $ 26,900         13 years   

IPR&D —MARQIBO for NHL

     17,600              (1)
  

 

 

    

Total identifiable intangible assets

   $ 44,500      
  

 

 

    

 

* Recognized on a straight-line basis.
(1) IPR&D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but rather tested for impairment.

The fair value of the acquired IPR&D technology assets was estimated using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts.

Goodwill

Goodwill presented above of $10.5 million represents the difference of the Talon business purchase price of $44.1 million minus the net assets acquired of $33.6 million. This goodwill includes benefits that we believe will result from combining the operations of Talon with ours, as well as the know-how associated with the MARQIBO compounds for future product development. In accordance with applicable GAAP, we will not amortize goodwill associated with the Talon acquisition, though it will be subjected to annual impairment testing. This goodwill is not deductible for income tax purposes.

 

F-28


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Supplemental Pro Forma Financial Information

The following unaudited pro forma financial information is presented to reflect the results of the Company’s consolidated operations for the years ended December 31, 2013 and 2012, as if the acquisition of Talon had occurred on January 1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2012, and may not be indicative of future operating results.

 

     Year Ended December 31,  
     2013     2012  

Pro Forma Total revenues

   $ 155,854      $ 267,707   

Pro Forma Total costs and operating expenses

     200,651        210,433   

Pro Forma Net (loss) income

     (68,146     57,274   

Pro Forma Net (loss) income per share – basic

   $ (1.12   $ 0.98   

Pro Forma Net (loss) income per share – diluted

   $ (1.12   $ 0.89   

Talon CVR Fair Value as of December 31, 2013

The CVR fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value
of Talon
CVR
 

July 17, 2013

   $ 6,500   

Fair value adjustment for year ended December 31, 2013

     (2,171
  

 

 

 

December 31, 2013

   $ 4,329   
  

 

 

 

(b) Acquisition of Rights to Captisol-Enabled ® MELPHALAN

Overview of Acquisition of Rights to C-E MELPHALAN

On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled ®, propylene glycol-free MELPHALAN (“C-E MELPHALAN”) from CyDex Pharmaceuticals, Inc. a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”). C-E MELPHALAN is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts up to an aggregate $66.0 million, upon the achievement of certain regulatory milestones and net sales thresholds (“Ligand Contingent Consideration”). We also must pay royalties in the range of 15% to 25% on net sales of licensed products in all territories.

We accounted for the acquisition of these rights as a business combination, using the acquisition method of accounting. This requires that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. Aggregate transaction costs of $15,000 are included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items:

 

Cash consideration

   $ 3,000   

Ligand Contingent Consideration

     4,700   
  

 

 

 

Total purchase consideration

   $ 7,700   
  

 

 

 

 

F-29


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Fair Value Estimate of Asset Acquired and Liability Assumed

The total purchase consideration is allocated to the acquisition of the tangible and intangible assets acquired and liabilities assumed. These amounts are based on their estimated fair values as of the closing date. The allocation of the total purchase price to the net assets acquired is as follows:

 

IPR&D—C-E MELPHALAN rights

   $ 7,700   
  

 

 

 

Acquired IPR&D is an intangible asset that is classified as indefinite-lived until the completion or abandonment of the associated R&D effort, and is subject to impairment testing. C-E MELPHALAN rights will be amortized over an estimated useful life to be determined at the date the project is complete.

We estimated the fair value of the in-process research and development using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts. The fair value estimate took into account our estimates of future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights, and included estimated cash flows of approximately 10 years and a discount rate of approximately 25%.

The fair value of the contingent consideration liability assumed was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable inputs and are therefore classified as Level 3 inputs – see Note 3(x)), which assumes that FDA approval of C-E MELPHALAN will occur on or about December 31, 2015. Upon receipt of FDA approval, we will be obligated to make a milestone payment of $6.0 million to Ligand.

We do not consider this acquisition to represent a material business combination; accordingly, we have not presented pro forma results of our combined operations that are otherwise required.

Ligand Contingent Consideration Fair Value as of December 31, 2013

The Ligand Contingent Consideration fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value of
Ligand
Contingent
Consideration
 

March 8, 2013

   $ 4,700   

Fair value adjustment for year ended December 31, 2013

     (700
  

 

 

 

December 31, 2013

   $ 4,000   
  

 

 

 

(c) Allos Acquisition

We acquired Allos Therapeutics, Inc. (“Allos”) on September 5, 2012, which was accounted for as a business combination. Our total consideration for this acquisition was $205.2 million, through which we acquired FOLOTYN development technology and FOLOTYN distribution rights.

 

11. REVOLVING LINE OF CREDIT

We entered into a credit agreement on September 5, 2012 with Bank of America, N.A, as the administrative agent and Wells Fargo Bank, N.A, as an initial lender, as amended July 16, 2013 (the “Credit Agreement”). The Credit Agreement provided us with a committed $50.0 million revolving line of credit facility (the “Credit Facility”). The Credit Facility was to expire on September 5, 2014, though we repaid it in full, then immediately terminated it on December 20, 2013 in connection with the sale and issuance of our 2018 Convertible Notes.

 

F-30


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

The Credit Facility bore interest, at our election, at a rate equal to the London Interbank Offer Rate (LIBOR), or the base rate, plus an applicable margin (2.75% to 4.25%, dependent on a defined liquidity ratio).

We incurred $1.0 million in related loan costs and fees in securing the Credit Facility, which were capitalized and recognized within “other assets” on our accompanying Consolidated Balance Sheets. This amount was amortized through “interest expense” to the accompanying Consolidated Statements of Operations, using the effective interest method, initially over the term of the Credit Facility, though the remaining unamortized portion was fully expensed in December 2013 when it was repaid and terminated.

An unused line fee was payable quarterly in an amount ranging from 0.375% to 0.625% of the sum of the average daily unused portion of the facilities during any quarter based upon consolidated leverage ratio as at the last test date. A customary fee was also payable to the administrative agent on an annual basis in advance.

We recognized $1.2 million, $0.5 million, and $-0- in 2013, 2012, and 2011, respectively, within “interest expense” for this retired Credit Facility on the accompanying Consolidated Statements of Operations.

 

12. CONVERTIBLE SENIOR NOTES

On December 17, 2013, we entered into an agreement for the sale of $120.0 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances, as defined in the Indenture. The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2014. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option.

On December 23, 2013 net proceeds from the sale of the 2018 Convertible Notes were $115.4 million, after deducting banker and professional fees of $4.6 million. We used a portion of these net proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to “additional paid-in capital” in our accompanying Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reporting periods.

We entered into Note Hedge transactions to reduce the potential dilution to our common stock and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the “bought call” is equal to the conversion price and conversion rate of the 2018 Convertible Notes, matching the 11.4 million common shares the 2018 Convertible Notes may be converted into. The strike price of our “sold warrant” is $14.03 per share of our common stock, and is also for 11.4 million common shares.

As of December 31, 2013, the 2018 Convertible Notes were not convertible. Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture governing the 2018 Convertible Notes. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes at any time, regardless of the foregoing circumstances.

 

F-31


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

We initially may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval in accordance with applicable NASDAQ rules, we may settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at our election.

The carrying values of the 2018 Convertible Notes as of December 31, 2013 is summarized as follows:

 

Principal amount

   $ 120,000   

(Less): Unamortized debt discount (amortized through December 2018)

     (28,520
  

 

 

 

December 31, 2013 net carrying amount of 2018 Convertible Notes

   $ 91,480   
  

 

 

 

The following table sets forth the components of total “interest expense” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December 31, 2013:

 

Contractual coupon interest expense

   $ 73   

Amortization of debt issuance costs

     43   

Accretion of debt discount

     101   
  

 

 

 

Total

   $ 217   
  

 

 

 

Effective interest rate

     8.59
  

 

 

 

 

13. MUNDIPHARMA AGREEMENT

As the result of Allos becoming our wholly-owned subsidiary, effective September 5, 2012, we assumed obligations under a strategic collaboration agreement with Mundipharma (the “Mundipharma Collaboration Agreement”). Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the “Mundipharma Territories”).

On May 29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the “Amended Munipharma Collaboration Agreement”), in order to modify: (i) the scope of the licensed territory, (ii) milestone payments, (iii) royalty rates, and (iv) development obligations. In connection with the Amended Munipharma Collaboration Agreement, we received a one-time $7.0 million payment from Mundipharma for certain research and development activities to be performed by us.

As a result, (i) Europe and Turkey were excluded from Mundipharma’s commercialization territory, (ii) we may now receive potential regulatory milestone payments of up to $16.0 million and commercial progress and sales-dependent milestone payments of up to $107.0 million, (iii) we will receive tiered double- digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories, and (iv) we and Mundipharma will bear our own FOLOTYN development costs. We recorded the fair value of the related drug development liability of $12.3 million as of September 2012, using the discounted cash flow method of the income approach. The fair value of this liability was determined to be $17.7 million as of December 31, 2013 (inclusive of the $7.0 million payment from Mundipharma) and is included in current and long-term “drug development liability” within the accompanying Consolidated Balance Sheets. This value includes our assumptions about personnel needed to perform these research and development activities, third party costs for projected clinical trial enrollment, and patient treatment-related follow up through approximately 2031.

We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.

 

F-32


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

     Year Ended December 31,  
     Drug
Development
Liability,
Current –
FOLOTYN
    Drug
Development
Liability,

Long Term –
FOLOTYN
    Total Drug
Development
Liability –
FOLOTYN
 

Balance at December 31, 2012

   $ 856      $ 11,377      $ 12,233   

Transfer from long term to current

     3,620        (3,620     —    

Amended agreement payment receipt

     —         7,000        7,000   

(Less): Expenses incurred

     (1,357     (134     (1,491
  

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

   $ 3,119      $ 14,623      $ 17,742   

 

14. COMMITMENTS AND CONTINGENCIES

(a) Facility and Equipment Leases

We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring April 30, 2014. We also lease our research and development and administrative facility in Irvine, California under a non-cancelable operating lease expiring May 31, 2019, in addition to several other administrative office leases. Each lease agreement contains certain scheduled rent increases which are accounted for on a straight-line basis. Our total rental expense in 2013, 2012, and 2011 was $1.2 million, $0.9 million, and $0.7 million, respectively.

Our future minimum lease payments are as follows:

 

Year ending December 31,    Operating Lease
Minimum
Payments
 

2014

   $ 849   

2015

     950   

2016

     892   

2017

     843   

2018

     868   
  

 

 

 
   $ 4,402   
  

 

 

 

(b) Licensing Agreements, Co-Development Agreements, and Milestone Payments

We are developing almost all of our drug candidates pursuant to license agreements that provide us with rights in certain territories, among other things, to develop, sublicense, manufacture and sell the drugs. We are generally required to use commercially reasonable efforts to develop the drugs, and are generally responsible for all development, patent filing and maintenance, sales and marketing and liability insurance costs. We are also obligated to make certain milestone payments to the licensors if we successfully reach development and regulatory milestones specified in the license agreements. In addition, we are obligated to pay royalties and, in some cases, milestone payments based on our net sales.

The potential contingent development and regulatory milestone obligations under all of our licensing agreements are generally tied to progress through the various regulatory authorities’ approval process, which approval significantly depends on positive clinical trial results.

Our most significant of these agreements are listed and summarized below:

(i) ZEVALIN licensing and development in the U.S.

In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with Cell Therapeutics, Inc. (“CTI”). Pursuant to the transfer of the ZEVALIN assets from CTI to RIT Oncology LLC (“RIT”), in December 2008, RIT assumed certain agreements with various third parties related to ZEVALIN intellectual property. These agreements relate to the manufacture, use, and sale of ZEVALIN in the U.S.

 

F-33


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

In accordance with the terms of such agreements, RIT is required to meet specified payment obligations including a commercial milestone payment to Corixa Corporation of $5.0 million based on ZEVALIN sales in the U.S., which has not yet been met, as well as U.S. net sales-based royalties of low to mid-single digits to Genentech, Inc. and mid-single digits to Corixa Corporation.

(ii) Asset Purchase Agreement between CTI and Biogen, ZEVALIN U.S.

In connection with the joint venture arrangement with CTI, we entered into an amendment to the original asset purchase agreement between CTI and Biogen, modifying future milestone payments. Pursuant to the terms of the agreement, as amended, (i) upon the achievement of the specified FDA approval milestone, which was achieved in 2009, RIT (as successor to CTI) paid Biogen an additional amount of $5.5 million, (ii) RIT may be required to make an additional $10.0 million milestone payment upon the achievement of an additional FDA approval milestone, and (iii) RIT is required to make yearly royalty payments determined as a mid-single to mid-teen digits percentage of yearly net sales for the preceding year, increasing with the passage of time. The agreement has an indefinite term and is no longer subject to termination; provided, however, that the royalty obligations automatically terminate upon the latest to occur of expiration of the subject patents, the sale by a third party of a biosimilar product in the U.S. or December 31, 2015. CTI’s rights and obligations, including its payment obligations to Biogen for royalties on net sales of ZEVALIN and an additional regulatory milestone payment, under both the CTI/Biogen Agreement and the amendment were assigned to and assumed by RIT in connection with the closing of the joint venture transaction.

(iii) License and Asset Purchase Agreement with Bayer Pharma, ZEVALIN Ex-U.S.

On April 1, 2012, through our subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed the acquisition of licensing rights to market ZEVALIN outside of the U.S., referred to as the ZEVALIN Ex-US Rights, from Bayer Pharma AG, or Bayer.

We currently market ZEVALIN in the U.S. and this agreement expanded our commercial efforts to the rest of the world. ZEVALIN is currently approved in more than 40 countries outside the U.S. for the treatment of B-cell non-Hodgkin lymphoma, including countries in Europe, Latin America and Asia. In consideration for the rights granted under the agreement, concurrent with the closing, we paid Bayer a one-time fee of Euro 19.0 million, and will pay Bayer royalties based on a mid-teen digits percentage of net sales of the licensed products in all territories worldwide except the U.S. Unless earlier terminated, the term of the agreement continues until the expiration of our royalty payment obligations which, in turn, run until the last-to-expire patent covering the sale of a licensed product in the relevant country or 15 years from the date of first commercial sale of the licensed product in such country, whichever is longer.

(iv) Amended and Restated License Agreement with Merck & Cie AG, FUSILEV

In May 2006, we amended and restated a license agreement with Merck & Cie AG, a Swiss corporation, which we assumed in connection with the acquisition of the assets of Targent. Pursuant to the license agreement with Merck & Cie, we obtained the exclusive license to use regulatory filings related to FUSILEV and a non-exclusive license under certain patents and know-how related to FUSILEV to develop, make, use, and sell FUSILEV in the field of oncology in North America. In addition, we have the right of first opportunity to negotiate an exclusive license to manufacture, use, and sell FUSILEV products outside the field of oncology in North America. Also, under the terms of the license agreement, we paid Merck & Cie $0.1 million for the achievement of FDA approval of an injectable form of FUSILEV. Merck & Cie is also eligible to receive a $0.2 million payment upon achievement of FDA approval of an oral form of FUSILEV, in addition to royalties in the mid-single digits based on a percentage of net sales. The term of the license agreement is determined on a product-by-product and country-by-country basis until royalties are no longer owed under the license agreement. The license agreement expires in its entirety after the date that we no longer owe any royalties to Merck & Cie. We have the unilateral right to terminate the license agreement, in its entirety or on a product-by-product or country-by-country basis, at any time for any reason.

(v) Asset Purchase Agreement with Targent, Inc., FUSILEV

In March 2006, we entered into an Asset Purchase Agreement with Targent, Inc. (“Targent”). As part of the consideration for the purchase of certain assets, we agreed to pay milestone payments to Targent upon the achievement of certain regulatory events as well as for certain sales levels for FUSILEV within a calendar year. In connection with the achievement of the FDA approval milestone in April 2011, we issued an aggregate of 0.7 million shares of our common stock to certain of Targent’s stockholders. We capitalized $6.3 million associated with this milestone as an amortizable intangible asset.

 

F-34


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

In addition, in connection with the achievement of the first sales milestone in May 2011, we issued 0.6 million shares of our common stock to certain of Targent’s stockholders. In September 2011, we achieved the second and final sales milestone and paid $5.0 million. We capitalized an aggregate $10.0 million associated with these milestones as amortizable intangible assets.

(vi) License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute, FOLOTYN

In December 2002, Allos entered into the FOLOTYN License Agreement with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. As a result of Allos becoming our wholly owned subsidiary effective September 5, 2012, we are bound by the FOLOTYN License Agreement under which we obtained exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN and its uses. Under the terms of the FOLOTYN License Agreement, we are required to fund all development programs and will have sole responsibility for all commercialization activities. In addition, we pay the licensors royalties based on worldwide graduated annual levels of net sales of FOLOTYN, or sublicense revenues arising from sublicensing the product, if and when such sales or sublicenses occur. Royalties are 8% of annual worldwide sales up to $150.0 million; 9% of annual worldwide sales of $150.0 million through $300.0 million; and 11% of annual worldwide sales in excess of $300.0 million.

(vii) License Agreement with Cydex Pharmaceuticals, Inc., Captisol-enabled, Propyleneglycol-free MELPHALAN

On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to C-E MELPHALAN from Ligand (see Note 10(b)). This product candidate is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts of up to $66.0 million, upon achievement of certain regulatory milestones and net sales thresholds, and royalties in the range of 15% to 25% on net sales of licensed products in all territories.

(viii) Exclusive Development and Commercialization Collaboration Agreement with Allergan, APAZIQUONE

In October 2008, we signed an exclusive development and commercialization collaboration agreement with Allergan for APAZIQUONE. Pursuant to the terms of the agreement, Allergan paid us an up-front non-refundable $41.5 million at closing and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones.

On January 29, 2013, we entered into a second amendment to the license, development, supply and distribution agreement with Allergan to amend the agreement and reacquire the rights originally licensed to Allergan in the U.S., Europe, and other territories in exchange for a tiered single-digit royalty on certain products containing APAZIQUONE, and relieved Allergan of its obligations for development, commercialization and other activities. As a result of this amendment to the agreement, Allergan has no remaining obligations to us, and we have no remaining performance obligations to them. However, we are obligated to pay Allergan a tiered single-digit royalty not to exceed mid-single digits based upon the net sales, when and if earned, of certain products containing APAZIQUONE in specified territories. Additionally, we are obligated to pay any royalties or other payments due to certain licensors of underlying intellectual property, as well as to provide indemnification of Allergan for claims arising from the manufacture, development, or commercialization of pharmaceutical products containing APAZIQUONE by us.

(ix) Collaboration Agreement with Nippon Kayaku Co. LTD., APAZIQUONE

In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (“Nippon Kayaku”) for the development and commercialization of APAZIQUONE in Asia, except North and South Korea (the “Nippon Kayaku Territory”). In addition, Nippon Kayaku received exclusive rights to APAZIQUONE for the treatment of non-muscle invasive bladder cancer in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct APAZIQUONE clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of APAZIQUONE in the Nippon Kayaku Territory.

Pursuant to the terms of this agreement, Nippon Kayaku paid Spectrum an upfront fee of $15.0 million and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones. Under the terms

 

F-35


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

of the agreement, we are entitled to payment of $10.0 million and $126.0 million upon achievement of certain regulatory and commercialization milestones, respectively. Also, Nippon Kayaku has agreed to pay us royalties based on a percentage of net sales of the subject products in the defined territory in the mid-teen digits.

Our license agreement with Nippon Kayaku provides for payments to us upon the achievement of development milestones, such as the completion of clinical trials or regulatory submissions, approvals by health authorities, and commercial launches of drug candidates. Given the challenges inherent in developing and obtaining approval for drug products and in achieving commercial launches, there was substantial uncertainty whether any such milestones would be achieved at the time of execution of such license agreement. We expect to recognize as revenue future payments received from such milestones only if achieved.

(x) Licensing and Collaboration Agreement with TopoTarget, BELEODAQ

In February 2010, we entered into a licensing and collaboration agreement with TopoTarget A/S (“TopoTarget”), as amended in October 2013, for the development and commercialization of BELEODAQ. The agreement provides that we have the exclusive right to make, develop, and commercialize BELEODAQ in North America and India, with an option for China.

Under continuing terms, all development, including studies, will be conducted under a joint development plan. We have final decision-making authority for all developmental activities in North America and India (and China upon exercise of its option). TopoTarget has final decision-making authority for all developmental activities in all other jurisdictions. We are responsible for future costs of the ongoing registrational PTCL trial. We and TopoTarget will conduct future planned clinical trials pursuant to the joint development plan, of which we will fund 70% of the development costs, and TopoTarget will fund 30%.

We will each pay 50% of the costs for chemical, pharmaceutical and other process development related to the manufacturing of the product that are incurred with a mutually agreed upon budget in the joint development plan. We have the right to manufacture clinical and commercial supplies of BELEODAQ. TopoTarget is obligated to purchase its BELEODAQ requirements from us on a cost plus basis.

Pursuant to the terms of this agreement, we paid TopoTarget an upfront fee of $30.0 million in 2010. In addition, on the successful achievement of certain development, regulatory and sales milestones, we are obligated to issue 1.0 million shares of our common stock (subject to certain resale conditions) and pay TopoTarget up to $313.0 million. In February 2014, the first of these milestones was met, resulting in the issuance of 1.0 million shares of our common stock and the payment of $10.0 million to TopoTarget (see Note 17). We will pay TopoTarget future royalties in the mid-teen digits based on net sales of BELEODAQ in the defined territory.

The agreement will continue until the expiration of the last royalty payment period in the last country in the defined territory with certain provisions surviving, unless earlier terminated in accordance with its terms. We may terminate this agreement with 180 days notice to TopoTarget. We may also terminate immediately upon a prohibition on the use of the subject product or clinical hold by the FDA. TopoTarget may also terminate immediately in the event of a challenge (without TopoTarget’s consent) by us of the patents that cover the product.

(xi) Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Company, SPI-2012

In late January 2012, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Company, (“Hanmi”), for SPI-2012, formerly known as “LAPS-GCSF”, a drug for the treatment of chemotherapy induced neutropenia based on Hanmi’s proprietary LAPSCOVERY™ Technology. In consideration for the rights granted to us under the co-development and commercialization agreement with Hanmi, we paid Hanmi a fee which is included in “research and development expense” in the accompanying Consolidated Statements of Operations because the technology has not yet achieved regulatory approval. Under the terms of the agreement, we will share the costs and expenses of the study with Hanmi, although we will have primary responsibility for them. If SPI-2012 is ultimately commercialized by us, we will have worldwide rights except for Korea, China and Japan upon payment of fees and milestone payments related to further development, regulatory approvals and sales targets.

(c) Service Agreements

In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers,

 

F-36


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients.

At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. We are in a position to accelerate, slow-down or discontinue any or all of the projects that we are working on at any given point in time. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered and our future purchase obligations would reduce accordingly.

(d) Supply Agreements

We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements, and the contracted prices do not exceed their fair market value.

(e) Employment Agreements

We have entered into employment agreements with certain of our officers and other “key employees” under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

(f) Deferred Compensation Plan

On September 2, 2011, the Board of Directors approved the Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”). The DC Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is administered by the Compensation Committee of our Board of Directors. The DC Plan is intended to be an unfunded plan which is maintained primarily to provide deferred compensation benefits for a select group of our employees, as selected by the DC Plan administrator (the “DC Participants”). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, as established by the DC Plan administrator, and we have the option to make discretionary contributions. At December 31, 2013 and 2012, DC Plan deferrals and contributions totaling $3.9 million and $2.4 million, respectively, are included as a liability in the accompanying Consolidated Balance Sheets.

(g) Litigation

We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims.

We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.

We are presently responding to Abbreviated New Drug Applications (“ANDAs”) filed by companies seeking to launch generic forms of FUSILEV and to certain shareholder suits that purportedly stem from our March 12, 2013 press release, in which we announced anticipated changes in customer ordering patterns of FUSILEV. These complaints allege that, as a result of the March 12, 2013 press release, our stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of our stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.

 

F-37


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

FUSILEV ANDA Litigation

On January 20, 2012 and February 17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate ANDAs, to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our fees and costs incurred in such matters. On December 9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain.

Shareholder Litigation

John Perry v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH. This putative consolidated class action raises substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr. Rajesh C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August 8, 2012 to March 12, 2013. The lawsuits allege a violation of Section 10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section 20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company’s March 12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.

Timothy Fik v. Rajesh C. Shrotriya, et al. (Filed April 11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May 28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against certain current and former directors and officers. The complaints generally allege breaches of fiduciary based on conduct relating to the events alleged in the consolidated Perry action. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, and costs and fees. On May 15, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.

Hardik Kakadia v. Rajesh C. Shrotriya, et al. (Filed April 23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May 31, 2013; Case Number A-13-682668-C) (collectively the “State Derivative Actions”). These consolidated State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. and are substantially similar to the consolidated federal derivative actions.

(h) SEC Subpoena

On April 1, 2013, we received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed our March 12, 2013 announcement that we anticipated a change in customer ordering patterns of FUSILEV. We continue to cooperate with this SEC investigation, though we cannot predict its outcome, or the timing of resolution.

 

15. INCOME TAXES

The components of (loss) income before (provision) benefit for income taxes are as follows:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

United States

   $ (30,437   $ 82,165      $ 53,834   

Foreign

     (6,199     (2,235     (199
  

 

 

   

 

 

   

 

 

 

Total

   $ (36,636   $ 79,930      $ 53,635   
  

 

 

   

 

 

   

 

 

 

 

F-38


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

The provision (benefit) for income taxes consist of the following:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

Current:

      

Federal

   $ (8,357   $ 16,222      $ 1,255   

State

     (691     3,412        2,449   

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
   $ (9,048   $ 19,634      $ 3,704   

Deferred:

      

Federal

     36,183        (24,013     —    

State

     (1,637     (9,892     —    

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
     34,546        (33,905     —    

Total income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

 

The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:

 

     2013     2012     2011  

Tax provision (benefit) computed at the federal statutory rate

   $ (12,822   $ 27,975      $ 18,250   

State tax, net of federal benefit

     (246     2,442        2,918   

Expired tax attributes

     —         —         385   

Research credits

     (2,254     (2,129     (1,464

Benefits from credit study

     —         (4,148     —    

Common stock warrant liability

     —         —         1,186   

Transaction costs

     880        1,497        —    

Officers compensation

     2,178        2,908        3,801   

Stock based compensation

     501        134        1,676   

Permanent items and other

     (1,080     2,111        2,039   

Domestic manufacturing deduction

     767        (1,262     —    

Tax differential on foreign earnings

     1,123        382        —    

Change in tax rate

     (283     338        —    

Valuation allowance

     36,734        (44,519     (25,087
  

 

 

   

 

 

   

 

 

 

Income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

 

The American Taxpayer Relief Act of 2012, which reinstated the U.S. federal research and development tax credit retroactively from January 1, 2012 through December 31, 2013, was not enacted into law until the first quarter of 2013. The tax benefit resulting from such reinstatement is reflected in our 2013 tax provision.

 

F-39


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

Significant components of our deferred tax assets as of December 31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.

 

     2013     2012  

Deferred tax assets:

    

Net operating loss carry forwards

   $ 46,482      $ 45,391   

Research credits

     8,066        1,848   

Stock based compensation

     3,486        2,896   

Deferred revenue

     58        4,596   

Development costs

     6,495        5,298   

Returns and allowances

     3,117        7,889   

Other, net

     5,551        6,021   
  

 

 

   

 

 

 

Total deferred tax assets before valuation allowance

     73,255        73,246   

Valuation allowance

     (49,586     (1,818
  

 

 

   

 

 

 

Total deferred tax assets

     23,669        72,121   

Deferred tax liabilities:

    

Basis difference in debt

     (1,082     —    

Depreciation and amortization differences

     (28,096     (36,372
  

 

 

   

 

 

 

Net deferred tax (liability) asset

   $ (5,509   $ 35,749   
  

 

 

   

 

 

 

The increase in the valuation allowance in 2013 was due to uncertainties regarding the realization of deferred tax assets acquired in connection with the Talon acquisition and a change in our overall assessment regarding the realization of our domestic deferred tax assets as a result of larger than expected operating losses sustained in 2013 and an increase in our expected operating loss for 2014. The decrease in the valuation allowance in 2012 was due to a change in our assessment regarding the realization of our domestic deferred tax assets as a result of positive earnings trends in 2010, 2011, and 2012 and operating income recorded in 2011 and 2012.

At December 31, 2013, we had federal and state net operating loss carryforwards of approximately $117.4 million and $132.0 million, respectively. We have approximately $4.1 million of foreign loss carryforwards that will begin to expire in 2028. The federal and state loss carry forwards begin to expire in 2018 and 2014, respectively, unless previously utilized. At December 31, 2013, we had federal and state tax credits of approximately $6.9 million and $2.2 million, respectively. The federal tax credit carryovers begin to expire in 2026 unless previously utilized. The state research and development credits have an indefinite carryover period.

As a result of the prior ownership changes, the utilization of certain net operating loss and research and development tax credit carryforwards including those acquired in connection with the acquisition of Allos and Talon are subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986 and similar state provisions. Any net operating losses or credits that would expire unutilized as a result of Section 382 and 383 limitations have been removed from the table of deferred tax assets and the accompanying disclosures of net operating loss and research and development carryforwards.

Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized.

 

F-40


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

The following tabular reconciliation summarizes activity related to unrecognized tax benefits:

 

     2013     2012     2011  

Balance at beginning of year

   $ 5,482      $ 3,928      $ 2,803   

Adjustments related to prior year tax positions

     (200     (527     5   

Increases related to current year tax positions

     648        2,515        1,120   

Decreases due to settlements

     (1,227     (434     —    

Decreases related to prior year tax positions

     (2,491     —         —    
  

 

 

   

 

 

   

 

 

 

Balance at end of year

   $ 2,212      $ 5,482      $ 3,928   
  

 

 

   

 

 

   

 

 

 

During 2013, we continue to believe that our tax positions meet the more-likely-than-not standard required under the recognition phase of the authoritative guidance. However, we consider the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.

Approximately $0.3 million, $5.2 million and $0.2 million of the total unrecognized tax benefits as of December 31, 2013, 2012 and 2011, respectively, would reduce our annual effective tax rate if recognized. Additional amounts in the summary rollforward could impact our effective tax rate if we did not maintain a full valuation allowance on our net deferred tax assets.

We do not expect our unrecognized tax benefits to change significantly over the next 12 months. With a few exceptions, we are no longer subject to U.S. federal, state and local income tax examinations for years before 2009. Our policy is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of operations and are not material.

During 2013, the Internal Revenue Service completed an examination of our 2010 tax return. No tax was paid as a result of the examination. As a result of the examination, the Company reduced tax credits carryovers by $0.8 million and net operating loss carryovers by $1.6 million.

 

16. SUBSEQUENT EVENT

BELEODAQ NDA Acceptance by the FDA

On February 5, 2014, we received a communication from the FDA notifying us that our NDA for BELEODAQ (Belinostat) for Injection had been accepted for filing with priority review. As a result of this achievement, pursuant to the TopoTarget agreement (see Note 14(b)(x)), we paid TopoTarget $10.0 million and issued an aggregate 1.0 million shares of our common stock in February 2014.

 

17. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Selected quarterly financial data (unaudited) for the year ended December 31, 2013 and 2012 is presented below:

 

     Quarter Ended (Unaudited)  
     March 31     June 30     September 30     December 31  

2013:

        

Total revenues

   $ 38,667      $ 33,232      $ 42,439      $ 41,516   

Operating loss

   $ (6,457   $ (12,529   $ (13,287   $ (6,512

Net loss

   $ (5,435   $ (9,721   $ (7,812   $ (39,166

Net loss per share, basic

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

Net loss per share, diluted

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

 

F-41


SPECTRUM PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except percentages, share and per share data, and number of years)

 

     Quarter Ended (Unaudited)
(In thousands, except per share data)
 
     March 31      June 30      September 30      December 31  

2012:

           

Total revenues

   $ 59,859       $ 68,702       $ 69,042       $ 70,104   

Operating income

   $ 23,596       $ 23,028       $ 23,109       $ 11,041   

Net income

   $ 46,838       $ 18,350       $ 21,524       $ 7,489   

Net income per share, basic

   $ 0.80       $ 0.31       $ 0.37       $ 0.13   

Net income per share, diluted

   $ 0.72       $ 0.29       $ 0.33       $ 0.12   

Net (loss) income per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.

 

F-42


Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None

Item 9A. Controls and Procedures

Our principal executive officer and principal financial officer have provided certifications filed as Exhibits 31.1 and 32.1, and 31.2 and 32.2, respectively. Such certifications should be read in conjunction with the information contained in this Item 9A for a more complete understanding of the matters covered by such certifications.

(a) Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934 (the “Exchange Act”). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of the financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. This process includes those policies and procedures (i) that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) that receipts and expenditures are being made only in accordance with authorizations of our management and directors; (iii) that provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements; and (iv) that provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that the internal control may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2013. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (1992 framework) (“COSO”).

Based on our management’s assessment, we have concluded that as of December 31, 2013, our internal control over financial reporting was not effective, as evaluated under the COSO criteria. This assessment was due to management’s identification of a material weakness in the design and operating effectiveness of our internal control over financial reporting that relate to the accurate and timely reporting of our operating expense accruals (which in part was previously identified within Item 9A of our 2012 Annual Report on Form 10-K/A). This internal control failure relates to (i) ineffective design and operation of controls over our process of estimating the required period-end accruals for services performed under open purchase orders, which resulted in overstated operating expenses and accrued liabilities in multiple reporting periods in, and prior to, 2013; and (ii) ineffective design and operation of controls over our identification and recording of liabilities for vendor invoices received subsequent to year-end that related to our 2013 activities, which would have resulted in understated operating expenses and accrued liabilities, if left uncorrected.

A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

Notwithstanding our material weakness, we have concluded that the financial statements and other financial information included in this Annual Report on Form 10-K fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.

 

61


Our independent registered public accounting firm, Ernst & Young LLP, has issued a report on our internal control over financial reporting. Ernst & Young LLP’s report appears within Item 8 in this Annual Report on Form 10-K and expresses an adverse opinion on the effectiveness of our internal control over financial reporting.

(b) Remediation Steps to Address Material Weakness

We have developed, and are currently implementing, a remediation plan for this material weakness. We will continue to execute our previously communicated remediation plan, which includes hiring additional experienced accounting personnel and expanding training for our accounting personnel, as well as modifying and expanding our internal controls over our recording of complete and accurate period-end accruals. The successful remediation of this material weakness will require review and evidence of the effectiveness of the related internal controls as part of our next annual assessment of our internal controls over financial reporting as of December 31, 2014. As we continue these remediation efforts, we may determine that additional measures should be taken to address these or other control deficiencies, and/or that we should modify the remediation plan described above.

(c) Disclosure Controls and Procedures

In accordance with Rules 13a-15(e) and 15d-15(e) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.

In conducting our evaluation, we concluded there is a material weakness in the design and operating effectiveness of our internal control over financial reporting, as described above. As a result, we have concluded that as of December 31, 2013, our disclosure controls and procedures were not effective in providing reasonable assurance that information required to be disclosed in our reports filed under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and regulations, and that such information was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(d) Changes in Internal Control Over Financial Reporting

Except as disclosed above, there were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2013 that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required under this item is incorporated by reference from our definitive proxy statement related to our 2014 Annual Meeting of Stockholders, or the Proxy Statement, to be filed pursuant to Regulation 14A, on or before April 30, 2014.

Item 11. Executive Compensation

The information required under this item is incorporated herein by reference from the Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required under this item is incorporated herein by reference from the Proxy Statement.

 

62


Item 13. Certain Relationships and Related Transactions, and Director Independence.

The information required under this item is incorporated herein by reference from the Proxy Statement.

Item 14. Principal Accountant Fees and Services

The information required under this item is incorporated herein by reference from the Proxy Statement.

PART  IV

Item 15. Exhibits and Financial Statement Schedules

 

(a) Financial Statements and Schedules

The following financial statements and schedules listed below are included in this Annual Report on Form 10-K:

Financial Statements

Reports of Independent Registered Public Accounting Firm

Consolidated Balance Sheets as of December 31, 2013 and 2012

Consolidated Statements of Operations for the years ended December 31, 2013, 2012, and 2011

Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2013, 2012, and 2011

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2013, 2012, and 2011

Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012, and 2011

Notes to the Consolidated Financial Statements

Schedule II – Valuation and Qualifying Accounts for the years ended December 31, 2013, 2012, and 2011.

(All other schedules are omitted, as required information is either not applicable or the information is presented in the consolidated financial statements).

SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

Years Ended December 31, 2013, 2012, and 2011

 

Description

   Balance at
Beginning of
Period
     Additions
(Reductions)
     Deductions (1)     Balance at
End of
Period
 
      Additions
(Recovery)
to Bad Debt
Expense or
Deferred
Tax Asset
    Charged
to Other
Accounts
      
     (in thousands)  

Year ended December 31, 2013

            

Allowance for doubtful accounts

   $ 228       $ 11        —         $ (33   $ 206   

Year ended December 31, 2012

            

Allowance for doubtful accounts

   $ 471       $ (128     —         $ (115   $ 228   

Year ended December 31, 2011

            

Allowance for doubtful accounts

   $ 339       $ 139        —         $ (7   $ 471   

 

(1) Deductions represent the actual write-off of accounts receivable balances.

 

  (b) Exhibits

The following is a list of exhibits required by Item 601 of Regulation S-K filed as part of this Annual Report on Form 10-K. For exhibits that previously have been filed, the Company incorporates those exhibits herein by reference. The exhibit table below includes the Form Type and Filing Date of the previous filing and the original exhibit number in the previous filing which is being incorporated by reference herein.

 

63


Exhibit

No.

  

Description

  2.1    Asset Purchase Agreement, dated August 15, 2007, by and between Cell Therapeutics, Inc. and Biogen Idec Inc. (Filed as Exhibit 10.1 to Cell Therapeutics, Inc.’s Form 8-K, No. 001-12465, as filed with the Securities and Exchange Commission on August 21, 2007, and incorporated herein by reference.)
  2.2    First Amendment to Asset Purchase Agreement, dated December 9, 2008, by and between Cell Therapeutics, Inc. and Biogen Idec Inc. (Filed as Exhibit 10.48 to Cell Therapeutics, Inc.’s Form 10K, No. 001-12465, as filed with the Securities and Exchange Commission on March 16, 2009, and incorporated herein by reference.)
  2.3#    License and Asset Purchase Agreement between Spectrum Pharmaceuticals Cayman, L.P. and Bayer Pharma AG, dated January 23, 2012. (Filed as Exhibit 2.1 to Form 10-Q, as filed with the Securities and Exchange Commission on April 27, 2012, and incorporated herein by reference.)
  2.4    Agreement and Plan of Merger, dated as of April 4, 2012, by and among Spectrum Pharmaceuticals, Inc., Sapphire Acquisition Sub, Inc. and Allos Therapeutics, Inc., including a Form of Contingent Value Rights Agreement and a Form of Tender and Voting Agreement. (Filed as Exhibits 2.1, 2.2 and 2.3, respectively, to Form 8-K, as filed with the Securities and Exchange Commission on April 5, 2012, and incorporated herein by reference.)
  2.5    Securities Purchase Agreement, dated July 16, 2013, by and among Spectrum Pharmaceuticals, Inc., Eagle Acquisition Merger Sub, Inc., certain entities affiliated with Warburg Pincus & Co. and certain entities affiliated with Deerfield Management, LLC. (Filed as Exhibit 2.1 to Form 8-K, as filed with the Securities and Exchange Commission on July 19, 2013, and incorporated herein by reference.)
  2.6    Stock Purchase Agreement, dated July 16, 2013, by and among Spectrum Pharmaceuticals, Inc., Eagle Acquisition Merger Sub, Inc. and Talon Therapeutics, Inc. (Filed as Exhibit 2.2 to Form 8-K, as filed with the Securities and Exchange Commission on July 19, 2013, and incorporated herein by reference.)
  2.7    Contingent Value Rights Agreement, dated July 16, 2013, by and among Spectrum Pharmaceuticals, Inc., Talon Therapeutics, Inc. and Corporate Stock Transfer Inc. as rights agent. (Filed as Exhibit 2.3 to Form 8-K, as filed with the Securities and Exchange Commission on July 19, 2013, and incorporated herein by reference.)
  2.8    Exchange Agreement, dated July 16, 2013, by and among Talon Therapeutics, Inc. and certain entities affiliated with Deerfield Management, LLC, including the Registration Rights Agreement by and among Spectrum Pharmaceuticals, Inc. and certain entities affiliated with Deerfield Management, LLC, as Exhibit A thereto. (Filed as Exhibit 2.4 to Form 8-K, as filed with the Securities and Exchange Commission on July 19, 2013, and incorporated herein by reference.)
  3.1    Certificate of Incorporation, as amended through June 24, 2011. (Filed as Exhibit 3.1 to Form 10-K, as filed with the Securities and Exchange Commission on March 2, 2012, and incorporated herein by reference.)
  3.2    Second Amended and Restated Bylaws of Spectrum Pharmaceuticals, Inc. (Filed as Exhibit 3.2 to Form 8-K, as filed with the Securities and Exchange Commission on August 8, 2012, and incorporated herein by reference.)
  4.1    Rights Agreement, dated as of December 13, 2010, between Spectrum Pharmaceuticals, Inc. and ComputerShare Trust Company, N.A. (formerly U.S. Stock Transfer Corporation), as Rights Agent, which includes as Exhibit A thereto the form of Certificate of Designation for the Series B Junior Participating Preferred Stock, as Exhibit B thereto the Form of Rights Certificate and as Exhibit C thereto a Summary of Rights of Stockholder Rights Plan. (Filed as Exhibit 4.1 to Form 8-K, as filed with the Securities and Exchange Commission on December 13, 2010, and incorporated herein by reference.)

 

64


Exhibit

No.

  

Description

  4.2+    Registration Rights and Stockholder Agreement, dated as of February 2, 2010, by and between Spectrum Pharmaceuticals, Inc. and Topotarget A/S.
  4.3    Indenture, dated as of December 23, 2013, by and between Spectrum Pharmaceuticals, Inc. and Wilmington Trust, National Association, dated as of December 23, 2013. (Filed as Exhibit 4.1 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)
  4.4    Form of Note for Spectrum Pharmaceuticals, Inc.’s 2.75% Convertible Senior Notes due 2018. (Filed as Exhibit 4.2 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)
10.1    Sublease Agreement, dated as of December 2, 2010, between Spectrum Pharmaceuticals, Inc. and Del Webb Corporation. (Filed as Exhibit 10.1 to Form 10-K, as filed with the Securities and Exchange Commission on March 10, 2011, and incorporated herein by reference.)
10.2    First Amendment to Sublease Agreement, dated November 16, 2011, between Spectrum Pharmaceuticals, Inc. and Del Webb Corporation. (Filed as Exhibit 10.2 to Form 10-K, as filed with the Securities and Exchange Commission on March 2, 2012, and incorporated herein by reference.)
10.3    Second Amendment to Sublease Agreement, dated November 12, 2012, between Spectrum Pharmaceuticals, Inc. and Del Webb Corporation. (Filed as Exhibit 10.10 to Form 10-K, as filed with the Securities and Exchange Commission on February 28, 2013, and incorporated herein by reference.)
10.4    Industrial Lease Agreement, dated as of January 16, 1997, between Spectrum Pharmaceuticals, Inc. and the Irvine Company. (Filed as Exhibit 10.11 to Form 10-KSB, as filed with the Securities and Exchange Commission on March 31, 1997, and incorporated herein by reference.)
10.5    First Amendment, dated March 25, 2004, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company. (Filed as Exhibit 10.1 to Form 10-Q, as filed with the Securities and Exchange Commission on May 17, 2004, and incorporated herein by reference.)
10.6+    Second Amendment, dated March 7, 2006, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company.
10.7+    Third Amendment, dated February 12, 2006, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company.
10.8    Fourth Amendment, dated July 29, 2009, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company. (Filed as Exhibit 10.29 to Form 10-K, as filed with the Securities and Exchange Commission on April 5, 2010, and incorporated herein by reference.)
10.9+    Fifth Amendment, dated November 21, 2013, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company.
10.10+    Sixth Amendment, dated January 31, 2014, to Industrial Lease Agreement dated as of January 16, 1997 by and between Spectrum Pharmaceuticals, Inc. and the Irvine Company.
10.11    Preferred Stock and Warrant Purchase Agreement, dated as of September 26, 2003, by and among Spectrum Pharmaceuticals, Inc. and the purchasers listed on Schedule 1 attached thereto. (Filed as Exhibit 10.1 to Form 8-K, as filed with the Securities and Exchange Commission on September 30, 2003, and incorporated herein by reference.)
10.12*    Form of Stock Option Agreement under the 2003 Amended and Restated Incentive Award Plan. (Filed as Exhibit 10.1 to Form 8-K, as filed with the Securities and Exchange Commission on December 17, 2004, and incorporated herein by reference.)

 

65


Exhibit

No.

  

Description

10.13*    Form of Non-Employee Director Stock Option Agreement under the 2003 Amended and Restated Incentive Award Plan. (Filed as Exhibit 10.5 to Form 10-Q, as filed with the Securities and Exchange Commission on May 10, 2005, and incorporated herein by reference.)
10.14*    2003 Amended and Restated Incentive Award Plan. (Filed as Exhibit 10.1 to Form 8-K, as filed with the Securities and Exchange Commission on July 2, 2009, and incorporated herein by reference.)
10.15*    Long-Term Retention and Management Incentive Plan. (Filed as Exhibit 10.36 to Form 10-Q, as filed with the Securities and Exchange Commission on August 4, 2011, and incorporated herein by reference.)
10.16*    Deferred Compensation Plan (Filed as Exhibit 4.1 to Form S-8, as filed with the Securities and Exchange Commission on September 6, 2011, and incorporated herein by reference).
10.17*    Executive Employment Agreement by and between Spectrum Pharmaceuticals, Inc. and Rajesh C. Shrotriya, M.D., entered into June 20, 2008 and effective as of January 2, 2008. (Filed as Exhibit 10.1 to Form 8-K, as filed with the Securities and Exchange Commission on June 26, 2008, and incorporated herein by reference.)
10.18*    Form of Indemnity Agreement of Spectrum Pharmaceuticals, Inc. (Filed as Exhibit 10.32 to Form 10-K, as filed with the Securities and Exchange Commission on March 31, 2009, and incorporated herein by reference.)
10.19*    2009 Employee Stock Purchase Plan. (Filed as Exhibit 99.1 to Form S-8, as filed with the Securities and Exchange Commission on June 29, 2009, and incorporated herein by reference.)
10.20*    2009 Incentive Award Plan. (Filed as Exhibit 99.2 to Form S-8, as filed with the Securities and Exchange Commission on June 29, 2009, and incorporated herein by reference.)

 

66


Exhibit

No.

  

Description

10.21*    Term Sheet for 2009 Incentive Award Plan Stock Option Award. (Filed as Exhibit 10.8 to Form 10-Q, as filed with the Securities and Exchange Commission on August 13, 2009, and incorporated herein by reference.)
10.22*    Term Sheet for 2009 Incentive Award Plan, Nonqualified Stock Option Award Awarded to Non-Employee Directors (Revised July 2012). (Filed as Exhibit 10.2 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.23*    Term Sheet for 2009 Incentive Award Plan, Restricted Stock Award. (Filed as Exhibit 10.10 to Form 10-Q, as filed with the Securities and Exchange Commission on August 13, 2009, and incorporated herein by reference.)
10.24#    License and Collaboration Agreement, dated February 2, 2010, by and between Spectrum Pharmaceuticals, Inc. and Topotarget A/S. (Filed as Exhibit 10.37 to Form 10-K, as filed with the Securities and Exchange Commission on April 5, 2010, and incorporated herein by reference.)
10.25#    Amendment to License and Collaboration Agreement, dated October 3, 2013, by and between Spectrum Pharmaceuticals, Inc. and Topotarget A/S. (Filed as Exhibit 99.1 to Form 8-K/A, as filed with the Securities and Exchange Commission on November 18, 2013, and incorporated herein by reference.)
10.26#    License Agreement for 10-Propargyl-10-Deazaaminopterin “PDX” dated December 23, 2002 and amended May 9, 2006 between Allos Therapeutics, Inc. and SRI International, Sloan-Kettering Institute for Cancer Research and Southern Research Institute. (Filed as Exhibit 10.1 to Allos Therapeutics, Inc.’s Form 10-Q/A, File No. 000-29815, as filed with the Securities and Exchange Commission on August 17, 2012, and incorporated herein by reference.)
10.27#    Second Amendment to License Agreement for 10-Propargyl-10-Deazaaminopterin “PDX” dated November 6, 2007 between Allos Therapeutics, Inc. and SRI International, Sloan-Kettering Institute for Cancer Research and Southern Research Institute. (Filed as Exhibit 10.13.1 to Allos Therapeutics, Inc.’s Form 10-K, File No. 000-29815, as filed with the Securities and Exchange Commission on March 1, 2010, and incorporated herein by reference.)
10.28#    Third Amendment to License Agreement for 10-Propargyl-10-Deazaaminopterin “PDX” dated May 10, 2011 between Allos Therapeutics, Inc. and SRI International, Sloan-Kettering Institute for Cancer Research and Southern Research Institute. (Filed as Exhibit 10.3 to Allos Therapeutics, Inc.’s Form 10-Q, File No. 000-29815, as filed with the Securities and Exchange Commission on August 4, 2011, and incorporated herein by reference.)
10.29#    Amended and Restated License, Development and Commercialization Agreement, dated May 29, 2013, by and between Allos Therapeutics, Inc. and Mundipharma International Corporation Limited (Filed as Exhibit 10.1 to Form 10-Q, File No. 001-35006, as filed with the Securities and Exchange Commission on August 9, 2013, and incorporated herein by reference.)

 

67


Exhibit

No.

  

Description

10.30#    Amended and Restated Supply Agreement, dated May 29, 2013, by and between Allos Therapeutics, Inc. and Mundipharma Medical Company (Filed as Exhibit 10.2 to Form 10-Q, File No. 001-35006, as filed with the Securities and Exchange Commission on August 9, 2013, and incorporated herein by reference.)
10.31    License Agreement, dated December 21, 2007, by and between Biogen Idec Inc. and Cell Therapeutics, Inc. (Filed as Exhibit 10.8 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.32    License-Back Agreement, dated December 21, 2007, by and between Biogen Idec Inc. and Cell Therapeutics, Inc. (Filed as Exhibit 10.9 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.33#    Sublicense Agreement, dated December 21, 2007, by and among Cell Therapeutics, Inc., Biogen Idec Inc., SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Glaxo Group Limited. (Filed as Exhibit 10.11 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.34#    Sublicense Agreement, dated December 21, 2007, by and among Cell Therapeutics, Inc., Biogen Idec Inc., Corixa Corporation, Coulter Pharmaceutical, Inc., The Regents of the University of Michigan and SmithKline Beecham Corporation d/b/a GlaxoSmithKline. (Filed as Exhibit 10.12 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.35    Security Agreement, dated December 15, 2008, by and between RIT Oncology, LLC and Biogen Idec Inc. (Filed as Exhibit 10.35 to Form 10-K, as filed with the Securities and Exchange Commission on March 10, 2011, and incorporated herein by reference.)
10.36#    Omnibus Amendment to Zevalin Supply Arrangements, dated October 1, 2012, by and between Biogen Idec US Corporation and RIT Oncology, LLC, a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc.. (Filed as Exhibit 10.14 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.37    License Agreement, dated May 23, 2006, by and between Merck Eprova AG and Spectrum Pharmaceuticals, Inc. (Filed as Exhibit 10.16 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.38    Manufacturing and Supply Agreement, dated May 23, 2006, by and between Merck Eprova AG and Spectrum Pharmaceuticals, Inc. (Filed as Exhibit 10.17 to Form 10-Q, as filed with the Securities and Exchange Commission on November 9, 2012, and incorporated herein by reference.)
10.39#    License Agreement, dated March 8, 2013, by and between Spectrum Pharmaceuticals, Inc. and CyDex Pharmaceuticals, Inc. (Filed as Exhibit 10.1 to Form 10-Q, as filed with the Securities and Exchange Commission on May 9, 2013, and incorporated herein by reference.)
10.40    Purchase Agreement, dated as of December 17, 2013, by and among Spectrum Pharmaceuticals, Inc., Jefferies LLC and RBC Capital Markets, LLC. (Filed as Exhibit 10.1 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)
10.41    Base Call Option Transaction Confirmation, dated as of December 17, 2013, by and between Spectrum Pharmaceuticals, Inc. and Royal Bank of Canada. (Filed as Exhibit 10.2 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)
10.42    Base Warrant Transaction Confirmation, dated as of December 17, 2013, by and between Spectrum Pharmaceuticals, Inc. and Royal Bank of Canada. (Filed as Exhibit 10.3 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)

 

68


Exhibit

No.

  

Description

10.43    Additional Call Option Transaction Confirmation, dated as of December 20, 2013, by and between Spectrum Pharmaceuticals, Inc. and Royal Bank of Canada. (Filed as Exhibit 10.4 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)
10.44    Additional Warrant Transaction Confirmation, dated as of December 20, 2013, by and between Spectrum Pharmaceuticals, Inc. and Royal Bank of Canada. (Filed as Exhibit 10.5 to Form 8-K, as filed with the Securities and Exchange Commission on December 23, 2013, and incorporated herein by reference.)

 

69


Exhibit

No.

  

Description

  21.1+    Subsidiaries of Registrant.
  23.1+    Consent of Independent Registered Public Accounting Firm.
  24.1    Power of Attorney (included in the signature page.)
  31.1+    Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
  31.2+    Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.
  32.1+    Certification of Principal Executive Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
  32.2+    Certification of Principal Financial Officer, pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.
101.INS†    XBRL Instance Document
101.SCH†    XBRL Taxonomy Extension Schema Document
101.CAL†    XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF†    XBRL Taxonomy Extension Definition Linkbase Document
101.LAB†    XBRL Taxonomy Extension Label Linkbase Document
101.PRE†    XBRL Taxonomy Extension Presentation Linkbase Document

 

* Indicates a management contract or compensatory plan or arrangement.
# Confidential portions omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
+ Filed herewith.
XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections or otherwise incorporated by reference.

 

70

EX-4.2 2 d640093dex42.htm EX-4.2 EX-4.2

Exhibit 4.2

CONFIDENTIAL

Execution Copy

REGISTRATION RIGHTS AND STOCKHOLDER AGREEMENT

This Registration Rights and Stockholder Agreement (this “Agreement”), dated as of February 2, 2010 is by and between Spectrum Pharmaceuticals, Inc., a Delaware corporation having a place of business at 701 N. Green Valley Parkway, Henderson, Nevada 89074 U.S.A. (the “Company”), and TopoTarget A/S, a company organized under the laws of Denmark having its principal offices at Symbion Science Park, Fruebjergvej 3, 2100 København, Denmark (“TopoTarget”).

WHEREAS, the Company and TopoTarget have entered into a license and collaboration agreement dated as of the date hereof (the “License Agreement,” together with this Agreement, the “Agreements”) that, among other things, provides pursuant to Section 7.2(a) thereof that the Company shall issue and deliver to TopoTarget upon the satisfaction of the condition set forth therein, one million (1,000,000) shares (the “Shares”) of the common stock, $0.001 par value per share, of the Company (the “Common Stock”);

WHEREAS, upon the satisfaction of the terms and conditions of the License Agreement relating to the issuance of the Shares, and pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”), the Company has agreed to issue the Shares to TopoTarget and the parties hereto have each agreed to certain restrictions or obligations, as the case may be, relating to the Shares upon their issuance;

NOW THEREFORE, in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and TopoTarget hereby agree as follows (with capitalized terms used but not defined herein having the meanings ascribed to such terms in the License Agreement):

1. RESTRICTIONS ON TRANSFER

(a) Volume Restrictions.

(1) During the period beginning on the Issuance Date and ending on the date that TopoTarget is no longer the record or beneficial owner of any of the Shares, including during the Effectiveness Period (as defined below), TopoTarget shall not make a Disposition of the Shares owned by TopoTarget in amounts that exceed, after giving effect to the proposed Disposition, either of (i) 100,000 shares in any single trading day (the “Maximum Daily Sale Amount”), or (ii) 300,000 shares during any calendar week period (the “Maximum Weekly Sale Amount”), in either case without the prior written consent of the Company, which may be given or withheld in the Company’s sole discretion. For purposes hereof, a “Disposition” shall mean any transfer, sale or other disposition, or any offer to transfer, sell or dispose, of any Share or Shares over the facilities of, or otherwise through, the Nasdaq Global Market or, if different, the Company’s primary listing market.


(2) For the avoidance of doubt, the foregoing restrictions shall not apply to the sale of any shares of Common Stock other than the Shares, including shares of Common Stock acquired by TopoTarget on the public market. The restrictions of this Section 1(a) will, however, apply to shares issued as a stock dividend on the Shares or issued in a stock split, reverse stock split, or other recapitalization in each case with respect to the Shares covered hereby, in which event the Maximum Daily Sale Amount and the Maximum Weekly Sale Amount shall also be appropriately adjusted.

(3) TopoTarget acknowledges that the restrictions on Dispositions imposed by this Section 1(a) are in addition to those that may be imposed by United States federal and (if applicable) state securities laws, including without limitation Rule 144 promulgated under the Securities Act (“Rule 144”), and undertakes to comply with federal and (if applicable) state securities laws, including the restrictions of Rule 144. In connection with any transfer of Shares other than (i) through an effective registration statement (including the Registration Statement, as defined below), (ii) pursuant to Rule 144, (iii) to the Company or (iv) to an affiliate of TopoTarget, the Company may require the transferor thereof to provide the Company an opinion of counsel, the form and substance of which opinion (and the identity of which counsel) shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act.

(4) TopoTarget agrees and consents to the entry of stop transfer restrictions with the Company’s transfer agent and registrar against, and authorizes the Company to cause the transfer agent and registrar to decline, the transfer of the Shares except in compliance with the foregoing restrictions.

(b) Legends. Prior to the Effective Time (as defined below), the certificate(s) evidencing the Shares shall bear legends in substantially the following form:

“THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.”

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A

 

-2-


REGISTRATION RIGHTS AND STOCKHOLDER AGREEMENT DATED FEBRUARY 2, 2010, AS AMENDED FROM TIME TO TIME, WHICH PLACES RESTRICTIONS ON THE TRANSFER OF THE SECURITIES REPRESENTED HEREBY. ANY PERSON ACCEPTING ANY INTEREST IN SUCH SECURITIES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SUCH AGREEMENT. A COPY OF SUCH AGREEMENT IS ON FILE AT THE COMPANY’S PRINCIPAL OFFICE AND MAY BE OBTAINED WITHOUT CHARGE FROM THE COMPANY.”

(c) Agreement to be Bound. Subject to the other restrictions on transfer set forth or referenced in this Agreement, TopoTarget may assign all of its rights and obligations hereunder with respect to some or all or its Shares, provided that the transferee has agreed in writing to be bound by the applicable provisions of this Agreement and that such assignment shall be in connection with a Transfer of all or a portion of the Shares held by TopoTarget.

2. RESALE REGISTRATION

(a) Direct Registration. On or prior to the 30th day after the Issuance Date (the “Filing Date”), the Company shall prepare and file with the Securities and Exchange Commission (the “Commission”) a registration statement (including the Prospectus (as defined below), amendments and supplements to the registration statement or Prospectus, all exhibits thereto and all material incorporated by reference or deemed to be incorporated by reference in such registration statement, the “Registration Statement”) covering the resale of all of the Registrable Securities (as defined below) on such Filing Date for an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act by TopoTarget and any other holder, if applicable, of the Registrable Securities (each a “Holder”). “Prospectus” means the prospectus included in any Registration Statement registering the Shares (as amended or supplemented by any prospectus supplement, and all other amendments and supplements to the prospectus). “Registrable Securities” means the Shares upon original issuance thereof and at all times subsequent thereto until the earliest to occur of (i) a Registration Statement registering the Shares has been declared effective by the Commission and such Shares have been disposed of in accordance therewith, (ii) the Shares are sold in compliance with Rule 144 or could (except with respect to affiliates of the Company within the meaning of the Securities Act) be sold in compliance with paragraph (b)(1)(i) of Rule 144, or (iii) the Shares cease to be outstanding.

The Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance with the Securities Act). Subject to the terms of this Agreement, the Company shall use commercially reasonable efforts to cause a Registration Statement to be declared effective under the Securities Act as promptly as possible after the Filing Date. The date and time that the Registration Statement is declared effective by the Commission is referred to herein as the “Effective Time”. The Company shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act from the Effective Time until the earliest of: (i) the date on which all Registrable Securities covered by such Registration Statement have been sold in the manner set forth and as

 

-3-


contemplated by the Registration Statement, (ii) the date on which all the Registrable Securities held by persons who are not affiliates of the Company may be resold pursuant to Rule 144(b)(1)(i) under the Securities Act as determined by the counsel to the Company pursuant to a written opinion to such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders, (iii) the date on which all the Registrable Securities cease to be outstanding, or (iv) an additional registration statement covering all of the Registrable Securities has been declared effective under the Securities Act (the “Effectiveness Period”).

(b) Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

  (i) Not less than twenty (20) calendar days prior to the anticipated Filing Date, provide a questionnaire to TopoTarget requesting certain information, including a certified statement as to the number of shares of Common Stock beneficially owned and the person or persons that have voting and dispositive control over those Shares (the “Selling Stockholder Questionnaire”). TopoTarget shall have at least ten (10) calendar days from the date on which the Selling Stockholder Questionnaire is first provided to it to return a completed and signed Selling Stockholder Questionnaire to the Company. The Company shall not be required to take any action, including the filing of the Registration Statement, to name TopoTarget or any other Holder as a selling securityholder in the Registration Statement or to enable any Holder to use the Prospectus forming a part thereof for resales of Registrable Securities until such Holder has returned a completed and signed Selling Stockholder Questionnaire to the Company.

 

  (ii) After the Effective Time of the Registration Statement, the Company shall, upon the written request of any Holder of Registrable Securities, promptly send a Selling Stockholder Questionnaire to such Holder. From and after the Effective Time of the Registration Statement, the Company shall (A) as promptly as is practicable after the date a completed and signed Selling Stockholder Questionnaire is delivered to the Company, and in any event within fifteen (15) Business Days after such date, prepare and file with the Commission (x) a supplement to the Prospectus or, if required by applicable law, a post-effective amendment to the Registration Statement and (y) any other document required by applicable law, so that the Holder delivering such Selling Stockholder Questionnaire is named as a selling securityholder in the Registration Statement and is permitted to deliver the Prospectus to purchasers of such Holder’s Registrable Securities in accordance with applicable law, and (B) if the Company is required by applicable law to file a post-effective amendment to the Registration Statement, use its reasonable best efforts to cause such post-effective amendment to become effective under the Securities Act as promptly as is practicable; provided, that if a Selling Stockholder Questionnaire is delivered to the Company during a Suspension Period (as defined in Section 2(c)), the Company shall not be obligated to take the

 

-4-


  actions set forth in this clause 2(b)(ii) until the termination of such Suspension Period. For purposes of this Agreement a “Business Day” means each day of the week excluding Saturday, Sunday or a day on which banking institutions in New York, New York USA are authorized by law to close.

 

  (iii) Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities.

 

  (iv) Cause the Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and as so supplemented or amended to be filed pursuant to Rule 424.

 

  (v) Respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto.

 

  (vi) Comply in all material respects with the provisions of the Securities Act and the Securities and Exchange Act of 1934, as amended, with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.

 

  (vii) Notify the Holders as promptly as reasonably possible of the following: (A)(1) when a Prospectus (other than the first Prospectus filed pursuant to Section 2 hereof) or any Prospectus supplement or post-effective amendment to a Registration Statement has been filed; (2) when a Registration Statement (other than the first Registration Statement filed pursuant to Section 2 hereof) or any post-effective amendment, has become effective; (B) receipt by the Company of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information; (C) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as deposition) (each a “Proceeding”) for that purpose; (D) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any

 

-5-


  of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; (E) the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; and (F) the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided, that each Holder shall not disclose and shall maintain the confidentiality of any and all of such information provided pursuant to this Subsection (vii) until such information otherwise becomes public, unless disclosure by a Holder is required by law; provided further, that any notice provided pursuant to clauses (B) through (F) of this Subsection (vii) shall be accompanied by an instruction to suspend the use of the Prospectus until further notice by the Company.

 

  (viii) Upon request, fax or email to each Holder, without charge, upon filing with the Commission at least one conformed copy of each such Registration Statement and each amendment thereto, including to the extent specifically requested, financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits (including those previously furnished or incorporated by reference).

 

  (ix) Upon request, fax or email to each Holder, without charge, a copy of the Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto.

 

  (x) Comply in all material respects with all applicable rules and regulations of the Commission.

 

  (xi)

Use its commercially reasonable efforts to (i) register or qualify the Registrable Securities covered by the Registration Statement as necessary under such securities or “blue sky” laws of such jurisdictions in the United States as the Holder (in light of its intended plan of distribution) may request in writing and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may

 

-6-


  be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may
  be necessary or advisable to enable the Holder to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph, subject itself to taxation in any such jurisdiction or consent to general service of process in any such jurisdiction.

 

  (xii) Prior to the filing with the Commission of a Registration Statement or prospectus or any amendment or supplement thereto, including documents incorporated by reference, the Company shall furnish to the Holder and its legal counsel copies of all such documents proposed to be filed sufficiently in advance of filing to provide the Holder and its legal counsel with a reasonable opportunity to review such documents and comment thereon.

(c) Suspension Period. Upon the occurrence of any event contemplated by clauses (B) through (F) of Section 2(b)(vii) of this Agreement, the Company shall, as promptly as reasonably possible under the circumstances taking into account the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare, as may be required, a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (B) through (F) of Section 2(b)(vii) to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, or the Company otherwise notifies the Holders of its election to suspend the availability of a Registration Statement and Prospectus pursuant to clause (F) of Section 2(b)(vii), then the Holders shall `suspend use of such Prospectus. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable, except that in the case of suspension of the availability of a Registration Statement and Prospectus pursuant to clause (F) of Section 2(b)(vii), the Company shall not be required to take such action until such time as it shall determine that the continued availability of the Registration Statement and Prospectus is no longer not in the best interests of the Company. The Company shall be entitled to exercise its right under this Section 2(c) to suspend the availability of a Registration Statement and Prospectus for a period not to exceed ninety (90) days (which need not be consecutive days) in any twelve (12) month period (the “Suspension Period”).

(d) Registration Expenses. The Company shall bear all expenses in connection with the registration of the Shares as provided in this Section 2, other than underwriting discounts (if applicable), brokerage fees and commissions and expenses of TopoTarget’s legal counsel.

 

-7-


3. INDEMNIFICATION AND CONTRIBUTION

(a) Indemnification by the Company. The Company agrees to indemnify and hold harmless each Holder, each of its officers, employees, affiliates, directors, partners, members, attorneys and agents and each person, if any, who controls (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) such Holder (each, a “Holder Indemnified Party”) from and against any expenses, losses, judgments, claims, damages or liabilities, whether joint or several, arising out of or based upon any untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus, any “free writing prospectus,” as such term is defined in Rule 405 under the Securities Act, or summary prospectus contained in the Registration Statement, or any amendment or supplement thereto, or arising out of or based upon any omission (or alleged omission) to state a material fact required to be stated therein or necessary to make the statements therein not misleading, or any untrue statement or alleged untrue statement of a material fact in the information conveyed to any purchaser at the time of the sale to such purchaser, or the omission or alleged omission to state therein a material fact required to be stated therein, or any violation by the Company of the Securities Act or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration; and the Company shall promptly advance and/or reimburse the Holder Indemnified Party, as incurred, for any legal and any other expenses reasonably incurred by such Holder Indemnified Party in connection with investigating and defending any such expense, loss, judgment, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon any untrue statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final prospectus or summary prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by the Holder expressly for use therein.

(b) Indemnification by the Holder. The Holder will, in the event that any Registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling holder, indemnify and hold harmless the Company, each of its directors and officers, and each other selling holder and each other person, if any, who controls the Company, its directors, its officers or such other selling holders within the meaning of the Securities Act, against any losses, claims, judgments, damages or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary prospectus, final prospectus, any “free writing prospectus,” as such term is defined in Rule 405 under the Securities Act, or summary prospectus contained in the Registration Statement, or any amendment or supplement thereto, or arise out of or are based upon any omission or the alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with information furnished in writing to the Company by such selling holder expressly for use therein, or any untrue statement or alleged untrue statement of a material fact in the information conveyed to any

 

-8-


purchaser at the time of the sale to such purchaser, or the omission or alleged omission to state therein a material fact required to be stated therein, and shall reimburse the Company, its directors and officers, and each other selling holder or controlling person for any legal or other expenses reasonably incurred by any of them in connection with investigation or defending any such loss, claim, damage, liability or action.

(c) Conduct of Indemnification Proceedings. Promptly after receipt by any person of any notice of any loss, claim, damage or liability or any action in respect of which indemnity may be sought pursuant to Section 3(a) or 3(b), such person (the “Indemnified Party”) shall, if a claim in respect thereof is to be made against any other person for indemnification hereunder, notify such other person (the “Indemnifying Party”) in writing of the loss, claim, judgment, damage, liability or action; provided, however, that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is actually prejudiced by such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought against the Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent that it wishes, jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall have the right to employ separate counsel (but no more than one such separate counsel) to represent the Indemnified Party and its controlling persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party, with the fees and expenses of such counsel to be paid by such Indemnifying Party if, based upon the advice of counsel of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, consent to entry of judgment or effect any settlement of any claim or pending or threatened proceeding in respect of which the Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment or settlement includes an unconditional release of such Indemnified Party from all liability arising out of such claim or proceeding.

(d) Contribution. If the indemnification provided for in the foregoing Sections 3(a) and 3(b) is unavailable to any Indemnified Party in respect of any loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in connection with the actions or omissions which resulted in such loss, claim, damage, liability or action, as well as any other relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to, among other things, whether the

 

-9-


untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 3(d) were determined by pro rata allocation or by any other method of allocation which does not take account the equitable considerations referred to in the immediately preceding sentence. The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 3(d), the Holder shall not be required to contribute any amount in excess of the dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received by the Holder from the sale of Registrable Securities which gave rise to such contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

4. MISCELLANEOUS

(a) Governing Law; Jurisdiction; Jury Trial. Resolution of all disputes arising out of or related to this Agreement or the validity, construction, interpretation, enforcement, breach, performance, application or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York, USA excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction and without regard to the United Nations Convention on Contracts for the International Sale of Goods. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.

(b) Entire Agreement. This Agreement and the documents referenced herein and therein constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement and the documents referenced herein and therein supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.

(c) Amendments and Waivers. No provision of this Agreement may be amended or waived other than by an instrument in writing signed by the Company and by TopoTarget.

(d) Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when faxed or emailed (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) the third Business Day after the day deposited with

 

-10-


a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The mailing addresses, fax numbers and email addresses for such communications are:

 

  If to TopoTarget:    TopoTarget A/S
     Symbion Science Park
     Fruebjergvej 3
     2100 København, Denmark
     Attention:
  With a copy to:    Dechert LLP
     1775 I Street, NW
     Washington, D.C. 20006-2401
     Attention: David E. Schulman, Esq.
  If to the Company:    Spectrum Pharmaceuticals, Inc.
     701 N. Green Valley Parkway
     Henderson, NV 89074
     Attention: Legal Department
  With a copy to:    Edwards Angell Palmer & Dodge LLP
     111 Huntington Avenue
     Boston, MA 02199
     Attention: Eugene McDermott, Esq.

(e) No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

(f) Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(g) Severability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.

(h) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including, subject to the provisions of this Agreement, any purchasers or transferees of the Shares.

(i) Publicity. The Company may issue a press release regarding the occurrence of this transaction and may make any and all disclosures that it deems necessary or appropriate in connection with its filings with the Commission or other regulatory agencies and authorities.

 

-11-


(j) Expenses. Except as otherwise specifically provided in Section 2(d) with respect to registration expenses, each party shall bear its own fees and expenses, including, without limitation, fees of legal counsel, that it incurs in connection with the consummation of the transactions contemplated by this Agreement and in satisfying its obligations under this Agreement.

(k) Termination. In the event that the License Agreement is terminated for any reason without the Shares having been issued thereunder, this Agreement shall automatically and immediately terminate and be of no further force or effect.

(k) Headings. The headings of this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

(l) Counterparts. This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by faxing or emailing a copy of this Agreement bearing the signature of the party so delivering this Agreement.

[Remainder of page intentionally left blank.

Signature page to follow.]

 

-12-


IN WITNESS WHEREOF, the parties have caused this Registration Rights and Stockholder Agreement to be duly executed as of the date first written above.

 

SPECTRUM PHARMACEUTICALS, INC.
By:  

/s/ Rajesh C. Shrotriya, M.D.

Name:   Rajesh C. Shrotriya, M.D.
Title:   Chairman, CEO & President
TOPOTARGET A/S
By:  

/s/ Hakan Astrom

Name:   Hakan Astrom
Title:   Chairman of the Board
By:  

/s/ Peter B. Jensen

Name:   Peter B. Jensen
Title:   CEO
EX-10.6 3 d640093dex106.htm EX-10.6 EX-10.6

Exhibit 10.6

SECOND AMENDMENT TO LEASE

 

I. PARTIES AND DATE.

This Second Amendment to Lease (the “Amendment”) dated March 7, 2006, is by and between THE IRVINE COMPANY (“Landlord”), and SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

 

II. RECITALS.

On January 16, 1997, Landlord and Tenant entered into a lease for space in a building located at 157 Technology Drive, Irvine, California (“Premises”), which lease was amended by a First Amendment to Lease dated March 25, 2004 (as amended, the “Lease”).

Landlord and Tenant each desire to modify the Lease to make such modifications as are set forth in “III. MODIFICATIONS” next below.

 

III. MODIFICATIONS.

A. Signage. The first 1st sentence of Section 5.2 of the Lease is hereby deleted and substituted therefor with the following:

“Provided Tenant continues to lease the entire Building, Tenant shall have the non-exclusive right to one (1) exterior building top sign on the Building for Tenant’s name and graphics in a location designated by Landlord, subject to Landlord’s right of prior approval that such exterior signage is in compliance with the Signage Criteria (defined below). Except as provided in the foregoing, Tenant shall have no right to maintain signs in any location in, on or about the Premises, the Building or the Project and shall not place or erect any signs, displays or other advertising materials that are visible from the exterior of the Building.”

 

IV. GENERAL.

A. Effect of Amendments. The Lease shall remain in full force and effect except to the extent that it is modified by this Amendment.

B. Entire Agreement. This Amendment embodies the entire understanding between Landlord and Tenant with respect to the modifications set forth in “III. MODIFICATIONS” above and can be changed only by a writing signed by Landlord and Tenant.

C. Counterparts. If this Amendment is executed in counterparts, each is hereby declared to be an original; all, however, shall constitute but one and the same amendment. In any action or proceeding, any photographic, photostatic, or other copy of this Amendment may be introduced into evidence without foundation.

D. Defined Terms. All words commencing with initial capital letters in this Amendment and defined in the Lease shall have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.

E. Corporate and Partnership Authority. If Tenant is a corporation or partnership, or is comprised of either or both of them, each individual executing this Amendment for the corporation or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of the corporation or partnership and that this Amendment is binding upon the corporation or partnership in accordance with its terms.

F. Attorneys’ Fees. The provisions of the Lease respecting payment of attorneys’ fees shall also apply to this Amendment.

 

1


V. EXECUTION.

Landlord and Tenant executed this Amendment on the date as set forth in “I. PARTIES AND DATE.” above.

 

LANDLORD:     TENANT:
THE IRVINE COMPANY     SPECTRUM PHARMACEUTICALS, INC.,
      a Delaware corporation
By  

/s/ Steven M. Case

    By  

/s/ Rajesh C. Shrotriya, M.D.

  Steven M. Case, Senior Vice President     Name   Rajesh C. Shrotriya, M.D.
  Leasing, Office Properties     Title Chairman, CEO & President
By  

/s/ Christopher J. Popma

    By  

/s/ Shyam Kumaria

  Christopher J. Popma, Vice President     Name   Shyam Kumaria
  Operations, Office Properties     Title   V.P., Finance

 

2

EX-10.7 4 d640093dex107.htm EX-10.7 EX-10.7

Exhibit 10.7

THIRD AMENDMENT TO LEASE

 

I. PARTIES AND DATE.

This Third Amendment to Lease (the “Amendment”) dated February 12, 2006, is by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, formerly The Irvine Company, a Delaware corporation (“Landlord”), and SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

 

II. RECITALS.

On January 16, 1997, Landlord and Tenant entered into a lease for space in a building located at 157 Technology Drive, Irvine, California (“Premises”), which lease was amended by a First Amendment to Lease dated March 25, 2004, and by a Second Amendment to Lease dated March 7, 2006. The foregoing lease, as so amended, is hereinafter referred to as the “Lease”.

Landlord and Tenant each desire to modify the Lease to make such modifications as are set forth in “III. MODIFICATIONS” next below.

 

III. MODIFICATIONS.

A. Signage. The first and second sentences of Section 5.2 of the Lease, as amended by the Second Amendment, are hereby deleted in their entirety, and substituted therefor with the following :

“Provided Tenant continues to lease the entire Building, Tenant shall have the non-exclusive right to one (1) exterior “building top” sign and one (1) exterior “eye-brow” sign on the Building for Tenant’s name and graphics in locations designated by Landlord, subject to Landlord’s right of prior approval that such exterior signage is in compliance with the Signage Criteria (defined below). Except as provided in the foregoing, Tenant shall have no right to maintain signs in any location in, on or about the Premises, the Building or the Project and shall not place or erect any signs, displays or other advertising materials that are visible from the exterior of the Building.”

B. Security Deposit Section 4.3 of the Lease is hereby amended to provide that, upon any default by Tenant, Landlord may, in its sole and absolute discretion and notwithstanding any contrary provision of California Civil Code Section 1950.7, additionally retain, use or apply the whole or any part of the Security Deposit to pay amounts estimated by Landlord as the amount due Landlord for prospective rent and for damages pursuant to Section 14.2 (a)(i) of the Lease and/or California Civil Code Section 1951.2.

C. Late Payments. The reference to “Two Hundred Fifty Dollars ($250.00)” in Section 14.3(a) of the Lease is hereby amended to “One Hundred Dollars ($100.00).”

D. Waiver of Jury Trial. Section 14.7 of the Lease is hereby deleted in its entirety and substituted therefor shall be the following:

SECTION 14.7. WAIVER OF JURY TRIAL/JUDICIAL REFERENCE .

(a) LANDLORD AND TENANT EACH ACKNOWLEDGES THAT IT IS AWARE OF AND HAS HAD THE ADVICE OF COUNSEL OF ITS CHOICE WITH RESPECT TO ITS RIGHTS TO TRIAL BY JURY, AND, TO THE EXTENT ENFORCEABLE UNDER CALIFORNIA LAW, EACH PARTY DOES HEREBY EXPRESSLY AND KNOWINGLY WAIVE AND RELEASE ALL SUCH RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER PARTY HERETO AGAINST THE OTHER (AND/OR AGAINST ITS OFFICERS, DIRECTORS,

 

1


EMPLOYEES, AGENTS, OR SUBSIDIARY OR AFFILIATED ENTITIES) ON ANY MATTERS WHATSOEVER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, TENANT’S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM OF INJURY OR DAMAGE. FURTHERMORE, THIS WAIVER AND RELEASE OF ALL RIGHTS TO A JURY TRIAL IS DEEMED TO BE INDEPENDENT OF EACH AND EVERY OTHER PROVISION, COVENANT, AND/OR CONDITION SET FORTH IN THIS LEASE.

(b) IN THE EVENT THAT THE JURY WAIVER PROVISIONS OF SECTION 14.7(a) ARE NOT ENFORCEABLE UNDER CALIFORNIA LAW, THEN THE PROVISIONS OF THIS SECTION 14.7(b) SHALL APPLY. IT IS THE DESIRE AND INTENTION OF THE PARTIES TO AGREE UPON A MECHANISM AND PROCEDURE UNDER WHICH CONTROVERSIES AND DISPUTES ARISING OUT OF THIS LEASE OR RELATED TO THE PREMISES WILL BE RESOLVED IN A PROMPT AND EXPEDITIOUS MANNER. ACCORDINGLY, EXCEPT WITH RESPECT TO ACTIONS FOR UNLAWFUL OR FORCIBLE DETAINER OR WITH RESPECT TO THE PREJUDGMENT REMEDY OF ATTACHMENT, ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER PARTY HERETO AGAINST THE OTHER (AND/OR AGAINST ITS OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR SUBSIDIARY OR AFFILIATED ENTITIES) ON ANY MATTERS WHATSOEVER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, TENANT’S USE OR OCCUPANCY OF THE PREMISES AND/OR ANY CLAIM OF INJURY OR DAMAGE, SHALL BE HEARD AND RESOLVED BY A REFEREE UNDER THE PROVISIONS OF THE CALIFORNIA CODE OF CIVIL PROCEDURE, SECTIONS 638 – 645.1, INCLUSIVE (AS SAME MAY BE AMENDED, OR ANY SUCCESSOR STATUTE(S) THERETO) (THE “REFEREE SECTIONS”). ANY FEE TO INITIATE THE JUDICIAL REFERENCE PROCEEDINGS SHALL BE PAID BY THE PARTY INITIATING SUCH PROCEDURE; PROVIDED HOWEVER, THAT THE COSTS AND FEES, INCLUDING ANY INITIATION FEE, OF SUCH PROCEEDING SHALL ULTIMATELY BE BORNE IN ACCORDANCE WITH SECTION 14.6 ABOVE. THE VENUE OF THE PROCEEDINGS SHALL BE IN THE COUNTY IN WHICH THE PREMISES ARE LOCATED. WITHIN TEN (10) DAYS OF RECEIPT BY ANY PARTY OF A WRITTEN REQUEST TO RESOLVE ANY DISPUTE OR CONTROVERSY PURSUANT TO THIS SECTION 14.7(b), THE PARTIES SHALL AGREE UPON A SINGLE REFEREE WHO SHALL TRY ALL ISSUES, WHETHER OF FACT OR LAW, AND REPORT A FINDING AND JUDGMENT ON SUCH ISSUES AS REQUIRED BY THE REFEREE SECTIONS. IF THE PARTIES ARE UNABLE TO AGREE UPON A REFEREE WITHIN SUCH TEN (10) DAY PERIOD, THEN ANY PARTY MAY THEREAFTER FILE A LAWSUIT IN THE COUNTY IN WHICH THE PREMISES ARE LOCATED FOR THE PURPOSE OF APPOINTMENT OF A REFEREE UNDER CALIFORNIA CODE OF CIVIL PROCEDURE SECTIONS 638 AND 640, AS SAME MAY BE AMENDED OF ANY SUCCESSOR STATUTE(S) THERETO. IF THE REFEREE IS APPOINTED BY THE COURT, THE REFEREE SHALL BE A NEUTRAL AND IMPARTIAL RETIRED JUDGE WITH SUBSTANTIAL EXPERIENCE IN THE RELEVANT MATTERS TO BE DETERMINED, FROM JAMS/ENDISPUTE, INC., THE AMERICAN ARBITRATION ASSOCIATION OR SIMILAR MEDIATION/ARBITRATION ENTITY. THE PROPOSED REFEREE MAY BE CHALLENGED BY ANY PARTY FOR ANY OF THE GROUNDS LISTED IN SECTION 641 OF THE CALIFORNIA CODE OF CIVIL PROCEDURE, AS SAME MAY BE AMENDED OR ANY SUCCESSOR STATUTE(S) THERETO. THE REFEREE SHALL HAVE THE POWER TO DECIDE ALL ISSUES OF FACT AND LAW AND REPORT HIS OR HER DECISION ON SUCH ISSUES, AND TO ISSUE ALL RECOGNIZED REMEDIES AVAILABLE AT LAW OR IN EQUITY FOR ANY CAUSE OF ACTION THAT IS BEFORE THE REFEREE, INCLUDING AN AWARD OF ATTORNEYS’ FEES AND COSTS IN ACCORDANCE WITH CALIFORNIA LAW. THE REFEREE SHALL NOT, HOWEVER, HAVE THE POWER TO AWARD PUNITIVE DAMAGES, NOR ANY OTHER DAMAGES WHICH ARE NOT PERMITTED BY THE EXPRESS PROVISIONS OF THIS LEASE, AND THE PARTIES HEREBY WAIVE ANY RIGHT TO RECOVER ANY SUCH DAMAGES. THE PARTIES SHALL BE ENTITLED TO CONDUCT ALL DISCOVERY AS PROVIDED IN THE CALIFORNIA CODE OF CIVIL PROCEDURE, AND THE REFEREE SHALL OVERSEE DISCOVERY AND MAY

 

2


ENFORCE ALL DISCOVERY ORDERS IN THE SAME MANNER AS ANY TRIAL COURT JUDGE, WITH RIGHTS TO REGULATE DISCOVERY AND TO ISSUE AND ENFORCE SUBPOENAS, PROTECTIVE ORDERS AND OTHER LIMITATIONS ON DISCOVERY AVAILABLE UNDER CALIFORNIA LAW. THE REFERENCE PROCEEDING SHALL BE CONDUCTED IN ACCORDANCE WITH CALIFORNIA LAW (INCLUDING THE RULES OF EVIDENCE), AND IN ALL REGARDS, THE REFEREE SHALL FOLLOW CALIFORNIA LAW APPLICABLE AT THE TIME OF THE REFERENCE PROCEEDING. IN ACCORDANCE WITH SECTION 644 OF THE CALIFORNIA CODE OF CIVIL PROCEDURE, THE DECISION OF THE REFEREE UPON THE WHOLE ISSUE MUST STAND AS THE DECISION OF THE COURT, AND UPON THE FILING OF THE STATEMENT OF DECISION WITH THE CLERK OF THE COURT, OR WITH THE JUDGE IF THERE IS NO CLERK, JUDGMENT MAY BE ENTERED THEREON IN THE SAME MANNER AS IF THE ACTION HAD BEEN TRIED BY THE COURT. THE PARTIES SHALL PROMPTLY AND DILIGENTLY COOPERATE WITH ONE ANOTHER AND THE REFEREE, AND SHALL PERFORM SUCH ACTS AS MAY BE NECESSARY TO OBTAIN A PROMPT AND EXPEDITIOUS RESOLUTION OF THE DISPUTE OR CONTROVERSY IN ACCORDANCE WITH THE TERMS OF THIS SECTION 14.7(b). TO THE EXTENT THAT NO PENDING LAWSUIT HAS BEEN FILED TO OBTAIN THE APPOINTMENT OF A REFEREE, ANY PARTY, AFTER THE ISSUANCE OF THE DECISION OF THE REFEREE, MAY APPLY TO THE COURT OF THE COUNTY IN WHICH THE PREMISES ARE LOCATED FOR CONFIRMATION BY THE COURT OF THE DECISION OF THE REFEREE IN THE SAME MANNER AS A PETITION FOR CONFIRMATION OF AN ARBITRATION AWARD PURSUANT TO CODE OF CIVIL PROCEDURE SECTION 1285 ET SEQ. (AS SAME MAY BE AMENDED OR ANY SUCCESSOR STATUTE(S) THERETO).

E. Prorations. The third sentence of Article XVI of the Lease is hereby deleted in its entirety, and substituted therefore shall be the following:

“All payments requiring proration shall be prorated on the basis of the number of days in the pertinent calendar month or year, as applicable.”

 

IV. GENERAL.

A. Effect of Amendments. The Lease shall remain in full force and effect except to the extent that it is modified by this Amendment.

B. Entire Agreement. This Amendment embodies the entire understanding between Landlord and Tenant with respect to the modifications set forth in “III. MODIFICATIONS” above and can be changed only by a writing signed by Landlord and Tenant.

C. Counterparts. If this Amendment is executed in counterparts, each is hereby declared to be an original; all, however, shall constitute but one and the same amendment. In any action or proceeding, any photographic, photostatic, or other copy of this Amendment may be introduced into evidence without foundation.

D. Defined Terms. All words commencing with initial capital letters in this Amendment and defined in the Lease shall have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.

E. Corporate and Partnership Authority. If Tenant is a corporation or partnership, or is comprised of either or both of them, each individual executing this Amendment for the corporation or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of the corporation or partnership and that this Amendment is binding upon the corporation or partnership in accordance with its terms.

F. Attorneys’ Fees. The provisions of the Lease respecting payment of attorneys’ fees shall also apply to this Amendment.

 

3


V. EXECUTION.

Landlord and Tenant executed this Amendment on the date as set forth in “I. PARTIES AND DATE.” above.

 

LANDLORD:     TENANT:
THE IRVINE COMPANY LLC,     SPECTRUM PHARMACEUTICALS, INC.,
a Delaware limited liability company     a Delaware corporation
By  

/s/ Steven M. Case

    By  

/s/ Rajesh C. Shrotriya, M.D.

  Steven M. Case, Senior Vice President     Name   Rajesh C. Shrotriya, M.D.
  Leasing, Office Properties     Title   Chairman, CEO & President
By  

/s/ Christopher J. Popma

    By  

/s/ Shyam Kumaria

  Christopher J. Popma, Vice President     Name   Shyam Kumaria
  Operations, Office Properties     Title   V.P. Finance & Corporate Secretary

 

4

EX-10.9 5 d640093dex109.htm EX-10.9 EX-10.9

Exhibit 10.9

FIFTH AMENDMENT TO LEASE

 

I. PARTIES AND DATE.

This Fifth Amendment to Lease (the “Amendment”) dated November 21, 2013, is by and between THE IRVINE COMPANY LLC, a Delaware limited liability company (“Landlord”), and SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

 

II. RECITALS.

On January 16, 1997, Landlord and Tenant entered into a lease for space in a building located at 157 Technology, Irvine, California (“157 Technology Premises”), which lease was amended by a First Amendment to Lease dated March 25, 2004 (“First Amendment”), by a Second Amendment to Lease dated March 7, 2006 (“Second Amendment”), by a Third Amendment to Lease dated February 12, 2006 (“Third Amendment”), and by a Fourth Amendment to Lease dated July 29, 2009 (“Fourth Amendment”). The foregoing lease, as so amended is hereinafter referred to as the “Lease”.

Landlord and Tenant each desire to modify the Lease to add approximately 21,960 rentable square feet of space in a building located at 153 Technology, Suite 100, Irvine, California, which space is more particularly described on EXHIBIT A attached to this Amendment and herein referred to as the “153 Technology Premises”, to extend the Term as to the 157 Technology Premises, to adjust the Basic Rent, and to make such other modifications as are set forth in “III. MODIFICATIONS” next below.

 

III. MODIFICATIONS.

A. Premises/Building. From and after the “Commencement Date for the 153 Technology Premises” (as hereinafter defined), the 153 Technology Premises together with the 157 Technology Premises shall collectively constitute the “Premises” under the Lease. All references to the “Building” in the Lease shall be amended to refer to the two (2) buildings located at 153 Technology Drive the (“153 Technology Building”) and at 157 Technology Drive (the “157 Technology Building”), Irvine, California, either collectively or individually as the context may reasonably require.

B. Basic Lease Provisions. The Basic Lease Provisions are hereby amended as follows:

1. Effective as of the Commencement Date for the 153 Technology Premises, Item 1 shall be deleted in its entirety and substituted therefor shall be the following:

“1. Premises: The Premises are more particularly described in Section 2.1 of the Lease.

Address of Buildings: 153 Technology Drive, Suite 100, Irvine, CA

                                     157 Technology Drive, Irvine, CA”

2. Item 4 is hereby amended by adding the following:

Commencement Date for the 153 Technology Premises” shall mean the earlier of (a) the date which is twenty (20) calendar days following the date that Landlord substantially completes the “Tenant Improvements” (as defined in the attached Work Letter) for the 153 Technology Premises but for minor punch list matters, and to the extent required, all relevant governmental authorities have approved the Tenant Improvements for the 153 Technology Premises in accordance with applicable building codes, as evidenced by the City of Irvine’s issuance of a temporary or final certificate of occupancy for the 153 Technology Premises, or (b) the date Tenant acquires possession or commences use of the 153 Technology Premises for its regular business operations. Within twenty (20) days after possession of the 153 Technology Premises is tendered to Tenant, the parties shall memorialize on a form provided by Landlord the actual Commencement Date for the 153 Technology Premises and the Expiration Date of the Lease. Tenant’s failure to execute that form shall not affect the validity of Landlord’s determination of those dates unless Tenant objects in writing to Landlord’s determination of such dates within such twenty (20) day period. In addition to the acknowledgments contained in the first sentence of Section 2.2 of the Lease, Tenant acknowledges that the flooring materials which may be

 

1


installed on the ground floor of the 153 Technology Building may be limited by the moisture content of the slab and underlying soils. As of the Commencement Date for the 153 Technology Premises, Tenant shall be conclusively deemed to have accepted that the 153 Technology Premises is in satisfactory condition and in conformity with the provisions of the Lease, subject only to those defective or incomplete portions of the Tenant Improvements for the 153 Technology Premises, which Tenant shall have itemized on a written punch list and delivered to Landlord within thirty (30) days after the Commencement Date for the 153 Technology Premises.

Landlord represents and warrants that Blizzard (as defined below) is contractually obligated to surrender possession of the 153 Technology Premises on or before February 28, 2014. Landlord will keep Blizzard reasonably apprised of Blizzard’s surrender of possession of the 153 Technology Premises. If Blizzard fails to vacate by February 28, 2014, Landlord will keep Tenant reasonably apprised as to Blizzard’s holdover and Landlord’s efforts to regain possession of the 153 Technology Premises. Further, notwithstanding anything to the contrary in this Amendment, if Blizzard has not surrendered possession to Landlord of the 153 Technology Premises by June 1, 2014, then Tenant may terminate this Amendment insofar as it pertains to the leasing of the 153 Technology Premises, by irrevocable written notice given to Landlord at any time thereafter but prior to the actual surrender of possession of the 153 Technology Premises by Blizzard. In the event of such termination, the “Landlord’s Maximum Contribution” (as described in Section II of the attached Work Letter) shall be amended to the amount of One Hundred Seventy-One Thousand Six Hundred Dollars ($171,600).

Landlord warrants to Tenant that the windows and seals, fire sprinkler system, lighting, heating, ventilation and air conditioning systems and all plumbing, electrical and life safety systems serving the Building and the 153 Technology Premises (collectively, the “Building Systems”), and the roof and structural components of the Building, shall be in good operating condition and in compliance with current building codes, as of the Commencement Date for the 153 Technology Premises. Notwithstanding the foregoing, Landlord’s warranty shall not apply to any supplemental HVAC, electrical back-up systems, security systems and telecommunications equipment (collectively, the “Equipment”) located in the 153 Technology Premises. If Tenant notifies Landlord that the Building Systems are not in good operating condition within seventy (70) days following the Commencement Date for the 153 Technology Premises, then Landlord shall, except as otherwise provided in this Lease, promptly after receipt of such notice from Tenant setting forth the nature and extent of such noncompliance, rectify same at Landlord’s sole cost and expense and not as part of the Operating Expenses. Further, Operating Expenses shall not include any cost incurred by Landlord in connection with bringing the Common Areas into compliance with the requirements of the ADA and other applicable law and codes that are in effect as of the date of the execution of this Amendment, including any penalties or damages incurred due to such noncompliance.”

3. Item 5 is hereby deleted in its entirety and substituted therefor shall be the following:

“5. Lease Term: The Term of this Lease shall be sixty (60) months following Commencement Date for the 153 Technology Premises, plus such additional days to cause the Expiration Date to occur on the final day of the calendar month. The Term of this Lease for the 153 Technology Premises and the 157 Technology Premises shall be coterminous.”

4. Item 6 is hereby amended by adding the following:

Basic Rent for the 153 Technology Premises:

Commencing on the Commencement Date for the 153 Technology Premises, the Basic Rent for the 153 Technology Premises shall be Twenty One Thousand Five Hundred Twenty-One Dollars ($21,521.00) per month, based on $.98 per rentable square foot.

 

2


Commencing on the first anniversary of the Commencement Date for the 153 Technology Premises, the Basic Rent for the 153 Technology Premises shall be Twenty Two Thousand Three Hundred Ninety-Nine Dollars ($22,399.00) per month, based on $1.02 per rentable square foot.

Commencing on the second anniversary of the Commencement Date for the 153 Technology Premises, the Basic Rent for the 153 Technology Premises shall be Twenty Three Thousand Four Hundred Ninety-Seven Dollars ($23,497.00) per month, based on $1.07 per rentable square foot.

Commencing on the third anniversary of the Commencement Date for the 153 Technology Premises, the Basic Rent for the 153 Technology Premises shall be Twenty Four Thousand Five Hundred Ninety-Five Dollars ($24,595.00) per month, based on $1.12 per rentable square foot.

Commencing on the fourth anniversary of the Commencement Date for the 153 Technology Premises, the Basic Rent for the 153 Technology Premises shall be Twenty Five Thousand Six Hundred Ninety-Three Dollars ($25,693.00) per month, based on $1.17 per rentable square foot.

Notwithstanding the above schedule of Basic Rent for the 153 Technology Premises to the contrary, as long as Tenant is not in Default (as defined in Section 14.1) under the Lease, Tenant shall be entitled to an abatement of 4 full calendar months of Basic Rent for the 153 Technology Premises in the aggregate amount of $86,084.00 (i.e. $21,521.00 per month) (the “Abated Basic Rent”) for the initial 4 full calendar months of the Term for the 153 Technology Premises (the “Abatement Period”). In the event Tenant Defaults at any time during the Term beyond any applicable “cure” period with the result that Tenant’s right to possession of the Premises is terminated, then unamortized Abated Basic Rent to the date of such termination (amortized over the 60 months of the Term for the 153 Technology Premises) shall immediately become due and payable. The payment by Tenant of the unamortized Abated Basic Rent in the event of a Default shall not limit or affect any of Landlord’s other rights, pursuant to this Lease or at law or in equity. Only Basic Rent for the 153 Technology Premises shall be abated during the Abatement Period and all other additional rent and other costs and charges specified in this Lease shall remain as due and payable pursuant to the provisions of the Lease.

Further notwithstanding the above schedule of Basic Rent for the 153 Technology Premises to the contrary, in the event that the current tenant occupying the 153 Technology Premises, Blizzard Entertainment, Inc (“Blizzard”), has not surrendered possession thereof to Landlord by April 16, 2014, then Tenant shall receive a “day-for-day” credit against Basic Rent for the 153 Technology Premises first coming due for each such day thereafter (and through and including April 30, 2014) that possession of the 153 Technology Premises is not surrendered to Landlord, and (ii) in the event that Blizzard has not surrendered possession of the 153 Technology Premises to Landlord by May 1, 2014, then Tenant shall receive two (2) days credit against Basic Rent for the 153 Technology Premises first coming due hereunder for each such day thereafter that possession of the 153 Technology Premises is not surrendered to Landlord.”

Basic Rent for the 157 Technology Premises:

Commencing July 1, 2015, the Basic Rent for the 157 Technology Premises shall be Forty Two Thousand Nine Hundred Dollars ($42,900.00) per month, based on $1.25 per rentable square foot.

Commencing July 1, 2016, the Basic Rent for the 157 Technology Premises shall be Forty Four Thousand Nine Hundred Fifty-Nine Dollars ($44,959.00) per month, based on $1.31 per rentable square foot.

 

3


Commencing July 1, 2017 and continuing through the Expiration Date, the Basic Rent for the 157 Technology Premises shall be Forty Seven Thousand Eighteen Dollars ($47,018.00) per month, based on $1.37 per rentable square foot.”

5. Effective as of the Commencement Date for the 153 Technology Premises, Item 8 shall be deleted in its entirety and substituted therefor shall be the following:

“8. Floor Area of Premises: Approximately 56,280 rentable square feet, comprised of the following:

153 Technology Premises – approximately 21,960 rentable square feet (and containing approximately 19,447 usable square feet)

157 Technology Premises – approximately 34,320 rentable square feet

6. Item 12 is hereby amended by deleting Tenant’s address for notices and substituted therefor shall be the following

“TENANT

SPECTRUM PHARMACEUTICALS, INC.

157 Technology

Irvine, CA 92618

Attn: Head of Legal Department

With a copy to:

SPECTRUM PHARMACEUTICALS, INC.

157 Technology

Irvine, CA 92618

Attn: Chief Financial Officer”

And with an additional copy sent electronically to:

legal@sppirx.com

7. Effective as of the Commencement Date for the 153 Technology Premises, Item 14 shall be deleted in its entirety and substituted therefor shall be the following:

“14. Vehicle Parking Spaces: Two hundred (200)”

C. Right of First Offer. Provided that no Default has occurred and is continuing beyond any applicable notice or cure periods under any provision of this Lease, either at the time of the delivery of “Landlord’s Notice” or at the time of the delivery of “Tenant’s Notice” (as hereinafter defined), Landlord hereby grants Tenant a continuing right (“First Right”) to lease the space on the second floor of the 153 Technology Building (the “First Right Space”), in accordance with and subject to the provisions of this Section; provided that this First Right shall not be effective until the Commencement Date for the 153 Technology Premises shall occur and shall thereafter cease to be effective during the final twelve (12) months of the Term unless and until Tenant exercises its extension option set forth in Section III.D of this Amendment. Except as otherwise provided below, prior to leasing the First Right Space, or any portion thereof, to any other party during the period that this First Right is in effect, Landlord shall give Tenant written notice (the “Landlord’s Notice”) of the basic economic terms including but not limited to the Basic Rent, term, operating expense base, security deposit, and tenant improvement allowance (collectively, the “Economic Terms”), upon which Landlord is willing to lease such particular First Right Space to Tenant or to a third party; provided that the Economic Terms shall exclude brokerage commissions and other Landlord payments that do not directly inure to the tenant’s benefit. It is understood that should Landlord intend to lease other office space in addition to the First Right Space as part of a single transaction, then Landlord’s Notice shall so provide and all such space shall collectively be subject to the following provisions. Within five (5) business days after delivery of Landlord’s Notice, Tenant must give Landlord written notice (the “Tenant’s Notice”) pursuant to which Tenant shall elect to (i) lease all, but not less than all, of that portion of the First Right Space specified in Landlord’s notice (the “Designated Space”) upon such Economic Terms and the same non-Economic Terms as set forth in this Lease; (ii) refuse to lease the Designated Space, specifying that such refusal is not based

 

4


upon the Economic Terms, but upon Tenant’s lack of need for the Designated Space, in which event Landlord may lease the Designated Space upon any terms it deems appropriate; or (iii) refuse to lease the Designated Space, specifying that such refusal is based upon said Economic Terms, in which event Tenant shall also specify revised Economic Terms upon which Tenant shall be willing to lease the Designated Space. In the event that Tenant does not so respond in writing to Landlord’s Notice within said period, Tenant shall be deemed to have elected clause (ii) above. Any Tenant’s Notice electing either clause (i) or clause (iii) above shall be accompanied by Tenant’s then current annual financial statements, inclusive of Tenant’s most current balance sheet. In the event Tenant’s Notice elects clause (iii) above, Landlord may elect to either (x) lease the Designated Space to Tenant upon such revised Economic Terms and the same other non-Economic Terms as set forth in this Lease, or (y) lease the Designated Space to any third party upon Economic Terms which are not more favorable to such party than those Economic Terms proposed by Tenant. Should Landlord so elect to lease the Designated Space to Tenant, then Landlord shall promptly prepare and deliver to Tenant an amendment to this Lease consistent with the foregoing, and only if Tenant and Landlord fail to execute and deliver to each other an amendment within sixty (60) days, may Landlord pursue a lease of such space to a third party. Tenant’s failure to timely return the amendment shall entitle Landlord to specifically enforce Tenant’s commitment to lease the Designated Space and/or to pursue any other available legal remedy. In the event that Landlord leases the First Right Space, or any portion thereof, to a third party in accordance with the provisions of this Section, and during the effective period of this First Right the First Right Space, or any portion thereof, shall again become available for reletting, then prior to Landlord entering into any such new lease with a third party for the First Right Space, Landlord shall repeat the procedures specified above in this Section. Notwithstanding the foregoing, it is understood that Tenant’s First Right shall be subject and subordinate to any extension or expansion rights previously granted by Landlord to any third party tenant in the Project, as well as to any such rights which may hereafter be granted by Landlord to any third party tenant hereafter occupying the First Right Space or any portion thereof; and Landlord shall in no event be obligated to initiate this First Right prior to leasing any portion of the First Right Space to the then-current occupant thereof. Tenant’s rights under this Section shall belong solely to Spectrum Pharmaceuticals, Inc., a Delaware corporation or any transferee by virtue of a Permitted Transfer, and any other attempted assignment or transfer of such rights shall be void and of no force and effect.

D. Right to Extend the Lease. The provisions of Section 3.1(b) of the Lease entitled “Right to Extend this Lease,” as amended by Section III.B in the First Amendment and Section III.B of the Fourth Amendment, are hereby deleted in their entirety, and substituted therefor shall be the following:

“(b) Provided that Tenant is not in default under any provision of this Lease, either at the time of exercise of the extension right granted herein or at the time of the commencement of such extension, and provided further that Tenant is occupying more than fifty percent (50%) of the floor area of the Premises and/or has not assigned its interest in this Lease (other than to any transferee by virtue of a Permitted Transfer), Tenant shall have one (1) option to extend the Term of this Lease for a period of sixty (60) months. Tenant may exercise its right to extend (i) as to the entire Premises, or (ii) as to only the 157 Technology Premises. Tenant shall exercise its right to extend the Term by and only by delivering to Landlord, not less than nine (9) months or more than twelve (12) months prior to the Expiration Date of the Term, Tenant’s irrevocable written notice of its commitment to extend the (the “Commitment Notice”). The Commitment Notice shall irrevocably specify whether Tenant’s exercise is as to the entire Premises or as to the 157 Technology Premises only, and in the absence of such specification, the exercise shall be deemed to be as to the entire Premises. The Basic Rent payable under the Lease during any extension of the Term shall be at be fair market rental, including subsequent adjustments, for comparable office/research and development space being leased by Landlord in the Irvine Spectrum area. In the event that the parties are not able to agree on the fair market rental within one hundred twenty (120) days prior to the Expiration Date of the Term, then either party may elect, by written notice to the other party, to cause said rental including subsequent adjustments, to be determined by appraisal as follows.

Within ten (10) days following receipt of such appraisal election, the parties shall attempt to agree on an appraiser to determine the fair market rental. If the parties are unable to agree in that time, then each party shall designate an appraiser within twenty (20) days thereafter. Should either party fail to so designate an appraiser within that time, then the single appraiser designated by the other party shall determine the fair rental value. Should each of the parties timely designate an appraiser, then the two (2) appraisers so designated shall appoint a third appraiser who shall, acting alone, determine the fair rental value of the Premises. Any appraiser designated hereunder shall have an M.A.I. certification with not less than ten (10) years’ experience in the valuation of commercial industrial building in Orange County, California.

 

5


Within thirty (30) days following the selection of the appraiser, such appraiser shall determine the fair market rental value, including subsequent adjustments of the Premises. In determining such value, the appraiser shall first consider rental comparables for the Project taking into account size of the Lease, the length of the renewal term, market escalations, rent abatement and other economic concessions then being granted for lease renewals, appropriate adjustments for additional rent obligations and the credit of Tenant, provided that if adequate comparables do not exist then the appraiser may consider transactions involving similarly improved space in the Irvine Spectrum sub-market with the appropriate adjustments for differences in location and quality of project taking into account size of the Lease, the length of the renewal term, market escalations, rent abatement and other economic concessions then being granted for lease renewals, appropriate adjustments for additional rent obligations and the credit of Tenant. In no event shall the appraiser attribute factors for brokerage commissions to reduce said fair market rental. The fees of the appraiser(s) shall be shared equally by both parties.

Within twenty (20) days after the determination of the fair market rental, Landlord shall prepare a reasonably appropriate amendment to this Lease for the extension period and Tenant shall execute and return same to Landlord within thirty (30) days. Should the fair market rental not be established by the commencement of the extension period, then Tenant shall continue paying rent at the rate in effect during the last month of the initial Term, and a lump sum adjustment shall be made promptly upon the determination of such new rental.

If Tenant fails to timely exercise the extension rights created by this Section 3.1(b) within the time period set forth in the initial paragraph of this Section 3.1(b), then Tenant’s right to extend the Term shall be extinguished and the Lease shall automatically terminate as of the expiration date of the Term, without extension and without liability to Landlord. Excepting any Permitted Transfer, any attempt to assign or transfer any right or interest created by this paragraph shall be void from its inception. Tenant shall have no other right to extend the Term beyond the sixty (60) month extension created by this paragraph.”

E. Operating Expenses. Effective as of the Commencement Date for the 153 Technology Premises, the provisions of Section 4.2 of the Lease shall be amended to provide that Tenant shall pay “Tenant’s Share” of all Operating Expenses. As used herein, “Tenant’s Share” shall mean 100% of the Operating Expenses reasonably determined by Landlord to benefit or relate substantially to the 157 Technology Building, plus that portion of any Operating Expenses which is determined by multiplying the cost of such item by one of the following fractions: (i) for Operating Expenses reasonably determined by Landlord to benefit or relate substantially to the 153 Technology Building, a fraction the numerator of which is the rentable square footage of the 153 Technology Premises and the denominator of which is the 153 Technology Building, and (ii) for Operating Expenses reasonably determined by Landlord to benefit or relate substantially to the some or all of the buildings in the entire Project rather than a specific building thereof, a fraction the numerator of which is the rentable square footage of the entire Premises and the denominator of which is the rentable square footage of some or all of the buildings in the Project.

F. Signage. The first and second sentences of Section 5.2 of the Lease, as amended by the Second, Third and Fourth Amendments, are hereby deleted in their entirety, and substituted therefor with the following:

“Provided Tenant continues to lease at least 50% of the rentable square footage of the 153 Technology Premises, Tenant shall have the right to one (1) position on the monument sign at the front entrance to the 153 Technology Premises and one (1) “eye-brow” sign on the 153 Technology Building for Tenant’s name and graphics in locations designated by Landlord, subject to Landlord’s right of prior approval, which approval shall not be unreasonably withheld conditioned or delayed, provided that such exterior signage is in compliance with the Signage Criteria (defined below). Provided Tenant continues to lease at least 70% of the rentable square footage of the 157 Technology Premises (but without consideration to how much space it occupies within the 157 Technology Premises), Tenant shall have the right to maintain its two (2) exterior “building top” signs and one (1) exterior “eye-brow” sign on the 157 Building. Except for the exterior signage rights provided in the foregoing, Tenant shall have no right to maintain signs in any location in, on or about the Buildings or the Project and shall not place or erect any signs, displays or other advertising materials that are visible from the exterior of the Buildings (provided that any signs wholly within the Premises which are not intended to be visible from the exterior of the Buildings shall not be a violation of the foregoing provisions).”

 

6


G. Hazardous Materials. Not by way of limitation of the obligations of the parties in Section 5.3 of the Lease, the parties confirm and agree that: (i) Landlord’s obligations in Section 5.3 (g) of the Lease shall be applicable and binding with respect to Tenant’s lease of the 153 Technology Premises, including without limitation, Landlord’s warranty to “Landlord’s knowledge” (as therein defined) which shall be applicable as of the Commencement Date for the 153 Technology Premises, and (ii) Landlord’s obligations in Section 5.3(h) of the Lease shall be applicable and binding with respect to Tenant’s leasing of the 153 Technology Premises.

H. Parking. The first sentence of Section 6.4 of the Lease is hereby deleted and substituted therefor shall be the following:

“Tenant shall be entitled to the number of vehicle parking spaces set forth in Section III.B.6 of this Amendment on those portions of the Common Areas designated by Landlord for parking. Said parking shall be unreserved and unassigned, except that (i) three (3) of the spaces shall continue to be marked as “visitor” spaces,(ii) two (2) of said spaces shall continue to be marked as VIP spaces and (iii) an additional five (5) of said spaces shall be marked as “reserved” for Tenant, all of the spaces described in the foregoing Subsections (i), (ii), and (iii) to be located within the location generally depicted by “cross-hatching” in Exhibit B attached to this Amendment or in such other location(s) as may be reasonably agreed upon by the parties.”

I. Communications Equipment. Landlord hereby grants to Tenant a non-exclusive license (the “License”) to install, maintain and operate on the roof of the 153 Technology Building a single antenna or satellite dish not exceeding forty-eight inches (48”) in height or thirty-six inches (36”) in diameter (the “Antenna”) in accordance with and subject to the terms and conditions set forth below. The Antenna shall be installed at a location designated by Landlord and reasonably acceptable to Tenant (“Licensed Area”). The Licensed Area shall be considered to be a part of the 153 Technology Premises for all purposes under the Lease, and except as otherwise expressly provided in this Section all provisions applicable to the use of the 153 Technology Premises under the Lease shall apply to the Licensed Area and its use by Tenant.

(1) The Term of the License shall be coterminous with the Lease;

(2) Tenant shall not be obligated to pay any license fee for the use of the Licensed Area pursuant to this Section during the Term of the Lease.

(3) Tenant shall use the Licensed Area only for the installation, operation, repair, replacement and maintenance of the Antenna and the necessary mechanical and electrical equipment to service said Antenna and for no other use or purpose. The installation of the Antenna and all equipment and facilities related thereto, including any required screening for the Antenna and any required conduit from the 153 Technology Premises to the Antenna, shall be deemed to constitute an Alteration subject to the provisions of Section 7.3 of the Lease, provided that Landlord shall not unreasonably withhold its approval of the same. Landlord may require appropriate screening for the Antenna as a condition of Landlord’s approval of the installation of the Antenna. Tenant may have access to the Licensed Area for such uses during normal business hours and at times upon reasonably prior notice to Landlord and shall reimburse Landlord for any reasonably out-of-pocket expenses incurred by Landlord in connection therewith;

(4) The Antenna shall be used only for Tenant’s use; it shall not be used for purposes of providing telecommunications or other communications transmitting or receiving services to the public (other than in connection with the conduct of Tenant’s business) or to any third parties;

(5) Landlord reserves the right upon reasonable prior written notice to Tenant to require the removal of the Antenna should Landlord reasonably determine that its presence results in material damage to the Building unless Tenant makes satisfactory arrangements to protect Landlord therefrom;

(6) Tenant shall require its employees, when using the Licensed Area, to stay within the immediate vicinity thereof. In addition, in the event any communications system or broadcast or receiving facilities are operating in the area, Tenant shall at all times during the term of the License conduct its operations so as to ensure that such system or facilities shall not be subjected to harmful interference as a result of such operations by Tenant. Upon notification from Landlord of any such interference, Tenant agrees to immediately take the necessary steps to correct or substantially mitigate such situation.

 

7


(7) During the term of the License, Tenant shall comply with any standards promulgated by applicable governmental authorities or otherwise reasonably established by Landlord regarding the generation of electromagnetic fields. Should Landlord determine in good faith at any time that the Antenna poses a health or safety hazard to occupants of the 153 Technology Building, Landlord may require Tenant to make arrangements satisfactory to Landlord to mitigate such hazard or, if Tenant either fails or is unable to make such satisfactory arrangements, to remove the Antenna. Any claim or liability resulting from the use of the Antenna or the Licensed Area shall be subject to the indemnification provisions of this Lease applicable to Tenant’s use of the 153 Technology Premises;

(8) During the term of the License, Tenant shall pay all taxes attributable to the Antenna and other equipment owned and installed by Tenant, and Tenant shall assure and provide Landlord with evidence that the Licensed Area and Tenant’s use thereof are subject to the insurance coverages otherwise required to be maintained by Tenant as to the Premises pursuant to Exhibit D of the Lease;

(9) Upon the expiration or sooner termination of the Lease, Tenant shall remove the Antenna and all related equipment and facilities, including any conduit from the Premises to the Antenna, from the Licensed Area and any other portions of the Building within or upon which the same may be installed, and shall restore the Licensed Area and all other areas affected by such removal to their original condition (or as close thereto as is reasonably practicable), reasonable wear and tear excepted, all at its sole cost and expense; and

(10) Tenant’s rights under this Section belong solely to Spectrum Pharmaceuticals, Inc., a Delaware corporation, and any Permitted Transferee; any other attempted assignment or transfer of such rights shall be void and of no force and effect.

J. Moving Allowance. Landlord shall reimburse to Tenant an amount not to exceed Sixty-Five Thousand Eight Hundred Eighty Dollars ($65,880.00) for the “out of pocket” expenses reasonably incurred by Tenant in connection with Tenant’s move to the 153 Technology Premises (the “Moving Allowance”), which expenses shall include, without limitation, purchase and relocation of furniture, fixtures and equipment (“FF&E”) and moving and purchase or relocation of telecommunications and cabling equipment incurred by Tenant in connection with its expansion into the 153 Technology Premises. Landlord shall reimburse Tenant for such expenses up to the amount of the Moving Allowance within thirty (30) days following receipt from Tenant of invoices or other reasonably detailed evidence of Tenant’s expenditure of such expenses, provided, however, that Landlord shall have no obligation to fund any portion of the Moving Allowance for invoices or other requests for reimbursement received after December 31, 2014.

K. Cabling. Landlord will request that Blizzard leave its current cabling serving the 153 Technology Premises in place for Tenant’s use, without representation or warranty by Landlord whatsoever with respect thereto.

Further, Landlord shall provide Tenant access, to the extent available and co-equal to the rights of other tenants of the Project to use same, to an intra-Project conduit between the 153 Technology Premises and the 157 Technology Premises at no charge.

L. Broker’s Commission. Article XVIII of the Lease is amended to provide that the parties recognize the following parties as the brokers who negotiated this Amendment, and agree that Landlord shall be responsible for payment of brokerage commissions to such brokers pursuant to its separate agreements with such brokers: Irvine Realty Company (“Landlord’s Broker”) and Cushman & Wakefield (“Tenant’s Broker”). It is understood and agreed that Landlord’s Broker represents only Landlord in connection with the execution of this Amendment and that Tenant’s Broker represents only Tenant. The warranty and indemnity provisions of Article XVIII of the Lease, as amended hereby, shall be binding and enforceable in connection with the negotiation of this Amendment.

M. Restoration. Notwithstanding anything to the contrary contained in Sections 7.3 and/or 15.3 of the Lease, the parties confirm and agree that no alterations, fixtures (excluding movable trade fixtures), additions or improvements installed or constructed by Tenant in the 157 Technology Premises as of the date of this Amendment shall be required to be removed by Tenant at the Expiration Date or sooner termination of the Term of the Lease.

N. Tenant Improvements. Landlord hereby agrees to complete the Tenant Improvements for the 153 Technology Premises in accordance with the provisions of Exhibit X, Work Letter, attached hereto.

 

8


IV. GENERAL.

A. Effect of Amendments. The Lease shall remain in full force and effect except to the extent that it is modified by this Amendment.

B. Entire Agreement. This Amendment embodies the entire understanding between Landlord and Tenant with respect to the modifications set forth in “III. MODIFICATIONS” above and can be changed only by a writing signed by Landlord and Tenant.

C. Counterparts. If this Amendment is executed in counterparts, each is hereby declared to be an original; all, however, shall constitute but one and the same amendment. In any action or proceeding, any photographic, photostatic, or other copy of this Amendment may be introduced into evidence without foundation.

D. Defined Terms. All words commencing with initial capital letters in this Amendment and defined in the Lease shall have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.

E. Corporate and Partnership Authority. If Tenant is a corporation or partnership, or is comprised of either or both of them, each individual executing this Amendment for the corporation or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of the corporation or partnership and that this Amendment is binding upon the corporation or partnership in accordance with its terms.

 

V. EXECUTION.

Landlord and Tenant executed this Amendment on the date as set forth in “I. PARTIES AND DATE.” above.

 

LANDLORD:

 

THE IRVINE COMPANY LLC

a Delaware limited liability company

   

TENANT:

 

SPECTRUM PHARMACEUTICALS, INC.

a Delaware corporation

By:  

/s/ Steven M. Case

    By:  

/s/ Ken Keller

 

Steven M. Case, Executive

Vice President, Office Properties

     

Ken Keller, Executive Vice President

and Chief Operating Officer

By:  

/s/ Michael T. Bennett

    By:  

/s/ Brett L. Scott

 

Michael T. Bennett, Senior Vice

President, Operations, Office Properties

     

Brett L. Scott, Senior Vice President,

Finance

 

9


EXHIBIT A

153 Technology, Suite 100

 

LOGO


Exhibit B

 

LOGO


EXHIBIT X

WORK LETTER

DOLLAR ALLOWANCE

The tenant improvement work to be contracted for by Landlord hereunder (“Tenant Improvement Work”) shall consist of the design and construction of all tenant improvements (“Tenant Improvements”), including work in place as of the date hereof, required for the 153 Technology Premises pursuant to the approved final Working Drawings and Specifications (as hereinafter defined). All of the Tenant Improvement Work shall be performed by a contractor selected by Landlord and in accordance with the procedures and requirements set forth below.

 

I. ARCHITECTURAL AND CONSTRUCTION PROCEDURES.

 

  A. Prior to the date of this Lease, Tenant and Landlord have approved both (i) a preliminary pricing plan issued for pricing on October 18, 2013 (the “Preliminary Plan”) prepared by H.Hendy& Associates (“Landlord’s Architect”), and (ii) an estimate of the cost to complete the Tenant Improvements in accordance with the Preliminary Plan dated October 24, 2013(“Preliminary Cost Estimate”), which Preliminary Cost Estimate is based upon estimated costs provided by Landlord’s contractor. To the extent applicable or not otherwise specified in the Preliminary Plan to the contrary, the buildout of the Tenant Improvements shall include Landlord’s building standard tenant improvements, materials and specifications for the Project as set forth in Schedule I attached hereto (“Building Standard Improvements”), except for changes and additions specifically requested by Tenant and approved by Landlord in writing (any such addition or variation from the Standard Improvements shall be referred to herein as a (“Non-Standard Improvement”). Landlord acknowledges and agrees that the Preliminary Plan does not specify any Non-Standard Improvements.

 

  B. Within 5 business days following Landlord’s or Landlord’s Architect’s request, Tenant shall provide in writing to Landlord or Landlord’s architect all specifications and information requested by Landlord for the preparation of final construction documents and costing, including without limitation Tenant’s final selection of paint and floor finishes, complete specifications and locations (including electrical, load and HVAC requirements) of Tenant’s equipment, and details of all Non-Standard Improvements (as defined above) which have been approved by Landlord as part of the Preliminary Plan (collectively, “Programming Information”). Tenant’s failure to timely provide the Programming Information shall constitute a Tenant Delay for purposes hereof. Tenant understands that final construction documents for the Tenant Improvements shall be predicated on the Programming Information, and accordingly that such information must be accurate and complete and that any defects or problems due to incomplete or inaccurate Programming Information shall be the responsibility of the Tenant and that the Landlord shall have no obligation or liability for such defects or problems arising from any incomplete or inaccurate Programming Information. Any delays in the completion of the Tenant Improvements due to incomplete or inaccurate Programming Information shall constitute a Tenant Delay.

 

  C. Promptly following delivery of the Programming Information, Landlord’s Architect and engineers shall prepare and deliver to Tenant working drawings and specifications (“Working Drawings and Specifications”), and Landlord’s contractor shall prepare a final construction cost estimate (“Final Cost Estimate”) for the Tenant Improvements in conformity with the Working Drawings and Specifications. The Final Cost Estimate shall be based on competitive bids obtained from at least three (3) separate bids for each of the major trades. Tenant shall have five (5) business days after the receipt thereof to approve or disapprove the Working Drawings and Specifications and the Final Cost Estimate. Tenant shall not unreasonably withhold or delay its approval, and any disapproval or requested modification shall be limited to items not consistent with the approved Preliminary Plan or Preliminary Cost Estimate. Should Tenant disapprove the Working Drawings and Specifications or the Final Cost Estimate, such disapproval shall be accompanied by specific reasons for disapproval and a detailed list of requested revisions. Any revision requested by Tenant and accepted by Landlord, shall be incorporated into a revised set of Working Drawings and Specifications and the Final Cost Estimate, and Tenant shall approve same in writing within five (5) days of receipt without further revision.

 

  D.

In the event that Tenant requests in writing a revision to the Working Drawings and Specifications (“Change”), and Landlord so approves such Change as provided in the Section next below, Landlord shall advise Tenant by written change order as soon as is practical of any increase in the Completion Cost such Change would cause. If the request for such Change occurs before construction of the Tenant Improvements commences, then Tenant shall approve or disapprove such change order, if any, in writing within four (4) business days following Tenant’s receipt of such change order. If the request for such Change occurs after construction of the Tenant Improvements commences, then Tenant shall approve or disapprove such change order in writing within three (3) business days following Tenant’s receipt of such change order. If Tenant approves any such change order, Tenant’s payment of such increase shall be paid within 10 days after delivery of invoices for same; provided, however, that the Tenant Contribution must in any event be paid in full prior to Tenant’s commencing occupancy of the 153 Technology Premises. If Tenant disapproves any such change order, Tenant shall nonetheless be responsible for the reasonable architectural and/or planning fees incurred in

 

2


  preparing such change order. Landlord shall have no obligation to interrupt or modify the Tenant Improvement Work pending Tenant’s approval of a change order, but if Tenant fails to timely approve a change order, Landlord may (but shall not be required to) upon at least two (2) business days’ notice to Tenant, which notice shall be the same notice contemplated by Section I.F below, suspend the applicable Tenant Improvement Work, in which event any related critical path delays because of such suspension shall constitute Tenant Delays hereunder.

 

  E. Landlord agrees that it shall not unreasonably withhold, condition or delay its consent to Tenant’s requested Changes, provided that such consent may be withheld in all events if the requested Change (i) is of a substantially lesser quality than the Tenant Improvements previously approved by Landlord, (ii) fails to conform to applicable governmental requirements, (iii) would result in the 153 Technology Premises requiring building services beyond the level normally provided to other tenants, (iv) would delay construction of the Tenant Improvements and Tenant declines to accept such delay in writing as a Tenant Delay, (v) interferes in any manner with the proper functioning of, or Landlord’s access to, any mechanical, electrical, plumbing or HVAC systems, facilities or equipment in or serving the Building, or (vi) would have an adverse aesthetic impact visible from the exterior of the 153 Technology Premises or would cause additional material expenses to Landlord in reletting the 153 Technology Premises.

 

  F. Notwithstanding any provision in the Lease to the contrary, and not by way of limitation of any other rights or remedies of Landlord, if Tenant fails to comply with any of the time periods specified in this Work Letter, fails otherwise to approve or reasonably disapprove any submittal within the time period specified herein for such response (or if no time period is so specified, within five (5) business days following Tenant’s receipt thereof), fails to provide all of the Programming Information requested by Landlord, fails to approve in writing the Working Drawings and Specifications or the Final Cost Estimate within the time periods provided herein, fails to timely deliver the Tenant’s Contribution as required hereunder, requests any Changes, furnishes inaccurate or erroneous Programming Information, specifications or other information, or otherwise delays in any manner the completion of the Tenant Improvements (including without limitation by specifying materials that are not readily available) or the issuance of an occupancy certificate (any of the foregoing being referred to in this Lease as a “Tenant Delay”), then Tenant shall bear any resulting additional construction cost or other expenses, and the Commencement Date for the 153 Technology Premises shall be deemed to have occurred for all purposes, including without limitation Tenant’s obligation to pay rent, as of the date Landlord reasonably determines that it would have been able to deliver the 153 Technology Premises to Tenant but for the collective Tenant Delays. Notwithstanding anything to the contrary in the foregoing, no Tenant Delay shall occur unless and until Landlord gives to Tenant written notice that a Tenant Delay will commence to accrue if Tenant fails to make a decision or take an action within two (2) business days thereafter, and Tenant fails to make the required decision or take the required action within said two (2) business days. Should Landlord determine that the Commencement Date for the 153 Technology Premises should be advanced in accordance with the foregoing, it shall so notify Tenant in writing. Landlord’s determination shall be conclusive unless Tenant notifies Landlord in writing, within fifteen (15) days thereafter, of Tenant’s election to contest same by arbitration pursuant to Paragraph III below. Pending the outcome of such arbitration proceedings, Tenant shall make timely payment of all rent due under this Lease based upon the Commencement Date for the 153 Technology Premises set forth in the aforesaid notice from Landlord (other than any amount Tenant is contesting).

 

  G. All of the Tenant Improvements shall become the property of Landlord and shall be surrendered with the 153 Technology Premises at the expiration or sooner termination of this Lease, except that Landlord shall have the right, by notice to Tenant given at the time of Landlord’s approval of Working Drawings and Specifications and any Change, to require Tenant either to remove all or any of the Tenant Improvements approved in the Working Drawings and Specifications (except as to any Tenant Improvements shown on the approved Preliminary Plan) or by way of such Change, to repair any damage to the 153 Technology Premises or the Common Areas arising from such removal, and to replace any Non-Standard Improvements so approved with the applicable Standard Improvement, or to reimburse Landlord for the reasonable cost of such removal, repair and replacement upon demand. Any such removals, repairs and replacements by Tenant shall be completed by the Expiration Date or sooner termination of this Lease. Landlord confirms and agrees, however, that no such removal or replacement shall be required for any of the Tenant Improvements shown on the approved Preliminary Plan.

 

  H. Tenant hereby designates Rick Nichols (“Tenant’s Construction Representative”), Telephone No. (949) 788-6700, Email: richard.nichols@sppirx.com, as its representative and agent for all matters related to the Tenant Improvement Work, including but not by way of limitation, for purposes of receiving notices, approving submittals and issuing requests for Changes, and Landlord shall be entitled to rely upon authorizations and directives of such person(s) as if given directly by Tenant. Any notices required to be delivered to Tenant by the terms of this Work Letter may be sent to Tenant’s Construction Representative at the email address herein provided. The foregoing authorization is intended to provide assurance to Landlord that it may rely upon the directives and decision making of the Tenant’s Construction Representative with respect to the Tenant Improvement Work and is not intended to limit or reduce Landlord’s right to reasonably rely upon any decisions or directives given by other officers or representatives of Tenant. Tenant may amend the designation of its Tenant’s Construction Representative(s) at any time upon delivery of written notice to Landlord.

 

3


  I. Landlord hereby designates Michael Johnston (“Landlord’s Construction Representative”), Telephone No. (949) 720-4367, Email: mjohnston@irvinecompany.com, as its representative and agent for all matters related to the Tenant Improvement Work, including but not by way of limitation, for purposes of receiving notices, approving submittals and issuing requests for Changes, and Tenant shall be entitled to rely upon authorizations and directives of such person(s) as if given directly by Landlord. Any notices required to be delivered to Landlord by the terms of this Work Letter may be sent to Landlord’s Construction Representative at the email address herein provided. The foregoing authorization is intended to provide assurance to Tenant that it may rely upon the directives and decision making of the Landlord’s Construction Representative with respect to the Tenant Improvement Work and is not intended to limit or reduce Tenant’s right to reasonably rely upon any decisions or directives given by other officers or representatives of Landlord. Landlord may amend the designation of its Landlord’s Construction Representative(s) at any time upon delivery of written notice to Tenant.

 

II. COST OF TENANT IMPROVEMENTS

 

  A. Landlord shall complete, or cause to be completed, the Tenant Improvements, at the construction cost shown in the Final Cost Estimate (subject to increases for Landlord approved Changes and as otherwise provided in this Work Letter), in accordance with final Working Drawings and Specifications approved by both Landlord and Tenant.

 

  B. Landlord shall pay up to Seven Hundred Sixteen Thousand One Hundred Sixteen Dollars (i.e., $171,600 + 544,516 = $716,116) (“Landlord’s Maximum Contribution”) of the final “Completion Cost” (as defined below). Tenant acknowledges that the Landlord’s Maximum Contribution is intended only as the maximum amount Landlord will pay toward approved Tenant Improvements, and not by way of limitation, any partitions, modular office stations, fixtures, cabling, furniture and equipment requested by Tenant are in no event subject to payment as part of Landlord’s Contribution other than as described below. In the event the sum of the cost of the Completion Cost of the Tenant Improvement Work is less than the Landlord’s Maximum Contribution, Landlord’s actual contribution toward the Completion Cost (“Landlord’s Contribution”) shall equal such lesser amount, and Tenant shall have no right to receive any credit, refund or allowance of any kind for any unused portion of the Landlord’s Maximum Contribution. Notwithstanding anything to the contrary, however, in this Section II.B: (i) Tenant may utilize a portion of the Landlord’s Maximum Contribution, not to exceed the amount of One Hundred Ninety-Four Thousand Four Hundred Seventy Dollars ($194,470.00) (i.e., based on $10.00 per usable square foot of the 153 Technology Premises) towards Tenant’s cost of purchasing and/or installing cabling, furniture, signage, architectural fees, and any other moving expenses for Tenant’s expansion into the 153 Technology Premises, and (ii) Landlord’s Maximum Contribution may be utilized, at Tenant’s election, either towards the Completion Cost of the Tenant Improvements for the 153 Technology Premises as provided in this Work Letter or for improvements to the 157 Technology Premises reasonably acceptable to Landlord, provided however, that the Tenant Improvements and/or the improvements for the 157 Technology Premises shall be substantially completed no later than June 30, 2015 to be eligible for funding by Landlord, and that Landlord shall not be obligated to fund any portion of the Landlord’s Maximum Contribution towards the Tenant Improvements or other improvements completed after such date.

 

  C. If Tenant fails to provide to Landlord corrected Programming Information with two (2) business days after Landlord gives to Tenant written notice that such Programming Information is needed, then Tenant shall pay any costs due to inaccurate or incompletely Programming Information and the amount, if any, by which aggregate Completion Cost for the Tenant Improvement Work exceeds the Landlord’s Maximum Contribution. The amounts to be paid by Tenant for the Tenant Improvements pursuant to this Section II.C are sometimes cumulatively referred to herein as the “Tenant’s Contribution”.

 

  D. The “Completion Cost” shall mean all costs of Landlord in completing the Tenant Improvements in accordance with the approved Working Drawings and Specifications and with any approved Changes thereto, including but not limited to the following costs: (i) payments made to architects, engineers, contractors, subcontractors and other third party consultants in the performance of the work, (ii) salaries and fringe benefits of persons, if any, in the direct employment of Landlord performing any part of the construction work, (iii) permit fees and other sums paid to governmental agencies, and (iv) costs of all materials incorporated into the work or used in connection with the work. Unless expressly authorized in writing by Landlord, the Completion Cost shall not include (and no portion of the Landlord’s Contribution shall be paid for) any costs incurred by Tenant, including without limitation, any costs for space planners, managers, advisors or consultants retained by Tenant (other than such costs not to exceed $2.00 per usable square foot in connection with the planning of Tenant’s lab space). Landlord represents and warrants that no construction management or review fees and/or charges shall be charged to Tenant in connection with the Tenant Improvements.

 

  E.

Tenant shall pay to Landlord the amount of the Tenant’s Contribution set forth in the Final Cost Estimate (once approved by Tenant) as follows: (i) fifty percent (50%) of the Tenant’s

 

4


  Contribution prior to the commencement of construction of the Tenant Improvements, (ii) fifty percent (50%) of the Tenant’s Contribution not later than thirty (30) days following the commencement of the construction of the Tenant Improvements. Following completion of the Tenant Improvements Work, Tenant shall pay (or be refunded) any different between the estimated and the actual amount of the Tenant’s Contribution towards the Completion Cost, which difference shall be calculated by first applying Landlord’s Contribution, in full, to the actual amount of the final Completion Cost. If the actual Completion Cost of the Tenant Improvements is greater than the Final Cost Estimate because of Changes, modifications or extras not reflected on the approved Working Drawings and Specifications, or because of Tenant Delays, then Tenant shall pay all such additional costs within ten (10) days after written demand for same. The balance of any sums not otherwise paid by Tenant shall be due and payable on or before the Commencement Date for the 153 Technology Premises. If Tenant defaults in the payment of any sums due under this Work Letter, Landlord shall (in addition to all other remedies) have the same rights as in the case of Tenant’s failure to pay rent under the Lease, including, without limitation, the right to terminate this Lease and recover damages from Tenant and/or to charge a late payment fee and to collect interest on delinquent payments, and Landlord may (but shall not be required to) suspend the Tenant Improvement Work following such default, in which event any delays because of such suspension shall constitute Tenant Delays hereunder.

 

  F. Landlord shall obtain a commercially reasonable warranty from its general contractor covering any defects in the workmanship and materials of the Tenant Improvement Work for a period of one year following completion thereof, and shall use commercially reasonable efforts to enforce said warranty in favor of Tenant. Specifically excluded from this warranty shall be appliances (dishwashers, refrigerators, ice makers etc.) purchased on behalf of Tenant, and any appliance warranties will remain solely between Tenant and the appliance manufacturer.

 

III. DISPUTE RESOLUTION

 

  A. All claims or disputes between Landlord and Tenant arising out of, or relating to, this Work Letter shall be decided by the JAMS/ENDISPUTE (“JAMS”), or its successor, with such arbitration to be held in Orange County, California, unless the parties mutually agree otherwise. Within ten (10) business days following submission to JAMS, JAMS shall designate three (3) arbitrators and each party may, within five (5) business days thereafter, veto one (1) of the three (3) persons so designated. If two (2) different designated arbitrators have been vetoed, the third arbitrator shall hear and decide the matter. If less than two (2) arbitrators are timely vetoed, JAMS shall select a single arbitrator from the non-vetoed arbitrators originally designated by JAMS, who shall hear and decide the matter. Any arbitration pursuant to this section shall be decided within thirty (30) days of submission to JAMS. The decision of the arbitrator shall be final and binding on the parties. In no event shall the arbitrator be empowered or authorized to award consequential or punitive damages (including any award for lost profit or opportunity costs or loss or interruption of business or income). All costs associated with the arbitration shall be awarded to the prevailing party as determined by the arbitrator.

 

  B. Notice of the demand for arbitration by either party to the Work Letter shall be filed in writing with the other party to the Work Letter and with JAMS and shall be made within a reasonable time after the dispute has arisen. The award rendered by the arbitrator shall be final, and judgment may be entered upon it in accordance with applicable law in any court having jurisdiction thereof. Except by written consent of the person or entity sought to be joined, no arbitration arising out of or relating to this Work Letter shall include, by consolidation, joinder or in any other manner, any person or entity not a party to the Work Letter unless (1) such person or entity is substantially involved in a common question of fact or law, (2) the presence of such person or entity is required if complete relief is to be accorded in the arbitration, or (3) the interest or responsibility of such person or entity in the matter is not insubstantial.

 

  C. The agreement herein among the parties to arbitrate shall be specifically enforceable under prevailing law. The agreement to arbitrate hereunder shall apply only to disputes arising out of, or relating to, this Work Letter, and shall not apply to other matters of dispute under the Lease except as may be expressly provided in the Lease.

 

5


Schedule I

Tenant Improvement / Interior Construction Outline Specifications

(By Tenant/Tenant Allowance)

 

TENANT STANDARD GENERAL OFFICE:   CARPET   
  Direct glue, from one of the following options:   
  Designweave-Z6354 Tempest Esq.:    Designweave – Z6356 Techno:
 

a)      553 Steel Wool

  

a)      336 Lido

 

b)      773 Melba Toast

  

b)      252 Topaz

 

c)      575 Silver Smoke

  

c)      518 Night Sky

 

d)      535 Dolphin

  

d)      997 Silver Plum

 

e)      454 Denim

  

e)      496 Galactic

  VINYL COMPOSITION TILE (VCT)   
  12x12 VCT Armstrong Standard Excelon, from the following options:
 

a)      51803 Pearl White

  

c)      51908 Pewter

 

b)      51899 Cool White

  

d)      51899 Cool White

  PAINT / WALLS
  5/8” gypsum drywall on 2-1/2” x 25 ga. metal studs, floor to ceiling construction, no walls shall penetrate the grid unless required by code. All walls shall be straight, and parallel to building perimeter walls. All offices and rooms shall be constructed of a standard size and tangent to a building shell or core wall. Paint finish, one standard color to be Benjamin Moore AC-40, Glacier White, flat finish.
  BASE
  2-1/2” Burke rubber base color: Pearl 137P, straight at cut pile carpet, coved at resilient flooring and loop carpet.
  RUBBER TRANSITION STRIP
  Transition strip between carpet and resilient flooring to be Burke #150, color: to match adjacent V.C.T.
  PLASTIC LAMINATE
  Plastic laminate color at millwork to be Nevamar “Smoky White”, Textured #S-7-27T.
  CEILING
  2x4 USG Radar Illusions #2842 grid and scored tile on 9/16” T-bar grid. Continuous grid throughout.
  PERIMETER WALLS
  Furring, 25 ga. metal studs with 5/8” gypsum drywall, with batt insulation.
  LIGHTING
  2X4 fluorescent, 3-lamp energy saving ballast, 18-cell parabolic lens fixture.
  DOORS
  1-3/4” solid core, 3’’-0” x 8’-10”, plain sliced white oak, Western Integrated clear anodized aluminum frames, Schlage “D” series “Sparta” latchset hardware, dull chrome finish.
  OFFICE SIDELITES
  All interior offices to have sidelite glazing adjacent to office entry door. 2’ wide x door height, Western Integrated clear anodized aluminum frame integral to door frame with clear tempered glass.


Tenant Improvement / Interior Construction Outline Specifications

(Continued)

 

TENANT STANDARD GENERAL OFFICE (CONTINUED):   

WINDOW COVERINGS

Vertical blinds: Mariak Industries PVC blinds at building perimeter windows, Model M-3000, Color: Light Grey.

TENANT STANDARD MECHANICAL:

  

HVAC

Interior and Exterior zone VAV boxes shall be connected to the main supply air loop. Exterior zone VAV boxes shall be provided with single-row hot water reheat coil.

 

Air distribution downstream of VAV boxes shall be provided complete with ductwork, 2’x2’ perforated face ceiling diffusers, 2’x2’ perforated return air grilles and air balance.

 

Pneumatic thermostats with blank white cover shall be provided for each zone. Thermostats shall be located adjacent to light switch at 48” above finished floor.

 

Exterior corner spaces with more than one exposure shall be provided with a separate zone.

 

Conference Room (or Training Room) 20’x13’ or larger shall be provided with a separate zone.

 

Exterior zone shall be limited to a single exposure and a maximum of 750 to 1000 square feet.

 

Interior zone shall be limited to a maximum of 2000 square feet.

 

  

FIRE PROTECTION

Pendant satin chrome plated, recessed heads, adjustable canopies, minimum K factor to be 5.62, located at center of scored ceiling tile. Ceiling drops from shell supply loop.

TENANT STANDARD ELECTRICAL:

  

ELECTRICAL SYSTEM

277/480 volt, three phase, four wire metered distribution section added to main service at Main Electrical Room.

 

Electrical tenant distribution capacity suitable for 22 watts per s.f. to accommodate HVAC, lighting, data processing, computer loads and convenience outlets.

 

Tenant Electrical Room, located within the lease space, to include 270/480 volt and 120/208 volt panels, transformer, lighting control panel, as required.

 

  

LIGHTING

Double switch per Title 24, paired in double gang box, Leviton “Decora” white plastic coverplate, 42” AFF to switch centerline. Provide occupancy sensors as required by code. 2x4 fluorescent light fixtures, 3-lamp energy saving ballast, 18-cell parabolic lens fixture based upon one (1) fixture per 80 square feet.

 

Exit signs: Internally illuminated, white sign face with green text.


Tenant Improvement / Interior Construction Outline Specifications

(Continued)

 

TENANT STANDARD ELECTRICAL (CONTINUED):  

OUTLETS

Power: 15-amp 125-volt specification grade duplex receptacle mounted vertically, 18” AFF to centerline, white plastic coverplate. Feeds to systems furniture by Tenant to be via walls, furred columns or ceiling J-box. Power poles and furniture by Tenant. Ratio of one (1) feed per eight (8) workstations. Assumes four (4) circuits, eight (8) wire configuration of systems furniture.

 

Telephone/Data: Single gang box with mud ring and pull string, mounted vertically, 18” AFF to centerline, Cover plate by telephone and/or cabling company. Teflon cable by tenant.

 

One (1) empty 2” conduit to be routed from Tenant’s Server Room, 4x8 backboard to building main telephone backboard.

TENANT STANDARD WAREHOUSE/SHIPPING AND RECEIVING:  

FLOORS

Sealed concrete.

 

WALLS

5/8” gypsum wallboard standard partition. Paint to match Benjamin Moore AC-40 Glacier White; rated partition at occupancy separation as required by code.

 

CEILING

Exposed structure, non-painted.

 

WINDOWS

None

 

ACCESS

7’-6” H x 7’-6” W glazed service doors. Glazing is bronze reflective glass.

 

HVAC

None

 

PLUMBING

Single accommodation restroom, if required.

 

Sheet vinyl flooring to be Armstrong Classic Corlon “Seagate” #86526 Oyster, with Smooth White FRP panel wainscot to 48” high. Painted walls and ceiling to be Benjamin Moore AC-40 Glacier White, semi-gloss finish.

 

LIGHTING

Chain hung florescent strip fixtures.

 

OTHER ELECTRICAL

Convenience outlets; surface mounted at exposed concrete walls.

 

SECURITY

Lockable doors.

EX-10.10 6 d640093dex1010.htm EX10.10 EX10.10

Exhibit 10.10

SIXTH AMENDMENT TO LEASE

 

I. PARTIES AND DATE.

This Sixth Amendment to Lease (the “Amendment”) dated January 31, 2014, is by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, formerly The Irvine Company, a Delaware corporation (“Landlord”), and SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

 

II. RECITALS.

On January 16, 1997, Landlord and Tenant entered into a lease for space in a building located at 157 Technology, Irvine, California (“157 Technology Premises”), which lease was amended by a First Amendment to Lease dated March 25, 2004, by a Second Amendment to Lease dated March 7, 2006, by a Third Amendment to Lease dated February 12, 2006, by a Fourth Amendment to Lease dated July 29, 2009, and by a Fifth Amendment to Lease dated November 21, 2013 (the “Fifth Amendment”). The foregoing lease, as so amended is hereinafter referred to as the “Lease”.

Landlord and Tenant each desire to modify the Lease to correct certain typographical errors contained in the Fifth Amendment as are set forth in “III. MODIFICATIONS” next below.

 

III. MODIFICATIONS.

A. The schedule for the “Basic Rent for the 157 Technology Premises” contained in Subsection III.B(4) of the Fifth Amendment is hereby deleted in its entirety, and substituted therefor shall be the following:

“Basic Rent for the 157 Technology Premises:

Commencing July 1, 2016, the Basic Rent for the 157 Technology Premises shall be Forty Two Thousand Nine Hundred Dollars ($42,900.00) per month, based on $1.25 per rentable square foot.

Commencing July 1, 2017, the Basic Rent for the 157 Technology Premises shall be Forty Four Thousand Nine Hundred Fifty-Nine Dollars ($44,959.00) per month, based on $1.31 per rentable square foot.

Commencing July 1, 2018 and continuing through the Expiration Date, the Basic Rent for the 157 Technology Premises shall be Forty Seven Thousand Eighteen Dollars ($47,018.00) per month, based on $1.37 per rentable square foot.”

 

IV. GENERAL.

A. Effect of Amendments. The Lease shall remain in full force and effect except to the extent that it is modified by this Amendment.

B. Entire Agreement. This Amendment embodies the entire understanding between Landlord and Tenant with respect to the modifications set forth in “III. MODIFICATIONS” above and can be changed only by a writing signed by Landlord and Tenant.

C. Counterparts. If this Amendment is executed in counterparts, each is hereby declared to be an original; all, however, shall constitute but one and the same amendment. In any action or proceeding, any photographic, photostatic, or other copy of this Amendment may be introduced into evidence without foundation.

D. Defined Terms. All words commencing with initial capital letters in this Amendment and defined in the Lease shall have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.

 

1


E. Corporate and Partnership Authority. If Tenant is a corporation or partnership, or is comprised of either or both of them, each individual executing this Amendment for the corporation or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of the corporation or partnership and that this Amendment is binding upon the corporation or partnership in accordance with its terms.

 

V. EXECUTION.

Landlord and Tenant executed this Amendment on the date as set forth in “I. PARTIES AND DATE.” above.

 

LANDLORD:

 

THE IRVINE COMPANY LLC

   

TENANT:

 

SPECTRUM PHARMACEUTICALS, INC.

a Delaware limited liability company     a Delaware corporation
By  

/s/ Steven M. Case

    By  

/s/ Brett L. Scott

  Steven M. Case, Executive Vice President     Name   Brett L. Scott
  Office Properties     Title   Senior Vice President
By  

/s/ Michael T. Bennett

    By  

/s/ Abraham N. Oler

  Michael T. Bennett, Senior Vice President     Name   Abraham N. Oler
  Operations, Office Properties     Title   Vice President of Operations

 

2

EX-21 7 d640093dex21.htm EX-21 EX-21

EXHIBIT 21.1

LIST OF SUBSIDIARIES

 

SUBSIDIARY/AFFILIATE NAME

   INCORPORATION

OncoRx Pharma Private Limited

   India

RIT Oncology, LLC

   Delaware

Spectrum Pharmaceuticals International Holdings, LLC

   Delaware

Allos Therapeutics, Inc.

   Delaware

Allos Therapeutics Ltd.

   England and Wales

Spectrum Pharmaceuticals Cayman, L.P.

(1% Spectrum Pharmaceuticals International Holdings, LLC and 99% Spectrum Pharmaceuticals, Inc.)

   Cayman Islands

Spectrum Pharmaceuticals, B.V.

   Netherlands

Spectrum Pharmaceuticals GK

   Japan

Spectrum Pharma Canada Inc.

(50% Spectrum Pharmaceuticals, Inc.

50% Prodev Pharma Inc.)

   Canada

Talon Therapeutics, Inc.

   Delaware
EX-23.1 8 d640093dex231.htm EX-23.1 EX-23.1

EXHIBIT 23.1

Consent Of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-150260, 333-142628, 333-135029, 333-125208, 333-121612, 333-115759, 333-110103, 333-108658, 333-105814, 333-102587, 333-64444, 333-64432, 333-60966, 333-51388, 333-42852, 333-38710, 333-37180, 333-92855, 333-73009, 333-52331, 333-37585, 333-185115, 333-190413; and Form S-8 Nos. 333-176681, 333-160312, 333-160705, 333-164014, 333-134566, 333-119833, 333-106427, 333-54246, 333-30345) of Spectrum Pharmaceuticals, Inc. and in the related Prospectuses of our reports dated March 12, 2014, with respect to the consolidated financial statements and schedule of Spectrum Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Spectrum Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2013.

/s/ Ernst & Young LLP

Irvine, California

March 12, 2014

EX-31.1 9 d640093dex311.htm EX-31.1 EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Rajesh C. Shrotriya, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Spectrum Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2014

 

/s/ RAJESH C. SHROTRIYA

Rajesh C. Shrotriya, M.D.

Chairman, Chief Executive Officer and President

(Principal Executive Officer)

EX-31.2 10 d640093dex312.htm EX-31.2 EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Kurt A. Gustafson, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Spectrum Pharmaceuticals, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 12, 2014

 

/s/ KURT A. GUSTAFSON

Kurt A. Gustafson
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
EX-32.1 11 d640093dex321.htm EX-32.1 EX-32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2013 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 12, 2014

 

/s/ RAJESH C. SHROTRIYA

Rajesh C. Shrotriya, M.D.

Chairman, Chief Executive Officer and President

This certification accompanies this Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-32.2 12 d640093dex322.htm EX-32.2 EX-32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2013 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 12, 2014

 

/s/ KURT A. GUSTAFSON

Kurt A. Gustafson

Executive Vice President and Chief Financial Officer

This certification accompanies this Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-101.INS 13 sppi-20131231.xml XBRL INSTANCE DOCUMENT 313000000 1000000 10000000 65287782 4700000 200000 175000000 100000000 1.00 0.50 26300000 6500000 6500000 195000000 4000000 2000 5000000 12300000 449722900 0.30 359500 4.17 8397094 3.96 2803000 53557000 6.45 4192312 -92000 -307635000 77241000 51459284 51000 26 160000 384757000 339000 952525 5.46 10185521 10.11 3928000 0.2 121202000 5.04 9808000 9064000 992000 4000000 445000 -227000 363055 -2926000 -257704000 192086000 59247483 59000 20 123000 452761000 471000 60026675 60026675 1034604 6.57 10399265 5000000 175000000 0.001 11.00 0.001 8449000 7315000 2819000 463710000 1818000 123243000 273000 5482000 14520 4367000 288681000 105252000 228000 75000000 12275000 2400000 -175485000 12300000 30814000 27879000 571000 60000 2366000 504955000 2522000 1132000 216274000 16885000 5200000 814000 228468000 3310000 2881000 264873000 7279000 2896000 5298000 200234000 6745000 45391000 3310000 304000 73246000 504955000 20369000 139698000 23276000 35749000 7889000 92169000 14478000 2476000 6289000 72121000 9863000 1848000 4596000 2745000 6475000 7302000 12473000 887000 6021000 2548000 2287000 4835000 143008000 36372000 4367000 2650000 15153000 2287000 5056000 3050000 856000 5.45 12233000 143000000 2881000 2365000 143008000 11023000 11441000 298000 11377000 19735000 41900000 22165000 2192000 23490000 20943000 14149000 28634000 26176000 76318000 1451000 4355000 5056000 44000 395000 2480000 2480000 987000 987000 11698000 11698000 2323000 2323000 273000 -175485000 288681000 60026675 60000 20 123000 463710000 228000 12233000 856000 11377000 2480000 2365000 17889000 2881000 2365000 14520000 2287000 12233000 1492000 886000 4540000 2799000 146000 2980000 16778000 13798000 895000 27900000 27005000 116323000 118400000 2077000 128000000 128000000 128000000 987000 987000 987000 11698000 11698000 11698000 2323000 2323000 2323000 20 2000 40000 0.001 20 123000 0 240000 10000 0 1500000 0.001 0 64104173 7876025 11329218 64104173 1007119 28101704 7.10 11329218 6.11 7.10 5000000 6.11 7876025 175000000 0.001 10.09 0.001 2430000 950000 9070000 8867000 518144000 4402000 843000 49586000 89984000 894000 2212000 26071 5965000 281606000 79837000 206000 4000000 50000000 868000 9498000 3900000 -237619000 156000 7168000 12796000 48975000 366000 64000 3949000 499155000 3000 1352000 217549000 892000 8329000 30020000 0.3 849000 3432000 280668000 3471000 93867000 5361000 235190000 18501000 3486000 7539000 6495000 231352000 12577000 46482000 22468000 3471000 190000 73255000 22313000 499155000 112820000 156306000 -5509000 3117000 49483000 13519000 5700000 3593000 22468000 8413000 23669000 10605000 8066000 206052000 24080000 58000 -4573000 3213000 25849000 12576000 3312000 22468000 22468000 1659000 1794000 5551000 1535000 4329000 44100000 6872000 1600000 Longer than one year 10526000 1770000 159777000 28096000 5965000 2327000 5074000 28100000 2900000 6.29 616000 3119000 6.39 17742000 9.38 159800000 5361000 1082000 3949000 33574000 P8Y10M24D 159777000 28893000 91480000 6433000 298000 14623000 23455000 41900000 18445000 5343000 23490000 18829000 5373000 27843000 33967000 55818000 317000 1317000 2900000 122000 445000 407500 13100000 11400000 1000 10.53 120000000 14.03 1000 120000000 28520000 91480000 0.25 10 50000 0.15 3 17700000 3593000 3593000 410000 410000 100395000 100395000 3061000 3061000 2862699 6.19 6.26 2565220 1192794 2.16 2.16 1192794 3019654 11.09 10.86 1105079 2329167 8.26 8.17 1147138 1924904 4.23 4.23 1865794 894000 -237619000 281606000 64104173 64000 20 123000 518144000 206000 6576000 26300000 44500000 30000 109000 44100000 5231000 131000 10526000 6500000 4329000 11807000 33574000 44500000 611000 45381000 17600000 26900000 7700000 4000000 205200000 0.08 17742000 0.11 0.09 3119000 14623000 4540986 346500 11400000 11329218 12400000 445000 40000 6500000 3593000 3949000 109227000 5361000 3949000 4000000 26071000 4329000 17742000 1575000 1063000 5154000 2813000 10000000 5000000 5700000 10000000 0.25 17600000 17600000 1107000 26900000 25793000 4821000 16778000 11957000 3662000 27900000 23215000 107813000 118400000 10587000 7700000 7700000 55911000 55911000 55911000 410000 410000 410000 100395000 100395000 100395000 3061000 3061000 3061000 6900000 117400000 4100000 2200000 132000000 20 2000 40000 0.001 20 123000 0 240000 10000 0 1500000 0.001 0 1300000 -2171000 0.30 30000000 0.70 0.50 -700000 1000000 1000000 19000000 1023000 700000 If all sales and regulatory approval milestones are achieved, as summarized below: • $5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year • $10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year • $25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year • $50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year • $100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year • $5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion 200000000 50000000 60000000 10000000 400000000 100000000 5000000 30000000 5000000 100000000 25000000 3000000 The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs - see Note 3 (x)). 0.25 20000000 10000000 41500000 100000 600000 2500000 83950 1781000 5.17 0.86 159987 57959714 4.78 4.81 0.94 P4Y11M5D 12.33 7.92 4185224 248193 2.65 0.00 43288000 4.07 3622150 12.48 53272767 0.558 0.0082 1126257 40000 0.05 1.000 547479 1104025 0.0240 5000 180663000 297000 7115000 1120000 49796000 164000 180663000 220670000 -199000 280000 53834000 2042000 17027000 49931000 56546000 1464000 12300000 -3488000 -38000 14000 53635000 30897000 -2911000 49931000 31000 6528000 -135000 2926000 192963000 475000 12300000 -135000 3720000 136417000 -1525000 4100000 23611000 -25087000 37000 24808000 15711000 8255000 22237000 245000 67645000 1676000 2449000 157000 2918000 18250000 746000 26662000 5137000 5650000 655000 4700000 3704000 900000 22237000 18255000 700000 4086000 2094000 1255000 72197000 3704000 33838000 3519000 1186000 3801000 0 6.62 385000 22190000 12874 834000 2039000 200656 4032000 11637000 180663000 3747312 27553000 153110000 0.847 P10Y 65889 593000 1628000 20609000 -135000 363055 2926000 49931000 -135000 5137000 49931000 655000 21644000 2926000 593000 24808000 11778000 7392000 -4032000 -12000 100386 1126257 998711 1000 1000 1311082 4000 1000 65889 3747312 1000 426562 6 37000 5136000 655000 21643000 -37000 593000 24804000 11777000 7392000 -4033000 139000 7000 11778000 6300000 0.153 SPPI SPECTRUM PHARMACEUTICALS INC Yes false Accelerated Filer 2013 10-K 2013-12-31 0000831547 No --12-31 FY No <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>6.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>STOCK-BASED COMPENSATION</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2009 Stock Incentive Plan</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We have one active stockholder-approved stock-based compensation plan, the 2009 Incentive Award Plan (the &#x201C;2009 Plan&#x201D;), which replaced our former stockholder-approved plans. We may grant incentive stock options, non-qualified options, restricted stock awards, and stock appreciation rights under the 2009 Plan.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The maximum number of our common stock available for issuance under the 2009 Plan is 10.0&#xA0;million shares. Beginning on January&#xA0;1, 2010, and each January&#xA0;1st&#xA0;thereafter, the number of shares of common stock available for issuance under the 2009 Plan increases by the greater of (i)&#xA0;2.5 million shares or (ii)&#xA0;a number of shares such that the total number of shares of common stock available for issuance under the 2009 Plan shall equal 30% of the then number of shares of common stock issued and outstanding. As of December&#xA0;31, 2013, 5.7&#xA0;million shares were available for grant. It is our policy that before stock is issued through the exercise of stock options, we must first receive all required cash payment for such shares (whether through an upfront cash exercise or net-settlement exercise).</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Stock-based awards are governed by agreements between us and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2009 Plan at an exercise price of not less than 100% of the closing fair market value of our common stock on the respective date of grant. The grant date is generally the date the award is approved by the Compensation Committee of the Board of Directors, though for aggregate awards of 50,000 or less in each quarter, the grant date is the date the award is approved by our Chief Executive Officer.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Stock-based awards generally vest 25% on the first anniversary of the date of grant, or for new hires, the first anniversary of their initial date of employment. Awards vest monthly thereafter on a straight-line basis over three years. Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 90 days from the last date of employment. In the event of an optionee&#x2019;s death, disability, or retirement, the exercise period is 365 days from the last date of employment.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Employee Stock Purchase Plan</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Under the terms of our 2009 Employee Stock Purchase Plan (the &#x201C;ESPP&#x201D;), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of our common stock on the first or last day of the offering period (whichever is less), minus a 15% discount. We use the Black-Scholes option-pricing model, in combination with the discounted employee price, in determining the value of ESPP expense to be recognized during each offering period. A participant may purchase a maximum of 50,000&#xA0;shares of common stock during a six-month offering period, not to exceed $25,000 worth of stock on the offering date during each plan year.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">A total of 5.0&#xA0;million shares of common stock are authorized for issuance under the ESPP. Beginning on January&#xA0;1, 2010, and each January&#xA0;1st&#xA0;thereafter, the number of shares of common stock available for issuance under the ESPP shall increase by an amount equal to the lesser of (i)&#xA0;1 million&#xA0;shares or (ii)&#xA0;an amount determined by the ESPP administrator. However, in no event shall the number of shares of common stock available for future sale under the ESPP exceed 10.0 million&#xA0;shares, subject to capitalization adjustments occurring due to dividends, splits, dissolution, liquidation, mergers, or changes in control.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Stock-Based Compensation Expense Summary</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We classify our stock-based compensation expense (inclusive of our 2009 Plan, ESPP, and 401(k) matching) in the accompanying Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within operating expenses for years ended December&#xA0;31, 2013, 2012, and 2011 was as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Selling, general and administrative</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,762</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,609</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and development</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,017</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,843</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,628</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,779</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,884</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,237</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Employee stock-based compensation expense for the years ended December&#xA0;31, 2013, 2012, and 2011 was recognized (reduced for estimated forfeitures) on a straight-line basis over the vesting period. Forfeitures are estimated at the time of grant and prospectively revised if actual forfeitures differ from those estimates. We estimate forfeitures of stock options using the historical exercise behavior of our employees. For purposes of this estimate, we have applied an estimated forfeiture rate of 8%, 5%, and 5% for the years ended December&#xA0;31, 2013, 2012, and 2011.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Valuation Assumptions &#x2013; Restricted Stock and Stock Options</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The grant-date fair value per share for restricted stock awards was based upon the closing market price of our common stock on the award grant-date.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="57%"></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="5" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected option life (in years) (a)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.95</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.50</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.93</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate (b)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.35%&#xA0;-&#xA0;0.78%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.34%&#xA0;-&#xA0;0.51%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.82%&#xA0;-&#xA0;2.4%</font></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Volatility (c)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">58.3%&#xA0;-&#xA0;71.5%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">64.2%&#xA0;-73.6%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">55.8%</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dividend yield (d)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average grant-date fair value per stock option</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$4.66</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$6.20</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$2.65</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(a)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(b)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options&#x2019; expected term).</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(c)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Measured using our historical stock price for a period equal to stock options&#x2019; expected term.</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(d)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">We do not expect to declare any cash dividends in the foreseeable future.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Stock Option Activity</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Stock option activity during the years ended December&#xA0;31, 2013, 2012, and 2011 is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="60%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0; of</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Price/Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average<br /> Remaining<br /> Contractual<br /> Term&#xA0;(Years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,397,094</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,622,150</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.92</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,126,257</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.07</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(1)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(547,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.81</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(159,987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,185,521</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.46</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,821,915</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,287,430</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.52</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(1)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(316,825</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.93</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(3,916</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.69</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,399,265</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,041,300</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.92</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(825,884</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.40</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,435</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(1)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(202,882</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(82,581</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.91</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,849</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested (exercisable)&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,876,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">24,080</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested (unexercisable)&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,453,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,770</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Represents the <i>total</i> difference between our closing stock price at the time of exercise and the stock option exercise price, <i>multiplied</i> by the number of options exercised.</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(2)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Represents the <i>total</i> difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, <i>multiplied</i> by the number of in-the-money options as of December&#xA0;31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes information with respect to stock option grants as of December&#xA0;31, 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="62%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercisable</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 48pt"> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise Price</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Granted&#xA0;Stock<br /> Options<br /> Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Remaining</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Contractual</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Life&#xA0;(Years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Granted<br /> Stock<br /> Options<br /> Exercisable</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">$0.92 &#x2013; &#xA0;&#xA0;3.15</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,192,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,192,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">$3.55 &#x2013; &#xA0;&#xA0;4.95</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,924,904</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,865,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">$5.05 &#x2013; &#xA0;&#xA0;6.90</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,862,699</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,565,220</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.19</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">$7.00 &#x2013; &#xA0;&#xA0;8.99</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,329,167</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,147,138</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">$9.00 &#x2013; 16.32</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,019,654</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.86</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,105,079</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,876,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, there was unrecognized compensation expense of $12.4&#xA0;million related to unvested stock options, which we expect to recognize over a weighted average period of 2.54&#xA0;years.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Restricted Stock Activity</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">A summary of restricted stock activity is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Restricted&#xA0; Stock<br /> Awards</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted&#xA0;Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value per<br /> Share at Grant<br /> Date</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested as of December&#xA0;31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">359,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,781,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,104,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(83,950</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">952,525</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">586,639</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(472,160</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(32,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,034,604</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">523,800</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.74</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(501,660</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(49,625</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.60</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,007,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Represents our stock price on the vesting date <i>multiplied</i> by the number of vested shares.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,202</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, there was approximately $6.5&#xA0;million of unrecorded expense related to issued restricted stock that will be recognized over an estimated weighted average period of 2.4&#xA0;years.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>401(k) Plan &#x2013; Stock Matching Contribution</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares of common stock issued</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">99,359</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56,254</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">65,889</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Match contribution value**</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">860</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">**</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Represents our stock price on the date of the stock match <i>multiplied</i> by the number of shares of common stock issued.</font></td> </tr> </table> </div> 49625 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">A summary of restricted stock activity is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Number&#xA0;of</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Restricted&#xA0; Stock<br /> Awards</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted&#xA0;Average</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value per<br /> Share at Grant<br /> Date</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Unvested as of December&#xA0;31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">359,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3.96</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,781,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12.48</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,104,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(83,950</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.78</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">952,525</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">586,639</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11.76</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(472,160</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(32,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,034,604</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11.00</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">523,800</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.74</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Vested</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(501,660</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(49,625</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10.60</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Unvested&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,007,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Represents our stock price on the vesting date&#xA0;<i>multiplied</i>&#xA0;by the number of vested shares.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Accounts payable and other accrued obligations are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Trade payables</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,796</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">30,814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued rebates</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">28,893</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued product royalty</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allowance for returns</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,056</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued data and distribution fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,430</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued GPO administrative fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,327</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,650</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Inventory management fee</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">616</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,050</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued income taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,522</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allowance for chargebacks</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,074</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">15,153</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued drug development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6,433</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,441</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Other accrued obligations</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8,867</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,819</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">79,837</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">105,252</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 523800 P7Y <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Other assets are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Investments in equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,476</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">304</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Debt issuance cost</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,432</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,576</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,475</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>14.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>COMMITMENTS AND CONTINGENCIES</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(a) Facility and Equipment Leases</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring April&#xA0;30, 2014. We also lease our research and development and administrative facility in Irvine, California under a non-cancelable operating lease expiring May&#xA0;31, 2019, in addition to several other administrative office leases. Each lease agreement contains certain scheduled rent increases which are accounted for on a straight-line basis. Our total rental expense in 2013, 2012, and 2011 was $1.2 million, $0.9 million, and $0.7 million, respectively.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our future minimum lease payments are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="82%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year ending December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Operating&#xA0;Lease<br /> Minimum<br /> Payments</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="bottom"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">849</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">950</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">892</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">843</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">868</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,402</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(b) Licensing Agreements, Co-Development Agreements, and Milestone Payments</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We are developing almost all of our drug candidates pursuant to license agreements that provide us with rights in certain territories, among other things, to develop, sublicense, manufacture and sell the drugs. We are generally required to use commercially reasonable efforts to develop the drugs, and are generally responsible for all development, patent filing and maintenance, sales and marketing and liability insurance costs. We are also obligated to make certain milestone payments to the licensors if we successfully reach development and regulatory milestones specified in the license agreements. In addition, we are obligated to pay royalties and, in some cases, milestone payments based on our net sales.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The potential contingent development and regulatory milestone obligations under all of our licensing agreements are generally tied to progress through the various regulatory authorities&#x2019; approval process, which approval significantly depends on positive clinical trial results.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our most significant of these agreements are listed and summarized below:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(i) ZEVALIN licensing and development in the U.S.</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with Cell Therapeutics, Inc. (&#x201C;CTI&#x201D;). Pursuant to the transfer of the ZEVALIN assets from CTI to RIT Oncology LLC (&#x201C;RIT&#x201D;), in December 2008, RIT assumed certain agreements with various third parties related to ZEVALIN intellectual property. These agreements relate to the manufacture, use, and sale of ZEVALIN in the U.S.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In accordance with the terms of such agreements, RIT is required to meet specified payment obligations including a commercial milestone payment to Corixa Corporation of $5.0 million based on ZEVALIN sales in the U.S., which has not yet been met, as well as U.S. net sales-based royalties of low to mid-single digits to Genentech, Inc. and mid-single digits to Corixa Corporation.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(ii) Asset Purchase Agreement between CTI and Biogen, ZEVALIN U.S.</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In connection with the joint venture arrangement with CTI, we entered into an amendment to the original asset purchase agreement between CTI and Biogen, modifying future milestone payments. Pursuant to the terms of the agreement, as amended, (i)&#xA0;upon the achievement of the specified FDA approval milestone, which was achieved in 2009, RIT (as successor to CTI) paid Biogen an additional amount of $5.5 million, (ii)&#xA0;RIT may be required to make an additional $10.0 million milestone payment upon the achievement of an additional FDA approval milestone, and (iii)&#xA0;RIT is required to make yearly royalty payments determined as a mid-single to mid-teen digits percentage of yearly net sales for the preceding year, increasing with the passage of time. The agreement has an indefinite term and is no longer subject to termination; provided, however, that the royalty obligations automatically terminate upon the latest to occur of expiration of the subject patents, the sale by a third party of a biosimilar product in the U.S. or December&#xA0;31, 2015. CTI&#x2019;s rights and obligations, including its payment obligations to Biogen for royalties on net sales of ZEVALIN and an additional regulatory milestone payment, under both the CTI/Biogen Agreement and the amendment were assigned to and assumed by RIT in connection with the closing of the joint venture transaction.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(iii) License and Asset Purchase Agreement with Bayer Pharma, ZEVALIN Ex-U.S.</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;1, 2012, through our subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed the acquisition of licensing rights to market ZEVALIN outside of the U.S., referred to as the ZEVALIN Ex-US Rights, from Bayer Pharma AG, or Bayer.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We currently market ZEVALIN in the U.S. and this agreement expanded our commercial efforts to the rest of the world. ZEVALIN is currently approved in more than 40 countries outside the U.S. for the treatment of B-cell non-Hodgkin lymphoma, including countries in Europe, Latin America and Asia. In consideration for the rights granted under the agreement, concurrent with the closing, we paid Bayer a one-time fee of Euro 19.0&#xA0;million, and will pay Bayer royalties based on a mid-teen digits percentage of net sales of the licensed products in all territories worldwide except the U.S. Unless earlier terminated, the term of the agreement continues until the expiration of our royalty payment obligations which, in turn, run until the last-to-expire patent covering the sale of a licensed product in the relevant country or 15&#xA0;years from the date of first commercial sale of the licensed product in such country, whichever is longer.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(iv) Amended and Restated License Agreement with Merck&#xA0;&amp; Cie AG, FUSILEV</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In May 2006, we amended and restated a license agreement with Merck&#xA0;&amp; Cie AG, a Swiss corporation, which we assumed in connection with the acquisition of the assets of Targent. Pursuant to the license agreement with Merck&#xA0;&amp; Cie, we obtained the exclusive license to use regulatory filings related to FUSILEV and a non-exclusive license under certain patents and know-how related to FUSILEV to develop, make, use, and sell FUSILEV in the field of oncology in North America. In addition, we have the right of first opportunity to negotiate an exclusive license to manufacture, use, and sell FUSILEV products outside the field of oncology in North America. Also, under the terms of the license agreement, we paid Merck&#xA0;&amp; Cie $0.1 million for the achievement of FDA approval of an injectable form of FUSILEV. Merck&#xA0;&amp; Cie is also eligible to receive a $0.2 million payment upon achievement of FDA approval of an oral form of FUSILEV, in addition to royalties in the mid-single digits based on a percentage of net sales. The term of the license agreement is determined on a product-by-product and country-by-country basis until royalties are no longer owed under the license agreement. The license agreement expires in its entirety after the date that we no longer owe any royalties to Merck&#xA0;&amp; Cie. We have the unilateral right to terminate the license agreement, in its entirety or on a product-by-product or country-by-country basis, at any time for any reason.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(v) Asset Purchase Agreement with Targent, Inc., FUSILEV</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In March 2006, we entered into an Asset Purchase Agreement with Targent, Inc. (&#x201C;Targent&#x201D;). As part of the consideration for the purchase of certain assets, we agreed to pay milestone payments to Targent upon the achievement of certain regulatory events as well as for certain sales levels for FUSILEV within a calendar year. In connection with the achievement of the FDA approval milestone in April 2011, we issued an aggregate of 0.7&#xA0;million shares of our common stock to certain of Targent&#x2019;s stockholders. We capitalized $6.3 million associated with this milestone as an amortizable intangible asset.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition, in connection with the achievement of the first sales milestone in May 2011, we issued 0.6&#xA0;million shares of our common stock to certain of Targent&#x2019;s stockholders. In September 2011, we achieved the second and final sales milestone and paid $5.0 million. We capitalized an aggregate $10.0 million associated with these milestones as amortizable intangible assets.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(vi) License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute, FOLOTYN</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In December&#xA0;2002, Allos entered into the FOLOTYN License Agreement with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. As a result of Allos becoming our wholly owned subsidiary effective September&#xA0;5, 2012, we are bound by the FOLOTYN License Agreement under which we obtained exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN and its uses.&#xA0;Under the terms of the FOLOTYN License Agreement, we are required to fund all development programs and will have sole responsibility for all commercialization activities.&#xA0;In addition, we pay the licensors royalties based on worldwide graduated annual levels of net sales of FOLOTYN, or sublicense revenues arising from sublicensing the product, if and when such sales or sublicenses occur.&#xA0;Royalties are 8% of annual worldwide sales up to $150.0 million; 9% of annual worldwide sales of $150.0 million through $300.0 million; and 11% of annual worldwide sales in excess of $300.0 million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(vii) License Agreement with Cydex Pharmaceuticals, Inc., Captisol-enabled, Propyleneglycol-free MELPHALAN</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On March&#xA0;8, 2013, we completed the acquisition of exclusive global development and commercialization rights to C-E MELPHALAN from Ligand (see <i>Note 10(b)</i>). This product candidate is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April&#xA0;1, 2013. We are required to pay Ligand additional amounts of up to $66.0 million, upon achievement of certain regulatory milestones and net sales thresholds, and royalties in the range of 15% to 25% on net sales of licensed products in all territories.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(viii) Exclusive Development and Commercialization Collaboration Agreement with Allergan, APAZIQUONE</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In October 2008, we signed an exclusive development and commercialization collaboration agreement with Allergan for APAZIQUONE. Pursuant to the terms of the agreement, Allergan paid us an up-front non-refundable $41.5 million at closing and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On January&#xA0;29, 2013, we entered into a second amendment to the license, development, supply and distribution agreement with Allergan to amend the agreement and reacquire the rights originally licensed to Allergan in the U.S., Europe, and other territories in exchange for a tiered single-digit royalty on certain products containing APAZIQUONE, and relieved Allergan of its obligations for development, commercialization and other activities. As a result of this amendment to the agreement, Allergan has no remaining obligations to us, and we have no remaining performance obligations to them. However, we are obligated to pay Allergan a tiered single-digit royalty not to exceed mid-single digits based upon the net sales, when and if earned, of certain products containing APAZIQUONE in specified territories. Additionally, we are obligated to pay any royalties or other payments due to certain licensors of underlying intellectual property, as well as to provide indemnification of Allergan for claims arising from the manufacture, development, or commercialization of pharmaceutical products containing APAZIQUONE by us.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(ix) Collaboration Agreement with Nippon Kayaku Co. LTD., APAZIQUONE</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (&#x201C;Nippon Kayaku&#x201D;) for the development and commercialization of APAZIQUONE in Asia, except North and South Korea (the &#x201C;Nippon Kayaku Territory&#x201D;). In addition, Nippon Kayaku received exclusive rights to APAZIQUONE for the treatment of non-muscle invasive bladder cancer in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct APAZIQUONE clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of APAZIQUONE in the Nippon Kayaku Territory.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the terms of this agreement, Nippon Kayaku paid Spectrum an upfront fee of $15.0 million and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones. Under the terms of the agreement, we are entitled to payment of $10.0 million and $126.0 million upon achievement of certain regulatory and commercialization milestones, respectively. Also, Nippon Kayaku has agreed to pay us royalties based on a percentage of net sales of the subject products in the defined territory in the mid-teen digits.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our license agreement with Nippon Kayaku provides for payments to us upon the achievement of development milestones, such as the completion of clinical trials or regulatory submissions, approvals by health authorities, and commercial launches of drug candidates. Given the challenges inherent in developing and obtaining approval for drug products and in achieving commercial launches, there was substantial uncertainty whether any such milestones would be achieved at the time of execution of such license agreement. We expect to recognize as revenue future payments received from such milestones only if achieved.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(x) Licensing and Collaboration Agreement with TopoTarget, BELEODAQ</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In February 2010, we entered into a licensing and collaboration agreement with TopoTarget A/S (&#x201C;TopoTarget&#x201D;), as amended in October 2013, for the development and commercialization of BELEODAQ. The agreement provides that we have the exclusive right to make, develop, and commercialize BELEODAQ in North America and India, with an option for China.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Under continuing terms, all development, including studies, will be conducted under a joint development plan. We have final decision-making authority for all developmental activities in North America and India (and China upon exercise of its option). TopoTarget has final decision-making authority for all developmental activities in all other jurisdictions. We are responsible for future costs of the ongoing registrational PTCL trial. We and TopoTarget will conduct future planned clinical trials pursuant to the joint development plan, of which we will fund 70% of the development costs, and TopoTarget will fund 30%.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We will each pay 50% of the costs for chemical, pharmaceutical and other process development related to the manufacturing of the product that are incurred with a mutually agreed upon budget in the joint development plan. We have the right to manufacture clinical and commercial supplies of BELEODAQ. TopoTarget is obligated to purchase its BELEODAQ requirements from us on a cost plus basis.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the terms of this agreement, we paid TopoTarget an upfront fee of $30.0 million in 2010. In addition, on the successful achievement of certain development, regulatory and sales milestones, we are obligated to issue 1.0 million&#xA0;shares of our common stock (subject to certain resale conditions) and pay TopoTarget up to $313.0 million. In February 2014, the first of these milestones was met, resulting in the issuance of 1.0&#xA0;million shares of our common stock and the payment of $10.0 million to TopoTarget (see Note 17). We will pay TopoTarget future royalties in the mid-teen digits based on net sales of BELEODAQ in the defined territory.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The agreement will continue until the expiration of the last royalty payment period in the last country in the defined territory with certain provisions surviving, unless earlier terminated in accordance with its terms. We may terminate this agreement with 180 days notice to TopoTarget. We may also terminate immediately upon a prohibition on the use of the subject product or clinical hold by the FDA. TopoTarget may also terminate immediately in the event of a challenge (without TopoTarget&#x2019;s consent) by us of the patents that cover the product.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xi) Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Company, SPI-2012</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In late January 2012, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Company, (&#x201C;Hanmi&#x201D;), for SPI-2012, formerly known as &#x201C;LAPS-GCSF&#x201D;, a drug for the treatment of chemotherapy induced neutropenia based on Hanmi&#x2019;s proprietary LAPSCOVERY&#x2122; Technology.&#xA0;In consideration for the rights granted to us under the co-development and commercialization agreement with Hanmi, we paid Hanmi a fee which is included in &#x201C;research and development expense&#x201D; in the accompanying Consolidated Statements of Operations because the technology has not yet achieved regulatory approval. Under the terms of the agreement, we will share the costs and expenses of the study with Hanmi, although we will have primary responsibility for them.&#xA0;If SPI-2012 is ultimately commercialized by us, we will have worldwide rights except for Korea, China and Japan upon payment of fees and milestone payments related to further development, regulatory approvals and sales targets.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(c) Service Agreements</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers, and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. We are in a position to accelerate, slow-down or discontinue any or all of the projects that we are working on at any given point in time. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered and our future purchase obligations would reduce accordingly.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(d) Supply Agreements</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements, and the contracted prices do not exceed their fair market value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(e) Employment Agreements</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We have entered into employment agreements with certain of our officers and other &#x201C;key employees&#x201D; under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(f) Deferred Compensation Plan</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On September&#xA0;2, 2011, the Board of Directors approved the Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the &#x201C;DC Plan&#x201D;). The DC Plan is intended to comply with the requirements of Section&#xA0;409A of the Internal Revenue Code of 1986, as amended. The DC Plan is administered by the Compensation Committee of our Board of Directors. The DC Plan is intended to be an unfunded plan which is maintained primarily to provide deferred compensation benefits for a select group of our employees, as selected by the DC Plan administrator (the &#x201C;DC Participants&#x201D;). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, as established by the DC Plan administrator, and we have the option to make discretionary contributions. At December&#xA0;31, 2013 and 2012, DC Plan deferrals and contributions totaling $3.9 million and $2.4 million, respectively, are included as a liability in the accompanying Consolidated Balance Sheets.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(g) Litigation</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&#xA0;Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case.&#xA0;Litigation is inherently unpredictable.&#xA0;Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We are presently responding to Abbreviated New Drug Applications (&#x201C;ANDAs&#x201D;) filed by companies seeking to launch generic forms of FUSILEV and to certain shareholder suits that purportedly stem from our March&#xA0;12, 2013 press release, in which we announced anticipated changes in customer ordering patterns of FUSILEV. These complaints allege that, as a result of the March&#xA0;12, 2013 press release, our stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of our stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>FUSILEV ANDA Litigation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On January&#xA0;20, 2012 and February&#xA0;17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate ANDAs, to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our fees and costs incurred in such matters. On December&#xA0;9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Shareholder Litigation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>John Perry v. Spectrum Pharmaceuticals, Inc. et al.</i> (Filed March&#xA0;14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH. This putative consolidated class action raises substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr.&#xA0;Rajesh&#xA0;C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August&#xA0;8, 2012 to March&#xA0;12, 2013. The lawsuits allege a violation of Section&#xA0;10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section&#xA0;20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company&#x2019;s March&#xA0;12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March&#xA0;12, 2013 press release, the Company&#x2019;s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Timothy Fik v. Rajesh C. Shrotriya, et al.</i> (Filed April&#xA0;11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April&#xA0;22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May&#xA0;28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against certain current and former directors and officers. The complaints generally allege breaches of fiduciary based on conduct relating to the events alleged in the consolidated <i>Perry</i> action. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants&#x2019; alleged profits, and costs and fees. On May&#xA0;15, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Hardik Kakadia v. Rajesh C. Shrotriya, et al.</i> (Filed April&#xA0;23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May&#xA0;31, 2013; Case Number A-13-682668-C) (collectively the &#x201C;State Derivative Actions&#x201D;). These consolidated State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. and are substantially similar to the consolidated federal derivative actions.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(h) SEC Subpoena</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;1, 2013, we received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed our March&#xA0;12, 2013 announcement that we anticipated a change in customer ordering patterns of FUSILEV. We continue to cooperate with this SEC investigation, though we cannot predict its outcome, or the timing of resolution.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xiv)&#xA0;Fair Value Measurements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;1:</i> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level&#xA0;1 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;2:</i> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;3:</i> Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#xA0;3 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">&#x201C;Cash and equivalents&#x201D; within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. &#x201C;Marketable securities&#x201D; consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of our &#x201C;drug development liability&#x201D; and our &#x201C;deferred payment contingency&#x201D; within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i)&#xA0;internal estimates of research and development personnel costs needed to perform the research and development services, (ii)&#xA0;estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii)&#xA0;an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">&#x201C;Acquisition-related contingent obligations&#x201D; within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See <i>Note 10(a)</i> for a discussion of CVRs granted as part of our acquisition of Talon, and <i>Note 10(b)</i> for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(i) Revenue Recognition</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <i>(a) Product Sales</i>: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(1)</td> <td valign="top" align="left">appropriate evidence of a binding arrangement exists with our customer;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(2)</td> <td valign="top" align="left">price is substantially fixed and determinable;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(3)</td> <td valign="top" align="left">collection from our customer is reasonably assured;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(4)</td> <td valign="top" align="left">our customer&#x2019;s obligation to pay us is not contingent on resale of the product;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(5)</td> <td valign="top" align="left">we do not have significant obligations for future performance to directly bring about the resale of our product;&#xA0;and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(6)</td> <td valign="top" align="left">we have a reasonable basis to estimate returns.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Our gross revenue is reduced by our gross-to-net (&#x201C;GTN&#x201D;) estimates, resulting in our reported &#x201C;Product sales, net&#x201D; in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Product Returns Allowances</i>: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Government Chargebacks</i>: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Discounts</i>: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Rebates</i>: Rebates are estimated based on the customer&#x2019;s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> <i>Medicaid Rebates</i>: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management&#x2019;s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Distribution and Data Fees</i>: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>(b) License Fees</i>: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>(c) Service Revenue</i>: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.</p> </div> 8.91 -1.02 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 24px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>SCHEDULE II &#x2013; VALUATION AND QUALIFYING ACCOUNTS</b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Years Ended December&#xA0;31, 2013, 2012, and 2011</b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" rowspan="2" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 39pt"> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Description</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Balance&#xA0;at<br /> Beginning&#xA0;of<br /> Period</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Additions</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>(Reductions)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Deductions&#xA0;(1)</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Balance&#xA0;at<br /> End of<br /> Period</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Additions<br /> (Recovery)<br /> to&#xA0;Bad&#xA0;Debt<br /> Expense&#xA0;or<br /> Deferred<br /> Tax Asset</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Charged<br /> to&#xA0;Other<br /> Accounts</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="18" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>(in thousands)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Year ended December&#xA0;31, 2013</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allowance for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">228</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">206</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Year ended December&#xA0;31, 2012</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allowance for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">471</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(128</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(115</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">228</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>Year ended December&#xA0;31, 2011</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allowance for doubtful accounts</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">339</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">139</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(7</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">471</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 2px; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; WIDTH: 124px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>(1)</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deductions represent the actual write-off of accounts receivable balances.</font></td> </tr> </table> </div> 82581 0.583 60729128 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Stock option activity during the years ended December&#xA0;31, 2013, 2012, and 2011 is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Number&#xA0; of</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Exercise</b></font>&#xA0;<br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Price/Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted-<br /> Average<br /> Remaining<br /> Contractual<br /> Term&#xA0;(Years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" nowrap="nowrap" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Aggregate<br /> Intrinsic<br /> Value</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8,397,094</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,622,150</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.92</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,126,257</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.07</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(547,479</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.81</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(159,987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10,185,521</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5.46</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,821,915</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,287,430</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.52</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(316,825</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.93</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(3,916</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.69</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10,399,265</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.57</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,041,300</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.92</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(825,884</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.40</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,435</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Forfeited</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(202,882</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(82,581</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.91</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">25,849</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Vested (exercisable)&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,876,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">24,080</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Unvested (unexercisable)&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,453,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9.38</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,770</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Represents the&#xA0;<i>total&#xA0;</i>difference between our closing stock price at the time of exercise and the stock option exercise price,&#xA0;<i>multiplied</i>&#xA0;by the number of options exercised.</font></td> </tr> </table> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Represents the&#xA0;<i>total&#xA0;</i>difference between our closing stock price on the last trading day of 2013 and the stock option exercise price,&#xA0;<i>multiplied</i>&#xA0;by the number of in-the-money options as of December&#xA0;31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.</font></td> </tr> </table> </div> <div>A summary of warrant activity is as follows: <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="77%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br /> Shares</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br /> Average<br /> Exercise&#xA0;Price</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding&#xA0;&#x2014; December&#xA0;31, 2010</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,192,312</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Expired</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(3,747,312</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6.62</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding&#xA0;&#x2014; December&#xA0;31, 2011</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">445,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.04</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Exercised</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(50,000</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.79</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding&#xA0;&#x2014; December&#xA0;31, 2012</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">395,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.45</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Granted</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">50,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.51</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Outstanding&#xA0;&#x2014; December&#xA0;31, 2013</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">445,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.39</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Exercisable&#xA0;&#x2014; December&#xA0;31, 2013</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">407,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6.29</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(x) Comprehensive Income (Loss)</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.</p> </div> 10.60 8.22 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following table summarizes information with respect to stock option grants as of December&#xA0;31, 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Exercisable</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 48pt"> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Exercise Price</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Granted&#xA0;Stock<br /> Options<br /> Outstanding</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Remaining</b></font>&#xA0;<br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Contractual</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Life&#xA0;(Years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Exercise</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Granted<br /> Stock<br /> Options<br /> Exercisable</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Weighted-<br /> Average</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Exercise</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$0.92 &#x2013; &#xA0;&#xA0;3.15</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,192,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,192,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$3.55 &#x2013; &#xA0;&#xA0;4.95</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,924,904</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5.9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,865,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4.23</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$5.05 &#x2013; &#xA0;&#xA0;6.90</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,862,699</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5.5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,565,220</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.19</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$7.00 &#x2013; &#xA0;&#xA0;8.99</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,329,167</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.17</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,147,138</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8.26</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$9.00 &#x2013; 16.32</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,019,654</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9.2</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10.86</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,105,079</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.0</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7.10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,876,025</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6.11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Property and equipment consist of the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Computers and software</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,154</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,540</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Lab and media equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,063</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">886</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Office furniture and equipment</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,575</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,492</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Leasehold improvements</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,813</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,799</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Assets held under capital lease obligations</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">146</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment, at cost</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,605</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,863</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> (Less): accumulated depreciation and amortization</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(9,070</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(7,315</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Property and equipment, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,535</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,548</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&amp;D to developed technology) for the five succeeding years and thereafter is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 93pt"> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Years Ending December&#xA0;31</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">22,313</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2019 and thereafter</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">93,867</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">206,052</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -1.02 <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="77%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">343,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Common stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,934,625</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock awards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,007,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Common stock warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">160,816</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,486,160</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> </div> 2014-09-05 P7Y <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following table summarizes the estimated fair value of the net assets acquired on July&#xA0;17, 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Cash and equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">131</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Inventory</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">611</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Prepaid expenses and other current assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">109</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Property and equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Identifiable intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">44,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total assets acquired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">45,381</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accounts payable&#xA0;&amp; accrued liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,231</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred tax liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6,576</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total liabilities assumed</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,807</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net assets acquired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">33,574</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Goodwill</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">10,526</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>11.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>REVOLVING LINE OF CREDIT</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We entered into a credit agreement on September&#xA0;5, 2012 with Bank of America, N.A, as the administrative agent and Wells Fargo Bank, N.A, as an initial lender, as amended July&#xA0;16, 2013 (the &#x201C;Credit Agreement&#x201D;). The Credit Agreement provided us with a committed $50.0 million revolving line of credit facility (the &#x201C;Credit Facility&#x201D;). The Credit Facility was to expire on September&#xA0;5, 2014, though we repaid it in full, then immediately terminated it on December&#xA0;20, 2013 in connection with the sale and issuance of our 2018 Convertible Notes.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The Credit Facility bore interest, at our election, at a rate equal to the London Interbank Offer Rate (LIBOR), or the base rate, plus an applicable margin (2.75% to 4.25%, dependent on a defined liquidity ratio).</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We incurred $1.0 million in related loan costs and fees in securing the Credit Facility, which were capitalized and recognized within &#x201C;other assets&#x201D; on our accompanying Consolidated Balance Sheets. This amount was amortized through &#x201C;interest expense&#x201D; to the accompanying Consolidated Statements of Operations, using the effective interest method, initially over the term of the Credit Facility, though the remaining unamortized portion was fully expensed in December 2013 when it was repaid and terminated.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">An unused line fee was payable quarterly in an amount ranging from 0.375% to 0.625% of the sum of the average daily unused portion of the facilities during any quarter based upon consolidated leverage ratio as at the last test date. A customary fee was also payable to the administrative agent on an annual basis in advance.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We recognized $1.2 million, $0.5 million, and $-0- in 2013, 2012, and 2011, respectively, within &#x201C;interest expense&#x201D; for this retired Credit Facility on the accompanying Consolidated Statements of Operations.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Our future minimum lease payments are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Year ending December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Operating&#xA0;Lease<br /> Minimum<br /> Payments</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="bottom"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">849</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">950</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">892</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">843</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">868</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,402</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -1.12 <div> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>9.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>FAIR VALUE MEASUREMENTS</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2&#xA0;<i>(x))</i>:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31, 2013</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value Measurements</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 1</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 2</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level&#xA0;3</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Assets:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market currency funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred compensation investments, including life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">109,227</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">112,820</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Liabilities:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred executive compensation liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Talon CVR</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,071</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">30,020</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31, 2012</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value Measurements</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 1</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 2</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level&#xA0;3</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Assets:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market currency funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred compensation investments, including life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,889</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">20,369</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Liabilities:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred executive compensation liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">16,885</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We did not have any transfers between Levels 1 and 2 for all periods presented. The following presents a roll forward of our liabilities for which we utilize Level&#xA0;3 inputs (see&#xA0;<i>Note 2(x)</i>) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within &#x201C;acquisition related contingent obligations&#x201D; and &#x201C;accrued and deferred development costs, less current portion&#x201D;. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration liabilities, approximate their related fair values due to their short-term nature.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="25%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0; of</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Unobservable&#xA0;Inputs&#xA0;(Level&#xA0;3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfers in (out)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfers in (out)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs (see&#xA0;<i>Note 13</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,509</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency (see&#xA0;<i>Note&#xA0;13</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration (see&#xA0;<i>Note 10(b)</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Talon CVR (see&#xA0;<i>Note 10(a)</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,071</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> P4Y11M12D <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2&#xA0;<i>(x))</i>:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31, 2013</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value Measurements</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 1</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 2</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level&#xA0;3</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Assets:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market currency funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred compensation investments, including life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">109,227</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">112,820</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Liabilities:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred executive compensation liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Talon CVR</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,071</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">30,020</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31, 2012</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value Measurements</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 1</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level 2</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Level&#xA0;3</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Assets:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market currency funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred compensation investments, including life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,889</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">20,369</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>Liabilities:</i></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred executive compensation liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,365</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">16,885</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 9.72 <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>17.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Selected quarterly financial data (unaudited) for the year ended December&#xA0;31, 2013 and 2012 is presented below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="61%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quarter Ended (Unaudited)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013:</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,667</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,232</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42,439</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,516</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,457</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,529</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(13,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,512</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,435</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,721</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,812</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(39,166</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share, basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share, diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2012:</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59,859</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">69,042</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">70,104</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,596</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,028</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,109</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">46,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,350</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,524</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,489</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income per share, basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.80</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income per share, diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Net (loss) income per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net Income<br /> (numerator)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br /> Average<br /> Shares<br /> Outstanding<br /> (Denominator)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net<br /> Income<br /> Per&#xA0;Share</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Year Ended December&#xA0;31, 2012</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic net income per share:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,201</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">58,588,916</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.61</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted net income per share:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Dilutive preferred shares</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">40,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Dilutive common stock options</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,749,299</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Incremental common stock assumed issued on exercise of in-the-money warrants</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">224,437</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unvested restrictive stock awards</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,034,604</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted net income per share</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">94,201</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">64,637,256</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.46</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net Income<br /> (numerator)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br /> Average<br /> Shares<br /> Outstanding<br /> (Denominator)</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net<br /> Income<br /> Per&#xA0;Share</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> <b>Year Ended December&#xA0;31, 2011</b></p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Basic net income per share:</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">53,272,767</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.94</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted net income per share:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Dilutive preferred shares</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">40,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Dilutive common stock options</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,185,224</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">248,193</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Incremental common stock assumed issued on exercise of in-the-money warrants</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">200,656</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Unvested restrictive stock awards</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">12,874</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Diluted net income per share</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,931</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">57,959,714</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.86</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>7.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>STOCKHOLDERS&#x2019; EQUITY</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Authorized Stock</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On December&#xA0;13, 2010, we filed the Certificate of Designation of Rights, Preferences and Privileges of Series&#xA0;B Junior Participating Preferred Stock with the Delaware Secretary of State which authorized 1.5&#xA0;million shares to be designated as Series B Junior Participating Preferred Stock. On June&#xA0;13, 2011, our stockholders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of our common stock from 100.0 million&#xA0;shares to 175.0 million&#xA0;shares. The amendment was filed with the Delaware Secretary of State on June&#xA0;24, 2011. As of December&#xA0;31, 2013, we also had 5.0&#xA0;million shares of preferred stock authorized, of which 1.5&#xA0;million shares were designated as Series B Junior Participating Preferred Stock and 2,000 shares were designated as Series E Convertible Voting Preferred Stock.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Stockholder Rights Agreement</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On November&#xA0;29, 2010, our Board of Directors approved a replacement rights agreement, effective December&#xA0;13, 2010, that replaced the stockholder rights agreement which was originally adopted in 2000. This replacement rights agreement will extend until December&#xA0;13, 2020. A stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive tactics that might be used in an attempt to gain control of the Company. A stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire the Company to first negotiate with our Board of Directors.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Under the terms of the new Stockholder Rights Agreement, the rights become exercisable upon the earlier of 10&#xA0;days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or 10&#xA0;business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our business, even if doing so would benefit our stockholders. We currently have no stockholders who own 15% or more of the outstanding shares of our common stock. Five days after the rights become exercisable, each right, other than rights held by the person or group of affiliated persons whose acquisition of more than 15% of our outstanding common stock caused the rights to become exercisable, will entitle its holder to buy, in lieu of shares of Series&#xA0;B Preferred Stock, a number of shares of our common stock having a market value of twice the exercise price of the rights. After the rights become exercisable, if we are a party to certain merger or business combination transactions or transfers 50% or more of our assets or earnings power (as defined), each right will entitle its holder to buy a number of shares of common stock of the acquiring or surviving entity having a market value of twice the exercise price of the right.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Series&#xA0;E Preferred Stock</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In September 2003, we received gross cash proceeds of $20.0 million in exchange for the issuance of 2,000&#xA0;shares of our Series&#xA0;E Convertible Voting Preferred Stock, convertible into 4.0&#xA0;million shares of common stock. As of December&#xA0;31, 2013 and 2012, 20&#xA0;shares of Series&#xA0;E Preferred Stock were outstanding. No dividends are payable on the Series&#xA0;E Preferred Stock. Pursuant to certain provisions of the Certificate of Designation, Rights and Preferences of the Series&#xA0;E Preferred Stock, we have the option to redeem all of the unconverted Series&#xA0;E Preferred Stock outstanding at the end of a 20-day trading period if, among other things, in that period our common stock trades above $12.00 per share.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In the event we are the subject of any voluntary or involuntary liquidation, dissolution or winding up, before any distribution of our assets shall be made to the common stockholders, the holders of the Series&#xA0;E Preferred Stock shall be entitled to receive a liquidation preference in an amount equal to 120% of the stated value per share plus any declared and unpaid dividends thereon.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Common Stock Reserved for Future Issuance</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, approximately 28.1&#xA0;million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="85%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Conversion of Series&#xA0;E Preferred Stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,400,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercise of issued employee stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercise of issued warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">445,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ESPP shares reserved</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,540,986</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term retention and management incentive plan shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">346,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares of common stock reserved for future issuances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,101,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Warrant Activity</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through December 2015. A summary of warrant activity is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Number&#xA0;of</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Shares</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Average</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Exercise&#xA0;Price</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2010</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,192,312</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.45</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(3,747,312</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.62</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">445,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.04</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(50,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.79</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">395,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.45</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">50,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7.51</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">445,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.39</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercisable&#xA0;&#x2014; December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">407,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> 8.92 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Inventories, net consist of the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Raw materials</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,794</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">887</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Work in process</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,312</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7,302</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Finished goods</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8,413</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,289</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Inventories</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,519</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,478</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.0275 <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Selected quarterly financial data (unaudited) for the year ended December&#xA0;31, 2013 and 2012 is presented below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="61%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Quarter Ended (Unaudited)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>March&#xA0;31</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>June&#xA0;30</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>September&#xA0;30</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2013:</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">38,667</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,232</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">42,439</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,516</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,457</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,529</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(13,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,512</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,435</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,721</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,812</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(39,166</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share, basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net loss per share, diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.09</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.16</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(0.63</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2012:</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">59,859</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68,702</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">69,042</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">70,104</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Operating income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,596</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,028</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,109</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,041</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">46,838</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,350</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">21,524</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,489</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income per share, basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.80</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.31</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net income per share, diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.72</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.29</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following unaudited pro forma financial information is presented to reflect the results of the Company&#x2019;s consolidated operations for the years ended December&#xA0;31, 2013 and 2012, as if the acquisition of Talon had occurred on January&#xA0;1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January&#xA0;1, 2012, and may not be indicative of future operating results.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Pro Forma Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">155,854</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">267,707</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Pro Forma Total costs and operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">200,651</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">210,433</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Pro Forma Net (loss) income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(68,146</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">57,274</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Pro Forma Net (loss) income per share &#x2013; basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">0.98</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Pro Forma Net (loss) income per share &#x2013; diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">0.89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following presents a roll forward of our liabilities for which we utilize Level&#xA0;3 inputs (see&#xA0;<i>Note 2(x)</i>) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within &#x201C;acquisition related contingent obligations&#x201D; and &#x201C;accrued and deferred development costs, less current portion&#x201D;. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> &#xA0;&#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="25%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair&#xA0;Value&#xA0;Measurements&#xA0; of</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Unobservable&#xA0;Inputs&#xA0;(Level&#xA0;3)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfers in (out)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfers in (out)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred development costs (see&#xA0;<i>Note 13</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,509</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred payment contingency (see&#xA0;<i>Note&#xA0;13</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,287</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Ligand Contingent Consideration (see&#xA0;<i>Note 10(b)</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Talon CVR (see&#xA0;<i>Note 10(a)</i>)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,071</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 0pt"> <b><i>(vii) Goodwill and Intangible Assets</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October&#xA0;1 each year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset&#x2019;s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">a significant decrease in the market value of an asset;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(b)</td> <td valign="top" align="left">a significant adverse change in the extent or manner in which an asset is used;&#xA0;or</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%">&#xA0;</td> <td valign="top" width="4%" align="left">(c)</td> <td valign="top" align="left">an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.</td> </tr> </table> </div> -1.12 4.66 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(iii) Marketable Securities</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in &#x201C;unrealized gain (loss) on securities&#x201D; on the accompanying Consolidated Statements of Comprehensive Income (Loss).</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(v) Inventories</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-LEFT: 24px; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b><i>(vi) Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset&#x2019;s carrying amount may not be recoverable through on-going operations.</font></p> </div> 0.00 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(ii) Cash and Equivalents</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.</p> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>10.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>BUSINESS COMBINATIONS</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(a) Acquisition of Talon Therapeutics, Inc.</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Talon Acquisition Overview</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On July&#xA0;16, 2013, we entered into a Securities Purchase Agreement with Talon Therapeutics, Inc. (&#x201C;Talon&#x201D;), whereby, on July&#xA0;17, 2013, we purchased all of its then outstanding shares of common stock. Through the acquisition of Talon, we gained worldwide rights to MARQIBO, an FDA-approved drug that we believe complements our other hematology and oncology products.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Since July&#xA0;17, 2013, the results of operations of the former Talon business have been included in the accompanying Consolidated Statements of Operations for the year ended December&#xA0;31, 2013. From July&#xA0;17, 2013 through December&#xA0;31, 2013, our revenue derived from the former Talon business was approximately $1.3 million. We had nominal earnings from the Talon business during this period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Talon purchase consideration comprised of (i)&#xA0;an aggregate upfront cash amount of $11.3 million, (ii)&#xA0;issuance of 3.0&#xA0;million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July&#xA0;17, 2013), and (iii)&#xA0;the issuance of contingent value rights (&#x201C;CVR&#x201D;) initially valued by us at $6.5 million.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs &#x2013; see Note 3 <i>(x)</i>). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Direct Costs of the Talon Acquisition</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our direct costs of the Talon acquisition included employee severance, banker, legal, and accounting fees which aggregated to $5.7 million. This amount is included in &#x201C;selling, general and administrative expenses&#x201D; within the accompanying Consolidated Statements of Operations for the year ended December&#xA0;31, 2013.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Consideration Transferred</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,300</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">CVR</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Spectrum shares of common stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,300</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total purchase consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">44,100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Fair Value Estimate of Assets Acquired and Liabilities Assumed</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Under the purchase method of accounting, the total purchase consideration is allocated to Talon net tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date. The following table summarizes the estimated fair value of the net assets acquired on July&#xA0;17, 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash and equivalents</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">131</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Inventory</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">611</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Prepaid expenses and other current assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">109</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Identifiable intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">44,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total assets acquired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45,381</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accounts payable&#xA0;&amp; accrued liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,231</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,576</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total liabilities assumed</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,807</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net assets acquired</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,574</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Goodwill</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,526</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The acquired intangible assets consisted of developed technology and in-process research and development (&#x201C;IPR&amp;D&#x201D;) for MARQIBO treatment of acute lymphoblastic leukemia (&#x201C;ALL&#x201D;) and MARQIBO treatment of non-Hodgkin&#x2019;s lymphoma (&#x201C;NHL&#x201D;) as follows in the table below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="75%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Value of<br /> Intangible<br /> Assets<br /> Acquired</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortization<br /> Period*</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Developed technology &#x2014;MARQIBO for ALL</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13&#xA0;years</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">IPR&amp;D &#x2014;MARQIBO for NHL</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total identifiable intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">44,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 2px; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; MARGIN-TOP: 0px; LINE-HEIGHT: 8px; WIDTH: 10%"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Recognized on a straight-line basis.</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">IPR&amp;D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&amp;D is not amortized during this period, but rather tested for impairment.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of the acquired IPR&amp;D technology assets was estimated using the income approach.&#xA0;The income approach uses valuation techniques to convert future amounts to a single present amount (discounted).&#xA0;Our measurement is based on the value indicated by current market expectations about those future amounts.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Goodwill</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Goodwill presented above of $10.5 million represents the difference of the Talon business purchase price of $44.1 million <i>minus</i> the net assets acquired of $33.6 million. This goodwill includes benefits that we believe will result from combining the operations of Talon with ours, as well as the know-how associated with the MARQIBO compounds for future product development. In accordance with applicable GAAP, we will not amortize goodwill associated with the Talon acquisition, though it will be subjected to annual impairment testing. This goodwill is not deductible for income tax purposes.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Supplemental Pro Forma Financial Information</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following unaudited pro forma financial information is presented to reflect the results of the Company&#x2019;s consolidated operations for the years ended December&#xA0;31, 2013 and 2012, as if the acquisition of Talon had occurred on January&#xA0;1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January&#xA0;1, 2012, and may not be indicative of future operating results.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="78%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pro Forma Total revenues</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">155,854</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">267,707</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pro Forma Total costs and operating expenses</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">200,651</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">210,433</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pro Forma Net (loss) income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(68,146</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,274</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pro Forma Net (loss) income per share &#x2013; basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.98</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Pro Forma Net (loss) income per share &#x2013; diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.89</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Talon CVR Fair Value as of December&#xA0;31, 2013</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The CVR fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to CVR fair value are recognized within &#x201C;change in fair value of contingent consideration related to acquisition&#x201D; in the accompanying Consolidated Statements of Operations.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="87%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair&#xA0;Value<br /> of Talon<br /> CVR</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">July&#xA0;17, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Fair value adjustment for year ended December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,171</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,329</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(b) Acquisition of Rights to Captisol-Enabled &#xAE; MELPHALAN</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Overview of Acquisition of Rights to C-E MELPHALAN</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On March&#xA0;8, 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled &#xAE;, propylene glycol-free MELPHALAN (&#x201C;C-E MELPHALAN&#x201D;) from CyDex Pharmaceuticals, Inc. a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (&#x201C;Ligand&#x201D;). C-E MELPHALAN is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April&#xA0;1, 2013. We are required to pay Ligand additional amounts up to an aggregate $66.0 million, upon the achievement of certain regulatory milestones and net sales thresholds (&#x201C;Ligand Contingent Consideration&#x201D;). We also must pay royalties in the range of 15% to 25% on net sales of licensed products in all territories.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We accounted for the acquisition of these rights as a business combination, using the acquisition method of accounting. This requires that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. Aggregate transaction costs of $15,000 are included in &#x201C;selling, general and administrative expenses&#x201D; within the accompanying Consolidated Statements of Operations for the year ended December&#xA0;31, 2013.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Consideration Transferred</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The acquisition-date fair value of the consideration transferred consisted of the following items:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Cash consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Ligand Contingent Consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total purchase consideration</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Fair Value Estimate of Asset Acquired and Liability Assumed</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The total purchase consideration is allocated to the acquisition of the tangible and intangible assets acquired and liabilities assumed. These amounts are based on their estimated fair values as of the closing date. The allocation of the total purchase price to the net assets acquired is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">IPR&amp;D&#x2014;C-E MELPHALAN rights</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Acquired IPR&amp;D is an intangible asset that is classified as indefinite-lived until the completion or abandonment of the associated R&amp;D effort, and is subject to impairment testing. C-E MELPHALAN rights will be amortized over an estimated useful life to be determined at the date the project is complete.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We estimated the fair value of the in-process research and development using the income approach.&#xA0;The income approach uses valuation techniques to convert future amounts to a single present amount (discounted).&#xA0;Our measurement is based on the value indicated by current market expectations about those future amounts.&#xA0;The fair value estimate took into account our estimates of future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights, and included estimated cash flows of approximately 10 years and a discount rate of approximately 25%.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of the contingent consideration liability assumed was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable inputs and are therefore classified as Level 3 inputs &#x2013; see Note 3<i>(x)</i>), which assumes that FDA approval of C-E MELPHALAN will occur on or about December&#xA0;31, 2015. Upon receipt of FDA approval, we will be obligated to make a milestone payment of $6.0 million to Ligand.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We do not consider this acquisition to represent a material business combination; accordingly, we have not presented pro forma results of our combined operations that are otherwise required.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><i>Ligand Contingent Consideration Fair Value as of December&#xA0;31, 2013</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The Ligand Contingent Consideration fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Ligand Contingent Consideration fair value are recognized within &#x201C;fair value of contingent consideration related to acquisition&#x201D; in the accompanying Consolidated Statements of Operations.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Fair Value of<br /> Ligand<br /> Contingent<br /> Consideration</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">March&#xA0;8, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Fair value adjustment for year ended December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(c) Allos Acquisition</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We acquired Allos Therapeutics, Inc. (&#x201C;Allos&#x201D;) on September&#xA0;5, 2012, which was accounted for as a business combination. Our total consideration for this acquisition was $205.2 million, through which we acquired FOLOTYN development technology and FOLOTYN distribution rights.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following tabular reconciliation summarizes activity related to unrecognized tax benefits:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at beginning of year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,803</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Adjustments related to prior year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(200</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(527</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Increases related to current year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">648</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,515</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,120</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Decreases due to settlements</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,227</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(434</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Decreases related to prior year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,491</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at end of year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,212</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> Goodwill is comprised of the following (by source):</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br /> 2012</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Acquisition of Talon</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,526</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Acquisition of ZEVALIN Rights</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,525</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Acquisition of Allos</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">5,346</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,791</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Foreign exchange translation effects</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(37</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,501</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> -2086000 4.40 2041300 <div> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>16.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>SUBSEQUENT EVENT</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-LEFT: 49px; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><i>BELEODAQ NDA Acceptance by the FDA</i></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">On February&#xA0;5, 2014, we received a communication from the FDA notifying us that our NDA for BELEODAQ (Belinostat) for Injection had been accepted for filing with priority review. As a result of this achievement, pursuant to the TopoTarget agreement (see&#xA0;<i>Note 14(b)(x)</i>), we paid TopoTarget $10.0 million and issued an aggregate 1.0&#xA0;million shares of our common stock in February 2014.</font></p> </div> 8.74 0.715 60729128 <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>15.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>INCOME TAXES</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The components of (loss) income before (provision) benefit for income taxes are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For the Years Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">United States</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(30,437</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">82,165</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">53,834</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(6,199</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,235</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(199</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(36,636</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">53,635</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The provision (benefit) for income taxes consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For the Years Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,357</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,222</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,412</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,048</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,634</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">36,183</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(24,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,637</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,892</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,546</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,905</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total income tax provision (benefit)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,271</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax provision (benefit) computed at the federal statutory rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(12,822</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,975</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,250</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State tax, net of federal benefit</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(246</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,442</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,918</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expired tax attributes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">385</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,254</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,129</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,464</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Benefits from credit study</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,148</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Common stock warrant liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,186</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Transaction costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">880</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,497</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Officers compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,178</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,908</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,801</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">501</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,676</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Permanent items and other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,080</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,111</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,039</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Domestic manufacturing deduction</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">767</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,262</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Tax differential on foreign earnings</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,123</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">382</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Change in tax rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(283</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">36,734</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(44,519</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(25,087</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Income tax provision (benefit)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,271</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The American Taxpayer Relief Act of 2012, which reinstated the U.S. federal research and development tax credit retroactively from January&#xA0;1, 2012 through December&#xA0;31, 2013, was not enacted into law until the first quarter of 2013. The tax benefit resulting from such reinstatement is reflected in our 2013 tax provision.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Significant components of our deferred tax assets as of December&#xA0;31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the &#x201C;more-likely-than-not&#x201D; threshold under GAAP.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net operating loss carry forwards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">46,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">45,391</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,066</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,848</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Stock based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,486</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,896</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,596</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,495</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Returns and allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,117</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,889</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other, net</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,551</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,021</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax assets before valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73,246</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(49,586</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,818</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,669</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">72,121</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax liabilities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Basis difference in debt</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,082</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization differences</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(28,096</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(36,372</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net deferred tax (liability) asset</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,509</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">35,749</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The increase in the valuation allowance in 2013 was due to uncertainties regarding the realization of deferred tax assets acquired in connection with the Talon acquisition and a change in our overall assessment regarding the realization of our domestic deferred tax assets as a result of larger than expected operating losses sustained in 2013 and an increase in our expected operating loss for 2014. The decrease in the valuation allowance in 2012 was due to a change in our assessment regarding the realization of our domestic deferred tax assets as a result of positive earnings trends in 2010, 2011, and 2012 and operating income recorded in 2011 and 2012.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">At December&#xA0;31, 2013, we had federal and state net operating loss carryforwards of approximately $117.4&#xA0;million and $132.0&#xA0;million, respectively. We have approximately $4.1 million&#xA0;of foreign loss carryforwards that will begin to expire in 2028. The federal and state loss carry forwards begin to expire in 2018 and 2014, respectively, unless previously utilized. At December&#xA0;31, 2013, we had federal and state tax credits of approximately $6.9&#xA0;million and $2.2&#xA0;million, respectively. The federal tax credit carryovers begin to expire in 2026 unless previously utilized. The state research and development credits have an indefinite carryover period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As a result of the prior ownership changes, the utilization of certain net operating loss and research and development tax credit carryforwards including those acquired in connection with the acquisition of Allos and Talon are subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986 and similar state provisions. Any net operating losses or credits that would expire unutilized as a result of Section&#xA0;382 and 383 limitations have been removed from the table of deferred tax assets and the accompanying disclosures of net operating loss and research and development carryforwards.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following tabular reconciliation summarizes activity related to unrecognized tax benefits:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at beginning of year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,803</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Adjustments related to prior year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(200</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(527</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Increases related to current year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">648</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,515</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,120</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Decreases due to settlements</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,227</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(434</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Decreases related to prior year tax positions</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,491</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance at end of year</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,212</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,928</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">During 2013, we continue to believe that our tax positions meet the more-likely-than-not standard required under the recognition phase of the authoritative guidance. However, we consider the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Approximately $0.3 million, $5.2 million and $0.2 million of the total unrecognized tax benefits as of December&#xA0;31, 2013, 2012 and 2011, respectively, would reduce our annual effective tax rate if recognized. Additional amounts in the summary rollforward could impact our effective tax rate if we did not maintain a full valuation allowance on our net deferred tax assets.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We do not expect our unrecognized tax benefits to change significantly over the next 12&#xA0;months. With a few exceptions, we are no longer subject to U.S.&#xA0;federal, state and local income tax examinations for years before 2009. Our policy is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of operations and are not material.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">During 2013, the Internal Revenue Service completed an examination of our 2010 tax return. No tax was paid as a result of the examination. As a result of the examination, the Company reduced tax credits carryovers by $0.8 million and net operating loss carryovers by $1.6 million.</font></p> </div> 1 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(xiii) Research and Development Costs</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Research and development costs are expensed as incurred.</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The components of (loss) income before (provision) benefit for income taxes are as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>For the Years Ended</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">United States</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(30,437</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">82,165</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">53,834</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(6,199</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,235</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(199</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(36,636</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">79,930</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">53,635</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The carrying values of the 2018 Convertible Notes as of December&#xA0;31, 2013 is summarized as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Principal amount</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Less): Unamortized debt discount (amortized through December 2018)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(28,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">December&#xA0;31, 2013 net carrying amount of 2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">91,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> P6Y2M12D 0.0035 <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>8.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>NET (LOSS) INCOME PER SHARE</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December&#xA0;31, 2013, 2012, and 2011:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="60%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net (loss) income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(62,134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94,201</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">49,931</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,729,128</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">58,588,916</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">53,272,767</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net (loss) income per share - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.02</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.61</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted average shares - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">60,729,128</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">64,637,256</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,959,714</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Net (loss) income per share - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1.02</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.46</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.86</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net Income<br /> (numerator)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average<br /> Shares<br /> Outstanding<br /> (Denominator)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net<br /> Income<br /> Per&#xA0;Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Year Ended December&#xA0;31, 2012</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94,201</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">58,588,916</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.61</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Diluted net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dilutive preferred shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dilutive common stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,749,299</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Incremental common stock assumed issued on exercise of in-the-money warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">224,437</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restrictive stock awards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,034,604</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Diluted net income per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">94,201</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">64,637,256</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.46</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="65%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net Income<br /> (numerator)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Weighted-<br /> Average<br /> Shares<br /> Outstanding<br /> (Denominator)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net<br /> Income<br /> Per&#xA0;Share</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Year Ended December&#xA0;31, 2011</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Basic net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">49,931</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">53,272,767</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Diluted net income per share:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dilutive preferred shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dilutive common stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,185,224</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">248,193</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Incremental common stock assumed issued on exercise of in-the-money warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">200,656</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Unvested restrictive stock awards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,874</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Diluted net income per share</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">49,931</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">57,959,714</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.86</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="77%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">343,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Common stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,934,625</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Restricted stock awards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,007,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Common stock warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">160,816</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Preferred stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,486,160</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> </div> 825884 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Tax provision (benefit) computed at the federal statutory rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(12,822</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">27,975</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">18,250</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">State tax, net of federal benefit</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(246</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,442</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,918</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Expired tax attributes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">385</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Research credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,254</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,129</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,464</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Benefits from credit study</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(4,148</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Common stock warrant liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,186</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transaction costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">880</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,497</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Officers compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,178</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,908</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,801</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Stock based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">501</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,676</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Permanent items and other</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,080</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,111</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,039</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Domestic manufacturing deduction</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">767</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,262</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Tax differential on foreign earnings</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,123</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">382</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Change in tax rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(283</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">338</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">36,734</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(44,519</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(25,087</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Income tax provision (benefit)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">25,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(14,271</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(viii) Stock-Based Compensation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Other long-term liabilities are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Accrued executive deferred compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,366</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred rent (non-current portion)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">366</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">571</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Business acquisition liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Other tax liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,352</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,132</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,965</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,367</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>(c) Operating Segment</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December&#xA0;31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Intangible assets consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="79%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="22" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Historical<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Accumulated<br /> Amortization</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Currency</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Translation</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Impairment</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net&#xA0;Amount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Full<br /> Amortization</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Period&#xA0; (years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Remaining<br /> Amortization<br /> Period&#xA0;(years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MARQIBO IPR&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MELPHALAN IPR&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MARQIBO developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,793</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(23,455</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,445</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; Ex-U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,490</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,343</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">682</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,829</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FUSILEV developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,778</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,957</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN distribution rights*</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(3,662</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,215</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">118,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(10,587</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">107,813</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">280,668</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(48,975</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">682</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">231,352</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">On May&#xA0;29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma&#x2019;s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the &#x201C;amortization and impairment of intangible assets&#x201D; in the accompanying Consolidated Statement of Operations for the year ended December&#xA0;31, 2013.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="59%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Historical<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Accumulated</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortization</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Currency</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Translation</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Amount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19,735</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,165</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; Ex-U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,490</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,192</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,943</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FUSILEV developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,778</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,798</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN distribution rights</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(895</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,005</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">118,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,077</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">228,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(27,879</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">200,234</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>2.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, our management evaluates its estimates, including those related to (i)&#xA0;revenue adjustments; (ii)&#xA0;the collectability of customer accounts; (iii)&#xA0;whether the cost of inventories can be recovered; (iv)&#xA0;the value of goodwill and intangible assets; (v)&#xA0;the realization of tax assets and estimates of tax liabilities; (vi)&#xA0;the likelihood of payment and value of contingent liabilities; (vii)&#xA0;the fair value of investments; (viii)&#xA0;assumptions used in reporting stock-based compensation; and (ix)&#xA0;the potential outcome of litigation.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Such estimates are based on our management&#x2019;s judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may materially differ from management&#x2019;s estimates. In our judgment, the accounting policies, estimates, and assumptions described below have the potential to significantly impact our preparation of the accompanying Consolidated Financial Statements:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(i) Revenue Recognition</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>(a) Product Sales</i>: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">appropriate evidence of a binding arrangement exists with our customer;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(2)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">price is substantially fixed and determinable;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(3)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">collection from our customer is reasonably assured;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(4)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">our customer&#x2019;s obligation to pay us is not contingent on resale of the product;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(5)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">we do not have significant obligations for future performance to directly bring about the resale of our product;&#xA0;and</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(6)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">we have a reasonable basis to estimate returns.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our gross revenue is reduced by our gross-to-net (&#x201C;GTN&#x201D;) estimates, resulting in our reported &#x201C;Product sales, net&#x201D; in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Product Returns Allowances</i>: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Government Chargebacks</i>: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Discounts</i>: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Rebates</i>: Rebates are estimated based on the customer&#x2019;s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Medicaid Rebates</i>: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management&#x2019;s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Distribution and Data Fees</i>: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>(b) License Fees</i>: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>(c) Service Revenue</i>: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(ii) Cash and Equivalents</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(iii) Marketable Securities</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in &#x201C;unrealized gain (loss) on securities&#x201D; on the accompanying Consolidated Statements of Comprehensive Income (Loss).</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(iv) Accounts Receivable</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management&#x2019;s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(v) Inventories</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(vi) Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset&#x2019;s carrying amount may not be recoverable through on-going operations.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(vii) Goodwill and Intangible Assets</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October&#xA0;1 each year.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset&#x2019;s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(a)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">a significant decrease in the market value of an asset;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(b)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">a significant adverse change in the extent or manner in which an asset is used;&#xA0;or</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="4%"><font size="1">&#xA0;</font></td> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(c)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(viii) Stock-Based Compensation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(ix) Foreign Currency Translation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(x) Comprehensive Income (Loss)</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xi) Basic and Diluted Net (Loss) Income per Share</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xii) Income Taxes</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in &#x201C;income tax expense&#x201D; within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xiii) Research and Development Costs</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Research and development costs are expensed as incurred.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(xiv)&#xA0;Fair Value Measurements</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;1:</i> Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level&#xA0;1 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;2:</i> Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Level&#xA0;3:</i> Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#xA0;3 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">&#x201C;Cash and equivalents&#x201D; within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. &#x201C;Marketable securities&#x201D; consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of our &#x201C;drug development liability&#x201D; and our &#x201C;deferred payment contingency&#x201D; within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i)&#xA0;internal estimates of research and development personnel costs needed to perform the research and development services, (ii)&#xA0;estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii)&#xA0;an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">&#x201C;Acquisition-related contingent obligations&#x201D; within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See <i>Note 10(a)</i> for a discussion of CVRs granted as part of our acquisition of Talon, and <i>Note 10(b)</i> for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.</font></p> </div> 0.08 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-LEFT: 24px; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b><i>(iv) Accounts Receivable</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management&#x2019;s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.</font></p> </div> 1.000 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Significant components of our deferred tax assets as of December&#xA0;31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the &#x201C;more-likely-than-not&#x201D; threshold under GAAP.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred tax assets:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net operating loss carry forwards</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">46,482</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">45,391</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Research credits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">8,066</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,848</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Stock based compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,486</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,896</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred revenue</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">58</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,596</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6,495</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Returns and allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,117</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,889</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Other, net</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,551</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">6,021</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total deferred tax assets before valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">73,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">73,246</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Valuation allowance</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(49,586</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,818</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total deferred tax assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">23,669</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">72,121</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Deferred tax liabilities:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Basis difference in debt</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,082</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Depreciation and amortization differences</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(28,096</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(36,372</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net deferred tax (liability) asset</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(5,509</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">35,749</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 202882 4486160 0.0425 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(ix) Foreign Currency Translation</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.</p> </div> <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Stock-based compensation expense included within operating expenses for years ended December&#xA0;31, 2013, 2012, and 2011 was as follows:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Selling, general and administrative</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,762</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,041</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,609</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Research and development</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,017</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,843</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,628</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,779</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,884</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,237</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(a) Description of Business</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (&#x201C;Spectrum&#x201D;, the &#x201C;Company&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D;, or &#x201C;us&#x201D;), is a biotechnology company with fully integrated commercial and&#xA0;drug development operations,&#xA0;with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We currently market four drugs:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin&#x2019;s lymphoma;</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 6px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"><font size="1">&#xA0;</font></td> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2022;</font></td> <td valign="top" width="1%"><font size="1">&#xA0;</font></td> <td valign="top" align="left"> <p align="left"><font style="FONT-FAMILY: Times New Roman" size="2">MARQIBO injection for patients in the U.S. with Philadelphia chromosome&#x2013;negative acute lymphoblastic leukemia.</font></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research,&#xA0;regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(b) Basis of Presentation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Principles of Consolidation</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201C;GAAP&#x201D;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201C;SEC&#x201D;). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the &#x201C;ZEVALIN Rights&#x201D;); on September&#xA0;5, 2012, we acquired Allos Therapeutics, Inc. (&#x201C;Allos&#x201D;); and on July&#xA0;17, 2013, we acquired Talon Therapeutics, Inc. (&#x201C;Talon&#x201D;). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Variable Interest Entity</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We own fifty-percent of Spectrum Pharma Canada (a &#x201C;variable interest entity,&#x201D; as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its &#x201C;primary beneficiary&#x201D;. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada&#x2019;s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(c) Operating Segment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December&#xA0;31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-LEFT: 24px; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2"><b><i>(xi) Basic and Diluted Net (Loss) Income per Share</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.</font></p> </div> <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="57%"></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="5" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended December&#xA0;31,</b></font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected option life (in years) (a)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.95</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.50</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">4.93</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest rate (b)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.35%&#xA0;-&#xA0;0.78%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.34%&#xA0;-&#xA0;0.51%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">0.82%&#xA0;-&#xA0;2.4%</font></font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Volatility (c)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2"><font style="WHITE-SPACE: nowrap">58.3%&#xA0;-&#xA0;71.5%</font></font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">64.2%&#xA0;-73.6%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">55.8%</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Dividend yield (d)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">0%</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Weighted-average grant-date fair value per stock option</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$4.66</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$6.20</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" align="center"><font style="FONT-FAMILY: Times New Roman" size="2">$2.65</font></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(a)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(b)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options&#x2019; expected term).</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(c)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Measured using our historical stock price for a period equal to stock options&#x2019; expected term.</font></td> </tr> </table> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">(d)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">We do not expect to declare any cash dividends in the foreseeable future.</font></td> </tr> </table> </div> <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The provision (benefit) for income taxes consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>For the Years Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Current:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(8,357</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,222</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,255</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(691</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,412</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,048</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,634</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred:</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Federal</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">36,183</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(24,013</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">State</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,637</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,892</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">34,546</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(33,905</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total income tax provision (benefit)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(14,271</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> 501660 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>(xii) Income Taxes</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in &#x201C;income tax expense&#x201D; within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.</p> </div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December&#xA0;31, 2013, 2012, and 2011:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="60%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net (loss) income</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(62,134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">94,201</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">49,931</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Weighted average shares - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">60,729,128</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">58,588,916</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">53,272,767</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net (loss) income per share - basic</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1.02</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1.61</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">0.94</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Weighted average shares - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">60,729,128</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">64,637,256</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">57,959,714</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Net (loss) income per share - diluted</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1.02</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1.46</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">0.86</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <br class="Apple-interchange-newline" /></div> 0.0078 -200000 143475000 -2192000 359000 648000 -61513000 143475000 224301000 -6199000 175000000 1470000 -767000 -30437000 -62134000 -38785000 -68146000 2254000 12400000 -356000 155854000 1200000 -1222000 -36636000 -69000 -42559000 2149000 -62134000 -1570000 621000 1651000 155854000 161000 12379000 1110000 20074000 194639000 2491000 425000 4202000 35258000 36734000 -2235000 1023000 34546000 7000000 -23897000 3435000 12423000 104000 127000 16608000 101000 501000 -691000 217000 -246000 420000 -12822000 36183000 682000 -14330000 46670000 0 3576000 100000000 1023000 -1637000 22096000 495000 1227000 21200000 -9048000 3000000 1200000 12779000 1123000 1200000 183000 -2034000 -8357000 1652000 -283000 43000 99315000 25498000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Shares of common stock issued</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">99,359</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">56,254</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">65,889</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Match contribution value**</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">860</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">691</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">593</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">**</td> <td valign="top" align="left">Represents our stock price on the date of the stock match <i>multiplied</i> by the number of shares of common stock issued.</td> </tr> </table> </div> P6M P180D -33252000 28580000 -5917000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The following table sets forth the components of total &#x201C;interest expense&#x201D; recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December&#xA0;31, 2013:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="91%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Contractual coupon interest expense</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">73</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Amortization of debt issuance costs</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Accretion of debt discount</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">101</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Total</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">217</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Effective interest rate</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.59</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> </div> 2178000 1200000 -2871000 December 2015 1.20 0.00625 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The below table presents product sales, net by geography for the years ended December&#xA0;31, 2013, 2012, and 2011:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="22" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> United States</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">133,462</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">93.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">245,697</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">96.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> International:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Europe</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,953</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,113</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Asia Pacific</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,060</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,295</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> P3M 15000 66000000 200651000 <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>4.</b></td> <td valign="top" align="left"><b>GROSS-TO-NET PRODUCT SALES</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross product sales</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">224,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">383,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">220,670</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Rebates and government chargebacks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(63,610</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(91,059</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(22,190</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Distribution and data fees and group purchasing organizations fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19,067</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(32,793</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(11,637</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Prompt pay discounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(183</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,814</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,086</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Product returns allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,034</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(159</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,094</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 120000000 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We will assess this liability at each subsequent reporting date and record its adjustment through &#x201C;research and development&#x201D; expense in our Consolidated Statements of Operations.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Drug</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Development</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Liability,</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Current &#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Drug<br /> Development<br /> Liability,</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Long&#xA0;Term&#xA0;&#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total Drug<br /> Development<br /> Liability &#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">856</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,377</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfer from long term to current</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,620</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(3,620</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Amended agreement payment receipt</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(Less): Expenses incurred</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,357</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,491</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,623</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <br class="Apple-interchange-newline" /> </div> <div> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>13.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>MUNDIPHARMA AGREEMENT</b></font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">As the result of Allos becoming our wholly-owned subsidiary, effective September&#xA0;5, 2012, we assumed obligations under a strategic collaboration agreement with Mundipharma (the &#x201C;Mundipharma Collaboration Agreement&#x201D;). Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the &#x201C;Mundipharma Territories&#x201D;).</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">On May&#xA0;29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the &#x201C;Amended Munipharma Collaboration Agreement&#x201D;), in order to modify: (i)&#xA0;the scope of the licensed territory, (ii)&#xA0;milestone payments, (iii)&#xA0;royalty rates, and (iv)&#xA0;development obligations. In connection with the Amended Munipharma Collaboration Agreement, we received a one-time $7.0 million payment from Mundipharma for certain research and development activities to be performed by us.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">As a result, (i)&#xA0;Europe and Turkey were excluded from Mundipharma&#x2019;s commercialization territory, (ii)&#xA0;we may now receive potential regulatory milestone payments of up to $16.0&#xA0;million and commercial progress and sales-dependent milestone payments of up to $107.0&#xA0;million, (iii)&#xA0;we will receive tiered double- digit royalties based on net sales of FOLOTYN within Mundipharma&#x2019;s licensed territories, and (iv)&#xA0;we and Mundipharma will bear our own FOLOTYN development costs. We recorded the fair value of the related drug development liability of $12.3 million as of September 2012, using the discounted cash flow method of the income approach. The fair value of this liability was determined to be $17.7 million as of December&#xA0;31, 2013 (inclusive of the $7.0 million payment from Mundipharma) and is included in current and long-term &#x201C;drug development liability&#x201D; within the accompanying Consolidated Balance Sheets. This value includes our assumptions about personnel needed to perform these research and development activities, third party costs for projected clinical trial enrollment, and patient treatment-related follow up through approximately 2031.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">We will assess this liability at each subsequent reporting date and record its adjustment through &#x201C;research and development&#x201D; expense in our Consolidated Statements of Operations.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="65%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Year Ended December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Drug</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Development</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Liability,</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Current &#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Drug<br /> Development<br /> Liability,</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Long&#xA0;Term&#xA0;&#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Total Drug<br /> Development<br /> Liability &#x2013;<br /> FOLOTYN</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">856</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,377</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">12,233</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Transfer from long term to current</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,620</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(3,620</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Amended agreement payment receipt</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(Less): Expenses incurred</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,357</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(134</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,491</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance at December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,119</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,623</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,742</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 18px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> </div> 2871000 63610000 12612000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>(a) Description of Business</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (&#x201C;Spectrum&#x201D;, the &#x201C;Company&#x201D;, &#x201C;we&#x201D;, &#x201C;our&#x201D;, or &#x201C;us&#x201D;), is a biotechnology company with fully integrated commercial and&#xA0;drug development operations,&#xA0;with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> We currently market four drugs:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin&#x2019;s lymphoma;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%">&#xA0;</td> <td valign="top" width="3%" align="left">&#x2022;</td> <td valign="top" width="1%">&#xA0;</td> <td valign="top" align="left">MARQIBO injection for patients in the U.S. with Philadelphia chromosome&#x2013;negative acute lymphoblastic leukemia.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research,&#xA0;regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.</p> </div> 8989000 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The acquired intangible assets consisted of developed technology and in-process research and development (&#x201C;IPR&amp;D&#x201D;) for MARQIBO treatment of acute lymphoblastic leukemia (&#x201C;ALL&#x201D;) and MARQIBO treatment of non-Hodgkin&#x2019;s lymphoma (&#x201C;NHL&#x201D;) as follows in the table below:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="75%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Value of<br /> Intangible<br /> Assets<br /> Acquired</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Amortization<br /> Period*</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Developed technology &#x2014;MARQIBO for ALL</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">13&#xA0;years</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">IPR&amp;D &#x2014;MARQIBO for NHL</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total identifiable intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">44,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> <p style="MARGIN-BOTTOM: 2px; WHITE-SPACE: normal; BORDER-BOTTOM: rgb(0,0,0) 0.5pt solid; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium/8px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; WIDTH: 124px; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Recognized on a straight-line basis.</font></td> </tr> </table> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1)</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: 'Times New Roman'" size="2">IPR&amp;D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&amp;D is not amortized during this period, but rather tested for impairment.</font></td> </tr> </table> </div> 3453193 880000 73000 <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(b) Basis of Presentation</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Principles of Consolidation</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201C;GAAP&#x201D;) and with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201C;SEC&#x201D;). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On April&#xA0;1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the &#x201C;ZEVALIN Rights&#x201D;); on September&#xA0;5, 2012, we acquired Allos Therapeutics, Inc. (&#x201C;Allos&#x201D;); and on July&#xA0;17, 2013, we acquired Talon Therapeutics, Inc. (&#x201C;Talon&#x201D;). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Variable Interest Entity</i></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We own fifty-percent of Spectrum Pharma Canada (a &#x201C;variable interest entity,&#x201D; as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its &#x201C;primary beneficiary&#x201D;. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada&#x2019;s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.</font></p> </div> 2153000 10000000 12.00 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="88%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash consideration</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> CVR</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Spectrum shares of common stock</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">26,300</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total purchase consideration</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">44,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 0.00375 0.0859 0.15 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Amounts presented within &#x201C;accounts payable and other accrued obligations&#x201D; in the accompanying Consolidated Balance Sheets for GTN estimates (see&#xA0;<i>Note 2(i)</i>) were as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 39pt"> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Description</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Rebates&#xA0;and<br /> Chargebacks</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Data and<br /> Distribution,<br /> GPO&#xA0;Fees,&#xA0;and<br /> Inventory<br /> Management<br /> Fees</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Prompt<br /> Pay<br /> Discount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Returns</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance as of December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9,064</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">9,808</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">992</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Allos accruals assumed</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,371</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">182</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">941</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Add: provisions (recovery)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">91,059</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">32,793</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">159</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Less: credits or actual allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(76,318</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(28,634</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(4,355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance as of December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">26,176</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">14,149</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">1,451</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,056</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Add: provisions (recovery)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">63,609</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">19,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">183</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(2,034</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Less: credits or actual allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(55,818</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(27,843</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(1,317</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(122</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Balance as of December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">33,967</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">5,373</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">317</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> -1080000 <div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, approximately 28.1&#xA0;million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="85%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Conversion of Series&#xA0;E Preferred Stock</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">40,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,400,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercise of issued employee stock options</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,329,218</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercise of issued warrants</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">445,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ESPP shares reserved</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,540,986</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Long-term retention and management incentive plan shares</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">346,500</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total shares of common stock reserved for future issuances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,101,704</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> </tr> </table> </div> 0.50 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The following is a summary of our cash and equivalents and marketable securities:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="51%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Cost</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Gross</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Unrealized</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Gains</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Gross</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Unrealized</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Losses</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Estimated</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>fair</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Cash&#xA0;and<br /> equivalents</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Marketable&#xA0;Securities</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Current</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Long</b></font><br /> <font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Term</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>December&#xA0;31, 2013</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total cash and equivalents and marketable securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">159,777</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">159,777</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">156,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,471</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b>December&#xA0;31, 2012</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Total cash and equivalents and marketable securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">143,008</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">143,008</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">139,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">3,310</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> December 13, 2020 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The below table presents product sales, net by product line for the years ended December&#xA0;31, 2013, 2012, and 2011:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="22" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> FUSILEV</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,397</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">204,253</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> FOLOTYN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">44,370</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,412</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> ZEVALIN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,393</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> MARQIBO</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,315</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> </div> <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>3.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>BALANCE SHEET ACCOUNT DETAIL</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 6px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(a) Cash and Equivalents and Marketable Securities</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, we held substantially all of our cash and equivalents, and marketable securities at major financial institutions.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, with limitations on investing in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation (FDIC) and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks on our portfolio by investing in highly liquid, highly rated instruments and do not invest in long-term maturity instruments.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Cash and equivalents and marketable securities, including long term bank certificates of deposits, and investments totaled $159.8 million and $143.0 million as of December&#xA0;31, 2013 and 2012, respectively. The carrying amount of our money market funds and bank certificate of deposits (&#x201C;Bank CDs&#x201D;) approximates its fair value (utilizing Level 2 inputs &#x2013; see <i>Note 2(x)</i>) because of our ability to immediately convert these instruments into cash with minimal change in value.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following is a summary of our cash and equivalents and marketable securities:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="51%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Cost</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Gross</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Gains</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Gross</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Unrealized</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Losses</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Estimated</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>fair</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Value</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" rowspan="2" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Cash&#xA0;and<br /> equivalents</b></font></td> <td valign="bottom" rowspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Marketable&#xA0;Securities</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Current</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Long</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Term</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>December&#xA0;31, 2013</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bank deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">55,911</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100,395</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">410</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,061</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total cash and equivalents and marketable securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">159,777</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">159,777</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">156,306</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,471</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2"><b>December&#xA0;31, 2012</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bank deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">128,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Money market funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Bank CDs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">987</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Mutual funds</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total cash and equivalents and marketable securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">143,008</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">143,008</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">139,698</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,310</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, none of these securities had been in a continuous unrealized loss position longer than one year.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(b) Property and Equipment</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="80%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Computers and software</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,154</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,540</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Lab and media equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,063</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">886</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Office furniture and equipment</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,575</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,492</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Leasehold improvements</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,813</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,799</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Assets held under capital lease obligations</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">146</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment, at cost</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,605</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,863</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Less): accumulated depreciation and amortization</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(9,070</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(7,315</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Property and equipment, net</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,535</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,548</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Depreciation and amortization expense for property and equipment (including leasehold improvements) for the years ended December&#xA0;31, 2013, 2012, and 2011 was $1.2 million, $1.2 million, and $0.9 million, respectively.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(c) Inventories</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Inventories, net consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Raw materials</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,794</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">887</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Work in process</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,312</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,302</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Finished goods</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,413</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,289</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Inventories</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,519</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,478</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(d) Intangible Assets and Goodwill</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Intangible assets consist of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="79%"></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="1%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="22" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Historical<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Accumulated<br /> Amortization</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Currency</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Translation</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Impairment</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net&#xA0;Amount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Full<br /> Amortization</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Period&#xA0; (years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Remaining<br /> Amortization<br /> Period&#xA0;(years)</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MARQIBO IPR&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">17,600</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MELPHALAN IPR&amp;D</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">n/a</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">MARQIBO developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,107</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">25,793</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(23,455</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,445</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; Ex-U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,490</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(5,343</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">682</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,829</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FUSILEV developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,778</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,821</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,957</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN distribution rights*</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(3,662</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,215</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">118,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(10,587</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">107,813</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">280,668</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(48,975</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">682</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">231,352</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">*</font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">On May&#xA0;29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma&#x2019;s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the &#x201C;amortization and impairment of intangible assets&#x201D; in the accompanying Consolidated Statement of Operations for the year ended December&#xA0;31, 2013.</font></td> </tr> </table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="59%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31, 2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Historical<br /> Cost</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Accumulated</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Amortization</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Foreign</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Currency</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Translation</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Net</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Amount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">41,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(19,735</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,165</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">ZEVALIN marketing rights &#x2013; Ex-U.S.</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">23,490</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,192</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20,943</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FUSILEV developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">16,778</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,980</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,798</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN distribution rights</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(895</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27,005</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">FOLOTYN developed technology</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">118,400</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,077</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116,323</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total intangible assets</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">228,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(27,879</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">200,234</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Intangible asset amortization expense recognized in 2013, and 2012, and 2011 was $21.2 million, $8.8 million, and $4.7 million, respectively. Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&amp;D to developed technology) for the five succeeding years and thereafter is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="87%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 93pt"> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Years Ending December&#xA0;31</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" colspan="2"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2014</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2015</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2016</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2017</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,468</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2018</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22,313</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">2019 and thereafter</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">93,867</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">206,052</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Goodwill is comprised of the following (by source):</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="72%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Acquisition of Talon</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">10,526</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Acquisition of ZEVALIN Rights</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,525</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,525</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Acquisition of Allos</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,346</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,791</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Foreign exchange translation effects</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">104</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(37</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">18,501</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,279</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(e) Other assets</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Other assets are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="73%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Investments in equity securities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,593</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,476</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deposits</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">190</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">304</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Debt issuance cost</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,432</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Life insurance cash surrender value</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,361</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,881</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,576</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,475</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(f) Accounts payable and other accrued obligations</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Accounts payable and other accrued obligations are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="79%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Trade payables</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,796</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">30,814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued rebates</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">28,893</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,023</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued product royalty</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,498</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">12,275</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allowance for returns</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,056</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued data and distribution fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,430</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,449</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued GPO administrative fees</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,327</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,650</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Inventory management fee</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">616</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,050</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued income taxes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,522</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allowance for chargebacks</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,074</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">15,153</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued drug development costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6,433</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">11,441</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other accrued obligations</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8,867</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,819</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">79,837</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">105,252</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Amounts presented within &#x201C;accounts payable and other accrued obligations&#x201D; in the accompanying Consolidated Balance Sheets for GTN estimates (see <i>Note 2(i)</i>) were as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="61%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom" nowrap="nowrap"> <p style="BORDER-BOTTOM: rgb(0,0,0) 1px solid; WIDTH: 39pt"> <font style="FONT-FAMILY: Times New Roman" size="1"><b>Description</b></font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Rebates&#xA0;and<br /> Chargebacks</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Data and<br /> Distribution,<br /> GPO&#xA0;Fees,&#xA0;and<br /> Inventory<br /> Management<br /> Fees</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Prompt<br /> Pay<br /> Discount</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Returns</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr> <td height="8"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance as of December&#xA0;31, 2011</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,064</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">9,808</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">992</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Allos accruals assumed</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,371</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">182</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">&#x2014;&#xA0;&#xA0;</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">941</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Add: provisions (recovery)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">91,059</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">32,793</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,814</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">159</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: credits or actual allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(76,318</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(28,634</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(4,355</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(44</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance as of December&#xA0;31, 2012</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">26,176</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">14,149</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,451</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,056</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Add: provisions (recovery)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">63,609</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">19,067</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">183</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(2,034</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 3em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Less: credits or actual allowances</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(55,818</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(27,843</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(1,317</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(122</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Balance as of December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33,967</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,373</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">317</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,900</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%; MARGIN-TOP: 18px"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>(g) Other long-term liabilities</i></b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">Other long-term liabilities are comprised of the following:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="82%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>December&#xA0;31,</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2013</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accrued executive deferred compensation</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,949</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,366</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Deferred rent (non-current portion)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">366</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">571</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Business acquisition liability</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">298</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Other tax liabilities</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,352</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,132</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5,965</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">4,367</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> </div> 1 1509000 6000000 -2869000 5500000 19067000 1000000 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Gross product sales</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">224,301</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">383,817</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">220,670</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Rebates and government chargebacks</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(63,610</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(91,059</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(22,190</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Distribution and data fees and group purchasing organizations fees</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(19,067</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(32,793</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(11,637</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Prompt pay discounts</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(183</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,814</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(4,086</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Product returns allowance</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2,034</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(159</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,094</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 7.51 -25692000 <div> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>12.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>CONVERTIBLE SENIOR NOTES</b></font></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On December&#xA0;17, 2013, we entered into an agreement for the sale of $120.0 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the &#x201C;2018 Convertible Notes&#x201D;). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4&#xA0;million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances, as defined in the Indenture. The 2018 Convertible Notes bear interest at a rate of 2.75%&#xA0;per year, payable semiannually in arrears on June&#xA0;15 and December&#xA0;15 of each year, beginning on June&#xA0;15, 2014. The 2018 Convertible Notes will mature and become payable on December&#xA0;15, 2018, subject to earlier conversion into common stock at the holders&#x2019; option.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">On December&#xA0;23, 2013 net proceeds from the sale of the 2018 Convertible Notes were $115.4 million, after deducting banker and professional fees of $4.6 million. We used a portion of these net proceeds to simultaneously enter into &#x201C;bought call&#x201D; and &#x201C;sold warrant&#x201D; transactions with Royal Bank of Canada (collectively, the &#x201C;Note Hedge&#x201D;). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to &#x201C;additional paid-in capital&#x201D; in our accompanying Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reporting periods.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We entered into Note Hedge transactions to reduce the potential dilution to our common stock and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the &#x201C;bought call&#x201D; is equal to the conversion price and conversion rate of the 2018 Convertible Notes, matching the 11.4&#xA0;million common shares the 2018 Convertible Notes may be converted into. The strike price of our &#x201C;sold warrant&#x201D; is $14.03 per share of our common stock, and is also for 11.4&#xA0;million common shares.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">As of December&#xA0;31, 2013, the 2018 Convertible Notes were not convertible. Prior to June&#xA0;15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under the following circumstances: (1)&#xA0;during any fiscal quarter (and only during such fiscal quarter) commencing after March&#xA0;31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2)&#xA0;during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3)&#xA0;upon the occurrence of certain corporate transactions; or (4)&#xA0;at any time we have not received stockholder approval, as that term is defined in the Indenture governing the 2018 Convertible Notes. On and after June&#xA0;15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes at any time, regardless of the foregoing circumstances.</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">We initially may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval in accordance with applicable NASDAQ rules, we may settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at our election.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The carrying values of the 2018 Convertible Notes as of December&#xA0;31, 2013 is summarized as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="87%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Principal amount</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">120,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">(Less): Unamortized debt discount (amortized through December 2018)</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(28,520</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">December&#xA0;31, 2013 net carrying amount of 2018 Convertible Notes</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">91,480</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table sets forth the components of total &#x201C;interest expense&#x201D; recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December&#xA0;31, 2013:</font></p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 12px; MARGIN-TOP: 0px"> &#xA0;</p> <table style="BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <!-- Begin Table Head --> <tr> <td width="91%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Contractual coupon interest expense</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">73</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Amortization of debt issuance costs</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">43</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Accretion of debt discount</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">101</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Total</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">217</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr> <td height="8"></td> <td height="8" colspan="4"></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: Times New Roman" size="2">Effective interest rate</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">8.59</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">%&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 18px; MARGIN-TOP: 0px"> &#xA0;</p> </div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>5.</b></td> <td valign="top" align="left"><b>PRODUCT SALES, NET BY GEOGRAPHIC REGION AND PRODUCT LINE</b></td> </tr> </table> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The below table presents product sales, net by geography for the years ended December&#xA0;31, 2013, 2012, and 2011:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="61%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="22" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> United States</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">133,462</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">93.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">245,697</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">96.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> International:</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Europe</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,953</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3,113</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Asia Pacific</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,060</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4.2</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">6,182</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; TEXT-INDENT: -1em"> Total International</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">10,013</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">7.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">9,295</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">3.6</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The below table presents product sales, net by product line for the years ended December&#xA0;31, 2013, 2012, and 2011:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="62%"></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="2%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="22" align="center"><b>Year Ended December&#xA0;31,</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> FUSILEV</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">68,397</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">47.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">204,253</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">80.1</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,110</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">84.7</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> FOLOTYN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">44,370</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20,412</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">8.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> ZEVALIN</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">29,393</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">20.5</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">30,327</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">11.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">27,553</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> MARQIBO</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">1,315</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom" nowrap="nowrap" align="right"> &#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Product sales, net</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">143,475</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">254,992</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">100.0</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">180,663</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">15.3</td> <td valign="bottom" nowrap="nowrap">%&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <!-- End Table Body --></table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"> &#xA0;</p> </div> 800000 P5Y P10Y 0.930 133462000 0.028 3953000 0.042 6060000 P6Y P8Y 682000 -19067000 -63609000 -183000 2034000 50000 2018-12-15 95 Prior to June 15, 2018, holders may convert all or a portion of their 2018 Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Notes at any time, regardless of the foregoing circumstances. 1.30 0.0275 11400000 4600000 115400000 0.98 P30D P5D P20D P365D 0.25 P90D 29393000 0.205 1315000 0.009 44370000 0.309 68397000 0.477 P10Y 0.25 16000000 107000000 300000000 150000000 1.00 0.15 150000000 300000000 99359 860000 0.50 7000000 4000 5509 -2287 4329 2017000 10762000 P5Y6M 5.05 6.90 P4Y6M 0.92 3.15 P9Y2M12D 9.00 16.32 P8Y2M12D 7.00 8.99 P5Y10M24D 3.55 4.95 0.070 10013000 621000 -235000 235000 1651000 -1651000 -62134000 621000 3577000 -62134000 495000 11913000 1651000 860000 1509000 26310000 -14443000 -235000 74925 825884 471875 1000 -159545 99359 3000 3000000 40000 3576000 495000 11913000 1651000 860000 1509000 26307000 -14443000 11000 33000 66000000 2934625 343600 1007119 2012-09-05 2012-04-01 5000000 40 <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">The allocation of the total purchase price to the net assets acquired is as follows:</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">IPR&amp;D&#x2014;C-E MELPHALAN rights</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">7,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> <div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> <font style="FONT-FAMILY: 'Times New Roman'" size="2">Adjustments to Ligand Contingent Consideration fair value are recognized within &#x201C;fair value of contingent consideration related to acquisition&#x201D; in the accompanying Consolidated Statements of Operations.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12px 'Times New Roman'; MARGIN-TOP: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <table style="FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1">&#xA0;</font></td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: 'Times New Roman'" size="1"><b>Fair Value of<br /> Ligand<br /> Contingent<br /> Consideration</b></font></td> <td valign="bottom"><font size="1">&#xA0;</font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">March&#xA0;8, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Fair value adjustment for year ended December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">(700</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">)&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="MARGIN-LEFT: 1em; TEXT-INDENT: -1em"><font style="FONT-FAMILY: 'Times New Roman'" size="2">December&#xA0;31, 2013</font></p> </td> <td valign="bottom"><font size="1">&#xA0;&#xA0;</font></td> <td valign="bottom"><font style="FONT-FAMILY: 'Times New Roman'" size="2">$</font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: 'Times New Roman'" size="2">4,000</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: 'Times New Roman'" size="2">&#xA0;&#xA0;</font></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: rgb(0,0,0) 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <br class="Apple-interchange-newline" /></div> 2013-07-16 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Adjustments to CVR fair value are recognized within &#x201C;change in fair value of contingent consideration related to acquisition&#x201D; in the accompanying Consolidated Statements of Operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="87%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Fair&#xA0;Value<br /> of Talon<br /> CVR</b></td> <td valign="bottom">&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> July&#xA0;17, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Fair value adjustment for year ended December&#xA0;31, 2013</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">(2,171</td> <td valign="bottom" nowrap="nowrap">)&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> December&#xA0;31, 2013</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,329</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> &#xA0;</p> </div> 2013-07-17 11300000 8.77 <div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The acquisition-date fair value of the consideration transferred consisted of the following items:</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"> &#xA0;</p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Cash consideration</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,000</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Ligand Contingent Consideration</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">&#xA0;</td> <td valign="bottom" align="right">4,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p> </td> <td>&#xA0;</td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"> Total purchase consideration</p> </td> <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,700</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td valign="bottom"> <p style="BORDER-TOP: #000000 3px double">&#xA0;</p> </td> <td>&#xA0;</td> </tr> </table> </div> 11169000 26310000 10526000 4700000 3000000 3000000 -7000000 1491000 3620000 1357000 -7000000 -3620000 134000 P2Y6M15D 160816 P2Y4M24D <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"><!-- Begin Table Head --> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td> <td valign="bottom">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2011</b></td> <td valign="bottom">&#xA0;</td> </tr> <!-- End Table Head --><!-- Begin Table Body --> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"> Restricted stock expense</p> </td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,202</td> <td valign="bottom" nowrap="nowrap">&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,500</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> <td valign="bottom">&#xA0;&#xA0;</td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,100</td> <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td> </tr> </table> 2019-05-31 15000000 126000000 10000000 2014-04-30 0.15 50000 25000 1000000 P6M 1.000 P13Y P10Y 2525000 P11Y P11Y P8Y P11Y P9Y P10Y 1023000 P12Y P13Y 5346000 2026 2018 2028 2014 P20D 32400 586639 7.69 1.46 3916 0.642 64637256 9.57 7.93 1.61 0.98 P4Y6M 10.26 11.57 4749299 0.89 6.20 0.00 71959000 4.52 1821915 11.76 0.736 58588916 0.0034 1287430 40000 0.05 1.000 316825 472160 0.0051 -527000 254992000 -485000 -9483000 2515000 94701000 1712000 254992000 383817000 133264000 -2235000 50000000 -359000 1262000 82165000 17157000 976000 26430000 94201000 580000 80774000 57274000 2129000 12300000 267707000 -132000 495000 -107000 79930000 -84000 33504000 -844000 94201000 9000 -3530000 500000 9057000 4148000 267707000 312000 12715000 9011000 797000 8818000 186933000 -9726000 6500000 61025000 -44519000 202000 -33905000 89000 24038000 11500000 14884000 -37000 -128000 18496000 134000 3412000 2442000 213000 27975000 -24013000 -355000 -114690000 41560000 5817000 125000000 -9892000 12243000 606000 434000 8800000 19634000 1200000 14884000 72463000 382000 900000 4814000 159000 16222000 11983000 338000 89922000 -14271000 34605000 46633000 2376000 2908000 500000 20000 210433000 1.79 91059000 1034604 5000000 1497000 1208000 2111000 224437 1434000 32793000 0.964 245697000 0.012 3113000 0.024 6182000 -355000 -32793000 182000 -91059000 2371000 -4814000 -159000 941000 50000 30327000 0.119 20412000 0.080 204253000 0.801 P10Y 56254 691000 12233 2287 1843000 13041000 0.036 9295000 500000 -1103055 740000 9057000 -11983000 94201000 11982000 500000 5817000 94201000 606000 14193000 9057000 9011000 691000 89000 1434000 -1103055 54521 1287430 554239 2000 1000 -120197 56254 50000 5815000 606000 14193000 9011000 691000 89000 1434000 -128000 115000 25435000 1.000 2525000 4791000 -0.09 -0.09 -5435000 -6457000 38667000 0.72 0.80 46838000 23596000 59859000 0.29 0.31 18350000 23028000 68702000 -0.16 -0.16 -9721000 -12529000 33232000 0.33 0.37 21524000 23109000 69042000 -0.13 -0.13 -7812000 -13287000 42439000 0.12 0.13 7489000 11041000 70104000 -0.63 -0.63 -39166000 -6512000 41516000 0000831547 2013-10-01 2013-12-31 0000831547 2012-10-01 2012-12-31 0000831547 2013-07-01 2013-09-30 0000831547 2012-07-01 2012-09-30 0000831547 2013-04-01 2013-06-30 0000831547 2012-04-01 2012-06-30 0000831547 2012-01-01 2012-03-31 0000831547 2013-01-01 2013-03-31 0000831547 sppi:AllosTherapeuticsMember 2012-01-01 2012-12-31 0000831547 sppi:FolotynDevelopedTechnologyMember 2012-01-01 2012-12-31 0000831547 sppi:ZevalinRightsMember 2012-01-01 2012-12-31 0000831547 us-gaap:SalesMember 2012-01-01 2012-12-31 0000831547 sppi:CommonStockWarrantMember 2012-01-01 2012-12-31 0000831547 sppi:ZevalinRightsMember 2012-01-01 2012-12-31 0000831547 sppi:RestrictedStockAwardsMember 2012-01-01 2012-12-31 0000831547 sppi:TwoThousandEighteenConvertibleNotesMember 2012-01-01 2012-12-31 0000831547 sppi:CommonStockOptionsMember 2012-01-01 2012-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2012-01-01 2012-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0000831547 us-gaap:PreferredStockMember 2012-01-01 2012-12-31 0000831547 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0000831547 us-gaap:ParentMember 2012-01-01 2012-12-31 0000831547 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 0000831547 us-gaap:TreasuryStockMember 2012-01-01 2012-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-12-31 0000831547 sppi:InternationalMember 2012-01-01 2012-12-31 0000831547 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2012-01-01 2012-12-31 0000831547 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-12-31 0000831547 sppi:DeferredPaymentContingencyMember 2012-01-01 2012-12-31 0000831547 sppi:DeferredDevelopmentCostsMember 2012-01-01 2012-12-31 0000831547 sppi:FourHundredOneKPlanMember 2012-01-01 2012-12-31 0000831547 us-gaap:MaximumMember 2012-01-01 2012-12-31 0000831547 us-gaap:SalesMember sppi:FusilevMember 2012-01-01 2012-12-31 0000831547 sppi:FusilevMember 2012-01-01 2012-12-31 0000831547 us-gaap:SalesMember sppi:FolotynMember 2012-01-01 2012-12-31 0000831547 sppi:FolotynMember 2012-01-01 2012-12-31 0000831547 us-gaap:SalesMember sppi:MarqiboMember 2012-01-01 2012-12-31 0000831547 us-gaap:SalesMember sppi:ZevalinMember 2012-01-01 2012-12-31 0000831547 sppi:ZevalinMember 2012-01-01 2012-12-31 0000831547 us-gaap:WarrantMember 2012-01-01 2012-12-31 0000831547 sppi:ReturnsMember 2012-01-01 2012-12-31 0000831547 sppi:PromptPayDiscountMember 2012-01-01 2012-12-31 0000831547 sppi:RebateMember 2012-01-01 2012-12-31 0000831547 sppi:DataAndDistributionFeesMember 2012-01-01 2012-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:PreviousMember 2012-01-01 2012-12-31 0000831547 us-gaap:AsiaPacificMember sppi:InternationalMember 2012-01-01 2012-12-31 0000831547 us-gaap:EuropeMember sppi:InternationalMember 2012-01-01 2012-12-31 0000831547 country:US 2012-01-01 2012-12-31 0000831547 2012-01-01 2012-12-31 0000831547 us-gaap:SeriesEPreferredStockMember 2013-01-01 2013-12-31 0000831547 us-gaap:StateAndLocalJurisdictionMember 2013-01-01 2013-12-31 0000831547 us-gaap:ForeignCountryMember 2013-01-01 2013-12-31 0000831547 sppi:FederalJurisdictionMember 2013-01-01 2013-12-31 0000831547 sppi:AllosTherapeuticsMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynDevelopedTechnologyMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynDistributionRightsMember 2013-01-01 2013-12-31 0000831547 sppi:FusilevDevelopedTechnologyMember 2013-01-01 2013-12-31 0000831547 sppi:MarqiboDevelopedTechnologyMember 2013-01-01 2013-12-31 0000831547 sppi:ZevalinRightsMember 2013-01-01 2013-12-31 0000831547 us-gaap:InProcessResearchAndDevelopmentMember 2013-01-01 2013-12-31 0000831547 sppi:DevelopedTechnologyMarqiboForTreatmentOfAcuteLymphoblasticLeukemiaMember 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember 2013-01-01 2013-12-31 0000831547 sppi:PurchasePlanMember 2013-01-01 2013-12-31 0000831547 sppi:HendersonMember 2013-01-01 2013-12-31 0000831547 sppi:NipponKayakuMember 2013-01-01 2013-12-31 0000831547 sppi:IrvineMember 2013-01-01 2013-12-31 0000831547 sppi:RestrictedStockAwardMember 2013-01-01 2013-12-31 0000831547 sppi:CommonStockWarrantMember 2013-01-01 2013-12-31 0000831547 us-gaap:StockOptionMember 2013-01-01 2013-12-31 0000831547 sppi:DrugDevelopmentLiabilityLongTermMember sppi:FolotynMember 2013-01-01 2013-12-31 0000831547 sppi:DrugDevelopmentLiabilityCurrentMember sppi:FolotynMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynMember 2013-01-01 2013-12-31 0000831547 sppi:MelphalanMember 2013-01-01 2013-12-31 0000831547 sppi:CaptisolenabledPropyleneGlycolfreeMelphalanRightsMember 2013-01-01 2013-12-31 0000831547 sppi:TalonMember 2013-01-01 2013-12-31 0000831547 sppi:TalonTherapeuticsMember 2013-01-01 2013-12-31 0000831547 sppi:MelphalanLicenseMember 2013-01-01 2013-12-31 0000831547 sppi:ZevalinMember us-gaap:LicensingAgreementsMember 2013-01-01 2013-12-31 0000831547 sppi:ZevalinMember 2013-01-01 2013-12-31 0000831547 sppi:AllosTherapeuticsIncMember 2013-01-01 2013-12-31 0000831547 sppi:RestrictedStockAwardsMember 2013-01-01 2013-12-31 0000831547 sppi:TwoThousandEighteenConvertibleNotesMember 2013-01-01 2013-12-31 0000831547 sppi:CommonStockOptionsMember 2013-01-01 2013-12-31 0000831547 sppi:MilestonePaymentsMember 2013-01-01 2013-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2013-01-01 2013-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000831547 us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0000831547 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000831547 us-gaap:ParentMember 2013-01-01 2013-12-31 0000831547 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000831547 us-gaap:TreasuryStockMember 2013-01-01 2013-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-12-31 0000831547 sppi:InternationalMember 2013-01-01 2013-12-31 0000831547 sppi:ExercisePricesRangeTwoMember 2013-01-01 2013-12-31 0000831547 sppi:ExercisePricesRangeFourMember 2013-01-01 2013-12-31 0000831547 sppi:ExercisePricesRangeFiveMember 2013-01-01 2013-12-31 0000831547 sppi:ExercisePricesRangeOneMember 2013-01-01 2013-12-31 0000831547 sppi:ExercisePricesRangeThreeMember 2013-01-01 2013-12-31 0000831547 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-01-01 2013-12-31 0000831547 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-12-31 0000831547 sppi:ContingentValueRightsMember 2013-01-01 2013-12-31 0000831547 sppi:DeferredPaymentContingencyMember 2013-01-01 2013-12-31 0000831547 sppi:DeferredDevelopmentCostsMember 2013-01-01 2013-12-31 0000831547 sppi:ContingentConsiderationMember 2013-01-01 2013-12-31 0000831547 sppi:MundipharmaMember 2013-01-01 2013-12-31 0000831547 sppi:CanadianAffiliatedEntityMember 2013-01-01 2013-12-31 0000831547 sppi:FourHundredOneKPlanMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0000831547 us-gaap:MinimumMember 2013-01-01 2013-12-31 0000831547 sppi:TwoThousandNineIncentivePlanMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0000831547 us-gaap:MaximumMember sppi:CommercialProgressAndSalesDependentMember 2013-01-01 2013-12-31 0000831547 us-gaap:MaximumMember sppi:RegulatoryMember 2013-01-01 2013-12-31 0000831547 us-gaap:MaximumMember 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember sppi:FusilevMember 2013-01-01 2013-12-31 0000831547 sppi:FusilevMember 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember sppi:FolotynMember 2013-01-01 2013-12-31 0000831547 sppi:FolotynMember 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember sppi:MarqiboMember 2013-01-01 2013-12-31 0000831547 sppi:MarqiboMember 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember sppi:ZevalinMember 2013-01-01 2013-12-31 0000831547 sppi:ZevalinMember 2013-01-01 2013-12-31 0000831547 sppi:ScenarioOneMember 2013-01-01 2013-12-31 0000831547 sppi:ScenarioTwoMember 2013-01-01 2013-12-31 0000831547 us-gaap:MinimumMember sppi:TwoPointSevenFivePercentConvertibleSeniorNotesDueTwoThousandEighteenMember 2013-01-01 2013-12-31 0000831547 us-gaap:MaximumMember sppi:TwoPointSevenFivePercentConvertibleSeniorNotesDueTwoThousandEighteenMember 2013-01-01 2013-12-31 0000831547 sppi:TwoPointSevenFivePercentConvertibleSeniorNotesDueTwoThousandEighteenMember 2013-01-01 2013-12-31 0000831547 us-gaap:WarrantMember 2013-01-01 2013-12-31 0000831547 sppi:ReturnsMember 2013-01-01 2013-12-31 0000831547 sppi:PromptPayDiscountMember 2013-01-01 2013-12-31 0000831547 sppi:RebateMember 2013-01-01 2013-12-31 0000831547 sppi:DataAndDistributionFeesMember 2013-01-01 2013-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:PreviousMember 2013-01-01 2013-12-31 0000831547 us-gaap:AsiaPacificMember sppi:InternationalMember 2013-01-01 2013-12-31 0000831547 us-gaap:EuropeMember sppi:InternationalMember 2013-01-01 2013-12-31 0000831547 country:US 2013-01-01 2013-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:UnitedStatesMember 2013-01-01 2013-12-31 0000831547 2013-01-01 2013-12-31 0000831547 us-gaap:SalesMember 2011-01-01 2011-12-31 0000831547 sppi:TargentIncMember 2011-01-01 2011-12-31 0000831547 sppi:CommonStockWarrantMember 2011-01-01 2011-12-31 0000831547 sppi:TargentMember 2011-01-01 2011-12-31 0000831547 sppi:RestrictedStockAwardsMember 2011-01-01 2011-12-31 0000831547 sppi:TwoThousandEighteenConvertibleNotesMember 2011-01-01 2011-12-31 0000831547 sppi:CommonStockOptionsMember 2011-01-01 2011-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2011-01-01 2011-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0000831547 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0000831547 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0000831547 us-gaap:ParentMember 2011-01-01 2011-12-31 0000831547 us-gaap:RetainedEarningsMember 2011-01-01 2011-12-31 0000831547 us-gaap:TreasuryStockMember 2011-01-01 2011-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-01-01 2011-12-31 0000831547 sppi:InternationalMember 2011-01-01 2011-12-31 0000831547 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2011-01-01 2011-12-31 0000831547 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-12-31 0000831547 sppi:FourHundredOneKPlanMember 2011-01-01 2011-12-31 0000831547 us-gaap:MaximumMember 2011-01-01 2011-12-31 0000831547 us-gaap:SalesMember sppi:FusilevMember 2011-01-01 2011-12-31 0000831547 sppi:FusilevMember 2011-01-01 2011-12-31 0000831547 us-gaap:SalesMember sppi:FolotynMember 2011-01-01 2011-12-31 0000831547 us-gaap:SalesMember sppi:MarqiboMember 2011-01-01 2011-12-31 0000831547 sppi:ZevalinMember 2011-01-01 2011-12-31 0000831547 us-gaap:WarrantMember 2011-01-01 2011-12-31 0000831547 us-gaap:AsiaPacificMember sppi:InternationalMember 2011-01-01 2011-12-31 0000831547 us-gaap:EuropeMember sppi:InternationalMember 2011-01-01 2011-12-31 0000831547 country:US 2011-01-01 2011-12-31 0000831547 2011-01-01 2011-12-31 0000831547 sppi:TwoThousandNineIncentivePlanMember 2009-01-01 2009-12-31 0000831547 sppi:TargentIncMember 2011-05-01 2011-05-31 0000831547 2006-05-01 2006-05-31 0000831547 sppi:AllerganMember 2008-10-01 2008-10-31 0000831547 sppi:FusilevMember 2011-09-01 2011-09-30 0000831547 us-gaap:SeriesEPreferredStockMember 2003-09-01 2003-09-30 0000831547 sppi:TalonTherapeuticsMember 2013-06-18 2013-07-17 0000831547 sppi:MilestonePaymentTwoMember 2013-06-18 2013-07-17 0000831547 sppi:MilestonePaymentsMember 2013-06-18 2013-07-17 0000831547 sppi:MenadioneTopicalLotionMember 2013-06-18 2013-07-17 0000831547 sppi:MilestonePaymentFourMember 2013-06-18 2013-07-17 0000831547 sppi:MilestonePaymentOneMember 2013-06-18 2013-07-17 0000831547 sppi:MilestonePaymentThreeMember 2013-06-18 2013-07-17 0000831547 2013-06-18 2013-07-17 0000831547 sppi:TargentIncMember 2011-04-01 2011-04-30 0000831547 sppi:FolotynDistributionRightsMember 2013-04-30 2013-05-29 0000831547 sppi:ZevalinMember us-gaap:LicensingAgreementsMember 2012-04-01 2012-04-30 0000831547 sppi:TopoTargetMember us-gaap:SubsequentEventMember 2014-02-12 2014-02-14 0000831547 sppi:LigandPharmaceuticalsIncMember 2013-03-09 2013-12-31 0000831547 sppi:TopoTargetMember 2010-02-01 2010-02-28 0000831547 sppi:TalonTherapeuticsMember 2013-07-18 2013-12-31 0000831547 us-gaap:SeriesBPreferredStockMember 2013-12-31 0000831547 us-gaap:SeriesEPreferredStockMember 2013-12-31 0000831547 us-gaap:StateAndLocalJurisdictionMember 2013-12-31 0000831547 us-gaap:ForeignCountryMember 2013-12-31 0000831547 sppi:FederalJurisdictionMember 2013-12-31 0000831547 sppi:MutualFundsMember 2013-12-31 0000831547 us-gaap:MoneyMarketFundsMember 2013-12-31 0000831547 us-gaap:CertificatesOfDepositMember 2013-12-31 0000831547 us-gaap:BankTimeDepositsMember 2013-12-31 0000831547 sppi:MelphalanInProcessResearchAndDevelopmentMember 2013-12-31 0000831547 sppi:FolotynDevelopedTechnologyMember 2013-12-31 0000831547 sppi:FolotynDistributionRightsMember 2013-12-31 0000831547 sppi:FusilevDevelopedTechnologyMember 2013-12-31 0000831547 sppi:MarqiboDevelopedTechnologyMember 2013-12-31 0000831547 sppi:MarqiboInProcessResearchAndDevelopmentMember 2013-12-31 0000831547 us-gaap:InProcessResearchAndDevelopmentMember 2013-12-31 0000831547 sppi:TwoThousandNineIncentivePlanMember 2013-12-31 0000831547 sppi:PurchasePlanMember 2013-12-31 0000831547 us-gaap:LeaseholdImprovementsMember 2013-12-31 0000831547 sppi:ComputersAndSoftwareMember 2013-12-31 0000831547 sppi:LabAndMediaEquipmentMember 2013-12-31 0000831547 sppi:OfficeFurnitureAndEquipmentMember 2013-12-31 0000831547 us-gaap:FairValueInputsLevel3Member 2013-12-31 0000831547 us-gaap:FairValueInputsLevel2Member 2013-12-31 0000831547 us-gaap:FairValueInputsLevel1Member 2013-12-31 0000831547 sppi:RestrictedStockAwardMember 2013-12-31 0000831547 us-gaap:SeriesEPreferredStockMember 2013-12-31 0000831547 us-gaap:WarrantMember 2013-12-31 0000831547 us-gaap:StockOptionMember 2013-12-31 0000831547 sppi:TwoThousandEighteenConvertibleNotesMember 2013-12-31 0000831547 sppi:LongTermRetentionAndManagementIncentivePlanMember 2013-12-31 0000831547 sppi:EmployeeStockPurchasePlanMember 2013-12-31 0000831547 sppi:DrugDevelopmentLiabilityLongTermMember sppi:FolotynMember 2013-12-31 0000831547 sppi:DrugDevelopmentLiabilityCurrentMember sppi:FolotynMember 2013-12-31 0000831547 sppi:FolotynMember 2013-12-31 0000831547 sppi:AllosTherapeuticsMember 2013-12-31 0000831547 sppi:LigandPharmaceuticalsIncMember 2013-12-31 0000831547 sppi:CaptisolenabledPropyleneGlycolfreeMelphalanRightsMember 2013-12-31 0000831547 sppi:TalonTherapeuticsMember sppi:DevelopedTechnologyMarqiboForTreatmentOfAcuteLymphoblasticLeukemiaMember 2013-12-31 0000831547 sppi:TalonTherapeuticsMember sppi:InProcessResearchAndDevelopmentMarqiboForTreatmentOfNonHodgkinlymphomaMember 2013-12-31 0000831547 sppi:TalonTherapeuticsMember 2013-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000831547 us-gaap:PreferredStockMember 2013-12-31 0000831547 us-gaap:CommonStockMember 2013-12-31 0000831547 us-gaap:ParentMember 2013-12-31 0000831547 us-gaap:RetainedEarningsMember 2013-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000831547 sppi:ExercisePricesRangeTwoMember 2013-12-31 0000831547 sppi:ExercisePricesRangeFourMember 2013-12-31 0000831547 sppi:ExercisePricesRangeFiveMember 2013-12-31 0000831547 sppi:ExercisePricesRangeOneMember 2013-12-31 0000831547 sppi:ExercisePricesRangeThreeMember 2013-12-31 0000831547 sppi:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2013-12-31 0000831547 sppi:MutualFundsMember 2013-12-31 0000831547 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2013-12-31 0000831547 us-gaap:MoneyMarketFundsMember 2013-12-31 0000831547 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2013-12-31 0000831547 us-gaap:CertificatesOfDepositMember 2013-12-31 0000831547 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2013-12-31 0000831547 us-gaap:EquitySecuritiesMember 2013-12-31 0000831547 sppi:MundipharmaMember 2013-12-31 0000831547 us-gaap:MinimumMember 2013-12-31 0000831547 sppi:TwoThousandAndThirteenStockIncentivePlanMember us-gaap:MaximumMember 2013-12-31 0000831547 us-gaap:MaximumMember 2013-12-31 0000831547 sppi:TwoThousandEighteenConvertibleNotesMember 2013-12-31 0000831547 sppi:TwoPointSevenFivePercentConvertibleSeniorNotesDueTwoThousandEighteenMember 2013-12-31 0000831547 us-gaap:WarrantMember 2013-12-31 0000831547 sppi:ReturnsMember 2013-12-31 0000831547 sppi:PromptPayDiscountMember 2013-12-31 0000831547 sppi:RebateMember 2013-12-31 0000831547 sppi:DataAndDistributionFeesMember 2013-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:PreviousMember 2013-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:UnitedStatesMember 2013-12-31 0000831547 2013-12-31 0000831547 us-gaap:SeriesBPreferredStockMember 2012-12-31 0000831547 us-gaap:SeriesEPreferredStockMember 2012-12-31 0000831547 sppi:MutualFundsMember 2012-12-31 0000831547 us-gaap:MoneyMarketFundsMember 2012-12-31 0000831547 us-gaap:CertificatesOfDepositMember 2012-12-31 0000831547 us-gaap:BankTimeDepositsMember 2012-12-31 0000831547 sppi:FolotynDevelopedTechnologyMember 2012-12-31 0000831547 sppi:FolotynDistributionRightsMember 2012-12-31 0000831547 sppi:FusilevDevelopedTechnologyMember 2012-12-31 0000831547 us-gaap:AssetsHeldUnderCapitalLeasesMember 2012-12-31 0000831547 us-gaap:LeaseholdImprovementsMember 2012-12-31 0000831547 sppi:ComputersAndSoftwareMember 2012-12-31 0000831547 sppi:LabAndMediaEquipmentMember 2012-12-31 0000831547 sppi:OfficeFurnitureAndEquipmentMember 2012-12-31 0000831547 us-gaap:FairValueInputsLevel3Member 2012-12-31 0000831547 us-gaap:FairValueInputsLevel2Member 2012-12-31 0000831547 us-gaap:FairValueInputsLevel1Member 2012-12-31 0000831547 sppi:DrugDevelopmentLiabilityLongTermMember sppi:FolotynMember 2012-12-31 0000831547 sppi:DrugDevelopmentLiabilityCurrentMember sppi:FolotynMember 2012-12-31 0000831547 sppi:FolotynMember 2012-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2012-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000831547 us-gaap:PreferredStockMember 2012-12-31 0000831547 us-gaap:CommonStockMember 2012-12-31 0000831547 us-gaap:ParentMember 2012-12-31 0000831547 us-gaap:RetainedEarningsMember 2012-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0000831547 sppi:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2012-12-31 0000831547 sppi:MutualFundsMember 2012-12-31 0000831547 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2012-12-31 0000831547 us-gaap:MoneyMarketFundsMember 2012-12-31 0000831547 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2012-12-31 0000831547 us-gaap:CertificatesOfDepositMember 2012-12-31 0000831547 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2012-12-31 0000831547 us-gaap:EquitySecuritiesMember 2012-12-31 0000831547 us-gaap:WarrantMember 2012-12-31 0000831547 sppi:ReturnsMember 2012-12-31 0000831547 sppi:PromptPayDiscountMember 2012-12-31 0000831547 sppi:RebateMember 2012-12-31 0000831547 sppi:DataAndDistributionFeesMember 2012-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:PreviousMember 2012-12-31 0000831547 sppi:ZevalinMarketingRightsMember sppi:UnitedStatesMember 2012-12-31 0000831547 2012-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2011-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000831547 us-gaap:PreferredStockMember 2011-12-31 0000831547 us-gaap:CommonStockMember 2011-12-31 0000831547 us-gaap:ParentMember 2011-12-31 0000831547 us-gaap:RetainedEarningsMember 2011-12-31 0000831547 us-gaap:TreasuryStockMember 2011-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0000831547 us-gaap:WarrantMember 2011-12-31 0000831547 sppi:ReturnsMember 2011-12-31 0000831547 sppi:PromptPayDiscountMember 2011-12-31 0000831547 sppi:RebateMember 2011-12-31 0000831547 sppi:DataAndDistributionFeesMember 2011-12-31 0000831547 2011-12-31 0000831547 us-gaap:AllowanceForDoubtfulAccountsMember 2010-12-31 0000831547 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000831547 us-gaap:PreferredStockMember 2010-12-31 0000831547 us-gaap:CommonStockMember 2010-12-31 0000831547 us-gaap:ParentMember 2010-12-31 0000831547 us-gaap:RetainedEarningsMember 2010-12-31 0000831547 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-12-31 0000831547 us-gaap:WarrantMember 2010-12-31 0000831547 2010-12-31 0000831547 sppi:TwoThousandNineIncentivePlanMember 2009-12-31 0000831547 2013-06-30 0000831547 2012-09-30 0000831547 sppi:FusilevMember 2011-09-30 0000831547 us-gaap:SeriesEPreferredStockMember 2003-09-30 0000831547 sppi:TalonTherapeuticsMember 2013-07-17 0000831547 sppi:TalonTherapeuticsMember us-gaap:MinimumMember 2013-07-17 0000831547 sppi:TalonTherapeuticsMember us-gaap:MaximumMember 2013-07-17 0000831547 us-gaap:MinimumMember 2011-06-13 0000831547 us-gaap:MaximumMember 2011-06-13 0000831547 2006-05-31 0000831547 sppi:LigandPharmaceuticalsIncMember 2013-03-08 0000831547 2014-02-28 0000831547 sppi:TopoTargetMember us-gaap:SubsequentEventMember 2014-02-14 0000831547 sppi:TopoTargetMember 2010-02-28 iso4217:USD shares pure iso4217:USD shares utr:Y iso4217:EUR sppi:Segment sppi:Plans sppi:Country EX-101.SCH 14 sppi-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 108 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Balance Sheet Account Detail link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Gross-to Net Product Sales link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Product Sales, Net by Geographic Region and Product Line link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Net (Loss) Income Per Share link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Business Combinations link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Revolving Line of Credit link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Convertible Senior Notes link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Mundipharma Agreement link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Summary of Selected Quarterly Financial Data link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Schedule II - Valuation and Qualifying Accounts link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Policies) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Balance Sheet Account Detail (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Gross-to Net Product Sales (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Product Sales, Net by Geographic Region and Product Line (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Net (Loss) Income Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Business Combinations (Tables) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Convertible Senior Notes (Tables) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Mundipharma Agreement (Tables) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Summary of Selected Quarterly Financial Data (Tables) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Balance Sheet Account Detail - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Balance Sheet Account Detail - Summary of Cash and Equivalents and Marketable Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Balance Sheet Account Detail - Schedule of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Balance Sheet Account Detail - Components of Inventories, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Balance Sheet Account Detail - Components of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Balance Sheet Account Detail - Components of Intangible Assets (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Balance Sheet Account Detail - Schedule of Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Balance Sheet Account Detail - Summary of Other Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Geography (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Product Line (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 161 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 162 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 163 - Disclosure - Stock-Based Compensation - Summary of Stock Option Grants (Detail) link:calculationLink link:presentationLink link:definitionLink 164 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 165 - Disclosure - Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) link:calculationLink link:presentationLink link:definitionLink 166 - Disclosure - Stock-Based Compensation - Issued Shares of Common Stock (Detail) link:calculationLink link:presentationLink link:definitionLink 167 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 168 - Disclosure - Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 169 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 170 - Disclosure - Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 171 - Disclosure - Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 172 - Disclosure - Net Income (Loss) Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 173 - Disclosure - Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) link:calculationLink link:presentationLink link:definitionLink 174 - Disclosure - Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 175 - Disclosure - Business Combinations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 176 - Disclosure - Business Combinations - Acquisition-Date Fair Value of Consideration Transferred (Detail) link:calculationLink link:presentationLink link:definitionLink 177 - Disclosure - Business Combinations - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) link:calculationLink link:presentationLink link:definitionLink 178 - Disclosure - Business Combinations - Amortization Period for such Intangible Assets Acquired (Detail) link:calculationLink link:presentationLink link:definitionLink 179 - Disclosure - Business Combinations - Supplemental Pro Forma Financial Information (Detail) link:calculationLink link:presentationLink link:definitionLink 180 - Disclosure - Business Combinations - Change in Fair Value of Contingent Consideration Related to Acquisition (Detail) link:calculationLink link:presentationLink link:definitionLink 181 - Disclosure - Revolving Line of Credit - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 182 - Disclosure - Convertible Senior Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 183 - Disclosure - Convertible Senior Notes - Carrying Values of 2018 Convertible Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 184 - Disclosure - Convertible Senior Notes - Components of Total Interest Expense Recognized (Detail) link:calculationLink link:presentationLink link:definitionLink 185 - Disclosure - Mundipharma Agreement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 186 - Disclosure - Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) link:calculationLink link:presentationLink link:definitionLink 187 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 188 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) link:calculationLink link:presentationLink link:definitionLink 189 - Disclosure - Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 190 - Disclosure - Income Taxes - Provision (Benefit) for Income Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 191 - Disclosure - Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) link:calculationLink link:presentationLink link:definitionLink 192 - Disclosure - Income Taxes - Components of Company's Deferred Tax Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 193 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 194 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 195 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 196 - Disclosure - Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) link:calculationLink link:presentationLink link:definitionLink 197 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 15 sppi-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 16 sppi-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 17 sppi-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 18 sppi-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 19 g640093001.jpg GRAPHIC begin 644 g640093001.jpg M_]C_X``02D9)1@`!`0$`E@"6``#_X0!:17AI9@``24DJ``@````%``$#!0`! M````2@````,#`0`!`````*K%&!!1`0`!`````5>(^!%1!``!````$1<``!)1 M!``!````$1<```````"@A@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T, M"PL,&1(3#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T M,O_;`$,!"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(`;\"M@,!(@`"$0$#$0'_ MQ``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0# M!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*" M"0H6%Q@9&B4F)R@I*C0U-C+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$! M`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<` M`0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B7J" M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z***` M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HI"0`23@#J365:>)]"OM0: MPM=6LYKM<@Q)*"W'7ZT`:U%9FJ>(M&T5D34]3M;1G^ZLL@!/X4^ZUS2K+35U M&XU"WCLGP%G+C8<].:`-"BLR\\1:/I]C!>W>I6T-K<`&*5W`5\C/!J'4/%OA M_2K@6]_J]I;S%`X220`E3T-`&S16>-=THZ2=5&H6YT\#)N`XV8^M/_M?3O[) M_M3[9#]@V>9]HW?)M]'3=4M;J5!EDBD!('TI+_Q/H6EW MBVE]JUI;W#8Q')*`?_K4`:U%4KO6--L!;&[O8(1@'K3VU&S744 MTYKF,7CQ^:L.[YBOKCTH`M45%TN;@@D1QR`G`ZU=&JV!U1M,%W%]N5/,,&[ MY]OKCTH`N45ES^)-%MGNUFU.V0V>/M(+_P"JSTW>E5[+QEX;U&[CM+/6K.>X MD.$C20$L?:@#\AC@N&5 M8I&;`X_&HH_$NB2O>)'J=LS6 M2EKD!Q^Z`ZEO2@#5HJC-K6FV^GQ:A->PI:3%1',S?*Q;I@^]21:C9SWTUE%< MQO=0`&6(-\R`],B@"U1574-2LM*M&N[^YBMK=2`9)&P!FJM[XDT73K*WO+S4 M[:&VN`##*[@+(",\'OQ0!J45@1>./"\^_P`K7;%]@W-B4<#./ZUIV>K6&H7% MQ!:7<4TUN0)D1LE,],T`7**Q[CQ5H-K'/)/JUK&D$HAE9I!A),9VGWP#1IOB MO0-8NQ:Z=JUKM6<-Q$=KQO(`5/O0!NT5C_`/"6:!]EMKG^U[3R+ES'#)Y@ MQ(PZ@5>NM1L[&6WBNKF.%[E_+A5VP9&]![T`6J**R-3\4:%HUR+?4M5M;68K MN"2O@X]:`->BLN/Q)HLNE/JD>IVK6*'#SK("JGW/:JUGXS\-:A=QVMIK5G-/ M(<)&D@)8^U`&[17.R>//"D4C1OK]@KJ<$&4<&M.QUO3-3EDBL;Z"XDC17=8V MR55NA/UH`OT5DR^)]#@L7O9=4M4M4E\EI2_RA_[N?7@T:9XHT+6;@P:;JMI= M3`;BD4@)Q]*`-:BL^WUW2KJTN;N"_@DM[8D3R*^1&1USZ5)'JMA+#:S1W<31 MW>/L[!N),C(QZ\4`7****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#C?BI/=VWPWUB M2R9UD\L!F3J$)&XC\,UB'1_A]9>'O#-U2">M>D7 M*026TB7(0P,I5Q)C:0?7-A*D9'UJ:7P;H$NAP:*= M/C33X)5ECAC)4!U.0`^,':^\)2:*S9_P"$922-QCH3,%3_`,'+W^U?/T\-_:I5KS$C#S"O3 MH>.G:KJZ'H^GZN^NF-8;LVZVS3/(0/+7H.3B@#P_5-.F\)>'+#P]K@$8UK56 MOKFRLPTBV]NN"44#D\XZ59TG6;:;X2>-M`A:3R]-\QK82H4;[._*_*>1@Y_2 MO:/[$TF\UR'Q"(UFO4A,,4PD+*$)Y`&@ZG>WUY=66Z:^MOLMR5 MD91)'Z$`^W7K0!XM%9WMSJ7A+1=:L=&T:WG,5U:ZC:0'S)F4?ZLMGACGG\*V M;VVLKUOB3:7^I#3H9[R%!8Z$)/#OC#0+;Q#H.DF MXFS!8:II,NS=\O\`'&#R".Y%6/AUIGA_6=!\07OB2&UGU-[V<7SW6"\:@\`9 M^Z`,XQ7_O=+5 MKB0YD:.1D$G^\%(#?C0!XHUE<>(/A]X/TV6YF2.369H+2=C\RQ@'80?0&NI\ M'ZW=:O\`%O3H-2C,>JZ=I*1U=7.&'LP(/XUZ9=Z+X:FDTRUF6UC;3)`] MI"LNSRVQ@84'TJ>/PUHH\3R>(HK9/[5,?D/,KGD8Z$9QG'XT`<9\6C'+?^$K M*_]AJ=K'AK*T'P+X=\-73W6F6`2Y==AFDD:1POH" MQ)`H`\O\!:3K-[<:E+:Z-X?N[$:O,))KU"9P-_..W3I7K'B]UB\'ZKNO([)3 M;.AN)`2L6X;2D\S3R#<6R[')/-7;BWAN[:2WN(UEA ME4HZ.,A@>H-`'D'@RVG\(^+-!T@7^G:O::A8EXIX;-(I(0H'.Y>6!]6YK>^* MVGR:?IL7C/2W6#5M'^97(R)8SP4;U'.:Z30/`WAWPS=/=:5IZPSNNW>SLY5? M1_L9[_1?"MO:+'N,UHI\X?+P1GOZUV6H:#I6 MMZ!_8]U")M.9538LA'"].0<]JP[3X8>%-.N$NH+6X1XN06O)2!^!;%`'C.O^ M)+.[U_5?%*_:CJEEJD36+)"YC^SQ?*P+@8`.2?PKK?%DEWK7Q/TF[T2PT[47 MET1ITAOP3&R[L\8_BKU.Q\,Z-9>'FT6VM$_LZ1&4QEBVX-UY//.:@L/"&@Z/ M=6E];6WE2V-L;:&1I6.R(G)')_4T`<7\'(X[K^V]9+6]O=W,X2XTVWB,:6K+ MQC![GUI_B*&UU'XU:19:VJ2:>M@\EM%-_JWFSSP>"<5W-AX:TG3=:O-7LK;R MKR]`\]E<[7QWVYQGWHU_POH_B:W2'5K-9Q&=R-DJZ'V8`6_^RAKV"(GRT.!C:/N@^N*@\67,$_PZ\%K#-'(SWEGM"L"3@PT_3XX[>?/G!LN9<_WB(/$S,$2ROHK>5L?P2Q./_`$(+5'P]82VQ\=;U)FNO M#XN7&.2SJS?UKVN]\#^'M075%NK'S!JCQR7>9&^=D^Z>O&/:I%T7P]I.I3WS M+!!F1F1'\V']ZS1HWJJD[1^`J35_AQX8 MUS5I=3OK*5KN8`/(ES(F0.G"D4`V5HRW"0"W5Y)6O:MO5K]/`/CF#7'PFGZUI!CD/0?:( MEW+^)''XUWTGA?P['X3&AR0HNC+\P1IB!][=][.>OO2Z_P"'_#GB'2K.WUB. M":S@D5X"TNT!@,#!!YXH`\AUS1;G3_A3H$TL43ZCJ>N0WDJS_<9WW$!O;&!] M*]&\):9K%KJS2ZGH_AJTC\LA)--4B3/''/:MOQ#X?T'Q#I]MI6L1H\"R*\$7 MG&,[E!`Q@@]#5#1O`WA;P_K,=SIZ/'?*IVJ]X[G!Z_*S'^5`&MXCTZRO]%NS M>6D%QY<$C)YJ!MIVGD9KQ=K2*S_9XT^]M+:.&:492&RPYZ5[S* MD5S'+;2$,'0JZ9YP1BJ%CX=TK3]`30X+1/[-5"@@O)-`'F'C_2_ M#VD>$]!O/#\-M!J"75N+*2UP'<$C/(Y88ZU?^)VE6!N?"D[V%MY]QJ\0G?RE MS)E3D,<HEAYAU-4FSV=1@Y_*O4]+\.Z7H\U]+96VR2^E,UPS,6+N>,\ M_P`JQKGX:^%;JP%E+I[?9UN6NE59W7;(W4C!X^E`'5JZ/]UE;Z'->.>-+?4Y M_BXQTK2]-U*XCTC>8+]25(#'[O\`M5Z/H/A/1/"AF;38Y(?/VJYEN'?/H!N) MJ[_86G_V_P#VYY'_`!,/)\CS=Q^YG.,=*`/!X88;CX/^+M92:!+B_N5,]A!& M8X[1U8`IM/\`.O0/"6E:[%?6$U[HGA6&U"`F:T4^<.."/>N@O/`WAXJGI'PZ\'VMW#?Z;%(\ENX9&6^D=5(]MQ%` T M/21\9/"L`TVT\F:UNFE3R5PYP,$C')J;PO\`9K'XO>,+<>5`OV6V, M@]!7=W.A:==ZY9:S/!NOK)'2"3<1M#?>XZ&L[7_`OAWQ+=I=ZG8;[E%V"6.1 MHV*^A*D9'UH`\5O%:7X93F!(I#)XK'EB3E'.]L9]JZ'PY:7-U\7;:#6;32]% MO]+B9XH-/A*B\5AC.XGD#/2O2+KPOX7BT>RT:>WMX+*WF6>WA\W9^\4\'KDG M)J[J'AK2=4U>QU:ZMMU]8G,$RN5*^QP>1[&@#Y[TZ:Z\->'?$&J[GDTK5I[R MRN4QD12@GRV^ASBO2/#W@6U\2^#/".H37DL$EMIT.U8U!#D`?>SU&"1CWKM% M\%Z`N@W>B?8`=/NY&EFB9V.YF.2NZY>V6DZ8ER^FW\:7,5Z'19'5H54KZ MCD$<^AKTCRT\SS-B[\;=V.<>F:9]G@\PR>3'O.M>C?9X,8\F/&W9C:/N^GT]J2*SMH$1(;:&-$.55$`"GU&.E`' MEU[XMUA=+;[3X@@TR:UM9G25X%/VR1'9<8/3[HX'.36YXN>"^\.:))?WT%M) M(4D#7<)>VD?9G;)@C`/8^M;.N^#[+7I8FFN+B")05>&$@*X/7C'!//(P:W#9 MVS6BVKP1O;JH41NH9<#H,&@#RNRUQ["PBM;2\L-'@DU-H9KRT/FVK@Q;LQ;^ M%YP".@.:BU+QQXABMM/2*Y#1F.9Q>IY,0NBDFU3^](&".2%YYXXKTR[T&PNV MLM\"+%:.7CA5`$.0005Z8YJY+8VDT4<4MK!)''RB-&"%^@[4`<-:^([^]UN% M;S6H-+*I!LL3$KFYWJ"Q!ZGDX&WICG-96AWVMA39VVMR2"".[N908E9V=),* MAXX'/UKU!K6W>>.=X(FEC&$D*`LH]CVH2VMXG9XX(D=LY94`)SUH`\Z/C*]U M%+:/2]3A9Y(K)9)%C#".25]KY'K[=JM:=J7B"'5+476K"Y@749+!XS;JID4+ MN#DCHW;CBNXCL;2(8CM8$YW?+&!SG.?SJ3R(`] MLIWAU&7/N"<@#CUKO(].LHB3'9VZ$G)VQ*,]_3V%2F"$DDQ)DL'/RC[WK]:` M/)];\7Z[IU@+1=65;RW:XS<2)'$LHC/R[BV.E;FD^)KS4=:MVNM< MM[,E8=FG&$$W`>,,6!Z]3P1P,5W$MC9S;?-M8)-K;EW1@X/J/>G"SM1,DHMH M1)&NU'"#*CT!["@#R;2/'/B6\>]:3/F&UGE,.Z`^0R`[0J*2_;!WBKVJ^(WU MJ_M/L>N".R@ELG>6$*5W.7W`D_0<5Z6EG;13231V\*2R??=4`9OJ>],73[)( MO*6SMQ&?X1$N.N>F/6@#SO3?$-X\UA!-KEMI,*0+*D9@7%VS2NK*/H%'"\Y; M-9]]XPU.Y\2W%BMZCV$[7-LUL_EJZA8V(8(,L.1C+$9SP.:]6-E:L8BUM"3$ ME)]@LS,TWV2#S7^\_EC9V'BC4[#Q)I=E+>!M/<00K#!Y M3D!D`^="1(#GG<,@"NT\731S^!-9EAD61&LI<,AR#\IK9^Q6GGK/]FA\Y5VK M)Y8W`>@/7%$-G;P6@M4B7R<$;",@Y.3_`#H`X6;5==BUAYHM15;&VO;6V^R& M%3O60`,2W7//%6_"?B"2]>2YU'Q!;R2.C/+I_EJAM"&Q@GJ,=/FZFNR\B$YS M%'R0Q^4]KHUO)*S1*YE(ED'EGTQR#WKUV&UAMY9Y(T"O.P>0 M^I``_D!2)9VL:LJ6T*JW#!8P`><\_B:`/-+'QIKUQXU6U==L+7GV;N[YQBM#QEIM[J7B^!;'3M+OY8M-=_)U$,5/S_PXZ$].:[P6EL+G[2+ M>+S\;?-V#=CTSUJ38GF>9L7?C&['./3-`'F6AZ^F@:581S7T5O;RVUT[QLFQ M8KA2#Y2@Y/R\@#O4,7C+68]>TC[3?!K6YBMMT,`B9MSJ-V^,D/U.RM)/OVL+8??S&#\WK]?>C[%:>='-]EA\V,;4?RQN4>@/:@#RJW\ M@#B+F[T.R^'6BS:]&)H@D8AMV;`EDP<`Y.,=^>!C-8*0Z)"+!=9NK&72WM;N M2$1R;K>*X+J?+4]-RKD#\<5ZK-8VEQ"L,]K!+$OW4>,,!]`::--L!;K;BRMA M"K;Q'Y2[0WKC&,T`>17!M/[-N3K)8:J--M_[+\TGS-W.WR^^[=C.*TC]D_X2 M!3(5_P"$F_MJ(`9_>>1@;L?[&W=[5ZA):V\LL(-6?3YQ!OUH`\6@\6ZWI.C:/:V4NV$6;7`D#0QB=S*X(/FL#C`'"\ M\UVMMXBU&3Q=!8SW:1Z>ZK+))L'R2[,FVW=.GSYZXXKLGL+.18U>T@98CF,- M&#L/J/2G/:6\B,C0QD,=Q^4=?7Z^]`',^-]>ETS0;6:PO!"]U<+$DZ[-H!!. M=SG:HXZG/H`2:Y.R\2^)M5TC[3%J\,#VFGRW,ACA619W1V`YP."%[`5Z>+"T M^Q)9M;QO;H`!&ZAAQTX-/6TMD4JEO$JE=I`0`$>GTH`\NU?7+O4K^U6YUB&$ MKJMHJ:7Y0W,FY3OSU[]>E:?Q(\4ZEHDT<.F7JVTJ6[W!\SRU1\'AM96K2B5K:$R*``YC&0!TYI9[.UNBIN+:&8I]TR(&V_3-`')>,9)-0\#V M*XDN);9O(=MJ.6(."<'`_`U@7T&M>$M-O]8MM+LM+:X\FV%K8S"14&X[ MI2SA5#8.!GCCFO3S%&45#&A1<;5VC`QTQ2R1I+&T'[0AF'F7LD#7BS6Q;8J!AEMWE`DDCKVXYKHO#>LZYKNJ:8+B[%O"ME]HF MCC5'\]O,91\PR`"!GY37:&PLS:BU-I`;<=(O+&S\L8J5(8HR"D2*0NT%5`P/ M3Z4`>::NVCIJ6NOK-O87&K"4"VBU*X\E#!@8*,0<=^@ZTVUU_65TA[NPE>"V ML=+69+1U\XL267;0^++NQE9/^$@AU2PCFMS+?B-56,.2&1BORXZ'U%17'B^[N[Q5 M7Q)!IME)->A+EHE8,L;J$`SQT)^M>D)I]E';M;I:0+`_WHQ&`I^HQBJDV@:? M<:A!>26\9,,;1K&4&P[B"3C'7@4`)X7:!;B:%6R-X; MDL;.2WE-BXFB"^;(GS22@-N+'A0,<5ZU10!Y*GA3Q";&343HZK<+J=M=#3?/ MCRZ11>6?FSMR3SU[5WG@S2KK1?"EG8W@"W"!F=%.0A8D[<^V<5O44`5+:2;[ M5-#+('"@$$+CK5NJD7_(3N/]Q:MT`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`%2+_D)W'^XM6ZJ1?\`(3N/]Q:MT`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!7#>*?&&J:+XOTK3(8+2.PN2/,N+K<`Y)QM5API^O M6NYKF-?\#:9XBUFSU*[DG5K+=6TFXL!:PV M<4/M;^P/:O9V']L&_@M$(9_(Q+'Y@8]^`",>M=AX7UIM M?\.VNI21+%)(")$4Y`8$@X]LBLI/AWHR:/)I_FWQ9[A;G[4;@^>LBC:I#>R\ M#VKH=*TNUT;3(-/LT*P0KM4$Y)]R>YH`9:S1S:C;5M1'6WM<$)_ON?E7\:X&&\URTU M[7%U>ZU#1UNKI9C#I=@UR7'EJ,B8J0.F,!>HH`]+T/Q%8^(([A[,3J;>3RY4 MGB,;*V`>A]B*U00>AS7EWA#PEIVLWVN7EY_;,T+W2^3)>32Q/(-BY)'RYYR. ME=2?A[X?'^KBO(6_O17LJG]&H`ZFBN5_X1&]M.=+\4ZM;$=$N&6Y3\G&?R-- M-[XRTC_C[T^SUJW7_EK8MY$V/>-R0?P:@#K**P-,\8Z/J4XMC,]I>]#:W:&* M0'Z'K^%;]`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`%2+_D)W'^XM6ZJ1?\`(3N/]Q:MT`%%%%`!1110`4444`%%%%`!1110`444 M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!115' M5]7LM#T^2^OYA%"G'3+,3T50.23V`H`GO;VVTZTDN[R=(8(QN>1S@`5R:/JW MC8[T,^E>'S]UON7-X/7_`*9H?^^C[5)8:->^([N/5_$<)B@4[K/2V.1$.S2] MB_MT%=?TH`IZ9I5CH]HMKI]M'!".R#J?4GN?>KE%%`!1110`4444`4-3T73M M9@\G4+.*X7L77E?H>HK`.B^(/#WSZ#??VA9KUT[4'^8#TCEZCZ-D?2NNHH`P M-'\6V&J7)L9DFT_4U'SV5XNR3ZKV8>X)K?K.U?0].URW$-_;++M.4?H\9]58 M<@_2L$CQ%X5&4$NO:4O51C[7"OMVD`].#]:`.OHK.T?7=-UVV\_3KI90#AT( M*O&?1E/*GV-:-`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`5KS4;+3_*^V7D%O MYSB./S9`N]CV&>II5OK-[Q[-+J!KI%W-")`74>I7J!7F_P`5]-NKG4-&N[32 MY+R9',:9C66(DD?*ZGIG'WATQ6/9^'-:;QW?3?V3+`\ANG#A`$4/"JJPEZMD MC&SM0!ZX-6TTVTMR-0M/L\+;9)?.7:A]"&]22U%TWA^Y6PMYK$75EY(W7#1K()'"?Q1M M%,JD^6W5`22%_`$4`:\7_(3N/]Q:MU0M%E74;D2NKG:N"%QQ5^@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHJKJ.H6NE:?/?7LRQ6\"[W=NPH`9JVK6>B:;+?WTOEPQ^@R MS,>`JCNQ/``K`TC1[W6-2C\0>((MDB$[+4KD7]O))I^J*/EO+8[6/LPZ,/8UGKXDU+PZPA\4VV;4<+JMJA,7 M_;1>J?7I77TA`92K`$'@@]Z`([:Y@O+>.XMIHYH9!N22-@RL/4$5+7*W'@[[ M%>&KQM)N')9X%&ZVE/O'T!]UQ3$\7W.D,(?%&FR60''VV`&2W;W)'*?B* M`.MHKFK[QQI-I=PVUNEWJ4DL`N!_9\7G`(25!)!]0:GT;Q99:UJ4NGQVM_:W M4<(G,=W`8R4)VY'KS0!O4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%2+_D)W'^X MM6ZJ1?\`(3N/]Q:MT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`444A(4$D@`>XZ3..X'\(_&FN7\>:D8@67 MPS:2?.1Q]OE!^[_US4]?[Q]J[155$"(H55&``,`"@!:***`"BBB@`HHHH`** M**`"BBB@`HHHH`****`"BBB@`I&574JP!4]01G-+10!Y5XAT*ST;Q\U]96FJ MZ=#-IRXGT6'@S>8V=ZCY3\N."*BT:\\5R^-)M2@LY=3BBTX0%[RW-F[#S"V! MU!;GV%>M44`3&=+(V=UVN+&1H'!])$O8ATAU6W#''_71,'\P:/^$EUW3^-7\,SE!UFT^03K]<<,/RH` MZRBN?LO&WA^^D$0U!()SQY-R#$_Y-BMY'610R,&4]"#D&@!U%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%<5XX\7Z MCX:OM+@L[:U\FZDQ+&=:.O^'[74GB$+R`B1` M$9]3_$>PXZFI=:U6[UG4G\.:%*4D4#[??+TM4/\`"#WD(Z#MUKH-+TRTT?3H M;&RB$<$0P!W)[DGN3ZT`36MK!96L5M;1+%#$H5$48``J:BB@`HHHH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@"G?:5I^I M1F.]LH+A3VDC#5@MX"TZ!C)I%YJ.D2?].=P0G_?#97]*ZJB@#D_LGC;3/^/? M4M-UB(?P7<)MY3_P-,KG_@-+_P`)A>6)QK7AK4K,#K+`!,$_GUK%/ M@:"U;?HVK:EIC=EBGWQ_]\/D4`=717*;/'&F?I48KJ:*`.+C^&>CQ6,L"W-[YK2121W'F_O(?+!"!3V M`#-^==/I.EVVBZ7!I]H"(85VKN.2?4D^IJ[10!3A`&IW.!CY%JY52+_D)W'^ MXM6Z`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`****`"BBB@`KEM;UJ[O]0;P_X?8?;<#[7=XREFA_FY[#\34>I:Y>:UJ$ MNB>&Y`&C.V\U'&Y+;U5>S2>W;O6[HVBV>A:>MI9H0N2TDCG<\KGJS'N30`FB M:+::#IJ65FIV@EGD8Y>1SU9CW)-:-%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5S M?B#0-3U#6M/U72M1@M+BTAEA(GM_-5UD*$\9&/N?K7244`7]JN88/-8(GF.%W,>PSU-2&>)9EA:5!*X M+*A898#J0*`)**J_VE8F"2<7MMY,1VR2>:NU#Z$YP#5A'61%=&#*PR&4Y!%` M%:+_`)"=Q_N+5NJD7_(3N/\`<6K=`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%0W5W;6-NUQ=SQP0KRSR,%`_$US+^+; MK5V,/A?3GO!T-[/F.W7W!/+_`(4`4?\`A.M3?3I]4CT.!--BD=/M$]\L>=K% M%M=TIU?5?#YUB MXAF>2`O>J+>(LQ.Y(SP#SU.37=>"M-O=+\/"#4(5AN'N)9FC5MVT.Y8#/XT` M:^G:;9Z38165A;I!;Q#"H@X_^N?>K5%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'EW MQ8L)YM0T6ZM].FO)46A@YG>-9 M!(VS^(99.>^/:O5O`MG=V'@VPM[Q&CF521&_5%))4'Z#%='10!0M!*-1N?.9 M&;:N"JXX_,U?JI%_R$[C_<6K=`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`454N]4L+!"UW>V\`'_/20+6)+X^\.HQ2&]:[?^[:PM*3_P!\B@#IJ*Y7 M_A+=2NN--\*:I,#T>XV6Z_\`CQS^E'F>.;W[L&B:8A[R/)J>V\"^'+:02' M3EN)1_RTNG:9OS8F@"*7QYI#.8]-6ZU2;LME"7'_`'UT_6HS<>,]8XM[:ST. MW/\`RTN#]HFQ[(,*#]2:ZF*&*!`D,:1J.@10!3Z`.8M?`VG?:%N]8GN=:O5. M1+?ON5#_`+,8PB_@*Z5$6-0J*%4<``8`IU%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`445QGC#Q"\.IV.B6>J)8O.LLUU<1@/+%$@!PJ\_,<\ M<=C0!V=%<5H-_>6'B.TTM]3N=3L-1LWN[>2[0+/`4*@AL`94[QC(R"#7:T`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%2+_`)"= MQ_N+5NJD7_(3N/\`<6K=`!1110`4444`%%%%`!115:]U&RTZ!I[V[AMXEZO* MX4#\Z`+-%1N`?H*`-?Q+J*Z9X=U"Y^TI!+';NT;,P&&P<8S[UY=_:WG>'!=:= MKWBS4KX6GFR&U/[F-]F3N=@%P#Z$UWG_``KW0Y895OEGOYY$*F>[E,C#(Z@' M@'Z"JZ_#]DT_[`OB;6A:>7Y7E"50-F,8^[Z4`0Z)<^.=:T+3Y]VE:;'+;1L9 MWW7,KY4'=M&U1GKC)J]_PAMS=\ZMXDU6[!ZI'(($/X(!_.NCL+.+3M.MK&'/ ME6\2Q)N/.%``_E5B@#`M/!/ARS8.FEPR2#GS)LR-^;9K;AMX+==L,,<:^B*` M/TJ2B@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BJUYJ% MGIUNUQ>W4-O"OWGE<*!^)K.;Q'#+>R6=A9W=Y.L/FATB*PGC*CS6PN3[$T`; M5,DECA0O+(J(.K,<`5B1CQ+??8I9#::8H8MSA>2ZO(8O.:WMD+N1VQVR>PS4 M45]X@OC92V^F065NY)N%OI"9D7/`54R,D<\GBMJ*&*!0L4:H``,*,<#@4\G' M6@#GO^$8EO;6:#6=6N[Y9)1(`A\@(!_"-F#CZDT_4?!^C:BH8VWD7*L&2Z@. MR96`P"&Z].*VO/B#A/-3<>@W#)KF?&GC/3?#6E7*'4+9-29`L$#.-^YN`2O7 M`Z_A0!?T7PQ::-=37GGW5Y?3*$>YNY-[[1T4>@]A6W7+^`]?EUSP^!=RK+?V MC^1YNG*1+R/EW`8#'/&?2F7'C/4[#Q']COM M+A2SDCFDA,JD=/Q MZBH+3P)!::[>ZD-3O'2\3RIK=]I4Q@$*@.,A0#T!H`P(/B9J4L(MSI=LNI7# MVWV1/-/EE)@Q4N<9!&PYQ[5VWAK6AK^@6VI&(1-("'3.0K`D$9],BN>B^&6F M164L*WU]]H,D3PW1<>9`(@0BKQC`#-UZYKJ='TJVT32K?3K7=Y,*X!8Y+'J2 M?L]6M-#MSZ?OY\ M?^@@_G0!T]S=VUE`T]U<100H,M)*X51]2:YE_'EG=N8M`L;S6Y(0?> M5L+^6:DMO`>D"=;G4_/U>Z4Y$NH/Y@4^R?='Y5TR(D:!(U5$48"J,`4`!M$MIEN;J&34;L<^??.9CGV!X'X M"NDHH`155%"J`%'``'`I:**`"BBB@`HHHH`****`"BBB@`HHH)`ZF@`HJ.:X MAMTWSS1Q+_>=@H_6JD6MZ3-)-%UQ9FTO4K>[$`!E,39V9SC/Y&@#5HKRW7_BK M:6OBBS73KQ9M*M#_`,3$K$Q+;SM^7C^#[Q]J[Y_$6F1Z(NL-._V%@")!$Y)R M<#Y<9_2@#4HKF8?'_AR>:.&.[F+NP51]EE&2?^`U?U?Q-I6A2QQ:A/)&\@W* M%A=\C_@(-`&O16+I/BO1M;N3;6%TTDP7<4:%T./7Y@*@NO'7ABRNI;6YUB". M>)BCHP;*D=NE`'0T5FV?B#2+_2Y=3M=0@ELHL^9.K?*N.N3[507QYX39@!XA MT[)Z?OQ0!T-%4KO5]-L;>*>[O[6WAE_U;RRJJOWX)/-16OB#1;V98;75[">5 M_NQQW",Q^@!S0!I453N-6TVTF,-SJ%I#*.2DDRJ1^!-2V][:W:EK:YAF4-X/"]C8S0>58`/)7F1P<] MAT]R*`.NHK-M_$.C721/#JMDWF@%!YZY.>G&:EOM8TS3&"W^HVEJS#(6>94) M'L":`+M%9]EKNDZE,8;'4[.YE`W%(9U<@>N`:IW7C/PU8W$EO3;O(3QGD*"1^-4[#QA8ZC?1VL-GJ:E\_ MO)K-XT7C/+$<4`=!17,ZOXUM=)U%[$Z??7$J)OS$J[2N,DY+#@"JVF_$71[^ MT^TRB2UB>3RH3(0WG-Z+M)YZ=?6@#KZ*\^?X@ZY)+>Q6?@K4)7M.'#.%W'./ ME.,-^!K6;7?$]QI]BUEX:"75Q&'E%UG7<-U;MTDA<,/TKPKQ]=:GJ'C71=.\6 M76CV4"QM+L.^6*/YARWNV,9]`?6I/`VFW>I^*/$&E^'O%*VNGQPJOF6L(_>@ MDX9<]P.-WTH`]Z9T3&]E7)P,G%8L_B[1T@N)+6=]0:WD$622_U4I(Y-'&,G MLJXH`MR:KJLL\B6^E""V\CS%N[N8*N\C(4H.1CH]=';^'],MM(?2A;>;9/G?%.[2[L^I8DFEM/#VBV./LF MDV,!'0QVZ@_GB@#&O4\-^&U+W-K<737TGFX\B2[+L.0<`,%QGCI5W2_$JZG> MI;0Z+JUO$5)\^YM?*C&!QU.?TK>HH`Y[4-1\3B^E@T[0[5X%.%N+B[VAO?:% M)JYIW]NRV$XU/[%#=MD1&VW,J\<$[NO-:M%`'*_\(WK]P/\`2_%MV,]1;0)' M_0UJW^@VVJ:=!97DUTZ18RR3,C.0,98KC-:M%`>"_#VFW4=U;Z;']HC.4 MED9G93Z@L353Q%X1DUK6K#5+;4%LI[,,5Q;))N8C&23Z#I74T4``,4`TEDU*Z'_`"QL4,I'U(X'XFO!=?\`#_\`:'AFR2RTG71JR1K'<0?9 MRD;YR68D>AQCV%>VZ9\.M/TRQ6WM-5UR%.&VI?%<>W`%`$OVKQEK'%M9VNBV MY_Y:71\Z;'^XO`/U-.3P)8W,@GU^]N];E!SB\D_^E.[)W'?\WS<^M`&]"+* MQA2"`6\$2_*J)M4#V`%+&KV[@NKS2TN98(O)C,\CN%3&,8)(_'&:`-2WUK2KNX M^SVVI6DTV,[(YE8X^@-4;WQGX;TVY>VO-;LH9XSAXWE&Y3[BJ.#^0H`GL_$NBZA9 M27EGJ,$\$>=S(<]!DX'?\*Q'^*'A-$=QJ#LB':[+`^%/H3BM:'PCX>MQ:"'1 M[-!9G-OMC'[OG/'XU*OAG0EBGB&D67ESMOE7R5P[>I&.3S0!7O\`Q;I=A907 M):6?SE#K%;IOD"D9W%3REN)@JQAO3.:Z(:'I2 MW"W`TVT$RQ^4)/)7<$QC;G'3'&*1="TA($@73+,1(^]4$*[0WJ!CK0!A:UX\ MMM)O;JWBLI+T6L7FSR0S1XC7OG+9'_UZ\O'Q$UJRU\^.+F!4T2\58(K%YAYC M0Y($BCU!SGZU[9=Z%IE[;7=O-90[+R,QSE%VLZGKDCFO,I/@H)%&GM>QMI@; M"RM+.9UCSG8%W^7[9V_A0!LI\1[JYL9+^VM])%FC!3++J(`4GD`X'!([5MGQ M2TFG"!;K38M::'S_`"#(S1B/KNR!DC;S706NFV=E916<%O&L$2*BJ1GA1@9] M:G\F+.?+3.,9VCI0!Y_%XIU=X[:ZDU_0!:33>4IBMYF+$8R`?7FM/6];^TW$ MZ:=XECL/L*$W:?8C,W4#//\`3-=:(8@`!&@`Y`VBE\M,D[%R>O'6@#C=(U/[ M-J%F]YXHN]06\CS#";`(AYQDD+D=#U-4KY]*O?M>HMXD\2K`LXC:*V+QA&/8 M`)DCCK7H&U1C"CCVHVCT%`')V=QH]I;W.B&YUBZ\V!IG:X,SOL*Y(#]0<=@< MYK$72/`QM;>=](U.9+B0QJ)_M,AS_M!F.!SWKTC`]*,4`O8)K*^T. M>Z@TS`5);$NO'R_)D?-^%-L7\-VEY8?8O#302W";XI8]-">7U'S-C*GBNMHH M`YA_$&G2V\M__85_))'((2&L?WC>XSR1[U<.O1I=RVL>EWX98?-\P6_R-QG` M/<^U;=%`'@EAI&OZUI]Q=)KFJ6\5_?7"2V]O8HP'S;29LGTXQV`KN_`WB"]C M\&"&XL;Z_FT\&$3)&,7`5RHV$GG@5MW_`('TN^O9[E+C4+/[2O%5SXDO&L7N5\-ZFSK)L\DJ@8C^\.>E=%10!BMK-TE[/`NA7I2.+S%F&W;( M<`[1SG/;\*A&N7;0VO%=!10!@-K=T([\?\(Y?D M6Y`10$_TC)P=O/X\TP78DNK:W;PM.(YX][R-''MB."=K<]>/UKHJ*`.7N=1F MO-,62Y\'W$Y278MM*L3$#'WADX`[41PPVNISO;>#HD>"+?%H/ M.*ZBB@#D;FW34I+.ZO/!%O//.VV=KA8F>%0<`DD'/%.LK>YTR+4?[-\(6=JQ M8!%BDC07`R1DX'''KZUUE%`'$CPO:27D`;P1HHADBWS2,$+))@Y7&WGGO7#3 MVMQ'XROH=;T+P\JQVT:6%M?7&R"*'G=Y65VDD]>_2O;ZJWNFV.I(J7UG!U6U2 M[-KC<\]JL#P]>&]2>34H=OE!942QC'F28P7R'=1-BEO)XEOS(LWF&6..)"RX^Y@+C'ZU*WAI7GO)6U;5,7*;-BW&U8 MNG*8'RGCK6Y10!AIX6LP]D\EWJ4KV?\`JVDO9/FYS\^#\WXTA\&^'VMKBWET MU)H;B02RI.[2!F&<'YB?6MVB@#/BT+289EFCTRT658Q$L@A7<$`QMSC.,<8J MW%;001B.&&.-!T5%``_`5+10`4444`-:-&.612?<4*B)]U5'T%.HH`****`" MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`** M**`"BBB@`HHHH`*0D*"20`.I-+69XC@-SX0-!NV^8)!MSZ9]:M`@C(.0:^?M)L;EO#%F;C19Y-)@OI@XCM&5Y MF:%E1FC&>5?`R.,\U[3X4M[RT\)Z7!?!OM<=LBR!CR#CH:`+L7_(3N/]Q:MU MGK'?K=2S>7;'>`,>8W&/^`U-NU#_`)Y6W_?UO_B:`+5%5=VH?\\K;_OZW_Q- M&[4/^>5M_P!_6_\`B:`+5%5=VH?\\K;_`+^M_P#$T;M0_P">5M_W];_XF@"U M157=J'_/*V_[^M_\31NU#_GE;?\`?UO_`(F@"U157=J'_/*V_P"_K?\`Q-&[ M4/\`GE;?]_6_^)H`M455W:A_SRMO^_K?_$T;M0_YY6W_`'];_P")H`M455W: MA_SRMO\`OZW_`,34>W4OM'F;;;;MV[/,;KGK]V@"]157=J'_`#RMO^_K?_$T M;M0_YY6W_?UO_B:`+5%5=VH?\\K;_OZW_P`31NU#_GE;?]_6_P#B:`+5%5=V MH?\`/*V_[^M_\31NU#_GE;?]_6_^)H`M455W:A_SRMO^_K?_`!-&[4/^>5M_ MW];_`.)H`M455W:A_P`\K;_OZW_Q-&[4/^>5M_W];_XF@"U157=J'_/*V_[^ MM_\`$T;M0_YY6W_?UO\`XF@"U15%QJ321,%ME"$DCS&^;@C^[4F[4/\`GE;? M]_6_^)H`M455W:A_SRMO^_K?_$T;M0_YY6W_`'];_P")H`M455W:A_SRMO\` MOZW_`,31NU#_`)Y6W_?UO_B:`+5%5=VH?\\K;_OZW_Q-&[4/^>5M_P!_6_\` MB:`+5%5=VH?\\K;_`+^M_P#$T;M0_P">5M_W];_XF@"U157=J'_/*V_[^M_\ M31NU#_GE;?\`?UO_`(F@"U157=J'_/*V_P"_K?\`Q-1S+J4L>U5MD.05M_W];_`.)H`M455W:A_P`\K;_OZW_Q-&[4/^>5M_W];_XF@"U15.3^T7C9 M1';*2,`^:W'_`([0AU%8U4QVQ(`!/FMS_P".T`7**J[M0_YY6W_?UO\`XFC= MJ'_/*V_[^M_\30!:HJKNU#_GE;?]_6_^)HW:A_SRMO\`OZW_`,30!:HJKNU# M_GE;?]_6_P#B:-VH?\\K;_OZW_Q-`%JBJN[4/^>5M_W];_XFC=J'_/*V_P"_ MK?\`Q-`%JBJN[4/^>5M_W];_`.)HW:A_SRMO^_K?_$T`6J*J[M0_YY6W_?UO M_B:0MJ!4@16P_P"VK?\`Q-`%NBHK='CMXTE8,X&&([FI:`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`*UW<1Z=8S7!BD=(E+>7"FYF]@! MU-<;+\0;H^&(-;MM`E>)A-)<"6<1K`D9P06P?G/9?UKNB,J1ZBN'O/AY)/I6 MGZ=!K4L5O:7#W+(85=9F+;AO!Z@$\"@!^K_$!K.^L+'3])DN[N]@6:..241; M:QI-I;Z;(8-02)@[3*)`9`2,)U95P+:K#,PB)!4'S'R/D4#Z]JJWGQ*BM?#NFZHNF222WK.@@$@&"" M%&&Q@J691GT.:NZKX':_LM9M[?5I[0ZK=+<3/&H)"A0"GT.!FFW7@*/4-.6U MO+]V>.U6WADBB5!$5D#A@HXZJOY4`9-Y\5UL[?,FCMY]OYIOHS,V.NZKI=MH][ M-+86@N%^7:;@EBNU`>HR/O5U5<]J7AE[W5;[4K?4);6YNM/%B&10?+`8MN'O MS0!G6?CIY])N)[C2S#>07R6+6Z2^8K.Q'W6`YP"2>.Q%5Q\16N+(O::+.;R3 M4#8V]M/((BQ"EBS$CY1@'CGM5W0_!1TFVTVWGU%KF*PN&N(QY2IN8H5RV.IR MQ.?6FW7@..9)W@U&:"[;4#?PSJ@/E.5VD8/48)H`W=`UB'Q!H5GJL"-''G>4#`)A(',GW5W`<-V([5LZEX?\`MVN6^K1W;P3P6DULFU0<>9M^;ZC; M6/HW@-],T]+*XU:2[B6\2[8M"JM(RDD[B/O9.T_\!H`DM?':7$&MRG2+]?[+ M94\H1DR3$C/"]A[GMS6]H&JC7-!L=4$1A%U$)?+)SMSVS5:W\.QV]]K5T)W) MU3&Y2!\F%V\5:T+2DT/0[+2XY&E2UB$8=A@MCO0!H4444`%%%%`!1110`444 M4`%8&N>*$T;6-*T[[%<3-?S"+S@N(X@<]6[GCI6_65K.B)K$VG2/,T9LKI;E M0HSN(!&#^=`&-:>-9VUVXT[4-'EL56VENH7>4,S1QMM)=0/DSU7DYJ.Q\>/? M7\EFFB7GFIIIO@,8\TY`")G&[KUZ9IEMX$N8KG699]R6TPTUM/C*J#L!8,''N,4`)X6\2S:_]NAN]/-E=6<@ MCEC$HE7)4'&X`YKH:` M"BBB@`HHHH`****`"BBB@#"\5^)D\+Z4+UK*XNR7"!(EX7)QEFZ**HW/C"YM M/$MIITVC2I9W4RV\5T91N=RFXE4QDH.A;/7M6QX@T=-?T6?39)6B6;&749(P M0?Z5BOX.NV\6G71K4G$0@C@>%6$28Y"'L2>2:`(T\>I)K-AIZ:9<,M[=RVZ7 M'2,!`V#G').T\#MWJYH7BFXU7Q#J6CW>EFSGLU60'SUDRK$@;L=#QG'/!IW_ M``B%N(="C6YD`TF9IE(`S(2C*<^GWB:31/"7]E:W-JD^IW%[,T)MXO.`_=Q[ MMV,C[QSW-`'24444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1 M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%4M5AU&>R* M:7=PVMSN&))H3(N.XQD?SK!_LWQO_P!#%I?_`(+3_P#'*`.EENK>!MLL\:-U MPS`&I(Y$E0/&ZNIZ%3D&O,[VVU^VU^Y.I:UI6]HDVR2:.\BL.>!\QQ5[P[IW MC!M++6NN:;#`TTA16TQAD;CR`7&`:`/0*RM:\2Z+X=6)M7U&"S$IPGFM@M]* MS8=.\9K/&TVOZ8\08%U73R"1W`._BN5^)]LRZUIU_P#8=2REN\:7EG;+=*"3 MRCQ'L>NEV]W;W5M'<031R0R*&1U8$,#W!J7<`0,C)Z5X0^8[CPO;:[IE M]:P_V5=%K*RCDX._Y&*(21G@X[$U!;Z;XL:^MDU>YU*VN#%;_8&2SDG8`'D; ME8*C#^+=U%`'OK2(@8LZ@*,G)Z"H[>\MKJW2X@GCDA<95U8$$>QKR73[![B^ MO+/4K'6I=?E^V)-(`XMS$RG9N;[I7&``.0:H>&/#O]H-I%FUE?QPP:+*'CD$ ML2BZ#=\XY].U`'MVY'KUHWK_>'IUKPJ.?5[O0K.TCM-66XL_#]U!<&2"1 M?W_&`"1\Q]QFG7_AV^M4OWM8M4WPZ;93P8>0_P"D%AO/NV.HH`]BUG7]*\/6 MJ7.K7L5I"[;%>0X!;TJO8^+=`U-+9K+5;:<7,C10['SN91DCZ@S6\/DH MO[G:H`7[HX]>:`/7RR@`E@`>^:0NH."P'XUX+J,.M3^'-,L+BUU-4CANQ%,D M$LLAD$F(TP/NG;R&;C%.N=&U/4?#NNWUS!J;W\<%B+9AY@8$E!(5`[XSF@#W MG".AHTE-0T>YTC5#)JM MWI*7TWRKI\L>P-$`-L9+.5+#J1US0![# M*T(K>XC-A_;]GKDR'3K4:<+-9"RS`_O`2.%;./O8XH`]FEFBAC>21U544LQ) MZ`=34=G?VNH6<-W:3I+;SKNC=3PP]17B>LIK$_C1KE;;4H95OFB>-;>5D,#1 ML`6DY4@G'`Z52FL-7L[#0)8K;4);E+"!8[)[>8*7#@$X=L#`_B]J`/=2P!`)`)Z M4M>.S)S":3>06MQN!,D\) ME7;W&,CVK*L[#Q?'>0O=Z[ITUN&!DC2P*LR]P#O.*`.C)`ZD"EK@_&+:M=ZR MEM:ZM'86]NBS)OL9)=TO8[E../ZUM^%FUZXM%O-7OK:>.:,%(H[1H61N^F[?UQWQ7GOC#P]X@U'QGXFN]+"K`ME;AXY+0.;A=IW"-F&`P&>G>@#V&*> M*>))8I%>-U#*RG((/>G[ER!N&3T&:\BOI9-*GTZ>RM=6?3I?#3V=NJV\C,)@ MV0'4#Y6QW.*Q(;76K76M*G6#4;JZ9+7%O-#,I4;0&,@#W@," M2`02.M5;S4[+3UA:[N8XA/,L$98_>D;@*//:J>E:7JC?V5(LFHSQKJ=B;B&33Y8ECD#'X6>JV-_8M>VMU');*6#2@_*"IPW/M@UFV_C7PW=6US`?<&L3P/%_9_P^NAJ5I-Y:S73R0-$2SH78X"]3D?G7".O]NR+KJZ= M=PSVLUOC34L)4%O9QOTR5`D;H2%S[4`>MR>+=!BTB/57U2W%E(VQ)=W!;N/K M[4L_BO0;::TBFU6V5[Q0\`+CYU/`/T->80VEW:W\7B2;3[PZ1)K-Y<)$+5BZ MQR1A4GA<20 M/;EG8\\AMW';M0!ITSS8_,\O>N_KMSS^58)LO%7V!D&M:?\`:_-W"7[$=H3' MW=N_KGOFN:2RUO[5)$;J#^TR?DQ8N&1]P_>&3=@IC/R_A0!Z-1TK!6S\3".S M#:O8ET.O#&HZFNG6NM6DMVS%%B#\EAU'UKH-P)(!&1UKQWPE\/]4U"PL;Z^OT M@MK>\EN(K(V024.)'V[I#\Q!Z].AK$M].\6-%J#6UUJ2:RL-P+F$64@#Y;C, MK-M8XY7:/7I0![[O7&=PQZYJM?ZE9:78R7M]*6.C7UVF MEPB?4Y].FUBW$T?V.:V5%\M]_P!YBV"<`G@9KN_'NDR1Z;HDUMILNH:=I=XL MUS8Q#>TD04@$*?O%3@X[T`=-HWB31O$$3RZ5J-O=K&I'%;?BS29+#5+NT%GJC MVPL`FB"S$CJEQN).2.AR0:5?6VI/ MJ,VL6ER9(H9&C\O:F\AP-H&X'(S4&DB>ZUF8V$>IOK*^(Y=LV)#`ML&^<%ON M`8SQUS0![G1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110!3DTNSEU6'5'@4WL,311R]U1CDC]*N444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110!''!%"7,<:J9&W.0/O'U-2444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`53T_2[+2HYH[* M!85FF:>0#^)VZG\:N44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444` M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4 M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11 M10`4444`-?<(VV8W8XSZUPFLZ[XITRQM&O/LUJSW&)988?-"IO4*&7<2`03D MCTQ[UWCLJ(SL<*HR2>PKE[T:!XM2&03RL8&5EEB#+E2PRN>X)`H`9>^);^SO M)&\JVDLDTJ2]1HV),KJ`>/1?UJDOB#61K%IHCW,!N+M$F%TL'$:E22H7.#R. M">U=2=)TTLC>2F(K8NT8`5LY``. M,4`5[3Q#+)X:L=0N%VS2W`MW\H<%@Y0D9['&?QJO;>.89'MC<6$UO#<(LB2L MZD*A)&6QTY'ZUK6MAI-YHUI!;*KV,3!H=K'&Y2>_?G-12^%M%FM/LDEN&A,' MV7:7/W`=V.O7-`&5!\0+2XG"+93[0XC;!!<,1N`V]2,%>?>H9?';C[%.+-$M M6>7[3F4,Z*L1<<#H>.A]*WCXH&!GVJ'_`(13 M1CF62-Y&9MS223$EOE*8)SR-I(Q0!0@\;I>;;>VL'>^D)\N+S!M*[-V[=TX' M;UK4TW6';PE%K&H`*RVQGF"#I@$G`_"F#PMI(18P)A(K;DD$[>8OR[-&:2%E99))2Q7 M`(`R3T`)XJTMOI^D:&T.1%801,&)8D*G.>:`.:NM=UO^R-)OHI;17N;:-Q`( MR[W$S8RH&?E4#)SS5K4]6U=;"[O[1XHX+9V&SR3([[0!Z\+NW9/H!3K&S\/: ME=6[V-S.LUI;+%$$E="(NW!ZCWK3N-"TZXMH8FWK'&&12DI7<&^\"0>0<4`4 M8==O&U^*"5+9=/?36NU=&+,S!D!]@OS'ZUEOXFU5%GO6:!;>TFMXY(#'S()2 MHSNSQ@./R-=/)H^GR2JS1`,EL;8!6(Q$2"1CZJ*K7NCZ.\S7]RH"Q@22#S"$ M.SH67H<4`9?A;Q!J&IW[17ICV20>?'B/9CYB,*<_.N,O%:FE:1I=B%N[+)4QA8V:0L$0\A5R>![42>'=)DDG+PY:X M$@D^<_,'QN[^PH`BU3Q&FFW%E%]F9UNAN$C.$51QQD\9YZ5DV/C6X:U=[K3B MSQ&628Q2#:D*RM&IYZGY3Q[5IW<>A:O=C3)K@M)`-C0+*RJ0,$J>QQQQ45KX M>\/:A$TMH3+"))$;RIFVGY\LAP>1NR<>N:`*U]XOE_L>[U"TM&2VC#&*ZDPR MMM8*V5'([X]<5KVNO0W&@RZPT3):HK2*<@ET'?';..E,/A?2CYP,#^7+G,?F M-L7)!.T9P,D#.*MP:196]I<6D6:1UB"QJ5`W.^T&=,M M98I4BD:6*19$=Y&8@JI4#)/0`D8J>ZT6QO;Q+N>(M,A0AMQ'W6W+^M`'.WOC M2XDL)_[.L&^U0?Z_>P*PXDV'O\W0]*E3QY:R-/Y=I))'&)"'5AEA&<.2.W0D M9ZXK1F\):1.3F&1=S,S[)67?E]Y#8/(WTJ_75-,@ODC:..==Z!B,[3T/'J,&L.[\6FTO9[6.SFN9$EE7&Y5" MB-$<\_1^*V;'2TTZ0+;2,EJL>Q+?.54[B>2 MZJK?F%%`&7)XLDN+.[FL;*0PQ1,1`5SG';/K4:^-[>'2X;JYMY,L M)`Y3'+(@8X'N3@5ICPOI2LV(7"LA0H)&VG*[,XSUV\9J,^$-&+'=;NRE77RV MD8J`R[6P,XR0!0!DMXOO+*YO?[2LWB$!=EAC*L2JQ;SELU:_X3!C*]J-+F-\ MISY'F+]S9OW;NG3MZU=_X1'2"DBR12RF0,':29F8[EV'DG^[Q4&K^%([XM)9 MRI;3OP\C!F)&W;P0PQQ^!H`LS^(5B\-6^LI:2.+A8V2#(#9?&`3T[UF/XXA% MU/:O:R(T3-$[*X8K*J[B,>G;/K6W#HEHFB6FE2!I(+9(U4DX)V8P>/I44GAK M3);N:X:%]TS%W02$*6*[2V.F<=Z`,D^-O+CW_P!FW$D0D\GS`RY9_+\S[OIC M/XTRY^(-C%&`#(`,E?4Y.,>QK#]%BMX8(;9HDB5D'ER,"58Y92<\@GM0!E:AXWE%K=FPLAYT31B,3R M!2P9U4G;UQAN#3V\=,@9VTB<1*'?EY4=/2GMX8TIH#"T#%#&\9RYR59MS=_7F@#(?Q_9AKDI:2R1QF M0(489/:@"/5]:. MF3P6\5H]S/*DDNU6"@(@&XDGZCBLS3/$LUYS`)I=I$CQ``%F!0.2>^>> ME;6I:-9ZJ8VN5??&&"O&Y1@&&&&1V/I1;Z-86T5Q%%;JL=PH61.Q`4*!CZ"@ M#F7\87\5U*T^GR)$3"8(4*L[AD=^3G'1:L3>.;1;G,,,TL/E_NRNW$KDH`H] M#EP/2M.W\*Z5;2+(LV%0X50YXW ML&)'/7(!![8H`Q3XXFL9KJ#4++%PDS[85<#;&JJ3ST8\\5;?QS;1-)))93K9 MHQ03Y'S,(Q)]WKT./K5X^$=)8-E)S(S,SRF=M[;@`P+9S@@#BIW\-:5(K*]J M&5I#(5+'!)0(?_'0!0!A-XQO;2\NUO=-,:*81$OF#"AD9B6?IVQ]:Z^"43P1 MRKC#J&&"#U]Q6.OA33%CF0&Z_?;1(QN'+,`"H!.>F#C%:MI9PV4*PP!EB50J MIG(4`8`'I0!/1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`17 M2-)9S(@RS1L`/4D5R=OX?U&U\$6]E&UP;[,&^-I\A-LBEL'.!P#78T4`>>IH M>L1O+&ME/)9"YCEE221%FG4,V5!#88<@\[2<8I-5T77II;7[)8SQ)$D7E!;A M&,9$F6#,QX^7T!STS7H=%`'&SV5SI?@*,2XAO;.1IHDW_>;S&94R.NX''XUF M7'AS7GFM)09G,L(D._.,YZ5Z'10!YH^C7VD65C+=J4MA'"+R-K@#SG# M'(R3C/0\D`XQFMC2[2ZOOAO>V\,$@EN5N?(BD?)VL[;!N)QC&.^*[(J&&&`( M/8TH&!@=*`.#U32M;UB.WEM;2:QDM+,P_O73=,S%\0S7]XRB8L[2,DB2 M*%,9C(";B=W4CC`Z9S3I?">HQPR"WM6WM(0/WX_U9MF4CD]W(_G7H=%`'FY\ M.ZT+>W%M9SVUE'Y2S61='9V"$%@-V"-V.XSUK=\,Z'>V=]]IU)7=TM8XXWDE M#%3ELCCC(!`S_.NKHH`YFXL+V[\2VLPL###`\@DD,BF*2-AC(`Y#GOQ^)JUX M^G>-8]N%1G)4]>F/QK GRAPHIC 20 g640093g86m48.jpg GRAPHIC begin 644 g640093g86m48.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````'@``_^X`#D%D M;V)E`&3``````?_;`(0`$`L+"PP+$`P,$!'B,E)R4C'B\O,S,O+T!`0$!`0$!`0$!`0$!`0`$1#P\1$Q$5$A(5 M%!$4$10:%!86%!HF&AH<&AHF,",>'AX>(S`K+B65[/-M(+YUN MR@&S#`X5XZU"X>J\T_FC_HV_&06J*J]5YI_-'_1M^,GJO-/YH_Z-OQD%JBJO M5>:?S1_T;?C*Q@8^.%DT`.D(`+B.&@0=$1$!$1`1$0$1$!$1`1$0$1$ M!$1`1$0$1$!$1`1$0$1$!$1`1$0$1.A0=$55ZKS M3^:/^C;\9/5>:?S1_P!&WXR"U157JO-/YH_Z-OQD]5YI_-'_`$;?C(+5%!L[ M*]@E+Y[UURS#39E@:*\=:E34&41$!$1`1$0$1$!$1`1$0$1$!$1`1$0%AQH" M>(565J_F.[10>>&=9]=S/ZE8M%NP`;1SL=7$!U-&'@/$NK+G>N60,;!;QBA) M?*'T[7)?V4'3_5G'8]R7WURN[G>FTMI;E_4G,B:7.:!)4@<6E8.]D8&(Y?=TU5P MLXP/#[*C9AO'URQGMH["Z#Y6%H):R@KQ\M!.V^\IMNL,9:NY&-L8QXCHKA'9 M7.TOL_N@&@6T4V$.?!()&2-KV'`5'95?'O;F$3(K=N5/,CJ1Q5?SG4%-&'LA M7K;?,+AUK/<[**2(A[@P.+FU'+CQ5I1!"L+W>&^A=,QMJT-D?'0X]<;BPG\B MD_ZE_P"T_P`Q8W;]`D^\W'\5RMD%+<3[R01[0BT(Q-;3E_"(;^=)Y-ZXPTPQ M6DQ+@'#$YN%O"[E*?F?HO^)'TVJ6@JC^)>#JE>#Y11W3;U-N(X#U+%(U[P:2 MTY!:#P_I*]427VG;>:GZ4*"#3>SCL>Y+[ZW;^)ZQM**V1!2P3[QS[3" M+0"-[HS7'I+>%;N_%%.1U.O9VGYE*R[_`*K[Q)^934%*]V];&.>38T:"=4O! M[JU@DWJFACF;U("1K7@$2UHX5XU<7'R$GB.[RYY?Z!;>:CZ(00O]2_\`:?YB MY3S;R6\+I7BT(;K`Q\)HKI1,T]!E_5Z000G?BJO)-E3LB2JQ_JSCL>Y+[ZN4 M04;YMZ(Y(F/ZD=LXL&'::"&N?P^*MKB3>J./%#%:3/J!AQ.;H.LU=Q*?=^D6 M7GG?P95+057^I:?])_F+G3>OCL>Y+[ZN404W^K..Q[DOOK9OXGIR^IU[&T_. MK=$%+%/O)+)*P"T&R=A//TF@=^=='?B>G)ZG7L[3\R"6YAO)G,Y+[ZN40 M>>O;[>6Q8R286CV/>(Z1B3%4ZM96)LSWD@ADFDMHFQQ-+WN+7:&M%2=#N)3- MX?D+;[PS\ZEYI%)-EEY#$,4DD$K&-XW.80`@J69CO+)&V2.VCY+[ZCW-YO=;AX;:07+FT+-EB`=76*O=HHM MAO8PF@R^[KJYK./#X?&LP;U-N97PP9==ODC:USVAK-#7\T\_A02SO.)AM&H(,HB("(B`B(@(B("(B`B(@(B("(B`B(@+5_,=VBMEJ_FN[10>>=W@JS>'/K?UR6-@GDZK&^"1S(R6XRYKM!"Z[IYWE=A8RQ74XC>Z4N`()T4 M`X%#=FUAUJ]?M>3+<2/8:'2UP;0_D0<7;P0F/#U2ZYQ-=D?"8?S*3;9C++;2 M73+&Y,#`0Z0L#0*>,X<:.SC+S%A$VG$3J/A,/YE8,SC+),@N;=MRP3.:X-C< M<+G$ZJ`ZT%4P3,N(8YX],C] M-OOH.69^B_XD?3:I:H,RN;EUK;7KY=E!/<0AD.@#9N=B!>X\)H#V%<];M?GH M_+;[Z#LHB65"MKX?O(;Q[([B%V%^D-:\$8FO;4\(*[];M?GH M_+;[Z#AEW_5?>)/S*:J[+[JV'6:S1BMQ(1RAV.RI?6[7YZ/RV^^@VN/D)?$= MWESR_P!`MO-1]$*NS&[NI[.^GM91%;VL;P'@!QE>UM3KT!H6F5W=S%EEK>RR MB6U:'M<-8'#5!>*)FGH,OZO2"Z];M?GH_+;[ZBYG=6ILI`)HR= M'PV^$.R@L$7'K=K\]'Y;??7.?,+6&%\FU8\M&AC7`EQX&C3PE!B[](LO/._@ MRJ4O.9M/F4-]E+)+@,?=3D%C&MI'HPT:3I.AYUJWANGPS/M;V1F-H#XI31@D M8=&D<#@=:":BX];M?GH_+;[Z=;M?GH_+;[Z#LBX];M?GH_+;[Z=;M?GH_+;[ MZ#R-UF-ZW>YU@)"+4W%N[!1M"2TV-\N71Q,89'/F8`QH+B>/0%V MN96Y+(U\<4TEG*'`P01NEV>_8>I2#P3\VDE,SH\N MOG!\DCA2!W")&T/E(XMZW+I&2/+',*;O#`)2#:W6)CZ.;LC4$2%Q![.E M2]VL[@&=O:^">,7C(88G/C(&-C3K)XUS;F%I;9A?LGDP.ZY(:4.K:DHS-LO% MW8O,O)BFB<\T.AK6/!/=*"WWW^0L/O(Z)7IAJ7C-ZW=DEHYT3"XLTDM!/.*LNJVOS,?DCWE!W:]AV?B?M%6B#CU6U^99Y(]Y M16VUOZTE;LF4V$9IA&O')V%+N;AEM"Z5X)`H`UNESG$T:T=DE<+6*Z-P^[N0 MV-SV-8V)I+BT-+G5P(.W5;7YF/R1[RW9%'&"(V-8#K#0!WENB#CU2TU M["/R&^\G5+3YB/R&^\NR(-'Q12-P/8US!J:X`C1V"M.J6GS$?D-]Y=D0[C3J=I\Q'Y#?>79$''JEI\Q'Y#?>06EJ""(8P M1I!#1[R[(@T='&\M<]HTO:^:``&K0`UQ;HK6FE<[?,'7&;OABD$EJ M(&R-#:'E.<[37W$%HB(@*)F/R4/GX?XC5+43,?DHO/P_Q&H):(L.<&M+CJ`J M?<01;WY:S\]^PY2E6VQZ\^&[FGPZ=I!:L+:`$&A?PEU#7L*R05,US;64KI+: M9SOWE)[;E/:<3N46:#A<*UT:%)S&2.*2T?(X,8)=+CJYCEMEH&QD\]+TREZ` M9[,'2-K^PY!RRR*UFMWRX&2!TTY#\(-1M7\*E]5M?F8_)'O+CEGR$E/GY_XK MU,05.?V]NS*;AS8F-<,%"&@'GM5J-2KMX?8]Q^ITVJQ&I!E$1`1$0$1$!$1` M1$0$1$!$1`1$0$1$!:OYKNT5LM7\QW:*"AW;8Z?*(!#>/!C&%[&AO(-2::6J MTZG<_;).XSXJK-TUKV$DX6!FFF,EK M:Z%VRJQN[1\KIYS*QX:&-+B^A%:FI`UU5BYK7-+7`%I%"#I!!4&UB;;7\MO" M7"`0QO;&7$M:2Z0'"#JU:@@GHL&M#37P5XUSMQ<"%HN2UTU.68P0RO8#JE!U M1$0$1L.+G,ZMA&%H! MQXZZ:FM*+J@(B("+"YVXN1%2Y!!U1$0$1\Z1J/.4Q&.A+7/<\8XR7);M@OFFK70`\8C(_:01\NS"U:9;=SBUXN9F8BTAA> M9'.PA^JM"K55UKE6SM;JWN'B7K>@C;R311Y5*Q[@UTI8V,<+CC:="M!J7G=XVWHMV[62,MH:AK2#3$SC<5 MZ(:D&41$!$1`1$0$1$!$1`1$0$1$!$1`1$0%J_FN[16RU?S7=HH*O=>**/)+ M5S&-:9&XGD``N-3I/&K946[UZV/)K1FQF=1A%6QN(/*.HJR]8-^SW'T3D$M0 MV>UI?N\?3E6?6#?L]Q]$Y:6SW39A+/LI(X]C&P&1I95P=(32O;03D1$!$1`1 M$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$%5O)% M&_*9G/8'.C+',)`):<;=(XE:#4J[>'V/LK7^\^C?\ M5/65K_>?1O\`BH):*$SS2QOG/9:R[1S`"X4<*`ZN<`@EHB("(B`B(@(B("(B`B(@(B M(*W>'V/HH)%C!5K3SL-`K;/\MAS-]K;3.@OWS0VDDEI"V>X: M*QQ&@Q&J\OUS,PUMSU:EZ

TV_Z/5V:.=Q& M1K0.ZM+W/\DN[>.VL_W4IGB.'9E@-'>%AH5Z:R=++:Q27,38IW-!DC%#A/$H M.\+6BRCH!\O#P?I(+4:EE8&I90<+NV%U;NA)PDT+7#X+FG$T]T+E:W$QF=:W M$0CF8P/VC""QX)+:CX0]U3%#'M5WW<=,H):RL+*`B(@(BP@RB(@(B("+"R@( MB(*W>'V/QQ+6N!26SF-#72-Q/(^$:D5*MD!$1!@UH::^"JYV_6-BWK M.`3TY>SK@KV,6E=%E`1$0%QN.LX6]6P%^)N/:5I@KRJ8>&FI=EA!E%A90%A9 M6$',=9ZP[%@ZMA&$BNTQUTUX*+@[VM']W?TXU+5?<7$<&:Q%X<0;>0#"TN^' M'X(06"RH%QF3!!(86R;7"<'[IW.IHUM7!L[L(Q7=U6FG]RS7]"@DWGIEIVI> M@J?) M1$U9W<-[F,HC<86AT@'):XX03V2`5X-K(#E+VB0X/6,IQAQ/*P M,X2PXM/8TH)C&Y?!+8FXQ`RX8YX8-M%^])T/UC&W@(X-:FYSEMQ%9QNEG,PB MGB9;-JX!K"_2YYKRGTX5PM9+AMSEK;&-DDPB'[QTKG8[4.H_%C8WE`ZJ:1VE M<;Q>@Q_>(>D@DC+HZ?+3?2%9]71_/3?2%2AJ"R@B>KH_GIOI"N5O`V#-'@/> M^L#>>XN^&[C4]0;>:*XS%\L!QQ-A##(`<.+&30.U'W$$H]9ZR*!G5L&DZ=IC MKW*475$0$1$&%RM^LX'=:#`_$[#LZTP5Y%<7#36NJ(,HB("Y7'6-B[JN`S_` MVE<&OAPZ=2ZK"!VUE864!$6$%'O2'FV9@I33BJ"=%6:J<*O!J57O)#%)E4KW MM#G1%CHR=;3C:-"M!J00LYBDGRNYBB:7R/91K0*DFO$H[HIK:];1KG8K=\;9 M8HCA:]SP6U#-`5JLH/./L[B2VBAL[=]M=Q1/;<2D8,9+,);M/AESM-5M=6C[ MC38VKK>,,8R1CH\(>[:,:.#--&::]A3LMBV-C#'5Q+6Z<0+36NK"[2!Q=A25E`1$0$1$!$1`1$0$1$! M$1`6K^:[M%;+5_-=VB@K=VO8=GXG[15HJO=KV'9^)^T5:("(B`B(@(B("(B` MB(@(B("AN]K1_=W].-3%"NHKIERR\MVMEP1NC="3A%!-6%SM MYX[B%DT=<+Q45%".`@CC!75!J_F.[159N\"WUG:7$]]+'LW![(!%$PQECB,-6M%-5"I^\7H,?WB'I M*#EF:W=G%!EDUC<2W36%[G$LJYN.A>=/&=*G;Q>@Q>?AZ2"T&H+*P-064$:_ M@EN+5\,1`<^@.*H!;7E-T<8T+2VFG;<&TECC8&QA[-F32E2VE"!Q*6H@]JN^ M[CIE!+641`1$0$1$!$1`1$0$1$!$1!6[P^Q[C]3IM5B-2KMX?8]Q^ITVJQ&I M!E$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!:OYKNT5LM7\UW:*"MW:]AV?B?M%6 MBJ]VO8=GXG[15H@(B("(B`B(@(B("(B`B(@*KSC+[BZ+)H\QDR^.%KMI@YKJ MT.)W*&JBM%7WMK++=Q3")EQ'&QPVQQY0TZU,ZG/\`;9NY%]4FVS'[+'],?JTVV8_98_IC]6@P^SGP MG_G9M1X(OJEYVVS^PLLICMG7."8O:R0L:7/8T@8G"@I713MKT>VS'[+']-_\ M:URMH-A$7-`<<51KH<1X4$3([[)+M\OJP$RM:-J]S7![AP8G/TE6Z``:A1$% M/G=_D=G+'ZR!$SFG92,8XO:VNG"]FD:553Y]8WV710"XVD[;EC6E[2QSV-?R M7&H'`O6D`ZQ50LW:!E\A:T%P='0:JG:-X4$T:EE1-MF/V6/Z8_5IMLQ^RQ_3 M'ZM!+4,>U7?=QTRL[;,?LL?TQ^K6(([IUXZXGC;$W9B-K6OQDG$75YK4$Q$1 M`1$0$1$!$1`1$0$1$!$1!6[P^Q[C]3IM5B-2KMX?8]Q^ITVJQ&I!E$1`1$0$ M1$!$1`1$0$1$!$1`1$0$1$!:OYKNT5LM7\UW:*"KW8DC?DEJUC@XL;1X!!PF MIT%6R\_N@'"Q=B#141TP\(P_"[*]`@(B("+!K0TU\%5SMS.86&Y#6S4Y8826 MU[%4'5$1`1%QN#K!CG8FXL9(&"O*I3A0=D1$!$6$&47(&YZPX$,ZOA&$ M@G'CKIJ-5%U0$4>\G?;P8XVASR]C&AQH*R/:RIIVUSKFO@V_E/\`BH):@6RVNWRM:+BS:YSXVDT<`W&TBHK0JDL9 M-X[^WCN)61SM#Q*T;41MJTB1HPB$G1XR#U2*IZ[G<%U!J" MY==SR5SW6UG`^$/L15+;K>,M!ZE;:1\^[ZM:3YAGMO&Z6:UM6,:*DFX(T#_#07*+S M-KO'GETX,BRMN(@NH9::/)[*[MSW-(K^TM+^P;`V\>6,>),?-UZ*=E!?HN1- MQU@`!G5L&EU3CQUU4U4HNJ`B(@(L+E;FY+'=9:QK\3L(821@KR:UX::T'9$1 M`1%RN#<"%QM@UTWP`\D-U\)'80=46!V5E`1%A!6;QR1LRF9KG!KGX`P$@%QQ MMT#C5F-2HMZ@XVT>$--*DXN`59S>RKT:D&41$!$1`1$0$1$!$1`1$0$1$!$1 M`1$0%J_FN[16RU?S7=HH*K=>&*/);9[&AKI&XGGC-2%;JKW:]AV?B?M%6B`B M(@PBRB`B(@+"RB`B(@(B(,+*(@B9EZ.SS\'\5BTS7-K;*;<7-R'.878>0`3J M+N$CB4/-,VC:##U:X.RFC[Q9/=,KK=L]PR"5D;6.C>=(PM'% MQH+FZMQX]6+%VO<7#\2Y%]M MC[I]Y/Q+D7VV/NGWD$ZUMQ;0B(.+])<7.UDN-3J4#>?:>H;S9L,CL'-:*FF( M5/N!9_$F1?;8^Z?>4?,-Y%QJCSO>-V97$>#+[HVMLX/B.``N?IKCK71HT>ZMWYUEY((D.L_!/# M(7=Y89G-@(W-+W5)'P3QR?&"";NOFDEWF>R=:30#9N..04;\'0K#>#VUD/GY M.BU5F5[P97;W6TFE+6X2*X3K.'WEVOLWL9-!%`X-IK[2#UJ M(B`B(@PBRB`B(@(B(,+*(@(B(*K>2&.3*I7O:"Z,L+#Q$O:K0:E7;P^Q[C]3 MIM5B-2#*(B`B(@(B("(B`B(@(B("(B`B(@(B("U?S7=HK9:OYKNT4%;NU[#L M_$_:*M%5[M>P[/Q/VBK1`1$0$1$!$1`1$0$10)X([C,1'+4L;#B#0YS17%2O M)(03T4/U59>`[Z23XRJ4DFS\V@MX\IP/8<<&>3IK72NN[MC)#E4=Q`UKKAE67$ M)YLQ9R=9U.%-![J],JO=WV>[S\W3*";;26MU$)8FBFIS2T!S7#6UPX"%UV47 M@-[@4:YM96R];LZ".1HTFC&!H+GNX&M'"2J7-[1SK6*[NV-$^WBV4;0,,+7.U=EQX3 M[@5M;6LAEZW=D.N2*,8-+(6G6UG9XRHV\7H,?WB'I(+(114YC>X$V47@-[@6 MPU!904MM966731PSVZ%77%K/:MN&V<(D MM[EAK$S"PQR8<-6@T!:>%:Y+E]FQBBBN878FT:&AX(HYCBT<(/=4;+1,TZ6DC6$%NB(@(B("(B`B(@(B(*W>'V/:?WE*47-/9UUYI_>025E864$3+ODI//2 M],J6HF7?)2>>EZ94M!A5>[OL]WGYNF5:*CR>[%OEQ:UIEGDGF$4+><]W8_.>!01EMR)#F(>WUD10M_P"%@'_"_P#RU^YH M4NUM'1N-Q M@Q_>(>DI5U:.?(VYMG".Z8*`GFR-\"3L=Y5N;W;;G+V`M,`\*"\&H+*P-064$/,-=K]X9WG*8H>8:[7[PSO.4Q!A1,I]FVWFPI:B93[- MMO-A!+46/VG/YF+I2J6HD?M.?S,72E02T1$!$1`1$0$1$!$1!6[P^Q[C]3IM M5B-2JL^$DL'56OP1O:7R:*DX',('85J-0091$0$1$!$1`1$0$1$!$1`1$0$1 M$!$1`6'"K2.,46404HR[-X''J\\9&S9&PZ8_DQA!?BL>[,K5$%1LMY)'@ROMV,`(#87.;4\9+XWHZ'>% MI:Z&2$D'E-E>7M(H='(B8?RJW1!55WGXK'NS)7>?BL>[,K5$%57>?BL>[,J\ M;O9@^Z?>W#FON),6(-G>(J.-=$;HG:EZ5$%';V6?V9D%MU4Q2$.PRND<0:4- M"UK='N+;8[S=8ZQ_R.+!@I66E*XE=(@JJ[S\5CW9ERN(=Y;B"2!_4FLE:6N+ M3+BH=!I4%72(*GJ^=T^5;]+_`/`L-&]#6AIZDXC1B.UJ>X%;H@I8(=YH&N:W MJ)Q.<_29=;C5=:[S\5CW9E:K""I,>\DCP97VS&`'1"Y[23V2]CU%M^S1D\C([/%&UU&/TG$./0@PR/>&-SL+K M>1AI02O<2".RR-JWQ;P^!9^5+\5=;"YO9S(+JWV`;3`=/*KKT'B4U!43Q;P3 M&(EMH-E()!RI--`13F]E;R?B-S'-8+1CB*!X=(:'CH6JT1!27679O=0F&24M M8X@DQSECM!KSFP52UM]Y;2VBMH^I.9"T,:YQE+B!HTT&M7:(*JN\_%8]V961S=H^U9&*XA"7M<3P:7L?WD?!O` M`##+%C!!I(\N8172"&PM.KLJW1!55WGXK'NS)7>?BL>[,K5$%57>?BL>[,M6 MP[PN+G320@D\EL3RUH%/TXGG\JMT05`CWDC>3$^V>PCFS.>X@]@L8Q;5WGXK M'NS*U1!55WGXK'NS+!_%!!`ZB"=1_>Z%;(@HX\IS5[ZW%R"US2'ESC+SBVN` M8(L/-[*NQH%%E$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`15UU?9C%.Z." MSVL8I20N(K77H#'+>QN[Z>1S;FUV#`VH?B)J:ZJ%K4$Y81<[F26*"22&/:R- M!+(ZTQ'BJ@ZK"J3F6;_R\']=WU:M8W.=&USFX'$`N;KH3P(-D1$!$1`1$0$1 M$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1:3.>R)[XV[1[6DM96F(@ M:&U[*#=%4>LLW_EX\MWU:LK>266!DDL>RD<*NCK7">*J#JL(H5]=WT$K66UK MMV%M2_$10UYM`UR"\=G-;3V\<5R9Y(GAK&PO<=(PUY%>$J!DE]N_':/%Z8=L97FLD M>(EII33A.A6D6=;LP$NAF@B)%"YC,&CLD-"#>2QN(>KQV&**">C+IK301MIB MVC`>:XTPZ..JXR7UEDEU<"2&9D#FL?M(XGR,T"CG/>*BO'578((!&D'2%7[P M^P[[S+^\@B-WNRIQ<&B5Q8"7`-%0!K)&)=6[QVKFA[;>Y+7"H(BX#[JUOGV; M-WI+@%C6R6]&R"@Q%[=&GLE6&7^@6WFF=$((7XCL?FKCZ%_O+67/8YF;&TCG M%Q*0R-SH7!K2XTQ&H^#K5PB"EE=;91>L?LII=K%A=(QKI7O>'5Y;EC\6992N M":E:$A@T$:Z\I72\_D#[`VQBFC:97W$X#G1U!.T=08R*()+MYK%H!?%<-!T@ M[(FO:PDK;\1VGV>\_P#%E^*K*8`0O`%`&FG<6Z"J_$=I]GO/_%E^*@WBM#S; M>Z)X087-(\NBMEA!4_B.TQEG5[G&`'$;+@.@'7V%D[QV@-#;W5>(0/=T,2EM M]J2^8CZ?@ M_BL4M!4C>&U.D6]R1P'9$=\H-XK8BHMKKZ+^M6J(*K\1V?V>[/:MI#^4-*?B M.T^SWG_BR_%5LB"I_$=G]GNQQ5MY&_E?^++\56JR@J?Q':?9[S_Q9 M?BI^([0F@M[JO$8'MZ>%6RP@JOQ#;5IU:ZKK^2_K6';R6;!5\%TW_!<[H55L MB"F.]66@5,5T`-)/5Y?BH-ZLM(!$=T0=((MY=7DJUN?1I?$=WBM;+T.W\TSH MA!`&\5JX5;;W+AQ[(CI4*#>&V-?^6NM!I\E_6K9$%,[>C+V.#'Q7(>17#L'D MT&CX(*?BG+OFKK_QY?BJ<[VI'YB3IQJ6@IAO1EY-!%=5/_;R#]E;/WCM&,=( M^WN0QH+G$Q:@--=:MU$S3V9>>8EZ!00V[QVCFA[8+DL(J'"*H(/#H*T%S:9Q M>PQ]7GV<3)'%TL4D0!.$-+7FFGM*?E/LNS\Q%T`I2"I;8W-PRY;F%9HX"YEJ MPZGM`J)'@P%439KNUP2M<]CW-Y):T5)JTNT M*W!!`(T@Z05Y+,[S(1/;.LC!&&1W0>Z-H8`'0N#02`-97JH/D(_%;WD'1$1` M1$0$1$!$1`1$0$1$!$1`1$0$1$!<;OT2?S;^B5V7&[]$G\V_HE!PRAC?5-ER M1Z/%P?H-47>4Q-R:\CT"1T1QIA#WMTM:XTB^29XH[RV(#A0BH.L%>'?:,V9! M?-0LU;:6GR6+P^->CW8MXK?)8&1-PM)>2*DZ<;O")00\ZM+R+*9[1D;9+6.K MXY`0TL8*G"YIUTX"%:9T0JK>'-'LRF^=;P[2&)KHY)7.PC%S2&C6Z MAUJWL6X;*W;KI$P?V0@[HB("\AD^;VKY8\I%>LQWLCG:J4O'Y/ ME$#9HLU#W[:2]D#F_P`QVH@9'$3;RW$+63D@!Q;(UU6MUENC6KA` M1$0$1$!$1`1$0$1$!$1!RN?1I?$=WBM;+T.W\TSHA;7/HTOB.[Q6MEZ';^:9 MT0@[HBYSSQV\1EE-&CBTDDZ``.$E!P=[4C\Q)TXU+5$_-;@9S##U-VU=#)1F M-M<-6/KQ5T:J^ZKBWN([F(2Q5H:@@BCFN&@M<.`A!U43-/9EYYB7H%2U$S3V M9>>8EZ!0,I]EV?F(N@%*5+E>8S1V$)EB'5(F1QF5IY31LV'$]IX.5P+7?.&. M7()L8K@=&YM"10XVMX.P4%Q<^CR^([O*LR'JIRRSB+Q&]Y5N2.(X=(]PJRM_1XO$;WD M'5$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!<;OT6;S;^B5V7&[]$G\V_HE!1661 M3W64VS9,SNA%+!'6,%@:`6`X1R*T6!N9;MYM]R;'[O%T M&J8@\Y^#+?5UZYXNCL M\[%TP@XSY-!<928W-POET8W&N(N.BE2N+I;S^;7?^7]6K9$%3ZEO/YM=_Y?U:VM\BC@A;$+F8AD MAE!JTRK1$$1EB&S,F?-)*8ZX0\BE7"G`$?8-=,^:.62)TM"\,(`) M:*5TA2T01.HO^U3>4/BIU%_VJ;RA\52T00?5SVRF5EU*'N:&.)PNT-)(UM[* MR^PGD8Z-]Y*6O!:X`,&@Z#\%3401;BP@G;;M=5K;9[9(PW0*LU#M*4B("(B` MB(@(B("(B`B(@(B(-7L#V.8[4X$'M%1&6$\;&L9=R!K`&M%&:AH'P5-1!#ZG M<_;).XSXJ"P<98Y)KA\PB=C:QP:&XJ%H)H!JJIB((;LL@=F;,S)=MF,,;6UY M-#K-%EUBX2R20SOAVIQ/:T-(Q4#:\H'B4M$$/J=S]LD[C/BK67+Y9HGPR76'7<79_QW(=RLK-*SW9PG$/ MW[M!K6OY%Z%$'ELVW>BLLEOW17EV8Q$]^R=*7-+B"78JC35>DM_1XO$;WE"W MC]@YAYB3O*;;^CQ>(WO(.J(B`B(@(BY3W$%M&9;B1L48(&-Y#14Z`-*#JB(@ M(B("(B`B(@(B("(B`N-WZ)/YM_1*[+C=^BS>;?T2@XY1[)L?N\70:IBH-W;> M.YRZ-SI)J,:QK07N;0"-FH<2M/5T/SDOTCO?02E6,D9F$F.6<10LDI%;M+0Y MYC=SGUTZ2.:I/JZ'YR7Z1WOK09/8XVR%KG.:X/!+B>4#4%!.1<;JX;:VTMR\ M.YK15Q#16@"UL+R.^M(KN-KF,F&)K7C"X:::0@D(B("(H68YI#E[K<2 MQR/ZS((F;-N+"3PNX@@FHB("(L(,HH46:0RYG-EC8Y!+`P2.D+:1D.IH:[CT MKO7 M9G%F(G,48DZ*FV_H\7B-[R\WO9864.6NPL+Q&] MY!U1$0$6KWL8TO>X-8T5F+%?+;T8Z^J?KO7F>;RV.3MV;OW]X15ELPZ=.ISS\%O]`O`9CFM]FMTR M>]DQ87MV<3=$<=7#FMX^R=*ADN\XGO<27.)X7$Z25@@$4(J#K"S6S M3,QIV1J[.#]=3'2WJTODM68U_P`UUV?=]D1?&L+>),+>)7X\;)9>DY/DIYOL MJ+XUA;Q)A;Q)QXV2=)R?)3S?947QK"WB3"WB3CQLDZ3D^2GF^RHOC6%O$F%O M$G'C9)TG)\E/-]E1?&L+>);1@-EC(T$/90@GP@IC/$S$:3VHO^KR5K:TWI^- M9MX^#[&B(O9S1<;OT6;S;^B5V7&[]$G\V_HE!#R"!T.56[G/QNECC>33"!5C M0!K/$K)0\H]DV/W>+H-4Q`1$08191`1$0%A91`1$0$1$&%%O?E;3SPZ+E+4: M\@FE$;H"T21/Q@/!+3H(IR>V@DHH]I$'@*D(,.Y MI[2C99[/@\0*2[FGM*-EGL^#Q`@E(B("ILTRTMMWNAE++=LC)C`6XAB#AS#4 M803KUJY43-/0)>T.D$$H:@LK`U!90$1<;N26*VED@:'RL:7,8=1(&K0@Y3>T M+;Q)?V5+4"V;<7$L-X^6)\(8[!LFN%<=/"<>)3T!$1`6%E$!$1`6%E$&%E$0 M$1$%-O3;F3)KF5K\#H8I7:14$.8YA&L(WO*%O'[!S#S$G>4VW]' MB\1O>0=41$%1O'DDF$QVIP7UU1,QRRRS.W-O>1"1FMIU.8?"8X:053)CB^Z6KE.21>M_V^G_`)@SZ`_6I_M] M/_,&?0'ZU.#?<=3Y;;;VO)++/E&>.SI!>L_V^G_F#/H#]:MF?_S^8/:YV8-( M:X$@0D'0:_.J8PWB8GL[U,G['E[8[UB;:VI:(_';#VB(BU.&+C=^B3^;?T2N MRXW?HD_FW]$H..4>R;'[O%T&J8H>4>R;'[O%T&J8@(B("(B`B(@(B("(B`B( M@*'F=G->6XBAN'6K@X.VC=)('P=!:IBA9C&R4VT4@Q1OE`>PZG#"XZ4%=E%A M/BN7"]DE87M:V<`#&6"CN?CJ&G14*SZE-]LF_L?$4EK6L:&L`:T:`!H`"V00 MW64U#_SDVK]#XJSE8IEUN*UHP:2I3N:>THV6>SX/$""4B(@*)FGH$O:'2"EJ M)FGH$O:'2""4-065@:@LH"PLH@@"".WS&/8@QB9LCI&`G"YPP\K#JJIZB3>T M+;Q)?V5+0$1$!$1`1$0$1$!$1`1$05N\?L',/,2=Y3;?T>+Q&]Y0MX_8.8>8 MD[RFV_H\7B-[R#JB(@(B(,$`BAT@ZPO*9UN3%-*+K*2V"0O#I+=VB)VD$EE. M8>QJ[2]8BB8B>]:M[4G6LS76-.S9(B(I5$1$!$1`1$0$1$!$1`7&[]$G\V_H ME=EQN_1)_-OZ)0<+H-4Q0\H]DV/W>+H-4Q`1$0$1$!$1`1$0$1$! M$1`42]^5M//#HN4M1,PM67,+0Z=]KLW!XFC+6N%`1K>'#A02EE4^6VLLNV>; MVYFM\0$$CW!I<`.41@:VK:ZE-ZA_W$_TB"4[FGM*-EGL^#Q`M76-&D]8GU'_ M`(BJB14MSEK+2!UQ<9M>1Q,YSC(-%33@ M8JGKL6!K_65T;4WCK?K`><>$1,>!AP>&:T+;Q)?V5+428CUA;>)+^RI:`B(@(B("(B`B(@(B("(B"MWC M]@YAYB3O*;;^CQ>(WO*%O'[!S#S$G>4VW]'B\1O>0=46%@/8[0'`\&@H-D6* MBM*Z3P<*5%:5TC@X4&46`YKA5I!'81!E$1`1$0$1$!$1`1$0$1$!<;OT6;S; M^B5V7&[]%F\V_HE!7;L2NDRN,%[I&QM8UI<*$`1LY.H:`K=5F[\#X6YEKLX6E[Z"IHT5-`M+&]AO[2*\MZ M[*88F8AA--6D+N0"*'2$``%`*`<`091$0%"S#-;7+C;MN<5;J00QX6XN4>/B M"FK!:#K`--(J@RB(@+"RL((<6:6LN9398S%UF!@D?5M&X74I1WNIF#&2/M62 M-#FF85:141W MHMC!;`;;#&^=CL1T--2VCM6A5&WMSEC+@M8(NOO.SV7(KLF,I@VG'IKB7J79 M-EL$3R3)'$27O&T>&U<:N)%>$KS`%UZL+=DW:=?D`94X<&S9I'*%='907-EF M&9`6D%LVV,%RS%`7,?`QK6G2UM"ZKNQ[JYYW?7$]A&)(`QL<\;;DNJ&F3%A# M(]&D<9U*,8[8OR]UY,61XF;2*.1Q++@._=GE%W)X.3J[2NMXO08_O$/205%_ MN_?W-\RYALK>.(;/D;9[2,#L3J-8T,.(:-(5MU0_RFW\MOU:M1J"R@J>J'^4 MV_EM^K3JA_E-OY;?JU;(@IK=K(\W@BZI':O,4CJQD.Q-JT::,:KE1)O:%MXD MO[*EH"(B#"B9?FEKF(G-MB_Y>5T,F-N'EMUTXPI:!H&H`5TFB#*(B`HU_?09 M?9RWMQBV,(Q/PC$ZE::![JDK!`(H14'@*#G;SLN;>*XCKLYF-D944.%PQ"H7 M58``%!J64!$1!0[WRN9E4C`]S&2,E#\(KBI&YP!T'14*YM_1XO$;WE5[U0/D MR>XE8X-,,4KB'"H(0=%YZVM9[6QL9)8S5L['2-9$=H MUO+Y^&KCK7HD04,L3I-O^YD-]+,U]K.8W4:SDX#C(Y(:*U:>SQK46\FSC8V! MXS%LKG3SX#0LJ[%^\I1P_*VGGAT7():(B#5_,=VBJS=XTRIA`K3@_5"LW\QW: M*K-W?9W<$;I)LJN&QMYSBZ*G37FQMAE#GLDE#S?R/Q$MVE"QFA MQV@'<SC_>8N>@D MV4UW*+&XBR^>Y,0$3IIG1EKV8N4\!8NIPIRJ\OFOHIH[.XM8[>$L<8S'(7FK*:]`XU:(" M(B`B(@(B("(B`B(@(B(*W>/V#F'F).\IMOZ/%XC>\H6\?L',/,2=Y3;?T>+Q M&]Y!U1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`7&[]$G\V_HE=EQN_1)_-OZ)0< M+H-4Q0\H]DV/W>+H-4Q`1$0$1$!$1`1$0$1$!$1`42]^5M//#HN4 MM<;FV%PU@QNC=&[&U[*5!`I\(.'"@[(HG4YOMD_^5]4G4YOMD_\`E?5()+^8 M[M%4V43B#)6.P&1SB&,C&M[G!H#=*L#92D4-Y/I\U]4O.9CNU/%&R*/-[D5D M'5K9F%IQ'D:VT.ANLH+&VW7L1=ONKJVMBU[`UMNR/DL-:EV)QTGW`IWJ+)\& MSZG%LZUP81AKQTU+7*\FCRQSW,NKFXV@`(N9=H!3P=`5@@H[C=BR%XR[M+>V M`9&6&WDCY+G8@X.Q-YI&K45MF]P+C*XI,)8X7$37QG6QS7TXZJ\"=3F^V3_Y7U2VALV1"4E[Y7STVCWTJ:#"! MR0T:D%9E&;EUJ9)8"RVVSV&8.#@USG5Y8U@5=2JNU#M,JM;2SDLH\3H92XOQ M&I.,4.D`+864H``O)Z#5\E]4@3>T+;Q)?V5+46.RP3-F?/),Y@+6A^"@Q4KS M&-XE*0$1$!$1`1$0$1$!$1`1$05N\?L',/,2=Y3;?T>+Q&]Y0MX_8.8>8D[R MFV_H\7B-[R#JB(@(B("(B`B(@(B("(B`B(@(B("(B`N-WZ)/YM_1*[+C=^BS M>;?T2@XY1[)L?N\70:IBJ-V9W395$#)M!&UC&NH!0"-FC0!J5N@(B("+G<3Q M6T$EQ,[#%$TO>[B:T5)6EG=P7MM'=6SL<,HQ,=JJ-2#NB(@(BBWN96=@81=2 M;,W+Q%%H)Q//!H02D1$!$1`118\RLY+^7+F25NX6"22.AT--*&ONK&90VDUM MAO)#%$'`X@_9Z1J%>'M():*FRW*K5PEE=$XP/<-@)7.+\(%"[2=`<=2XYUEU MHU^7QQL,8FNFQR%CG-):6/J*@]A!?JGW=9$Z&XE+09Q=7#7/.E]!*Z@J=-*+ M+MVLL#2:SZOGY?CK&Z^R.4L=%0M80C+G24:+K$QMNZG*Q8VF@(TZE90VMO`XNAC:QSA0D#315N]# MXH\KVDC@T,EB<''13EMJ4$W_`-I_.:\;=,AN&Q MELC7$.CQ:"VFO%VU,4:._LIIQ!%,Q\V$O#6FIP@T)4E`1$0$14VW]'B\1O>5/O=.Z/*98P_9MFCE:XT!)I&YP;I!UD*XM_1XO M$;WD'5$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!<;OT6;S;^B5V7&[]$G\V_HE! M!W>@DBRN!TA:3+'&\!M:`&-H&OAT*T4/*/9-C]WBZ#5,0$1$&KFM>TL>`YKA M0M.D$%(XV1L$<;0QC=#6M%`!V`%LB`B(@+22&*7#M6-?@.)F(`X3QBJW1`1$ M0%A91!S$,0E,P8T2N%'2`#$0.`G6H]\`9+0$`C;#0?%K+K%O\ZSR@J#>_#+CJ%Z3)H88,M@9"_:-+&DO)#JD@5U() MR(B`H.:Q6,ML_KC8G$,?L]J&G33@Q*FW@FRS][&UY$D;07`$@.>T.H3J MJ@\\+?*\+/W<'#70WYQWYEQGMLN;AGCBA<^(&K*M`$+T_X1W=^PQ_ ME6?PAN[]AC_*@J6-E;9EDQM[>.(ON@'%C M`VHY.N@72SR#+\IW@CN+>$1Q3QO$1!-&R:,3/=:*CW5TWC]I9)]Z^*@O0Q@- M0T`\8"V1$!$1!A``-0HLH@(B("P0"*'2%E$&%E$0$1$%+O7!))D]Q+&6@PQ2 MEP=72'1N8:4X=*M;?T>+Q&]Y0MX_8.8>8D[RFV_H\7B-[R#JB(@(B("(B`B( M@(B("(B`B(@(B("(B`N-WZ)/YM_1*[+C=^BS>;?T2@XY1[)L?N\70:IBJBK+G,)W7 MMI;69C,=RQ\FU=5PHRE*83V5WP9I\Y#Y#OC()B*OFFS"U:V:8Q/@:X";"UP+ M6'07:^!=D[`7.TC@8*$M>QS`'-<-;7#C51O M6RULX+*X;$UHCNF.<6-`-`'&BL+:QS.W?+(;B.5\Q:7.K6NH_`?\=2MV]&51#^G-:@M41$!4C[>\SBVD MM;BY9"]CQMHV1$2,+78FT2*,60N`T"9LL0;(-#@"]M1B&E!O MZDN/YK>^5']4GJ2X_FM[Y4?U2M%E!33;O23LP29I>D`AS2'Q@APU$$1:%6Y? MN[=3W4%YBJKW-W13Y M<+7!)#>R87/-=#:M')IP\I2'W-Q-X%PQG4P4(T@:T$U%#P9I M\Y#Y#OC+E;R9I-M>7"-E(Z/FNTX::>=V4%BBAX,T^YD;&UY;O@-%=-25,:W-2T%S MX6N(!(PN-#Q-V!CW`NQD#E$4(T`Z$$]%#P9I\Y#Y#OC)@S3YR'R'?&0<=X_8.8>8D[RFV_ MH\7B-[RJ-X&YCZDOMI)$6;!^(!KJTIVU;V_H\7B-[R#JB(@(B("(B`B(@(B( M"(B`B(@(B("(B`N-WZ)/YM_1*[+C=Z;68?W;N\4''*/9-C]WBZ#5+4#))F29 M9;,;4/AABCD:X$$.#&\:L$%;)96L&96LT,362/V@);HT4KJU*Q46Y]-L^W)T M5+08(!%#I!UA5,N4Y<Z@J-(+:4TZ-9T*W423VE!YJ3OL026,9&T M,8T-8T4:T"@`[`7*]]#G\V_HE=UPO?0Y_-OZ)0;V_P`A'XC>\NBYV_R$?B-[ MRW0'-#@6N`+2*$'2""JEN4Y=ZSD&P;38L=33KQ/''JIP*W41OM23S#.G(@E` M!H#6B@&@`:@%E$05TMG:W.;.=/&)#'`S#7B+Y*CL@T"L``!0:`%%;[4E\Q'T MY5+0$1$&K^8[M%5N[GLN/^G`%9/YCNT56[N>RX_Z<`06B(B`JK>3V9_BP_Q& MJU55O)[,_P`6'^(U!:!96`LH"B9C\A'Y^#^*Q2U$S'Y"/S\'\5B"6L+*(*V[ MRO+WSPO=`W$^0XB*CX#G5T'0:@%3H88H(Q'"P,8W4T+2X^4MO.'H/7=`4/+] M=U]X?WFJ8H>7Z[K[P_O-02USGMH+EF"=@>T&HKP'C!UA=405>49?911"6.%K M9&O>&NUTHXM%*]A6:B99Z+_B2=-RF(*^_M;>ZO[-EPP2-:V9S0:BCN0*Z.P5 M.8QC&AC&AK6B@:!0`=@*--[1M?-S?_K4M`1$05N\?L',/,2=Y3;?T>+Q&]Y5 M&\.8V;\MO+&.3:74D,H9&P%Q):WE:0*:.%6]OZ/%XC>\@7-S!:6[[FX>(X8A MB>\Z@%0R;\Y-@?);"2X;'SGAN!NC]*3#7W%<9K;"[RRZMCIVL+VT[):5\?AN MX#9#+7B2-Q?A<8_A$GA:30H/HN[>^46?WTUHVW-N(V;1A<_$74-#HH*:U>#, M;$R/BV[,<9H^IH`:AM*ZM97S7=E@RC>NSC#ZMN0Z)P<"UPQC1B'9<`O9RVEB MZZNCUYC'`XY(@SD!^-K@Z1N+"XBE-%$%\)8B2`]I+=#@"-';6#/"`29&@--" M<0T'B*\PW+LGA=)$[,2)'RXG'E8L(Q;2,U<1AF,\(J#(T$$-/*&AQU#MH9X0Q[S(W#$"9#44:`* MG%Q+R++2T$,LPEEPM&-[#$'!H=6-SA60\H:Z@Z.)7$5E89=%+$^X:.MPEM)& M@X@W$YSW-^%H?I06<%Y;7+"^&0/:-!.KOK/6[7'@VS,5"ZF(SV+LSC&C!714->YKVAKL=:5; MQH/3FX@%*RL%0"*N&HZELU['DAC@XM-'`&M#Q%><.391&(XI;IA=*Q^R<148 M<&"H!A@G9-;.;R7-C#7/'P7.?B.(]GA06*(B`B(@+G<`F"4`5)8Z@]Q= M$0>?M,XM[,3&9DF%HCQ.HUI%(V@\E[FNT=@*;^),C^VQ_E]Y6)8PFI:">,A- MG'X([@04MQO!DSKNU>V[86L+\1TZ*MT<"D_B3(_ML?Y?>5CLX_!'<";./P1W M`@K1O%ETCRVV<;@-`+G,+`T5K0?O',XN!1I<^L69C`^X)@C,7&[WBR1]K,QMY&7.C<`!722#V%; M[./P1W`FSC\$=P(*N'>+)&PQM-Y&"&@$:>+M+G'O&R67(W-!-VQM17":U'8.A6.SC\!O<"SLX_!'<""N_$F1_;8_P`OO)^) M,C^VQ_E]Y6.SC\$=P)LX_!'<""K=O%E%8V;/!'<"R@K3O'D8)!O(P1H.OWE`S7-;?,;)T5D#*!*PB3%&QIP.# MG4QO:?R+T&S9X([@6-G'X([@05[-X,LQ.9/*+9S0"!*YG*!XBQS@M_7V2_;8 M?+"F[./P1W`L[./P1W`@@^OLE^VP^6%%S'/1D-DJ[7H&!XXNRNWXDR M/[;'^7WE8[./P1W`FSC\$=P(*P[R927-9!,+B1U:,CIH`X27EH_*N$&=6UJ) MGW#',C?,7X\4;@UKJ`$ALA/Y%=;./P1W`L;./P1W`@K_`,29']MC_+[R?B3( M_ML?Y?>5CLX_!'<";./P1W`@I:&NHN)'`I#=X6EIJ6: M*QN?Q*5^),C^VQ_E]Y6&SC\$=P+.SC\$=P(*[\29']MC_+[RX7N\N5=6>+>] MCVKJ-!%33$:%U*<`5QLX_!'<";./P1W`@\I-=6\[K;J\4@CB@N(HB,+MIM(C MRL,;G.!);PCA7J801#&#H(:*CW%L&,!J&@'C`6R#"\/#_P#SDC,)+N6[:(W/ M<^.-K,6$.-17%H/<7N40>EQ<7@T-2*+O#E>7PL8QMO&=F2 M6N5.-71$^[HX]5**U1!6R;OY7(_:&*C\1= M4'A--7%I:#H4Z"%EO"R&.N",86UTF@71$!$1`1$0$1$!$1`1$0$1$!$1`1$0 M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0 M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0 M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0 M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0 M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0 #?__9 ` end GRAPHIC 21 g640093g97m74.jpg GRAPHIC begin 644 g640093g97m74.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````'@``_^X`#D%D M;V)E`&3``````?_;`(0`$`L+"PP+$`P,$!'B,E)R4C'B\O,S,O+T!`0$!`0$!`0$!`0$!`0`$1#P\1$Q$5$A(5 M%!$4$10:%!86%!HF&AH<&AHF,",>'AX>(S`K+B@[117*#M%5\;-QPW'NJQ0%%%%`444 M4!1110%%%!Q)%(+HXZ$4$M%1S31P1/-*VV.,%G;V`=3I5>/EN.EEB MA2=3)D)W(5L?.GM6XUH+E%Q]AH/5%>7=8U+.;*.IJB.=X M@B`_5);*)&.38KW%07\R'\2GHP^%6Z#M%%%`4444!1110%%%%`4444!1110%%%%`444 M4!1110%%%%`4444!1110%%%%`4444!1110%%%%`4444!1110%%%%!RBJ.;DQ M23GB1))#DY,+NDT8^0#RWOX&J'E]+\>TLCSYR/*O<8D'MAM"UCX4#QHT>Q90 MQ4W6XO8^T4IBCR^)ES%A3/'GCR($GB.Z.50R'I< M'4=:]R1I(C1R*'1P0RD7!!Z@T'F">'(B6:!Q)&XNK*;@BJN7RN+C9F-@ON;( MRB0BIJ5'YF]@JKFKF\1!".&PXY,2,L9\=;A_-K=/MZU8XZ&6>*#-Y''C3D=I M!95\R*Q-EN;GIUH.\5Q&+Q<2++, M9+2Q#^5T_%TOK0><#.S5RLC%Y0QHZE&@D0%8V60?*"YU8,*F/*XXY$<<$E:> MURPC;MK<;M7Z4N7#Q,*/&;U%+%E9*2;,/(=6W`$[@&)OK?QIQD9>/C!#,^WN MNLG<>6!#EQWB4+VH]Y9@JG=M,H(+Q-U"N-*;Y_(8W&X M_>G-@2$1!:[,>BB]A06657!5@&4Z$'4$4E3TX(L^":'(=<*!VF3#(!"2,"/( M_54U^6JQYOU/+^OC\4!B]0KM^H1]A'[J9<-SN+R\1,=XIX_YL#?,OO\`>*#U MR69*I7!PR/K9P=K'Y84'S2O\/#VTCPY<3%Y(O@7F[8:.5A)<3,+--D3'4!4\ M/;X4XY+AAE3/E0R/'*T9CEC0A1.HU5&8@D?96;GP2\ML<=O,+;&A`8193(5+ M1*EU"Q1VL6/6@V<&1!DQK)$P=6`;WV8;A<>%Q2/F?3_=WSXX:7N$&;&W6,JK MI'"C7`CC!\S6I1A5LQ6*SJS/DQ.1_J)B/U9)'&BPQ*OEMUK3\=SN!R4K MPXY<2(-ZB1"GG'/<;/.JSX,*2RET^JB8A&GB0W M6,R'HH.I'C27^K3PY$\'+7R^/F![\3)M,071GB30]I6\H)U/44&EXKF,+EL? MO8K:KI)&VCH?8P_MJ]6)B]/[J*!E7&4,"K"X.A!Z$44HYSELC$?&Q./" MS/-P3*,&)MSPP&\L&XW9H;^'N\*U<'( M8,F+%D)D(89+*DC,!=C^$_Q>ZIXRS(K.NQB`2M[V-M1<>RLQZ@]*":)IN,!4 M%A)/A*=J2D:;D!T5[4&IKM*>/YKC/Z6)S*88\4+#.L]^Y$XLFV3WW\::*RL` MRD,I%P1J"#0>J***`HHKFM!VBN5V@****`KE=HH.`DBY%C[*[110%%%%`444 M4!1110%%%%`4444!1110%%%%`4444!1110%%%%`4444!11101]B+OG(VCO%> MWO\`'8#NV_?7L@$$$7!T(-=HH%N1C5/R$D>.>2FV8J+\I5-;MI92;^-`_HHKM`4 M45R@[12W-YN##SX<%HW=I$:61P#MCC0$[NFO3PJUA9V+GXZY.)()8G&A'A[B M#J#\:">J')X&E2., M=^:Y4;FLP46]WOJ'DHO4XRRO'SQG%G(\SJH;'MUM^:].D%@+ZGQ/2Y]M`BS\ M_F>,D7&P\%VG$.+#'(^0(D3)F"]]U&K%1[>IJ:B@ MKYV!B"%U&'*H9G0V"M&PZ>?H/ M]M:66>&$HLKJAE;9'N-MS'7:/?2;T]!D9,,^;R),KS3[X5D!LG:NBLJ'Y:!U MCM(\$;S)VY64%TO?:Q&HO[JYDY,.+`^1.P2*,;G8^`%25A_4?)Y_)YS\1B1M MVHVMV[6>5UUN;_A'A020>H9\G-SM->&X MOLCTQP- MGWY3I.Y+K*\PN')OOVFP.M!>BX!&"39>5DRYJC6=9GC`)_+&A"6'P^-97+BR M(^8*8RS?U'%EM-F0IN$D;V(E=$_'8Z^#5H?^ZL+%A$6:X;,06(B/<1R-`P== M`#U-^E0\9S7"X2SRY.=$YC@<'RL^7%%%FJJY,D0FC9#=98^F[W$'J*!"..P9>3G_JLD8C MX[8V1(WD5]X_3A5;Z1H!IXFKZ9']:Y/'S..3M8G'LPDSV.T2+;6)$\5]YJYZ M@Q,2/'?DNW`F3'M!R)XFFVK>WR)JQ'A6:1<6;/R(Y#F&'(()(2L64A!21ENI(Z%Q^+9I,6;D'Q#&T<(V@18 M67E<+EM'#`QQ;A),*^Z0NPT=#J&E8`NRCR@>^K?,8_([#:WD$F1C M+Y8GB4>:1=0L9'RK?5J#1X/)SKE?TWDT$>7;]&9=(LD#J8_8UNJTR[,7<[VQ M>[;;W+#=MO?;?K:LOZC7,Y;C\7DN)+Y?*X4/!+%(^#"?U\9B&R,('\6G MSQ'P-;-&5T5U^5@"/@:7QLF#*A6? M'D66)Q=74W!J6L[P&9C8"OQ.3CC!S8]\SH`>W,.K2Q,;W^'A3G`Y#%Y'&7*Q M'WQ,2+D%2".H(.HH+-%%%`4444!1110%%%%`4444!1110%%%%`4444!1110% M%%%`4444!1110%%%%!RNT44!1110%%%%`4444'*[7**`I3R\),B<@\1:)2?,+Z!K:UWB\67#X^#&F?NRQ MK9WN3<]3J=:"T```!H!7:**#E0YVFE5Z),B!18NEO/L_BZ4UHH%O']WD,:/*Y'%2*5 M9#)CQL+M&O12=PT:F5%%`4444!7B66.&)YI#MCC4L[>P#4FO5*9,K+R.;EXQ M2(\1<8M(P_F%I/*&0^%J"!(FYS(XSEEC,6/`TCE)&N38VC*J--2+WI[46)BP MX>-'BP@B.)0JW-SIXD^TU#-G81S/Z9*P,LL3.4N+;!H0=>I!H%F;S^".6CQF MRQ##C7>9E-UD>UA"2M[;>I^ZJV+WN2Y*3-:+22R1#Y)(HE.W>LB]'!.JMK:J MQ^ER.667!@CC@Q5[,/Z>X2$Z!Y$'F[1^57'C6HPL2/%C(469]7).X^Y=WCMZ M#W4'N#%@QR[1(%>0@RO;S.P%MS>^J7J)Y$X?([3;7<+&&Z6WL%/[Z8AT)(#` MD=0#2WU&+\1-I<7CO_OK09/T_P`(F9G9>'E3.J0KM<0/82$-;YO%:>KZ&X,& M_P"J?BP__C7GC(DQO56=%&NU)(A(`.FNTG]IIQEYCP9N%C@#;E-(K$]1L3<+ M4)48_2'!1D'LL]O!G8C[KU97T]PJBPPX[>\7_?7C,@S>_"JYS@RRW6)51`$7 MS/IL-[6.\BYZ:?;0>N8XS`AX?,[&-% M&>T3=44'37K:D7IF%H>1X]S(SC(QI39NB;6/E7W:5I\_&1>)R<>!=J]IPH'P M)\:RW!S%9^#)/E_U$8^))H-9RP8\;D[06(C)L).R;#4_J?A^-8J7)A;+BDDE M`WP.&9N0>37\*M)`MQ_='6MSG*7PIU%[M&P&U0[=#T5M"?=6)F;,27C],Q22 M\27CQL8W9>BGI?3\5!IO2W8'#1)`T;*A8$Q;]FZ]S_-\U(>=@RL5<["Q#,^& MW^ID1L<.BLUF8K.6%@.N@)%/_3:9J<<4S23)O8J3*LQVGH"R``?"D_J2&$YT MS,,/>81K/)+W=`?E1/+\*!E@YF3@Y.+@Y4WUD&8E\6G4U7SN&@Y ML_7\/_I\Y)`,S%8A61R=7T\0=;CKX:UK\K&AS<8V9G\5+%A\O(,B"4A, M?D`-OG(TCF%S8GP;QICD\=AYZL[GSY'JCAXXL$K M'DJROE8CG:Q6WE92>J>(/C5^"3/X)8H\Z4Y?&D*AR2//CN=+2>V/V-X>-!/Z MAY/*P<7;A1-)E."P?;=(XTL7=[Z=.@IEC3QY./%D1-NCE0.K>T,+T2Q094+1 M3*LL,@LRG56!I?RW(Y7&)&,3".1%&I>=@5C2.%.MB=-WL%!9Y+B\7DH@DX*O M&=T,R>62)_S(WA2C@)!Q,AX;-B7'R'9FQYUOLR_XKF_GMU%/<3)3+QHLF,$) M,H=0PL;,+ZUXSL''S\=H,A=RG56&C(PZ,C>!%!YX_D\+DHFEPY!(J,4<6(92 M/:IUJU6-R,7D.)SEF61%S&!6#)/EBS5'^3D@6VR_E;QK1\1R^-RN.9(KI+'Y M9X&T>)_RL/LH&%%0+EX[93XBN#/&H=T'558V6_QJ>@****`HHHH"BBB@**** M`HHHH"BBB@****`HHHH"BBB@****`HHHH"BBB@****`HHHH"BBB@CEFBA0R3 M.L:#J[D*H^TTKY#U#CX,8?;]0KNJ(8R`K%_RL=&T'A5W)4Y$XQ)L59L-T+22 MN5*A@=$[9U/MO5')^HX[%FD7$QABXSHV-&@-U4L-\C#;92`2=*"SB<3@0YLW M)P@M/D_,Y;>!?KL]EZ853CRL&7+^FQYE,\0WR1QFX`/E\]M*MT':Y7:Y0)<3 M+P_4,F3%/`KX^',IA+7!9A<;BNE.K6I=/BP\>V9RN+`TV5*@+Q*Q\^SV#6QJ M?C,].1PTRD1XMUPT<@LRLIL106Z***`I;S/)9&!'$,7&;*R)WV1QB]O:2Q'2 MKTDBK9=RB1[]M6-MQ`O53AH>1BQ#_4Y`^5([2,`=RH&.B*?8*"U!)(\2-,G: MF907BN&VGQ%QUM4E4\CBL:?/@Y%BZY&.-JE6LI4^#"J,?J2-LR/`DQ)XLN27 MM]I@-$L3W=W0K;V4'KU!E/)QN3C\?+?)5HXI5BN9$$I`MY>A(IG!CQPJ-`9= MJH\I'G?8+#I#-%O`<*XMY3H/"K',<@\.S#QR M5GFU>51N[$5[-*PJSGYPQ=D4:]W*G.V"$=6(ZL?8J^)I#F09N+#/%FJKRYK> M7DT.Q82WEVR'YE46T\*";+X[`P6X_.XX!9/J8XY)D8GN)(=K[M2#>FG.IOXC M+'LC+#_!YO[*R7TV>7@Y`0KC8$$T*E(W(25E?9WE3IK[36SY--_'92=;Q/\` M\IH$4$P?U;$X!428HON!6_EW>-.\S#>?)P\A"`V+(6-_%&4JP^/2D$DQ;U!P MTQ%C-CK"W-V(^.E1RX$W'(RQ^4=&N>H-;^L M%@P8':Y-LB0ID1S;8@)"A*[]=`1?6@T/(8'(QX.5*_*3EEC=E"K%&N@O;1;_ M`+:S[8T$<>#%CD.9B%>3Z'?(;I?1LBZL2?9\:=9T7IQ<:>-2DLYC?:Q+SMNL M;'=YJ69$F*>/XYE[.]6B9B[S2Z$;3NTT'ML:!QZ4Q(L7&G"12QL[[G:4(A?^ M[%&2$`KSS<7:S?J,>%1/+$5>?ZKZ8V'0;==UJ]^G$5'RE3LA;J;0020"^OXI M/FJ3FXG:;'=(I9-'5C"D+6!MU:?Y?LH$_$3AY^/R9Y87GD\GG>;(F-_+<+JD M9]]-_5$;2<=&ICDF@$T9R8X@69H@?,"JZD4EXZ2=DQL<#(`@E*6.3#"HL_0J MOF:U:?EE#<9E*TBQ`QL#(Y9573J2EF^Z@S_&\M#Q^5+!BQ9!XE%$KI+&R-B! MC8%0_F9"?NK23P8O(8IC?;-!,NA!N&4ZZ$5D,/E(^%/"JO`8Y)8\;(F5M MI!&XN268^!K0>EUQTXL+CS&<=QS(Q0Q[7)NRA#\H'LH,[G<=D<3EC),Q3(5B M8XN;CXV&)R:`?48K68.OY5?V&XZ?+T-:& M>&*>,I*H8=1?J#X,OL(\#666/DN.R,H18_TT<86/#R6M*HB!OL1;[FDF8W;W M]:"KP7J/*XJ<<3S*-'$I")(^C0CHH/YD]_A6T=(IXBDBK)%(MF4V964_L(K. M3Q8WJ#';"Y!$Q^7@T4J=PW`7LK>(U\R^%28&'S/!<=$5)SU0DSXBGS*OA].Q MM87`87!^*M[*\\&@6<-)Q"2 M9.)A2=S*C<_5M(297?QF&)F8N;$)L259H MCIN0W%Z":EO+X7)Y#X\W'91@>%[O$W\N121?=8'P%,Z*"I#R>%-F2X$@`J&;"B$TF=!%'_`%`QF-)7OJ.JAK>% MZ7\;FQ"AA8K;_`.M!)B08_*Y&+SRM(%6-E@@< M`!2Q*E_B:;5Q55%"J`%46`&@`%=H..Z1HSN0J*"68Z``=2:I01X7(38_+PL9 M`L;)`2++9SJUF%[Z5[[QRSDN7GBS'7;/#!AI8^936@FDCQ,5Y-I[<"%MB#7:@Z M*/LKF%"\.-''($$H%Y>V-J%SJY`]YJ8ZBU!DW`T4PVN-DCV#QM)9@2!;2U/,7`P,+>N-"D)F8 MN^T:LQUO4WWOQ99(5VI`55?Y"0>U&'[*@RN6X[#V#)R$C,A(76_P`NC?+?IXU95ED0,I#(XN"-00:# M)R!1/Z=G&A($?V"W^VM=6,G$D>)Q,TCW^GS&B5`+`*LEAK[1MK9T':***#E8 MA8TQ9.9R%C5GAFVDN0&[_RUI<2$ M&6+)LQ+8Z*6)NG@;`>VL_P`NTRGD@9-J?A_]N@-[&U]9"?LH+W`9!FS9B.,RM_(JC M3*[-&0%^K[S6`'2)%"U8]0Q1OC1-)'W`L@%B9A\PMTQP6-!GSCP2=X9&+(D6 M/-9A#!!CBPLR[Y&-P?A6OR8DGPY(G171T(*.?*01T)'A6-BP]F1E"&)V.]&B MMAO,R@C\)G;0?&MIN"X^Z1M@"79S8;=-2?`6H,3)GPE\5`^/V%#(\/U4\D?R M^7?IT'A:M-Z;>-^-O&L*H'8`8ZND?_\`D`)/OI-,RM!CY&/GXJS8\@DAE7RNI\#^XBLEZOC3ZN5I"@)B0HI>(, MUFULI3N?<:>/A3XS+R/%J-SHIR<7HLPL#=?!7'A[?&@J\IPT,$*F$%(80"DB MBYQ@OFDE4`[GDD.E>H.5FG@;C0:Z$W`)H/&!P_) M<#@OEIE&62/?)-A'6%U!N=GB'L+W]M/\#/QN1Q4RL5M\3]/`@CJ"/:*K<;.< MSA(I)W,;/"5ED-@RD`HS?LO6&XO.Y+@9/K(8WEXR1RK,1:.8*2H96Z!O?0:[ MU##STLL']*=UCL0W;9$VR7%FD[@.Y+>`IVE]HW:M87/OI5Q7J+%Y;*:'#1C' M'$)))6\NUV-NWM(Z^^J7JK)SA/AXV"N096+,.QY`6*E4N]B/*=2I\*#1LJLI M5@"I%B#J"#62Y7TS!AY`S\))%@&KK`3W,9AJ)(%\5]J^SI6HQ%GCQ8ERG#SJ MBB5QH"]M34M`@X?U$))(\'D'4Y$NN+DQC]+)7H"OY6TU%/Z39N'D8&0>1P(1 MD17W3X84;R>ADA)Z-[1XU[7U-Q;28D>Y@5YA\'+Q<6*#O/D$EKL$LHZ[2VC-[%IK M53DL2+-Q'Q7V;Y`>R9!<+(!=6`N#=>NE!')-B\D(ADY.+DUDDBGC78X0^65/!7!\ M![J.+Y>+D6R(A$\$^*^R2*06-M=K?;:@85RNT4!53,2;*C[6'D"!UD42R*`S M!1YF0>QC[Z]9.;#C2X\+W:7)?9$BBYT%V8^Y1UKN)A8^&CICIL$KM*^MRSN; ML2303TEY[G7PL688*--/&0DDH6\5@2#`1X<28LTY4".6:3JT$18%"^NXW^;H*"CPO'2K)]=.2^9* M#)&#:1@K])GC/\Q6OKMU6MA@X:8D=K#>VK$:V\=BDB^U;^6_2J_&\:L02><* MTPNT8`VJA;JR(U^VS`^8`VO7KG#GCC9?Z5YG( M1F7#EB@BA=(YLB74EG8*RQ(;;ME[D_92YN<78LTF8S2L(C((P^V\&04D;:@. MT,AN:D7"GY*=6AP'PDQ($CA^K4`LZS)+==I;P4Z^^K;<)R,J21]U(ED7*2XN M=)G$D3`"W2VM`OCSHYLKCYXV=QCY&3=W5UWQO(%54W#S'SC3V5+._;AF5<>7 MRPOUMTCR=P\:LS>FLF1(K9*[X\MLHL5(T?;<"WCI5^;A(IC,6F?]995-K:"9 ME+%C(25B4*">I]YH,GRIV8`!-FBY-P/M. M[^VMG6)YR-WY#(P<;&>?*,ZY09!?R%%!6WQIO)S?-_+#PTE_:[BW[!0/Z*0+ MR'JR71>,BC]\D@M^QJ]__P"WR+J<."]Q^)B/?XB@>5CN;Q)VY[)6*4PID8N^ M0^#HM@RW\.E77PO5-R7Y>".WL0`6]NJU1G@S()CEMGQE!J,"6-<'&NZ@=M`#<:V'A67SIGR<_D8HDXZ)(SM?(R`!(UUZWUN??5 MWC>(XW)]/1N^*CS]EP6=;L)!N!^;4$$5X;&QQZ7Q)E@CW1&"5O*-=K@,3]G6 M@\<=G9/]3Q,>/+PYP]UDBQXBI"*NI[A'NIGZC7DSCP'CFE4B4"8P`%]A%K[3 MUM7ODDV\EQ4RK\LKQEAX!T.G[*:;E\2*#'2\3R\@D[+<@\K@#?-+%&C$=-P5 MR:TV)BS#BX\7+;N3=K9*Q\UR18]>M>Y>1X^`$S9,48'7H#,H'A5V@RWJN+N9`0RH@ M>!OYDXB&A_)L+-3$YT_]/P\;$`;.RHDV7U5%VC=*WN7]M5O4"97]1QF6/(>` MQLBG%(5N\3H'?J%M5[@^(3B\148[\E@.[(23[PHOT`O06N.P8N/Q(\6(DA-6 M8]68ZLQ^)I-RV9'),LB29$)-XL.;%8D23&]XI(B"`01^(=*MK=;4$ZI+R M:1 MMAXUS.R,/A,?%X:-S`LJEI?EF@RFTA=186]CP#=O'_`,#6G7!<]C;&8"]Y!UVD]&&AI MRCHZAT8,K"ZL#<$'Q!I=RW"Q9_Z\1$.-'E0DF*90Z$BQL?=4U`4444! M1110%%%%`4444!1110%%%%`4444!1110%%%%`4444!1110%%%%!RJ;XN+E9\ M67W"TN#O01`C:KR`7+#\VWI\:FSI`]@UM?K:JG#8F;C8G_P"PE$V7 M([/*XU`N=$#:7"U7QL;)D]0Y67DJW:AC6/#9@-H#@&3;[[C6F]!VO+E@A*C< MP!(6]KGV7H=TC1I'8*B@EF)L`!XFJR0]_*CSTR&>`Q6BB7^6=Y#=RX^;2UJ# MWAC)>"-\Y8URM2PCN56YZ`GW=:[F946'C29,QLD2EC[[=`/>:DDD2)&DD(5$ M!9F.@`'4FL-R_)2^HN0CQ,+=]+'?8/SV^:79I>PZ#K0,\_EY,[B(<;&EAEGR MU_U2!H]UE_,% MH'F1SW'8\+S%GD2-T0]M2Y)=>X"MNHVZUV?F\:*_DD>QD%P-+Q1]XZD_B7I6 M=QI)8HX3,8C&_8\JWW6:.;'`/^(:UR9\UD*G*CAV20$D1E@!DXYCUW-0.LWU M",?"?*BA+E!`P5VV@KD#<#<7Z"I).8G7.&+V@%,X@#DDW#0]Y6^\$5G)Y-F` MTTDIG5<7"F6)@JHRAF3:UA5F/'EDDQY)),AUDDPFW7V[M\3J3=`+;306<[G. M3_I,V1'M@FB&.V]1<;9AYM'OXTT]/9T_(<3#D9.LY+*Y`VW*FU[?"LT_&M_2 MLH#%E4G&20R2;B>Y#,ZL?,>NS4#V5H/2[32<89YDV-/+)(%L1H2!H#X:4%/+ M*0^HIG$LT<\D"=M(8Q*7%SNT*L-+"K,^;)C0-D91SHX$T=ML0^VR7-4.?R,C M$]184N.ZQ-,BQ&1QN4!G(-Q3F?BWR8'AR\F2>-QJ@"QJ?$?(M_VT)5FQ)*2%IX\6->MYLF>4GXJY45`(GY3F(L/(R)8X(L1) M(XXF*%B0H:[+[ZO_`/9_"DEI%DE8]6>1F-!XCCP8KEY>-2_Y4#'_`(GHDY7C ML)3(.0@LO6*&);M\`K$U.GI+@$-_I=WL#,Q'[ZL1\#PT?R847VK?]]!F/^Y8 M<>*413F87X6/`ABR9)V0(Q#,$ZW)55ONK<+@8* M`A,:)0>MD47_`&5,$50```!TMI08ILF.95W<7R&<5``>=V!4C\NP:?95;$P^ M3$BRKPTDK+J.])(`2#<$AV7[JW]%!AX_3_-RR_4+@XL#-(9@)#OV$_AV79;? M95F;T_ZDS=T>3/C112%2X1=04^6P51^^M?108O(XWE#RV#QO(Y[28\BLT79_ M2VM&/+Y0.H/2G6#RF5BY2\7S!'>;_P!ME+HDX]A]CU!S+;/4?#M;J76_][3^ MVN>K88)OZ:L[]N(Y(5W!"LH(Z@GITH-%2SEN0R,.6"-(=\$^Y9)0^QD-O*$) MTW'P'C57#Y+(X_(7`Y-S+#*Q&'R!(*R#2R2$=&]].I8HIXVBE4/&XLRL+@B@ MR,V3L!RV4RRR/V\+'*['R)%.DV1%TO&>FFM/>(XX9K>9ST M1>F@KN)PO$<4\F7#&(VM=I';=L'C8MTJKCQ'F\R/DYS;CL1BV#&1;>Z_YS7\ M/8*"]FXW&12_U?,0=S%C-I6N0JC71>E_9XUF)\^2?-CS\L.DY\V)C[=XP\4L M%;*F3\Q!N/OI@R/ZCS!.Y[?#XS,L`8FV3*OXRAM=5(J#B^,G?+9)SOR89?\` M7$L!(A928YH95UV.!M,9TH/&5Q!DBS8XXGY%YNU-AY[-O8JY574/<+=;7T\# M5B+N<3E3#`1U@WK!#@R,SME2C61XC(QV!5\>A\:TA;'Q8@&*0Q+Y5O9%'L`Z M"H,O`Q!!Z/[JK.G(8>8V2+8V6H5;*"8,WD\7BA#CB"62Z^2/'C+[$2PN;=`*@;,CX6=,?+G'T< M]^Q)(Q+QG\CD]5]C'X4V5E90RD%6%P1J"*`1@Z*XO9@"+BQL?<:J-R>. M(9KJR'?%,FCQN/Q*:CY/E/I)8,2!>[FY+`11V.W:&&]BW066],*!!_6,[BH9 M<;DHQ+D1J3B3KY(\JWX/X9/X?NIKQN>O(8:92QO%NN#'(-K*RFQ'WU)F86-G M0-CY48EB;JK?O'L-)TRLO@B<;-WY.!_^-FL=4)^6&;QMX!_OH']%+.*YJ+/+ M8\J?39\7\W&8W('@RGHRGW4RH.T444!1110%%%%`4444!1110%%%%`45RB@[ M1110%%%%`4444!11105))4ES1AO#O"()^XP!4,&VJ+'QTO5JO'>A[W8WCO;= M^SQVWM?[ZDH%N4G(?UK"DAW'""2KDC<`H)`*$KU)IB#<7JAG14:]:1^G\7$*C&ND>5*^^7&E MW-(T`.Y-UK;64:JZFU0\/QQEN()Y9('F9\-F\H\ALI-+>4X[.FS<;/P9(A-C!E$>0 MI:.S]77800U>']0PE:!&JOB=_0 M7'<615<"YZ;30,9N!XJ;';'>`;'01DW.[:&+BS'71F)JTN'B(;K$FXA`38$_ MIZ)_N^%9Z?E M')"LQ"VU=#K0:9L?':,QM&AB(VE"HV[1X6]E>]R*.H50/@+5DFY%`,J(M-*W M^OB3MJ\EE+(RM<>'[JJO-!!QOTX[D\D6%+$7B1C$1'*"K!C^'W^%!LWR\6,$ MO*@LK.1N'RI\Q^SQJ+!Y+!Y%&?#E$H0@,`"I6_2ZL`=:R62TJ)(@PY-1G1V) M0%5E59OS'\)O3WBBIYG/93=7BQF!]HV:4"WUICR2S8KQH7[:LTEN@0,NI^^F MV1QV1DW5!'CJX`,RO(TJ_P!P:+>EWK@LF+C2(2IWLK,I(\I%['[JO'/R9U0X M0R".VI4B`!&:VA+RE=#[J!;Q;6]18IU\V'LN?'8=O_@K5UD<&25>;XULA=LK M)D12CP[@9R0ONK74':ARLA,7&ER9-4B4L0.IMX#WFIJH4K$;:D)(P1V^Q2347(P\>N&F'/.<7'%@$B;8SH@L8_+YBM MNMJ"Q@YL>=!WXU95W,A#@`W4[3T)!^RK%+^&$HAE'F^D#VPQ)<.(@`-=UC;= M>U];4P)`M<]>E!VBBB@SOJ4;.0X><=1D;;?$K5WBXX\T2YN0BO,TLD:[A?9' M&Q15`/3IK[:I^KQ;'PI?"/*C)/LZU*B.GTY95#2[!YBSE5TN:;^ MFX\+Z$SX>.N,)7;>BRBR^E4_46TX?%Y%B2LT86T8F/GC(TC/S' MI3#@C-]&>[W@>XUOJ(TA>WN2/2U`MR,CC9N6RFYH[4Q@(\;&F4LA6VYL@``@ M[NGNJUQG:P<\X.+-W>/DA&1$C'=V-S`*JL?P/?R@U6YXY<><6[R#%DAV&*;* M^G2YW`V1$+M]]+8>/S\+B,7D,='R%VB:6"6Y,4H`2.8`#9%D9:?ZR!?Y1)[9+]/VUZR9H/3D\;"4#CLIRK8S$DPL?QP MCP0?B'W5XY'!RDLJN[3,U\?(6ROWB"%W;19(HU\/&JTJX'.J,/.81\BBE<3, M'E2=5:W9$612C@,C`AU87#*1J*3\IQ7)Y'*XN9AY31PI99DW6"K>[;%L M0VX:&].J#*\IPAPQO0O]#&;P31W.1@,?Q+XO#[5\/"F_!Y+Y.$.L?BTL'O]J_=0.Z*4<%S4W+'(T$POMD77\P&H\:;T!1110%%%%`4444!1110%%%%`4444!1110%%%%`444 M4!11100SJ55YXHEDR40B.]E+>.S=X`FN8>0#;,D'8R(YB\C;%LMQ:_MUIF#<7'2@[1110*^8QN60_I2J MUOF]X\*YQTG]/PC'R$J'-#-),$?>SM(;@A38Z]`+4TI3R>)#%R&+R,&#]3G% MQ%W%.T(C:,[G^%>E!+FVK-:X-Z\&-&=ITDF?&82L MAA)VW3+5EV[1TUO6R^DQ;L>S'=MVX[1KO^:^GXK:UV&+'QHEAA18HD^5%`50 M/&PH,@./WS2)(F2Z;\\!BSKM-PRMY;?-]QJ3`XZ3/XE)QBALF6'(1I7`&XE@ MT;"_2Y]@K6[TO;<+]+7'CK59>3P&$92966:1H8RNH,B!BRZ=+;30*I.-RI@] ML.&%D[RHRJH+;HUV-IX[A:O`X;DMBM.$Y3!=Q M&L@+,ZQKH;%G3NKK[UUJ"/G<.:!)X%DD61I40!;'="K.1J?$+I00Q\+D#(>5 MIP%:7(D"J#JN0@6Q^!%Z@QO34J8,6)+D@;(\B)]BZ%KL?-P2=O; M&_ZG8ZVT&3NV'["-:@QO4!R4++CE6&4<0AFZ&Q*OT\2+4$YX/%8>=I&)8.WF MM<]KZ<_85_;7GB.&;C7EDDR&R7D"1H64+MBB%D73J;>-0_UK)81L(E5'DQ5- M[GRY(L]O>K=*@X7FL[+YG,PYHS-'%*CR(IL2MRI_?7>` MR(QP^);'>^RWD2XT)%[T"6?)WYO%9;1]DG-E!CN3J[(+ZVZWO6SK)H^#QI#'-F1AUT95)T[,! MXB-O]E02^MN/6PAQ\F:_B$`'[3>@T=]1M_?0:*BLVLWK:74P8L`]A-_\`Q-7LP>LW_P#R M<6/W*I/WW4T&AHK,-PWJR=P2S^)$@46^!)H M+'JZ/?Q!8=8Y8W_XK?VU;Y?.7%PRB@R9.0#%CPK\SNP\/A>YK)Y?&)BK,5Y& M3,R()XS'!N++(K;3JMS=M?"M%/CG#ER.9R5?*GL%Q(56_:4V`4+X,6/F-44L M:&3B,>+C\%(VYO+"M+8>2-5%F=O3/DYLIX_#E[90?ZS)4:QW'R1^&Y MOV52B2?&8Q)M;GN0'-'EXTN+-?MS*4>VALPMH: MS/K8!=GQ5P99L-\>+:%>2%I'<)\I9=P4'X5/P/ M!2<2^0[SK+W]MD1.VB[;]!N;VU3R^8]2PO,QP(X<:(D+(Q[A:YVKT=.M7.%R M^'0U$?3&`Q M!EFRI+"WFR)#^XBH?4V1DPMC"//&'$Y8.GF5Y"!^&1(Y+6^%9V.3-R8#8BB_\0H-7!Z9X:&19>P970W7O2/*`?:!(Q%79.0P(#MER M8HS^5G4'[B:,_'DR<&?&C?MO+&R+)^4L+7TK%)E8D31XD.#Q[,0;Y'8GE4NN MA4*8PU_'J10;EU@RH&1MLL$JE2.JLK"QZ>!K/\GQ\D.5'!B0`X\C?4Y&3*?T MXNS;M*=-$CM<*.OWTS]/0B#A\:,$D!2;E#'U8GY&U`JZ)<>5GB#H[+I(@()% M_!A09CZO%S7&%S?^IQ2PEQ,T@(X4D`=Y4'Z:N=%8VW"K_.PXV!C_`-4Q7&)E M8X"IM%DF!_R706#7\/$5ZY#B7O))CQQO`WZDF.QL)IOE5IF;_+C&H44KCR8( M<$8N9NS>&D!"NP/>`4^:=`G2%3\I/F^R@?<3S>%RD2M"VV:UWA;1AX&WYA?Q M%,*4Y>'Q2\='D(PQX<--^-E0_-&H_*==P/B#UKG`<]!RT&UB%RX_YB=-P\'4 M>P_LH'%.RL/*/*<2NYV_]U@WVI./S+X*X_;5;%]5(^O2M%2KE^%3,)R<=8QE[=C"47BFC_`"2@?L/4&@:JP8!E M-P=01T(KM9CTW)G8^9+QH1OI(?GBF<&3%:VBH?\`,C;\)'VUI@P87!N/:*#M M%%%`4444!1110%%%%`4444!1110%%%%`4444!1110%5.2S(<3%9Y06,EXXT& MZ[R,#M0;`2-U3RS10C?-(L:$A06(4;C[S[:\8^7BY1<8\J2]IMDFPAMK=;&@ M48*B?CL7BN=B`ER%;M1L6.Y8K$!G/^8!KUJR9X."@P\,K+)C._9$[$-VRVJ! M_&W@*9-&C,K,H9D-T)%]IZ7'LI+EQS\UA/B,5Q>1Q)0[1F[(2M^VWM*,/&@> M45"N7C]_Z5IH_J@H9H@PW:^.WK7K)R%QL>3(<%EB4L0HN2![!0#SPI*D#.HF ME#&-"?,P7YK#W7K,R\IS_#Y$\.9&.1[R//`T1L(@FANMK[!<5'#ZCQZ],>)QLK+S).1SRI<';&$U15%[(IT=2NH<'0T'G MA>,ARL09DS=Y,Y1).6L3/O!NLRBZ^3\)6U-97@XW$CC@C`&D6-"N@+'Y5%59 M/3G&LY>,S8^YB[+!-)$A+=?(C`?=6?3CHI\KZ"2/*.6N668N\Q1,90;%9B=N MNFO6@>?U#+QW$6?+$#'/&KR(-B&.9&(4AB;686OXTKQ_4#OC`2YZ+,'RD8,5 M#;0K-"UO<>GMJUB\'DQ;"8(E:^*\ESNN\>Y9M3?PM7KCN#R88K2JB.N5/*!H MUXI4:,=/C>@AAY4RY4YFOTM?44^P.(GQX<02RCN8ZQ;U5;@F.,Q&S:=0:]87#''0I+D/*%F M:6,]+*R[`A]P!H$N/ENQ1AAS7#X+$OM0;@O;OJW0BH\$3X_;QX(T=4RTD0F@1/JHH5AR^T#V MMS*6C9%MJ!J=*U:<7QZ,K+`MT`"WUM9C(+7]C$FO>/@86-O$$*IW',KV'5S^ M+6@QRF8112OFN=L.&Z]I%4$"9H];@GRGQJSAP,N5EHDLKK#R<6X&S;MS6W,0 MM]*><_C/-Q,R8J*TB[6500M]C!K`]*M8$_>BW20C&R#YIL,^9V`'9R6``6X_P`L[A7/3N-.OJ3+GCC?Z93-&\K7M$'].224J6'O4*:K,_K)P52+!AO>S;I&M]EJ!MF8RY>++ MCL2HD6P9>JGJ"/@:RN`>:XZ&3!R4S-JM:`XT<;KM\2'<'K6MB,B0)]2R]T*. MXR^52UM;7\+TNPG3%DD?)Y9<+<'\P0U1.+Z:\WZF1ED':P5YYK'K;R4%N3CSD?)QV/$-DD;;F6_G'_E MH178LW*BECX\28:Y2J%9"[EB0/!0H\/?7,',X_$B,/'X.4(R=S`0R"Y/C>6U M3?50B8Y4G&RQG\62T:;P/:;,7M0&5GRX;1KEY4$3R7VQK%([/;\MGO\`LJDW M,/*&$<^06N;"'"?=]GI6Y#-R)I8^.CB[<#F. M6>=F4;QU5574V]M`K^MY%B/T^4D]VR&*_P!RTWQL'N0(\TF2KLH+(\S;E)\# MLL+U!B\IE)FQX6<<>1YK]M\9R2"HW>>-M0+>-7.5RWPL";)C0R2(OD4`G4FP M)MX"@68/%#)FE;DN/$:(;0M).\[-KUL3I5C+XJU[_AVV MJ&!H,EEBFY>5YI.B)M@#&W1/(&_;5#G9^)XF6*')^KG:52]ADR`6!MKYQ0-6 MX[ER!;D5ATZ18Z`?\3-1'E?00'&^K/)9[D]I/+O+>PA/E4=236=RY.\V//B\ M+DM&+$&1I").A\P!:^E^M,L3)YR._P!)P4.-N&IW+'?XVVT#GC<%L2)GF;N9 MDYWY,OYG]@]BKT%7:S[9'K%P0F)C1$]"7W6_XJ\I#ZTDD\TV+`IZD#=^RU!6 M]>*WTV'*.B2L"?B`?[*U$+AX4<:AE!!^(O63STSAR+X/)9AR8FPYI5L@C`;: MP^5>MK4^]/2M+PF$[F[&)03\-*!#R''X#'D2,>$R+O.X0SR/891#%@;!=[K>_P#!8?96SP2QQ(2\IF8H MI,I787N/FV^%9'/B?#Y!EC:.97R#O;);'>1=^MH^XS%;>\4&DX!63BH%:,PV MW6C*=NPW&WEWO^^DJX_%1S3Q9,OT/++E2''RE!61A,VZ,WM9U.[;8TR]+Q+# MQ[HH`'><^61902;'\`"K_=%*_5T+--(3W"#`'C*C(=59"?"+])?BWQH'N!R$ MLF1)QV:BIFPJ')0WCEC8V#I?4>\'I[Z.0XQ)PTL**9CM+1L;)-V[]N.1K$A` MQO84K],"`Y4LBH1(\$9+M"\9(\?/+*[-<^X5HV=$4L[!5'4DV%!FH3D\?),S M@=B62TZ37"RW/ZTZ(3:*.,&W3S4NY+A5#-R_IR4VA-WACN'C8==@/A8W*G[* MU65Q6)E929KKNR(D*QDDE-=060$;K&DD\?(864\L)_U[W*ER`D\:E6FFR.H1 M%^5!U%!+P?JR+,B*YX[,D8&[(`/9;<;+=NB$^^M&#>E7$9G'\CC.B8ZP22#= MD8K*%)W?CM8;E;P;QI3Q'.?2Y.3B!)I^+QW(3(VL[0+>VU_';>_O`]U!K*Y7 M$=)$#QL'1A=64W!'N(KU04N0XY:!;]K)4:F6`"^R3Q9/NN*U MF'F8^;CIDXSAXI!=2/W'V$4$]%%%`4444!1110%%%%`445R@[17*[0%%%%`4 M444$.7BP9F/)C9"AXI5*NI]AJGQ&%A<5"O%PN&F5>ZU[!V#,1O('PM3*J>9Q M\>3-#DJYAR<<^29+;MA^:-K]5:@N5'(K;7:$*)BI",PTO^&]M;7KRN5CMD-B MB0'(10[1_B"GH:E-!3AQ(L@P9^7BI'R")8G1F0D6(##J/96T@QQ11Z*U[7):]S[*C[\G-Y MRF/R8>.Q,+V/G(\O=5]0&7\C#I05_3W`OBJRS*.Y(!]22+J5/2-?PLIZ[EU! MK2EHH(BSL$CC%V9C8!1XDFB**+'B$<8"1KX#0#Q-(.2Y.";)B,T,N5QZAI84 MB56$SQ:L[[V7R)?R^T_"@=G.PNR)^^AA*&19`P*E!:[`CJ-:\#D\`O/&)U+X MQ43J+G9O^6]9O*>0]U/I-B;,W8&D4#:\<I)X))^1Y/&,+S%<4/"+MN?N%'* ML;B]RO[Z!@_,\@=R)'$)+Y2I>Y!.*X&NOBE>,SE-R78X7TG9B:"24,0.VKS1 M)'L\;,'!/PH.97,[7E=,]053+6-`PM=&5XVL/<=HKSD<@(VS9FR9^U/^I"H5 M_(3(#]1"()W5YLPF.VTVDB287W$?*=:DX'(63U)D3&)X3 ME1D^?JWEB=1I<:"Y&O0TZ'!IW>Z9G)+F1QIJ6A&.W[!>O&'Z=AQ,Z/+6>1Q$ M@58G(MN""+?I(QD2G-@@;)8R.J1E]K6MY2UO96AH(N"/;09KTYG\H^#+/ MD2+F`R,!OD"-'M^:]QTKQ.>3S,S*@ESI%A0+:+"B[GE<$[6>W6U0>CXA%R/( MX[;7*VU%FO9B-/=7K)Q-N?R*Q-'(96#MBWG#+M&A*8XUW7H'&7BSG)XIH49H M\=R)6.A5"FV[4OY7&C^IRU^G3:\9;>(A=B5ZEWE5;_93B#*CQ^/Q7RE^F+B. M/M:G:[>4)[:6\H>UR32RPQ]MHALF`B,NE]P;ONM@/"PH%_!Y$4>7QZC9$9HK M$)V!O-O$1J7O<>)K4Y89L64*S*VQK,C!&!MX,=!\:RW$9)VX"0YB1*TEA"SQ M[FCW'RE$CON/]ZM7D1)/!)#)\DBLC6ZV86-!CY9FQ)L+(SE.479HT2?)6?87 MM:0"-+"WM!J3UA!)%QT<*10VNTLLB`AAM(7R[K]=^NM0S0Q\9QCC!@W%F[XP M-O)0-:*78F;RD\$\\F%V0`3C0LWZCD?G\%O4$/)\H<_&PY\-85F5F9FE#N%0 M:FR"PU-!%SB1'D\%>V#+.LT77[2:G]*F_`XH\5#+_`+KL*H>JISBY MW%9*QF5ED=0B]6W`#:/?K5GT>LB<08959)8II%>-M&4WO8_?09;.WXWK?D%C MV[IHPPC;>1+=$O':+76FWI^7'ER,5$2+O!2LRC&8NJV(UE9R`#[;:U1YYFP_ M6\>2(VE63&4,BR=DMN#1CSW&EQK4+M/`D"_2+CY7>"13_4]R507\JK'N-P+U MFC=B/;G\H]\>YHN5XG)Q,>5N,D*8LA#3XH*^7 M6Y:$R`A3[JQW%9-N>SY&E>)9XS('DR?IBUB/F>-#<^X"M=RF?FCC\CC_\`+QUYOHO#3"?C()`RN"MMRNTH-B1\\@5F^)%( M.?R)(,N4*ZQLLD,J:P*?9NMM:0_%J<>G#RC<<#RNX9)=K!U56">%PFE+^9D$ M$V4N?+'/`ZJT.,)1"^WV$;=S:CK>MO,O\%D&9)PT_?9).N\2!01T!1$7[KU6 M]28\LSILQS,O:D#-L#A3X:M+&H^XU+P3O)/.?J5EB"KMA21IMI/XB[JO7V5X M]08D3Y6-E2*9MH:)82B21W/FW$2.@!T]]`O])[N]%*D")%)!M>15B4LRFVMG M>0]/=\*9^I$QBN&^<-W'+-_JE()2S*0A<+X!J4A7<`7C%NFI'PIVR8G(X@/EGQYE#*>JL/F%_:/=63AY.6#.3(AR82TN.R MF3(F;(4[6!`'8C47'NI[Z94#`D?O+,99Y)"8U=(U+&Y5!(`;4"SE,#(QIDG, MH7,O>'+0;69[7D:9B"$@C3HEZ8\/R<4K=G)A7%S9QW18!1DKT[H'77V-K3:: M&*>-H9D$D;Z,C"ZD>\4@SN/R8,R)T"R8P+963FY!U25-$-EMHB_*HL/;0>8G MS>(^JSEA$7%=W3"8VD1>C2Q>;:-QUV>-:&">+(B2:%@\<@#(P\0:STD_]5A; MC.38P]UE>"90`VTM^FLRZK&[=0/'XTJAR\_TIG_29![^%)=]BC0@_C3=;S#\ M0H-U14.+E09F.F1CN'BD%U8?_'6IJ"#+Q(\D()'9F2_\Q`.C_F%:>JV;@X^;$(IQ\I#QNIL\;CHZ-X$4 M$L,T,Z"2%UDC-[.A#`VT.HJ2L]Z;A''3YG'Y,C?4[S,H;1'B_P"K'\;^;WUH M%8,`RFX.H(Z$4':***`HHHH"BBB@*Y7:*#E=HHH"BBB@****`KE=HH(9(5W- M/&B?4A"B2,-;==I8:[;UGN2Y/E(%Q\CD9!QD!F6.3'B*S/*GS/)OM=5%O#P] M]/\`-S<;!QVR,IQ'&HZGJ3[%'B:QN/#/ZBY)/CF+18[*0H#7\B#KU\3 MXG2@TG*S0E4&9BC(XQUO).OF,;7NIV*-VT_F%3<-O;%:5ELLDC-"Q%G:+HC2 M?Q6]M>^*R9,C&(E4++!(\#[?E8QG;N7W$5XY#DVQ)H\>&`Y$\BM)L#!`(X[; MSN;QUT%!-R6(<[!GQ`YB,R%-X%[7]VE+X^(SIS&,^6$10P28\:XZ%21(H0L2 MY-M!TM4[YVXM,9G%O"8ND@U/YETJLG,Y?]0Q8I9HQ')COW[;=JS@L%-_#Y=*! MV<##+;C`A;S:E0?G`5OO``H&#AK))*((Q)*`LC;1=@O0-[:1)R@F:\F8"DRP M:*W3NQR1L`%U'GUJJ,@,[Y!RI#&N-'BD6?S=R)SN"VO?>M]U!K0%6]@!?4^% MS[:\=Z#?MWKO*[[7%]GYOA67AR%FGQZ;I482$N%+=!MM0:ELS%4@&5+L0`+@ZL"R_>!I58L_%D9$:12?2A0B8#&\BZC>\0.E_;:O6'#DK) MVU$44PCB6$ZR*#%ER(=P\O3=:@>+SF$XC*!R)7A0>6VN0"8SK\-:C'.QOE8> M/'"Q&;$\L;L0MBO12/?:D$4N:88U.3"#&<8JO9MM"9#PC\?@U=Q)523BQ+(S M322210NJJ.T5G97`O?1@:!S%STLCXZ''V]](')W$[>^[1D=/PE:KMS?+=K'E M2*`[E'>5BRW=Y3"`I\`"-;TIRL+9#]26RF[*;PY=P%,>5M?1;?A-Q]XJQ.,; M&XV6?$WM!,C]G(.][LD^^,DM>VAZF@>Y$7+S8<\15!Z78"]>Z79^)A0 MXCB/'C5Y;1(507W2G9II[Z8*H1`HZ*`!]E!D^`+)ZIY&-C M=6;_`':]R[H?34W9O&R1,5*]Q3<'J.[Y_OJ3DU+18D[3=G;;]V1R M?@+4"+B9W2+$C`1^WD%+B:0M??UV11[;:^)M6TK%8L>,8\ATG#18^3OEF$F1 M)'M-GO:/:OQ)K9JRN@=3=6%P?:#08[F>T,+,4F'N0R:*LTTKBS>(;RJ::>H6 MOPT$IUZ`CV]R)E_MJCS39#+R&())'=R3%#'+ON#;0QQQ$CX,U7.1"YGI.[,8 MP(HR[$&Z&,@/<==+&@M>E&+;N5& MENA%7_1S;N`Q];[2Z_Z(R-I;S:C7451]- M8,K\IE9@R)I,;%9L:$RMO,FOFN3[#[*U5>8XHXAMC4(I))"@`7/4Z4&<]:AT MQ\+(CMOBR%VWTU.O7[*O      Quarter Ended (Unaudited)        March 31     June 30     September 30     December 31  

2013:

        

Total revenues

   $ 38,667      $ 33,232      $ 42,439      $ 41,516   

Operating loss

   $ (6,457   $ (12,529   $ (13,287   $ (6,512

Net loss

   $ (5,435   $ (9,721   $ (7,812   $ (39,166

Net loss per share, basic

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

Net loss per share, diluted

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

2012:

           

Total revenues

   $ 59,859       $ 68,702       $ 69,042       $ 70,104   

Operating income

   $ 23,596       $ 23,028       $ 23,109       $ 11,041   

Net income

   $ 46,838       $ 18,350       $ 21,524       $ 7,489   

Net income per share, basic

   $ 0.80       $ 0.31       $ 0.37       $ 0.13   

Net income per share, diluted

   $ 0.72       $ 0.29       $ 0.33       $ 0.12   
XML 27 R54.htm IDEA: XBRL DOCUMENT v2.4.0.8
Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sales Revenue Net [Abstract]      
Gross product sales $ 224,301 $ 383,817 $ 220,670
Rebates and government chargebacks (63,610) (91,059) (22,190)
Distribution and data fees and group purchasing organizations fees (19,067) (32,793) (11,637)
Prompt pay discounts (183) (4,814) (4,086)
Product returns allowance 2,034 (159) (2,094)
Product sales, net $ 143,475 $ 254,992 $ 180,663
XML 28 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Investment Holdings [Abstract]  
2014 $ 22,468
2015 22,468
2016 22,468
2017 22,468
2018 22,313
2019 and thereafter 93,867
Intangible Assets, Net Total $ 206,052
EXCEL 29 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`JNP`/3A(4P,AVN^3M9TA;5566*EJD?3=!"?8Y7RSQN^(L M;O9=&SV0=8WIEW&:S..(^LK43;]9QC_OOLY4'#FO^UJWIJ=E?"`7WZS>OUO< M'09R4=C=NV6\]7[XR)BKMM1IEYB!^G!G;6RG??AJ-VS0U4YOB/'Y7+#*])YZ M/_-CC7BU^$QK?=_ZZ,L^_'Q,8JEU.^[^%H;%-3=*NM_Z:[$(/M6_;;V-TO8W;) M^2(G4IKUNJFH-M5]%TX@<8,E7;LMD>_:9+HFG6[ZI]QG^D^+'9LNZ96#C/]O M*GQA#@Z2(P/)D8/D*$!R")`<$B2'`LE1@N1(YRA!4$1-44A-44Q-45!-451- M45A-45Q-46!-463E*+)R%%DYBJP<15:.(BM'D96CR,I19.4HLG(463,463,4 M63,463,463,463,463,463,463,463,467,467,467,467,467,467,467,4 M67,467,467,460L460L460L460L460L460L460L460L460L460L4606*K`)% M5H$BJT"15:#(*E!D%2BR"A19!8JL`D56B2*K1)%5HL@J4625*+)*%%DEBJP2 M15:)(JM$D56AR*I09%4HLBH4616*K`I%5H4BJT*15:'(JE!D+5%D+5%D+5%D M+5%D+5%D+5%D+?^7K#Z,+Q&;/O_]>9G*O#$_X_RA)7?E=]Z/1=_JO-66ZA_> MAD&OJP=X6?M>9KU.S4\\=PS#9 MY0U?#6_1.*Y64WVB-YO&XU9_````__\#`%!+`P04``8`"````"$`M54P(_4` M``!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/; MT?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W> M;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I" MRTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````"\FTN+VS`4A?>%_@>C?>/H+95Q M9E,*LVVG/\`DRH-)[&"IC_S[BI`F'6C/;,+9#-AAE,/EGN]T[TO] MI[S='7-35QER)[:E'#^V;5YNTZ'/L_&8AOK)>IP.?:F7TZ8]]LN7?I-:-9^[ M=OI[#;%XM6;SM.K$]+123C3/IV/]ZK<7']?KW3)]&I??#VDH__B.]N1M M2J4NVD^;5#IQO97;\R?*S:IFT?Y'CF3+D4B.460Y1D$YGBW'(SE.D^4X#>54 M+U%;V04D)QBRG&"@G,B6$Y$:.A-R1;.Y(R!W-YHZ&W-%L[FC('SB1%@=Q8:@@A!4;`@J M"$'#AJ"!$#1L"!H(0<>&H(,0=&P(.@C!P.9.@-P);.X$R!VVL:"O)!N"$D)0 MLB$H(005NW,4[AQZZ\#>T6PF:\ADP][R&;CELVPF6\ADQW:6P\YB1X2"$6'8 M^W,#]^>6/5Y8/%ZP0\+!D/#LWO&P=SP[)#P,B<`.B0!#(K!#(L"0B&RC1VCT MR,ZL"#.+71Q8&W9I<&78)I?0Y(IM<@5-KM@F5]#DFMTZ&O:.84^"!DZ"ECT) M6C@)2G::2YCFFLU`#2%HV).@@9.@94^"%DZ"CMT[#O:.8X>$@R'AV2'A84AX M=DAX&!*!;?0`C1[8F15@9D4V=R+D3KQKA.9M/Z75US+58U*YOB*['"5Z=1N] MR&+7!I>&_8X/54:RD2,A86ASD['SS.A[MN(DH]<)IN;7R^;,]_86;>5W.99-@0MA*!G0]!#"$;V(X(('Q'$N[9.+J=]_8G=[9'2^?K/$Y/V MU:_N%K\!``#__P,`4$L#!!0`!@`(````(0!WM;+MU08``*8<```/````>&PO M=V]R:V)O;VLN>&ULE)G;],;\&))#8D^$V MRW;O1R,;;%4L[3NS4PE]LS%I+#,RTX>1W:5*AG:K5!9'H\EXO!C%4B?#2N%] M^AH-L]GH0%V:((]5DE4BJ8ID1N[;K=[9X>F'C8[4CRJB@=SM;F1,?C]'PT$D M;785ZDR%)\,YF>9).1^D^>X\UQ%]NYZ.I\/1Z3'(VW00JHW,H^R.PCNH4[XF ML\ED4?QFD8H?6CW9^J'"'#S_U$EHGHI?I=3NC]:4''@JO_JIPVQ+WX_'X^-G M?RO]L,T.'Y+\"/3+#-+?*7\.DC*\0T8$54I<)9G.]N(ZJ;*O#96PR/HU1>8- M!^E[3?])KT.O@L;D#1KB5J(,D75T MIKIHZ?Q[%,]X6& MKQ\237TEDTR?%;F(96[K7:$D!J/,>QG)OA% M":4N($QHDMERP#@*2(S'\"T5MB8*:0Z)J]\Y]:/S]`(#8=@62?A"^:`6#DRL MQ*U*J0UEBMQ[8\3$8]!^DCH5/V24*_%529NG50,Y7F`'>HS7(UJ4@WN=5#/6 M>1YQ]QBIW]2CB1YI(1%?"-$"M(M4T?A%"0*A;CR/04H#B=:F3-]'-(=4HDTJ M;DSF0N$AGA[C\VN>A'I'R8NE.'M(59D&QP4$DX8TFXEQK+-J^!3#E5S**"9: M)'7##X1SPN!\*>6=?&X\ABA..(KYO56_#ZNB2J)*%<:4C.:7*"`(08D_VSB^I8 MCPMB`90XF[@X-::.N'.$$-()@[1S[H@[>>_$5JS?QS5BPE#M'SY.;`0'*#%B M.Z9/Z9#+#N%2"TT9NBU#J$T$N9TR;CMG$4\0DCQE)'<,I#:/D.LIX[IU+K7) M(-531G77;*F4$"&B!M+,J&Z=,&W^(-)3AC1-V>Y!X[3K!)&>,J1QTK2X09Q` M-(QCW!?PJ>%P3+"`$N.XO]L)W;K;B99::<9!ADG&]RKHTPQ=(J,QS/LV*^(, M/)HY#C&6>W5\T/$(7XB,L]PWQWR,S"."08GAW.O2A>,2MM>,X=POY+J$'39C M1/N1[WB$/39C;/<+4K6&?%.!H9/_46B.<)/1 M\*A_<<6ZS1%N,MXDA'6;(]MD-(2Z%NFSD':X&B+SG)$T9VQW"55S&(3F#D<, M[2Z=:ME%'8I7C"JNW>?Q<$<=9#J!:.Z6ZT(\G<]'40::7C.FNS3#K>F^&*"X9TUU"9T&F'W$.+1T= MAG3[IOK`$"8(B5XRHCMT`KH"L<[1?XE$D]%(=+M.E1[W\#IS'&)$MPN=Q8:N M%?Z3&!@2O61$M^OX^6X7T94"ZB#12T9TN\[%5M*=@L"">;0UJX?0DB'==;U2 M-3XXM$*DR6ADNO,<5!8?=#S:X=4.K1C3G4(7,DWWCA"F>L68[A:BGL?+[!4R M348CLO:#60O3*T2(C%?I'&Y%(+`55HR,AD[_"0]71&^&$*T8U/U*N`!YM'>% MHC&LG<-B,5/I+<_+/3L-.(S-\8AA[>C0=NV1VIUNJ,]5HC9.WZ\.B*$''HRUYG:`UH]H1.K`CHY>W*R"TQLT' M&7T.'>88W8E^3U+:"Z,.0KUF4/N-"T$+"[VX1AV$>LV@]OGA_A-=\M*U)@5W MB3H(]9I!?6B#]LM!A'J-XX,,2M"H/`#0NZQ`1@&]9"M^%&\+RG*.#J\83_\' M``#__P,`4$L#!!0`!@`(````(0`#DYK;#@8``#@8```8````>&PO=V]R:W-H M965T&ULE%C;;MLX$'U?8/]!T+MMD;H'<8I*0G<+;('%8B_/ MBBS;0BW+D)2F_?L=:FB3,VYDYR6Q/4?#,Q?.H?CXX7M[<+[5_=!TQ[4KEI[K MU,>JVS3'W=K]Y^]/B\1UAK$\;LI#=ZS7[H]Z<#\\_?K+XVO7?QWV=3TZX.$X MK-W].)X>5JNAVM=M.2R[4WT$R[;KVW*$K_UN-9SZNMQ,#[6'E?2\:-66S=%% M#P_]/3ZZ[;:IZJ*K7MKZ.**3OCZ4(_`?]LUI.'MKJWO6TJ+KV!"Z> MFT,S_IB';N^?#Y`W-]%4%9GW].7*_=M4_7=T&W');A;(='KF--5 MN@)/3X^;!B)0:7?Z>KMV/XJ'0B;NZNEQ2M"_3?TZ6)^=8=^]_M8WFS^:8PW9 MACJI"CQWW5<%_;Q1/\'#JZNG/TT5^+-W-O6V?#F,?W6OO]?-;C]"N4.(2`7V ML/E1U$,%&04W2QDJ3U5W``+PUVD;U1J0D?+[]/^UV8S[M>M'RS#V?`%PY[D> MQD^-E`\@.=S9,CC$NM;H4*,RLE'Y67R!5$,4)]O3ZGWN/H&*:TT)$,( M[(@+1%!$?D:H_"FOA?7#"NA>.$,F.&4W$<4<@I"'9>P:S)-7 MX+4+F;DP2WU*+4-(//6."/P@9GG-;8`,@Y2'7]@`D7A19)8@S&''W<]<@1GS M@#%'2(3,I1^GU)Y3>RQ88`6U^Y[9.(1V]![:"LQHLV4SA&C:89B$+*[OB#"%0[DLW,41^$U',(4C:E82S^1A`Q>;[ M73W$TL^2ER$$TP]#/#%5GV9?;ML#Z&73S#@;;;OO)WYRZ3I"/Z7TYVDK,*-M MW$[+9@A!VFGJ\V;.;7L">Y3-J,*VQU*D)BV$MH!Q;J=]GO>$9L39+LPT!IE# M0F.><`H`466`@@!D%$4F-LI=R19KF=OR)%#L[!DIK%&`V=<@W36>%_,]2P!) M(ECY"F+W8VEBI"$H$;-"N)%^E#Q*W6B>IHX@I"[2(/)9A7)!$$F47O4\1?A1 M(-YJ'R5C]_-'T:/\37$U?P0A_X6?Q`D;J+FP$8D7\^(4!!!&86#&%LV^4K+[ MV:/NP>*7<2@\-BTR@:"YF7D;4LQ":`A*U.X/`260%H"U=J;.VS"==`%@=+`* MY1H03$*\"'A]"F*7;TX>I6H6( M&$X61IFFZ`L""/W(>N^B[)GZSG>,_(GJ"K9TID'GQ,&[!RM-3A`BD'QK%P2P M\&//%(>RAQ:XOVVD0K/<6U7%MM$@?+-:1%+X9NT)D1-$&DC/-(;./:Z#+N#- MRS<`REXIX-U-+U$OB7`)-M0S#9J9B?EM2#$+H2$HH;P_!(7F!>#:*Q&4HB[! M+2&+,2<`L8Q,=G7Z;0?>,C7UH]3?I;GJRNB*NO&L>P=!,]1M@%A:)QI-W;9[ MR\1L>TJ=B>Z-38LZ2AN'BZU$$*3NR.$G^BLN&H< M!.'31X;`R_Q29(*%FYWS?DOC-,PC:VU,`J\P,7[S;;N=W5>'PZ#4W4OZG)6P`Z\ M_(H7QQE<'$^WK*N+`>YM3^6N_E+VN^8X.(=Z"X]ZRQ@ZN<>;7_PR=J?I.O&Y M&^'&=OJXAQOZ&BXNO26`MUTWGK^HN^7+G?_3_P```/__`P!02P,$%``&``@` M```A`#\'!>OM!0``1AP``!D```!X;"]W;W)K&UL ME)E=;ZLX$(;O5]K_$'%?@ODF:GIT4D("R4JKU7Y<4T(2=$*(@)Z>_OL=8P)X M:#--+TKP/![L><<&VX_??N6GR<^TK++B/%>8JBF3])P4N^Q\F"O__!T\N,JD MJN/S+CX5YW2NO*>5\NWI]]\>WXKR1W5,TWH"'L[57#G6]64VG5;),IKFGV-(^SLR(\S,JO^"CV^RQ)_2)YS=-S M+9R4Z2FNH?W5,;M45V]Y\A5W>5S^>+T\)$5^`1C MVD&CP)_E9)?NX]=3_5?QMDZSP[$&N2WH$>_8;/?NIU4"$04WJFYQ3TEQ@@;` M_TF>\=2`B,2_FNM;MJN/<\6P5R^)M`N,8LJ"Z MQ'Q68#,&KJ_))E*C2[_/L@_2CGOYSMTTSB"Q*A@R/Y^8J;F/TY^0YTD++00$ M,1Q"N@P]7R&>U]RUCPN6N"#`!2M*QKC&2SC`U2CK?UI?3,!,/ MDM\V42\7@H')LAL@B'@F"9\DEB01D,2*)-8D$9)$1!(;DMC>(B0Y(>QWR,GI MN0+)TDG%#"360C!.,QT^&!ZS$?`L`8[+4+KZDMUS]#X1FZEQ*=DM$^=R,+0[ MINMU>=Q47PW-.K-T-,+70SMS#4N3ZX=#NVF[!IKOHZ']P=:9@1ZP&0*>J6NH M?]NAW?0\H[=+RL$'@J08CE3?#!'+M5P7$E].G*V$&+JC.W8_ETO2PN>;).WM M.9;3LJ2VC7)N(9A;BI*$3Q)+D@A(8D42:Y((22(BB8T@A.:F!G](S<_MDI3P M!7Z'E)S&4J(OAX5@;DE)$CY)+$DB((D52:Q)(B2)B"0V@FBE=$Q/]]"$MY4( MYEKZX*T@R=UTF=>O"B1989$ZDM4D9>6U1K+V;^OF M]N`-+>1LH5MZTHA/(TL:"6AD12-K&@EI)**138L(89EFF#9>76]E1'>=_CM& M5I;O0N!YF/[X96+S0EJ_F'C]L6BIFQ(+1S<0G_:RI)&`1E8TLJ:1D$:B%A'Z M??(9+#.F;3CZ8'2*X2LQEN-9GL,^TYGO2PQU)D:PV,9`^O9S?CN$!>6)%:JF MV@AXYCN",+%W`$.`/P+Z":AYQ!(#>(452("FXB>LD!U/@6ML1V^=$-G1:B62 MS`]PJH+6X!L)8*J-_&\ENZ9ZG^G']R'NT$]L6R#]>M^M?H+JY!GKAP`<71_. M,62!1_HA8*S?$`#]4/Q6TA,TU4`9M$9VW?6D/Z17B'`'/2Z2[!_J.6PO4_$> M'#_9Z2.BJ6X?$#'OBF,;L8>>I^4A?4Y/IVJ2%*_\2$:'H=25BN.B!9O!=C/L M&J/RB!\C-0=!G0%.<2[Q(?TC+@_9N9J79JOXI:CA M_*;Y>83SNA2VRS45X'U1U-<;>/"T.P%\^A\``/__`P!02P,$%``&``@````A M`/59FDN/!```^1(``!D```!X;"]W;W)K&ULE)AM M;ZI(%,??;[+?@?"^P("`&/7F6GRLFVPV]^Z^1AR5%!@#6-MOOV<81>;0.K4O MBLSY\6?.TP`S_/&>I=H;+,YI40*6@:53#_\I`< MRZM:%G]'+HN*U]/Q*6;9$20V29I4'[6HKF7Q8+G/61%M4O#[G?2B^*I=GW3D MLR0N6,EVE0%RIIAHU^?`#$Q0&@^W"7C`PZX5=#?2?Y+!NJ^;XV$=GW\3>BY; MO[7RP,[S(MFNDYQ"L"%-/`$;QEXYNMSR(;C8[%P]JQ/P=Z%MZ2XZI=4_[+R@ MR?Y00;9=<(C[-=A^A+2,(:`@8]@N5XI9"A.`_UJ6\,J`@$3O]?&<;*O#2'<\ MP_4MAP"N;6A9S1(NJ6OQJ:Q8]I^`R$5*B-@7$0=F?[';AMUWB>L]H-*[J,"Q M4?GV%&"RM1]P;"Y^V`_O(N*W11[V`SJKG@H%BPLP9M#%50'B.^*)`!`>EKL8G2:,KOJ^J#LN,J M/[E,+0:%54+'O(U)SR)#\PWJ/+Y`$P%!#-N0+4//5XC7-9<.\<`4#\SPP!P/ M+/#`$@^LK@.MN[D2UXFM6P,F1+,)*42Q$U('TO=Y_UXCR*^2(^C[\@PF M700'KTM`&AQ9)NQ"/9F8=@F00="L"SFNK#/O(J"#H,6GD"F1#L72I(J06YW4*]=$,/?2J21" M)3%5$C,E,5<2"R6Q5!(K0?CUX^')LXF#EI27-A#T;/P`6;?MO2!P;@&7,@DO M#`]DDM-R)CW7DI>?B6#@]DVV<6,JB5!)3)7$3$G,E<1"22R5Q$H07IU)S_+M M@-A].60O;<3MN_U^0%#,UA+BV+[M>[2D7TIF`"48N6 MX:&'Y#.R$V0/L1WY-D5V*Y##,VO;+0/+SV6S M%,S7/8CLN$E";$>^39&]TX-M._0@ZH.Y;'90/2YDL]T/I#_4=$N9]M&]5FWS M9SW9MA,#OSC";@2/MHBD9?1O@1`]*;8:Q'=?1HL]?:9I6FHQ._%M!!L6P694 M['!,R``^D>!+!XVO8.>C'C<;`^P\'*,]_2LJ]DE>:BG=@:1E^+"X%V+O0IQ4 M[%A_WFQ8!7L.]<\#;#%1^,2S#(!WC%77$[BQV6Q:C?\'``#__P,`4$L#!!0` M!@`(````(0!MYN*M-P0``&(0```9````>&PO=V]R:W-H965TGS,SRS!9?WLK"^N5US(7U<9FCF=;O,K$/J^.&_OOOYX? M'FU+-FFU3PM1\8W]SJ7];?OS3^NKJ%_DB?/&`H9*;NQ3TYQ7KBNS$R]3Z8@S MKV#E(.HR;>"R/KKR7/-TWVXJ"]?WO-`MT[RRB6%5W\,A#H<\XXG(+B6O&B*I M>9$VH%^>\K.\L979/71E6K]\XA!MR!-F8"?$"T*_[_$6;'9'NY_;#/Q16WM^ M2"]%\Z>X_LKSXZF!=,_!$1I;[=\3+C.(*-`X_AR9,E&``/BTRAQ+`R*2OK5_ MK_F^.6WL('3F"R]@`+=V7#;/.5+:5G:1C2C_)1#KJ(C$[TAFH+Y;]QW_<<[F MX32+2XI:@TG:I-MU+:X65`W\ICRG6(-L!X+3]N`?<-/(0J(&."&00&1."7#)GL50)$A.!XB'\B@?<-/(P4R5$ M!"*%F57RL+GO:[F2X'`YW*^H77U&/FT;J-7D1@4P9F$0DA*`(A$[X?Z$J M'K"M:\_,Z9.`FT8>M$*."'3[_4"KD7BX/$Y0HBX/$J2H7WY%/6X:J5]H]4.@ MFWI?5T_+A@0E)H3B@< Y@"\[.T1>OJ'_6':8IH\$HQZJ=8=17@@5MNTA6,X]SU/K+NYX M"#&;C1&)BF!+']Z\>A+5"?;#@9.)RJ+NJ3KPM,*/&*%('ZH;&2"`,1LR&B(].2Z(@M-.B9@&[ MX<#`?6]\,(>-"FJF5WS4H3HCW@+JI3^/;;[B#F'(%XY\GZ>4K-!(1Q-/R>LC MCWE12"L3%QS7?'BF]'?[4?+)QU%!NQ_AB(GWW7X!)KQS>N2_I_4QKZ15\`-0 M>LX"JJBF&9$N&G%NYZR=:&"V:[^>8);G,.!X#H`/0C2W"_R!_K\#V_\```#_ M_P,`4$L#!!0`!@`(````(0#?:O1#B0,``.(-```9````>&PO=V]R:W-H965T M[]@V!)!1[XP$(G'M\?(Y]XRQO7XO<>V&UY*)<^604^AXK4Y'Q M\:4!PRE7/E[I:I%$,AT MSPHJ1Z)B)?RS%75!%5S6NT!6-:.9*2KR(`K#)"@H+WUD6-0N'&*[Y2E[$.ES MP4J%)#7+J0+]60K4A>Z@M9/S]5-*HH**#8\Y^K-D/I>D2Z^[$I1TTT. M\WXE8YH>N3`/@&F]S#C,0-ONU6R[\N_(XCXB M?K!>&H-^'3S7/OO*2@=N0DTY@(\23AG[)]$]0'`RJ'TT"WVLO M8UOZG*L?XO"9\=U>0=P3F)&>V")[>V`R!4>!9A1--%,J],0C)K!S`Z[Q$T M/@.=1'8D`$]?0FR5H(M6/HS12DCB:4\!8A+C430C(9F&XQ;2D0`J_UV"+NI* MF$Y:>O0`(0X>0.I]`?88=)$U!@0Y2$B&$NPQZ**N!\,8$(,QC$-XM29U,IAV MQ[^^`C6X.RYL@G[^"'*8NKY5]/:AW7U=9'4?00X2YD,)=O=U4=>%H?N(0?<) M,?Z_$P"!37=NP_4$#+H[.(F2$S5N@`;E8`"YT`SM(9@J:PH-RD7%A7YHSX%@ MK[O>C1K0,8DXFD?DU#,[6X'T6J(EB6$OA,UPHFZ20)2+!X`Y7P?ZMN20A*ZR M)X$H%Q476J)#$MCN+$D@J.E(X\F[+8GT>J(EAV$SA!SF;;=K>$K' M0VQ%=^P;K7>\E%[.MK#&PO=V]R:W-H965TO"MF0=%X5&32,6SN(;XY3DMY4TM3QZ1R^/JY5)^ M341>@L0^S=+ZO1&UK3Q9_3@5HHKW&?A^8],XN6DW!P/Y/$TJ(<6QGH"<0X$. M/2^=I0-*V_4A!0(R@1D%F8DW0Z5$9!``?%IYBJ4!,Q*_-?^OZ:$^;VP_F,SFKL\`M_9/[(*'E'D"54V-I0[#)>0G]OS$*-%I\8\2D8E0H@_4Z!]+`PX:K2:"3#9&B63W,M(3P(?Z&&MR-("4\EPE$B,A%*^$LU M_,>*"0>-%A-!)ANC1&0B%!L,.E8_#8_Y:$8-\J'?W"U%]00KTT)?A<.64+SJ M%65F5#/8]!ZN*48M4EEA_<7`!%%*B%I5M4(&)#(BJ@?LCCT/#R:$>NI(TV-$ M&0(-QY'(B*A>L$-^W@OU524OP[6*$47%Y4_]8+!:M83B=E!<30AT6IJI[AKCS1(5/]>#8Z&44 MB8PJJA=LF)_W0FUVK+B(HN+REOX4]@EZ7N[T:XV)F)%1W6#C[+D9J2YJLXH+ M=SFHKCO-6'L'GV/#RX=%'+':LN4V-N'NE#-HI$1D3U@AWT\UZH M[RIYN;-T$=7V1=>=,Z:E+H0M^>!F&E27D2$WM"^G;6O.JQ,/>99)*Q$7W'-[ ML&_HSG;O`YX\W.]IYW?XG@#/.]T/L$TOXQ/_(ZY.:2&MC!]!TIW,X2:O:*-/ M![4HF\WR7M2P06^^GN&%#(==JCL!^"A$?3O`"W2O>+:_````__\#`%!+`P04 M``8`"````"$`/T["E!('``!$)```&0```'AL+W=OR.M"NM5OMQI@E)4(<0`3T] M\^^W[*HDE`T&]C+3P<_%G&??LJK.R\O6\>:N,\LN:;G/+\>M M\_=?7SY$SJQNDLL^.9>7;.O\R&KGX_///SV]E]5K?I4G!?"=<-%D>07!R-LJC$QRL,A M3[//9?I69)<&@U39.6F`?WW*K_4M6I&."5O;]4-:%E<(\9*?\^:'"NK, MBG3S]7@IJ^3E#./^[@5)>HNM?ACABSRMRKH\-',(MT"BYIC7B_4"(CT_[7,8 M@4S[K,H.6^>3MXF7OK-X?E()^B?/WNO6W[/Z5+[_4N7[W_)+!MD&G:0"+V7Y M*J%?]_(2=%X8O;\H!?ZH9OOLD+R=FS_+]U^S_'AJ0.XEC$@.;+/_\3FK4\@H MA)F+I8R4EF<@`/_.BEQ.#6 MOM5-6?R+((]"81!!07Q@3^UB+J*EMPR'HRR0D1K@YZ1)GI^J\GT&LP;N65\3 M.0>]#426(PMZ1P9#DGT^R4ZJ*Z!KD./;LQ<(]VGQ#7*8$FB'(%@"=Y#@B-A$ M^,L[9`$$[RQA[#I+'U3LSO^-I>S$6?K!/;P:R`XAD^J&G M$6PWBRAZ-#-V,)G:[.R9DV#."B;6(S"*AJ`0YYTG(GWFQ6V`>24(V(;@G%;<6Y2T^$)+SOQ[(71BC/8(0:3YZ^#1VK4 M$.)VL_##GN4H?:U5-.R:2K#.*M)8(88D7:T";;7$K%T(W[_W9UE;3^$EP9S7 M4D\60FR"(@*)"]'*-N/E0:T:GS"%YLS"2!-J1R"\<^"Z6O6-J;V;.R>G68!= M30^+-BL<:^WF.P(1.5]HY&-J'T-.%N314\W#\MTF!_5#FTP[0B$[WW6-^L$` M7AA%/>'ZX3.D2J/OFI"W&Z89P?H"9D$")-A*H%V6!*-)VN=;:8]8N@NA1 MM3FU27XA=\4F-:UF[`C5G1C*W`J'$'6][6'O_ZQX?!MIF:'\P M56C.#.Q7?^%#**3FN6LAM$D0<\0J:FV7N;Z3#,3'NL_7KEY;"&35=[1_^)I_ MC"N"JA?/HOGBAT"TA,TW/ZR]_]6//\E!%)HS`WWUG1&A^JDQ!^E]*^7_+P=1 MO0R*^M,]H:PJCW80?Y*#*/1@E1EV$(K3/02V2H))#J+01@*U)[P=H?JVY:RY M=UL>:/XQ;GFH7@9![9W4CE#=Z4$?L4)X!B?Y2(#UG]<9?9$0R,IOM(\$FH_8 MJ[1"&PDT%)8QM\ZM2G=LSRD.(?JWYP$,LNTA(V66O726_F,GH33>KX?((?UGHEJ?(M1(6]E.3"_ MQ5#[&'*33`/.8YCEV'CT(Q1^8Q:AN]+6M#S6(<,@P`N6K8\UF#D\M(%G&HJL M.F9Q=C[7L[1\DP`&`L$?37E5!PU>R@9.;Z@_3W!:)X,3!>XR;&X_ MY#F3^_F?Y_\```#__P,`4$L#!!0`!@`(````(0`@_/"'K0,``($-```9```` M>&PO=V]R:W-H965TNHTV4)U$J<[YT7[EV/ZT^?EB) M8:ZNX9"[G8CY@XR/&<\-D2B>1@;TZX,H])DMBZ^ARR+U="QN8ID50+$5J3"O M):GK9/'\ZSZ7*MJF4/<+FT3QF;M\Z-!G(E92RYT9`9U'0KLUWWEW'C"M%HF` M"M!V1_'=TKUG\PV;NMYJ41KT1_"3;GQV]$&>/BN1?!,Y![YW9CV4"/Y23\%UT3,U/>?K"Q?Y@(.X0*L+"YLGK`]C<.:/&<"=+=?F42"EZ\1';63VET"LHB*2 MH"(9@_IJ/!@%MR$+I\,L'BDJ"WR(3+1:*'ER8-?`FKJ(<`^R.3!C96/PAW34 MM?ZO5*@12>Z19>G"=H?I&O)Y7K').%AXSV!J7('6%T`V8G-&8!:@KQ8)I3=% M7K;]K`7!J`5C0'%K>@'#7XY8P<.IZ80CN"'N+A5PC$"Q?JV^[UH>PQ$UM<==%BY,&HR50G\@^ MA"5R9HOLCQ;!'0=;_JP)-"VC#4/_KDZN-'C3'&9!T-BVEBZ\Z2X<(_WZ<%)' MW\P6L"90GWE]"$OD75?D\)<7)PTF3*`^D7T(2R2#T[=I9;^%);KC83OC"D4A MWP3!;$"_.V9&QWKKB+EMY5RA^CSLA=A"\41O"1V.FM$],'!0 M5ZA>H41T&6(+Q4.](70@;;H"6DYVTB84I3WQ_;?#F+[2C,:O40>8=ZA#=&'O#Q.,<+#>4B,:KLMUX6IUE\/Q;'!(.=B MGS>0?[TK3_5[M,-Z2+A#?O[R]?1A71U.$.*EW)?-CS;H=')8/_SV>JS.^ M='\/XGS]'KO]H1?^4*[/55UMFQF$FV.B?'@NXVE`G6X&7JOIBT=\V]I_@ MX'GOZ,]M!?X\3S;%-O^Z;_ZJWGXMRM==`^5.0)$5]K#Y88IZ#5<4PLS"Q$9: M5WM(`+Y/#J5M#;@B^?>G:0@G+C?-[FD:I;-DN8@"P"3IM` M[T'F]2FWG1P\0&1[?2*XRN[K`Q?&'O/)'M0>"G0-1?WV',3QXG'^#2JQ)FCE M@(+[F$.9`XKCD$/&`5V(.>BXB($JC1=C#^J)"2XG:!6OG%#$H:P/224:P91` MJW25Z.6P,)1M.NF60USI%4)0X@N4BO2]A-$(ECZQ1[:A= M4H2V2GB6*X2Z.@"24OJ0((Q&,"DPYETI>B4LW%.P%`H0ZBH0R65>PB"Q;&@);F"F!MN>?57Q&E M:?`CAA"J4ZOR*I-KL/8WN(D"-$LPFLXBFEQ#XPP3I6K`0`IB*`K-2M(M%%=@ M;6^X`C1)H4`:$[YTJQ'*8`\U/VT)E?L2H"-<` M5VN$!DOWID$NJ`%2V`.V!;I=0!H0@>^7BR&6!<.BI*JAV6W$"!%HE+R9>J[0 MQGR:LF$4(Y,1HZK0?)M7PAK@\&Y"N^0B$K&W7`5(*0EF?L2H"-=@;7"X!C1- MWT0@I6KP(B;0$*[!6N%P#6B/!#JH;R20 MHKF^-1*:&9,*#>$J1OEUZ/+K1#Y0(DJYS)D?,2K"-5A/'%X)=%#?2&@^2R/A M14RH(4R#?40\7$-+RZ6I-Q)$Z0LL04JQC(IP%:/\.D*;]#!_1196M8B$?=C*Z*4!#,_8E2$:["F.%P#6JAG)B*D5`U> MQ*A1N`8XTP@-EI9UZ,\$4LPF9"\A`M]OWEU'&L(UC++K"%V63428RETX44J" MF1\Q*L(UC++K"(W8UTM(J1J\B*%SN:-P#=81._,P[-=R$?HHJT>XM9($S3:`17,LJQ(X=CAZE\]D>4J@`#*8A1HW`-UA<[U=`? MXT?HHKZ.TKR6JN!%#)W++9-IB(5C#^NH]BBY2O4ZBBAW%JB%D&M'A;*C-((K M&>7:L<.U@T`^TR=*5:`9':-G>SJ**%4#!E(0HT;A&JQY#IZ* MV-*]3I*_6R1*23#S(X807+SB(%Y>%Q"N`,[353!P)NQ1/26]CD)*5>)%3(S( M5IN`U=Q4BI2A"AK7ODV/(:-0K7,LJ_8[3=KN6+!1FE_^\O0M4$9[]*,^.'9X= MI]=&;=?&%5%J"?R>35'NVVMP-UM>]S9A>UM%R74OD`D"B4D>*S6'%'X4>,BG`-PJV'K4R)P[7C5&P9 M5D310-Z['RP3I#2>41&NQAIHQ_.LFL#>FGA*@[XK.DS>="=(=3.%/KRV..ZD M')0(9%2$ZQGEX8G+PU/IX43=WNIE1'2%]B3@J=P(EP!,MR2>2EB:#TGOICM! MQGUN*@(BU'GN3PE1F!L,UV#]L]-6'@WHMMUNZG]0*$%(%8$()GCCHT(4Y@;# M18SR[<3EVZ(+5@2I(C`.)GCC\T(4Y@;#10CC'KA<.0U<;@D3I%0U7L2H4;B6 M43:>H/O"W%V>(\&'GWKVX?7HC`(I,HV*<`VCG#QQ.?E2;FB)NBY0PE"8WPA2DPL2'=51[%%^GV'T,;JJ(!*Y4?,2K"M0@SU]>I%$W#AN0PS%N05Q&<*U!RY/??>&L9#W?"E2JAXO8M0H7(LP;\_RA%[K M6YZ\CIRE7L2H"-OKQA$E"(/K4LAEC/)M>`-, M[LJAG>3>@RA5!@9Z7XCM2UW\YM:^;&9/Y210`;Y+AB])G?+7XH_\_%H>Z\F^ MV,+.:#%;P@B>\4TR_*&I3NW[0R]5`V^`M7_=P1M_!;PIM9@!O*VJYOT'^Z[: MY1W"Y_\!``#__P,`4$L#!!0`!@`(````(0"A0L9_;P,``*$,```9````>&PO M=V]R:W-H965T;&;NG]_/=_>N(Q4M4IJ)@LW<=R;=A_GG3].]J%[DEC'E@$,A M9^Y6J7+B>3+9LIS*@2A9`2UK4>54P6NU\619,9J:3GGF!;X?>3GEA8L.DZJ/ MAUBO><*>1+++6:'0I&(95<`OM[R4![<\Z6.7T^IE5]XE(B_!8L4SKMZ-J>OD MR>3;IA`5764P[S<2TN3@;5Y:]CE/*B'%6@W`SD/0]IS'WM@#I_DTY3`#'7:G M8NN9^T@F2S)RO?G4!.@O9WMY\MV16['_4O'T.R\81!ORI#.P$N)%2[^E^B?H M[+5Z/YL,_*R3H#:! M9VU"HD$8C.+[6UR&M0L\#RZDMXN'\S)A>J**SJ>5V#M0>T`N2ZHKF4S`6<X5,)+5H<49D*Y8'A4X@X!R9($Y-IB%D M_GS.#DRZD\TT#.WQ%FU)8"N6;04)P^%19%%"M$XIN^FT&&K'=4XB%C;Y4!2> MB*+CT";PRRZ%!0&T>.;"W(]P<=`8>8&:V"0[#(GO-\BP'3Z/'A\.%AD4 MURF9+KCKR=6=;$(HN(\!3'`6*#J/@.'K4EB0D0W9G5LMOII;%'7!=2DLN/@6 M."VV(Q<''P6-@4--9'([]%NIQ>;SZ!:8/C1/]I+NJ&FQ#1;=C^VB6J`&P<*X M!8;-/<#&MX!IL0W67@VH0;"X#8;-/<`(;&O]0V;4-AHAI!FT6G5^=%P'G1(K MI:1Q/G3GU*BO+H5:U0F(1\-YB0VHM^S>14=P@[>WNN9RJ$6874)@1=AEN:P% M?>CTAMV?#K=WFZYY2!`4(5TT:L-=;+?C!O0WD&FU77EQT#KP481D070F;I<% M-EOCC+A2=.W#H;U@]9T/)G#Y_*H%0'CQ`,-+)MZ>2KIA/VBUX85T,K:&/OX@ MAC$JO&+BBQ*EN9&LA(*KH?FZA;\"#*Y0_@#$:R'4X47?@8Y_+N;_`0``__\# M`%!+`P04``8`"````"$`03L!L(L#``#T"P``&0```'AL+W=O3T/=8G8N"U]NE M_^?W_8>9[RE-ZX*6HF9+_YDI_^/J_;O%0<@'M6-,>\!0JZ6_T[J9!X'*=ZRB M:B(:5L,O&R$KJN%1;@/52$8+NZ@J@R@,IT%%>>TCPUQ>PB$V&YZS.Y'O*U9K M))&LI!KVKW:\42]L57X)747EP[[YD(NJ`8HU+[E^MJ2^5^7S;]M:2+HNH>XG MDM#\A=L^C.@KGDNAQ$9/@"[`C8YKO@EN`F!:+0H.%1C;/,W`;^F0ZL!;BP4"_%>8K6!R,5M_;#OR47L$V M=%_J7^+PE?'M3D.[4ZC(%#8OGN^8RL%1H)E$J6'*10D;@+]>QVNF]#TWE+Z7[Y46U3\$D98*2:*6!#Y;$A)-HEE*TNG; M+`'NR!9X1S5=+:0X>'!J0%,UU)Q!,@=F4UERLC(HR:SY9!;9I8!6T(['%4FR M;!$\@H=Y"[I%$%R!#A1UB`#4NRV`[/$68FC1Z^:^;,$L4M0NRQ MVH"7/E31&9B-:D1,9GL0 MQVG6>^#H0D<#M]<(VK`KFB2I!TO.HT8 M5)V2$ZH$[NFP5A,?;]]=N^I(O\\&E&\Q;=5A?PZT,4D&)9QZ>.;BKSRRL#A"V>3BLDM^\S*4GFYV)O!BD#Z==_BT'<+0U]DQ[;N M!YBY&KIE/ZC<\EIY)=O`TG"20:LE3FWXH$5C9X>UT#!MV7]W,%TSF&W""8`W M0NB7!S,7=O/ZZC\```#__P,`4$L#!!0`!@`(````(0#-C7)_&08``!DB```9 M````>&PO=V]R:W-H965T6IX_( MY4GYY?7V*2WR&TB\9)>L_MZ(FD:>[J+3M2B3EPN,^QM;)&FGW7P8R.=96A95 M<:PG(&?)C@['O+6V%B@]/QTR&($(NU'RX][\S'8QVYK6\U,3H'\S_E;U?C>J M<_$6E-GA]^S*(=K@DW#@I2B^"#0ZB")H;`U:^XT#?Y;&@1^3UTO]5_$6\NQT MKL'N)8Q(#&QW^.[R*H6(@LQDMA1*:7&!#L"KD6=B:D!$DF_-^UMVJ,][<[Z: M+-?3.0/<>.%5[6="TC32UZHN\O\DQ%HI*3)K1>"]%6&;R6RS9,O5!U3FK0J\ M=RJSCZLL6A5X[U2VD\URN5AMUH^/",@F+/#^KO+1L*Q:$29<_6AP+6E4X[N; MU,GS4UF\&;"8P(KJEHBER79">=QIL%C`GP6]-V&U@XD53,^OSVR^6CY97V%. MI2UD2PA>WR&5<#I"3""AZW:Z78&'"_RN24^4;1>J;C`"J438$=T71;@@[A58 M$*-[H&`V?B!0@A:!ZK['[@K>^S]3N^8,B3F*K"L1Z.%[9.>KE:KC/0+YH]!: M50J&$.IS."1PGZ,A@D3B(=$343R`M:QX(!Y/*#17(7\(K9&K`8V$-!*-(&AYQ%I$"30\[@:!7I&!%JW`$'5Z;M2`V!*" MU_L<1A/8(0F7)#R2\$DB((F0)"*2B'6$X@EL'HHG^B>UH/BP0=>H..=W5*:8#LTXM*(1R-^B\AM;;AE!W<)L8)GZ+D; M:FLCI18UC7]0J49?Y'CXV43G$4RFAOTS%6P':,;;+:5U00II$)=6\6C$;Q'I MPF+LB!<,$?5\$E)`1/1 MX(Z,KY%N,&.UD=)VL$;Z3=\K52-$LO@31L@<$QF!_K!@,TEIC2`1EU;Q:,2G MD6`$@86/$MMPA$(3,**16(NH#D'X%(>(/43@@ST$9R-,4EIG2,2E53P:\6DD M:)&U/`CB)Y?LZ&AE1(O'6D2U0B20_<5"6"'S3761#-)S\7=W,$QVGZ$SL-/6 M:HQR:<2C$9]&`AH):22BD5B+J(Z(]+'OR&-9(9-9)W(&97QV2VEB[]"(2R,> MC?@M(F>).&B)'W4A!+1,2",1C<1:1/5'Y)$_X8],/Y$_:&W83%)=5L(F"'!: M0&.@2R,>C?@T$M!(2",1C<1:1#5'9)38'#IW9S(11>;@C+&EVLQ@PT8FK-,R M6G]T66]SJ>31*CZ-!#02TDA$([$64?T1>2;VYX'\1::GR)]!%CE,8ME\@[(< M!RZAQ>:D=8A$/%K%IY&`1D(:B6A$W+S_>-#2(7FS+F]8N,,OE\I(BU=Q M:[Z`<\J]]'ZC_WDNK@E1N&ULE%7;;J,P$'U?:?\!\5ZN@5P44C5! MW:VTE5:KO3P[8,`JQLAVFO;O=XP#P62;=E\2S)PY/F?&'M:W+[2VGC$7A#6) M[3N>;>$F8SEIRL3^]?/^9F%;0J(F1S5K<&*_8F'?;CY_6A\9?Q(5QM("AD8D M=B5ENW)=D568(N&P%C<0*1BG2,*2EZYH.49YET1K-_"\V*6(-+9F6/&/<+"B M(!E.67:@N)&:A.,:2=`O*M**GHUF'Z&CB#\=VIN,T18H]J0F\K4CM2V:K1[* MAG&TK\'WBS]#6<_=+2[H*5KE;^F6&104*!Q@D@Q9:P&`?!K4:).!A0$ MO73_1Y++*K'#V(GF7N@#W-IC(>^)HK2M["`DHW\TR#]1:9+@1#(#]:=XX`2+ MR(_B]UE>.'<;!VGZ&HV0FTU2"X$F>0B=CU"%5!Q9N.7K@@>%`-M9BJ#J&K_^Y' M+U(EF2+G0I;^`#%LA*:-Z_(5.+&!_%R^,`X'XJY@ M6PV"1@Z@V$3LWD6DUQ"&?-AFVH79F[>B[X)*@O,_4N@'\<(4N=6@:S;>1:37 M$(8-D#RV<;T+"FQV(?9G$_4:$W?W8+D,HZ49WXWCZO).\M-Q/(X6BW.^H3O^ M']T*;.J&&SK9>*M!\T[X(O8FLL?1>'2D]54=1Z/E^5QJR7JTZLE#,2_Q#M>U ML#)V4&/3AQV'MWJB;V&B=_//'0(P45M4XD?$2]((J\8%I'K.',K%]4S6"\G: M[IKOF819VCU6\.G$,%`\!\`%8[)?J*D_?(PW?P$``/__`P!02P,$%``&``@` M```A`,EXK@:4`@``6P8``!D```!X;"]W;W)K&UL MG%5;;]L@&'V?M/^`>*_Q)4[3*$[5Q,I6:9.F:9=G@K&-:HP%Y/;O]V&2-&ZV MMMI+8LSY#N=\%SR[W\L&;;DV0K49CH(0(]XR58BVRO#/'ZN;"4;&TK:@C6IY MA@_>%"/)IH]5JS1=-^!['XTH.W'WBRMZ*9A61I4V`#KBA5Y[ MOB-W!)CFLT*``Y=VI'F9X8=HFH\PF<_Z_/P2?&Z3%L47T7)(-I3) M%6"MU).#/A;N%023J^A57X!O&A6\I)O&?E>[SUQ4M85JIV#(^9H6AYP;!@D% MFB!.'1-3#0B`7R2%ZPQ("-WW_SM1V#K#R3A(;\,D`CA:)CR0C4'_1UGK_^R"AX=R8-CZ;G`A8'R;.=1,HYF9`M)94?0PH-@))Y!0\3RA'`9=+SY MQ0L"@L^J(1()!U"\FO(W7,J!C:2 M_['A@J"!+M*8AI.AA(7'0#W/J1X/$&PO=V]R:W-H965T.=K!^_ZVWN>&6^BK%)9;$QF.:8ABD3NT^*X,?_Y^^GAT32J.B[V<28+ ML3$_1&5^V_[\T_HBRY?J)$1M@(6BVIBGNCZO;+M*3B*/*TN>10%7#K+,XQH^ MED>[.I+\LQV'2>P\S@M3+2P*N?8D(=#F@@ND]=<%#4:*446UZ"_.J7G MJK.6)W/,Y7'Y\GI^2&1^!A//:9;6'XU1T\B3U8]C(UZGX('*NQ&*0X;\SM;<9>9]G;=!.C?5%RJ MWGNC.LG+KV6Z_STM!$0;\J0R\"SEBT)_[-57L-@>K'YJ,O!G:>S%(7[-ZK_D MY3>1'D\UI'L!'BG'5OL/+JH$(@IF+'>A+"4R`P'PU\A351H0D?B]^7])]_5I M8WJ!M5@Z'@/<>!95_90JDZ:1O%:US/]#J/'H:L1MC?B@OKWN6N[C@BV":2LV M*FHEO!A0-7#/ZARK&F0KL-QYACJNOG[F*OBHC'Q75AI;X$4%^7G; M,M=WUO8;!#5IH1U"T!,WB!)11Z@(*KN\]X4-@J^J(1:Z:@^R>C\?G4BUB(KT M?"I@-T1<2D1#PEM0A`^1D%T1XH9'W1B7KV`HG'[X7/]FN`G8#B%(Y#7&P?76 M#1%-$GR,(/+A-OTLC,M7\,:$V%R5A1Z5MD-DB?7C>_Y2BVS4!]R%'X9:=G@? M8(].$-QN091#U\U7KF"J'(I;N_,.(0:[0E/]U+-H]"K_["J1''Q%LH('DF^Q MP%I!"$)VS8A>*Y,$'R.(_.57Y"MXLM01&I,_2?`Q@LA7D[RW38Z7NH)I]`>E MCDB`Q>)Y?J#54]0'7'\1A$M:4KP/C)5Z^!7E"J;*[Y0Z0EVI.Y;N7#0``B_L MOW17D">9O'4^20.#37Y^'AIZX(Z^Y[<4N3V-=32-\%&$^J"&VNQ:8C@")[;] MEAKU`0V-('S4"O5!S;CY/N!$'-W[&3)M1S@.TW:KB`"A&]XJI'U40`/$OQM# MU:L)-U\]SL.^^CM-P9#JNF)I.?2U_.5!;W%MB63K5,DB-"(S4(SX$ M8P3AHPCU08W*^3[@8.T7G;[-[A@RV#)>N!AT#+G.]([B[7KBWBW35+P:E//% MXUCMB[_7,4AU'>-:C[1CV)V.H4N8Y0X8SI"9Y96:H3VO9K8(3E[-.^W1:<>0 M(C+T%IE$^*@5FB$U1'N^C#^A,!RY4RUR9S#K/DPBO+W7_4@0']PO3?>&IEO5 MH$5:!G]2!$Z@_22-Z'7VJ&W1O+U.M'_2(NZ7QGI#4_%W6J2ENA;Q+3CWZ;^\ M0?E'VA+7\@>,.BH9[&NZ5W@6@D<%N2B/(A)95AF)?%7G'`P>7*_?XAG,#LY@ MF@,+^WH!CD#.\5'\$9?'M*B,3!Q@J6,M85LM\1`%/]3RW/PN?Y8U''XT;T]P MV"7@!,"Q`#Y(67&PO=V]R:W-H965T8Y@!7[!L'QV8ICU2*U55+\\$CVT48RP@-,1N<&9R')#8? MF[UF%K.P9_7M(SM:[[(HT_RTMMG$M2UY2O)M>MJO[7_^?GY:V%99Q:=M?,Q/ M9'$% M+XN]4YX+&6_KD[*CPUUWYF1Q>K*QPK(84R/?[=)$BCQYR^2IPB*%/,85]%\> MTG-YK98E8\IEQ6(7=K^SM;"H_;SF95#]"_ MJ;R4G?^M\I!??BW2[>_I2<)HPSRI&7C)\U>%_MBJM^!D9W#VS>G\^ MKDVJDVB3GD\;"(<(IT0T)+PI1<00"5B+$!D>E:%O7\%@G.[POX+4-8]-V%GBTM1"1.?K']_QY;V2C+L"G M?A#T9D=T`;9P9[/;)4CG<->-[US!M',P=^_*(4(,5H7:_519I#TJOCI*6IX] MTK*"!RTO:%,A0C!D[8STO6(DA(X@[<\?:5_!1JLCI&O?2`@=0=I72=Y9)O56 M5S`=_8'5$9G59IDMO*"W5D;=X]SU^?1F9%P9NP";>HRY[>R2QH-'&E\;\GGE#AM3]JS<*C(C0 M5J$:5*2-UX`!"+_;A1%N@W[2,EU,-AJ,B-!6H1I@M![0H&AZ*P_6((8,NH@' M7A^("."Y'N^M4H(`?#[MK%*T=Y5PX\6;S6/^)K3FNF26A M16C[*O3&MX\1V6T?/FX-;F.D-`U&S(@(+4(UJ.@;KP&#TF0C79PV-C(B@ND0 MHH$_%,HU39>B.\_/#?75`[3^L.@==B?P2-0^MM#>'PIC/@QC\%`O3,.&TGG( MC`@M0C6H;!SM(:YHXT-10VDU8"$-(K15J`:5C>,U8)+2>WGP&8PC=?60._'G MLZ#[T_L$%`U.6+C,[?[TEC,Q/,'_Z@I4+0S:`VH5W;]C.H:N;^F0(Z69CLB, M""U"-3P4XNHKJ1&N,R9TU!32R!1:A&I043G>=1BL)M0NGD)/KMU%[!@X*S^"8PM="<(CB?<'R6B3WVA M.EY?30_6K)N%<Q"9 M+/8RDL=C:27YF]I`8?"-6/LN;NZ$L+E3[X0X[0'86SG'>_E'7.S34VD=Y0Y. M=2=S2),"=V?P196?ZR_\7_(*=E7J?P^PBR9A:\&=`+S+\^KZ0NW_M/MRF_\! M``#__P,`4$L#!!0`!@`(````(0#/+I%ZV`<``*PS```9````>&PO=V]R:W-H M965T;\J^!HKR=8@[Z];6[O/ M9H=GX;* M:#(<),=MMDN/;T_#?_\Q_U@-!WD1'W?Q/CLF3\,?23[\\_GWWQX_L_/7_#U) MB@%%..9/P_>B.*W'XWS[GASB?)2=DB-]\IJ=#W%!?Y[?QOGIG,2[$.\3G MKQ^G/[;9X40A7M)]6OPH@PX'A^W:>3MFY_AE3_W^KLSB;1V[_*,5_I!NSUF> MO18C"C?F&]KN\\/X84R1GA]W*?6`[?;!.7E]&GY1UI&J#,?/C^4.^E^:?.97 MOP_R]^S3.J<[/STFM+=IG-@(O&395T:='6NBA<>MIH[%$31*V"S&CKJ\_5D;J: M*_/%'5%H?>6F+)HHO[`IRRH(Y7?=']JZ&_OQ4"U,_]?]>!BMYO/98K6\?6\H M-(A\G[+1K/;'P]T[56F&9MJ$F<[N#T.#PK?F,CK3Z6BFSI>K>\:8)16/0[]4 MO5*G-X_RF.==F<9Z7,3/C^?LBWM*@;OCI(F$MZD6BNJ%KD3&-3S-(=`@)@]0] MN]1CP30;BWH]&F^@M36]4<7>;.I%+F(Z%XG>)@^*2`RX'A,*"PH;"@<*%PJO M+11U,1,[[+>1M&,#*$(HHCXAI`E-5$*:L&-Y2I-@?[JPI81TX0W7Z4+'\E+L M^D9>2I<;C,XP*S&,V8D>1&1UH,F#A.P.I"XF8B2G$TEI[':BJ1C)ZT32,>/? M@H);4-B)I/DUZD27@1-RARAX\V[.EGH9T2FD2@[)'FDLUCOJR!PH="@,*$PH+"AL* M!PH7"@\*GXL%OS:>\'_B.26`04(HHNO5S*6U".E#=VJ_D#YL*3E]EM)95N.H M+WV@T*$PH#"AL*"PH7"@<*'PN.#)H?)A$W/#AS$"*$(HHCXA9`^K7UW?-O:? MLIAN98UT*M4XZLL:*'0H#"A,*"PH;"@<*%PH/"X4NFUG-]R3D72-ZL,(`10A M%%&?$'*&RCIWY`S3K9R1+O4TCOIR!@H="@,*$PH+"AL*!PH7"@\*GPL^%U$E MDOT3YZ(`Q@B%&.T(T?7G2KF*JY4(2<.J>7=D3[@-VTAQ="A,%I"E6*8E>C)9`L3&Q,'$Q<3#Q,? MDP"3$).HEX@9Q`IS=V00K^-)&22=@S2%JYZ1VV"B8V)@8F)B86)CXC2D?,(D M79>XPJ?2.=]K/OSI:=W'),`DQ"3J)6+JT/C>DSJ,MRY_+B7@\J&:IG#5FSJ0 MZ#B*T4$4=2G-=&:WDFI25H>2#@D;$P<3%Q,/$Q^3`),0DZB7B+G$2HO7T]!M MSX?84^%63JVD8T^K5&].]94VJ\>]D!AX128F%B8V)@XF+B8>)CXF`28A)E%% M+MI-(E@"U7$4`Q,3$PL3&Q,' M$Q<3#Q,?DP"3$).H@U!"709;3"16<[Q.I-N>@BF\5"DEE%P?JE1O0O75/*M9 M"1(#K\C$Q,+$QL3!Q,7$P\3'),`DQ"2J2%63$NI)8BZQ6N0OY!(O84JY)%U` M:DI?H;-,E`TF.B8&)B8F%B8V)@XF+B8>)CXF`28A)E%%EF7MKWS6TM3_Q%QB M-VI1RJ55`XJIW7H)$5R`Q,#$QL3"Q,7$P<3'Q,/$Q"3`),8DJ(CS4 M[[3LM8/7Y&+B8>)C$F`28A+U$F%24N5J]FVW<.5BK722;I^U2O6F$R^/]Q`= M1S$P,3&Q.HBBKJ1:A]VMI!*$TZ&DO>-BXF'B8Q)@$F+"7GI@=^W=(\5SBK_4 MP+\-?DC.;\DFV>_SP3;[8"\LL(?*36OS,L67&?M:L=2N*6OZDG6[W5'6]-7J M=OM&7=/W!=OMNKJFKPU2^[A9`;TK<8K?DB`^OZ7'?+!/7FG3)B/V.L"9OVW! M_RBR4_E=]I>LH+&ULE%9=;YLP%'V?M/^`>"^?"2112-4$=:NT2=.TCV<'3+`"&-E. MT_[[76-"8EBA?4D`GWLXY]Z+?=?W+V5A/&/&":TBT[4F7;/,EQB;A%:US! M2D99B03TY3F"7B%2F8EBQ]W#0+",)CFER*G$E%`G#!1*@ MG^>DYA>V,GD/78G8\53?);2L@6)/"B)>&U+3*)/5TZ&B#.T+\/WBSE!RX6YN M!O0E21CE-!,6T-E*Z-#STE[:P+19IP01^>"N8M?@2!I;I:\QY@ED%&@L;RZ9$EJ``/@U2B);`S*"7IK_,TE%'IE^8,U# MQW),Z>B\OF45/$J2!\G2<($+#O5YWKC>8KFVGR&I M20O:*A!\$U>0CMA=$#*#DC>^>6"#X$XUY**OVH>J_K\>%Y$R2!?ISW0!VR'$ MTQ&[(<*?ZY!X"%FZ'42SX0]MS-YLJXL-&00-=)M&+UAT+V@2MU4@*&B7ZT!' M["81\1A"LP&O^7@U9%!D0JXZA:ZW='216P4*VXX*PUY+[;3UV6+1JV=\N^YY MGA]V_)H!R/G'#0V@VPJ&-Z8];!@VJT6\G!0I4.SEAT/^XM77?F?6J&=^N>T[@7-M1,R"/ M_9L]=7Q7DN"!\)ZPK0*-Y7\2$8\A-/E+7;X\$J;;2`9-MI$"C=F81,1C",T& M#`1:&:2/Z3YJH@;UZ#=2BU(;D^>XUWVE^>QWVKJ[F/G=OM.>:U);9+8;6^!= MMV]E04TBZJ`N,3O@'2X*;B3T)*<,%QJX>ZHFH*V<@)H9IEN``:1&!_P=L0.I MN%'@#$(=*X3MA*D11MT(6C>GXIX*&#V:RQQ&30SGKV,!.*-47&[DD-0-KYM_ M````__\#`%!+`P04``8`"````"$`0!UZ:-4#``#$#```&0```'AL+W=OU(AE.: M'4M<"47"<($$Z.<'4O.6KS[6#QDM:Z#8DH*(MX;4-,IL_F5?48:V M!?A^=0.4M=S-R82^)!FCG.Z$!72V$CKUG-B)#4RK14[`@4R[P?!N:3ZZ\]1U M37NU:!+TF^`3'_PV^(&>/C&2?R45AFQ#G60%MI0^2^B77%Z"8'L2_=14X#LS MB*0TC>S(!2W_*%#CJ"/QSB1P/)-X@15X83R[ MA\4_L\#QS.)&EC<+W3"Z0TMP9H%CJ\6_68NMLM,D.T4"K1:,G@SH8/#/:R37 M@SL'9IGE`/*CXB_L%RAP=@:M+X!T MQ*9%R&I*WG1PP0;!G6JHQU#UY9YHQ4FP%->RKM4%X.[4>B,A4X0?ZI!T"DG< M#J*)A;(/QM,%"USD>D(S;_1:37$)H+>,S0 MQ77U$KPT(46=,NB'0!>W5J"A?`"-TKRY"!K93"^"XNYQF@]H[MM]2/#$Q[@, M"N3"YB0;W[="1_NX'Q]&*V$SCO`3[3.;1*1ZQ,R"E]'P$P\C-+O1/78E>&(W MZ?*HNDZ!6KNQ%6O:DV@HI8G8Z!&AY0ZE.TXPB4CU",\"2+]$-7_Q/?XD>.3/ M=YR1/P5J_3E6./,TAZ/FVXSQ4:`7IQ>N]C2%'[9]SZA9DY/,8&N^ON(D>&*M MWY!4Z12HMQ:[@6:M7S*J0>:Q(\L3;*ZEJ!+C]:F?DO M(E6(/CUA.-,ZM=^;M#JYL)G?7J@&/;$SVB'69U2G1>_1S?7;Z3]OZ[KEVW70 M8+>]F&#F&Y/+6[V@VKCYX<`$;7UW*(;<;0[@;,D#7:XV^([4G% MC0+O@-*Q8MB!F9I"U8F@=3,];:F`Z;'Y>8!_"QC&%M@S3&-'J6A/X,%V]_]C M]1<``/__`P!02P,$%``&``@````A``Y@E<<*`P``1PD``!D```!X;"]W;W)K M&ULE%9=;YLP%'V?M/^`_%X,))`/A51-4+=*FS1- M^WAVP`2K@)'M-.V_WS4&!B1-TI<0G./#.>=>?+.Z?RURZX4*R7@9(M=VD$7+ MF">LW(?H]Z_'NSFRI")E0G)>TA"]48GNUY\_K8YT1)^2;DHB();L<>R$I0D]:8BQY[C!+@@K$2&82ENX>!IRF(:\?A0 MT%(9$D%SHD"_S%@E6[8BOH6N(.+Y4-W%O*B`8L=RIMYJ4F05\?)I7W)!=CGX M?G6G)&ZYZYL3^H+%@DN>*AOHL!%ZZGF!%QB8UJN$@0,=NR5H&J('=QG-$%ZO MZGS^,'J4O>^6S/CQBV#)-U92"!O*I`NPX_Q90Y\2O02;\^KYL_E'6"8- M"UP;%C>PO;GO^L$'M$P;%KBV6B8W:\$FG3KLB"BR7@E^M*"!P;^LB'X=W"4P MZY2GD(_)I,O]O=@A;TWRH%E"!&\>;)?0*B]K=^),5_@%"APWH,T9T!"Q;1&Z MFIHWZBU@$-RIAGKT59_OB5:O&+`!WI]8;"3E%3/PA)#J%+-P.,A`+ M9>^+;2.^+%IO@I;M:72]8-X]H(YG8T!0MLY(,$1LKR*B2XB!#7A,W\9E^1H< M(LBH4P8-,8IP8T!]^:ZW&(&V9T$CF]%9T*S+8N`#NOMV'QH\\N$%_^MLRF!` M?1\C?=NKB.@28B`_&,J_K9OTIJO=9$"7;%Q%1)<0`QNSH8W+W:3!HRJ<=I,! M]>6[GNMT/5"7:GL+"*::?MR[3,:'&5SF+"VHV-,MS7-IQ?R@AY('AV"WVLW+ M!T\?0J/U#NK@[@>88Q79T^]$[%DIK9RF0.G8,V@282:AN5&\JD_P'5

JO&?QAH7!T.C:`4\Y5>P,/QMU?H/4_````__\#`%!+`P04``8`"````"$` M"CI1,,<%``#[%P``&0```'AL+W=OMO^^_5@`MC0M#0/ M;9(Y<^)C>VPS=U]>RJ/V,Z^;HCIM=&%8NI:?LFI;G/8;_9^_O]T$NM:TZ6F; M'JM3OM%?\T;_;TVSR0YYF39&=6:9%B<=&6[KCW!4NUV1Y4F5/97YJ462.C^F M+=C?'(IS90/?]6%]L_BE,.WH8XJ0@\5-6C@G[?JJ]@LSG;_:V+P)^U MMLUWZ=.Q_:MZ_CTO]H<6PNV"(B7L=ON:Y$T&'@4:0[J**:N.8`#\UG]75\\:Y!Y8WIQ3EVY=V9/R$T60^*$`0G:P111'Q!J#@H MWF3RA0D&#U:#)[G5-N3&:04`P0(@-" MNEZ&V@1I.'&C:P4#?^>W"#$0S\'5+!CQNXCD&H*H@)]9KT)MVNC@JL%"R!@> M#@1YF%"6'8;28\Z.*40$KBM'9V,232&!'?I6Z`SN(D+@1',ASINUXI)5:M-, M"(\'@L).B*H?P^]W%L;39==P6*R2Z;)CB'$WL=ZCUE\_"PH\LSJD9D4(0O=+ MRX$`61013Q$BD"(4+#[)%&%[4@IWY"#F^VO,5V!NOAB)\1`@",V_":0;!&/< MT>\$(63@.S8C22A$2*BU;_A?C0R32GK=_PH\$\`2-T)0+T!:,@AX-2((6WB@ MDD8H(0C7\1U_C#+Q?[C&?`6>F<^,BQ`T\3_3%Q.`'0J>]V1=N&$8O.%Z`;5_ MZGO5Q=[O!]VNF0J;.C#J42A#"%N&4K#C'5/,8J%*&(95*A(*H=K>))4^*`>; M)2VI@J5\U'%O=)3C![YG\92)>PB4S:$V\\AF`=[JHQ[%Y#!;XP44@R17(50. M),[ZI)-JURPZO`'U*":'U?%X`363@S\W)1HA5`Z;#:Z/_7)I)I"LDD8]RN\> M%VV'7S#$9%W`$Q6K@PD!P#/!.#A1VT'?-!3OV*[0/`3\>2F2B,)Y!IZY'"8N M[@'+KNW/!G(L0ZB"3[5[=5TV5\)*;=2C>B6.%3`OQSU@V"?[2,H0J^51G MAZO3!26\%O;W/X_QX;+2L>E+WJP*2 M>?@6[WXCN/OM+DK-80&N7L_I/O^1UOOBU&C'?`=;+<,'-]9X>8L?VNK0] M5"U%=5[>6#NAX>KNWO_P<``/__`P!02P,$%``&``@` M```A`'@[F#HT!@``K!T``!D```!X;"]W;W)K&UL ME)E;;Z,X%,??5]KO@'@?@B^04#4==78TNR/M2JO57IXI(0EJ"!'0Z__\_>7#SO? M:]KT>D@OU37?^S_RQO_X]/-/C^]5_=J<\[SUP,*UV?OGMKT];#9-=L[+M`FJ M6WZ%=XY57:8MO*Q/F^96Y^E!+BHO&QJ&\:9,BZN/%AYJ%QO5\5AD^>ROS M:XM&ZOR2MA!_MS%S,E6G]^G;[D%7E#4R\%)>B_2&-^EZ9/7P]7:LZ M?;E`WM\)3[/.MGQAF2^+K*Z:ZM@&8&Z#@=HY)YMD`Y:>'@\%9"#*[M7Y<>\_ MDX=/$?,W3X^R0/\6^7LS^-UKSM7[KW5Q^+VXYE!MZ)/HP$M5O0KIUX/X$RS> M6*N_R`[\67N'_)B^7=J_JO??\N)T;J'=$60D$GLX_/B<-QE4%,P$-!*6LNH" M`S`UX+.YI6(&R0-8[C+#./I< MYU*%'(619V%E[\.X0Q8-].?;$V&,/6Z^05$S)?J$(OBN1;UB`^'T,4$R,^]46BZP8 M='(8`XJ&Z4,@ND:C*.)Q%/>]"['E?=NGA]Y1E,@*;`/2OSMRNUWC5H@MM[JJ MZ!9%6/CM;AN'5+=FY%I\*`QVW/V,A=AR;6:,(LPX#LA,RLD:OT)L^4WZ6F+* M*!KV64_"*&4"TVI7*(0`'*N/$%Q/! MHT'B;I21JZPH]'"I*(1M8/80B#31JO$(&KA;*,,DY\Q])XX`$`!V@`9DSO4J MQI%)R)FT42J7#JQ"'9EDG94XJA837X4Z,L4ZKC>4:CJJADV?*[L!/$?H(-06 M/N"),_JH@;[[GN.1IZNXIU46ZY-Z"@5NN9!,N=Z%>_H M%.^LDXU2J9%/*$_"&>A0`WENT)&KS`(P/5PX?THUG#_"N#[JCCL@"#6@WT+S MA=H*P-Q[%%5=!R@+AU]S%5E%/_%08@=B(DBI5#]V<33[(4!7`5"JE\LP/.;Q MP+$,JUA(IUC(=8750*!J.!!Z9L;38.#0#4@4@;<`)*5RB<+`XL),(NB,HXAY M"J*HPIF,@G"&"N+QPGT[2+4Y!]P$DE*AZSC01]11Z=DJ%$JUZ=GBD5+A_--= M3.-DSKM!0S<>L4DJZMG"\5.J8>.!1W,-,,!XO_=,J*TRF#Q2JJX!5``G,8JK;XG-\_EHVS7\4Z-LDZ M"SA#UNV"N3W/5[%.JJUYU[L8VZY4:M[A?SLDUD,Y2IP;O',CCEQE1:$G2T6! M#\;#M@-QY@(QT'>_\WP2>=JT"@!5N/%V`='OCVNP"G9\$G8F<91*G7D(WQ*F M)6/O@F#.O.-";55>)Z821U67^!QJQ3\Q5[B>@AW762G7J!HV7<_%.'&#=V[$ MX4BT!>(HE4L4!O<6Y@YYMT`I<.!92)(XT@?@D??(`)X;&/5N%.JBW?YM93JHXY811NYS)?13RX,'-@CE*IS.&. MT_2-EV9XIU3F]2G_);]<&B^KWL2%&(&/Y_ZO_67=,Y77;?T;<%=V2T_Y'VE] M*JZ-=\F/L#0,M@"=&F_;\$5;W>2-U4O5PBV9_/4,MZ(Y7/N$`8B/5=5V+\1] M7G_/^O0_````__\#`%!+`P04``8`"````"$`%CG9O`,$``!<#0``&0```'AL M+W=OM#3-^T55:=J6Y9M56M0Z M,JS;CW"PPZ'(:,*RGHN%7MBK["%V5ML_GYB%C50,4^Z(L MNK>>5->J;/W]6+,VW9?@^Y6X:7;E[A\6]%61M8RS0V<`G8E"EYY#,S2!:;?) M"W`@PJZU]+#5'\DZ(8YN[C9]@/XMZ(7//FO\Q"Z_MT7^HZ@I1!OR)#*P9^Q9 M0+_G8@@6FXO53WT&_FRUG![2<]G]Q2[?:'$\=9!N#QP)8^O\+:$\@X@"C6%[ M@BEC)0B`OUI5B-*`B*2O_?]+D7>GK>[XAA=8#@&XMJ>\>RH$I:YE9]ZQZC\$ MD8$*2>R!Q`7UP[QMV"N/>/ZO64Q4U!M,TB[=;5IVT:!JX)V\244-DC4P"V<. MQ`=UC%[_SRIX%"2/@F6K0[G#<@[Y>=D1Q[,VY@L$-1M`T0V0C(BO"!%!P9O, M!DP0/*J&6,Q5W\[#59P`"W%7U@@'@'M4:RM"E@C'DR')$A*2$2*)=62QUQ"_ M+UHL@E3,-'K6:N3OHQ,A!K(V^O!E1/Q+1/(>0G(!KYF'_&,NQ**M#J$:%4)= M3&%"&PCRL6PLQ_4M5[$Q1X2>#;\R()D#'"_TK*GV)!.PV^XW(18M3"@5$R$( M37BVLYHIZ%W&$F#E^TZH>)@#2+`BUHQ",N%_QH18M##AR!(B!*&)!\\BOC_% M$5U("#>PB8I()`0AEFO-LB7Y"#[C0RQ:^%#J)4+0X,,-X7R4C<82P+'=6:A[ MGXD$6#E042.#Y$'<\#>.S_?WMEBT\*!(C!!TW1560(A2,+&,N+%ODCE"V3>2 MB_`S+L2BA0OE`(H0%.#>5C9^C)/AL/$-HLPG\WG'""=N23R!Z^K^'/2K%O*# M,$".8-&(=R0#;<*M/L)``#__P,`4$L#!!0`!@`(````(0`L(Z%"#0,``#(*```9```` M>&PO=V]R:W-H965TP(20BT*J M5E6W2IM43;L\.V""5<#(=IKVW^_83@B7)F%["7'RG>]\YVI6MV]EX;Q2(1FO M8H1='SFT2GC*JFV,?OU\O)DC1RI2I:3@%8W1.Y7H=OWYTVK/Q8O,*54.,%0R M1KE2]=+S9)+3DDB7U[2"?S(N2J+@*+:>K`4EJ3$J"R_P_<@K":N095B*,1P\ MRUA"'WBR*VFE+(F@!5&@7^:LED>V,AE#5Q+QLJMO$E[60+%A!5/OAA0Y9;)\ MVE9`3UD3W8-X":^0P^0`NO\`U"`\\-Y(`+=]"1,HT-`RO! M@D9(@&JW)5R.7H.[T<_":<^SQ42F+\)PZI\:HQ-ZU/6K.^]ZV;51US^$?BJK M#=V"1H0^^Q\)VNAJ]BUHA`1]1;3F[W+V-7@0_:27?@MJN\8!/J6H4X-%U_NX MZ==&`Q7]X;.@MHHS$X!AU-L9&-<'QNIJ%0ZH,2IZ>_!R';#=;>TE,!R#`\C. M01`MSLT!UGNJU0(C$V"W6UL"3$)_%`TW;/36JCA7AMX2'*G"+KHKJPA;U!@5 M@&GGXDH9-+K;B1^4P8)L&?`L&I3!WOKV4JS)EGXG8LLJZ10T@Y7DNS/89\+> M^?:@>&UNG@U7<%>;KSF\FU&X&7T7P!GGZGC0;Q7-V][Z+P```/__`P!02P,$ M%``&``@````A`,^P@``!D```!X;"]W;W)K&ULC)9=;YLP%(;O)^T_(.[#9_A(E*0JJ;I-VJ1IVL>U`P:L`D:VT[3_ M?L=V0C!L;7+1A/#ZS7/>8XZ[N7MI&^L9,TYHM[5]Q[,MW.6T(%VUM7_]?%RD MML4%Z@K4T`YO[5?,[;O=QP^;$V5/O,986.#0\:U="]&O79?G-6X1=VB/.[A3 M4M8B`9>LE<,#.U:#SFE?NR@6GW:8@4(&,W6*XW-KW_GJ?VNYNH_+Y3?")CSY; MO*:G3XP47TF'(6QHDVS`@=(G*?U2R*]@L3M;_:@:\)U9!2[1L1$_Z.DS)E4M MH-L1%"3K6A>O#YCG$"C8.$$DG7+:``#\M5HB=P8$@E[4^XD4HM[:8>Q$B1?Z M(+<.F(M'(BUM*S]R0=L_6N2?K;1)<#8)@?Y\/W""-/*C^'T75Q.I`A^00+L- MHR<+-@W\)N^1W(+^&IPOE6F.H=;_E0HU2I-[Z:*\H`H.[7G>^%[`7P#9!0^A0RA";^._X+DUPT8TK,7\SFHL!4[.>*,!HD M!B7$-Z9\FTZ*81N,PDB\JZ]*-=.:Y4@SB73_EL)@`Y/;V:1X:T/A0Z.2:!)+ MIC6)[G44I=%R"$7![\>"($X2[QJ]008/P)A,;L#W>RL730E#$R#3FE@1RG$9 M^:9@;PA\;QE>'0S"V"1\NZ]2/"6;1)-ICA6VK':<]*KF:;5AX">D2UF%=[CIN%63H]RP/L0R?"M/GLR.'O4I':'&S#[ M>U3A;XA5I.-6@TM8ZCD)[#BF3P]](6BO)M2!"ICZZF,-ASR&D>HY("XI%9<+ M.1.'?QMV?P$``/__`P!02P,$%``&``@````A`*J-PXR[`@``LP<``!D```!X M;"]W;W)K&ULC%5=;YLP%'V?M/]@^;U\ARQ12-6D MZE9IE:9I'\\.F&`5,+*=IOWWN[8#C4.6Y@4P]]S#N>=>F\7M:U.C%RHDXVV& M0R_`B+8Y+UB[S?#O7P\W7S"2BK0%J7E+,_Q&);Y=?OZTV'/Q+"M*%0*&5F:X M4JJ;^[[,*]H0Z?&.MA`IN6B(@J78^K(3E!0FJ:G]*`A2OR&LQ99A+J[AX&7) MC.DY_''; M\>+NG,@=#@<:+)IHIYS4(@"MJF)X,,(2\ MFON>%:K*<)QZDVD0AP!'&RK5`].4&.4[J7CSUX+"`Y4EB0XD<.])KD^.#\EP M[Y,C+TR"]&,!OBW&>'-/%%DN!-\CF#>0*SNBIS><`Z\V)?FO*>"&SKG32285 MT!(:^;(,DUFP\%_`_OP`6IT%A2YH?0Z41`/(!Y6#5/#L5&H,4W"^?[U4G>1* MC9.!WE2S&D/>!1C$^A+"D0@.'DN\+$V#M30]:MK65?\"'=MZJN4,*`QG0TF. MG,25HYO[L6,Z"7#841$/'[!2+0BN@]341:PO(1R1,&W7>Z;!&89^#-^%R3MM MJ`5-S6`FT^!D,-?'X71R%'9DI:ZLZ[S322-Y$]>9E04E1M[-6)X-IS8/HF[KZ+H^:!H]TG71L94$'VX(C7^PF<,)Q=#IR]MRU9TM'MO2)B"UK):II M";T*O"G8+NRI:Q>*=V9C;KB"T](\5O!SI+`3`@_`)>>J7^AS??C=+O\!``#_ M_P,`4$L#!!0`!@`(````(0`T64^E]`0``,H2```9````>&PO=V]R:W-H965T MG]%S=U/+D*W)Y7+Z\G@<)R\\@\9QF:?W>B.I:G@S7 MQX*5\7,&Z_Y!W#BY:3=?>O)YFI2L8H?:`#E3!-I?N]WP()IN] MV8O&@#]+;4\/\6M6_\4N*YH>3S6X[<&"^+J&^_<9K1)(*,@8ML>5$I9!`/!? MRU->&9"0^$=SO:3[^C36'=_P`LLA0->>:54O4BZI:\EK5;/\/T$B5RDA8E]% M'(C^BMN&'7K$\Q]0<:\J<&U5OAP"!-NL`Z[MY(?7X5]%`EGDX75`9S6AP+4- MYJ-YGT&R"#2HD]R/%5G MV:>`#B*M/B3YJM+Z0Q+*SZ9/0OG9]ADXYEV?$I$V&,5IV!S_A]-\%NS)4AM$ M$5KM5'!@VVQ;!3&>[C)F=QGSNXS%7<;R+F-UE[&^R]C<96SO,G:?,11;(>V* MK9\W+F>/=2B:UJH(%?A44()F7W2)1["7"FZ[3M26F]@"9=QQ;`<5]5S!0]]' M;;&0\<`BN)&7,NY'EHOT5PH>!GC/7LNX%X4>BG\CX\3S0@_M)%N98/M!8*$5 M[&0"B>S([[8TQ3IX5GC`.LY6K8-?+13;5)#\QKR![Q&4G"<%)XZ--^V92K`] M&Z5GKA!\UT.+7\@X`?>ZW:@ICZ6,VPZQD/Y*Q2T[5,MKK>(>WHPV,CYPPB!$ M];V5":$5!"B%.QGW?,_MZE\Q#Y[5'C"/LY%YEHU2,Q4DT7D#)R)^=^LF=T\* M(0BQNS,%CP)\@[F">R[^,5G(>."&R)JE#-O$LU'F5C).0L>SD'4R[OJA@ZS= MR/C`MPFN[JU,B%S;0@GV)OBU"F/79'0`+_IHR]G* M.#%\)+Z38_:G9OWE6=6PR%"\_$$9T84WMDL M`\@'QNK;%[BQV9Y"37X"``#__P,`4$L#!!0`!@`(````(0#[=MR*90(``",& M```9````>&PO=V]R:W-H965T5M6U&B&$5E]0$JN4-_%,J+:F%HUX2TVI.BRY(UJ07ABF15#38,V3Z M$0Y5EH+QF6)KR1OK232OJ07]IA*M.;))]@B=I'JU;I^8DBU0+$0M[+XCQ4BR M['79*$T7-?C>17W*CMS=X89>"J:54:4-@(YXH;>>1V1$@&DR+@0X<&5'FI7%!72B@#71C M,XG2WFA,-E!#=@!-[X"2)#R!"`@XJ8#,URKBOZIP0=_=5 MQ/^CP@7E&-)SQ MX.Z1T_4^^0T``/__`P!02P,$%``&``@````A`&_NH^)9`P``^PD``!D```!X M;"]W;W)K&ULG%;;CILP$'VOU']`O"]WDA`E62U! MVZ[42E75R[,#)E@+&-G.9O?O.[83P*1-5GU)@#D^/F=FS+"Z?VUJZP4S3FB[ MMGW'LRW+>P+2Y06Z":MGAMOV%NWV\^?E@=*7OF%<;"`H:6 MK^U*B&[INCRO<(.X0SO<0J2DK$$";MG>Y1W#J%"+FMH-/&_F-HBTMF98LO=P MT+(D.Q,Z^B]_LLJ>)0D#Y)% M<8$+#N5YV?BS8+%R7R"I^0F4:A`Q.174,8ZF&;<1&NJY?@M0VIZ94E\TGB4HV9J_Z)H\4T M]>-PF$S;*QN'@X47]L8-T7#>QJ)EO]_N'+EH*GZ2V%1C(B7^#E[/_?8Z[T8X M#N9F.!N'A[08RF?_HUPNFBI/S+U3C='*9]'DU&YU=*9\!?"R,1=GX[#O!X-M M0_O40UF>[S%=O:G,/O5I'3[`,S>#NWQ5\3VI.56C4M8ZCES.&5,3V]](VBG!L*."IBZZK*" MCRP,H\=S`%Q2*LXW\ON@_VS;_`$``/__`P!02P,$%``&``@````A`(=;7_SI M!```)Q4``!D```!X;"]W;W)K&ULE)A=CZI($(;O M-]G_0+@_0J/B1]23$3*[)]F3;#;[<5!1'RR$ME_!#$9BH)X,@C\E4&8/YEY\\7RD2A3&676 M1/$FWG+.YOZP%H=\U6D*HRK:;0IQM:#W0'EYB;"3V1HBW_)#;NX9^RIAD"D, M\H11MC8L&LA%"55^WS&?L8WS#J6));0G"%X;2"6"&X%UP+AAZP,'!-]50R;; MJONK>1.',(J[1=W3!VTA7D>(3DSG*A+JR*HQK(B%PHT7BS`T63M)/NO(VQ,$ MY;IGTE?5!8-$:"(4^?`UX^4CO+4A-W=ET`A35=R>H$7=)TO7]UW758F@3;#E M;*D1(1'P>O^B)@6*?%BF;?G8X+,O-X!;R^!-FHV9*G)/T*RVX4XZ)@.ZZM=7 MY[#KZQ;4^YL:*_)]5;ZYTQ'69'<:=T\0"G@-;F:$X^PIK\1:=G")(]HUX+;M?Z6IKR M;B(4X:M'A".L"5^JXO8$&;(:#!*AB5#D,YCSXQ-?TX-[IJ1,#H:1T(BH'G!V MC6X>1I.NLW&N.D60E.Q^MICU];^$#$9#(Z*ZP#'7QA9$KRKN\J]9NC0[LJ(:JN`DG1'6P_5:)5V]$`-HMK! M,3B^)#0TU9)XWL"!.-X#C4_HB?NS"SPD::4P M#5GI81`)F0E1/>!4'.^!9JA:!Z;M5T3)_6I*3T&=;2!@IG$LN\F$J"YP1+9< MC%P<-%A5-_I^I8]?6!R=QZN`Z52G]T(CHMK!D=FR,[!?T8!5;>C[%5%4%*_O MR31@IDDM2V)"%`_>0\.\IK5]JI/!O:1,"WP8"8V(ZN&A8>[1,!]8X)(R>J!` M!B0T1E$]0%^,[R4/Z6X=M`4N*?HI-V-]LT\B1@_T7?V(Z@$':6L]C%O><,"D M>]&6MZ3:*F!Y=Q[@@QZJTYQXGO7U]"$[=%Y%!S$9+TX\X&E:6K%XP[,H!C\: M[Y_>S\F>O/JDZWX!CJDNT8G_C(I3DI=6RH]PJSM9P&`KZ*"+WE3B4A_SO(@* M#JCJ?\]P(,GA?,6=`'P4HKJ]P:.T^Q'G[G\```#__P,`4$L#!!0`!@`(```` M(0"LGMT>+`,```0*```9````>&PO=V]R:W-H965T?/VV.E#WQ`F-A`$/-0[,0HEG;-D\*7"%NT0;7$,DHJY"`1Y;;O&$8 MI>VBJK0]QPGL"I':5`QK]AX.FF4DP3%-#A6NA2)AN$0"]/."-/S,5B7OH:L0 M>SHTLX16#5#L24G$:TMJ&E6R?LAKRM"^!-\O[APE9^[V841?D8113C-A`9VM MA(X]K^R5#4S;34K`@4R[P7`6FG?N.EZ9]G;3YN^VWP@AZ_,))^(S6& M9$.99`'VE#Y)Z$,J7\%B>[3ZOBW`=V:D.$.'4OR@QZ^8Y(6`:B_`D/2U3E]C MS!-(*-!8WD(R);0$`?#7J(CL#$@(>FG_'TDJBM#T`VNQ='P7X,8>Y9WLW`7P7466REJ#<9(H.V&T:,!30-[\@;) M%G37P'QVIG1T7M^R"AXER9UD:;G`!8?R/&_=P%]L[&=(:G("[10(1N("TA'1 M&2$S*'GCW@L;!'>J(1=#U3Y4]=_U.(N4BW21_EP7L!M#/!T1C1%#G_$8LG([ M%LV&_S\VY*+0A$TN:0S\H-N@3=Q.@:"@'6B`B*XBXBF$9@.V^7@UY"*8@YY" M:)GEP(8"3=FXBHBG$)H-&,6^C>EFDN!1%6X&\A5HV0Z$YPVB43\Z7UY:1+5^ M/^K[JXY9DQSHDN7T7I\#N6@D_;*!:B`%FJM9'FB+^L&9.S06]\/N6]*7NO3I M;$OP4/+#O.X42"5]YONZ MOTB+NN[`6ZR%+X.D25Y]1+($CR0/OH<[!3JUN#/\R&C149_TH_T!4)+5::P. MJPJS'$>X++F1T(,\:5WHS.ZMN@3LX!+0'IEV%X!#N$$Y?D0L)S4W2IS!4L=: MPG`Q=8RK!T&;]F384P'';_NS@-L6AC/(L0"<42K.#_*BT-W?MG\!``#__P,` M4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q M+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE] M&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_ MW^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$CO MVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T M0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I M@O%TS?`4P2AG6NO76U=VJ^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$N MCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+ MKS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX M.(N#UO5D"53,+2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-Z MAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@ MK,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D) MQW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)Q MTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2 M(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-% M[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@ MA_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/ MR"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR M@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NM MK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1 M?F#R`Y+<'2E(7.T6_>V?X'%I<[JZXU+I&X*L3Q6X8+(WQ^<@8.,$ZW+C!X]+XZ[UU=FD,XL0.-K87!L[2>'%B MX[N;7__J.DY>/.?SD^,D`R`1Q$OC*4EV5\-AO'YR?#L^#W=.`)]LP\BW$W@; M/0[C7>38FQA/\KWA9#2Z&/JV&Q@9A2M_+4+$MZ,O^]W9.O1W=N(^N)Z;O*2T MC(&_OOK^,0@C^\$#J,]CTUX7M-,W!^1]=QV%<;A-SH'<,-QNW;5SB'(Q7`R! MTLUUL/CUK)PL<9Y6$NP_#+[:'AP9([QUZ(71(`$K@WSID<#V MG>P;*]MS'R(7O[:U?==[R0Y/\$#J&/GW?!?,A`>'&8?3\GE`-(5,EPBC)M,4 MCU"9?!#)QH/M,MG_;I"IQFO&Y]5%?S5>J13M@7!SKLPJNT%>$3/3XL M#C5"MU&`],5NL1L#O9,PN9B>3;&I-K;E2R6J^>&@W9#BU5*J2P]!Z M/_]P,G6J9\:2+D_#IXH`##BU6G0A=%OB>V[AWRG\Y,0%K1^+I51K23\-O2HW MWKN^$P\^.3\/?@Q].T#%TJ*6?KM6DVN.UP_YF@NH9U%XUV'Q?:4;-Y/7P6?PZ[X5;!( M:XI:0CWU`C?7:Z5QEY2YH+MY:LF'FP&[\:%V&/?,JY2)1$?9N*ON)$IF1*C> MF+&2<&\,"^E(ONR-%W41@:39S1]9FNRSZ)`L<1(ETCCKC6'A(>DRKK\*@<[! MLED/LJ7-:`Q=JNMYY>1M:N)L"H[<7,,0,'&BP((W@_SU_NX&43RNTGE8+OKJXLY:W:5\"3)1%`RBEK6:]T#T M[G:Q4H]TM4A3U%"A^!,+_A0C?3_#/\5$+?C?2IE.\PR8UDX5ZBSI#1(7Y]>C M\_EBL;@<7UQ>7B[,Z=@T4R4_Y![M!AOGV<&1MC(U'2*8`8+%]')Q,0$@(_,R M9752!%,`,)_-+F?CQ<2$_Z>UH7\$JG4*(WS-5B4(-%F5(-!DU;3V*HQ5V$W2 M;%6"0)-5"0)-5IVK*A-Y_IMKMRI!H,FJ!($FJZ;K>86Q"KNTFF.5(-!D58)` MDU65-9]YK"ZT6Y4@T&15@N#45BV65:N[.RO=!CKLS-C]<;J2@[7C0QAMX!*7 MXKH-F-46QVZN/6>;P"HQ6%CP!?*)P"<$S5,A8 M[9"+RDC.$).1G"`H(SE#5$8(G:;@*C2Y"?=PM=9K`UO6Y6B4KL2D_:69(`'> MX#'<(RECW MFT:)RW$"IN<&)*_T7?OZ<3"`479B@>=5$LSS$VYM9)=)"+MOL[A<\D1JH"!7 MK@H97JGI4`853&0D*8!QSVDS8EZOH?RO'<_[C`7Y[]NR!X!1U\WU\Y9<9`E7 MON)5B'@-)[Z$>7+^,JO[V1O0,>ND"?.D@;W;>2^?]OZ#$UGIY;`IB_0HSJVK M=[=IHU*]?^^YCX'OI,,Z(R/S0Q0FSCI)+]=--[I8>*8,/..+OQ-!G_0 MD[`^NO"'85"C$4$O6OF#&%R[M1@`NK4;7A4(H`E?X$`C*`#`5Y( MG>L`W%,'`EA*%0C`02L$`*?%*[K$`>P]EBS!!RJ6P+\OEI!C"BEK+'N4DI5^ M@7^+E%8M_792,\FWX.B5FN%-"X!.+%DI5E>*(6:'2*M4`&]:5&!!U553\L:L MG*]-(23I`H9*(Y`&VC2BSBM)S@6>%8!VC=PJ[$.(4V`JT@T!X&B!0`PQUE1_ MQQ2#I@I,O4%3":80:C7XA#%!+5&KD)HP`!XM45'U">-:Q3BA&@@$71F2>,-$ M5XJD&'3ER,H4$UTIDD#0E2&I)72E2(I!5XXDIM"5(@D$T(B6#$DMH2M%4@RZ MJ8 MM6H"6L7IV?(I6SJ",=+%%%E+XV_7[6)X.G@*(_<76&7B;]C7,$UU(@/O>9"X M:WKDY\C>W3O/L!;--IZ>MYT$Y&"J^,-TW1C(,%>NGPY8!"S-4017\G15SYW, MO_*,^G2;ZR%<$#C=T8T!PT(W!K1WCD&Y&RH*4ZB2!41A[U3M+E1-4#%YR?#H M;(8[O#27R><2U%8^$@?0M1;GJ%S+C22B&NSRM3''!:=2YM1].]M%N6K>=HXG M3H$OA1R26>X[B(K+;S'N%F1![!2Z5C0(*.7$6:ME& MZ3T%RMN\[1($G9),6%T[3OW;]'B;;S9P8XDFV**-EW'Q,:G$T]?3G3:$5KH? M(X6/6P`&^/.J+(6`18>"BPT>;#&@,DJCA8C'O982!94F@T4^6#C9F7I49XN1 M)8(XT.;&4["X4/CIE7N2Z\@^.Z`,#\^UJ:+Z\"ZJHA6U:)+"86=A-6HP!W>%13J[D.3(*) MC0;6AVUU6;ASD$*CB0GHS71U;(2J?+FS#ED>I27: M:'8\*O-*9R.YX39I2OJ&)]X1I+J:I*=R=,S)PO[DS.? M0IDI'.KM,-=>6I2H@J8\\0R3W5JE;:+"M!E>FJDD6<0/6!I3>'9[K86^E.\'*6QB``Y&T1R5SYR+@8;8WZ-NLQ MJS"*3TG\43_+`;VE45T;)$R*Q?X^U0O';CV-OMJ08MXJKI403J`B.)D^WV!6 M_N(+H37`U*I//FKB!!68M*W`Q1,QOPM>Y]2BXW,E2M>*I;Z MEU\JXU)E<.I$\^Z-Q`R1&^I'1L]1N`5]]"C:$CJ1=]D^$'$]&+TV[RR0?Y&W M.%A$.B!+;#1'DYOH)B4#='NR%<$LU+6)HL3RE:N6EK)VE/58%,*C-/K(0EXY MT&.655,6H#Z;-KE$RT0(;MJV+*Y&X1)IY2@=DL!6;E1Q[^-OT$ADH'J<')%K ME.*6WB/@6)R;MDENF0JO6^LZ8^86&>:FULDZ\6M.P:J+?H2[')'TV:GKK>QZ M3W5N1TD,ACI;+PMVZM@R'>G)]\U,\C,B.B#@.+E(AW.$ZXMG2OZ/\NC$@2.- M(J.W;/W*^`"KR$,B;J[Q@LN0T]=C[MA%]92?=OC'M"\T42A15XM+<)5#2HX2 M+#0G<9FK'M?),&=7,V8(9$U.U>:VA`2U<1]YH8/)Z=[FR4W.W'?F*)W9W'4- M1J8;*`3$BP,FAC[7A%Q0)#/TX<'4CJ'<'3$Q4:T7MJ7)!<:0)>7IO!;B;`KDW;?W.M.6]%P;XZ-ZE,1G] M=G`V>+]&HF6#C]W;P][UX*D3>$\%#.?U/H:;J]]F!_,;&;31*B]WP5_@45I0 M#61I`86L6YE`3TMIP1I2EA:PSVCAE3J$%MRV5YH6K$-R6G@GFTI?V`C+XH)3 MN^.A7T M54JKLF/=5U%D65R5'8$JT9<)'\C2JNQ8SQ.F8)Z@,E9VK.M^)JC[UQFU[O'8 MG8E(EU&I;`>OB(ZP8(M3J:Q6]_*IH)=G6"I[U?T;1VKB6"I+`3TBD0D?B%,I M;83#1$I%4+NW]J;(NG6'P3HC`@.>3[O>>S;>,[T@A)?'$BCX(U3+PG5XP'+J`BAN^>=9P=V$D8O`[SG4$FN;O29(+D_AF&IHSH%O"Y%!-"? M''OC!H\#T$M>Q&L*PHY*ADP9"W7UX!U(9R? M1,A\'^SVI87JN11+MPB)CV[PQ=G4/:>>)?!'<"*4/CG[)+)+_ZN'U$10,9_P M*00EC7J*R)Z>73PR(>\_/\%#!PHE8J=-8@>[?Q'@?]DG1(UX%B$R$911!&G^SHP"CI1:ZKWR4(5%U6S7H_C?/U1,I M4KTG-CP,)WU61;D>`$5MG*V]]Y+[\L.E4;W^<_H8)G"F_%L_N%_#)"6Q-*K7 M'_'Y5A#%L-*$=/,QAF0NC?_>WQN32>DF1W-1S&ZR?'M^-SWUU'81QND_,U M/#8KW&[=M3.,=Q$DE?C)<1+?&TY&H\5P,?3M](DU0.0J]N!;42YL#OYS=6QI MD#<9_/2A-@`;[I=0"#&,\<$>GY')S?\!``#__P,`4$L#!!0`!@`(````(0!+ M=UZPI\@```2=`@`4````>&POEN'-F5Y[\/ M,.\0*-1,I08DQ46EI:JL!L5%IELBV4RJC)K&?`AF!LFP')]70^SI?\.;]YN)C-BWRX MN"V*Y7CT<'=[^_'#<5Y.OLD&T]5DR;@[>X_VOLE6D_+/J^+`__:8GY[_M"B? M_[1\?C@=K,;%9)DQD^QHLBR7=]G)Q`W!S+/>F_YA]NV#GQXNG__T4*^XUW9V ML]?3R?)VP3O#8I@^/BP&6]G>SD:VN[VSESX\+JZVLMVG]O!1^O`/JPEO;G>_ M&2>[WSW9?]V_6BSG^6#YO])NOTM_B%U=WLV*].%W.]N;_YS^N`^9AD:JXU%^ MDS[][CH?+5H=Q5'.BWDY%8&'V6&^7-_NN%P,\E'V2Y'/LV.V9M$:IXNB<1C_ MNA^MNX/C7](^+^>YV#+KWXVOIJ/TZ7?]\_.3]$?/*1?%32F*PS^G^;BU+%X] M.KB\>/,Z.__]_L7K_8.C-YSMI'WYE?RQ&H\VWD^G[2=8O M\@4B.LQ.%HM5,4]?^.YTFO[D^PC3N2AFT_G2*+S,EQU[^DO1VF??Q<_3T6JR MS.=WK&F$,EDSDCW,#N"LF^F\3;']P:#@;1X/73]KNCF8CL?(?'\Y';S=R/JW M^;Q89&>KI>DIYK_FM?/5U:@<9,>C:;Y,FQQ,)XOIJ!S:V"_R43X9%/2,OEJL MTRTGD^SR=KI:H)$6&ZBN4;%89-/E;3%_7RZ*;#$K!N5U>;_2V6W-P[-&OE@P M]`^MQ_GBUE1@\>=5^2X?%9-EB]:O\_G;8IE?C9A#,5C-RV79WC=(+2V[R.;% MH*`G6F]DDV*93:^S?#2:OC<"H%^SX71UM;Q>C;(\O$*3;W>W']L\OMV5AH3^ MK'99OBM&K5T]$T5JP[3F>S)YQS*F\XY9GL^+65X.L^(#)F7!)DO[&XDS%F8R MY`B5TNFPN"YX/LR6^8>LN\GE=(GXWM_-^1Q;-L?4:%R1?";%:H1*1SR!_2'\]5--N39:&H$ MC>.WF*>Y2?=,"T#(WN9ZV6#T21FP95M/JWS$#<.MFP'A+8\]%,2F1Z\ETV58+CMYA9AT#2O662U'("6-<]Z"C\7>? M/G[ZF%+:M/;M=#3$3'QG0K6\:_$L@N\%>"$EG_;A#8`]V\B^W=[:WM[)9F`1 M5.*J^#';>?+]!M97_\L6SCSDJ^4M.N8OQ?#'[/&CC9UM_O=DS]CY,0UW'V\\ M?O)]5LIT#IV:J>Q)EB\SH&(QOD*3!;AHC4`YN_>KO_TAVP$OH&NDRC;+23;( M9R6Z)UT4DK8:KYQD>1TW'<_FQ2VJ#\V:E<#R-G:IOS4LKLM!>_/=IAJQ$KJG M4VAMORWR2][L`QS1SR\R@+&XZSR'VP;E##F`.:OM[&L[LW]];;1LP5_?RU&& M.8[\^O/TJ_K@U?66G&G!NK<%<\M'#[[,LAS2-_?[9EB^73-YKRL[;C9K.O[-4W=Q)U_P1\TVDE<6G[%C'N[7U= MZZ\:``B,)C"%DLZFSIVS2E.9HDG;MN8RPL45SI37NJ[WBH'[FH93MRCW,]"( MLRSK6+?NT;9\!JR%S'$;5H)SAJO!,EN`*,&RX,!T&:_*@1!8=EUX%+8HYN_X M+5MCXITF\0];=M"O`\TPF"Z\)0E@HF4+#F@BRS:K3S+K(9:CU5"S&Y`NJX_[A(+:R##TD-;!FWPX+B?F+PK1IJ]<%`N\WH&# MX340D[;;KT]+J*D<8P#F!BZ896MNZ?N.@A5]A$2=-@V42M_HO9HN%@^\GIM["D*`G`Y`Y,2"3>0JNB=S%#K*S:T,3R.>"T(%!IVQ]!,WQ-4BI-F"# MA+;SXDXHWEK#FPEQRI%08G9#?#(0'U6=O\O+D=RG339M4XKR'N_:KU`HGU=7 M2:=?V]LQK%7>@!O-Y1W<98ID+0"*,B'Y\$^KA0/DZ29VD2*PM3'5/4)P#P'3 M8>[9][Y,8L2<1T@ZOO2:#6^&4UJ@*QW59#7]L3*V]^-,#VSN;U1#[N="[DPP MLM\:_%H'XX[Z]W'^.A1<[P6/49!^+6*^A%\7*^)N]Z_%:39KX[FM%B#,=.NNS@Y:)'UG.Q@FC2NQ#WZ M%BB&NF^9883@=@44%]V^IER1K^TEK#U=B6*S%EIC1O51-8M'VSN]MP^R&<'' M7_G:5X\J`W1$X/R+QPLOK!MIOU)'&;AA-3+?S;#((*($@[W:$V^\+0HYO9F8 MWD7K*M*V;!GRM:1;S=B[XD,Q'RCN2K>VCV"?SAC,K^QFW8*_O+NPV"^F=6M= MH8=U3D0PG',(KX>YQ.@C@%TM!%Q`D5= M)(T1,G@41%0Z^!@/Y\02%&A6!\5X-IK>%85%G=^7RUOI6E3H?3O^V\YD'6V. M$]Q>J<,0$D,_7>9SW"2'6L>D>:#?;:G=5,@`7:/M6GYLLWFH5,?J8M& MJO4:.:X:B_G]9&T2E,7UW1=OX:_M)TPT98G#\AWN$9DDBQ*F3R^,R8+K>+]@ MW-=VW>A-8J9$;"6IFLU#IY]]K2Z`#2TDV;E4?<%]WN#7O1TFE5*RW@O!VZ>- M2.-I5TB\N=ATD7OI`,WF81J??>T>$'V@G!])R_=K,Y&U%L?R^JOPRKZ2\4GIWQ>&ZS!3:;N#B$;2F$5-]P6# M6U."$Y(^0<^WXEH@=]D#!SB'Q=4R&U(HH42K:$C(IQ%+D6_X93S8B"75*7== M3D"3TILN4/0?&N5%/F1/F'2`"STQ!>#WK@4&%&G2]%G>;(HS;."A_``S=.HB7WY!+M`-M%#LJPK0.1H8V@IA*9(CK6`#W)+FX%,"Q";K M<[?WI!OE5WVET*832%6+DO4+P_3WJ):^PLBV?`K`?`&".&3\)94)`=C!7[_F M#;121\H^759CD*\*[1#%&Q0%=MI\&HL#,<^OZJ*6/]8:C2909@X!(A@=5ZQPV@7)"(HYX)"8OW3%S;X[]S^P#OC'9=[9C6Z;;!A` MH9O6*!55S7J6(<1C)KG5NN9^-#AQD%-=XV,6_X'91!4QJ\&SBD[K%X`6V>$8#XS;+:2^RWK!P_U(ZRMD@6=9[7C>] ME+3)-LF4A#`D$[LC\9;2<\U[!:.M>:._FLU&YN:#6P[!9T`"(AYJ'I5CO;:X M9;>ME=6ER7'Q@9:^/7E%]^VK_-'.0;FUCYRFNBUL?U$*Y`;9KFVJ$22<9XAKKNCPL%H-Y M:=%$,G1_T^4]COG_3UT_G%4?_H]')?33:R M_=/#[.S\Z((_3U]F_:.7KWF63J&7/Z"LJ7-M:=.^RCOGJW%V;F9_4`"^45C0 MX&1"";VEM\GCOR?@-;K;I!H9WEJLKDCYEKD5!O7^]M?_$SKYVU__[T9&$4[& M;VS7+)_+#!AF9Y=E5B%`:WD^EH>G,G]E,/ MF>)M&76JHSOD@`)C*:^A,6=!8!A19Y*?/@[3TD./VDE/;WSZ:'WD>+8E4/4. M<$-ENZ0*S]@-IH7JD,/2_MRBZ)AL*^DXQF/8A4UF3A3:E(]#!^SP!BZ%%3O: MO]6'0\+:_!QW!FN'SIR5LR)4\]D+^]M?_E_9P#'N].OJ9E?^);9<[*PF:P=Y2_"*( M=N_-5G_+43T?OI-A9%G4'3-K>`-*C'#U!E9CJX=((.LV=;&2'XPAROAUJ2QK M8:;'`?Z",CT"7!\@@$:9Y[.[']/Y!:WR!?/3H.]@0>JTC2WF$Q-2R.DH`\\: MW\"WY8#B.]5%3C9_/QW>O"TG?_OK_UYDH[OQ['8ZSENS"+#W"V9A8PAAS(PU M5`Y]+0I0!*^$/6":A8ZRRTWJWT?5B")9NO;7^Q?_FBXH(_S;7_]M4JA*E1!W/J`$P(]Z-6(#V;Y1L7I;C,N\B[N0^VEV M2V4`S%MG6L^1F'O\`RJ,&]^\])&@U1/]M9;"NZY?J M]S&Y=E5BVK9Y:2XGFZJX)_6.OB0^3VXT6Q;Y&,5@%DT"!:M:%:78MN;?;U2" MU/@5NVG2)0VNLAZTP+RX41FF-B>_5G1HL2&=8XPMXCC7E@7F,%%(&3BU;[,' MIU,H4'+:B?G7-5`Y8==1%XBM`(>$2H)4*0.L2Q#44.[DJ&(D'Z%$K!A#+RE& M`T:&%OZE]]/YB-KR(8J$VDNKED#:@`9$2[0/[B4.!(3XE$:Z\K8L*#'M0LIQ MO:L'W98N;7@^9Q=*L)5)L("?\8:I;NU:UAFC>)T4B^B@37_YF M2T#%[D\F*Y[@;%#VI1C4,1N>Z224XYVKHIA`/)P=I67$@(PS'TH'.5GWI5XH M1YY0V:E= MKT(`Q/,2)+!7]=#T9C^>S+`WCT(4[$#UU>P9ZS*3>72@WKC;)]MF^T:>/[D0?E=GOQ6;X+&(%#8>25S4U@WN0 MJ8(FR0P+BWN#V'BS&0Q-3\_8[?"W@[/:F1_%@7UQD8K#/WW\WDX$)B-;A$=; MB#4SY(1",=RD+;:'KBL9*[K[PVITQQJ>N,.%S44X\+NF*WOH^$7`Y*L%K.*C M$,$,M-/,:J',NL?!GDP\2@C\#Z?6X#:+E13Z.GA!`%'3LZ)VPLH$')=4#(G* MC:Y?Z!=NX5`/$6>7*JR-H;ILIU"+7-Q9%16VN.1GT(`=@XFEC4=BNU:Y`;9( MI^JNR^OEW2:Z5@EAL4F4$JR7(F`'F(`ARB`7@PAJ6.=5K-\ZWV!7()I"R_@. M0TK"%';*<411)#HS)#T"OG7"]9Z6G)K-8T'$OZR*JV*P$<:"G'_(T8(8*([2 M/MW*#CR08GK1?D3G=E?";8/*:O5%$C- MWDOV78;!!"6^8JK"C)[V%$E&]SE73[8'5.XK@%GX'*A!FESY*>F62A5M97U4 M+NH$;4`Q)^5M="4@3U>+MXXOY@6!FJ%7H7%T$XTQ9_3LE82:G(1!;[,=HKM& M9'MF'MB[^DN\@KD\#W07T3P&[7CL%`,CKMW9-0QAV/'*'R2T@\]N)37%K=V" ML0R0\A#"0X?HEVLC#^K:L=,J:FT4$R^A'N_G#9UX$$M@;C&>Y5PV-2MZI,E`XM?/I8SBV M$_2S-!J!/BR%R.(%)W"K'H:`H$^&X2B(PF)Q(8>ERT#9>IU&,Z47)YJ7XUAY[I&)@Q!R]+O:#H(1DZ<*(R08J;^:HQ9@F#H(,I!!7YUH'F_ MPBXQD*#YOV%"-#T"L>*OMF.\_3>O\25^4>R@?_+R].28$\^GE]G^P<'9FU,+ M&YR?O3HY.#GJ6S3A3?](38_ZER>O]R^/^NGL+DU^A+J,GS5T!49J3(_N0@G! MCAPC\TZ[=!_D-C.-B,/W%:R6!AKG;\5F>D>\$Q9DO&*A+U?HY;@,Q(XU,D9P M+,DKP(V5'%?F%$@.@6KV3"#)'8VP3L.6.TP?&(&T8RU4R"*4!I-1J'5$1`!3 MIX#!YLU4O$LQ5HD!3!95J`).FV***:ZH[L;@!K.!86RHT"L?R#6Q:=:K?G_D MB1Z);7"Z1ZS>G04U3B&`L<3=4U`@$J.45+NHHP22/XHK+PX3 MS`PL!:QC<[WRG1\G%O#=^/.L1C9L7O,(+*^$-UQ9=60-54;7MB)20)/0LQI) MU4E8WZA\"R"\95`U#.D,<7N<4?>^6">AEV;"WR7-%*(3;=Z51LPZ6ZU[5+2017#% M?.C()@>9=?G3:FBA18\:EHB)/&Y97J<3,FR[#E8K>F3^(DXSAM;1R\5$:@O= MRLC2BR?P76!9L+K\K(#.QKF"2690I="&)7(V=^:\DE:;5ES`%B#7YATFZJ)^ M=6?+1SXWJE4[F:M-"^N@$.45'WSCD0MU?D97N?4 MX=WY'O3#0^MT^?P'A5(6"B8Y$C@;*64JIZU8,!=LI!@A%E-,YX0:SB#8?2WB MX:IFO^K(1K-M\1:9KA4`9'X,BSG>1)`42EFLA-")E5I@DQ_0=#,=B!73T1$H M[!V,%LV^%[29`F:X;\PR$-_`9(@Z:4VP?Z.6V"IH%[?NV+ZI#+\9*#\B(N42 MO*HA!33U6#4HGK]TQ,)G.IB^J!A4J9NE5GJ-NIV^EYH/W@T"4\%.Q)>`J&^=&QYI\-6KQ`3GVDN,D>[72#!^NAV(-1MCZ4(ZPN&.%5\`P9)WSJ5A?U5TP9 M5-4IX@(T=K:R39I,"?]6)I0A433LH(A08Z+6`#@)0ZK1>-N\CIK4!Z_%`@R" MN].N4,T>+83QM0C/53]^^@A_-"5[^9Q)N#`E MD_8D,4T-X1DAZ#\>,H%).Z!V1O\W<[%:,.?&M3AFTG&8[?!\`_2JNQ$Z<1??$?$,K MC(J3%C+PJD_]FL=67C]THF7AJD`)Y]QHTR*]L"`U5E1Y@^8%5#4.T*1;UE%D M>WEY6E&`WD2S."&_N`4W_'@_ATY]SP%(V1Y[)3&7AR#Q]VZ73:&2Z7'^)[A( ML)S+:HA*)78`@5X^#U0FA:NMMEH>NSKE-]3THDO(V`0=Y2B^O)O)]B.O["-X MV_Q^E7IJLH'%G5Z!=HOR0T9<3I=EY=>H"8=-/\Q*C^@58I'VOE)22(P>TC?P MH7+!8L1X/'C&3OL;%YSI]?C><)8Q4V".FAGW`D/HAQP!$(\Y6;LNL8,IRCNOGALC737UO9X8IQ*SO`K.F^CFC+B3H!UR%U00V* M(J::S5>U5XH/0@>R@U0Q\$'$`V#K)F0N'68 M77"O:R&55*\92VNHS8])&8ZK32>@>W,;G,N]=NZ`O[P<+P(=6XZ%UATQ2)R] M-PDM43GT[/`;2D<<,NM5^238?,Q-(<$O#1S%F7RY:MCAV5+]!`,8[$'NB_?U<7Q@^8$"_:!B.*5_2&-2&./-:H3I0O'67# ME>E\M9[;"JH&CNH5GF^F%P+!G1>LM2/?Z#>D3LZT;*"VQ<]`$D_JH63,=01\ M;:EFKC/[S2DIB+!.EUMLKJ9A-IT[/\SB=(/V1@.BM@"HD;&-NQQ5G8V@J3L3 M`C4(!>*OA2N`TF&\LPD/J^S"I04#2.-E2+N(&X8JF[,+PLL6)(RB!']7@"#( METE,W)8QJ`8E3^14GG)D'LO+XVO%N(#/^$E<8N8$8.-J`K2Y05$K[ZD,Z%H% M&NG1K3']8V>RPIPEY"3FN7G`30B$$*=:`SI>:VJ26*2";)F5XELUE&Y.]?*^ MB!6.&$CV*PG0A'",2X>S2,?,"K22L>F`6BAY7%'%E@+6P7KITL.?8RPAGJQFWH9W/!R11V9.C9!7Q,Y.R_&J@7K-BH(RY27BA,-[ZQ07QJXZ<*-= M/!0*/N8J(.<9_Q;&H#4'0^+.W\"X6CFN5+!W.F#\-(YE5C,?D75`?[GUX%)( M\H+WI*6%JBX"5%0WN;2ORO!HYOF+Z(I@N_+YT-AN05(^S2N^X$L&Z\$^5;<) M32=UEZ,2RXW0MY>O"A@@O4&5!4?"!H,G5<;0]*0</BFOZ;I;,H$JU+:I M*&@$[UB8LO(G0!,&#N4,J>!-/)S-IW=B5/)&JB^/CC;ZWE1\-EJ-9YO4?(>N MY7>KH;-,85H^S&'TL/(9VUXW^[6[1_:W[Z_VNG`Q[M].QMT&FA*V;7/^9`@S MV$5/+B*J3/+1/C?'JX+Q:2F08X M8:G-KP)FJ"89;?>0A_5JQYG46#[R?HB%]_Y2Q=="9(_)ULMPXE4`LGT>`@^- M=;7&&C,:L>QN9%"5XB%U-S]F3#&9_@!Q!X^24B$_Y\YI2%L?Q65Y4U1=_7Z@ MVC:UJ9:N^FRJOW#[(<\M=2HP@+N.C\W7\2J+3KF])>3'R1.4`KXI'H0%*GB+ M*2-JWO1#/>7*G*>JQ<:7H@^BH)E?1S4UUL`B7E>G(:MJ0"=L5=-:H^HR9ZT+>FCJ)#(N%+Y`G/W2Z%BR6=X M?841>ZQ=MY@7@=-KI%\[Q-`V7)RUPX#U[%,MZ4,9/B4\KJOBPVV^6K#U[1U@ M`TZJ.H&4\.APQSQ5:-4'[:`BEC"TG"J5V%ES2FD/5.S`1D6'SB+-&NF:4N_E M9@E(<_]2:H@,WBWE!KWCD^,S7C83I?+P.;H#W:90337PG[G;R0\?E!:>M2NXDZWL]%*FM1:&;>91\^H!-S$Y(45FSHGFBF18:1+ED(M"1E!54<0%3ISZ$-H1N]@15=VD MHZP^Y''P4V=J9I#-7PO!?EJ_VL8%%STCM('5.H:YEJJ&3OH&B41,D#`TM^$< MKA;'6-B'3K5#>%6UTIIV(5?/X2_O`AA.!VVAI(,9,N(]L/U78@/G&8/,S$DS M52[VH)QS$334I5;#\*9\VUBHK_2PZ8D'6[ MJDT?08AF-Q0I556(7:P"KX1KZVTA)U69S[Y]I2#EF=@:-P;5:4O4OE#U)P9F M2VOUN8YYXMXU:W/TECC:EFAOZA=[VV"4/[T@IHF#"F0#>*"3:FTI`:VXBVW7 M3L`KH@H:7_?&%@@E=TGP`NJ.&S`(<)O;,WMU($!1C/YS`/U)*5K M!J*DJ+5J[/?(*BI0&/``O<%@[*/KIQXU8;I0Y(S\EA60[[C0L(H86YM!7Z%R MS#1CFR=KJW;RZ$G@Z@V9:K-`2\(K?I?TZE3%R+D=C2Z-\?X"L94 MT22!M2;_8_LD^:XPUNV4J*X-M*P36X7J$UO$S&V2J+4RG)1'44U5P1"JQ)]; M1FNKJX:!$;^BR\3JK7($G-W[>^;TDQWNJZ"5^@^9'3-V'-5A?=YW"R.)2=&* M0PH0IJTSSY3HMD:UA(^[/UY^.I.65L;?K)8)]S).)86:28A,>;1+$Q?;]A)@ M3:IB>I-=3XL6=[K:.<[)Z`*>%Y;!%;(+E]"E,S9+&EP,TK6=M_;8;.S>:<0Q MW-+@+*HKY+`(CE2ID=5!XERUXN&Z!%\)4,LIR_34U(S7H@+J6AYYRHD'>[5& M/)#QDRIWA>@Q4A+)!1?*A3`G*&B6SQA!S=E"VAS5B;$D/V&$X7,TD?@'Y]Y9 M?L>JE<%#[?C[_#+ER$.*4+PUTX*'YAW(ZR-$SM^M/663X$(C[HL1^=#-_L#J MQZC^-E\U)(#'4XX8-J/D6ER3@K;)X4VCLZ]I\KZYO+.AE=(Y_]Y?>&$Z6[V] M)@-6X/O-1Y`Z1IWCT`X.AFA!<[O,V_%271M%.O+^P8-39:-4"0A-1X2!X-Z/ M].%F!9!1%<1G+*51ST_H'2@-W->76JPZ5S]YC]D2_707YA\FZRX\#GD!2VFU M*XI4O53N+VKFY;UH[IA;(52.#0PK^=(<0"GPW4ZV\$KOC&86W+M./ ML_<%'P$)]U)#,TW1=B(R4,.;QG"J[MC=Y]8EWE(B:,MDROZ.:<5B[+R>V[2X M5S9OL-T[[L0VO.F>!QT:R>;>CWDF\A8ZL6">:9W65X4Z\39>QAZMJ"2',4@- MG$86]X1MS++=K=7H30S_$MZK&4(#=XI]N-U'*@VE=CF[R-4]X8E4K)I-&[27 M74!*+-F)WF6-\NOKYU)]ZF)),@TECFQ%((^"^AD0EHE,H9DE"E%5\8Z:C@P MKCS"(+7.?NEXO>Z'P&E'L^`0M)BR]P&/`_Q`@%V]^1OJ*7RF$/(5PJGP`RLT M7)WU"7FT;N3!:D52*X_J>QJZN^X[+CB$#]P-]UYYB,COT7B-*_`G*_O^CW2T MOV-$8T/PZK,E]6(#QUOUDU9R;,.O])+;1%1R;.`DF:25(E?SDO[0K%39=Q@9`Z>X:0RU-D@]$/:$OQ!Z.K=XWJPX?N`"7*W*%49PJ+">+*(&KG MS*+-22GZ3AA[9;DD;XQCT+^^9M&P#GP5Y.<*$U7F6[C-L"$L;@7#\M1K^P%Q MB-Q@W&7QK$#?%VH')G:9A>:@1`5+`%QYETWA6O3W8JA'08KV,RF%&8P-DSYBY"8[&R$\BB M^=$?:XI!3=>9GI@#?<5T%`2U9=NK!NRZA@F\:#(@,:Z5&@1?NX+?%459NDC9 MU:6;`_J#:;.XFOWQ@SFUZ.*X80FNJ$1GH550$<."%C.K5F=A&(F"*H9#L%ZD M5VX+-B./JAL%G.G*/QA/N1H!_1Y.HUB\##$+M/*JS@23Q`=_RN"(BSWJ5)I# M3H6?_T']H&X?$^[O9H`F50V],<1!PS9[918_)L.ZS*[)VNJ?[#;9"91JB/YW M8A1+)UV`8>)WB0ZA4OBXHN+=K>Q8HW4MQXAM4]0@"#CXVGQ$"""OHB,;\*'4 M$;]CW1_^,SX97AI;O"*TJK!?BH^0S;%[7'<-&TK8"G*]8HK;@2PK*PQ-..AE MJM`'(10Z#:4?!M11RQC6H&\MX`$#JRI&`7MKXD%IT-O>T0*,NVHU!62]!^+G M:LA:V-:BPJY,RZ43'(M6Y5>.+<>PV1CAM!WT7N+T2GZFB6`YF8$8C!E4&9*V M7$W:;5FV&2A7$(R"6>A+CN"`ZMKVVES=]D6JYKQ+TG+3BAK*B'7A-XJ#EL]?B1^YTZ(Z#/7WK1[5 ME\E_6,SR`>?H9D+W\W?%-\^I/N=$IHK0$"IJNE;RP!=YM"$&3\JV^M>KV6\("F$<%N<^_2I%'1J\QSR6_UB(BU5;<,*RC MOX()"B(Q0^T+NS3-`NV8HAC'&SSH%\^3U4F\^P\F\5G%Z'51%HTB1WHNDRG[ ML]L1)8L:U,?`$I-7H<'4JB_8-2MDU*>-[2.,@1%]7X$3?7]^:(`0?A\%"B1R M.S?PQS"!H`4<9\`,@0LB0M)LW1RY\X7D$GNLN*W)?TZ$E&;NEJ"]]1*T?(Z5[ZH8J=EY@1OY[%;<(QS1,/HO MFM\,#_PHE&HW-?AP%]!7%S,Y[4_4I[JACTJD&AZW8":QK*5J@C68:0'N3?-* M0.48KZL"DF;]!1'.4.4RLV^>87T5Y865PDHL M$L@M;1:==EXH*"!>88IRI;&D3!$5%5E`(79.6,_2\[I+R%YVG-=EFGVM@=N> MP&%F3JQL4#-Q*,''J96U-?]$PW(7W[(1F/).%^J0QR#E0#A!V,!2=A&$(5V5 M)P6GU5Q.6;J(`>L;`+Y>J+9-D2+ANPE7F+-6",`3M.38J+#V==E/F2MW"RKJ/KT4;[*+&8SXJZ:UVOC.ZH:AB?3`$Q=)'9$6LF5=4`> MS5@>BQUZ)B5*\KI136_IG9!!M7H'"D!4>@"361@@<4YEI[N1";*P7Z79/O-5 M\5^KDV(Z/AR-#F$(O,1804Z6RQQV=U@;0XA(_LE']ET@5S/Z,4,G=!'^GJPY.@71<_\=5"ZU1_SXC=N^@BRD;RZT`@BX% M>_#SQ<)E%.$F5(V>D7`W3$-3:YLF"5JV MRM39FPI#56D]M,+(YF%*#D>O"E8UKZA)DGOU6EMZ7%"02W0C?$JK"]HOGS>` M1:S[.^2FW;+U"?E+"@NR%Z3C^,3Z/DA2YP5;'UE_L<\EVP='6?_W1T?QOJ?L M\.AR_^258[VJ_%07F$18=(1N@'P&&J1T:_BC'Z^S3'O8-\/4=0\76L<.73`$%73 MN;I?XG84Z@L=F`KTN*AZ+@/LO8)T8.P1SRPL[K+!FPJS"DI$E!52[V)!G!,6 MH.-HEAF-G_,B+\P9-VQ.XV>N/QF\I;-JH?2EXETK?S%LP4LJ>`KYH2%`)@Z^,$Q=P"&2I^L^N7C$P[PK: M^D;NB[)%Q33@5G&GS3*(KG9AY7(]_B9AM^Z.YA<>_3#32:W&R:J^IKYHUK@I^1 MB-]Z+!3U34WL;6BE%A^\%BM5^U7EB.>7Z(3;@VYWO MGVT]E4:&.&!)FGV[\VAO:[OZR?:DK*B\P6J7W*//MPF6RK\@@.@*B]J9KHA* M&QZAJ:E'TW<6KD7M^Y'$@FGCGY4< M2'^4J,MK:_50$_WTG="^@)"^_`H-D?YV2?%W^EM;P-,6)H1! M+-.'WZ8__.VO_]ZU7U2T)1H@?3'(>OK[:[)S<*(NYVUM[J6TV5>R5]I_BP"[ M:8OUP(X2#ZN,PW(A3S4HOX?..V)1OT`M?;5!WC@-#*D[_)$V[[T"O#SX0>'26,V&K)#&\\WGE7/&W@B7:EN M:SY9?QJK]LB=A_IB5K_(W^/MP,ZD(EH:YH_3^5L),=13VBN=U#%I3?OZA:Z' M;3WMD6T[J4XB>*[4NL,9CK2_6FN?_?CB9?R>TYYDTLC@I9WN5[S9>G0/9QZ[ M4MCT%6=O!G?I[Y=SJN6(%0`GTTYNE/U5>\UKX5NO7Q M:6#W,G[-*>VNM[.QL_TD_35\AL$Y!!)2?^F\8&W7U=F]W;V-1]^WU,2]_1Q] MV.SLZON-O4=[Z8S"K0I?M*9'&T]W6Q\F#_=.-&Y;<,OZ'^EHO;V-QX];!AE: M;>^V9Q8^FNO2,9^A]O;&]T];Y'9X0L&"R8W+<)LA:,JF<60`@E*7X MZQ?$9G-RZF@#A0)1-]+>E7)M)*RJ:TN):(-TPK4KP2&G"G,R5/IL(SM:R818 MAY_20V%RG,#2W/P-$`XJA`"AK]ZS M_FV]G.]V'J;[BW.!/O`L,J(J0[AT36\J<'5GXBU(!OE!9;$:7^011E,045@3 M9>^.IH:+_EPUGI('KJ;'[1[T=0?GXS&]E'/"^5P-<`_;N].VH1I,C&NWDX`> MH^(,VW%/+VJ"A:T\>':M@Q35K3")= MHGSS\/;ZG'$L%-,D:W5BRCL%:)$YN6@@3WVX8"^)IRR?8S52D>RV(;V=9QM/ M]EJ"VMO=V'G6UBI[;;U)RV=/6^CLGDU(Y]5[^JQK^.TG+=W3VWVR\?3)L[2# M%!$TP&0$>-K'<$#*/K6^YX3+Q6DD9OH"A(-DNPT4]NW3*@SDWOGVT=:3-9@L M?F-!#--4DMWSZCGE(,,%SG2U<@A8@\JZ3) M+AK!X6!`!U>]^B.YZ6YZ1<,I0:M[`M)[;I?/?R'HN@0FW?F`!RTGK)8HE=Q8XBP=)FD3#/V% M:;S/--Z'"BW0ZF&?U+I3D*C%`.Q"C7C:;V^OSP<+SJ!=(W7Y77 MBG6'B+T%LOA#E\*Q,HN)I:_TKFO7=E#M82D4<:&+ZZ,CYXJ`U^QNV@-XW5V# M\45O?RWQP.E#,C-N8BV2,+9-S]\?US$U>XR%U->5@O%N-8O7<+C"`OSZR=JA MK/A)!&H`0EV+U.K63^[E^5GCLC'DOJMY<`GKUP*JX;INT5"^]KECZ,:*D(SF M-<55'C$0L%499.4HZ=!>"C['$^M3",[NU<[>6,8,H9`E_RH^^B([WDC1ND*7 MYD7EO7]0K+W\#6/MADI;5H0]BF6JR^>'U=>&TSV_<+?+=D:##]8SUJ$J)Q&3 MM+O#<,4?@'@C?8BD4+*.*&UT#A*13G[E#%\%#XUR+8_G#X0QWB]P2> M2(O8?Q),@K1GWGCPF2OMAI\A1!O*[FYL=PSW_?<;3[LF!_!L._HXV7L[;;.^L]L:[3.SVVLM^R9` M@RJ/6BM>29L['=G9]&MM7U#.Q0?[.BQV(]9E"GZLN\#A,!1OVE7F/1WL'+BL MBR68$;P6ZX1/I\,RH!/W@5+\ZK ML*;5\N*LW]^\/-L\I>SE_.+L\,W!9=;??W743UM>@D4Y[<6WAEQU`\%D=XM- MGDFO!S/ORG:1KF[KZW/7VC M]YC8T4[+=^L](WCT_;-6ZUWYA*W6=>5J8QM8$=AP,^'R_EFXTDL^A_^6I1$( M\]BA*^62;C]NR]7>[L:39VU1X;-]C]O@VBE<@;A8^=EB@M[.TW9W!.1V6MJE M]VAC^^GCE"*!P^9.-^O#?NY"N+1ACU*"UF\HH&>M@4*7QK0;QL=X/R\+?3)A MQN'O[((/H?IJA-#V%>4A:>\-EJ8?N/S%+]G+H[.7%_OGOS\YR"Z.7IZ1_5^=G!ZE_:SE_IF7+N-[ETY@HC=^HNX;DW+COBXCTN)[N9OR-G$'&L8M MG6?CN\SIP__63A41,^"#&L:$^:@UJ@OCI=WL+TC2G><#E9&DSUQ8M-%KJ\DZ M1?+_V3O3I;J2:\^_RHD*N9MR`&80&NQV12"$JNA&0E=05>'^QB05MX!#<*!D M]6OT)W_3$_1#Z,GZ]U]KY;`S]T%237;?OO?:8;'/WCFL7/.4XZ!,3ZU96F(D MOQ":X9EN5Q;.FO9Q&,KMXW#9MX^]0\T38H\GUB5AKJ0H_0KV2-.L9`JX[8F4 MRER8>36_EPF]]-ZILSL2&?TRN2/W ML7?34?$X3ENY1%Z>'W81F>^C=%B19B_U\>IV159/KY<\UY2]6LG[R/U_DRL& M]?PVF[/,MJEZ;)MSDNZ2MC>T"DR,+U-Z(!EUM-F1(8P#%PS0'38V6[L$S81K MFA4K<]N:Z(Q4HW&LE8;[!][;R/U= M\>0*V9>"MA%DN34K7X2>M]#Y(L5#K`R2'L6E;X([]R_(>XJN`;FRQZ*IV>

/,G71#-L7(N<;@!?\;U8H^?RTXSH&LL/#Y6? M5UFDCRO5&@'^\Y8:=6-Y$KTMA.F1OLUGG2%R'TF M8BG6W3*70EBN6O_2+U@OTY!TB[\('^3ZRA^T3*V:_U*6WBZFGL45G]2(5HQNL'=[%W90N,'PYR@#,=C# M*L8(D90/MINV@7ZJ/!5@?$E.+5JWY4U?0JL%D=2K1FJ@929&EJHY"?59QQ.@ M8M],RJ+TN]UY-3#BP"A*C810.Y71C`I"/QEPV,-_]E1#&!#U>V;0,Q>XQOAFA&^L+*ZLK,@6 M-@C(^ZK2L:@&<@[C/#HM6Z$"S!8UPESAG.TRSPKJ&T..H$Z!B;S"D[4- MZ-HAZUA/PT?$X/4L;I3.ZTEPMF:[VN\E'6[)NE;QEUZ:]S6!5G7;)%LDGY?W MZQ/6PPZ\(8FM!:9ZH];;#)<"$"SMCF:Q5K_N:F6TQ4M"S.GXJ%`[]6#R40Z:J\`]^L/-CYQ#:W*M$TW^ND[$H0-LR8OZ=1D M#>E?CFA-WV9]0*`S>A#NFG)PUSA9$]K>?_G2E2`ZK'B&@8-'!J5JJ'-WZ(%$ M3LP7+GU-Y`JGA6Q_+"78WP$`R5\YBP(>+N+P%0A>B2ME!C:/$SG&B[;]`'/G M/MIL`VH86T#?F'ODT#@I0)8LZ0[9,4.M=`>COS7`$`=D2)4 M>G)KFS(.UFP1.K8:-KO6"08L<9'!3)VM&E^@\8'#SA$_O`^)R9/!V<4IE@(1CG%`(5YNSNO1F2K51+L')D`AS M^[J$F!]5,H>:8?2+DANBTE`"J0U99"FTJQ]>73ILJUG?I30E+Y`\(6CFA&XV M(.`)UU'0!D3W70;KK*[Q"/-@>F$/L&;:8R_)+&D#EFA=)#]2^VK M:<"`U#.'-'#66(ONMS8B]#1X*)3/H-'1U_Z('Y,:X+EZ\LL MH:QQ8/K+H;*J-E[M'2I:'?:H501=BXDGE MF<)MT@2<*SB;_I(BG=XX"8^3X&.&9SQ% M')'6@.+`L-:!(A3`>*MBL"HJ5N?J*I88_QOB"3>S_VG/0M&S@@!.SDUHRN5>5?D$2T=%2 MRY[CZ3&<=W?;K:F^#)?4HK#3/JH=N9%5%M'M5VNL%M:=MGW*::AO1SHKSL;1 M<:"@5XCQ<:7)=<"2461AST`P"U7?"HW%WN,>\L$JTUD[8H8UGE::>&*Y556D MWGN4[9)0)HE>V;C?:,3+Q\88OISDC@6%R;PZF_VX]%HW#)%(AG&$P:#:2]*A MNE#:RO+Z!D[NI0_O5Y8?/OI#BQG\?#_]O+$Z\O.C-?]Y;?E^]^MW4ZPFKX(= M:36_\6AYW;]]N+J\T7W\X/ZR#?UP??E!]^/3D*63=V>Z;YM2@';AWT?;U:5# M]&B5KQ;4JM'(\-OZB3ITVV&>IE/->DG%2VIV4^RFN8QELI`46QDXTNV3)=D[ M<5R49VJR2NX#*5ZWU^]\TU9''GU>0E$5XPT;HDA&WY=:?Z)X)M1;$&+F?KRF MO27MOMX4Z:?_,`7?^WZRZGZESU/2KC<)E4K0@2<<$_/UDPK48 MXB\%;9JW7^ERU8E\IOP&+>Y0'UZ8'Y4:C>GK;B'FR&Z?9CIH?]ATNF@?XR0R M=V?[_*7\A7E)ANXF_?B.NSP==K#VB+G7.U@LK*\^H&9DHYM\ M??'Q:A>B_OC47:[*`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`S-F%$T\R-L>6K)D*&D?-UV>E>;Q0*3]W$P7^8.,`-I?G^(>:9]E%7`."^KT M:]T.?<P0$N'\99A>/3O/5C>**P. M7N0'\A.91I2K7[MOV8J6:#<[E M@A&94L#*1(0Q(!H)>*!*O;A1(^@9CRQO84+@(5;M`!:''X1VV990-4<2Y&HB M8G>I+FY)-=`+L08B(OCC+A8]%&YY1RE@-AA'8^1%(2-@1UGYP"VI`H-.A_OC']LWVR2\AW^23+\:<[7[B<_Y_3LES,,S/;U1' M-43V]-[9?YUL6]5N>WS^]&.IT-_L[3[=?K4OW^_VOWV[<_"W=IA-O_B&:X/& MY??>9:78+V(!JOB()EA M*!L8_JB:/S'$&X_+[9,VBL&F1`WMN$HX*>96P3'- M/.`3EFQ&[F6?_B#>O?H0';S-BTCV&!D.%IZ7DNS'_4EPAS\Z/-;N>_GA7:F_ M8!+=I*8TP">B.IYS8-@N[%V.-]Q21,Q]@9M.SV^(O2@D\FF&N(*ZBVE@F4OD)RZ<#`WRH$2==Y] M>FJ%;Y,H(+"3C'S]G#2\&(T*E`12C*1"YR;"JL+R5?:ZKC91P3-RQ6]P:XV#",L.K-X8^GTD^<1T4G`K6U!T`W"@D= M1Q?H"_6-$.NPH#%[$V'?Z#[`&\VF"TU=#$_/A:0"W997_WUTX;;[2U+=0'Q+ MBZH6=4.HS^Y_$0LU]X?IT7XW#H%A\F=ES-YAWHYY8-)Q MX-X1ECOI*95;WR\0U$!$JDCJL*R05:I$+/76FYM8N'0>+0O+'21([HD/Z* M*MD$7111+:V24$9YERZ)X'6`X<22-WG-+NV+\YV6D%;B%_S2,62^TG+R70F# M=0GE;6[REA>4F_PL7=6P9`;[;[W`+WHW<\?C">F>&P]XQ91Y6)3QB!P"XKG<& M30R1..+8F.--O:'ZD(B#>ZY*63BTV-,"BIIQ4EBHKE)2+^C@EGK]EL9BH!`T M:O:$*-.]WI:[WL>!0TY M4&&1UH3H(P<#8DE]@"M!!NB+U`_0FQD9+.;K:9L10Q=E M\Y+]#='-R%/NB`5F0&<>O09/B6MU:2=/[BLL@$YN>72'8,L"H)R$WX9G#N.G`Y^N]5<6F5DYQ(E&:ENUQ\CU3$,.`EL M?+^3$9Y*U8\73*D?Z.F)V:_WD-I9V13JY=9)RB?18!D=KF0/ M&^I2JV")*T@C0:!LL*&]995<"#JF7R0LQ_&0.O`%PFS-M<86DX[IYEH=.9"Q]5GG>=UW7H M#U9K@ZYT!6?1@W1Q@Q9($M)/Y'G3U(WL+;#V[++\.4C[KA+"]=[;,V^6=GN% MKN:EBAJ+M[(_2`#0#H+;@%]HP6B8NNM6X-92:DP-V]+UH?@C\='YP,_#&@LQ M&UXG&06/=>JZ]$\XHK0/`=HLUV&)P.J:>*5KM]1Y2G5R3I]A3/WSK71I=NII M7!C8IM3;%:TEDTNGBCK1'[X@.TXWGLA)N,(!H>7)K>,[2@62;*F6_7WOINY:8+?0XWOKM1` M&AW50$<8T0$@,LW53V4M/5^24TW+Q./`^!" M-[M:1HY=&;S82-2Z)FH2(6V8&5NNKP@(J`3`U77+FU^6J[735]6R<+NO9`U3:V MA,)0Y8SCD>X5L/,V'BI\T17JPX_"*NFB*\5OF(C$HDP#I$@:V>>EO';!BX4' MQ#/[#EOI^'/<.VAER2Y)//X<>,SY9($&OQV2S)_VY(S:K3Z7\ZZ#6$)XCWYT M@)QVO->Q9"XO.L)2B7OED]O(CU(O4G5!9Q^QOAC73K0]_\71HA,(3JWL>>3'\=&@`G)1Q@A%6<-C#7S$ M2;I3(F$>0`B=V\UWZ/743^`S7I;I[WJ-^*6C70L5&U4O)O*HJ@HZ:0$H MP?M67L(<(5SAJK6&,$B02N*C74@*P,/@O0Y(BS*'B7\ZDRXQ M82OW`!_LL8H"'ZC3)\;)W;*[W&QHP4\L>(A"=JRBG_(5H$]M;:"K32Z=>W->RPS?"[`=\,`27Y\2SA;J@>:0\5(,]O%7VP-*T3" M^7:^.`DH]NSUDBN#8LH7=`*9HO3!J*VN[%C21UJ_WSS%$.J,0"T?"7VV9/1O/BHO-QU;$+1A^FQ'$EMUBYHY*AR*-%9'U^:GQ9#!4/-PM$K5 MB?H111HZS*Q>>YI[/]W5RNG9YLZKR7>;N]_J!L_-_6]?;3_??G&P/URC@M9? M'>A,S(:V`'K-<8_#&60FE:%FZAM(;S+E&)FY$BY].9+@.,-"4MEC<_OVI8:. M^S^*(:(-?5:.2-#]WN(7"?TNR8W`60 M20YUCOJ%KK1=2QW,/B&B?OWFZ*]?/'N&2L3_?<%=N]?/2#W0?O_ZQ19]GXZN MS_3T]2$4B4FKQVMZ,#O^@17Y`[C_]%H/_V1I.#=?<5-;R(EJ!6.9T;_)[('J M3%UEP?A]K1V_BKO1A]AR\Y4])EVQ?;YI#KZ.EIY;^FKX,-TOS76@HS=LY=:7 M\,>20.A*OA&$G!7"+8EZJ_O[O&[9$>\O+*W=PF[TS"2,WNTC+PX)=$Q"C(NV MLLQ,%.V@^%/=L*C:PHZ3NSM4>TXKD+X%CT^JDZO/LP>RBCR'\4^=. MZQ&"H@MK,^^3S+0$"MT((ATX9W$"MG-2A"<)A3A.='"N7Z3R[)]-ER^,.WSJ M/8J_"7%:7X!4."L<]X-8DF//F&P*+-4`'G!<"5\.0&C#1:2R/$\F0P:;F*&U M["[=8I,2@@1.N%[;F&F]_FVINSZ$Z\]=[\P18?9M&]0SZH(0Z7&M0SC MF"0UW7Q+4@6"$<9$,>*+VGN5#45AB^!$:"UZ1+5Q&/A+-D1*J?&6'O MZAYE!-VM7`;N#G2U!7HQ7UTD_DG*I=?"=>URCZ<&W.I\B8C8E3="ASK<-7)@ MG%UA%C41,GCQUX5P3=\764H4QE4EE[ZS'[A'SIU*)"(A8SN_HM21#^^_TPV4 M'][7>LMH/>:WE],C.5OV4T!8U-OE,$#KN@>Q$U8&NC;#( M$WBR@&/FLX9KK"=CH/.Y]N=R*\!YA?!3Z'A4P$HG\B<=Y\=1<;[53X)S+0);BQ6E.4 M?S;$4T8<>^D.G^V3;_=IA[V_/\%?^V3GA?42WF\'I6L'L8*BC^!"\&,](*AU M>'6*5G",V,11U(DA?Z_^>(^`]4]GIV_;2?:45'G^#F;P(`6RB%"B9YO?WX+; MAX1\Y=YJ%:T(5?D M@95E(*):8<=A-5:>L_%M*3A1Z6MX%KAH;SWE%UMZEUQ][E@^+]DTV2'7@"GW MWD#E=H.B.Q:(+(";<%)QLDJ9E$&>[Q2S-G:*9*>&%<,NO:4&]=YJM?#%:'*7 M0H8ZV_7Q5!(!C1GQ^+BCUJ+SN'ZSGBVM_]X:M8H)*K3R.925P!?4?"7[KPJ0V?T+%>9=9ES/7#049D>@%S".M;M(YQ8$U: MW0TD[RMQHUO.\<8*@=(R&\!+>DW^?G'^Y]D5\<:_?H&98/'=+\P=Q]!66FF6 M'SF\YCL]-$/0W:S6Q1+L8Q(([BBZF"YYJ(JN3[E1TNT-T(2?+:`E`W2K[-U:4OO.F2ASKVL8? MK`LI8V#XN*^`7.&B_R=;3T"7F0?$,>S4>CI=R@<$(8/&-%0-*YX"=^2M_ZZ5 M,9_J%V`G8\K^`?W?9MQ!\7;R:DI0OO4:FFV0'(1? M#VXR"ZMS^Z2IAZO]!7-3;ONY757!M.(_W=*98N4\A>=D.E!_,E\ MN<,/:T]-5DY2(20\#`55*9H$M`XO?SRE@H(BKD,Z:QM#=->0\6FU:G;O:1:V M1$<0?G3[3[0H=J%$$6\]R[_RA!PV(FIV>L[-)V\64S]WG^2$P(3RYH`@ZEUR M3,G1%]$20>$WTZ-::&X-M(WDS<&UV+XHSNAG4X,X:RTN\DV#X@8A!80,7.7V M6)@C>O[PQFU7G^7'%/@KWQLB",XH86[*12($)"&<-'4.S1&P%'"M%R8/K+/S MXCSO^F4(TL,==,&'+?D9!RI9"Y@N#'#SU;ZZOUW3.-HC],+06JMJ1_#DK[R0 M.V>3ZV]BGK]\2Z^&]Q"0&W()GKLEIJ+?!<]VYF]SJ_,\N\=_-69X2@V#!2EK MVU3@-5BF)4S5!^^H(J%4SOR7H`#ZI=8P=OQ08.8>/PL%Q@9-7$4[`!F50&]C M"[B=4=EAS4M=H:Z4?N&UM.D6^CLG/.0.&XO^=L31ONU8TJRE?6FS\6Y_ M>/]?#B^N_J*S;/W;[:<^_@@1MB^^Z$'2OB)FD<'5[QSQD">3+H\T>4-@KJ3_*=?`>S8;.Y$A-SM]=7/U`@.40 M/G(,\[_]\?2"*[$TSN;NKHV@,QL=0=<.?3,]>?/C&7<<_8..^#;6A7_]XIOX M.J<-2MLPNBG1_0Y1G)+[WB0[F56VH'5*[YYZ@5M'X"\MH/C']O6GR,%S4!0> M?7K\PZ7[#NA'E[8M(`*.]K/5]>CITOZ0CP"Q-Q@$J+3OJN.._K]][OB'J^0S M:.)5:7UC!JC$JDH;E^S&,0MV-9;?S5=EK9+=).UD4#NA-Y:0O4&\37;F*>/* MCW#+$L_M;&6>GY]Z[@VY%B@5)]/+I)+K\*'7J>Z;XJNY2$SS5"(^KH.DCA,H M%53CJK)=!9U:9^%29-]11>EQ>%22(SDX\*2A5_!Z)!])_MD*(:%_EZ[$9F.Q MIR=L33I$O5>I8X(DRI7268IIC&*FPQW5U!M M>/K9\Q!((;(`Y@TY$`JKU6:V+FZX?$-J?#*:0ZE;2"8V)5+,*-VS3GP!>-G] MH35J8JWIA/QJ'3F^B!2)C3P,]PW8XL"^(YF5;O,/U]0`=+Z_(M\_'PL7!EB] M"!Q/YENYF"L[!,S5B0JMUN96'L&K6GSCOF"G>%%Q@UNW0R,4SGOT-6[H+7UTP\*&WI:]F_9''XD1,(Y5813=>!'OI>D MAIW286^4Y7%OSY1BJ3>(B$.RI<0#@*M\W`Q39S38$Y,;K+C0+EO%'W/L5(NQ%FN\A)W&M4(X%5-8X@.&:'7MY.84+=--6?2%)B1ZDVK!(;67XTR6[ ML`$Q?CGS^E:8MKP#IDBG2YRR&1\_!D7!TMTQ@#/XD]#.#$1\I>6($L#+&CD; MZEO8C@!;-5@$01(JL6[-"$1U?Y#(`)$<0D`V/K!\*YJ/4P([TC1-`NVBI1+K M]&H[!CB`^\R@3@I<'J42F;&3`,IW+2'(O%M$(VINOBIX[RI91%&Z<&3[7CFH M,D=R;[3$4KZ5-3$H_&A?77CP:''U?M<5^HX1JH"#'-=2`X^[45>7^]S]3Q_3 MDIQ[>]I)1@[DRDYWZ[2/:;5+.N#<]6FE-QDOA-+)#$.O@#F`6*>NW3@U'J8[ M^4`/5WDADEJBWO6EAC$F M!KRK:1V!Z&PC_:H]P\0VV^?#P&7[JR&+ZXZ%41K#$1>?&Q1MAR&[9?5AEZ%% MTD@;X'\E&\G/X9`K1)`C2]N7DN@GDP__9_)\>_?E-YN[FR_:\5-T7]BQ68"K M/ZL1EY3R/F^$2SK<8<=_>/^H"L?K0#"B'%WJ8]/()ANL@\V;$ MC:`"/49HBT-:^/]RI3^BA*#`5MH>#NG8'EWN<,Z\(^I!/>OY.^+F?D%)7K/Y M`K;J7;A?09&[K7=/3_\^>4F1T`5,6*D1M'_RY`C"G[3&@$TOT=^#K:"^@)9G MT=,K\HN:+ZVN"74$1.,+^2#\/4VX/!FLP>PW[O%"-8'4P66:1IS]9/>]40P! M6(Y.1;<0@Q0?1L/TB$DEN#"+I"$2HA6Y2N_0V\4_@HXOJH9H;BVM8'I+A2_I MFS2D0+.HDZH$#(;\$O\,3AYA6 MF.K?KEPIK2+Q]QX\*),0HH4OFAY6,T^6DFHZJGUF1NM:CHP,#^2IYH)DT/,3 M`L@9-Y1NFQ*%^6=A?8XTWW/.ZDAF]P%K$]?3=X<<$`9P,$!4JS<&%?6@8:>* M&;/6,BVK#/B9\FKY)(9QP@32CL\(;S)>QQ8UM;L?`:$.N55D&)A''$L0J"%D MTA)%QRGS*46XVP'&?--A`,1%QV%=@7X#CZT4HQ'/IL1I)7;<=8)_O21S90P'L3*O5B4P/TH'G#RT4-N)6-B.5 MR8>)-IB)OX9O^55X(1_?0_TF.Q(W,N,AHHS MIG/^E'"0)T;IY!N_\']P;['[PHLTR:(`/C#]$6!(LW/9;(F1"=8FVT(,`+%< M"H[5X8W"#&GEU4#4A29#^$.Z3:7`F)C`?#'5^L(R/=P7@7NF7[55`+ MO@>S3!K6D&\F%<+<2Z;?*EA1!5\*_B'T4UZ@5D/9DND`TAJ$GDF:2E*D34;I M=<%W-"*@?L50@)X*MN<$3+> M:$H$J9N+0E6K%"QJMZ4)X.L'O\[)G7\;U\M>>C-7U9VR?+!1RCWN[.1*8M&1 M-XS^SAOA_4,U8CGHU)+[EK7^EIMV^Y9^>']AL=>$F^SM+N! MZ3W7M/8&6FX=)*[A7C.WV!OVH9%I?+FQO);BFPK5>=5%+BXW?B,=^-G>[M[! MWUX,7'1U@!_AEU^I50-7`SJ.\.I4]JZDW2Z,Q?@TLYQU>51/3X\H5ZH MB'JU_=W>[G<[+[Z>[%(9-=E[-MEZM?UTYV#D@,3MM"?7G2;H1LR,OR<:G$LR M]`?B'K$GI)9JM9OX);',%R%59;^K^33+5]P+J!R]Q!X-FE_$4O_"=># M*AU\`W(37ER94@3)+AN'? M]AXG543W&EWG:=NDHG*-CT;Z$G8X6P$X[_!(]17@ M$?@T4YH/D4`&/%64%SO6'B!-6:Y2!?$R`@TMA=Z")!/A(^;#(Z'4GEU&_THO M+NSN/-E[1?5,N-ED5]L0Z.#>LU+Z38K3DWM"]"R8F0&5V!J!0BZ_.B,);"I2TYLI/5\)#7@R':H>W#PPS=0W0 MSH_QI*),[WD3OL/(]3$NFM.N$I<#E=/1I61MS11G-'^F>?5NM6_3;\U6B#A/ MD=HO*=TLNJ`K_TO0$E8GXR!HN$`N\B?T'E8Z9.SE4VY^8,&T,7J3=OW:& M(X=W9+*IXB.UWG+_DQFPDGXY@>+<"@/>&`V=82NC1-_8<$H4M5P36J[+![5) M0A?%/%`4K71BE^9P3UM-B#'&YD5E^H_ELEBX5K`_//E)+N,.IE!9A?30626# MN<`P9W;!0*"/>TLK2QI-S"UI!WK.WV1J*`0C=D/H3)J]MV6:@]I9$:"EJ85# M&F03E0G2GX_[W191RY209WDZ^Z=V=3%WL%V5\R\5S"9\$Y=\CL4YP`]"W+?;G!^D(B[$FN)E\L_$),PO;.K'`82 M5CI'G;<-Z^N19(]+D`5!#L"/BY,B)<=_-UL*Q,U`@V]P"W)7G5?1+M6EUNZ1T!U`D5D5N MD;.;6+:R3P\8=-!"T'^S%;K_%C6T*3I5+N.Z97;4X_M8U>>V0>%]]2P/6;E# MJS@[B7#`(`7FSDF`D.)P?'9]?'M!7VA(GA)41+(8X,`,WT@5 M+9>BO@2UA"JG#?"7=-_YHJ-5T#S>7^FR7UO.:;/>.@0)Z[C$8^6)UA`RRSI2 M&WJN\CA9NIDNV;\DW-V*!6'=U8TF#9)>79^B_%B^"=Q>#EB6'!YR5"&=,3@" MS:I/6X>O@'0@:"J05DO$$)17#KBAU`'X*PX&CS/GZ+TS'9;A4ZMXN:=>35^_ M5DC0ZUCQCT.;\AV&L^TM=`N2)R^;9C)O([LHE<`V:2/-(F6AHEM'Y#G("C-(^E5WM2 M<5$!\-CJV&!&2]4,B?WJW7&FO2@W*3EO'+1>NDNZS1^$,2QJXC.;*0JI._-M M-R8@C5`[.[NWRJ4?+O9,GHH*6Y"Z_L?+IH=*G;ECQ1W*;EH,J'#U.*CY1$E*14D@_I>@>!)+Y0`'HBUWK#-PD*CQ\*/,ET?LEJK:S$ MTP>2^L^3A54Z252J_VL<0V!'L@`6Q%IMK'C'.LH-7_I2G`"B.A8*N'QX[FEK M`1T\$KK40[!&EIW3"O6&92L!0,YSOYUI`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`# M,L21NW:?0$QH?11S;+/>X$')2#>W1GOH>RHY>??A_=ICLT;676VK1Y@#50M@ MI""KN+4PE%.D4$-`AOR)[W*^-(O@TO=`T#EC:65*PD;Q$4+(*)]2@/T.:R7U MO9L=DS=CW(7!<_X]=&'Y]CCMZ9&'QM3E#"'FHGN>9_I;T,X\EBQYX>PGOJD+ M*2KLM.I>I'D7`_WT?04:A;)VB)X0!9SW'E91P?!0>)BGAKPP*ZF*0!=7C!*U M6'>]8I6!_D0P3'GOYLI!R>9#ZPZD5G^==(3,4W*28`,`MF_5C\5&/KC%#_3. M/8%1=@K^J[:G6E@4V+9U1=UAH*I("Z#D6FQ?&FOERZD2)/M#TT'?6A')O542 MONQU`>DKA!Q)%:R'78R]FYD\+QD35H.]5GOB;SE4OQ MT0W):8X:%4S@6+F.I&QV7`Y3DYS%GQNE6D?5>H22P-Q\"$K9"030W/.UG-:E:TW3 M3&M-2V"'G+H)4"]8B8Q+*'TF_G2.@L=MK>;+#>K7?E'"/X%KB.&?<44&5=P8 M6YZ1(,8#::DQBHZ3()85H'DEW>FEKM:03]61]@I9S1^8L-%-:"GE.+C6:(0< MWF2S47..\MK*^FK'GKX/"E36`H1M&9L%(5#]S0>A\D%\*IJWN)UE*=KI.?I; MV^(JD)5A% M]FZQ_65+:23LDDKM]B==KOGA/0+^0K)%&6. MWH>&),[,21&5H>N>)4:LE-G-K5Z6,(^T;#--=E\DHUC![@Z=T2_Q%VP1,X?_ M7-)U['-79XILN*!19]EQBK9)-?*N&'C588UPTV$"2@#)MC%;GFRKHL#W5/#W M&#S!(*!$*2X>*RXM(U%`#PL4YD9*/8$FL?U;S#>O^)1)8\9.VX3+KFUUNUE# M'=(]VZE`FT#2HI:[O!6^\J]5T[Z[G)?'5?"1%\F"R# M`R*Q%[']'#Y3V`Q9ZSR]K\_[&]II\L0/A''++?:04$@,L:Y=0:O]_;E/WSY^ M&6&\]KG*]W>MG%GV5+;Y4*BVIDL5QQW\)"@^3VV')_.&%FZSZ="/-/SA^84" MOF:(>:#)Y#^4PYU6"!\RNF[+->ZAYQ4K-MRR@)+UX1*5-"&3QH6L.:`T2:Z_)BA5@ M.1!EY?%,7(A-29>/QU@DPA?[JV@"U0UKZH"3]V;LJ"\G2:`=,0H`IC0T!Z+N M;'8O:]0D>78.A`U'J'9@JQFS87`8DDI&S;%KCF5DL"DE5;':G<*0N_RH(/K*5;(](&&2;I*/V`[9;HNKB:\!7Q_$I&TS+K#TX M"E8Z03@4[;CR;HV,"FZ@+KJJFHRWI)@)5EQ.?:;N"A5HZ;G`E4]FXBH7)L4Y MI*$>HR("/J]@NA)A'9[7-=\@L=N#J-"T!IJJ>Y-"9D.-%I&E*QXZ,(DI&L'7 M5>1N2T`JY31M?^=D[+,O87+E,3ZJNI:G&W705\VR;(/M$OX71\` M#$$0D3.IY7I@3V*RB(,5LJ!HY^\2[@ASLF(])]Y/,;E5R'Z1ET2WIE&&(I;U[9K)KFEL'.WK] MU<[!9"]=U[&[NV4#\S"[B)I]Z_WD6DPT7IV,^0T33A5#1]Z29*4P:5J/&)!E M!BG-'&Q"5-V\,S-U>-[^:=I=Q71E$,.]#`G@8-IO&?NNTVQC-CH'I,"%&;<6 M_"R;6C0@8:'6S/N"?@H5YPFQ/:!5-V@-TRH^W[,1[6L+@OO[H?[G*CECV$F78NC]WQ.OIBOZF.L.1%C*8"(/%Q<\E. MNIY2N*HS?G(VA:TMYC.>0ZHPV,Z)^._$&;FV@X5;+N$U5M<;ZZP79':P8S2M MCL^"%S M=1%#SIDB9Z6EY(230M`\AQVF+4WW-IA/,4>^HRS:UASD7P1D70]:$#'AC;P_ M\;EY8>!TJ/6B^`5^"?F,)G8K!J&].('$'A# MJ&!6"RVL6P\X)02]/;*FP*ZDSCPF(O:FF#U"L7*8Z7`G1V=H%F`#)A`+MO23 MB@TJG2-)K1R4W:"!E<3E/V#CWFY,,*FV8N".*X75I&Z,HW.T@>[2L2N&V?0K M2AQ:4PQ1L5*S.FQ&F%E\[@B+V6#'@O\4\VTFY8[Q4.;$##)GLNPWT(+6.Z[H MV;31\0H`&FZK^*GGBJFA29S#D$F:%J%PQ_1RC&_#N'>CKY4FW+3.,"-,W%#W MR>$[L.ZEA4T+_][^^](8"R=&-FB)A=\[J:S2L^6+]%9FBY-\M8$/G9N@X=9X MAYZP.-E=?KELG)THQM7IP/[U%,Y>S5&6X,KEK_R81T'F)ED'Y2BB$2"P:Q<'N".X?\2`CD9NH:E/.)8?>\DVV M+>R*`J&+59J-:"8T"A=T>#-325Y<2UF"2GZW-274S#EQJO0X23MMS-@_($C= M\Q(`Y*/3$U@%>%51S1QG2`LCU?A1&`G@%*?'+$K!0J_.;T#Y@B+B%_10&\CZ MAID!8>V@(BDK3()4;OK)346VBB<*38W^A`Z',48?.67FXX9S+U`,WL:A&!OG M$^,*VR^/=G:WONNP07&XROQD:*7,S^([HF9@B+2))RDX0O^7QH,CFF!`[MGL M"`>U#P01`BBZ9$?9UB.@JNG$9D(=4^*+QE,KM`'0B[9G)_2\.TZE&\JI&W$) M>*Y<:(5(=>]6P]0,P#2F,48!N@3G8I@R+N3L(5JS00FQ-U+[\L)XC2OR^6#< MRP_X%C,TVZ*RL^)S`5MQ4%$\`Z#2<$Q^V+.4+C!&A?FUD\H24`W5I;+H94?B MJVNLQ%O2/(@@LHU+LBBIU[!@7#><>DSF,F<:JCSP,%U7NJ-Y31$\QLP"Z!\,JF](5*H? M)4F4K\U9"O@L/H:7:BP'?BIJ30J@J;*+MX'93E%6

`ZO\`<&7=$Y,S`.6=AHE@<)%SP\LE[S;$QI5DL*C`X_3GR4;;` M^\ZM\X[E<,X&!-9!*5>K'?@FJS^[\H]:JSX&=NL-E*;*63@FAG*4D(P!OPYWQ"5\Q M1V#XKGL91S**&%<2F#TRH4/SNHY>')Z*'-7%@@LMZ5^F+DM)JDP@N]3PT6Q# MMH@O+ELP?JOZ@K2SBTL@CP]*T*MZ@?)#RZ*-\#.K&D0D(YHGTMC)J%=6/J36 M/H2L#7Z4C\.B9L%8[-`.KBQ5R6>^ECJ5`B(BABDIJLB_CKH[F&=9Y\+<>!K> M2M?R-]PRN21A:NA?=JJ@>U<>C0>5YS^XY"$G1QDYQ@C4&Y%7ZSDYV MLQCA=*L)N5M[P!P78GXK^?O`S/4;-0B`]`/$Z+[PJT*(/3>2JOQCX6I=U0@5 M%.*.=""!>[2WJE],AI4.V@KXC;MN>K+JJYB@R218&";/NXDZ=C+\L;#'6UKF MD9J?+']+O82KUSN7T]OS6\:/83\?[F!%\79#03VC+M!N_!77=K.@$9OA!"VEC'"6"]\X]` MUPP`+`M8(V[`2=_GB6K+97V(^#SO6IE_$&UV.-PA[1HI2?$T.\#S,O^TKG:F MME5)V\T*:M>X=J]0)"V`OB#LO=16@QF%R8Y<,P=;4Q4.645H&U%`SU"4=8/.C6<8FFDGO,O\#+L)& M$W:]GLVSV#T_Y]NRUP;#@4=(B`C(+L<52\[Z2E*D,A39S1F3N(P/6].3(!.` M8]*N!-1P=G/0J,+DW+"^Q";Y9\`E\AINJ6O;#^,'CZ+]I[SRO\0@_LLI-( M=*DQA[GX,TT7V?+*RKRUX-3R,F`X:M7&ZY6(@"_U,Z:-]V=]\PN4F!1F081A M"4L4](9)"9V#$IH,2?U4NT=GX5U\\7<=^K!<3*!PE`D-$(>:8>[;_OLT.MU3 MRX65A^3P5%^=_E73XO[XNY6'FDE^R@A&5&REQ&, M:@^0D`('AY).9RUC?.B!T5A,?&75_QH3T6##XHQD1`K8%S=`R' M:"FW4=LLE.Q2/8%'9(X))PF#(5SV9A[,O8H]6[!5S.+7F?'0;#LK#@.+V4IN MG4TI^E9TE,6XU$VM(')S>LQ/LO1P>A?=_[TO+`KR4AN*KM7B#TOH+L.)63//)NZF]:@W)G;P` MIH'965Q;G4D2@P),F"$%R9QA!#"0W*;M?[&^DD.U,E]C<$@;AUH;V5+>,CB' M6(,+N#5_L@>G"J@HA/)ZAI5^=8,/H!-"&>TJX0(K3_/?D%#YR0%U$NB MS6-J@7$Y`I+:@!KR#:SE6W)!'P[C=+8 MK+&JDX$''F,*`=\(FH49Q.FR`]%XA"F&0`0;SZ3EKI/;GT=!-INN93A"K-0+ M:#QI8[FLGU'9=#(B`S^6Z]>2;,57,X(%,L9)!BD1V@L4(0J6XEA$3>VK#>C5 M*)ZW7NAR;1W(=T7I-Z]+#VM@O=AK`L9\6%^2?\.BTI.`8)^;+X7)$S-%NY:Z:#2G M%EHW&"#HH=F9,O_F+&Z1\B$+5,'H2=0:NFEW'J_I8D,&.](E^CZ;X>'-SHBL M>$NXR)*XL$)U7`LNRU!:!CE#AJ)3U4(`NNHYYO>/[S?1*U2K;=LF#W MSO'/7PZ^I7_:VQF//ACL'F\^6"!/]@A^O0L"A:R;FHG-E135)PF:\DUSXC5^ MDRO/B%8`+PWQU%4D*"KD4>*7ZV(.,'KX0KIK'8/`M`6+:?6EIBGX:WQT< M![;%N%!-$T."1@V%ZH@&P((_GDGU2:3GJ'RQ&Z&&/M4(,RO"P["I4TQ,YA/A MR,:QSWCU,S!3RJ=\!^$4@V'@IVK[U'F2^W)J$2RRE)QOQM=RZ'#6#5HQ$:QI M;MK,6YBI^=6+33937\WOK3TW7TZP:>2SJP-NUF0T[^S!8'M&#P!UIF@N8%\_ M*:QJCB_PC#&IB;%Z?8_%L$R!=NE7KJYS=5),<13@-F?KE7">D\J&-E%P]N91 MS*^6TCI,7W%U)43>L6*+6E[CDTDBP6EA*_\8W:08!7=;^E&*@P:1HI@'G4ML MKX&OFB%-2\G1"Q:_:UZ"I9$U M7/7HCEFM3ZX5C+9&:EL28SJ0D`5'AV=V><0IX7]LD0.HO*!<5*D7)"F+Y(@* MJ_9QSD5_3`*M*V3-(P3AX@[_)+Y`#TZ2Q&Y+02TIH@28)P1[?@]4HCPB*82< ML4W>T%RAT'+Z=[BQ>58ZR;6V1/11'@R>P]<<8&A_"%K2$01;6`/8)5B&HXCD2!KH,2Q)59H3!854! M]'@-493$Q*34+%, MK/:NK*&0W'6>1GI6H1TC8HJR)P%JK@9P?'5]94$:\JZ?;>UN[=,%J,.&W)Z< MW,S4NID2,TK\:IGO1X^7.%<#R)\06I(1W;+5CN'QN@]O=W#)W&%XLB!J7YKN(R.+0IXEI[\/QH?'C\XH4!(7H-GG6[O,0/:TA`M"NE@!8LIVTIRS MDY0M-)0RX@P-RJ%?"BXS;LC,-"M>5_/*A`=81#!$BVG]LCT):JX^_66&6GYV M;FFB4SNX[`J)F+(>+:2\>[D[^Q/%DT-ES;]@F#*S+6#!X0^.-W;1Z6`JOAJ' M+`[0T+/"J@*YXC1M9DPLNE$6TWU99EVE*(RM;]&,+Q_^2Y1BQ>W`$ZE^6WO8'NUU^Q788.M:41LL:?`HKYT[`,#LWRF1FL[+33-%]QS,L#"[L]Q0 MD9ID`C25)`K3`J@A3%-,C2YU/^BU,TM<=?IA/FL8ZF[$#'[+@#F9T9S7I(D6 M[H9>1G4]D](L"M,L7TN3GR`:%*AR`5=PE(RL;:=3RBT0=L):8>LO085L"$^)' MX1-*':/$,:\4EQ7UN>*"*Q=9*QHM_M3AJ[#P^:"8AO'Q0^[O5N47#*.B5MCV MT+!2\,7T*..#FN\;XQ7^%H`('N4U>C$G[=5.70JW=4\V#=EK1O[PJ5(M@"]9 ME1(?U0!G4!<("E8ZA[MKI/1*SO?HVY*(U(J2)=M-DP5Y:!]`\X+6R_GJ2BW5[ M[1H[4:T)70.Q"H#T+X0102EW_S4=K"M/'GKK6GQIZJC0N+2TAJ7SY87*!I=N M,$F_?<.P;U?9'0`*+`76&!$_LD@$A=]>H\:19'.PLJR5"6ZW:N03AN,#@AQ?3(_,# MAL1!BM0SN`B=HK(WHRD*8ERF1'>LH_D[T@QR>\*56VE2<9.FSI)4BX==&;R@ MXE0.J=W1P='R\XVC;=Y`@@_,JHJ*;\.+)%%L$G=\K689R$[4B\O)[%8UJFJ5 MD2S@L(._68B3>"0][-#G]:6-?6:$_/`?__O_XOHZ?7-)1/7U>T]A@*-V9,ZU M:A:"I9J2,SX;@'8;)KX>Z$8"='I2C*:_Q5)? MVQ[LOM.Q:$^OWR:HF%8*D5O!:C3!2CLZFLX,N$SP,$X2:20ACAW6>*4)._N0 M:UC"N.0*B[2/@H^Y"C4ZKH$46.4:?2`,MF7,@N%>*<)1]X:@U?ILL8`Z[W2K MKQ+R*58F$499G(9_91O:6IIB^RM`T5@^IW<$'`CN5:UO+E62(4S-UQG<#VFL MK1!O-@U"/R>9&H5?(P7HE;L/FP9/X;"(@%:@D+PGRYL$H=$".S+.&"UX-$$4 MP)H3*YEV\`?0O4JE!)*>6*;OE(R!FY%R8J096+*#RRZBP518%ZOA%*EB-WC) M!%QF*,A+D_MK3<,&37R=36Y8RVQ_&(*Z(E\M!U7;S+P4[2.1B/J@9M,"%7#: M^^GOZ0Q7"A<''L:+)#!3Y'-%=CZ1/GE1XILZJVTU,AX&<)C5D\Q@4P/UF(HF M]6Z(#;,0N5HVV$76&SV'QHC_PLT(324:4*3$&SM`U5HLMX*(T2RIR#`8:3@0 M,TXLORL\1*&OKT*2X5]&KA%56B.HQER:EG6HW$ MH]#?##TORD)B&HY*>-;<>;4(PU)C/ MP:Z5BQ8Q37#NWLLT;/*/P,<8G@CO"CN;FH%^& MJ4)NU"'4O.F&#`W"TI@9)#/P:2Z%DO[E,PE##F7-`\T3PEGQTH5S!K;(33>Z/X.)<(ZMA(^[P5#DR68[&0X-NJ=-)H]B')7$%[7HY&OV\.:$D0>K=02N%2LG\"FPFQ3RV>CQ1M$_TUFN)A;\-@,=V^@=S& M/UY1+0_%"8A!HJ0(2PU0Z0#.&%#DU%;6UV#4I;2V MF:E.?@U1<]`;)U#"*]EFD9"@$C.=0PV`$U.T8R)UB$V;+N-,4H4Y5MP2-@`^ MBXVCZQEF!$L,$XA`A42.P?CJ0KQ9=[,1S0RPB%5U"W'OMO[K*YBS?Z`&\ZO[ ME/N'.FPM1+33Y9X321D04`Y2414P"/R`@UL?LK$U_G8] M6\,T`0+4;=DA>$H($O+::7FW"6M-1L-(E6S"*"<:R>O,VF3$("Z(P_L3+!,. M&$$?#X^4!/EB[H)^I=;I7`,6T1O\QEX:!0G6X663'7&?\>_%:_D&6Q6;'J+V MP9NV<[G73%3JL'A?]=_)6TN9/)["*2;;#+CR47A1JF:T3L`EG.SH*@Y&3DP9 M"#+W],X"$=W&R'6>$%5A,[9C23VJ]=BLK"&CX9`<-R6.S-!KU"/EL*2N&VO& MD]PG$`'N]RF%2=RGL0BG#B,4/@! MMS]JLS5ZTP7)SQ6`&P5N!J^B99V)7H7T"L=UY'+Q%`R2<)Z*HP-50S>C+/LA0H/N?H:1?S2C$JK8E"!.O/E\HEI8/JL&IK=QLA?OZD/>#YG? M@33)ML:E]/%S_&HP+%B517`4/27K9ISB9GO8;&)V<"*'8VADM@W\:;"H_8X2NG>JY MY/6DJ?'(1!*?5!X1$DT\'Q\$E$%-B=EIW*=GD+CYSZP/88"=(78F,$+(N9SF M,?.Y3RCXYJT7,:&77]-M8'+&;FFY^,Z9G&`4RFCD\(7%K]FIS-T$'7!IP#^% M577%2A&!(#`[)55U1-<'+2G(QU@C^\Q>$#AXA!M"+((XJ:#_V#!(IX45*N#' M94]>RZ$X)M7">#\0Y;+TEC!QP1YU#*N@9?-R9&&T0E1Q*'#QG>@Y*[Y73LV[ MGM%_0[F&L&CX2'`G1$5=(H\L>^WWW1BEC*0@>(4N79A*F)X_`!4Y8@"P'!6A MXWR\*?/$11L*6KXP\.E\F*:&/+Y]#IU.Y!K9Q?@GOTOA!=A&P)7L`'?@"B$$ M)WQ5[K8^&[]S3U!VF:;-P$N!8_&*R:_#]&[BC/%%19H@T MQ'B(R`5'NYV=H(YBF0)4DEM$YR!^4ZCXNU0O6!J,2FTQ`E57:'R$63@)_#.+ MS:;*J++$K[ZY>G,Y.,"H>3_X\<$BLY($##)A?)6B2O"WJ=?KKI@<#+=-SD1> M2C3?^#U7^Q(O-^`_$N.:)CQS]%O*_P9''.W^0%DGT-R;>:K[?]TYR@XIS./X+=6X?/VQP:0S8($?I/1EHS["(;@>[_.WT MZE9"",+Z!@\E_.';":P`[?1;U4+<.$-V`:)DI4)0<-K1[/5L>OOQ`\5DLI>$ MT1'>0;ZV&'J01./!C^=7%Z[9`>;D&K`RST"Y^BMI6D936[%>:.3JY\K3M?4$ M$=:$7R=AI:.8@8:G!I$V!>)1"9?9!21[/KZJ&M,[?IR%PGV(`K,25VS$3QYN MLUL?T;L;I@118/"W:1MVO;J)Q$'234QRV5^RCF*!^^"U6JB;`*U?2S-I'^@_ MEY82KLIUKQ9B_]-I*F6]J3'PXW-E![P?;)^_%0=WOC!HLH5_(KX=FVGBY_SU M^?;CU?7E;S9>B&_?A[N_P:EQBQ:%FO@-@:GQ+<;(=`&0HGP)^UR-]L2O*E\> M/_%]?K>QS3[%V8YN)Z_0-EXPU>CTS1L4W\L[[I,V-;B.G5&O]4NTI^NKRZ.# MY\L'HUUW]R+XSK`Y%?V4I5"P"E2P$UR7:O*&,2?2S_IK-L`\Y2U.YH49GTS( M*4+]HGV%6I=@S+I9=/X*02#U]X:Y(I&[1F/$O""H0`*!+`!NZBP[O/ECC"<$ MKINWF>/(0?9@K!(F1@"S@U=8WG@JT&E2;HS,X!E2!KN`([N%J[,%YT.4A$'; MY.EL<5?ZSCE="7X;G>5`D&NPC1- M0%/;#>]7'F65/9IX:-0>I92V$"[1C!<;+XE5:T%/7;T?5`:R^SQ`\Z9_B.0D M:`1,IF8[JBRERI3_&ZZ\NI:YLB"TI2+Q M-X-OHN,OVF[!I./R])0IW"*[8,U!0X&>!QMX[][JZ[=^,:QYTQO@$8[,9&P9' M[$6.RJZ[R33`[B,Z@]21\0<:Z,!D)I6\(32_M4%X_N3ZBL8W3>OQ]JM]*G#Q MHES@ZHADB($;TU+0QS&%[,40BA"JL)P<`6=7IV1(R;>$!IWJ(L@&A&5`;Z;; M"J,HFY73VV<&.TO*BYH3A&/)E&Z9)TF/-C>VJ=)LK73WE:KT'?U]N#P`)\*# M>";@/;UR_VN(JYB'6.=K[%FF?,SA"[[E:W=5>UF,F_;FLM5UR?N&;.+DF1E5 MMCW^(+D#CL<_UQ/A\F\R>-4U8X8\__,(FU3I:?^S?8<[>TRHVQH0Y73OH0(3]SFA;>!$''XR&*8H!,G"'K^W.PY/W6J;AJC8:'T3Q+:#_?=X:>7IT^KAU:75M4?57[N>7'N\]'CM&3KD&'QK"J1Q_7 MKC]I/[D9PM?5)H:KZTMX/]K/,T/Q<0?(GRX]>5HE7P_7UI:>/JQ@ M[I,H,\BZH%I_=GUI].S;%D`".3H_7)]^=>G) M:@5?EU7L9XYB?IR[IN!-*YMH/[-N83/!&V!)3=MH/':FY:3`HYCV' M"H\;'5*'PUNT068,>'?37A#J>OCD8?NOF_!V1-YIX8N72(`C8KZ@G+2?9Y75 MQQ6V""6=&-B((HM`2]R:N1S6R(4E*RALI(PHH8=HHOK6ZI.*1WPWOJ"-H31L M;*BKGZ3[5Z^MKR\]6JE18_41`*@X^HY+%^VA@P.WUQ93&&$WXF.]E$@DFPSM M\=!C2VAG8LSR8<:`%2`@W,+9(`)>]1D1@2Z1N=V)X-I+0%(SB? M28$@5X-PEX:)QSFT$%54=H$4O"3"C#YE`Y8)'"HX^A.^_%A&Y95I_S8C_LU1 M?/]KKOQH(X'/+DAS,]IT6X(C3GP?/1Z*""692LSED-*I60W6/K M(63/I84<#P5>($QXV%E%D)LX)V+SN$Z^=3C10`O@+U,@4E^US+Z8CTF-BGAL M3'07C(+HZ[BC]AK#]:=+CYY4D@:V]&2E4D!<&^CX8'O5!CRCGY\P7`749]8? M/K(ZHN;@^=GDY+:]H#';BDUN3M#&\10Y_Q(4P8+;B$1YU0JF0UQN#Y_6IT:; M7/NR^HQNOG'H83S2>^I8A2W5=A\M/7I8<4PQ.W03I039086Y'5-3\#8Q"X4S(`N_)`?]HDIQ% MZ!``%JF-<+*]:E)9!JT^W;.$Z%7P902V+H0TC3M>R*IQ_W`A;=@(T+\%3-+@ M4T2;DJO@=]@A9Y;HPB$\=P'))1@XJ^:_9)@%55C\&`>:B1&>6DF/5YQPU)5Z MB=Q3)F=V0>AK)H9=F26@YU[9S!4C4]2]6O#_YUC%]L7*RIY%RD@H;897$5^=35$\<*T61!X_>-H"[.J#U?27YKZ:)\[KDI^`5!.M2YAW`>LQHM2*M3M/)*)RW.A5 MR%P9FX)2!"\@=B*UU`TH_I\_'A*?:@1M\@PQ0+Q8D+0:K-],WYQ?QURPD(=A MH'81`8[$T(44D4PF=LNZ]-XMM^&3\!L*"VW=O)AH$:MMS3H:66-[?3KP8%`2 M'YEUND)U(J"L$C2K1[(S*&M$:DP(SD\':T\\OH4?*3\HH:-XC(D,KH]*09-+9<59P4BFEU&C)8R6?+TE$10[K,\ MCN&`9=726A.LBYG/G",DAGF,H5):`9D.VR@=)C@1G&9&'?5![/2]EVR8'V^V MQCSJH*3F(W9?STCG5*HW\80;#0QW-51["4^P"C<5LH2O@`C19RS51020_ACJ#A9HL\2^!(6>,VIWJA2+! MR/3:6,['7IDQ9<5[242":B<"N/[.BC0DE0UI^BDXT6CW:4`/78=`22@X08/> MB!Q+:31Z"#3-YU(1+#(RY;94!H`>V"B[! M7YOP-GRU*AT'<#;K1X.J].>B9/D]+8`58XG+AX6_T[UH6D)#_0V-*@ M]0+I\NB.=M%IU#B'E4&J"5P6WG2C:7:9/V#G"89CEP[M90<0I?%KR\&&%6CR M:WMGH[._D!KDV%%\S#FH7FB"KOWZD!;5U=\>K78Y`4RILA1>M];QN+L+U?8U M_S.8HN'UH&VA8M/FT+9=?1X'2KV!X?I:Y;7*JW[6R9?6:S]MK/@`]"AEXK]= M0-^<6?$VBM>::5)E&`)[6IV1G:=*:VVB[GRLA=0U:DABR\@C-A,3FA>TIZH, M+(X@'6*CP";M-ML5FUM<8D8KQ9[OXD?P((HC5`\CGA=6#!F.HGH`(4^.D8?, M>7#9"O92-F2^R5S1I"/'76E9?:C(W^^E!`G^=_!?"+ZXT2BEIEX^S%9PR*6B M)<33)>UY3!/6X9P*60!R#9Q?"=,_UJG%HVL.G[78AWDNA:DI,G:S>,1>=+DX%VT) M\\=+OI[N.$B3+J@@VJC&CL4F?*?[`U@*9U0G`V08)5R=_T.`5`UVDW1IN7U+:/5B1BDQH M\`WZS_QX3BF$)Q^U6#W8G&*GWT*+32D'O2!RG#,PK@B`Z$%:#[0]MLU$3V"(NS M=SE&K`U-2]G4QXIEP'#7KLHJCN)W-Q`VV(0*$IR"4"KY0.0AI2GT7D3]1%U1 M-(#>+KA#OVR]L?+@<7RCPN4C(O_P;32UP99JHMN2K?W[=$X@^.CELZ.M/[W< MVCL>;'W'?[;72CW#5!#7`_AN3K8MA`X M3&2".F0>(D(Y#$?THH48N/-A=K"`\U>6KC,+HD%WJ@U(@TT[&CY#!%X2UQG3 MKDJ_[%S*^A&,Y7(PTP!=D1WS0?T>ZA\LA]\4%]><5#S7<>,04=%_A"891<:" M\*5HWI:*XP=JX_;Q@X,$4.A_#_B/OLRQF]2GC7)GMPIHAH[IE+QTV96;=? M'(>RM2.3("IU!AS_-+,H"4+=3+YO-\6V5Z]+UW$Y1QWBG9(LCNN]N'&]M M#O[TV=OM+>Q,]H=;(Z.1X/AR[W1R\T=G@D7EIEBVG((#+'E M;+)A5M#K?G8Y)E,++'OP M\=+ZH\JP&!(*?-05IEY;6JUCD:SQJ.XSMX>N(8=/]<5'9*A4&1"D8GRY6@%C M^"7QD2I0,%Q[NK3RN`HKQ`_*N/7$VR4%HL]/JQW0]K.*&@R995PMJ3^N=;S^ MN/ICU\?/SBFDK7-T\H6XSM)>7TLM^F7A&?,BY:,].]+#S:PE@=!@9]@?7HL- M/*6:2*>PK`TY%5%Q5)TN8D-P6,_?!= M#K#"7J'?BR!-$=_R,E7XFU\8=;\P3W_8^'IK\^7NEC[]'__K_PR^&^V^'!WO M[.^I3D\,;W=G^X>=O>>#T<;&_LN]XZ,V;OQ@FNQ6#ZMR$R9%*2IR"G;TQP_C M2@MZ)A>T7!IR\;>_>H`&>G76_FOT5U40&A[&-(QIQ:`WTT\?/PQ7JI\Y&5II M^TLLZ*6+U?.W5Q\_/!N???RPV1'-W'+=FQ-5#IK-$)]O?^D8K734%6HD[8.H M604#?=\BQ^V%^K!G:*8?X0F0N8:.KEWWI^X&V]) M/6NO,.]S-===6:TBU<.5E8J3SUNTPLAA)7HR@J#_!G'K_A%O+/<357&397(= M9+V@L!J-!E79^DF<>'N0NC'(IKF"S=34N\]2TPR/CO.G`Y?N9CDZ%65>?31Y M;>[AX8&L1JS!"A=[UF\#O?-K[8>J[[8?B#$'408FM_3X]B/4;6)C0U!;>*W0 MAN'0%:FBAKREDIR&$`IUX$"3G=M>*.(R@0X9)'JZ_7Y:BQ\^*!-\VL_ M]IRN4-;204]AK\9AU49RU7>W0RK6AGDTL=0M1>W"KJ>]LLQ+:GFQM>5`WO'L MJ.&N,G';C^H"7.YLNH`F)?^V^8K)3*L.;K]\6&8_E:DG&UTI<]%Q::UJ9!`* M6]$Q<==<#(;'@F2]OT(#[[I"@_"=[NTH"CI#[2M$Z:+[$11S(M,.>>4D7JF3 M)>.+ZO2+]M,+KG-K2N*V>:G;-T]N6I%0$MAV&_+Y=1PT$7&4#X"CIGP]>ER& M.)9"R!!MRH,[^(D:SX8,6#.U&W$3,8B=@\/_-GYW_8=-*1>AXRF,^39UPW]2A`5XZ?=)[I"WKNRT$RXMH*5&Z7+K4&0KB<^ M/]Y+/8.F_SPNB=7A>>!.P/^$EE_A*WOI]A4X2NW2EV'YF-3>P6[H MY]4A3I[?P)5IMV5L%\%A%8='UKFXCR5*RA4Q/?#?%A%ABG2TF9W:_&OVH'U=O* MK5Y&?('XXKTQ![M_IX4OI^_='FYK>=S+)_:MT_);D;W"4^&NF5XE7I#,1.W# M$TY=[\U@Z5-IVP:+N9PKI,M>D^TQ+4UD@%F8S7/-]SUX`$:0WLY^7EH)P[.+ M,;`"WHRNGP[\&?`$S8T=OJ#/XD4%W1:PXDND1UO4N/F\,:^MGWU^C__41:`@9X301N;9SS!%/YNJK*#*O24*8@OL.SH;%B M^M7>7>HX79_W^M<^(:W(;\^M&*"&G1QUQ!4>+*#:`H#<+*( M&1O@W7]A:!5X^`0,Q5DF#$5#!55#^[`SG%_`7-D.4='\+TQ5)*@"], M7U*\,%E6&S6@&`0(<@>`EJYT+]CU#$[L!MEN/('Y0:*);$B,:B21&;0A_NT" M,]S7*TDK@BE8V.%1$0E(TT+N96`I-P3Y5LX`5B9,]R;0,ZGQ`W_\W->`0;59ZI^ M9M'QU42L'89R\83Y-`S/42!5'&BWTE1M;K\J;LT%I7K.D0S_YQ<6@:KJHYMJ M6?%VN//.NAW[+;1&N6<^*KP3?09`][X'.I59AIP$.T_)U%+ET;:B:B:"/52# MAFE4$-N'+=PMWX<:R6XDO?UJE/*86)5#64%ERBJ<;]^'!FJU<]N"+^:HBCXH MW.U^4;W@D/9O_2MUV%=F`[FOJUJB.FUAO$3;^Z4,"DQG7U7JT5P76=K>O+6S M-Y&K"):">5M0.$[)T[3$@^;6,2#\V.UU"_1ZD1-UL=47.]#,L6CR,1JDQ+"3 M$=%BJ%QPS!!E9[NJ*QNL`5%`37LR_[)%KC!'<4E&0+56,;9\C+C.J:G!N8'_ M9Z`$./GK11*Z.G&Z6.:$K6RN_-2#-61[^U8("G-)MI=_FKR)U7]LSH20-F8P MZC;`(.)4RUB;+F]-7&3 MMEU1LA[+'(06)[L0DNEBF&W\')HTSY[2.(_*#/`/8 M4%&QW$Y%)49/Q#1.4K)='T6.5!CGH%LF<83$I42#.I;V0@](^0^X$?/RLVTR MQ=J<`(Z5"P_A0YH`I)"S5;&VO.UE"I:OPI"05<5&CJW4\R#.:I&_ M0#%E8[`>H^A=LTGQ'E*9FDN!]%RSQ).7D3WK^*X]AEN]E!M;SFR81*PB!!;? MS"[H7!::Y*Y5Z29>S,*G<659,W@<]<0^'O1*ZHU4O5[=0,3CYF4\.RR.*Y&X\3J5,Y4Q1IVDW38`45,5_+5`CDAW?,"@Y2MW) M\UL@-B`/\346#]B=?4PO)ALYUZ+^QW308J8%4BCS? MZ;O;S(>&[EZ$64V[5@U-$*BSN@.>D9HE]:[>!&%3WPRYU4/#FTLQ`^\ MK\VA!!)E![&O35@\'(F,D#HBW@2%_D5J\SW:*<>V#RF/I*4<-HSCEV6-@MX( MYY_W3DIP#)F&54YF[_7UI"?0#CEJ%P<0`YJ,2>&^](?EHDP-48/P):0KJ3WT MJ'85;0]Y$^U;C^D4&/T2Z5!TN=B?+0"SH\XPE;&9#"EDBMYU^P_5CWVPS-3S M--K?^]=90S+W0?M\+2#]!TJ9NG@?.-3;&E^.S<>_W]U-9+>XE MXTKD4.-&U7V\KB-!1:PB5US$:*S`$+-4S/;!P).:%2/H4]+>8O(6S+P$?-\M M$B.3T:8V4$$/ZN^6EB_(JSU0:_$BT'T&U0:.))FB\2L(#:\W0(CX5+@VS.^1 MU&_U(NT?4EJ$ZK%0HP"2YC3`\+Q@RNV`]EOWUGJ6:P2%(Q!CEL9"4)'E>[0Y M^*)"_!T:U7H1`TI9J.2VX/5/=$#/@Z+:NTPAPGTR$!!JL8RP']Z"QI*->(B@ MD,1POZ,1QS1E]FC$1TR*H!4%C2T4JST97[XMQB(@8$`6LCH)E<3>HMZNSV0' M*9C2`:I]IX_(*G/-9:;AKJJ4"35J2@=.XRX-OSO2"N\IB(PK@"HWK#/BL`HA MMK_6:$D2`H[M9PI[P#3K9NI'STL+<*&P'!(2%NE51FV=N3F)/_:A"W[G!X/0 M`:G*[TY(P<4TD&(.GTS[.P4_2O184A_(F/55XH92F-I`_/15/#(OV19N_?D8 M;_EOL*Y\9AVB6:<5`=SYV)$M!K/,-,L[;[?]8`':X`*C[[XGL%6P[7Q6V#\X MABRKE2U8\<[#"9K+U^^/+18.]\LF@NT,Y^VZY\Y7[@*99V(>&YN?N)F[(4GG MIJI7N_'@!?HOPFT^H&SS\!+C=+VRV9[*_+`+?*U'JCUVTL"BE[H/UGKK;G=4 M3,RK!5S)75"GD9[M/,&%W"N^MF3C,JUTTESZE@4ZF*?.!?5Y-"T$#VOJ80:2O+'[-S"4%)U2)BX417&*] MG@#WW+R9\`*4B?1B(/:Y+&5-F$/YRFEJ<[!L[B4U38YV:N;""XHOO+];Q]L% M8K"]F92/&93#J$;V";N5P0M3[+J;V+X8'?YIY]E^D8#9!_<76[L'7X]V1WMW M>79\\V_G)]V9G+V7$LT&9[M2K,,^WLW] MW?WC'_;D^_56I;+&%NPRO>.]\Z2-IZS6W@]!XY:J%\)I\XCZ:XV4P'D*`71Q M2[)&9Z2OF&.Q=.FV19Y"8_P^JXMVR[,&^'G4OAM73^9%[3WO^3F5BYPN_E(8/X,-4 MZT]HLSJ^H#=\,/#[:'K!Y[*<*O1R8Q=-H$5?W*+/935X\#5\&M*<5[C=_B8F MF9#+_(!MO%APD%):QD3MA0+(1WRW`G^L''6OD$+G(<9G[+3 M7YX!OW#[AY,3V*(K0P1KJ#D[(9&U7[N.VV\F+T5#LJJWFO]X5?-%K&YLZA:7 MGH7+\X-]"LG#)K-B\0(/5QA88K_V24'DR+MKDK9)8!,N65I5W[.'H7=KW^_Q M/$>:!=VAV;;IHC-!?>&EA.3VG-)^-R7*K`#-E1:KB=+S"'>5''`]*>W=CR^B M8U\TUH3I<_WNHL9&JI3U.?GPR\S+"Y6SN"'F+T,FSP)QX5LN?8_S6".B-+A" MY9NZ#IK(5+#L[-G;G'+8ASU%&,C;Q:"O?,ZS@W\?;,UD.'WNVZ,IQLS!^%2M ML634"<3BW"-;_$VP[B]/QGILVHD?TN/5RN/[8/02W-E8VA@&#`@(.;< M]CW^8DP+,,KZ^W[_H:VTQ3AGWPN%>[7N_:"64/A5Q6%4R#>RY"P!M/?[EG9M M&8S%>W/?R$DE\]8]4@9G*+N1D9U*?$9*-@S2E73F\KD0U`W;GL=%65$YGWX% MH16<,C*40J/&,M:KR/T7Q`D"-*[9;QO:P,HZ!]*`+&7_GY:+3W6."ATM75/] MD,"I\O&.Y/ M.G]H"LP2V*WDC?:7FGA*G3T'P.W1?8Y(IG.Q8-"\O9P[@IOLFL9"-ER^OM`% M:Q/K(O?^\Y:.Z*M(5=ZZXVP;-UN?:)&)V&0^4`>E-&+\7$.FZ)X`U/=,'WFC MC"N:-C.UG.7=NV'ATI">8MU7$FOH6>A><`L,UD/8<["ZWHDJZ<$8;AVL=..4 MD4)7_2&:85:T>Y^ZJV7O6IG=QIP"Q#;>DAAQ`:(N^3QV%#DY>L=G5(/(=,$A M`V/O$PZ0(S'&4X\;E'Y].WR*XV* MCXD--C2'(*1G)K47[G_>58+V\]_9*&TZI1+BZEFR\756W`V.('&\#;\HY8/9"K-_0=>@IRA#X8&,_2UR\F]W$\Q`*WZ"-::V_C MCG=P9Q@FU9_6>[_17GJOZ8YGZ;V[.[X/V6$`53=_I[>;%#+_DN^TX-+@-[[Y M7_5"<^R$'%X$M7=Y4@+$8/B#F@?0&;,@@S:RWONR._A10>HNW_ER&4-2#6%;;6HP6ZIA+M\D"G$QKN$3HIRUW;%S!Z_?J& M.4FDT.8'.U-H>A_\?'R=L^0O`=IG"$BOSUTH'DU\=9CW2V[0$[3PB0_6T-WR M"/Q:W`%CN16(U,CMK)_%9'`HQ\#<'(O`JKW8,VFC9R`0C[I`OVZ>S-%Y;"&\I%504>V?;SOQ!?F%UCD-WE MA?"!XY^N>K=T+X2`%U-G<_-QZ3=2J_O.FQ;O4^$[U]Q6/5SODI&;+.)SW4O/ M,\%B='LA"[T;<18.%J>@5-FY*"Z1]:AZ#?D%H;_(6^Z@S]YAM85Z5.\^7%RU MT?8.G^Q5=^[P;C[\W5250=3DMW/)GRC(6*%ZK]CY!T0:Z>AZ9_O@DU;M@7#D M4)^T5C?,/VNIWEOXK-7FW\8VVC:#U0 M++S^<&7X]KX)N<2!(+;.Y/JN9]N$\&)\BTM'F>@VP5EI4>8T;#]GL&DW(OCL M.`S]NQ\,-(&&$$$5?J>)-TG>-DWP865WI>CJ_JM`'53F`#C`E;V&11Q@.G@6 M`@$JX>'!9B#`=08R!^;DB&=ZCQYB\]O',3&H(6U@[3&Q@\P0NFMYO"#1J#W*CL/4O/I6!V+0W02&@T1$(Z% M5U,=(*2_M;\>"XN%@U810*&#VE6'B8_74@7:[Y`&@P<3_K:'2?@JD MPW\AZQNG%\-1BM!(^P-8/7K42B"+8WB4+!^__5J^.6PF93^9&T_8;N6R%M() M3D'S')]Q/268M'Y[S7NK_X^V<]N-Z[;"\*L,BAB6`2FQ9#MQ&Z"`XP,BU'8$ MV4ZOI='(5B+-J'.(JU[V>?I4?9)^_^)QDYM[CV3WSO*0W.0BN;B._^IW,@03 MF*J!&!!CV=%?Z)5-.LS'.5;$ZFU/JCXGQ.GCR!=D)K`'*D4/8*=+"&9_"E*4 MO;O'I&B,=$9<,.=/5][]IA3XP6U(W"G?+.<54W;J1IY4MZT!8B2>/J;KK\%' M>:;JXY%)V@$V1"A95AC3N)++:=6-J3T\\[H*-S[)3;ZI8JAM!I;:(_E,Y%6)OJF'ESMX51,]HOC%/QZ]&> MMQ>YPK><^BEU=-#X%<6KJM^@/7-TXGZX/MTP,4=W$3H6I"1DED=TN)L3L,H^ MV2R(I8K.<'\!LXM?=E205C>'&I[FW_T]>_.W`_B)][,5E_MH,-8^DTCJ2A?D MW\2OKY+<$YG'5,%P!*,SHMY547^^P,FHW%@LE?;E MJ9\H#9,=1:D+G%R%RF$:1$@/=1CO7_5$W8'.GID M]I*2.ASE-C:(WM]T?%Q_)],IZ88]^J0^H3#<&MX\(]A.U39 MM^8$;Q$`EFFE'H8-%GZ7?&GMQS\8&3P]#N#_S26X^DF MW.GS9OMTU;[>VV1O!B2L%AG340CH;9;`C@\T"FRPL##*.,[;Z'E*'R3=UF5@ M#,#&R9"XH#;ATBIJP->X@]A?4#)2]>*A&SUL\8FI'7D\R]32/%KT"OHQ;\M\ M\MUD!^W[@71E3Z'R/,RM1ZDF`0)J)"0'.">5V#(I0DUN`_#P_:`\!N`7YJ,?'/)L2?&XQ"Q3 M:-"^P[2=Q"#-W1W^J]GZT^*L8G?W#[&)`$UH(?4FA^#5"Y`?)]4;(OC\),JB4Z)_E==9G,`V\?V\U9?\+7O\W&: M7SOX2FO;?[C5YY[DK;Y@<00[;T?+O-D7?._Q=M^KB`EBW.R"F\;V4+#W#/7?JHY:$NIK:J36!9+2[4@G,#N:Y>U[ M08@'I9`=#V56&0)=V?0UL4JJ^GNN+"E;"+>D;)2\UYC,YBLB'V2R<,-C'-(` M59\T96_L;8M;5=/)+P/>T;KUD..RI_6@+[)N/^AG;&U@D_DRJKB%G"\P`A'\OCXM'GH.LA?@=!BH_Z551K_.)1R4`J[)M1_`V%XAA M[S3LLIFMVD-4H@(",E4?QI>QH--Y!\]R<"I>1`B(Z-YP>N[0Z@RS)3Q5]3+Z M^VI%CA^?[[Z&IQ`<5M38:@-1@I2!.[$\WP)4*@PAYB!.T7)SZ%)>] MSQ:3;29;'VZ[6:,S<;=WN+D43OSH]*@G#^\)U@J&?N^!O:%G/K]1^)\+^,&) MSR"E$7L,!BC6Z944?[\K84:AGX7*B@,>/+DWV:$+8^!]\9TVN?CHX6`MZIFG MF;9X+E3O?.H+6W&X6'J0=GWS/?#29H:Y"-(Q8+X/*CC,YT&H*W:L,\62VN]- M6H/D+5Q2E`H?K-N\TZT/BS5:S#-!W=5UVNK#([E%A_,]\TL@>HC0MPH,3U?" MCO(YX26-U(F^EH,TC<(?USDA[DJ70?6[`[;NJ#9#-OCZ@FKU>SRGN$"0\B#+ M]0U"UVSR\?*&JC8NKOLJ`J;ZRWQ;"3V+.A;,7@(<=3IXRD@9@.,=7DP)1%A8A7A8+:N_%@&+%U>@>9VW0W">'1]MBSY*<%R M5H7,U_:<$),72N5YA71(H_0PI0RR3G`@>U$DAYU,GKU^W;RQ&&1Q9/[+L5*L M4CV)3[?\`FQB]$:7A$]E^[HS?_MSFOE=QFUMZ#LBPB[-]\WS?[1<3(CK`"4V M06KG.JP8/I]J:Z9IB-S:%WBV:05["&G,IB7A-RVLQD5:^F@ M1:_GT1J>S"5ZXC)^SS\ST.=^".K1"T'$*S:H]2<,M8I'*%?GT9H=.N?4P+,% M%(%UN7F^XXHR%@*X6WH@N_,>NFFV=/_HCWK@4F,2FG[;.$1(\_`KS6>"$LR- MC6YBCR'XJ%QP&@67W:#K#9ETP%@NUC*<)4GW-L?:]T]2]#)^ M@J0MEP_J/G%.$KR2>)5-DI?I>PAWIR;JB1G6!P_&&%43J;8NT=E)AKH'F_E&#BVC"^.5A"BZ M^Z5MW9T'P='`:YCE\!SA&([R;I8A]AD<[6O4OW&([=#QVO28WVFPLS,6K4TXM M]/-B>^WNEX,[F[EK9#,9&3QN9N^!SFB`CB%L=2,%1\Z`B M93EKWHES['1._^TYL1G/,$0AE%6/CE>.](Y(O=\#J#PJ_+"&ZDB*@%KQ=CLR M^;Q#3%)?JF/5F(XKP&PM8W2H(P'6?>/=?]0?1?4>"\G*(`596<8!RNTNB?*\ MM8]A;G9(REY=-L&.&G0;5\.*R#GD;(ZAS*ZZ&D1'V;5)^`#E@,UI9/,?TK^/ M$`RR&I^CDL,$ M@C=\1VS;AO)MK)1(M]$#)G:%]=QJA[I:SCC_B"WU3^UC8)7/\?QIRFM#?%S# MTO)*?1@*/@.DACZLB,/Y0E;$>,CB]+0,#D_V4SY&2`3GN=SAX7@,@`$!EF M?"I@-B.20%[L*)A"'F$2<;LWP8N`[@0QHKLIT3YS08 MV30++I5``/-UIR/A-A[G>MX]7T/H/9]8\26WF2I^TUFI+80MODI5J/QW'2G# MB&Y-C#GY9G_WX<.'U>,CDF1'62>G(JL,57A;9#I"QOCSTTC'[#)_E?W3#=!` M_?NCIT6'K9P?V_/H@0N+5.<%D(Z$R09P#R):3\3G%TNNL$:`-,'$O?I1EV#G M,28R1;S,0FIXYH,)<6*_?8O$V,YR[LQW&`^=87\C4)P.93'/L2#Q/_F[Q"BR@S4HTJ5,0/^E.@B*_V29-W^N0R]7(5(BRF-N%[F M8UY&9VZ*0A5QC>;$.8Y583(R]*5R3JKAI`(15=?Z MC##<);H7-S./0?#F_7*78C1!WE;.L+)A3I.VSD#MOH5#AM88:%/>EE^-5AB# ML0P=)\=W:_PC)!#X!V_<5?"(1P_[%E^`0OAVINH/3^/QA,MK`R2-K?9`&I=* MKTO2`+7.2?`L9EYT`]6VJSLT>J)CP.4O!%QZJV<6%#5XC\<-&P4.&\0?F+9' MT6]2I41U&QXMXNPWQ],N7:S%K3P<9S#T6`VFT4M8GH-AFWDP.T!#A]E2KT?G&]L(FT+XKUWT<^ MI__C;0B^^L=&%\TAW;6NV\^ZCLL5TVVU.%QB+FNGXOXR78=)F1_6#_GQ:'28P*ZD%Y4SN@8DL": M&A:BY,MO.6HSA=^_U:;W`UMW?/A>6L%/%PNBQ,K/9MTJKIH$S2Q`0S(;=#M) M-DG%@00Y,;'F\D/!\SB/X?H&0KM44"_!`S(]3PRGW0W%^Q7P'R6HKZ7KB"N4 MP[Y2L(>M5$L\N4'\-Y70$M:,ZA85HG\Y1UDYP)&/HZ/[&YZ'W[VSZ?F%10,X M&=U%7)D(Q>H[Z]7?']X=OG[Y:SGP,U>[W(G5IH!QEB.=Z(=(0*D,_!8B:6,0 M'W%`@VFF$:+Z]F;$12AIYPTBA&#!>Z>,.)5_3'MCD>S)246[61V1H>/.C)T* MZK[7M,]96MG)A0,UM`7GV66?+#>1,%](P+':$EB.VWML/N?Z\^-JS7"O.IQS4 MGR^.1F.M4,$5-0YK0&L+'M4MZ/!5Q^\ARM<=OY="B4?Y^"/S%92$[#M#QI52 M#)-NZ&@(TX=K7/.(*VC3\SWB0*"Q7?N&[/WAVK7N,=X&GI0EJT0O3C5[S[]T MYKM\2AS#";S!/1PY?!5^U:7!F#8PW!J>B1;-81,%X#T\09G4(.[\&QKTNJN? M]*`X=K^R1&H0W%,0^?6DX?$QUF\OA(P*TCKP.,@H4MFGLY?.[\A*+EA&A'1F MBBG(Y\TI&3%*VK\EPA$C[K6S@MDL3/ER[%?.V0U/?%F M,FV$4)YR4_^[V7BG+GIJFXJFHY,N/GO44[)4.]9I-A8IX+4A#(]]U?B"-MWX MN34##JQ2Y-9]-4\[L]O+)JN@A_]_"=;;$KF[M_H+FT1_B=;;#IU=W]LXP3L$ M'+)_';>BSMB7R=3\Y-4-[.#,JMVIJZ6[DF]"!E5?V'@7.61#E:H3@'VG:V,V M,_NG+$+J)VMMR2*.9_(>R1&3S0`G'@8Y2F,MJ\FD]IG*H=J/[2XO_WG"'7;< MBH^4,WCEJ_:V%#"Y+?N^Q;4B*[%.=QAK[^(+W'049%'.!ZB$_4J3VV;?V!?B M1>=2`DS]&OS$P??E=ZV*>5-3U*PJ-?<5=F+"=XH@SM9*?L%),H5W?C:4>;UW+Q:;T_7YYE*&11FADO&JM8_;]B]G M/#['%WA&\0/A-1JTJ(1Z,TB5R;J)4(.`V!/M&!X*W+]R(L`J;QZ8_>-$\5J$ MM007@X@1<&9TIRQ6LUP$@7-DB>.%6H2"3)YL9<,7@5U7C#F;_DLVJV?BWZU6 MZ[_^3P````#__P,`4$L#!!0`!@`(````(0`S2#"J*`0``*\0```8````>&PO M=V]R:W-H965T&ULE%C?;Z,X$'Y?Z?X'Q'L#)@DD49+50J]W M*]U)J]7NW3,!)T$%C+#3M/_]CCV4QN;'ACZD@?G\\R?/YX>5K;%15RF<#G8\9@E]9,FEH*5`DIKFL0#]_)Q5_)VM2.ZA*^+Z^5(])*RH@.*0Y9EX M4Z2V522;KZ>2U?$A![]?R2).WKG518>^R)*:<784,Z!S4&C7Y[6S=H!IOTTS M\$"&W:KI<6=_(9O(\VQGOU4!^B^C5W[SW>)G=OVKSM)_LI)"M&&?Y`X<&'N6 MT*^IO`6+G<[J)[4#WVHKI17+,T@VP"P] MFT-\^CT#E^2:+W*16@IH#MOQL@_\K?,"$4P:2(@02(`6XNF(J(N8+UN(`_): MC>#Y=(URD:$Q:.F5&R%"5BK*TJ_HYH8F``(S78!'"!F,UZ!9$Q5,$27!AB@CM4*$ M8+Q(T!^Q<8PF3[:QFQHQOIT2;,@S#E&($)3G+XB[(($!B32(ZWJ^'PP4A_44 M<1)LB%L8&XJ047$:9%0<@5)Z&[H[RZM6=#/K;EQ:P?HQ!M@XG1 M!<9W6*$->689:3"#>3%LUX7)BGSWT2-8OV]+;J>4-)@F-S`U]!,0C4)T>49C M^$W:Q$SCE%($#,@J=^H2S+: MP9U)T.T+-R6@B19B0,-P$HQ!=)F36@/I]H:@DP2#U5_)CQJ.GB31A4UJ#Z2G M/Y@O/@T&7SR([*=F"B!)'T"7-JDUD)[>8#PY;#"8GS#F&/9HV*X+F]062$]? MZ&0F8C`-O(ZL`:LFRC.ZP7BY4&B]S*[,W&PP`Z*&K+JH2;7?P[=VK6!\O)DV MK]6(P2U<])RNAJ0/H$N3]?SN6@8#H-DU5V9&-ICFC7MA[N*@&67A?(CC4T'K M$XUHGG,K81&9!.JL=2X'\EY54VM M+:^%V)8A:;/)WW>HH47-R%:DOFQB\W!T.#,\AS(?WW\['1=?\ZHNRO/&$\NU MM\C/VW)7G%\VWM]_?7H7>8NZR\XWW/:^]]T\___3X5E9?ZD.>-PN( M<*XWWJ%I+@^K5;T]Y*>L7I:7_`PC^[(Z90U\K%Y6]:7*LUT[Z71"Z.1?.]#>HM3MN'SR_GLLJ>C[#N;T)GVVOL]L,@_*G85F5=[ILEA%LA MT>&:XU6\@DA/C[L"5F#2OJCR_<;[(!Y2'7BKI\GPK0&9"3[UO[[5NR:P\93P=(/ MUTH`?/&#' MK,F>'JOR;0%=`\^L+YGI0?$`D6^O")9BL!\,N)T"9&LHP]>+#*KB@J9-00$K9% MA8Y2:\Z,`%0,I.FH*P34XH(='27G-'@R;TF4+$).5 MEM2H\G1RJ.&$'/-E)D1YNG,4,8),]?%-FV(N2U; MMJ0(N696AB[UE!SS@W'!%4,CZ#6+)==7>CC5A2ROJ0V"U(+[ZC'+"L0-+W#U ML,SZ9J#C6/ALHZ0V"E+SUSKN(6C:9OF!0#6'9N]LQF?RD%C,:$TQS&T(I?>_ M?$$,C<%G/9]8#&8HC"-^>DH)0*Q]V=O2A*.)2$DFUJG$\=MKH!QG&84<&@4_1B86 M@Y4+1<"XIW9\"K=9/B%1X/O>'S@ML'E##'+SXX!MG=3&P'&M@GN%90XQ[OMR MZ`P!=P:+N9T4VW08QN;57]\3.O/31G_3CI-KT72S!DSZ$XO!)\="1RRMJ07< M9D_:3V_] M:I93M&A&BPNRQ:"LO),J#`;G.PHQRA.YWJ2EG>47:N@7_#2>6(Q5O4@$@]]9 M&2(*(K=$0DXSOYA6VG86RR&79HM!DC=?&0EB[)51,]^82'+X>M'3?NR_-C+\ MC-M72::`HQ":RUD.HM%!1@7:8D;I89C;$$IOEG]H]`^([OR#"[3%D&>[3=!F M.!W'4((0J.\@$\ML9K%>9"02C1A"E)=Y#$)I,A\9EVIS0P#TQLM\]8]>KCF] M,0BE-\M)X,*39Z]W[K6;!#'V6F?PLF9##(>1%MZ'XG7A*:]>\C0_'NO%MGPU M=YT27NR[;_$>-A$/B337:NS[%.YGV^]7W0!8=+K_?LL4`6S2/>0E"=3Q\:F+RY7UE[>R,%Y9+7)>;4RRM$V#52G/ M\NJX,?_[]WD1FH9HDBI+"EZQC?G.A/EE^_MOZRNO7\2)L<8`ADILS%/3G%>6 M)=(3*Q.QY&=6@>7`ZS)IX+$^6N)DMD7X#?;\1+TAMW^S"A+_.TYH(?FB7062ATZG-D118P;==9#A[(L!LU.VS, MKV05D\"TMNLV0#]R=A6CWX8X\>L?=9[]E5<,H@UYDAG8<_XBH=\R^0H66Y/5 MSVT&_JZ-C!V22]'\PZ]_LOQX:B#=%#R2CJVR]R=:<-J;K+VE@NP3@QIZ)YCF7E*:17D3#RY\((AT5DC@=B0OJ M.[NS=$)*J/]K%@L5M0X^)4VR7=?\:D#5P)[BG,@:)"M@EIYY'WH&+LDU7^6B M=BF@!:3C=4M\8J^M5XAAVH%V"((CT(,<%1%/$2[M(18([%6"[[I*%[)X/_XW ME7*1JM+U>OK6D1U"PC;.TK-X]$(1`*$9"_A\8PF&%(\\CZBK[8P8;X3Q543\ M&4+1!B3SM4GPQ@0W^ZQ$5(\*8H(VL9[OA7K>%#MU(](K5W1!&O M*,3XK:[0]O6`C;&&$(.J7"_458W-3A@-9B56P2.J M)%A5-2DOA'AMJ.@0B59QC$94[-&/),G+:]09/B]Y"58E170XRQ@HQ."VOA=I MYGALIDXTB%8"%3VB2H)U54,"4!5BNO01$JC9C-=!T)AE-+AD&$2%;MO.X-=57:GP?^Z=1)LS6J;&#*"D>M`J#!P'3WAL0[P MAMBK&F77G5UJ!'NTHLV;1`]!J&T!Q38YEQU-AR`A&=Q3QU-\8X-+`&P"H#2=E M'"1+5A]9S(I"&"F_R"G8@6NG?XL3^HZL8-B"R5A['\/DWKZW>@,,SN?DR+XG M]3&OA%&P`U#:RP"JH\;1&Q\:?FZGNSUO8&1N?Y[@+Q*#,`OC`>7-[D,-] M_Z=K^S\```#__P,`4$L#!!0`!@`(````(0`(&PO M=V]R:W-H965T@`WA$B49#:#> M'6E'6JWV\DR(DZ`&'&'2Z?[[+5,$L)E)Z)?ND#H^/G6QB\KFRWM9&&^L%CFO MMB99VJ;!JHP?\NJT-?_Y^V41F(9HTNJ0%KQB6_.#"?/+[M=?-C=>OXHS8XT! M#)78FN>FN:PM2V1G5J9BR2^L`LN1UV7:P&-]LL2E9NFA7506%K5MSRK3O#*1 M85W/X>#'8YZQA&?7DE4-DM2L2!O0+\[Y1=S9RFP.79G6K]?+(N/E!2CV>9$W M'RVI:939^MNIXG6Z+\#O=^*FV9V[?9C0EWE6<\&/S1+H+!0Z]3FT0@N8=IM# M#A[(L!LU.V[-KV2=D,"T=ILV0/_F["9&GPUQYK??ZOSP1UXQB#;D269@S_FK MA'X[R*]@L359_=)FX,_:.+!C>BV:O_CM=Y:?S@VD>P4>2Q4%'K8)(VZ6Y3\YL!50-[BDLJ:Y"L@?GN M&>KH??V9J^"C)/DJ65HN\$)`?MYVQ+/#C?4&0"Q?@J%P1N$+[8&WC5>$&,AC'V*OW[E%Q$\1R2.$HAZV^7P2Y**M"2'J%894 M"V"$&+^MHP6A`=63,`90/_0U@F1L)P%=V7T0%`?@[(T=>!Q^"=:%^STOAA\Q M+@JGKAY[-'NMF;JNYE6BF$,2].2*:.\SHB58%ZT?2\1`R/J,Z+J?(I([0IY\ M)QC2H2CW/Z-<@C7ESI!&##=B,)X+2E?::8Y5.Z&:YXEB)ZXWK%=TRRX^NB(? MEXD$Z[H'7M2-F$<11T3GF4O:1]J>(!!'H M'2'!L(4BG<"%/C_N+5H7KY_/#H0'-`BT>HH[=2`41XFOV6/5'MJ:/5'L3C!J':IRV;WF*\=>IRK7CEE$$(11 M7XTV;FLY5LQ$;\E)9^Z2XOD_JQ;9MN;KQB:GZ':U: M+QY[G!IW_7J4;];@89=Q0IV^$78%@W9TS@DFVN_FY]IEVYJO'9N.Y^M',58`"]==D:&B ML2^I"'CQ"H9-U)J7'6R^?.QW8_DP7V@W7`03H*P;?&^$MX%0`\0*8$%VA-%$]3H@X0)6L/K&8%84P,GZ5TQ^!-[O^6YQ,(SF9MK-E;X#!\)*> MV/>T/N65,`IVA*7VTH>RK7&TQ(>&7]II9<\;&`G;CV?X"8#!7&0O`7SDO+D_ MR.&U_U%A]S\```#__P,`4$L#!!0`!@`(````(0#[,=6(T0,```$-```9```` M>&PO=V]R:W-H965TQ*B6WD>+TZDP7Q..])"Y$!9@P4\LJ/'.T9PJ18UM1?X?N(UN&I= MS;!B4SCHX5`5)*?%N2&MT"2,U%B`?GZJ.GYE:XHI=`UFS^=N5M"F`XI]55?B M39&Z3E.L?AQ;RO"^!M^O*,+%E5L]W-$W5<$HIPQ)*I MH#4(@+].4\G6@(S@5_7_4I7BM''#9!XO_!`!W-D3+IXJ2>DZQ9D+VORG0:BG MTB1!3Q*!^CX>S(-EC.+D8Q9/*U(&1"M@OCK3.@:O M_V<5/$J2;Y)%<8$+#O5YV:+$C]?>"R2UZ$&9!L&>N(%,Q.Z*D!F4O/GH"P\$ M#ZHA%[;J$*KZ?CVN(N4B4V08F0*R>TA@(G;WB-#RF=]#4C2P "T\9C^1(, MC3-*7XINO"I?F<9`'8<4)\.;%6+W(2)_A##4PVO&17BL7H(W+J1F4)8B*[>9 MQBQ4_\R68;RPM(_C*`D":WUNQ(/X5A=#-NRXZ;(EV)9M-XW&1%IV,JJUSK@. M)RH<1K;I?!P.HB@=/!NBD\^(EF!3=+BP.T5C(&-#/9);OK3PCR'Y0XAA8/$9 M`Q)L&H#CQ.KD3(-T7F>I'RV'S&GYXSA*$WNOY^-XN/!O535TRRM\=#X^;G() MMK>HU<29QAB)MX1_B,@?(0SUZ6?42["9]?LMJC%],R=H&5K:Q_%9$/G(`N0: M\+Y]0SJ"\WQZYA7:%G\KJ>J(K`?U+8.2T*K-S@2DR]0^87K`%/GRZIK<.$A? M=./C\7[+]B#CY?:>G8#)'V/,(LB[;+H+??.-7<"^M9*<(8VZ'HAQ9&WLG0&8 MA6%J3Q)YCS`R,32B:4#>9M,-Z+O/,F`=+!E,FG*CZ'LJB*/4`NP,P`Q%@7WZ MRF'U1O'.X:,G43VH-80=R8[4-7<*>I93)H*[9/A63\"9G(#5##L$8`#M\)'\ M@=FQ:KE3DP,L]><+N'"8'F'U@Z"=FHKV5,#HJ3Z>X*<&@?G+GP/X0*FX/L@A M>?CQLOT%``#__P,`4$L#!!0`!@`(````(0#]C@=`>@,``*P+```9````>&PO M=V]R:W-H965T/D+(EY)4!=:M MTB9-TSZ>'3#!*F!D.TW[[W>-`\6PT30/!/#Q\3GW7IN[O7TN"_1$N*"LVEF> M[5J(5`E+:77<6;]^WM^L+"0DKE)@7.:U%RU8FU]"5F#^>ZIN$E350'&A!Y4M#:J$RV3P< M*\;QH0#?S]X<)RUW\S"B+VG"F6"9M('.T4+'GM?.V@&F_3:EX$"%'7&2[:P[ M;Q-[GN7LMTV`?E-R%KU[)')V_LQI^I56!*(->5(9.##VJ*`/J7H%DYW1[/LF M`]\Y2DF&3X7\P!8DI8`0+@BDJJ2@,B M@I^;_S--9;ZS_(4=+%W?`S@Z$"'OJ:*T4'(2DI5_-*AQU)',+B1S4'\9G]FS M5>`%B[=9'*VH,1ACB?=;SLX(J@;6%#56->AM@+EUIG5T7O]G%3PJDCO%TG"! M"P'Y>=I[\_5RZSQ!4),+*-0@V!.O(!,1M0@50<4;]UXX(+A3#;'HJ_YW'EIQ M"CP0YP6!N70X!LU,1#1&^`.2>`Q9>QV+8\3:1"C8$, M=L%=F(CH340\A3#4PS+]\*NB\6%33:=!3=I9$*).(=3(RA09:M"R*:'`-0 M@0?B`W<0V5"#/#C3U-Z=V-U6NOPUJ#4P MAV/8[?_\L1T]8\K.%,*PHS[SO3-TNI@4>&1G$.M0@^;Z)!WL@G;L_[M@"F$( M7YO"K]O':M+(@&^*##6HSW5V,H%,^5E$F*:41^]J\L)VIY_I&/P80HOJ+4N*'M0;I$Q[-J#V:JU M4FOH4_GUZ-"J==.D>XJ2\".)2%$(E+"3:H@\6+%[JYNU4#5K3;O5#4"O5.,C M^8;YD58"%22#J2Z<0A;BNMO2#Y+5S8?\P"1T2```9````>&PO M=V]R:W-H965TLU,M1$IV3&KH?W7(SE6KEJ=#Y/*D?'L_/Z5% M?@:)U^R8U5^-J&WEZ>+G_E24R>L1XOXD?I*VVLV'CGR>I651%;O:`3E7=+0; M\]R=NZ"T7FXSB(#;;I5LM[)?R"+VQK:[7C8&_9NQ2W7WOU4=BDM<9MO?LQ,# MMV&<^`B\%L4;1W]N>1-<[':NCIH1^+.TMFR7O!_KOXK+;RS;'VH8[@E$Q`-; M;+\HJU)P%&0<;\*5TN(('8#?5I[QU`!'DL_F[R7;UH>5/9XZD]EH3`"W7EE5 M1QF7M*WTO:J+_#\!$2DE1#PI`G^E")DZOC>9/3^B,I8J_DW%<[SG"9E,'^@+ M]+H):'95&1Z0*\QIO*9)G:R797&Q(($A_.J<\.E`%B#M@-Q=Y MX2HK&V8>&%I!JGRLR60T7;H?,+ZIA`(!P>\;I!*;EN"#R76IWA"*!N5&JD;4 M$JU&?-?@0M#7R&%([R/O3ZLV0`[S`%O5H&VX!3,G:D\V7<13"=HEQA,5"04" M,5Q-TT0BE(A-A&()Y.F])3P9QC!OS=;PBQ1K](:-WD#UAE`TW$<)^3-3K8B& M0#$"*>'"=+P/UQPFAY4P]8:-WD#UAE`TB!6&YW?4-MQ&EWC3L1IWW`O=DDT) M"=:(X2%Q&$;X+K?`]6?U[H&`H`_7!-3F]08E*$J$*!&A1&PB%).FJDG#TIQ? MM+)A*EU]`+/FFED",IF%$A0E0D',Q#H+54GSH_8D0E5B$Z'8!=O"\)SBL&X3 M&:F="P1DL@DE*$J$+<&WH[FVKD;ME[?AU-(Z-A&*/[S@O-M"SO3X;DEJEDMM_3BG+\/ M`4N-9@E$A#DAS\3G>:&N?E3JM%Z,9X3;H4*A`I%Q@VA,A'Z8 M*&@UQ[3E(B"FLK>IOC8X0G$DE(C<$GUGU-D2T9[$QMNH5O%J=;A5HK95K?*T ML0R(J0*65@E$Y,VT+[$4H"^I[H%OJBR\([$149WB5>MPIT2-JSFEU^O$5`E+ MIU"$XBHACD0]"!G/M(4C[J%N^Y;J%Z]@[_P:]K1,1-VK^::5.8&DC,N7J8!N MK*6X2H@C40]")IXV:>-^ZE9,*M9Y6DD_S+KF*GV;]/0"3%(FZW"$XD@HD;9> M)8YF281KQ$9$M>RATM[K*^V]6R(W^1%(RF@57MKC*J%$OGVBQB5B(Z(Z!7/K M\7GI\:LZR:778)(R.B:$#`C%54*)M,DUFS3^AI(RN#)!D`5^I= M'>HMX,TZM+M7(3CV.R=[]D=2[K-391W9#KHV@B=KVRK%P:'X4!?GYL3KM:CA MP*_Y]P`'O`Q>Q<,["]O:%47=?N`WN!X9K_\'``#__P,`4$L#!!0`!@`(```` M(0`(3>O]J`(``,<&```9````>&PO=V]R:W-H965TB;$O_\<7NQP,A8VE>T4STO M\2,W^&K]_MUJK_2=:3FW"!AZ4^+6VF$9QX:U7%(3J8'W\*966E(+M[J)S:`Y MK7R0[.(T28I84M'CP+#4YW"HNA:,WRBVD[RW@43SCEK0;UHQF"CGRCV"X/A%]*UOP#>-*E[376>_J_TG+IK60K=S,.1\+:O'&VX8 M%!1HHC1W3$QU(`!^D11N,J`@],%?]Z*R;8FS(LKG248`CK;Z@A.X`V`00G8`2E(R*&[*,$2'LJ M(7M3@@N:2LAF([U7N0F0A>_L<;YLFN]UJPY<8J`:79!L,3_)%$"S(U`Q(B96 M`7)L]?74#@R3DAD$[/[4#3UTODM/R!LP\M!_V4?(\`!// MQ32QF["WV^N"3@7D)]8#IO`"+N`@I/\0,/\?`2YH*@"*_SS`H?@!%$IP26:+ M4P%AH83S)KEN^`?>=08QM7/+@H#R\6G88QO88ZD?V/$%[)&!-OPKU8WH#>IX M#:%)-(?RZ[")PHU5@S\/6V5A@_B_+7PP.)S7)`)PK91]NG&[;OP$K?\```#_ M_P,`4$L#!!0`!@`(````(0!#T59TH@(```\'```9````>&PO=V]R:W-H965T M9(V>N39"-3DF0801;Y@J1+/, M\>]?#X,Q1L;2IJ"U:GB.7[G!-_//GV8;I5>FXMPB8&A,CBMKVVD8&E9Q24V@ M6M[`FU)I22TL]3(TK>:TZ()D'<91-`HE%0WV#%-]#8C?&X7S6U>>/X!MS M\(Q,I39?M2B^BX9#L:%-K@$+I58.^EBXOR`X/(M^Z!KP0Z."EW1=VY]J\XV+ M966AVT,PY'Q-B]=[;A@4%&B">.B8F*HA`;@B*=S.@(+0E^Z^$86M)-Z2P'U+0D9!&@^S\14LH<^H,WA/+9W/ MM-H@V#2@:5KJMB"9`K-SEK[I#"RYF%L7U(4"VD`WGN=DF"2S\!EJR+:@NPN@ M'A&">I\"R)ZFD$"++A=WEX(+.DXA27OZ+LN[@`:74X!((-^[`^<8[/72XVC2\WKS'I-US;]5CO&KZAM7L(Z(.?"Q*XGW?O*C'^/K& M)+MLU1W_!\/U?E<=^%@5!KOG]:H>0^#L<4,W#H:3Z/"7?AGL(WS1_9GF1[ZE M2_Y$]5(T!M6\A-T3!1GT3/L3S2^L:KNY6B@+)U'W6,&'A\/<1P&`2Z7L;N'. MS/Y3-O\'``#__P,`4$L#!!0`!@`(````(0`WTB"S(@0``#81```9````>&PO M=V]R:W-H965TTU`2=!"QAALMG]]YUA"(LAQ][M33[(XY=Y9\;8SN;K:Y$;+ZP6 M&2^WIC.S38.5"4^S\K0U?WQ_^O)@&J*)RS3.>%W$#7^N3):J:Q6D[J,@MU[9]JXBS MTB2%=?T1#7X\9@D+>7(I6-F02,WRN('XQ3FKQ$VM2#XB5\3U\Z7ZDO"B`HE# MEF?-6RMJ&D6R_G8J>1T? M_$N0@T'U(FXG,H?HN]_=3XO`[=I(X/U=Q'U8.`M?'XI%MMHLA7$3[S8UOQK0 M>A"XJ&)L9&<-RK?TD)D^83_+%WA$D4=4V9HP9R`5`HK\LG,6WF)CO4!ED@X* M[D`RL;\1F#O4#<<7(KK09M<"![T-R/#0QOWJWJ)%&*.]W2:@"Z#=A^^.(IL2 M8WOA%%DYLDHT19RY_9XFR9$G.\+"S*%`:F M2X1:(E(1DE$(9%@Z-.K!-%<;Q4%;$_+9>P"CRY%1@I;4CZNY[ZULVY:9O<0\ M^"O/FS"AQ'C^W%E.F(@8>.T#>D^J9!=J.+2KMHGPQ.:#;"$@Z/ZMVVFTUQ*A MEHB(\"F9+F9ID$O)H?\9APA/'*Y&#@E2.=02H9:(5(1D<"D;_-C4Q$':J4F0 MRJB6"+5$I"(DH[@)&BT.^JF)@R85'4]-@JB;<#8-FXEZE@A%*D(M$:D(R>A* M-JJ>E`B/#P-+5/\7OK)\=I;1+0@HDU*M$2D2VBSN+ M@5UU`SNT#Y%7S_EHRQ-T5-?"_MU)VC%*GW0S!1(I562?N*L8^/S8H]>AO(S]N0H9I6,J'<`*5I_8GN6Y,!)^ MP2.H"YNK_FI_/'YT\:`RNAXX:S@P'FU_7B&_R<8G+?L&&PO=V]R:W-H965T,J*R$9+U[9H$;,D+4Z1 M_<_?+XNU;7%!BH1DK*"1_4FY_77_VY?=A56O_$RIL"!"P2/[+$2Y=1P>GVE. M^)*5M(!?CJS*B8#'ZN3PLJ(D48ORS,&NNW)RDA:VCK"MYL1@QV,:TV<6O^6T M$#I(13,B(']^3DM^C9;'<\+EI'I]*Q>.N[Q<_L\GN5)C_2@D*W84YR`@?&7B7T>R+_!8N=WNH7-8$_ M*RNA1_*6B;_8Y0^:GLX"QAU`1;*P;?+Y3'D,'84P2YU&S#)(`/Y:>2JE`1TA M'^KSDB;B'-G>:AF$KH<`;ATH%R^I#&E;\1L7+/]/@Y!,J@F"ZR#P60=!JZ6/ M@W`](XJC,U(%/A-!]KN*72Q0#7#RDD@-HBU$EI7YHY5!-G+--[E(+04TAW&\ M[U'@^SOG'7H8UZ"G`5"#<("]20%HS10\&-%PQ`T!*I13QKDMT"K!M'I`4#:/;A?NP1'-I37IKX%UM0:%*KIK(/; MKQU:F/1\6@GNTJ[QNBE'LVK,2K$N0M=UF]\[O*M'>"6XRXO\WK`U2!-["&V& M><-'>"78X,7^+;`N6(-F3%B>!<9&FU:Y7#0I,@V:D<*FF\)]D4FP47W@WV2D MJ]<@W76$L><-MQW!=FX7?Y]9H;O4?:'5($T]+C1D^-L$L_:L]LY:8W/B*F1D MUQI'_@:-%"W]IS7Q"6KM5FWJ`94CC:H;'H;^B*.A`4N;8>O:KCHY!'[8E*=G MKF+#*=&RGYLL.KL<20]J=4`>+M.:5ZLF15^CYF3QD,G)8WU:]S7*O^^NZ"&; M4VA3]K?.ULWO^-P*C_@K>LCH%-ID[LE>.]U5]EYPTT5WZ(;13FU='XJ`-[H M3/'5J-I]D!>.2`!+EVKM^_L24.@N]QKWJ-O&M_!&A8\-XYN@[AM>_Z11(:]^ M/W[28,/L)I@EVBS:W'(JI-2H-8[3V?'R3O$`^T>,+C^CE,Q(UN_/B)_ MAE\_,`$W'/7U##=: M"O<)=PG@(V/B^B#O8LT=>?\+``#__P,`4$L#!!0`!@`(````(0!9"DAGV`\` M`,V.```9````>&PO=V]R:W-H965TM MVN_@\OO:1K)\JR1;*W._WWG6V$KB&MM*2O.R>O]\KEQ%V]+S^?_[/G7:OWGYOMRN3TK([QO/I]_WVY_/%Q>;IZ^+]\6 MFXO5C^5[N>3K:OVVV);_7'^[W/Q8+Q?/NY7>7B\G5U$>UNL__SYXS]/J[5^O%'Z_EVMB[?PS"O[T\K5>;U=?M M11GNLM[1X3'?7]Y?EI&^?'I^*8^@^MC/ULNOG\__ISP4U\KYY9=/NP\H?UG^ MVNS]?+;YOOIEK%^>W9?W9?EIE^>I.@-_K%9_5M1ZKIK*E2\':^N[,Q"NSYZ7 M7Q<_7[?QZI>Y?/GV?5N>[EEY1-6!/3S_HRXW3^4G6H:YF,RJ2$^KUW('RC_/ MWEZJKE%^(HN_=W__>GG>?O]\/KVYF-U>3962G_VQW&SUERKD^=G3S\UV]5;4 M:'=$79!)$Z3\NPFBS"ZN)[/;NU.B3)LHY7;;*).+R=U,F=VE1;ILH99HT4:97%[?*U?WT]OB/Y;X)4O[=[LK]A7)]=7C]$RN3S_)2GN"JA_:O;DZ_:@F[3FJ?FCCW)YZ5)/V5%4_M%&N M3CY5DRX9]\[X[#<.JCWED_*'9G>4XS/ILK[.["Y;ZF*[^/)IO?IU5MX+RH/; M_%A4=Q;EH0K=7K#JRTMW"3MT!2LO7564_U5A=L'*B].FO.S^]4697=]_NORK MO%8^-6@^@I3[ZSYZK%'9DSXB]87:BNKJ66U<$QMTL<&H&\H_/X(.MFR.H/Z6 MK5:T6[;;!EEJ& M\D_)1Y>.H-GLJA\Z:T/O1>J+O!7MQHN1N/OG[;+LQ%U/+O.KUY/';[EMAZVT MT&&5V:R_/_,&*3>['CV]N[NYZXO'89A)7ZA#,14VHPW)O=*/H@^)L!UC*,KC M$9`Y1(*P4-A#46[HIK^_SA`)&W)1>"A\%$$CFC-8WNO%ZTTXC%$>CG":HR$2 MSU`\),(1)T-1#J6$)$E'D1`I&R)!Y"B*H2CWYN,T]E*KO"^)Y MV["7^+.9T,,?CT'J,4@[!NDC2+F>]GNQ<0PRCT'6")J(]T=[%`E=T1E#-\*. MN\<@;Q0)I\4_!@4C:#:[[7^8X3$H.@;%HT@8;"1CZ$8XNO08E(TB8=B2CR+A M0E^,HH_/J9=SYYV%"T#0?VNMOLO M9*@YBH0,M5K4?E:VV."(#6[;T-NX<*'Q6M3&]=L&V5I!B]JU0K$A$AMBL2$1 M&]*V0;;EK$7MEG.QH=AKZ/6/CO"[1"G']L(`:5XC63:A4%%H*'04!@H3A87" M1N&@<%%X*'P4`8H0180B1I&@2%%DM9CM)EBNE=N9T$OSWO+IC2)<\0O9%GJ9 M5,Z_]3))?C^JM)A!M\*S^KQ&L@RJQ7T](7HA/*2K^TNO+H0CU_I+/YX2=GBNJ^,)#@-$N.QC?1&&AL%$X*%P4 M'@H?18`B1!&AB%$D*%(4&8H<12$3OXAZ'=:H,<$NX>\T;)DJ@C MNUY^(?1SM5M\L*-K3'0F!A.3B<7$9N(P<9EX3'PF`9.02<0D9I(P29ED3'(F MA93T,ZQZ0RB^O[XNYR;DP[NJ#F-XEQ)F+>>-DF98'>BZ'N$)`T25`VA,="8& M$Y.)Q<1FXC!QF7A,?"8!DY!)Q"1FDC!)F61,O% M_A3$K3`E.V^4-,'J0!*BO"&:S-QF+A,/"8^ MDX!)R"1B$C-)F*1,,B8YDT)*^@E6O13\C02KWR4*"2:,\.95H6!YGY-DSR,3 ME8G&1&=B=*3*'D68$#&[I0>SQV)B,W&8N$P\)CZ3@$G()&(2,TF8I$PR)CF3 M0DKZ"5;V_D&"'3%$K%8;/(0)$PWSJ@!WEV!5C[VZ$.8Y'KO%![NLRD1CHC,Q MF)A,+"8V$X>)R\1CXC,)F(1,(B8QDX1)RB1CDC,II*2?8=6[X-^XA=6OD(5; MF##1/:]JU/>P62S*LC7"0:!Q%9V(P,9E83&PF#A.7B$Y])T)'ZQB0\78?=XH,Y$3&) MF21,THY4NRH\YV?=PH,[FC,II*2?4]4KZ!-RJGYC+>24D.O/"#*O3+3QXYETF'A.?2<`D9!(QB9DD3-*.[#)*N,)G MW=*#'VS.I)"27DI5ORS>2ZGC!H*[U<1IPCMAEF+>*-D\/!.5B<9$9V(P,9E8 M3.R.C'4!IUMZL`NX3#PF/I.`2<@D8A(S29BD3#(F.9-"2OH)-E:JP6^2)V.E M&G?"Z'G>*&F"M:4:!WN3RE$T)CH3@XG)Q&J(4LXC5?ES=7$E3/'8',09!%&$ M6YS+0;Q!D(D0Q.<@`9.02<0D9I(P29ED3'(FA93T4ZP$A$Y6)QD1G8C`QF5@-V4LQ88['YB`.$Y>)Q\1G$C`)F41,8B8)DY1) MQB1G4DA)/\E^KV"C^G*=89()E\EYHZ3W,:SI4#F*QD1G8C`QF5@-^4@R17@T MM3F(P\1EXC'QF01,0B81DYA)PB1EDC')F112TD^RJJYB?X*C>AKCHHU)M=K@ M3B9,*\T;)4VR.I"$J!Q%8Z(S,9B83"PF-A.'B%UBP_FAM^1*L+T2IA["[K%!R.$3"(F,9.$2PS1LE&?8] M=F37/?K?<:9V"P]V#HV)SL1@8C*QF-A,'"8N$X^)SR1@$C*)F,1,$B8IDXQ) MSJ20DGY>G5:N,1DMUQ`FR>:-DN956ZY1Y=7>%U'NBCE4#J`QT9D83$PF%A.; MB(Q\9D$3$(F$9.82<(D99(QR9D44M)/++%FX\@7S&.U&_?"B'T^P<*, M1R8J$XV)SL1@8C*QF-A,G(;LS3X*D[(N!_$&088OP/`,!;R=D$G$)&:2,$F9 M9$QR)H64]'*L>IW=XHVFGEEB^`:DU5K9Q+]9% M3;$FXY&)RD1CHC,QF)A,+"8V$X>)R\1CXC,)F(1,(B9Q1ZJ^*A:J)-W2@T_? M*9.,2DGUN\5:DS'"C7$_S9DWBCI MH)`+-3B*QD1G8C`QF5A,;"8.$Y>)Q\1G$C`)F41,XH[L$FPBE"0DW6))AF%W MRCA*SJ20DGZ&E=W_E,>MB@\>MX2G[?FT5M+,0J)R%(V)SL1@8C*QF-A,'"8N M$X^)SR1@$C*)F,1,DH9\3/$(]0HIQ\B8Y$P**>GGUN_59TS'ZC/NAP<:J-.Z%:\I\RE4:3%0F&A.=B<'$9&(QL9DX3%PF'A.? M2<`D9!(QB9DD#?G(,6'LE'*,C$G.I)"2?HZ=5J284CR;B,'HQ12TL\PL6(#AH5CE1JW@\S" M.H#'*1*5B<9$9V(P,9E83&PF#A.7BO'D0OBB`8TWH#,QF)A,+"8V$X>)R\1CXC,) MF(1,(B8QDX1)RB1CDC,II*3.JLO-]^5RJRZVBR^?WI;K;\O'Y>OKYNQI]?.] M_.WDZDM8NM:S]?+KY_-'Y4%7SLO_0UEH=Y0'?ZP]4!["L?9(>8C'VC/E(=^U M7W8;V'SY]&/Q;>DMUM]>WC=GK\NOY:Y=7=R6L_GKEV_5C;;^QW;UH_I_N<_^ M6&VWJ[?=C]^7B^?EN@(E_KI:;=M_E`=P^6NU_G-W^%_^#P``__\#`%!+`P04 M``8`"````"$`=I$0V]("``"-!P``&0```'AL+W=O6=G=KCD%3TK\`-3^'+U\<-R)^2M:AC3"!AZ5>!&ZV'A^XHVK"/*$P/K(5()V1$- MC[+VU2`9*6U2U_I1$*1^1WB/'<-"OH5#5!6G[%K0;<=Z[4@D:XF&^E7#!W5@ MZ^A;Z#HB;[?#!17=`!0;WG+]8$DQZNCB:]T+238M^+X/8T(/W/;AC+[C5`HE M*NT!G>\*/?><^[D/3*MER<&!.78D657@JW"QSK&_6MKS^)9ZR3R8A0!'&Z;T M#3>4&-&MTJ+[ZT#AGLJ11'L2^-Z3A)$794F8I*^S^*XB:_"::+):2K%#<&E` M4PW$7,%P`RC!))V6,(L?%>`@F>WL5&_V/WHF"=HV<9.="3I,/,&D M8TDGC@$R=?RR4P,N<&2/.0K"QRY=>&[#69P_+0@=?;N@`4\$DY'2-G_MPK$5 MS)-@C)XX3-\C:,`3P>.A.4$7=H)9_LPEFK]'T(`G@O/1@Q-TX;U@/!NC)P[- M:I\,SLL]-.")8#92.D$7W@NFQ^B)8'XJ:";U]3$Q24;X.(0PJ4='3MZ!W!6* MX\D@.WVW%MW6Z)BLV2?6M@I1L34K+X2+,/[KMO$:MG%DQVX,P#8<2,V^$UGS M7J&659`:>'.X3-+M4_>@Q6"G>B,T[$'[LX'7'H.M$W@`KH30AP>SL<<7Z>H? M````__\#`%!+`P04``8`"````"$`C8!PON,"``#'!P``&0```'AL+W=OR/S>US75E/A`O*FM3V'<^V2(-9 M1ILBM7_^N+]9V9:0J,E0Q1J2VB]$V+?;CQ\V9\8?14F(M("A$:E=2MFN75?@ MDM1(.*PE#5%=NX'FQ6R/:V(9AS=_#P?*<8G)@^%23 M1AH23BHD0;\H:2LZMAJ_AZY&_/'4WF!6MT!QI!65+YK4MFJ\?B@:QM&Q`M_/ M_@+ACEL/9O0UQ9P)EDL'Z%PC=.XY<1,7F+:;C((#%;O%29[:=_[Z$-ON=J/S M^47)60R>+5&R\R=.LR^T(1`VE$D5X,C8HX(^9.H5+'9GJ^]U`;YQ*R,Y.E7R M.SM_)K0H)50[`D/*USI[.1"!(5"@<8)(,6%6@0#XM6JJ3@8$@I[U_YEFLDSM M,':BI1?Z`+>.1,A[JBAM"Y^$9/5O`_(O5(8DN)`L0/UE/G""5>1'\=LLKE&D M#1Z01-L-9V<+#@WL*5JDCJ"_!N;.F='1>_V75?"H2.X4B^8"%P+*\[3U8V^Q M<9\@5'P![0P(KL0K:(S8=PB5H.(]#%ZX(+A7#5E,58=0U;_7HQ.I%HU%AE.) M#\HZ$PYU[OW`%'@L/E]/8#28VPF,_22:Z1_-!,#LQ9GYAU@^7CV3'_R-; M@<>R?6\B:VF-?T'+5)H8@"N.!+R/<-%33;VK""[(G M524LS$ZJ6?K@MW]K^O@.^KCN>FX_`7VT107YBGA!&V%5)(>EGK.$S+CIQ&8@ M6:LO]Y%)Z*#ZL80/)H$VXCD`SAF3W4#U^OX3O/T#``#__P,`4$L#!!0`!@`( M````(0#,+^[?900``)<1```8````>&PO=V]R:W-H965T&UL ME)A;CZLV%(7?*_4_(-X/8,A=28X&T+1':J6JUV<"3H(&,,7.9.;?GVW,Q9>4 MDI?)[6-YK6VVC6?_]:,LK'?MW#+)*ULH[)HY&N1\SE,HO*2EKD#CE1=H02L[,`3E7S;]VM"TK'?99#`EYVJ\'G@_V"=C':V.YQWQ;H[QS?J?3> MHE=R_ZG)LU_R"D.U89Y8CNIPC%/7_JD-;$Z3N>PYK[<3$0[2H0 MQ;W6T9&)Z.ZG",7]]AGW'-;<:P.'`E'<:ST=F8@F$D\1BGL$R^/\XK>TYE]; M3L*.40+HM_X#1D\PB:@1^,8U^_Y!8IN3ETQ?6U3"CI$C^%IW1P\8(X(82I89 M$34"W^'F1Q#[H1)![V`D&'EL7V_A!\SHKWLF,&5&1(W`-[CY$<1VJ$30VQB9 M6Z:O]_$#9O3713!E1D2-`-5Z(@*GU5[P1V&Q$B'!*+.@-_,#1I.))Q$U`M_M MYL^"V!N563#:V=P_S5DP&2/"%*)&X+O>_`ABCU0B:*M-B,Q]--!:/GK`&!%, MF1%1(_"M3XHP[SD4B0U3CA)HJT[8,?(--7IH[[FH0U;M<\=JZ6_6ZXVV.L23 M,FH4O@]*4:8W9SC3ZCT1:&.''3,986KS[;I:(&OQ=+78KGU_ZXV3*C*(8Z\X M?Y6XN>`(%P6U4G+CQU@$UP[?#N?R[L`\_``GW#JYX%^3YI)7U"KP&2[U''X: M;<0967Q@I&Y/=R?"X&S;OKW"/T`PG*P\!^`S(:S_P$_DP[]4CM\!``#__P,` M4$L#!!0`!@`(````(0`%C'QK:0,``/\)```9````>&PO=V]R:W-H965T;F;XD@(^/S[D?7-9?WKK6>Z5",MYO?+0(?8_V-6]8?]CX MW_]Z?LI\3RK2-Z3E/=WX[U3Z7[8__[0^<_$BCY0J#QAZN?&/2@VK()#UD79$ M+OA`>UC9<]$1!;?B$,A!4-*,F[HVP&&8!!UAO6\85N(S''R_9S6M>'WJ:*\, MB:`M4:!?'MD@KVQ=_1FZCHB7T_!4\VX`BAUKF7H?27VOJU??#CT79->"[S<4 MD_K*/=[L%ESRO5H`76"$WGO.@SP`INVZ8>!`A]T3=+_QOZ)5E?O!=CW& MYV]&SW)V[45E#0(%F@9>:J>8M"(!?KV.Z,B`@Y&W\/[-& M'3=^E"R6:1@A@'L[*M4STY2^5Y^DXMT_!H0N5(8$7TAB4']9QPN<+=$R^9@E M,(I&@Q519+L6_.Q!T<"9$3J"FK>:/0A`\*0:8N&JCB"K/\['5:3>9(N, M8EM`<0_!-J*\1T1+&U+=0W(T02P;D6WCL7P-AL*9AP]'^40\!JPP($CD%./$ M1I0?(JI'"$L^'#//PF/Y&KSQ(3:3LCAUM!4&DXX%A'$XC?;*.2#*H@RE MMKMJ#L`X3-)P`EC2H>T^+UV#7>G.P87!)*/TIR1*T.U@(]T"Y"A<.JFK+`#& M*+\Q6-(36[KNV(]K7V]R+&1.<`N#N5B`XQ/'8VD!(ISFT11.^]0F-3ZD`M#%B;)+5]&N1G$9DYU5!QH2=M6>C4_Z2&+(,W3 M4S/_"YC_X[0,I@68OP,YT-^).+!>>BW=P]9PD4*;"3/!S8WBPS@4=ES!Y!TO MC_"A16'\A`L`[SE7UQO]C3!]NFW_!0``__\#`%!+`P04``8`"````"$`G1;T ME0X%```M%0``&0```'AL+W=O0V*'#>1E%_#) M\?%X9H[CQ;>/(K?>655GO%S:9.K:%BM3OLO*P]+^Y^_7R%4D#7ZN# M4Y\JENSD0T7N4-<-G2+)2AL9YM4S''R_SU+VPM-SPDS=$52O9U/DY07)Z#89GG6?$I2VRK2^8]#R:MDF\.Z/XB?I%=N^:5'7V1I MQ6N^;Z9`YZ#0_IIC)W:`:;789;`"$7:K8ONE_9W,-S2VG=5"!NC?C%WJSF>K M/O++;U6V^R,K&40;]DGLP);S-P']L1,_P<-.[^E7N0-_5M:.[9-SWOS%+[^S M['!L8+L#6)%8V'SW^<+J%"(*-%,:"*:4YR``_EI%)E(#(I)\R/^7;-<JX;7OR'(**HD(0J$@_4JW$ZI;.`!.%C%@<5R06^ M)$VR6E3\8D'6P)SU*1$Y2.;`?%T9ZKBM]:NEPAH%R7?!(KE@%37LS_N*4!HO MG'<(:JI`:P1!3;0@';&Y(L1>@+Z;2%BZ*=*#3;P?_JLF\9"NR?/U^=9]"-41 MFS[""VX032,$KZMQ6)L`+VT@;T-!/?=&+(.Z1I#?`84Z8C.$T,0!R?/B!!@R MM#,O(:$9.@0-B1M":.*@!)X7)\"]R!$]+FL$13(1:4@B,V[=\=CMK$W3%8[1 M)<"Z+C_P#%F(&8H9(D(4[D7MNC1AT1AA`FP*,S<3,3AMZ(6N4;F;[GA,W*`= MUW0)N^OTDN$2$&!35UM:6`&(05V3()B1F1[1C0:(0J\#T)3%8Y0)L*Z,4,]H M#&L$H33/B\/(4-8=UU-0$T:@C75C)OKOX]8FG^I)----H8;R;1"B"S6,8GAS M"7;R!SU$H08%(M%]B"Y0M.JGLX]@8SE=;OY<0!-T/C!)WA4@_GK49K&L#BA':!%K//#\PVPE!D`H; M-%BS.#2`1Z.X35U=VRAK$">RGC:SI2B0ZBDTFOGMW"IL2'-%S,+.L4%7-\H@ M2-\A[K05A<+)`R_JB>LZA)Z1NK91'D'Z)@':>MN*J,&4&X+H`D>9!<%&#PG= M'ICZ9Q*%&A2(1/T'+H&L; M90_TKCVT^X'VH%`8M3O2D`2U:[NM*Q-M^FESH-C4N^8`I=HN6BF[MOZV7LPS ML")ZHA(H8$8(%.B'KP^2=7(%6NU#4] M9*,`JM%\]2)!1YF#1#]L)-?&+PY#$[B=,,[KB@2%3?RO.MPH4X`KJ3N99LR\ M5BCUMAIW,DG5`;+@>-#-1-Q-O+7"2YV"50>V87E>6RD_BQLI`EYR^Q5OR]9P M6R:OEIS;`%Q6G9(#^YE4AZRLK9SMX5%W&D&25WC=A5\:?I)7*EO>P#65_'B$ M:TD&=T#N%,![SIOK%W&)<[OH7/T/``#__P,`4$L#!!0`!@`(````(0`WC$>' MMPH``#,T```9````>&PO=V]R:W-H965TE1A./YOO]RN;PNA\/S]J4Z;,Z# M^K4Z4LE3?3IL+O3GZ7EX?CU5F\?&Z;`?NJ/1='C8[(Y]'F%Y^DB,^NEIMZW\ M>OOU4!TO/,BIVF\NE/_Y9?=ZEM$.VX^$.VQ.7[Z^_K&M#Z\4XO-NO[O\:(+V M>X?M,GD^UJ?-YSVU^[LSWFQE[.8/"'_8;4_UN7ZZ#"C*;5X,%T.*]'#W MN*,6,-E[I^KIOO_)69;>J#]\N&L$^M^N>CMKO_?.+_5;=-H]YKMC16I3/[$> M^%S77YAI\L@0.0_!.VQZX#^GWF/UM/FZO_RW?HNKW?/+A;I[0BUB#5L^_O"K M\Y84I3`#=\(B;>L])4`_>X<=&QJDR.9[\_FV>[R\W/?=\6#L3F9SA^Q[GZOS M)=RQF/W>]NOY4A_^SZT<$8M'<444C]+GY=YT,)F-O";(%<>Q<*1/X3@=S)S1 MPIM1Y5?\J+1)FSYEVB,M[2N>4^%)GS?5.!-^]"F;Z`R<\6C*9+I2'TVT)E/Z MO*F^A?"C3]E"9S"?3,;3^4^T<6@0\3YEHXEWQ\=4==K10+_[4_W6HQ6*VGM^W;#USEFR8'(: M\8YM)]9[\XHF%(ORB86Y[U-7TXPYTV+P[6'N>'?#;S2!M\)FA3:.:;&6%FRV MLK"^#0(;A#:(;!#;(+%!:H/,!KD-"AN4&AB2M*V^-"I^A[XL#--7*K.20`GN M6F)*"^GBVR"P06B#R`:Q#1(;I#;(;)#;H+!!J0%#3)HHOT-,%N:^3S_;P>HY M$U.]%;=A#Y36:&J:K%N35F$@`9`02`0D!I(`28%D0'(@!9!2)X;8M!C\#K%9 M&%I1@\($$0$(@$9`82`(D!9(!R8$40$J=&/*R`YN^0[D^,YBUJ:$@ MVG@$X@,)@(1`(B`QD`1("B0#D@,I@)0Z,02CC;,AV"^/1Q;(U)(3:SS:S\76 MJ!V/0`(@(9`(2`PD`9("R8#D0`H@I4X,>=DIP]#W^H!LS$T5)=*&)"(?48`H M1!0ABA$EB%)$&:(<48&H-)"I']LJZQ.:C<\)P1M72W9FLX:G0-;XG+7/N>90 ML596[0!%%"`*$46(8D0)HA11ABA'5"`J#61JS7;2NM8_&:M\XTV;-:G,BAUK MF M+NQ`*JX(^0Z?:I%KW,H1R&W16B%UY/%;(6V@JMTCI MUZ$RMUK06&Y5GCL+\]D5.*V54IFCL=?6&`DK#<7*\4KX1%G)\"G&RA#ERE$+ M[ZI+CV94%LI*AB\%XGJ9?<$.!3?T!3]#&".>(Z,O`/D.1W.:'DIX=V0+WUK) MU$/AJ(6/$,4?"I\H*QD^Q5@9HEPY7LF^4%8R?&G$,H1W;SMS->;FF4L@39DU M(E\@2WCK:XI`6R00RA.=6&O*%E26\M>P'RDJF'F+X"%&L''5EK"^H$F4EPZ<8 M*T.4*T<5?C*REQIE)<.71BQ3>/OD]DO/7!7JZSP^AF4LJJ6-Y7GV8UA8+=A6@+Y]G5BW M2\>KU2?2:LR_@'"\F=785%I<32##!'+I>#6!0EJ)!%S7LZ9W*2W>2\`<`NSX M>,,0$*=-;=OE(+JYGZ`C@0:,[[VYO:VX-0^NB[ M-QAAAX6C4>/$NNO(L,9$R=ZW6K-E+,'30^]D4YE9S_O(0^U(L$(YS MH^/M!H;22CE&JD;58R*\VF\GTI%/A]EH9$F72@.]>3`\,JPLEXZJLD*B]RHK MI<%[E9E=Q\[.>M?]VJ./1;'V@!Q9,]):2->N<#0ZQEXH?6&E39)`(F.2>);N MH;2B6MJIY-F3)%))J$[F>6DU)C*66:.UGTREU=4:,ZPQEXYJU2DD,FNT]FFE MM'JO1K.[V26`WMT_V6(R8CFY;O#;CF\.<+*V_6.@:(0A5+ MAH\0Q>B8($K1,4.4HV.!J#0<34G9^?L&2?EQW5C\.#+V+_16HWD"7;O(90&5[LT4BG)SHJEX]7Z$VDE]@_CJ6NU-I46 M5Q/(,(%<.EY-H)!6(H'9;`S32@CY7@+F&*`I>LL88.;6M!)(^^K'!>0C"A"% MB")$,:($48HH0Y0C*A"5!C+THW>73?V:I]"\N?3L6*'4/6?C:"HIT$*M,VM$ M/J(`48@H0A0C2A"EB#)$.:("$7O7FPT@WD:N)']WF[]N>JA.S]6ZVN_/O6W] ME;V7/7;HJ-!B_M+XRIDLV=T]S5V[Q%TL66]UE'@C^::Y[4,NG1X.>=`7U!VQ M''IKG;Y.[2IQJ:2YGK5K<3PJ:79#4#*FDN8[`*N$[ABI-5W1Z+7Y3UU\Q1+K MRHO2ZK2GI+IR^C1>?J*NZF@@Y=J5ZFJZI%>?.NQG2WIGIX-3RYH-@]5DNJ)= MLK,Z>M!-[9+=PW:5+*BDJPOIKFO);K(Z?%R'2KJDHFL!*NG*@*ZBE^RB&:/1 M72F5=&5`EWE+=E77X4,9L+NDKA*72KHRH#OM);O<0!_ZKH,TZ%2:?%:=/FLJ M8;7;X4$O9I5Q7B4LE71F$E!N[)4(?^HY@ MR2Z+J&38#A[ZEXW7S7-5;$[/N^.YMZ^>:.D8-:OPB?_3!__C4K_2FDO_MU%? MZ'\UFE]?Z)]S*CIJC=BK>$]U?9%_L`K:?_=Y^`<``/__`P!02P,$%``&``@` M```A``@(;05P!P``%B```!D```!X;"]W;W)K&UL MK%G;CMLV$'TOT'\P]!Y;E.SU!>L-UI+8!FB!HDC;9ZTLKX78EB%IL\G?=X8< M4KPHMG>1/L3=H^%PSEPX(_'^X[?C8?2U;-JJ/JT#-@Z#47DJZFUU>EX'_WSF M'Q;!J.WRTS8_U*=R'7POV^#CPZ^_W+_6S9=V7Y;="#2\@S^;YTE[;LI\*Q8=#Y,H#.\FQ[PZ!5+#JKE%1[W;5469 MUL7+L3QU4DE3'O(.[&_WU;E5VH[%+>J.>?/EY?RAJ(]G4/%4':KNNU`:C([% MZM/SJ6[RIP/P_L:F>:%TBS\\]<>J:.JVWG5C4#>1AOJ*KK+RCZ M:8L0+)YXJ[F(P%_-:%ON\I=#]W?]^GM9/>\["/<,&"&QU?9[6K8%>!34C*,9 M:BKJ`Q@`_XZ.%:8&>"3_)GY?JVVW7P=1/)ZS<="5TBIT4T.0_)/(2;B$4.MC+)#1^$JG106'!0>V\("44=,3?!]%.3\UP' MU#($'&,:(HJ;3<=XKKZQP%&3;24A=LTOM!VB@!,MI,BE'I)Y"#<1B\_PDW$HL-@#C*C M<[F(A;1M-$%1K+M'XD.I#V4^Q"W(-A,;H)-$,\#>6-Y,]E$X297W-@JRO>Z> M1KV46ICZ4.9#W()L2M@/#4I7/"^[IV4Y0;;EL9/^3$OUEGM0YDMQ"[(MQW9W MN^74'$V?2P@"J&Q*F`>E/I3Y$+<@VTQL7+>;26W.-%-"4\-*%TF9BV0>PDW$ MMA";W.T64DLT+910#&EM'!E3-P6D5`0GM):*(R?%4QR+X$""5RA#*G9Z0Z:D M8NK:(?QG;\>5"'AF<#O;!=@$#1=@[X[N\`UJU.VKXLNF!@#H#50'FD!C.752 MTS,2BNSB<`;"!$A58A,XPR4DJLM3/^N'!]@0V M4,,3`XS!*YHRM5N3LH2BWLR$::@WZT3/:*$!\5X7%*UM.3C9M/Q] M,40E3FN1D)/=_0PH9R\FI:YE-^FR0N%G-TG)[%ZRZ<)+;I*X+;FQ[1HAE6^= M8BX5R?VY/O\HN8B=*.@R5D]#,\F4"H1U(/R3R$FXAMX9L&`Q@9/0LEY%2\ MTX,26GBEXDGJ2C\CJ>E4]+.Y,SUQI>2FNU0X[1@<'6/MIOZ-G9YUP42LC.` MN2]!M/!:!I`N\5%8G!X9+:1P,_?MBM/S&%PQZ%O;!S@7&#ZX@#A!4KV=HMC<#4974E2.`E9$)=1WB"0B(7G'(;Y?^U#F0]R"+"OC M@:F"S?HYZ:;#1"BQSU."G,/$>?%)2`HS9;#F9[C4L;QLW$5PW2I>Z3^)(742Z3Y8K^!`'7G)Q%J[PV]?0$]@% M/B$-/8%=X`0=>A+#$_$YSMTG@GU@#/;70%'#DR';X%;U<7@7V&1`TP;,&I0' MHX9L>IRN'B$@ODF;Z0IN'@;PNQ5\.!_`YROX!#V`+U;P,1?PB?8&W,J>\^?R MS[QYKD[MZ%#N(,BAR,M&WNO*/SIZ/7NJ.[B/A3R`>T.X?R_ARB[$5YY=77?J M#]Q`W^@__`\``/__`P!02P,$%``&``@````A`,\AVH0'!```2PX``!D```!X M;"]W;W)K&ULK%==;ZLX$'U?:?\#XKTA)"0$%%(E M5-V]TEYIM;H?SQ2) M=*RD3>+ZDZGKD":G1=D<$O?[M_N;E>LPGC5%5M&&).X+8>[MYL\_UF?:/;(C M(=P!A(8E[I'S-O8\EA])G;$);4D#GCWMZHS#8W?P6-N1K!"+ZLJ;3:=+K\[* MQI4(<7<-!MWORYS)&J?.?(B#Y`V MZZ*$$Z#L3D?VB;OUX]0/76^S%@+]*,F9C7X[[$C/?W5E\4_9$%`;\H09>*#T M$4._%&B"Q9ZU^EYDX-_.*<@^.U7\/WK^FY2'(X=T+^!$>+"X>+DC+`=%`68R M6R!23BL@`)].76)I@"+9L_@^EP4_)NXLF`2S1;CR(=YY((S?EXCI.OF)<5K_ ME%%^CR519CT*?/V%GJ0OU+C+>+99=_3L M0(D!/]9F6+!^#&"##!)!"?.6+B`(@FP1)7'A;L")&23S:1.N5FOO"1*0]S$[ M.\;7(](A`O,&]!1'4.<3."(*PDS%8F"IHJ8>D*L1D&7P*2T2!XEB.&-BY[8/>HZE"3)JP:"SFY0LX%!H& M"S8JB](2SD75^69)*>^K?F$T50IJ909'O)X(!NM$>HML%EA@Z=BB[13J.XE+ M%XA&TS>+JR\>(NDTI"6"TE45$T:F+"K(3`:^WD;MX/UD8+"^>6\9:3"V:!I$ M']D)@_6=I"4*U'5.QQ9M)Q]>#MPVFT;$TD[[;A8ZZG$]"J,2/-E79 M#^'JJ6+WIQI6EE(DR%%8$JAHBPI/M3Z\%U@W,;!-);BS>X'8YTEQ2_>$+O]"?#$ M-:18F%+8#5!.BG(VJDEW("FI*N;D](13H+^"]XLRRQ%UYR]A1A45:7G"87JU M/%/PB-'4\N#$*\9#RS,#CRA@RS,'SQQ+V_($X!'=T?(LP",297A@Y-Y>W@46 M7-H#:%V,!U*7.&V#>"M'>F/C'7"]2!7TO2@OJ"O^&I@XJS@5\YUICV)X.V#1 M*P>,\FUV(%^S[E`VS*G('I(\%5VZDW\&Y`.G+20?YGG*8887/X_PIXW`ZWTZ M@?NTIY0/#[B!^ANX^1\``/__`P!02P,$%``&``@````A`'%8Z5&^'```UYL` M`!D```!X;"]W;W)K&ULK)U=;]PZDH;O%]C_8/A^ MXE9_J6TD&<3=^L0NL%C,[E[[.)W$.'$7N]^?+[[_O1C_^'RG_N7R[]^_/=_>__GT_/O+]_V^]<+U/#CY>AT./WJ_ELMKYZ MO'OX<>EKN'D^I8ZG+U\>[O>[I_L_'O<_7GTES_OO=Z]H_\NWAY\OH;;'^U.J M>[Q[_OV/GW^Y?WK\B2I^>_C^\/K/H=++B\?[F^[KCZ?GN]^^P^]_%,N[^U#W M\`^J_O'A_OGIY>G+ZSM4=^4;RCY?7UU?H::/[S\_P`,7]HOG_9_JS>7[X_!\//_8(-SK*=<%O3T^_.]/NLT,H M?$6EZZ$+_NOYXO/^R]T?WU__^^G/=O_P]=LK^GL%EYQG-Y__N=N_W".DJ.;= M?.5JNG_ZC@;@OQ>/#RXW$)*[?PQ__WSX_/KMP^6B>#??K(K5&O87O^U?7NL' M5^?EQ?T?+Z]/C__GK0JIR]+XHQ*EE()_DHEJW?+^:K< M#)4<.3O:.?B`OV\_^UHJP5^I9'W:V4LIB+]2#\M#,6R"[?V2[-?#^5Q]IZY9-ER+W=W>O=Q_?/3W]>8$0C&UY^ MWKGYH;AQM8:L\^Z.>7@H#9%_KI9/KIH/EP@`$NP%@^?O'\O9\OW5WY'O]V)S MRS:%M=@&"Y?-B$[RZ#2`& M:YX$(EB$(KL45"FH4]"DH$U!EX)>`1,(3`:_(A"N&LQ*)DE6UO-;;^/FO3&3 MUM9D.YJ,T2%2$:F)-$1:(AV17A,3)$QVOR)(KAH,1DQ>8P!X*(G1L2B-)F.4 MB%1$:B(-D99(1Z37Q$0)3391RJ]N85IQUD,P@A.W0F;#'%/,DM08C^K@Q?PQ M+4&$SVB)L[8M\:3$F%$=528-&HV"`SLB%9&:2$.D)=(1Z34QOF.%.\-W9VU] M]V2.]4+YODE\'XU&WXE41&HB#9&62$>DU\3X[@1SNN+-5^^0.F>N>:XB&Q8A M=AF\3L(R&HUA(5(1J8DT1%HB'9%>$Q,6:)!?$Q97D0V+$)PZ9@L-W=%H#`N1 MBDA-I"'2$NF(])J8L#A-]&OB,M1D`Q.0C0RI(M<$%(P*8A<+AFA5C&I&#:.6 M4<>H-\A&R,FG=$`M-FZ3'/.*O,%W&MEPV$6"W'@E61*5@6BW&6MEXX(:.] MF&BZZ![==$&QF[8%H1VCBE'-J&'4,NH8X5H&/,.L,K3+^NQ4E/;Y])X3_:7= M%Z1[3M!$SXF5[KE,P;*(VTSKA1,_VHN)GO-:R8PY0;KG".V<4A_C."1=Q:AF MU#!J&76,>H.LST[T:)]/[SDOEU!UF$!O"T&ZYP1-])Q8Z9[+%"R+N/>S7CB- MHKV8Z#EGGJRK@G3/$=IA0:6>(U2S5<.H9=0QZ@VR/CL!HGT^O>=$NNB>$Z1[ M3M!$SXF5[KE,P;*(TZSQPFT(C!?'>VXPMST7D.HY1CM&%:.:4<.H9=0QZ@VR M/A^1/Q/NL]J9"U(]%]#QG@M6JN<"T@7+(FY0K1?G*90Y*Y2`=,^1:-FQ5<6H M9M0P:AEUC'J#K,^(C,G6D\?0[CE!^'-$H82Z=,]E"I9%W%Y;+]PZ MKF>.B:2395]-%W./7(J/[2R+=-L:K<(*L6-4,:H9-8Q:1AVCWB`;!J<-=!A< M9[YI6^_V+6GG"L+J$",T3R\^A8)JG\:H8E0S:ABUC#I&O4$V0DZHZ`A-)(KH M&ITH'ME$F:?;U?EH%1.%4,56-:.&4K?RM17)J\''Y=LW77Z2>=E&ZJ*E;OW.WHUV\/][_?/CF0O3?K(CXX\VDA*DSE MJJ`D$>)V3*+@"TXE@K="E6$RJT+UOM?GZTRO2Z'3>MW)(1V&B5X7]:3]]0B* M.+1QNQA1OB.&$.S$:E&.!2M&=:P+U=L>=-)*-_UM/>@%FMZ<+SQ:ZD%:SN.V M3'I0"B+:V6P3)\4*B12M>"A[*TQ/[N[^%)E>%9TT M/&4D74AHMR!4,:H9-8Q:1AVCWB#KL],M9_@L,D>/38\241FWJ1*&T2J,X!T& MI9O=43"@BE'-J&'4,NH8]0;9,#AUH\/P9E&)5*,U2Y!=L^)V4"(T6H5P[$)= M.J')JF:KAE'+J&/4&V0C=)[`6K#`$J1%):,=HXI1S:AAU#+J&/4&&9^7YRFV MP=PJ-D%*5!+9$:F(U)K8)CH]HA/W^)RU]/)%SUF"C)98I,-7C":D1*C*+""T M$(G5GM9;(WV$JYJ=Z6JI1P ME(*A:V?)=J*6XT[\9*-HG75RY(RN]>K%I+9'IFO+>=*H+5H[1.E0#TC7BI7N M6H^D:Q?ISDCJ/6VKL'3:13O[)J$YU)*DMX@B+0[+M*U;*3C5XU*7[G%!?JN` M<4.J4JH^L<^=--)AF)C.O)(R?2[B*O;3=CFB?-9)!WLK:(2P_E924*$ZU@4K MFZY.SIS1=*]^3-,]THN%&/G'Q8I85YIHJ_-4R6!NYP1!*M&"4?IDQ?I$ MD!Y5$>6[07P3-:*F;RFH1U6LBT:56\SUO#B1KB('U`2X\DB/*C'2HXI0)>74 MC%X;9"/\2W3"RJ_:>O$1E`RV]-JR6$T--M8)H7H_V(IB,TNV&'6P0(!.&&UN ML3ZCM_S:;OP=14%8[K>K$>5;((GFK51655)0H3K618GF%G#=]#E>JT:%[23D[ID\E@L5F5RMCI8'#J;S6VW@!^+S&F7 M%%5-G#+4D'GFA8D;>,IG?MJ'VMU"BKI'J%:D&^>NM2JD1<7[_I<9(UBY2` M,#F,2U6Y2"\91:LPTG:,*D8UHX91RZACU!MD(^24B)YMCPN>M0B7.$G<"H), M#@YN&>T858QJ1@VCEE''J#?(^IRJIPF?62:M/5(BC\B.2$6D)M(0:8ET1'I- MK*M.IIS1O5[5:(6T%J&CEIB(8N+KN]\RA_F"[IJU&A[)QJ*2NF`5LJ>.U0?4 M1!3KHC.VL2YE5287Y+IH%:KO8_5`-GZI3)M(%=9C:X]P>R&<;LMH)R@)5K)X M5-$JU%5S70VC-A:,D2F7%!G?5-47O:G+1L9IHC,RRTLHDUFBJG1D".W6'B61 M26Z;5=$J1H;J:L1*]47+!3M&O2EHP_!+I-V:I9T@U=8MHYT@=[-$#;+DND`5 MK6)T_!E5]0U7WW+!CE%O"IKHE*E,C.OO\8$T%+0B0I#=FBZ3RW];L9J0OZ$N MR(LQ;+RQ"5;A`9AKNJH=+`[M5H>9L#FI36VH*UY6[P2Y6PAC,\OT/DT?"FHK M/3G:'ODEZK?T4E>/9D'F`E6Y3*\ ME2M9K`M*9H]4K(O5U.SAJW?/QXVID)D]Q.KP/;'0ID,#5S+6UW.\36UH>13F M':/>(!MX-,*D9+HK/NVJ2^FJ2>9MCTRJCD@%D&I54KU`M2%7?1'2D M^C9:Q50=VQ50;ZQLQ,[;1;BG/=/("(H7AK?!*J(=HXI1S:AAU#+J&/4&69_/ MVTZ4O)T("$D=Q\YU(N>V.:MR&?<.ME&I1A]2=X;1.:$Q6*R7@OR85=/W,!2W M\7!L?*DN\=AF.?VI)_FH?I2)J.: M4<.H9=0QZ@VR$4JU\T1_L4@N/3)/':K^D%X;C6(4"%6QJF!5,VH8M8PZ1KU! M)@J;G$9^VXL7AJKL[!N0391D@["-5L'Y':.*4*)L M6)T*PJ_T@H-;1CM&%:.:4<.H9=0QZ@VR/CNAIJ>/"9^]KM-SQ,8C,SC*5;+I MWT:K$)D=HXI1S:AAU#+J&/4&V3`X]:/#X&91=TO^S#ETXU64B8\@,S164;+[ MV2,4C!/FCE'%J&;4,&H9=8QZ@VQ\G&31\9E($Z]P3!@\TM=O-X1VC"I&-:.& M4R(5$1J(@V1EDA'I-?$NIH*KE26G[0?VK`. M"RA>;=A&%#4%;R#%REQQ6EXG&ZDJ6H59I6;4,&H9=8QZ07A^#-7;@&7%X+D_ MMMJP-`Q(!TRL,,^.(BP3,&^%1P;=H[_SF7I'S3##5%(S#&*LQIH#:OC\;2PH M-2K-0E.4%R^]F]9SI=/.M@Z^WA\!W.KK04E^9XDX%:L M)O(]U!5C4`FR5W]7R4Q;AX(FNU;)3K")C1CS.Q2,9^P"\LF\*N?IDSQ]L#!G M4\EB(YS*]E-S^9H%O"![>7D5KPAXL18*'DJ`P6H7K'"6."70W")6]H+O*KDE M5X=VF3-R^,6A&.OVI$9TL1%NBI^]2Z^4]-GS'^P0M/)-D\NU*Y@DOT=)\B=Y MMY6"4\DO=>'/L0[Q5LEXH`Z1NDR&"T'SI,*D8UHX91RZACU!MD)PIT MUH&\/'.;=^UJ2A)5D%D%U^DV.!14VSQ&%:.:4<.H9=0QZ@VR$3IORW/-6QY! M>IO':,>H8E0S:ABUC#I&O4'6YW3O,S$X>)-S[9':YA'9$:F(U)K8)CJ=KM7: M1!-%UBO-?.V1N@^_C2@.:=Y6B)5]+F*=7+VHHE48^'6L'LAZX_3[&=YXN:\5 MY[5'QAM".[%*FI[L$ZIH%9NNZ[)-S\GFL^\;7K.&%F0\\E8*[<3*;(KI?215 MM(H>Z;J,1W@QPUF]X>WMU!>87:37B6S>!K.)53J83=SW',V\BLR\/66T,&OT M(=%2S+(R%UF5>4Z5?!C42,-5'N]K!S-XJ8%KW/V9[`J MBD[FO-0&5PZK0K@O9C[GEXOT MY\4(AEB3N-SVNUX;)(S/>^9[?F1*3[-U/UWN$X,SH[5<<^? MIV3P5'O&`\_<8R1CIY3K=#,8BL(LS+=XX_I8-#!X0`P>$,-+UXGAK>O$\-IU M8GCONF;):#Y/YQ0S%CJ!V7L]ZV1OA`'NBZJ7K2`BQ!`18H@(,42$&")"#!$A MAHAHED0DE54N^]>+X8U99VX(BAEKKI%!3JC\2?>NRBSD"J(EU<5]`J)%#-$B MAF@10[2((5K$$"W-DF@Y593.%6^X15;,O+S2@FYD-E3)IA>))45C6!`J8@@5 M,82*&$)%#*$BAE`10Z@T2T*5RL3C>AT?#8//.Q##]QV(X0,/Q/"%!V+XQ`,Q?.-!LR0BJ=R&;4R#)P7UB<)\8W"<&]XG!?,34G=,&23XV,246Q6QJ@Q3,O%C$ M:Q63BU%P^BRQ.'P#0@']CJ]YHFA[($E1N8NT+#/!D#8T=#"FAJ\79C8K/#,*V7W+#C/5U-Y(S-0^ M"%GMBRJ&'AZKPV28>."$D?;@C=WI]95US#/W,IZQG_A]DP7*#+Y"[T M9I/I+F8^W7&#E--=+-#1V?,E\7%2Z%A\3MP;A2]CF'SW,LOV_,CRK9/=OU1G M]D;,T/-C==SS3KEHSZ9R5Y2.\<`S_:0;WK/@^S,^_8;9EQ@2E1B:2PQ+#S$L M/<2P]!##TJ-9TK%.IISCOI)P7UB<)\8W-ML"%3V[HV4^8N?A7EJ3GQ&Q*SX7:X,DX/OB'/D4P.[S`!8O3 M%KCA\QBZ)]/XG+C`R6T2$&")"#!$AAH@0 M0T2((2+$$!'-;$2&;WKHB+AEZ(TC2KX/8J(5&/I$S3]T:3F:Q6@QP_=`M3(< M9O4ZPYH,:S.LR[#>LB1:3IGI:$WDCY,HZ8@29M0GLQU>ECV4579PGQC<)P;W MB<%]8G"?&-S7+''?J;USW/?JT":$4HQ#!VX+=VT!48J"%,ZG"+ZG"*XKE+0T M59]3'>6OQ=F6RO4Y]>J2(GQ1!`-J3.?,11,QLP^_;))+(G#)GP%F(>OADSYK MXI337.>$WVLTZY1GZKD6Q)\8.L"SQ(-DBPT/1C/E@:XN\<`)H7,\$.&DU;][ MR@+98CT@!@\\2SQ(]KWP8#13'NCJ$@^<.-$>I++]M,NP\I4.VS5>]UC'B,$Q MS^QS2)MD^P/'1C/EF*XN<(I#8,\FA&3W`74AO&C7M8-W=M.5@@+V-%:NN3!,+)!QT(U\/SLY]$P@Z* MIW[/G$`9&U+RDTBAJ'%@(7M<(\A(^JC^QX-+P9LC44Q9?6B>%3ZV-UW/.(I/%L(G?#9SWTM";, M/HFTH5UA-`NMQ:?BW>D_7*JGD^`!,7A`#%^+)]9F&+X73W;X8+QFR5AP`H/F MM]4[K'GG/G:3^>A($9B9XS:T88QF*EA>^N!:16`(%C$$BQB"10S!(H9@$4.P M-//!NGKYMM^_[NY>[SZ^?]P_?]UO]]^_OUSXMOB.XW*N+;C_D2LW=VWQ>V0J-W?G M\],&'UNY8\,+=.C8S!W#HWBY\\UP<_[AF:/L,>6.#+LH-)X7*,,?I63*7.- M,O@U2N;(&F7P.MG<$93!2U%=( MYH@;$OD1,<=Y\N-A@6Z''L[4MD!M7EFD<5N@-K_RT!&T&F(C4]LP#+*>ND3/ MY_DQWDTE^+D&C\VUV*9J-M!_PN?,7;JK+MKE` MF_&T1Z;-A1MZN3YP>]X;_"=W[%-Q\RE_'E26.XL+9HXCH7/Y_&EY\^G`O`Q' MLG[`C5Q+;Y%(V;D#:93-".?U;=YK2./%#?Z3.P_V?XL;"."<-V[;[H[EVNTV MQ.Y8;H2Z/:4[ECW?9GWCWL[`/;K;E#?NO09\!"\M0)GV2'(^XW3EP&/S+"D5QT\6,=',F=!S^-NJFS1VZO,:KP2S4^#UY-?./> MG,I'\#KB&_>RX=P1Q`!OULT=V>!(KM5X%2N.Y,Z#MQU/W(U3LDO']__O/NZ_\^[YZ\//UXNON^_0)_-AH?(GQ^^NJV[ M_\>K?*+VMZ?7UZ=';%$N+[[M[S[O\;WSF9.^7YZ>7L,_X,C5GT_/OP\:\.._ M!````/__`P!02P,$%``&``@````A`!IE"*4T#@``Q4L``!D```!X;"]W;W)K M&ULK%S;;B.Y$7T/D'\0]+XCM]2ZV+"]&*O)9($$ M"()-\JR195L8RS(DS>WO<]B\%*N*HTMC7G;6IXI4G2J2I[K5ZMO?OV]>>U]7 MN_UZ^W;7KSY<]7NKM^7VULM5LUU^V:S>#GZ2W>IU M<4#\^Y?U^S[.MEF>,]UFL?O\Y?VWY7;SCBD^K5_7AQ_MI/W>9GGSQ_/;=K?X M]`K>WZMZL8QSMW^HZ3?KY6Z[WSX=/F"Z@0]4<[X>7`\PT_WMXQH,7-I[N]73 M7?]C=6-G57]P?]LFZ+_KU;=]]O^]_'00!@_4:-M6X%^[WN/J:?'E]?#O[;>_K];/+P>4>PQ&CMC-XX]FM5\BHYCF MPW#L9EIN7Q$`_MO;K-W20$86W]M_OZT?#R]W_='DPWAZ-:K@WONTVA_LVDW9 M[RV_[`_;S?^\4\LH33(,DXP0O9[DR,`Z#,2_<2!]^)%Q"*V-&O^&<=7560,G M82#^/><#!SY;;?*;Q6%Q?[O;?NMA12,?^_>%VQ_5#>:*6?M$_%/>;1PQ773=M(P$C`9L``C!(M M%/(7T'*S.%HQH(<($,^AX!`]XI!&`D8"-@,8!RQ"R6&$;57>$+$2;A"6/JM$ MS6-\\#YND8 MN>22R"G$*,3F"".'C\K)':^/\DR$G)Q2R`HQ"K$YPD*^ MOB1DY\Q#]LC8RZ@[M.<*:11B%&)SA,57X<@[/Z>M-X\P0'4ZQ><*:11B%&)S MA$?H1.CLJE=>LG"*Q?H]!&@,IMG.NQ9U#UXC9"IYC89"?YK@5;.YZBL^ER&O M&(2EZ0%Q?DZ@SN?GY8SQ\Q#XQ4^;5QX"F0@U`1*1BQ[!D%<<:-EA7TZPG$<>IN@:GG!/,0(>8@1\E"-#T@%F]6B8*9* M7D0HGXL3S5FV&5TIO*N\PQ!&7@BZL,N\U0A7) M:R16K`ESU77[8;-:V&VPCS`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`BEQ>&>5&R<21?>$,-C:5<31%BU1B+*_0Y>1&G,%N=-"L36ZR=LHJ&IV+D6(UT-)K3#8;<2`MJ$9#1D.603QR(=EMDSX9=[F+/M)Z'B&^R&0G0EZTR,)< M^:97D&4#.2TGGMDB.W$$.V]Q!`>(%T1V(K@^;`?F!5&0T5Z603QRY"J/W!5D MBB^C+]\?;B)!*D"\'+(7P>51.Y!RWVC(:,@RB),2(G^B'%K+W8UKD,D:C[F& M&@T9#5D&L3#=[6.9^PY=8#L-SWR$>.9E+T)>:2-HR&C(,HA3*BBZZQDO/&S= M?6BQF"+$=LA$W+Z$/1N]Q9P MUU"MLB36F:1/9)L2!U+R&PT9#5D&<58727JM)3U"O!ZR&2$OJD?J!2)DM)=E M$(^\(.E=3C$MYW62X+P8LDLAKQA_HR&C(T9S]&0T9#ED$\G1NO=J)>*DBQ$G)!H"\ M(H-&0T9#ED&<5*$!Z-1/NB-$K+\(,5)3V0*0%Y$*<]%Y;;2791`G)5J`XV(Y MUC(?(;9SIE+FR8LB#W/19C+:RS*(1RYDWJTQQ_/"?FRL]3]"O!A2_\F+*(6Y M\F(HR+*!G%)!_[NM,"W_XY+\3Z7\DQ>12@,C9+2791`G)>2_:YUT7S`.$*^3 M[`O(*\;?:,AHR#*(4RKT!=WJI#N#<:DSF,K.@+R(5!H8(:.]+(,X*:?!F8:Z M.G5["'`5^TEBW!A%"D-3P3&5K0%Y$2[<&VLLRB-&:B-;@ M>$%:;UZ0`/%O?J=2_\DK1:XAHR'+(![YK]+_B=;_"+%RS*3^DQ>1TOJOO2R# M."FA_V[7=^L_)[HWB!!G)7L#\B)68:Y,2+6791!G)7J#$XM,MP`3#_%%-I,M M`'E1Y&E@A(SVL@SBD1=:@&[?5$QT#Q`A7@_9`Y!7I-!HR&C(,HBS$CW`B7IH MJ9]X2-1#2CUY4>1I8(2,]K(,XI$7I+YC/;363Y)D9X?P3&H]>44*C8:,ABR# M."NA]2?JH?5\XB%1#ZGGY$61IX$1,MK+,HA'CK6;Z[D[K[K=OYBXF82T!(CO M#ZGU<2`=3HV&C(8L@S@KH?4GZJ'E?.(A40\IY^05D]]HR&C(,HA%/A5R[NK1 M;7^T,_%Z1(C70TH]>256&C(:L@SBK'Z5U$^UU$>(D;J64D]>1$I+O?:R#.*D M?IG4NV4FMDZ$."LI]>1%K+34:R_+(,[J(JF?:JD/4/Z%F(8:#1D-60;Q,(6N M']_A4ZW=$<+Y20V[?/9[3EZ4X#!7=I]%>UD&\V MA0@F&(,KQY(%N<;55\F"7./JIF1!KG&%4+(@U^C`"Y8QQN`.8LF",;@)5[!, MD&O^:2!;G&][@E"W*-[T(+EC%RC2\4 M2Q;D&H=/P5)C#)Y"*EDP!@_SE"S(-1Z(*5F0:SQP4K(@UWAHHV1!KO%01,$R MPA@\NUFR8`R>C2Q9D&L\7EBR(-?^=V%RSXV0:SP#5QJ#7..QLX)EB#%X.+YD MP1@\8UZPC)!K/,-=LB#7>!*Z9$&N\:1QR8)\?MOW7E=/$/*K M]MN>G7\-D__C$'[K]VE[P.N3T%KA;4%X7=8*[WS`*XOZO:?M]A#_0+B#]`*N M^_\#``#__P,`4$L#!!0`!@`(````(0!.C'W#7QX```JH```9````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`$?&Z" M*1*BLK<@M2"S(+>@L*"TH+*@MJ"QH+6@BX`*)E7*WQ%,9X9V"96L)A4_>1FW M#_49O38![D7Z"`-)@61`#O"+8S0XL+;31] M('%I8*&Q:/!+"@J%&0C-UQDBB%Y@#V0%$@& M)`=2`"F!5$!J(`V0%D@7$Q5#.AV=$4,GK6/HRA*6A<4\+`O^#.:%EG28CA;PI:[GM!>2 M>LZ`Y$`*("60"D@-I`'2`ND\\4^OPNKZ!157?P1^MZ%%\^7;_=UOGQ[IP>E\ M-[`D+VBYY0.PLZ+C?31,YXPHX(CVC);DH(_O8KDS\0U2?8`1Y8@*1"6B"E&- MJ$'4(J++@F,DAB+M#LG8;)P;:7_4IA.%A.*3Z]M<\.<]2@**P@JYS5++]7'; MG%_/S#Z5!@%QE@7+@G)$15!TS1!9-F55!@$Q4Z&9&E$3%-FR.;JV04`L=\J, MSGYWUH[G9"#+Z1:B3W-_-%?!]RA:>UTK[*;#W];X1@Y0BE(9HAQ1@:A$5"&J M$36(6D2=0CI\[OA\1OCXM!WGKD>+N/Z7.]MKN$L""NF<-M"P2F`ZLRT*=I!: MP%KBI99T%NVE=M?FR)BQQT4LM5AM];J4AW%)KA6B.#J(4J3<"OK'Q^U\MC8# MJ$1"#<`^K&I%_&4G,54DR&?A`A&1@% MC^6PQXU.K.I5'FN6HOH4CXV@X+$=]FA2N9ORJ*?;=51GU#TW8''=>S0/XTS< M;8,K\G@IP/,82RTV_3.GB+)@2R*3(RI0L414H6*-J$'%%E&G%'5(73<5A_1M M%<0]61QICY84W3[%9W.3XHF[H7C%"NNE%JH0<(5ECY3\O?M'0.GM/C$XSO0J%'L49A!"LV?%1;B7 M31%E:#Y'5*!BB:A"Q1I1@XHMHDXIZE"[%C0.]<2AT'>L*J0>S1=]E),9H#VB M%%&&*$=4("H158AJ1`VB%E&GD(Z?:S;/B)_O357\&%',P@HR,P64] MHA11ABA'5"`J$56(:D0-HA91IY`*Z=QVZ>,I>137!RE&\:4:HCVB%%&&*$=4 M("H158AJ1`VB%E&GD(Z?:Y%?GY+N#&(.HHRB/@_('D@*)`.2`RF`E$`J(#60 M!D@+I(N)#AEM;^>$S(F;E/,HO@%R1VB2(A0*&S<6EIJX=`M24OX9HAQ1@:A$ M5"&J$36(6D0=HX%+(=HB=)3?=.P[6C'!YV8XNGYCJ6@^]HPFKM^"5(@T=]'A M_)ZC5(&H1%0AJA$UB%I$':.A2+M>+%X"WA9I9\5$FE'HPI)YCT;3W$N=OGYC M,R00XMY;%I0'9X**H'CB^BT(B$Z%9FI$35`\(,D2YH-`C%(*"K1)1A:@6%&PU M@H*M%E&GD(ZRZZ'.B+)ON524N:.CMB`ZCYD[W63.BK3&]U(#BSM+Q3.V@!Z2 M;>F+&7L_G;&46UZ#1[B8">.2E"P$C0ZB%/.[XRW=;#VW5TJ52*@!6*E:O(45 MHA$T.H!6S/,`YBO;0HK`*?\Z#UQ7=T8>^"90Y8%'ZBYA-S,WAXDK,ZK)J6KS M4G27(+.2LJ*^FK5O\S.6FK@X"(,0\X4H!H^E(-^D+Y;V/44E`K3LA@S#">Z? M6)PUHAB[2D9PJ/#%>N[D;6 M;82G,L^_/64I*E`)3,IH01U-,+\TO5V&BGGP*+8*E"I?9;Y"Q1K--RC5OLI\ MIQ3UK+F>-9ZUB1V/6]RP]'^:>T3G=@E#$E`44IND>Y:*;TX19<&6F,\1%:A8 M(JI0L4;4H&*+J%.**J0ND\X(Z5%N5+M9W@W,R]B$G>PG%[F6"I<#J1` M,B!YL!WFTKL+ADI0JX#4:*@!H19(%Q,=7)K)>Z4%1>CR9N) M5%#,@T>Q5:!4*6C4?"52P7R-YAN4:@6-FN]$:J#TSKO2C^(#'4NZN M-J02UAG?A82K@Y05HS-?%FQ)E'-$!2J6B"I4K!$UJ-@BZI2B+@2:"U4($ZN9 M$S?;D4>A7A.7G4YH8N5BJ;".I*Q(QU%W`;98KI9PD&-GHZ;S,`"9AD)0\%8R M<2MIW]D\=@$14&M>)Q8M?IG)$4]6:X5CAN->Y6N[,GI^)!"V"_9C@QBMG M*1J31+D0Q=$!E"RE#QYS<]2IQ)8:!,Y^'Q@91".*HX-H1>KTN9W#I/Q'BY-. M#W=M,)8>K_L:`WWG`/+#([5L]FAD>O9L*_X:`Z*,460^1U2@8HFH0L4:48.* M+:).*>I0GW?5X-[)V9)C1&'LTWLW-WU;(HKA:R![1"FB#%&.J$!4(JH0U8@: M1"VB3B$54O=&4F7O^$YT%->K&*/X-3RB/:(4488H1U0@*A%5B&I$#:(64:>0 MCI]K;^/JGXB?[X;CRTGWII*R-!SK$B![("F0#$@.I`!2`JF`U$`:("V0+B8Z M9+0ZJY"]:3]=.BLF$QE%AR*14AM"M)+[.UV6HA'S*T"S(:5!0+::+%@6E",J M@B);-KM[&03$3(5F:D1-4&3+Y@C5!@&QW"DS>DYH=G=(F$MHW M>RJAN4O4QQKSGB=98L66VM7MJ2(/ MXY*P%:(X.HA2I/ALM=EMS"-7(J$&8).QQ@$THC@Z@%:D_`!FV_G*W`5T(G%J M`#HE2$JEQ$0B.'%3CQ[I^\BYO8]TL^84U9:JY$8/19:K$L9< M^Z_#8XK$1%)ZQ'?9H#@8=2YWTJ.?5M95GS*OO0M6\_LSQ!4HAA+P5O#&CTV M05$&T0H:?:!.I(Z1T#/FVNTS9LQWYVK&N&%7#>?"'$V2)2N>6LKYF,JV0DA3 M5AR_D<]8BK)4(I,'CX(*E"I?9;Y"Q1K--X+B&N,'XB\#S;8F+EVP'#(F/B3J MR3KO=H#>C1]7O^B+"(ST%K>``XM7G-KBO!2=7"7`*9OG36*[-<>S3-RKS(\V M"?^&CZ7BNS=1#+Y*07P87.[,4U0B,.JL1F=-4)0':P5-E!E'!,ML==XEQ%%< M'S49F0W/G)@241PO,Y$*B9J*>3Z+S3;&'L7-1/K;$%."]I3) MBA,ER%)Q"3+B$ES9I\U$9;0J\N!>2J`0Q1#M4ON:V6VZ$I517S7Z:D0Q^&H% M<;FO-W8E%8%3SO0TTF2?L>VMG+B91H]T/=J31"**IW++;WLB%;(V9:0/H$N3 MNAE+G3R<^?54S(=H%H*"QU)LR0I@OY!=B<#HL]1B.3AK!`5GK=AB9]?VPJ,3 M@5/.]&S:NYWQUF^%-SJ,=%':YC=AJ:FBY-NA$(&4%;DH-VNS567B_E3N\CSV M%TJA*,%7&7R%$\5N:8[UU:!'>U54LU2T$S=!40;1"AK?'$5J8'.DQSZG&)VX M*4:/3#':EQXK5CR54UR,+!6R-65%?G\\F]G7>9D(C%K.@W\)72$H."L94>7[ M1MNV@*_R58OAD(1-4!3WK?@:?W&L%'7AG7?GLL([%T:F\,SE0L)24X7']S?A MF5-6U`T9O/V70=#,]VT;-&1Y&(3$KQ#%X+$,'H_3MX"C#0]2^;)'X!I]->(K M=+.MH(G"ZSW2N/7TD:(JO#>]IU@Y*Z8>/3+U:%:]1!1'JV8O4J%$4D;R?8[U MQIX\,I$8-9V+Z3!]A:#@K61DMF*85WYDY1$75(Y5\-B@QW;8HSDB=BQUJ0JL4>CE>BEZ.LG,CTIFX]0QB@R MGR,J4+%$5*%BC:A!Q191IQ15J-?GW:X/J>J?[PE73MQDY*,=$J:;B`1Q5#2>T0IH@Q1CJA` M5"*J$-6(&D0MHDXA'5+7Z\8+ZD1(?6NL4M(CNBD**0EHOP:4(LH0Y8@*1"6B M"E&-J$'4(NH4TO&C;>N<^#EQDY(>A0XD65NR!Y("R8#D0`H@)9`J)OI17![!:[,R9JA*)4P/0<^#.\6=DIS_V MJP+V2&_(?8@K-2;/$+BJW]]<:5")QRIF*[40W*Y-IQ%-=; M+R.5MRN[J++01-J*J9!)*2-Y:6CR*!.-4WGD7T\$[WU@13&X*@7YI%VN(+`B M<,J9#JQJ4Z8#BVW*QB.S*-L+:)::6)1%*DI:,>_S:+W<&YH@*5"P154I1AV&H-7K-ST&X/RYB`^*1J6^S>R2L.%7?;"ND1,J* M7-^;!?PJK4PD*+ZG\S@/`Y#`%J(8O)6"N,`7<_N:L!*)4]YTG&TC];8*Q_YJ MXY&N\"54."N>*@VN<)8*19>R>?VV:V46NTP&H;8.]&B-5Z]R^3=2ZEXH*.V5;$&2C9>:JG"V%;(A947Y:>W%>@V)QDJG:HZW\'X` M(='`6ZF];>8SW%`FO.GHNJ[AC.ARDQ'N'SYM/-*EO#8M>L)24V=/;ROA-&\G663&1 M]LADG^E/$E%4*[V]L-B+5+21,-(;"=R'L-3)+S'X^A;S82(+0<%C.>S1[(S5 ME$<=?'IL%?SQ%73KQ$V4/8HW$I::.#2R5+1KI(BR8$L2+D=4H&*)J%**.@RJ M77ES#F*[LO7(5+L]0;+45+6S+96I]OHI95MF`;#;CHQK8@'P'FE<$OQ"%$<' M48J4/VLN5AO[:T4KD5`#B,I.3P])J2RU2\3KOFJP=69,]GJDLK='T7H6C:Y MT>9F(3HR;1GI:-L#:9`*T>X5!:4HE2'*$16(2D05HAI1@ZA%U"FDHZU:'4[N MMT4;NZ`M(QUM>T`-4A+:/:(4488H1U0@*A%5B&I$#:(64:>0CK9K$/Z>W':6 MS&++2$<;CKZ]5(@VH'0+*$.4(RH0E8@J1#6B!E&+J%-(1]NU(G&T)TY?OG-1 MB[-'\9>0MH#VB%)$&:(<48&H1%0AJA$UB%I$G4(J?CO5C=':,!Z_H[A.24$Z M)4V[E`2I/B41I8@R1#FB`E&)J$)4(VH0M8@ZA71(;3Q5]"0K1' ME"+*$.6("D0EH@I1C:A!U"+J%-+Q<^W0ZTMZY[NGN*09A6N-!,@>2`HD`Y(# M*8"40"H@-9`&2`NDBXD.F>LRXI#9T_VK_MKWSO=B)1J7^!PSU*G MO\P4!&1!R()E03FB(BB>^#)3$!`S%9JI$35!D2V;,V,;!,1RI\SH.7%-4#PG M$\N`$SZ\[6_4"G9>:F)SI>E)GZ'E$CYIG.%WP42`?+9=S+P5C`/0Y(X M%:*HLL9VWJ5(<=.[FYLVOQ*!4?\U^F]$<=1_*U+>_WQ[;4Y6G0B<\J\S8*BI M?,U[M!VVD(ST39S]`>=$%-538FVR^7`OEK*BOHG;F'NQ3`:AS,.=9QA$F'WP M6`Y[A/GVBN-W?S5Z;`2%9VR#1U?>YA*SXT^UIRAT>F9/]Z\358[MZLXC4^7F MMBEAJ:DJ9UMAN4Y9D;^W0U_OTW^2.A/WIS+:WZX&]V%.P5-*(8':P5Y9_03M^8^I1.!4\[TC-H>>6(>L1'>>:0KU/YZDX2E)M[4 MB%3(WI21KM"MV:$R&<1$A?+H0S0+]%@.>S2=??4JC[68#QZ;H"@IU8I'ZDG" M[F+?@W1*44^BZVCC+?=MQR#NBZ,KI9U'ND;M'Z=(6&JJ1ME6"$7*BOK">6M: MJ$P&H?(95U]O/KYP#HH2Z5(0U?#I2%`SHPVB MKZN=_88\S4,@@^,@@^,@@^,@@^,@@^,@@^,@@^,@@^,@A\S M$_RA*Y0W!A_O46;7S'3P38-%P>_%HN`#H^`#H^`#H^`#H^`#H^`#H^`#H^`# MH^`#H^`#H^#'S`2?SC1_5^8[4S;SF>G@FTZ(@M^+1<$'1L$'1L$'1L$'1L$' M1L$'1L$'1L$'1L$'1L$'1L&/F0F^Z['C!7^\]9E=LA.7S__GQQ]_C[#UJ!Z5?S1/CBZ?#EP^4GJI*;8ZE0@'J5_K.E M^^QX7,;/5NZSE?N:B?ULN[EQ[RN'/MG2)\?`@\Z./CG^X4S[R>[ZQKW\&+"V MF]$GQP.WU:&%UXWNV/+8S]9DCW[)P("]-=FC'Y\?^H3,T4^!#WU"X:.?;Q[X M9$L!HF\D#'VRID^.V6S'1O$>C#8I#,I3H`?C/*,XSP;C/*,XSP;C/*>XS(?B MLE^O;E+Z\5Q\$OI!WQOWL[SXR7ZWN$GIKAH_H?OTFW+P$[H/OW%7WJCSR^SF ME\'HTX0-SA=-UZ`\3=:@_>7-+\.YO)\O;U+ZP_,XIH(^*0<_H3]N?],.?K)? MSF_9 M/_6;W,OIDVKPDYH^Z08_^32?WWSR+[*-M80^208_V=,G+=UZXMCV_/KX\O+X&PO=V]R M:W-H965T;B$74$B54'6WTJZT M6NWEV0$3K`)&MM.T?[\S&`B0;-5*?>$R'!\?GQE[6-\^EX7Q1(5DO(I,UW), M@U8)3UEUB,S?O^YO5J8A%:E24O"*1N8+E>;MYO.G]8F+1YE3J@Q@J&1DYDK5 MH6W+)*KGFP`YL8-JL4P8K0-L-0;/(W+IA M')CV9MWX\X?1DQP\&S+GIR^"I=]81<%L2!,F8,_Y(T(?4@S!8/MB]'V3@!_" M2&E&CH7ZR4]?*3OD"K(]AP7ANL+TY8[*!`P%&LN;(U/""Q``5Z-D6!E@"'EN M[B>6JCPRO:4U7SHS%^#&GDIUSY#2-)*C5+S\JT%N2Z5)O)8$[BW)PO)6^ M0))7!L[:@7!O!\Y\:S6?^XO5\NI(6\MOW+@CBFS6@I\,J#`0*&N"]>J&P-;9 MH.?NC?F?+V`(DFR1)3)A:\"2)>3R:1,$SMI^@@0D+69WB7''B+A#8-Y`7J\1 M[/D`C\A4)@P:FGE]`W:%AN!&39]%'5G.FJISI^;T M7\_^!<$YS:,R@R6^70B"QT+:B#XLL,#B860TT_(],R%X/)..!,$H);-)6?2@ MJ=_8P`8[_G6_$3R>O(T,ECF,C)8)`H+`WOJG8<+THPUZ$@`5/VN"`)_ M8D`/Z@W0S4`??R45!QK3HI!&PH]XT+L.E%`?[IO0UL,38Q+?07-JCO)IW`OC MJ_A9&,^N\&S]<-LTN2F/'\;^%?QN$4)57=&S#./EM?@JC)L3;\H?M,W5[C]` M@U?0XKB"MM8\YO`70Z'@'0O`&>>J M>T'G^_^BS3\```#__P,`4$L#!!0`!@`(````(0#.BB=V\0H``(4W```9```` M>&PO=V]R:W-H965T?S/__Q^)F=?IS?T_32``_'\U/S_7+Y&+7;Y^U[>MB<6]E'>H1?7K/387.! MKZ>W]OGCE&Y>\D:'?=ON=![:A\WNV)0>1J)%.3NE^ M<\;`_;X.GY\64'9R"&O7%*7Y^: MWZQ18CO-]O-C/D#_V:6?Y\KGQOD]^UR<=B_^[IC":$.<1`2^9]D/8>J^"`2- MVZSU/(]`=&J\I*^;G_M+DGTNT]W;^P7"W8,S$BOEKFIZW,*+@IF7WA*=M MM@GIO/0ZO4[C@7FC>_I^3+?"9?-QO;G^9(= M_BN-+.5*.K&5$SA><6)HZ*B&<+S2L&;O7>4$CNC$J!;.*S]E."K[8:MK]_J# M_)0-:A]40SAB1RU[T+-Z#V*L#`W[JB$<54.['&-#.[A(2`R4"5"S:9%"L&'NT[/PKP1'[!3XPE:F##BP[VGB'EB51*E MYBEBRH@KZ[Y3Q)RQ*DEC/D5,%JO,EMI1Q(2Q*AEC/,6V+`=Y=9EN+IOGQU/V MV8"2#;$\?VS$#<`:"6]85V2V%I7F5J&!"B.\?!-NGIK0'FK(&:KCK^?AL/?8 M_@45;:MLQMS&TBTF:"'*EW`[I6!&P9R"!05+"EP*5A1X%/@4!!2L*0@IB"B( M*4@JH`WA*6($5\W_(T;"C8@1CNX801DTFP0$+;#)E((9!7,*%A0L*7`I6%'@ M4>!3$%"PIB"D(*(@IB"I`"T@4)180!PHJ-=OQGB-B%9PV]6ND0=]P,?21I2? MXD(B)I/"I`@*(S-&YHPL&%DRXC*R8L1CQ&&531F9HE:8%%%C9,;(G)$%(TM&7$96C'B,^(P$C*P9 M"1F)&(D92:I$BQH,(8N:W6L!-E];HET>)AS>L2*=_&9D]?7K;%+\6@UK::1I M@MAKFLQ*A+6N1!']YC@@@@HC/($I(S-&YHPL&%DRXC*R8L1CQ&G)9(Z88$T:FC,P8F3.R8&3)B,O(BA&/$9^1 M@)$U(R$C$2,Q(TF5:`,/V7O'P`MK?>`EZ1:3CPD%4PIF%,PI6%"PI,"E8$6! M1X%/04#!FH*0@HB"F(*D`K1QAB6=-LYR/M[J0\&ZO.^V/\:97*5?*4(.E#HY M&Q=.].%7Q"['OR!E!71L,O^;2J,N3$PK=[^A7KIFA1&6KCDC"T:6C+B,K!CQ M&/$9"1A9,Q(R$C$2,Y)(`JM8.%,M:F)9_;^'+?>BQPU1)7`E*H/"(Z>LNE!) MB]!9G4Z'Q*XT*X)7^D>TX&A9-M3\DQ6=6YJALQ5WYG'DEPTU_R1!@](,_:^Y MLY"CJ&RH^7?T\8E+,_2?:,[T+!`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`Z='KN`56AA[\[`WHY6/5D9-`?8H-=E6SR:U M;HT6QMY"[,UH%:&545.,/:KZVQV06V>"!K8D M=26BE9>HFHA)J&@)A]N+D"E:0>Z55C0J,V4%ZW"9NGURGKDO14%G\.J4Z"Q5,A\K&X.Q]GA%=46)8K M!&NN0@G,+\B=;((MR^>'IQS-.)ISM.!HR9'+T8HCCR.?HX"C-4DMG:3[_;FQS7Z*MW1@L_OYL<#R%:)Q=P0/1L)6 M"^4/(W@@[@KOCY)\WY7:VPZ^BT1^F0Y'\?"*IZG5&!SSG,1(/I;OA%&=(WAY:G\D3S*;3B1*W[&<(+YNU;$ M_EL7_.<_M(M?X"6HC\U;&FQ.;[OCN;%/7V'X._D#52?Y&I7\?\H_O\+I;"L\(=L3SIZ]9=L$O<&;MX@6ZY[\!``#__P,`4$L#!!0`!@`( M````(0!Z&PO=V]R:W-H965T[MO=J[:S<;F;;U[W+Y] MNV_FF?/';;-Q.*[>'E-V_4\K3;OZZ.]-_]M];A?;]9/9Z47E]:W7;[NO6Z MVKXU2PO#_6=L[)Z>MNO-9+?^\;IY.Y9&]IN7U9'\/SQOWP]L[77]&7.OJ_WW M'^]_K'>O[V3BZ_9E>_S[9+39>%T/_6]ON_WJZPOU^Z].?[5FVZ?_@/G7[7J_ M.^R>CE=DKE4ZBGV^:]VUR-+#E\V._>;IO_MD9%MV[9NOARVF`BNWF MUT'[NW%XWOUR]]O'5C]> MCNGNE[?9?GL^4K@'U"/1L>'CWY/-84TC2F:NN@-A:;U[(0?HW\;K5J0&CQT2;WS='([.5IAL-M8_#L?=ZW]+H8XT51KI2B/T M*8UT;Z_ZW<'-[256>M(*??YS5_K2"'VR$=6=FBY09T_C0)]2[^:J>SOH#*[% M.-0H7DM%^I2*G:O;P:!_?7OS^0&\D4;H\VSDTB#0C#[U@#ZYY[6.WTEY^CSW MN--O?]3?#J5HF3$B5\MLH+A_,E,Z'&3Q![NI`O19*QSEC@KS/QAU,4_*KJBH M=RYWAC.@HU*@=W73:=_U1`;4I$Z'PR[^D(.ASYLZ58YV1X7[\U'H<@S%'^/VY>=(]%PE5)3X?LU99MDY5<+(ZKAZ^['>_&G1K(3\.[RMQ MH^H,Q26X_I5C=ZZ(ORN(5`F%E3^%F?LFC275N@-5\9\/G79W\*7UDTKO6@J- M*H1,B3%+B#HK[$YL,+6!8P/7!IX-?!O,;!#8(+1!9(.Y#18VB&V0V""UP=(& MF0UR&Q0::%&,SX&FV/X_`BW,B$!SA$8,5.2[5E!9@E4F-IC:P+&!:P//!KX- M9C8(;!#:(++!W`8+&\0V2&R0VF!I@\P&N0T*#1A!I9L`!+5'-:GZZ84GJ]"B MYQ1SLEZ;41N50J+$GZ>T)3(^BYPC"V0*Q`'B`O&`^$!F0`(@(9`(R!S(`D@, M)`&2`ED"R8#D0`J=&,&F>S4$6\3GPE(MS%"UIYOM.;`5M5I*U87_+'(./Y`I M$`>("\0#X@.9`0F`A$`B(',@"R`QD`1("F0))`.2`RET8H2?0F&$OWZ."^E3 ME#DX(TG*EQAQ1RZ(M)`V(RV)-E6!3(!,@3A`7"`> M$!_(#$@`)`02`9D#60")@21`4B!+(!F0'$BA$R.`]")S00"%M!E`2>RI>FM- M525VGJJ(IH@<1"XB#Y&/:(8H0!0BBA#-$2T0Q8@21"FB):(,48ZH,)`1:5J] MN2#20MJ,M"3:5`4R`3(%X@!Q@7A`?"`S(`&0$$@$9`YD`20&D@!)@2R!9$!R M((5.C`"*];0+(G@2-T,HT5WO_%([1C1!-$7D('(1>8A\1#-$`:(0481HCFB! M*$:4($H1+1%EB')$A8',N(J%#'UEJOYYMU.N>]!K#9?2D43],QD#F0"9`G&` MN$`\(#Z0&9``2`@D`C('L@`2`TF`I$"60#(@.9!")V8(Q;*%'L+3XN+=%3TA M7_C.VBD70(SH2M2FS_/C<+]W9]UBI6:/ZL=9JM>UEJ@F4NJ6'@C.4O12;!F; M*C%.,D?99^0JI(S!)3UE2TEUVCW+,U^)L?T9H@!1B"A"-)>(AH?-+Q12CH'[ ML;*EI,C]OCG\B1)C^ZFRSVB)*%.*NGT[(KD28V.%8+UQ,BPDFG#-9%BVD!,$3D2:8HN(D\I&@-A M[13X2HP'8H;&`D2A4M3M]ZT\C)08VY^CL06B&!431"DJ+A%EJ)@C*@Q%,P'$ M@I*>`/_\<4DN3>FYP:M5^BVI9%J()V);P*PA4T2.1)JBB\A3BGKL>M9ZI:_$ M.'8S-!8@"I6B;K]OW=XB)<;VYVAL@2A&Q011BHI+1!DJYH@*0]',#;%4I>?& M![[/($SI4X^W3!2XA<']-S0")CPI=,"^6D4Z);=:1CBLB1 M2%-T$7E*4<^!OO5"XRLQE0/@6(#V0U2,$,U1<8$H1L4$48J*2T09*N:("D/1 MR`%QC,S(@?KJ?A(WUS`9:?-=(14,>"J>2"GKW:)OO<=/E1B'S$'D(O(0^8AF MB`)$(:((T1S1`E&,*$&4(EHBRA#EB`J):'F"AM`,_V5+G5U(4D1+1LK5C)&RE2,J#&1FB;V:^D&1P"53<;Z3;O>G.XLZ MIMFW7M;&4DRLH]4EB31&-V\E92^_3OF2=ZSG<#N]=B@K]O*L^RF/ M/+95ZY'/4J5''>N5?<;-M0X%RB$NAZ%29!0Q,G+,OAO.6:KVB@MUQ9J!BME6 M[1`D+$7WW/.@=]I]Z\4L93'#L8$5P:5RC/N=L6*M%SE+R=1H6VE8<+MQ>2TU MS,EA+^U^,#EPS;;+:[96";7Z.Y9R'Y70TII10@$Y;$N5!)>1D3-:KT]KSAY+ M*44?T0Q1P$C5I9"1LA4AFB-:,*IU-68I93Y!E"):,E*N9HR4K1Q182`S2\1R MI?ZL_4&6E*N;]%;.J3WJENC#$BHU/RBATECM/)GR), M<:54?5'WV%:M1SY+6?7#>M6;L9CAF%T_`N48#W*H%!E%C(QIW]QE"VXW M+J^-BSE)Q(KQ!9-$+CKKDT0BZVET8&7N6'PSC)Y'/BJE4DI=8,J*"CF(7$9& MSFB]EJ44S/NLJ,S/$`6,5'T*&2G%"-$].RG58?;2>S\ M8`25P952'Y72SWCD\Q5+CSJV1S-NK_4H4!YQX0B5(J.(D9%D6$.EW[577*@K MUHQ4S%>LC4K"4E8-M?9X4A8S',,:6KI?OF6?9GC&BK5>Y"SUF]MLP>W&Y;5J M8LX.&N-+9H<0MV:'1-K!0E$GA91"$T131`XB%Y&'R$UIL;;B65(=$ND*12O");I317DLI30T M031%Y"!R$7F(?$0S1`&B$%&$:(YH@2A&E"!*$2T198AR1(6!S`A3%8((=P?B MS%I%@.G^R"<^Z$<*(,(ENA%I\//A#WC\D1IM>C$\WVXZ[8':P"P]*W^[H/S6 M[NMF_VTSWKR\'!KKW0_QNP377;)^QN6/)HQNAG2VG0J_S6^'=!2Z@M\-Z8!M M!>^TA^*(9D5+ERY!\Z2JA2Y"XXLM=)!B*%;/L856H8=BR11;Z.D+Y85V&_3_:K7!KUA_15+%08#8;T#9\*?CVD+X0@ MIUWJH=B"KFJYH9:J(:2]+FJI&D+:`:&6*G_I7,Q0['S@=>AXS%!L@&`+[5L, MQ48%MM`A.AK?JI8Q61M7MM#)HJ'8%$)K'K7X=/"EJF5`+57C2:<'J*5JW&A; MF5JJQHWV(*FE:MQH9XI:JGRC@XQ#L?&#OM%!Q:'8_\$6.J](B5R53G1LD4:T M*@'I4!JU5.OTJ:5J=.A$";54C0Z=)Z"6JM&AS6=JJ1H=VJFDEJK1H4.L0['# MASVELZP4TRJOZ?PJ96)53^G8(;54Z=!I4\K1JA8Z=$HY6M5"Y\F<K?Z%C9 M4&P2HM=TNHP\J!I1.D]$+54C.B(/1I76QM0B3F_B=>C8\%"<":YJZ5%+M4Z? M6JI\HW-9U%+E&YW*H9:J:--Q#6JIBC;M[5-+5;1IQY=:3N/6.E=/^DF;]]6W M3;3:?]N^'1HOFR>ZM;1/SS7[\D=QRO\<=^_T%$,_5[([TH_9G/Y\IA\OVM#7 M2=OB'OFTVQWY/S0LK?//(3W\#P``__\#`%!+`P04``8`"````"$`@`\LEM@1 M```@8```&0```'AL+W=OG6Z MNGBJIKI/S7#8'W[Z_?GIZK?-_K#=O7R\KMX/KJ\V+W>[^^W+EX_7__[7S^_F MUU>'X_KE?OVT>]E\O/YC<[C^Z=.?__3AVV[_Z^%QLSE>P/UX_'X>GMS M<[A[W#RO#^]WKYL7C#SL]L_K(_['K9WFV9W]_5Y\W+LG.PW3^LC^!\>MZ^'Y.WY[BWNGM?[7[^^OKO; M/;_"Q>?MT_;X1^OT^NKY[O:7+R^[_?KS$^+^O1JO[Y+O]H_"_?/V;K\[[!Z. M[^'NIB-:QKRX6=S`TZ5K>AJD;7-Y\^M!GZSW;S[2#^ M_^KPN/OVE_WV_F_;EPW2C0L5+\'GW>[7:/K+?80P^::8_7-["?ZQO[K?/*R_ M/AW_N?OVU\WVR^,1UWN"D&)DM_=_-)O#'5(*-^^'D^CI;O<$`OCOU?,VU@92 MLOZ]_??;]O[X^/%Z-'T_F0U&%7UU=W7PW'W_-_.J")7G9,1 M.<&_R%U'4NW MNH7CF(\1LMK1R!GZ7H*0F>AD&;U\O,8JP?0#+NMOGZK!9/SAYC=F$8T4L,(WW^*@$@%ETQD?CBJ-,=59Q.=Y\LSU29U-LEQ%$B0B(H$A?D#(HE>4(53 MP1)%--%$5V1U*I9LDF,ID"`1%0L[(6G"49C39"0P33O'W4)-244%*08+32C M=+%/,XN3-#-".A6*&VM-")9TWA*&([,I-&0TZ(0PS@ONO%FN;T6^@HZ\/9^M MM::=()E1!VL<+&A,\XHB(JYSJWGSJ/??:0/2+T]NW&B*0"" M9'8)PC\G*A=N?A.=J-`B"C.9)?D1!8&02)K=55BC8,%C>GL1ET0 MO-Z>71(429$@F5V"SF27K%1VO9GCP7>R&S7"1#$=O9_!QX4Z%ML%6S19@$2% MC$U/5*>)W.PU)104I"]$5!$30H_VK2(Q`N=.M(;XL)0MI$!+978ZL<00D% M!>D(')GLMTB'I6XF2(=@NSFVXA#(%Z_;H*QT"!=IY+#42()BDD2F[(L%TK#$Q/SH"!-TY'2'O>#PU)'$Z0+A_LEXI_5-I%M>&*"@H(T M_Q^CHT-?1TVV5\GL9.&0*ZZ2AJ=Q1-)*1X2$75`XT=IL[P3A$WC3L4_3ZF&V M2IR:$@H*TC2CFIE-IT_A=**(1BG16`VS3DK^Q=Z>K=+$AB%BF MGO5*,[U('4>E.B9(99#,!-8X=D%CFI>1PS-Y*R5O1)#,&T&4-].4-FD&K,22 M8]G1_(S6G>&7)2T5]6I$D,A1[6"-@P6-:5Y12LR*?E/ED02))3PB2&:0(,J@ MZ9>;-$-GD/=?S=2(UID,EMHT(DAEL,0:QRYH3/.*FWJ?#)(8R`P2)#-($&70 M].O-*`_+&F2]U4PO$IE1*3()4ADD,X$UCEW0F.;EJ,KH+<_61J6.)$BFD*PH MA493FC1#%>'T.P\AQA<)2&NM!21!(EVU@S4.%C2F4CCN*2#M/,.P%)!D11ED M:>B^<.-A4813EAG-U`B(>!AUX7W+N!27!*$F>4N>FHV[9JNTNS8E%!2D0XBZ MX*[X2R.(CDSV"=(1F(VS'FAWVWZN%0J@O3][]3L7#5; M<0B=+WG_JZQT"(YP];O_'9=21I`)P>P<-5MQ")TO%8*$=`A&T?Z/I5"JW;B# M3`AFZ=9LQ2'DB0D*RDJ'$/7GARP%$C*AAN,.,A%P?]7=2[)5HMN44%"0CB#J MEXC@=%LQ)K63-#L(CSD2@9JL!-244%"0YN0((M[UZ/-P9UQ*)$$FK]QU45Z[ MB:*2&YZ8(@T*4C%,C%+VWV):3WJ7),B$P&U/%P););Y-"04%Z1`<4:6^Y,*- M/MXCFXV>(!W"C-L."J&;**\"3TQ1!07I$!RU[?5$>5**+4$F`I9]BJ";J"(H MH,"^$)2.(.J:6)^QCGH\))R0/&)SRYT!'A*:DEDE,^S9VVRV$KIDF^^+EA4%::9M0MD_CNSO#2XN\$4#[M MF1"DNIR9[7+8BB/($Q,4E)6.("J9B:!/Z72"&+_6R^FN!N(.H2WTU83,P#"; M%:63;1+]AJ]NK)+1J27&-AP/^>:K%I25C@?.I>"Q3-B1FXEYH2I#>FTV35;,5\\\3$Q24 ME>8?1MDADRG)="L;^0*ZZ2AJ=Q1-)*1Q2E241T MIG!(R&3B"6("];2`FA(*"M*1$D-Z;Y_869\IF*5.-@P6-*:JS MBZ2MM=;K+D$B?274E%!0D.9DI*W__>^LE#V"]/8\-UU%S58YL244%*1#B/(D M*J#G]CPCE<,2SPL(Z\QT^ZMD=FJ=L0U'5&AH4%8Z(B.8I]?9K-3%!&$EYUB& M<[-EU&S%-,F7N/525IJFHXL]-NA9UL5$8Y4@[`V"O[D4-5NEB4T)!05I_E&- M3.'T>W`2W^XT&ID@'8*]A6$K#H%\B?Y?6>D0HB")$,Y4"LF7V/UF!,DO>ARL M<;"@,ZEJ"1"83I'-D6LK&M5IPJZ$9_QA=FSNZ M-AF8:[Q*5J=DC6WR9E5"04$Z("3G[6ML'JU-:1"D9&UA^XDTD36L*:&@($WS MQ\C:O)2U!&$+X'UK8669K3C-Y$MH@K+2_!U9ZR'+\U+3$J3Y6UEF*^9?:IJR MTOR-IO7LY^99[#C9Z.>,`J^2V^ M":5FJ\2I*:&@($TS2I/0P)CX?E^WSTGDA#XF2->.T>R:K3@$\B5K7T(Z!$M76:2E\MR.QD[60;CJB``GN"E8[(B/&9 MVBDU=T$0[]UU"34E%!2D.44U$_OD&4[16O%Z19K8<;)XZD)"]I. M4S5:>H9JELSD>[4HI*\NH::$@H(T)Z.&_65F42HE07&)Y!9K-.`.F]99-Q%6 M*="&)R8H*$B'$`5(5$#?=48ZAAQGL@M+=K4@*USY;&668LTVB7U30D%!.B"C MFV?JI-3&!4%RBQX-;&O.5DPS3TQ04%:*9C5PQ+%?B]*YTNLR8W*7'@UL@R[, M$F?\3C\R@SNQ3VO,!&(T,590O_<"JT$IF!G3@=A.79B)0,B="D1B)A!'-7M\ MRU$-LF9RE:-=-R*_RG:G5H,P$G'1![`0X"`%B9FXHDJ))7YZ150#$C71\69, MKPG;M0LS09;BNA4G=\_IS#!&P9#9Z8+)1B*L`D/!2,R$%952A'6N8$A85<$0I@O&[O58 M%5W@7!S8?@H,9"5FR$8!%&3[:W`5FQC3WV1,%Y-9RR@FFLJ%@T`*#(%(S`2" MC["!]'K]JQI$3U8/.DR].S@:V*X]394O#SH8XLCN4&4F#B/`\8+T>&A3#4II M3IB)PG:;PDRL@$L MODZQN]A,'(XZ][L5K-+!-RJ0+*>L=:/*-DMYJEP>R1UC""2[*\JJ/;/_LJDW3T^'J[O=UW@> M8X6F\=.'C*?C(@>3VR4=&&G&HJCA,,GNC)IR;!K'V@M5CLWB6"L>ME^3U+.&\9Y[2U8.3:*8^UO%VB.S:. M8Y[/Y6)PN^SN5TU"\`@/L;G\%Z"/YUW.)RU`T/6V7(SP.6Z!8"0^J/&\@38> MEW@CJ%,\GO!&4*5X1N"-H$9=!LLY4H[O#9PY&(E?/'DC8(WO>KP1L,:W*-X( M6+N?LYQ/P<"M(XS$;P`\;X@'#]V]$=0KGGA[(ZA7]W.6LY@#]YIB)+Y3XGB; M(0=XC<,;00[P@H0W@AS@O0-O!)'BJW]O!/'@NVQG9(X:Q9>SYX/>"+BYWI;3V>T2[Q!Y] MG)$9(L7K5MX(5J/+8#E!5>$=;V<.1N)[]MX(6./5=F\$K%UOR\D"N7;K`"/Q MG6S'VQ3QX,UH;P3QX$UD;P25B->!O1%4HL]@#-;XJ9DS9PQN^`&7,S(!-_PN MRAL!-[3/W@BXX6<\YB/X'/S(U!O!Y^`7GMX(:@<_B?1&4#OXJ6$YLAQBE;C9P?$RMP%G MQ91S5D-<.9S%XHW@RN&4$V=DA"N'@T:\$60'!VAX(\@!CHCP1A`ICC[P1L`- M/^EW1L9@@%^J.R-#,,"!5MX(KD_W:TFCPRV5=@?5WFBDPP+&+SN=4^)SN]TXVG@IUX$:*X_HPQZV#"KGN'G\: M;ZL*=8#CY!P&0UR%[@;,SAEB!>/TLW(.SE%?NE<'$SS[5;RH[B2O=P9-\=W\<=Z^XC<`A[;LC#F9O__<1)_%O<*SM(![/\[#;'=,?R.A- M/MO_T_\$````__\#`%!+`P04``8`"````"$`)3K#'*(9```,E@``&0```'AL M+W=O";%L#W1 M(NM\KIC=O5;+M*UH2W1(ZG;/VT^"0#(+^%E@T>N;EONKQ(]#`@E4%HM\_\^_ MG[Y=_;5[>7W M?;C^]^[U^I\?__N_WO_8O_SQ^G6W>[LBA>?7#]=?W]Z^KV]N7A^^[I[N7]_M MO^^>ZA@B]W3_\L>?W__QL'_Z3A*_ M/WY[?/OW0?3ZZNEAG7QYWK_<__Z-^OWW>';_P-J'_P'YI\>'E_WK_O/;.Y*[ MT0W%/M_>W-Z0TL?WGQZI!VK8KUYVGS]<_S9>MZO1]TX]4AU;?_KW=O?Z0"-*,N\FW_=/_:9NQ4=(:$Z-! M?UEC\6Z^'$W'%XA,C0C]/2'BJ7UF"M)?4_!6*O>4H_X=>DY_N<+QH((+4Y#^ M7E3ATI2COZ;<\MUR/+J=+JD)GH;24CTTE/Y>5-^M*4=_N8,=MW@J'-,LU)-" M34?M\=6[U7P^6ZS.M'5\G$_TCXMZ.>99I/YQ43_'/'74/[BGPUPYYLFC_G%A M3WG^J-5V64]Y`HTOG4%CGD+J']S3@3[E6326:>3WZ8V.%(?`L[U_N__X_F7_ MXXJB.7GV]?N]VAO&:Z7&(4?/J&,0ZHM!%'R4RF]*YL,UE:?X\DJ!\Z^/B^7\ M_C,T=VHQMBPU;J,BF9+R"Q`6I"S(7Y"XH7%"ZH')! M[8+&!6T'W)![CCZB-?0K?*1DE(]X=.\8B-,FCD/8@HML71"X('1!Y(+8!8D+ M4A=D+LA=4+B@=$'E@MH%C0O:#K`<0J'I5SA$R=`6;2V:A>V!.VVCPI*L+-MD M@E(`"0$$@&)@21`4B`9D!Q(`:0$4@&I@31`VBZQG$:;PJ]PFI*A8$G1 M7AP"H>WT49BW(65]<`X/ZITFR^EA3[IU5L[Q8M>7RZ.1U1!R^`4-4=9V0PS1QW:U MN6V`;($$0$(@$9`82`(D!9(!R8$40$H@%9`:2`.D[1)KX.ET=,'`*VM[X#6Y MI5C>6;"KHY,/!XW-T8@GSA9(`"0$$@&)@21`4B`9D!Q(`:0$4@&I@31`VBZQ M?$$'O`M\H:QM7QC2601`MD`"("&0"$@,)`&2`LF`Y$`*("60"D@-I`'2=HDU M\'3;=\'`*VM[X#6YG1X/?QL@6R`!D!!(!"0&D@!)@61`'7[?,'('\SMH3=H)D,/9`LD`!("B8#$0!(@*9`,2`ZD`%("J8#40!H@ M;9?80Z_NA[KWIOZ]7V4KG%EOT/2V,_;:BI!L!].)<]^S-057%`B/F\9T*B># MPZ81B!7O&B&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'4&J1'U?:8NF'J>DQG$]ZI M/-/;U\>'/^[V-)SD@1.>5"IZS:#) MT9$;E=53BY2<=W31B>6GK5;=1;I8.J?WP&B1E3CR*,\H&E1C+%K2KL5J9)\2 M$[%B^53D&66"1`OZF(N66"U63D:L$"N6+T6>425(M*#&6K3$:CQQ$@Z-6+%\ M*_*$[`6O[MNZ4^?$PJ;'!L>5;6[SNG-$H^[NV+T7-&E`0('*\:J))$?)$%&$ M*$:4($H198AR1`6B$E&%J$;4(&HM9+M"WX`I][VL%67,[3"-[7)N+E;,U M;E0JB@9^8FV-N($:*_%TP`4%A8@B1E[YF*U$*T&4(LH8>>5SMA+Y`E&)J&+D ME:_92N0;1*V%;%>K>^4+7&UNK:6Z.Y6^(B<>]F5.V$]GX&I3\$RP-EKTYSAM MIE,(UL;*&IF9$V!#;I/1:'KK/"Y+V82.R[*N<#(.&89ESPZB_SRV;]/79GFDJ6W)!&%3FSDS3R`F#,--,06ND7$=LU<-3%5)EC0:, MR$7B09QI4#`R!<_%/%-0GN@EIN!*';G^^C@=+9SS9,I-ZEO*A_-6-JC^7+1D M4IDF>7M<8L%J4(TU%Y0>-P;U]KCE,GT]MJ>4R@-UIY2Z@9VNU*=M3MVS=H^V M.H-$H9('XVZLD1/'9FX,/+VN&0K*5@-JK'F@M+CAE%?CULV&!2P M)FXN\:?2(P<5.XX99,6QQ4R?3VV0MN$IJ@5VORWZ@=S9Y8I!;KSDX6U,5;JC^QP.*5TP>GR&!L#4["# M0M'B,8\$>>1CU$H0I:+%\ID@CWR.6@6B4K18OA+DD:]1JT'4BA;)VWZEY6SY M]>>"BE)QW*W13-)KFXE&_IUC:ZQ6E(N32>'>^01LI4/K]$10T96MO',K&M2D MF"OS-BEA*SZ@WDXF3LH_91-OH[)!CJ]2M>_0:S^79P;_VWVF"GCN'392,,Y$U MHB7$2W-CK-2JDD'%N*4+3B4F!Z9@!X6BQ?*1((]\C%H)HE2T6#X3Y)'/4:M` M5(H6RU>"//(U:C6(6M$B>=O?*H';]?>9_V5CO9MHM.IN?XN5D\_>&"O_ MO=366$D:.@`2`HD&:<=0+@&2`LD&:>=0K@!2`JD&:==0K@'2=HGM7I4`OL"] M.E_&U=#MI*"T:`:8RXH-Q,)([/C MW#:JRYH/2X8=37XY8-^GIL3RE: MZ)=,*67N[`0:.?=)[F?!)J:@-4ZX.1@M"4B!*;CTWB*$;"4%HT$UQE@P8>2M M,64K:G'_;I<-:D3.6K(G%@:9^Y3Q8E\TR9._-,(R=T.?2M1V)]^9P[?.ZUJS3"/KINJ(/![8 M3K15)_,3(`H-ZLA'@CSR,6HEB%+1XM-1)L@CGZ-6@:@4+9:O!'GD:]1J$+6B MY=Y437])AOF@8N]H!G6300:IH"?+TEUP6V-E9W'<)$?`5E8TB5;>-M4 M#6I3S5K>-C5L989I-(*\#UOTM"//(U:C6( M6M&"$$5KW/*W?^N9*G/'KP;)1_\V;"5HBRA`%"**$,6($D0IH@Q1CJA`5"*J M$-6(&D2MA>RUIQ*QJ>:M1]/T&0)YINC97]HLG,>7(?B!4' MZQ!1A"A&E"!*$66(Q3;&JLS+YJ(%7LM%'E&D2#/ M@H]%2ZSP11.Q8OE4Y!EE@D0+/J.:BY98X8LF8L7RI<@SJ@2)%M18BY98X8LF M8L7RK<@3LD.TRNYTI\Z94Z-.!EES1"/9"S=TOC],D>ZA$5"`5B&B"%&,*$&4 M(LH0Y8@*1"6B"E&-J$'46LAVA4K@7.`*G>^Q7*'1DDXGQ]MQ?-&$`HARS[G\ M@K&2?&'`!06%B")&%">.C8"I'+.5:"6(4D09(Z]\SE8B7R`J$56,O/(U6XE\ M@ZBUD.7JF9M.\J^Z@[F]GQID/7'#%TVXH#]8LY:5X72S.`%;62,#J22VDI&) M!C4BYH(4*&3:N(U(V$J_47&[;CQ>W#H/LE.VH&[*7'6ELT$-R$6+ M&U`PLE:MN])*MI*D;36HQIH+2I<;1KU=;MFBK\OV#%*)I.$[V4R9.^%-(R>\ MP0PR!>E/OQ^V1K[[`@DC:VZX(QRRE4R]B)OJK3'F@G(WDAAD'G--IA.G+RF7 MZ5NB.@<^J/Y,O%$E92N)H]F@&G,L6##RUEBRE=18#:JQYH(RQHU!O6/<O(\W,11*DX)R&-NA\0F&GD#YI; M8W7F;1&V,G'T1`31E=F?,W!C4S2H23%71MN,G-?<.ZJ$K^1JT&42M:$*)4#O:"NS*3LI4]]&ZFT9D7 M0XS5F1=#C)6DC0,@(9!HD'8,Y1(@*9!LD'8.Y0H@)9!JD'8-Y1H@;9?8RUDE M;"]PK\[O6FD;C9S;(B?%MJ&=:$#ZV%A9MT5&WAM#0RP8#:HQYH)RDY`P,@%S MNG">_Z9LT!Y:/&Z+AAY>URR57?7&%)CS06EQPVCOAZW;-#78VM* MS2]+4Q_,[9W`(.?^Q\FG;;B@-4ZP.;"6!*2`$6TNBH(:/@#E\UJ`$U:TD#FK,- M:+E07P/L2453[X(X-5?FSJ32R(I3>4:8,LVFA0 MC3'+2\&$D;?&E*VD8#:HQIP+2I@H&)DP,7&?HY1L0+WT32D]"/XQKEE+ZF\8 M]=7?LD%?_?:,HH&S9M1/W7O-E8HST31RHI=SZ-YP0&E.VDAJS037F6+!@Y*VQ9"NIL1I48XT%&T;>&ENV.M1H MSR:5!!U^CIKKG&GW'&50Y_YD(\BSGK;&JI.."1"%HL4'C4B01SY&K011*EHL MGPGRR.>H52`J18OE*T$>^1JU&D2M:)&\[==?DN.=8X[7(#I9<8\V!OD#X]98 MV:D5-_40L)457G`_TNWJ;&31H$;$+.]-/21LU7>N3-F@+V#KD_2@)N6LY6U2 MP5:Z2>/9W'U=HF0+;YNJ06VJ6[HEJVZ&N3/67=9+&[L0W+ MT,PQB6R0%:*T%2'/*MR:@MT,#:(0Y2-!'OD8M1)$J6CQBLL$>>1SU"H0E:+% M\I4@CWR-6@VB5K0@1*EDX05;C\XM6EN/0?+1N\TAUM$`:(0480H1I0@2A%EB')$!:(2486H1M0@:BUD>^ZR/.<<\YR, MNJO(6`G:HE6`*$04(8H1)8A21!FB'%&!J$14(:H1-8A:"]F^4(FL"R*:SGM9 M$4TC9ZFXWZ@]/UK)4@$4H%6(*$(4(TH0I8@R1#FB`E&)J$)4(VH0M1:RW+.X M+,%W,+ M%RR5A3)W?*%1]\>HC%4';1$%B$)$$:(848(H190ARA$5B$I$%:(:48.HM9#M M"Y7X&1ZV%CI/U`U;!LGCK0V0+9``2-@E=A-5WN&")BIS9[IH1)]2YYBY61R1 MYYB[-5;6NW4+][MK`[%B^5#D"=F]^24WYPN\.3?(ZJ2VZJ"ML;+?.[MU/A`8 MB)7TJ*ME]\B]=_-_BGJ!]V@&66GNA?MM]AMC=2;5P%K6S1VD&MC*GVI@JT,B MVN[S9?B6]J5CWGEQZW[U(!>TV@D95V/5S;@R\N8&0[;"W.#"O2DX MXU0\^1\4/ES?=AU!:0+GN\N-U3FG:OG.9]<#4W!E$A#XL"ADBVX#NJ_GV`YU MC])N`F+0ZZ`+/&$;9/D9'N%PN3-NUNI+>6(5F(+\D3UXO!$:`YH:,LWZ!T$= M)"^(M/K<:6T&&G6S+8LC.MV"0[YL:ZRZ"6%$H6BY875YV?GN8&YO$@8Y0R!:#YNN2K"YPU<'PI?N=>B%;62%H M+AN!%8?5&YT_YW8\$1VT'+? M6>MXKCHHV%_9)$BF:7KN0(A"T8(=R#TQ_9P#\2"EOB>1?&IM3,N1 M\]&8C;$Z-XV-%L6%XXJ%'SD+N$8]LT]\9UC(%L,BVKFSU;"'.S3K8&YKU#UN M&*LS#W>,5??A#J)0M,#9ZE`S_*2TU&>@[DF)42>=A&B+*$`4(HH0Q8@21"FB M#%&.J$!4(JH0U8@:1*V%K,BI%L8%OCB8V^<#@SK?-[5!M$44(`H118AB1`FB M%%&&*$=4("H158AJ1`VBUD+:%S>O7W>[M^W]V_W']T^[ER^[S>[;M]>KA_V? MSQ1HZ$-.'7SULOO\X?IN>;M67J6E=2Q@KJQ&:U7'B2OSQ5H]R3IU94E7#F_W MN&KS%5TYW#/!%6H!I8Q/J"VH!93`/'5E3%<."0%7;;9N#TDPEU.33[:8&GRR MO=3OT#?`K-67N>!PT?>YK-57L^`5^G:6M?JB%;Q" MW[5"_3QU93.>K=6O$V,9^H'BM?JM8;Q"/S>\5K\OT#>0T>@<]C%GK.E;KNC**37Z8B[JZ:DK=U/EZU/.OAN/U^IG MW$^TC:YL3E[9TA7U`_18AG[JG:Z<4J-?IZ?1.75E.Z;%03]EC6KTZ]]K]=O> M>(5^I7NM?H,;K]"O:5,+#E=NC@/W^O']]_LON^+^YV?:#N[OOJZN_^THY\G':DG]Y_W^S?^'ZKZYL?^ MY8]#B/[X'P$```#__P,`4$L#!!0`!@`(````(0#?7'.'K18``*![```9```` M>&PO=V]R:W-H965T:*T>: MLGTJXOU:6UMG=Y\5>6RK8FE'_=.'R_F[V>7%[NE^_^GAZ[IT]W MW_9/NP^7?^U>+O_Y\3__X_V/_?-O+U]WN]<+4GAZ^7#Y]?7U^_;JZN7^Z^[Q M[N7=_OONB8Y\WC\_WKW2/Y^_7+U\?][=?3H4>OQVM9C-DJO'NX>G2ZNP?3Y% M8__Y\\/]+MO?__ZX>WJU(L^[;W>OY/_+UX?O+Z+V>'^*W./=\V^_?__'_?[Q M.TG\^O#MX?6O@^CEQ>/]MO[RM'^^^_4;7?>?\]7=O6@?_@'RCP_WS_N7_>?7 M=R1W91W%:[ZYNKDBI8_O/SW0%9BP7SSO/G^X_&6^'3:SRZN/[P\!^M^'W8\7 MY_\O7K[N?Y3/#Y^ZAZ<=19OJR=3`K_O];\:T_F00%;Z"TL6A!O[K^>+3[O/= M[]]>_WO_H]H]?/GZ2M6]IBLR%[;]]%>V>[FGB)+,N\7:*-WOOY$#]-^+QP?3 M-"@B=W\>_OYX^/3Z]ONY;5X,%*7%_>_O[SN'__/'IRSA"V\X,+T MEPLODW?KS6PYIW.=*K)D$?H[(1(Y^XH+TE\I^&XSG]TL-W3R2#DZ>KAD^LOE MYM0;(@42+D!_QQ-=K]>KY/K(F2B2AS/1W['@?#5+3'0BYR-O#L7H[UCLE`N[ MX7+T][0+FU-SL[5OVIVMX>5),9R/[8;^9RQYPK7-I&_U M.^IP1N47(_/ADNJ5NM8+)8L_/B:K]?NK/ZB#W[/-+=K,?8M4+$QO-K)9"/(0 M%"$H0U"%H`Y!$X(V!%T(^A`,#KBBT([QI<;P=\37R)CX2F1N!6C`%T$PQ4** M9"'(0U"$H`Q!%8(Z!$T(VA!T(>A#,#C`"R;UC[\CF$;FPR7]UVFLB1^]6VMC M;CAJY)NDH\D882`YD`)(":0"4@-I@+1`.B`]D,$E7K`I&?P=P38RE%SH%J.! MA-3`1K%HCR9CM('D0`H@)9`*2`VD`=("Z8#T0`:7>-&F2_>B/3W,D71KK`]! ME6#<,ID=B"#2[P8TK#HC!@::S^&EJSMF-3<"%,@&9`<2`&D!%(!J8$T M0%H@'9`>R.`2+V#46LX(F+'V`V;):KP]IB'(0I"'H`A!&8(J!'4(FA"T(>A" MT(=@<(`7(QK\>C&R([5W9J3^^O7A_K?;/258&H9,9(XE904[3C,B?NB8+#1V M(]%LL5P$HXO,&JWH?&-:7]T$([Y\-))N7@`I@51`:B`-D!9(!Z0',EA"0W;R MT(NVF4'\^^$^J/CQ%N0$7)$&$R/.5JODD.(7L_ER3."'NLW58`RW*@LJ$55: MT`S<23FH[%H-1*9!F591Y#(ZU>*3!9.`7@WD9(,J$_*KR8R[W?G+1.NG2:DT M?S.["]H_HZ7;DN?SP*F4K)ZK(RB]I_*I6RYNPGJS5BL8"HU6R"JP* M\BGJFI0K07K"6K3L"=?7 MZ^OKFWDP<6S$*'K"5M2C5IU8J0^]R+,/R\5FL4ET*'^X$PQB]):Z7\_4F=!.+O!2:K(.^FYK5)=,:CJ10UO)!E:=:(5C4OONS1[=[/R.]L@,EY( MG)/Y+`BGD#9AZAZ MJ3YH)X(3UL$)5\ERLUA#`CWEA*V>,-IKP(?>]V&]N5G?;.;038[XX->SF=:> M4<]V%DQ^2*ANYQ8%"31P*F6K8PF4M;SZP@1JK8XE4-;RL@4F4&M%?LD%57)! M42=JMAH3Z`J:PM3YPY;=GA27[B27>M^EV;OKP*5!9+R0."[Y+\^"W"=8WXA/E@[H_V M&#GW="`9D!Q(`:0$4@&I@31`6B`=D![(X!(_9&:^?GJ36]CIO=N+&2UOQ@R9 M*HK4&E(M6">5:E6FJU7@5#CEJM1+Y1>4&M M(M6",W:JI5:K63!+[-5*Y`>5)^37&-UWSJDQ8QXT8C>5J M):X7C!SY$E&E!34RZU4P+*C52N0;U&H1=5I0Y9-UL`[5JY7(#YZ6'_CSU@P6 MN&;`R(E,BBAC1($7IW)$!18L$55:4,.P7@5SR5JMY(P-:K6(.BVH\DD"S=M& MPKF@P=/RHVQFC&-&^+O"@#RA86.4[EB`I&CE:)J-*"&H;U)AC(U&JE M40:_6I3OL&"/:/`*^B$U$TXWI#^UNV)^_A1&VB(G.BE;.2AC1-LIZU603_29FKE1OK(`(1G<,X`;L&3,XJL MWA3#Q9=4K&@*,5K!S2<3*Y7/$16(2D%1^4JL5+Y&U"!J!47E.[%2^1[1X"&_ M+LS\RJV+GVOU1B7(+Q;Y"Q=)D%-3,Y,U!>DN&JLBMJ)AE5K!A):U>"UC8C^C M$(OHVT2#:I$3?H6<-QVF[@&!M\A?>TJ"`7_* M!4UCB=6%U:*$(\'*I:"B`E$I*"I?B95JU8@:1*V@J'PG5BK?(QH\Y-7%\KRI M]<'<3YN,5JZ?21(,^%,I&$T/F6AI50`I@)0G:5=BI9VU9D31,7F&YF_A#*X1 MBZC;K4A'K3JVTC6('LC@$K^>**%X22P^`C$](TA6C%;^""08S*9L=:3/B)6V MNAQ1@:@4Y#86&.!4;$4_29`N60OB;?;-ZF9Q$\SZ&K&AP??;_;T]R85.K/0* M>T2#A_SZHK;@U9<9I2ROS6,?4S]VKJ2@MM4"42GH2->S\A0C[7J,;->;SY:K M9!:D]X;%_5WK<-C3GN1")U9Z.3VBP4-^-9K)MSO>.Y(J[5S=7?HTET%=T!W7 M*8HTTHRMEKJKE",J5$MB7"J*R%>H52-J5$OD6T41^4ZMI&"/:/"0'WBS;.`& M_N?ZCU$)AA@6F1'EF"&2)/C53$K3A4/!:![)Q,H;H,/,C*TX;4W-S,0B>K92 MSA:UJL3*S9M\R;S-/;WK?)(/K:A'?>C$*AJ7GJWHCYV9A;N?`QN\F#WX2.HTYD%7M\N,7+C4+`- M2K42^<'3\@-O)O7N^"J>7=$V9@'S=LB)Z3I"E#&R(NRM7)0 M@05+1)5J:1APHU*M)`P-:K6(.BS8(QJ\@GY(S0S2;;CA..^DQ\!6=A[J3M08 M>9'FV:KFEHRMJ,KENG-$!6J5B"HMJ)'&C4JUDC,VJ-4BZK!@CVCP"OJ1/F_N M:WY*&39>GOO2_$.S;A(LM:5<\,A:A5CI3#Y'5"`J!='(<70"[FV56*E\C:A! MU`J*RG=BI?(]HL%#?EV8*=R_W^IY5JM>W)IU)*JU8#H<;E2R57S!+!,K;U8$ MTV$Y(R^4XT-.A5A0!GN[QDHY6]2J$BOMK[7(\T;EY!,DC1A%U5M1CUIU8A6- M2\]6/!V>>'3AF$M^@_E[IL/TL"5TZG'N*_DH9:LC&Y5J)05S1`6B4E&D/51J M)?(UH@91JR@BW[$5S3U$OD\&99'9)QB[10(; ME69AWW1H^C-:0;K+Q$HS08ZH0%0*BLI78J7R-:(&42LH*M^)EWP MNX-6I*,7U[&5KD'T0`:7^/5TWGQ^A?-Y1B9U.O44;E2RU;$^8^7=W1(IJ`VQ M0%0*IY%?L\+'[!.I6"T;69LI6TS!U(`*4_2 MKL3*[7G6=>YY]"C\)DR67.C(G4VDHQ?7L95>7`]D<(E??>$J1GPTN,;E"D;N MKI2BR*T@8RO:>)"!;(ZH4"VQ*A5%Y"O4JA$UJB7RK:*(?*=64K!'-'C(#[Q9 MDG"'X3^U?+2V"QONZ)Q1,#H/]Y79ZECVL_+FQR5Z3X>)M)R11P<3$VFQB":L M\B2?*M%R?LPAR#HP_21Q(T91']J3?.A$*QJ7GJUH,<7L*T\\PBHR;[GD-YAC M*R^G[2NO<>F%D=>#>37&G>+!8"[C@LY4-$=4H'RIR&E7X;9UA5HUHD:UI".V MBB+R'6KUB`;5(GF_0L*5C2.I$UR"=X+DDI!74O)$.6( M"D0EH@I1C:A!U"+J$/6(!@_YT3YOJ6&-2PV,:"@H'2U%E"'*$16(2D05HAI1 M@ZA%U"'J$0T>\N-WWA+`&I<`&.DX+062`F!#"[Q M0I9,S<+/GAH<5/S.+4B'`*DB[>]XPV(KLT\Z9@5\6:):24,O$)6(*D0UH@91 MBZA#U",:&-%^2'AW2J9FU.<''V?7!V&J#S?X;.4-A\+;><8%:67:#(?7.H2:KE2+3Q;L)-5J(,J-*@MJ%45.UJD6GRRXS_1J(,J#*A/R MNPV%T;LOQL<5B3$/^H=%_A1@&40@Y8)'I@!LY:Q0Y(+L<'NY6B;A(R:%F+PU MLCVLW)8G>5"IE@2O%D3CI[$?+U?!JEPC5E$GVI."1SHL6^D-/Q=YNV6YN*&?S2^"1>Q";*+BI?@>M:I4 M2\)>,S(/%<7JWOI^9('E)"=T>V,>='N+_&Z_ M"=9\T\1:'>OVK*59/N>"](R"R7+SV6PSGP<_H2C$ADIKY3A7S/W^%!!#MT*5H1ZTJU9*HUXR.=7OV,RK?GN1$ MAT[T)SDQ:,'I]N=7/34CK]O_U#I@8E2";&!1D`W\3;N4R\4[0<96WAB`U7G- M#Y\R+:306QV`4X'5B3M0J9:V!W:`_FBFP2$`6T6=:$^*0H=.](*B3@QB]983 M?GL(5T6.I`)<^D@L?\:VNDXH M/?O=O!`7HFFQ/,F%2K6D@FI&QW(S.QIUHCW)B0Z=Z$]R8M""TVW);Q+AFD_8 M)$Y;M%:%ISP[Y,N."[I([H@+E2T41^0JU:D2-:DD3:!5%Y#O4 MZA$-JA7V4?K,X<3-\OJPV3R1)\W-Z1"V7PX%_?LC(]H9E8M($66(D3FLY!F6&"OT39M^YE'^^6YQ]WSEUVZ^_;MY>)^_[OYA./& MA&S$]ON2M^MD:Y;Q*4QP9$-'#ONW<.2:CAR6U<,CFYE\KC(\LMK25YDFSD*G MGSP[G7SRW',Z-[VW=$)I?D-'#C^B#\^])#%[XPN.T#-#Y-9AAR8XDB6SK5F3 MP_/04M/$+K4ENS](1':!&)U*:.T/<]?SDTTN#\M_3=SRG[V\66OMN& M9[A=TB5.\%]66],_L``]C;4UO^?'(_0$UK:W#R@$3M$C0MO>/NL!1^@"[>,* M<&1!1Z9](">@=K6DQ[0*]Z<*6W5.9VLDQ*1]+)(_1$W]8\KX?GH8?)MN91 ML:DCU``GKY2>T*$C4U=*3Y30D:GKH4<#M^9)$CP//2&X-0^4X!%Z"^G6O,<. MC]#+2+?F=79XA%Y`NC6O%YTZ0BV$UG*FCE`+H1CTC'9GRFEXG M2$>F/$CGZZUY*S]Z0"_FWYIW[.,1>LT^98^I([=T/;?3YZ$CYIV)J$:OQ]V: ME]].':'V-AD#>G4H'9F*`;WNDHY,Q8!>STA')CV@A#391^;41^BK1>@9?6QI M:[ZGA$?HRTA;\_$C/)+.%Q3IJ79(WY"A2$\=H2_"4*0/1Z[&=$#?1_Y^]V77 MWSU_>7AZN?BV^TPWW]EA'/-LO[!L__'*;W'[=?]*7TBF`0Q]%Y:^A+VC+]'- MS$;YY_W^5?Y![EZ-W];^^/\"````__\#`%!+`P04``8`"````"$``RF+@>4+ M```E.@``&0```'AL+W=O#]`7R`!)3E*H*_:E5:KL[O/#.DD:`(=`3.9^?=K=[FZRG9S&\UY.$R^ MMEU5OE2Y.N'NSQ^;]][W:K=?U]O[?C`8]7O5=E4_K[>O]_W__)7^<=OO[0_+ M[?/RO=Y6]_V?U;[_Y\/?_W;W6>^^[M^JZM`#"]O]??_MX' M]4>UA27]:I: MU*MOFVI[,$9VU?OR`//?OZT_]M;:9G6)NO,!)KZLW]>'GXW1 M?F^SFA6OVWJW_/(.Z_X1Q,N5M=W\H,QOUJM=O:]?#@,P-S03U6N>#J=#L/1P M][R&%:#;>[OJY;[_&,S*>-(?/MPU#OKONOK<>__N[=_JSVRW?O['>EN!MR%. M&($O=?T518MG1*`\5-II$X%_[7K/U_ZY MJ/8K\"B8&81CM+2JWV$"\/_>9HVI`1Y9_F@^/]?/AS?XUW00WHZ#\03D>U^J M_2%=H\U^;_5M?Z@W_R,ILF6LA&0%/LE*-!F,;T91<(61B(S`9X>1$Z/'I`B? MI!B&;O03BK#`9O'P:16#BQ0GI`B?I!@/;L?C>')[`[9.C'A#BO!I1[QLJE"O MS53ALQTQ#L#4H$.37$VN+I:' MY0K6GE$,_=]<`$DY!YJ[?O# M)+B]&WZ'^EB1S).6";C$W$I@,:#9A02)!*D$F02Y!(4$I0>&X);6-U`SO\,W M:`9]8U?U9(%S5B@<826LRD*"1()4@DR"7()"@M(#S!%0][_#$6CFO@__]Y)D MRE?^9&1PGW1"7&3>BK3>4211)%4D4R17I%"D]`ES$NQQO\-):`:*$?8OYP!5 M2B1TRDNM2.LE11)%4D4R17)%"D5*GS`OP929E[I/0[NMH'3C#+N()R*C9H^Y M$9G1/O1\%XY:(381>46>G#89JZL ME,84]XQ%W#5CX1HGU?I&HT2C5*-,HURC0J.2(>XB;)W\]O%TT02FTX+#S:[F MB9`HFXET@U$$*:NX<(H6)1JE&F4:Y1H5&I4,<3=@X^2[X1?K)S`-&/,/(9XF M\N"SBJ[)7&B4:)1JE&F4:U1H5#+$_8--D_1/.![\0B%1^^5G$"'N(7'YF`>M ME$V7A4:)1JE&F4:Y1H5&)4/<0]@P^1XZ4TC47_EN,$@4DFBOYT$KY=R@4**E M4HTRC7*-"HU*AK@;L(.[P@W4\/EN(,2R(7(]H#F&\7Z!)Y5?+PHE6BK5*-,H MUZC0J&2(NP$[MRO<8!H]MFT8!$V=C?,)K MQL;LBC53'^>'WJ#86[(DBT"21)'4)WR*D%373!'%Q:%O4`3'F>N'(GEK@+1$ MQ1#FVDI%LHU>D%04MNM-+(J:VU$\@O_X09I:":CY3M-\O=@:71$2ZJ3\D!@4 MPH+:X2:1O!`$I`A'72O5L5Z2LLR7C]GG%DAMQ M'F)"(L3R'D!29T)L;7DAMLB$.`BB*Q.)@W?E;*BS(ABG(J:&*.X6+!!(L:R=P^-U+D8DRT_ MQH2HC,?Q:'HK.N*4C$>7A;BS_YHT-YG#VWKU]:F&PH,H=G0=.(DF-(^A[KT( MB?H60.C%AF9G<,PVCSRV.I=O:"&*B\@;!/G6 MGJLDA2EX:G5&,;II%1-2]%#J;(%Y/G5L3_RIXQ4CO#J$U.1X6S3>9F&1(I?E M!8.DSN4RV?)SF9#)Y?`V&`4W([$UI'8.X*-.%W)/R.8(/1&,!_C[G2:9_ZH_ MCB4S#-1FLVZ:0H-8<%O4/3/:M(Q4Y-K)A&QY*&7F^9*P*_&#VU&'_M1-$P.] ME$W")PP,M@SL=60D+T%.RBHN-$HT2C7*-,HU*C0J&>)NP+['=T.3X[]R3<0- M258N(7Y(R?N157217&B4:)1JE&F4:U1H5#+$/82]C.^A,XE"+9.?*`9YMX`Y M;*_H+`\M-$HT2C7*-,HU*C0J&6)KCJYKR1IQOFD3\BX&BBP4211)%[;(* M;A*36!SFA9.RMDIFBSL+NZ3+:P'N2Z96-QA$B=EIYX2\LQG M&N5.T7EF'(L3LG!2UGS);''/=+5[_@EY4;L7Z7:/D+>BN48+0K'KD1*-4JV8 M:90[1>>=22S2LG!2SCMF]F:JW#O8B5V1-Z9Q\P];;+JA[C`UVW9E/!:3FI,4 M'G>ME+[56EM>RV01M?_!-(0_UA%MKY4YUC$U?4GFIF#]DEM%R',WJT@<@P5) MQ7%SL9X,8G&W*:V98^-SCV,/Z'M<=FR7Y:/I)%D@#(I]%X_'LNN)2)$M6;U. ML5)^UAI%?-+Z:B(K/R5%O)"U4I&<1&;-NSCG%KD1"T+PT?P)S6`BXEZ2`!_, M6POW.[:EOM]/=PN1Z6*9@]OVUR;0G*3.7'=(RKO;)!JESI8UGVF4:\5"HY(I M]&D>I]/)`WM-*:.38^=WA7'W_]^:-[>+A-H8=%OG5B+FS62E7?0DAK+%6<1(+\RE)\1+4]4ZS=V'.]8B%&Q$C'PQNQ$9< M=@[FK87[_;K;`9R-JB,RR+\!D]2Y>C>*D"8V\Q)2]%#J;%FI3*-<*Q8:E4R1 MN0$[M2OJO1'G%P9"HMY%3S8GJ3/U;FVY1$@L,O4>33M>:%J18_5FZMW-P/HS MMXHL^56]DU1;[^I\MV:.C<\=+J\MOW2^0[\HTY&0J'=Q)LZM(ENR5R.FWJV4 M5^^$X.J)U8=1$%MZ:B5.FLZL:1?BW"(W6D&(SO:;@6P8RW.#<9_#E*Y))/P6U#IGHMN0+&YC_B=*2%\8]C&>B+?'LRM(LL([3`R[_:LQ)HW M.V0\NM&_@+$B)VUG;@8V&+E%_BVZ(TW-I-H;42@[I'/C\SC(&Y&,PX5IJF]* M\$TBS%POC^8.N=AT[*9&T[%INO2L&O%V;XWA[&5D]NX4E38NK)%)XT[R'EDP"^ M>05_3-=A+0CA2;--*IT(GD2=.C$\:=[M*ITQ/&F^6J6>3.!)\U9'-/I%W!+IU?`*=T^&<&,FC]O%#."MZDS?#.FO04O56?XRK3K20A/NOP( M+]3@29-,Z*SN?P!?E'KML/6$8.T9_@B!VRD,(NT9^C&>/D*9Z&4\PI:?. M*<%+[1F^>M0Z"WB"KZF[GH3PI&MB\,82GG19@[?;,WQ3"=:&;5S@2WH?R]?J MG\O=ZWJ[[[U7+U`VH^;WCSOS-3_SPX%^#_FE/L"W\YI?2;[!US$K^&+3"/_T M\:6N#_8''*#]@N?#_P$``/__`P!02P,$%``&``@````A`%.\-+1C`P``V`H` M`!@```!X;"]W;W)KL)FOWA0CW;O/YT^K(^*,H M")$.,-1B[192-DO/$VE!*BS&K"$U6'+&*RQAR?>>:#C!6>M4E5[@^S.OPK1V M-<.2OX>#Y3E-2<+20T5JJ4DX*;$$_:*@C>C8JO0]=!7FCX=FE+*J`8H=+:E\ M:4E=ITJ7W_8UXWA70MS/*,1IQ]TN+N@KFG(F6"['0.=IH92$-2?[,$X6$S1=':;Q=.*V@`3+/%FQ=G1@:Z!;XH&JQY$2V#N(M,Z^EC? M"A5B5"3WBJ7E@B@$U.=I@]!LY3U!3M,39JLQL"7.&!,1=PB50$6;#%YXH+<7 M#:FP14^@J*^7H].HG$R-D]`4L+V$!"8BOD1,IB8DN81$J(<884P^$H9R@OX9 MIA'->_XV;UN-@7+VJ;:*$=]$)-<01A3PF6$QKA=!@=\30/O^( M=N5D:0\L<5N-T>)&T"&6=L,,#6::D\[\6OT,_>I^MP[/VQVDG&S]YP[56T!C M3OIG5F5BP[JP#K&DL]Y4'WU$O7*RU5N'Y%9CM'K8OV9VXZ%UZENE28;6MQL' M+GLC\]VVB`U$%,XOSAT#$$;SZ+SM==OH`4/?OQ7A M>Q*3LA1.R@YJ>$"PE_JW>K#9JL&F'4UZ`\P5#=Z3'YCO:2V]OMF(2)HGTL8((D<*_Z8P#GC,ENH6:??B;=_`<``/__`P!02P,$ M%``&``@````A`-5;")9T#P``Q&@``!@```!X;"]W;W)KV@4HV6^`1Z@,%@'FM7XE2,3N+`=G5U M__LA14HVKV@>.YMVE_GQBCJ\I'A$.?KRRY]OKU=_K+:[]>;]X3J[G5U?K=X? M-T_K]^\/U__YM[B97U_M]LOWI^7KYGWU__^W+S\WV]]W+:K6_ M,A'>=P_7+_O]Q_W=W>[Q9?6VW-UN/E;OIN1YLWU;[LT_M]_O=A_;U?*IK_3V M>I?/9O7=VW+]?NTBW&_/B;%Y?EX_KMCF\MZ M<7WW]4LOT'_7JY^[H_^_VKUL?LKM^NFW]?O*J&WZR?;`M\WF=XOJ)_N5J7PW MJ2WZ'OCG]NII];S\\;K_U^:G6JV_O^Q-=U?FC.R)W3_]Q5:[1Z.H"7.;5S;2 MX^;5-,#\]^IM;5/#*++\L__\N7[:OSQ<%_5MU=0^7(Y&Q_$?`YGL3B[!69@]\TWGT/EXF(= MS>'Z(.9S.(WBW*RXQM'-*=F\"#YGJ\FK, MW5.I:W+6!OG51NECF:SMPA\2ECT-W"5/=J MC-OW3>N8>3\WV,[JZ!>,?L'I%X)^(>D7BGZAC[X(SL],)>>?GX4?KDVH0\X4 M-*\<8V:#D:%9Y8C&Y65-^I@=EU:D<_EQ83$OFXIDHS@&;A:DWV506LR:NB"] MHQR1:+T^CM$T>7EH8J"K"7&LJQW(A;EPI?/'5J+ZDA:VCDFTL!L(.^YS(CYS MA74O?I65U2*?DQ[D0_V3/2@@(2&A(*%31*"UN0H=:YW6V,)48R)2ZQ@G4KE8 M%(<^[L=PY\I-^T[E.(,$AX2`A'3$R78J&$&?CA`H;"[5QPJ?E\VV$E6:C-?6 M,<,9-`O2$YTK3RD-"0X),1!VQ-QD=%*00_')[E:0T`,Q.42@LUG-7*ZSK41U M)E?@UC%E/^QO"M(+7;*4#:4G3Y\/A#TY&EP,A2>K2T@H2.@4$4AL31U98>&) MV5:B$I,%3.N81*IV`]'G`,ETY@K=2,B,023713Y4/BFC@(2$A(*$3A&!T&;Y M>KG0MA(1NB1*M(Y)"0T)!@D^$+:SJL5A==A?`<10>K(W)"04)/1`T#8$.F=F M67&YT'TMJC2YSK4>2DF-$>81E]IU-9^3D<-Q#($1B1&%$9U$0MVMBSB:2=++ MCLQYCF#M7)+U:>NAI-XN3@)A.`H?$9M9=476F&(L/IW>&%$8T2-"VQ$J;.@PB,2(PHC.@D$@IOS<[E MPCN+%`I/3$:;0:?5881AA'O$]4U34$\H<`B)$841?;HAH>8F%S^AN:U%IW,R MK-O,0:C.$F+IFS,]DIX[Y3C`PF,2(PH MC.@D$BIO+1-1OC23`U@P.J,5*D]6SFV6>8BP,4IT1G?U?:9G=4F64&*L MG:X<1YA%W(HO%O,DF MEU%X'(&/(S&B,**32"!\3IQH.L%[FBQ9Z`W_UD.)*V2'$881CA&!$8D1Y1'7 M^3?Y@MZAUPD@5/LB_YE'_&=%YM?60TFUL?_$43A&!$8D1I1'G-I%7)``A](8D1A1">14'EB0L&*)6(^J:=O5.3Q:,(ZM_D.%4$BBQ1WECXC%OGLZ(YGJ#"QG4#AB-VL M#J/&3][02W;Y@%B%<[**9[[4-=X\`5$VY9QT`A\CG)PD!$8D1E30F/@*93B9 M6%-"L:W/.G(^0&SGR@+'0V_8M?FQ_5N4^8QD6^>!Q,!G&.$8$1B1'G$=&VFL MPC%T(D:H=<1EGG&1C+A,NF/>Y@X:3J.9:@[M(?,Q$MW",2)&Q(ZCBNY)R[$X MEIG]8%48T2-"#Q+H;;4]SNWS-H'Z6F11,ME0]E!"JPXC#"-\1.R9U@LRE,18 M?%).B1&%$3TBM!VAXL1@GJEXQ&@>/23GIO`"NL@.(\PC?AXW]]?),I_C&`(C M$B,*(SJ)A+H3GYF>Q8N(OYQL+'LHF>'87^(H?$3ZS)J1Y:@8BQ,9#MNA) M^(FYW-:B$=*,4&_KE([\ MSYEZ.W]EKCOCX]Q924UGD3)A?9=T&&$>\5.'>]P%A'_69+;':V'$M-'AQ&&$>X1/Y65V>213QQ#8D1A1"=:$JH><:!G MJ!YQH)-]S@(:S`XCS",^VZLR+TCO MZZ%4NF.$881[Q/7-35;2WW$)'$-B1&%$)UH2JOXI.UI&["C]S5GKH:3JT+$R M'V60U-PJ6Y"K-L<'$AB1&%$8T4DD5-Y:LJ/+:MH>E<[`!9=3>H^Z]5!2<1(P(C$ MB/+(V*UT&T8G@%!MDU\7Y+:EZ1Q._&%;.BB1N!U&&$8X1@1&)$:41YS:33E= MM^IDD%!PXD9!>D=<*-UE;^VBQ_3*,/%F"[J;TWDBT25L1*S!N*'W6<;2@T<@ M7EA@1'KDJ*$D=U1`9-,ST4.20@8!;K*F*N?DCI@:(YPUPUA.L^X7]!.=I3/B,#'""=%$!B1&%$8T4DDE)N8 M3"!WQ%Q.MI1+!_GQ7^<9]1Z=)Y+3-72H'$<1&)&PM0H'T:D@@=S5IZQE7XLL M2R:[RAX:9,_,KW/"@=YY(B4[1CA&Q(C8"'$881/B+V3.=TAA=C\4DY)4841O2(T':$BEM?=[0N.>\F M;>7<8+`^F6PK>RBIN(N30)B/X@:*^>L?]"8-QX<1&)$841C12234_2)?645\ MY61;V4,),3N,,(SP$;&952[(Q5F,Q8D,AQ98X2AZ1&@[0J6-()_(<%N+3.*3 M;>7*04G%(<)\%)?A3;G(B:`<'T9@1&)$840GD5!W8BW/G%DB%K,D@K25@Y*Z M0X2-46SZD*L>]X6N4XJJH?YRK)Q((OSU0[XC,GV\J5 M@YP4\]S\R0CBBCI/)/J#P2`,SS-MNJB-><;+9Y**%J MAQ&&$>X1U\'F-@==B@H<0V)$840G6A*J3FSGF:I'[.=DLZUR4%)UB#`?Q4E: M-MF<6EB.CR,P(C&B,**32"@\,:!G3C,1(TK7<6T%/62'$881[A'7-S=9-2/[ MH`+'D!A1&-&)E@2JV]]97;Z$Z6N1)0RU(ZV'4NF.$>:14=)%1:_9'$<1&)$8 M41C12214GAC2]`V7.F)$)]L_'DHJ[N(D$(:C<(P(C$B,*(\,O5_34]8)(%2; MF%&@=L2$3GY$6T.'V6&$881C1&!$8D1YQ*F=%^9W`.06L4X&"06_R(76$1'(0MX@0\C,:*"PV21S$ZU-)3:G/#Q'`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`0``__\# M`%!+`P04``8`"````"$`;AVF)^T+``"6/@``&````'AL+W=O[V8_J>-K6A\>YN$OF ML^JPJ9^WA]?'^7_^_66QFL].Y_7A>;VK#]7C_%=UFO_V]->_/'S4QV^GMZHZ MSYR%P^EQ_G8^O]\OEZ?-6[5?G^[J]^K@1E[JXWY]=K\>7Y>G]V.U?FXF[7=+ MF23Y'N9@X?XXQ4;]\K+=5+;>?-]7AS,8.5:[]=GY?WK;OI\NUO:;*>;V MZ^.W[^^+3;U_=R:^;G?;\Z_&Z'RVW]S_\7JHC^NO.\?[I\C6FXOMYI>>^?UV MGM_KC;\?M\S^VA\KMMHN3C\#7NO[FH7\\^S^YR["]-!/YYG#U7 M+^OON_._ZH^_5]O7M[,+MW*,/+'[YU^V.FW9K?J2))A8//OE:G\Y>M-SF?;;Z?SO7^?P`2:`J,2#22 M.>]Q7-[)E1(J'[>R!(\:@G9]7C\]'.N/FUS4-P[RQ=FX$?+]1I5 MQ]$;^=U;:6PY%B<7GQ]/HA`/RQ]N3S>(T8!Q)=%A*,)<$'X#O5D;_&'I_&V= M=EO!G4Y=4(?##A,2&@S&3"#-AP/"O+M!LGCKN2"QWW*9]=+>9+]OA)?/M3NKD:,,Z+EB3? M_E&$C2$(B[S/8KP&_"06AH(7`6!R"(.069)0FH8!4@ZP$0"A4%`*\0SR8.XZ M*ST-&'!=RJ3DVQ^."RDS%D`;CJM<=<2)VU[5@Y89=]N#N=O,+0T8<-MMN&1N M&3*>K58L8C8X#"-V7+,D, MVH#AA9`LAI:,RZQK#=1O+V_3_08QI'YWJH)^QQ2S@1AQ@30GHY3)MB7#:4>, M>N[5+?!\8OJ#)E(&;'TM`'1I0)*-&QR_)!:+C&V'A^J#8K91,13KO@QVC1KNQ-+TVTE M*R+;CH['PHL=XS!^#!(@D80#UR.-((C%0JYRUJD,`J+!@(6&(32IO/PQ(N.Z M)D`T76&VAS6QZ@4#0,-.8&F/0BPN-6R%4O%*&%`9Z:J@FS063'VU",4UDTKU M8A$"%FFJ$GZ\("86:;(JNPY`W)=,H>/N-VBJ:1GOK8C!JG8W9BIYAHRG*F7C MEHPO!9FDK%J!D"6*19SIN91<2$S)=>(2=G?H-F[G>R"8T4 M,=B$5N6*)SX"AIUK;-@HA&Z_,Q/Z/TV=I9]%>8A55UQ(!$!(1*9A^4$/0C.` MVX`B!/$(30KDL:NN(LF#Z/%+`?5WF.:+]DRG'$-+?M9]V7?0JY'AI(E>CRCWK.='C$ M\[[^YJSI:0D83`>A6&$;,BYDPBK'XCC$;!4\A:%^?TIV)'43> M=6WN9]D[3KM3/XAG$HJ\1%`T!V&DWN,\"`.TN=(V: M[K];Y!-UX&=Q%MT*F$@`BK(8A=CT`FD>`JA.3B@-)L$3@]&78M<5VTI#&A2*6OS8(_R-5IJ*T+D:6\;@U#B"SG[*' M04O'Q;5'\-FGQ+J919N4^P(`JVX$17;:M!#?@?A]R.(H;(',5L&YD$0A8TH] M+0K-+,Z!"9I&$%1DQAN8(<-YTA4L)!(=OG;0R&[2Z0;-W68ZJQ%TD;!<,5Z& M`LHD:/[H.B@Y6I!E<`^B>^^U,+@F^[T??VB7@8*&%2`3+M4(NI!0"2L1PP!9 M<#%`$K`,6G#7T&Z?*`F7HR&)^%$O\V@>`29*&D'1Y`<[Z%V9!'=@=!\`PS8H M`:;1(P3ZVBSYDQ+M@]CEV+)JTXW M)KL'[TX"6&1%?NUK"HKI]$02`WHMV#%" M-Z9;O4[+G-_I#$5()RB]:,!"L!$J5<%YEL;B)K56`VK-+UH:01@#E:?\0&(H M8H"@I0A*D/K/M'IB&$!)7=FVSP"D8$6K54QN,9M&(39JA5+QZAC<'$8:$V@I M;;%*'?>^0;..Q+\IH1&$KO7N MTP;'K]Q%+1D67;NC;M^DS_F`/DMVE=0(0K?=)]IT0PT=%V7O`V4$3.BD^8`Z MCVM:,XMO/O-2(VC8"4B=%N)/&8I_6\RVPUV1=9V.!H%)\TCN#$@R_S*1S@$4 M=1\@$*?^E<)&35#_W3)AY4YK0KF?QD<0!'_ MS#C$1B&4`A/DB;G4%^;^IPLY@*)4``(UL9`JXZ=`&S5"F3!I'@D&2"G1L^`9 M&U;#J-Z:?!1BHQ!*X29)SD%*1_)I7)+13B1.-@HA%`JFR]/RJ9E%>U,_GQ"$ MR>)>,F!7;8.`&)$HA!*Y2:F+(:5F1QN-H(A_9AQBHQ!*@'`D`1/\TXQ$8AE,I-RET,*3>__"`(@B'SE#]&,PB(<+11""5P MDVX7(,EA-DG)KSX(BOAGQB$V"J$4/J7;!>BM2]KV"#*03N.ZC78B;&T40JG< M)-SNK=[^,;:73J.J;-!.E`)8@?3^0CO M%<,OY_J]>5?U:WUV[P,W/[ZY][\K]U9L&PO=V]R:W-H965T M&ULK%A=;^HX$'U?:?]#E/=+2/@J"+@J)-V]TEUIM=J/YS08 MB$H(2M+2_ON=<6QG)DXI5'TIY7@\.>=XXC&>?W_-#LZ+*,HT/RY\>"KW0E0.9#B6"W=? M5:>9YY7)7F1QV,W&LZB2%.,05\"_WZ:G4V;+DFG197#P]G[XE>7:"%(_I(:W> M9%+7R9+9C]TQ+^+'`^A^]8=QHG/++U;Z+$V*O,RW50_2>3516_/4FWJ0:3G? MI*``;7<*L5VX]_XL"D:NMYQ+@_Y-Q;DD_SOE/C__5J2;G^E1@-NP3K@"CWG^ MA*$_-@C!9,^:_2!7X,_"V8AM_'RH_LK/OXMTMZ]@N4>@"(7--F^A*!-P%-+T M:AI)?@`"\-?)4BP-<"1^E9_G=%/M%^Y@W!M-^@,?PIU'458/*:9TG>2YK/+L MOSK(1U(F2:"2P*=*`O]=B!^H>/C\_$.!GF0.GS9&?':A4 MT%F>8JQ[?P:)M9NU%N/O>_:")9CD'K,L7'C%P+D2:N)E&0SZ<^\%UC%1,2L[ MQN<1:QV!3F/:L`U$!/!`@%$![G^!"LR"*O3S5QH@LEJ4=82>$K:!B`",,I3" M%U#&+%#!S/B6K:LZ!M\1LSKCE@P38G182$01IF3X)4HP"Q3AF+"T:T@%79)B M0HP4"XDHPJ1`XO:B#.YP'WEG>]'UC_,D>?W0E4+Z\F5HK"IDP6P?F4?(]6YL@33^TD(@BC""DI@1Q!QG!>WKC#H)9 M.'.%\$UEV&)N@@QS"XDHPICCD8#L?9>MQ6!.4"&O.PN@IB!JK(.Z/9:R*HL9V3KQ[QUAL#D3$!R6!T:V24!`UUH)"WX(B!G%C M<9!D,;BAC$:6)#N9ZF:C^49@T%T'X(S?89!BH<"QVB&IH6%+$H1A/3 M4YI8U1/X97AS/7OA!LWCT!U-"I!0=SIYD13OY5Z8F-K:$,1@[@$[$)$PN7-(U`] MB])4$-\\FO.!HFFBM*VASC4A3M,H3A-[%:&)3G_BUP7^@FN=.#3$;6[:L.*O M)E*;+0CONV1Z&57SK^^OZJN63!0[L1:'0^DD^3/>34%I+><&KB_.5D$?;LYD M_5DC>*W;5'?&``9]B.;#X\ M!PYA72.0#4X172,3&)'K;SWG#D:DC=;(%$;D*:8U`A>.]YT.(.6NIZ-E73@( MZ=)Q/X3\G3+`QTX;QS/XM=PA&U1WB@;-G9)!L13L&<5PD7F*=^*/N-BEQ](Y MB"T44U^>6HKZ*K3^4N4GZ$!PG9E7<(4I_]W#E;6`2[4^MK1MGE?Z"Q#US"7X M\G\```#__P,`4$L#!!0`!@`(````(0!_+Y+^.`L``*HY```8````>&PO=V]R M:W-H965T&ULK%M=;^/($7P/D/\@Z'TMD10IV[!]L$5L;W[[U,S[)GI[AG;$N.7NW5U3ZM8,]/%SZO??FXWHQ_- MOENWN^MQ=C8=CYK=JKU?[QZOQW_\Y^N7\_&H.RQW]\M-NVNNQ[^:;OS;S5__ M/QT.SY>32;=Z:K;+[JQ];G:(/+3[[?*`/_>/D^YY MWRSO[:#M9I)/I]5DNUSOQGV%R_TQ-=J'A_6JJ=O5R[;9'?HB^V:S/(!_][1^ M[ERU[>J8UWD_K[O8$P>!*-_FIG MX%_[T7WSL'S9'/[=OOZ]63\^'3#=)8[('-CE_:^ZZ590%&7.'I>EQ49^5\6F1('WUKNL/7M2DY'JU>ND.[_6^?E!E2 MODA.1?!_*H)_O9-?4/[,YQ__HY/^`*P>]?*PO+G:MZ\C+#)0[)Z79LEFERCL MA.AI>&G>4@9'8XK,LU3=3]P1,NV7L9+2!X/:>1FF1%#"X6M*638[0U^C77[T]C*5)$E" MY([+%5F?Y(ZMYHC@.H^Y5L40JJ:0I$J(I%HHJC[)4^6(H&H\F'6L=,MVTVN2 M)1U"4-[OE[R<*3H^R=/AB*!S(>F8!CI,.5-(4NV1'.[&J):*JD_R5#DBJ&:H M=+QT-EL26CBH ML#OW2]B59"941+33,O1*R=0T=L;T`WZ]#0A^!'&I(JC.."0)F!9]/`%JZ%P@ M@KA`!)%`JEW4F0_S]3;WZTWR,YWX>'[4MSD_@KA`$51G')($3"MF!(Y>2]3" M.16"N%0$D52J7=7&;LUFA6)L:YZ_(97INHSI!VN)>C3G1Q"7*H)J8[>&D\V2 M4IE>R@@<+17U8$Z%("X50225:J5UYL-=+IJ;-JEDMP>+$JYR< MNC5;;P["@@J-H%*==1&RG'_5`I)D31M69'N3/)4N]7-.ER!)5W6W1>ZS`ET. M2;JF0RNZPTZ`A4OF0/G&\/*;YJIRURGQ74Y9#D:[K] MY_`EW^!\>TCQ#2TC)%4Y22"Z?Y0Z@#@,!";:%\AQCC\,VNZTD_8@@Q3>< M*?1\0Y;G*R#)-V%1`QI_$3L609+L/%@UD>T'(BN0Y9`DFW"I\PM[#^/$Q5#$ M1D60XAO\DOCV`P5?#DF^QA..WCL%.0C;.P["[@S=?:[-,V0%#:G6W,@J.27< M:)!Y%K$9.0C;F]'5YAFR`EVJ96\U2KJF\1\O86\3_#*S($A*J`TR9`5.?F`D MH6GNC!,[!3YU&?8V(?@2)#74%EGXK,"70U)#T]P9W_=;>-%;@>!$D-10VZ`; M:->R&*'AN?83 M-Y`M0@%)3@D_F>,QU6L=3HK>)TD?)(KF!,$-;$."O(L M8J@6D"20L("C;F>6<,LJ1DRDAK-U!D701KDXR1Q7?%^]O27"AKR0C" M5@P+_T([DQO(C%1`DI,RAN%7O65L&@X2??A"FT;(\JU-0))OPC2&7:67L6\X M2/+5OA&R`M\W?:,T39IUP@_FG%HZLP=;`!MO/"#0POJ-0"DE-N'$#1'7:?L#25%%^")-_@$OV]`S>0 M\_4#H;CD>Y*7E+&7.$A.N>K6BY`5IIQJQ5->)>S%M-83KWIM&2F@@Z2`P31Z M`4.6)RL@(6!UDK78;,6)W$8*J'KWP@UD?5)`DE/";8;UG2JV'P=Q#8MI0U-EMIF/":8JJ]Q@WD&OJ!$:>$UPSJ.U5L-0Z2$FJK"5EA M&5*M^)2_2EC-D*03[@=&XIYD-%5L-`[BFZ:8:J,) M64'!-XVF,F;`.O?[YF>SE4ZF`"`YJ]I-W$"NDQ\8Z81:)W`RV8H305(G[1B5 MSPHZ<4@V%^48PT_"JMA-'(1?]R>-Q52[2<@*?*E6O#/F"3<9YLBVDM27('$W MOYAJ0PE9GJ^`A+YS92@#;UG:,HIL[S2*K'8:&L@?/0A(DDTXS:#;_//8:`B2 M=#-M-"$K:-O7ZH]`TE5&,U1;<@UVYCLG2"S<3#M0R`ID_4!`DFS"@0:^MSJ/ M/:%6MZMC+K#GIO92FKQ>C-AG2'3+N0&LNXJH%[@_G.$ M_O7[;;-_;!;-9M.-5NV+^=0`'?KFRL/]=Q!W\P(?0MAGRU%DALC,/`"+(J7[ M>$)'JOEEC9])C*G.$;'LHS$7B-C[#SHRG^)W[)/-*&(^W[`?.T21'!%[!T%' M*HS!J66*&\;@)"X5@3HXNTI%H`Y.9%(1J(.3AE2D0L3N+BT5@=:X6$I%H#4N61*1"EKC8B`1F8$!;GRF(F"`VX^I"'X'M]D2 MD1*S@&N>5`1:XQ9)*@*M<3,B$9F!-9Z9I"+X'3RY2$4PVWAND(J``>[>IR)@ M@-OJJ0AF#O>P$Y$"8_"L-A7!&#PQ346@-9Y-IB+0&H\#4Q',-A['I2*8!3P4 M2T1RC,$K(ZD(QN#UC$2D@-9X$2(5@=9X72$5@=9X,2`5@=9X\)Z(Y!B#E]=2 M$8SIG[3H_9-#:[RDE1H#K?%"5"H"K?'J42H"K?&23R*200.\?9Z*@#5>MDY% MP`UO&:M7'DV%^<+Z=&).#07\"H,;@B[;;].^C5+(2"J5P,S$)_'9V M>0O+25`R>R.%X^B2\D+=I+@XYN0A8T7:!3GQ1XPOY9Z7C\T_E_O']:X;;9H' MV-O4?DVR[[^UZ_\XM,\P6WPOUQ[PC9S]YQ.^B6SPZ=?4/*9\:-N#^P,'-O%? M6=[\#P``__\#`%!+`P04``8`"````"$`)S89,N1+``!8N0$`&0```'AL+W=O MRMN^_B.\_*'1_K.;2F\/V"3:7 M6KCORYU&UHP58UD.26//_/N3(#(K@7R+8%'C&W?[4>)%%O`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`?KOJX\?G#FH3=[^^_SSSP\_ M?_WEQ]?MQ^_:3_>M^P>*?_6W]U^^CCXXS=>OWOWKR]=/'_<^JN6RJE3:K-*A M]/V_=QZ^NW^\Z[1N$.FR"/UDD:<@DT3ME.?Y&NBG7,/S=X^MN^?.(Z%$P0F/OU[4\_?/[TYRM:`I!S MOOS^UBTH6M\[-;E+^0:N[EN7;EMTIW$J/2?SXVMJ`[HA?:&[[1\_=5K='][\ M0??'=QSS@C&M.*(O$>X&YF0'%@PM&%F069!;4%A06C"V8&+!U(*9!7,+%A8L M+5A9L+9@8\'6@IT%>PL.%APM.%G0J[I7.J97=69%H/-H><6FH)@W9+?*D*HSI:MZ?8@)>R\R&-V8_@J#.9D? M7]-_@TGM/G;4BX]QZY@JZ"$.Z52/2)'UN]*R/+.19^-)X9Y M87+GUWIFQJO^,?2I3HM1(F3F&Q)QT7$B3&B9'HR)1Y-0%23Y#X`,@8R`9$!R M(`60$L@8R`3(%,@,R!S(`L@2R`K(&L@&R!;(#L@>R`'($<@)2*^'Z`51'U'4 MKY'/R"`W^,Q%QSYC$C_B/!F?54&5SX`,@8R`9$!R(`60$L@8R`3(%,@,R!S( M`L@2R`K(&L@&R!;(#L@>R`'($<@)2*^'Z`51']$@1)'/R""1S]P#=?O^.YH2 M;WRD=D*Q!9G$%GPV%JR"*@L"&0(9`#]$+HCZB08@B"])^4F3!]+W=1<<^\Z3=J9ZL M^T`&0(9`1D`R(#F0`D@)9`QD`F0*9`9D#F0!9`ED!60-9`-D"V0'9`_D`.0( MY`2DUT/T@@B[M1?U:V0J=WYQ@ZO.X;&M!)%O=:G6OC/SET95$QBB(:(1H@Q1 MCJA`5"(:(YH@FB*:(9HC6B!:(EHA6B/:(-HBVB':(SH@.B(Z(:(]0V<8T0'1$=$)$=D0.I)LB*Q? MP^(>CVWH-B-OL*'?NZ2=&['.BSNB)6?>^^-Z=]K11S1`-$0T0I0ARA$5B$I$ M8T031%-$,T1S1`M$2T0K1&M$&T1;1#M$>T0'1$=$)T3D.>A;\ARRF@ZG0Y,P M+O:\P7.\C1EZSJ-NY<*^._8G%RH9`!D"&0')@.1`"B`ED#&0"9`ID!F0 M.9`%D"60%9`UD`V0+9`=D#V0`Y`CD!,0LI;M,'(6(.Q6\E40%=O*;1O>8"O> M90QMY5'G.?!5A<*UGCF.&[@71IS[:%40K`@[\8IPJ%$R>8X8!35FBD(M4V.N M6F&4.:DN-$IJ+%5>T%A1J&5JG*A6&&5JG&J4R,]47M!<4:AE:ERH5AAEMJJ6 M&B7R*Y47M%84:ID:-ZH51'7,DFJK42*_4WE!>T6!5MO4>%"M(*ICG'/4*)$_ M(:(Q5=E0PFA0(>O7,+&P=V(\KMPN>#BN_*L5W[DWW[[^\N'=/U\^D>EI)5*S M@NW0MCJ_6,%[Z>%P\R@P?]^=/])`"M"`$8TMN:@AHA$6S!#E6C!H[;8Y"BTT M2FHL46N,:*(%$_)3C1+Y&6K-$2VT8"AO]LV6&B7R*]1:(]IHP4"^8PR[U2B1 MWZ'6'M%!"NHZ\8CHA(AL[4W1U9)D:V1BGC!.W%-G:[?I'MJZQK[TLE;E7]ZC M#_WK46#6OCO2]/X-VM`.^@%'19;V!0,T4BUIZ4Q10CY7^3!*CZW.`[+0*)$O M55[06%&H94PQ4:TPRAQ>335*Y&`8T00+3A'-L.`T0$+'A&=L"`9%CJ2W%GU9&#BCIG&R)U5F`P)4W$J7R6T0[1'M!2?F#1*G\$=$) M$8V%)M:AX<%A6@&-!62QQ^*QX$Y2;A@+_N"%9GX9:"_NPP'.Y52MNKQCGM#Z M'.4VA#0*QP++TX.$1G7,ZG8H-3Z?W]>YOW]NF:>SD40D:\L:Y937:MF<"HYR M;YUKYEVS%BEKM6PKC!OE-:G5LGE-&^4UJ]6R>:DM&'6JU;/\=.2KMJU.MENT_FE5X>"43 MHUF%1W049C.CB<:'I5.C^W"=6I!;-!VYSPW=,!V=P^.#64:=J*N[9H+H<]25 M6[-HZ:)W*,AM:OSQ4^ONKO-LULHC":%-%YT*@@L^/WIEC3+()4KGVP)1B6@L M*'F#FDB4RD\1S1#-!27E%QS5T?9;"KKPDY!D M!OM&&1PD2IOXB.B$B#Y&X,^7TQ[MO4B85D"?+N"B`1M$+!YT-%9N&70NW`PZ MC^(U0-<\K_?;7#":5^S`&$A4\/#&J.-V8O[XJ=LRM]41_[O[^%]JQ#6I/E$44GWZWJX%$TF,.2J]#IJHEB0Q;93$3`LFDI@W2F(A4=H12TGB0D>L&E6_ M%N%D=VU42]I@*]4G.V*G!1-ML&^4Q$&BM`V.DL2%-C@UJIY&=Q,WTNCFD:43 M&(UNSZ[=>+5H?3O$%&GPNFY[H!1P7WDZ$@ M/YMW[A[,G7XD`K?J)8TPE90LA%V$I5,8M\HB8-H:2,< M!5UJA),$).NGV<&/FO1XH-F!!Y>^\D"S`[-D._2JL70ID7AV<.?MS7<)Z&U; MF`8\HCE).JS/46Z:TJ&#RP%?L/-8%1QRP0"-5$OD,T4)^1RU"D2E:HG\6%%" M?H):4T0SU1+YN:*$_`*UEHA6JB7R:T4)^0UJ;1'M5$OD]XH2\@?4.B(ZJ9;( MT_"HW)30I^$!WJ'A@6R@'!?'[(6?4'#^BE3UFK9F6+<**])K9;-:]HHKUFMELUKWBBOA40E.W$I-5[NQ)6$)#MQ+=4E MHS82E4QJ*S5*4@^T#(M?>]I)2+*ZO527C#I(5#*IH]3HD^IT'\W"\"0!R3&,5:4D)^@UA31 M3+5$?JXH(;]`K26BE6J)_%I10GZ#6EM$.]42^;VBA/P!M8Z(3JHE\C22FEB' M;MK@'1HVR`8J1U7$`X*6OM&`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`YQ8-`?83:)&'^`ZJ\2/!XS,S=B>[W)4>JX; MB):.S:$@/YFW.VVC/)*`Y%R>-:H_5RWIC$(0/70%,Y]Y'"DE*IG$N%$2$]62 M)*:"DDG,)"J9Q+Q1$@O1TIY8"KK4$RL)2-:_;E3_1K6D$;:"DHVPDZAD$OM& M21Q$2QOA*.A2(YPD(%D_?2NG&X[7/AK0>U$U:0;ZJDY?M)-L!_KZ3@Z[E$@\ M.]!C4S0[I-?D;K";70)&P5YN7U$P=.P-<\!1P6'N$-%(M:0A,D4)^1RU"D2E M:HG\6%%"?H):4T0SU1+YN:*$_`*UEHA6JB7R:T4)^0UJ;1'M5$OD]XH2\@?4 M.B(ZJ9;(T_#P!DN_&D##PX<%WJ'A@4P\YLT9&Y_6*)'QO^E\EQY_8#QXY!;E MP7W#GN]*P>1*:2!1=&6J91_6AQQ%BX?S^6ZWLI;IDU$:BDDEMI49.JO,,.R(["4E6MY?JDE$'B4HF=90:?5*=CGTI^"0! MRY-U;"QW>[=&]V MOMOQ+[Z$C_6,HINVCTK/O`,N&!SF#A&-4#Y3%#1C<.'G3;DE]U+">&\?,6&_AV&:/YE%.VQ=\WN9Y^V1<_^U3=@ M!XB&B$:(,D0YH@)1B6B,:()HBFB&:(YH@6B):(5HC6B#:(MHAVB/Z(#HB.B$ MB&P('4DV1%;3X63#,"ZV(6T$W&)#%VYF0T;Q;&@>'OINP\$5U'>Z!HB&B$:( M,D0YH@)1B6B,:()HBFB&:(YH@6B):(5HC6B#:(MHAVB/Z(#HB.B$B&P('4DV M1%;3X63#,"ZV(4UBM]C0A1L;>A1^B2@]V;NH``T0#1&-$&6(L7\/B'H\]1S/6 M+9YSX<9S'NGG9_JT+G5!2@9`AD!&0#(@.9`"2!F2^%+=84^XV+`/@-$UWY7AT;)&GJ$*$.4(RH0E8SH MM3.2CQK,?0_G?]]@9Y78,H*"!E,4-`4T&$=U'\X;=.V[ECG*&FI`U5:J+"A# ME&M!M_5'RN:3UX4&B$P9R<0M1ST:M5QZ7>L,8$85([<5JYLE]^;0K,]15\X$ M12LRH]UX&4J4/Y>A/RMM=EI'$D"K>4W)=E&F*4D[Y5(P67\A4;[^[CUL<4K` MI?KC'G#;0^%@O](#+MR8U*-X^_G>OB)%W^;68*!+E)Z1#QG)7O/=@['R2`*H M@E1S5_5KMVVFXH6G]QD0X879YKR(VMQEQ M?8ZZ9F[6TKED*/+>2:W[1_/6^4@"+CG)?[V(UJ]-"Y45HL65=9_-9902<*FR MN&TIZI:V=>'&MAX9VQIS];M<,&FN@42IDX:,V+;M)SL#CR0@J9R)LO9:+D@K M*T3+;U"W'Y_-K;&4@$N5Q6WKGO]"WW[3_;_+3Y'Z+MD+(S-7F^FSSU'7[.SE M:7INT(G`SHXCB:*.U2BOZCL'T]"O?8:07@C']ECYVC:$4L5SM$-%(MB-F<$OU&YK!K^RC6=,C,[+-W-;OD1Q*1E,Y$ M6OV4"]+:"M'R0_OYR=[^2@FX5%G[EB*/<-FJ0A-EJG&N/'M M<]65`8X/4%V/H@%>H>":[70VX(+1`/<%`S1"^0Q1CEH%HC(J#_5_RM'16 MB>_HC*)Q#Q^DDW*7AHL?]A(5+;S@24`JY,/J^XZ=""0@65DFE:G[TW._NE#32[U&(4VE91RK8<13L5,E2'B$:J M)5$9HAP+%HC*J&#:EB_ MAL4]'MO0/5DU7Q[=^P>Q<'G$B+Z(1(9+']$`T1#1"%&&*$=4("H1C1%-$$T1 MS1#-$2T0+1&M$*T1;1!M$>T0[1$=$!T1G1"1YWQW!WW;>ZEA-1W>BWL\]APM M;V[QG`LW4Q\C6G,'4Y_=([JOHL29`T1#1"-$&:(<48&H1#1&-$$T131#-$>T M0+1$M$*T1K1!M$6T0[1'=$!T1'1"1#:$CB0;(NO7L+C'8QNZI^D;IC[_\!U- M?8SB.[#9B.K?5U%J0T!#C!HARA#EB`I$):(QH@FB*:(9HCFB!:(EHA6B-:(- MHBVB':(]H@.B(Z(3(K(A]!K9$%E-A]-L&,;%-KQMG^8>]VD8T5I3#-9'-$`T M1#1"E"'*$16(2D1C1!-$4T0S1'-$"T1+1"M$:T0;1%M$.T1[1`=$1T0G1.0Y MW]U!WY+GD-5T.'DNC(L]YS:K;ICZ>&\KV!N\]TBW2_M`!D"&0$9`,B`YD`)( M&9+X4MV62GBI]C&TT>GSO=^8B29_1OJ8W9>H2\_'O!G@"[IC-5V\P.DS:U&4 M#.H1H@Q1CJA`5#*J.7V^=QLY_WV#^>V@J,$8A0U6H:`I8+?IG!&]UW#Q]%D# MM*TJ94$91Z6_YR57K0L'TAH@RJ4J$XK<]V`WI])/^>?P>*G+*#[DL+NV?8ZZ MLA,J6I$_81M*HOAD[?'9G*B,)(!68&I@VVM9HY1RT4JF5'`4'XP\V4_9EZ)R M*:.X3^S&U)4^P0VH!X^BG<'.@VFF/D>E_3:0*!WG0Y'W^W#T^1"SHAQ)0-1H MV`&<>#(JQ_H+D??U/W;N3/VE!%Q2CIN;HO[[^>3!J9B1X9$9&6;/M,\%KXT, MUM*Y:<@%Z?W^\]E]%TY<)>"2Z?QI=J/Z<]'2^@M!OOZ']I,]+)"`2_7'O7#; M/L\#[O,P"G==%24F@@%'!2<#0T0CU9)I-5.4D,]1JT!4JA9,T=1^?X$_G8KQ MIT?N0*V:)N&ON3QP.?)?%=2Q0WD@432B-0HG;J\E)XF=^Y:QS(AUXH^"V=HR MJ2V94RY1R9P*J9'/-+K=1WNH(!&7:HMM[!ZC4HN39H<*#_PT%BQH&47V]E&$ M@E:WK37@@N&A`J(1RF>*$O(Y:A6(2M4">[N'@+#%KMSM_#-#N&Y[8!3ZN/-@ MSV(U2L;O`-$0T0A1ABA'5"`J$8T131!-$1C9D1$]/.@<^F#/[_D,5I38$ M-,2H$:(,48ZH0%0B&B.:()HBFB&:(UH@6B):(5HCVB#:(MHAVB,Z(#HB.B$B M&T*O]5YJ6$V']P917&Q#]^Q]@PWY&3^\3W@4;,CT'P`-$`T1C1!EB')$!:(2 MT1C1!-$4T0S1'-$"T1+1"M$:T0;1%M$.T1[1`=$1T0D1>0XZDCR'K*;#R7-A M7.PYMQ5Q@^=XYR+TG$?!9MN#)0,@0R`C(!F0'$@!I`0R!C(!,@4R`S('L@"R M!+("L@:R`;(%L@.R!W(`<@1R`D+6LAU&S@+41Q3U:V2K1[NU]$T;FV>5^+E% MD#Z+]A4%]UY8"7,4?;!%[KU#1"/5DJA,44(^YZAXW]3^Y>I"HT2^1#1&-$$T M131#-$>T0+1$M$*T1K1!M$6T0[1'=$!T1'1"U.O5L)<:)DX)MJU[`XZKV6M^ M=%M4S:?&<[@QJU.@+]15S_4YRGV^2A>*:%9?T'V62*,>S,/ID+4H2MPT4GE! MF:)`R]:8BU;TH/M@'M$+C1+Y4I"^83-&-!$4R=L_'3+5*)&?"5+YN:+$!2TD M*J[1;(,N-4IJ7`G2&M>(-H)B>;._M]4HD=\)4OF]HL0%'20JKM$\Z1XU2FH\ M"=(::<2PP6@G30UF3=%[D;"X3N/#GIB:/C`DE=*X"KT?WQM([99QY<+-N/(H M&E>`!H\>Q8/(?L_E4*,D]Q&C0#Y#E&O!H`D?S1N.A4:)?(E:8T03+1C*F\WN MJ4:)_`RUYH@66'"):(4%UX@V6'"+:(<%]X@.6C"\;-.J1XV2RSZA%KD<3$&6 MKG.%[3:R=!4F-9"E0[G8TG8#^]N6.[BO_>A18,4^H@&CX+XV1#3"@AFB'`L6 MB$HL.$8TT8)A9YJ/G4TU2IIZAEIS1`LLN$2TPH)K1!LLN$6TPX)[1`A2?>3V9L=OGJ"MG7J)%0TYO4'"H(%%R&OP`?]!$(B@UU;$WNJQ13GFMELVI MD"C:F-8:[2?S2HE*YC76O*0')[4%;1)3B4HF,9.H9!)S32*X(-N$BUHMF]=2 MHI)YK20JF==:\Y+&V4C!I&NV$G71-3N)2":PUP02#7-0+4GS*"AJA2?SAO!) MHI))T`1!_T[KH_1XHCG#AP6?(:4)@EDR#YHSJJ+UUQE/(_80+'VD\XB'78SB M%QB>S,JG+P6CKK:N'$A4\`*#R/,+!(\X9?#)6E(Y$^5D5"Z5ZQ&TTRGF<)+.@45ZI21HTRCU+ MYT&CO"I:W_3Q**F<6"61OV'WU4>G(;<%3X(5I!?HYO/SSC M,.<$:'+3^[2=0+)&">126SC,O;S[,@*5?S+[#Z44C*+NS0/V6).07IUH04%3 M052QUF@7'C.)BFJTESW7&@,M&[50+4EB*2B9Q$JBDDFL-0F1WTA!;>BM(.[I M^\=G8Z*=1"1KVVMMB4L^B)8F<&0D7XP`M_$F/J,![L/23J2R MYZR5?O%S@4DL&R6QTH)!X]B)8ZU)R#5N!&E#;T6+7\]ZZMH/N.\D(FID6]M> MI)-1!XG2!(Z,^!N2X)O0&]5.([OJXT23T,CF,*V?1K9GG(`90C2PK_1X/+#= M&?`-`]L?&8 M:PLRMPUS$"U-X,B([Y6F;T]2(%DYC>BJW.Z&\8T?Y(/QK1'IE;M>F2_B,73,Z?`XG2^6O(2-[Y?7BT[]>.)"(I MG8ET,BJ7*$V@8!3?JNVT4M8F@2.Z:@4Q^$0+"II*C5=NU=SNR0N:L]:U6W6E M)4DL&R6QTNP3+EYK$B*_$:0-O14MOE6WGNWW%>TD(GG)>Y%.1ATD2A,X,I); M-2S"JT9*7"L-[*J/4V$O$J;UT\#V13D!,['0P+Z20#2PG^S;,^D]M'-X_'3- M*+Y5/YM6Z7-4^L8Q$"V=QH:"^%;]B&MPB;@TD?G/GS1*(!:Q)RC1LIJ#5N!:VV)2SZ(EB9P9,0W3%B#2XED M[;U>H^I[+Z*F]?=DD'`"YM[8JT;'I03B@>U>B@COV-]T3OSD7ZT(;^2,XANY M_6QD7PHF9]>!1.GL-A1YF=Z?NK"=)B%)[4RTDU&Y1&D&!2-S)S=>+&N3L,X? MB[SV\D0+RF"82HWI.[D63/AZKC4FHA:J)4DL&R6QTH()^;4F(?(;0=K06]'B MKKY[A&]SW4E(LA/WHIV,.DB49G!D)+=R,[N=&M5.(YX'2;)Z&O$HM42T4BU)=8UH@P6WB'98<*\H MD>I!HR2)(Z(3(G)\$U.0XZLPJ8`959[99RM%*\H+[W557M+;$RF83&*J2=1O38E*5+U=]LTY*MU7"]%* M9K34C((>M8<]*]&*\K+-LM:\I%DV4C"9Q%:B9#W.6(Z(2(9H.JXQ/Z-!MPF%9`LP&R0<3BV8"N,SD;-/O4\Y.3,3<^ MCZ(;7X425S5@K?!3SXA&C`+Y3%%"/D>M`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`^KNG9EARMHDT'I5*ZCU&&F-T_H:S2=,9HUJG'.47R:>%T,+ M05KC4K3\V7#[[KEKKF\E$9>:+S:5VQRY8=;S>RG1K.>1F?7,LJ[_[*.NS7JL MI<\?0R[(IT.MFO<7)8)Z1\>Z]6O6*(%5<'$9<]9B]I=:ER(O%[C4I"?J5J=1[L=M9*(Z/J"1HY-Y?:N M;C`5;W4%#Z+/'D4S5??.GD)R5/KES(%$Z2`:BCP/HIIWYR3BTB#R)XXBG8S* M)4H3*!B9F+]8F@:;BYM/^G&A!Z?6IU)A^E48+)DT%-2ZX8$NO<2E:TLAW M]N^6KB3B4O/%IG([5J&IOFU5[?>]H@G,HW@"@_>VGGW4M0F,M;0OAEQ0)K!6 MS7M;$G)I<+'9FF20BY9F4#`R,YC9<"ZE8)0$FJU*0IPUT8*"IH+()SHEX_*+ M&RNJ,9A3SI<]9ZUH!H-67DJ-/(.U'CKV6X96$G*INMAMM^UN/N/N)J/@:+.O M*&@6>\$#C@I?&4(T4BUI]4Q10CY'K0)1J5HB/T8TP8)31#,L.$>TP()+1*NH M8-QC?\FFZ#-NBC**OJ:]`V_$2,%+<]G9S`.)HGT;'1CVZ67(4;*0;C]U[<;< M2$*2U65273(JEZAD4@5'F5N66>>5M7GA+%)M*HN[)HV2F-8G`>MM+Q^_'&B3 MF$N-.E,N!"5;8LE1TCUW=_2H\\.;/^@ON[S[Z8=S/Z\DY%+#1\YMW=EM8'MK M:_;ZAM>)'_F$A=-0P`(7PCPD8>$K'#5L)"RH(@M8HHIP MB;!`;UK#9L("O7D-6P@+])8U;"7,ZYG.=7NTX;HEOM1CP*A[@%'W`*/N`4;=`XRZ!QAU#S#J'F#4/<"H>X!1]P"C M[@&VKF&;&K:M8;L:MJ]AAQIVK&&G&M;KU<&7.EAGA9[Q@K$D34LW6=+%6TLR MHX5/=2?KVH^&4&I5F,STE!DP&.O+#PM98:1FGXLD$<61(861(861(861(861(861(8 M61(861(861(861(861(861(861(861(861(861(861(861(861(861(861(8 M61*8LR1"LB1"LB1"XP5C27IVO&GB=/%VXO1,]_LH#8LH"8O(CQ:1'0-D,G6[ M@^&JPRXI&_U5R]:=WV0,MTN$=>.9WYR8TD5Q41K@U0T"_W"5A`4'F'2EO+6I MQ]ITJ94/LJV&]LW7E&FT#\5QW-BIZNQT=:C"Y&P(G_"J$.KCV@8TC>#V1&YI!+^'$O>L9[3KRHU@=KFI$;C4M4[E,-T- MI$YE<=X.;-==,8=<4C=7?-L63>L.]VB$:;?;+6:)N-KM7CS\^C,I*A]LJ;UB M+M:PC^T6QS6CXV9&ZXZ?C:L^-IO.U,=TO>$R"Y[UZ1I]'#%MBIJ;$X>%6[%2-&!T494IND"_-Q5ZWLPZ[=I5A-W'WW<&<_:477SE(-[4UAR>9H MN-75ZF"=%>BA.BIN)M0;U\HTX>`X M\RQX6*8\@%$:P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2 MP,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P,B2P)PE$9(E$=99P5DRC#26 M=*O^6R9.?KB()D[/PH?JED64A$7D1XO(CA:1&RTB,UI$7K2(K!@@<]5NY7_+ M5?LG!6I'F?.I^3T+GIVI]2N6ON'YL/B=\*XYS:/FJ<*D5FJ?J@9AU$`52]1* MC5;)!6&V5FK(*DQJH):L:B!FFM(]4H1-^8U++'[NB5K8L[B%@9&S/*-WKOG) MV=RSJ26K"+DF:DE0HI8$1LU6E65U\_8[M5@5(>K48J%2W&+M&Q^KSO%FM<4L M>FVFVX)M$PZ[MB`5-5I(5\\F^+YS2\+X-0]:CIH']E$50BLU50H>,,Z/KYF$ MI?/*)2SXDPU%Q6A*TQKLVRUE%78I$=,E]KGORO+1/;K8!3"S^*TY^V5A_984 MC=K:MM"@"@L?\*0&?L"_;YL=(FI^G]?%YSMI?DX_F0,U/X?1#VUJ^[X$]0A7 M>BDMZ@R.N%2?Z0P*BV:4:YWAXNWX\,R,#V-7Z@P?EO8A=0:KA7L/POQ@N.]T MC3AU!I>Z9$'IC"8Y4&=`#M3RS'P.W4?[_8;4\E=R,"WOGB;_^[F<3L6Q0SPS MHP.VOZ0HI:V6JQD=7$,T.CR3+ZVZ,Y,A]0>GD-2FN8FUDV'4'Y`"]4>5@F;? M;9D=+^J4ND2"-V1,I[BGWK!3K@T'%V^'@V MV_8/K%&/7$G+=))[#$EU4L/MI[9_G(E6X\QBA_LX=_>YW&@TN_NP:/L)&?5! M)1Q0PXXU[%3#:#L!&Y5VN&I@G15H.R&*-$/XE+_ M8!F[E!G]4)>VS9]"H-2JL,"EP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BE MP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP,BEP)Q+$9)+ M$=99P;DTC#0N=0_GM[C4/\S'+O4LVH>EHS>W]`H8I0&,+`F,+`F,+`F,+`F, M+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F,+`F, M+`F,+`F,+`G,61(A61(A61*A\4)L2??'Z6ZQY#G>K/*9A?NP@`8M0$-$H_]C M[5R7([F-+/PJ"C^`U;*KNB?TAR.=3""S,@]00!:J6J%KA6X4NE7HKH/<5:?"P!$#,>WG_=[&L*Y* M.&+C+238VYC:7!UV5"MW&N*3/6FL$J"*35@E:%EMVBJ!K&K%*I&L%L!<*--. MOPWE]^V`TEY%(IRQYEHOEJ;78#`KZTW484>-VOJK-852 MZ;',:KURTP&!MU9Y,/./W\A\#,NN,"GW7\; M^.^!*I.3#FDYRE7%@:MTX,`OY*59A'JFOVD175.9FT8.\8N`'^(7.>C\ MVJY/W:,^,C+CEF-RVHY,)>G`TBOK/5T#9:PKO9K>7.G5U+B6PEP8GKMK,'(@ M)F!XQ9H,^WLV`9?NB*Y@Q+-V)PQ/*_4N>#/3P*#O]F8%:VF[]@]P+Y:C6@G( M98!=!=BC`+L.L)L`NPVPNP!['&!/`NQI@#T+L.2_9+1.&/F`N MN6=-QV.*98+!4,%@J&"P5#)8*!DL%@Z6"P5+!8*E@L%0P6"H8 M+!4,E@H&2P6#I8+!4L%@J6"P5#!8*A@L%0R6"@9+!8.E@B66*@A+%8RHD%C: M:CJ6??S[_V_]=WO_^\_V_F`@7?^9!MWU=!$]R%:.? M.#/6EEY-;81PPFO!1P]!1P_!1@]!1@_!10]!Q09R5YUJ`NU5?]^R/7W72L:G M8>-VG:14;+RSR&:<"&6U-('4&Q"?LNR?4!.UJE:6281-,.(F&($3C,@)1N@R MQMM%NB!,V_H_(':Y.M`3R;`N=A5K@N)7NL0NJZVW>X_!CAI-V&KG!2-L%9LP M2"2]05>"(:Y5HW1.7&OG&M>T.V_C.C<2K0;0[AFY_$3(5"FO#%J?R$$S4YNK M/)7>F#UJ;\')V*)6MI&G_@M5T-/\@E5C3SZ)A#ZK3?M%Z*VW2;^(OZE9D6RQ MTQ)54=GGEYLU4AW@F`SEND%/\8RYFJP[)<>,84V[2_0!@_6F-M97F![,@IU( MW>VT0EY4)GLG'8`P%4]GGA(M]VO$?$_M<(>AC;U6# M?G2X^9789[5I%A)[ZVV M+!CM]3?)2ZMT*KCZ('=A6'^(#X1>?"#TG0^;Q48>`A6-?3[TD=\<67L9]-U^ MP;#^EK!R]>F+I:G-D;[TUI*^8)GT)Y+61Z7S]"1F*O('^7!3>QM]N*U8]F&W M]JNFNZJQSP<7^;2).X+S;,=D)6A8/]7[)S5$WIKNHX1QOJBUG"\6C/,K?Z'XZ*?-+WG,^8X[P\@-MD MM5G.6V\CWZZ6UI1E5-$/@9'US@ MTV[I&,KGW54WS6\RYB@O3]I,+7V[8/]\<+DL:B/="'RVP+/%X.[89ELF\6IRRF1-PW^V9]3(I_5IGT@\M;;Z`.1-RS[P+2R<2.:T)L* M_X1.N-"GS=@QC+?-6[OCVF3,,=Y-!X2^[OMBQ\HD;VHCX6"\63G7^1 M@828QCX?7$+2;JQ-R'^FZX`;V_1U8\%V="-[(7[%QFS(HILP9S6>M)=:"6$6 M#*K7[HH>4TK%)DP01>F.*`I&W&IW4J+9I*U5&Z3O9&W>H?6LS=A(,T)G:I/# MFM"96LOWH$IC:AS-33=.?F;##PF":SY,&B3>A_A%O`_QBQ28T>P7']L[\1_Z M(24SCCDJIUW85)8.?-R_L1U>1W';X744K]@$_\A35FL>[4-QP,4F M3!!RZ8[X"D8\:W="\>V16\Y!WRU'#.--SW(%%TO%+@/L*L`>!=AU@-T$V&V` MW078XP![$F!/`^Q9@#T/L!;<;&!_FXX2&<\!!\]!!T]!!L]!!D]!!<]!!4]!!,]!!$]!`\]!`T M]!`L]!`D]!`<]!`4;""7C52;."8;2=]/$!E+A?)F;RM/L+99+9WJK&K!ILO4 MTK&ZJK;V7Q,BD[DWU,JL1"JKA8*12\%(9FW;FI!'Y:-:Z8X,2W>D6#!R')IP MMW;R7M6*"1(OW9%YP4A];=M,`9HQEVIW!:2ZJI6FI%JZ(]6"D>K:M@F2_XE0QG)5*R9(M71' MJ@4CU;5M:\+1GU17M6*"5$MWI%HP4BUMR:M@Y+5MZ_*:"B_'Y#47:KIRP#9C M?5ZMH-/E-6/-V"2)@I%$:4L2!2.)M6T;85?L)8E5K428)$IW)%$PDEC;-B;\ MPPN26-6*"9(HW9%$P4BBM"6)@I'$MJU+8JH"'9/$7#7JDYBQ/HD9ZP=GQOHD M"D82I2U)%(PDUK9-A-?N<0!)K&HEPB11NB.)@I%$:4O&!"-CTI:,"4;&I"T9 M$XR,M6U=QE*1Z)B,67VJFTXSUF(I"Q MJM9D3+HC8X*1,6E+Q@0C8]*6C`E&QJ0M&1.,C+5M7<92&:K-V/>54[>YFM4/ MO8SUB2R1)3Y4S`2*6U)I&`DLK9M$^D>/I#(JE;,,O2D.Q(I&(F4 MMB12,!(I;4FD8"12VI)(P4ADV[9/Y.F11<-!WRUM#6LW&D5M4Y-SN53L*L`> M!=AU@-T$V&V`W078XP![$F!/`^Q9@#T/L!Q@!F'^`!9Q`?(KV6&3LS.W?8),A[@` MO\0%^'6("U#.U'(8UHN%.^4#`6=\<)Q,58MC.)FK'-TQ")TZB^N= M/W`/DPXQ")/$($P2@S`I8S8S\ERS/P\&DV;L.2:E8DW+I.];D)[FFD]/L(RY MR7,[$M;LB\8J9:VY%4P\BIMR:M@3!QM6Y>Q5#4Z)F.YRM1GS"I/ M+)K&P;IUBRJF@ZPV>[^QWL9APW1@6+[?G&P!^LF1G)H*?*U."$5(6IC&I$&8(@9ABAB$*9U!?<$# MWLP8=%1*Y:QCJ)3+7SV5,N;N++ITL:9S=Q93Z^XL&;-E\':U7;@Y#RJ9RF3O M4*DZT5!)+$*ESN*2K9_>40ZQ")7$(E02BU`I8W7E[0[9PJ1#[,$DL0>3Q!Y, MJO;&L;?VGXV"3I'5YF[MZ)1J;2V=OG/]DDMV/T6.>*]4;7+UEM=L+* M:OT"V2RT0W6]=3L@F&9-6[55$Y&R?JF.-$P3JS`MM.JRS^WJ$*NP3:S"-K$* MVT*K;LS"N4.LPCFQ"N?$*IP+K;H16,)+9M^XSM?+7V^V:)H1M7Q#6L?QMBZQ8>%\O2=/)N<5G5VD52 M<+*Y&,TGB%'P-XM'I:=^T^/?W+DN:OFK!\-$K4YE"BIN3 M%_VX=-3X\*1BDSX\+6KEW:BENV<^*PK387A>U!H77E1LTH671:U4S.0MW%=5 M8U\8'%>QU\TNGJL'GN7>I7X\63/6S3JF-_?I-E/KSG(K!N_$!"03#))EK.D/ M1@EV5[#&90@C_4$8:0L[!(,0TI;L"T;VI2VI%HSDMFU=)DEXE\F9^\0NZ?N, M&<:B:%R$^-'.]%+5RES/7"+858"1,=$C8X*1,<'(F&!D3#`R)A@9$XR,"4;& M!"-C@I$QPPT'4M3O?"(U[U4S!6$8U+'7%*5RSINU9<\5@J>C!4L%@J6"P5#!8 M*A@L%0R6"@9+!8.E@L%2P6"I8+!4,%@J&"P5#)8*!DL%@Z6"P5+!8*E@L%0P M6"H8+!4LL51!6*I@1(7$TE;3L93-SU$L3?I^+LU8=]9\)QAN"`8E!8.2@D%) MP:"D8%!2,"@I&)04#$H*!B4%@Y*"04G!H*1@4%(P*"D8E!0,2@H&)06#DH)! M2<&@I&!04C`H*5BBI()04D$HJ:#C@J-DJI<>,W'F^FH_<6:L/0*R\Q!.>`@^ M>@@Z>@@V>@@R>@@N>@@J-I"[ZE3M:Z_:+T\??N$6P*(H6.RDPNRPQR`MN6C8 M!\.PL:9+4BHVWEF"/;&IS7U';E0KRR3"EBTTYZ&(FV`$3C`B)QBARUC>2KC8 MI=+6'Q"[7"'K8V=8%[N*3<,L%5LPB"1 MK-V905?Q(JY5HW1.7&OG8"ZNJ7S3QC7@7OM%QUTN]_0!M!(0S&V6,*[J"Q^S MVERUS]3FCOL4M?S$8L77L_P#BZ+!W%3=$OX3^4/<(O)VD:R`Q][\5]()OZG9 M@Y25+V>0#-/8YY;+3ZK,').?7,GI\V/5'0Q7U]>G\OAH9TV[*_1E#V944VMK M_H:56H*_:&8*08KYX14&:4V/\/2RJ'55<&MJ)QI.]`-RQ85]9+/Z]T$NW`0N MW!9LGPMW16'OY[Q)"&FL:]SEQ#4 MNH3,#82D[P="QII"%&&NV,0E$N:LUE7L%2.PM;MRVR.*%9LP013%!%$4C+C5 M[N0N>I9V7W\`:VT3UYZE';K^ZY_X%&"Y,&*7]69GC*PV=R>UWNSG@39G6_>, MA^!:1W.SR"%N$>]#W"(%II;OI.N5K]R1D!FW')'Q?C)'!Q:'SU(_GN`9ZPE> ML0GV0?"LUA1SKP*,'-3N"@\@>,4F3!!P,4%T!2.>M3LE>-K4",%W?TX'7X() MH=FMG.7M4#\39XQOTI5K@=."$1O!B(U@Q$8P8B,8@1",0`A&(`1['&!/`NQI M@#T+L."'>#D(IO*%REEA3:0N%Z$`[5".GV;).$7$'4 M\N0L";E?1\+U(@GSFV/2[7HY"(<5B`J'2^%;_E&WVZ%;OJ(2"H=N^7A%)%P, MW2[B;A=#A!9QA)9#$)9Q$);;="EYDI!+.3D=(C2\CZ'"W2`N$V]\MIF M<"';U"?O!T:BU",OH@6B7;H&"CR1*'7(1CL0+1=#1!=A1%>)."R.@W:K9(T- M321*5\8OM$6BY$A>+_EX;%+R\JPKHI0ZOD49=)CZ"Z\KQ2D,4V)TS.>!=S'M MAAB%(5H.G(LHQW#GY4(!162JDI';193W`DWJ9O,*W/A_>XU,9K_*MSX=W]U3& MZWOK\^$=/I5QS'1QS@F9*(D=5S3)^\3 MJB^\\K@^']Y[5!FO/J[/>=)%T3ZU#&&Z7K\^&U4KUVWBQ=0^_PVI%MDBRZ=F1I.(77 MCBP-F?#:D>V2++IV9&=)%E_[.OE)[4"O@;O>AKCP$Q@JNTDRVD4R[O#K<_Y$ M]OC:Q?JP2!E:1!EZF*+)GRB:%TG& MGTC&>B1EB*_`1?:6:=2&[1ZE=OR)^KQ.,OY$LILDNXWM(4NC*&SWA*@\I8*G M7CXY6R*),O[D[`1)%,EG]/8LE#Q'\CR4O$#R,O3@!1Z\##UX@0TZ ME-P@N0WMW&#G-K1S@YW;L+<[>KL+)8^1/`XE#Y$\#"472"Y"R262J]#K2[R^ M"KV^Q.NKL+=']/8HE#QX<,H2Y0$OL2D3'CQ,L@M>NPUEK&`N>(TRE+&(N8C[ MO$Q]7H:RR]W9^4LJ[MKC.QJ]"]N\1_(^E'Q`\C'T_L.5WH9M M[NCM+I0\1O(XE#Q!\C2,]1,\>!IZ\`0/GH:]7;*PNPK7=3=((%8T;26N/@R[ M@\#G,1D3%Z]"MR]Q^RIT&^HBB2CRB-X>A9)K)->AY`;);>S!BKD[?TC$W;`O MV=]?A;O[&R2WH>1RPUV";QSKT+K<<$_B:[TJN4%R&TH>;M*.@R_A:Z.'F[3_ MY$OMD2AM1_AFN(H^L)7_N(Q6R)^0?`HE5(?H[T$L8RT'4<+2``4D-J?L2`(_ M*"8_D?5BC^(`$4U$T4H4FF8ID.,[Z(G*0M3LK@4C"CH9= M321A+\=^+I*\1O(ZE+Q'\CZ4\/.6:=<5!.\UDM?A];Q!\G89T>4-!9ZW>]IL MD41D>4/^WH8>\%.>:;<8^,8/>A*#*-;\K"<[VLBW%_CV0!)Y MP*^1I5UNX!L_7DKF(M_X"5-V@)%O3_#MZ9XVPTXTL,.;(K2)/."'/EGK1A)^ MJ@PF1KXE^O(>3&"'7R!+>_U`PB]?P=ZH-S9GK%2C*^63XTCB-L.^,[##.S:T M&3SXL4Z>O__TEW]__O7^Z>>OO_[C7[__\-O]+]1[%\/#B*__^#4],<[_\^W+ MOX?S5/_UY=NW+_\<_O/O]Y__=O\U*5#C_^7+EV_E?YC)?OS?+U__>Z@I__3_ M`@```/__`P!02P,$%``&``@````A`#,(.3QQ!P``D2```!D```!X;"]W;W)K M&ULK)K;;MLX$(;O%]AW,'Q?V[+D(^(4\4%G&8M% M=_=:L>58J&T9DM*T;[]#D4.)'!^2H#=5_&GXDQS.C$BI#U]_'@^M'TE>I-EI MUC8ZO78K.6VR;7IZF;7_^69_&;=;11F?MO$A.R6S]J^D:']]_/./A[=KO%9I\1)OJT;'0[?? MZPV[QS@]M;G"-'^/1K;;I9MDF6U>C\FIY")YDC+7Y5HNW7<3+V74Y;'SP>8]T_#BC>H7?T@\L=TDV=%MBL[ M(-?E`Z5SGG0G75!Z?-BF,`/F]E:>[&;M)V.Z-D;M[N-#Y:!_T^2M:/S=*O;9 MFY.GVS`])>!M6">V`L]9]IV9>EN&H'&7M+:K%?@K;VV37?QZ*/_.WMPD?=F7 ML-P#F!&;V'3[:YD4&_`HR'3Z`Z:TR0XP`/BW=4Q9:(!'XI_5]2W=EOM9&\Q: MSTE1VBF3:KC]\P'+RAEP%2(?G\Y0:,!5:(!WWNE/2,JJ?[A^ M?A(3(0+73T_"@#CD8<$"4L3%NZ=A8%RP/SX_$0,C@_WQ^:E@9!AU:-Q=D2[/ MDBKIEG$9/S[DV5L+*AGD0W&.65TTIDP0TXTGB4S`:_D'B<=4GIC,K`W+#"E6 M0-'X\6B-S(?N#TCTC;"94QM#M5B@!F:.H'9X7W,F6F"3I0Y6.K!UX.C`U8&G`U\' M@0Y"'40Z6#>`XDQ(F]_A3"8S:\._,EA-8Z!Z;\YMV(-'&@U5DX4TD1XF9$6( M38A#B$N(1XA/2$!(2$A$R+I)%&=#,?@=SF8R4%S@Z2$=24N#,+KE;6DBO4W( MBA";$(<0EQ"/$)^0@)"0D(B0=9,HWH:I*]Z^O-W!B,^:"]'CMU2)5 MWFRN@26-E('`0GU@(,Q:'8@@ZJ-`RZZ%-,+Q+PE9$6(3XA#B$N(1XA,2$!(2 M$A&R;A+%AR/-A_RAVF$;M]OKRAJJ[N1D,)&5?T'(DI`5(38A#B$N(1XA/B$! M(2$A$2'K)E%\!X'S@?ACUJK#!.'[>K:)6!"R)&1%B$V(0XA+B$>(3TA`2$A( M1,BZ212'P;98<5@CV,I]NOD^SZ#PPO;D0N294"WX_HV)J'[D9@2=)747, MOK;K6`JC<56'^CU#VP2NY'W,?%O*(G$(<64KMK,$5:U73]Y'#9]H!(2$LI50 MU;:CD;R/JNNFAK((['RAK,(%;\,1$MU=F:O^%LB$E6H\*/4]!UK!#DE:T46X M:&5.9,&OUGR%5BP*P*M]R^QI'K#1!!Y;U[MST*HO8\6M4:.A/@(/K?@(S+$Y M-D;J('TTN3F"`*WJ$80UNC&""*W0![WAJ*>.8(TFUT:@Q@$[!S3/4W?B@!\; M8'>$(38W.+*@0$J76R/-+0MAQ2[2ZD(<"/FZ&*Y$0Q,>1;*A-1JK<[:%55\) MLX%FY=2#P-&[%'F7>]2"T7]7CP&5#RF*+O8X)NO*G7-UCNJZLB-)T/ M.G>?Z.R-@599!;*4)1AKJ;<05J:R!*3A@$RKO8L$;>Y1ZURN]CPYL]!FA5RX<419=[K'>T58%;8\-K/:HKS`Y"S16^ MD[GBW-3,7([4S!WK6U_V[H<%Q)W,E5;H^)5HJ&;N6'M`V,+J:E17GG'J0:"\ M2Y%WN4>M%/GOZC&@\B%%T>4>M;JSOM>CNJZP^LJZ?FI_Q%Z-Z6G,D9;&6EU; MB(;WTIAK-?)LA0W%DZEG:M%MHP$TE964>M2*XQH;7>E17&@JJLM)W,IB9:WLPC@:6+'<+]@8(K`#= M\/(2K?@'"7;J6%%D(ZKE'8I<1+661Y&/J-8**`H1U5H116M$E9;J4G;$;1;% MSR6/."@W:R5'`[C(X)UH3XP%>VG$?`^U4!J1"%\**[6@ZEO-E;#J3ZK-KF&9 MUDBKS#::W'SB.O6@ZM(IYJ>4='T$'LKS$?0'UF2B/91]-+DY@H".(!3HM@\B ME!<^&/>&0\WE:S2Y-@(U.M@A_E9T?,O.D&`7CY[-PQ!_%P!=HT?G\(%19!VB M18UN!H-H6'V@%,<<@NQ:"^4=BEQ$M99'D8^HF8AD]"%:U5H11>R[:CUM[FK^ MG91_LCDF^4NR2`Z'HK7)7MDW4%CPQP>)^0?:^6@*;U=@8AI?3J9P^J;G%_AP"J_B@'?EB."#\#E^2:(X?TE/1>N0[,!9O>H%7,X_*?,?I0C0YZR$ M3\)5K.[ATW\"!;S']O:[+"OQ!^M`_F>"Q_\!``#__P,`4$L#!!0`!@`(```` M(0`C>D;B'!(``/)@```9````>&PO=V]R:W-H965TR'/_YZ>KSXN=D?MKOGCY>E0O'R8O-\OWO8/G_[ M>#E-._^[N;PX'-?/#^O'W?/FX^7?F\/E'Y_^^Y\/OW;[/P_?-YOCA=#P?/AX M^?UX?&E<71WNOV^>UH?"[F7S+#[YNML_K8_BG_MO5X>7_6;]D#5Z>KPJ%XOU MJZ?U]OE2:6CLS]&Q^_IU>[]I[>Y_/&V>CTK)?O.X/@K_#]^W+P?2]G1_CKJG M]?[/'R__N]\]O0@57[:/V^/?F=++BZ?[1OCM>;=??WD4_?ZK5%W?D^[L'Z#^ M:7N_WQUV7X\%H>Y*.8I]OKVZO1*:/GUXV(H>R+!?[#=?/UY^+C56E>KEU:'[[E=WOWV(ML\;$6TQ3G($ONQV?TK1\$$BT?@*6G>R$4CV M%P^;K^L?C\?Q[E>PV7[[?A3#71,]DAUK//S=VASN142%FD*Y)C7=[QZ%`^+_ M+YZV,C5$1-9_93]_;1^.WS]>5NJ%VG6Q4A+B%U\VAV-G*U5>7MS_.!QW3W,E M5-*JE)*R5B)^:B5E\>N9C2NZL?CY?@^J6HGXJ964"C>U6K5^+*7]X=6#E-LZZ4>7C>D:^R5"@U/#[O"&R9)H_\Y=S`7JF"EM7'UOJX_O1A MO_MU(18=$9?#RUHN8:6&5$B54=6QO%:^5BI%C91:/DLU'R_%2(LJ>!#U_>>G MZFWYP]5/49/OM*"D0O&+IBX('7!U`4S%\Q=L'#!T@4K`UR)-,ES14R#?R-7I!J9*S3* M=P0X>9S4:9($-6FYH.V"C@NZ+@A<$+J@YX*^"R(7Q"X8N&#H@L0%(Q>,73!Q M0>J"J0MF+IB[8.&"I0M6!K`20Y3%?R,QI!JQLS**2*54LTO$G9*1*UQ>:>JV M2#,7R;,%2!M(!T@72``D!-(#T@<2`8F!#(`,@21`1D#&0"9`4B!3(#,@(+@4:2%?%N4B>18!:0/I`.D""8"$0'I` M^D`B(#&0`9`AD`3(",@8R`1("F0*9`9D#F0!9`ED91(KB\200A:5:P6!3W_7 MHPV,;)>E#0WWG2;%;#?CE*%F_J&9996\$%DNB52T7/([(J5M1S2Q-U?5W%:V M4VKF0N1_"T@;2`=(%T@`)`32`]('$@&)@0R`#($D0$9`QD`F0%(@4R`S(',@ M"R!+("N36+DAOF)9N:&VWP7Y==R?)K*AG2:*U&[S?5432`M(&T@'2!=(`"0$ MT@/2!Q(!B8$,@`R!)$!&0,9`)D!2(%,@,R!S(`L@2R`KDU@Y(2:ZE1/^1)#2 M=B)HH@Z?Y->H)I`6D#:0#I`ND`!("*0'I`\D`A(#&0`9`DF`C(",@4R`I$"F M0&9`YD`60)9`5B:Q$D$<;%F)8!2'X_?M_9]W.W7F>")!*F+54M_,I1([/Q2I M5;A0Y(17LTK9^0[6TD+"6V-CY:R+[5R(EJ$.D"Z0`$@(I`>D#R0"$@,9`!D" M28",@(R!3("D0*9`9D#F0!9`ED!6FF2C:F61/.'\YVF4:;'S2",SD1AQDF`F M::EZ.=M:E8LEWCAE.=MF@3R-$'41!8A"1#V-#,?[B")N*(^SA)?.A(A9@+P< M(!HB2A"-$(TU,KR<($JYH?;2.5.;L@!Y.4,T1[1`M$2TTDAY:>>=/$;"H\5L M;W-^^2JIPRCQ?8[1UISJ%&UFGEPZTR8'K4PK5=OK^UN M]$FJG,? M,;4Q[4,$)B3%$4@9>2(P)2F=`3?%>MT9@QF)F!Y`!.8DY8W`@J4H`DN-1`0, M/ZM%>XA7U-"4,L-@SU#AA#5#3VPDQ*4%[23D'9>SE="HEEW=JB^BC`P_W11O MD92Z;)6;U#:B#B%6WV7D41^0%*L/$?4(L?H^HH@0ZXH1#0BQKB$CCZL)2;'Z M$:(Q(58_09028EU31#-"K&O.R./J@J18_1+1BE"FWLXW>?9GK@AOY)L^*C1+ MOT)E>Q-Z8T^"IKQ%%8DJUB1/;UI:2LP8FF-M1!U$W;/4!]@P1-1#U&?UY%>$ M4C&B`:(AZ_)$(L&&(T1C1!-63ZZF*#5%-$,T9UT>5Q?8<(EH92$[!45A_)T4 ME.+.KE>AJCBAR1?ZZJVS8VC*NWC1L"[VWKD4+`8M+25V'Q2_-B&UT%1N:\XR MTR$!8>!US=VS[`>DB^V'&NF%MEQPYE:/FICFS04F6P3Z;)XZ%E%#MA43TGTM MN=\#!B1@&H,H#MF8)R()Z6+[(XUT7TL%9T\WIB:F>>CKA,U37U-N2&A*2)P$ M\K"YR_>,I,S2+*R_F4D+:LB]6VKTUH9!J1 M93^@[K']4*.*W$N))R/<1.N=,F\.@IY4JA?&%\((;<6D2_>U=.-D]8`$O'T= M:BE_K!.T/])(][6,&W4]%J9YZ.N$S=,,2C428T1H2K:L*HN3*K=(#>>LWC/> M"RUE[!"69%&HY$1Q+:ZTE)5.9A_M224O!\Q)]<:N2-\EF+LBA:Q=>(X,/W$7 MKJ5X0]>6%Z=BHR\J@/2(IUA8AZA%A]'U%$B'7%B`:$6->0DA&/#CE9MK64GJKAV MT^M`0+JXVH0:Z>V"<[C2HP:O+:2ZAN?&*6P1-61+,2'5U=ORK7/,/B`!TQCT M=*BE_)O0A'2Q_9%&NJ>5@G.V-J8FIGFSOF5]G;!YZFO*#0E-"8FZ\WI%G9&4 M.5OR4!H-W41:4$/NW5*CMS9&.MU>ZZ,]I^0=CCFGWJCA^LK'G#P*634\1YX. MMDI:BLM!&U&'$,>OR\BC/B`I5A\BZA%B]7U$$2'6%2,:$&)=0T8>5Q.28O4C M1&-"K'Z"*"7$NJ:(9H18UYR1Q]4%2;'Z):(5H4R]G6_RML?,M_?5<'5G9-5P MA:P#%O>TN5G*[YH\?6QI*7DBR1/;/5IN:RF]-2]5*]5KI]AU2,3<,4*QZY[E M5,!.40$*-=(;UI+[K:-WRCP4NSZ;)\41V_($(";U:K]>KHFS!-BQZT'Q!F#( M'ACFW'J8L%/DYTBCUP(P)@]-\Q"`"9LGQ2G;,CQR,V!*ZE4`2B>/UL\)P)P] M,,RY`5BP4^3G4J/7`K`B#U\+@#4UY1\L>*=FNGL1)TIO/=^3J;%/GC0REPA& MGBZW2.HZWZNU$74(<3'K,O*H#TB*U8>(>H18?1]11(AUQ8@&A%C7D)''U82D M6/T(T9@0JY\@2@FQKBFB&2'6-6?D<75!4JQ^B6A%*%-OYZ&\V327"/^6I"S% MG7Q32/S1"\V4II8R4`M1&U$'41=1@"A$U$/41Q0ABA$-$`T1)8A&B,:()HA2 M1%-$,T1S1`M$2T0K"]DY(BK:[^2(%'=R1".Q"3]FEE:C-WG&U5&WHCZB"%&,:(!HB"A!-$(T1C1!E"*:(IHAFB-:(%HB M6EG(SA%Y1O]*23G_83'Y%[9NZBAD7)HTM93_:J-%4N;*5G4/XMHL17ND#J(N MH@!1B*B'J(\H0A0C&B`:(DH0C1"-$4T0I8BFB&:(YH@6B):(5H3P*5CYM\W_ M0H*IVQ%K_=(7)N8N.4>\*8(#BU;FD7A$X-6G8%F`<;\1,Y=TK*/9%I MDRYU_5"_J;A/>W9(0BS"KUOKDI37IX"E:&A"C?3]0_6ZX%ZV4!O3/AQ)]4F* M9TO$R'#<#4!,4BH`Y:)XJX@3[P&)F!Y`O("Y:B>"PU MHGA4W8Q841O3OAD!>U+*.Y/?F)3JBL6:E`HY#ZPXP]*4Q^AR/R(.4EZ?)BV6 MHNZV-=*GXM5JY=J)=X.H^\C4\9AZY.4&W*#P_SG`/]%LL17UN$]+U^[;B7F%U2,(L%U"NNB3E3;N`IYNP%/DTTDCWME1RB\68VICVH;<3DN*NI8BFA/387M?F0@#=\7=;,906&(F`ILA]JI"LR+C^GS$-&]5%QQ`W)5DRVO#5Y@`V' MK-[3NX2ER.*(+'IK\I@MLGKHXP35I]R0+$[)HK>/,VPX9_7L!(S@@J7(XI(L M>ONX8HNLWNRC/9GDA=3YZX[\`T'G-$@C\PJ5$7L`'6R1%#^PT4;4(<27?5U& M'O4!2;'Z$%&/$*OO(XH(L:X8T8`0ZQHR\KB:D!2K'R$:$V+U$T0I(=8U130C MQ+KFC#RN+DB*U2\1K0AEZNU\$\7-RC?CGN/\0TFY?7'34"%I.?]>X&Y1FKJ= M_^F]EI:R]TCN%]HV2>DO<*>>LB$1[ZK9U5)^IP+2Q2MYJ!'M$>`I&VIBFC<+ M@=H0L7FJ,Q$UM!8B-P`Q2>E=PZFG;$C$]``*P9`]X*$#J81T<0!&&KT6@#$U M,>`"Q(%P=@J1$%H%9PCE16 MU,:T;T;`GIN>.\AL;I[WF$T%+R0ULM8(?4=I>@:1:5%#?F*CC:A#B*M9EY$G MI`%)L?H048\0J^\CB@BQKAC1@!#K&C+RN)J0%*L?(1H38O431"DAUC5%-"/$ MNN:,/*XN2(K5+Q&M"&7J[3P4.0%K1+DB7R-]Z@U.V88VJV6?Y6/J[KJ@4-VX M2]!2!FHA:B/J(.HB"A"%B'J(^H@B1#&B`:(AH@31"-$8T011BFB*:(9HCFB! M:(E(OLI<#JT:-)4NZM7DZM6[3YO]MTUS\_AXN+C?_9"O'1>/<7WZD&/U3O2[ M2I5>BNY\(MZ6_CDKK`Z_$V]1SZ[(75YNB%=WB@7#Y15AX`3_7&W([#S10'AT MDM<;XA5G)^2O&^(U5R=X67@J'DLZ]8GT]92SK=N&>.L-MFB5B@WYDA?\1+S! MI2%?K(*?B+>F-.3+3/`3<>W;D!>+ISZI-^0U&GXB[L@:\NH*/Q'W4D+;J4_N MRB+VXI$)T>8J'Q7QQOF7];=-O-Y_VSX?+AXW7T5J%+,7INS5.^O5/X[Z"=(O MNZ-XU[PX%Q"O;1;_;8&->(N".&FZO/BZVQWI'])`_E\K^/1_`0```/__`P!0 M2P,$%``&``@````A`*8)30D2+P``D@P!`!D```!X;"]W;W)K&ULK)UKD]LVTN_?GZKS'5Q^OV/=1YI*\E0LB7=2=YW77F>2N-;V MI#R3S>ZW/PT!S0;ZCZ$H/TFJ8N?'1@/L;C:`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`_WWSY9.)#3+)A__\^'9,'7_ZY>5W^MOL;GH_&`])_,T_'Y]?DD]&Y=LW M'_]\?GGZ\O^LT-"ILDHF3@G]&5'2T9"ZN/1.?W+#Z=U\.IW,YO?$.EK.7$OZ MDUMZX^YH>.\:TI^NX>QN,IK>SR\GW-&0+IG+6.G/VWI=YG#$G=)?;NN48L@.5X*I[YER!`TEA'J>*8>0 M"?H;SY1C:"A!U+-3#J*A1-%XU"^,AAQ'YB]NP.:LN^*`(V@H(=0S:$<<0N8O M-WESQ"%D_N):CH9W]\/!8GSEVAQQ")F_].GTG4U*EQRW^O#RX:R9DO2_?YH.[G]X M]V_*JQ^=S'N4&8822Y8P2=2H76FPUB#1(-4@TR#7H-"@U*#2H-:@T6"CP5:# MG09[#0X:'#4X:7#VP#MR<>MGCQOB9/?2>@3A^I)S*$MQDI<%:@T2# M5(-,@UR#0H-2@TJ#6H-&@XT&6PUV&NPU.&APU."DP=D#@5-I%@"GCBD-Q9MSD.GO;YN/6L9BIG5"7]UN1 MUOM`UD`2("F0#$@.I`!2`JF`U$`:(!L@6R`[('L@!R!'("<@9Y\$WB=7!-[O MOL*-],7)[)SWC@PN4[.^DMN#?DPLVLL]&`@%S@T#,=+A0"RYIXPF\3<R`[($<@!R!G("_H4K]QPC"*0G<[$KI;K_I:H=;=0-9` M$B`ID`Q(#J0`4@*I@-1`&B`;(%L@.R![(`<@1R`G(&>?!.ZF;>O?XVZC*'2W M(]2UE[''*F.W0JV[@:R!)$!2(!F0'$@!I`12`:F!-$`V0+9`=D#V0`Y`CD!. M0,X^"=QMRE5_C[\OFD*',PH]/E$>%ZG6Y8C6B!)$*:(,48ZH0%0BJA#5B!I$ M&T1;1#M$>T0'1$=$)T3G`(518#;[?O&F>U5H*I7JVG9(+<>FVM6V(4F)JP&M M11=+)8A21!FB'%&!J$14(:H1-8@VB+:(=HCVB`Z(CHA.B,X!"EUM2@"^J[][ M/C?59QT%#H47O-XE<$,I_JP0K1$EB%)$&:(<48&H1%0AJA$UB#:(MHAVB/:( M#HB.B$Z(S@$*H\!4!_Z>*'!UAEE[2;\?.A1&@2KB+D6*K_(5HC6B!%&**$.4 M(RH0E8@J1#6B!M$&T1;1#M$>T0'1$=$)$=W3M-?IY7(+H\!4"?PHN)+V75'! M=[5%*NVK&N#2W#.A3!&D?4!KE$H0I8@R1#FB`E&)J$)4(VH0;1!M$>T0[1$= M$!T1G1"=`Q2ZVI1F;G"UJ^3XKG8HO*JEN&,++J:0:"8%/[<#6J-4@BA%E"'* M$16(2D05HAI1@VB#:(MHAVB/Z(#HB.B$Z!R@T-6F/'.#JVTUAPJYG(??FZ(N M.7%JGQPP]\^6B%:(UH@21"FB#%&.J$!4(JH0U8@:1!M$6T0[1'M$!T1'1"=$ MYP"%?C4EFAO\ZBHZOE\MFK2>7IJ;XN1I(2L@:R`)D!1(!B0'4@`I@51`:B"- M3T*34;(*3&9O2M^9F^(OOW_Z^*_W3U2*H!U(9.(;4X7;W9(V6M3.UB'9R"S- M,P)&RB](CT>JFK5R4A/JLRV"3!9JG[06*;XF$T0IH@Q1CJA`5"*J$-6(&H?H MM&FHH?%-T<&/U^\SOBM=^&'LD&_\%HE9(\:W4I/9Y>;%:#!4Q:>U>6C#7`[2 M6>*0/;]+/*2".CK+1)=YB($Z4Z&0BP`[N1#-C$I!'9U5HLMUIHKFM0BPYD8T M:\^9!U`"ST4N#WKDC*^/BWAX?3@T]L-\H9>%3FA$.:B]%M!IK"JXKL9JW;%F M*7/5_ONGX>!^ILR=L`0M/%_O+>TUIHQU=8XI9RDWIO%@HKQ2L$3GF,I>8ZI8 M5^>8:I:R8QH-9@-ER88E7AM3<(V/3/7F?WV-7[2H`#**Z48#)=766PLUU"6W M"TX94BY+R6IF[=!HP8E`;4X3%NC4G++F3JF,I:3_G-7;_H?SB4I$!0MT:BY9 M2D07JT\%27R!^@QUY8@*T<7J2T$=ZBO452-J1!?DZ5@5 M9SB]<7DSP@J.0T'Z'HYT'<])7R6/,WT[*YTVMY MR<[-O<:4L:[.,>4LY<8TF<_5K8N")3K'5/8:4\6Z.L=4LY3+WZ/16*6NAB5> M&U-XZ9)4<.GJ-=KQZ0^Z5*,+9'\%8-2H2]JBX))ND1<)F*ZMU%@J".L1H,0A M3WTJJ$-]AKIR1(7HDDNZS^@KU%4C:@+UH4-,L41/J-]UN]V\$Z!]TE9BQ$+3 MD7YFAAN*`U:(UH@21"FB#%&.J$!4(JH0U8@:1!M$6T0[1'M$!T1'1"=$YP"% M47!;"6>$)1R'PL+L2*T_ER+%8;Y"M$:4($H198AR1`6B$E&%J$;4(-H@VB+: M(=HC.B`Z(CHA.@S+_F0O>7RE.=5I-7SVT0K1&E"!*$66(2?B!K]>Q,-UL4-2<5\"60%9`TF` MI$`RGX2G\;>4;'C*O:TYJ.U)9[Z:3,+-M*1<+)JI]9&T[NX`Y+ M+S6)DVK5J/LT:2\MF=:R$(>&)C0[3#\4KYC0;DC]I>#8[5'#]8$:]=))7;E3 MY:1FYE99^RJFK@&M>^E*XKI4Y2+MI2N+ZY("9FA2O9V^8E+<,X\M4E&IBE-+ M)W4M*JVN&6W7Q*1CM?]>]]*5."FE2RY.6P[KI2MC7?>7C#.XFT[G`_\?":#0 MN+?M4L>X2W7(K*,\@ZA$M>2&G?ENY:1F6+-0RNIN]%H=F(EHA6B-*$*6(,D0Y MH@)1B:A"5"-J$&T0;1'M$.T1'1`=$9T0G0,47B1Z$V4NDO'<_#A*[($-PGQ' MFG[%!99C#M'"H$TUH[E$E+M*(E+3L:Q!@O%-]&;`C(]V9U<&=VD6;@H8A8-3 M\^,R)C4=RRF$@XLM\7L9SZS!U5J643@^/0G&I*9CR2#A^,PJU[]H^V;`B5T> M^\L>1O[PIOK&R#(N]T0'1$=$)T3G`(6NOFTG0L_WP0QGD5=;73HI#ZT0K1$EB%)$&:(< M48&H1%0AJA$UB#:(MHAVB/:(#HB.B$Z(S@$*_:JW25Y^$IK]M4S7!395#]A<5[?):D"S" ML7CGI.YI>=TNU:?ZVU%/*`P(?S=F;C9?N19Q M"S:Q*`@(0"LGI;RO*@AKD>*A)Z@^191)0]\RLL.[!&HN4JR^0%TEHDH:=JBO M18K5-ZAK@V@K#3WU4[4BV8D4J]\'N@*_3OU=['6_7L3#G8Y#OE\1K1PBO_*@ MUH@2;)@BRJ2A9X:)[(2M$T6*>RQ05XFHDH:B?GPO.\6+^EJD6'V#NC:(MM+0 M4Z_+P#N18O7[0%?H1'^WW\.)N,4W=0M31;S\_JW-UHA6#@5.M`T]E&##%%$F MNL0,]&NR8>$V%RDV0X&Z2D25-/35JYI*+5*LOD%=&T1;;+A#M`\:AA[SZQ_& M8Z;^6CEI.[EB>LUH@1UI8@R;)@C*K!AB:B2AK[7X-*S M)^2-OD%=&T1;4<_NWB':!PU#K_EEH1[7F:T!^7O*J45AM7ZJ[MLLG=25:CWK MDEO,:T;V^>#Y>'$_6*C)+6$9JFVTZRM80J0R!#95Q@W)^M)0ESYR)T4;G(W5-=[8BDIYM>(&D0;1K0_D'/1ZKIWB/8!"N/% M+S?UB!C49#O9Q(7#/S M'D([A$B\N+%+,&;87^X0W7$T_=W?+=29%+TZ*UESYY`J)R6;OQI(`V332_<6 MVNV`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`#:8!L>NG>0KL=D+U/@E"9W583 MO(B'TX%#:CI0B_VED[HR'3@I?SI@Y%[-G8^&BZ%:/B4LTYF?4QD"7U49-Y3@ MR1UR>]KAD+[L$]:I"F[4V5LIO77%!4M)NJX1-8@VC+IG`Y82]3M$^P"%T6$J M?OX:HOM.P,P6"/TBB$-JJ:EW+]RP\U)?L9272!P*EYHS56-)G-25I2:KEV#( M&$F/N?1H=R_3H;_27.BE9K1KG1Y*[J?S_"LGY241(`V032_=6Y;JS)D[)^5J M"$,J(*@I8<\2_IF\NI.9D=0MX67$5?*Q2"4?Y83EI1]Z0*OS8EDYJ2#Y./7^ MI3Z%WYOAAKX4KD5E$))^K'JOQ]Q)N?1#51-UJ131SC"@K.;N,ZYX2)(>:D0- MH@VC3H-N64K4[Q#M`Q1F'UV"_:X=S`PKLPZII*1W,-R03"G+"&WI%4M)BE@[ MI)*2NK?0;@=D[Y,P7N@"O"6=&'&53BSR]R[T1I"1(M09!5;*W[NXAAY*1!>G M@!11A@US1`4V+`5U#+42*1Y$C:A!M!'4H7XK4JQ^AV@?H-")IM+(2PYS<5Q9 M5[C<4$U8 MB,+B]=R1RAC85ADW#)(.[%VMF4L$RG\I25^Y.!&Y7TESLI5PR=XXV77IV5TEEG<#C; MM:=;NW;^9*!E-KUT;T'3#LC>)V%84-3=$A9&7$T&%JFUI9K&ES,K=2V/6*D@ MCSCU_B4ZQ43B&OI2D;5E.PB.NLR-R^LQ=\AECNK?0;@=D[Y,P M#_FU6&/E[]O$8(F67KF\1`_-].V50:_SA@N!I9.ZEIY<+50FEC6K#ZZ%F5IG M)$[JRFT8&81$#_282X\V>A:JC%-$.\-XL9J[S[CB(?D)R344U*#4AM&5A`2Z M=MQ0U.\#%$2->2;VAMGK(A[.7@[Y6QE!$C%P0W/EI+Q]RQI1(KK8I2FB#!OF MB`IL6`KJ&&HE4CR(&E&#:".H0_U6I%C]#M$^0*$333G47YE^UZ5/C[[IE8E# MZNZ,OO2Y86?B7+&4I/$UJW=W9X;CT6(T5-H3%NK4GK)V22P9(W][!H],Y$[* M+6+O[W0NZ-5]R7UU#K)B*3%!K;H/DVK3J_,-J^WL?,M2G>;8<8_6):/I7#_A MOV<)O[>I5P<*(Y.D.B.SWX^!FC[Y=\6Z)#&L&=GE^?W\?C88Z3M]+..O2F`*2V4(;/J, M&_J71R3KN$*F?:!U=J>_2%NPFL[^2^F_P\\5ZQ(3U`ZU=1U5@VBX26?WFU[= M;UE7IT5V+&6=,IH,YLK?>Y;PQ_1ZXB&ISMCLF7B,&K7>L2A(/"WJ<,/JWDH% MB0=0XJ0\]2FB#'7EB`IL6`KJ&&J%NFI$C>CBZ-\(ZE"_15T[1'O1!8G'%!UU MXAG1;\*8+4KO;["8+[9HWUH4KG?NU9)@R0V#@-;;@Q5+R62_=HB?C)Y,QT-] MVRUAF4[E*2N72SICU#F_YT[*+7<6=^/P9YG4XJOH-9J2N^X<<\528I`Z'`U5 M$/7ZQ_FC4_&&%7=*;5FJTSX[)\4WGN_UK+-G`;^SU[.0*4CJ0/7?R.F9A5SM MU9\B+?+2Q/*^11W7WLI)!5G(-O10(KKXTDX19:@K1U1@PU)0QU`KU%4C:D07 M#W4CJ$/]%G7M$.U%%V0A4POUG=M]`^G>ED[]&T@.T1M=//0EHA6B-:($48HH M0Y0C*A"5B"I$-:(&T0;1%M$.T1[1`=$1T0G1.4#ALM84%WV_FMVT>>ONBG]= MF=*_2!VR:YI_P#S2'I8PG=[+4BPK>EHB"P'/(#4RZM&]I M<@M:I$K%[UYN2`0#F]]60;J(ARLJ1F0.KSMUEV`I4GRQK!"M$26(4D09HAQ1 M@:A$5"&J$36(-HBVB':(]H@.B(Z(3HC.`0I=31=!$(/=5\3(#HB. MB$Z(S@[9T8>A8XH0?NAJV9A'$B$7FMR2\"5S=PEO.7;&#UAZM5"1LK)3Y M9<56:JI_*&/M=)$4&RMA)#^.F`H27=!CQE)!C_JG='*1XAX+1M)C*:BCQXJE M.GNL18I[;!SR?G5A(ZBCQZWH$BEXY7LG4MSCGI&N"%L;#4DR&\6!6'C:B;RVS:KN44J;&#":Z5XZ(EK MZ(5@BBB+J8=?$,I%BM47J*M$5$E#W_!J]+5(L?H&=6T0;:6AIUY_D'$G4JQ^ MC[H.B([2T%.O?[WI)%*L_ASH"L/FMO+.',L[#@5A8Z4\5Z^<%(4-#VJ-*''( M:Y@BRJ2A;P8U$>K:(-I*0T\]KI.L"3U[ M[5'7`=$QJEZ/_B12//ISH"N,$5/!\5/+=SUX,7=U(*]RY%`0.E;*BX"5DZ(E M-H]UC2AQR&N8(LJDH6=\?0\N%RGNL4!=):(*&]:(&FRX0;3%ACM$>VQX0'3$ MAB=$YZ!A&`&Z+'=E\8RUN+E%XPTA8UTRA-RA]G%@-:D4W*2S^[)7]Q7K\I>=6I;Q4R>K=TV>+T62A'TU/6*93 M>W5>L2[JOP^[I>1(]+7";SOXWO?K?LB[I?\?( M>8!>TJ$7&\)'(O8LTSF$0Z\A'%F7#.'D4/M@V%!%P)G;O-9_&/-T!0;KX^[5 MT<*(JSG`(C4'*+\LN6'G!;]B*;G@UP[Q*W/T`/(07CU@F4[E*2OOE,I82H:0 M.^1RSOPN_)D'_7Q0T6LT)??3.9J*I60T-8Q&;1Z;7OUO6'-G_UN6DOYWK)X? M"9_<#\?JH:0]RW0J/[#R3JDC2\D03@ZU#M%9X'RM__`2^%MNS"SPQHQ#:C90 M[EHZJ6NS@57OO<.W9O4V%XT'P\5LJA8$"K: M(=J++E9_$-2A_HBZ3HC.HHO4AV&C[P-]5]5M@;>'')*`7[)0YR2R8BF91-:L MBN>QZ*M-+-2I/67MG5(92\D8R\8BG:LT@!2;\67:OQ MZ%>MFEXCVG!?G2/:LI288\?JK4NBKWWL6:93^8&5=TH=6:K3*"Q\F*EO*>+UTZ7AQ)4GPKJ M4)^AKAQ1(;HX5Y6".M17J*M&U(@N5K\1U*%^B[IVB/:BB]4?!'6H/Z*N$Z*S MZ(),>]L]L`7>`V,4/-LY5ROZI4CQ":X0K1$EB%)$&:(<48&H1%0AJA$UB#:( MMHAVB/:(#HB.B$Z(S@$*,X>^E75EJX[WK!86>9\B72):(5HC2A"EB#)$.:(" M48FH0E0C:A!M$&T1[1#M$1T0'1&=$)T#%/KUMAM4"[Q!Y9!Y#[2=W*=SM?!? MBI1#VVZY6/EP0]6R(&$O5!5RZ8FQ;U<1MHZP),+2",LB+(^P(L+*"*LBK(ZP M)L(V$;:-L%V$[2/L$&''"#M%V#ED*@+,70-__=>=Q8<#(Z\CP#+O@7QR-S!R M-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R-S!R M-S!R-S!R-S!RM\^4NRDGW^1N(Z_=;9GWZ/YPH!$Y6R/RM4;D:HW(TQJ1HS4B M/VM$;O:0.FM38[HER&U-RM_-#`>N3B7/[U&0MTPF.G@,@DQAQ<+G_/1O")%Y M6C'.D&2?M@=F9"!@9*&VK8QDJA_;(*NU8JR.S.:K4W:[K=PV'&"]C9GW,!'9 MSDR4C-2*\1F0D4`=&0D8&:EMZQM)W3(D([5BW`49R5>GC*2+ M2],NR$B^.F6D:V6&7F^;#`=89F`6VLZ5$.1B)=M9YC_[%F%D*&A+A@)&AFKU M^89213,R5"OF&4UT=)--:,7=S87P'/W'/$N&/ MP'D%)V7[VW:TPP%N:9E=^<56%NO^/6NRO>M!BI)T<5O6_N#`G)9W:K5-QG=" M-"5V&M_IEPT7&1_Z)$M;YFJ.P]'=1$437?Q7>E2FOFV3.1S@+I-9^"NH^@$4 MRJ.VZ=4PMV)AF%M&`296G$6,[9KZ8OA+J-Y`O$B'7LG8;:_FUP;)V&.5X,G8 ML1Y?C>NAWN5]U^V/X46-6@LZIL)=S1;+MFEG.*Y:,3_<70\4>KX/U"/D"3>] M\F.A+.:]DI>U3'K-F;F`G]SI]\D*E@@[?-T%9DE^PPJ4?BT5UMV.^07UH3"Q M#B19,JQ5Y]^\C#"RHI7SND@CC$P&!R1+NZ9T M"JU8+!R=F%QQ9&G+W+0VG<]F>L(G2SN93O44L>TH)-$RDR[)TE:.9[7AG7YU MA`+X2H_*TF:7<(NEC;S.J)9=F]6&5NQJ3%NQ8%9S3=6LIN88,K9K2G^(+_6O M^)*QVX%XQH9>R=B625CKIZ3(V*X9_2$]OIY2S6[#-_9WSFIVTQ)&NV579S77 MM#,<*?DZ,0D]BG;+U*RF'Y=BL7"2B?B@'8CG`^B5?-#V:E86"_PX`TN$';[N M`K./\5UP9>M+1L9XM\R;")>,2H:U8N&L!HPBN57'YJ&P!4:S&C`R M&3"*4Y^I#&"V)+=8Q&YA2",/[?UP:)F:U=2T0T:R8E#*#%QE:H=>N1I[6VF'P&9`AH4\RI&5\_:L%'!G5M7FM.V5GL]NXQ/JP36]=I4[L>`JMXSGM)'Y[3Q8/3B93O44K^TH/#-#EV1FR]R<-K^[ M5SF%#'VE0V5HL].XQ=!V9Q(&M-O04/9I\_H4-VI#*W8UH*U8.*6Y'OS@F0W4 M-H02@6OJBT4V:C(0S];0*]FZ[=6FT_ONCPJP?,]EV^COV;5=U*@UAF,J\I6Y MED-NVAF:JU;,CWS75,UOJCB6<--PNL'Y308B#F$FO>:LCA=T@SMU2@5+A!V^ M.K^9!Y5N"?Z+O+:UOP6ZY$PR;,OD@H@LDYU8,+\A(RNVZM@\:81E$48F@[9D M))^%Z<`8+K#(]RVZ+FJTH8QJV,RI.A/9SHI=RQ).+,@2S'C:&]S3):GS,0L% M.<*+$#?MR3#8YF1?=P;T1YOGX%52,KD5XYEP`,]$DP>Q('EF6,4$GR>Y`*W*:(PD?/4)J*\8,6\A_;6$4;AVZKC+BA\@9%Y M01_9$A@9SV^K+$4QU9<$Z,O(Z3BT+[G8[.8_1Z8,D#H],'5D98%6%UA#41MHFP;83M(FP?88<(.T;8*<+.(5/N-OL=?6&,Z>L_ MQ*]YWFZ5@G6,:6:B@>)+XA[OJ\3$9MY[#VJ,9C/AC_':P.SF(QR895[XT44* MC$(2&(4D,`I)8!22P"@D@5%(`J.0!$8A"8Q"$AB%)#`*26`4DL`H)(%12`*C MD`1&(0F,0A(8A20P"DF?*7>;;TA9T.Q??`OJV:[?K63S@BBD=L=DKTS7 M4 M:B58.;FH51DI.\XD%^=A#PC17[M M,P;R:Y\QD'.#,H]?DX1`(PB`!A%`#"*`&`4`<`H`H!1!`"C"`!&$0",(@`810`P MB@!@%`'`*`*`400`HP@`1A$`C"(`&$6`SU0$F,WP+1%@-\_!/$%U@$M4A#E` MS=$4`:T8SV`4`<`H`H!1!`"C"`!&$0",(@`810`PB@!@%`'`*`*`400`HP@` M1A$`C"(`&$4`,(H`8!0!P"@"@%$$^$Q%@-G1WQ(!M@(01H!EP1Z);NN;J/`8 MN1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8N1L8 MN1L8N1L8N1L8N=MGRMVF@G&+NVW%(W2W9;(`HXM;(W*V1N1KCA*=_#7.J8OT=B.;J"VQ56 MI)[MQ#KV2"+!^9>L#QV2^5O6T2&YQ(I)AVK*)P^U$MPAN:A5SHQ\U+*.#LEO MK;K7]D@BPR8E1 MMN83H&O&]>">DEJ,IU!69Q$*V780$"+DV#Z#(,>Z#F40Y,I@$-/92/_Z#'G6 MB70.@IS=9Q#D;!@$7:7!(&;3N7[MD;Q]91`J`$P=Y)8`L'63,``L,UOQUO:S M(3Q00/>9+E?[M:O8B?GA!'ZD4S!$Q>0.OQWCN^??'Q]?5A]>/OSTPY?';[\]+A\_?WY^\_'ISZ^DW"P" M/?[FV^.O/[Y]3]6`!SKAR\^;MVW:8T-S['(W$H^-S+'+G(#'QN;8Y:,4>&QN MCEWJ/OK8XO[!_`0"375PA!K12_2Q(PLZA.3.G(-'ID1DDBVIJ`G#Z!$3A#%?FOK_PZ7$C^.E66#Z0&D_=BYF$?YP66=C.[->)IW1=C\/ M'WZ.>X<&&!LYN3,J3P$0\^7/DX>?30[#4;TW%U2$TYM1$SH3>A,4V]`Q;C^2C:+7'7TKAT(E M&BMF)._C(S$O.C_0?^*CI&.7=Y?QS.G]M8DY%K,8'3,Q$[48'9N98['^Z-6V M\0/])W:,7B8UL2QD(?&Q@NQ6*!O%CV87__'5O3IH@?S$0`\0I\K>C`? M(XH=F=*16"301T?H2&SD]*D).A*[MNE[`W0D-@+ZMM.#^?X!CH`^\?1@/H.` M1^BS3@_FHTVQ(U,Z$ALU?8F%CL1&3=_?H".Q4=,7%^A(;`3T#:P'\P4('`%] M"NO!?`@"C]#GKQ[,QZUB1RB!1$=-GZ>A([%1TT=)Z$ALU/3-"3H2&P%]*^S! M?!8#1T"?#'LP7\?`(_29L`?S$;#8$4H6T5'3-WOH2&S4]*46.A(;-7V(@X[$ M1K"?S!_VTUA6I&_MT9G&K@7Z]AS%6^S(>SJ?]]%^Z$-M#\OHD14=,9]>0QO0 M-[/H2"S>Z+-(="1F`_KR#1V)V8`^;$)'8C9HR`9-U`8;.K*)'MG2D=TDIFT[ M6="1V*RQG0X>=O;K*VJ>WTZ'="0V9VVG(SH2\T]!(RBB1THZ4D:/5'2DCHZZ MHE'7T5%7-.HZ.NJ*1EU'1UW1J.OH"%;49AUMLZ(VZVB;A$:=1(^D="2-'LGH M2!X]TXS.-(^>:49GFD?/-*-1Y]%19S3J/#J"U=`LAF(1LAHN:.J*14A&1_+H MD8J.U-$CJ_'P(8OO=L@&[Z-C6]*19?3(BHZLHW9;D=W64;NMR&YK:[=W;6`_ M__3#'Q]^>ZP_?/OMT]?G-Y\??Z7-W.#.?.G^VZ??S/;3_L_+TQ^TR7O[YI]/ M+R]/7RY__?WQPR^/WXP`"?_Z]/3"_T,IXMU?3]_^==DP_O3_!0```/__`P!0 M2P,$%``&``@````A`!,MIE/Y`@``,`@``!D```!X;"]W;W)K&ULE%5;;YLP%'Z?M/^`>"_W2X)"JH:J6Z5-FJ9=GATP8`4PLIVF M_?<[MA,"9$W;EP3[?.?S=RX^7MT^MXWQA!DGM$M-UW),`W;O7P\W M"]/@`G4%:FB'4_,%<_-V_?G3ZD#9CM<8"P,8.IZ:M1!]8ML\KW&+N$5[W(&E MI*Q%`I:LLGG/,"J44]O8GN-$=HM(9VJ&A+V'@Y8ER?$]S?D<0']4>[9WF+T`VCMUELK4@%>(\$6J\8 M/1C0-'`F[Y%L035$/MX:;B1T[VHPM\1JTC' MC0:70.E8,304TR-?+P3MU5394@&C6GW6\#)C&(R.!>"24G%:R$=E>.O7_P`` M`/__`P!02P,$%``&``@````A`&W[.>CB3@``K,4!`!D```!X;"]W;W)K&ULK)W9DANWTJWO3\1Y!X7N?ZDY=9,.VW^PR1HYS\.= MMBS;BFVI'9*\A[<_"0)9">0J@D4=WVSU_IQ8R`(6AD(5R1__]S^?_GCUKP]? MOGY\^?S3Z]:;A]>O/GQ^__++Q\^__?1ZMTW_I__ZU==O[S[_\NZ/E\\??GK] MWP]?7__OS__W__SX[YO/[W^_=NW/W]X^_;K^]\_?'KW M]7+IW??Z/]^^>WMUS^_?'CWRZ70IS_>MA\>'M]^>O?Q\VNK M\,.7)AHOO_[Z\?V'\[;Y3_U]\__OF5U3Z];R+WZ=V7 M?_[UY_^\?_GT)TG\X^,?'[_]]R+Z^M6G]S\4OWU^^?+N'W_0=?^GU7WWGK4O M_P?D/WU\_^7EZ\NOW]Z0W%N;*%[SX.W@+2G]_.,O'^D*3+._^O+AUY]>#UL_ M#,>M0?_UVY]_O#31_N.'?W_U_G[U]?>7?V=?/OXR_?CY`[4W]93I@W^\O/S3 MA!:_&$2%WT+I]-('RR^O?OGPZ[N__OBV?OEW_N'C;[]_HP[OT3692_OAE_^. M/WQ]3VU*,F_:/:/T_N4/2H#^]]6GC\8D\/ MG1:%O_K'AZ_?TH]&\O6K]W]]_?;RZ6"#6D[*BG2="/WK1-IOVOU>J_=H1"(% MZ;]>:J=_7<%!LX*/KB#]RS5&*WIR\?2OBV^]Z?=ZW._N4*']YTV[VG_J5A(R5;Y(%+E>8/KC-Z<2WN1/,'U]8HRU:;ZZ(_ MN*YF/=`BQ]@TQ3I/S2IEN[0\O\0OD'UBG'W?!;)16DV=TF*KF#]<74_-O-)B MLY@_N#7C%\8V:7D^:=2(;7:)^:-176UVB?G#E>B_:74?;@W2-IO$_.$*-AP] M;3:)^:,J6DTOD5'09I.8/UQ)THB58).8.<>5:#B;M-DEY@]7E*XU5AF[I"TN M:;UY:CT,.CZ]"WJN"0HC1AQAEC6C.]8@T2#5(-,@UZ#0H-1@ MHL%4@YD&(I)NY#X?8 MK<.@7P-#TI[G[S"DD:&5FC8UE=EHG1V$?GMV43%+5B%\.6,@"9`42`8D!U(` M*8%,@$R!S(#,@2R`+(&L@*R!;(!L@>R`[($<@!R!G("<@0R'B*2;N0^'(XP* M^C6P)-DCL&3]`0-O\$STQ7ED. M4YGHT%26#&BEKR:X3KL5SF^C*HB].`:2`$F!9$!R(`60$L@$R!3(#,@\ MR0O(&$@")`62`R`[($<@!R!G("<@0R'B)X18;<.@WX-3$5G M>W>8RD2'IK*D*Y[28*Q!HD&J0:9!KD&A0:G!1(.I!C,-YAHL-%AJL-)@K<%& M@ZT&.PWV&APT.&IPTN"LP7`(Y!G("(C?>X%OS,.B.XQS"0^=XU!G(-X1Y.^O MU"'9V$7U:>[T=F&=62!1OPU*19Y0)\K54C;EH^5'=L,9"HEB^%'E&$T&^ MEJIQ*EI^E*IQ)E$L/Q=Y1@M!OI:J<2E:?I0Z(U])%,NO19[11I"OI6KY!D=!'E:;57C4;2\J(YRSDFB6/Z,B,Z/[__Y_$*FIZ":^^$./=EPSSOLT3:=Q/`E M/)MGM91N,-P`C5V4=U$)HA2U,D2Y%/1:NZT.*`N)XE1+U)H@FDK!B/Q,HEA^ MCEH+1$LIZ,NKLZR51+'\&K4VB+92T)/O*,/N)(KE]ZAU0'3D@O+TX83HC(AL M;4W1EY)D:V2C&L;NJ;.U.1SW;5UC7WJ.6OG7GJ4'_K4H\&^%O#;4@WYLWCD( MQVF"*'7(D\\$1>1ST?*CU!E[(5'6+ZBF@0V3!5IYH.AR,)XTKI065E=&+A M!?CCRCX@OW>Y<$\4_.7"(F\\C,P;..$*,G;(FRP21"D6S!#E6+!`5&+! M":(I%IPAFF/!!:(E%EPA6F/!#:(M%MPAVF/!`Z(C%CPA.F-!,BQT)+G3,NI) MS\0=-8V1.ZLPSYV^7.A.<^#ON_/&K.^>#_@V=.B!5B!OI*K);F3>[")KFI=C M)$H/P3%'B7Z"*$64,8K*YQPE\@6B$M&$451^RE$B/T,T1[1@%)5?6W'"7R.T1[1`=&4?DC1XG\"=$9$0V&)M:A\>'"I`(:#,A"CX6#P3S. MN&,PN*8I/+K_<"O![3)V.ND4;N2BS9L3&@M,*Q[O:WB9.JV]V9O_Z MN=<;M-3M6D45[36BV=UXRC MHGG-.2J:UZ)17DO6BO;ARD5=[\,UZT1SVC3*:PWW7O:SYT!FJSG')(L#GP M+OAR&)(URB#G*)EO"T0EH@FCH'-T$E..$OD9HCFB!:.H_-)%]:7]5HRNM]^: M0Z+MMVF4P9:U)(,=H^L9[#DDFL&A409'CI(F/B$Z(Z+1VL2C-%I=F%1`0Q/9 M.&#AH*->O&?0F7`UZ"P*]P!==<,^,I\E,`6CT\_813W)44_":'`9=-V66E93 M_N]TU3+FM=FS1M7GHL7W$@4C2E_D<6UW;1!-8M(HB2G7*'TZ8Q1-8LY1T206 MC9)8LI9TQ(K1E8Y8\W^/5K]I5/U6M+@C=HRB;;#GJ&@2AT9)'%E+VN#$Z$H; MG/F_1ZNGT6WM$A\,-+HK5W$KT.AV+-H,M/!613W;>J,BG`-H:Q3,`=]W9&-4 MU-1@D5J/U=.-D?FL$!6\=:OLM&0V3UQ!MQYW'A[52I]R0'0NSQK5GXL6=T;! M*)C3<&YPB4>3F#1*8LHUV@\?FG<(9XRB2:":NH(=2T>(:,T$1^1RU"D2E:+'\1%!$?HI:,T1ST6+YA:"(_!*U5HC6 MHL7R&T$1^2UJ[1#M18OE#X(B\D?4.B$ZBQ;+T_"HW!31I^$!WJ'A@8P^F^Z9 M,U@6S>=*`^.;9;']:#Y%?L>#[XM*N"PZI';,ZEG/B`L&8]E;PNT082T:T;(_ MU??KB8MR)RZMWN#I21U8IRP4W;IDC9+*:[5T4@5'1;H4)M7I/JF-X9EEHBG19^SLRS.W]NFU:MI6]&D\J_84]=5P MS&'7<@OG*-I+P!S5ZLG3UNW+GS3YU+Z"(O(Y:A6(2M%B^8F@B/P4M6:(YJ+%\@M!$?DE:JT0K46+ MY3>"(O);U-HAVHL6RQ\$1>2/J'5"=!8MEJ>19$UA_I%E2EMG^(QJ-&S`3S1& M*CFJ(AP0M%P&`R+^@-=\H8.Z:644/N#MJI/>D0N[<=?*4;(;3A"EB#)&P62A M&RSG*)$O$)6()HRB\E..$OD9HCFB!:.H_)*C1'Z%:(UHPR@JO^4HD=\AVB,Z M,(K*'SE*Y$^(SHAH,%C3Q:U#@\&%204T&)"-`Q8.!O,>1/-;-_,5)7HP6!1N M5>$!+Q>DY*Z/[K&+HL-=+THODXF+XEU.N__PH(]\6>C:"FD?LC1**J_5TDD5 M'!4X`DYZ."J:UZ117M-:+9W7C*.B>2]:*=N+*144Z<K"I`(:E\C8R?3M7;`A-J]@W#'B[!L;P8AS+W&88Z_J M)2]XP&M.Q,KG3$FO][M/I-H^JWHL7W MB#M&T3;8NXE:@T>U8M!EH MU:V*>H/2&Q7AJDOI!G/`=SW@-5\-J&\/+%*+L7[`ZPK>6HR=EDSFB2OH'O"V M.VVEG')`="[/&M6?BQ9W1L$HF--P;G")1Y.8-$IBRC7*H[(9HV@2:`:/V;1O5O18M[8L]%B^8.@B/P1M4Z(SJ+% M\C0\FEB'A@=XAX8'LK'(417ALDCG!8'QO^\!KU%1X\&B\-2L"P]X7<%@+.,0 M<5KTCPPD?;.>M&T4'[AT.P\/<-_JA&AJ$"%=7>:$XMOXW$4]!5HZJ8*CJ%.D M1EP^F^0U:937E&N,YC7CJ&A>N7%2D$]BW@L\L$TV)IAKKO;C;::JQ M87&[T^SCPJ*^HL6Y3LTS5CA'F==3_-MWO75O^(#7ON42W-;[+[YYB:NH(=2T>*9/1/DS0?>A5^2R%&K0%2*%LM/!$7DIZ@U0S07+99? M"(K(+U%KA6@M6BR_$121WZ+6#M%>M%C^("@B?T2M$Z*S:+$\C:0FUJ&1!-ZA M88-L+')413`@S'>NUPP(_J[ZQE_`?M&Y+-O2(*V')_6LZ9G#Z':[6L/4"RXC MB>'V&"-*$*6(,D0YH@)1B6B":(IHAFB.:(%HB6B%:(UH@VB+:(=HC^B`Z(CH MA.B,B+[&V+WO(]]R./0,P)U+7V2,<6&/AXZE>Z#`L?'[JXX)#_>3C&CAJ$S8 MZ:H-WDBB.-,QH@11BBA#E",J$)6()HBFB&:(YH@6B):(5HC6B#:(MHAVB/:( M#HB.B$Z(SHC(ALX!L'8>\4R9$8T0)HA11ABA' M5"`J`Q1>LWE2YU^S-^2:?W5:QS[O"YK"HIX<3HY<%"%OC=";ZS%'A2N)^D*# M1*)X)4D198AR1`6BDM$E^[#!S%.-__\&L\]&@@:S*&BP"D4;S$8]MB\?/VT_ MM-0CB*13!4A;5WJ]#D7Y!74]1<<9>OO]N!HB@.NU1_V@#E[]+U[HP=,N.H!B\SY@%QN3[_: M0B?CEX)!/V$/5%%LGL05I%LK]W-3RLHI!T3[-I/Z63E'5#A$AC65]?OJGJF\ M55?8M.;$Y(ZF->&J:2U2YE8C;D3G%Z:@6=BD`[!IJRAN@(0+6B>U>D_J;>&4 M`ZXYZ7+TD7&4[V2HK.`H5UEWH"ZCY(!KE85M:^Z^[VA;>[,>S*T6*=LJ]N:V+:*DK9U\M:V[;Z>@5.G;%Z#O=YKF=3/RCFB@K5<94\#M326''"MLJ!M MN_5G%?+IC$9?G7I1">WLD+*SFCY'''4M5_L,CJ/D&[,31C2+2XOJV3'E*"F8 M,?(,C*APJ.O>T>KJN8&+-/)OU]SP-/?O)5PUIKUEZLEUC%P4(:\!8"+@*#DN M2!"EC$0^0Y0S$JT"41*_A(LXE$Z889NRA:O+AA$H=HH'D%>_H%.RX81JG3 MI4R28/F<"TJ-17V->A+E@M=J#!N?HNYQM@E7SK8H&.`5\EH&F]1%R:!,3%N2 M?$]0RL@?X)6\-!84++B@:)6,:@:XN:GPY[GONI!R8"E]&UL6DW2Y*2M'&3^HNP_G9/'Z26''"M_M">YE8G MUB_-'M!U[1V3OZ]R*+"MC;JU+KDH[VL36$M0RLBW;24O30I:!1<4K9)1C6W- M?0@VS]V/:[KN?H;2J>9`>ERC;HZ>.8R,4(7!=.JD9-B-I1A?>((H190ARA$5 MB$I$$T131#-$#B@S1V7[]CX?7S7WJ`%`]=1W:6-N*"<\H\1)8A21!FB M'%&!J$0T031%-$,T1[1`M$2T0K1&M$&T1;1#M$=T0'1$=$)T1D0VK+J[LMQS M#:OI\&'8XZ$-S6VO;T-OO;_A2'.Y:Y#^N031&E"!*$66([KH9R3W@"-$848(H190ARA$5B,H`A=>LCQ*\(=?\<4W/'B?X M"X)#WNG_2)"W1L`-"$<%*TE7W4XE$L434(HH0Y0C*A"5C/!Q38]VR-?FJ#L: MS*@H[U@4-%B%H@UFHZX_KKFD_--K"I"VJI0992XJ?KN3B]:5)S@2P,JE*!,* MW:.:FI&ASAU&''4M5WM> M+E'<"@DC.PSZ77A$P0'4S;%AX+*,UI^SELQ@!2-;_V.[KU:(D@.NU1_V@KGE M]WOAANGM"4%@>G=H($<+HUZ%(BTPYBBY-4\0I8Q$/A,4D<\Y2N0+1"4C/,SH MF1M)OV6^SY_N=M3WIT7F1K7R!WQO_:5V.GJDF;D*ZN`DX=2#J43/DHG3XC.X M3J^E+)-R1-2,6:.<`88N2@SV\7ZQA64D[.$"PI*&8E\)B@BGW.4:!6(2D8U]C9W M#=AB=Y_5T6VFV]!)MG16IY:&9PZC6:]J,WU6)S'T0[1$=$!T1G1"=$0V'-WFDPHI%9F;#SJ#:-(XGB3,>($D0IH@Q1CJA`5"*:()HB MFB&:(UH@6B):(5HCVB#:(MHAVB,Z(#HB.B$Z(QH.:]AS#:OI\&'8XZ$-]<'! M#1OB"<&C172KS08;(1HC2A"EB#)$.:("48EH@FB*:(9HCFB!:(EHA6B-:(-H MBVB':(_H@.B(Z(3HC(@\!WT[?*YA-1U.GO/+AIZC3=`]4Y\)5U.?1;+-&-&I MB`D2,@:2`$F!9$!R(`60$L@$R!3(#,@%-:H3 MTY5$<8UK1E+C!M&642BOC@)W$L7R>T8B?Q`4N:`C1X4UJCO=DT1QC6=&4B.- M&&AN1*:6FHC$XL'%?F?/*.<66/,X-%P)UP MREP^>@0T=B@<1/J[OQ*)XMQ3U,H0Y5+0:T+]P>]"HEB^1*T)HJD4].75X<=, MHEA^CEH+1$LLN$*TQH(;1%LLN$.TQX('1$4('W?WW]]O+)^SZ!YD\T'_%(W*%@ M1;%1'AJ[*&^=2Q"EJ)4ARK%@@:C$@A-$4RGH=ZYZIWHF4=ST<]1:(%IBP16B M-1;<(-IBP1VB/18\(#I*0?^RU=[P)%%\V6?4(D]#=Y.G+0LWGT]J\29/5V%< M`WG:EPL];9X`W#%-NP<&W@'WHT7A@^2^&LLC%V6^7^OZ4C1FK6`ETF?_"4?Q M@^1'^-)WCJ#5Z7IM6:.<\EHMG5/!4=304J/^%$S)4=&\)I(7]^"TMJ!.8L91 MT23F'!5-8B%)>!>D]P[+6BV=UXJCHGFM.2J:UT;RXL;9XZ( M)G"0!"(-:,YP@U-.:6B"<"R:!\T9 M5='ZZPRG$?.PZHYIQ#[;"G9[%H7O/O353FCTZ`H&7:U=.>8HN5-,''+/,)^> M<,IP]4>5,U:.1N5R4"X?,E\'$YHL=:[B43Z.@]!T2[\,#*T:BC:'%*)X?" MCL91WJ2C:90WL3N-\DJ-TZ!1;ED\#QKE5='ZI@]'N7[F>^.LI'JTRVD]/UJD M-@MJ;SAR4?');NN&>2!+/$VWTI6IS$BE$TB35' M19/8N"A*@N6W7%`:>L?(]73O::!,M.>(:&T'JRU<%<69L$C&R6E^Z< M2D%V_8QKC&X9YE+0RTL;>"$U1J*6HL5)K!HEL9:"$?F-),'R6T;2T#O6K"(5W5%1ES2]'B,;=B%%^L.2J:Q,9%>1>\Y8)RP3M&[M:[WV^K4ZL] M1T1K.TAMD4L^LI8D<'+(K96J;\]<(%HYC>@F#4XCVH9Y7ZU`(]HR5[]:-&A$ MNR+7$@A'-,TH]XQH$ZZ6:HO44JVZ9/3D"M(_LN!I%XXY2N:OQ"%^7?CQ2;^: MFW)$5#ICZ6A4SE&20.%0N%3K::6L30)'=-4*/'ZF4I#1C&N\L51;K:L3]^4C M`PNG%?^:\24FL6J4Q%H*1KIU(TGP-6X924/O6,LMU:V!_KJ0/4=$^_#`TM&H M(T=)`B>'>*G6F_!&M=/`KOHXTB0TL%V8U$\#VS*7@)I8:&#;_WRUQ\.!;=YE MN&.IMJ\^!$NU1>%2/5"M,GJR4;>6:J:<<$@"1S852NPPZ=2D-&,472MG'-44*.>*A^NN6"0A+[LC23!U[CE@E+CCA%ORMHMM0O=`6AMI8-]((!S8U$C! MP/ZN3P(]&16UD%L4+N3Z8Y4C+DAS46PA=_(RNR6N("_DK7X7CM,X)*J=-3*BV5M$MKY$Y:77IY*01X,,Z[QQDKN&CYZV0NI,=+P2TQBU2B) MM12,R&\D";[&+2-IZ!UKN97\X0F^.7'/(=%K/K!V-.K(49+!R2%>RM7L=FY4 M.XUXY^)H]33BP>PTXBWC!-23)QKR-_H\'/+F)9([UG+[SDFPEEOD_TR:^8DH MF@%N_$R:BZ+O3.4.3Q"EHL51F:"(GW+4*A"5HL7R$T13+#A#-,>""T&15)>H MM4*T%BU.=8-HBP5WB/98\"`HDNI1HCB)$Z(S(G)\$U.0XZLPKH`:+U&1]&JB;Y)'Y/25C?GHJ+5%ZPS%V4>&7\NKW$1*. MKRQHEE;-6,"GII`H7I79YZIRM9*T@+USKJL;BWIYR MP6@2,TGBRM&4%39?RGZ]619.)=Y7RT89K20CKT;]L&?-6D%>NEDVDAFI]V'-(D('VYT$R\*Y&1QTY2MZR.B$Z(Z+9H.KXB#[-!BY, M*J#9`!D/)_J%4&JP<#8P;X?X"YR>#9I]8/K)OF02+'P6!0M?A2)7-79:](76 MW+L)HM0A3SX3%)'/4:M`5(H6)S%!-,6",T1S++@0%$EUB5HK1&O1XE0WB+98 M<(=HCP4/@B*I'B6*DS@A.B,BJS1_X%-%^6A,:($48HH0Y0C*A"5B":(IHAFB.:(%HB6B%:(UH@VB+:( M=HCVB`Z(CHA.B,Z(R(;0M^0Y9*,:%O9XZ#GS\-[WG)E>VX]/EX_6W?"??>X? M3*D.T:&%K-H#=5HY>JJ-DJ./($'S*^Y!@O&D+N'AML\A;P2,$(T1)8A21!FB M'%&!J$0T031%-$,T1[1`M$2T0K1&M$&T1;1#M$=T0'1$=$)T1C0^2QBPH_ M#:%?%4DDBE?_%%&&*$=4("H131!-$QO(LH?9<@+2"ROF"/V8+FQQ0D2M]X)T[+^Y1ARD@^VI@)\K1T MC3E'A37*BG9Y'%5(%'ND9"0U3A!-&07R\'%7B6+Y.2.17R!:,O+EX01^)5$L MOW;(?E8L',9T=WI/[YMP-5XM\CZ'-NH#&CL4?OP./I0I49QZBEH9HEP*>KVO M/]U72!3+EZ@U0325@KZ\NN&?213+SU%K@6@I!46^^Z">TJXDBN77@5;8K^8D MSQ_5WS<]V_/`8+!;%'0WH#']"+WQB?])1$2I0YY6ABC'@@6B$@M.$$VEH+1T MYTD]6IA)%+?T'+46B)98<(5H'10,>\VK)+LE:0ESXBG$A>;(9I;4&=Q(RCJ*WELN$]?(X*DM!=L<`DEEPPVA(KCG+G ME.W6H_+"FB.N)1`:U)R3W&%0>ZP2&-2=M-`-L;1*7QUJC_JN8'!QNE7&'"4/ M#1.'W!/J=LW+HQP1E)E\W0DI'4N&(M^VRX_3#HJNM;<\2UY@M-90Y'[C"5/4L) M3&61FO74MF[4MU'QAQ!C%^6]K9DPLH.H5?/^(D=<&T3V-:=&">2L)3=`A4-J M/E,CN>2"01)HJJH5Q%2N^>0SH3/6NC%Y506]P:R'Z<)I4;MSC4N6EVM<,7*- MW'G2QU%KC@BNSZLM-)4YN[K#5.ZH2YY_//&_+ M1=V8P%A+QE;"R(VMNO>V..3:X+)F:Y1!SEJ20>&0FL'4@7/)!8,DP&R2!#MK M*@49S1C%9S"."FKTYI3+92^PQB47E&M<,>)6?NSH&]PUAURK+G3;?:>;`SS= M=,A[M#D2%!E=8Q?EOS*$*!4M;O5,4$0^1ZT"42E:+#]!-,6",T1S++A`M,2" M*T3KHXS2+!(O.]\T/1D7-#Q8%W_#>@3=B!JX@_2-[:VWF,4>1721*W[TD M+HHWTNU^5Q_,I1P2K2[CZJ)1.4=%DRI@C_0KWMC@*?##@5SD(TBY#D0?6JC_+T0[1$= M$!T1G1"=$0V'-.N^_PG`E7^R^+S)):37PT/ZHE=S2HPGAXC!$EB%)$ M&:(<48&H1#1!-$4T0S1'M$"T1+1"M$:T0;1%M$.T1W1`=$1T0G1&1#Z$CB0? M(JOIWN%#=];KG4D-')+Q,4(T1I0@2A%EB')$!:(2T031%-$, MT1S1`M$2T0K1&M$&T1;1#M$>T0'1$=$)T1D1>0[ZECR'K*;#R7-^7.@YU$8#0&-$":(4488H1U0@*A%-$$T1S1#-$2T0+1&M$*T1 M;1!M$>T0[1$=$!T1G1"=$9'GH"/)<\AJ.IP\Y\>%GC-GLW=XSAWE^O.<1?)` M8C309`PD`9+Z)$BQ]?"W'.5:F7"O4+$':J!JM]#57P@VJN+\307^(A^'>6]) M)#4L95;SBE?K@>ZT[^@0&Z^ORFC\])I>VKQ\UO^AI3<_7.K&\32'F7>2JM:! M1_ATB:X^^TNL[3:>/U4AU\X15(^;`Y_FKFP]F'C=");19^)<(ZAG<-2IKA3] M(U<'9QL<1N^`\Z1*5VR+TNLA%_':*W;UTQ:C5EU=L3E!N>>*[8F+/_FW'BR3 M;M?W^QQQL]N=D"PC=,6.Q?K8A33L8WT>$C_V:#U4YQ[<#<_,I(_5(S'J8U?J M5A_;L+"/+8OVL2O6L(_ONY]N/>`--3/I8_5C-X]:#W::'9K?,?.2U&EY=_:/(U!JNZ*W^=VK! M&+?,]?^@T]<_%DCSN"M&_U1)^,N"&N-FY^>WQBW'NYVBM]C2C>QEIO./:#U6 MG\7EC'G,8?Z#HAI&%^57H:[`["/\*_C._K3;D;`_+>MZ;R:WS*I,T_I-*]NP MFZN4"W/N?GA\T)\#I6MW,0WMK3=/NCF:G<2W'G!7Q2SL:!MWXS">BWI'[S2T M;5&/T<56>P5E M'L.XM"8NJV%Y#2MJ6%G#)C5L6L-F-6Q>PQ8U;%G#5C5L7<,V-6Q;PW8U;%_# M#C7L6,-.->Q\PO6>D?)C.:(:K:' M7X"GU%Q164LH,V!)#2.70ARY%!BY%!BY%!BY%!BY%!BY%!BY%!BY%!BY%!BY M%-BJAI%+(8Y<"HQ<"HQ<"HQ<"HQ<"HQ<"HQ<"HQ<"LRX%"&Y%&&=%8;*"\JE MYI[AROIZR[#V=B-84\V;;F1B^J5E'CF4$C#*"!BY$QBY$QBY$QBY$QBY$QBY M$QBY$QBY$QBY$QBY$QBY$QBY$]BJAI$[(8[<"8S<"8S<"8S<"8S<"8S<"8S< M"8S<"9F[Y[+MS>'X>4[1CL4;T@*E(7%OXUP&_@6Q]%4 M4RU`]-I\^#()M9/$<2744`RE9FHI@9ZB/@*AUN.X:,W4HA+'-5.3,KS4K-K4 MW''Z;:IWT,UN$%OVQC5L:L?"ID9(7K.PU^>3(O4N!;5H%<&710V*4M2@"*GU MJM+N)$I]&HW:K8I@?6JV0$HUF[GO])OMUDBT]ZEA^U@6O,?:Q9-"*F/6D/"3 M1=HAU(9U8?"F6A7FWKND.S"UR:=V=4KD&C&YKI!:NJY"'49M7ZEQRU)K.T;_ M2`WZTS[4`551+\RK077)G3?WK9J;>\?"U]CUMW?2?.F*!H/12XRGBRJ,+YV, M;!F_*MAKJQLQ:GX70R*W6&"XNV%XV/*HQKH,YPS`Z&7J>KQ*DS7,2ML5") MQSNC"N,5OY*!:WIPI^"W_G1.Z/9H(.\0=5U`^E3.[+3CQ M;;FBMT9'%<:-01UB&7^+Y(-Z;$+]X5*(=C8-CDI;,H7UG`9'%<8I4']4*4C1 M;DL=\E*GU"7BO3<;=DI;G^;<6"XN\>IQBF,][SE?2Y@D"]&5G>L: MS^J%ZZ^>0:D]79A;6/L]_9ET:EX7VOHG3ZE+;J2E M>LG_:>Z;7>7Y.^@Z%17K5_/+8ZCK6SE<15$`\&)R=BE M*0,8M2,!H\8#-JEATQHVJV'S&K:H8,*+4JC/.ES("12X&12X&12X&12X&12X&12X&12X&12X&12X&1 M2X&12X&12X&12X&12X&12X&12X&12X&12X&12X&12X&12X&12X$9ER(DER*L MLP*=FP61RJ7F3OX>E[H[?_]NI&V9_X5[+624!L21)8&1)8&1)8&1)8&1)8&1 M)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1)8&1 M)8&1)8$92R(D2R(D2R)47E"6-&<;]UC2GH4$]V/TQ<)F,I7=.J6A$26A$?E1 M([*C1N1&CDA=M3E$\*_Z$.-]_ZOK]]>/N4?/OYV8:]? MW5I)W,%&,$8M\][^HQ:IF.R`ZG;Y-BS\SBT\V75J%,:+$#5=50,S:KN*16JE M]FQ2*[5Q%<8U4"-7-1!3K6P.#*"5>Y=O/_WV_U@[L^7(D2.+_DJ;/F!$,I=* MTC0R*S*Y[ZR]WGI:I99,2\FZ>VPT?S_'$0LB_'HF,FGSPNH^'HO#_2(`.)#` M7_[ZT]]VJ^E:%4R.U8GU$1:&Z!+CG5:YXBH5W;%%V28B*2,126&$S8\N]=RQ M11F=B+4CN8C9U7P;L2GQY<)!)[Y<..!JJIYJSX_X]\G/T-Z=9F9F*JB!F/M`G!V6KEW@?;-U;3;>1CLOK%2O_#?S+DH#NT"L M+DCN+TLSNQ&XN=E5;3:Z<%U8=F'F"V@WI<%&%US^IJR]KFC2;NJ5G[QJ'*\DXPG[GE@,#G7A,[P4X^$'CQ@<`GQCL[;,%; M^=LX!'["!1=X$XM&:F9Y7M4LAY*\VALGBF& M$WI_T"*Z>23^&4?RQP8"OHM?!'P7O\A!;I;\6L[]HYMD)+?@G]`MER2[4MF6 MI!T+N/9B$5E;$NL57EGL7;Y9FH=KGH]E(4E=&T8.ZG"-PBO;,@4!E^&(;LM< MH.PR1@.U_Z7*+%T/V>WLFA^*M>[&V>EA:8=+M9T4:\=&9?LY*.8)Q@(NL1-& M[(0A5F$$2AB!$H;PA-T&["Y@]P%["-ACP)X"]ARPEX"]"]C[@'T(V,>`?0K8 MYX!]"=C7@%%ST*!2K`T@QPX)/V6P#CI!VR5C*^B)JQR.++J'9S9*#3^$X88P M)"D,20I#DL*0I#`D*0Q)"D.2PI"D,"0I#$D*0Y+"D*0P)"D,20I#DL*0I#`D M*0Q)"D.2PI"D,"0I#$D*,TDJ1)(*(RF8)-N63I)V3;Z/)-,U?%<&X_!@,NW> M-S'WCS7A6FW6+)S"4*DP5"H,E0I#I<)0J3!4*@R5"D.EPE"I,%0J#)4*0Z7" M4*DP5"H,E0I#I<)0J3!4*@R5"D.EPE"I,%0JS%2J$)4JC*1@*FU;.I5:L6(? ME:;B1J_2S+J%4QAN"$.2PI"D,"0I#$D*0Y+"D*0P)"D,20I#DL*0I#`D*0Q) M"D.2PI"D,"0I#$D*0Y+"D*0P)"D,20I#DL*0I#"3I$(DJ1!)*G1:Z"5IA>I] M)#FT=Q6QS-J751PJ6P?L/&`7`;L,V%7`K@-V$[#;@-T%[#Y@#P%[#-A3P)X# M]A*P=P%['[`/`?L8L$\!^QRP+P'[&C`DJ0GF]#*`9Q%T6G"2M`K7'JND?7S( M7T!FUM[2$H03N=A6ZRCHT2/DZ!%J]`@Q>H06/4**#7);;66D=JM?5_.P[_I( M,#(;7WA)4BH;KQ&EA$R$4C-["WB]E`Q^J#`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`Y'L?E@NW MWQ'Y"1_ZR"_VO$8>VKMKY,R'N=F4YLMHK>8SX\V]=KJY/'0[^D49 MV[XNNVVQV7T1@-?'-_D@PL\S?:1/`_5RL5/9D[R\IA"Z3HA M^3):*_G"TGF^2REA3TY-G=GLY`!ASZ.-#A#VQ,H^M_`G93>EQ48?7-@)PEYA MM_9>[XDYO;L?J:+WU&Q2[WFT46SGI2N?XS2]+^3%T$0^]R(\6P6_BP]$7GP@ M\IGE$YO%X<*EG]!/..%";Q=C>RSRBWSQUB[RF3G%N^6`T-?KOBW169=FW0OU M6?>#=!'-W`D'H)YQPH;=KLS;T MKRO`\*,SW1GR95]W#3R3:^#<=7)GR*-U.T-F28BKX`UW>?#)U3\-M-T',B(^ ML#-T/ARM#MUE#`G)+3;MD"XA=C76)N3?VZL/BW3UUIUJ9M8]2#*R[<)/PW'3 ML=1*6'.$(?7$FBDN&[9E"J(HPQ%%8<2MG<(%R2ZMVB"]4K7I"JV/76)MY6N1 MF[&F;5Y163-2,]:,IIFOAA#-U"SOPGQ[T.\2!#>/Q#^;)R3>J=GVBS3BG4?; MZAZ>./E+B4FZ%X8(A=&/(413V$$3QC!$T;P MA-T&["Y@]P%["-ACP)X"]ARPEX"]"]C[@'T(V,>`?0K8YX!]"=C7@'X/* M#:X`LK=)^'D,H(-N-;"KSW8UF#JPI:O5?J_/;)0??@C##6%(4AB2%(8DA2%) M84A2&)(4AB2%(4EA2%(8DA2&)(4A26%(4AB2%(8DA2%)84A2&)(4AB2%(4EA M2%(8DA1FDE2()!5&4C!)MBU[2=K+*_:1Y-#>7?)EUCT_Q?+JS@+/#L=VX\JI M[#QH=Q&PRX!=!>PZ8#`/07L.6`O`7L7L/(4>/4*-'B-$CM.@14O0()7J$$#U"AQXA0X]0H4>(T",TZ!$2;)#+ MAA6]]LE&*I+UVPBT-I.'6DA;:K;BFKLVF_OW9I+* MVJR.A9'DVK>=PEW-D_C:K$Q! MYF4X4B^,W->^S10+5VA&#[59F0)!M,,Y15@Y;Q]%I/)?KXC,4$29D_0G2/H+ M(]>)N5R[32#7M5GI2JYE.'(MC%S7ODV4YNZ>`+FNSQJ8C8)S:S/K$)]HE-C,26 M;26+PLBB]"6+PLAB[=N&V-TH)8NU69F6+,IP9%$86:Q]FRG\36*R6)N5*#V M25FNV+6W39>9]2E+L$]98GW*A)$RZ4O*A)&RVK=-F2LXD[+:K$F9#$?*A)$R MZ4O*A)$RZ4O*A)$RZ4O*A)&RMJ]+F16CVI2][L;5,M>TNDQFUFPDI2Z@P,BE]R:0P,EG[MIET]WG)9&U6IF7GD^'(I#`R*7W)I#`R*7W)I#`R M*7W)I#`RV?;M,_EFS]KAT-[5#C-K+S=*L['^LCY4=AZPBX!=!NPJ8-`/0;L*6#/`7OIF"N+E!&;L$_FWU`+*E9XP-BR5VY?ZCH_=-11BRN/P MSSB.?P8,?:5FC0OH*W?=Z@*2R\U2&.8'_D%F!)A;\$_H@].D%33VT60J@'1G M6&]R4:1[IL8_?H4F]\X=8; MM)2:3:YOJ5GW0=;<-3^L>,S75]VU*V+*W5HGHM6L.E$2R6HF,R*FS-(^RW/8 M_CA MI(GYG)*L8M,JZ75GI&]2X:<76&+'_6+EKLH06.[*#C#ND'Y/XP":FO6+56:< MIM6N<_]C#T26FW'U6YO-FL]-Y.NE^I<)RD)I-'F_R:.WS MP+EK/MX<+1FK7QS):>ZV52*DN3I14D^:94;2G%DZWO!#=_V]4VFR=4:$(#,B M!)D1(;@9?5T>6>066R=$*3(A2I$)44HWH?Z6#MU,3.BD9`6M?:24"F"]E!)S M1Q8]=[=X&2=ID/)K+#%W@JSG+ZG9Y(*5FO4GR'D&%MXJH?G270&A MM-RUVZ.;B)3SE^I(HS29%:6%L[KL<[C:95;4)K.B-ID5M86SNGT6S>TR*YJ3 M6=&)85$9#CW6TF2^/G9?1\N&) M!OY@<5&:V,%Y'$D/3Z-?1217M>M6)ZY+L^S$8O9&EI"R-5M]N"T#=9=`I>M6 M'^Y+5U)OOX><^>\I/M0&6UUX+,T:%YX*L[5AC*#/Q7-I5BIF\L*#E])B8RJ< M5EGFMVIUQY_-V(_>_`]4,^M6G9$UF^F%LC[,S9J?R"##-$7#T%UBS127`4-D MTA=%";LIK!D/P<@<=X4UOJ`.&0]!2%^R+XSL2U]2+8SDMGU=)JVFUQXGTJJS M_V]X5C:0_(9GY:Z=3BF>IG;M6J0K46U4]GB2*XSD"B.YPDBN,)(KC.0*([G" M2*XPDBN,Y`HCN<)(KC"2*XSD"B.YPMX%['W`/@3L8\`^!>QSP+X$[&O`>,92 MG>9)]`!R4)+-XTGT#CI!6VFQ%?3$B8_=[9(E*+/Q#B=^",,-84A2&)(4AB2% M(4EA2%(8DA2&)(4A26%(4AB2%(8DA2%)84A2&)(4AB2%(4EA2%(8DA2&)(4A M26%(4AB2%&:25(@D%492,$FV+9TDK?*XCR13I;([%Z=@9#+M?L,S7[K2*J[5 M9LW"*0R5"D.EPE"I,%0J#)4*0Z7"4*DP5"H,E0I#I<)0J3!4*@R5"D.EPE"I M,%0J#)4*0Z7"4*DP5"H,E0I#I<),I0I1J<)("J;2MJ53J956]U&IM?<7&IEU M"Z53)7B_EB> M6/M,G?T*`.6.""<\0H\>(4>/4*-'B-$CM.@14FR0VVKJ"]U6O[(V9I_UC5""[W4[.I=R#GT9J'20E;[5K.DXB;,`(GC,@)(W2)I=J, MBYV5_%K%O#)VJ7+8"RFS+G:5;8]=:K;E'ZG\I.*5)W`[;X6&NP+UV]<38G\Y*X3ZT49 M;7SH[;QT+<59O]$7M0''B3%Z02YV<8%V90JB*%,016'$K0ZG1U&[)&N#]$K5YBN[3K6)\4K?LF'$+K')%2,UVW[( M0K6Y63ID+8Z7[J8YP[;<&5;U,PC88\">`O8`O0O8^X!]"-C'@'T*V.>`?0G8UX!10]"@%BG\"E?9G;+;&+,5W8O/!*&0\(0 MIS#$*0QQ"D.?OYU]^_O??_WAI^__;9\3.CHZ0(65__#+MS__Y^^HLQV=#+Z@/&>CW(:- M*M90FU#C;#`.5P1JG`_&H1BFQL5@')9B-2X'X[![B/'XC1G3?J+&U6`= MT=XXR6;R$$6TF68;7BH9&H\'XW`&Y$8]Y75J9N2E:E'/Y>%@C.=<#J'E[4/: MDT\2$@-[:ZO:^#+A$!^^(!P:A_BD=TL*WY&QL' M61[%LCP:9,DWMW38M\=T/#P(16"F-:?GVNOTV$;D1#$R61HYYXE,EL18X\>6 M0O9\[?5V3B_>BZJ64[.L^1)-9++Q^%1*9#)!I!-_'_\%)J[C@DYF6?,JS,`T M["KQGC+L*+P;+NCUQAQ,E[G.B].5B9+R1M#+8AN&UB(1!L*FB<+P=L8L?#\I MF,0LZUDX_\R4/0LW:&:ZGD5["POMZF0H3>MDV(Y/N'D01=;JLM8OLKW%D6BN MTV'7B[;*W`M[V&H?Y?PM\C^*YCZU_2+<+6ROB'8*WJPP/QE>KZ`1X`T+\Y/A M-0MJXTT+\Y/AU0IJX^T*\Y/A%0MJXU=`!R<\P!SED&>8#TYX&#FR\3SR`7Z& M-IXM/F"^T,:;*.:,R>L>U!?>2#$_&5Y+H3;>3#$_X54443"Q+_#%' MW>&V8UN8+=IV;$NS1=N.[8W9HFW'9GMAN.W8;$\+M\$^YXF-#VGJ-MCG*HD+ M'X-4VY79Z!?9.+^8G_`GBK6]C^Z$/Y'-7D)G>8CT8B\M,UL4,VQ+LT4QP_;& M;%',L*W,%NGEAJ^'H/GT*G>_A//Q2+;O*.IW9C;^1#8.[^8+%2B-)S;S)>QW M8?WX$XUY:3;^1+8KLUW'\V$SO83];JP??Z(Q7U:SDQ=JM=$6'!RP!0?1RL-) MDRDBC.:9V?@3CXGMG`;A?(>FB+#?A8W)GVC,2[/Q)[)=F>TZG@^;[;5AOSNB M0LLCEL?0\H3E.?3@"0^>0P^>5@LL41PN M&>TRM%QAN0[GN6*>ZW">*^:Y#D>[8;2;T'*+Y3:TG&(Y#2UG6,Y"RQK+>>CU M&J_/0Z_7>'T>CG;!:!>AY>U;5C#^1"O1VU.SG86K&S9.+L["U0T;YX5G\9AK M&W,=VM9>@VTL42S7/!:!>AY1++96BYPG(=>S##,HN6X?4,W\)K\BLLUZ%E MO3@\N>8+>QK2]>+HY)S/NZGE"LMU:/E,S>#+892%KUB^AA;J<%SQ4$P(9J)6 MC(USD-AF.8_[<0["8A+:/E(M^1A:/F'Y%!9#/EN%A0-[Y,;:;%18`AN.',RQ1#!Z8YR&T/&)Y#.=YPO(<^O:$;\\;^G!<"7U[PK?G MT(,;YKD)+;=8;L-Y[K#';?>C!*?-0G@R5>&`GIH'% MY'L>]KG`L:77R8/?UPN77__X MAW_]^/.W^Q]_^?FO__SUA[]_^S.5]8/AML\O?_W9;@*E__GM^[^X2_N['_[K M^V^_??_'\)]_^?;CG[[]8@VX1_3G[]]_*__#&O?[__G^R]^&ZOT?_T\````` M__\#`%!+`P04``8`"````"$`"RIF/O(1``!38```&0```'AL+W=O%J\*EQ>;Y_O=P_;YV\?+-.G\[_;RXG!-B+:X3O(*?-GM M_I2FP8-$HO`UE.YD5R#:7SQLOJY_/!XGNU^]S?;;]Z.XW%71(MFPQL/?K_&TE:DA(K+^*_O[:_MP_/[QLER[JMX4RD5A?O%E MYHKHZ*64B(E+2+^:I&2^'AFX;(N7,D+%Z]NJ]5*[?;F M_!H(RZP9XJ^NP=M;4=,:-[G&.RI2UR+BKZY(Y:I2JM[19$&ZJK(?-"7 MY>R`%NERR`^Z]#M:4J0+(S^\.ZA%<5E54_C2O*4=@2]1YY(=S`WNM MQJ)L:&NMC^M/'_:[7Q?B?B'B""O@L&+@A=,'3!R`5C%T0NB%TP<<'4!8D+4A?,7#!WP<(%2Q>L#'`M\B1/ M%M$/_HUDD3(R6>@JWQ'@["DYB4$65*3E@K8+.B[HNJ#G@L`%?1<,7!"Z8.B" MD0O&+HA<$+M@XH*I"Q(7I"Z8N6#N@H4+EBY8&R`+($LC*)E41B^O)O))&4$7\T,>R`+($LC*)E1MB4+!R0\UV MK^33KS]-9$$[312IUO-93!-("T@;2`=(%T@/2`"D#V0`)`0R!#(",@82`8F! M3(!,@21`4B`S(',@"R!+("N36#DAGG*MG/`G@K2V$T$3M4PC'UJ:0%I`VD`Z M0+I`>D`"('T@`R`AD"&0$9`QD`A(#&0"9`HD`9("F0&9`UD`60)9F<1*!#'B M6XE@#`['[]O[/^]V:G7N1(*4Q2.O>A"6(G9^*%+-%B8SFV9.>(92+CE//"UM M)/[DTYA*W9D,MW,CN@UU@'2!](`$0/I`!D!"($,@(R!C(!&0&,@$R!1(`B0% M,@,R![(`L@2RTB2[JE86B=7(?YY%4L3.(D7,+,H))PAFD3*JE;(EF5*AZ"S) MM//O\P0"T@72`Q(`Z2MB5'@`),Q+R04C43NG#PSS[ZEV(R!C(!&0&,A$$:-V M4R!)7DK7KF@_0J3Y]U2[&9`YD`60)9"5(JIV5G+)U>I_GEV9BIU>&I7%RH\Q MW+@/UF0EE@%R*\RYDU;ENAV]-EG)H5.L%I;+E9IS^3MD(J;ZOW?7)2MOI7IL M15T0F M9@T@W&.R\K8_8BMJ?ZP1M;]VY3SD3*B,Z1\B,"4KCD#"R!.!E*QT!MP6:C7G M&LS(Q*P!1&!.5MX(+-B*(K#42$3`J&>E8%_B%14TK^1Y9L7R` MJ$^(Y0>(0D*L-40T(L1:8T:>JD9DQ?(QH@DAEI\B2@BQ5HIH1HBUYHP\55V0 M%H)&8T^2A;J=_:G:`I-SA%07%/8BOHB2UM M):I+Z=Q&U$'4/4N^AP4#1'U$`Y:G>H5H-40T0C1F+4\D(BP8(YH@FK(\535! MJQ31#-&P4E"NZ;QCR]`*P.>0I5!'+,$8*.C.&IMP<%RE8 M$W.@W.I$"BJK,M^.VKJ@.!LBIQKE>M6YS73(P!SA0;E[EO\>:;'_0"-]HRU= M.7VK3T5,]^8-)GMJ'+![2HR0"K*O(2'=UJ([XQ^1@>D,VCIF9YY81Z3%_F.- M=%N+5\Z<;D)%3/?0UBF[I[8F7)!02D@L[7!"N+?O&5F90_,YF;2@@MRZI4:O M31AT"OZNC7;O$596[WG7LH,\^^&.ZPI5Q'I''IUJP9G<-'7!U\9U+6^.ZPJ5 MZEFGJA5JCG)'*\O#$[E_2+3N6?Y[U#SV'VA4EG.IGY\J;J+U3[F'1!NP>\JJ M$'T-24NWM7CK9/6(#+QM';,S3T0B]!]KI-M:PHFZOA:F>VCKE-U36Q.-Q#4B ME)(O:Y3%3I5[I()SEO>T;J&MC!G"DCR:HW_9];C25E8ZF6VT.Y7<`7C#+4F: M.[,BA:Q9>(X\#6S)G6DY4>()71M1AQ`/2EU&'OD>6;%\@*A/B.4'B$)"K#5$ M-"+$6F-&GJI&9,7R,:()(9:?(DH(L5:*:$:(M>:,/%5=D!7++Q&M"&7R=K[) MW04SW]XWB*L]"NMA4*&:N2Y3+3@K44VYV7W&S$A963,CC?0C>`$6"#M:NBSZ MNV\4/Z<"/=+BT2;02$\7G,65/A4PG9M]7D^,#-J(.(8Y?EY%'OD=6+!\@ZA-B^0&BD!!K#1&-"+'6F)&G MJA%9L7R,:$*(Y:>($D*LE2*:$6*M.2-/51=DQ?)+1"M"F;R=;W)+Q\RW]XWA M:F-(]`?JC7=%A:P%%G>UN:F-7IN':W7S=E!VEY;;Y%!-5XN5KHGW)O#@1Z8%>M5?L@&0K9EY$*;@"&)*\" M4*I6ZG68L>N+X@W`6`OYKTK$E:)K'FOTNP!,J(:F>PC`E-V3<,*^/`%(25YG MP,FE]7,",.<:&.[PAI"G)=5SJ0O^+@`KJN'O`F!W3;DAYNN:R>Y%3-]?.\13 M5/MJ5M_46VT\VC2UE;AK>)K<(JN;O)^W$74(L7R7D4>^1U8L'R#J$V+Y`:*0 M$&L-$8T(L=:8D:>J$5FQ?(QH0HCEIX@20JR5(IH18JTY(T]5%V3%\DM$*T*9 MO)6'\L9-K*\ZH.H/T'9F))\I\&N=,&YML0UVOA:B- MJ(.HBZB'*$#41S1`%"(:(AHA&B.*$,6()HBFB!)$*:(9HCFB!:(EHI6%[`R3 M^X'F2.>?]):DN;UP04@,R7G25`O.[:_)5IPV6HM_E]%&JPZB+J(>H@!1']$` M48AHB&B$:(PH0A0CFB":(DH0I8AFB.:(%HB6B%86LM-&W$:MM#'FKJ]DD"SI M9)!"YM%6N>HF%[7XM&L+41M1!U$740]1@*B/:(`H1#1$-$(T1A0ABA%-$$T1 M)8A21#-$)'\)*=.&%^2;B%J(VH@ZB+J( M>H@"1'U$`T0AHB&B$:(QH@A1C&B":(HH090BFB&:(UH@6B):67M%6OS\MRP:<6\J9*$.HBU8]1`&BOD9&SQ@@"KF@/I?JS.V&;$!5 M&B$:(XH0Q8@F&AFUG")*N*"NI;-GD;(!U7*&:(YH@6B):*61JJ4]L,E%Z#?< M_-2:M95@"EG'5:H%YU!)4_Z:7@Q]8KN%)^*PQ-8Z:>4N:+7)2FU>U&[+[EG1 M#EEX5RVZ9.6M4X^MZ-($&NG=B\K-E;M50V5,_["@-2`K[BTA(R-,;@"&9*4" M4"J(]WPX\1Z1B5D#B/>8K+P1B-B*(A!KI"-P6[@JU,W_N6=G2<&L#<1C2E8< MCX21)QXI6>F-NVJY6'3.7\S(Q*P!Q&-.5MYX+-B*XK'4B.)1<3-B165,_V8$ M[$XI=US>T"G5!HW5*15RCKLXEZ59T@7%LV[^=`Q!:;$5-;>MD3[N4JF4;YQX M=\C"&\DN2WLJT&,KJD"@D5Y0+1>NG.-Q_5/^S7BK-754#A$-24LOH!V8I3VMC=B*6AMKI%OK')B;G'(.39VB;,(%R5-*GOSG7;#@G.4];5NP M%7EF:7K+QIUV,K"GJ@D1ZN2H4KIVE]*F/Z M-^.MNP\T+:2"/(8/":G6E@OEDG.[')&%Z0U:.R8K;VLCMJ+6QAKIUA:+[F`Q MH3*F?VCME*RX:0FBE)"^MC=5]]8\(PO3&[1V3E;>UB[8BEJ[1+2RD-U57MM+ M.NMGGN(^`,^U"CDW(%BOUP5?N0'E5M3(MO:H;T!%>#%*APR\X>M2Q;W^>VQ% M_@.-](A\XO:CJBP7G?)1#3)J@,*A1J(@^1J2+^^8/,*"8Y;G2D"B16Q%'F/R MZ!V3)^R1Y:&-4Y1/N"!Y3,FCMXTS+#AG>:X$M''!5N1Q21Z];5RQ1Y8WVVAU MIK*[(>9?;,[,[=4@CY1F?.<=RU*RE^Y.HN2&EF_?W6G*$UMY#_[UR(ID,.'5& MATS,&D``YEP#3P`6I,4!6&I$`:A>.4LJ*RIC^C21[Y$5RP>(^H18?H`H),1:0T0C0JPU M9N2I:D16+!\CFA!B^2FBA!!KI8AFA%AKSLA3U059L?P2T8I0)F_GH;NY*>\1 MI;)\)_.IESQE$]IL+/LL?B`(J:=0S=A+T%8&:B%J(^H@ZB+J(0H0]1$-$(6( MAHA&B,:((D0QH@FB*:($48IHAFB.:(%HB4B^%UQ>6G715+JH]WRKE^$^;?;? M-LW-X^/AXG[W0[[#6YRU^/0AQ_H%XZ5"0R:)&.B=;\11K88\U7/J&_%69.Y\(UYQ_OED">'DM`_AXI1OZ>`$_UQI?!;'WTY4MM(0 M;]P[P:L-\;:U$[S6$&_<0MZZ;8B7Z9S@]89XAPSRL-Z(3_&DWA#O34%[L4G< MD-N0I[ZI-N2F&WXC=M0:XOZV^;X7K_;?M\N'C< M?!7I4LC>(;=7+X57_SCJ,ZE?=D?Q,G?QU"->KBQ>WK\1[V40JT^7%U]WNR/] M0[B^SO_O`#[]7P````#__P,`4$L#!!0`!@`(````(0`]5_Q!W`(``)<'```9 M````>&PO=V]R:W-H965T^[*^?>E:XQDS M3FB?F:[EF`;N"UJ2OL[,GS\>;A+3X`+U)6IICS/S%7/S=O/QP_I`V1-O,!8& M,/0\,QLAAM2V>='@#G&+#KB'2$59AP2\LMKF`\.H5$E=:WN.$]D=(KVI&5)V M#0>M*E+@>UKL.]P+3<)PBP3HYPT9^(FM*ZZAZQ![V@\W!>T&H-B1EHA716H: M79$^UCUE:->"[QD8)332EA`9VNAEYY7]LH&ILVZ).!`EMU@ MN,K,.S?-8]/>K%5]?A%\X)-G@S?T\(F1\@OI,10;VB0;L*/T24(?2[D$R?9% M]H-JP#=FE+A"^U9\IX?/F-2-@&Z'8$CZ2LO7>\P+*"C06%XHF0K:@@#X-3HB M3P84!+VH_P,I19.9?F2%L>.[`#=VF(L'(BE-H]AS0;O?&N0>J32)=R3Q0?TQ M[EE>$KIA]'\66RM2!N^10)LUHP<##@WLR0NNW+7]C/4L#B"MAH$-V`$>7-$?HGPPQ%B@\!1)7A?JO2ABW^O_TFE M3)JK](.17AG9:DBBZBR=Y9.%F0`HS53`VQM+,+1XXAS*LS"_U:!@`HKFXO*W M$#-Q0'*].`G.3/`YML6/_/G.6XV)=6?CU:)J^32<)/&8/!,%A^AZ41*\%+78 M=:LQD1+EP\T9MU6MS*?AV'?.X9FJZ#VJ)'BIZGQ`]0G2&*TJ"=Q%)?-I./*2 MU2AZIBI^CRH)GJL*EE=/0X[]\T/WO*VNU2P>!'&RD*4'H9X3'68USG';SGD/&C!N*KG[]9-X2[!X%NLYS"7U;H]!F`N#JC&7Q&K2<^-%E=`Z5@Q](_I MR:I?!!W4Y=U1`1-1/3;P`<1P2QT+P!6EXO0B9_?X2=W\`0``__\#`%!+`P04 M``8`"````"$`Q.FD03\$``"-$```&0```'AL+W=O6]+*PWVO"<51N;S%S;HE7*LKPZ;NQ_ M_GYY6MH6;Y,J2PI6T8W]0;G]9?OK+^L+:U[YB=+6@@@5W]BGMJU7CL/3$RT3 M/F,UK6#DP)HR:>&Q.3J\;FB2R4EEX7BN.W?*)*]LC+!J'HG!#H<\I<\L/9>T M:C%(0XND!7Y^RFM^C5:FCX0KD^;U7#^EK*PAQ#XO\O9#!K6M,EU].U:L2?8% MK/N=!$EZC2T?;L*7>=HPS@[M#,(Y"'J[YLB)'(BT760D8AS,P+1:24%0``/ZTR%UL# M,I*\R]^7/&M/&]N?S\*%ZQ.06WO*VY=9V(/4A6$%FL+/CIRF!)8LY7,4E. M!34'.]ZVA"R#M?,&.4P[T0Y%<`1ZD:*-#>OM[?%#G0TU"W38G;O:>#P>CY9SOP=7L&`[C;'$%ILV3TS2 M\;3$[%`SEWA/D;MP^^_'Q"GC"Y\,^`K?7.4SITV(5:Y@"(N.H@2Q2#C:TD@U M'O;"8-E#*U"+ST`)L0H%&TW/%HK`LMYP31&;%`JW&P]DQ5F.3I@*)@KV".RQ@D>PS(\!P>JA.G16FYI!!VF2J*"0Y?\! M*F9-'F2"JOL^=J`FB0JJM9`)J^_U#KU(B] M8QL8GY;;@DU0A!Y[2S*\GW1PRO@B&HQ0R;1.\F`*;UL*(='0%23"CJ#*Z+5) MHH!Z6F]Y#%3.FCS/G]V)C'P8IWN=#8:W'V3#VQ]> MCDK:'&E,BX);*3N+FYT'-;__%&^=.[+:>>+JH'T>B]NHO$_V`W`9K),C_9XT MQ[SB5D$/$-*=+:`(-7B=Q(>6U?+&LFX]E.XFK@S$!\8:Z\/XL+: M_R-A^Q\```#__P,`4$L#!!0`!@`(````(0`3&FW[4@<``&PH```9````>&PO M=V]R:W-H965T3M.]307,V02\FY<=;BQQ%_SHC\K?#AX[?S:?*U MJ)NRNNR\8.I[D^*25_OR\KSS_OG[\X>U-VG:[++/3M6EV'G?B\;[^/CS3P^O M5?VE.19%.X$(EV;G'=OVNIW-FOQ8G+-F6EV+"[02K;[UU0;W+.M[\]7ZHZ>SJ![F_!/,MOL;LO1OASF==5 M4QW:*82;X4!-S9O99@:1'A_V)2B0TSZIB\/.^Q1LTWG@S1X?N@GZMRQ>F][? MD^98O?Y2E_O?RTL!LPUYDAEXJJHO$OUM+R]!YYG1^W.7@3_KR;XX9"^G]J_J M]=>B?#ZVD.X%*)+"MOOOHFARF%$(,PT7,E)>G6``\#DYE[(T8$:R;]V_K^6^ M/>Z\:#E=K/PH`'SR5#3MYU*&]";Y2]-6Y_\0ZA3I(*$*`CU4D""Z>IU`U<`]FVLF:S#80F2I;/ZN,I`D^WR2G;JN0#>0CJ^/ M0;`,'V9?80YS!<4(P2.@(48D)A$M:!!A(IN`(JF)P&`B#U,I.5&TTU^&["8D167>IES.4\`N"7TA[%\@0(SI$]]`D#,74FV/0S@>' MT+P'+>GPDT%"#!*IBR`"82#WYT!VVGDP9[J80"@KEABA%1;D8K-:K9A.`LPC MWU]30"``G_HV;*I2%T%DPD-TOTS9R9#)AA`C1`;)9B(91H0%H9.1N@@B=?DC M4F4G0RI+6(R04^HP(BP(D^HBB-35CTB5G0RIK/1BA);O%R\!;,6+`)DL)M-% M$)G2N/1V!?.D;H)F\9^:RJ$P)$F^6&39`@0!B$/MM.TCZPB!:+ MMV(BVC;W:),PU[;RF3:$4%LT7[$-*B'-4L9R%[&(\H-GJ)<6C&.(FQ: M$8!//:EL@4[57>P(U2J=P_A\HL^@^5SR_4/^W(*9<&DDA$TC`G8!7=6DZBYV MA&J4EF&\1C085"/?*.+`94.Z`28VA!6VL#%T(4N="-4I/<-XG>@PF$XVP#AP M^1"E3DCF(B&`029T(E2FMQ'B9 M:#Q8-HV5]F9/Y'N`.;SI=")4,/-!(P5;_1#+3!PBY18\S`A;'"[8$D8C M5#`48[^`1PJ6O8P,\VTT1&K>_00S"YDTFX6LFVU5VM5ZZD2H3.E-1C^G(3H9 M^IP:.ZBBW/G$2"Y&V.+H9"FAEC`:H4+A5G<(E;211_:#*@Z1>C>/_69+'F_- MCCRZ$"I/6H[Q>42#0O-HN`3YLA[.<(1&A&68&P5%O5O*I-U2RJJ=3!@7.MH113#8OE#WN]J.YADU MK(*BR`"-C,K[NKS,(R(821U(E3F79XH0D\$!>4R"XIRRL1`#D0,1TF=")5YER>* MT,K0YW)M/)=(X7.Y6&P"[A94&`2"<.W[+(10A&,:4B="-=YEB"*;(5HS";&B MR`"-1Q,CN1AABT,K/W4B5*@T'>,76;0H+)G\/U8BBY$QA`XSPA:'"[6$T0@1 M.F>&R+V;=#1?;-?,HL:*>K]J"6"M6D60A&L!N*$X$:J1>:`!C3;O8U@#.&8E MMQT\9&%[,@E@U^CR-DJC"T&->%@+SS*=B_JY2(K3J9GDU8L\B"5__.NK>$@L M#K9Q*$_HL.M)L$ULUT6PA5,[)I_"8;/N^DP'@K->U^RY^".KG\M+,SD5!QB" M/UW!SE7C:3'\TE;7[B#14]7"*:_NSR.WMBSR/IL\)/OX/ M``#__P,`4$L#!!0`!@`(````(0#'^"O8$0,``.T(```9````>&PO=V]R:W-H M965T M'3!@+<;(=C:[?]]CG!`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`>K]@_7";:E=?*G)'^-MFF3)/N^`7%<4M%[G07?0!:7GQUT,->#- MWDJC_5/[3S;W'+J[#S7B%1ON?CI1MH46!9F. M7A1CFQR@`/"W=8QY:$"+A#^*SX]XE[\]M0VST[>HFRW(VY9+NU?<_R MY/B?@!@OU%5$OX@84/J+7^_H=I_US3M4>A<5^+RHZ&:'];1[-*#,177@L]2P M[R^)>5&!SXO*+S2*=1%AO$\O36OBT)$K1F3"(\^AO"M];4!0T.=J,JNY4_)76N@6HP$4BV2+M=B7">,OHPX M]?<@D0E)N"0Q)8E9GH(*NJ\3F"111U!(LLZ@47\"P+)@8^Y'NOI:-"M MZB+H->LZ@5\3U!$DLJD3%1$I"B$-_D(4\J=X%);#8"0,]M4PQ@:G?$0:@"CJ M)DK(E$/354*6#$V5D"U#LUL@[Q9H?@NT4$"ZQN0R+6^!?"6$@F!U"[2^!0J4 M$`KM#0%)40IZ5H$X9*M&&#@Q^98(.+#=/2(`7H0.Z=V2V0IX!@ M$R`KS6^!%B54CK,E-OC8L,*&-38$V+"I&*1>@I71';W$:5@L5]<3NH;G)@'! M"Z^+#C2ZQR3AD,2$)%R2F)+$C"0\DIB3Q((DEB3AD\2*)-8D$9#$IHF0(@]6 MUW=$'J>?VC#G78.*Z1J:6D8"LHJ96;'KR;!D"*.W[*6-W@-R]\.%V+.S1AC@0DRO;0 MLP<6RGQC"=`MVT*+&D<`#9$[(0E7>@EC&EZ/2WY(3WU4RID$L(%5V;`4AP^> M!/2-'EI_SB6_S@9H.;R0_#U;QPMOR:\/;)0_?>%O:*65I&"8)BK!NE3@F\,' M>X!:("C=G],8ZNI-$R&%V>"N,.,T&68":JC^F"0%>%)HE;;N>2NUW9Q]7]9 MVR6-^#2RHI$UC00TLFE$Y.CC)ZVW3Z[\AP2<]A31)ZBFO'<1:D`<&IG0B$LC M4QJ9T8A'(W,:6=#(DD9\&EG1R)I&`A6"INA-,R-'(S^#O2,:Q9%M=1-K6+54 M**!KHL;'RV,F@,90))$)K>+2R)1&9C3BTOPT-$I[C+)BX"':/T-1I'AT/6VB;O_)X:GV>O5G&';L2&<#D'?A1$=H<- MX4I.W>ZR(=R[J=L]-H2K,W5[P._H*>PC?3CJ*>QC?3@N[-UK@>!*W3E\C?PP M?8U/6>L0[:$J6L>"UDC%I3SQ)4_.Q766ER2'RW3%OV]P>3*"BT!:!^!]DN3E M%RAH]WH=\_E_````__\#`%!+`P04``8`"````"$`?\8(MDX5H5SG^]?/AXA(C;6A;T%JV/,=O7./KQ>=/\XU4S[KBW"!P M:'6.*V.Z&2&:5;RA.I`=;^%)*55##2S5BNA.<5JX34U-XC"LG7#6^--%*^I`7Y=B4[OW!IVCEU#U?.ZNV"RZBRAKI?HY2RG;=;'-DW@BFI96D"L",>]+CF*W)%P&DQ+P148&-'BI$[([Y$Q@&D[W M<<=I-PTYDP.`VZTDFKHRTBB-DQ[`%7MW;!+WB@$BQ+>/.(YFQ3!,&.U%&![" M>5&Z)YKV/^WAQA0#.#`Y'\Z*M$8W)AB`)=]!,Z*A\D=M]1K3C3, MS]J[CSV5/X/]X=+1%7^B:B5:C6I>PAB%00:I*W\"^X61G?MS+J6!D]/=5O"B MY'#"A`&(2RG-;F'/^/[5N_@+``#__P,`4$L#!!0`!@`(````(0`&Z17]X0(` M``8(```9````>&PO=V]R:W-H965TP)"0#X54S:INE59IFO;Q[!@#5C%&MM.T_W[7=D)(VC7-2PCXW'/NN=>^ M7EP_BR9X8DISV>8(AS$*6$MEP=LJ1[]_W5U-4:`-:0O2R);EZ(5I=+W\_&FQ ME>I1UXR9`!A:G:/:F&X>19K63!`=RHZUL%)*)8B!5U5%NE.,%"Y(-%$2QUDD M"&^19YBKCW#(LN24W4JZ$:PUGD2QAAC(7]>\TWLV03]")XAZW'175(H.*-:\ MX>;%D:)`T/E]U4I%U@WX?L8C0O?<[N45O>!422U+$P)=Y!-][7D6S2)@6BX* M#@YLV0/%RAS=X/D*QRA:+ER!_G"VU8/_@:[E]JOBQ7?>,J@V],EV8"WEHX7> M%_83!$>OHN]VYY8>H"DS"9CO$X.\\2^8R+:(GJ"&=`=:>1`<@1Z4](@(U/L40/8TA11:]'9Q]RG8 MH.,4TE%/[[)<>-!J"L1QQ9!>N5=^N6]9(K3/J6C[3.[ M1-*"K>3A_(WPX01Z78_QNK-TFAU*<:0+L_4"KPY]K`QG!O>6O/0.M=N_<1:/ M#\EY<3^._;023%7L"VL:'5"YL:,6PR[LO_IK8`770.*.>[\`4[@C%7L@JN*M M#AI60F@<3F`G*S_'_8N1G9LF:VE@_KJ_-=RW#*9='`*XE-+L7^Q-T=_@RW\` M``#__P,`4$L#!!0`!@`(````(0!#4D\0=P,``/T+```9````>&PO=V]R:W-H M965TKSI\6>BR=94*H<<*CETBV4:N:^ M+]."5D1ZO*$UK.1<5$3!I=CZLA&49.VFJO1Q$$S\BK#:-0YS<8D'SW.6T@>> M[BI:*V,B:$D4\,N"-?+H5J67V%5$/.V:FY17#5AL6,G4:VOJ.E4Z_[:MN2"; M$N)^01%)C][MQ9E]Q5+!)<^5!W:^`3V/>>;/?'!:+3(&$>BT.X+F2_<>S1,4 MN?YJT2;H+Z-[V?OMR(+OOPB6?6FW3/\%F_VSW8]M!7X* M)Z,YV97J%]]_I6Q;*"AW#!'IP.;9ZP.5*604;#P<:Z>4EP``GT[%]-&`C)"7 M]GO/,E4LW7#BQ=,@1"!W-E2J1Z8M72?=2<6K?T:$#E;&!!],0J`_K&,/W\8H MGGSLXANB-L`'HLAJ(?C>@5,#]Y0-T6<0S<'Y&)GAZ&)]+U2(49O<:Y?6"Z*0 M4)_G%<(8+_QG2&IZ$*V-")Z)D\A6)$>%K@7P=9`0^A`RA"*^G?XCD]YD,X61 M?;_UN63`G)PKPK@SL1@A>7W&<38MAD/03P7&86?<)G5M1%%/-+$5R9C"@@.3 MR^&T>.E"Y%V=(C2U[[PVFJDI=3#(:])?O0E/>RTF./F7,VGQ@.ED:])E)!.# M=!L'R$9.^NM3/)UURQ;5Y!HJ+;:I,#X=#X-E-)"1+IO#*HXI++;I-6Q:_.$1 M,Z(QN#&%!:??=;U&,G[^M=A.'/2+P2E:&Y$I*(Z'B4W>7;:P9M=@:?$`"T7# M@AK16,[&%!8<@B9V>=):]8563Z=[]SO%'6@\K4-0ZC MX>-@K4?3V>DYMM%T:[[XP"'3R/MH&`\[R$$TFCKC\[;$YM/-^7(^T\KALVL3 MD+KA&P&--?RVW22C$AL0@K@"4*L'S\;Y(PM#F%8=WPLQ/BNN$W/`L9L"C--X($XYUP=+_10T@WNJ_\```#_ M_P,`4$L#!!0`!@`(````(0"CO/;%]`(``#((```9````>&PO=V]R:W-H965T M[I`$A52%JKN5MM)JM9=G!PQ8 M!8QLIVG_?L=V+N!LN^U+$CQG3LZ<&<;KZ^>^LYXPXX0.F>T[GFWAH:05&9K, M_O7S[FII6UR@H4(='7!FOV!N7V\^?UKO*7OD+<;"`H:!9W8KQ)BZ+B];W"/N MT!$/$*DIZY&`1]:X?&0852JI[]S`\Q*W1V2P-4/*WL-!ZYJ4^):6NQX/0I,P MW"$!^GE+1GYDZ\OWT/6(/>[&JY+V(U!L24?$BR*UK;Y,[YN!,K3MH.YG/T+E MD5L]7-#WI&24TUHX0.=JH9,\GORW>TOT71JIO9,!@-K1)-F!+Z:.$WE?R")+=B^P[U8#OS*IPC7:=^$'W M7S%I6@'=CJ$@65=:O=QB7H*A0.,$L60J:0<"X-/JB9P,,`0]J^\]J42;V6'B MQ`LO]`%N;3$7=T12VE:YXX+V?S3(/U!IDN!`$H+Z0SQP@F7LQ\G_65RM2!5X MBP3:K!G=6S`T\)]\1'($_1289671JY5!23+G1B:I5$!SZ,;3Q@^">.T^@8?E M`91K$+P!)U`P1Q27B/!,XH+`DTJHW5090A?_[?]1I4R:JPRCN8)<0]3DJ,J* MR<%,`%CS<0$R"5H]<0!L2@P)&A1-0`:B>`LQ$PDD4Y%ONR/!F0WUGMH3!;ZA M36,6JL-AO`KGX6(:#J+%6?=,%4S3^U5)L*G*&)M<8R(]=RO/$#6-AMZYX3-- MR4K,JX8YUQ@M*@X3H[O% M-!PLE^?PS"IYA4T6Q-M#)<&&JN6\/[F&Z)F"]3>9&OT&3N-)M#`7@M[1>H7U MF#6XP%W'K9+NY/X-H`&G4WTUY'X*KSGL9..\@"M#G;NG`*SL$37X`;&&#-SJ M<`V4GK.`D6)ZZ>L'04>U5[94P+)6/UNXFS&L1L\!<$VI.#[(:^5TVV_^`@`` M__\#`%!+`P04``8`"````"$`](0,D,T#``!N#```&0```'AL+W=OR!GS`6'GCH^<8_"3&L M@H#7)]Q5?$$'W(/E0%E7"7ADQX`/#%>-6M2U012&6=!5I/>UAQ6[Q0<]'$B- M[VA][G`OM!.&VTH`/S^1@;]XZ^I;W'45>S@/GVO:#>!B3UHBGI53W^OJU?=C M3UFU;R'N)Y14]8MO]7#EOB,UHYP>Q`+W^UR(DH48GD7$2`[VQ M1XLH3U&:O>\ET$0JP+M*5-LUHQ1`8U<\U4N M4DM!S:$#L]4@PEGD4.ZB8R[DY#=.IR%:RY!TV:Q!O[WPI=JF00Z4UABIQHM-,:0Q6[)Z*TS%DZI=*B0M"3;D^64KM[6-YM1JA[1(HV5)/'W9 MH,WM""7)=')LM`_U>_2;AA]?W=5:I-'R/'/LI7%BZIFC5TZEG(GF29/3Q/OW MM%IEGP.4.P0[(])WTK+(W1#D_"=/N;FTPC1*W4VGQSL]_728'7&)VY9[-3W+ MT2V"$S:^U6/E#JU@0H`9S'E?PKBIW@>C`::]H3KBGQ4[DIY[+3Z`RW"Q!"BF MYT7](.B@1I(]%3#GJ3]/,-=CF#W"!8@/E(J7!SF1CO\I;'\!``#__P,`4$L# M!!0`!@`(````(0`BN-UN.@<``((?```9````>&PO=V]R:W-H965T/XZ'U//F'KECG+^^G;]LLN,9))[30UK^ MJ$3;K>-FZKZ59DN[(#)]U)%Y0> M'[8IW`%+>RM/=K/VDS&-C&&[^_A0)>CO-'DO&O^WBGWVOL[3;9">$L@VU(E5 MX#G+7IFINV4(G+O$VZXJ\$?>VB:[^.U0_IF].TGZLB^AW`.X(W9CT^V/95)L M(*,@T^D/F-(F.\`%P-_6,66M`1F)/V;M/@1.M^5^UC:'G<&H9QI@WGI.BM). MF62[M7DKRNSX#SG;@NZ@(=JM,.5V^KRCJP:?!F7\>-#GKVW8-:` MFRO.,9N#C*D!6K*U>>54LW_6Z]#D3.6)RM<6%U+MS)1Z29D18A-R)H0AQ"7$(\0 MGY"`D)"0J$FT=,.MDW3W!QWUM+Y[+F9"5<)EGN:"-*=G:X0:?J&,I-N2D!4A M-B%K0AQ"7$(\0GQ"`D)"0J(FT=(+_4?2:PPZ(W"XO(R3CS;FJ*>3D\%$3<8+ M0I:$K`BQ"5D3XA#B$N(1XA,2$!(2$C6)ECM8U&FYNYXP9JTG3!"^GF7/]04A M2T)6A-B$K`EQ"'$)\0CQ"0D("0F)FD1+&(PT+6%\554U6[E/-Z_SC"_W+R32 MA-437U,Q$3V/G`S,NO$4J2=7LX_FUJ4P&E?KLG[/,/7GV$K]+D>^K60E61/B M*"^VV@-5%-55OTL-CVCXA`3*2ZBB-62H?I>J45-#*P+L%+0B7$@V[(5DMIFU MGFU.3%C8J0>7-<)K`&$$"Q9E1`MPR1AAN.[FK1S;$Y-D;Z]7GW1/=5+!D]4.1*]%"+WN_WAJ.>'CVZ$5TK M/-OJ_43E*W.]]`)9,,!5JJT1RLA".C8[A!:_MI(Y60EDPK.G(3_6;]D65GVM MMP;(:DWE'8K#'B&)?U5D2]KFR/A3>K?(ET?6RS+3P: MW`)96@GPCG4AK$RM!&1^K:WJ"O.(5G.L6GC1:TO'II5)*\RUX"*DO",=:^0* MA"*BJ=Z3CE>(-;2JAY/#D6N0/H(GJ`9TY..6D0\9_C2JHX84!1>CHB6 M'9%T_"RB7FFPTBI]8P0SA2Y$E4:_D4!1+56B%%D425EIY2MJ?]_X.'J:!, M'6S7?JT[OF5G*/NM4PYV/H?;0YP'U-V]$%:W!J)P'*D1O)*.-;(EJN77%#D2 MU8XN19Y$M99/42!1K152Q%XDBLD&>HNGFK\8Y.]-CDG^DBR2PZ%H;;(W]M(/ M6N[Q06'^1G(^G,)Q"@@@OAQ/8;M-N3.>PH:9\F`\A2TOY?#&\ZF:VY'^G+T) MO6`_[T_A4)WJS,TI'`!3_F1-GR`1](>Y-84CS`M\,(6S-^!==47P!O0->=P`3>8\>?NRPKY1<6 M0+T]?_P7``#__P,`4$L#!!0`!@`(````(0!.X_;1>@(``-T%```9````>&PO M=V]R:W-H965TYJ=770-=F!=5) M2@DTTN2J*3/ZZ^?=Q9P2YT63B]HTD-%'0C0^SR\PLWL;/===P#?+YKS(Z MGB73RW3,$4XVX/R="I24R*WS1O^)(!Y$]22C)Q*\/Y'P63(932_G[V!A45%G M\%9XL5Y9LR?8-%C3M2*T(%\BSV[- M^62^8CL,53Z!;B((KR=0CV`HI]>$.H::7D_Y6#J`0^D05=!R$U\,RXQ>+S/^ MGS(!C-$,Q?/)HB>.I2-H,@#->L0SAP@9.CRF_K;3L"FC:.^4'Y^F?8$H(8*& M$CB?\A[T3`7VWE#%V]4#^*SZ*=E8/8)>5!^_J!['+':A!EO")ZAK1Z39AA'B MV#[]VWZZKT?=@/8?<+I:4<(W84O5.%)#@5O3Y!(%V#B?<>%-V_7XQGB&ULK%M=<^(Z$GW? MJOT/%.\7L`T)II+QG#F MJ/M(W6I+PG[X^_=^U_B5'4_;_/#8=%J=9B,[;/*7[>'ML?GO?TW^ZC<;I_/Z M\++>Y8?LL?DG.S7_?OKG/QX^\^./TWN6G1M@X7!Z;+Z?SQ^#=ONT><_VZU,K M_\@.\#^O^7&_/L/7XUO[]'',UB]%H_VN[78Z=^W]>GMH2@N#8QT;^>OK=I.- M\LW/?78X2R/';+<^@_[3^_;CA-;VFSKF]NOCCY\??VWR_0>8^+[=;<]_"J/- MQGXS"-\.^7']?0?]_NUTUQNT77QAYO?;S3$_Y:_G%IAK2Z&\SW[;;X.EIX>7 M+?1`#'OCF+T^-K\Y@Y7K--M/#\4`_6>;?9XJGQNG]_QS>MR^1-M#!J,-<1(1 M^)[G/P0U?!$0-&ZSUI,B`LFQ\9*]KG_NSJO\,\BV;^]G"'B0Z-GCY,\I. M&QA1,--R>\+2)M^!`/BWL=^*U(`16?\NKI_;E_/[8].[:_7N.YX#],;W['2> M;(7)9F/S\W3.]_^5I*)'VHBKC,`5C71:]T[']^[!B*6AIQK"535T6OU>KWO7 MO]*PJQK"535T6VZ_Y_3NA&R+1_C?HK]P50WOK?P[Q8>K=M1U>_?]8GPLCL!L MX0BNMW4-9F;1$*[:8ZVN^:HA7+%KM8+@0-+)'!#9)^/KMFIUTM'I`Q]NZZ:# M22,^:*]UDL;!K!$?5$N_Y70[UV+O8-:(#]IEO8YBWHBY=6-',86/M;@5.`-A#2N, M]*YKSJ62`[5&6/DFS#PVH3U4DQ/4R5]/CN/U']J_H+AM%.GY"Y+)&")#5#)A M=T2!,04F%)A2(*!`2($9!>84B"@04V!!@24%$@JD%%A5@#;$1P<)YM#_(TC" MC`@2CNXS`F747!(09&"3$07&%)A08$J!@`(A!684F%,@HD!,@04%EA1(*)!2 M8%4!C(!`:6(!\:"^?GU?QDDB6L$=N#))?/_.'/!GR1%U2,\D0AEJB@X*0\8, MF3!DRI"`(2%#9@R9,R1B2,R0!4.6#$D8DC)D546,&,%=@,5(C.N-E4V8@>(( MU5T'Q/=[)&J*9(N:INBH,63,D`E#I@P)&!(R9,:0.4,BAL0,63!DR9"$(2E# M5E7$B!H,H1$U^XP2["(X.*C/"JG>B7R?W(B&FH3-1@P9,V3"D"E#`H:$#)DQ M9,Z0B"$Q0Q8,63(D84C*D%45,6(!.7]#+`3;C(5$>G(W(6[G0X:,&#)FR(0A M4X8$#`D9,F/(G"$10V*&+!BR9$C"D)0AJRIB##RL!V\8>,$V!UXB77VC'U)@ M1($Q!284F%(@H$!(@1D%YA2(*!!38$&!)042"J046%4`8YRA2ACC+!>_+;$[ M/;]O-S^><[DY_J((>;#(E4M?8<0"Y9:XTDJ0N+P,J=QC?O M-&--PM(U82@$)0E8!*9I7`IR>0[;"*V1<$F`F(;!N24)!)T5#0EY5 M-A3WKID80Y%_(E>OU`UE#"ZV-)2L+FR8-`MM3 MWXY#ECH317,-ESPUM;`R-15D51%>4$$61;-:*N:*!<.#*B*$K"KB"RI(Q5[4 M4K%$EZ6*!"&KBO2""K+06EU38:8F)/`MJ2GHI&I*B%1-AU5-2;M6-94Q(YMX M:DH6J5<.JYK*&%QT!G]1-24+A&%2!.(G)NBE9U41*A95P:IF'15S9:RB(JJE M(KZ@@E7-.BJ67$522T5Z006KFE=4F*DI3JYNJ)J"3E)30J1J.JQJJI9&N'G5 M5"SK'!V+(VB1.G#1.>=T>&I*VK6JJ5R6E2)0]L7*2-MGM3N\H(*E9AT546&FICC;NR$UY5&@L>%14&6# MZE7^7):CDG^M?"I6N7(8BY\V("'=$IIP:(J0=4T;(*NT%7)HQJ$Y0E;S$;)* M\S&'%AQ:(F0UGR"K-)]R:&5`9M#!_"U!%W12CR1DU".^RU7MKE0CQ;+F_E@\ M>B""+[=8/;_?(WDU08;5VU2Q[.O*`%E632%ZE)K@8:$.64;-D&'5-$=O5E:$ M+*NF&#TJ37ZG2S0MD&'UMD1O5E:"+*NF%#U*3?>P\B9+JA4R+GDSLU<NZ>U-`5HRZHI1!9JZKCD5C)#AE73O):F"&U9-<7(0DWP])YY:+%` MAE73LI:F!&U9-:7(DIH<2%^R:5LAXY(F,W_%:?$-^:L.EZOY*R&C^D+^$E5# M1Q]+6S)JA*SJ9&#KL+%BJ?H+3T;2AZ8FR##&DN=O'4U!+4TA>I1UQ>E[/3*# M9\BP:IJC-RLK0I9UG&+T*#6Y3L\EM6Z!#*NW)7JSLA)D636EZ%'5WVZ?3*D5 M$BXY,]+7O>TGC8)N+AX41,LON5$-%>U*^45CAG96?A4+=KBB_'9:I-!-T,JE M"5S\@CJMI2A`6U9%(57DD=D[0S-62?-:DB*T9944,TET?X-FK)*6M20E:,LJ M*:62''I$A&8N23)3%^;)#977%722NA*BE9>H&F)+HW.T%HZ099V]8\6"?;A, MW7LR3R:*8.[`J;,I.K-*"I!EE11226[?-_[([)K54CA'WU:%$;*L"F.JT",1 M6M22M$1G5DD)LJR24BK)(7$4[V<46YQ+SF0JRU[4V.0_ MQ>L5<&+Z]*!A^>['P-XI.H+_&X`3_QP?-0?I,4SN<3.R!^, M_2_X@3^`G_BYG<@?P,_S'$_\0?H5#N^N?"O.2HC?9WBGI7ADB^(NO.ORA?UG M;P`/87*_W[I@OS#4UI;@W92/]5L6KX]OV\.IL87#A91(X6CG*MUODEW/^ M`8,.;ZCD9W@KI?CX#F\A9?`,64<\Z/&:YV?\`I[;^KVFI_\!``#__P,`4$L# M!!0`!@`(````(0!'L+;?W"X``)\$`0`9````>&PO=V]R:W-H965TSSS[[\7!+(`Y(NN8FM&$S&2'R02J,Q$8JEBU0__]Z\OG]_\\^';TZ?'KS^^ MS6XZ;]\\?/WX^,NGK[_]^/9TS/\Q>OOFZ?G#UU\^?'[\^O#CVW\_/+W]OY_^ M]W]^^/OQVQ]/OS\\/+^!AJ]//[[]_?GYS[MW[YX^_O[PY.?#U]1\NOC MMR\?GO&?WWY[]_3GMX[;-3H>?_WUT\>' MZ>/'O[X\?'VV2KX]?/[PC/X__?[ISR?1]N7C->J^?/CVQU]__N/CXY<_H>+G M3Y\_/?_[HO3MFR\?[ZK?OCY^^_#S9USWO[+^AX^B^_(?I/[+IX_?'I\>?WV^ M@;IWMJ-\S>-WXW?0]-,/OWS"%1BSO_GV\.N/;]]G=^>LUW_[[JL#S`U'&1?\_/CXAQ&M?C$(E=]1[?SB@NVW-[\\ M_/KAK\_/^\>_RX=/O_W^#'\/<$GFRNY^^??TX>DC3`HU-]V!T?3Q\3,Z@/]_ M\^63B0V8Y,._?GS;0\.??GG^'?\:W@QN.[T,XF]^?GAZSC\9E6_??/SKZ?GQ MR_^S0IE3997TG1+\[91DW9O;K#/NW4))0T647EK'WU*QNHKXVU7L-G81(^721?PM#677=7'L:N)O5S.P;(-1,@3!ID#8'33'0VRP=`$0%-5\7KFW=YL2A.7MK'`WU?% M22;N-O^H+S#K=UH[*>[.O+_'US4ICL^\YWO7.3X3SYM_N-YF5S7:%=>;?]37 M>94[NC*2S3]<55QS@P.[$C7F'])8JL8[FS,N*6CZX?G#3S]\>_S[#1([6GKZ M\X.9)K([HT22CVVT3D8:+#18:K#28*W!1H.M!CL-]AH<-#AJ<-+@'(#(JR(+(DLB*R)K(ALB6R([(GC1DEL1TL&/3\0:N(GLUY7K5RF M3BC,C_WQ($Z/LUI(TF-.I"!2$JF(S(DLB"R)K(BL';EB>#Q68MPV,B)=0;QQ+^]#I]Y8GY-?U9I)K2_5FFA'1_5E%_NIUA1QEPW=*?*#3,85,4&]^5-"]: MXIAQJ(N@K+TT5CV=2+TPLCAJO)2$^DRTCV6\J_U&+@*-\5AXS;Z3U'[II:3] M2M3;]K-17^6;N0@TMK_PFAO:7WHI:7\EZEW[PZX:CFL1>*G].`C,OC\\R&E. M$.9<4F4(AP:7D^[+1#KQJ.':IB)ESZ;-*F7&*!?DU1<>-:@O1) MQCXMKNK34G0U]FDE4K9/W6ZWIU+76B1>ZE,<069_'PY='4''QS\1&FW;O\P= M$PSK1>Z]0]&0ME)`023H26PJ%6]K73-&N2`_Y@J/&M27(N755XSF@KSZA4<- MZI MR\C\,?75!,T8Y8P*1B6CBM&<%.&\5S]T;YYL8")=:@ZY:D4R\E%2<,IHQRAD5C$I& M%:,YHP6C):,5HS6C#:,MHQVC/:,#HR.C$Z-SA.(H,$<7812TK+/<24?H:HL& MP:&..7F']P,T931CE#,J&)6,*D9S1@M&2T8K1FM&&T9;1CM&>T8'1D=&)T;G M",5^-88`(;P,O9:X MZ@#-I"&3C<*KZ-%(J-26I M\6Q5 M:G*M1AWJ%E=I*;66L7=H;,+7;B! MWEC.KM*5IW6I[5!QE:XRKD M+4.>=YY=B^)X[:E$-7%2S?ENZJ2&(WL1VJBN<7B@-CVEC;Q11W%5/\J7=,2F M2^T=[2ZAQ8CU9E%FP'MD>!-[<83V?(ZQAW1.JBU"K:ZA/6WLWPS5#G-VE9K< M23DUPQOET>(J+66LI7LS?"D.S:XHG,);3,C[*O,`)$P8K*PGC*:,9HQR1@6C MDE'%:,YHP6C):,5HS6C#:,MHQVC/Z,#HR.C$Z!RA>)"8_4[H5[-*[>&A57BK MQ<5VIQ0NQ[H.(0_4"0"/6\9I8I*2&O3\&B3NG]X,F/XAAMHZQYL",RK-O!-W M3LV/DY34H.Y<:HE_G?%X66\2-/>/)L&$U*#G,TC< MS>!>1E+_E-&,4T8[1D=&!T9G1B=(Q0% MK9ECHZ!M3D,7\7@Y*9B,6OQJU_'A]&+NF2%#CL/UY:"OAOG$2_DA7%<4 M-&.IG%'!J&14,9HS6C!:,EHQ6C/:,-HRVC':,SHP.C(Z,3I'*':UV0B\PM5& M7`UAA\(A3&C:(S1CE#,J&)6,*D9S1@M&2T8K1FM&&T9;1CM&>T8'1D=&)T;G M",5^U3NJEB',^RC\>.\RA(/'_QA-&/5[N2BU&Q1<.+>TV1*9$8D)U(0*8E41.9$ M%D261%9$UD0V1+9$=D3V(8E-K_=?+4.*-UT]BWK!H^4>^94N'<1,G506G?D, M]/-XLT!,9L_<-R"H8%0&-7T_!OKAKBH0$VUSUK;PR"NCBUH&RKP8M;D*Q*3- MM6]`T,8CKXS:W`;*O-B@K[9NNT!,&MC[!H#BP-`;WY;`X`UOSZ(H,`A-G92. M`G6:-`O$I/,Y-U`P*H.:H77\?O^R\ZH",6E@SMH6C)9!S88&5H&8-+!F;1M& MVZ!FT,!`+3QW@9@TL(^TQ?[59PK?^".$2+JM`3!I8L[8-HVU0,VA`WR'8 M!6+2P#[2%GM3G[2T>)//5^!&LS**O$EHZJ1B;SIE@8=SUE8P*@-MWA1X74!\ M8%<%8F**.6M;,%H&-<,&U*';*A"3!M:L;<-HFZBY2[!]5#7R7#]]"'7YD=?U MOW.Y:(FW,`ZA9;FF":.I5,2QI(C-$BSGJ@6C,E&S2K`Y5UTP6@8U0^_IH1B( MR26L6=N&T391]&7E[,U97,A>!QL86OK&&+BV=E-\EKHBLB6RN MTKVE>CLB^Y#$86$.DEX1%N[=._2CL1&^@\G7A.^$#@UJLY((D:W0H:[@Z46-ZP"Y\8[[C-!"6 M(N4-NF*T9K01U)(UZLL+.J'SY,[IDE3='?B[?I!%)Q2+WNK*S/ M9V4.J4RC%F<3J=B2::SZ8.3/7,5;K!Z#D%)>SD4J&OX<4J[W?H]12D6?VRI! M\N##J#,._Z@KFXMXU#0'6-VTOXQ$@%FI,/-HLG;M>9F-(]$!">G>4KT=D7U( MXC`QQV1AYOFNIT3[]K`MFJI")WQ"HA8KI\LM8P:)98RK$PY/\M;BJBM>BE28D%PO/5JSU$902T(B73NI MZ-7O(Q1'#<9$%#7-V\V^$5>[$XOPH)_8?.*DS+-_M4O)?E,GA8,-J3ACE'M= M(E4P*KEBQ6C.%1<>-71UZ:6D$RM&:T8;CQK4;[V4J-\QVDGI0KD;)SQN!&'T[,1:"Q_85O/VA,SR5+)^5G@!61-9'- M5;JW5&]'9!^2.%3,N=XK0L4>`T;3@45J.E"+_4G?2K5-!U8JF@X3P9:!\4O@L^4JB]RDFYR2#+\'K&>"T\OZJUA6^M,2Z<67QN7DE% MC]:,-H(PMGR,ZTO>BI37M6.TCU`<'>8`4*+#_`JC)9&X\T+?W'W?(K74I-V+ MJ]B22*Q4M-1T"'_59A@,*9,XJ6@D\U+32@6'G:7K?=!B)4B6FH,L7&F.::F9 M:EK[:>&4-B\'ETXJ3")6NR=KDME>[=C`7+2IJC&(\[A6?M.D=C%1L3DI.*D@1,T$8G$%24H[, M12H<*7RDXCOAH\;V/FBQ$EURUC94VZ6Y"$2-Z7A8^,9\QVF=OG12/NFLB*R) M;*[2O:5Z.R+[D,3Q`D]%\=(\6PV,N`H,B\*]BY-JV;LXJ7#OPBCWNL29!:.2 M*U:,YEQQX5&C^^@:5[ZB]&O-:.-1@_JMEQ)=.T;[",5.-"=JUR\Y\`(RNUJBBIK']A6\_:$QGA:5(^32^8K1FM!'4,DM8$^.W M&V*$G53T:!^A.&#,<=LK`L:=ZGG=]^8]*3P=J%E^XJ2:UVA3)Q4DYYE#;M'4 MQ7O)>GK9E$NUQOQ<^"Z(J4JIZ#?7E2`[&8SXQHL(-#:V\(TU!H<^[%RY>GYZ M6!/97*5[2_5V1/8AB?NRIIWU8NKKG\I M4G[4K1BM&6T$M>20^F*]+2EK[IPNE[E[_>#'5_8VC`B$QGYY\X+A\YH`,^)J MM6&16H;2YL55Q+1=QPDMRJ8#*Q7E'8?B9:A2GTM%"'OU'&!U)WR`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`1.O4>*I48,; MIJYBE'ALQ0#EK+Y@5+*NBM&<*RX\:NCJDG6M&*V]+HG^C4<-ZK>L:\=H[W51 MXC$G>=JY7;P_R.PAKOZPQ]">!T:^M2A>[]RJL3F1BG">7UCHW#!U4N%&V2$W MN?;Z@UZF;[OE4BV<7FG97_@NB.E+J=@XOU_`HOM?B:BWAC;Q:^ M-PT&68HN/_&N!,D^7MU-6DMY8_.;JYK?BJY&^^RSD+Z MR%@OS*_,0GR4C%<64A:J48,7IJYBD')FC')67S`JN6+%:,X5%QXU='7)NE:, MUEZ7#(6-1PWJMZQKQVCO=5$6,F>!DH7,N_&:[P*:-R3J=8Y#P2LB1,JC*:,9 MHYQ1P:AD5#&:,UHP6C):,5HSVC#:,MHQVC,Z,#HR.C$Z1RA>UF)HO\:O1ERM M7RT:^P77Q+R`$5(!FC*:,F+5@H.=>QG&_Y!:P1?[G,0?F7L%]IQ MWS`K4=]&XRO>88<765+X.21]\VU>[CY,I`K*H[[Y.TYQW\S9AK:;>:?Y*U]4 MC]<\NIY&K:J[0?@@SFC'*&16,2D85HSFC!:,EHQ6C-:,-HRVC':,]HP.C(Z,3 MHW.$8E>;TXXVAY6A+/@K4/A$"8T9:D9HYQ1P:AD5#&:,UHP6C):,5HS MVC#:,MHQVC,Z,#HR.C$Z1RCV:W@\J$T931C%'.J&!4,JH8 MS1DM&"T9K1BM&6T8;1GM&.T9'1@=&9T8G2,4^S4\3;C"KWQJ<&N1?WAA0F1* M9$8D)U(0*8E41.9$%D261%9$UD0V1+9$=D3V1`Y$CD1.1,XAB5UH=OQARM4' M0E?=,C'GDWK2=2EZ+5[EI43]W*L7M/#(ZZ(6EUZ7EZ(65UY*U*\="EZ< MM/'(ZZ(6MUZ7E\(O5N/'`G9>2EK<.Q18]>"1UT4M'KTN+T77>/)2TN+9(7N- M<:3J@Y:6=26?KMS*Z4F8SBP+;#IU8B.4!#&H;B+,O)3T/72M2?(UUQW*0.P;[CH`FWW"CUR9%8&%"6!4$P=3550-%D:"L&-LM=Q4!7 MP:A,J<>9H-)?>3$QVIR5+1@M?<7`Y7VE?N6E1/V:=6T8;7W%0+W^JN_.2XGZ M/>LZ,#KZBH%ZW?N3EQ+UYTA7'%'ZZ+(E$]4GE*+[WKQ;QDRCF#.%31P+G#UU M*`B)&:.<*Q:,2E\QM(.:I2LO)?V:LZX%HZ6O&*@?J?/KE9<2]6O6M6&T]14# M];R*LF8-[+5G70=&QZ1ZW?N3EY+>GR-=49"8QXS^\S7Y14M\$"8HC!W'PMAQ M""MPZ>R,4,MEQQQVC/%0^, MCESQQ.@<58Q#X'6'GN:7*FIM[9!IPB]%1OZ.BKWSXJ1:'ED377Z%/!/D7DZ1 MC;NW]`Y&D4'GZB[0>J^XJ@NEZ/)=J!RJ?]2CII6Y5&EL?G%5\TO1%=Z@HI_9 MK.(>=6\RM5=;BYK&+FVNZM)6='F+[`0U.&4O,HU=.%S5A:/H:K3*R4DY/[%5 MSJ+FI2[%(\,*XZW-!.I&&Y-*7BGHBM, ME;9%>6!GW.V/]0_,7%5%TK1Y;M0";)/,0UNU`9D+N6-S2^N:GXI MNGSS*T&V^?Y-%[_Z#/XH2Z]%O+$WFZMZLQ5=OC<[A\0?H^&`,M5>JC5VX7!5 M%XZBRW?A).@Z@YQ%_*7>Q./!G(R_8CS8@_3PG@F>1#:3AYHI5#:=.*FVF<+I M\DEI)NK=<[2C87`R6157=:$47;X+E4,N`^&;]O%8GTN5QN87 M5S6_%%V^^579QBXJ-WC6@0:V]]>K1X+]4:NW"X MJ@M'T>6[JD<)HLEI@YA`%C MTF>6)7^@+/40L4TK"]?1QCZ4HLOWH1)D)S(U,\REM+'QA9-J6TC8+IKC='\A M^@?3*VG1]>=&G1ROI;RQ1YNK>K057=X<.X><2Y(_WMQ+M<8N'*[JPE%T-1KE M)%+6*,,;_7O.LPB\U*5X:)@;3$U#X[J?#9EG.O38L"C*M#4*O$Z_9G.ZPI\- M,EZ@_ M>-2@_LBZ3HS.7A?4Q^&D[X+93/OJ!_A']>TQWUO?`_V.OYF7DA5H M[M4+*AB5OF*H7MUEK;R4Z)I'NF)C85?X&F,9<97'+8J,16B*Q[!-1649]4CH MS$M)UW.'`O4%H])7#"VC[OY57DK4SR-=L67,D82$4885:TLF=(\5\1-O;,5 MW?=CB^(;,V-U$VOBI)KO0TQ%EY^-9X+2-=+ MJ8@U@*^HS_$J)X6L=+DU=*/W\7-1\U+[D<&S3KB=;+>XE8^3F#"SMZD[3K]^ MF(A8\VGF5,3"\UQARJ)P]BI%H,# M3V5LL_<)C?U=>=8\/Z[G;&$JW-6L`!^XJOC+6RCH[R7T$.Y6+`@]^,"Q<,$T M[*@3>P2\$XO"CU[-+6)QP%.K\$'=JLDL_1O]JS"X(-5@<$G*!>%VZ)K4POLA M?#WC8O_@9!J&K5FS8:U8>)-1J@8,5JS528@6"8:P)3F8C!B,%#)ED7`C<8U% M>">1=2R+)CB\"#-^4`E&LF*M&>8G>/&@R[^%ZN'T9Q,-/R#2+`/ M'XA8//RI2=C1,AG^';H1`[.VM*@L;;8/[F%I5R\:Y`E+U[V0*$;$4I.PM&-N5LMN]&\\8.F6 M%I6ES>;D-98V\GH!85GKK&;%6F/:BL6SFFL!EU8[:=A1KE/G2'GFF$L5,M!NY5QM;[JN^@/7EEEX MJY9U+(MGM9H%EQWT0I8+5BR8P9"PB<&*M3HQ#V8U8L@1Q&`R8HC3D*F@-%NN MUV0`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`W,;B;&-Q-#.XF!G<3@[N)P=W$X&YB<#0)UE=DN'L2->OJ^9.<2L%S$]NG^6 MEL-^QJ]V5#?-3B?L9EM4VIU1W#?'HB1$#%%)#%%)#%%)#%%)#%%)#%%)#%%) M#%%)#%%)#%%)#%%)#%%)#%%)#%%)#%%)#%%)#%%)#%%)#%$9LMC=W7"K>L4B M\B*O=E".14F(V31C-DNP/,&*!"L3K$JP>8(M$FR98*L$6R?8)L&V";9+L'V" M'1+LF&"G!#O'3+G;;`K#T6U7R*]^4CTSRRN[&O/9!UE%+8CO:SFL>NHLI?8] MDT!(\AN"Q37@&&&#Q/#)XG!L\3@^>)P?/$X'EB\#PQ>)X8/$\,GB<&SQ.# MYXG!\\3@^9`ISYL]?NCY-G?;,X'8W8YEH;N)P=W$X&YB<#9KZ_1QG6LD&X!71R8#[K)H[P M1&QT>4*MV]%Y&6YPRGU>AANH0;BA9@T-PC.U.G,$B@;5_0SXJ9:0%`$_U%@-%*6@+=;.J$" MP.SP7Q,`]D0@3HR6=>-%$=U#-:?(9K2'<9(*@)28/MA%3%BQGKT?-!K2O3XG M8)8#C1&1:DZ?KR(B4F*Z5PB2J%=#_2L"A(@5:.X50B35G.X50B0EIGN%J(EZ M-=!O%T+,M/1*Q4SJZ"<;7/%AM,S$"&5\R^)E%#',J\00!<20T(EAW!.#2XG! M?\3@,F+P#S$X@Q@L3PS&)H9E%#$LHXAA&44,RRAB6$81PS**V"G!L(P*Y93G MS/A#34H( MEOIXPLMQL-1"$A@(%F((%F((%F((%F((%F((%F((%F((%F((%F((%F((%F(( M%F((%F((%F((%F((%F((%F((%F((EI"I8#$'"V'R:UDK]XR\.EMV+-K=,(.[ M;=U`#NXF!G<3@[N)P=W$X&YB<#LFI/,,S_R$JM/$7MY#^DE9'3"#;8308-P0\T:&H1GG%C=(.TAO80T M"#_5RH7!3S5K:!"NTPW2'M)+B'(XLE8.IAQIS@E"1[:-"W>N$*X$>I:9T>EF,`>7$[+:RW]4_9H!?G83__33\FE*NE^;P:TI, M]P&#,.K#D'[5!U?7?6BX9G@_U9[N%KR?$M/=PEB.NM6GF0P!T=(M&R/OGGY_ M>'B>?GC^\-,/7QZ^_?8P>?C\^>G-Q\>_OL*!V67W5O,WWQY^_?'M>^3@._S? MQ>:JS$R@=Y]Q]H]Z6"QRV;TIP\KVCL>EFJ@BO0KHS;^#A2O=CZ,,CA*D27!F>]DR5 MX+KPTHA4":[*WM^DCF=#=-QF4RZ[-667G]1Q&;IN[LPF6L/%HBQYQ>^',(;] M4;#6B!+S.>&$OENHPP=I4R6P!;Y?FBJ!+?`%S%0);(%O*'+)>_CP/;Y]S27W MQKM)Y]Z;^$062]5!#S`=IDK0`^375$D?);B60W.!`?-4]H0Y54 MC?=9_^[]"\,&[>/QN(2N#,JP4$Z5F`!*MM]%'9Q%G?( MU2G[F-GS#CDT568F.NA,EKU'HDAZPB2)1/_NX;J4_/N>252I"L:C*0Y[ILR) M5R'):GPQ)LC[LQOW5D;#E$&,&;2">8X&\9,EN'C M;4A,R2&'MNZ3;>'M&W>39`G>N'%GWJ>1Z!_L,$O:`6]<0$G*#GBU`$I25XL7 M=-R95PIP.WA/QYUYLP"7X'4=L&JJ;_ADWIWYO`S7P9?S[LQ79K@$7\N[,]_" M2Y7&>^L\,E M^*K@G?EF8*KD%B6I7N-C7RA)]1I?>$))JM?XI,^=^88/MX-/,-Z93PQQ";[$ M>&>^-,0E^/KBG?FV8JKD%B6I7N,+:"A)]1J?O4))JM?XJ-&=^8H1MX-/5=Z9 M[RYQ";Y8>6<^O\0E^$KEG?D&9:H$(S_9:WP7#B6I7N-;8"A)]1I?>KHSWW'B M=O8]Q'4_58)OO<(&J;&`;Y\B$E,E][B>^V0[^$[HW219,D6)^?(G]PU?;$1) MRG/X]!Y*4C;`M]50DK+!%#8PG\KB=M:PP3II@PU*-LF2+4IVO52OMSV,$OM# M`C4Y;WL8)?:9:BK!*+$O3-$E?8R29`_FZ,$\6;)`R2)9LD3)*MGK)7J]2O9Z MB5ZODKU>]C!*DKU>HM>K9`^FJ#-+UIFBSBQ9)T>O\V1)@9(B65*BI$I>:8DK MK9)76N)*J^25ENAUE>QUB5Y7R1Y,3=I)1-L4H9N*W!*-I_@2YD_Q:3:Z*_$P M+TUAKUG27E/8:V;M]:X.VZ>??OCSPV\/JP_? M?OOT]>G-YX=?L=7K7.X.??OTFSGEL?_Q_/@GMH!OW_S\^/S\^.7RS]\?/OSR M\,T(X`SVU\?'9_D/7.*[OQ^__7'93O[T_P4```#__P,`4$L#!!0`!@`(```` M(0"@0DC_40H``"&PO=V]R:W-H965TSN,X_5^W;QN]N]/_?_\4?SV MT.\=3ZO]ZVK;[.NG_I_UL?_[\]__]OBC.7P]?M3UJ0<,^^-3_^-T^IP.A\?U M1[U;'0?-9[V')V_-8;Z?0;Q::^[V#T&_VZP/S;%Y.PV`;J@4E39/AI,A M,#T_OF[``G1[[U"_/?5?@FD5I?WA\V/KH/]NZA]'Y]^]XT?S8W'8O/YCLZ_! MVQ`GC,"7IOF*HN4K0C!X*$87;03^=>B]UF^K;]O3OYL?RWKS_G&"<"=@$1HV M??US7A_7X%&@&80),JV;+2@`_^_M-I@:X)'5SZ=^"!-O7D\?3_TH'23C412` M>.]+?3P5&Z3L]];?CJ=F]S\E%!"5(HF(!'XUR2`.D_%#2W)A8$P#X9<&!N-! M$(]2G/S".'C::@V_>EPZ"!^2(+DV,J61\&M4'0>C232^/..8QL&OGO$F3:'. M6DWAU\QWDVLF-!!^:>##;18&D$/ME/B/F^8'P_-CQ[4+43] M^+G"52"8(IM.+A49DV[GL@W2#%E>D.:I#QZ`1#I"B7Q_#H)1\#C\#GF])J%9 MAY`OD6D)3&+DG7,@YT#!@04'EAPH.5`YP!#\8IP#%?,KG(,TZ!QMU4P#UELA M$Z"%>Y7.`EIH!IA]3(.@%IB"3(CJ4MN M,B+&30+)!5((9"&0I4!*@50NXKD)5!9N"I.!69MO7G.0J'64MF]&B+L,I=&( M98\1TL/F`LD%4@AD(9"E0$J!5"[BN07B[;FE>W?7ZRU*^[8K)%&[-JZ=F4#F M`LD%4@AD(9"E0$J!5"[B&0K;ZQV&HK1OJ$)BLYIF')AS(.=`X0">;I`Y=^B& MTKYN"HE@/S&UFT9L&\R44`@Z&*$H9/4])Z;0F)D3$K6[:SR"__S$+D@`"J^3 MUS,46HX[#$5IWU"%A#"EF2N-F`T9#8--Q0A)0TG(YFU.W!-J(UI3N:TD6%]3!"1S6XBQ#W%#C)U["$Z%7D MHSB%T/M.+K0&Y[C]R&.CX?JAPU[PB3$8Q5GD%11:);/`0!>M4U+1V,EK`166 M"[+?5QV;`5?UOQ9":BG<$"J(Y?+8=W.&/3:XXEHN$Y>;RP2I7`X?X*0W'K&E MH2#V"!S2F2"^)[!;X)X(D@&>V-MD_J/Y/)?,;G!5TP&]LUYH9MA'HY%N<`W4 MK1DM6DHJLL>VG+@4Y.N/#8747U]PW-S2!JHQX*HI7*K0$')Q!1&%@AH+J%<0H6$ M%A):2JB44.5!GOGA?4U;*^XOZQIR*E]"9@=K60?;@1`U:SJ$#9L`XH=^3T%(7![+2+#FQI,'>.-&;[ M?^F(Z2DJ@ZF[HNBQWQ="0YS82<["YD7/U3V)V[LD=,:U_ M83#717**I9'SIV"+5^F(Z2DJ@W6XJ*M9=/?7FYK%4#:+&G*\E'5@<\(29S>5 M4-$QU0FZIIS,[9I96R+B(+E+I^\6'G=D<6J4;/RR+J_;S()4RK+"0I MB+TILXYJ-%):]UP/I!-$,`GA!8[?TA5:!D:?)U]H*=O2+2WD#(S8W6Q)4G'< M'LW30')"3+(.V8E*=O-,I)*H:&QB2`]0URV)G-- M3P7?=4>B1<[56^OUA=7`)IF9SE%*UKN2HGI/!KR'KJ[-[SN\N^6_M]YEPX]7 M%1`'5N_LT)215`);P*4X$+WM&G,:R.J=T1%3TH84,A9BSMC.V;U,&8 M+<15YV1.3OE^YR>)*_4NCP]P38<.]NK=0!>]25*V1G/-9:%"0VZ]&WKK)\%5 MZH&6J]*0K/?HOA-%*^[O*P2Q>F>M64925^I=Z.U&HMY)RM2[V-\US;GYO;Q#/WD+[%_:WUL6%@J"%*@UUI"F>)-P6E+OGIA,0-B;<.PK"-L&D:1J+G4I)75LAB=Y= M(8F>WMZ-QO(=#BGEMT-RB30:6)^:Z:SJ$<_"DNAIU82W7KQ#NC:_GZ;\1,3C M<&.:RI,2?!>*L?'2U$".@=PSNM2@BQ7J0>VD/*%^OY4 M?1RXJP_O=59OM\?>NOF&WY;"9`J?^<`T'$^F\)U+!YY.X;,0 MB;\$X^D+:"2?P)N.*;Y$Z'KR`$_:ZR0^>S"!)^U--WL"=Y)3O$^2;'`S.<5K MQZXG(3QIEVC&!K=0\*2+#2XKIU7G$_A4^*6+:P8#NF:?A4#4H=4L@D^.._"7 M>/JB#NI,V1FH-.M4">Z'IWAE)TV?PQ.\[NUZ$L*3+L7@H@^>=+'!)?$4+_B` M;6B4@\^4/U?O]3]7A_?-_MC;UF^0:J/V1'A0'SJK/T[T^N]+&ULK)W;;APY MDH;O%]AW$'0_DNJL*M@>6'D^8K&8W;U6RV5;:$ME2.KNF;>?8)'!(/E3K*S> MOFFU/P:#P0B2R6!69G[X^S^??ES\OG]Y?3P\?[R<7=U<7NR?'PY?'I^_?;S\ MGW^4?[N]O'A]NW_^/FO_>OEWS_]YW]\^./P\NOK]_W^[8(T/+]^ MO/S^]O9S=WW]^O!]_W3_>G7XN7^FDJ^'EZ?[-_KGR[?KUY\O^_LOQTI//Z[G M-S?KZZ?[Q^=+K6'W,D7'X>O7QX=]?GCX[6G__*:5O.Q_W+^1_:_?'W^^LK:G MARGJGNY??OWMY]\>#D\_2<4OCS\>W_YU5'IY\?2P:[X]'U[N?_E!_?[G;'G_ MP+J/_P#U3X\/+X?7P]>W*U)WK0W%/F^OM]>DZ=.'+X_4`^7VBY?]UX^7GV>[ M<3._O/[TX>B@_WW<__'J_/_%Z_?#']7+XY?^\7E/WJ8XJ0C\'P@PR@_UX\/:JA01ZY_^?'RSDU_/CE[?O'R\7Z:K6Y6M; M^:A47EX\_/;Z=GCZ/RTT,ZJTDH510G^-DM75_'8U6ZV5DD3%I:E(?VW%S>QF MN]BDZU'IT6KZ:^K-;Z^6\]7F]FAVHL6UJ4E_SVIQ8^K17UMO4A=IHAU-I;^V MXI0N;DT]^GMF%VK5NSG=+&TT&/"#M!WIL?-#&4 MEL]*S<=+"AD-_5>:U+]_FLUNUA^N?Z>9^&"$[B)"OD3&$FK:*;UY"(H0E"&H M0E"'H`E!&X(N!'T(AA",#K@FWUH'T[CX*QRLU"@'LV?N&(C'YX$S68*KY"$H M0E"&H`I!'8(F!&T(NA#T(1A",#K`08D!U(`*8%40&H@#9`62`>D!S(`&5WB.8RVXVO]/VQQVQ9W*)E4\7.=;)&Z- M.%]+W6Z/B=3\9K8(_6X%N+$2&ZL0U0:)YB#NC0BPYA;5=((2W>A%E\H'J1LS MOQN#"'!CHV@FY(=)Y01NF")S@0Y/[&30*807#Y-5T#2Q8WH6&I6IC)ZB-JME(%4:J5L*JI5:K(*-2"5VL;-JKI@T MHF&IY7$T;9<4"-_,EB4\`\(EH1,#'#-#J9YU)6T:6$K;M-QN%X%-(TN\9Y,_ M-E0.<\;84.+!0JF1@AWWTJ M)SG#?2:%<9$!,C*#=2&SGK*`RZ5=/[]T_KF\U\ M.YL'$Z3D>K37E6D4CL]*;)!I9(R7!AN_P=7MZO9V.PO2_W92@YTTF#"K9UUB MPQ#8L)AOYIMUD#:/7.^]3OMQ5JG4&7$VF9<;9XUNW25TO0KF;J8.328LH487 MS3.)%RZA6LI?0E?!9:LT+9Y:0JU=$OLI1C1&/1EQ/-F\6@<];J/MAV.OF^27 MGG4E_3+X)MU<;9?^9!M9S;0%5"6(9XP,G4]Z%U>-W`74"+D+**!"G0OYRVR) MJ$)4(VH0M8@Z1#VB`='H(7]BJ73Q#/>9[-*=6!H%"VBP[\MFIB)M/F3*A,,L M-U+>`JHKGEA`C0T4D?>U5V*#3")341:OQDAQ@\OU8C-?P0(ZI<%.&DR8U6.G M!]^&U6:[VFYF,$U.V.#'666Y9\19)\4T;MA5=S.-@@4T,"HS4J?VH$97'1E_]CZ:/B)02XV=@W1:'NQU[F9&C*Y>5BRP M/Q,9#E:.J$!4(JH0U8@:1"VB#E&/:$`T>LCS_CP\/TGGAD=Q?__/B`:X.'05 MG'=D(F5=BJA`5"*J$-6(&D0MH@Y1CVA`-'K(=RD-^\B`/AY)G?"NJAEX5Z/5 MUJX;V1Q0CJA`5"*J$-6(&D0MH@Y1CVA`-'K(=Z4Z*W#7AA/^TT<+[E5C;I#^ M$; M"Y,ICP<]5HS&J[,R!(MMX8AQ"Z5ETFKE,%$'K=96S&UUM0SV@XTCQJVVEDFK MG<,2K?96S&UU>1.D\8,CQJV.END?7WD_@%#I]1G#WQP2.)NFN4%>^)#E5LZU M?[T*B>$06=%WN+D$%>%)#EZA=L:O[142X;5D18:9GXHXJPVC+7'ZME M<`30.&+<;&N9--%%6&^9V\1Z#0,?>S;:JA&7J]3V#)>;3-@=^`9Y+D>6SYFY M+D=66CGQ1Q5AM66N/U:;8#O4.&+B,C%YB+#1LHA_5>KF^O=/ MW;A1R41XN3#(AVF8(U(B50*CGBY17V[,W*#JF2)Y("HHJV%9PBU2'&7&U:O#7CGM)^% MDC9THEV\!W[IHU*A7P8CM7COU'D\99(W8!9ACARNEO\X_*2K=O0W!G21X_NJ M1S7^[MJ@E7/V*RCAAERD.!0%HA)1)2BAOA8I5M\@:A%U@A+J>Y:2P[`!T4>UJI2"R, M>MD:%=RBH!)1-4E]C14;@VA!4>>SE/*%25_+$F3:^Y9WDPSHT8`!T>@A/UHJ M=3\C6B;3=S;6"XV6_CXDV-]F1NK4S-&ZR%R9.8!*H\N1JB:IK[%BPTC]](NB MM5ENY]L@/6Q9AM+D5+RTH>D>]JQ+>C@@&CWDQTOEZFZ\U*5G<:N>KXK]HLV] MVI@LWPV=1L%$"\YCLH66.C71C'J9586IZ"2O):)JDOH:*S8&F8DVGR^7B^!X MHF61$S-M2@=[M&!`-'K(CYS*>,/(S>@!)S5Q)O\PD78PL%QJ%$S`P!69J9@> MGKF1@+.;Q7)]$RSU+=;D34%=T M.CUZ4GX855+NAC&=N"U,#N_..HV\/9Y%B0[F1M=*?@50("H9R1:R$I107[.4 MJ&\0M8Q$?2&@49&G!;<+, M5#RU"AKU[C9R$68CA=%E5JY8EL82R86KFF13;:2<9;AA]7J/0@]LQ7Y2P$)) M&[I)-O1B@S-$0K\,1HHF7_S6]GC*)'_`J%.'U("9F*7IPPOWZ&6AD3>#+7(Z M&";,.5>4/*=`5#*2*58)2JBO64K4-XA:1J*^$Y10W[.4J!\0C8R.ZOV`),Y9 M3JRB>+:RT,B]#XHH1U0@*A%5B&I$#:(648>H1S0@&CWDN7(9GD"D_7<4]Q-> M1K)?RQ#EB`I$):(*48VH0=0BZA#UB`9$HX=\_ZETWUT;3OA/GPZX:\#2(.!W7$ MV/[2,O%:%6&U96X3>!_4$>,F6LNDB2[">LO<)O`^J"/&38R61:*@,MXS)I%. MD+U)9)`7!63YDIFL5D6$E9:)/ZH(JRUS_8'W01TQ]D=KF33115AOF=L$W@=U MQ+B)T;*(RU6J>H;+35+N[':7!GDN1Y9;.=?E+">LM'+BCRK":LM, M_=%:)DUT$=9;)N8-$39:%O&O2@5=__ZI)$.EXN%Z8Y#G=F2YJ>K>!T54<@.. MMBK":JGJ+EY!:M.(E+@<3>LB#?18=4`T^C7]"_%YZ?02TVF#U`&8+-#KX`PO M,U*4XXL4GA:+%'NB0%0BJ@0EU-H;1"VB3E!"?2]2K'Y`-'K(C\5?DF&K MT\1P\$!_42*6/6G/6)4>M!:(2435)?8T5&T0MHFZ2^AXK#HA&#WF38W5>BGX4]W,4 M@]24=*YLP>%X9J1.'$RR>MD:%8A*1-4D]356;`SB)3AR'Y0ETLO?)`-Z-&!` M-'K(CQ8->&_CEYXY*R4>1$LCM==QHA7>!S453\P<(^7IKK-@P M,O=!9[-&@\>*E-NI*_$3< M5+4@;AKYLVP3_%XU6VFI4[/,J'=G&:#2Z'(.Y*M)ZFNLV!C$-T&7M[-ML%BW M+$*&I,(VI8,]6C`@&CWDATTE\F%^->GVM?)\&#F-@AD7WKXV%4_-.*W+FW&` M2J/+D:HFJ:^Q8L-(SSCUYMKP!+!ED1,33MN9[F#/NMP)!QTI+"! M55,;H)[)>=_R;I(!/1HP(!H]Y`=1I?5N$$^LEN84P#D^HIO/*H#4!&^`,T&) M#N8L)7>7"T0E(U%?"4JHKUE*U#>(6D:BOA.44-^+%'=[0#1ZR'=\>,SQI\Z5 M5GCZ85"P7P].>#(CE5XB1AZ!9S7LF^0-&I?/N3`T'S+2; MURMS*N#.8(V\&6Q1(F"YT45_>`X4B$I&,L4J00GU-4N)^@91RTC4=X(2ZGN6 M$O6#AWSOQP\V^'7BDU_E3,>XYG(GIM$CZ,'AY!V+>:F#O_G.1(:]GR,J$)6( M*D0UH@91BZA#U",:$(T>\KT?GF*HL3]?79%[SGR5-OTZ`+8;!E%D[.*TW@0O MH\KRM+@K>2I/>$QS%_0S*(,J^ M>&AFB')$!:(2486H1M0@:A%UB'I$`Z+10[[_SCLY6./)@4&RI&5`B`#D-$EOLM4KIFZN$WZ*=]::0E&HD&R6\A8RKMXPP^SC)3Z MR8%=%?`=G2+%`[U$5"&J$36(6D0=HA[1@&@TB%[]1Z;ZSE=9W__?^3IW=&_F MKPURG6^1N!5.C')3D6Y,J9U3Y!V=(B!^MYH95=)^HK%:=)G&@MM0C0BPYE8T M,^H$)1KK19=I++C.#"+`FD?13,B/G,HDW#`_-/*SA47@@6RMI=33 MJW8R1*)F=$FX"U.1GEY0W5TL%^OPV9>21:CR^[JK21;4HHN=US"B1$G4+X/# MO):EDD9TDXSH11<;,3!*&C&RU'M&^*%7:?<9H==9NC<[-?)_Y;R!T)N*)U9+ M(R47_&)MU.O[G?,M_8Q_'IQ]ERR35%X9*?724@EANHHO=WABDGA*4BAA[ M8VA2?3?)B!Z-&"89,4I%QU2GCW[LP[.#$],>#PG6&OG3?A.<$V=&ZM2T-[K< M:6^0GO:SFYO-;!:D."6;\-YH/[Y0NYID0BVZ)/;&!/J3BKV12AK133*B1R,& M1DDC1I9ZSP@_]BHS/V/>ZT3>F_<:!?,^.*3,UJ9BZ->S_O9^N8V M?+=K:6JE#T`KUIVTH!9=$GIMP:EI;^Q,JN\F&=&C$8-!:2-&J>B,TG>G??P, MXLSGQ=;V!((==F=0L!H$QPU&Z-1BH+4[]T,*UFZ.!_&V;\D2[TT`LQ1HU6D# M:M'%W6L8)6=ARU))(SHCE3:B%UULQ,`H:<3(4N\9X2\%X:G(B"$NI[U#4@&D47 MJ?<BVS_1YU#!)-HA^Q,"=R!#EB`I$ M):(*48VH0=0BZA#UB`9$ZJNPJMNZC]J3^BNO^H.63_N7;_ML_^/'Z\7#X3?U M!5=Z`_:G#Q:;S\NN;G?*@>2FH(3N:.S4`7^L9$LEQY>7AG76-SMUS!JILYGS M=VS#.LL=?00N4F-%C<3XFIJ(\0TU$./4C5@O/L^VN\]T^RC2,I6HM^M&2N;4 M/WI);*R$OM.K9WS8OP5IHZ<`L0X]'45=C_4Q7\]WZD00Z]!!VZZ@XR4LH5.Q MG3KXPA(ZPB)ML1+ZN/#G6"MW9-CQ*A3VA8(8E5]0%R,M?U[N/M-[H]$D>O1L MIQY&P!)ZVFPWT!ENK(2<0H\RQ4JH@_3$3:QD226QX46//5!)S`)ZRF[71"V@ MQ[RH)&8!/8U$)3$+Z*$9*HE90$]V4$G,`GI8;]=&2^C%HA2!Z*"E.G?1.O1( MXRZ+EM!3C#OUB"+ZC9Z9HY)83^DY+BJ)]90>-Z*26$_IB1@JB?64'H;[+I3K_K#.O0NUYUZ46NLA$8(O2@T5D(CA!Y) MB96LJ22V"-%+!:DD9@&]_G:GWGV(VN@EN#OU!D0LH??>[M1+;6,E-*JB5M/[ M0:DD9C6]QI)*8E;3NQ:I)&9!-EOOU`,[=#[;:DD%CEZYRJ5Q'Q`KP:EDIAM]/9**HGY@#[^ME.? M4(M8,*/YHW\"&BR4]&6QG?IX&-:ASX"1MEA)-J,10E\EPCKTP23R=:R$/G]$ MOCZ67%L3Z//L/^^_[8?[EV^/SZ\7/_9?Z>)_<]Q'O>@/O.M_O)DWW/UR>*,/ MLU->0Y^[WM]_V=.W4F_4C?JOA\,;_X.,NE8?EC]^,?O3OP4```#__P,`4$L# M!!0`!@`(````(0#;>ECS40,``+T+```9````>&PO=V]R:W-H965TBMQY95)Q448N\0+7864L$EYN(O?/[Z>; M6]=1FI8)S47)(O>=*?=N]?G3^K.&,%59ZH6`G_ MI$(65,.EW/BJDHPF]:(B]T=!,/4+RDL7&1;2AD.D*8_9HXBW!2LUDDB64PWU MJXQ7:L]6Q#9T!94OV^HF%D4%%&N><_U>D[I.$2^>-Z60=)V#[S<2TGC/75\, MZ`L>2Z%$JCV@\['0H>>Y/_>!:;5,.#@PL3N2I9%[3Q8/9.;ZJV4=T%_.=JKS MVU&9V'V5//G.2P9IPSZ9'5@+\6*@SXFY!8O]P>JG>@=^2B=A*=WF^I?8?6-\ MDVG8[@DX,L86R?LC4S$D"C3>:&*88I%#`?#I%-P<#4B$OM7?.Y[H+'+'4V\R M"\8$X,Z:*?W$#:7KQ%NE1?$/0:2A0I)10P+?#0F9>N%H,KNU8/&QHMK@(]5T MM91BY\"I`4U547,&R0*8]\ZPCM;K1U;!HR&Y-RR1"\<=7"C8G]<5(>/YTG^% M4.,&](`@^#R`6H0/Y;0U01W=FDZGO)U/."-KLSHM,SX&AD#/I+! M&UT90L+@M%)XK&1"'L,A/&_,+`)<-RX2DE8`S2((/MM,IRWB*%,X9]U,[4HP MBR(7`FW9P>,A32P!02'N^FGQZ;'X>=\&/!`=M\0HBB`+W[-C:3O?9M'%Z!%D M48)Y"W0>L?/N#7C@/NRY1]"DCCPD0?#!L9M?(VS``^%)3QA!%IX)'.^N:;O< MZU47@V]0-E68EF,=/3'H003][!O4/GPRF;49'3UPY*HN5J/[VF300;&WV3CO M-3?+_+&I7>@Y!%$V50#FBOP-NI]!.,@?4?O\P]FA'QWGW^MXYQ\[\S8?:A]Z M*7:=!F7CO-?R+//'MG8I?^OF!S/1-?EC1^NU^\/Q;C)`%($LS'L^\`X]`O/' M*0J'C(+)#?O"\EPYL=B:"8G`JO9N.[W=C^OYJ_T#AJ>*;M@/*C>\5$[.4E@: M>#/8)8GC%UYH4=4CS%IH&)OJGQF,R0SF`"C,=5(A]/["#'CMX+WZ#P``__\# M`%!+`P04``8`"````"$`X1)(52,9``">D```&0```'AL+W=O?A,$D@G@)\%B3]^TW%]E_C@DD`6@6.3[?_[Y_/WJ]^W+Z]/NQX?K MT;O;ZZOMC\?=YZWQY^?'[XOONQ_7#][^WK]3\__O=_ MO?]C]_+KZ[?M]NV*%'Z\?KC^]O;VOY^,[Z]G=\\/SS]N-8*JYMYO=XV_/VQ]O M6N1E^_WAC>K_^NWIYRNK/3\.D7M^>/GUMY__>-P]_R2)7YZ^/[W]>R]Z??7\ MN,J^_MB]//SRG=K]YVCZ\,C:^_\!^>>GQY?=Z^[+VSN2N]$5Q3;?W=S=D-+' M]Y^?J`6JVZ]>ME\^7'\:K?K%_/KFX_M]!_WOT_:/5^O?5Z_?=G\D+T^?RZ\CT#[Z/=/OT]=L;A7M& M+5(-6WW^]V;[^D@]2C+OQC.E]+C[3A6@_UX]/ZFA03WR\.>'ZS$5_/3Y[=N' MZ\G\W6QQ.QF1^=4OV]>W^$E)7E\]_O;ZMGO^/VTT,E):9&)$Z*\16;Y;C&[O M)@O2"/A-C1_]-7ZCT;O1]':NR@[XT=5]I>FO5'J`W]SXT=^+REL8/_I[4?MH MDNWK27\O*N_.^-%?:=\A*(&.&='XV9>H_L%%W@[ITA$/!/6/BQHYHJ&CRY0Q M-"R,(QXWZA_2T`&!'/'(4?^XK)T\=M0DN:R=/'I&EPZ?$8\?]0]IYZ"`\A`: M66,H%-`;/;_WZ6+S\/;P\?W+[H\KRL$4UM>?#RJCCU9*C!.%'DV'U'$J[WCZ/1Z/;]S>^4HQZ-T?T1(]=BS18J(2G=C0\B'\0^ M2'R0^B#S0>Z#P@>E#RH?U#YH?-#ZH/-!;X$;BL\A2#2#_HX@*1D5).[=>P82 MM;$7$+9@EXT/(A_$/DA\D/H@\T'N@\('I0\J']0^:'S0^J#S06\!)R"4F/Z. M@"@9NK-:LV:^F+L1N-'O")J2H6Q)V?X0$,IU(R]LQBH4MH/)(6Q`(B`QD`1( M"B0#D@,I@)1`*B`UD`9("Z0#TMO$"1MUH1.VXTM8OA$IZWUTN%/O#=&K7'53 M60/9`(F`Q$`2("F0#$@.I`!2`JF`U$`:("V0#DAO$Z?C:81?T/'*VNUX3>XH MAQXFRGRQ=.?)^F#$\=H`B8#$0!(@*9`,2`ZD`%("J8#40!H@+9`.2&\3)Q:T M0KP@%LK:C84AUB0`L@$2`8F!)$!2(!F0'$@!I`12`:F!-$!:(!V0WB9.Q].2 M]H*.5]9NQVMR-SDLNM9`-D`B(#&0!$@*)`.2`RF`E$`J(#60!D@+I`/2V\3I M>-KD7M#QRMKM>$VFTN\^V/@@\D'L@\0'J0\R'^0^*'Q0^J#R0>V#Q@>M#SH? M]!9P^ED="5S0T7MSMZ<-FMQ)7PN2W#\9>YN+C;%:TN0[W"$FDX5[AXC$BF\1 M,:($48HH0Y0C*A"5B"I$-:(&48NH0]0;I'O5C9C:)N*>_9TZ57O[]O3XZ_V. MNI.,CJR4)K0W-SMVO=FD=2QWZ[TZXZ%9Y`02T,98+6GF'J(V7\S\J&E'LF+Y M6!P9)8A21!FB'%&!J$14(:H1-8A:1!VBWJ!C45-[R?\\:GI'ZD3-H/&AI]?J M[$VE0_IS"-&1Z:>MEI09#E;SQ9T?R(,51RT6>4:)(-&"$E-CY9:X](Z),K%B M^5SD&16"`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`K(IZB5(71C MK)9TCB-K#'_G$[&53JT33"IL<"JUZJ0RJ$HI:P6KE+$5+U#OQF/OR#]GDV"E MBD&5*H]J^?U4L57XIL=6P7HU@^K5LE:PLSJV,ITU&B_'WFZ^9Y-3E7+',34P M.([_M?M)^>C<.FRL9+R\I1'5AJ?FVEBI"LH0]9?!&V,UD9P<(8I%B^4300'Y M%+4R1+EHL7PA*"!?HE:%J!8MEF\$!>1;U.H0]:)%\FZ\U3&OG;?"1\=C9>[% M5:.E??N;+[WS[#4[.O,'0ZVUY!@Z,GY"8B#)(.T4_#(@.9!BD'8)?A60&D@S M2+L%OPY(;Q,WO.H`^(+PZO-B>U$[ULC;/GD)>6VLSMV2C):D@(CEG7'A;R9B MMA+'9%")*3O*9B)C9.YX=U/OC#1G@V!6*@:57XH6S^N*4;#%-5M)BYM!);;L M*"WN&)UJ<<\&IUKL#BEUA'S!D-(GSLZ0,H?0].>0]N=+_X-?:K.O4HW33Y@Q MC):L]"/CN`AN$6*V$L=D4(DI.F:,@B7F;&4G2CQ)'%2)DK7DGE@99/8IH\7" M?Y!0LU.P`LV@"K2L)17HSE:@9Z=3%7#'&5E=,LZ4N7=GTLA+7=YT7X^UU;G4 M9;1D/D;&\#*I$R5J232I&.IM, M;V^]]6;-!L'RFT'EMZPEY7>,3I7?L\&I\MU11G/6&67Z_98+#X/4X/$'GT;N M8="=UU=K=G0BBDG.:$FNBHSCN20'CLF@$E.6EQ(S1B1YR-H3''R'$BTKOT'% MH$J47*+DF,H@D^2FD[$WFVOVH>DJM?3+;P:5W[*6E-^=*[]GGU/ENX-/'<%> M<"O5)[;.K=0H52&J18OE&T$!^1:U.D2]:)&\&]>_Y81YC"?,!CF'0=I*C;O3`WYC')=. M3O0/.2*V`[V:+8)U:@;5J66M8)TZMC+=='N+YSYZ9+@QM_K)&;(3 M_US:OP\.._?9R[BK,(/L>O;D75Z5`2#X@N&8K M01M$$:(848(H190ARA$5B$I$%:(:48.H1=0AZAWDSCW*MY?$0IE[L=#H3H[) MUA-`&T01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J'>3&0IU`#E^2392Y%PN- M[%#X9&/D_N(['B9!TC2A"EB#)$.:("48FH0E0C:A"UB#I$O4%' M7EF8J,,W>[+XBX9!+YKL5;PYI$_UG$`"VAC',R^:B)5$36M9[YXD:)4BRA#E MB`I$):(*48VH0=0BZA#U!AV+FCK*^L^CI@_$[,WHQ"#K11-!P>FG'=W7/N!% M$Z-%5A)(*#$95&(J6E*O.;QH(E9<8B[RC`I!H@7GNJ5HB16^:")6+%^+/*-& MD&A!B:UHB16^:")6+-^+/"$W1:O3'7OHA)\6TE$"W!TUDCO?FHWL1:/Q$Q2A M58PH090BRA#EB`I$):(*48VH0=0BZA#U#G)#H4YK+@B%/MQQIJM&9UXTH>V7 MBF%X:[]A*SDOC!#%B!)&%'$Y$_"W@BE;B7R&*$=4,`K*EVPE\A6B&E'#*"C? MLI7(=XAZ![FA]H^3SLPZ/#>BNX`*HG,8C2^:&*LS3]Q8BU*O1,P_Q8G8RND9 M.$IB*^F99%`E4G:DP7FZ$AE;Z34^N0=YC.N_#K6MC M=28/L97T7(0H1I0P<@+C#X746-%GZOAFF3'2YW"CT?S.>Y"=LT7P;+`85(%2 MM+@"%2/:[\M4\&=:S59R:-L,*K%E1VERQ^ADDWNV.-5D=P1==A0U->=.$N)[ M@[ST!B/(.#H=Y8=XPUHB'S%RQH;?PS%;B6-B4#BAINPHCYDR@\QCKO%D[+4E M9Y]34U0_XQU4?BE:,J9T5X6?+M;HV`PJL65':7%GT,D6]^QSJL7ND%*'7_;B M:/`+)%-];&:ODPSR\I/_`HFQ.I>?M#R=R7-?1RSO#$L<7>"8#"HQ97F9OQDC M\SACZ;_NGK,!C0))*?Y,*0:57XH6M[AB%&QQS5;25# M4RUV1Y=_1OB7CCVF>'1HD)/'\`42=G2ZSX_.AK5DCD4&\1R;^OO=F'U.S3'] M6>]!Y:>BQ7'/&`7S:,Y6DD>+0266Z%@Q"I98LY64V`PJL65'Z>/.H)-]W+// MJ3YV1]IE1Z)3/!(UR'[Z)B@PNS?&BC:@'+\(42Q:;)4("LBGJ)4ARD6+Y0M! M`?D2M2I$M6BQ?",H(-^B5H>H%RV2=^/ZMQR<3O4QIG.OTLC^@("Q.G=C,D>B ME)0DY?O;E\AH+4T>/9)!C,RI/&HRB+8*5RGEPH)5RMC*+$87RZ7WD:"<+8)U M*HQ5N$[E42V_FRJVUD[G5,SQ:G.L8= MLI2P8$EEOS4Y[`,"4R7C[?\T0K%!EGPB*""? MHE:&*!1;U.H0]:(%*8KNF4Z\S^SKE;D75XW. MO!@R-8[.7,%0:RLY-HZ,GY`82#)(.P6_#$@.I!BD78)?!:0&T@S2;L&O`]+; MQ)W.ZEC7WB&=":\^!79N-1IYVR+OB&T]U5;AM+HQ5LZVR,@[X\+/H3$Z)H-* M3-E1-@D9(Y,P)W/O^6_.!J?RI=ET#VEQ*5H\KRM&P1;7;&7?-8:4V+*CM+AC M=*K%/1N<:K$[I"X[IJ8U"F2,(\?4^&((.SK]A!G#:,FB/C*.X5.-F*W$,1E4 M8HJ.&2/*7K*J\@=QSE928C&HQ)(=Y098&63V'Z/Q>.(='=7L1#=/J9/??RRX^6]N7L;,LC)4S,_31FC,VF*I63N18R

A' M.&8K<4P&E9BB8\8H6&+.5E)B,:C$DATE352,3)H8^\]1:C8XE2;VB;$95'[+ M6E)^Q^A4^3T;G"K?'5%DY=SY_M+IS4RI>`--(^_TQEMTK]G1"9\__3;&ROX: M(T;!7!*SE>229%")*3IFC((EYFPE)1:#2BS1L6(4++%F*RFQ&51BBXX=HV") M/5OM2W1'$\71&4WA==1,F7O#1B-K?[(V5H0"*7ICK.P3&D2Q:/%"(Q$4D$]1 M*T.4BQ;+%X("\B5J58AJT6+Y1E!`OD6M#E$O6B3OQE6=SMKKX[^6)92*%VZ- MZ";(+5K/-#IW\]%6[L?Y_:.'R&B=>2F1K>3ND`RJ1,J.5!=9//B5R-CJU+HR M9X/@`"\&5:EDK6"5*K;251I-9_[K$C5;!.O4#*I3RUK!.G5L9>I$*UUOQ]&S MQ:DZN4/6/RSVA^RP$YH9'B(;Y*0H;74N16DKZS@F,EH6BE$^$62-,_\NF:)6 MAB@7+9YQA:"`?(E:%:):M%B^$120;U&K0]2+%J0H=5B(*8I_`7'P3[/-]*$C M[>VEMO1[1=[7T-ZS&5D?IK[_+1]BPWVQ010ABA$EB%)$&:(<48&H1%0AJA$U MB%I$':+>0>[,50>9=B3/+"*4N7=7,4@^,;F>`=H@BA#%B!)$*:(,48ZH0%0B MJA#5B!I$+:(.4>\@-Q:T$G1BH;+H>/:.AOV%/WDX4TI>F#1R?O*(IIJW15\; M3S*3:73P9!2A58PH090BRA#EB`I$):(*48VH0=0BZA#U#G)#I\[!+IA&^MC, M/M.<&61/(T`;M(H0Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E'O(#<6_F'@?C%" M/^\[6RLC97Z\.OI0;4Q5LZ;8G/_FU@CL6+Y6.0)N:WQCQ#\=?N@MZCF>+)@ MD--(;66AC;%RWZ*Z\S[>%HF5M,C6D^4(M.JP_.A%PO4>WUU%PC^^!`T/$* M[)\5;(R5?;:)*!8MR*GV4I#:>J;FN!*<:^0E(/^QD;$Z-UB-ECS2B%C^Y'%4 MS!;#!JN]VCK?7%Q1S35R1N61W&,;>7D'H/.Y![;T9F,"WM-0NV3/5DX ML'L_-PL9Y&8A_YV-M;$Z$UAC96[];Y`<@Q'V%C9B8<1A?"05Q;^5\/%;.5DGYF\,.,&G2KQEQJO_+S& M:^0$?7'K?8G/>J&MS@5=6SE!-T@'';\2+S;*[A+$NFF[[;973V:PVQ^T&[0< M7.":RB!G!"QNO6.^-3M2DPZ!M&\0.C\;*V<$F"6;_M$3_&JVF'VW]CWTKTN M_="(O3QWAX^OG_>OGS= MKK??O[]>/>Y^^T&3AI[M6?CJ9?OEP_6GV6SU2=\2#P[Z"AVLK]39,(TCN#*G M*_NU(UQ9T)7]1_/ARI*N[%>$<.6.KNPWO/Z5Z:K?;]9]KBIVK%Y4K:.UHDH= MK1-5Z6B-)J.5^EJD(RV?CU;WM.7$*[1-7ZV/7J&M^4IMO-&'MKATY9@:[H2^M M6&5'K]"72ZRJHU?H2R!6W=$K]+T+*_45"E@.?8O"2GTA`EZA[T18J:\WP"OT M#0?4SF-7UJ/)2OTF*/K0SX*NU"]\XA7ZD<^5^KU.O$(_V4G]?^S*_62ZNJ(5^E?E$7K]!O MXZ[4+]_B%?H-6ZK!_LK-(6>\?GS_\^'KMGIX^?KTX_7J^_8+I<+;_8'OR]-7 MM7+5__-F?D#BE]W;V^Z9UFFTG-\^?-[2CP+>JJ&ULK%G;CJ-&$'V/E']`O*^AP?@FVZLQEV2E M1(JB3?+,8&RC,<8"9F?W[U/5-_K">#S)O.SL'$Z?KNJJKBJ8]>?O]=GY5K9= MU5PV+IGXKE->BF9?78X;]Z^OV:>%ZW1]?MGGY^92;MP?9>=^WO[\T_JE:9^Z M4UGV#BA3=IKN4%GAR:MLY[^+4]>MVU+?,]752?O<#W M9UZ=5Q>7*:S:>S2:PZ$JRJ0IGNORTC.1MCSG/=C?G:IK)]3JXAZY.F^?GJ^? MBJ:^@L1C=:[Z'U34=>IB]>5X:=K\\0Q^?R?3O!#:]!=+OJZ*MNF:0S\!.8\9 M:ON\])8>*&W7^PH\P&-WVO*P<1_(*@LBU]NNZ0']794OG?)_ISLU+[^TU?ZW MZE+":4.<,`*/3?.$U"][A&"Q9ZW.:`3^:)U]>SZK$))URF>N[ZI_V$D@D9)D9"+3*7(;$*F_@PE;BR#IW1O^,GW#H+)G/C+ M<'Y[X8POA)]\(0'W%A&)7MG28U[30TSR/M^NV^;%@.$(T"1!U39N'"EX*0ZR(%O6P+'M_:^0>`*3MJ-D'1&+!AXM*B;F$!J M`ID">."2]`O"^0%^H0KZ)0S:"6!P-#!\$`RQ)#&!U`0R!=!\@*SZ`!]0!9): MB4U(S-`P#EX;&<"9X9>D2,FIX4?&@&1)+$LL9#40C(5 MT4R&,[S?9"3K)C,D8F41[VYL(8F%I!:2J8AFW_P]]B%9MX\A4WF38Q-(3"`U M@4P!---PE%!JZ.UH(UDWC2$A5#*9Q`M_:D2;D0(P09+"P*@]"5>">C*0PJ6N ME')2R,HT3"N^KS,RSH#L'F24O33?E[KOV#^"&79:IS]5Q=.N`0`\&SD3-(!U M#]30CX0A`1@B+5CX1M&*^3+-6\5,UD$X:?LG5O.10,1L8#-%AIQYNSPKE,Z]2&LD$+*H5N.79/)7/_4_0( M:\%0A$4AVG'(2.FY/#X:FIBSWLAIH:6%PDIJP6)9O233A9G4@G%75A/8S3P8 M$DUP*J-I_;6YOI;6D/HBKZF*$6H4ABNBAEI"-T/-6.$PBZ1J8YW;ZC)\JI`>S7BN".RR0\TXS[%`TJ!8?4.V%!"0YYZ-_`2FTHTR#= M3.S>]YO)>KUF)H.,HF9TUY@PU@QZ@KPS(X6;:\&E'EAV46.LZ92VZKDQ`&9\ MJQ#2:Q!1&J#N/C;U^]UG(X#F/H/TGDR,*AL3QHJ@)(S:Q)HR9VFQ9`NA+>/; MX]3RE>^N'=BKOF+W5GQE+[5#];YK*"%\&,/[\OWL&[AA+*UHL'AR)E9!Z@6\$5+/K-A\8[M:%,0%1>RU3H MC?\_>E3$<(C-*5H"6^^*,5_X1@(+>3430NO^,CEH%7B`5\:C0F&0[-05LG8 MAA(;2FT(/T*C/--B,6`?E=GWT+ILCV5S*%)_2@K#41/!E5"^#)Z#[P/?V!9J.E!5)CNP<@-(:#N6/6 M/DQ7#_!F,>(&>#'J!%@ZZL)L!5]S0,>3EL)W]VM^+'_/VV-UZ9QS>8!C]NF- M;]F7>_9+SU^O'IL>OKA#).##-/R%I83/2OX$PGAHFE[\@AO(O]EL_P4``/__ M`P!02P,$%``&``@````A`/A/J?)?'P``]JD``!D```!X;"]W;W)K&ULK)U9<]M(DL??-V*_@T+O8XDWH;`]88&XC]C8F-U]5LMT M6]&6Y9#4W3/??K-8F:C*_(.@Z.F7EON'/`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`W[/0[8B0EDA%PHU69W=G069!;D%A06E!94%M06-!:T%G01^!*XKM M$&!*B[\BP,Z,"[!$YE9`B+@)=RH2HK*S(+,@MZ"PH+2@LJ"VH+&@M:"SH(^` M"B:-E+\BF,X,3?=1MB;7,YV*MU[&+2A#2J^U2#J(#!$&D@')@11`2B`5D!I( M`Z0%T@'I8Z*"3;/!7Q%L9X9F%UIVAD#2W+#0L;QEJ:EP#R)#N(%D0'(@!9`2 M2`6D!M(`:8%T0/J8J'#3K:MPC^]C9,)UTH>H2C!NF?BMCIL\4R`[(!F0'$@! MI`12`:F!-$!:(!V0/B8J8)119P3,2>N`>9+07#,D9G)M\C(=A"3..R`9D!Q( M`:0$4@&I@31`6B`=D#XF*H:TJ3LCADY:QY!)E'1`=D`R(#F0`D@)I`)2`VF` MM$`Z('U,5,!<^1COEZ9'J9/6`?,D60P+>0ID!R0#D@,I@)1`*B`UD`9("Z0# MTL=$!8RV\6<$S$GK@'FR#/&R8&=!9D%N06%!:4%E06U!8T%K06=!'P$5(U>O MG!&D@[B.$J-%$N(44)C?%G.S2=RQU)82/IH%EWIUSH*43(,YH@)1B:A"5"-J M$+6(.D1TYG!((1\)'66W18_'KJ]UWKFZ^?7KP_UOMT\4`A(:&=,+JFFXTO$; M?=K/2"AN7=%(6:N"#VC'4EL:*4.D%\O$1MHKDI28SX.BH`)1B:A"5"-J$+6( M.D0]H[%(N_W[OQ]I7P6H2#.:#]%)70'NI@SZ$\**:>ZEMLFA-IU?S\PZG[$9 M$I`@Y\&RH`)1&11=U4N6S0BK@H"8J=%,@Z@-BFS9E"A=$!#+O3*CL]_M\^,^ M&*G'S MFQS+)-/D['%+$\\@M5AMM501VB6Y5HKB9",JD5H>1MYV/EN;!M0BH1I@ M1W"##6A%<;(!G4CY!JP6VX59W7J1.-8`G0BN'HD3X>=6$:YJXOSPZ+`:26\M M-F;,I^Y`X@W3'=L*JTC&BAO:@PS=G%R;],M%B@J&06HD&89&A&0`CY78TAXW M.K%JD9KTV+`436_BL17%<(^=(.W1I'(O4L<\ZNYVI5/F32=NMF8>S?V# M@T-A[@Y#W"`_EG!\]NFE%IOAGC-6C%`>;$ED"D0E*E:(:E1L$+6HV"'JE:(. MJ2NNXI#^W`CB$BT>01XE<5AG:: M#%&.Y@M$)2I6B&I4;!"UJ-@AZI6B#K6K2.-0GYC=G+B9W1B%+6`Z`[1#E"'* M$16(2D05HAI1@ZA%U"'J%5+QFY]7N!_$=?P8)=&N&M$.488H1U0@*A%5B&I$ M#:(648>H5TC'CR8$E7\_^?C1K:0^,<,HIH<,9J-W*V*T5QEV-W9Y"#(R;>P0 M98AR1`6B$E&%J$;4(&H1=8AZA73T75'\]M$_YTH[FE`%T20Z!#29F>4G#5(A MI&PKFE!1*D=4("H158AJ1`VB%E&'J%=(AY16RG-"ZL3-A.#1*MHNS@'M$&6( MH5T_%S)>D9*^@HW7N/G'L7SJ24[D,F`Y$`*("60 M"D@-I`'2`NF`]#'1(7.5UQDAX]HM'L4>Q>>7[NTE2DQ"86##CG''4LOX2".Y M-K-N%J1D^.>("D0EH@I1C:A!U"+J$/6,1HXTYZX8BZ/\4T7+P8H9[USEA8/' ME*6B_M@Q6JH--!P>!ZD0:6^>%`45*%4BJA#5B!I$+:(.4<]H+-*N6/GW(^U+ M'C4S,`IG"*DK`MW\2ZO1L'Z-I+F76JZ/'1ZS&1*0(.?!LJ`"41D4CQP>!P$Q M4Z.9!E$;%(\<'@Q/6BPFBI>\4LS"E+G1AM++4(0V7QIU]E>!(XYT[U)J:-&]4_M M'-S$:2H%1FJPXP,#43R6>?ZLF:5H@$HO9(SJM>F5SP:'=`]'E'Y+6%(6(\F!+S!>(2E2L$-6HV"!J4;%#U"M%'=+S:N,%UL:,EM%>F=&I.R;-4.!S(@.1`BF`[]*5W%PQ5H%8#:=!0"T(=D#XF.KBN2G_[AM%MTFQP M/3(;!?,*2\J*IP:9MT6#3,*4L2)ES&'97L^VYKV;7"0HGD/O0@56A`:(Z5(4 M@[>*T3*VEFR#HC2B$T1%=FB]72-[D3IDB^Y`>ZIP8I7Q MQ7Q<5RVXOM<[?MCIL:(:^7;*V+$M>J]+;C!CY.Y@N,%D9A]PLM2)[;V8#SU6 M"@H>JU&/<[/MJ-_DL1'SP6,;%.4>._$XN='IE:+N1'<\$(_"G]O@.2MFYO-( M#^84[7+89[U$8KZD(G9BYAK,* MB57&BE1X^XJ1/B&KWXK(16+2=!$:(*9+0:'C*T9ZGIR;XZUZU*-]U:X1\R$* M;5"41G3B\<2LQ0$]V%*=Y0[M5?[_U*QUL*)G+4:NM!JFE<2N-2E+G9BUQ);J M(MBWBQ37ZZME8M;\7"34FF_;5(0V291+49QL0,52>N,Q-UN=6FRI1D#O8R-: M49QL1"=21_?M(J#\1T'0Z7'JU.)M+^&X!Q9FC#.*Z^*`0LK`)G#'4C3_2/=D MB/)@2Z0*1"4J5HAJ5&P0M:C8*:3C2ITX,NSDNP+>_('KI;-S&'@A9/3&@SF# MNQ6Q>/]FYL$TR$C$=H@R1#FB`E&)J$)4(VH0M8@Z1+U".OKG'4$L\0A"4/2^ M$Z(=H@Q1CJA`5"*J$-6(&D0MH@Y1KY".'\T=*GNG-TUN0K2CWR/]JD]'_F@&SU,@`G!(_5)K61NME8I*YZJ8-@6[22&:@B? MHK,M_3D"^\F%G*5.?(X@M$O"5HKB9",JD?*O\<\WR<;<L8BNJ7@11B@RYD781&#+TNBL%CQ6CKTI\^K+IM*`9GG7$&)_&]Z!QSIGO3%J0G>A,+3WJEUHUT,ZS-67;*4B>& MM=@*1T"9()4&]EE`+E)!L0@>0]=Q4X-4)8J3YFN1"HH-FF]%*GP+1<>(9B"7 M&8NM&?J]J%##0A9&B:'[RA6G\61\HJ^FQ08^M*(9[[`1I MCV9CT(O4,8^Z7UT]?$:_.G'3KQ[I,6B?<*`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`HC>@$J22W0Z$7*5P=PQS$=?RU>]K@G\)72F*P5DEB-]+V=H3&+D^Z:M!7VU0%/>=()HZPZ(. M/2=2A]E/#;PU3;9G#+R#N.DY9\&>N2S-X4+*BB<&'DO15[+(#6:,:."%&TS@ M11]15$N''0Q%:(28+T4Q>*R"Q\,YR<)N;41%^;))V*"O-BB*^TZ02FCL/@[Q MR,`C1=5]/_6<8NVLF%[UR(Q',^NEHJB:;T.Q8ZEXL\J(Q^-BO;$'!+DH30Z2 M(C1`0EJ*8CP@^69HJAT&2;*$?F4IY='F4(,>6_38"=(>S1:Q%ZEC'O5(=8<5 M;U\BU_YL(]ZW,HI?RPDH1`:.^WJ6H0^IJ^SBD/S=Z_`F!BC0?&L1O[B7V44>Z]E*GYD2V1?TY)"\^7F);6WZR M,_*"G$A,3EM%:)-T8BF*DPVH6$K/TW:9K<66:@2.L2$PTHA6%"<;T8F4C\(" M/]@B`LI_-&'I]'!'%E/I\;87Y-;^Y$/EAT=J)`XHZN:H9?YXC6W%+\@ARAE% MY@M$)2I6B&I4;!"UJ-@AZI6B#C5-@2.A/ON=N;6SMTE=", MPJM'J4@%M$.4(H5TO%SM7@.^#<3SOR1G;6O MZE5H/=*OTZU,39&R8OPZ':(,48ZH0%0BJA#5B!I$+:(.4:^0CK:KF.-HG\A6 M7V"KD#(*J9FN`>T098AR1`6B$E&%J$;4(&H1=8AZA53\-N<5ZP=Q71PPBMZ= M2Q'M$&6(H5T_%PU]O;\VSAQ$S^/HM?I6"B0'9`, M2`ZD`%("J8#4,=&WZDJB^%9_:H.\\855/`(%1:_!!1369"Q%6.KX:W!!0);M M/%@65"`J@R*_K&:FV"H(B)E:F=&1<^57'+GI26KCQ$V2>*0/-%?F%#!EQ1,U MA$B%T^\,48ZH$!0]R!,4;%6(:H5T9-SF_HS(^%I`)8]'^FQB9<\*-ZQ(R3?L M\4;RB6W1(AND[%EVQK;XN&*Y7MHSO9PEZ+EW9,=NWXO0)DFA4A0G&U"9!JP6 MB7F04(N=8PW0?>"*C3/ZP-Y"!PKY/QY;?`?X@W.*K'%#Z:V<#(D`L>IO!2%(.S2CN;;^VO M(=2B<\R9CNUYAZ:2U7Y*5TAGP89T[,2FS MK9!'&2MRTJZ7B7G`D+.`2Z=AT,!T7P3_(;;@K-+.5G/[8=/ZE#,=V_/J%??` MV&X%/%))FZS,E)BRXJFL95LAE3)6Y,EV,;/?O)*+P+%4XKSUELE_B"TXJ\26 MS]O-=FL.Q6L1..9,Q=:%1.7M3VU0#U;T[HN126?[_$,4I]-9;$7IS(C3>;5: MF>4\%YWI=`[^AY"+8G!6:6?K:_C0NN@<;`E02D0E:A8(:J5H@Z#*VKB&3.<^9P(B%,TR>:1ZX9A[DKL MZI&Z5UY)\<3X9JEX51+$0VX!WUV8B\2Q,><'>&B`!+84Q3";5((&;_9A;2T2 MQ[SI.-M"ZN=&.-97[G<_*)QZA"]AA+,BQ7[H&EA6=F(K#+I,$,V`@V*R,I-= M+E)JY-F>+U@J^FF<4A2#QTJ0\K@V+W#6(G7,HPZ^JX[B)#^1VEQRA=+PEA:5 M0](>'ET?TB@-*$1F)*1>48UU0'FP)2E9("H91;8J1+52U&%P-<,98?`E1KP[ MHHG>A4&/\+69]%.6.C7"V588(E7$P';Y4@ M'N'S&2XH)[SIZ%(JGA-=)V[F3X_T4%Z;\YMTRXHGAK*7"B=Q&>L%D@,I@FW) MPQ*$*B!U3'1,W.;]C(SS>WV5<;S]5VO*VAX?N1\%?<.:PK9"#F2LJ!_WKLT9 M3,Y2;A4=)D'\8%MH1`@>>PS31B6V5/?95V5JD<)79>C(4(?TYQ82+F#B*8X+ M",KYX283^Q-XZ<$]I:UJOCT@VK$4U1<2BDR0GM;-YC\7*H1$CD>;61S6[ M*`:/E2#MT:R,M4@=\ZCSF6R=D\].W(QQC]2F<4#1/6-(O50T^6?T$Z#.?(1R M1I'Y`E&)BA6B6BFJ,"1_2;ERL**CP\BL+^8-IY2E3JPO8HMV/B&5[/%3QE)F M`K#+CMB:G@!"NR3K2U&<;$0E4GXE6JPV]GN<:Y%0#8AR1':4!1F*.6'5;D'4O%+WP@RH,M"6"!J$3%"E&M%'5X:.X:"<_9 M+VFX1]D^/N'.Z24-,\')O'U+0`]G(0D918^]12J@':(,48ZH0%0BJA#5B!I$+:(.4:^0CI^K M'LZ(GR\VXBT5_8*;"ZGKHF%B3#9FSY,&J9"2@Z*@#*5R1`6B$E&%J$;4(&H1 M=8AZA71(W3;_C)#ZJD"%E%'(O]2M*&YV"&B'*$.4(RH0E8@J1#6B!E&+J$/4 M*Z3CYVJ-,^+G2Q,5/X\HZR6ST@30#E&&*$=4("H158AJ1`VB%E&'J%=(Q\]5 M"6?$SQ<5*GX>A=HN32S9`A:E1LR`@.9X'RX(*1&50//)&1Q`0,S6::1"U09$M MFY.<+@B(Y5Z9T7WBRI$STMA7+RJ-/=+;?_O=/FGBI4YM_]G6Y,X[8UMT9N8B ML,(7(D3@V,;;'SB%)DF<2E&<]%^)%._\X3MU:A&8]-^@_U84)_UW(N7]S[?7 M)FM[$3CF7V7`['JL,'S+=UMY35T,"M/G8?;CMJF(G3B2$+'X3&)@E"O15LCL MX/-!C):D00Q/)40L/M\6%GFM!J:]FBJW'L0FO38B%GEMA45>NX'YC_.9Y\[] M<%EYB^HXT]&N-HS'^EL?&\VNG:;M:,_,N#=%.'6T%SLQ\$6,GA#(8,R$T1[& MC7-Z\Q^&196.2/NICOB,?5RO[D%/4N2]"?D%/6(?7N M<,]R,]2[K!IND'J7F7U3UK'^XIV9I5C,8OBZGG'GZ+5^IA+Q9YI1X>5"6:U,/,:&,WW"O\"`)U0HWY]BPOJUUC5].MY1P*S:SP3$!:?[$4LNGD[1>U$+#J&IM[R+B)&7>-9 MY*(88=0/H$O]`(R"#O8HZ,`HZ*!+00=&$8YU381=,6]'SFSU[C"UG3%R^$P@ M>NHRN_;,3))F>::1PZHJ$4?Z@JU181/R%0Z]Q1H]`3UL_.G1)ZR';$A-F=8? M]=_0+!DSU']O:0-UJ1?C-N#6FSKX+6V@/H1]=NWLV"G6LVCX4%8,+.INVTLT0KU8?/H^PFB$#N:D-ZF'@5$/ M@SWJ3F#4@:!+O06,>@MTJ6N`46?$NC[R5R]?]_O7W=WKWP*6:-?`QB[0OU#7VH_=H7ZA[ZN?>P* MQ9J^B'SL"ET8XV1JU)+KM#%YZK+1'J,.&^VO&?77;*R_=IOY348?X,&VTD>! M;MRG??#*+MG>N/,HO$*'33?5Z!4Z++IQYT&H\XG28LS++27%>+90QX_8N:4N M'.O!3TNR/Y:0N_GF)O.EF$DN^KGRFVKT"OW<^$TW>F6WI*#0UW;C#=)7B]^X M;P_'*_35X#?NV[_Q2CI;W.2SL=LIZ$H]>J6A*_WHE=OYZN;6_XJXN=.4KJ2C M5W9TI:.M/;9M-U_3E;&T[$G'_>`]ZMS.:5H8[06J\VYN_2_QV;;1E73T"BU) M-S3%C_C9S69T92QM:/JGZ(Q=V?_L!&C#\.7IZ57^AT)Y]>?3\V^'=>KC_PL```#__P,`4$L#!!0`!@`(```` M(0#,8$;.Q`4``,P5```9````>&PO=V]R:W-H965TJF**NRJOGYYOGPI:W<#%8WDIV^^=4]NJBOC+Z4KK_/$"O-^\ M,"^$[^Z'X;XJBYHV]-C.P)W#`C4YKYR5`YZVZT,)#'#9K9H<-_:#%V>^:SO; M=;=`_Y3DM9'^MYHS??VM+@]?RRN!U0:=4(%'2I_0],L!(9CL&+.S3H$_:^M` MCOGSI?V+OOY.RM.Y!;GGP`B)Q8?O"6D*6%%P,_/GZ*F@%P@`_EI5B:D!*Y*_ M=<_7\M">-W:PF,V7;N"!N?5(FC8KT:5M%<]-2ZM_F9''73$G/G<"3^[$CP8G M=R8&?"(\Q<2[+PJY/3Q%M+.EYZZ")01[YSTPVK&$)Y_GN;/0GR^CCN:=F0L^ M$YXBPID?S;WY`M?'G.BP]>WD2O(VWZYK^FK!'H`5;&XY[B@O!F=")^:A5^Y' MPH%BZ.0!O6QLV+R@20/9]K+UO,!=.R^0(@4WVHT8J19[88'Y@'X3'4AU(),` M!RCUO$#S_X$7>D%>(J"=``:BOL9!6(@IB0ZD.I!)@,(!TD_G$,!.'-]#0@J< M!+M%DB(*0C7&';/!_=CKM5!-]KU)S\-`4@/)9$2A`CM#IX*O_V":H1=(5,C3 M/F[(,T\-?<>M[K'K37IV!I(:2"8C"CMXE'QFI\#%E!FO;+'@61NNK[WDC02@PD-9!,1I20EQ\)&8W5 MD#DB+:F!)`:2&D@F(TI\V*A(Y^9]R=%8C8\AJZ`_6?8&DAA(:B"9C"CQK3X2 M'QJK\3$D',+3@40'4AW()$`)S8,S;/K:==9J<`)RU8Q<:1G)S0*(H\_;P-?. MZX1;1:!T;Q6%6NU*!RN1WMG@'B"5(!:ER,P':S$Q$SQI8:.M4@*G?4#,^QCVG-9/.TH+!($/)+O`=1]W@VP@J8P MXI#"B&$*(P9%D-:2&)IDJ==;#8QD7RHCK$D2HY'(H67J0^<53!:#0U[8-3:^ MZVGE=.\Q"U].H9%$8U81/'IN0:`E;5[-M0V7B7$H M$*..59Y8^:;SY'52YLF@R!4\]78(FQ4(]SV)N9OA6$_Y1*'G2LOEC(]/U!/+ MY72>K+@JVY!!@YY+74\^YQT]N1M93PXQ/:,P4!UGV+2AWO"8H">678GGSYU" MO';+,C-HD%EO8CQF\)[,W(TL,X.$S`O-<<8=3Y09J[I$_YTCB_4`BLP,\MGG M<-=1>CTTOOY\HS*K8-D7F91/E*!L\`7GK[H1L>9+D?^<<*QQ4`@Q2"Z'W.B= M1&562Z`U9)UYYC*KB)UR8>@:FY2[F92\<*UR=PV^T=N/2JA4B#HO:MO#(5G5 M`9+X2=6`J!W5'7)7"Z-5=!GO+H!@;;K M'N[OE1XZE31\!_=-G6,=]^$>"I--QX,8/B9-_"&,'R!0P3TWWD%#8H[L860_.@(]9XP=I3D'6CH8&5NH MQ/-A9.P]T(C"VG8C3K^*<)=VRT_DC[P^E=?&NI`C".9V?5S-;N/8CY8GXR-M MX1:MR\LSW)H2^`AU9U#-CI2VX@>$Z_3WL-O_````__\#`%!+`P04``8`"``` M`"$`[[1/OF08``!&@@``&0```'AL+W=OX7$D6?W(PG#QI-=*,!-$"*?/^/OQZ_7_UY>'YY.#Y]N,[>S:ZO#D_W MQ\\/3U\_7/_//\UOF^NKE]>[I\]WWX]/AP_7?Q]>KO_Q\=__[?W/X_/O+]\. MA]#[< M?>XK/7Z_F<]FZYO'NX>G:Z=A]WR)CN.7+P_WA_)X_\?CX>G5*7D^?+][I?:_ M?'OX\>*U/=Y?HN[Q[OGW/W[\=G]\_$$J/CU\?WC]NU=Z??5XOVN_/AV?[SY] M)[O_RI9W]UYW_P]0__AP_WQ\.7YY?4?J;EQ#T>;MS?:&-'U\__F!++!NOWH^ M?/EP?9OMNBS;7M]\?-][Z'\?#C]?HO^_>OEV_%D_/WS^CX>G`[F;.LIVP:?C M\7_R M\')/+B4U[^8KJ^G^^)T:0/^]>GRPL4$NN?OKP_6"+OSP^?4;_=_ZW2J?+3(2 MO_IT>'DU#U;E]=7]'R^OQ\?_[(J//[ MZ]G_X9K;=_/-*EN=\.2-Z\P^-LJ[U[N/[Y^//Z]HQ%%WO?RXL^,WVUEM/BJ< ML4.PT6?U MEAI4&A@-:@T:#5H-N@C@^"MN7*$E_!52@TJ#8P& MM0:-!JT&702$(VC,_XHHL6HHT&A0QF&RDK;O68K&^B"UEB+%(#+X!T@%Q`"I M@31`6B!=3(2;:%8#-\UI!O%3U<7#R2KJ'>7MVS.)1U@^UU$S"/EJ)9`*B`%2 M`VF`M$"ZF`BWD/W@EFSU+B>>7GS\K&(K2CC[+7;P_WO^^/U`[JKD0D6J^Z==PJD;8ZHOI93=F%$QKI9];4M[R_ M6L7$=>I\C9W*`DLPUJ8JPMJ$5913>K-Z<6D7HU6OVTTE`9WK,B_E,EC02AHC+YWKI9*F1N/3JX^&]@$')4G,7 MK,ME!M'J)3!<,YMKG'/#/X\_3L5KW+,N91%^<$CT[("":W`BZIOTX7J5#SZM M$!F/$CUK$P,T:?+JGW&"07-WZ,B5FO#V7HJ6H$$*.CM.5=R,$ZKYP*D0&40U MH@91BZ@32,S#F4T98H>-C&+.,.*89Q0&8]$KI<@)J$14(3*(:D0-HA91)Y"T MV:8,LDS#2I@!@@-9`&2`NDBXDTU:8QL:EO2LWH;%#G9AZ%H5P$%.:`Q$KG=&W( M.\-,L=RJK*YB723EX\P@JA$UB%I$'2-:3TF]<-A<9W=O#6=4",]IY/+\[/G M'+-(1IMXSY:O5*,*EK*GL$,`);SFU&_$'@BR2'_%I=O;K5:;E=I+&2]"^DY? MK@Z-\IYJ?,6S+6B]E&O!?)WGLURNFIT7.=4"V0LVW=0#WAT$C?2'RU/CF7WN MD#TL&4S/5RK\"I:RN>D@E>@/UA4&=,45-W:O9,-OMM8)@_$MH#7TM.XZM"`X M'R[7JLMEL^5"F=*-74YZVB:XL:='_,OY<+2*S!U2\:X"L&"IL7AG76$5KKCB M5G:?FFF-;X2(KM5&QF`=&A%<#%=LO2X7S*M\GBMC.B\AKG;JK&2N'H?C8H+!Z- MKWBV$:V7MM^Q@><Q0V=`6B$E&%R""J$36(6D2=0-)FNQ/14?*F MFT/VW%F[PR&Y\U^H5:;@BO'.'U&%R""J$36(6D2=0-)#>ILTLI;C?H@.(GO/ MQ%$!J$2I"I%!5"-J$+6(.H&$S0N]TSEOH>4+M5!40D:GY2.1A"9$A`?3OW"X?D!F&I;RFPE$U^AI0T,2.Q+@KS((7.8BE_%K.% M>XJ^333E!SU1\M([E"6Z@"L\Q5/-4+V@\YWWQ:EF`8O M')(;ZJ4Z42E8:F1#[75%AT.,^'`HR]?8%]P`ZK1S?<$MI[7LM%2##6@]HB1N MJ)@O]7F&EUKWV[G?0G3*3M`)^,A@P"Q[X1`=!?KQ4004&IB(?%>1VNDK5EPQ M0B;H\E)U0&?4-T'*5VP1=0))S]@<^5^?1#G3CL[6:"ZS69F:/?2VA*7&9@_6 M-3)[L)2;/99+?'[&M^G4P.79P^DYWZ;&MSR8W"+J!!*.7^KL7\\+EST#T:N1 M&3*C.%0#.A-+)4M1L/A8JA"9H,M+U0&=4=\$*5^Q1=0))#UF\_PX5,\/XJ45 M5YYA%.T1O51`):(*D4%4(VH0M8@Z@:3->A/11\GFU/.3X6&N)6XG&&W#3%0@ M*A%5B`RB&E&#J$74"22MMUGQA!YW2721A=^3)L4&3;;'(9N\Q-*Y,/))E5B543 MMNLLQ;?2LD78?/43O_%:J*G#XA!OD*3].M,9Z2+,;U8.B0TQ[0+DC?2"I48V MQ%Y7E`I[Q$_G9V`M7YYF_@NLM7G)Y8/0/K&M>]LAT=OZI*+@>F.]S:K"04C% M%7W7SM1-4L/EE]TDI:>Q)QF+.5*O03\\,%>-*EAJK&N=>GIXP"])E5?ONG:A M#F>-+[ZL9VUJ$_>LWM==]%N,%2=(T8K+2'1XKMM:L-18CSOU]'!6\`&CT[MG MWX#+AK--@&(WC`QGSI=B>QV*M[&K`:6'6#_ME"P5':]4B$S012Z0,]&TY(A^ M,@!CTZ%XL6"A*"?P]0*J$!F!9#-U[O*V0,.49N60F$=S/;D7+#4VV%A7/-@< MXH/%Y6JQ@9F4*U%O7S"33DMGZ.>#T%L.B4`;4+H%'&A.2@0:(,-7=.I%#]K? M3$T8([VXS$H818'FA4)4E8@J1$8@VDUS-BL;:YB/*JX8H1,T*6G[_6T;*,75TUW M&4(\JC@EB4<5H,JK"E)&(#FJ?DF>L,8\@9$:;/J^$$N-#3;,$[QZ-]AHQZ\? MES9>XE0W2S?8)?WR/&'M,H!X-\I(!)J3&@LT)Q5%5<6Z(F2$>METG2>\;:+` M]&'MT):6AV$.R!?JSE?!4B,+,$N-/"K+4CQY+!8K_=RP\7K(9T.;3N[EUG8! MCSM5>^:R>QN]&C4T76H@.GM`Z9;QC.FDXGL;K#Y"AI%3+SO;+NSG3+HHK5^[ M]$"$KT-T=N%3\8*EQL:FJTA/6OJ*E:\8D!%(6)1/RSYZ<=D9C.+.".A<9[!4 M-,PJ1";HTE-\;E.,?[DS>BW*(JN83C7CD1>=M/>A5/AZYY=HEAH9>"SE[[+/ M5OHWV\;KN6C@Y6.YRV4#KU>C/..2%]'7`SK;UTXJ&F45JX^08908>+G.1-Q< M,OF&1J^''F2/YB\ZKU;IUYZE[!/4^=I^WS(@\YX;)`)'@-4!4U>RB"J$36(6D2=0-)C.A4[ M?U9A-\;J,,XC6F2&L*$?DJFCQR#E#2P158@,HAI1@ZA%U`DDW6#SH1.SZHA' M;$TU7S@4OZTG!U0BJA`91#6B!E&+J!-(FJ_3N1&;,6_+&47/""$J$56(C$"R MG3:3B;MII)TN\8E3#KLF47?9)Y=#M.+[>YR4/1<8I.*,S^557E<\K^(O?[R4 MN\5-[WI10\-X`9H5DA>3'O@EN5B.N1@C^S.%H15K_0.A@J7L$?@@E7`,JP_! M4'GU[IAYF:,7.*43SHR>;A1>L!N\"7'0B\LQRHB.M_U\5`1TSC8O%3:Z%2+C M4:]>-OV7Y&_VYH.:=1C9F_U#U^!K<%AJ)+)9RCZ@/NC"R/92+K)ISM>1[04N MBNP-74STZ=LV3KT:U==6,[UL).[K`44&1M'F!CCKHG-H'R05(N-1HJ]_4?YF M?TCN>CNT-LOFRMU[+Q9'@$[@@HPWJ414(3*(:D0-HA91)Y`<'38UNGR"WW`F M%39]>X_B>8Q\I<[9BR`6_,#*HO-ZE#*(:D0-HA91)Y#T@T[+HL%P?LVC[13, M#`[%^0A+1:A$5"$RB&I$#:(642>0-%^G8R,V8PZV8126H`)1B:A"9`22[9R6 M-]E?D^A9V^=-_4N,W2;;B]EWJ87I%V4$>@RI3C%ZC70#$S-]V.K2+!R8++]ZM9(%8EY=69@B?;_D@2)7G@"/>63 MFM@L9"57M?<(A\[+Y^H$LPI2P2BA3,29/929T"F]N%P#&*-CE[@HNQ@FTJ;YFO[RNZK":]YQ+2I5TQG(Z*[UJJ["I:R MK_4;.A7SWB#E.[5B9'^K-%3,U^H@P?A&"+]'O_N7P6!SE\O72/N8HIIT&,4) M44"AG0D#G2YZ&B(8",@$720EFYY.B":^`Y(>O@.+'!+AO8`'P+CB2/++4B/) MKY=RX;UX++QM[A'W:;3>]^%]V>'EEE.8*!]B)/K:21$ZV]+^6@KO%1`):(*D4%4(VH0M8@Z@61\ MZ[SEC>>/6Y>]T-`:)@W*8=7*N&>ILP>V0<;[L$14(3*(:D0-HA91)Y!TF$Z@ MWNJP(;,2'M,[)/K]1S]SQ+.QWB$%F>"QH9I'%4H91#6B!E&+J!-(>FQ:?K;% M_,RC,(D7B$I$%2*#J$;4(&H1=0))FVUF%,^.(U,))U+Q+.B079GB$07YSR#F M.[K<`JH0&40UH@91BZ@32/B!WC,\R1%.7DZJ`XNZ/\'*!*/W/=OKD[Y0EU[X M#*Q.L";!V@3K)%/FZR3P?!QD,TSW/*/5V7=QD6!DOJL;R9'YP,A\8&0^,#(? M&)D/C,R/F3+?IEJ7#X-LYE*S>&_F6704AHB,=S6#%-FN$9D>(=52G>>-=11F M=)G]V1K%&OV*-.JH@85AC%FJKVIWN<-HSS=J,2"3G#82\U<@FX8K$%-&V81H MBOM=`B7=[Y@T"AAU@&/*`KVUC\0B"V)URH)I*5DVXP0LFD@]DQ8XN8B1!8XI M"U0*0WTPB$46Q.J4!>D$:^(&(IOQZ9`PS+'(")H8@)%ACMDCB"BXU$I"A@UB MD6&Q.F6833&F!!>G),("Q^R]AZAE>BN;S9S8R",V7LR>U0[:\![`(,;/SN-- M@$&")K:@*$IFE2-T?F,SPLD;_6R&>8]G]B[PT)`;.3A,B]&=^]\!U.G MNZO:FUWA"AN]VQ_$*!P&L<6I[7XVLQG(E-!P&8N<=QR+'V%Q>LFWI_K%W0/Q M8O$#2PE&,V=\"=FG_4]WLF8AXW_EYL+.;Y"F,Q[\4X MYO&6KK^>O0$6>OADS/=?BSCGG\MV__2$2L)!CHF>]U^G.-4Z[GD6BYY5JOPE M(F8\2SS`1)M6%;MOW-\Y17TF&QQ*%U8_\:-O@;B.!+R0[=,,#)V4.;E MR%A@=8(U"=8F&'WZ,-:GAHW-1>*P&,FB_`2"/^1F8?5,[)NY:K2X4[^[JA&CCA_446"YGG>?WW6?6'T\/'\]%(?O MWU^N[H]_V$_KTB,R']\/V'_X-YOO;OG3OZK,KN/VL\#]U(ME"UO6'^!@V=*6 M]>&-92M;UL][6+:V9?U(T65;*J(3;#)5E=QNVIR![B8J7]=D,E M_:8!ZFRII#_NT"5T*$;-HY.VA#XZ,;)EJ5;URM;NEA^^QA%[M0W62+5B2#^C=,JDZU./TMI54"?4X MO9,D54(][G[]`CUNXSCIG8S:=B*(;0PGVY91VVBVQA;[6WK+$I;0^]9W M]E7FJ1+21A-KJH0LI3OIJ1*RE%X'G2A94&C32Y.QQ![&[>@_J3;05\-ODSUG MQT)"UYZ"("5_2X&;GF4H;I-A2_V2=!?U2BI@;C.Z`CVD@.;1A^RHK9 MK5C/=O97U:F2)96D6K'?Y+L]/1:3J$,E1;*DI!+[@!/6H:>+J"05BO2`#I6D MKD./1>U,LH1^&T-37ZJOZ!W1._L*6VP!O1=Z9]_ZG"I94$E*&[T7F$I2WJ%W MXE))ZCKT&FD*U51)F6UW]@-4V()R/MO93S=A"7V7:6<_O80E>[K./GF=@DJ* M9$E))?9=VZB-7CU-)2D?T*N7J23E`WKM,)6D+*67=^^,*[D99M*7C^]_W'T] M_.?=\]>'IY>K[XO-N-R_WCE#VY^.KZ^'A\IW:2OP1_N/A_H M"Z_]!^8__+P````#__P,`4$L#!!0`!@`(```` M(0`'_0"R"PD``)(H```9````>&PO=V]R:W-H965TQ,9F-1\5E7QW*R]OS^+__\?^P MQZ.ZV5T.NU-U*9['/XMZ_.?+/__Q]%'=OM7'HFA&$.%2/X^/37-UIM-Z?RS. MNWI278L+E+Q6M_.N@:^WMVE]O16[0^MT/DW-V6PY/>_*RYA&<&[WQ*A>7\M] MX5;[]W-Q:6B06W':-9!_?2RO-8]VWM\3[KR[?7N__K&OSE<(\;4\EE0 M0@N([*-;\?H\_F(XN6F,IR]/K4#_*XN/6OI_5!^KC^!6'M+R4H#:T$^D![Y6 MU3=B&AT(`N.7).1X MM'^OF^K\?VK4MJ@+8K(@\-D39,#18H[PR1S-RJ7#%'^.15+B;V8C%?VK]H M)CNFMW+TZWZ&,'R!BVNKSNR6!H. MB<;G(!U-W:S\;%+";"11OI`PSV/H;)AO-:PDWU\,P[2?IM]A^N^9T:;'2+78 M<@LRUTE<5P>>#GP=!#H(=1#I(-9!HH-4!YD.<@E,0=M.8!@6OT-@$H8(S)79 M<"`4-S4QN05W<77@Z<#70:"#4`>1#F(=)#I(=9#I()>`(B9,E-\A)@D##PMI MM%K&0E5O0VW(XZ@;TDO59-N9=`HCXB'B(Q(@$B(2(1(CDB"2(I(ADLM$$1M6 M@]\A-@D#JPL\>SHA86U8JUINF-60W)U))S3Y%W>#P2:U5#1J3QB(B+B(>(CTB`2(A( MA$B,2()(BDB&2"X313!R+)6W4L."$6M5,$K6\^X9OT7$1<1#Q$9 M#G()*!J18XTB$MV@3\CQJSF6^V^;"I8HV'SVC#8+-N)L>TZBJ.*U@0&98K@) M))8]R]2VE2ZSLJ%;N\5QOM:V3YZPXJNCCU&`48A1A%&,48)1BE&&4-` M^$Q8\?"Y$DL5GAP0'A">G2=DX2E2A$?();<@T#V:\(8N?&?%4_>9HQ0^P"B\ M*WPDK'CX&,=*,$J%HRR\MBIFPHJ'SY58JO#DJ/"`\.QD(0M/D:3,EMSQJ)/` M94@37EOV/6'%4_=QK`"C4#C*REAJOT;"BH>/<:P$HU0XBO"+&5IJ:+.AC3Q\ MKL12A2='#EGXO_?,90<7N3\H4OH#(9?<.9")(#]@48L\8<5;Y#,DA0\P"H7C M@&"1L.+A8QPKP2C%CAE&N>*HBD\.)++X/1L;N.[N=C;T_**L\Q39L.?I5O#E M>J4.N"VYD`"537F=[WD,LUBPZG2Q+`L]AJG5FJ3U_<5>:!=%/JO+AD>SB*)O MK`*1$9<\Y(Z#U4?<:LXN7JV5UMB86PPFD.`$4NXXF$#&K5@"IFEITSOG%I\E MH`X!+RZQ6XN[58\BF_6TM]>V! MSWU@7'P>.1#UBPZG*4F513P6G!"Z6+:)>I@Y*C4NM"N+!->8\O!"O8PC"-G5 M:,VU+5#.K5I'M?_(B>^!_J,'1!@B7(:-0=%:'BZV_GO"EEG]:@K36##Y>'B/ M.=I*Q^L-]+F5<`Q$C3Q6R*W$?COBB$Z'U6RF21=S`[EY:.U)<&4I=Q2591Q] M5EG.#3ZK3.TZ<@Z5N^[O/?KH:5;I48JT&:DMI%N#.2H=HR^4+K.2)HG'$?AW M0]:V--U];C4X20*1A.ADFI=48\1CJ35JV]686PW6F.`:4^XH5IV,([5&;9^6 MHW`D"DFR58@T1=H=+O,RA([,@\C7\3B?1%@%&+' M"*,8.R88I=@QPRA7'%5)89XI,^@7DA)S35**E/T+O-2@[5]`\3OV+\S*'GQ^ M>]R*KB&6H=\S^-P`ZNRF%^K20*3$.RODCH/U1]R*[1_F2U-K;@/[.?B]E9LB].I'NVK=_(:BT4NY#I, MW['9V`Y&H>;$(?LDG$)O)7SI;VTTSPVQ*''?F/"6SQ]W'+@M[^>^'.( MWQMH[L"O5]AALW#@1YH>OG3@UX4>OG+@$AUSN$ARR(D"E\!]DD-NB_I*3"CI M:QZ7/($0QG`#>RD'7[JA4:$H:SZ?790K1M;XD+)>1>L:\>$TKZ M6@IW-U#2UU*X7("2OI;",1=*^MKC0P;D+(LS@)M,AQQIH63:-17>"+ONWHIL M=WLK+_7H5+S"5)NU%^0W^DX9_=)45UAGX;VPJH%WP=I_C_#N7P&_E,[(CX:O M5=7P+Z2"[FW"E[\```#__P,`4$L#!!0`!@`(````(0!G!L:F,0$``$`"```1 M``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0`````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````"(#-Y)WO8$:[<&C);N\J(2EHG?PX'H++BCP22093X6M41N"I1A[T8+F/HL- M$\-M[S0/\>@:;+EXYPW@(L\76$/@D@>.#\#4SD0T(:68D?;#=2-`"@P=:##! M8Y(1_-T-X+3_\\*8G#6U"GL;9YITS]E2',.YO?-J+@[#D`WEJ!']"7Y9WS^. MHZ;*''8E`+'#?CKNPSJN`"9Q/?HT>Z4 M/)>W=YL58D5.KM*\3$FQ(3DE)2T7KQ4^M:;[;`;J2>#?Q!.`C=X__YQ]`0`` M__\#`%!+`P04``8`"````"$`EY,^2<<$``"B%0``$``(`61O8U!R;W!S+V%P M<"YX;6P@H@0!**```0`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````````"< M6%U3VSH0?;\S_0^9O)<$2IE;QJ03$FB9*2VW#MQ'C6)O$@VVY$IRAO37=V4G M(8:5J/V2B6T=[=E/[2KZ_)1GO35H(Y2\Z!\?#?L]D(E*A5Q>].]GU^__[?>, MY3+EF9)PT=^`Z7\>O?LGNM.J`&T%F!YN(#P8X3L8DA*+>QF-(P&AX]1G/`, M)KCQ:,$S`]'@^47T%;@SVAT7VHRBM3U?0V*5[AGQ&\UVTN_-N0%'YZ*_YEIP M:9&66U8_5/^SPE@]^E_I1[,"L"8:X(+Z9?7W<.WA?W$Z^G16K,/1>V)3,(D6A8M9Q_^R-$*",6@Y(PPCB<5EGG.]<S+/]OJ"R6.L8M_!,DRRM$PLBS$O:"4: M*RK,?,.^@%IJ7JP$*2"V*GE$)3%(T`%814R5M_ZU*Y6E6,'8U:\2HY!>V4=VW#-LR^:I/8#\A49(4$RZ3M-G"&-IL MOM(Z3O$\;M65L#H+26U\4NH:V@%"A[1/3,VL"X8V=%A..T/7)F@GY\:8$E*_ MV5Z<>[4OE?3T"I4V+R!51U@-"W\MY;D(DQ#_">M:VY:0&#LB+V1[.E5-[KZ[ M95Z([QP/A+,/,DZL6--)0Q_].\^0NG@@"?;VQM,KTY"=9]I(R16VW+]Y"TA< MXLT"]MLM(),5QXZ;T1;S#0FL,AHIQ=LN=8!,N-;T!.65X@*9GO?IIBSH?1KB MHMB-`A[U0YT<7?Z"8Q"CRU*C_:N4EKNK!4PZDEH#@N?4&D,8A_E+D+#PQ'(# M\OS@)FU$ORVE20R?WH;L',*S[07.VY!=;N$,>R\U'N[WFB^CZGQ(\>9K M]_WY1?05K_9TYC:I\SO=K7G]P=U&/M17KJ/CTZ/AAR%>-!Z\BP;H[>WEZN@/ M````__\#`%!+`0(M`!0`!@`(````(0`JN7!E&UL4$L!`BT`%``&``@````A`+55 M,"/U````3`(```L`````````````````V`0``%]R96QS+RYR96QS4$L!`BT` M%``&``@````A`(R<0(U)`P``OC<``!H`````````````````_@<``'AL+U]R M96QS+W=OULNW5!@`` MIAP```\`````````````````APP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`&WFXJTW M!```8A```!D`````````````````MR0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#].PI02!P``1"0``!D````` M````````````8#$``'AL+W=O&PO=V]R M:W-H965T*E$0D``(@X M```9`````````````````(T\``!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`*%"QG]O`P``H0P``!D`````````````````U44` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`')@QA?;`@``T0<``!D`````````````````C5,``'AL+W=OM@'``"L,P``&0`````````````````X M9```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$`=>FC5`P``Q`P``!D````````` M````````TV\``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`'@[F#HT!@``K!T``!D`````````````````'GT``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`,^P@``!D`````````````````!XL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/MVW(IE`@``(P8` M`!D`````````````````8)8``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*R>W1XL`P``!`H``!D````````````` M````K*$``'AL+W=O&PO=&AE;64O=&AE M;64Q+GAM;%!+`0(M`!0`!@`(````(0`&G^RD&UL4$L! M`BT`%``&``@````A`#-(,*HH!```KQ```!@`````````````````2X,!`'AL M+W=OK^J_08` M`)\?```8`````````````````*F'`0!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/LQU8C1`P```0T``!D````````` M````````WY&PO=V]R:W-H M965T```9 M`````````````````)B?`0!X;"]W;W)K&UL4$L! M`BT`%``&``@````A``A-Z_VH`@``QP8``!D`````````````````U*4!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`)/Z/UKL`P``:`\``!D`````````````````Y:\!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(V`<+[C`@``QP<` M`!D`````````````````(,&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``6,?&MI M`P``_PD``!D`````````````````U&PO=V]R:W-H965T'MPH``#,T```9`````````````````+K7`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A``@(;05P!P``%B```!D````` M````````````J.(!`'AL+W=O&PO=V]R M:W-H965T; M```9`````````````````(WN`0!X;"]W;W)K&UL M4$L!`BT`%``&``@````A`!IE"*4T#@``Q4L``!D`````````````````@@L" M`'AL+W=O```*J```&0````````````````#M&0(`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`,Z*)W;Q"@``A3<``!D`````````````````X#L"`'AL+W=OP``&0````````````````!/ M@0(`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%.\-+1C`P``V`H``!@````````` M````````3Z0"`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`-SX\]&=!0``21<``!@`````````````````M<,"`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"-Z1N(<$@``\F```!D````````````` M````N2@#`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`&W[.>CB3@``K,4!`!D`````````````````A6T#`'AL+W=O MO`,`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,3I MI$$_!```C1```!D`````````````````VM$#`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/JPJ].>!P``TRD``!D` M````````````````(>$#`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$-23Q!W`P``_0L``!D````````````````` MYNX#`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`"*XW6XZ!P``@A\``!D`````````````````P_D#`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-MZ6/-1`P``O0L``!D````` M````````````Y%\$`'AL+W=OD```&0````````````````!L8P0`>&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`/A/J?)?'P``]JD``!D`````````````````:X,$ M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A``?]`+(+"0``DB@``!D`````````````````E\$$`'AL+W=O XML 30 R70.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Earnings Per Share [Abstract]                      
Net income (loss) $ (39,166) $ (7,812) $ (9,721) $ (5,435) $ 7,489 $ 21,524 $ 18,350 $ 46,838 $ (62,134) $ 94,201 $ 49,931
Weighted-Average Shares Outstanding (Denominator), Basic                 60,729,128 58,588,916 53,272,767
Dilutive preferred shares                   40,000 40,000
Dilutive common stock options                   4,749,299 4,185,224
Change in common stock related to Targent and management incentive plan milestones as if they had been issued at the beginning of the quarter earned                     248,193
Incremental common stock assumed issued on exercise of in the money warrants                   224,437 200,656
Unvested restrictive stock awards                   1,034,604 12,874
Weighted-Average Shares Outstanding (Denominator), Diluted                 60,729,128 64,637,256 57,959,714
Net Income Per Share, Basic $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.13 $ 0.37 $ 0.31 $ 0.80 $ (1.02) $ 1.61 $ 0.94
Net Income Per Share, Diluted $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.12 $ 0.33 $ 0.29 $ 0.72 $ (1.02) $ 1.46 $ 0.86

XML 31 R55.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Geography (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sales Information [Line Items]      
Product sales, net $ 143,475 $ 254,992 $ 180,663
Percentage of product sales, net 100.00% 100.00% 100.00%
United States [Member]
     
Sales Information [Line Items]      
Product sales, net 133,462 245,697 180,663
Percentage of product sales, net 93.00% 96.40%   
Total International [Member]
     
Sales Information [Line Items]      
Product sales, net 10,013 9,295   
Percentage of product sales, net 7.00% 3.60%   
Total International [Member] | Europe [Member]
     
Sales Information [Line Items]      
Product sales, net 3,953 3,113   
Percentage of product sales, net 2.80% 1.20%   
Total International [Member] | Asia Pacific [Member]
     
Sales Information [Line Items]      
Product sales, net $ 6,060 $ 6,182   
Percentage of product sales, net 4.20% 2.40%   
XML 32 R78.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Supplemental Pro Forma Financial Information (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Business Combinations [Abstract]    
Pro Forma Total revenues $ 155,854 $ 267,707
Pro Forma Total costs and operating expenses 200,651 210,433
Pro Forma Net (loss) income $ (68,146) $ 57,274
Pro Forma Net (loss) income per share - basic $ (1.12) $ 0.98
Pro Forma Net (loss) income per share - diluted $ (1.12) $ 0.89
XML 33 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Components of Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
MARQIBO IPR&D [Member]
Dec. 31, 2013
MELPHALAN IPR&D [Member]
Dec. 31, 2013
Marqibo developed technology [Member]
Dec. 31, 2013
ZEVALIN marketing rights [Member]
U.S. [Member]
Dec. 31, 2012
ZEVALIN marketing rights [Member]
U.S. [Member]
Dec. 31, 2013
ZEVALIN marketing rights [Member]
Ex-U.S. [Member]
Dec. 31, 2012
ZEVALIN marketing rights [Member]
Ex-U.S. [Member]
Dec. 31, 2013
FUSILEV developed technology [Member]
Dec. 31, 2012
FUSILEV developed technology [Member]
May 29, 2013
FOLOTYN distribution rights [Member]
Dec. 31, 2013
FOLOTYN distribution rights [Member]
Dec. 31, 2012
FOLOTYN distribution rights [Member]
Dec. 31, 2013
FOLOTYN developed technology [Member]
Dec. 31, 2012
FOLOTYN developed technology [Member]
Product Rights [Line Items]                                
Historical Cost $ 280,668 $ 228,468 $ 17,600 $ 7,700 $ 26,900 $ 41,900 $ 41,900 $ 23,490 $ 23,490 $ 16,778 $ 16,778   $ 27,900 $ 27,900    
Historical Cost                             118,400 118,400
Accumulated Amortization (48,975) (27,879)     (1,107) (23,455) (19,735) (5,343) (2,192) (4,821) (2,980)   (3,662) (895)    
Accumulated Amortization                             (10,587) (2,077)
Foreign Currency Translation 682 (355)           682 (355)              
Foreign Currency Translation                                  
Impairment (1,023)                     (1,023) (1,023)      
Net Amount $ 231,352 $ 200,234 $ 17,600 $ 7,700 $ 25,793 $ 18,445 $ 22,165 $ 18,829 $ 20,943 $ 11,957 $ 13,798   $ 23,215 $ 27,005 $ 107,813 $ 116,323
Amortization Period (years)         11 years 10 years   8 years   11 years     10 years   13 years  
Remaining Amortization Period (years)         11 years 5 years   6 years   8 years     9 years   12 years  
ZIP 34 0001193125-14-094593-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-094593-xbrl.zip M4$L#!!0````(`&(Q;$1+330<^78"`*OP(@`1`!P`&T8F[0-)YEN[(M!2W1,M$QI2,JQY]?O*4IR)(I%4K(4*]T3 M--RV6*3X?77JW%G\Z6]/#^/!8Y(7Z21[=T).\7?R^2-R/_H7 M%R>#HHRS43R>9,F[D^>D.!G\[>=__[>?_@.AP?7U()AD63(>)\^#WX?).,GC M,AE<9.:480('A[.')"O_9W`;%\EH,,D&OWO7[P?TE`P&]V4Y/3\[^_KUZVF> MCY:7.1U.'LX&""V_XN_SVSL?#.0IA5M<.70]F66C\P&61&G**9*"2\1%[*!; M/!1(QY0,!8D)=>3*67Z>Q"5<<3""6ST?4$PXP@P1\HG2 M?KDO!_\U_&\8C`6",]C@^O3Z=`7[?PX^3K("1C],X^QYX(['@VMS5C&X3HHD M?TQ&IXN+/MWFXP'PGA7O3E88,!^?3O(O9_`5["Q=$'@R'WD^!*1E_OQR1C6Z M2(:G7R:/9XN#9^:^$":(D9?39GD.$VH[;W'4G$C73QPE:?,Y<*#A>Y*GX7WS M>'.DX80T>TR*LOF4^;&FDXH)I\1IHVT^8GE"!M,S>V@>/RKSL_)YFIS!(`2C MDCP=OIS7?=+Z"<5TFJZ=44R389G/'J;WOIQS%Q>WU4TM#C00!D?,W1:-YU1'FDXJ:`Z.:F"S& MR;/YP;6A9>-0,1]:K@X=MTSQ.,W^,+KD9;SY8&W\5U:-)EKKL^KHR]`B;1H( MER5GOW]X_W%XGSS$Z&7IP6(=#*KE.CXOJF/7R=V@NN)YG`_SR3CI=Y_5&?=Y M> M4=*7F3N\3Y/'Q'QT>>1FG60`?C"=3\]E@.,G*Y*F\-HB2R?CF*G2DT@C^ M`3",_A<(U30Y[@4^:%6+G%#H@)Z8R;N!N1VEJ7S>UDL M_YO/'X.3GQEAN/KWT]FKT*X0]B%^2A]F#Q]A42?%15',XMMQ)\6'%'Z48/H7-(VVQ,LQ);R.]T8S*C!_ MTHP([72@CQQ/!=IAR/$"%W'&"(*+<*2=$(M($4>ZSHWAU2X+"PJ6''1BG/,! MMNX\S,JT?`:S_C#)/I:3X1]SXBYG9>44@:.T/1]F_E@2D'JP5C[B'7,?SD$\#PD)?:.$S(P$MVH`[JP*P`\Y&O>D^&-?K MT\1+KI-ADCY6ZF0ZS2>/\7@[8K#$@I%UN6A8"S1DPA<>0]+%%/$`_%9/BP@4 M@PB4P@'GW.]@@C8KQ38H<^P+/^-\0Y;<67D_R=-_;JT;"'CNK!(&R9GSI,$F M\BX&N"\H"0(.RX&&AH$(@5X!O<")<(2DFE#WIB)R4Q$Z8JD&>F#Y7J`9U:++ M`/0"39M!8[PUZ+F2?%D0E?S/HYGPR3BVR>C:1'G;KGP'1+`VV2]Z@"A!N>S2 MBDP0%Q,`3CTP?]QA`KE!Z"*'"^QH-Z38#8SXLS5#.)WEX,U!Z/BB_[N@?4<: MJND_$`VT@09\*K:D82DV#4HSA-_*YPO`#U)4&F\"U$:^]"JJJ[I%D7[)MEXE MWVBR$=.P3$)"I::^BUSN@IT(A(-4`#Y#P/TP$&$82$_-_21FU8Z2U5;+ZV!W M&=<"?,[J@SP9+4WUYJP<%WG<1IX4G4:V'][O[))TLK7ID@A&?1\,+A+$N.1^ M$"`5$1_1(*(^A;6G`Z_#$/=@J[=+TO_LJTD)'Z7Q>.X$SR.A[R%?O916)5_8 MZL9K@7?CK!%UW<)GCQ#\I;""KR!63W*0T!4;.5_EGZ?55RQ2IENZ>`QKA@UM MH/,5!@NH':J[0K](B$A&"H(?#?;>(1*YE%#D*EB@A'`?_,;-0'AI_/FFZ=\: MY#I+]K/V34:3X>O/1I,K1->HL",Y8#1,EJBI=#C$OQISDWEK=_YT)(G$+I(1 M=2#ZQQ@4*.QY-AM<1, MGCN&(VXV6LF>&' M`KWD,!^'U(/0JDVO4-:A5EZ%N9Y-N)K=CM-A-)[$VQMV6:<#[Y8Z`)?3&BIS M6(I4&SH:[WE%.JI54Z713.$#0%>LN'D>@PHV5/PZ>[A-\LN[>ISA%E=)/H0! M\9?D\FXE(-DYL8*U2:E6"@4KK)_`JV;KJ26ZP912E%/J$Q2XH0=,N:!.`JF1 MXM3GK@B8XS!S:;KF+R[]:+:4EX.RL*Y^.[_*>_XV9&'GW*]Q/EJZK(6I2ACC M=UG>)_FG^SB[G)I+%+].JK)+,IK?[+99S3GYG5DMYC+N>3XBG`+ABOH(_@(A M#3CX$II@[D6;7M-2?S-A[/\W#?[=R-C3'"PNOC*YOR7&VP5!`%L+,A`^@3BD M"RWS^AG8%'B*N0K]0"*F0=;!QW<1K!7PP4+/"\!XAAHW\+^B'6ZF27[SXEV< M$F;BT/*?42IDEH31$-'($X='Q0-=A#5@0N.L-8J:H@6ECPK4&18 M\X-0O5&B4H79FG]NN?]:T`:N+#A?YG^&R$=P M9X%"M_3C/'\&\=Z3+#5`IA[(#W,UDCPD@!O+895XEE7:OV>&E:TF9HXF)527A M73H_$*'#L*>1P"H`6QM2I`3AR!$D=*GC!GX3,2^VE9@$.5V1C`Y(-15NO,C[ MR7@$,?Q2PPS',S/P:I)7JJDL\_1V5IJ,Y:<)*!E#23X9CV'(,K.Y,TV.T-1D M^#GC77DT$BDJ.8B/9SQ"AB%.$8Y$VA-<^*X$,UFQ)&^TB="LR32DUZ/[_1!P MC*1J1MB>2*W*YJVL,NQ()OX:S#+,:)?6[\DLP3?S[A,KLXY#.3DXKQN5OEU2 M=0U$24KE<3=@=F3#5.'K%,F4W3JLLB1]6 MD"@5:E^"1&ZX39"H_"%%J,[.*T0(1K:*$)'X+Z+D@=/.VEY/4L6-:B45+N;4 M_/M#\&IB@GFT.1Y/OIK6U0)"B$7;>>'%XZH3?V?:I&!S6:0=M&$G]"*J,2*: M0$3D!B'R,*?(BP+,(I^ID`8WK+UGD^DUNGI!^S$RI&2/&=**1-&@Z+2`:1+_ MRI#VG8$=,Z05_[)'."M.^3YR1#]RAK2GW/?*D&[P_JW)C2@A*/E7BO25XM\K M1;JA?FSB3_`IV<><''F.M('977.DE;=OS9$R,`';YT@M@X"^\K?);#RZ>)C& MPS*\NTN&9?J8P)`=VAH;."";G0R4!%$4!DBY/BQRT\NJB5!(RB`P*"/-U*RL2--"K]ZA+*$8\93G_^Q&T$FN2P=^@2F M3`C6]42$]OR08ZJ0BUT.A(&;#9YSB+#@2M-`,N&KCF=BM,+KRF17O,?!FE2" M=T4H?5EKB5`TEOS/PQH5\$%7.-R7-=;"6BT[_R.3I@43LJNLT9D/@!*F/D4)4QMJR,46M3/J+T\#FH_>2'-VCB M7'=&CGUY@O5F\N2T*6_"),-"_`A)XDZ*7B%)P!#M$"5-Y9\S3[S!Z[[*K.RE MS-K&JW`RJQV9@DX'NKP(GL8];>_.BM;UED;M1]\&7>X8C^B M_MM;G94MZZQV81+Z1Q6DO=59V;+.VBA(M.TAX^,5H7W56=FRSMJBCRC[BVCY M?=59V;+.:B>5"^K(P_=`'*+.2@Y59Z6M\3AWR&OKK'O<$H7V*Q$1Z>F`J!!) M&D+4**2'%!8>$BJ*2!0I['J`^T8T:2:P?51*I\W%MT:,^]')>P;)=P/9J(2/ MM&+>D[%>%7-A5+-NK!PR+O$^GJWX,Y;,&Z9@QY)Y-0&D7PNX^*L_5=13\GO5 MS#>)7Q%]#?'\/MI%^A7-FYZXWGD;G?WJ4^8TQ47U#&P[@$-M&+1GR]&44MW3 MSDA7<7Z9?RQC6&15C?$JR:MSWQ:PI72ZIG3P*=Q"(W@;IA^^'Z27;N_5#[)A M7*W](/,]F(Z)M#8-=93BS/KTG=7$N1^L-BI>)6`[`K5T&)T,GHKT/$O'[TY@ M^I/ECJ8K53)3$_L0YW\D9B<8L^70LBSV^HEKVIQ02D:$V0DH`%/,.0V0#AR% MPH#2T`M#+$,%<*S1JS(9_%J=SXI@`^OL838V,QDDTQSNLEI!\/LXJ992-G(? M3+C[S_DF./D$A*1\OH)PSI0(S3+:94/7?KPX"AQ#&C+DAUAKJ6\I-*3E<5FR+C7M(&IRL[(5 M;CJZR/QXFI;;[EC9$VE?*VT5`BY9E:U8%8/F^U\'&2STUZ?XR2V*I"PVDQP' M`:RE&W+BARCTM8*IY1)Y/'+-GSH(E`C![6Z=6J+(>F-.#R3KT+^3$/>4@?DXML.'E(WD^*XM>DO+P#OMY4I!WKXG68 M3:WU`76('M9^R/OVL%)[#ZO@:KT7J%>8>_I>7]YVQR:Y*4 M)HM[D4TA_KR&BV5#$*%J@9@_08S`BH(3F18O6S+MR6'>=&XB.,?AGD1:1-CL M4*:0YT<*,9F%TF_SF#B3SJ;M:[S_KLK(F^H'ZPY<5"FIN@H:7;UP M%H?@32V!W>9A\^121[N;!5&-B*5)C"9Y,)G=EG>S\?)2\YVMS=6.P"S:PIN? M::W)?RM$-4=@DGWYE.0/[]/,;#`&/D3ZIIB950`V$U!-]]X8ZEU/GN/QD3CL M+6WZU-F(99KNOMF)74V0O&CR_>'=W%(1^R&CGN:(^R'8,48TF+I:>\-J-]P*S#OT[,RSB241CG&1BR8BW^NTN';RO-0MF@(^*`G[,^ MW]U8FJ?^.GE,LMDQ:"S:(MWU7;.;[[[59GW*X]%!8?9F]?4R"KLBHXYRUC,/VV.S"7I6SM7\,3N"/HXNCK>^Z M((311J'?`IA5[-\TS+!;+R*IPVT2;@7SDH,)TF(XGI@TS$'P^8HSRIA$D?*, M?8XHPT*:9PSPV1JW)`R*5LJ[A!B!O\+!XOQ"DU]/B=+ZQD5VE MT9ICNI3;/62]?.3%\A=CO*.BVM=U>(_VM]4+;$Q^ M8;%O_6&J(DS0D$4A0JDU7U3WO=@CK<.M>Z2_Y MI"C"IT4_\"^3R>AK.CY,]:N_PVU_7QM57*YGA/H!6B=A7DXV4'&( MZ\BDNT%XN:,1EUZ$7,^\6$@Z0H?*`U7GSA,(UD088[6Z7PN&S2T=/E8'P%.I M]-WEW?OT+KG(0.,=KO+73\:M>6VJ:DG?3A@U[ZL2AB-(%-CZ/,U.?%S5BU^K M=[T.Z*!+LR\6ZW0YM!8(-R^\C>HM_++\;*&NUMJ?LM'2)C7W1YEVD+:V>+=&H[&33>>[<9?SW.G6VW#5N[_[DA MX)?3ZCUMV1?3YE!M4W0WR4VGYV'"R+XM.O8'SIAN3@'V0%2SV8]Q.C;3N7@9 MU[=9-6[M]W'5^@8;O?VT+4'5A6,Z*<`&'-Z;Z>FO69,)K/;(?N.==TA^Y;J_ MI9!;\P@.H[S#GE;[&M*;\]MM@G"$*9\6P\FD;L#5F>TYQ-9W M^RTY6K-<3,N:V[3%MG=6B5[-<2:'KD/U%6A[IPBC3L<2M0':BHH*S3CL!E[V>+/QVR]VQQ+RJ]WW\ MSI[^5TN#44W[;0'(,JVFEZ&X3T8FMISW6R_7Q$$8H*$OI.8*^:%YBWB$(Z0= MF&WI^MR#CS1V99L5E+2VR'L`Z="";ZWN[6_,@>_I"+HV)-SZ`-#AW.[^CSU9 M#9M6D1%K!]7!R'J9^RT9:-G2IBN7 MN@YBX]G-:9PNK?I+Y_2QE`>L;9.TGA#K`<2:_3L"RV7/_'''FOEK-U"_3?(_ M7M+!1V.@[$J;U?8F[P&DVT`=@0RW/+X';@GKM%/MLWP=?_T0ETF>PET>S21; M$2OE-,^Q%497.MBLAK?4RU8-)7&7#U+=>T\OY(V#"&)ODQ(U`]P&8>5-`HTI MF":OW'3AQ&/3O?'^%8[8SF6+[=IF*F@K]393APS2.YAX^`-D^Z4!J+R\':=? MJEKE'G?E>$7VS&J`*%VLV5=A6Z%GT3IY%3^;/?2JS>.JMN^%Z3X&MX/:ZSEJ M\8[3;:#L(O;NLF?I8$7\_FO`_BY`\TBV^L;';NC6ELZ+CEQ)R*UNX%#;M^%- M`U"K3\XD<^CJHMD2U?^3=ZV];2.]^J_L'U"AN<]\64#7/06V39'MGL7[J5`3 MI34VM0-?>OGW9T:V$]TX&LL:6WD/L.BFC9OJH4@.R2$?UA6FQZHV!S7[N(KN MM)@W"V^2<+47\&KH>0#W-#!==Q'=?S-UBJVY*OU>YN4L^L7ALGF',$"48XB"%&:BC['[W'N@\$32_=L+]F>(4&SP*T M#L03,`$O^E`YO^9+!B\,6TY4WA7+ M8D\YI@UX!BX(C-M(6'=!UN?O>MMTO?O2"O6N2P<`=WLWU!-^^DLM,7/BRG-: M8L9<=R>R-Y2=L<2LX<;:8INA8P8U'F']$[J>V0'2&!_F99`EQ5F>YY0%$6?& MD>E?XD@F099G),PS%28DM]57JH`\'!&0]ZA"O9_V;4626(VQS%`CX![R8YO\ M2&`#4GF>\IRA3"R=()S996*#-<92_!8XW(]]"XW2R#364MZXU='O=A9)"IR] MHQ"3SN'9?/#^T."OW=/3XZ]F:_D,D,*#CHA2U!LF6)#4H,>[S6)9;C;1W3%! M/22MSZ9RS:E=N#:K:DH]C,$M#)Q'IQOLWQ`B0CB%A%"+VZ48.,PF1*K$3Q02 MQC#_I`B27/[480SG8F@CBNNX(+++Y_)S^!R?O)"TX,IOQ:)Z[FRE MOY&;"\D''DG$B#.K?(8G8HR14,_HK+Y9=1:7-=YEWPE>C+=AOIJ MP:?%GS#T2M1D8I%8:)89>QU:HAAA?&B?NJM$J&52_WAM-GLEF5@BL(Z"7EE\PAL$5'U5HG9`*\I M@#3@UZ-M"GUP!::7&CLROEY:%-+1F?8*?DDK,K4HM1_ M18J$L5ES,HTB50%5OR+5-YZ](A5J2^<,%:I"#8L*(?S_Y/PD6J9#";RK4-DG M:15JSW)1'W+M+NS<5'-E^VG8N'@OB4/TG%%F<8Q4&2"$4T"C- M@CBD.(CS-"1Y0F2&TZ&KV]9V,B=H/GO1M0`D1^RG3@*(&(H.,A;'L>0XH)28 MGK.8!Y$.@H,TRE*6*9IGF3`"()9NW&9#LEMWNF?4GY2I51!S-T"H&C(>5R$@ MR\CWZ0WZ%Q6!F$@$MJYLYY8TK_2"T]<]457WA,D&CW7/$[D&?:S3F#[=WX\2 MP9LY"1^_6\/?FY\4/+POIL,I-_#J+SIYX$L<_SUS"+XDY'4JX3+N0TDRE4"( M;3^C.I]R\R47;S-O/NGOC#`D9S]1*`160_43)S8\ M>U\MHJV^VE/8\/Q*0`HDV102(-:42TH^4P$H3N@D`J#64)LR&LY2`DK;*9Y$ M`,Q&2_0[%DK-4P`DY'S()3H)@`\,\XTW@,\ MB@:F!!'B!)\[L/1V>5\^P%8W<]E8YO$E[1C/:4@;C$76O^K/!T\H*CB>">L% M]7%07?;;3%@8(#JRK0IJ7`ZV$B1,Q@D-`R69"JA"62#C7+L=PK(L%1D/,1FB MM*CNWAR6WEQS\8\GH5CNQ1V%TKL)"*8&J8ZT*3C-V@(9+8(1#&>]R"9@(?7T MDF$O^O*2'7&=^'K'TQ!/]GI/(R6V[3PYB[7E!8_#.(&0/"*(T4#$^A>:&%+5 MA&5!RI2YG>51KKA!QV!*.]5B#W=>\NQC%68;_&BX4,W;_C(OXI;/1`8Y8HL7 M\L4`/AFF$7S@GNB=/5D?Z%@'AU@@I^J+`72R=SKBM/0RGN#E?<++S4X<2KJ( M,ST,)HU$2V?L3%U&KMQQ6NBOSEAV>1%W-:T@+-GTX,35*0YK*N.>%KVMSG+B MO)G_*-%EX,P5.H>C1-PN,,TC3#R@'XUWOI[M7&1S#!//Q33#,'%:\[,0=@V- M.5XM3CSWI@[B+G,-AU6`C<.TKYQ(RJD<>K:ZB$2!M"O*A6-^L_]J:&XK*CCZ4Z^H'S4PP M@(MH+",(W^AG@C0'PCEL/.=-*'J2AQCA,OH&%)N?._-HZ$2[UJ:BB@`ID9GH0#B*9,H$0 M3;BI"EE;9.J+'1TPV5[XGPL=F=]7=Y+[;Y3+NW)^6L`LV]7;/9=N\&IQ4LM4 M9N\*7?:RH-HMU""^2X9.!`LQR'SF1L1>"0/W^,%91DY3`P][@",6VJS!'CQ= M)"R86`H$F&%Y-6'!U%J!3C>'RT0%!Z#CWS1$<#90@VJ3-(SW9*2[0V*\(__$ M^C@;.44A18)82"9`YU5].RXVSNQ;]>/G(87HI^%.O[FZ=J%>9A M29<)(M[OOGT^>;.UHWARK%-_I5"`,\$"BD421&DH`JS22!"FE,QCPU*B!=D7 MX@HI>(AK1"Z3PW:1:MN1_KV\UV[#O*3]3S7]_IO&UK-;\SC[?^#FH?8.#T_A M2=9)&J$X0P&+S0Z7B,E`(1(%BF1YG+`<9:DTUM4L&3X?)DB;+D9R2-:3"\,' M8\MZG/2L2$1K' M28"HH3B1.`GT[_*`IE1AJ;1(XOQ@S[U*%H8ZZ5$3V/.IX@"U+"F>%MOB^VNW5I7N$(&A17:49)AO(T"9(\%MH[DCA0@IH9)!X+0E(L9:CU MK[=J)E&(1$A[U<\-T[0'BN,^R/,%V=UQB4,JLR3E`5$1UZK((FW&.ML6F7:$ M.L'.5'A42N`JKQ%`BC(]?-$)UHME#C\ MZ[;WBWPHOON)#USI-O2>OT&H]2JN)"N/;ZT;?]B>)"Z_+)9+_=D#9=25WZ)+ M*:C'>\U$=AZK+]/&>Z0O%6'M?OY3BBT3IBTS/EQ'.AG_G)9#.1X,[%[UINRB([E6YX?!#I1@75BP$";B:V>ZH#IXAEOR_;_,"M/ M4OU88]M?G!PCUT86YT)GP;'2R1M3:1!1G@2,Z62.Z/]4@GM28?@*YTUXV<1X M4&H7N#"8^.!V2>\FOQ\X2\-&`CVMD?&9&6]/![EOK-*16478-*[CMN?%C=VF M;=OT6FV<;.ZV`A$TL=[H=UZ8C_Q9:A/9[$L?[Q;+Q;?=MX.];-)=^7;Y\@I#_3XS(0)"J'[!)-)?&P'`DS"LB?]D5!T% M.,XGI^736C]YY5;TUX]EY5^6C;EED-#&BZR<&'DJ'E!X;"\4'7V9!'!+MXQ+ M!9>J7=.2$$R.*WESI-$.HJ4W]_?5'O?B\4.QN'^[/!08O2!UC5U`)6!(HL,* MN('G'^4QKNDG8,IP&N(QCF*DS\Q7N_75G2;8*B9;>XI/A]7J)#N<]A^+GWN: MARZ]N!*M9BZ7.``C*<^G1O MCD:/P4A!*B6;-C_HTUZ.ALH5FCA[77[5H?;BN]:%N]6WTDQWO"^W-P]:7%?U M=2!9J504.N]<0#4E8B8@[E9?EB:1U=^,RV7YL#B9"-T->12F.0D3K=9:I;6- M9SR0,B5:$%JS*8J$S.7^L(>)?#%J^CS@^5MD8('>$QG5+&]TJZV;%LDL MBCC'*DB1J8:Q,-$RTDJ5ARI&VGO&&4]L^053+>9T^/F'=I)[S]N'W>/Q1VF#*!??:QW8 M5WW[,'55:S'T*8B:PHAWF\6RW&ST>?)YL:R\PC,5MB'%WBSNJQBK1I[N121N M1-;[<6TP/J3M@NX(=.TH:5G>/.SW2^?%7?6)@QSCU7J]^F%*%<63_LXD^MOMZE?Q.)."`=PG1PNP80)AG! ML3*#IYF.E@@208P1"K(LSA510J(D'C``TN83=0'3A'];;@MM-/=9L38WWYM& M^>EAH0WEJ@<%N#4ZP$1PU&3S'L;2_^IOR^_E'@Q%>DXY8?UK1*9-<^A@MTTE4I,2Q+]8@LZ]JG._GDD<>`=B=8CP)B[ M`,#[^8G2^#.<,XB/-TL\[8<^Y0!^+#:;Q<.B'#\".^DKM1S%5)UP%/?``JN8 M.OV;5_+.+>5;A1BXV:T72&^\N:_[:=<_BX@3K&62OG"S^^S]^E[[W#'!;YYU M\]!X>+R=,-RK\2<``W7^FNI-8&9MLR5>0>H]]C;_Z[J\?D9IV>@PZIJNCFNP M,%/W$>N%_O:7?+WZ]K*Y;,^+I..DV^=J^56C6/AR@V`U5*<9`=;C"K_IBUA@ M<<]LYSI]:]_`5$,&KX$&L'4CP\5^2:;A MM*NKTX4[O<81<#OZ%9_A@*.KA!M66F?#:9#:ZEX#2\O/V.`&7_33!I*?+ M>WV@9R3/@@@+&M!9:5ALS%4HCC_,@BB.BOQ),93+6;C\:N-(F5*!QA**V MK+^6ZA^T)7K8EE6GBRE4^XF'%4HU[BC(A6$#5&8TD*;:&HB(=:R<8VXV#,"2 M4*3=KW8&PBY1Z5^5#'7>5)V2-P]_+AYTD*7/27_-/&[^`+ZJ)KRI&H,P^O9\ MSZ`JBRQ\GJRJ07=V>?=JO%IJ!_H-]JX*15L0#/O^`#KTU MC&IJ+POLIO6<\!K=4FG%G3ZWKI] MA\O^PWX+7ZYX+7O%F>CK3&\]O$?^="A%#]6E.97_1T@'1.>'K>RV)CS_*Q^_E.RV6KWZDXQC!PE25F+:2 MF/-`ML*Y[\7BT>A_OEK_5=3-P"2'ETEX7$L8SMG.B:#:UO2TVNCHP'^@ZQC* MP]T'K2"W]\D'7,68->F3>@6PY500S`9.\A/WH7=M8PZI*SRT:$[P,PR_/VO= M?_RJ1SA8J.^YJ-P_;A^$&5;9P3X:A+#$?1GI57:93GOM8NF-(JW&X1/V.H$V M7[^Q+*^:@L!W*H%6XOZ^`P#&R;G\@8S-7"I4%]P:RFVYW:V7U9\<^[.OZMCA M^WF$Q*D9O"/>_D:TE]1W'ID[Z/&IHK+3O0!":">JW_6?K=:_?%F%(SCPM:-# M5:Z>CKX\U'KVLYM'O^I%&#A+ M&-P(RMGY M^=)V1R\'[[LT*H!=W5Q'[_O)*+N<5I^'V?[TO[5>+#>+NRKUF("6L\]F*,>1 MQ%&@TIP'-*.A%A3.`Q:1!.,\X5&./A'[B#H-93."\">#`7MK]I->T[[@*VYP M9J4/0C]>K8\FHZC"+E]FA&.F4A*I@-,,!33F*E`ZE@ZTDTTX2VD4"?F)58H! MIYJ4"=(+MX6@PSSV5"R.V=7S*/-<[O;!0@K!J+.^:PB(-TKLIN%W[X$$@9R=:IM_\ MFD$(/#8P1:IET)U]`;':3<"K/UY"<`?!!!(RX(9SLAD<.3#[%>)L.#.S.XK; MXL>[8ENN%_HA9^,G8,"BQ08UC&.H(<%XU&O&BF!`P1A#]I=;/;MCXGWEVBNR M7,80QYS[.52LED#VWMA,OLK^_,:9$QIE/@ MU`304X1NEI\_[-9W7XO)=@+TR"'6*1!-I0CR*(L"BO57<9CG01@G)E2)(I6% M^Q<,#ZY3%-:VEIX&JB:-PYRH#G?7J\='K?.W937@?CC+YI`587BT6PK\(@-' M*#7P.A->FVF8M-S__^W2>/=.SU4^71=9]YZ%YUFB9:"S8:QP0$,5FV@%ZVPX MRB3-HCC)V5X70#$@7E>%$T'55_OJ$VYU_X_V^^7[U8N/^Y_B/B[+Y=L#J=-N MM6NYO0^KO<9-Y/Z2A*N,]B[*@#TVAGK[C3@""=DF%N=Q@"P MFE3.S:;_/M#HSZJ:`&?+0M1,S`_V,?%'=)QI\S:XX!Z,P/Z)*7'H43X#74T\ M_70\=8;R%C'Y52^_X!*5#%7-'$]&U1O5W7Q^7'PY\HY6Y]_'5LGK78$":>:H:`UD/U/WE#E9X*>?/?X^.M_]Z[2S.N:C4CFY/Y>KC?Z]=^L MCTN4=$9N`O]-M83EL'!)'V&K]?XV0"M3S3G[B>.DB$-%E0ADEC&SVA4'2J@H MP#R*DHPRE9NLIG$VUY>1AG7U]RT`0),.K677U"*X**?J(NIYZO.R]S^*Q53A MJ_N!"25WMNS=<#7=//Q3F+>YO5E7;[UVJ5G%;?K[%]YREQ`6$AJE`=8GFE9^ M'@5Q2D20A`K%U-Q[)X=-IH";:"VYP^IH"^?C;>1[AX+>NV)9[&U!^]<9G!!@ MW,D1KV=VEL?OGH7I>O>E-N`W5:O@^.,?GF1!2'7.P;['KX%T7`Q\T)SK*KW; M9D=R5/K3H/7$Q6VQS;&^!V<+0E#\+M3%DZHW1$Z"74D3QC)+#!U+U:C)$N'O3W2AW5O5V:@<6K)NTPTV`H>[R3`YP! MU7BFXYRA8L"7Q,],HZ-PC2JR'KEX][<;=0([G2%]*^^K"UICJ5>NPEKZ45@] M(_:`W/]!>%M^TQE3M4%RN5T7=]M=\?BQ7'_+JJCEL+)\HH0JR@@6A(>!3+$^ M$W4\J4W6!)I:HDF:<9(J>;P._?V#_`\*WV&:^CWVG/"/.0XGW+E[5C$79N89 M6\QM[<6MA_JWY>=B.XM2G85431[&=N`';]9CM:)L%Y4$EHO5^OUJ>V4B67A) M*J*R47[J>_3^]/*OW=/3XZ\FD0^KHJ0]5:;];>QS) MD>&6O\,J$D<,;I6$>?#B8'C>AG+<_ZYA)-?92%LS:@]I[;L:0:_KCU[J0?&"[DSK=/I-^ MZ]*6IRA3-/0C*@8;'B/4G>AD+G;G5U:605&J7H/9^16/Q>HD;K,,G&IUW46/ MX'IS_;USSW\C,"ZP]E.(,:*&RC9QDM$0RR`*(QI027&@X69!R*A4..6$)=7, M&+;<0Q/13S)Q*E[H'KZ:7#4]9&,#?5\B`;DIL#CN^K:BF8>:<,DH_C_VKJVY M;20[OZ%*U3RY:@FPF,JE0U*S][],- MD!0`HM&XTM".7V3)(@F=K\^MN\_YSD28M+7:$<5#`U`7HR?38N+5$V8=D7PE M>H*9_8^0Q^V*"6G1$_1:M&1B1%J8;I!X'4JB&&&<3H1("_\9KF\5%JLD$R/B MUQ&,^ZI(8PE(Z8I\N.!"H:\**XXJ@E__G)[?)[+$)@]:`0:E`=0DV"9GB`+! M4!)A$9FXZ:K_>`M;WQ"%).I1[[,LX663\-`-6.Q8SE-S#G=W^0'5ZN'M:FUW M1/'J<;U?C4C0)16%.W2C7%LOD!'"<2+2!!!H/YG:3!QH;C"`1AJ&K<`1Y2XE M;R,")*AN_=!BZ8C953#F-UQOLUU^!S.YJ`UW29&D":8,V#T5!Y2F5D@>"2`5Q!2G2L:I M:%W72GD%JI^:GXE4$OHT,>E2TI]7EW27WG/]4Y/^#2,'\4/"E;N,=NO-[?IQ M]5`,%KNY+UTXY#S%VX>!`]7Z*7UW,%I&Z$)8+A/I(EISI?,O^]WZ?[-+ZT-W MN_=`4-4'^@:2\QKF!M$JI1`?]V[0L`U[Q4NJ$%[`)4"<0DF5!%@8!JAR=THT MU2".$1/*\6AHZ>:GM=V)EDL@6N6I-XQ_W%]OGO:[Y_PRXD`'.U)R;C>P!\E) MZ)*%L@1Q+@"+4@BH2#B(A"$`<938J&V30@K;1TB?]+^+2&W"E\=SK9]N%X9` MR[4PPVT`-(A54WX?6'DQQP*A\.8[M6ODSK)5&U!O[8M7GUP_P_;;ZF'_S65* M-ZZ#U1':#]_D<$J$37>)S5+:7:*,8Q(1"`'6Q$8%(2*@1:1EY M@O#XO,O<&$7,7MI/VR4I2?TNLRBM;_=9,9#8M7LX[Y$WL$XM<%-^#S&A-O)I M8&SHL_F]LB(K3H'21&$K-A(B=5&`5$3^FW-[!VG;))B(ANKGYR\?L]W-??[; MI_*D@[\,K^^NXO1!V60?JN+F#*D0;"CB5B&DC9O<(+M%,-KNAFD*HI1SC8BV M>P15:`IJV!:Q!EZ[&7"YH'$1K*H^9J!QD3ID1^-""S.N,X$'&Q=VQH6JQD5Z MVY:O?[0Z$ZS8<[J`U#P':D2;B$/&)I1?74TH5X'TVQBI"40I4,11JBJ*@48H M`5I*)%(JN/WO4#N[J!-,3PA!28=FJ--S4"G&OSK$6.@$OUNE+FD]>#NQ3H#@*ST,EK-\FITP!OX7I!&+,TP4L*(!F: M"@;\BF"P$K'076\WP?.C][9-*E%L@;+/H`+YM?>K0D(Q&KQ_Z28[;RW/(K#< MRK,8R6?0`>YT8#H0'/>:YV"_.@R\!LTE]/[ M$6;-9`-NVB=HEC"+Z1/P+95(%L:L?9',<@@V+NLZQ_C#CF MVA+Q5,M!FX\6"5:(BQ]Q;+(U&N[RO)?*%9C;S#Y$<5FC6*3KFF7*#;CFOX.H]C$;K,QBDG.%G"FZ#[I\_;!?NB3(S;< M?[O>'.A3WKJ.CNTFVN]WZX_/>=G(^ZUKUG92_,K:],MI`%@B MJ(J@4#-,5U#%A[R\=."+%:;!WH*L2D@\.!MY$/<`I@A0)TMB6799GD=I4PVB$G1+W MI469^/R^;R9%PK4&US&*A%R?:[,BX>;._J6K4!V=$2J$'+5)BPHA3'XG7MYB M&FK5Z`HJ^R!;065((CJ_;;HZWZ+C[DA)\Y3/CRVF?(^B,W>P<48*70QU^D"1 MZ!0K")!"R";.)@$:NLZHU$"2QD0FV+264SA#K<;$3J)5T3A2!%L[_[C>Y&]^ ME]UN/VUXX,2XO8K>/6G_:C`@W/?#6BF%CA`:8&NK:/!V?I;1N(#':?J#K)(\" MY#F8DUIKWSBQYU/P:[OMO/?SMBY+O[U>HZ"HFDO!`QC-MSAO=]O';+?_YLX" M'*.:TYB\Q7-9R^(?C#;?FGBAF6\UCLQV^2O?[K+'U?K8DVM??[/_G.V6:#1^ MAB^H9EN>SEBUS]`Y/B.QS[9K79XKLZQ(X._7I)7AJ/UD'#9@J`-)X[(TU$_< MB@EJQ6X$!(.PK:AUX^B8DUDL"V(_"<$PA'L`,0CHT6SFLZ#8,O41,LR'`%GE M,O>]V5$ZW-Q7/<7+F/$\5:3?;-[,/Q;QDB/^CJ\NIH?8.!+8;HWD%^P!)8ICBK7B M(&'8VBY*$B"Y3`%!.G51$RO"`SGVR\9TA*R#E/(T;7MA2N:AMMFW7YMO[.P7CH7LUF7(L32PL2":V("F;YB8J9Q9ED68& MIU0'3H%/_&Z3;_UGSFRQU0L9(G4B"DV#,V<6MX&^TB8UEIR#"@E;MBKYB#"A`(3)88EBJ9)L?ZDA>E+ M"%H>..*7I\]:YY6&UIZ*:0[O_[Y=TN(WT1(CU'7QST0;CLO-9H23F!Z7)D99 MUWD[4+3+68FC)8:8N*!"J`IEQEV-IH7-GB"D^MK,13$(I;9=,6BC".P\/=A; MY'6@F2TJI`[U%G?I=I<^[ZWZY;?48XI*%"3R*X(VDH8G^*@H3E!JL[`XU=9* M,-%`"2H`1EP+0@R6$IXKQ:F`GE&HROW,O87\OAA9=18J6&S9":.STIL3\0+E MS#/\YC5`=#X@8#!$9_3=I>8T_X2@5P"2PISA()E^)XQH/5"_8$2PPDA.AE'R MY?%A^RW+?K$OMAEM MX;I.?C?`OK-N=QD$UTFWF8]D[6P*WBNS?B5PL/&I$T*\KI(GA"9UCZ_5])5- M/D/#`ZA61,HT`C!VEX*0$:"52ES9K*LFIG%J6,#T>;W@;2&67YSOG0YHW)2< MA^W3\XAY8%,3[+=7RIX(]H,"5>4NW77-(?Q4K-+YM@'Y::45K=:$M8MUJ:6? M5'KOTMO=",:BS^(?)D45Y<]E.[K.S_O8X ML/6L&FKY2'@/K*HU3AV%:W`P]>.MY4/2'W M&UUY'%9IO2H.\HHICB6!BH`88N6&'$L048P!I!+&C$N.CBS/C4>W9V-^YP)C M'LA/'#&38]UP-D%,3#27$-"\O)MA!!2"!AA)8B4(BTTJS\\FCE"SN9`^8?`: MM%HQTF$(AY38ZG",W,6>:S*/.(@,5T!2'-.(&2($\5]KL?KPR-^E3I\CW:#2 MW8&^K/>HZ72>YM4KY8YCIM^M]H,SUZ(VT/ZC1("`4TG*(3($I";O[3`V<4UM MD+)AARG.$!91[*]'.(V/;A.BJD[U5^:!*_EZ($08VP5$D.3N>A#;V!J*SP11 M'A,7E8F0KA3#M;48^X5)A'C,TSC"G0M*^XG7#LG/V7[A@'CWMV%`FH2KPI&V M5)'>WCY_>7Y8N?/L8DQ];HBCP>%%N:%!#_61$3M9N)UV)+H4KKKN#PEC8;B=$KM:7IT/'')2Z$?#6V-!T@ M_KB$%!.OTI:"1?D=P1%^6R*D`\<`$XV-TX'NJ85CXX]#2-;K MU?I*6MDIM[>8S>:$)X2JA9O'[M!>+G^&R?J=W+`,78]U]3K8KTJB?OJU8"\\ M(1Y>MQ/$(^QTFEE<)KQ`)1C2O#B#RR`O;LRDCBD$2CH+4B@!4J?&?CY+$B,2 M#G'#T6CUMH@I5-T3=!:P"R[1/E[M=M\LFJ,:+F?!Q*LE73&I"5K!G6;^9;4>[F8K>`Q&P.=7K[X^K?^T63_\YQ_VN^?L#_\>DNS@3=U! M[W#>V5G6V.L97]:XHU@]5_>O(ZY+)UI=WP5I\^H>5?VGU>Y_LYQ4]Y?L]GF7 MU]C$XUACUS&]Y>=7815U87C7M M@OKI5X(+ZHDDI3$BQ9&E_2:V/Z\+[W._W>7MIZY]>+6['JZ)T.,!4C4KX#\,EU&=F6_"CJ% MZ.U7.J=!`'T%OZAA6#1DC4!RH%VTM[-@_!KLHA,:G70CT-Q#<+W(N*MVO-T= M@"L-M"L-]ATNOY*P(VT$XEH9)!/`<6+5@7$-I(."R=2*GTH8:7/8@92;KYMF M\P6D"8L^06'Y/)(WC0JNUMFTBU.G#]G\EMFTR`;6IK<5PZ1^?0;0KR=K6[V?VR=[?D>?KQ-MOE'[0P8#R9564H.'QC7^K3 M')^<8>,9-])S)CQ"XSS]@K0)/#*C;I:TB6NYNZ#>OK_Z:,X&26H9P_JW]5VV MN3L.P#E.:]G<37$^T2P[/.^"3AE+>2KM9D)%@`KD>`P1!I$T3-B,,^:0%64- MWLU$.3_H(%/;@O]U_7_/Z[N\+J;X1;:YS9:G!+I(6 M3(P"\8R]>35IP=1:T=2JN8BLX"#H\)7V$52U']TW4.J\W6W3[>[+ZGIS[_XI M!CK^EFV>L]-LK>R7M8T3)3YY8_4CNMT_KWI4/B(N_*,I`IMGDY+$C:P`TD"' MB]$@2C0%461@+!$5(@ZR8/IF[4X&Q:!A#-$+94UT]S_/!YZL.5`=.'6,M1Y7 M`?M=^X"97G)[B-AK;#;O/Z_VUT_I\^8NN]/?_$,PWG2`K9GH<0'R_U9FC\[<.S'W0 M=;';Z1&/+X!*T]@&UH1*-]F^B\.UN#0YW.F&X00<;FA:T%!_>_KUS7V)D[>< M$EGT?UH_9$_[;9^A%\2A12%&M*Y5+A=BD#K*"19DY^`$1[%U,H#'J0(T26,@ ML>%6TP31">-0*'U>FU=CYSB@UD_4JN.UT)Y^)8I$)+HP0!0IL(4$(0 ML!]"@1()9*E$@D<-,X.:L6@6J:P76?9TL+TB!7*7#6MKJ5;S/N6<>SV,A^2Y M,(;4?E-*5B`3BAZ[81PO)PPFA(HE2C!'.,2M)2$=`1N=.&!)E&+,="IPRR5C M\NL[BX.J*D58SEI?T)='JT=%_*KWT13-L`^N"ZLO.`0RK/IV:&(NF<01!R:G MBC;$`(T2#@B4&AE.J(D:TI):=5?M_+"C?#7B'Z<]A0V99P>A]>KK;<$._72< M.V63Z?Q3^D*#3GISH)0C!-/0=;2$-+'6P8`P$EF?*Q(@K1\&F%-J-Q4D-K0A M9A^-Y8P^J8]\56@..XD#9;;SR2>K^RG;?][>#7&N!Y41=A7/CU:%83'#CE8R M=74:-$U`Q!-7L9$**GD4*V1%MV_\\_7]U>KAX>HI'_*UVMQ=[;)/KE/0#09= M/3[NMK_9G=Z7X]]G7[++KE:WG]=6I+M_NUH]73T]?_FR*HZ%/MI\YN]_NOKG M?W+2_^N_?,4VH_B/JZNK/[(WT'W&@[ME>GZT7VQN>_P4IV97V_NK3;8__!7V MAY^B=_]UK6^NUINK[.NM#7/N/_](8.ES[*]6&YOZN1*TN]7NZENVVIT_&<%I M'LW[/QI/)+75T,"SFQ"?2&X\Y.'5OWC$TVGPZ1UT;9?=9NO'_)%?\FHC=W2[ M.AS]%3V_=@OR)?\34Q,Y`UCM\O/=G[+-ZF[MS/+]]G%MGWOUUZU[_8M3Z&[9 M/3U"]06]SEPKGL%%6JRH]9B("A[:YW5S&["-'_]0IU#VG/V%+5>\'5]ZV!#T M#ATS`^&KHSTR'9X*W>IR?'>%()2IT""*3CC@UMIQOG1]F!8'_R7MTO6!*9L& M3H%#45M*4(+]X`3X]!"6=A''1I./%T/ MTO[;M975[L'WAQ.\FUT^,.SC0U:ET^U[2WT&3?=+RP1AKG`<@8A&!%#CQO8: M$P%#8S>B-3%<2S^A,*DKQS22#YTF4^(M?C+9T^UN_=B/**D=R/I!.4,11"P" M6$<84$$8B$P2`4$9%"I*,(S,$;H_O[=;MOB_WUW]??5T]9L[UKV[QL7\/WM7WN.VL>2_BA$@0`)L>_LF>[$PP#// M6-MCV),$^,9Z^"ONKKN@_PK MR2*8R?-C!=RZ?-G?+!W!'?T&\^"FI6ZCHSZ\VRU?PE3__F@9(IOFPXC5\ MYG(-;NU#_M,27:/N^5RL*%<_O_H%W@*?L4JV M;WI:++_B_CL\1?!X'Y\V65@&XRZ8$4SNEUAZ,I^LU[/[&3PV0'^'F:178OMR M\FJ=)*\^+.%;Q*M?GG_]]?4IBW4LQWYDQDK6J)EX13%UQ'EI M#T8#APH6&2.]X/WJ<#S M)/B'Y0*(^;28XN7/E6`'@F"G"77!H3UB@`:./%9C(W<%=\<`5:L9UN\GTR3=0+_+NGC?5DG2U91)\0./B_0Y MFUMR(@'6BR^(]BC(C)#B@DT5$V%4Z+HTE%(&7YI*BFIJ&1IA])E*9!GCJ^*2 MG389$>4`/U#?D(@BO\Z+ZU*M>;U5/*MN5=KO%R=9_,-CAA M,DM_=3T'QK)S.+K01WA"^GY`F.1`>I>C<,(:DQ"7^QAP3_PXBSS4[3YQ<5I% M#X3O3H]+'42Z>65]/:=0N^W=<5D_%Z`C.3H>PMKVM?F'1\^/L\PFWGW#GZGS MD$P]L((FWY+H.5G=S=9@"\VZ+.*V'T:UU(I3Z49!J$%%@1@"E](C(,?`RHU\ M/P3++C(T/XHV31'J-7,ZG$O/%"HM\IZL%J!*UMMZ\W`V?]ITE_#MR.@JI@38 M,T1$E!$)]C+Q`JI)[(#5XU(A(VJP6,<2R"M5T[OZ8+]V/8R>!(*=T$/=_1CL M1FT,(SQR%)%H'GHA=0@WH0<^EC%N[%<9;M]_`2_HPF+=@1/`=HWE:\>]H*W0BFX]:["#K_X1-%B[ M4W-9CQJL(X6:-1A\R>QN7/UEB5R4])>1=OV5@JCAPZ_'[\;7,I'W!O-1 M_L78>Q66F&@0>)<2S7^`,[[W1:Y>.EMJ)8KMN_RU$)<0SQUIU[.$+CHPURR< MVUC&SFO#>Q3.[8E3WM]PMTJ_8#+/J_VSL,EFLYI]?4JGCMTNJ]]\\&!#&==: MQ\K7PB>!P8AKA%/-(ZT)TX'4T@34R#Q!6#L&!1,C_$!VGP_T!,+M$R;SEVW> M,7O=^%1C=?%++EUF1$>JV5'VZ]DU\OBE1'=+[6FI>2R(`/Y:J_[EH MFO3Z=MQ(QSQG_X>A:Y*:O03=VJ(O$OM#LL'IL!]72WS%U'_Y?8U:=3>MS+O; MP'MQS&,?5*MKB/'!XA">(5I&8"'[VA`3QXPX+@^T"J7GI603]E26X&YQ&V)[ M3+U''C/=]D,8!FVL.?F:]AMW[$"?(>5UN@-E_$A<711>:(X+^(:2Q2GR<;(> M5^_?M#&5P;^1%PD_G:5"+:'(2@RRM\C'Z;'5NGR@$MSACG:.QE;K`0UH3I2> MXX_E'#X-Z]/ZLBNJ"K*E7:%J[`JE^F#5SG08D/Z?9NM_QJLDV592XM>]GRUF M#T\/?5"_.N>G)?7K9HA0ZG;QJGLB0X!`+G/=Y-W21,$S,?843$[_P&C=KCM_/S]D&(WO24]38"IB M0I_AYCE-#',UB:@.8R>6(I9.&E2NN;-E)[AOQ)6QO_C[+%.*EWK_PC-B[$W: MA%$62QT[1"LO1GF&[A;GX"YH[0@>!T$8?"FN`\AHPUZ79_E:G[Q?R[TFU3.^ MC*JU6H":CNG/<*\!7J2LM]C,IIA=GGT_6,>0K85-IE@!C%\,%WV3WNYRQLA+ M"^%[2^5HZCLZ\CAQ/,R4[)*=<\".]2*83QB[+J M%1^5E/<1FNM(CDL;<9/GT8VXNJ%7E,NA@G,-9"@2'[?@;*O0;R?/?K)([F?H M&X)ZAR_"'0I/.4_PN&MLB.$UWY<9OU'0T7O/!K&@@8N.-<26)I&FKAN M*(CF80C_[H&S5S:/*PV&>_+V`;2VHV&PX"63C'K:(X'F`-^/!('+'A$AM`Q# M853@J"\-RW7`$=9:U#4F5#(\&8\`*98/"89U%^OD0W*&]&[$U=)Y9];^66Z< MDBE:__PU1CD<=)AD_W^+LZ\?)[/I=IE(_D9O,4V%5^?A1`,$IFVEAS^]<1A3 M57N\,[PS9$$^4_W:I(&58O`M]'2!8$5;MKD?'E?)W]CQ\3W)^!$8\>8>W@$_ M@>F$SB2N*,-1?(>>$LZE![*MEO,YO&3+T0.14@3*B8P&4<*1GE'H@",8<*(C ML+-",!P"1WQI6(,HC6-TR6+O%7>IO2[OJ;E=YM-WO>^3V1S?#U;LY\GANK"1 M\TCV[:E:%COIVD,JV4HX)"D7X[\ME]/U^'*Z@_ZI>_HC^'K+IM2)E#@*HMCS MB1-I$"E*@$,1&$%4(&,O\G2@I5_RYS-7@=7*$%W+9E]Z])GW84.CO&,@0,E2BB0!\SAQ!BCB8RIR[5' M/1K%32=-F#%E970BPM*J+M14("*6V^QJ0<6/S/?V409ND2>:49S-&R$VJF_Z M2;6.OGAA']; MC650[IRJ\Q!8I<4>C+-NVW<'N?76"4[2&%%L<=L_LV4!X?XBC`S*?GFU MDD5+K^;A+9<2N]L7=[/Y++W3NPV-0V&5VO.8X(*`'Y"ZRQ[Q7%^1((Y5")S( MHQB#SW:&E;I.3#4`*4<#=MW^.,\]<[IR2V#D2]J\*ZP8(+"#*,+%G+ M$'RB[Y--:OCOXG]@V('_N9D\C\S9UN@($;)4V=46D94.L_5C[A6>,-IX@'-O M`F^%7@51'RRZ`H5KGZE5OLC[1S[;VGH_6RQ7!^.6O,6T^"E9*#R;\_%V\3WI MO%I@D'M@'TTJM*A$DBY%E&,1.N\NFZ[T"-H2N6R M5^KH6.\9X88539Z67@[(TN%M'R_V?1><^TB'"B?[*.+2F!-XOQ^86$K'L":_ MI6K/%9ZZK/P?<^OVYO[=-L,YF_P\._^3J??9L,&1YMR<'VE9$E ML!T0';O%>.$7&Q`08\?G;)V0/[W1BKM';N\!BIH@14T`%+ED&P0=-Y!K]4SA MRU4U5'$$2[V["CXY\N7)/F4S'%;[KM9-E-V?%O';K4S MQ8_5#MA1E>W>]68UPR[`5#\.ZZ]X<+-5(`.B!-CQ$E=^>6FM,K4*[P=]8H?9VL8T7P@NR MR-$?V[G+WGR^_!=.BQTW]LNL1A*!&^%6_/U\"F[926R^?3<9-I+ M3?;I_./8'<.R@#R"PSX;^<\)%C-N=IV:(WL&]H2==&G1'6Q"<4Q#9.56>>P' M;%$,_(""@=^LGJY)8=B+5W!B]!&%T1IDWS/P2DV_M\O-9/YV`6(=[+B[WCH_ MZ_+B4G//Y1XQ89QWTWB"QT1Y(N`\#K07LR.3HUVNBHKX$N1H^275:+]76"UHLGNUT7N\C9Q@FM5YOCA3[A:=__^GMK\ M3Z>8?<>!FTVP/TJRTU"W"69K.Y0]86XUV>9 M1JFO(BML3ZMHK7DYS&)'T2!MAYH@<,:)6W,.BHD&&7M\9$"(2Y_NLCL$?Y\G MJ>&_N$24N"WVAAK!HFAH@Z7-`J5LHD"Z1>5MVA`^^YZF,FHM%\SEC"T/K`I8 MJXHYWPO>4LOV`7UO[L'KP]5EZ(?W5XM6LT")^D[`54RHST,B)7RB;ZA/-!?& MYZX7P+5H#,HZI:!L,XI:X]2B=,:U2JWW!02%K+-*+2AJ$>?=$CU"/@VD+:#: MW'5_*"`&8DMF7!I'AI%0X[0%(SEQC:,):#(A/>Y3)AMS!8;:95KIULWG8!YN MA_!7[NFPREK2V-.Q#(G03!.I0T$\A6T:5+@1F'S*$UZCAU2)J+2#4S[/+!:> MAB9VBE M<@@,KL![/J5#?_KDZYKK&](H5L(GD<"Y>@$#O@Z8`O1*QA&/)&7E*3M%`[Q< M"%'W[#75/-L=C^LTQSUNVZ$U626I6W0O:AZ]ME()SGJ!N>U=ANH:8%KU)*=& M5F%:4=3KR&L5$#=#HXE%G.1XVY;0-U08$,M/4=UYYROIL42G/0J9,.8,'QP8#)? MQ2E;4XE"N'GK21XS% MQSU`LJNX>)R!EW'YN>>!4"#:O)"`28([D;5'_%`XX$P:YDM.0:_7#-VV37G6 MKS7/,;<'=IRWX1=I<#W9K\<;E[>MGHEPU5'6KD%S0(+?ED"B!0K%3\E7$!%H M#@9`WF_PT]T_1S9H[6DGGHK]+?(C(,I*[]BLU=_39`)VZV9%C3BW\3JFR;+: MA;#<=>2A!CP57Z-QD)8E;=N7KJ?4RFH0;D=E=(1S7#I8#,N/\#F3!08?-\G# MR.E:>P$K%>:HP&@%L/Y.Y=R&PQ.3:3;V^6:QE;X8@GZ_7"0ON:R^AH5&K.8^ MX;I[I:L7JANX`P(=MD!E'W*[_`RD7M^_Y-/`@=A_SC9__YWU1J1=4X5ZZGQ* M\M=DU3P/5OU!O>`A.%D,PG1844IEN7`?GMEAFJ8D:?S7.K,V,%H=6@5&^PS$L`<%M#:]')1`A)6I MQI;-*9_'GCMPY\!S#4G@XO*798`A5 MY`CJ&Z*H&Q(91IRXBDGB*!:!V^V%09U7NEL%Y4A'L*TCVH2F]R-4\+=GQJAR MC#PB(*D?:J,C0X3'#9$,G&[7`YZD`0\BT%21#.-,0-I3G(Y2(\K'#"P'OE4X MKAV>%=E7*^-4@ZNN&VHF7!Q6(<`"C!5Q06^#!1BY@8XY:O=,L(ANUVY(:&"L M@LG0!S(QCN3/4!@J!>N#&66SME8B;:49E1LSL.4C:UKLT>K\*LBW8^Y=Z13: MQ[KL]KBJ#>-`0"T%DDPP6:U+\(+(CUU7$R^*)9&2`7\$?DBT$S(3>U))5VRM MN3K43IB;$6AE,:7(5!=!*4U?>S+$$QI M!D@WG)>L>4*[CC+UC!M,M.BC`JJ9-$R7AO^<4@-U(9((+MDQHZD527BCGL*< MACF;)@,IL?-]%WF"$=6#J7&^MU)Y\"YNY56L)D`R*,-1ATIQC),5BUV0DR'A M/JXW$C0DOG(T,;Z2*@!BA31U4A&;QU^S MP4/G>(8YU;"E[9@Z;4LV]TMJC!9F&N]7!0NJ#E9#-8!J0)^9)OGKL(`A&P'9 M/QG.8!Z@`L:![54ZE4%A;2#V/;YZ#QWL]F-*L2UTYTLV$L5>:MAZJ/6UB1>! MT?U^R,3H%R:N2+XTF6Z]-DT-24Q[[WNEE:HSWL'NWA!,UX MSO1O7%B-[ZJ*\X# MZNP"BX6W91(W7J[>S^9@ERP75RGE[&L3&7.<`]*T!5E_*XL+`O.Y^Y M+]K-2Y1H+;%PF08EG2Q:AT9%AA]GGG#RL\(*J6HJ]`AOB" MFI;JFC@&8;SDF1U!=D+"I&)H]J$P>B6-5K0-Y&@>6._L M9E]`\0,Y7WU3I<'WZLOO.C\*D/'F-5XWZMH+7(:BP[$;F<^ENM"][,$6477Y MS$*]:V>'&,C8FQCGA>2">K-#E:?S[,Z@O[ MT9\AZ>"5>/+V&29G[<,8P84%TAQK1&M+&_7%/9:[UWUZL2-EMGNGV+\3VP-S M9&->6XS@_E]2]O7.K?:%H:<)OVO,9_=/M?]'Z>S^+W!C-OL'"JCT3IGF9+;3 M5U!EK&1V_YST[USV9?FS,94M1@L+;%54=2_?.AT$NP8=#IY:.G!I>KLL+#`[ MA\Q:BA[FH3ZW!S`'TM+P89%M*?C>!*"RV(PL3KU-/:%%YC0(6[H`\B8 MX]^$(&`X^B'7C:MS6H>I5.;#H^[#;I+--CV/!="E6/&V[D03(DNR_;E>3-+_P\O!U.>^,4%@62AA/A@;.G-`PBL'@#0SQ/`%6KZ=X*",OE`X< M)DYM^/SQX]O__L_*D^P?,(*+N7GYE'Q+YY0O-A\F#]V=RC.?D^%S1L'MI]_? MO_KX#^_3>R^(?K]]&WCO/K]Z^R'(GK_N08%%-?\.LCQ04R)KZ5#E,-+/E]SLE_Z.L;S\%[A"()Q",^L^?XE3O9 M2>*!&J,;(;&2L./]]5O5+0D!`H.-T*N_)`:D[NJJZGIU=14"L@X> MCR??..;U2SI!OA).C6.TJ6K-EKH,[1)<:T*"26W[HV/2GW_0H[,Q@,W29EJJ MCF6&-L*U"O9W:MM_..ZCL<%OG_SG%S<)]@:X%N!'+4%B7C\T MO^P(.>S`9I)9-L&U271PILI%>`#2/_R=)CH2,*WRRU^N#2:SX7&Y>'0EV%GE MDQ5X5AIRP6ILUP<[B\6"$P=8-@I[UDEBK9&\/X#U7-HO*1F^:7%*OZ6TKQ6E MJ5RT.D`/[;)YH;9NFEJW=WFIM[H?KO30L/K5#LY-Z^'7^^`<5H*?V(5XX@=/ M-OWMY/+VV_7-M^;5[:=/%U_O;MX#A+9MS'QZ0D"%V?[,&($=\-N)PC_/#-., M/C]:9C#Y[01LVM,3,G0]DWKX?7(F+_G!)`^&;=T[X(&XL_CU-KP MQ\?'@*D(R`^W7P;-#Q>?/W[Z^ST96%/JDR_TD7QSIX9S0GSK_R@V%XC>'.(? M'1G_?#>,OGR'X\4?`G,+8!E`XO?H#.._NYAHFO;K]_/7FR]W%X./MEYVA M?+>$S'>,B(DO_M%LDI]#SY:&KOE$FLW$3[,(\,\7W_[U\4OS\G8PN/W\GBBS MG^=`1P,/6];\>R%8)^3PMI3OE$R,!TI`4\`X!BN+#Z/`BC`83KVF,9MY+GB4_,LF.].& MW9.X33*#U4HDF%""Z(!18E005F*.H8,T\(%?C>GL_)\_8<=?<=PQ3,5?7I^? M2>1Q8HTFQ*,P[(B:,)P[]\C8]::@7%,!P_E]F-+#&J<^N*4`3;Q\ MMB+Y0"17M4QH/I@@JGYB37(8QYE/A[``=\P0/6(G?Q$*HJ[NB']BA>F9'))?B*#H:1@-G(?QG.')3/XFE5@H&`!Q2. M<6H`$ZP_Y`>+#WC@0HUQ0#W.??%"8"`^)RYJ_P6QY<`85M@^P2?#)_;C/7P, M.*H:UMD"$$W6R?)BB>O!``TK^921P'3XE#^'1083(V##!VY@V&L/(>N^>!4X MAFW#$!0YGK244QR,33:ASCI`JS-9+':(!&'[,/`#^!,H*),+]O`U'5$<8K'* MEBHA%5L2T>7N)EZ`P1Z!=BL+83M7)A\#9"7DQ9EK6Z,GCJ`AA4=H#!:2A\,6 M3#QW?C]ABZ+A$3Y;$7LRWMZ/P/)S/R!CRX-_81-3+JH!/?`I*JYE^!,RX]8, M`XD1*,1-XW%"D>7B&1F3S&=C#S
W4QOT<<&C1]&@0V.Y6,?SHKN&RX6TAY MQ`Z3@0363^Y9MQE`$FP&`W8"6Q9L#1H\4F`E,,)QVR(54$+.+/Q57E(&2Q1A M3X,H7DCBY9]1E`^10(PKX.@O>,&Q*:^CZR#1$+;+6)\ MM&M1!HT-RX-9L&DIVD5SFBH!X0]X"88`#L"BJ+@.$YTE>#CDUP&3#*ATV`_` MN_>\XZ#-I0;[E@_"T(E/Q+HKE"Q+MS,Q^<(*`DHCD"]=?(W)M6O@TU'@>CZ* M/,:%R*;&/1#D'N<)"08OZHH$;BUR(L.$Y3"1"D,`QKU89BX#G@0W'5A`$%IV M$XN.R2@H#-!9FJ($:BL@1TC_B30EQ M/&8[_I%,@#Z^M/5]8#N,TUL&RN6(ERA+1,`M)7.CR>?P`"<&$\Y(H:Y#\`S4 M<(%GH`'2M"V'$E@5"LT'+IZ`=9[`@0:=>[>\J5`"LET5[1E3(M:8[2/;1M.( MV$S#X;Z!7<-'(2#AIFDKEPGF31%X86HYG'>7EB(1WG%IT]:.@0`G*9@`A_85 MF.(I,:%M^$$JCCY&^Q*+:@;X*P#,)Z!T85#VSWUB@M*>2,2T_+#-'R.8QW)` M.)3A2+$884X\%`6$I,UUX&7HVRA97T0Z7XP$K#$'N[@ M.%6"JX+X/:Z-@(NX[16X2^HGUE5$(J/<"`'"&B@M%28QP(^'4Q`IP88)N,''# MV0Q@NI]-)F[C27$Y;%J)610`*OV)#=#)6TUGRO71]=CCRW2+848YL;(>]%69 M5"VXKKP(O1$FY?3-7MVZ;X)F_1QL$P^IN>2@H+4<;V9D@N==PA6'$$9XH4NX M!B[3H#LY4XQ=F1\5>X3,!L8A#)X'L;3#E.(EJY"*N[:&$K M,GB,12MKUY/)[^XC;GZ)>:VHQKE:Y%!O1\0J&F`(1,1X'LS1WS+L-5R$FP"= M_4UK0D#\^?#?8*LB6D8\*SULR@S`QYFSQ!V-YA[?+7,F#4SKP3*I8_(Q9J"P M?::\?==F/<0D8EO@KID&_S"EWCU%Y(@?ET;F0+FP]/\T#MEXNMV M1GE6"'`)AR@4U"9%7<+<O8`E&VKN/_W,3*9`D MCR@AI^-`,5AKXQ_X>*67."#!@`'U-ARVX`D`4QMDP"#XG1KF\D'`ZG%,.$.W M=1IOPXTG(T,W"-QI\M1FTRN'^KZ.4R\?\FPZ/@NA6A:Z3.JH_,MEYMSIY&N/ M,?<8?7D71#O-NQ\VP`:5E#.BSGX2)J!.UG`..P6VAX,'C*L;X*7J1EU6-WB6 M3FY0W&``*4W@O.0,\6#4$_9I`?Y[H5PLDZ]"4`;F\ M;LBDV3F7:PD/@4>&]X`S%TRD?UY=W=Q\^'"2#C_F>VPQ#3_=?`!'0*73%=>@ M"5^]TN>YHZP/A13%V<.CQ(3["A[`=D/VR`R\=?1]E_]V[_DBQF?)!:^<756D M;D?;'P3'??2,V6\G_/_7>KV'IX*@<8+&+4EIJX+&5::QID@=I5\^&N]FV>>G MG/"VJ^&-)J%2,ND#M=T9QH.JJY%>,?%!65I2U&[Y.%K0^B4J2NJU6X+6-:%U M1^N5C]:KFFIITC!.GHB*;Z7?3G3>!.(.[Z[JR=#59J'[5#\[A3WVU699SYGR MN,"BP&(AL;@F*PH?A!E@*D=U3=J<'7!-ZG9+Z)P)&N]!X[;4Z[4%C:M,8TV3 MM%8)7=(*FJXM4-VF.Q_:](CVPLLG+:S9)?"8]Y(*B<=MAY")4T;^Z,K]Z[SS MDF\6F>;/IAABKAVF\R7R[38EP&S.N%MDII.&AZG^/*D9!J)^8$U9PB%\'E,+ M\V7],W8]9]OE',HNQ22SRV7R83$`2Z!>#!U=#0648#IR`FHB&EA3GITC<5E=T"B2?C5Z>C3TFNKURC)W`^S^>']B06_ M>=8(IHJOS@SIQ'BPW/@V<7RE@JT14_5GKL\'#B;L%F+<3Q5'6"7=+D%T=F>/T?D\L9G3?< MUF=;EHN$^2R^NQG=N0EO>R:OWJ1>O&%CO?DE`4K!;VL@WA:H>O/+^L:-;M$B M?M:DR]*%5K['88RU&T*I]X/XI2>>DLSNT2RQ*;OE/4=R8&9_=)4A2=9HTRY1 M,8*6)?(SBJ!,&#$-A;M;I#[OE_JL=_=/?=;V3P(NXE`BNS0EOTXO?J:QH-M: ME*-TF<`E1T_6F;HE1\_NF;2URWK%6WS,-N46$[&M,;OQ!I`PY^2,-(RS[39, MOH'<`S$-QT9;[NMY;Z!LUZ."AA5]_\_OO'P4WS[NO%%;@QB?,,16[IIXM%-!=_*G*W=[J^J`)M MA(+@K[T)?[HJ\/<\_GI:.OXTN;T7^LJ7N_&7:QL!*UM$&B,AJIYC%;TGM])9 MI:O*>GVW6JYR$UFR23%.Z(U`#B)N8X<+^'Z]6:=,O9($EIMT-J"&DLRC;B MN+R0?!@H33EXW\)^:QQ6:0Y(BUP=B0,NEU(LR)_R'99(&V!QQ+GWQ.U37G-Z M/,8:@&$)3'PVK*Z[J+86I2A@KL";1;WO!BML'3W.*BQ&0RRE-BPR8?KG+/4+ M`^\A*PGVV<(^:=&$(['/9\8GR$$L+X>7#%R3(#Q/9YT-,)=D(PN\^25F`L8" M@@,VFRJKJ<6CP_:&0;3`88SA-OJ!`7`XVJ/F(3")]27J^5 ME2A])8%WMD$V9OEMMT%V3@U3#EQ?-$S]`S`N,$?4"LI23#19LOY-V)((PY\) M'?+2#$_6S<"O9@'-OI9U%EE'V3^+K)-?%4LQ=293B\2L]()UV02O5])NOLR7 M1=T;3/7=(M>''GGW"H&\,COK^+@UE_P`I,MES%(Q01QZ7*'P!8]$'HT=;D+7 M_F@3?D6'X!WCPA(R88W9,?'M-SHU6$^0E>^O7.RVS&XNK?PR`"]N@;S&WRPN M).A?&/I?1,W'5NCV$0AJ.;XU6OD>KS3ENW]KEX]ZN^CU$:2-?E3* M$4=Q3JQ>AY>"%,WJ2:U^5U+ZM:DP<5PJYUM7HBV+0H>[CY[7U0'3EEI9 M:)]_\1,=H48REC0MJ:-IDOJ"RP@E%3>UI')7[HN2[@61O-5<5:;)>)EHF"@2 M)71,UM*GH4JJUI$T/6^;]DSHEBQ\%25ON@K=4DKQE*^/W0.!M/\5X\,R;D/= M7205W6,+ZY$)?9J]/M7;7:F=>_U@H4TST:8]T9BIYMI4>&IKE5$L3^B5(_AI M>E_J]_*VYH5>R8"VNCA1*HP$KN:J*EA3OE(M:)[%8D'644K<[?]N7L\5&N:B M%]-X54Y4BE\G#-A#]ZY6>[JD:[5QH8]+YGP#MKK>HR!43*575?137)$5=2QATU`EK=>5 MVJV\4V]%O#V32=1"QU2 MZ56)I*B2)_849!VEQ%T!$XS*"'/Y^IR\*DTJ)6PJ#-I#ITFU^GU)>[9/1V6, MG^.2.=\(;D><81=&=%=S544/C(BDJ.-(&DU2VJK4ROVXJ*)JI"!4[HG:4861 MO-5<5?F.<$66U+&D3Z.GZ5*OEW>56Q%^SR1'JET;TZ'H,KA9*%XY*N>7W M;EI@+9ON?&C3(YKH+Y^T8/Y-W;`G\"CP>$0\EN^VS%_4#Z@)\S8H3RO#IO%G M:Y1G;J)P$G.T+:5>MR,IN9<3$3YB)K=FTNIS5Y.N-=_''5GD251Z+VMM2>GE M'0<0/F*5K$KA(PK?1N"Q*G@L^FGAG\Y#[!/.'>$5%MF:;$EMO26I]2E&6"=+ MLB^W:G,B7/-]W)/S/E6J/*5SKFPM=;O"*11FI'`*2X(]@4>!Q]R'D[&-Q^?D^4V<]SDA38&GX1/L26IB1$^.:U ML/E6,'-U^^G3Q=<[&'7DVK8Q\^D)&5';]F?&R'+N?SM1^.>989K1YT?+#"9@ M$2C*Z0D9NIY)/?Q^2<^D4PJ=X>CU]FFLF&TZ?GT?G+/=M3(#XW!S?Z,SC_K4 M"7P23"B;S,+O`S+./3*R71^0"S.[HQ]D MYEGPNQ&PP0*8F+AC$KKO%`8Q@*'P)_ZT.PLLUXE_YV]+"R"FP=`-X.5K@V+`\,C6\'S2`0?C#R/MSCR_LE3R_ M58`GY367X$L!/^#0Q$@OXPW$RAAVEOL(!$1D\STXG\*2X3$?$#5VO:G!B/=H M!1,"K#2C(R"ZNTS9>RQ^AZ3@++"9&._7,3;;%2-%56GA9AW!)J/>!J&#FOV2 MWEM.J-M_IX89ZO8-8BF^T-K]RJ._%U'69>K=CBZ.% M_)&`2;V6MX9S$!`@%1S<^*O;_J5:6HW?'.(?R2M;"/TP7D>Q(NK%($,G(RK< M+`Z_!WL#!ZL^`U-D8Z3M&+^(KFWS;$YGA: M>!"^U#+BRZC&<+R>.S3"V,\>>1LT_B;&IY_)KB_ M]MP?J:*C3?BLPA.,=Q2]N4S8W95G4>S!>E-1B(^"."++QU2)4%;T8S+2E3C% MBOV8XE^/>ZO(?2V*)&+@K?EVEQWK&=:G";GWMNX\A0NR%X6LEOLZ,)2N.AW5 MG4S5CMQ/N1$G3-4#=TGN=32ITQ<&3#WHK8N(:4THW9&U$@9:!*E?),1U,%4U M+>\+Y(+>Q]K::@GU=>%CJ%U9478Q3'MRFKDD#-,#RS3L>:)VNN5C=$'O%U6X M$75/ZT)I56SJ>I!:E=1V5U)%F;*:T+M72I^SA#'4?HJIJG;D5HH.%7;I@2MJ M*FI?ZNCB6*@>].X+N[0FE%85N5="[25H_3+#5-$EI5O",)J@]TOHKE>O* MJJ!P3?9RW=KWUG-'E[.1;P7#$!5K#R'P*/`H\"CP6(`E%1*/F;7/.4+WA0OL M6P$C;&Z6(&$3"H^21\,G<\>C(_?>@0%,,G*G,^KX1MA5`__&NLKNF+Q5-;F] M&&EJV38^XU';".#%P(6!>)M7DFS@X$OD<6*-)N01Q\$1>9.'>$[B/E"/&/`[ MK\%'#%YTC\RH9[DF7XDFZXFYG[#<:DJ'C!?U>UBC26^G?@\[TSAJ'_$*^\N. M:^OZ@6>-$$FLPB2`&+P#6-,O`PM2;`[V7!FV`/DB9/56RR(\XP1 M+H=8K/L*;R'B5ZNU1[>3>6>/SOZ=/50EOTX3V<\M6DTLD)YY-=4O\V6EXXZW M2*=#5Q^/!,IB^M1JO!>/AF?ZVZ3F`0B:RYB%9HVHT.YB0<QZSW)5VI MS?'"<6F<;Y"Y)?=+F,=ZP.O!K2R$5Z(W@!!,F:;F=GNJI`C15&TJ:W*[A'DJ MF5X5RT1L_<4L+B&U,N;G!MXH:!?@`/],2*M,I%6K`L4!BR:;/KC>F%I"/!U! M//5:4E_/VZ02LBD#TK;E;A4,J?*G%%4J@_]9+.ZQO;)]KGS5&Z(PZ!I/:HK: M/M\6%DW)'12*\K#7_75-TG,WXD7L(>.+_E7(PBV:-2\"I,=A7[W7D3JM$MYF M%R)JGWH%W0JUDM8:U@$1T5P5`1']PV.BMJWV:=F*:VVU*E/7]MZ4EF5& M*FC/B_#HD<*C6DOJE9&!A8C:H\]`MX0Z2$1'AH3H:,KU%:$I#QT= M5;J26L;6S&50FOG>J0==*1K(%$)75JPRX:&T93VQEUE=Q^(5FE,5Y71#:;EM M_GGTNK8H4V?3\6O%X7_L+@H9$(>;^1N=>=2G3N`3=X[R#`L-SCQKQ`I;.E@) MDZ"-!-@CIA%0!HZ%;T[G=F#-;"L,&K#OR/")O>&P(F=8&)/;5S"6C[6CTNI2 M;F'`LO-8[__9>]+>MI%DOR_@_]`OF(>=/)`:4J*NSC&?_"WM M_[V*J6.)`^TW0F!I=>.`,GU[%D='1-C66^J3^39);&EF&4G\=FZUX+-9&/QP MI^#0>W/V4ZO6S-]7=U>W;IP<+R_%$# MYT3=U=DG'ML3C*`,8*#0'25X]\!GY([H-B1 MF,Z\8"[@!3#V[,#WA4T7I=RY\01?```*4\!\-R&?:FS&P]CE'O#@-$51$1)" MR?`5:8Q'.`FZ(X.X:22\X.ZX[K_80"V-0ZG1+N[%<\!;(5C45AB@6?&^9PB[>!_<^:`I5C45?[#95VRGAD MH"+P$X15MX2]42L"/\'TZ);^*HNJT'-5!1?JQEZST/.P*SVIPA,\5OQ;OD!Q M^2<6?=Z?*9"N[PN+0']QW%O\^,]?DDB_X7SVCU,WLKT@2D)Q,1X4[FC_(E-5 M@R"*(W+'^SP2SB6?3Q$-5^)'W/=@6K\!8/;/%%C^8A%4+PRY?R/PA_WY"BRZ M,'?XG\2-Y^=^%(<)#7"!";>K"?\/=-.J]W6K4Q_H\.E,MTZM;KW3-0VK?W;= M!>#79OT=2WQ7SD`2[=UO5K=5;^;8W2%"EBAA3X23>$!4@C]:GD)>E$-IMI[O M+#WY$U86I9?`DW#+:/Y\U"_AVFKW.W6CV==;#7,`&#X[U3OU9E?O&]:P>VIT MS,&9<8T__`UY5['N8R3IMS_.KX;ZU\O>`*2>'X1`;F7R7WWI??YZ=O'E$S[W M!;P*0I+>//_\N_HU",R++\7HHQ3-_V!3X;C)E/U]25;\?4TN\>/PZ@ID;P9X M81)YCO$#T^_$Z+L;ZXA0'2@0?!5C+.7!$9 M)`S>ACL&)1'<12])#6X)_:@4'T*^\6CDTYN/Q/XC%>YFJGQ@]RKD)V#GU=;V M6!L`R^0?E56])V?:>D:9O6GL+W.Y_;&KU.6K)&_N%7M+Z9O/R6)13S"F5:Q/ MYCSV3OC'#IYKU7P"LK)E:332^M&&F1UJEJ_L[/%-%5'E2^K):JH=(,F'5Q##+A&(\9->Y;^O(4S/2]LLU!MBYXP"9*FQ>@P;.Y]F]-B+%$ MT=L'T+"[I,0#$VDTN[LI;7X\0DK6L."!A6T]SO<0@6O='5S,\/K4/8#N8P\L MZAB:N99%3)E:NX.]52I!]09H7:]9.[C-=OLBZR!ZNSZPS"/H[EH6OO[9U$S# MTHQ=-%)\8"JE:Z58%AJ#[&KL(+/Z%LVMXVCW6A9&_KG3T+K-_9M;E:3:$H&M M6OLXC*SR=[.K.K^^A#[/?J_,X=,5KGRP]^N:@KY*;;ZZ5.TVZUKS``S\*DJQ M=4O?J*W;4X=/Y\.W]*O`ZN[8N-EI::W&#LZE5`)KWP++K+6/(A-4A54K"5:, M5%CMNF;NXD12%:K8FZE5/PK)=7ARJ@JJ[E14->J:=0`Y[$I2;Z=N M%52M@JI54'4G0=4UO7XKM;F%XB^C86DM8P>M4JHHQ;YI;=8.P$`Z2EN_"JON MCHV;]8;6*25H-I>^N<`]%`55:VBJE54=2=1U34':"J]N8VHJM'6 M3+.J_=H:K?=]]A\TIU%*\AZAYFR`%G."9.2)':K.YP^Z*]WY-K'WDAOCJQY_ M1]3C[X5]?NM/[?/[@*C>:J/?!\9>U^H7AJ5FOVFK7[0H\;X];/F[R#?W-OK- M7UON^,ND?7J2-OY]88??:M,JQ*QT.MYF2]S[FN_V;#M(@)]8P.L-AJZT;[&I857/= M=,7/%1WTLFOTG>WW7UZWUUK?VUWMSYTU74WQWG65K6UM;:J:\-JM)!1MJ3= M!E8J!EC#`-OKJUO=&;M_`NSWUM@RI@NN0NZ(U)2+-MMBYP) M6U'ZB;U_#:UC'D5UXN')*Q5..,%[748\/FZ1=3!)RWI'Z^SBZKI*=AT,R4U3 M,^JE)'D9S3`EUM@L#)S$CE&\!7/NQ?-*O.V`U[N:U2UE5\:*XL\WQNOM_1>O M'J>)AI%][MN"C8.0#+4X"?W*4-N)H:9UW]+QMXKB'YJ:T2QE5*',9IK#8XYY M3YB#XV+.?)1@MI.-1>60[DC.68U*SKTEBG\WC)+Z:14]'YN#A3UGVV?-^E'T:BF#?;:<-;`G/+P1(VY_KT3;+IB]J1GE[*A64?RY.="F9C9+ MJ='*8Z,Y87+#''$KO&"F/$X[B.)*I.W$Y]2L?!46'X'%I_DE MY9>+^SYHU>YJG4:E`=\`I4VCJ=6;QQ&,+;_J.[*VMZ'^5CIU;>I0]?2^ M44L=J+##57^YPU4O#+DO2SWZ\_P5&`0?]>YXZ`S_D[CQ_-R/XC#!AQ$YM5<3 M[E_,R).EZWNB<_]2A&[@/+];E2-L=\J]Z-=WYY_/5II7=1N]AM7O#W33JO=U MJU,?Z/#I3+=.K6Z]TS4-JW]VW07@UR;`2GQ7SD!V4'OW6[/>Z!A&`;$[0L<: M(JRT&:.G42^))T$(DM3YTW=$2/W%),A+C_O1\(<(;3<2E]AV[@O.\B*)HYC[ MV"5(#?U-H"H13N]6A/Q&?!%3[OKP]0!($G([3KAW)<)I_?4ZB@U.>V9_:.K- M?O]4MWK-CMXU&SV]VQB>]0?-,W-XVKEN75OO?KML_VL)^?M'PWTMVHBB@R0, MD>91).)M-63K6>WF::=^J@\:9Z9N]:VVWNO5S_2S0<S>SE^OWX;KOW2= M]<6-ZS/B'_:'X`[3]0T.4#I"X^F-NCK[:]2U]:&K/DVOTB;HG@W]PC9=HY#] M\@)Q4O6(JHCO'69_*I3?0]]9E=[KA'L_<.;+POT@4E0;U?@YW85!=BR#I0@R M;F$:D;"3D'R*S:K[P&,V&]>^]8C-QM$;6G,7_6(VSN$8PG('3.*Z9K5W4-/_ MVB0^@-JAC4LZ%;,@(?18HNV3?\WN#LXGO&T!=2"4;NSB"OMMRZG#M[9. MQ2AF;A0E6,5](@L=*RFV=4/+:NP@+5;)L0.@]4Z:BKXU>^NC.Q;@'$9)2(=/ M;!Y-T$.D^+@C0IQA4NXCPF5@[:;6:.V@;K<28P=`Z[K6Z920UD=8QW%4Q7<5 M%K=1POA4MZ/L,G*_,36SKC7+&%2K:/SXT5N:M8O.LY7Z>VOE=Q4>'S/H"XH4 M'ZJ<6JRX&@33J2N3CSW?P>HLU[\1ONV*Z-2-;"\`'W,;55?M3MTTN@V]VQX8 MNE4_'>H]L]?4A^;9:;/;;K?Z/?.^JJM7+B5ZX2V[UE-OV=TL\CR5AC>/L M$[/P3[]X]W'3&5Q\^G1^]6GX^>HKZWT^A8$'`.3\\^_#SX/SX=='3_4!OL:$ M_H]1Z&FCE4S^4VKM7FO5/_/W[`P8R'/CN6JDBZ6G=$:>?10\4JGY>U;^Z/JZ M[9<*?A/,P_GB[R$6F@&XS%>INSZ[`^**46!KP&X6^YP MEE"0B<,O_<#7;8Q!>;0+@YG`#IS^C0(O?LS<$#_V8`BO4,%B:`S$@55CWS#H MSKTHR"?$\&IG'MH3NJ2UT(>`/B]W^E3T`"@PU?/PUO6%Q@;`\^,@]-ULK@_, M%'Z>S?43GR_4VN!,NQJ"1VE!+9/C@$4"2UD]>8GLR4H'4H4^`A[5V)##0_&;5N_@E?A2?M_`D0:R;PNF7AS=?U6.IA[Q()7>^(M*]]$)>^_A)[N^EI^K8 MR$8]?:PEC1OUGK%#;;Q:F57#FV2E6:P?M%=Y:BA48=DW`ZU@8]D"R:MU= MM-NMBIR`E]?$YRM>?ETIW"UA25,)I/":5AD5Y[ZR_5#"4P^EE,)K[NNL>/EU M>;FU@SM1JS3EVZXOV2Q9RKZ3]^O,6IIE'($A=01;N%09\J=NXL6H6R&L)E]= M2D0^/G/1><5TX^@]^^C:PH]DT+B7)HXBC0T"_;20&"M^A2F:3ZXGHCB@9-!C M0IZ'E9KDE*!1B3_,R'%O&D0Q_.-A'Q-,$5*+45,[2P>,)CO*C^UG4$2R)VY\831O**3EFK#!R+11BZ<1"Z(M(0P#2`X2G% M!Q!@*H!?&$%-36,1,*H<3<,;NI(QMK+!#!+0(!*>!R"PZPK.-L)<)Z67;H2/ MF4-OSD(\W!T*!V$F$;5KF6(O'?4ECP(?&1&3D^-Q$.(RLL%SP)+DRY"C60", M@\R-:4).])2R!'#O*0[=NG2H0+L1<:HL?,\KZOAB+B`A;G# M%%D8S+F'9^]Q/,P%8ZXVF-+1"V"5=0NB9DJ8GT5^]44L,7K@*=(K0-,L0,8` M)CSY&Z6HJ0(H?A32B]VT9>:=LOO9MO52<5;-7U_[Y'6;YHJ9F^Q#]<4ISN>X#X M?\._>A_//Q=Y;JF<1(F%/VM?)37=;'V'KR9!:J5)9(!3-XR.%%ZVTBA*M<%& MRI4*_+R(@PQ#),U23&#U`_XM^1PYA@/O%]CEP4]C:,0Y#%H5]6?3$T)I0;5*K)Q&$P9 MP,$??#F_8A<^1GENYNSCQ\'B8/#MPF!*2J=84CA"&``ZF0*.4J5?V`RTNE3& M@,8/<1?,>$BB/Q1>JA-RU,6`"D$-[%#.S`#DO(:H6=AD)#?PQ^FZ"\:"AJI? MZG#4$(B)'#J^##_.6/3EI2CK!-`C2E$>S>[&MM@=ZYY"1QW3)CH1`XEP&B'. MP%"8%#`N*>U&"S;65`B2B)EAH)3U@MIR?=M+')(7A;V3ZSAB"/DS`#D`S?.# MXS^S("0(.)F?FC4C+9'*#8&OH*/>`IQSWQI72X'=0M,"S]B3;L63B MK7MU=6FOH/1VK0E(%5#=,\H>>X+%7IFW!"B.[Q#+*&`0#WTW`$M$*U"JK,H! M##=?D,0N[I9_!R"P&-XI3%Y*WEI5B?6K<](B5*]#=C.P`??)$0++*.5YA`2\ M<>/ZW)-R&OTOB5M^'VX!2(K=:>"XXSGN,%F-M\9Z7J,I<*,#$*4HLG%H=]#T M!!CFH/IS(9;,`KG#P&MP0>?)K3Y6,C67`F>GO=PDS.:2;DDLBE0`'%DY:71) MN@",G^$[Y:$$(>V9J_/WL`@W9258>>9=(+*F6+JI)$3SI%!FB9R:SQQEUQ3< MCI%8E%_H12U"_,DT:D8.:!65[#XL+,(!'""9UV`!]P7,;GEZRZ(5IS87//2P M%%>*HWGN##D"Z>?Z:&0".HL"1TFJ&'E%"A^4L"!UL6;UAO2AA)L[4>32XI)F M(6AWDM7XBI;6R\IX2<;U,^!1!2F&;4/JN<"H*',!&2YPT!B,_5CRFN)9%^4Q M2%38)R&Z^_^&344L2W[QJC&V[IZ8$'/[X!#N6!-U)&2\@I2CNY[T'&Y]H`9"Q'6T(=C2EX M`(48K'*04VN"W06AY]3R(:*%"4BM*JV':0!R!92#SRR#T4&.D`2>HE@V,Z7A M2%H('J=*NZ]C;3\=9ODC<&Z^`T1O/IU-`MQ;N<3-`9.,&B;HF0*+8=TTZ\&" M@/74UG4YA4!MC!8[0FF75+]*#@,(-]A!'U8@Q>F2`0:_5^0,N*'+69Q1B!T#7R`%S&T35Q$2JK$'2TS6%>L M5150300B%6CD>O3]HF*G,U"+%M2"UB2[5(4W0*7@(9S$+T#S>!3K<:`35)$& M^FU@03K?E)D(:`^L042Z0T+AB5M.OT1NFJ-M8#9S(J')I0(T$J.8BD&@8S>, MXN+.24?QS^53JE"1+F$^Q@\)U:*!)2CU(A)DP1 MPU/V*.R8QZ*&LZ]W+NQ'.X]79"Z%\%O2LW+4R!`F?KO!:=S]> M]4K7I)0>GC`)Q6"$L4>EY$&X>$GDWA;D4IH3+)BW,E6W$(=4_""MTQ-Y'C,# MEH&24CL-=RI?@7[SW0_N='!:"C`!2@JUF.I$!Z\8JD0UE+ZG!`8XTYXCC90@ M#=/"5Y]!:TY2K;.:;YOP6Y$KFTQ^()`9$#+&>V/F.!5?W`2QBS(&M.?J(LD, M6HJJ(EV6)YN)^Z+.3:>^.G&YA^74>UX4:`4=F`4?"ZQ05(RY[MO$#GB@TLP< M^%3U+GGK2_ZY]-]='YT_KI*\I&W4*FN;1W3I@A#,T@I0*Y0E!O2A,XT8Y3BC M>C:CA4#"XK205XK!$SFM`,_%+DUHY?QLIL1/_I;RSVH4LJ#?[]'GY,RC'BQH MVU49XBY$("0\R0;Z:*ZK/Q6S*"V$7Z2*C\[3*@5;R`2#;LUC`^#X.Z334^98 MF86,.ZQ.3JII,C]D\`.SKZ'`,^;C6`$CU4HQA;NE06'.Q?0T[=]-M*"R>U7"&V(14.IR-ARJOE$TX/(JTB57L-].`59$M,"I#V(A0I^6OE0 M/HU_^UZZPNCDW>,,*T6B4>B]Y.H<3^B30L=8VTK0^(&HP`(B,)):3.6I+Y=R MA[V(XECI+E_KL6"L*QT1WLLR?*3)9884YY'5=:PM1`$@:@;W!D]3P`7M+&ZE M5I6Y&NEBXZS25Z7[X:$^E5^D"@GQ@7-D-KSA.SRD8"8JRGO"2ZOA['M"V-)% MH%@%'?`G!&"S8[*[`!6`BQMEM!NU]HK_Q?Z?O3=M:AS)&H6_=P3_09>W*RY$ M2)0DRUO55$=XHYL9JF"`ZHZY7PC93H.F9,FM!8KY]6^>DRDIY05L\"*9G#OW MF4+6DGG.R;,O;%0;%^G4*@&='B[#!#",+?.]92I2WC>(-][[+O2/X+T>!O;$ MB3`6/51^K9U44C%#<>0/'%1"^$XIS\VV@DY:U!NI5';^AT*/DIKM,?&%&)8Q MTE2Q6NB;G$,\S%YC]"G2#JCLS.^;HQS]I/8,ITD<,^^ MCTHZC\.@#4OH_I@!,<)0U/0.X!>,Q4`X-HN1H`04R3!W%#"@LH@H69Y$*$2L M0A9^6DR3Z\@4VK8O;GO8O$D7,FP!C%YTHCJC&?7UU1O^DUUE< M!-.E``?75-.^IU?!`&:-782'3B_.+V[^\ZV$(O!@7A\'*A!-E1H*KA_F)2)R M:;;7!+2Y$,3SP$6!T8'DAR"%(@(V`1N-H^/4YCC%K0 M`_Q(CZ)+];I'T)D*SW5<3/SC/H^Q390_#)2_MGJG-J;6> M&L>9F9=YXC*W-UB\8"*.?'I8@;6(IBUW>U&I2!58[CD3+6>^&A[FHP_%T*DG MV\OW^6;>U"ZR/20L*LC';$<``7`KBIEGF-QHC\/,OXD:>>ACLF^:O,NR;'G^ M;BZ1BRD]$$-ZP,1'8=UG8GR,VZ!/4[FU,YT%F$]=:IAVI M'!80&A!2H7$'5!F*T49R,%2!7L+TEL0+R6T$%7)]$1+W)'4&\H^(+PY9)%38 MZU7.&&M\8`8H+!ETTI1BV+OB">#C5Z,J,/C/2E-X:/H1EFZ0?R(-\?Q:T7,O M@@T8QO-+<-!Q`5YC>&_N!644$\_)B<[3D/R<#G9QNX<^U;$GD4/I72.8XCY4 ME>3.?1K0'T;T=B06?EEDPMU$:V4*/CC)Q'K#%&.9'(Z\"KR4F>8!ZAEO"\YZ$L0ZPWQQ+ MEX$T"->_@V3+D,H2;%S%PN,3%[RL\#K*QYTL-W-,I98S038Y?J(`&=NLZH"[ M=Z%.8![_!/[N>W<^!L=X2C?73@03;@Z+/E&^SPMY99X]#M;,<\VC6K]6!)Y! M_SLW8EQ)2B:09V9"`SAV\N+I["'D'9R7U6K91^!4S7'1S3-51>V5?B+EZ:C> M4NB!'L[+2C))D42%(&4,WFM4/\`:3/H_8KH&XYG+!-=*R?&0Y?52K:0[=2H[ M,Z>R`UW:^DEN:,HD#WA^$M6]2'`'\?_69>O_G?W[^\6W7NEX'377+@:1/Y6+ MSG-GDX'B\)\VU8L"H;NFV10D8MZ!F)KW4YFGF4-:S4,KC*FFSR`UA#Z< M3C^>0T#,W&'XA\_`VZ="]$PH\$H*(0TBS7G%I(Z4P]&WI&_,970G61>8&<=* M"(7,`D0W/1CWR$]1QX?:)P``BX%H&`/)L@>S(L6$IS(/#US"%JOI8>"8&>D&!(-CUHQDB333B<+S#A[+W"$;GSX# M:CN9ERC/SG7B)P;^D4A"E=DSR"=&D";B@9HK2.14-F98!/),\8BI$6F6LB@Y ME5;*8=RGV4TR2,`V\\$A"-,@'K.\W)B(?MS,0D2,HE7N8J;VW$*77&4"J]E[ M8!8D)-..6=E9HM/F./?`M9WQE'G(P)>+X>8(TP_FT"88_3D;`]7+&;B*4.T_ M4?(JG_+A_`358X$ZP83C-V<"=/@O^\G^$=-;3Y3SFRZ:6^56+K[Y#T*E6W.> MM'A6:7@E_DDF3_#D&2G)@ED+!LB==+1 M-_S+I])&.8+7+UR-K4?;'R^[]+/03()\T7RW2E'28T\QFBF]LAV>"PF*/[3GMB,-7;NJ4@]F4$1 M.L5``0`+5%AJOAXWM4JF'T_!E>L,8.O``LP9DKIDT;: MW*&(YJT_31]I.L&+]/'L!@JNUTTE1/%,#*YVBXFU4P!FRG>2%LU4<-3`P7Y. M_6YB)&:!NKU8V8:W/!N\?4;9GGNP!65;6>`=MN=X@R%+(G)3U2-9Q52@"1JK M&Z9@SZ-.D<6\GC'GYY-9MEJ5^Y33-NT\D2F/$"R#R07'XS"7I?-R,LY,58I@ M_/,442BQ$929)S'W1TC?+3C57Z2]#.:D_DW1.=.)0N[+RKI=Q*&H-4YA6>13 M`B)YE6O($R#0@Y@6!DRS1JBHR8B$XF3LA"&KS4E2!4)0ANX)13$((J&1@CI% M5(IKQ][@GJ%XJOG*B?([):MD(]2@H8H>M6D`ZY2Q\D)[L9L+5@HEBEF:M0#P M@3>+"AP>^L2CQ1+;9U:$V=;TF#W:0*00JXIL;%]!U5=^6*@:3U5Q9L%X3PR( M@@_LT8_=(67U8H"956^QO"1TR.)<#,:]\?DYZ5U_\3$2O$2,2E__SL.B^S") MB"05CRDAI"*:1T@P]B&LS??`T3I*%U8^O?5G%B1(L/^L$GOC3WQ,$8B`;[5[ MY[V+;NO?951;3TD_`'\'RZ'0YZFM^>84SRFQH!.DD%%:'Z^G4J;2WZ::(&35 ML7"21#<=N%T6Z+7SM98$%TG.9;;`E,DE*8II@N&4YIE(;37S.DRS&C@PR9=F MTH?QWC/*>6PU\:""8V.2YH`Q=;+8TN,[;XS#:T%0?00E0IV.$XL:("B8]S_BS8++P#(@^IWV=. M7G2&$^4HU>B9;*-LD^*4Y>*AZPD1=7R2)V;0/%@&SXOKRCNK9E:&K8:0S_\W M#IQPZ&#R4YB+LN2U>WT(/#E#]Y2=="`DQ<(I3+DK#SDR3005D#AD"CX`F2XT MYGJ_4W2%?`4SE(=N17CEK4^>FY%KJ\`F9NE3U2O7D@MY26KB;EI]/UJP?8TL/QLUZ,=I@5EN:!)#@' MD-%FT5%4,]&$I6'`>L,(X7E2'RTS'I&M4HD5C=R-@#HA\Z+(B%KSD:L'Q M\T9#5X;V$_9E@I%^K#X@)97T+5A.E;W*H>QZ")G#5#ZPM`Q8_KW3YTD^2<^U M."0+W"88\$B$`*1DI(F4W=:4!O7"]SE\L4(AJ?I-[73E"+;IQY$RSX:`W&RH MM*!/'K/(22H@6:XE;L/FY<6BY"RAI>JP"(OVZPYP!N(=AR%B[>FC=N01>FAR2! M+IJS8XA88ETK9._G(BHP-U'[O7-]*KX%"H?1H<5"X>CT$8,@H&2B+FE/X"!1 MRB:0,15'$`.%`:.)`*`/3RT1S@Z$2@.'1"`IX?N=BS][5_])[C%,DR*-#.X] M+#J=SN)]KBE#VI*!NQ)3?W0>$0NC$/,0D2E'#"\V=\8S`\1)>N,QSBI"=N'$ M5AXH$0%^D-9[`F]&3(,VT*%[A=[]R+BOH1RL] M@5RN<5[JQ!/U+.YF%#SW>25Q.KT/Y1VJ'H+5`=M+8S]9)S%JFC_EP`@.54P2 M3EZ$JCXEA#'0P6Q^(MO/6,3_*"5K`#RH3&/&S'.>DB'CR:I@'>*G9K+E>?01 M:`BC<2HWTV%'+!C'PPV"(D61SSM`SU;)"2;4B$70#I[)7DK=S9FZ&Z&@69]= ML<[&ZX-CY9I0_6*0*U(H2P?UA=W_%IY2L:EZXGM/:_,/?LFS>M`!`WN0).1Z M,:7&M%LJ[S06,N@E?L$`0U!)["*PAXZO<9,=75IIOI9/[YR*8RAL>BB^(?TE MW8D/&263(0+N#/\CH+U/\29C\&ZD0S;EIN0>UL+]ARP;!YE@R0?B*3!\K$!-3HA%J7Q M`C98H>E,>W.Q^6D"ZP1960"#!P,I@E*E/<&6G[:$@Q\&-DP4QB0?GO63I5VQ M`"U_#C-S9NS@01!S3\PP:8:&W(4E@"'OKTSWE>4!<`AD M81R5'0H&?@:#7#0:G#N07I7@!RAMC!,,P,_G!S\2*,.K.+#HQP/?=9&K,O,W M"_NE]W#WL.#Z8F22]N0'6P@0X(=I"P:Z0.*":(5V_Z[_J`U!:8(PG!.FEAX$ MS/AN4X%'J00,EDRXKZ[S`L.$'')M`H]EZ\OH=HVP&6C(.[=X@) M:/DO#C]"W4^ZHHAUV/J!KZ;OY9]7N18@U&AFOD$J?T.2+30)\2FN,W8RUQ_& MZR*A%!8_DY9FG&"[W""79&?S9AFII760U(1FC)%GU:%-FVXL\7$P3LRD)U_? M47C,];3H'O*1'WP'73&8&I<X*9#(F-Z_-+K%,B#ZE$QOS>,@KDQ-7+Q2@JP((K+DE<%M@WQ3D^ MP2NN,PP&B3!E*CEWX')I@NDPR5S[Y!GNV*4G<0B,)TOU$GW-7`%(9'_2P!Q4 M32?BF:(^TAO/@V6>N#2ZD?FF19>RFGKGDJ.!)(]4S%Z'YP]?2.]R*,7:]/_P M?GU47XQ)(8F1'"L]RB'\Q+.U+P1)TDW-M,07RO=][$4[HE@,!'%S\$O.(/Q! MGOCKB#B5H_LY5^F;V!KPEC[EM",G8=40=H!Z9+0X>%U]WH?>L'1BUY=,1):GS@=[;?^(B)MD*?N/.]X?KZU&S?O(< M'2M=WNL3W5ECL%<9H"[I@2T)C6+!R)P2YXME#'1^[NM+W&,U&34SNF%F&/01)$#+#C3N. MQ4TRTJ#L/2(I_Y\%Y[.[8QE3T'D20LO`V^&FU%F$XZ18&3_S?#CNDU`E`.[^ MA$@'(O133L"*8D("90?*'34R)\E"4]8"(`#3$N_)-IHL.`$"6G&S*=;=#OAL M8;K'P*&'/@JG,)LE>?(7,@<97S^[/O6&S-J>ZE['>[=CF3FN-BEU03`<_,)+ M.FW!KDNZQ0=3^99,5J:=VP9V>#\%0Y7;%I1S.N']"W!)*FT2WQ%;?&(DX+I! MBPW0Y@#_%7),7EX%M2@@`^8Y_X@YN?,7D@_"HU9J.K[ M:^6DF4^0-4^LK&6^F-**G?[0RN$.2BQ`%B>5/>]Q/(#VM"ZJZ-?WI*A^J3N6 M2A=Q+;XDG#PU0!]\]P%!S'D""6RL#*5Q#J:J8'-^>FN?F=:8;W,@CAD$WSX. MPTD3<+)^_E MCP-C^SNFW!UC2JP:_[]QR/T'`1FA9,(D!LI5!GRL!K@_H\A-`N=)VU+FH?QO M/'304&)O2]DP9DC&+ALQ:0^9/V[$J/>`-5"D0DZD"L=#;UQ:H5)2SRLCU M'YF!GGF"TR2:XA],QOLFX`#&%AXL%#7DU-+J]^$((!C@'5UPE;>$!DH'4XT: M6]^ZK7"J4LYQF;[!)"V<]9"0'_P++&F?<31GP.*WS(LN=C(6G2,0@6-]X2@- M..DDUQB:/--U(K%B[Q`4*H#-J:8KALGU$-@U!J[HR2;8PS1)K$0UUO.A7@!X M"U/FT)^(5B*;$$O//;5'`^:#P3)DI$:/4TK:>#=UG5!MV,%P`&7X=XR,F<8N MS-9C$FW)%>-0";F MSK+51M")$MXTMH?@5`KI&IA_$'5#>H%"20FS.*W=]^,H@T-6`HW6@#?BX4(, MK^.;^":X1H_[2C;BVH\,UT`YK)!]E#:9YGV%Q[['HNI#>\RB)VF(%LB*)#4L MZ+]F#G%J>;%FR<@Q_DO1S=@N>W\RL0?5"I:S2<;UR5@?C'8SE`<52"42/ M3Q@IU_0U_O^R`7MGE+TPS1&NY=^"7-"E<@4.!;4E[;O`GMPK9W_B<4QKZ,,% MO>N=@"T!BP0(%?8@D)$QJ],IQ7;">!60@EQ:)XR+ON4OPO?",O3X(10'IG0Q M4DLE9P<.21J<2"[S[C_?R(,]9+D%74+?`[J5(`2(!VG13&(+G<.3O>#:,?D8 M2ZCH4I\2+I%F)+"SGNJ#?(9$HB#`7BZ\.39IVFX$VAP1Y>L36*-8GPER2BB_ MH0OEX6(!;1:0[^J=_[RF7),#,MX>3E[R)D'OD M"A.ME*-3/$[3\MWBX]0J0+C?/2=->0JG#IB:_9T>J\]*QT;U^EO,VN-^@C=I M@P=-UZU*13OO_JYU_OHC:>*62GI1QT6QCV$_UCG.=H#4A-I)2!H%NQ=M7,&: M1GTBU043;B>H"\]#"/;=S35PM/]+0@$T'0@0!S[=\I.M*NV`&E+*.;TV\*.( MR?-_^I3)8=L$0EDA-!<`@SK@0_U0W1GFU!HP;5KQ'57?IAOQF;Q;_GSMB[?K M3[@@UZ1LY<'QW21U`EW44PY<[*:7F*3TUYA5U$+3,!9S:#%L&LV*E4#PX!=> M=)7"D3$Y%IF@^Z"6K.!(8%KD2PLQ5UB(*JP$[=G4P!(6Q2#"J4'0P`7]F^FS M/(:2SX1<52UWHIQ:CNH92%A!/1?#.$NHY1M1RA._^LQ^!4T=E4E!5W^%ILZ< M/QE1KZBIHY&4U]5?H:EGJ!7T]96T=8#$C+Z^BK:.CITY^OIZM?4M&..IC*%W MT1T_*:?.#R9D&$]4\JQPD6B9;BN9.-TQ4^QUHH4+%A!1@FBIF9;VS\Y7$"W' M]+[[@#Y-U1^*J7]2S<>.J'(7YE8/+&EZ_0M6;9KJ?'$(XN)MJVZP5?_9.3UF M+7JO(S*B2M_7F'B#^WL;9H\NN^JOMF@P\&:NSWV]:9E:Z_)W[;)U?IPX!H!+ M/20B.6-'T"P;^PJCY^LIR=?D1D+&;46'"-;J]668Q5#1ADZ"_#,L*TUH3)A6']KE\>80(RHU!@X[ZFEM M5%(5.]TN)YF9P<4V9QJ#?&`F/2FHB`E'@(]0G5X>LJ$T&N8++@+TD;#I8$2Y M`\O"PY!/0-`-A689=DE/?*I#)[SS@SNAGB_CMR*W3W=`N0^$+E7!2$D8W(G" M6P*+9F4U,T@21I8DV]H"'%#(!^@#BS`MC(MIFX<1D[31&3\L_?(0I_N$F?S/ M*W]E89-_V,$0.>2_[!\VU)J_D5.:%5$)!U#UP$"[5_Z9>.BG;-U$D8KXP!3& M?#"FDYPBI>/:P0^XWXN>LVJ:&W.BO[I$SBM;1+2\_3"?N;R MH"3$"B">\S&S5FMHG6/E"`S;Q-N@3`?!<4,8P4T94XN1U6R>0SAE1S!@9$^" M]0?7<7_B$\\NB56]>'`RZ_^:ML*Q`7NXL]2H@!TGS4K]06WJ<6.9C`M5_<3Z8/U,DUQGT0`Y^$7,)'LN M1)!9(G^1K(Z6S<;Q69B)"(./8+^Y'8"(2$J*>""-1^CXU#CN/TJS\4'U9^T, M,JGP##VS_^(E:OK!Q7]\C$/MSK8GGSI9'FC+&W9P\50)@.(-RB2A(7(H&+KV+YU*VMOKF^YMI5:]!?P89L6XU0\59_CET!G>6J95 M:5C&K6FUVAWPA#0[]:YF=5I4"=,;'*\Q.7I+!G[()>NIQ ML*?-Y[MA:@@K7P0^#U,$1M@5)Y<&9'--"B0AW,)=8'T2/;(T>IY^/!&3NKBE M.5FOE) MJ9V'=Q[DJL-C;_;N1(5F]0L3/\2F-B<*4@@"$S8CT`@3R5D3/_2!:]#]6+FG M_P=XX!./KL)\!JHL_H^/!$B_&?.&UR+J>*(V5P_@=6F=*/>DI-&-3R71-<^A M($R0!Y\$;?+?L2^DL1_%7I(2AK4&O*>J+`G341L\!7%Z6QRK9;$`II9OBEBYR(Z' MR#1R%,]V>_`+UC'\S="8#%$B"<)4I1]#,X,@\#$2Q'(9.$^`\D+LO("DSL]$ M0NM_YP@#\)YHG2G6#WX1\?XY>23A..Q)2D4)\:1[@!6S=7YF7"Y)`6*<(+E- M8!)^P#.AIO<"SV>W"1MC2\ZIS6A`QFQJQSCSC,ZEXI)2446DHN]SV*R-Y36$ M#Z>B>XUE%\$'.]8--$8Y<^.5#"L1`-=`P>NZ,5DIR1@5[L@-I4LR# M!#[@NJ]N`<`S\=%AQQDY*8'+8N*\W:D!(L:F?CT/9(>5\A* M9Z?CX!=>E.M".163V/!!A+9B)D#.V<5?\26`33`G4_=);B/8H('U/)K@F#+W M20.G.;3@^E+^-ALC1(E#QWD#5V%RJM<3":DULC6!59,"G%O8)V>MJR M(V2?A/Q/JJ2E^>>"[$ASBD?8CYGG)!/(&6?2F)XN._$P>VGF,5/1L^3C,C3A MRV6&9@/MM*3:.3W$D5B*/.<\'_RRG&Q(SG-`>$8K+WD^^"6=E?;(FG/U\T,Y M>=\%NB`65TS2J7C&,C@A>5X_L(0^KS.DZ+V>-SS/%H;G\:(E()JWV*^7MB MWE5N6F!"P2(_$056F`HK^I:*:+D*=0]]X5GPR,)POLG,!%:F`W$W%99J.#^( MZ]Q#>:4_FNY_,:]GXL$*`[!FO5I+>Z;R#BU>BW?%NGO#KC;ER&ITVV;#;%M: MMVY4-*M:,[56I=,#EU:O:IJ=TT[37-V1%>634;,+"\[XRWZO2&0=TU-KCM/B M10%B"]U5R[&S5V^!.[2B9YD?6[A]#!-),6IY#;26+?D3>'W0\R36S`-%P]1D M[*N9QE#%SC8GR@6?K"S8/ M(#J0Q&$?`ZJ/0U$'LJ@AM!ZQ[O[P;_[WHS.,[K\<&KK^X5#IHR\3 MKHL+"\0_ALD3G,JG=A0-\S=31D_5S"^'D3\Y%)Y4^&67C!ALCHSCEY^??DC4 MJ`@4T?*>*+;2=S""C88:CACE[>.<,*FI%8ECSM(_YG;]$9$C:6%+M&"^@A98 M4IDSG78ZY"%`(ZRD6BL-FF*BNU"T"5HC ME0L2[\7"N_4*O(MXSB?)9G8@[U//QDXYK)FG:#"F+12+/*JO((^T MZ)H:2A@I% M0[77T1"O]YD#D"K1_O_F6+\].7:]3DQC@10%A.7E3SOA+T?A38V<,7\"??WI]H+,20!OAN@C?8$S^HCA-^YQ3=W'26Q44!M$G5&< MXL:B%+"'DZUY&EY$+46/L!N&UPS3?+J(/2;3[FQD:\R1ALR-6^3!D/?&$/(O M!.-Y;/\7_=80.;O#KK:OMYG7"HK4ZY*0VA4[I#`SVG\$'I]SOP#DDN*51*U( MVKI$3Q/(M*"$,`$RB-)>'?#"S'7"XT:A\Q-"AM$]?7P4@1**83IAIL60=4>= M.T`%2F"P12>O2D6/#>$SJWB;=;'?%Y)[RH@F/B3NL)Z)N%M5;!0;POARF(K( M&L:*D\#NH?(B8'V0LR@.O$)-P7'`VHDF7J'9C$05LPL]]*?>$S9;(M^&F6V( M>YTPD9?%N2'BFMV8=/-&#Y2"'B@<#\-K!%BW85@;2XY'['+M#M,2AP4YC2D) M_HYE`>A]Z-Q#C_*^/?@Q0WZ99RX@8,0J$0KFWD><_<.<&\\K#D: M0>.7`1&RX%@0(>19*8FG,O=6!2##Q@^P08*L@BS":9QC&PM`E(5Q_O^L';\2?]>`:B##'.L1!]C?E@NGA2Z M1=#7C`^(P1Y"T%8NUXT9;V/DS;O)]'.X7O"]V=Y$?*JG<).:5&]@C^STQKEO M3`HN4X@FS6Q`V''419D]G>ZA:`>KR\DG=Y;2B\I15E5$*9V201K[3^B.-4D. M,A:*S8.P3S?37)"_H:!$3LLBKTP!$'JU'_R2=6I6DVY[7&3,T#J4ZL?8/"'E MB#;KAX.I9GR%[/4"/>.0(:&!;7&P<$5I*LJ+4WYI"K2Y1-RYQOO!+VEG^(1' MN9C>()2O!OAN@8DA>D3?/J2G94V($LS$*!;Q64Q0?23I8%UA.4RUYX'"52#] M4D,6\XT-6=Z&27T91'Z%W'_(=9Z#T>H[$,A*&2OC*121#"H5AX MRHX@B^.P+_+3R-MA\K@Z3YJ.V,C2K,Z.*T"P,GK6!GSV0B@HLBPB'*8TD[;/ M3YI<"Z9+J@P)EAV>[Y0RQE2SR[J."EG/0CR?A>9YLA@6[$W/EU!9@T[>K&Q& M)+!&S7),,D[W_X;#^_$^<*\/HMWC7F:IWL*#;&XX@==Y_&[@(HLC0EQ MP4I,H3ZAF3Z(%>54"N`[2RC%SRC%;#&;=D1X"L5T)02.D=(UJ@< MFU&BFN(C0+#4($^7;`Q<3F`ERGK.E&#L+3'/H#C_>('8C\2>E3Q;)1/RJ,\] M(^:55M:]0.4-"IFMS5[%]L%L0\R32E;+>+&P7`I3!PT2OFCAR:*)L6ZBRR:5 MNETP34X)F=8N\G>Q/&="$FLQ*19);#9,\\W'YU%!P%&&.?U9;"[!>D9=G%_< M_.<;ZR61[]>;LF*T=U@E6I:.EO+/-+\UF=DBMH>$E*#,8LM.M'KPRQ2=9[H0 M-.%+H^G>,X]9]F?25G28+++)*1X2-JF6?1" M8@(+13"?Z0O9KSRA[D!,784#D@H/_`Q8H]Z\!F]889KU)9L=W&=[?-)UOB\Q M=\9"M+1RUB-DKB#I^R';%(=E&/P M.8!)2:SP.$S(!K`]PG!ZBD!LZ2;X57Q/8S/@L_GRL]0\FU+X8FY@/I40&Z:U M@8.(G?E;`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`"=]5'> M2GD>>3)=*>VCD>1]/)>MT?(@C/#'$_]$/G9[MOV,/NC2_HS ME`?=&T*!-OU@ZHYD1.S4Y1O[I]*"1D@E%`1EIPB6F#F-$1'M%^#U\[UB`2BC5Z.Q,8(]SE\`U-T(OTP["EE["(.,IUQ6&KVT7O>G@A.H#YX;.OP<@'=H-"]X^Z[N M>W^[VJ>][.>NBKF7Y83@+CED6BJ%J2E#/^Y'HQB*%FQ1[2DX(WSMYG]=7>SS M/W$JWYN_;YJ-U5(L@R(ZPU62!E M)9'WRPB.*I6=H_FX8`R@[#@U]=K.;FK4MB*$D-%WXNT MYJ5V]\SWK?H[LO/>+YJ/C`)X;8JFQ4LSOH"0DQQ@4QS`J.X_`CE^Z!JD87*V(]M1^[FJ?]K*?NRKF7J0=+]6[9[Y?J33+J`E(-*\8E7]/ M:"[01M^Z%&G/2TZP9GN^OG,L2VM>^N)G--.E9TF8"YML+"[%T4^JDRBI1U]7 MLY2/C3=VY."%\09K?2/[<[RZ/\=2#3E$4^>YT2IO.@5N4LSRNN+:N6-;WK*@ MK/!7&`#,VKSQGHN/,")2\T9F??3F)V:9J/6;!J:V:M7-J MS6;CM#VG&US:_H`X_&5[$$0R(3!O$OQ&(TJ`G??(QGM3E.O M5&N:T>TU-:O;;&O-;M?0VJ<-W6AUNQVS7BU?+[[:TK+<^K"TFO(&*88(57S$ M*)-F-?'K?V@*LJ^7%`B?GNCL*,*TBV^#!+[R!SI9:83$UYC5VX(Y)8M\( M(=$VM2DL<^USBR21]-%>],D<#M;]<6S>_1&ILH1$^:[)4[AZ1<8VSO.9NM[Q MTT$:4[_0.VK_3V'NC*+4\4)G,'4=G0D[Q6`9 M4_$$A\(,56%,]+G$/'T6(/N3A?*6$/!:0UD-M=*LJWK36GT=NP]HR6CE4M'* M$V/W(>@2)1H4,=6QZ+M:8])C93.RZ/?`AM&34JAL@>-4U)IIJD9UC@C?5[;S M;G%=/VF:[P?-1>?#^[FKC=H^&Y(WB>-)2IQM<*$C0S7,FFI6=Z_I[ENR96%P M;)WHN\>NE#0E956[ML(;E#GMOJX;TB1?ZW$LGHP]]8,1<:15MR496[7JJE7? M?5V3E+`;D["-4A8V2`E;GEV5TY:;.(&4,ENRY*I-M=G8O:8OI/]W-6,E!%)Y/KL__4^04+*`E'SFA4L`LT2STY+-)Y#@XGF5-^U1Q+3ZJSZ^\#HZM&HZI6S7=D M6&\;V;MV[59/K%).:=A/U6\_=U5&MXE,N=JBG%$;IJ$V"]`Z>&_%3'%P;9P4 M(,]!"IR]WE7QH[\RPVK+&59FHZY:E=TG]4K/_,;BOU69RUL8#EPV5K5K,]PP MU*J^>^[TEA2K,EAU,NEJJV*W8M2H:;=[LTX*W[TKF6!5\B2A@NRCE+`K8+)2&=?\[EI: MS7&N2O5V$RE7E693-6N[=YKL;2Q\U[[>FHR`%XB1[^>NBN\TD0E6V^,XIJI; MAEHI0(!I;X5*87#=D#VM"L2']W-790S]RHRKK;KI&V95;31VWYE7.NHWEF]E MO2-UHN@$6U*KMWL%S.;[TKF6]5\IRA@NRCE+`K M8.Y2&=>\YPVMYE312&UV_=E5AEHQFZII--Z/RK-M9._:LUL_F3=]`;W:$!*\W''FJ;:J-=4O0`-3:3UN+': MG'F]Q?<5N_),4X3+'(MW<*Y-2]4;N_<32.MQG_1-:3U*JT?"<5_@6/P(XW?O M(;468T_:BT77+2NJ5:VHQGMJD?C>],KF2>4=Q9+EF89\28GO_3_7AEJO2W-1 M*IC27"P-]"0<)1QW9BY^C,`.>\8P;%_7K0[E MRIX?C&V7VXLW5ZUOUZ<75U_AND?HK71?>.?9M]_YTYV+\XLK<9>?%6#RE+^; M=+`L,$WG/=N;BBPTM?FEI"8K'BG]DCZ/YQ(B\C/2`NCP/]!M$=G M&-WC[RDF%H,5X;*<[/NL<"32#9ZW+J\I;`:^Z]J3D*P`G;7M31D0UPTG]L#Q M[KXKBDM$Z9AT=+Z^W MX$+6^?4K,@E(2+PHI!^+[DF>,ARX)?(CVYVB&/QAZ(Q&)"#>@-!G^R1Z),13 M_#A0!JX?4J#3]?B#'\HD<`9$L2-XO1+1U2C^2.'.$'K=&\(/]`WL;G\2.;Z7 M_8Y/JW.6-8[=R)FX#B\L=/+GO_^$G_-B<*?`!]E[89?)JXW#A(F,,;#^S'H?,`?_[C8QQJ=[8]^70]N"?#V"47H^M[ M.R!M6$S''T^(%]JPVVOXZ@7;>&L0.0].]'0#;[VA!ZOMTA]_H^]6_C'G??#D MO>_2DQ/V_H[I<]_\B/QE!]!%,;P(KL#J#=/74';@P6&](J,OA\1W;R][]5JC MJ='_&!5#U_ZEZT;S]OJF>UNI56\!S(99,6[I476&7PZ=X:UE6I6&9=RV&JU* MKZ+K6K/3;FN6U;:T=J72TMKFJ5'I5?5:K=*\A0=_`XAP@+24,!Y3N".-/;(U M*C;?K^(@SD>47_F/X:<7U:6(:3>)"6O"A;Q"$[U*#>'ORSZ0G-NI8_L,KUV: M\37-C'4-Z)$GP30;A#7^'TU3VN3.\12D">4/8@\537N&2_+7U^L?EC;=DV=J MBQ]9U_6=?7H)5TCC);0OX2C9G)&5MVF2LY`K9XQX.>,,D"EQ4HKT0,Q,D5P" MK#[\XUO"E_%*H'SD*T#&%>*J^J]T!ZWGB2W`X"\"7).)+P$$K0<2V'=DZFK2 M/S!;]B4(QO5"*D^YP!!Z5)^=80?SN$7;'SY-EXV(M;9+4G9MW7EFHT3;7"&^^_QO.\M<7#C[^^;I>U$ZNZV0TN MXQA_^5!L[P@\TS4'V5#6_*9,U'Q44>M6_2WD/!T*V8506H*<:QL^KWL8YWE? M#2$*LH\BPFX]K'HO]1?C=1S?G>.@2BV@-8?[WZKO6%55YR,*MJWMK`2FUP#G ME=I1]42W=B].RJ0=B4W>]_FT'%7UMYR6URA3&S\D;X6)<5)O[OZT2.5+*E]E MA)U4OEZ8?;C/XJ32E,K7K/(E75.K*%_B1+=]/BMOT[R*?53>"IOZ2=78_9F1 M*IA4P)]K)L9OEZK:99U7I=:_6,CE8Y;5H-JU%K&D9[)I%]&O@O M):>O*NS,#_E<=J,A)+.[/$L5_H&U%4<_CY4@]MS8MOZD.PDOV:'K]F%-4,QP,!V![%K1V1(?U/LP<`/AK8W(,JC M$]W3Q^TXNO<#)[(C>/PN=OBO]\[@7@D(I;R`K@OJ/89."`4P<8"%'K;KTJ?I MQR:^!V4V<&TP9RDJ_*\;8UV,1Z*I!;+J&%9=$L(""9*Z,HP#>,!6)B1P_*$R M"OPQE-=X(10Z8&&+-U1\NBPH-R$/N`*X-'""03P&,WA`7WA'/!+@WO$%GN]I M_B.]I(1^'-`;3F;/[\R17/8L3=66S*U0:<'IO2-CNMSV4W;+I?T$EUJ/=C!D M9_W,"Z,@AHOA!6SRAD*(5[;P.;`4#6&28XT>\O9IO:U9[6:='O9F5VM9M8Y6K9ZVZQ7ZWV;'O&W25]\: M].'8<]CWG="W3*-^^_VZ>TO1>AMB+OSA;X9^4M,%%E@(R*V(S7#1HF8_?>9= M(DU/+2')K<"T]\W@S=2M1J_3K6F59HLRZ6ZUI37T9DNK]]KM;J>F]YKZ*<>; MM03>8(#J"FA;,X@6EG+-+PW#-;<8K_L?&7[WJ%P5ZL4N7'O-4LVK54ZU=:>J::1DM_?14M[JZM;JHW%S9^Y@,G7C\4N$[ M%,W;-D`2B4-;(J."I(Z+MXB1I6SM';0-B,8'58C0FRD`J[ M<$(&D1+Y^5+-.]2X%!LJ29^MI?PT:WHMIQS(G@7[6(F=+XU:KC`[J>$S5R\Y MK.RNY%!^>M\^O5RWSKDNJDUT+GQS_[0ERAU_OECN:.B+ZAU7%U)&^BQ:DF+H M+F]>%JN%9#$04=L8'D0/^"[QL-+YF^==7>#8>@[@5':>=6_^H`K:E)]D75"% M;A+SJGJ+TBAW+;2YL";ZS5!,$L#2':']@C]G==3[YW!D)<1[>^WE(^T]L[Y,OBD))?EN2J'GD+B]6BZ(MOG<\2C92*&.E#(,A?]5/FF;B MI03G[933,G/NGAAS!A+*<1YS\X'>LA`#&_+4F];JZY`#`$J+=>OD'8W[W!V^ M=SWPP3PQ:A+/[^A<2VXN3W?A\5S\F72_5DZJU6745.ND*=74[3"VIFFI35TR MMO>$]:J<2_:N\&V=F.]HK*1$.&7KC5I5ZJOO#.ME/>:E]+A63_2E5-G:27/. M;$BIRJ[?;*,\SU1K3:G:O">L5Z7']5WANW9BEM(Y(Q'^:K9>I:JL:>Y^P++$ M^C:/N5%*.5X"'VS]1->745P;)_-4*:FX;H##5$&ZIAU56CTI!8?T=8;Y34/BVE#[8Y1Y4U:B>5.9)5ZJUK)_6* MJAM-M5:50:;WA/6FU%O?%;X-_:112HDF,?YZQ56OJGJ]E`XXB?778MTXT4N) M\3WLJ;M7TUT]D"LD6\+WK MZKWZB2'Q_*[.M=JHUU3=E'F@[^!TUTX,HXQXWD,G1:E&UQ38J)%PW/66)!PE M'"4<7X#C"\._^H$R<.TP_'+8FDQ+P\>=&A6UH MY$E^Q,IEX$]($#W!J51K-J5;M6M;+%:6(+1G`UTA%<"6AP`A5)X`+@")TP@J$AD3B-Y-,,:2V] M:!,NY(=W9*VZ%Y/N[,B-Y8&P<`+'TN,PZK6W3<-HZ*M/PZCM;CC#QC^]A&K< M>.7,V?D,?]TB(L^1$V+__W3\#U7KH]=/`.C#/^:.Z,&5]%]I$D@OOD:%\H;UKNU'5IJU=KPE.O]FII^;O>1E&%0GIVI?UNG MZ-6>F$6\H>JU2CE(^ZU;;?`$S8)3>'&9^,5H!&-*1W'@XB;.TDO("Q5[QAEGPR5QHU M[JP=+G5'`L(J@&Y4ALANYD384H[EFS^X+1)\7U#;+W5G?BQ#56R(9X2O5.W= M.:DCJ9/TM1DB&V)_NEK3=V,+K`2E7<"FJ38V[2$HOV)5>?9X'9V3,#S^I-B# M03R.73LB0V5()@$9.*A.X;&SQWX0.?_#"WM_X(Z:JEY_M!_/V5%=K1BO MYD'/@D0J7T55(Z3R)96O1+TRW&2HUJENOA(BI5JW&[K6L,DF! M[64.OOV+19(#^P2W%](M9Q,H7TYHS"=`)@F7_NC4\9R(G#L/9'CF1;9WY]!O M,9?I:0SAL):@P/=^0DHFN8'U;"!5LMUL==JMBM;M5DW-,GIMK6'VFEK7Z-3J MM6K%J'5?D2KY\[/RUQ]G-SWM^K+5HG'U%:Y[A-Y* M\8QWGGW[G3_=N3B_N!+S;)F0_(1!\G@\6R\RG=5(WW'>N[FAY).^.+>(1'I: M'SXKVB/I_W`B#0"JA5'@_R`:YN+ABT32?&W]2B^,G#'8:O0]3HIQQ0:4YZPU MA3!L*T?DY\"-(1.2/C`(,&ADN_3QW-VCP!]C;BBU_R`7V!DY`_:+/U+.+J^0 MWN'_=Y7(IW;B`W$IS<(J(C*X]ZB)>_=TK(S\@"684H)4PG@P(`0__$1LGF5# M?PV(/8I(H#CT2DA?P+)1PT^SDFVYQ-3-D8AA4AZQ-@+!.Y>DD%42:!=2SC,9 MLRM`9VU[6S9)M]9X8Y)N??4DW>JV,V575J<6B+3D&,SK>D#1>=:]^>.3TJP( MN=FO8CY3D][_`^>9OJSGX?&>E^6*F^ZGP"AH0T5M*:I6K52=L`H_HP%2KMR?*TDXCUDR7,Z@4JREF1=+MX\9PZ# M)&))Q&7GS7-@+'6[8%>DU;H'5$J?/Q[YX=>(YW%UZ2 M(.DXY`Q>'\@>DH$SMMT0.RQ,1;4;5:-:Z=0MK=+3#O::?UQJG1 MT"M63V_>&K>F<:C$=)/X<2?T+=.HWWZ_[MY.2'`;8O^CP]\TXT0W,_C,W<7\ M0/_%J.5%SM!QXX@"\9H,XL")'!+V,+1+AJ>!/V;=#!"$%Z/I=Z\_W-]IZ,U. MW:AIW5JOIEGMTX;6,CL53>^K6K--7A?MG@JM34?:E`EDS:=@B,[N( M`\6/HY!2(H2OZ+O"%*+*(]5=%<+AFH7%[;[_0)2![0X@59K'Q3T2*4>N'X;' M]!T4TPIB6E7B$*)B\%A$%>$P#I[H(@'X$`%W1AK%P0,)(.%Z3*)[?ZBR0+A- MCYDS`+I7E3X9V'%(X"5.`/6>]B!2'OW8'2KW-EU)GQ#(T(X<+:$*91@34+Y] M85G9HA3'4P";;XFRY]L_S:)JU>CUV_LY-:PE0\7_1].4-KFC0$"^HOQ![*&B M:<_85$G'J%<$DRN[Z_BTSY]>*82^C%KY-F7RS:KJ\H'\9WH"&?JBID"K\L8Y M(7Z([V..SS)MK'8;%I?$X#W3(.J-M#"G@]9VL?WNP3_=V4N"?ZO@?S:;:D[;'SY-ZSF%"(D\JZ!#0$3I,"493$6Z@F]^1,+G==>">YJ> MW?'VG,G/+J-B5=2:OH49',L"HS`<:EL;?NM"UDD-?%G/]QXI!-0DF4@R62.9 M%"#:^NR6.OYX['O,IT2_[D^R]D=2.FY..IIJLV*IM6U,*Y*,3S(^22:23(I) M)H5,LGMVDU6@K(#0K(FJXVYA5G%9V@)=^3?$^2B223]VI37@9D1((@ M,2FEH-RPH+1T:DK*V*1D@/O)`"692#)YGV4U>U4S)Z$HH5@4*!;=Y73C1[8K M]>9-Z\VJU:BI1DVJSE(GVD^=2)*)))/WJ3KO646ZA*.$8Y'@^%SEC5!:PVZ= M:I^P="EU8_52:O9?O+2P[<+Z>@;D>Q*<.QY]=R<@0R.ZT1/O9\3)\#7 M=.V(&&MK,M"J5&I=JZIK1KU]JEF=2DUKMML53==KIWJ[7:^WVM:M<6L<_@9B M2M.;FE[-(+'$2J?:+<"V^W9(A@`8XH5X8PL"X7?8-[_]E-UR:3_!I1:DD5VP M#.R+K*G`7P1$,!FV'DA@WY$K,K8=@&Z'0B:P!U%LNS#:D7W%&#GT7]@EI#?Z.'8K)EC<\=^P^X)+2,OTM'I/AAB9:-&M-7:_4.UJK M#=37HN]H]^JG6ENW.OKIJ=5N5-OEFVA1*]A$BQN8%X$C(%@O#MXB(AZ/[8#> M%F(?#9*,O5!&MA.`K(@)=."`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`SN#]PB!8P_'CL1%*W]6M5/=&5, M]3R8'!V0!]]]@!'1P/^AC(V#<,2+5.DK8%WS5I74L2Y>5'*'\@C`].F["-2\ MDF?18JD4[GY\=Z\\$H6G>M-W.9XRBET7?B0>8'P,9&M'Q'U2*!50)&%-GH,X MGQT2:^HA3;D\3L6FXLKV!@@-/PZ412,`3YY7E'=2 MO?=R\1X;E[W%ZKWBWVRD_9R:$O2L\.% ML!7*G0@DB%.&0QDA8R3GOC>D9^$,'NT#D[L8C4B@7,&M1^=G5%,Y5A4_0.*' M@FI\B:I,W!@8V($X!%X94S9'3\Z1>5*O?H!/6"=F]8.J#,D$>!KCM#;]`H;O(!UW?!D87 M1E@>HXP(?2/].<3>"Y3=1_-H354>[YT!,%Y*<@-[XD14BZ)J/KXB2+5^Y)GT M9:),P.J;@S1E6Q`)0!E`L?:`"J&)[3W!YRD[12\+KK5MN\AOK^\)?18DB(.> M^S%D#*'LH/^DO!<^'=T'*!O$;R>'(ZD(RGT]/0Z+OW\=T?\!V1D"R[^8$-:5 M(52I".6P`M%%3\\`=8#T>V-")=50360]E40^%1((6Q!)257X'#AS"0>_!DEG M`B7VLGU.X!\4Q50+H0\3VQ3*!L.*.`I.5!$T6/("1F:6`":1X$_5O23"N.D M]"7Z28TRTX1:J*V<_--FO2N4H>W0E[&/II3![J&/DQ&]2]C+$PZ-"FJ$GW5M2ML1$#C<>J*TE$$<1A02P5.Z5]L-_73# MN(N%RK+/@.!Y()WHEK[M-K1S$JOUVX:5KUN=,O7^*5PA^>" M*B@C1#=]T9AAG+)(T(HG'.6*394BD,;8(":4O5MD[Y;U]&XQ5^_=8E2VW;QE M2^$I(^]O_0^QJ:F+_;SHQV>].A5#?8V#>#.ARGS<)SGP97M"247CPU]Y)OAXF[J:B+W-@SM%4.02Z:"/!.DVT8J+/@T94Q]W"091;YZ[+(WQ!=RP?LVI"E04*6?!XZ$""\#/Q3\/M/SQ%IVZ$S>'UL;D@& MSMAV0W333@7J&NV.;G2JAF953TW-:AFFUNK5ZEJG85F=IG5:M>K56^/6.E1B MSV'?=D(?1F+DH225;)"%239+9[0M\])"$E/98'`JE5 MF*`7$"*.8QE3H4$9'>;##^@;[_R`M2`YLD-XP2!P^ME:()M;,?-"T0$@'/T\ M/D8ZPK]DQ%]&_)$?-\VW1?QK]=4C_AL/^,M/;_G3*V58+&,.O\T(+D;Z@V%M M+/]A;O8(73YHM<_H%T(2Q%J6`?JX@@HYZ#B9G"I6:H4DQHWFXIR3!^+2U1H[ M1;K$`L."*;&P:RP(3%DB8X?(P+:-!99$:^ZL6:C;RQBXA6?1.&;]/YB)[,PG MG>*%&[ M4G_6N)3WRP;WE2$6)E':T'6UTIQ3_B9Q+AE$"1A$L4A$LH7=LX7B.X.^QA&T MB)(:D61XDN$5A.%55+U6RLF@DBE(IE`P$I%,8==,H8R.HW2`,"3+$R^T>>-R MQWL@882I@RI/KV=]W$?0H3:,`\R@']CAO1*BNVF(#7HQ05YJ5Y*12D:Z>T9: M52OE9*22*4BF4#`2D4QAUTRA^!ZFWM\Q&TK!YB!`S_0BJT)[0](5M=HL93,E M*>>DG)/$(HE%*D52@JQ'*=J#CD=[U;I,0E%"44)QGZ#X5B=_^:7VKM.*2RNL M):)738=JJJ8YIQVU1+4L(BD8P$I`(Z5G!X:I-LS]*"DIOYFV9XUI)1PE'"4< M]P^.Q8\:PK/8T^2<=SEUB.QT(G\.Z8NP6@M9XCS%'U/JDU2)DJU29*(E*$EDJ&6JNNE3*N1&']O&"^^ M4^G&=GU/Z?QY)54A*>>D*B1)1`K&4@G&BEG*:(O$^'O#^![FE.]5H:"$HH2B MA.(^0;'\I;^R3+`X6-DU*(GJU[YLU5:^7LH&AQ/2*1YI*MKU9:M#^;/G!V/;Y0'"FZO6M^O3BZNO<-TC]%:Z+[SS[-OO_.G.Q?G%E;C+ MSPJP>^3TLR+FL\)7@*`Q3'C#>>_FA@(K?6UN"4F,$K^E/9+^#R?2(O(STL(H M\'\0[=$91O?X>XJ)Q6!%N"PG##\K'(ET@^>MRVL*&VKTNO8D)"M`9VU[4P;$ M=<.)/7"\NR^'.OM[8@^'R=]X[Y?#IODA54<&Q(M(<*CT_6!(`K@K)YWS5,V? MKS4_+"V"DVKET@Q6T^1U;"'FVG'"_N;ZS&9C34T_/';U@ M6-,GZ_4JMI$^VX=_=,F`C/LDR/94,52Z?%,W6(YO/]V:N,]^H'P4-OKF99S: M3J#\":-LZ!N_$CN,`X*C<)Y9PSHPN9I5(8G1`QMM4[1X#D5A=+7&3I$NL<"P M\-SQEUC8"A8$IBR1L4-DW/B1[198$MT3L-#JSZ[O*^;)+4R- MB6&HM6:CC*>X[&)\C4N1\KP8)"*YPLZY0O%]%E_C*+;=X@ON`IU:R>\DO]ML MYKY:,>7(Z(T+_#./`]@9$&=CAO1*B5V1(`OK8`V3(2>U*,E+)2(O`2!L-6199+M*6 M3*&8)"*9PJZ90O$]3+V_8R>"X%!(!G&`4QN+K`KM$4E;C5(6A4LY)^6<)!%) M(N4B$2DW=BTW]K"9R%YUA9-0E%"44-PG*):_S^-;Q=2NW]9H MR+Z-.]BR+'"0)EHQ>("IJY5:*7G`'IIF>]8/3L)1PE'",%(FW)%(I)(I(I[)HI%-_R2E6D(70M]2=0UX)*4A@5 M.D6S0(=8LK]BLK\";5222#%)9&\DI&&J9J64I:$2Y>\.Y:5V)4WLIU1'\B+' MNX.V9U)3DF*PQ&*P0!N5)%),$MD;L4FE9CE[A$J,OS>,%]][=.[)JOO5=6AA**$ MHH3B/D&Q_'7$LNBP+-*];*ZTG1<=EC7_2B)ZQ9BRI59-V4O@/6"ZIC8:I3S3 M>VB:[5F]H82CA*.$X_[!,<]Y/T8V_<:\A?'(8_OBYN;BZR=%G_S\K/SUQ]E- M3[N^;'4H?_;\8&R[/"!Y<]7Z=GUZ>??N=/]VY.+^X$G?Y M60%V_TD9DZ$3CV>ES&>%+P*A8YCPDO/>S0V%5_KFW"J2L*CUX;.B/9+^#R?2 M(O(STL(H\'\0[=$91O>X&A$7KQ5[?Q%EZ`SI"B!@>F\_$,7VGI0HL+UP1()0 MZ9/HD1!/.8>D_%`Q%(BRFLK(#Z@6X"H3$CC^,*3/3@(2$B\BPQ/EYI[0&US7 M?X1Q%/R'4+&5@%Z$1Q_M8*CX(\6/@[3NT2'P%GCOX[TSN%<>B1)'](?_$?;M MC!PJBN--8OK"HY"0/)5@C?8W/R**>?3S&&D#+QW31^C;AR0BP=CQ<%FX$S]4@=+T>K)>'E<'O8-/-*FW;Q2D;U_>$T"4].M&]XRF9 M@=KY;`_^CIW0P2+/@+CPU(&0LA,(Q1A]ESW<\(Z?R+!D%,/PG7ASP) M$#>5EDNP8@E5<4D8\D&HD3+Q`XQ_"Z]F*.K;H1,"&J)[J$9%*"LI<#GPAPB$ MH1,.XC"D?]'-T=OI1NCW"=WX4`%PATKDTU=$",$<,DI1+_>76"DS_;A'Z>4\V3;^1-G:Z5_?B5V M2#D.\MSL*F7+N--^NF<1`/U`^?@FB3"UP.^>WP])@'P\6\,92OGL[Z-I)>OX MF26N@P)6=*V4H#`C405M4*6[5':.^T0@C8JA*E3[FC/797\3$67@:%MI(6\X M#I7-'(>;U(9$V^O(CZ/C]T3[,C=J^[E1ZY02&SH696USL,OC(*M52\+SRUN; MNC?DO3@QO<=@ M%@*+'A?Y*.V-?*BJ57TOQHD4^!S,-.PG997D@MGT@CHIARAWOM8@X?ZEO MQ+-91H9^U#^6YV*[Y\)2=5W:$9NQ(VR74GSGSRLP(I[7C_0C6U+^UBF_8NZ% MBB1]>]*W]U8R7,ZW-R?0LS^,:=>E6V9-U>MS$EHD0Y(E'NME284H\3!>3M(U M&EO.TOTX=![@SW]\C$/MSK8GGR`A$=,0NTXX<'W(/PQOZ.O;KC_X\1M]3/E' M-6/U2/"W2^L_AO'5,+L9*#:WOSP$BH#$D2VXREV&)((2Q_2"6ZY:H3HWHZ@AH:^ M(RTEXE5"4/X$513CB>U!X<9SE45877'P"R][&)*0,FQ6,P3%'O39Z#X@1/@R MA7F:>ZP,Z!OO_(#56!W9(;Q@$#C];"VL:&J.O7?T\UBP\SX]KT[)V@DNWO:^ M=J)IOK%VHKYZ[41ETZ43\M-;_K2L59E3JV)8&RM6F6LFT^6GAG(_W=HF2U)` M7U)08:)OS-7(+%[#]FM.)#%NM'`*"X[`D[Q3I$LL,"R8$@N[QH+`E"4R=HB, M&S^RW0)+(FH!WMU'7PX;BQ7H[)8,8%89;B]C(`*>1>.X!:Z`D)G(SGS2*5[L M85?WR5W)76WCON*/KFG;W@^ETRUT]9\L#"].C'/'VMN>Q;`MHY2Y9)(!2`90 M#,J0#*`8&2PEL)2^^AYY4L9V\(-$O#_AX(DN9!1[PW>E_LAZM3T6E;LDCO56 M[.JZ6FF6LC6[9!"2012,1"1;V#U;*+XSZ&L:E=248J&>GN&6E5K923D4JF()E"P4A$,H5=,X7B M>YAZ?\=.!%&WD`SB`"=5EQ:82T1O6HZ5%,US=WWZ2X!JF41 MB:21O6<'AJDV]F/.T1Z8:7O6%%7"4<)1PG'_X%C\J"$\BSU-SGF74X?(3B=R M5W)7Q=E5J1,[R4\RB"/G`3I"BDF>65?E(K.8`L72I(6[GW9M@:*03:N40X@D M4Y!,H6`D(IG"KIE"\2VOYX882YU(LK\2L[\";5222-'5J;V1E49=K5NF1+E$ M>0E07D:GTOE+,[VEVB1EHE2;)(E(&5HB&6JINE[*M!J)\?>&\>([E6YLU_>4 MSI]74A62,[V%.^5X5"DHH2BA**.X3%,M? M^BO+!(LCY_=+G]MU<6!ITZ0DHE?[OEE3]7HI&QA*3*]XI*DTE^6^!5'D]JPL M4,)1PE'"\'R.;?F/>PG@DL'UQ-ZZO*:PH4:O:T]"L@)TUK8W94!<-YS8`\>[ M^W*HL[\G]G"8_(WW?CELFA]2=61`O(@$ATK?#X8D@+MRTCE/U?SY6O/#TB(X M>::R^)%U79>?WNJGETLW6$&;W[&%D&?+"?>;ZSN;@3D]]?3QJGM!,J?,,J& MOO$KL<,X(#@*YYDUK`.3JUD5DA@]L-$V18OG4!1&5VOL%.D2"PP+SQU_B86M M8$%@RA(9.T3&C1_9;H$ET3T!]]^7P\9B!3J[)0.858;;RUBT`\]B*ZE6&))( M]I:2NY*[*LZNBI_1WK:]'TJG^ZY:(LC$!IG84(PH:+,A&Z!+!B`9@&0`Q4#N MJW,@2F`I??4]\J2,[>`'B90!CC4?P#S/4>P-"ZW^[/J^8I[(K++L;7N!0ISXM!(I(K[)PK%-]G\36.8MLMON`NT*F5_$[RN\UF[JL54\[M M*Q=I2Z903!*13&'73*&,_HVTX;4X!X0NQ/$>2!AAAIM*_QBX,:33*JXS(O3/ M,`YL;T"4@1W>*R%Z188DH(\]0(:D;35*&51N)1S4LY)$I$D4BX2D7)C MUW)C#YN)[%57.`E%"44)Q7V"8OG[/+Y53.TZY[6TPEHB>N7Q;8V&[-NX@RW+ M`@=IHA6#!YBZ6JF5D@?LH6FV9_W@)!PE'"4<]P^.Q8\/PK/89./\-X\;U'Y\Z=[0V53J()@5I$_PB= M(0DPP"85(RGU2BSU"K1122*21"2)2!*1)+(-R.UALOI>51U**$HH2BCN$Q3+ M7T=%A6?.O)*)7C"E;:M64O03>`Z9K:J-1RC.]AZ;9GM4; M2CA*.$HX[A\<\YSW8V33;P@7^H$R<.TP_'+8FDQ1(+!O>W=$V[<(4A>M[0J+?`S^>.-[= M#?D9M5U_\.,W^CWE'\E3U_=V0-IV2(8=H;"O%03P7N]F,`KPC])&)'AF7=)`L-^6!TC5=D].60^.[M9:]>:S0U^A^C8NC:OW3=:-Y>WW1OJ3)] M2ZVHBF%6C%O]4!F2@3.VW1"$HN(,OQPZPUO+M"H-R[BMZ7JM?5IO:U:[6=>L M:K.KM:Q:1ZM63]OU"OUOLV/>-NFK;PWC4(D]AWW?"7W+-.JWWZ^[MQ,2W(8` M@O#PM^9)W.1\G`L=TS;^0'8UQ=2@:OA_<4B.O5 M>K.IG_:T3JO2U:SFJ:ZUJO53K=

JUNY;39/&W4SUDX+NN/0DIV0^(ZX83>T#I^,NASOZ>V,-A\O>C,XSNJ8*JZQ\. ME;X?#$D`UW.*SF+_1_*X]2'5$ETR6D))G%+.9HOR^Z@KUD_PQ/;3L[N4RH@K MV\!RKGOGO_L_FJ;\[`>NVO>'3XJFS6/)/.>B?7%S<_'UDZ)/?GY6^#5DTS6X MD$O#H"@37O0ZR%P3EPSH\:(O^3LY.LHH.3O*T(YLY2CV['CHT+N.%7J6%'I> ME2=B!PK,IX$GNV1`QGT29`*@8J@*'!L%4CSH/TS%"94)92/TP).ATB>N__AI M%J:390$C*NSF-*1T085?+,'6?/R:9G:`!K#+8,%A!%IHDSO'4VYP!7\0>Y@G MB>GCRK]0,SXL;7P(IWK1(^NZ+C^]U4\OE]BU@A]C53-^F7>N\/;\`4P.^=RH MP0S,Z2&E)Y->,*SIL_=:>6'DY057)Y0>YW1'WU-6^!JQMC:T2"J80P7FAHC@ MJTU-$5&V[13U&WIGH3'PS]@C`@)TB8`M(^":3*)I%4]B8=M8F*=G%T@,@69+ M!>6L7CM/[6W/6$(%*>9;SI`$X^;3<[`O3J[ZKN_;Q!F7>WF/>RE`4*23ZE[=I\;#T`_^_5*0ZW5ME"4];P@V%::P;O";$4U*Z;$[/YA MUC)5J[*%UO,2LUO'K*%6C5KY,%O(1B+/;O)B@H6QWIWB^J'4+C9$ST/- MXKBIZI;$\5[CN*ZKAFZ5#\?ELUNR9&S'&_AC(K6/S5"T65&KS5T[R"37VC2. M=;,A<;SG.#9V'KB0.-XHC@V#:IB[SJ)<@_91-%T#`JU2R]AH$6--;52D!-IK M'!L-M5+=PGP"B>,=:AF&6C5+:/]*'*_@XU"M1@D5R?*Y.#*U0Z:$;XVZ]9.& ME%%[CN%*"6TDB>&5,+SKXG2)X0UC>.=)?GOMYY`IY5LEYKH,"^\YAG?>_T9B M>-,J1PD%DL3P2BI'";GTA=$[SF>$,R@0%)7@03E?R`OH38@WO%'^$`)3YM M*3<5"4:E*;ZW\`OT%7XT.Q,_)=UW\$/%,N'E/03X7>6YAST`S9\E2[AR(O'D/KH!],3L%;;80EA MDHPBU:9`PD>33EU%^19.7;S(Q/N1CZK;&\:=[\NI9+-.#":EDH/]ZM]#V\AMO4\^ZI= M5QMJM=%0F[Q51XEV_DHT&R>U#2-YF9,MS''>Z?VMA]QA/U2KGGSO'IIH;[^N,%N[I/[K%,>RR; MKEIY^=0Z#P3B$R,2!&D00I[8(NSQC0JM166:KN]$F=TK2BB_[%Z2"U"Q/?8] M^D&(R_D3"/9)3E"(/;Z5$ZAUJZF:S:9D!L5@!D4Y^F?>("!CXD&/K=SIM\,P M'D/HF?XORU<@/TDP<$("N0V.IT7W1*.WDR?ZED<["&PODKRB$'M\(Z\P34NU M>&Z[Y!0[YQ3%51N^>P\D!)N?V@M1X`Q0A>#<@W*$H60'A=CC&]F!H>H52ZWQ MAE.2(6R8(13%&[ZDPY2NEV<%S*&U#3EI7_W-U8^#A&(1H%B,DUDDI?[UOOC" MR^3RA:Q+),QK5))7ZJI9W4V(N_AD9)Q8&P;-'BH!>Q:JE7"4<"P2'#=37O7_ ML_>L38X:2?X"_P?"9\?V1"`M(!!H'+<1:CV\[1M/]W:/[=C[XBBA4HL=!#*/ MUNA^_646(-#[B01T;3AB6PQ4965FY:,RLY)7X-4<*]4<\@II>#4'A_GX]ZIUEE:!:@ZU);8:[Z^:HR$JNB+J MS=M$LJ]/9JG>RCE&5Z:C*RZ;^1$AK^;@U1S7?H^OL4QK+)NMRJLY2LS-O)JC M$)Q0?MW-JSG>N20094,3%86G9!9$&!1EZW?&Q'FE\76!Z=[WJ$W0F@]R]AE.3*2DH\)[[5FXN=X M%@@O*N.R8U5V2)+8K'[6:5ED1U$D!2\A>P^;7U9$0^?.RE7V?E'B;P>&:'CE M$\=B!>*JY;?H>459@=)F2J3;-5UL:2U1ERNOWT].RS%X1=D[3Q?A>.1XO-ZD MR_)@K21LO=O3B9V;5MH_H=<^=NTA]?S>7Z$5S#^[`>U:OFF[?NCET/"IIS?D M5O>^69-[;:.F=AI2[;[3DFJ2H6O=3E/6I%9[6\.GI;JU\PO19$GZ<;7T;"&/ MMQMQR>>9,C:;CLYM(H=?#O`//>K[-5@(]X-4'@,L!VA>OCQV_N>?CY\`U2\Q M+P-Q6PA![U^_/7SY]\'`[F%PK//X-O!L<;!6X'%(M[G('E9^7"Z';"YKT--Q M8>$?[3`8N]CL"_MPL9W#5F)M7OQA[;F^K0&<0[N\1P>]@;4"$KG!"D@D49A1 M8639&&P<4Z%#O<`:628)V`%_E_K`5:R''/R$@9[12O)%X8GE*U''Q/YZSA!^ M6V\PR"O\A,]>J&=1/YWL7O@E="S6:^^)P`2F-26L,]K3(NV)H11V5S!F<'2I MC<>)%(8R/1H0;\[�`N##2,+7,LD`5)!+FNI;--+-M&@./V?X$K#*@PC%>" M(5`_!A!&2B#;#5==>'3P1;J&/UD4W!#7Y6>$J4"F4\]]PZD<@4RH,V0A6P`$ MWEU!<11\<;VIZT5HAK),Q!T'&=-V0$5&J_N\LC)A)F3Q/(TT6C;%Q4 M-F8,B86($-JO'F4AQ3+)R<^P:Y=Y4FDE!`%.AK1*&"R0Q[#*,&8!,E0D5C.2)>U<6/VQ@T*//]J.<2V M,1I+ANXTZG@*`X,T@`UM^3LAA*UMVP(8>I1UFPR=P+*W@JK`B.W=@%G^@O^C M7)8AQ003T\4(\AL58881L3Q`K0=0DB']*T3)$9"O%##J^7'72Q?[IPID$/J( MNH``"DT_0M($IT3QGC3=1($;!'0R9>+VE5@.DXY.X+EVTN*UXTZFQ)GO!9]A MPW$#&`%$S!L3X2EH@4"$40AOX,;'9RKB)@,=QB M43@6O`9Z%;B-O((,=.:N@V(D7A7*"7B!F&"O>S2[''P\LCP_$!SZ"@(%,]O#A*%-?#KR?D3AK\H;UVTVH.:!X]`D? MQVD+S(D(IZAGX25*/-N*-*J<43%#,@=2C%C_7CPU]='Z0='VZKGA%-\F(]"% M%A/JP+O$]UTS^A6][8/:\A,B@76B_8BO35RF$.)E9#L&+ZGSE2Q0;PDTW`0. M]=G&RD*)6Y8M!#0(FQP'0?-L&&V4F1O:+&8;V@';)\C4R9HAB MR6@P?K)$D)=OF+:(<]QEVVPV M=G%QYQ"E+O1Q]V8($&70+?%$P6`>@FJ'.MV(#/5D-&YLM<(UDR]QE$B8X,QLF<.'[32N(=`.HA`!VD(5` M1]L/S>MP+B)3P5X*(Y,VQ=VZ*[!B.(G`O0<:MD!/7`$1)L3[2@/T?T/&EL$, M)&^THY/L)":,(V#2U8'(3\BUBUC`C;QX);Q/L-5`HPH1ZKPAM MRJH(YL"*_:3`(XZ/\ARIA/V<\3>L&/>L)JUM)Q`>-&`OTO@H1YBZ8#L*=P2U MQP@F&'Z(&"AAL3VTV(+0")7)CDDX/K/W/,$/O3>+X9@-/M^*<43(=IRG^"V- M!;O"I;U5+BV)$?O@P(8#JP^ISUPI*7*E0.53"XU4D"C(KL0?`[594Q1Z\A$P;9Y>XDD(C)J90=""3'M#$WQX`!F,6 MIC:9-IPF)Q+P`AA7X)$G1C1S#V*"X<=[\99507$..J`K$B4$J%$#;8JBDKT` M.LYRP9X?@7(``K\N5":*1Z9JF%$3O[9!4^!`>#(U`.M:^$%6ZN"6+\+?!3=\ M'V+;E#D<,V;[QY:^'P[^`[8[,PC`X']S;7#1V*$+^D_I3]L"F3Z,>`(-1=BY M+E8814;%S(JH$$[!5Z$C5$4X&KP5>-8@3$R)5#=%^AQ(#W[6!/"*#('@9#$> M6U>1[9V86@M6V<\>BPEBK3:,N(Y)+6:L9M84'_@@;RH3B8`%]QM-@1(--Q"Q^IK?^*">_LF-&+#YH73\!\\\,) M&$[L['9`;7?V\0PT+U_]^&WUZL>4@[8''2\<0FL:^^YRS(1W3KK.T3CA.D?U MNA<;GG]_V9DI9(?FA)V^_3J9;;#!1%JW(G9S^7%90@P.^?)YOR<*V=,G7L\S M.AV,3&'Y42!L2EBZ!"X.QW.*4V/AS*W#W#.SY7S&TI+5&2C_)Q??#[_;J5(E7-V MCD:*JG&!?B5&?WEZBKU;EH00>?R+QM&?7.>UAH%_ MX.8`SP1=)\X&V70'2G0#2N;F-,[U^7%]0VV*6B7D>OFK;BI51EH^O?O%Q0M3 MMH;8O>S1^R@Z>D^BJ%Q.Y2VG%$.4)5G4XSZX7%3Q@JSR*1=+H-^FF-\+4[P1;XYP#$F`A1MCSPU?QXM0 M*$8_-9;)S$*-B`PL>(B&$4A,54Q$QOH-U[;=F5^M**3>S#L*J2O'1R&-VW5V MRWWJPWS'(PR5\\R3LXV?`UIO?3N]]=:Q`DY>?#G`/SZ'RQD/[HBM8;!11&>Z M>%U@ZK2WVK$%J3>F?;DIGC3`NQJ=,YWUKC)?N7-O7<-45?U`LBF#Y42206A;K/>O#5=^7EIY4([E[C) M\+WBKGQAL;-\"YDK<)Z855XU?EO/0JM7(=I9/,\B.K#BOD7NOH56A"(`[ECD MD>A>UUOE%TWY85-:QX"&+R\NSGZ.[ M(KA@RIM[B^!55%0N%83$>EW;<')8=`)S]Z+8)C)W+[A[<:![T>!:G,"'@T70WA6KTKJR_JX8]HI^24`OO;2;Z^L"ZFM)+^=%`5Q?[]?7"M?7 M7%]S?7W%28]O$GIH?\^5MJ!Q&U$ZQ,Y"U/'9I=MMK"B.[MWQ[^?I.T]DCL_: M,^(-'Z,[`]FIMO_@/+'KV9-RMKC*+,FE825?IS<6'5+3FA#;9V5X*UU&%4DU M>IUNL]9HM9LUM:NU:X;4:M?TWOU]M].4>BVI_V<+AOY3AH]#QXKFMWQ7563] MS]]>NG].J?=G5#G^_3^,>DO)(/5ZV%DARZ+EZX.#5\.[WKP3=;I9[O%ZL6:M M7;G=D%KW_9IJ-%LU55?:M;;6-6H=I:TV=W M"00K9J2QN$T@08M%?9&UO<=:>\L/DHO@H^IWRWG]N+;1#@97P0?+)>_!8N]O MW\A+)>]'+O^*%?+;;N&6"G@+]PVG/L",,/;1]0`CXQPUN?O;S>7/_R6Q_X$) M%.RM?6YNJWT>X!\;?2X&R>!$\XG3X(CZ$TGU46]99ZLK=Y!KPW6*MAZ/FN M]#(<7A1^_L/UO@I1URR3^M?GZ..^6"=W8U%36R+6/G?1NMB05XWW(L M?XS-_5QW6#ZV-T0U-E7>$=LW1<5HW9[MRW#:F9J(5TJ..7O"G"WI=X^_LIDM M.W*'E\^M3I/=]H80RL(%OFP,[%2CO2%J"'&=![P"(KZP3,):&\TP@N!W^@3]?!L MBKQ2?/R,,:%?P3J?A)-+A+H>/O?7HC3W4E_JZYW[6E/J-&JJI*HU0^MKM9[: M4J66)C?4GLRB-&F@:QIZ]/M_2'5)T;44)V>M;ENHZE\A\6`@>]Z/[E,F]H,S MOLN-6[^6QQ_E:WN-:BEX=%C5G M].@;=<(JMUN\;250PQ";3?UX$&Y="\1KO/92MB$JC1+>!<\IN[:UXYRBEZ0HV(D&WZ,5HF@3C(A;&_Z'$[3HYQ"?:U389BG_J@%\.\`\L$N4)U7Q5 M?%6%6571'1">;GT-#:BU1$.[MP/HHFJV!@59N9>1:Q-@4C0;70)6FL6R(#>W=M(9] MGS169%%32NC_UW:OV&+M54HZW76O=ZM]95C49;:[1U M36F>U"?JCW\^?.G57I[:G=Y'H#DLSH[-LR_/[<\O__/A M\\_QUYW'3X_/V4ONH_Y*'X4)'5KA1/C;"E?\;4-CJD^]+U]ZS^G`2T"D#:M^ M$FHS.OAJ!35$:,T///.=3(DSC[<"4+WU MDX^<7QB,A2:K@^?(?1T,K7=.:6"3]\` M#XY)XW\,QB009M2C8-C#Y@OL.8Q!?-\%>B#:9E8P9NN-EI=9-:Q@#.3)T#&A M"<*)1Y,(*9!P2A`7B/0,>8'8T]";NK!(@-Z>,R@G9`Z\&L"7\+GE#"V38-\Y MQ.X,X707>5[)5#,WM(CTYH$=Z+;TE],-WE_N^..2J]5-GFT,Q[Q_7FN;YM&M;;9JZY7F M-O_&CI*]71TEV:H&B_5=&I67.#Q[9]QP?*.C0[D!C:";TCNG,8N/=J50VZP0 M8?(]#@?XE0)S+`56D0@@5*(F<<^JS4K\=3Q86+B;]-J6.7VTY=L;4%^9W21*;VA5R0]ZK M0"L.I65)5*\1L,E?LI7+/L,,@SN\L^X#.^TK?4E%61C^KFF(LGJ%,LX]<)3N M9JRR$%C3144OI2U>)E-M@_A*,Z62PV\\.?FI`DG:!?=.[N2K!.3?F4"[-56E M>NL*98#<+#M9KE4A%[3@>X!+MBI25:I?HVHN;\FVE$&&#P:>8-K$]__[^_9T M:M.:A?$0S#1_-\<=^!3[PU'>G"F80#_[#JF95M1AMO%<]#43EO36UVE MUN_TE9K:EI3:O:;*M9[4:"B2TC=:?;5\.6B8<5+H)+0XK\P7B.#!8\Q-FA%O MB(D];N@)0.X!T#RP:)0K-AM;YEB842$,X/'_87+1)_I&[4P\'!0EL(LOW/F4 M+N\F"P'X[`944.Z^?6!\SQY]@$]@H"&%+3*Q'#S@!2UKN<,:==C6#VF2896% M!W4P*&7,^F+Y90`OC-+)9KK=$YLE>+V,*<44*2L86TY&<7=^RJ9&>=3&KUC^ MF8/GS(`8P1V`Y(FRY=+ONC^QK*CE@4POA"GQ^9".*&:]L44!=MPI;LOH+%L4 M;-C6`DN+@V=3U\.QLT.SM3)'*$'LLCEM]:5_D!(=L M!8++.FBI::(6$V&W.%)OY+,=OF#%`MAN?F01W[EA\.$]\?X%0>&;X`9:(J=M MT8W]J:PWQ;PT\*>*O#UNN1TNF].HB$HU\D(*S-Q3,E\P=GS\8,XY>U^!O8&[ MC4KD@K5#R(VMM`/.#;U;T5.Z?LQ&:C9[J!18[E_;SG MW/#Z.W')-@3BN&"ZO-Y514VYPKU[[U'O\1_6PVRW;M1,R5VCP#7'M'+%BN'(%Z8RH9VY'[)T-_C`]\5U]X4J2A+W(_+Q(]AM4)W?G]&)V&T?27>$ M<_[5.;]QC4M&^=F>S<_V*G*VMR'04QW!=.M\=Z4I2GHIB^DK*)`:(!R&;CBP MZ14ETNF3'B>2+EZ3<.'2@>6ZA)]==SBS;+OM#!^<`&"RX/-HHB<0W^;\\B4' M]W*OU6]H_9K<:?1K:DM1:FU-TFJJ?&]TVYV6UE3;QY< MY"Y'DE_YYXB3_A_]JZV-W$D^;]?*=_! M_]6LE)PPQS/D5G<2(60GI]E)_I/9'=VKE;$;Z!MCLVT[&?;37U5UM]WF(2$9 M($`LW=[,`&[W0W5U]:^J?B5G+S,XZ6]I`VL&<[]X.(J#-UZ(N-;#2;LM6)J% M@-'K[)N+$?+A,,=;B@"D%=XSXJNUAB"*T`3E!FCBVX#%2-?*,BI<>E[D:&3+ MV6O'#A++G!"]*AOR@,/E-(G8,/$MGP\9S2:/B/34F6"8_E_,*T%36`PBBAFR MJ[(HEGRNV,ID"IVB0'\G""3':A)0L#_T13"5KP!;CD_,'RLVU5!$96CE"V48 M8H(/Y5_(EBR&`Y57:X=&=^/&8>[HKE+(_HGD\2WO;'VKM4<6&,:B.LY46H*+ M"R@S.&8X#&/F5=Z$_(?/[RE[@F?"K%;6B2T?]$XVQR6+TE)8@&R^%O*;X?J# MIB.]%E$C-)5:!O2$,TGXZP0+;\D<$$2=[`@QD\DR(`8)K%C&S9L-R6=EZRYQ MQY;+A9M,HACM+.1=1E)>E:5"1EX2@:987<\L0(/;>%*;\4`!P-)+ MA:,D`%H""X7RQP1(0Q`PI/Q6Z7-:%O!T@0/',P83BD(^]DH^W)?(![*LPR&0 M^/+(ANU/[E-XW!`<,`]`(C)CAPP6><"$<-7D`5D0R'3G*B-C"9N[H5G*SY:< M10M_?2-\[:(6?4=@1F=TR\0=TB9<2J*$EQOQH&OYQ/$C2E":L^@[%[U*M=>L MVHTF)1%7P:+OM]IVK]-H],X;5\U&NPD6??-'L,RX?#>/PD:MVO[CM[O+/\#R M^H.X':(?_V4CV\!:^=@K1IB?(?H&KD?,P_H,+(A(-+I"H-)`._!BEOWD5KH< MNYB)>S.EW--?X(=Q=!W<4F+L%X98!/.Z:'N,&'UY"29->D/;SO16&N>=3K5Z M97>JM8;=:#Z;-;L6JUQ83<:S;[=O>I>V95Z[Z+>K%]4VN=7 MKW[3K'8>O6IRO&IFQBN()DG^H$<_R20!+0TG0% MP4OBO<-];,4&)6Q'CL]*LAB($^`5#RP_F8N=60!D]IW\H*N:R,QL,UO<>&KD MP'>290:SV+,NY=+-J;2*O-.ZLL`+ILGGDKF-%&XX%G`C"0;WH@CK=%P3>0UZ MJ#[@BQ8OB(MGP>IMD=\^UP'>N4(QVQ9,IPFBB+!Y"`>!%R9#_(60M_ZT*;JI9[_0RGE958N$:(C M]PGM87K@K`RB'9'MK`DC)/T#7:&YB&*;!WC3EG\/X;X]8?$X]*S3J^NK&WC\ M"U[;1V"<";"O!+OG,$_9>/],X+0@89?0P52$9*$A/D%%C0)/EL1!S,%RIO#] M5&"!H!*!`<*S''SF'HP$VK,XOG``NY0ID$-9?-D;J:"3E[@P532='#9P0+?' M^;&OLVU7;';KPVC!VNN#/J10OVUMXDKK\J+:NVC;YY5VVVYT MT'3H5UKV1;_3;M7JM7JK6C\H>A>E!AK8RIPBV$8!H>]Q]2R#C9'13`L!B64J M`2N5TP$R@>Q;"3ASQA$BT'-.9D<4TS'N2*(8!8C"&:[*CR'V"[\1#AJW-CIK M$$Z4+#$(?:+:8%$,QCO^.@6R[]&VN9;JT24E/20$E8U#WY.P-6@K:3>4LA>J MLG,IX!Z-0ZQWJ$^`]$70@HF9@[(3;.)($A_4SOH!>F5Y'A(F'3/`B&FR.QL=&1)B, MQK!P]BC$![*Z>T]0ZRQJ]77U]88NG::G+YG(.U9?(1&7_)Y[+/`^X42]YC6S M95PSP01A/_ZK4JY4-G"I7'?T^EZE7A=A`8TL`=*(];745*0@H%9#*(Q)I5%3L.A M"">D@_1#\'QJ:>.-;QUK<"VA7([E]:@&)^V92QZY<$&%/;9Y0:[V*]5^_[QK M]^I]$.1>]]SN]CL-^ZI_WJPT^JWJ9;VV2I!SV/1.P>9U\>-'C87'BQKK_5*M ME!\SQ)Z%3&^@.Q>_W5U_[-_=X7:X^?7B^F/W\_7-Q[NUN_@$)OU_MFU]&PB_ M-`B]F67;ZYJ93O&^T*7/8SC-IRR)N0N&TW7@/KI,:]O+ MFQ\(:5(9I=S-5>J]`4L%;[]S^G8C_5ZI0U\^EAOL\[\3WZQ1VY(!BR6DI"22 M,H+:X!+M&/BD=:O59G<$BE9E\Q"")Z=E<2FM4Q.MHU^9<-Q9"2U-P08(:BSI M5MOHEM;98,WZ/@4]R#@7M#YCM$51#4E*:8015Q2FI%SE993 M4:27((A(QOA#*'P/%!*S*%P1J1]Q:?[_^N(&80OKZK)K$VB!YK4GDI$N>PSV MJ\_9O:J^//4UDIB`S8_Q*]88[/HX],/13&$AKOP'M.4E[O?5^UUD;]RX]-S! M[8$]LE)SE;2-&MGJ!H,Q.3`->ONGEX:L%'5*1JJB`%9"M?!X'JR]6:C(37$\ M3Y;CQHBA*[03EH\JO8*L;J%$*ZSJ`IX@7ZF@FU=J?9C#S@;]@+`XBM$WN@:" MT?.N6JXC^L=]GRIBPTT/"U`'X80,'J:<9%G#JS M'H5IF;FY1"@4`,%Q\\,JGW(C+PS=MB-01R.\1B53F!:98T@FIG(##V%685KU MI)8L-)FS)CA<3RB<.QS"D_5R)?M*/:'4BF;S-15+2>J@S)*5)+'O:JWLA=;I M@!0700]H`1(UK^#T2NM=I]QN&WSXCRC",PF9D@\I^Y;0X6P,!NMN&CFCE%A. M&_=^_Y33Q1;&C''REM-#GC6860F%BKUKE9N&4.Z_.,'8<&_I\2..0U"#E04` M3D*/^5)KP_X;*.#$?F!RJG3``!XE28Q>'Y@^O/)B.[3YFI6?\%1`:_=,HDQ@ MWJ/`X;$41CH*(6,-YD+31,M>E=)>Z2DC$`RTC.EW0Z];GO$X"U*1]18BN#!1.F'=RBZ4.5)I2:.,$TJ!GG#E M`EV53#"?%YT"M&?>5<^;Y4HJ[GQ(9S1Z^&3_I)]`^D'HT,2K&X=OXS"0GD2* MQQCCP8EN@38@P,U?/C'=\A<+GCGVT*9^N<&[[Q&-([!W/M8.LCS M;C6:%GBS]RTM7;7:"_M3W<98YP>8RLWF1O[.W`+)--3&"TDUH=.PL=$5)_<% M_$,9E)(X)8M@>E>OF)LI(/^XBX>+![8,&C1/P)Z;"7LK=DZQ*O?.&]DYS8\=.K=@[Q=YY4WLG?UI\U^9I%)NG MV#QO:O,LV&R"N8Q/:"/KHK++D)JCB"7UZ\L<#SX M!;,^AU,.^\;Z$%(MM!UMFOFHS4VY6B\YS$I,4V#"/C2(X`NLH10 M?VO(H!,J05([1B@W&J2NG?F5/H\Y@L'*1<*CG-?-=!-$H)F@W9(U8@'T0;(C M.!X6&,0HRIC?RRQ-C`R;2[90=0*?D6Z!WO27^O`VM/R;%.$F;,T4T]=-)-Q;Y,7T_=+6P94P`@6<0`V`KBH!`R;QV*-OKU9+]5TP@*YC.;\2 M_^=V9/CW3\2F-]N/7M3"&&[J^U!1&X6ZT3:-1JA;:9B^TS5$S MT>;OLL9E5?[TA9Z.ZDH$['&T8FUDJK(Y0`U32BW)S-17<)!$#26YEL2%-:KT MP4"5NA)5HD'L/^KV6^`Q35.6(E2*?H/X7#7:*_,MXIS6GPN=ES"OB+-*U$ZY?S+TN8S?"Y23*N+G&OKH'1+FCU935>;]A=:7QY`7P!\ M!U![+,AURETBX$J!1BOGW0]#C5BBW0KD=CE'7=14!R]29 MD3DD1V%QMMJYD.GTBY47J'R=JGR7C^D]F,: M7_0F`)37C;VHU\&N:A1*9@^4S%%'TC[?V-F??;W=WQVA)!?'Y0Z/2UWZN#@A MMQ7K4FK6"N1A'_3*49^0&\PUV1'GN[;-3WY8DLJ@JDO)`@(>4J*'4X1-F3L. MLF(X8U5!D!XA7K,Z'#_E693B6YE++M1J$@?T^ M]$9?N5%E!6OMR1=-''@PU_C']_.-1RH9(]+%-V3*PB8YV/:+=VG;R1+OY M_.2)]K:3)U[QU>N9+L^P`+[OW/]NJR(OBEK@K.U>2%\Z22B)U]7_=]CR7)W626*33H$JHTO#0<%W\;/UX?ICWW[?O_[E/1PA M'?SDR_7EY_<@W)7,N;4SS\8SBL:8IZ5^O+'1*B]_6U\S+2V_\O(W?V)N.`KX M7ZKP]@ER[PH'CQC;YP%#ZC(>+:D:\8BH+4C3,:_AR M8II;Z?QEPV$HXI)RPV*DBS6@4M^(TJ.HW3.!/@VEH/!=R,;GJQ((<+_8MT;'NDN,Z]L+4Q($,;96Z$-+Q%$H#>&[Z;D M&"A9@X0JBH^12Y"1\QOQ&SZ9.ES@8+Y3^/?!Z9\1#4)3>ADU#6!^TDQ?OPP* MP*HEYCK)"93F.E9\E\7*'7=5WZ*;7)>&9=V:\':L(39@303LDC;#8.09&F@G< M!=Q5E5(&LY2-2%:64I7M58D=9X!%W&6]>MF_$UT4:)EN?/6*.KGPLOTG\M3= MA4;4$N.>'X"24"57R\VT$)A@ZB>2]=+CPR&#=7/9?/&K`4HJ%L^;*\)#M?0: MY6K:8CIKH&N2*)LRS9MYLEB-A\J/U\NM?*$H:Z3&H:M$@=BQ`#1M+.OH.+'U M0$$B6/M/*D482N+'LFH9[)8!*&6YNZPP*_`$;]/%A;!6E!4F(BJA*G^`\Q'_ MQ-]_A2N9/0X?3/5,O\8O,V@:E26(K2?+1JF]!AO42T"9&AH<=&E`#*K"PX): MU!1.Q'3JPZ;!X_R7;O>VA`.B@9B*-IN')7U)U\<@.45^UC`9C2T>IV=%E`Q0 MP4LN5B<($D0+4IV,\XDZ*1@M3+U4^A[#$1&20-I\26$!2BC"=MR*TKD)!`4]7/(!UYO#I=3#$SPZH:%R.'!=:2@(G\3B*#@BV M1:.QANGX>#8^%)9,X8"<"3;T9>TYW#5RY=)Y)4E\'=@=PN3QI39KL#72(:G. M2!V#C,1*.S+4)-Y_DRB6Q>7&SCVJ*!;`.>B1)<:^D2Z#%S$;C`!L)<8";8Y+ M4RB+]&'O%\OPJ2^5YA-,E?;S9U*E+JBI!<5`Q,>DN?4ZZC7!?N*YC3V=(LF@ MT'9;MKR2[9FV.O3>E\&+$V=&"F(@#1@R`;@\:!ZPGVH-00OK5SV$B>]E$U.B M^5\D:H;Y`!T%;XF=K]@IW\'#9O7JE'1WH!W9H;GN*.6\T*%-J:TW$V#X`G;F MQNL%&&[]U46`X9+`M-:6`M/^@T4Y^ZC\H<-+U3^-:3\"TPI9V&J0(I[SK[K: M6VISWR>]MD=;[`W$?J;7"HM\O">8(W+/@N28^:->.=NMV2QUF@>8$/X:2NZP MEK;6:I?:QT`HLN=:*KO'XDT[O7*E!=N/5G/M271?K5(IM9H'R'UW""IL7]:X M6BDUZO7#6^/#BZ[+M!L2\YSZ812=I0Z[0IEM6=!/6YU2M?':]`-GA0[;`D-K MNU0[!NJE0U!82EVAQXX)627<2+BI_TRQ2>[Q:K/7O7F<5LL*.2E4V#&L9Z5\ MWCE\O768IM>3FLSC?A(7A(F%+BMTV7JZK'/PM>RV11VUP3!"&8_1^_V39504 M=R(9B[(ZEH4&V`T>KRJ9W@.B30!X$3&%\(`3/8K.2X-2PPN7/`$$ATPP"S?S'-<::[@KF!2<2(`8-^0&M" MV=:Z.`"ZYP1'G#6TG"1&$H0PB4!"V(30.YGW./4=>9>QIK`\!$]2`N,D\6,^ M)=J-R0Q6=.*4K2],%UZTAHE,]YXB5BK+S\I\180W@U%(_?9Y@!.%0&Z`[!JC MQ'?B$*;4%!)8Y9%P)F7K-[A$25#8&<%"XY%0?OSZ8EUV7DB.A!,I;W#O$R==$81RU1IEIJL(9G*;&WH$/1H MA&0=[UJMB?34&._&<"->#(3L<,#<]0I&*X#$S`T99.N4)R34Q8/`X]6=^#7I9E\2M)DRG#)XN\"[BT M1EW3=',-3#>&Y5"V,Q#C:H&A)>1A(!NQAQF5&UCQF)* M1;94W1.:&L6)HH>8>4?H/4\Q&\(G]Z%_SR1[`VHF>"@"RPJ><5'#:,H5+?LT MUBEY0$J*8((BU+->J(1AUXG&UI"JDQBT/#(UGLA88+_CN'.^(W1CI7MV,;^; M:#B:I4H%MS)ZC13#!1:#R7F+(M"3\*J2!7L/=IQO24TQ`<6&O%*Q//K2L'K3 M):1\3X^ZA?).(6CI9B'E?CV`:1]96WIS;K3/N`RR<>A M]&(:0Y7R)@>*CE2S"%%L9]DV$G[:MCU:>]\1KTRBUCT&PCP!`+;PWZZJBK=3/ ME3F[^AY7G*N[43_M0OWLB?HI_#?/O^\=$$VC$6[=5S"0A#NH_F1:<)+`E0\* M#YOAEXB&T0@.`BNP8@7>IX!<'A=`1FNX^KLZF'@Y&(D0:XJM47GB>:CM*?SP M?^Q=Z6_C1K+_/H#_!V(PB_4`I!YOD9E-`)VS?B^Q9\>>Y.W[8E!2R^8.12H\ M?.2O?U7-4Z& M[M_J\AUDL6[L;<)ZX"Q,+_%-<-(!:JF!(-]Q M+WGIG3\V,2A<<6=PUS%-_12B'CB`.3H)ACAB=X^RQ)%)G$I2R!>AA(8O8^X! M_-O,BYL+4`;B];,]BF*H[C78X_%F23O69-?;^18I7*MCZ@)^ZHG^Y#QSDIC` MO-/;;GA_X6Y]]7E9^UO%=\NFKC&;JCZS8]5SEI2!?6-R'7)63`+8>_SS(0BU>']/'$D7+.YSK/.(/B5R/5&`?$?J`VRW7F4@?OAT8Z6 MQX)J)4N]D7[%;R@?O[T,3]N?^2YQWL;-0:E0"*T MPWXG$TR<^Z*.3MJ>4#A_+C40N-4VIBYH+>Y;+/=C8L^I#8%/G+W+I3]KR@%[ MQ1N!NY">GV?6=R!8H<9X;CVG=NC#0IH6/AU?]U1<3D&K3SS$SR_$@./V3L5` M`6WMD.E.#G=AG"Z8)"Z=O2NF+GU*&I^@RGVFU*3@_PC2GW>+6&E)$.\15&M9 MDX5"/P@J"BAZ'LK>HXT95$E:715345Z\ZEM$!-B(!W#VKFZ(`/'*X^6FFFYQ MY07[MA4M``5B$U[`CF@!B9^R"2_@1;0`*M<;\0)>1`O8BQ:+6`))-E<>3J+9 M8;LA"!3P`\[>O1I!8$NJ&$,0V#.*MJ4GQ:8HFB0Q"(&&00@DZMZ;TK_F*`%) MYO[B'W.5L?K#TDWMAAH6ABYPZ#CL2M7*&:MW9.DZKU2L#%V@@O)>D3RU\_+E MGF$+L.PTABWP(]G:1N1\-T#YL,O-TF)W]"1U/O[(=1S'PXADH?9^VU&K0C&X M/_+.]#A_7`>F4L'FI%7D:?WY0M$O?6JQ@-USN6LR#Y?4L)9H83F-U.,=15;R M2BL(-Q:TMCB\5$LSUA8#5G'IX5+0&PZWOC[+_`^]X_TG>OQ/9E$#KF:?G/SF-^- M]=1-^IU_]1QGZ/F/EC^A.R4;AP;]X#^^DNG/[XGGW'X9M'7#%.!_DB*)PO^( MHF3>7M_T;Q5=NT6#*::0ZTGM87#`->4_M* M1S`-K2,8JM$755GL23W]%E_\!9>=K'H7$?_CGQ5 M`.(G[M?!S0VHN&S@A4GD>^T3)SR2T7<[%)"@`LB#]YT(-/RV&(GU.5Y2]KF MIAAUD[L\E_AI%I@_2&!^HVIF;84K0O9R&PO_L&272B5[)<-1+[AQW1C+!O,X M1WB+Y6;]!C!>OMT%JWA(ZH65'STH]<+W-5XU3M!YYH59'($5)VI"4W'V*KPI MGZ"K%F-O.>R5>4,\0;_:P[.W`E>X+RRJF&JVD.\50S#2>UP,%,R].)Q6[ZJP MW3EX1'EA$K7KE%8;[FIRFW&WJ=S52F?M(>X_:W":NL`")0MKN18, M5UH^Q4Q7*>*OJ\P1;SZ795Z3:JGH&)_WFHC$2W+YGF@C3UY]DIJO"2U:@CD$ M)`R=N%:&V:I3..(2+S-7O,'\5165Z51KHZGL]R\ ML;!B9?2AS*OF";I-,HW(-.*I*<<$@PG&.E-9_T*.1E61O4C%BJR#T:Y9M*M^ M/*B0'$;<"4L+.X5#+/.RQ-+"&LM>EO77:/;6-NNO@4YJPZJ-3^QJ,>HQZFW0 M#BO%[",_1DO]^7UG/G>(8&-A1XQC*+CDT;%=\CY&^:*OKQ0:O[YH>%/Q\6?/ MFR`$X^&KB]L=754E31;ZBJ8+:EON"49?,02YT^D-.Z;8[O7[^U<7AXOP@?D? M-E3&+]>GP]M1$K$^='M]*<[QU1");7G_\M,MO4D.]??2/KV#IV&\Q/8=_)"W MV(+M[^Y0!A>^O@QNA/^R%B8HT;0I6N*:XLZC6+P:TF6Y^O*-=#DT&N1K%-W[ MMUZPOLZ\O!A>.EM`DD&[)O";KKSZCO6'"KWWW MA7F\8H15JN36>OOUR]%(MLMI].4M4]$-\G^#WSN_7EQR7_.65J?<*7OR<$4X M9-@Q6IUVS!O4PPG6>AA1KXUUB`&YZB;S&J^HM;(2AUBTRK>3S)R*"W]51'WH M^00^S9&G./;!A;[E!DX,A$6F4S*NH;J71/5'$_QSI?W:)2_GD34]QMZH"WE& MQ6.D-9S&H=F9F\Z::[4LZG38R]'7GDD-7A./;'AK2YPV+[?-\IV2FJGIAEU' M,3J>Y%IOVT7=R@7;XDW<)0E[5G#_Q?<>[`F9=)^_!61RX2:-MMR[3HP%:Y/@ M]1=S$S*V9Y83_/Q>4%:NZ>2N9O:5CBGHZD`2U*YN"N9P*`EM0^[I6E_M=-K& MK72KP#B1:\=?MP-/E:7V[;?K_OM?!%DT=%$4\\7OOJ:E6\E[RR==[+':\V9S MX@;T0-#Q?3PCT,K*[G/^S)>X\6('[SJOYK009?!$_+$=D.#"_4)\VYO\05`? MDDGG`3Y]1]+?O_CVF!R"GO(J.475&/3ZNJ"8'5U0^PBG+)H=H3WH=OL]71R8 MXO#6A*%O)64]16^!3+HZ'"26SQ)CP'I\PNZG9Q' M.K>C3.CZ6_=Z\*]OP`#XZN!W^/^=Y_>"":TDGGP[.4,S"*ZX7VE#9B MC9*.Q]@.&7F)#3)2]G+G7>+8KA>$5OB1_G+A_H>,<4`8X]Z:<"-"7&S+@0T\ MXJX<4]O!86FW=EK)&W<8>+#)8XOK8,N.N&UN7+V0M.+(.N+RW#SR@\C"AAH> MG>^--_=N+/^.A)QUYQ/Z%+QX'A"RZ$I34;N,VWY+ZOGHXTK';^RB;4^*(WZ0 MQ):8==+&OAUV$$1(/ER@=0&O-!*>H9_#-&>VF[&IS.: M`:&^LN7'1I-](*]I\&<$_+EP05XCZME=88?AFWO+7>M4+/EQ],<^$`C[_/U. MV_P=Q=L%OU_O#MM=.#>8;4&%DX304?6>H&G#;EN!?\R>G'A:&\X/"]ZNT6JK M!W"[#DV[`[$T&Z^#O>U3AWP.VY9,?O?P]L.!:7^%+_]F/=DS4(,'X-GJ@4]4 M3<.0I*%@2+(JJ&U5%`Q9'`J29O9ZG8YAZ/3`IQ;X!5N?O/]%;+4E[0#LV9L. MB_1?8M=EA'E.5U/ZK>`J"D$GTD;=\%U[?`@2KO&F-4E3>FU54`8BG)FUH2YT M>J(N#-O&4#)$11V()I!05M><+G2Q+9N2;.2$W&M!B[2X<$&[D1OK:4V[H8.= M'41)%Y4N'&EU258K3H0AEVU+QM2KV]J[9W.#F_/0#VUH[Y;MS!).Y&; MOMMT+BY[5[\-X'LWG?\=7!_*0<>$O:>1[_"CE4R]DMN=88,E3-@&9Q.T.@P% MAO\<-D/P$B;CVGS).H9)4^%UA,V7X('+1PE3OE^ M4W>EZC6ZW[E%T$FSN)OJJ,J0-#`GW;V+Y MJ#\&V$%[B_8M9&(?X.L;$[XKT^2%2=^VK/TWLI\UL"J'Z*Q]50E$KU+SJC<7 MN2S.]IZ>!<%/V^Q#Y8_DQ%9+>;R2T(9;CPK?X#1.)MQU:(6DWK"%%6XC?ZZ( MO*J<`)IWZRRJ!E189XX:,B_I)X",WQ[?J"T42X4YJRF\<0J2LS,M*V3:'9R: MLYH"6[7LD\4!8AX-<$4;5B9X8H>*48]1;Z=KR<*]8_SH/L4WB^IE,8<-L]JR MY6]>R\X)@N+1$@2SU#\8Z3Q)_ONXFOTW]MS`#L(5V%>6!;AG%J#"L@`K\FF6 MA\6R`*N2+<.DCV4!-C`AC64!LBS`-T)=5SYUKA?Y/K#P!4>X&A'DLIX[QAYF M:]GUN0/F!!WE`F9(X(#%KF".=@5C\(K&LDZ;PU!)YV7Y!"T`V0W,R3G+RUH3 M+F`J?^=/"QV::W"JDM"F)_#OS.XTBJ\*KYZBP_"/:'\JPF&95]6R5(V2;4BSPB,E!V]-7J\C9`#C[,OQKK980\96 M'0NB3Z;$]\F$I4XT*MV@26NIW\U6XY,I*A(A5W1>,I3Z&84Z6/N*L/A<5ODT M<9BYZ"ST5T.J5?U"C.5AG$2127`R91F`3>2LR1MFV:D85>,LLU`UHEH-3U@L MB8/M`'9CST2"B003"9;$P2[362("HUUEDCBV>\OENZ;E&9E#!O]57E/+!K5D MP?^C1E84A3?%LHOQ6&B%N8S5#*T<)2.$0C$7@.?6H].M+KLZD9>WK;_<-"=9 MXU6S[(S$AEJUDG--)967VZP6MSD<;4A*8@.B&`V#RSWQ69Q1CU%O@W8X(%3S M,C3SD;"4<\<5ALI3HD?<%/?FW'AO15R\,(\PM:K46"[=S&V<_<[X5$LZ:SQT;'@V]]$LC,O7\%*+90EC5&)@Y8+#,>\(R2PR6 MN2*?9L"X.-WN1,$$\F<'G"`"A[/DK^S MW85A8;[7!X-DWB@=/Y(%@PX8N&WS9KOLJRH6N#U&3;G!RUH-F^U5O?28UIW@ MN9GG7$*[&N6G[L10-=?\5.6&72X]A:)91J@B?$7LR+*]BX8:H\IPV)1J>$]< MOWR(P=/<]C'B2R/*5ACZ]@@.3D&5;1-+$:HUU8ZA]"JS."8251&)1MA!Q:CA MH;OJ1[.O)""6/[[GQF#Y[+#2MJX14GPN\[)6=BX1.XD=A[.27#:,/^/L<1`] M5+T^>[9^)Z]N'`1,4G5B4T0S8ULCV[%#9O781JB3U:O,XIA(5$4D&N$( M2;QDE'UM_D/FO/907JI9-@YM93E< M&=O+/);ZG^:NIE-[3/P@R;8G8,K0DC$+=O34**E==IBJLAJN(1PV1<;A)G-8 MX0VQ;*R4'^*(=4UCC2,K(!-FITXKXUH=)9SIL-U/6JP39;/YR^OM!H0!JV:1 MOA`?_D;@53LDLX"S7+1,7GA/?&:2CI_3))8>_ZO:%7\C.`N'8HFY&\WFL*B4 MG6CZ0QR9^A[\&-IC#GZ)IM8XC'S;O8-Y3,@D&K.CTPEDO:VS*XPF\Q?\$%DO MNX"Y:GX(NYRJ$=6J?LI"9*@8"A-.6K;E<)[+3>.N>C`98ODNV#26;7&"5"*Y M[.[6S)0=MT"U;#M66?XR@U8CJM7OG-:[M]P[1(1.L#N:#6A8$75W+AMEV[.J M^>V-X*NBL(2+:BED9L::>"[[W7(B*TEXM["/@.6.F=4ZNG;3^3:[K6\TB\]5 ME=>DLB](F&]R%)]3XT6C[!N!-T!Q%+]5SPYKG_"(5*[(.1KMFT:Y^(98+ MUB:VG%P/UB:VH9QE;6*;QE'6)K8J3FK#6G6>V-5BU&/4VZ`=ZMUB8S1L`P`O?VM=MPK- M:OP4+=D"$DS(`W&\^0SK%]`MCF$KX9G0]Q#)!'Y]IH"6\.)_6VYD^<\YG26> M?A8^XGO1W3W7)V,R&Q$_?T*)'U%@9E8`-@+AP8@+`\/4;#?T.,=ZY"(WM)VX MJYOM!R'W)WPEA`7&JU):'%(`)Y>XZ?$:(B?$]K<4;#.(BJNFB[$#^,/4(KA.&C/>;!7EGX1*/(EO7L%/M*4H64A7+*3TL90F0 M]DBQ"9D2/VDGP5E!0$)L&HR_;N8UW@2`9%')L'S"!??>HPN\<[S'%M=!]1#? M&.3W!=P]C#DBQ`66C3V8T5^TNA/$PYM.X9M4-K#ITH;I^`14SE_QH#`UE(:S M=VL?=D'B//<.A&M&\+]AX)P_,./>IYGG$\&QOX/<"^&]Y0H@M/GO_4\H[`26 MY$Q`;F%+<9\[G2^'$J)J]$YNZT?OG6SLWSM9+Z^!\=$_S1H8YS1G#8Q?.6;5 MB5YN`^,?KI=NOV#^T"13`_C3=D-5C0AG6<\=8T$'`C2W??X:93#W_T?(G#4[9+S>,I^J\RE*Y&\E9C5?,LB/N/T3E+.LK=6+1 M-GA1KR%$21UT5D4X+/%&Z3TY#J"[JJ:I&"Q:B?>E:AW1U9G.V@.IQ#!KR.'Z M^5M9R,(G#\2-6!W!L25;JZ$I9HIK]Y,BKS5!<55/365WYF>LS<=I1%GG5;.& MG;.9LMK=%O%R'5.$Z^=E?25AY+LI4&F6A,%TV/%/BI)4=M47TV''Y'";-XRR M2S8;Z'!=(9@RCQE@3$<=W0IK6@WOEIB.VL.3%N4:DL@.Z#.2H*3XR.U_\V.>+L[2$A=GD8Z<[*;RNUS"*S6SS M[H<(F9>:$`2LFMI:JKES;&MD.W9H$U9X=^K]>=K"N^I;U*X5V$'60F>,?0;. M$"-AQ.[43G`2$DLOQ:O:&9>AT->(:M6WNW.?C.WDNB'.:YIY?IB"PN1JCQT? MCJ[M9(,72T\[KIJZ:P9K%9U7VO6Q9"RF5^VX%(OIO9YV]3N!7"X!N,$,SM,3 M\O/'.+K77.M<,DRSQFMBV3&]9MGDDE&:-;ZMELU0EL;70*C<$QOEAE&O[D## MMCOVB14DX4'$75V3QX=XNA1+%T%])Q%!I-8(_NZ'ENUBM)OSR9WE(ZYH,L@2 M0NM:'-?QGY'MQV"]8\]UR9@^_6B']\D@-Y:#L\#G`CL]ZG,6-\X:IR)DK?>` M.,<.'38(DB+-;#[K9D.!;CT@3&B/-T',6F.7&1.@48P"'XP MI\XK:(/\6*1.@39S#YGS0+*F[%SH$W<2)/,2*4BPQ)\548+=XL+MN$D+0@'[ MDXQX4O;X6\!V3["+.BAO6Y&P$>]XD@)RTV51V&J*<+S(?QB)XN6E8'E(7VL^ M][TG>P9O.,_&M;`(<"*;M3:J^^19T46(WYC!QL`N/+I#Q MWIXGNC#@Z8\QJ3)]EQ@QW(NH*1>U,5)N!_3\E5T+&LV)$@WK@?+>8NH21/*B MD8-9=4"YQY]/;"#"JD>C_\"+5+V[;@1RX]@S.Z0K0<41HY-?QV,'G&+$>E8Q M%!P1EWZ!`+\NO/@UAEOA>MZ$X(^2:>B)!@E@3+!VB0QEJ/E!B^NXSVLT%K`& M:)T*%"H#&.31BYQ)*K>1FTKGLN5(YEK8E_F8O\+OJ>P16 MCBT7J'-V%]D3ZC6,@2.X?*1WJ-P7$!"G-Z@2`- MJ/!ON"I$4R]L?]8'(H!),1#-64.'>.TD$O*#/2')=/H" MV1A^&/87&V>:4\C07-)@.EP+B,4)0JQ9XHER'H!67UDV&EKL8I"MX+G&!>NX M(3HJT.%0&"#%`R+C$.01R39OPG#8S3&X30[1K\X"&=)/41R^,4[' M8]@[_T/Q1W*RY!$>\4DFAVFPW-1BWL=D4U)0R=I&N/;.VT:\T(CAR4E7]HZ= M7]N(*G]:=JR8TUQVK'CGF$4G>KX=*PZ4Z$:N1#^X-B$MX@M/-Q$G#'AD)T+G M1PAV7G90Y'WL^V%69'.&2C+64AMFWD6/DK&[J(I27=TJ'V.+GKG;]/Z3QHDX M`YD'S?Q0"0]MT08MGWM4UR(5)@)K,RV`G(Q+C(%D1_/.%OR?*G^$]3";BD!`PRYA-QR)C+/&=USZ' M_1G(^W3,,$T0PB2KT1V00%35$E'UGDY@%JF?<.R(I=O9&0*`*%G/9H8#BWKS MA$9CCB>S6%.:0>E-:TKQ?!S+4?VE(M1I07X\XJ7X,!T:HW2P>,3K\&$`H*%` M),#OBYI6&"+T_:RL72']\(X6O;9]$94#1OJ;?F(I,]23O]5.3&4)G$-?^"%C M7H*M1S[\\H3&+UF22^P+,!?@E&8.,)&8A=]>Q'4,H]YJ$0*&,$<2*\:GZ8 M^DB*YU"&0@%<%*R`.F9`"P47D^^PVA`7^^&7##.`+V8]RW$+"02E&"P"K_D/ M$MABB(SR0:",!/0A@?DN8+W`U$;QB?(=-S70$J9"'P9TPM49URL(XQ&$BA_" MP#C,`J3'7R=7)_.A,F08-8/A0-'UPP&(0(:5)%0`?2"@'C*$C&&6/1]/^W&: MNMXX4K6=?)A)'I)G/ MB%,VF&-5H1;%@QH^T`*N`Z),";"-.:2$H`S*(D(H$+_@\K1HV#)Q>`*N$L">X*1S+83X0Z(A5 MO+*5)P3R35O@GV1ZR%N$./KPRQ+RT",J2G=)X\29OK.!?Y\\ M=H?_^<>G--9N"9G\=LK%Z)H\=&:`&=>PP5H@]C^^P%O*'],GSU+4PN?#2SH) M(^[Q7-%;(5GH7>CT[/>D<*\ST?,N[%-VW)MXZ9A.?6F:;6T7J_3U.QF MS]&:=J^CF99CV+K9J5EZZX:/DX+/P;^>3>GHBS%?XOJ)+R_P,H.=:09>9PXY MTQ6;ZT+LY7>O=&5I>KW7L"RSJQDU5]?L>JVIM5IZ3>LU#*M9:S>-EM/@2_N" M;,NXMG$3)LMP%?,?UFRNV9X5QZ?FWUVV;,TV]+;FZK:NP7]U=#,((M MGS'F^K)Y=M4[O_R&OP<4'H4XCS]Y>O:/[.WV^=?SR\6H3\C`;Q"I>"P=*[^N M",&OJU(`8WSM7E]#^#@;>&D2<^GX7='N:?\'2S0DJ!8G4?B#:ASK8QGLY24+ M]F0^3]!N>$`VAO!D:I>/4;%_G-KTS)$XGJ&`?9S:?NYMB*>$Z:)"5$F<`>C\ M%-3-CMB$OL`F)NFO9A)_\I5<>B4DS\O<^UU9"]GS!NIL;6U;1PE:AP%D2@R@ M@GQ:8@`]@XQBZ&^&1EFKF%?`4<#*]%?]E<8']2/GT4X9A MY?O/GGB\\/U]H[5("7PG-L]K!4#B4.5%=HE$E0O9BX1%M:K=1A2OR,&A6N\. MS1^9T\O.Y?%"UAYL"(C^0@!L3[G"D\IRUQ9L6.C.LS0V?/_8TE7;VD/-W(9Y M%*VRH.Q\=4W52N'\Y(W7^L-M6'M`?U,GHWDP]^: M!=LV_YA#EI]5L`1(%E!)ZA6C_.QM%6:[RN/;G,8GTO[WF,?W-/OV)Y-IUV7F M=F@_.0U@BBG/'-]^\FV[76LT+,/1+,O1-5MONUK+,-N:8_;JIM$RNK7V^Y)O M]]30GE6X%J^= MH^/NNIVC6W][*N<+'2"W\_O!-0"[B%@P8)-9/6&IH_D"HU$8)ABMW%NKE/.R M]&54RJ\TCC_^IOP5@`"#+D>E[(%9A)E@MV64:>5X_J=D%(7I[6BFXKDA^%A= MJ=_?-6.]RYO:>1I>8YHQFM\2JRF_?#+S%7-##'ZH<\[J=555OF: MZ(:AVF[>*DH>V97NV.2%0Q'Q_TU'`NNB^)6H?T0BVBZ;M56^+`',BP3OTLBY%!\02,^^O9/N6IVH]ZR>EU- M;SD@GE:WIC5Z;4.KZTW3,MMUN]%NK3OEVO*YBZ'K?W]E2>RB3[-0]3DUB3X= M_C3(MY\5P[@"8:`_,Q.O,I!\8CN8S5GW6CG^>GYU]5$Y/6N??^LJ%]U+^/S5 MG\W+[JLGNN$L&X]W'OJ1K_:?G.N\^F#3V_^O,J M?UH6'F^G]'V-FENIQ,2"=U'M#C.65>BE$(:WU^6^3A9D#7H^1"]C!7J%R%^D M2O0#N!1]QL-^V5F5AZ[OOAAR3-60G34KQ-&&K8+&RIFA>\ML/DP>VYB_7D(> M5QA3I6@V]/OJF5)VA*3!5/HD9H/J6M2"Y%PXNEHW&ZI1QBXX93"S!6%SS55K MKJLVC#V4B16#S8?.<$LUZZ9:=_:`F;3S7(42Q8)/[EI@,EK5;5G.T:%QHN?= MG$_&AEO,@CYQ2A@UR!W[^J_K)XV\#W-D7%C6N-!C/J8M5->:%L2#E)'A8;#9 M5AVKKIHU&1D>!L-K=;51:ZAUHP(FN/R18>6MF8P-96RXS=C0EG:JTAS63]P2 M]GD3>.R=W\5%-T(116+"M27#5TZG(: M>)8$/FV`+/.\WY/G72L@+L9A?EJF]NXQS1'=Z=-9KMU"][+C(!UCJ^$P$C@- M_=GZBN5N59L]TW,[;84[62'ERJ^\4"]>^?%\7CVTRN(.#4+>GUHR.><]N,*9 M9W?DQ6+]!6=UKCP[N/SD&;\VE\8HFY+WBW<8D==S9$@A5[7U0.F]K:(V;S9V!ULLHD,:1?R\(IZ=$]3B--`H]64NMV0S7WT9!6 M*J8J.$:GP2#BR*G$7]5$!*%2,2\'_@G_@+]0`6-+$9>1!5HRHAJ\0!^5>X(0 MK(G46E)KO6<:IFFKME7":N)JRG#YG*F_@CL:XV$*XCA';,`=JYD>0P!HJ9JD M:GK7O8"J6[;JZ"4L:*FF%)?IRN.5I^*5:HPCJ5A,*I8JU,GAPJ4,_D$9+]9E MMLP!>4NRX/LP-G4Y2R4KZ#I6+(M#TE'2L4ATW%GIK:PKW6`K#J"X,\=/R[K2 M.EALT?6E1X`DV5=:2ERHF?\>EU=Z8M=B8IW?%?-ZSVYJK<_5_2CR7M:5,N'A?DI+S,/13*Q?"\(>>J`$=>Y)/RW)X[L#G+$^!RQ%"R MKO0@0XIJKJKHY1.RKK2`(EGJP$#6E19)A,M7"B'K2J56VH%64@VWIIIF"6/9 M:DIQT1VC]H@$MS3#=%_40Q'U"88G2:AB(I!"_R#.U4^ M"90Q\RF\'-!854BLL"$,DHSHHS(BGM*G-)@6J)*$X\#W\18L0`SY<,A_^&]* MHH1'0)1$03GZH4@56#@5:-JN:C0LJ0"+(4109 M+KH;)POKI2+:C2(R3-6MRW"R(")ZS72Z&YYT]6/Z&M95P)BN6U2;I*.E8)#KNI<[^N9;7L^6O7\NK M6VCK.^F@?9Y&2CBO+T4WF@[2B"4,WKFG$57HP\!/L>OU,`K'HJUV/\0$$.(/ M4I]@V@?>(J`[?NR'%>*KR41)7$:/8H#/GXMRX;:(`SN:(0. M_9@FH]##6U@\_)M,?#9`7JA*GPY(&E,F-9\47AN;NF')SMUO0UBHU]^.L&#E!W-0Y4]+A(4YS6?5 MW8:^H_+NS>7"?%']V?*V3@EFVICBR5R''!/SN1;4I#-BW8 MC7;!J2;%1(K)#D_;BV8?VZ6M0RJU=335!C8N,6OEDVBI^*3BDV(BQ61'M]&% MCR@OLUQKZI4PU;K41M-0=;VN&H9LGRJU836UH103*2;5"RK+5!19;@/IZ*IK ME#`G4>H]J?>DF$@Q.=28\F**3R=LIC24NR['D3!N4@%65P%*,9%BZV;!@Q^8UA'2AHP,0/1#.;HBVO67->>K__M"ULAS&!$O=2GY\/N<$@Y,*=H M:7Q-'BY)0B\IT&'`?,8!`+@4S$C\?A*MT,34; M^>4W_#V@\"CL,_[DZ=D_LK?;YU_/+Q=WG9#AWY0Q]5@Z5GY=,=:_/@6&^%WY MVKV^AOT[&WEI%G.$A]\5[9[V?[!$0XIJ<1*%/ZC&R\R7-\=+SL.3":V$GB.: M(:G!0`EY4"91>,=B!'8X[M.`#EGR4?$8R$$43U$@2((@TQ..Q#:#>(#7A]2C M$?%A&B1)DS!Z5"*0%@'G(&#Y,\RV/AV&$<7/P)$R"@J3K;/+YGG?S8"HSMRYK>/2\ M1_>RDU;PFXH-M-DY*.>&[Q\C>+UIOGT6;SU4W#"/CWDKGHKQU:RKC?H>"F8W M3&-OEPJ'QE_#5RC,.S#`5AKNF:MOY^QV5-5`%XG/#<,O(YS*&6MV'" M\'F2)!'KIP5'<-LAJW]V*MO="?EG=NR.LI+7TY=%GH]-U:SMH9&3C-ERXZ]A[@%12/(W)_X:JNV4 M:?^6,49KB2/$++U)F">81YRDWF.1K52!G$KICDOUMPOU9ZN&G?]95=',6X'$ M5V[\JD1HB[!G4]`SF(?/2)_Y+)&64&Z(\EG"`BU/"D:1!*,R+I*A&OOHXRQO M\_#=:S"*,1E@U1-/EHSE,>9>A-QU2YE9)579&U69W:A+/I?`(DM?IBI1W_EP MR`8TBK/F:M3S/]PJK+ZK$)\;NN1S]?ELJ:YNE)'/90S% M.(R%TB>9;U63DF7&NUM$9F5?^Z!Y/+NXVZG7HDCQ.)9J0L:P8\4 M7F8)'<<*"=!:AF('`*?=2O_--<# M":TZ(?PU80,%_I0.R2#A&((P$X]ZZ4"&6'N2^;HC+T.JSV7P4$PG_[+KHGDH M\K*K=)0K?C2&N%<"RA0B,D9\A:=Q(!0I3$VA&6JP-&Y[4'N&:IA6D62[6.JO M,GRVW/QM6V&Y+(U"/U@^.R&#-DKR]]CPU;->O[98%5S7?/FJZ76]5*&GA5T7"O6 MUGC/[I>DGJ3>&NWPI&MV/U(&/HGCST?-R<2G&L.^>0-^DZ<%]-YG`3U2/LW4 MPY,>V#_3PWFY&W1[H;;NDOKPKM=&Y),+<.H'C]MO_-QN]]PN&'*MW3-ZFNUV MZYK;:K4U%QZP]5:GZYCVVQL_)\N]QN<_3/7_BOJ?-?@5\8#Y]Y4^SNXD692C M_I03C+LB=XRQCPJO4=1:6*.HM%T8CW M$*3_35GRJ)![$L%.Q,SBX%:9\([DJBC@5&!0CK]*6`1CP&Y-Z;0#H8>MG\*A M\.37>#D243W.0B+[3^%F%P23'893`XO@G"2PQ M(NBC:+B=<"YL/F^\*,>Q8P83B&ETQP8TF_9)QMGUM.$O9X3T\,-9WRH"3P`! MQKB)D'Y#RI(4YHI7\JIR/V*#$3Z=3G#92$\28_OL*)Q$L%'IR=ZDQ#!?%I,4 M^(_L:?D$"`'*)O1AL)"WE8?0EF%_9V4<>M1'\GL4E-<8:9QD_)NQ&8@B(`>S M=SF?8^6>):,9U4&S>(PWK.?&E`8T2 MPH)E@8%!^*?&)/I!D\4OX=@O3X!+(^D?'6$0&/TU7,9TPF;`$ MK-O_IO=B/CSKQT\%Y:F%>*5>7S8&YUBZ=@:6(XTPB?)KA@[):+QL0K9F#1HN M_*WEM+2FV>QH=K<'UJ!G.9IC-?_/WI7^-HX<^^\!YG_H#-X`]@/EU679VLD& MD*]=XWEL9^Q-D'P9M,B6U#L4J31)V]J__E55-P_)QWC&MDA*'23!F&)?5;^N MJXO5G6[OH#WH'/2_7QN\W77Q4^')9'K?FU@6PL^]5+W[X=GWQ;_`NR&V(GK" M8-S`O9K5_90HVI4@*:06T<8':?!:)[Z#.JZT-9(Z/%SFC3/_E?5/_/>.> ME_YM;I+?ZWU8ON>9#4/E"85O+;C"B^:Y:;_??OPJ^GON_:INKR]QZ./*BI_6#5XGWWNPJ\2/ABNE0J'Q)G9:S9*"O-I9G`?```-[T+OE.J?RV M#&BU*[7AZG"D.'!=E8!9)NZ$FZ"'@5ZX&`FEEGS3I\TT>[;XDO$[3K];?M+4 MRHX6-Y?1;:?3L[5RWJ;L0"JT,+"`21'@V31,G('-,&X7!FN=(%&9',&:0MSR M^P'`P`JQ%8"ZY71V-ZBV@N4XUDSIU)+C:Y@(N59?4E@J5N%[E/I+RK*# M<[M.O[=;1P%I&?U]XW>=3CV+8ZZA)ERSM&Q+QY6DMY>2%;9?O:RP^VF9S\VP M7,S+O!)CS!#]+.B@)!CK),ZW2M$?M$]V#W;[W<9N=[?5Z/;W]AO[K:-^H[.[ MUVGVV\W#0?MHY2GZW>]+T7>WV<5,*$[IZ(9\Q)'J).;O%S.N0YHLE7$#Y#-% MG*:2-\.>8^NYAEG`XPS:8Y^R&TZE0 MKL1$8GP&Z`/+=3PW2?T3,>6Q?N"I9(Q9RE@(/-IA)Z'.\9\+KB(F`D]X[,$\ M*N@%\>3@_[<=&A3^U7*PC@]FE(:)@B7=B``S_P,\`Z2$Y#2?/F*W0F%F`UCN MN`0>QTH.$[W^.,0Y1)@J'\[5\])HG[6OEO:JMF7.2;NCV53WTMN?N33@2?M MK:7ML?SI?$JA=W])^09DB604OVI*7]@.IOH^F\CX[K[;5;#XSL?:O MC08[$&.`,.&'_2:XQQJ-!9-ST71(4W?[WY]ZVRHO]=8.;8=>AZ'7+<'WB9S1 MLF9?,D5>)^/V^U-N'U&ESTEY-Z;:D@5L,]_+A\$;H>`W,*%")5WNTR.E/RN' MR>/G@*7"8+/Y,G#=9)J0'[3$F('^C#E/ZZX7@^K-EA-]7\@3="]PZA7&.Z1` MD#M?V8#7B@>17U=PK0O,3J/ZRNTJ>0_X2;RJI!CHL)BPF MK,2PZ%B5`6XMA>IRMH)0KI(`"'[BU2&,18)%0NT^H'S:"3X^N_QM<#8XWQPW M>'4?TSTYC3UGSRHY*]JLE5O%95IP5`\<%5RPA4GU8&*-B77G<`4A725!4$L_ MR2+!(N%AC[DV!\GI%VWTL5LLW$E`WZM91_J-=5^[Y_2M\ML09F^UG%9S!747 MGIQ$U:[7W`AE9OV;RB[8PJ1Z,-E([=#>=?;ZG4UA\88SN[6"BM&6T9;1K^+% M5LUG_<_Q/P=GI^?F#D[-L!O-NR'NS&,'NKW7&Z MNRNH$6E=6.N;K)L$L#"I%-6J)4/60CVT]IUNMVSM4`-)L![,MD;?9C"ZAANZ M?N>PS_5IC^\:UJU=1306')V^E7";P>RM7:?3+3OT7C6O=BTXV]M?P8T_==_# MUC&M%-6L&'@+QW2_O8(+QJO!X@UG]@HNJ[1\K@"?5W#)]J:=K)[\?G5Z=OQ/ MFPU"$;7T+:OWU'JR<79Q?6_SYDG(WW+H0P#F(4^3_U? MZ\2^]G#;,GI#&%WV$<-K')P6 M![TZ_<_QSWCS[R.GITO,>Q:3'YOB,]HN.\WFLN+KB\M';BI^`!O?Z]:^]9@/ MO&ZIN'HJ5F0=M:2=I:)%8,T06-I[E9[SFR91==XBJ'T=QMQG,HAY,)9#7\`, M>!2).+IO]:Q+/+O) M_1U<7%]??/J9-6=W'UG1K&CC`_,20:A9,#0>QPR-MX3`PXNSL\'E%?3JAK[/ M9Y%XSUSA^]&,NS(8__*^J?^><<]+_[Z57CP!BZW9_/">#4/E"87/%ZRAATF' MP?M#9O/[8O12D_^!CSX?XQ]-XO5&O@C8)S[/R=[N.PP+^3KLED*J4Q%X MPF-AHC2)@6`C)T9S% M$V">&\X$"T?XAU3,EZX((N@]%DK).%02YLD!,K[IL.-$X8#0)?1QG:BO8@[+4H*).]=/<%TC%4Z+ M<\]SL_H?(UCQ="J4*X'Y$\W0J>)0HPU0@^E@&T(*[_TTD/LU# MZCJ@SK;DCMAQ:`B328X<*7R[;*:WO>NCCVF/W`4\S'@PQ^+7AT!://!"ID$?5S'\(UWAQ4SH M31*Q4:BH[5QPQ?16.A*NF`Z%RO<<^/O0!>ZZ!\IF/R&?ZRZ"^P4A"I(`;S):SVW0Z]TZ.=]G[.R:.2+ M`T:+&S#=Y`\>Q]^C.6Q2V)GPH-5=WGL_:DBTLI9#_,<3\DW'-(?9PE8;);8P M>``&[3="P6^@U\&V<+E/CQ3[R4S^,(SB4F&PV7P9N&XR37PT6Y[@0H%?KS%F MP?RJ(>OKS?"34`GH=F7,/DR4$H$[7]F`UXH'D6_!50:XSL53LOS5I4@2E*LZ MG@J/%7R2],>BRU*(GN5G;I6O5&8O,L:6Y:8#V/N+UY_'6ZV^L]>Q:7=ON;H? MX+#]"'C-/@(N.;&K[;1Z96_R5_A0L*Y6BKV:G.WLEJVL+%_?0CPWG7[IE\F^@AE2_?")O:VL5*#;V\HVB-E@A_3WRS8Z MJZ:O;#VU2E&M6N!8BVW?ZCA[_1K*^*K'5)Z\H\9:+F]MHMLK:C:'V5O[?>MG M6[O%VBV;M.E!PC>;96_[S0C"V-L/2C70[>T'&\3MK;;3W+.7'UAKQEHSF[3M M6ZV>TRF]"-5KF#/U+X-CZ[]:*GXO%2NR#DN[]:+=*P:Y;0WA] M;R9OM?><_;VR[_&LFA-8:X[:3,!U8F>[V73:G6[]I/`:>FNV4%_92ZHG':NR M$$N]FE'OB1)B^K_TV),W^/!O/R518\SY[. MTX#<)OK4_5KEV^YV]KNM+^WC_GZWO]=L])LG@T;W<*_7.#C/<+-OP[KMGAX/S:QA_<'AX\?OY]>GYK^SRXNST\/3XB@W.C]CO M5\?X\O'5]>FGP?7QU;,7\XT2>EBWX6ZH?&=XKV##D]7UBL7T>OA@(5;1_5#D M^@\&*R:"S928<966H@Q';"0#'F"!2NC/5"",L%XA;*-1J*8RGNORG+\.!I=, M"2KQ&&'A1V@.(_"Q+EH8A_#75ZPDB:V$QT04RRD5L<1RB3R*DNE,5S3411U' M(^%B[41=J7,6*BI(214ZJ'ZC#J-08U_RH?1E#-O<@7=O1)#H;J&YN)MA!=#( MU-(45)<($PDV;<^R.)8J+Q1WBC^(HN M2HFB`>BB)SFGR4.#<"H4%8],TH;%EK<3`8V5J>`980%)Z$D&,*2IB`HBDPT% M%;B\$4IXV,7-XMBX/Q.BUC@,O5OI^X;`]PI;0N/EMDKPM+XIU>?D=P7V(9,R M+)A?"VS`[I;H`#]_%;ZY2MTM]S?B4F4-#6UR-MPL MDK,(U232Y4`U0!$BP`SW:P.`0ED@6,X3X$HBM-_XG/C90D/7Y'QUJ7&5N).<@\@%V%5$`(;L7M@K^1$N%K_](_'& MNKXOE8Z-03Z@:*&:O@;-;))5>:.M#'`-7&$8K6281$71L3SMO)BK9J6P-8J8T- MIR@%-,2+J/%$Y"HY!`(-A1_>L@F_$6P1"B`@HMR<\><(RBD8`C%-H""DLYK$ MCY6.92>I`']7*"(;_?QR4.FP>?O#$LKV%_WC%ZIM_(>D")'X$-NABS_@:C:``*;B9C[F>0GREY`W`#*>!2(IR6BO`88"Q= MW$\I-VD'F@$9SAK$`&X]I;G\)[1*9H#U:")G:0GD]'70;@&+9>QKJ:!D]!5_ M!NV./>BMA?7;8*T;:CBZB\X6>A@5C9<#8+@^,@$-`GXQ`8@_!A2/[@@R* MD;Q#EPJU@ZFHCPRUF%L7S'7*PYQQ4]$^)=VNPP&9JTJ7*?`H1,#-R31&I]," M;TV`URT/>$7MN>S(Y=>ZH!4X`U\P03N3!6%<#!;HZT#`",VO$C&VID7HNB!T MMSR$W@KFA80Y\DT*7OX"1/7%+J,DQACE3"B,FG(T(P&ZF4GW49O-.*P$>"55KGV.?SXZ_5Y_N?1Q^UB5-$QT4G< MR5+'%[/CCF(?E\7P",8V891BI]^\0ZH0_-,1YOP2*7.M%@9#T^6I/,"&/8\2 MWV=R])..MDQ$)!;"]A@<09%6L.J*/@7C))\8O&ZBV[B*BL>UD>G`N(5U:H[G M&-`DC_B49+0,S8UD^LQ#'_7@2C%Z6[@_C.X'H[,AL11ZFO(_0.J[T'!,)S.O M$*5]2Q)ED/9V-Y/9V26"'L.4PS]`66)/KE`QI\,: M.J1!>H^$.7^<`7*3>`)$SZ[A,V>9M&%H@V1"+0_3&_'FY.<=$4!#4>1PQ%V, MMA:.`8N'&2H][M)=.(5S/'TD9B*M^IY#.ES@0!(:+#VZF[.)\$G\%,.[:?C5 MQ')5F(PG2`R.HQ5>-(%6'=5E%-6E$PXP@G$%#I$`YT8Q6RU\C+4,%`Q]K^+[ M-P/GKWBH&9@CPL,)5V,QY.[7>\#,(^&`QP=P@X$49(0O`9VH"O2]AR/A(;W8 M.!L&>QHK/@5Z_B,!I3LB68R0P1/(+/Q>#+*G?$+QOQ"K-]($#ZSQE(EX(5VQ M@S-^]Y?%=UU:FWD?C[8H[C@4\:W04ANF'L6Z`P.2Y7X94@87G0".T`(U1W,3 MNF@27*;A@LG*?$Z'V\"''7:4B*+NOW^P+P/L!EH!,5/U@)1)[UND`S]L).YB M$^4O$-7-..L,@.SQ$:BZ<+>O5:.!3!\,BIZ&'1\9+ M#PG,'*$G.OXHO.*DJ]`GCOF+#_;(7)_+:912-#^3))9HUL59Z*1P!%F3+7=D M8+6PQ[*';,O(&#`38`<`/`IG^"DBHVW:A^G2/=P)@@/1\[-VK7))-H-&EC`G MS0-$5I0>C*9WEN*1U4RX!%P]L-D%V8BP7@6;$1PN?7:,Z)W-?'@?31@S0]-Y MT<9%S4/)`W7ASF?`8+R@F$EQ#S-3+B=ZIM>(E`\%5E+$%Z2:CW4PF)QAL&)EFF>,^L:0N24^&VQR0`-UZ8#C,)`Q,)X[Z$ M!XM)WO=Y\@S_]=D\;KXMBS\)#W`KO9RQS]5VE.55D%H-G1F!/:6=9OH-#U^! M/_-\TYHLJQQ*=$VP1Z858,KH7)G%H2+2:F#^^F[BFRA((6,J=3L, M(D#(*P!(E!IJ#V9>+8K_%#'0R13L1Q`!4ZXD!E)2F'-,V1F"UY+F5NB*_[0L M?=)-MAV@57``LT/AF/0^XF^HEYPNI'H?T"?F!4V&3+[`KTDLLP0JL,'2Z>(! M=VY2&IV"4P7-+5P>$96I$HW\;Y+FP$4)"#4R:\EU??>79^3GX,&DN2Y;9_(% M\P?L6]RY=%\T)0@:\Q(TF4*&%L1M2A$EQAG?M5&NK4YC>'W; MPD`_ZW$;HT#M0G#,S'/!"LB`;AB22RKR8,'HT>QTA=29.U$FX\`\QMP&Z*2@ MY(Q3L.BP:,_1ITC"E'MB.TTG0K&7VT-:C<$`CYD,#Q@,[Q:RE@HWF#O%#,.T MJ\POQ8U8<&"TE"Y.%_.R*1/43#MM61?%=[18:A*9>H2.T8D0RY9*?F4XF0CX MEG864:8A-+32,3XC$&\YXX:,#;IH?<%&!W:F#K`&?5H\BB.7@.1X?1[LQD** M2\3(V\+;W8$[Z@;QE7Z,<7'Q=1@WHGU8=(93J4S4*T6VE;2S=E-[OLKPJ3=A(#S21RFN@?IZGT\$8;V3`D;N"8(-I5I$_ZVO5 M#/(EG"/8'08O8G:X\9E!"9'X9#[(Z`8(ZN):";NFVX6P:I;U10$V`(>Q].O" M>7>;7>F-^BY+6;S/?%(>Q'(=2$AI5L@,TH37$CVU.4S&!I6:(^V61S\"-G7)7P,8D MLT.'FW?8I?&0C%J!O3L>8S8Y[F7MF(&1@S)DE.A6ODB-`8Z=1B0I"BMS,AB3 M8L/LJ=0&P]X1[&`$BEG,T_RJ@)T?#1"":&Z`50@6!^E%L)Z"L7'J?@I5:FF@ M2*1<+7AO9W%+IGA,`]ZT]PI>"AB0/L81`X*L<3X\@K_V>#(X$]%NI8Z8Z"\/7H[S5>?FRFUVR*.)4:K'&>D+,H_^5?WL7%Q&&H/-EX&[ M)9+T[028W..)CU(2?O:*WPJ8!#[`O=3)HZ`@P0FFH!^9<;"A4AL0<())ZAK9 MB)BT6=&1QA!V'<%`J=J?R'.BV,F5<`T=:@>'?!444D_7H<,D`(!X7GB:2F#\ M$H8N0N^5!+H3V3@9>U!H8#6'Z0H,<)4 M*F/I+1P)%EJ-47%L8=+SMCZ%R`A>/"(,@RQ*^:Q#0OAI.E,"1&"$NNHTP,]3 MT+4YPX%JB,P;!*;Y.#3"CPA`!]-9<]U@F:Y!&W/_S]ZW]K:-)(M^'R#_@2=G M!YL`HI=OD1/L`M0KXX-,[&-[)CCWRX"6VC8W%*DAQ3C>7W^KJKOYD$19LB5+ MHL"6Y67<7&TJEKF&96J>B[K=#:+VFG8Z!+T@G%*6/O<64`HT M]R$4;RHA.Y&'!MIQ1%%%?L?(H8Y%8"#[\0ID,@^F!();K]6,[$IR(KL!&+D/ M#/G]][L`[)Z-V+,O3-E$V*=E2=_!$?0746'XYJ>*N2I(&(X2`Z$W%?\(+V3$ M-+ZBED44G.;HE\*D*4'\?*E",1/^/,Y;D<#)\58\A\PM/&$G+4ROD'6+2+#T MA?#4X'9^^%CHFZ9PH: MA`A:E/#^E02&XMR&D)")\8R`')B*W78#_!.D!IR#CAB:-5*Q91,BX.['U4P MA&K*K3]RWT]EA(RN!3<007`/0_J<_#'H#L+./BJ80GC+*%N+N_RJ9AB5AI'TK;,"E3M;85WW(W%M]:?,VUK=URNN8? M*U7I2MDU1/'+;HN'=-TE.$08$W3]Q%/NJ!,L'+T=0Z#>C'OQ>%V_O'*S]>SX M&7()\C%21,-Q]6%QL41IZYQ^.>U$-_UOA!?,`(62([>TNG'13Q/?Z3.*3%+RRB9)$;>'@&[SU20FZ1' M$GTE)#K<(8E2^FP^%IDXO)-21CI$K2,-=]I)7;3JYA.!#'B$)^MQ';#P/)=* M:X6[OD"!T(M['[AA<="3?S;1K$ MPG]=,WYJRY>9)B5E4AH/OI;"N-*06>`RJ3I,>(27$S*/"U'$O4A(OGP,-]44 M!^EPX[>A],,`_FY82*[,E%Q\PI61*?F$QVIX7*GT`NZ_80,22QQ<)PH`19=# MRII2$LK?*RHLQLF(1?74RD5F+9&@_"Y1@`C!RO,88JR^K*:5U"62^3!&B;U` ME6Z01HE2&I'%Z_F[9%Y&G91$4H10%RMOXGV4EFU`A@GI/3R$PS-8$_GUR>*"/4P,J*(UF@1G&Q4C]EU)=3/H25 M8X+<).^[J/3?++IOON%=`0NHT,N,Q%M4P2UX1:5^0*R-;CX,\G$T\-!AD3\Q M+0^\J6TIR@L6)UB4RC%3(*Z"#NZ'(K_#B"=E9KS9'D\!&D^26-RH0DU">4&9 M4<-:N#RD<+F,RH/*"D7Z>1YA^R+*=:C1P#7C@>/BV'B1)V6.X0VIU#D/ MENP45IA;FJKQ37C[8:RS!X$;1(+)B_M(4:/B84NRO40F1X'QT%KL'#* MJ%[%K*@QX<2"&0?IB-(%>$H.3^N&B\J_?IN'XJ\B5U5T.9:5F64K83![2B8A MV.>B.UZ5X.B9KV^0JDT*/ZR(4V$F.6>)@2PVY\RO=M=BR8N$1Y?'N>K.59X3 M2CHF+A`GL9K M`9,_.)K^PDJJ%?';H3"K.+#4=D(*FP+8#($5XA;I]9ZA24/AUP`]\,"0XWQ\ MS0.T\*TQ]=D,>!/O*9(,$>F<-,YJ+`_CQ+)>A/)Y<3.XE]:"C>+G^#0*0]I= M('1?;*1`/%K<+/XX)LW"N[,*.)42,4RWN)>=LVL0K@/?&VI;(BLIDIC*:N#U M>&.K9@;`2Z6I%&14;G?HS(?$$WX7>RMUA#$1`&J0/E4+\K%:)CU\0'H6; M)7N(RY[W15>84.8;E7V=2QVWA3KK/;9^P%`HUWRP9P%79\CRA3>+]#L*T7'] MC1NUG$VP.."^$7@R+>KLJ%!OD0.%YR^4BKM,F:_!/OL=3)!/,:_C@E6M4"H` M*$]'XH42KL"4&*':3*V`16`*]:* MS&(&*7)#K1TP'Z#J_2'[`!;$OU%@&+[$$V42^67>.6,1Z4B[BU,,5:*619`R MAKP(M\*XEHN*6R[W+P/4/'Q8T>'$]10J&J87$@I$-R1NT`2\Y+-(KR)EK821 M\B'PPO+Q`CP[]TU1O0(7(8B(/W`%,/A.-"^45NH_S[MS"\XA<39C(E53R<7> MB8UQF[V6."Z:[G!$+LD7+UM*$HK]5J] M2KT6II`>GM"L@D,$70)$\:&"P\<9=YQ0;Y;T,$^P.L!D@%[G/\@3_!O<]5RT MA#JX`_R"_>MI_^1(Q[`'`553;:@KBA#S!:N5=Y':0Y!J(:)V*+!360Y=M-G' M:L]0.J/1NHYY$ZNHYFV1VE#I0R^:0Y#=RG7Y<8EQ7@V%*6"\&T*%:2-K+KH< M\,V/@2F.\:&*3SVY1K\\"8XPGN1"W\):Z3&/:56>S>/YIX6L$.%Y$(]92/E+ M@R(N@9J;"2N69W>+2=+T M)8S7<"$MCI)RZV?!$J>ZY]IGTZD8U5,Y*Z]'E6G4*)Y#"WM!1>\O?HR)/#)Y M8#R[#XMK$ZH]Y@7#@B=@XP7T^W-2%W="TOI?-<*@8@ZXR5&0EJ>.L8_J\"?Q M%+J%@%!LIKI7U^X%R.&_J2$\C'*DR"&C?2'*T96/#[Y6,5P$3]2:4K M/S?LL-=F)0.^-`_K5'R@5&16J>CW!6R6^ZN8J'(!6*=4?`G`QTD-?1BQEU65 MJUQ2"H3=LVRZ[(Z:!W)'*\K[XI+E10H\)4TWUGYV>&T=)JW<,5:Y:&@T4]Q# M1.O`%D?;D(O/)&;%=;W)8Y%E(2)^=!8C(;'QA81MQ9!(KADA#;6V-4`J==B3 M_#H*A]&#"EH%FC3"28[IYVDN`W[%36W8R8&PY#IQ2VI>J7V96DZRSYW14?\X<,JE#1K%PI:DI2$)IT\@8S','B6!?><4GN* ME)4SFH(RN"+:4PH+E=)=L`T@?9UN_9N?%FIKHHZ/'[.\U<+J#+/9=`])*L4L MMC%65%0#?L*[E8C^QS5]0EP4M&VKHP+)=,=P>ZT+66,C#["$,VS*07.GR*:* M&>.]TXJR!YYZ]$@GD!9MI+J3V@8*/]P0&4>23V^`+0KU-DQ'7!'G$O7-3Y5V M(K)Y&&4>R#RH8K'9!LCR>^B?%[W0!!!,5#'.S*D,:B6-95M&BA?SO7#,DY4Y MHM2HHN2^(CMX6:7(.BS[DU.=UDR_,])&9&4$J>A_Y0%6J_&><.&^LX7J#?;+ MS$I5=LVKCK4H1PLLN,_(45:1#?(^%T5)I0N\\#:QLK&8*#`2XS9XTYE_BRP4 M'FH54QS?5&KI*AWXX'@O&5,*5>(S:&^*KLGZ`:Y#4"2>R"7/,I[^@=SHCXN, M)X5Q=P02M>2:,TFH5T&$;;*0)&MO@E7@7=>S[YI+1>-EBH7)"\I:(BHO"<1! MSW_S4]%GAMHJJ'WEM_ZG\U_]3_YG2<&SL8<:NR0N!JN85=DCH/Y2.B$9&/,0WZSQ\\[^X"G=O9>=F8[,FCP$=L".PTRO`>SLX%]RW? MT?RVJ7J]CJY:GNZHGNXZ:E]S>H/VP#('5IOF@H/4"OF[)W"#WOY+.]'<"I:V M`7$=J5>H-_GQZ`Q-&]E1HFR*04?RL+EYZ:9A&(->7^WW+5.U-$")VS-LU7!- MV^UW!IK6=9KFI2_ELU]^/;WJJY?G?K?_"Y@(*1R,8+57%_[GR\'9Q6_X>26M1*>T'Y5/_ MZJI_4;ZLMC$I`V@'ZCV[_AI.5<2R"KIK\I6I5%:P>M'LW";WIA7*K@ZG=*2N M=!#6SR]Q#L>N+3OLVC(OB%;B?W66"3H1LE(>Y+H(LZ\E;]4W(4[,.;:I:_K` M<@9MU;']@6JU+4_U!H:AFI[CM$UCT.WVNL`VK3EQHI]HFE8"NVSG,[)V>,=& M><3.;F2BQ%7PG=?1`[(^E6K*%6*I$-@;$Q3MGF7H;M]5.[;352V_VU-]W6ZK MON5JEFG9GMW3#DI0E`V_]X@77=8&C]5R%AMCZ;RZO@#]R6Y2^YC/N0<>,'"(#NV&:#M1VTY9`HI\E:7K5:>VW;(\ MM;'6\SJ93I-Q\4ZG^2N;^GQGKZY7?,XB;6978:J]<+GR4?*&\O MMN11R-_R=@[G0/]`@3%9FW42JV]R'2F@URT#9-_+%/X-(&LG:^X_VHV=HGWV MFBG7MP!V`DSKO[O=?G\P>+MX`UAUOD3.<=M89^,9CJO"1\_`WI+\W4LOJOGMG$MM_O<:NQ_EU2(M27U!.NY?.I#(,FG@O^WM=\H>6B*3LEGO]]R M6I9KK+^).+E/@\D_W_)_G[V-+9S%-J3G`9ZOW3(]_1#/]Q!%JLSN15<`.?E> M->]ZQJLW2^1N2W.<0Z3QP^!A>W/.>LNUW$,\Y_U7PZC7#D\Y%7[,6H>E(P?; M+F6;H(4=.=CK/V>CY7H'>O*I97@'*:(.40>[$'./>5U5 MD;!RY&@O8U7J>OL0*?W(T=;:2+OENMXAGO/^*V.4U$IC[(X4X'J[ZV&`K7H(@]):6C:8LK?'>67XKL+P+&/N#M$^^(JF0;1HDSU-UB/@QVU%^7+'V7Y2VBE9LNPCPZ5 M'^.@K:,S>"O\[8]*<[8C^WI)JGYG>2U[#X+R[X]L:TL'K+=.X-7/]VA[ M[+?^?+0]?G3;XXTLHSE*Z!=@X(;9@H3MT&B7<@`*'^,U8M?':-P+64C:'A0'[IL%O$6Y\MRM;/;\ MR[8MUF9NQLXP=PAR>)(R['=)@0J>+<7G:/./*E.@CKSO)7B?X;:T/4AQWC?F M]WH.V'1:9ON0I-O1_[??/JRC_^_IN#M$Z^3S_)S`=T7_ZO?<$_B:9?6N>UN\ MLUNVMGO_WVN3T+L^5M-NM:W='^LQ.1`9O@D,']L@1^P%IM'T]#.<[]LI@KU?_.9^$.TF2,+\ZG]-ZSF[X8*@U+T7M]W@E]2\ATM$[; MZ?N&VO;;OFJYIJ5VS%Y/]0>#@=UQ!D[?\/_4_[07(-*R7$=W*DV^-P)H'7<] M=CT]+49JG8JF\Q?!E/5I(!*\J>PDCA]?X*G]AN,W\_&V<-;1!MJ@W>VHCM;% M61*6I;KVP%;[EF=IGJV;5A]H[T]]T8P-R[!+A#T+NCJB@`H9,+XN#KV-AP]7 MY:A39`+T:\2'VO#&\IMOG-XSVUVKXR/I]"W5ZAJ>ZFOMCFH;7EOK:!:02GO] MQNE3WE=:J@'E!PT3BAZ?VCNM"H5KR5;%7(KO[Q6!246B4JD@CQCPHO$4JW7= M?C(P8I[$M'&(TQ?&I]OBL!T^/T$T*:_4;`B.,?X=*4`9080#]8B$X,(C%(SGA@4_L.E$N>(\16>LJACCS80T%3'(245I.$9M[Q0@8#@V#J*[^ M$2<\<#3PN1%\:/E=N;9HWGX3Q@'`%T02#WR&[HC%"4U.YWB1B*N@`_=9##8/ MX'=<@$V"E,^-$)WM^82C83[..3A\H.>P-J)<#)E[ASO%^2AB1'FQ&UQCR3=. M7HP2=6,Y*?)Y(K/(J@U@+LBF.$C$UQL<8,MPJB;-B.)/C"IC0:HCG&F\%3#, M/,()ILJM/&D,Q_.SOF:X3'7J/'^?E3I&(*F^ZG24BFM/'IZ$P MN$5A.:>/QH'%N("82""7P0GFV>94'_-5IR MH(5.(RP#O@:FLXLLDR===KJ\]7$,I4QLMGKFARBLCN;&F0HK#SAPK6<..##7 M'W!@[6[`P6M^]0KN'O_;=&_U/TR?31EOZZUM33 MGU3*_P,>H?211+5`ZR_ M^*5Z7'2^?6Y`[SG&\Y+X'ZI$(*A!2+>46Q:#KA/QT:\C,);"C`:]?6-/,![1CN[N_X(82H2X7IA9*@ MGOW"+>N51_P=\;?9#+Q7IN93M>[3A'^T((NH\"9L-A_OJ;JPT6JWMZP>'BYR MK);K6D?D+-8NC99A;EF]?&U*Q\NE=3W_C?LI-H\8/&*PB3_,Y14NRQ3<<%RX M'GX^2V^#6!3@=9.8U"Z^8#PZY^%PL>I`)EU<%AD7O3`;1DF6IVSS46=+M]J# MOM5535^DC2EC6UA-[W^9??B]/SJ].RS/RF7_XV_P MMY5!>N0^_9>J*M^OTZAUG8P>%%5=Q`#F8N_?'TE(<^H"_)D8PQ]X)EN`"40] ME@W3<")3G#J80\4R7@B[*(NML>!F%?@D.(V)04^'[W+"AI@D"8N<`Z<:!T.6 M3\-A$&4MY30>GI"O,IQFROT=W,,'-;F/V6@VN>U=69;=+58L/^M]:%&&4?4I M9(9!_%!["`&I/'+/ZDM4_Y;D:?V/25K[>YY5__R^I80\>^PZ3*9L>!>#07C[ M0.DFL`F>[G23`WP*9HC?II1'!G\=LU3DK0$:2GDQ2O/;J@.WDO#4*I^B50-E MDH;C('U0;I)AGO%V$4D\Y!M`Y-ZQ<3"E7T^4LQPU47P]_!&V3"EI(6;&4([; M7WF(>7B(*/%VBA+A*O"*KXR28@(%N"M+,Z9,P@G#%'?\,J;&J1DFNRI#^`Q/ MF$-5`1.VFHSRX30[V1#)ZL96:/8+$]EDTPBSP3CH@%]`'I[,8VUBEFZ_8@`X ML^!H%8:R8C+/BTHS\0W[YQDI\CV:QB7JH;W`1>('L:3.]C0\48=;]1KNE&#LT]G5_^WTHT2 M!01$-:"\IF]PX.T-"J0$5&',WY_<46;3E8HD5%X94K2/U^9X;5[/M0&R^M_3 MSMG*U^;\+HR"$8LF=R&:K,.[-!DG63*NF,/FAYC=4AX@6(4YZ'#\_EQ'H!F" M7ABQ_"L;A\$C=MSF;M++&'U!E"6\/@CQ4K5NA>&*6O`(':*,T"J59F'WGM\% M8!0;).WI9UC$A(WDHY!E)UA'!8E00+ M3%DP;HD2%;2^X6BI#HT:I)4>@E9A==<^)55\1!^G(CFLXD!(V2TNA1PSN+D) MPC1KH0.#E'\\9UXW!>`&9`7'`2^JY@X!@H5E>(QA=H?05"W],`9FC-6Q0ZRN MQEV_X<5]I1]!U#.2KZ-P#"CR&"*`(D6L\D(SX.BP)\2H^-I]DD8CN+@,"#V= MQBREXD;`+>Q%'DUX0/)GG.R,:"U:WXR"\?J]0FU". MC:I;?CONP2V[/VF_YRG0>#B)9!UJ+?@P`]:^^CJO[I!`@Z%P^R&1EV#`#2E" M)DH9,^&T&F:*'\E(V1! MG+&+;&YR6L'?V`1?B@^!L8Z;F10X+H1"'.(SM!VJK/3A`@.[F/6Y?O3]\YK# MDU@`O93JA_.(%P$K@J50E:BH^T3!\P9SSF57`7JP+VM'N\`T0KBV`&_=S=OO MUMYXH@!ZB0,4Y;[58E]1Q$=O+!^8)%F(FVE5JD>1ODIW*G=1!AG87EB;AYN6 M#N;"-5WU1K=P)@U?Y?XNQ%Q;8&]5W_6)XD<1M_%4Z?\59\`AKU;2OJ&6EW`T MN.UAE590`A"RRJ,':526,Z/@KEZ1/7>IGN&&?2#`J!0_NJR4O&?"]XQ-Q0`1 M8`)CD336C&/2!AQ*/LV0U7.*@I5(F0%^+URSTA1_-QL%D'^XH'5J]/1!H0E# MEWA+ZC5:]J)]84`U0Q),@PE%,$3\8O:FT',S+\)3!_+^GSQZJ$#?EN6BU==< M!1%M:_Y%]=?08#RZS"?LI[(QL/R,V(@NQ*#P)X(A]SY@/4%[-* M-?<4;R?_+K]S68N3*9HA]!B<%[ZE+*^5=[)^!4$'`;D<8W\16EDH#L#JX/E) M$I,:5'D/+S)'E9<%>!_+OQR`9">A]@=P%M2&83792$3IX_U_.!#!!TH;\#YB MS3?3!W7"&Y_4>"D/_BE=T")'@?(NJ%W3;P(!G&T"^+`4,<"'5I7&L47#B`%W MQYX2\0C=T9,),`OZ*HJH]RW!E.^IWCKAR0R<7O\W9]=LV)([@$_^)P")"[JO MH6GNB=(5?NR*6HH\5FK50HTG=@^DC]HJ<:LTR6_ON`3G.^8J;$JJ*JC&MW3U M@/1OSOJ0^!/L2@"7A7IM``)2,,M&O!D& M2J=J,X3+D)0!V&*0`F0D#/,(M8HTS+Y*$8T=D&9W0&QHS!COVS"#5T0$R&YX MM'W@S M"3AMWDHBF^TEL==,:<;<&&(^PEG!M2_9;5%4=$B9"%^DZ&$R2([=3E#7)JHK MQ5+&`02J#*88)*?`.JIDV`T+>[=$#UQW*&/D,X'N\#]DX"Z.PDO64MJ\H.?3 M_5B[OP2L@L6O4BTY;L?N:^K`:?=4:Z"W5<\S>ZK=U>V!-8"G_/[Z75+@7GSY]?2J MKUZ>^]W^+TH,%F(0B%_OAR<7?R&G\<,'CV[Z-&3IY\_BF]WSSZ=751[ M)W(O]2_D)@(..]U`O6?77\.IBEA6 MLVF:?&4J.6#K/O%EU_RQ-J;S+.Q[B#P,G29#NA@];'4'9(K]C-]]P@Y,J&-C M/R;@`@H1QH;YVZZ.K62H*QV1]?-+G!`FV`31D/IIH390G,M(G$N,YT*=L62? M+#P7ZEXHNHDA=[EGJ"-1TD(@O(5QCDQ3=-L"RYI_AUN0TX#;#KS96*756$;< M6,IGH(1":F-6%&T&]]):L%'\')^&%?CNJ/49ZG#!F)6<73[.!/>I@",1@5X* MU"=@B=&_\VQ:@W`=^+C**.VZ)`;&+3L[PEDACTLFPCX#13`%[BZ\($5?LS%) M-_XL`VOJ6Q!Q'6H9$M?F\X]PXJ:V6(L;>E*3)]'5\P\Y0-A':Y5_5N^?NC$N M/^@:9MOK#U3'LRS>S]35-$OMF[VVUW5 MHP_E%HD#^V*!V@OZ."CO1(KUUF[T$+^4PE+O1,'PJPHGEJ!7D"^F@NZ/T4EE MG(Q81+X\T0Z+M*?RH.@*T"WG9M.(@3$PQC!,N5=2KGE[/=QNP.T9N5M2[F:, M&-2L-I2UQT]CYZ'IS!QTJ"MT!Y5<6C.H9T$VAW_;Z;;>,]1M0[>-2 MJ\U.>K&&]L^>@K"X`\_"(1?-37CLIB8\Z[(?O:ZEK=TQZ[DSKWZ,<]O*62UH MIG5$3PT]LZVWCNBIH6>V4=>J=QFE&/"(>1FV2,1UYHI\]F2ZSE)]K/\=W9R8 MS<:K?J+PABGO2)LAQ]![Y5WP_A$E^V4);#M$P[%AG7CVKB_0=N&SM=<-GV=N M1%KO[D)>A-E7]29EE8B$:'3][GJ_+V+#B-2-'.SL-V<<6T6?!.W$M'\N@5#+ M'[63MOOS/%![=!'V!']6$_YL_8B_Q_'G&HOQ9YQ8:Z%O+P?U+<71'PDZ%'$F MG_)N>&15CY&*[9Z8BTFEK9_8/^Y5')Y2\BG*?**L/X'^D`!T3HQ7;?C_S3AQ'O/<+//M59QW_-$G5ESN M29QNKYI%+70@OE!KJ)X,Y(Z4ZP>1QG\7`I-+17YMR>VP<"L=AAG6/=P%W\(D MEF:<)0N2$58IQ+Q55/`(L_5"U$`)6TH^20I M

#Z:38W%+"28B*2NWD1`4]1P%P!6$3&_M]1VJU\G/V5!Y%< MHI;:4,TA5\[_,4 M[PX55DRWE.YFV8[=L8V.ZG4]7[4,QU)=W^RINN5[6G=@#OR.\>QT-VUKV6Z3 M-/D68J4IA7`XIMX3KQ!)IM/@.\NHKA*KR$7]:I&F=DP@6R^![#BW<6]>?4R, M6FN2XS/S7&36-V:V84(K);<1'(L37ZY3Y1_/8'`S;W]>"MTVR.%(?>O,--S_ M%+V=K+GO2-]VXM\1Z<]*)]P^7_L!4A3YGKR)][N6VJ_H M0'6G91C&C@]T"]?J>+)ZR[#7S_#?^<%N->ED*R*'FF.\7H&S@;R'C4@>Q]./ M>TLG21EL89\%S];.\+D;V21YEWD.UBO# MVC8XVMX`=R2)(TD<26)MK+V6N=L+0RP+,+')J<>;>.>"Q]?#XI[`<<3=Z\+= M<]TVNU=6G\=`=^R6]UJ:Y>Y8AKPN]\B.G;=>RS&M_5$*CB>[.7]76SO`@]W[ M*FQVP]*4C8ZI$Z\JW>`UP7)XD:U7GTRQ)QYRTVGI[F/=O/90*!R"M-^3(WYG M6"V9.'Q4T8^NOP/$VKX'Q(YY&"_"R'2P3(\9@*_Q9+V6Z^TZ%6/?3O8HH0X( M:P=H81V3.(XWX!BQ/Y+$D22.)'%,XC@&TX^)"$?<[4T2QW)M>?>JZ>Z$S":= M_U;+MM9OR7IT_A_.$;\SS9:G[;H8[^A:.:J,^^E:V4I&R%4R#:)*X[G%W>GF MP=X?S\OSX-]MFI-AMRQOUQF)KU2J[3C75+=:1OM8B_MZ3O25I"2^`B^&"9;= M*,FO(_:"YN337_J8/?G"MO@1>S\,]I[=/WKM'L\SS:*+]M.X$'R)=YI.TR"^ M9=B.NO.PN$-U_Z\\G#Z6_W)G:5' M;!B.@RC[Y]O3SX.Y1M.>Z9M6I]-5=;K7[GFZOWXY[6N]677[0("B+7M;<6#)^KC>WUMW) MM'KEKJ5,"TE;^QZ&[Q6.*>4*VV_3S0@+P5<\OF*O[2?OGC;KX.,-O<=E"C\9 M:T&6L6FF!/%(B<+@&F MUN&C+C+J-<[@RJ=!^J",0O@T9?$05KQFTWO&Y!KX%5@VI"\T[0%^#\9)#M0* M>X$E\96A7.$FC(-X&-*\!-@,$74+EE+N613AO\F$I7`]XELE2N`%?#U\[Q!@ M#Z>PQ#!(89,W28HW)!/C&%@<\/$)\"1.R17["NXS>'$P)Q!GOU._B-E'UC:<9P:L@%`Y[^'[K&B(K1@K,!)(T87/81@,BGCG"\XU$$ M:0R;!L#QE7`L"$&)-UR1CQK!'>2PEW0:A/')BY&A;BRAPR],N0N^5>@L0`'' M9PF`VATE]W#`C.-KE,-/.#@G9M,"28*..)I:<`[#(,\8$`#\&(6`8SJQEJ!? MPEP`?T5-G@9OW,`"DR0#:H-'$6LQNPWHEQN@@22%-<,IHG^<`/JB\"N+<.!/ M$-/H!EP;=W#'X)V+SNT^!$+$)Z\11CQF-CI13F]P@SCN!2"#[X_D."%.7OBW M)(]&^"5JL$K@TY<)_@4O@D7D?`BB"[@%`.CHWWDVQ5N!*^`?%^&63R.B72S8 M/^TCC(-@Q`!@_C`<1SPM843X\3U9 M1I>:CZ5^@\,O1O](4E@Z#B+B`C=I,L9=$67GT[LD)>[0HM<6_$'BC'`QC/(1 M9Q6E5[#[H>*A8ES_*/_:^P"G-;TKF$L7)"(&?HC+71;\!?%UQMD*SNQ!DD$Y MG#*X]!G2#>?_Z/?Z!#SG_0RB\$>@!YSK@N@!NF?PI='\=9Q7J)I$<--H#3F@ MS^?S^3[GV$A=3//(MC14P^OX'7/@]54-E![5LFQ3=740Y;HY&'0]:S#HZYTG M#=68&7>;@KHEF,K5A?_YO+T\T?Q[>[9I[.+JC+,&=@O MRAC$0#Y6_C[#P?X^*TEAC4_]JRO0JHN%:YLH.=L'1;UGUU_#J8H(54'92KXR ME68CU(=C+#/?Y_93-^`_PS5\AQ+M/:=UI&F:LHA'2W0%'TWR*1]/1B-D\.K$ MQ=?DEXKA9?>"5A0YS#$F:D%BAP?'<)FY.@JL8@JR-J;U;L1H@`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`&.GU3]4VKKYJF8_5Z MIF=WVUB<:S5A0+=,JVW7<"!W/%MFS,F$USJ)&G%4&;<#EVOKMMEM6ZK9UW35 ML@>.ZGJN!B!J'IZLT7RTNF?4X&J"8*Z*+?CRB*FV?E^-MZ70[MM-XJC<8Z&K;-;J.W;-\GW..1BR8 MMC>#@Z=`]PQ^T,UAU7BZ;QRA$6&.Y3Z=(30"6T=@K2J14R.0X=D-?..4RB-A MN?,D)=X^G:;A=4XB^2KYG,2(M32)0.C>2GK>$B;-KMWN>PZP$@/1V>^U5:_? M-52G[VB=GF>XW;8)F'0:+Z"CV[I90^:&`9_1$8((CX-XU\ZCL6K11L@-&`= M35\.(>U_42\+K,ZEZP2@A7$.)UZ6]7;839*RHN"696)VP);PT/9\SX,#56W3 MADN@MPW5\SQ'M0:::SB^YFO]P5(%P]&].0[\1!!G]8H)5_"RLYM/H(+#/UUJ MG;!;462;C41/%#^C:33`4`>5)!&P@*)G1$V"[_B.V\V7O%V'=CD8#4U=+D#Z MQ,,P"HDV>MAJ89OBTW)\7S<-4P4Q2>JDK_INQU:[@X'=`WB,_J"+4#=>?+7M MM!?0^Q)(GLT!>O!#-@V'NV4!S1@Q-QF(.K@ M?@S"&`__#)A]&GZCWCV5'F=`(&![4LNG78+>;K[C=IW:5X5G]6N_W;-?\<(W M,CG=MMT9@E\!F,5>H_,@W$@7OZ>?L]-HJ.JS3L#JINO@"$V M)?"7;XSWR=JU*K"$33B.Z3Q7O7LJ5A882@N<++1(XR'#N^BWB$<3BM9DTC6S M6_]2H^=:=;QY\VKCP#_F'/:'0^IQ=D'MPJ@?T&Y=P_T;!5T:UMU-1#5FJYWNM[`LMJ>OM2R MG+>MEFO=,X>-?"2>`M_97G1J1:)M]I_I=GM6."\!8W5VN!_,K5%(P\FNS-P6 MLRH1_D76=\$F.0;L,][Q>9S$E]-GM1;O9S:^^$"O$M*^4P:*-S"RZ<-Y%,2H,*"*,*&>HKNU)9MCS<[BVZ$&J$8#4&5JKCOR81!LU*T_22#7/> M@]5/0VR9W(-?XUL>DMP/IM>,)UU?X#'?`ORSX=@,/J:0U"4LYX\Q`BF:/N^4 MH-Q&I4;3VG7.L02&>6`SO%I0I-3( M-@W+J_/-3<#ZF&[8'T^BY(&Q"Q9AF^5/E<[ONU45&S5],&\>412;89KUTV;3 M-,1V\*1<;-?"\8$MVEVKJ]HF>NEVI`Q/^8'H=K=?@]P_$2`]ZU/[[UP3;^M@>G;33XPYI">Q7@,P*CQ']3@OH%6"UK>(C_8CEW"S9:U89AU;O)<2&=H;CP) MPA0U6YR[,X4%P^N(<9P#P893%F'O^6WI:;KE=,V^K7IF&Z02F%NJ:_;@/[:K MZT[7&71]XT]O2V!'M?<[N>XW5!1S6`-'S'@NN% M;?`=J^.V?4?KFN8RQ<2T[)D@Z"-PS`7LAXR-A&,XBH+K!`@D27=\$ZQ&'M*> MS=EIA.`QC8+GDPK_(IA^Z%R$NP.?I/D^*1C-@1/#=+VY1(ZG0KFA`@D_:VC23["]Y_X//+8),%Z>71O!+,`CPS`9S8L!T$\[XL**DE\XTD M:GG$T?[Z5]TD+8HB9>JF9&*`C!.SCZJNZJZ[?)#]\AY1M.\K\"(H/Y'?I['_ MAXJ/08IH:*+!Z39(^EZ4^GO.!37F4C01!&$6EX02?2409X9E^=L09)` MF+$M61376LGX90EF/1`KEVW:ZM@-0CM(>O$P&>>L>6+O[!I;D5J^;FMA*&GV ME;)(2O[E>^K$=%T?&*TH_+)4OPE4R_CX$8+<<3L<+J)4;-R+OT110N188DTX M+1;J;1^EP.G7`6FDT'P+2"\"$G0)3U(FHU1?&P?$34.=IM;R)9=PLQ=82WR4 M)G'0OE)`>3=!WQNW3#JM3WI22J:B1L!4A^PA:HHD:ISJ5$0C=C%`QQZ8W)N"6A2\\5X.,C3$F.]A03$.;&<7[E' ML*MM!=F05IH,:J5U21$TJ=)DL!Z<4N@AM:/<$#M*V<12E(6G@[O,09Y)B<3R M>7`IOZ%%J99%%:T4D;@78!O9O--@NA;9O-&:8!@D27P3HW<%4"LN#NP!Z@"% M-OZ)QP%UL[R\\O+VZ#>Y6U,]PFWL@*WXCJ6H#EP M[B(1=7C=Y`QDBW#NAJ,AQS`M5UXGU%5=L6N@J#@L`SZ^SN5;"L@PZO2@7-GD+%)_1J6^U^@C- M%6]"]?:K!8)J6;=-8D%]X+B@E-("-P&JC`X09OMY9N5LC+/G\0BQ+$T9O3ZI MBM?+#I77@:GG]=PNDI<5^CX%&0N0")0$X@2)N*JT`Y"0LU,__/6A#;I<>Q_L M`N\.(30/.([':=_M'W[\]$A;@!N+#N"GC:59D\]6LJ_N%>C2-5R@UU6_Z%X0 M)*_J=;RI6J+LC+>C#6R!EI6*>+<99`L2?Q:O683<,R3462.5"[+`[9BL49NNUPELY; MCJ5K\+*L5=^EM2+&*AB5QYQEU>SQG+<[V3IN9WY%_L>I/_[]*@X3?/6/^C?S M0*;&XY])E,QZ#M$"" MOBJO^\-J=HAW#<5%-B<>5)9-S)%WED"4`B5N"##*FZ,1)."4QW2_AA6V`LEY0$'FI,F&G M!HSJ1S.U^;9,.*JW.6J2K%8)1W5P+`/]2*3H))Q3@PT@R@_)11[%:2(SB);) MJ=.5E'5Y:,M6Z2;`;!1;[$P]$J?="D_/NDJ:6J/+NQJJDIC2![TJJQV270^G M/?[:2`-4,DJM;KQTHV%:F_`S<`&P!;D,!A-_ZD=Q2`N%M,*T7FM@T'5)*$7@ M-0*GUL9^A)NM:6IX?1:5C'2MFK"KKK1H-O,+M:P+V:>IX8488O#`B/(LDZ]> MW'\"%))H<%K*DE8&*M:XWILH*ELNKQA`YI(AD`+3HLR9`DCBH@5ZH&WPMHI2 M;?"?I$)W5J"[IL6$>?OX>/OU(\//XD\,+3S^\.5_G8^,L/B'O!)YJ1#Y)R:; MXO'V[B.CD,^7FE1HO^6M+7Y@QJ?8RALH!4/`!<$G;(8@)@Z8(`D9G*$R8GRJ MHDTQK=D`,SS[\1/]!.2N]W]]8&9A,`J]"Z M>7MO._><=7MS8]P]P*`^B1?B*Z0,31S./9+_\?L6G?Y]Y@T'^]V=_$#_] M?J6AWUXJX1.[(0ZOF%X0POM.OEK3DRL;KTJ_U7<`*Y>[S\8H]4/V]>]O<>F5 MOC.K-*6]1E(UK6F*31J6*;E)6X>ZK@3EL=E^,Z+.^>Q_4G,5(\QB)@K&_N!J M!<,O[>7$,BWGF.J1'\@M2A?N;=25XJP!%M\:P,)^`6[`5*]?U%>[MH#:[BU^ MM6,4+/-0_0BG3_1V'9Z:$L/.I+?:P47764G6MVZ]LI^='QUJ66%!GGUK4"LR MJVD'/NO]<'];>)UJ)4LR,-E,@O_^]Z,S^KOMSEQ3^',C\RTA573AC4`JZ](Q MF7BEQ=5EZW<"S__64*,K7DSY\()V.,;#%-SLNJ@[+SJ\/.:>."\C&H5,5/)4 MR)B%?A\S<`O%3T0Y'Q`[*`@B\+?L`ZK&T_E],LF$1&/,QGXFF-!_8WIS.F!* M^XF1X:E9`>:KEFFN-R:015>S_9N!"N:EO"/:5_CX*3*&(-S>A0%)9')^S?RT ME$":>O#CR>\_60E`-<&AY4U3)T3V\=X,2R2>!@DP4C-%G4.V:G*Z*_.#L'^)7M%2!9S1=?*;EQXNSW^O+O MDB1F_I"FH!0`3^M347>9\ROK]%,,+&J%>;PV\U_4:*V9'/2&P*P]]ZP@@!TF MHT+H.JUQ=6(*J`]8E?4LZ6YSF)9(83(+IFG3EU+6WH',XXK-FZZ@:IPJ\3:' M5))`AER'"YHF88$H/#T(#D2;Y8H7P/[(<.ADDU,N0G#FG*+4P`MR)>?##'7LA@DI3+ M`+U@\D(LQ"5)8,D,TENSNRO::W9WLL?_YCC&Q",X)LH>S!_8&S`4':U_J&SH)CV M7C8O,2TO!#3(0ELNGG0$_L"FM2:T,_O5P-5Z!*-=F>(RR8;*4>&H]YYGX;\/ M9+^9:Z[B!#8EED.O^1J17-9K0,N;M9YIMQ0,0`'M>'5#OI&`;P9!`F+S$9EU M^T6/PZWM?8G3ZK+^3[R0]D'%;K^HO^LSK%UO[ZG_K6/IRV'I94-`0=-//]W6 M7:=M9Q8J>7L:6RR7+;Y5,?*WPZ'?3ZM/';C&:,.P_UIK+_R@+1E[&X*SA(,E M7!TJY1G`M%T3($4R^4-174[G#8$S1=%R)$-4]899EI6;+EJNLP0'U_-#6D+V M=EAHA)E6_1YAP,[)BVW4V_!%314*GHSF$!7PD+NZJ#\/__!(6=Y=W!;E\Y15 M&]FRS:F&`)2+))G3!:1QHJOH@BTYAJFD?4O_F9N2B?58SD"JWMSR[HFQU1L! ML'?A2\D-8-\;'T`?I.41Z"\PK:^YUX99X@JXE@E0"180K21I')($DS-US>"0 MXRBJJ3@BC\IM6F=)B(%NKT5^`?26,!400RK*Y`5E7(_P>#S_/DU(ZJU'C-GQ MG(SS:6TM%^/%FE^]7_XDF>P#/5^^N2L(LGG3D"4+6)MWX0]#-3E-=75.E$7- MM%1+T'FQ$D'\-<\K8DX8NX)7F062.:NI+]"1`_%LVHR'Q8+_$?LRQ.(2)X8YDICDD, MQRA'7^XV@BF(XRAZU7-$_Q19Q@,1@L3_OC5/4AKALT,*A[*%KT@\71Y%MW2W M=)0O3?1TSX>+23T1I6Q;3B<`\=N[2B<#L M,I8VLI=^)^6!L[BD+?W2KK=.V%AKX]T7]V_K MED(RJ^@'=DVU\#B5ZZW3S-I\G(+&LXIRX(B2]AWG(BH4;;V/-^N=68@`1XJ, MV'G!`\N]'?[V=(EU6.NHKJ.ZCNK:C+_+"J&C?M^THX8W7O4?M"[RYH3?=3"^ M#`HR7"UG;83Q_&Z6T/J8S"8/9Y8=P2JPNG\9J8815?9.B!K)F736BMM0&W27M<_]@;D>\Q M=U[?'_K]BW_R%98_40VV,T(2NJ#;>S]$(VBG\7V?$=&(Q_6M=D]^]^2W[,GO MW+Z=*^0"\=<&(,X/:QW^.JKKJ*YE^#M_N[W\>BV597?P5H=T3N*@P+-\9Y!] M#4OJ<0.9#ZJ=[0,?.BOJF=?CKE*MV8ZW# M7T=U'=6U#'_GYHM?'\E]MU)<9JL3.:;LMVW.(I)8I'8JV*O6#?["-/=M4Y9E MQ.IZYX7OZ*4A(DZ8$]W12\.'^9S4Z^/5L-U]Q78*G6\*@ZV`X@SQUF&PH[R. M\EJ)P6W[S#8J-%NL5>U%3\9T0/[G_#OQ`0^D\.I7+TY"/YZG19+W5I?6U6U7 MQ-HBD@8#/PT(N'&[Y/?N?A@5=55!2FBZ`J<9L)D2+=<3G-- MF1-MUS)E34.62\Y4J`-745)>RB&NVGH!-#.)_"F.HD+Y<2!Y-P@G7M9O$!RDI;$IRI8ZF[S7SN;D\Q[Y`:5=PGNOZD^5SM,.LXM&$86*WL5&LS5M9I>[ MS+ZU8MX:VJV6M\IO7LL;G:Z^\R4OW14ROEI?6?IB"AF_"N9E%#)^%*Q"K"UE3P MX1@$OC.,NL#RVS>A@D,V:6A,#G$5%>@W#D3?W_I%HJC"=?GA_C"SK+*UL_<>?!%)+(JOK6<0SG M`:,@L(ITF'.\K-?[+@PFH.K,O#DS\*-^D$SCV MS@Y[TT]U'N,;XC@)I_`^C\?!LS?M;UEO\X2,++*\M#69'U?!W/W.NGCAF^7U MP]Q9EQ8)>#G)$\>,)>JP]K:Q=FZ"^/I*&UVBSC&>^8VP&@7F-SAK;WAR(U#$POAC/!E'^-!Y(;!Y$L4)41)OQU:P?0G#F,? MEGO`4S\(OP4QCF#BVV'^$8V!/5"HIVC*NBT9.J<@1^"0J>B<[KH"IVJBI<@V M,@Q5^Y?P+QG5!O.*_%)XZVY0%M"UB/BVGKSI"'^9VGB(PQ`/Z)V]! MH#J21$.41$[1;8M#HNERIBG:G*DYILV;FJ5)1ET0:'T\WJ]/S(\_OCPZW,.= M8<'#,B71K^-,)GR\-[X]N+?W7\F_3S%\"K1/O_SR[7,VVKJ]N;W_R(2CWGN> MA?\^I/+G1V:"!WXR8?Y6$D#_MASO)XADDAOG\1%XZF7FI5WDDBGZ[1/#/>/> M7W[,$8QR41P&?V&.QHK1W13Y=45\R`7BE0U=,9'_'TQ"9\CP'YAY]L=CF,6+ M(AQ%3/SD1\S8]WK^V(_GC!J*(L&5 MX0`F\4GTY>#_DBBF'NCX*0R2T5.A@I+UB01I>B%,23U:^"<>!S/R\>(;FP"% ML]AY?\H$25@3F!DM1V9>K\I&S<(T#T<61/7:'TW0M1H2Q2;AI+7$LB9^=`/L M[`VV8X6L*O+F(:OJZ>)&+WGILG:P@3)%KSEA'^K3:W-N,'MUS./BXB@8:^K# M'@6^+NYQ\W=`>!G;(S_\"9Y\+_9\15:4 MI',\WV9*9*.W:4U8X"Y`T=H;0QPRPS"8,&,0]1B012:PE3A@^JGJ<,D/TPY+ M[Y?()581^7.D\?.XPUISSN_;<=#EF,M3G^\!"7G7K>SW_!?Z%=H/MYT, M\@I7T.6(L:=VMDFL(.@G?_XN5@$_]?$*B%7$L_2E=N?;Z'Q55D45H43M/]]7 M,O)Z(=,?>U'T^Y4QFXTQYY.8N3Y-%>.F^'GL3_'52Z1:/DE=4Y%F*6;%!A2Y MOR#:?P(:$F355F6-$TU#Y)!H6)PNF3QG2)K,Z\BP;$-LWH7@TC)L#M3I8&O" M'F=!EH)4;I/0B-]J>R;LO*&OW[_97^[^,.Z_&K"L\?G><;[":33>Y-9]%TZ= MZJBT+-/1(+F-F`EQE(R)'!L,&6,\#B*FA_O!A-;/3$+F^0F8;\X%SU,\H$F/ M_L#WPCG+X.$0]V/_)VD9\8!G<4D&EM-@499YQB23,@$<,4$/""K-3&22*3`* MX\'&0R_&([\/TU`^!Q9*.U(L?)_/?OS$?(41_NS)`WPQ[\G&BSF4A5_"/-;2 M/"]W8C&A\L,U\YWN@,S4:#2%),2QYQ-,#)/Q&/8[F<#E[@.?I$5&&?HXTE*C M09C'(9.,3;+*]^N':YKC:7E3;^"QJV`]>3\![?]%%K\."#CEC&T7GUI+Z.U M+J?XEIS&5V^^X`Y13S5$MDQ_==3'/'N$K+P\+H#F&$@#FK9R6 MW+N53,'2[.*0\D7`3(*!/YQ_9-[[!2L?62OJ!S-,[HNT8GE,IY@VYTH9BVST-40L6_&3()B!W7(Q'"OS3KWF&8!@3`9D^T_# M$(OG!@Q/-H%#4W`JTY"0AH6%R/(])^!>>P_F'.+UX"<64SW?!)OJGB%);^>JO)7YX M-B;>G&@N.7DQLR`&8H#!E.1&R=@C`YE5-B%,ELP(J;P3E&M^B:/&617LI=V0 M5A5`TU%:$9L6[N(&>$;8`)"X9@&8Y9W`JQ5KL&5&?4Y+)+Q``]0,NDE6`(6# MB0;^R(^9E)\)I?<\(4//#XE4G.07'OR:=@-D!F$R M6IKCI4A$*DR]$\1KZ?_9N_;FMI$<_PGR'7BYW:ID2\SQ*5(SM5M%46+BK23V MVDY2=?^D:*IE>?4Y_9@)!,(G90FB9C+2K58I_]; MXE.,)HG86J`>1<(V?86YW"I.KW:$(7%1DI:1MWID">FA&:UL7`8#E1';JSO& MD-'7B.K!B28FEI-\D*DZXB8J'!/C`A5TCD<+[M6$L1ZGH5#;^-ZG'286"'G*P..Q@^2Y"8EQ;D3:?DZ"Q-3>N>1Q"70B M:;=WVIWN3;D$B9$@,<=JY^R;O1(DYL3Y>ZH@,7NIJ7$?+ZK9;MU)N>`'S(`Z M\,T2])H*M@T'PSGOM[%HDN6Y%_UG'.Z*TR2N",,Z^ M4I7?;OK4N[9NF[YCJ697TU7+#IJJYVM--7#<0'_Z=]UC!V=@M_BW[D.R*&%W3];N"U5:?;#(`8 M9@>(T3)5V[<"K^LU_:;51F*LHD73;"(M2F(\LHC*=]/QT.T^2J`"F"7WX+LRS$VK?=K-UHVZV.Z;74IM4%06@W6VHK"'35<0V_ M:7@#T>3;8/!^4[NMW1 M?!]6;#=5R^GZ:MOT3/C#]0*GJ3L=^/T*.*C5^J_@ZJKT]64,Z2B,/+8#7IF.+G;ZIUI>5XU3I2 M#DI2?#O^C4:!5_Q@5`P<*K`S6)8S912/&*+#X8^QIAL.U/"636O"^:KFD!YZ MXZ@0];LO(9BZ\8!D?F-EBATPAB\0J`@D0OKG?SQ[DK0;ZD9*L89IL5BNN_Z: M5U;O[@(-3ORB]=>GA(.JT''F,NBXTC")CO[#$'B&QPM%DF]:YE,RCE0'RR!5;+@XA('XY;5T4BQLN(S(H,_K^/Z@_1HL"*B4>HXP;*M8I$GDF:,(&D MO$EY^Q/X]*^S]OD3Y.WB+AZ$/388W<6A$MV!!YKFZ;!BWYM_)@S!]WXBYM*X M(`Q`$KV;`1SA<(`/V/@'&\;ANYV)X+9-5W"A4L3?9.@#5"QQ862C'=(C'!VB M6&FT" M.1?V$3^,\!C!W2(##%G(\>-@P2$<>0DL<@9#16M![,F;09S?X6I>U1#HX@14 M%/A%0+9QQDC:T)^<^3Q`UM(OF#DQ%38,8!49^C[X,T0TRF!.K/P9(9K"]F`$ MI)6`[X26(=`6YDVD%#]C()G"J\>?W0C/?@HXRY8X3G/QR,>C*970"_C?&0/. M=QC_[UERCA:H!TS?=]3)L%9%G=R6VYH%G1Y<0F6I,X!R;XB@5AP!4:3H86"* M8?B?]3S.QX^@*/+S_EF/BS;KG25%F-S&L!7XT'4X\ZU%J+I!MVVV#4>U](X) M?[0TM>6V7;7CZ8[=T4S7UOVG1Z@D&-I\U1U![V&T0^BRDKFD\+CLX^;D<1&A MH@C,<1K:H;!5HHXPZ)ECC&HEH%XM>'5V<4E_Q7\[M1`2:1UQ\KVJX.7QR`P< M62L.K/KXWL>/]5$%NJ0X46NC/FK^ST?>/G^8'SP7*'[EH:QP@^D&%G__Q^*% MT]Y!VHS#NU`Z?9`VI[D92)LC0=HD--;^X%R^"IQ:^F"&QC*S".:^X`;"_(?B MM)F[FSFL=(M3YV35])OCSP7+XK3WM[VRYQ@S!CM+;*/:-9LU]>;1OD'SY$&K M0"8/;O)^H]EH'6=9U[%Q^F#J)71S-I4)."#Y,7)_BT5].])S-;]MF7I[Q1OH MH(MTP@KN<,3>:32EIONM6+Z4&H>(3?!&?_M42T_6C!U4[<[VJ;C[YX[1>^!( MJ;&(LF,@;%DT]I0/U'U[#);5L.4Y>L"[^/A/!A.T-&^T]8)'P_-?>OIGP]H9 M#,;*JYC5$3[MG3TJ^*F\O0O&_]FT$.C;6>?Z`][_6/B4O,4Y_F[1?UM?@6^] M,?0EB]+;!#Z@#H%X38H9&G@>JY2$54_9DU*@7EB@'O?:=BE2]?@2 M%I,D2TQA)1I@UA`FI.#=.^5D]5@_3N*"@>AA%]@QF-(#D1^'U1T#QE.*,B6\ M"9->FI2W_]1^,,_3**9BE&KZPJMZ%T/6[Z>9R*02K2F5D%^EX`[X2C>6&GG&!:\>Z1(>"^;"9;E*#!AUL/6]O MG/%&E/#-B&YO&LK-N,!>O-A8NF`Y3U3#J%P\'(5QAHO9<%?.95OM-JNHFKYT M%V:LC3U)L:X)1N>5E%A,Q_/.6\,^27Y2?0X2_A%US:2 MNQ:SEP+#<)NMEJX:7<=6+>^D-VX^6*NZ6A?V3A8 M">(D3"BKN=(]E;+SX*#TDF1,A9F7U-L5S=<`>P*CG/,LZ1O&$CB2V2C,>.-C M?%/6(U@@2K6_90D6<`PF?!;8';I'#XVIVA_+406-RYS`+VB>B&:N5//F#4$C M1POIA>\][V(A>9&_E)I8CW%,WH7V5J25YZ4E@Z4`,-X5B\`LH`[>^&#W5T3P M!`I6H<=@.<%ZZ[7$7;_V1FI/G2.!^U,RYE4R4M]EWF5[^L`HY7@'#=&Y7;2F MKM3L\CK8,+^C#MF\K799%5W6/U=+GN$'8&;1*/=W,1IE&:L52+]3O,&`UWFI M99&QX`%?>3$[`%#6P6P23;NCJJR@'4+$FK&>#6(PT^A;*B6.JEMDD[Z[BPG! M6]\:YSAA#P1P,//417.GAG(_2_DE0O`.[2BQ%$G%7MH%@E0(B7HERDO`?!65 MP64YWIOY4O/RBTL:IR9/?\(.([$4/=1G\[*7S0N8FN8H@EDXHC)Y420_OU/H MN;D7(==!O/\Y'DPJJW15Y0/#K*-^9OM& M9%A/)\/]C;(1->U<;&@NNJYC&W->`E3J@5PLA.^YO,'%%-U+>@SXA6\1FP^Y M*_9D?0N"K\!NXR3!)W!D&(+OC@R>!XN"ZE MT>B*S<^`U-"0,1X!F*,K$@+.;GASB#S`MU;95\).D8]BK%#J4?*^I\OW5D[DH8*]TV'ZTC6[*>"A$\<>B$`Q%_R,\3+[J+81/A MW\[[5PRMN?/^IQA,UR)-MD0->X$:NF[8;K?MJP&L2;5,SU/=KJ6I3COH:);1 M=^U`#]2V9SJJY9JF MVM9;CJKYANFT`M\RW&=$+':')(5E>V23UBRSD2`D:GX\ES`PSLG)S\19"#U9 M7NQ7-467&J(W&&)4,-"$)TR,T!FS:#?6(N.]P)B5D>UYLY&<2E$H1R%K88;! MX'!2@>D@#J[:.IZ//L3KQH\-ZZ#I;E8DYKI/+Q)KOG2EUK.H^WK33*Y-T.D> M2/PB"PG\J:@*[OBLG(ZE/@&?L#NJ05%LGL+SE[4$9"''"GO_T/[9VFF8XMJ+7I\BJ4ZA*F:OR3E;<;EWAC MLX7E6\_-9;&6+=ZU6V+M2R=<69!8XFS-Y_WS>P0/NXM'-5SU2\;C%]=I]Q<" MFJ'(E8$H-*]*0>3WD[N2"+_9;7;,P%-;1F"K5ML,U+9M>*K9;=MF8)F6V=7G M$GQ*HNBE..QHR4OC;[QQ07Z6>.+>_"*7;;MSK==H`1RJ.#^UH_G?AET+Z\(?$71IG>C]"=;YS4 M+IBF^1,C+@C\1IV224,N$+/;-KS?J5T:BE27U6DY96NM*[HX>L7S4M]??YY& M$G/E3@QXTW\=G9/^U9<#?%Q"(!+HFW).@T.`6ML%DAMZ@<8 M2)6OWG/D^LG>S@J;_2%,J&F9EMFJ]T#9&/BI@H9*BULC954B9U4)*-H9S58D ML+HK"%J5/D9$HGAH,DOB%8X<;<=^\OSF<$`.>JVEIF M<:2SY"=,.'%!N,C``)WG!;@VBX)!UJ[DT!YT:3'. MDOWNC8>/]SLJ6_O[:W>U(3A[9$8RZQ@>/T:8E&E;9E%9L+(SLWY0-LV)0:6T M&EK3>OH.4=RE4GO21$RCX;1,R>B39[35<'49(3U]/NO'J;8//]CRD>7Y M'TI$Z=`Y8782R!U&73#)#R^!3AH-_V`D_(W3;)CZ_J\#WDH5MB,&&VZC:>[_ ML)(,WA6#K89IVY*_I\O?8]J\IU+?]]LV?#J0=4C:2=I)VOT&F7Q+[@.EF[?] M^_5F0W>:>[45^ M*-)NVPU77I&?,(,-I^%:^S^X)(-WQ6"]8>K[-S\E?W?&7V/_947RCOQ4[MOD M7:6DG:3=<=%NB]'F?=^(+S%$3\>KVS>`@FDV6C(2>;K\M1NFLW]/3K)W5]OW M`-PXR=Q=)2DU6J*SP=LNOPUR6+T@2; M_%`#C>G'W5\CEN2L3>W:BPN6P>G#DN*L8,-==0^WFIZGFX:INH$;J%:[ZZF> MV[95/PCLCJ-I1C?PO^O?6ZOZ9:NZYFJU[N'/7F&U.0TU0ZPUN@G&@\'D*\L+ MUCO+\S&2^#R9=98^S\K^-^=]WNOF?19B@Y,O28]E%UF<9J+%?'+K91ERD]IY MT]CG!(B?`S._A?A=L:LV-[:F>UW?]U1+;^FJ9;C8YL9T5:_C6G;+LW0S>$:? MZ5_SC:-_+727J>[5E8;/0M?,6C+WF\C],MYW0#'RA2Y8;- M/@GS67/I'GPS2.\WZ0]3-=B,>;H_H^_*"W:+_B]55=KL-DX4DFWE`PM[BJK6 M[-*ZMB_[2=M/;X-BO6Q7#EQ;-^DMKFS9PMMI;S*_\(.HF'EP^_F5;=!7KE@6 M5YM0=&%"T[Y?RM6T<^RQ!@D?),7+72L^.`U+>QFLU75IL8>\ZYU(.APEKL+% MO8AAP\(,L/'7<>]W4^>+<@YSN!=NEI3L71LIEBT5^@L)^M7%A?!NT35E M.,,&2[SEOD`-Y.^FNC^FR:U:L&P(TERP!&T1[*P'$QE.>]TI M<8)AA_@G4T:#L`SO2*G?L=2;5K-AGX1>/_ZKT)/.DSO\<_']U@7AY4KS4]Q$@_'PPMX%_P<9$(Z/(2W>7G."IA+F"7PHHOTGF77:9M= MI8/>=8KWI''1#:.[#_!WEHF97J>7+&)@>M&JOX:#,>O^9QP.KM-/8?:#%?3) M>?_Z/J6M4:X3UA25B]W&K?+9YV#AHM-M>1W;];IJI^,YJN6U6ZK;UC15#TS- M"IHMRPEP0F"$F:`=?%*7Y]Z7V^"LXO/^'G"8-'00/0DV>? MWXM?^^D?<0;H_QAMM;=;0DVOR9LVK\X=Y M]J>R\FK]"=39VMK6OF/7E_7RU?+5I_WJ]2)YY:RR M])ZW9C?6F->PSWJV:T\DO7I;V_P?_PT M+V@--]/5/,GCE(S9$6/^G[UK;6[;QMK?.]/_@'J:&6>'=5 M8F^L=*?]DJ%(R,*&(O6"9&SUU^\!=;]:UHT`>3KM5)))`.=Y'AS@X/H[#\)P M`S-M/ER#NW/?;"&_:8?[A)F*OOTF(U%^*+\C9MH$&RGJ3T;]-<(H611]2CET M;,9/F%TR]"T M/S6O"G4.S!JFGL74#U(7C^@_8\XAR50K7=XY$"N13MB9:5'>D\K)2K$*XZ5S M$<;HK=PA""6:'%VT!E7YEEZD]1Q:A5:A56A5]JV28`GTB\?R^=^)2_M!R!3? MKR+YZ4ZEDE8SSCSZ;NBT`4$45$ M$5%$%!%%1%%.%.5?$SB\PVE\;<+//VVX.&'FVH3EKF-V9C32WG%IE&I:I5)1 M,610/;[$[72H$=1(_C2"3092K0S59?0*K0*K4*KLF^5_)/J>'/!J4;#S:JFZ[@#.@63<9`4-8(:R9]&L,E`JI'J MK%&-GA\U@AK)GD94'!3&RPO2:B\-K5RKJBCS;`YTH558/;%Z(N5(>=Y]%TZH MX,T%)W,ZM2KN)$G7Y'V+@G$QB@7%HJQ8L"7)%]_H'"1$3E:QH'/(%]_H'"1$ M+M/3+WASP6D=H:E9IJ6BNM$5HBM$L:!8U!<+MB5Y8QS=@X3(R2H6=`]Y8QS= M@X3([1QUJW^V4*9.1484$45$$5%$%!%%1%%.%.5?$X@W%TBWW[)H:;J.RY53 M,!GWTJ%&4"/YTP@V&4BU*E1;-=S,E`^J+[WNTP/R(5,J%/6J7JB6 M;QJ%AE&[KM6NK&NS5/HF7OS7^!H%8E@:,753'Z'PBE+/V/K@=*D;>_2N\YE& M#X!<>#FXYX$;.U$30)_'ZWIC51MVXOBE4S-(-6%NT"M5:I50PKZV;6LTH MZD;Y9FBMH'O$]IH)J,N[5NONTSNB]Z/W9+:#/OUA'"@LQ`GOR2B)I!HDC\]- M817?C.M.JTM)FWK!$QG.-?4Y#9,YJ/X0*A(*Y#3BTXBT!Y-?A6Q))^`DZE)( M94!M'I*$)++R,@QQ%49"JF%JR?06?#+>+=6]K1$PQ0\+-D[&G(=Z6?3HK6WI;=UW6-\DI*>2,GHF$\ M+.H[O7$:2Q=OP\JNI<8Q:Y+H(4`U7NX?K.H^7`;N8+'[L%,7Z&S?_=^[=6&' MR["L];)IZ43-+5M[HK.H71A;I-$J69HPF@/-$9_%(M7.;&<>7 MVQYI6IJ[YEWKS\\G;VGV=KY%S:KD3M26?E&3VD?M:Z"I:\51KSI'M%8O=E;R MT5E]`><=4EBV?SK(N7EMRM&+FK80CH7""1HT>8.IOQI_U)NWZC5Q9@VBJMQU MPTW]HB2M,SQ,&ZY99NZ"9L^EHI44#)J/_ERVPB5X]-^WEW?*M26&9AD[ MNU55?8[,P1)VJ[/>K4:5H$H.$WPIMG\A4R:@ZZ>=UWH5-B?4BUDJ:K5:.K.:J!?U]&)4=:U<3F$,3_"'O+K>K%2+^OU@E%J MB!WS5J50K58N"^6;:JUR4ZJ6+^OZNCWD7Z/\J2?MUJC8B1E_'IQ MNM_9HYTM3N1:&KZ9.^[*&^VOLBX2>ML3?6W5E4X*=H327-:;]<]7#?+PL=%H MD?K5U=W7SRW(_KK1JM\VMR[I"^=(B`KVW.:>UE[:S[6^-CTOC$B9;^9K4WF^ M6[XG$.(#$Q_.[;=$G%D!R8J]_HV%HZVG!UB0A_FCK=D$FC6(;7=8P/.2E6O/ M/]C=['I(@L[/:_;1CLX[>**D2SV7A'$[C&P_8K;G#4"#'KQ*@IBO.0!<6W\" M.+$C^,-_`TXZS`=O!"G"N\P/(Q;%$0O\\.)`J!GF46"[`ZN9_X.&D3BO`Y+J M!QYS!H0+^SF\%W7!Q.D3(7Q>`T6;PM\@A<`'4+L0YWJ#`KDQJ(N M\5B/178"-^2>$"#*"\Y3E':FB$"S[0\``/\1RL[",*;\@OR'@D7,AV;%3Q0@ M"C!L6Q)KZ3-\2-[M4/"[B6;`(FAKW&'.X;`4G/;C!!1X?Z*&>2V05D#LX4OP MLDO%.2F:.+2#W`R3!OGV@Y`)(FY%%J(0Y"K@_8`G]I'SF^O;J[>)(`-X3YSX MP;A+^C9/#!R62Z08T@D."?`7Y&/P1']0K@W_.L>I8,,/HHE9]J,MRCTZ3@1* M%#*@A$6#!$%HMWI]CT:40).;`$-M[@.F"67`*EC>!UM$(2'EI!Q05,@)D(.Z M]U_J0-)!8K<#V;&($D+@"0CCI0!P)QOLJL MCB"5H:B!/Z@;KC;^NJ3QI`AN,$)4I#!\W0O\QT)$>0]RCX0D![-O[>,HYH=V MEAW'"WVT5SDB_2A^Z.J55R]H`)WCQ:*#E.!*$ES;MO]=J(5";>@P!XA)A.(. M*]7(D<\*/Q+W/@![OQJEVD65],#OL,2#B`=_-8K6A3[^D=A)6NO;E_%!.J8& M[X/K[(/,V0_J#2Z28WTWZ/;B(?I\'S^!A`011!>&MCLVXZ'_%E)R#1_+8WZ(\ M3?`*'C$!%_!?X\[=AS2L4'VR%-` M+6:]'M0_*`#4$JC-X'RB&=X-AVYLXTA[SH=A0>Y-CN80+3LHL>4LJ M.`;'X05/`*HP$(@$_](#:@>+_8L-&HD1AY43@WJ>L M;W%`S?.Z`VIF+)TY%6K=836O;7>,^7C_*@BC709BD):CTO([AR!I`R]M/CQO M=,?.QT)NTY-'3Y:E..)TDX$H/!3>4;)L@GT4E2>?\AIAE,2=IY."B&Q/EMD? M(AI%V4DG.S&&-#4,PNH%ZF>";F1O&_9>/E]Q3\:F4T]3DQ;FH'8C:7]B7A72 M')@S3#V+J1^D)A[-=\9<3-"D6N7RS4`S\!]/UH5I4=Z3R+WN?X+NGON*#G+' M^';+,E9.((EIE>63I]<._,OA%]-Z#JU"J]`JM"K[5FT7A*37J"4K#\:+$E1H MLG8S\^A7(&_,O532:J,+#(YZN^WF[HN$`=51#3[Y[H#E1'=M6! M[0-RC!RKSS%Z>50'JD-"L'8HTM(Y%M*/\7Z:6K^;,;%>^CK0,*W]!U MS:J5U--W-H>LT"JLF5@SD6UD.Y\>"R=$DJV8V.L[KKFT2%(A9JL,D&'D!>FT2%(A5J&9U#B*+8]G#DYB>NS-+V, M:PK0^673^:%,4"82R@1;COQPC2Y!*M1DE0FZA/QPC2Y!*M1VCJ1G,U7S3JU, MW4Z**"**B"*BB"@BBHBBG"C*OG:O)>Z"6'E$_\\_K;^(8KGCF)59BG1W/!JE MFE:I5-0+%=2.*'%3&ZH#U9$7=6`#@21+3G)9L_0RDIQEDBVM6,&I`VS*,]64 M9W#&(&,WIB..B"/BB#A*8!+BB#@BCB_@J-YN!O%F6WS8<.:_F9C6GG3U))]* M2.LYM`JM0JO0JNQ;)?LT.9[Y?XIQ;[.JZ3KN3,9!T4P-BJ(Z4!WRJ`,;""09 M2CG41VH#@G!.L3$N?3#O'CL?QIMHZ&5:U7UY)W-02NT"BLF5DPD&\G. MH[_""1$\\_\$SJ96Q=T>Z1F\;T$PZD69H$P4DPFV&WEA&AV"5*C)*A-T"'EA M&AV"5*AE>/H$S_P_G>LS-?WY/1K\EEABF^&5N:J'X9M;^W3J0]9`$'4AAY>'_XNA_ M2X,>JT_A*1)U:3@[PT"ZMDO:E/J$^<2&1!PH`O/C(`Y)[',*5/U-7>(%84B2 MDYA9X,,W_Y%R2,OV":0+;PVHS2^6.ZW]5Z(TG(`QWRS`5IWOR^[8S?9&=R2( M#TQ\.&^_A13O>="G/!HDLS"-_X]9OT?!!%%\-C%D\N)^]B7FE(\B@EDS("$Z M-D00&K(P&I%/.H'G!4_,?WRWASFS<8:Y:)\^P];Z"CJ:ZIJK[E=WS6;]_@%2 M=:"4=C^D9\2AGA?V;0=*_.%,'W[OVZX[_O[$W*C[X:Q2?C.)&1TPF_(ST@ZX M2[EX:J%J7])'4/NP?TKA_H]M:RWFW%] MQ>#%DAQ/.R`R+\6QW%?.72]A#G(%C<(/Y441SA=R^TIMS/NLE:Y]DV:K56MVDR7=3I(*/T&W:N@ MUX^!P7#4B0F#3O1D<[JYIX)S([OF7M*,4O'U)4A[]#L-!Z<6L46M5%1PTDOV M17Q-NSU2V+?I9PX=I]%M@=% M\81_(T$;RFB+65:I'1N>-"$5:N@3C[`#)`OQJ/KK@C.U2_E%%"6Q0T;L9(]/ MYM813<93-&*+J_J<(,2AE:.[;%TKZSBVDF6*:UI5Q7F`HT8JUC&\V7F3AN'; M=\1VG+@7>W9$Q;B+2_N<.BR)3Q(_9_<"'K&_DQ_0OQU9_.I'XJ->)ST5S;FY)SY MCA>++6[C>4&Q[F%NU\XYJPW;/]9K:?3^I M?J3MI([83GKK_P!^`CX^O5.E/:0S91]U*''W:(J[1XOI[1X]>M:X?1!WCR+] MN'LT'_#C/M*3CI%]L9](SP8*F>U)O8QN/S/3'A.KU'*S>32?%%=5O+Y<]@'\ M_P3\NSAL"6)YAX89=D^2S*V*`X`5W(Z#7.]0C(IFZ0IRK=Y&AAOFL[!+7?(8 M!"[ZL*,WQ%HQ/UNP0[`;<9Y@Z0'Y7 M,>?4=P8GR[#%;3_T5!575F1VV^O;C$\.45:+!+6A_TRCJ2W@:V,E.<@*&S>Q MM]@QV;+].ZQ;O*>X45DCU/-DM]Q;%D9HXOM">S7SF/[Z@D)D_+?(H`XFY M6U,/.?S[]O).#%/??TE@$O]=+\.$L\P'F8&L:&4][;.>%)AE/JS!.W".YP]+ M=R`):B+[FI#%8%2'C.K`GD)6F950RC(Y`/\W6QY@4`FHA&SMW?S4:-Y_K#?K MG_,3!DNR*Z:B5;"10]>&O5P9S41QR"<."0U&F<@G$^Q,9)UA"24MDR-0,DY" M):`25D?,RDPD$Y?^H%[03^X5BJC3]:'8CP,,I(_<]IEEK8:-7T[(/CW600%/D`VRL=.7#Z(5K-#JS<-N M&],VG@L8UIYB-!8"G1IZN'R0?5[2K&+:0^^R1;698+9<5?`"(@Q,,3!%-W#@ MP+1JXBT1^2!;P9LBD.==VG;U>)9]9O7FZ\-ML_$'K@9.J9DJ:Q45+[I!LG<) M.HO0)TE[=8AL02>&(E*A)JL#0)E(A9I@$'4!J>]IU$Y=.9)!9T]),0\&U?UB-<3$O$KVN&`HN@I!^TG0< M;^*D:2JN2^PZP8`S)VR?&[I6JJ8],"Y;AQ,C3JE0D]4#H$RD0DTN'Y*)YL'0 M*UK52'L\0@%7D`VVD>B<$)WV%,,A)DYG,WVX_:OQ3MS\NV;V=(&\K4A>5\0M MWET,FD>7%;?N[M?<5+Q"&Z\-:X^=YXK'$<73HRB)'4IBARBB`A538&K/25WF MHRZBLHXQJ-T*(MLCS(]L_Y&U/0HEL,.01N%RKR((18X8>2[>Z8K'D<?WA&]__R>S'8K3/'#Z*%$0OI,1V.] M9I+\%A1X===LUN\?(%4G\#R['](SXE#/"_NVP_S'#V?Z\'O?=MWQ]R?F1EWH ML>GZFS/2#KA+N?A]KC>T&CHQV#E^W7PSZ?-[M+-OEW_%IL]U_"6%.%S.=S[Y M9`^FL)LUC8B#?#7RE`RI]JCO4I<$,1]"#(#98K\JL1\YI?#7"!")NN13[+NL MW[5YSR;,)PFL)`H@B5[@LLZ`1%T@SPGZE`0=\85QXC&'^B&D'E'.611P!N6T M07#B64[#/G4B]D,48[1R.-TAT663RID4;,18:0 M)*31BOEW.@"S."7TV?%B85>'![W9LD_79M7>AV!QKT>YPP#N_[%W[G+O3"?5R4[7_I42M@C:-C;C1[K93W^/9`.& M`$T(Q@\T53N;,;:D\]#1D%>8K*UO7FJ90>HCFF,1`N)`%-_'U!FG,IT0'"5A)E1@^B/UX0OL M_)U0]G1YI)X>J*,+VB9MB7>1(EQ%\O^D.=-8.>^FMTI89_1Y_S.4[EU;Z_4+*G%,T@I<X=ZD@HBR^'[(\=]BT] MTQPN"#OM*;%0@PUJH!:D!;_#N@Z^A8,]_BA$OV2#[P517*H:G+=[=.PZ'LOM2>8_YKC'9([@AU3\^$=7*2E5T4:WLC(0- M?HAME>UT5FV]$OG4*L6U:BE'(Z:]HDD=NX8VONIG*CMKU`C/I6@7792H.1]A M7UBVV&<+OT7X+>",I'VA2G)'%#\0WHSP M9LYIVBN**6FE)Z$ZACM3_S0X(O^KX.)+N5@1.@3OFL6[(QYRBQS"S4#`PF90 MY!!NMI`OU(YD=[BR?+!,C>K,V-'$5Q73"W7[B,V/_Z:9;'170U%UM]OTA_-X+1HBAQ'$)8QSP=WB+5 M8TCP*"8A&PT\8SGS/"_X'GW8O0FO6:X[TRHZUYW5J6"NNQ?EW-KD7VZQAKOR MH'Q$7Z_[][]_0+8VC5\SY]<2D/R;*RW8PG3J;,ISQDD>+EA1T1.D?%Z8XO=& M(M'*7ELR9<-^K#HJ4^OMKEK/,\>J0\1!9S><"C5%9RL266^*\M;"!)M"G84Z MU]46;T#=">45REM76[R!ST*=CZW.FM(`S%X%E=?.:HXL3[>$-A>LS;8F66;9 MR',1TVP\ANVEBV?=IW?94`53DNM8"[>!TUJ$.5\>ADRC3T>/0WX*`O<[]3Q$ MTZ)@DVE(62&UK`1:&D%C@;:+X0S,8A(ZY'VSXFD=L^AX6D=]>3QM1[FI8STO MK6M1/F=C`.V$190X&9NCB\5LRFD2<&Y6XI%%DRU`V1GJKO*$Z.$A&WUJO$M::X6HJXOJ%*9\Y;EW/"X0)*UJ_#4G3A0-W'K+6 MI8ZMU$_65??"LJJPB/QPQMA_9-=9XF4=541&(^((9^P$>]$:WL(5DC[H"GW9 MV(3];]`W,';9*$B"X*(`=M1]CZI8DB'7T+$3,MZ_]XZDEIX&2$!W&@C=$7RL M!P0JW<"J[]8P4=;J[#EP8GM9O)K]0;F+3=ZC&X:X_L=*&C^Z(&%+0/N@_!)F M(;@N/OQL\(R*D.P`=PE`UPL!7=K+`5U6>8"NPKL6@*YSPO0(0-<9"U\`NDYZ MNG[M/Y$H9FF5(I;_B?R=T'@&PXB(DX0TIJ3!)^OE;CDUR;!K>*51B/@EZ`:] M4\/H;]4C@GTR#2(J8GZ%ZZ]BBV)8YR%IK8[1W?JAL/ID&",:10GV'09D<((H M%E:L<$=+UVIX+5?(^H!A6)MR$U9=TE7WM_Z@(P*;PR@)F=E"#H[&;(>8A"'Q M71*R$29$F+'BH:2FB$*?AZQ5R;)J*.L&AJ,;A2,27!1HK+J?J2FJ9-3Q4$W( M>/_>34GO-.%66/V7OX:AB`0?!1J+?;D(+Z=HK-%[:+'K.$'"PJ!3/..$L)HO M08IR!&Q%=\+'`=!V*Z=J1]FH;L$HO#]-5 M>-<"T[4!UF-6!-9S:J2-$'^AJ"X!JBN;_0+6=M*0Q7V(73)W=!H,%"G]+*9C MB[.81LM8DR415"TD(4^ZY0K)$,=--E%5":E9DB7PMFK&S;`YJ&P7L M+G9(XB3TA3-6/+[)EL75@O.0M2')1@W/".KKBKDXQEE1/Y=&<4B'"<^4.")B MFWD"RZ9KPK*=AZPM2=<;D#2JJG;LT^T-PNZ$^LR(X9@^!C$4O>$=,(K4Z5M2Q"ZE[Y9?9.UR,7DZYGLLC6$Y*(92-@B63B M,?7G@U9EI?<1_S1IT=IV>O%M_R.K]\*JM+$V)E/LSZC_B'KP$O-N,.OP$GL\ M6'(W)FF5MU$0HD_WGQ&)8CIAUU;1140()Y/G0OH69@\SR,@>)K@OI^D4)\?D&9/X]<8M6?IB"(GI%-FDCAIPP7)53GJJW0^F2]9SH`%/6#U^8_+8FR] MM%QJH!??AA'Q.;D67EWW+XON1$W.MCG9, MV#'*KV^L[=[C\I4EO_4ZO%Z_(.=\,X4C%(S8O-^4DA'!SFQ#R+DI,<]R3P1M M23;/!H%V7H*UY+-)A7)6@K5K>'XOQ/JSWG5)KF/ZCR.B0[6BT.U1>NZ+/7;> MBJ,HF1"WN?Y$97`U6J>&0,$Z&*J*2%BQQ$)T:C)?.Y!CRG\9-]./(XDS48Y& M3'Y;H,!/XKZX[@>61_2)1BQ4#0.X"(D3/)%P]EZX,$7KN"+)1@VQP<*,[7^; MG&7K/YO+2VN?J%A%]PL[:&1KKJ!R=_D"CZ@)R0N#2.4,"P3=/"=[5BW=5K_"S=PQ[@^/9E+U; MNX)[@7@';MR-6C%C9V:GOUDI&6*OV^L"EQ,L2S[(_>&V$B\?WB-<^A':] MP']LQ22<((_B(?5H3+/X'%U0M/AZ^[YO[[(59B%E*])*C@M:&%U+:A`."6*U M)D(:$1?VM[S\1%H4@OJ/S2H+T3&++@MAJ2\O"Z&75R"A\*Y?5""A>%_[U6_:K%9ILK\Y;7_V[ M9=VTFA8B/XB3Q/2)()>,2!CR`EO,IR%^A!?U;,2Q_/'/^"3[?&X;G:>(54DS MS_LR2B&FJY\9*A3"&H0N_,!O.4G(_@/&,@U"9K7$K93"[5<=55M(^I`P8QUS M@=?PMG\249]$+.']WPF-*#-CN?.FF;!H12_7=MFX=F'1A*1KZY:E1^4Q_K%Z M2"[,5M$7"R7-*!L#+@S7J62M:#64=0,1)(T"$0LN%@'%?NF6H^XVLFPPK&V6 MG;>U\=4S+;L$_BJ;(K?^39<5^N+OO/VBF M\<#`!HJJ*0_R&^02ATZP%_WZYOKSX`VB[J]OJ/N@J[IFZM`?C#4I\FO;.Q_/F-R6C<\>@Q/ZM-),KG'/[[2>#P./`8,&P3A%Q+%(75BXO*F M_X+_A!^.P8B6]HP/ZJ5A][6NW3+U*Z6E7P(+[,%`:74LM6<:?;W;[5@/RH-N MY1A!HT!7E<[#O^[ZP`Y#MF59SIAR-')S+/R3>O`L\,DMGDV`RT?1B9;QC!67 M!A#<5_HMP[#Z+5WI*"W;'-BMP8#]?MF555M^X,ULYH0I\W\R3CP;=8ZBWAC[ MC^3:'V`:_H6]!)@U#[WUR1/Q@BG[HA=$<=3UW?E/64,](!X81'QG5JY.*%MU MHJ5:9DXICD5NCH-=U^7'^-@[E78HBFI85Y>]UD"3968PNBWK2I=;G//T?D']0'A>CQ M[$,#[/"(S%P'!M2')839B6/1_%RP74UFHK%;?:L#@C6-0:L[T'HM9="UY%ZO MJ\C&8)=@E95IOSY;"@F]&G,(C`;GXF\6T8N(D3WV'0$;[8+U;/ MPYFQ;O6ZJF+U;+.EZRK\Z[*OP4*H7[5,4&G+4%6UVU$Y^;^QM3Y;ZG_J6<2K MGL7RP9:MP#KB/%X[1;<6B//[,4%#L!G?40K#GL(:PZ<]1I_N/[-4FHQC*&(L M0^$*9]$H"!F0'%K!#D-B87_&5E8P,?S8`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`R_OH8O/P0ME\?>>CB*;D9?<1AB/_[$_D7<:_^6A#1POQ)F M!8G;?2(A?B17/TCHT(C:W3MN8P],/IC/'J^LH2MAYQLVH M%TPF@<\!VM#"_/V;T6T2][#GW4QYN*)4.+*Q`XYLF+:ZQ&B^D*R\\@0^<"RF MH%MWQ*=!^#F(0=>.#LJ4E;YV90[,UN6@I[=T6(U;7=.T6IV!T>W:'5,VE?XV M4.:1L],JLOQN3^A?WHG/H=OF'H9'1J^]I\:^''(?16USTS!<^`![.4=\9`4, MIW?S^:^K+_?7EW]=)7I5.6GQ(0M\)XC`MXB+JQP'"/L*/(4E!MADDEV^_H)U@A-XJJMR6 MT81Z'@^!/L*[CSAF2%\*=G^*/80G+%["7E;;'>,=RDU+:".=F8A/3>0F9#$X M-AX+7;#NLG'"@]Y'_G2U"?[M\IW^Q_=M#CQ>?S7K),U6O7S*R(164JO,AADD M(4O]"+8&^,L,!8X1SCZ)&)4A(Q!>M(WY5U.>Z_NM(K&U=Q/I\=;Q2"@.8M!R M_Q%:4)2VOI3*G*OSP:1]T1$:)9XWFQ-!7$XN?$W]%O33@G?)+#_>*5\1:83( MWPF%V<5$":)]J\AM0V-CSWJ891#&O4RRQ>E@N&5&?JUL&][Z&#_TXF8]CBQB' M!(=,=J"J49R**),+-,$U;\GF#$2>H:%%WX'\3,F M_&_BD]S<,#CI&R:-P21+L#/.&A^R=*@^C_-O:H9/,7TG4=]!XFB"&?&L4VAD M"`[4A"SS?-!#>M"7E9`'C"CW*U3(G-#ZEUW6;Z2:[X07O+&>1S>Q,P)?4 M]G-C>%!J^C2#^ZE,FJJE)HT=$C&XI$.(&Z%1&$P6)BP_,:&-#>(`Y8)IHAAM M?6[B0&5'H'.@M8O\;/$C%!1V-2!3QRT(I#H092;UMSK]OHZ\$)2Q/ M/IXG:C>%)A!T.3`$UC,?`ZAG0<`G4L0'VL(]=#*U=,*<$=(P^ M$6\FH77[S!B'?B?N(UFSR$`VN^`!GHG+/V(O0G/\5:;6F`O*"6`R#W%$4\8I M6EO)<9[=&PE3QL,7W.#D^\:+>UHP7ZC;@GGMX"D%Z[I"*CQF)CY_JR25_O)> MR;Q<'[\.&[71O[@MP].I1QT^#S]UN[?2@HZ4"F@DQT5F&OT@1N3'E+#[DDR: M0P*3._Q&W%8&Z`]HWY5N$J.)S].NJ5Y$MVIGP5U0/N,0E3#ASI_"6'U,0J$N])),ZDQXW M:WDSYKN_`-N"T2@"GH)00?+1F)G-])IA/`9#![X-YLR#93#-\`R-3?`WSEGR MPV%9!S.3L+Z&2RB9IGNFN2E-7V1KS693?I&N9X@\\>5VG!G:3.KIZIDZ&^NT M@.*`%X793(?/TE;6%][,Q6'HLV^$VXRLO?7YN,TTI-X`T`G:Y,K!T.>-T/K'7]G%GMC<'K0S2P=?;[)U0/M;6(CE MU/?AX]CD]TF<`Y1!!2*FLLS[W8.BBD_%[D\KD$J[9,*71+!K"[^"_]A&MR%S MXT&9-GH]X)ID'@83ZOQ+AL%(S=WZ6DC#;?T'/BR#J6N93K]%G9E5U_(#NE!R MX7$W"=DKS#",:/3_[%WI4N/(EGZ">0=%Q71$583EFZND[*4BM/9EA@(N175' MSQ]"V`G6M+$822Z*^_1S,F4;R\8+7O"".KIIL*64SG?VDYDG01L,$/Y,J=C' MTDGJ<0=7Y7T(Z:J7?=(\EGI#Z"`"^!)GK4X%O=(8L`:$Z`TM+:#S71F#1R-( M63F5K1OM^`F,PV-'ZCZ!<)%R$@!(/FA`_PE&&;R'8@-%XU^.CS(P_6!8VV7( MJ:_OPN-*1S2Z;J"S";Q_.P$E!D+!M[2DOJ!*9F-\C-+)@-+I6*FB:!5[I7Y1 MB(T_,U%^K&+%@-*1P<$4_31\K3&G.I5=E"G)Q-B_&!_)-&?UD4,*H7&T;H:] M9-O:D@P`&P?B67I*T9@88.RQ8_?WC,=.TNJ4/-;Q_Q3

'5)I+)!>PL/07TSU8U3MHJ&YB7+S','"%FA)=4@XT'"K^`0*F!V-A` M<>GY"S!_RM=WXN_:5*FX4P(WVR4QI2%2+YVED`RKL%+S13EH=4Y7,IF2/B>D M@ZT;0WF;E3G?F%*?N5\#]U]&UM>++A[E@(857E\%Y.4^B`HA.K73FA#G4H]]`_*E(OC& M&(W5V$Q);ADYWR2]>!@[Z*A?J=ZLVT""RY!;ZB1V[ZL;NA(',>P@2_VN.K(L MPED?,C\GP%.E0E6WNX=D!![55C>4CC`_KL/Z+&?KA_79K^^<8+UM#X%W<(K3 MQ43<-%^(7[?>I^X\.=9WF2`5I[[^'?:M]^2^"?#'4XBB/OUL?.N!`(,M5T:Y M+6]4%C;<<`2)ZNBK8/!#'0Q;F>+6L]MW/1V?#>J& M,_L6P@BCSH5YM77A:(W5C-S^N2NB6G.BBO_RI;4I0[-]DV@W3)U'Y6I![E] M,EC;KI<]'7%(O"?Y.SL"R=Y_X^VV6IF<$/1A$:L6\6U7:-$Q'%)\^+G?4=>I M]LWB7*E4[7A-RV[#08+KL\;VP:(<=35ITJ9T]);7WSXXL[GP?,ESKW$VX_+# M"Z+"V]MRC\5XXJL6P1VOF=N3",II#EJ.[<[@_53;N2.US>_*LZ,&UZ@CEC:_Y3[RB>_X/#0=RQ8F"XAK.MCW M38>&'@D=CAS!EMIR_^9']6QIA_Z-^H5/;K-_]O%Y7GPS;\ROKJGX=>& M<19>&=Y?QN_A^>^7[L4_3WP8[S+\_>3\S'#/`F-X]>G)63CO\=O8,K_I@ZO8 MXH.K'J8ZD*EEK7<#^7^:F)_)%T[0Z)^DW&JD#D-Y;T=7E?HP=TYG*!XK3>A8 M*TSHD-V=+U4_NG[TEN8-C^8LL4K):XD#J.:?0/67FD8/E97^CQF;(I=TJDM" M4C-%,<4ZW#/>-DWI_A[SMFE*MWK2V_K+(@ZNX?W\@^*^]9+1$:D'-W,O2N1+6ASY0.8)JM%6[$?JW;L9;QAB5V?AO?V[+2:*_?TWV=VODFS MX?UCY_,R3[;R>[R:U4=8VCVJ2?$:Q3=!<4_H.$CL:A1K":PE<.?/7(3BH1W1 M,C_M/%&I?]F0(^Y.SV:LO(9@2\>S[/*ZFL;W0=E[H/%X*=MW&H_]X,ZPGZ4/ M*Y[2^9:,7K/(0!N"[Z:RZ=4L5S^,6M+VM$^]3]CC?V;MY$AL7<2NY35I'[_*M!K)6GO9[ M+]:;'9'UWHS08.<`CD#==9SXIO.OMN?QZ:KB>%CER%/>$CH/$KD:Q MEL!:`G?^S$4H'GYMG\]-]W7GCNJ4\4I\.J20$8/(U$7;12C9;[L@>JL9W";P M$`TB>"TT"Z9#FM;1"$V=]N^QH-5I?QVLU2C62=>A85>C6$M@+8$[?^8B%`]M M3G_^BO"+J98Y*S'E+>/#5?=',MI@=IVF+:R`H"/+[E?='LU90XAZ-K^6ER6! MV.'^ZUI>EG3,!Y:"'UF_S1K'@TR"WAMZ-8ZU%.X>O1K'I7!\DQ[.4R:XPT^[24_6_7'WK3_NG"ZD4^'R.^B96C_Z_3RZ;L5:]\?=4Z;4 M_7'K_KB;U:1WV!]W_E;3Z-O7D]/PCY52DG5RJ!5KOY;3H.^ODRJSFRO3O,^= M5`EB#;*C?A\[9*>#FO@8V8FYZL2QF[WYOST_.JOLS?W M-&L;7]:@]KL3:HJ:8J]MU+H$$M1@^-VUV'?VN,/^^UOKOT-!V!8*;^#0]C>9 M^I_P#_?TY/!<'!&05;V[,)R@YLJ+%`_"Q5'4H.3=)A>/AEUGHK=;V5^C4PU5MCZZW4M;RL`$2] ME7JYA4W-E3%Z;SGYD>UZJW$\R*SHO:%7XUA+X>[1JW%<"L?M[*2>V.?KO'Z? M;_FO_JB=?% MXZR=&RT([F"`2WG[VP>9=J\O0MMRA`G_8(J1^=\(87']]2JXIA:_5GO`,*'X M>PVK*5W,?=_+'_%K/4R_EY0/3_*4$6Q??_L:?/CL(/7/`(^EB2D!Z.?F71P__!PE M,+0\3;[+]DFOB'MW"?#6S7-9Y)?R/H9O>W?N?9H5R;]U&_@+F25I&Z^*R+4@ ME`G[!T:4L$G:(4(QPQ*[)-B[N1R6PF3!$18E(!P%`2 M^7[@PT6HJA4/_4Q^^(R:@J)GXN>14B7Z4GZ7O;Y<63U%<(77!/V+SG*:*WM5H MJ4"XG[4Z$!2ZK5;:[Q4*SO;_]O/B7C<'V@XH<_5E28CH3&5QJOYO,TB,Y0:0 M.GQ/&@4^ROFR'/QYD+U_/Y%@V`2.#.:>+C(SP_)"! M&S1=Y#*3.8R8`J'01)PY@@06Y;YS;2-$0+1FX&9B@2S[.6MX'9D[Q,=R.",; MP@?/P<>B%A*'AP_A\,$BI5L6'SI/?AQZ<.A`",4MMB%PV&QP"*)L`^#XW3C/ MSV__A*0][A7GV:6:\SGKJ^X^HT_SW]5/V0[Z&9BPTA^N`Y,ML(Y[<`6FD[-H M"J>`AS9%GC`Y<@*3!2$!HXV9:7,0B:UF<,#:M$06V6JAY7P8,?$Q,3\ MV:MM@+:I-&$PV/GMUR)M_?U5\V4T\EIA8@6*^4+DN@X+">,F^'G+9"R"<-ER M;=,1B#`2"<>/["$RTT(D>"4]F$_1/&D)9-[*D@>%W[9D`)$(.4PX)K$#;C*P M)*9@D6?Z/N:V$&Y@>4Y)J0H'0;PSHTB-_^KWI(&Y;K'H-(Q.VFW#&QOW\9-Z M3T69$7>[!EP<&P\J+@8"TEO5OC')]#W&65J`X4Q[W2?`#VY6WQFW:;>;/H(B M&:TD:_7O-_^O'`&%F?%0M'O50@VOR M?JLS<=$G>+%[$,F6'N-6W?8EAE#+&+2+9`TCN6WH)I-Q871EG!?PL0%YG>JK M:+3CI]SX^-B1\)J9HJN7%HK47+;Z!41UH]=39%`T_M7X&,9#:0EE3W\"J*CK MN^IAXU>54!D)O'`[`9WIJE:8LB7U!56Z&L\C9%)!+=MZC1?%BN!%`]50,T_L0D-^XR&1>:$7%/42CA"5W%;$S13\-7BA\>NDE+5]U;(S$= M/FMZW%^,CZ0"S:T"9!R]&2>CZ,S3O>S2)2,G[C]!6R3GO'825J=DIDR MGJ!4$P(LO@<60SZOK-3@SA+*X;4E3?"-\9^X`4Y!?0#2\P"8Q/?*5ZJ1QD19 M/6P*ULY01L0J\`_C2-\YZF MKM39BN$Q5(+4U=>WNFFNWWHD3P.:0%)2N#MO=62[WX4'5*3^1053M]W'\/"D M`(L"WZYAX,;0:0`D=W'6UO(PX#L(C;Q+IPQ>T.O(O*,:\Z MX&W4ZS^7I0:.Z$()V%66W-W)S448\]WJ\LYFNNR&F^/%\S7I?66(=JFD?_,0 ML34BLI>F%Q"Q7Q.<*:H6A%^NMG1;#;]>F'=A21&,#3QW3,\*B(D")^`$,A>76=-Q9X5R9DT0 M/DG)%)TM*=MYE*7W8VJDA&??2)X]WX3Y)+?GD#6>YH_9B,%<_/GM*?CBRX$K M5K/WVFZ0/1U" M($(9>$O/#,!=FBP0KND)BYG"HX*@R,>V'5T3S6L8>$C=S->L2KHN7MS$N03. MWZO"8#EMH4IA=SJ5\IZ>+[F(G]1'KEK5HW_\(7,UH:'K:/FS85H7"2$X3FJ(F,QU5;H?PMI&6*T&BQ*6`1ZI:QL8+I;31K\P"#IMEA4'D=>8`DK M%"9U"801F$*XZ+J1B7P57B`4LB":3BVJY7%!Q0[7,HP3JR8K$5(>S^+"GK^6 MP7&1X$\PE M\Q,"BOFN>5O2NG'>3A$^R@>1V"5O!;>HC3;!6CH_XP%OO\S*E&WRMJ1UXZR= M(GS(6KICU@K$Z$:TELW-["R'"GO7K-6T;IRU4X0/6Q76KAR:1'&2_1%W M^VHY2O]>N_5'NTSB@.N'=WJGA;R,OT*>X6BV>R7-R_*7CFA:^VQ2Q" M(FPZGBJ2"#\RGV!LYDKFQ&JH+0&`"O!N->HS8ZS^:JHS3"]RF1_B;._9:$-]Z8*L16( M*'*04,NP:-6UOS2'A5V+!=11\`389$[@F1`@1*8;69:'J>=[KI@U18.;SSJW M)(F[<$B#PMG:#HG,2CKQ&@YIEW9(`[,5C2*S[=#J&K49.U0=Y>HQW6L8^;;- M.0`P$7@K-3V!>+*Z"K!/W33)RD]V9.W27'1C==9R64QP7]@#'\OME,, M>R&B'C:#((0X(>*>Z460B0@>11'U'>Q8+]BIT1(V0?E8AOE:&I="2!N[MP'H MA>QT>7QFQE'.Q(:85])9!>F/.$N4M)VH`_X@"@LA(BN>SA][,LL[R<-&RN66 M!1DLP".H;<^W[TZ$>40@P$00;)H,_*,I+-LRP\BBC"$O]-PY"Q'X&"A+TS69 MT>=%[O8VL<8:#`?$UDP@2RR*K2.&0DH]$W,,7DVO.>`A-T.'8,N%M-XF;$%^ M,8JL9Q$RL4-FF)!^>5Z.]F=2=+[UTIM<9M]+Y![Z:J,1(-!*NDE9"I!JJ1:( MF!?G27X*",,WQ9/>2W(+R(+C7`(@<$/2/<=C8!_=0*@0KTG(_7$6OH M`7I,;6P:^W'L!;>QM1&#H^OFSDR#`P'H#I!WN]VT%:LE-RIL M\B;+EP,'L0:(-E+Q-'&$11<%/RARK8@%)K6PI3)9:KJ<.^#HJ1.Z+N8N=1<$ M/_#D:F5^.?)V`@DE#"^:0%X*$C*_MHCLB;8'JV#R!50YJ/I>+6>ZU(5P\]!;(M8[S8HK\O_E&KY@6R[WV4&4==H_S(D.$46 MMPI(AE0EG*P#.B$0A2/;T5'XI`+[@0NA-S:YYP4F+",T:)-O"W'\1Z,EK`I8G@U!G%M ML\1?Y`LF06VVUN;!VAK#E[):HHFVY>8/UFIMD`7+&"UL->FV/,>[L%JJE=** M'&+::CFUU=H0#]96&;:4U;)KJ[5-%BQCM9RF$+716IU;`A&\8GI(!C4MC+X0 M5ENM]9FPMLJ0I:P6;?*ZK+4]%BQCM5A3["1!W-*V@@WWJ64S]__8NVHWO>G. MM%,D3LR[(+SOK.9%VGKDP2NTC/`3IG+M-N%2X8K6=;!APNB5I\RNFA:BN/_9^]*F]M&DNQ?X:JG M9WHB7'9=J,,*=P3.;FU(ED)F]ZSWBX,2(1DQ%*D%*5N:7[]9`$@")$""!$A1 M;KG;AW@`R%=5F5FO\@@4!200=:B#.,,>3YKS` MF0?87`GM`$NKTL5AEI2U8XU+Y=W9VMO%G&IC[=6)QDX+PV4EUQO&GN]N5E1G MOFMKXP#T)9$7(K+FU>:[([N?YCST!A>]J'\R='OWT:0W*&.0P_^.;I^D7P5Z;^%A3_\O0 MC%>#Z#:Y\$&:$JO2E!`KWTBAB=SYEGV@?$T)UT(.9U)?/UW\AZP&1:7W004C M^59^-84L+-OI#,V5D3,E)Y:&#[?@$:6?WY7;?L"PKLBEWQ4.S^-]MKV4JYU/ULCQK/&5PYU.HLQJ MLD(9B]KR+=`\PTG4CP9)Y>9/)I$Q,@57_$=#PX;]M&KZW?W#).W==./W8A,S M8HK6)E=KZ=G8F7;1^R5E-TMOB^#D]W586[[@%:? MY38XRCU$2K9UY/[2C&S["_M')63;7[&K^%@L&[G%.^=CVT=C-W2L`2:M'FSZ M#";=U^PA6`!3^2,Q]'[833X<#2)'\*C=YO(:2P>(!4UVP;E M95M=&;R>I)6=&DC17M65;1-$O-"T2FJJ0]M&I+I8+=L`D;EL.8W09FWCM)HQ M%PJOJ[BF7)?9\.R@`YA`7,(.SY&V!N$#EWN,JH`&:RJNB6)%YXH:QH>R\54, MFP1KF,&"MK+S72KU/`OAU(R+_''$#O:^AX%FTO=I+?52"TU651"3<29V3"0< M!)A:6C5"C&MAR1?+_\Y29S&6L(O;*9A.U@&T9W#W!Q.9BD/X$M-Z_W!#9->(K!)2(*5`4UGT*PT?08ME426%.;EOJU=RT:P=+A) MEW)`\Q(;N3Z\:.'`LS5-9M>O?Q],COO1M[_?3HY!4//3?6<\>1J$'X[.[,O? M3CXBY[S;/3][W\'WC\>=?_U^TO71IPO;]=]WAJ,8!O"XT_7_IXNZE_;'3\'Y MY9EY?1C"1\\OO>23)Q]_R[[MGI^>7[[OQ+=7O^`W\-\_CSO!^]X3^..]E#=,\OWG>$N<:IW^WZE_,+%Q[BY*/GF^OQ MGX\[Z'MX]>]H@@R^:#R)1_\.T?>H/_F:/,Q13N(;&(2IT.9Y4&"?G9Q^?K_\ M/$>=,8RXR6,T7^]^#>$*O;1Z7S3K[=V9C":]06=*3&0]VB>CY+UA..GTDFG2 MZ67S!*X1C4VK\[2+_?B]>:9WYJ',39(?[I]Y?`B]?UPW.KCVZ"2?K#D\O;O[ MXY\>;;R,0Q+V7V_8CCL."`O/!0*>VA>?`)MKP+IW/PXW0*_9_57VGG]7?%AX\[5+8S%"$3ZR75] M/PB.RI]S,KH_6K$*3OW`S-/P;F$\$+PTDVC;A7YR<9E,1//;RZ8D*&-^["(? MGN?,/[WXW3ZU/W;BI&GGZO6[;B2*#YL\!4E?G*^%XJHHW&JCJV\.Q=\VON-T M!B?8-+Z_?",QWOP9AJ/O<>_^PU'Z=^.GV&(HEN9]_K:?3OX7=!(IFJ7JP:LU MR%6/6..[BVLLTYZ)FI\;APX#H]`?/8`:7KSC-G-^YSAF@8?A_`]N.H\VXV1)E3E3OA;==UK/)+2S9" M8^1K=]H;]SGS4.X5A[]STHM@LQX>PTXO#3CR;F^`13+Y& MP[D3!D/M'N<^#M[N]?RJUX6KQN'`%+2&!S`>\GSRS2_E'7>B8>(2]ZZO1W?W MO>$37"EYN-$@ZB??_C2!O])-^>@&+G1^GUU__/;51W[UD5OQD?GF/C(A^W:2 M&SN,S=S$QDYHT:1/5V/.JH/KTTG6_=$2Z#`+81X,D^)!Q8'>WHLCL^]>F7^8 MY@Z=/S.EEMGZ=YD$J?Y<>'&N39??F&O!!(JK&2AMX[^AO_D"]EEG/7"HYA*J M-_`0QL%XW5#M;D/%?Y0-U>%-YR#G6LW0I[<2<<]L'+\<+KT+#3 M<\D9>?/#S_L&MVYW`?QR"//_GW]E'F%N_/='(VQ]S\U8A)=A=TLUT*OMW8/M MQ0>@>U[)S%;H6:@OD"8/C\#6H_T7`"6FA>*M.1D*S*Q_D!58;,_JS9BY^2,D%%UFOJ:,&ZS! M;F^0DFUY(N[/R^2!K^J.^<9^_38+X:CI;F`[_;AV\P"W^>^'P=-=+;.,^UGK>="7`HPUW)36W`3.US7FSVC>4)\@M]0R39 M=H8LTC,_Y&9HKK7W1,WO3[+2(29%](N;;.EGN=O&-7/K^=?TG+> M'['1_(X-68U=;2WK[8^>ER79:=)..0M0*VF'I?E=F\?B$"DU=&]G<9HA[ED3*\VSD<=?W+-_WA*,,442K,WD( M8;A8?FB=:+GDGC($X5^3IVG]^W&:SGX>)^G_L%RFZ7`[P*SX\M7TJ76U%@3BWWP\Z0I M"3./-7O=O;V2,2].[[.5B[M;S/K]2U@`^;J@7^F82CIF3HBTMMFJS0$D/>., M*]9"5\UTFT8IXV)=]Q#J6-ICMD:"^P1Q1YA6O`%!4E%7P([-MJ5**1%6W?R( M$*'K$@)+NQ^)'4X4 MA4=&F%"%.+$)4E:`D4<84X[EN98)AEE9G8Q@BQ8+**\2JYP+=$=W5]&PEY&) M.0IQOL5N90IHH=8`H@)!E:$$?1`>`-$`B*\QXM*W;`"$!MR9UC.J*H\L%SBQ M3:3<,U'8,B:5DV16TGTSGO!YE*5%%29MJ(JTJ7=E^]!-0%FC*R_BT748]L=I M);'!H'>#[ M\@NKKG:)Y!(25?+D"%`O?KCUPF_A8'1O4/,?3;GA<'PRO'Z(&\Z#MB6O[N+" M-9F7PEHC4;ZZ[?5U;,JM%[]@2EB/I]K$0'60%JQG/B6JVG6[R)MMU!>#O^CJ=IMSHKL[[VX M/T[8E_S[!OZ/H\GG<#(OMY*ZS\$HSO5N:.(3:\Q,/4-AF:Z22\5/A62P+4"N M)0+$+6XC6W&%J.]AASG8E]I/#S[)T:\7]+,X(Y8W7W+[Q>"P2LRFL"JL&&^E MQ*R5N)!E)68%5OFLC1U4F'UA?R`N-T"9>.HVNX?,(D9/=HZQQ_%7:*^\H"?!"5-LQ0 MIBAR',\'C:`"RI3#<&#/C_&KSIO79@&T<=QL:J&L/FXVC_A?"'6<\#8:=A+\ M.K^'O7X'H?6GT7+%T7+5:?2*ZBQMO?Y7O/4/FG=2R.]NFGHR"Z-M+87D1D M^\\UXF\HIBT<>AZNA'O(ICH86?D;LM\C[/DQZ=*Y:`TOM;B[.`W!C8;-=)0> M@IB8Z49[`"5,VQE,+;G,!P02*^P'!+E!X"%.`HP4\01BKL]A"RQA%VSGNU28 M%A6(Y5HTE#ULSEG_X_XFAB&A"*>X$E>K^6[38!G>/@P,4?ETN/!5-]S$ M6Z!7)O$^5(867"YW=:FE,G)=7;CIZL)P'94Q"PPH[=AJQ[$IV&`P<9[F'\G. M!A.]6HA!*?1$O(#IUXB89B"U-J!(30OMNY:+(C-MV320+E(6@7EB@!+[,WR?9S%^YSU'O.=6-)NG7"+ M*3NT`[S+&,/ZB)Q&KI'KF!3>HH'#+TU3U-K;E&W`,P;0S# MR?#:=$H.3X;%T<[Z+!KZTO[6BP;&S8-_3]NT[FE,M#`=W31#+J8:<4T5LCDU M[;44=BVA!/'4L@+*]6C#+0S(EA#E1B??%?W\YB9L(P9L`<>M)[/AQ,59AE'U M@Q;5K#L:&MV;VKW+:#Q5QKW;)N;:A-7)Y,2J>/Q7$J^DE"<(4XB#NX.X'X!X M'%P9(GSEBH#:@>^F!RM\R3"1MP4EN4J4HM!!!!<*3XW'?`+O#V]-3]ZT,\)E M>->+S&F+?3>*)YEKF`+7"`^)B8G@$I*2)0Q<39EKN01IX4N3NPC^&Z,N4I+TU""E)IX2]= MTIY!*QAIXC$4F+I>7'H4V8$MP1W#EA86H=)V<\+BS]F$KGS.?81IIAWE""&8 M\W7A(;7"-)?ZI"Y8G\S^;!ZE^0Q3.X$&)!8EH\T(%R[SS8269HU;``;S#"** M$`$+W+7I%_9%FJ$F;/`Q.HYLFYJ\-P45]P>?/?$`CKK837"0C MKE[N@&\M]TL?\.6#YUJ"RV3`]S!M1R$!;E@CA:<--I"G8WKL^0@YT`^1YE MH"P\2AWO"TG-''VQBV![P45]O[5R$0S[X4TU7-/]CGU];8*C#&ZY6JS/*WT5 MR]!Y'$?OA]'@P]$D?@B/WNW/D]7:4GA=8&8M1Y:MI.8MD]:TF2.;./O=WJ,+ M[T83MQ?'3S>CV.S>D_-KLR+F1*W9`#3`@@IJO'IX1KILT!WF^=S'/@ILSP-% MYV.D8=.-B.5I&_N.2SU_6E'F5XJIR#8JFSQ[3N2LXN[P]G0T'N>_.MZSW!1F M,.%8(`M;#N)!`)/:XQ)I)1P6D(!2B5.Y>4*FJTSNC05X3N$U_%ERD%!+=FID M9\F8OU3950D+44MV$]C]Q4H/45J0?4K#=>.>"1+T>D_C`D\:C.*+.$S3[9(7 M7!.]&8]-6.Q]4MBG`19:8/NUUYVFS$\R$T(MA3LZ.86 M11@@:0KD6MZ7V8P[CHL(IS"KE*&U'#=`W#,6M'(-L MCL>^!N(WN,1D?#BC(,H.HY003.]C&(IH;#@&XZK;9A>?:Z'9'?X5FOB,5R!5 M0!1FX+EIDWQ6I]H?>`R`]`]E[U) M>`:[R+N'NS;P7MXT8:Z5(B1`BE!SO,$Q4A0'L&O0KFO;2L&^<"&;;1IE(3AM M`>B-<2CBO[#*UU*@Y2K#9]+A-R+_BS!N9^--_`+_;")R=B_;OHS6 MGTGJ;,72/CR[)>LL7_R6MN'AMHU=R[:KN+4^9+-5:]#(9MY&>^@LGDI=Q\D- MDB1R0_,E#VA/)G%T]9!DX'1'RW?./=BNMGU"F,($S$&NM@!O'Y24]H5`1+A< M<.UBS:<5`DN\:%!JFNHR@KNA&%8.:/WI:EK M6LHZ*UZ\I6TPP=NALP>.PHN^1?UPV#<[\V<=#%%"3;1"PM>5O@CVQW!B(CYA M[9A/])VG/\;&B,Y.G6S3Q26IG](&:MM6#S0'X56'X))HJUAGM;Y,K5/@J25[ M$7Y`'=*!O[4V(7^GKCBJ&[881E62Z&HD0O982U*_GSG+X=_'9&U/., M_Y^]:VMN&T?6?^74OC/!G<#6[%21HC@G=3;CJ2136^>\N!2;3G1&D5R2G,3_ M?AN\R"1(4)`$BIS)SD-J9$LROT:C\76C+^%5W)GI':%&>+NHOAHUS-^N64&O M0NIC>4Z6@U.8OQ4,]Q9_.C_(SSIOI+F4C8NIDP`-J(NZ[BC=9EDU'4=@9T06 M:NE##\W$HO'#"EUES:Q9UGPA1D^!X_P?'9R#17JGKQJT$OY:\>=U_@V2G6E'EKE?EA\C[-U]K#4KF'1;4&W5WA:Z;-&[_C?8/&VQ1+">W_; ME$.J!PK>12A)*9I)\*T9:#2:BT#*A`:")`G\/@)?PV3'S0[LG(2-8\4'UJ;T MWF5?L_73<.%+S#"*1!3,!`$)Q',:P':?!Y0*EB14\5G?-;^N16=*D88,JBL[+S^:W:!_>X?=./F/F+[^`$FN<%&NP%T\')8Z22K>HD`*7U< M+.^3DIJ6'XS6][D!*\K3QHU-V[)@00A`UVF;DY^,[P*#4`XIF)I)L`\-XYB? M;Q*L:$W>_>5QFWT&00-U*A0RGRH$GX!70)^T0ZGK0L&Z-[RE7X'V@MBVF]4* MWE*I]$"BI#,>SI4`8T*T/.=)",[@C`1B#EPK`?(P"ZEQH]00I6(AP@9K]XK[ MR&2J>K.?]XM5C:..?)=DN6X&)R?$35M\`B:#,<'O=J4EUU69N_%-]0E'4-?3 M'\'G[4JERZ:D\]D\C>(@G.=#."AX%3-%`SYC:32/Q$RPV'#HFV.3))4X[$=X MQ5%K_C6:V7N:4DH$\S1:K;`8NA"Q<"YU(?@3V(/R9A7,;)P];+:E90&CDFDG M-EM^.JF0\`3QA"I2"C0\X)3K&NJ0!$HI$;`422(B%*%YVLL_":$F2SD7HDD[ M'TLQWSS\4TL7Y)J7+8^K*-S:DH\?^I0>A=!$FM,4.!\VU?5Z@^"-;/.LECZ@ M1M)`/XRN?0"+KP>6K.^6JV71US2[?[H;DELQ$468$AH`A\J=#3V,*.:Z+RM/ MP+Z1>:J#=[;2MKR7+^E0]QXD%QN`!/YGM_=SRW6^!;!*1!(L+K8`%4:+EF2[ MWX#@C[OQ11_GX6&W4A0/WGTHWCPDV<=]U<,QGY(VLFFSI+D!#PY%YP'8`>%L M1JN_:616:^^V*A@],EVU'UAK2B(X8/\.*4?,U-.C:(P:FXD&QZR&'92D MB=DQ+G85WAVE<2RC.)B+A.NQ!CR0"'@)PCB>J92Q4.$^-M+V#7NX=2,$6LY] MGRT>E_O%*I]I=/-QM?RT&#+DYQK\L..UQW3[`1W;P]J>KO=@?\>^SK-UD!DN4+HC7_E0[L>R^6^CU^+(%U[V8!\RHIG'H9SH M3^MQ-@OXFG']:NL)SS"3I_G5%2#[#>_HE]<]L+$;.(S@6)!D#YZ$1F:0 M%8'UQJ(L@Q[YP&+VP#6P&-M51?7L;J?4B^OYWYN53NMYB3V\Q/:C[7*G^^C6 M"FBF<;)9E2!4H=/)=BE\,UUL!S_.TT3>P]?51P:,NUFLEP52XN8AT`.AC76G MK49!\$<.(%AW"I9"4=J"6'_R8P2VF@[X+EOIP5>U^Y21^:S=+U,A$4?XK!V5 MZ=HTAE0/ZY%&L+'YC,T"3G4(60H:1#A404KA%U3%*$EHG],F3$;;_?1.K2W2 MY7H!+&@ZK2VX5LCNPGO/O=_E7Z$J-FW6>)K?.Y^5IAO45 M6"<N!)2"!]D0RQ$@K>2(NRR[SZ//_UKHRJ#]H>O)R*S3 M&BZ0S>W3!^'8F5K4+)3Q4""O.A@*R@,_V3Y-Z8BURH(P1%ON\[D@?3>6NATI5EQP2))(D"E:1E67I$21KPB,X(26&6K7N/^X6E5[ M2Z::;LPIJ)R([:^;]7V1PPRVN3RON[>/]AK'Y;96)Q[3ULWCY5@-=2KJY=[O M@>K!`OQS<[=838RJ67<1948DU`F,D_HTOJ*6<#"R$V0G+1;1/LWMPKE9ZW9[VF^WSR^<]M3$]7QGM7F6HPJZ* M"D^HNYW,\B.3]#7MX3QP-@P-=,/C/*RW3J#6]]Z&N)[B.422AC1,@.+1G!HF M02S@'XP0DQ$CE*7L5O110]Y4)C]HG2*%1<;8A"*%S)[IH,>-*N02*^Q`U8H, MY]?!(,,D^YJM-OGEX212EJRW_@QST8H0VU'88S:#]<2[8-6M5\'K58]BZ3XXNBG1E(X/J\X'2AIE^Z>`,L4!G.>N*OY\7&6E M$;W"5:?K+K#K`F'F(7H9_M]ZNB:_B_EOO/\'Y])#WM/V\&;1'BV)[& MRD>8X9-[Q6RT]ZNIZ\V#27:\R(>WV3^*PQGA:8!BD@2,P3?&"L4@'ZIB(J,9 M'#B]]=32L,O]*#JC$9,TPW;[HX2A$_TP.B&7J?8>,9^'TJ;W_2T:ZP9W(+W$ M2J)TKG"0"-V:4S$22!6*`$@B91&)$6:]&01YJ,AV2!C[;K6"<[.:7=DR?,,2 M88;22*0,_"6!1<`$F*:(Z\X&B,HY..8\HE%OEESKUL`-CL6M+M32^X8\3SEM M@=)^Y6QPXD5^4_=VL==!F^>;A[>+[1]9WN-J,LVI[+EOA`EJI_LNT)RB4>:B MZZA+LGP`C="48+$:.0AJ]8&I=`J"'H-G9,GJ4QSD^BYOH^US[W?8N`3-4T[C M8$[UI(H9AKT_PQPTA+-T3N8,8;-O=:O4HY$?V_7L'4G>R7)77#7EZ8'C]O"R M$R^)C=O0]J-W)K##?ECKM,!#LO6OUT MJ92Q%]S@6%3B*OO?M=K4>LVM&Z.'N'O]NW;^[O%QV9&5U4KK'#G%S'J245VT MFL-U15+#7>3QYZ="T>A?1Q!J+O8D]-N:7<>$*)/V3P'3N^QEUEVR??I4B_-/ MH!\9L9I]0LN&9*=#:HJBRT;>/#PL[XI;[($3W!RMOET,"LF&&!SA-&10-'[P M6JS2)N8`,TEC0,JX_D>$::!0A(.8D-F<1B14_<&'*O.Q\YGKF[L\WP[C`FX> M:AURBI3K3QD(9VPGU=[7@]20G@"G)H2>R;Z'IF!#%R>Y=3RR]S#'B-7MW"F0 M:I(PDZ_'FRHZHQR,>Y0$!.G>FE)$09Q0$`A2.&8$`'>VU'',<)0:UMSY"LR)$-]*2[EZ6]IV#I989Y-M]+*L!42D_LZ;[$ MX$..>(ZK@,6=`E/[9;'6-U7[[,O(>F'=$`27)?$7`^PVI*6%*3JH%@,E;];5 M>:,O+-]NUMES>4X--C/:W8AVS6LEA#$:MFWH:=AJ\JDW2BF^Y,/F/4AZ]_!< MCAD%6>LK[,]%/FS>6Z51D5N./QPY(<*^UZI[?+]P:R),%OM%HN,T^N`J\D]^ M>=RDV7"9#6ZLQ!Z#`S>FQEGMSS_\",M;12@4BQ>7 M:.B=`Y@Q&7=QC^`]>YR<"=CH#V3DE(^QTK`^RO]*4PV\":8C_3!I#./S@F&%VE0OMT9A#0L]E"G-=\2A.N6">I,-ZI(/_5+O)LUBL MFTFQR_;2;+78[6X>RHC'S?:=OF6XN,Q+2R%4.*>!F!T+]21\'E(4JX`CF00L MF9-`+Z:EM@]:ZU+>`'[UNBD;SO`JY"C&(? M2\OZ@VB($3YB:*4&UOO:MI!7:RL1/F=M\RCZQ^.]O3Z:O;T.N2+YX5U5+S]F M>;YGMOURB0`%HUID%+-V"4HTF\>IE"*(YBF0$X9!/V9Q$H@PP2J-&'`46@59 M?_X-H_\UVG(-@M60J;YH*&YQZDU&B@N+JNUK=?.U6IR=]I5+2G$X_>!U4[NZ M^`S#\1S1&`=),D)IFM*9U)UZV^'I`Y\1A-=B=Z=B=))0+N/K M"*CK`M19/M9#1:AF>NR).(UP8*5U;_-4\UQ#]=W6[^O-QUVVS>?7O%D_/N7S M;&IWK.]T%9'^8_%BM]Q5]\_%5*"';'O)@'LM4#BTP"D'"QO*ND#;.S6%+PE9 M++0`09XAED$\2R48=DI9&J'9;P^P-#H>G%/C>2614,+P,7?1K>BUEYQA MBAB^6"8#,3?/UV"MV/V!B%,Q$A'W??'5?SVAB#%YTL;#6YW(ARNBF2>CQ[8"QZD$=I$$)"9Q`-L\"6(> M@L6-.>,S$%N"\NB0N-7Q07N-@=ELU[,L>FKP"JY6UJY=+C/&U-'L*5>AR=L\ MEXQU!=8"^!5%G%MJ\1JHCJ(O)_%,%#[I@)_/HK85(C9!]:`OO)GR?2]UB_[% M<,'.`2GH`(V]EUIK@I@+Q.L5I0XJE)X+"0^UJK]M-^"27#(<\@6\HO@8TW(% M'VJZ!<;4FIO/W;[P>MW)A>L^M8-8WRUXVCD8W>;I5A,YB?LB M`UY;&PXI2WL+E%;#PY/Q#F:0AM`I#P;))524OZ?*>+HP,#:<4MB'0QG-['S;1_7U>LK=8Z<'V;];EO-SNL.^[K"CQR\J1A,7??E?TB--ON&A, MQZ`"[BG-P"G44]]6"0A0)1GU%1:C^QW=,R.D>LT5"?&B.=\E0 MW'5MRSC!)U[;MN&>(+.AG!?_XJ(=XL)$AO!!1X$Y."[]G_=3!'U>A!Q90O'\H%C]=L9(NL9;I34/)X1B7+SOZ#\7H_:MF5XN8>LK[R2B- MN,YZO[Q?KI[RGC&'KLA%[[GL7K=1UF)_VI>MQ^:+[1J46P\BS/^&+_M'")?M M%A`H#L4\(D$8A5'`)&5!3),DB-)4]X9(Q9R4>2$=5+4_B7J$`Q`0'BLB."VEX5%1*'7O;YC`*=[YOMBL:']Q\V>;>S2P=Y:\$)3@O*U6YKB<)Y MG!*%`JRP;EV?S(,8,1+$:8)H.J-R3I*SA^+TX]0&_"N8\LM\F3JV_O(G-Z3N M$\M=T9TBDZ288GWA1O$M$_NH!H-VNH*;EDLB*>*Z?09&HKU!G'R25CLB)Y]D M&KAU41UOJX83;FJI:?H3X%8ASW,'SX'=ZH_B!+NL>],LI;C8KGHB9[L\^TG3 M.P]9LQ)..EV7A1@[VE;-I8=@[F]3>[=KSFC3")R"SE$, M;N;L.RG&,"47GLMCN1EV*2HN\"LCL\^UXD(/[_FV7*TJ3:A[W9>`SEMK.6E_ MS+`D1-``/I^WUL*!U$5=":94QCR9<4*.-)J#$[:I^WVHS`DE]^!T6'MQ#=2( MK-9Z3+:-WPS+$`,Y#N8T!MZ,8A'$9$:#>!;&BJJ4I%%T:Z]LZ]?R(1=<*2[1 ML2I4I_7N;S?'0J,,U7V]36.5:#MWBJ%72`.GB![O50^V>Q8#I0O"5*_C3,H@ MBD08Q`E`9R)-.`]OW1K5!^@5JEU$6E#T0]45BG=C`K4H["E`B=(_#RXKB3BH0'P&6-^5$I MA)'5W7QLW[8$YT;498L!%CE'>M11)#7O20$:00`R-YLS"OBXHRU!KT)R95/B M':>+*=$M0X:W)#9H'>KIB,U^[`EI3*<;QI+XAV1G;I0K<2U+XA^7?V)((B+SO,&FPR=ABY-BGQCM/-DE!\-4O2@G:N>O;VCJ4<7<^2>(348TF0 M$1@>WI)XQ&6_(9W)-1EASG1+3=+`K0?BS%,B4^@COY-'U"OMJ0#V[FD MN>]"1H7$K0+0@RWQ"LGNWV#"B;JJ,?$*S.[@4$*O:DQ(82B5I^.:.M*2>D^M MJ]@2[S@=:4DXO"FQ03OWK*-]TRHY85A13XA.H*RWI`>K5EG1@._>HZ[$E02B-]L<#VA*OD'IH"27R M:G%7_\"LQD1_SU6C)<1]WK"+G62.M`1?.^[J':<;+;F:*7&;1^B(S6I*0B;5 MU5B)3T3VMIW8[%$Y."OQB_OW[][=NW5[OL M[M6GS=?7LS?_`P7Y)A\M>[_6*[3Q;[[&?] M4`$\J9ZO\/+3PQNS]7WM;2305R'5SZH_5?ORGUZ7`CE+.F2*TB%NTBZ=B MXY.2#@U0Z*0[2`6Z\<1PNC-%Z1`WZ9`AI=,(,$]*.J`4S$UWQ+#2(5.4#G&3 M#KF"=.@4K3+X"4[2H8-9Y49NVJ2D0]VD0P>43F^.\-#"TO+(/NDT[<,/X$?? M/VY7]\N_9]\?5\N[Y?YM]N4C_*'[Y1?=`W>S_L??*J;7,YXY?GZ[^/_--A]Y M&'U?@IM2U+^N5IO=A\]`?!^SI_WR;E=\^4^O.__FRU.^;C[F,%M@.&+2G]G^ MEUOE=+/:[)_7"?@`J\VC'HYU]WD-/_OT_$,O=UGH\9=;[O_+OBY6RW4^SO2' MW="U^J6)+W"K["E^CK/UW>LMB=K M+1+*I@@_Z#HV*DPGOI!5[6E>H+7+>X/\Q\Q:JZ$GOI@7U@?'S]U?4%.(=]EN MOUWJZ:/Y/L_-P`^M&%5[@!]>,SY\VWSXO'G:+=;W#VIL82RQ]X/JA;U+C03UXK^MC4O-/"@1=7;TLTVV3Q]W#\\ MK:H^33_J:M>:H/U%`B\=`3[K+>$WE1EG_-Q4!4[ MFWI19^+:5"K2[NC>JBMKQXD>;,OU?2]&#[N^;=^^&:V0+71STNQS=*5HV3YL M;3P;_8AM1MMZW%X5"7DZT5B3IK([\A>:4TZRXSP]3A<;*)"O$!@BD[E^\^BR9K^:_UWDJR%_G]`]X65OB+N1X MN;:'?@_\G8AI]_G:^Y4\L$6]T)2=+_[U$,>6)WXVV7J'?(`)+Z`3QC5O&UIM M3@UUR3)Z;TP*NQ$9AGL9^H$;FB3>CS.I)OW?F!1V(S(,]S&T'U49N$#K"^7/]`#W+"Y:3/&$DN\S+BM=PGV>U)57-M4T'EQAE M-8F+/D-X/T7(';#/RDRXU\&NTR!+1B8D$7\T MZ<&P3';>?IOR/-\=GTV=U[Q8=G0\C#E]H#F!PJK"]B.W'7SUVX\;O0#BDKI# M\7C\#6U?X>*EF9Q'#((WEE^/^Z- M:/A@.H?(::-?E-]!N\DY-H-[!VX53B/58CDO;L4MQ%;MBM8_Z8(174U#\Y3OT0&U(BM^L*TXC!WTTSS4;7\C MB\VTZTDM)FU2TH%*NA$2=.(H`#GH./#P1[,G7L/N038D=Z0C)H5G$SIW1+1+`)/O!ZMA%DNF+DEF7B>UP5^6Q* M>4=YHP.WPHV('XWVEPIS7OKO-N[*U'>\-N M8`9H)Z"R3Z/C.Y&%/FZ^OT_C5YHMYT3?F%I+TG'C`'WNPGZ2IT3XD&61T9S< M9C2%'?U*_$"_9*NDR.XXI6O6.I]V/A'W`O2S\7[B4Y+INV=H.N5&OH,_*Z$# M19,B^DC4"6W\:0@=U]0KE@RD%8\8Z%I#3.9Y.WYD*3Y@#Q*`.N3/'I2]]/BF MQL:$RWX\$TN\+$PU]H8^ION!%C92CE84*M#Q=#_'%]4?EWE'A8/Q0856UG'H M*]"2K?].UKO.X;2=M66/P2:\HK M\`6^%96NZ6NMG5AB?0_0;P_ZMY.-\]_FZ%!;LW!B[R'V@@A_1@9$T*_OCN&T M?B8=]:\S?AY?T-IW+E<9Y">0&_ MI^7+<_[U91<%/ROJV^JNSHX3J3>C+>VFG[:C@*-_T[&C:YJR1@5J0IC8Q9^2 M):L&D83"S%<`'@E?HY?SA-4*//0>>T>L&^Z4YDQ=_'ET78`G&TCF"A"+.L^G^0],?4(6Y$5"4G95/5NLI!/.$KK1J%<:PK,72_GJ].\A6J;AM8C( MCVSTH:M!+0):>BSA($#Z&P2MA4YM@*K_Y`V<:UM47%K$F'D MXB]X&]:7F,ND=3V-PH*2(=?Q\/=9;'9SZWWA\[*T)[WY+&/Y[`O-0?;X.$^/ MTP7+04&3P"'W^0,8D[;)#0UM)XH#].&Z3K1WBZRUD#5E',1^\!#[H1V@G^4O M".-PO`V9*)!^O"VJ]E0D**_2NIQ(8K5M-XP4$+]]@^M9>[C9)J&L,2>::I^V M<"W/\<<#=V-"/BU*S<>MY;B..Z+Y^%G1MJYD0P]2`F,K0+_#GHB'QF@Y+8`@ M)TE5"]]X=X)@G:=L*?99"TT%29T@L$+0H8[=$/V`_4[ER1?@74T%SI+(#B]B M#[SYRK/B[9RDC.3'=W\J` M]N594=:?::B4?/?Q<@6R_)U3O_06-LT\-P0XAVQ;$:JNV#*07/-4R#M M\5=?6QVLA,_>6O):H%1@55@AV+U1BW7-[$&7$J13"FU)B265&,*7V8*-0,)^GLAG#&5V"_KNVB=J[3Y8\\XN:AHW&I+`;D6&XE^&C/K69%C[& MI+16+-XP*>Q&9!CN8RB5:WWC+GR83;7M((U-J>PO&(B;2JMF8O@(F]);A7/3 MIK!;D8'X"D0OC&VQ&?2]"'WZXCJC_$9,"$0\B@V(C[_2MT9(@A2#,;#PMW[M M0E+?,F$W\L)6[S32*UGA(!N:%[R"%FEG]+;:.O<4MC,IF#`O>D]S*"6=4)XT MIZ6/0JDW-&<%EW*I9S7=(:IJC"_2Z^C`&!\JX\-N;L8$^C$!Z8\Z<8"_JE76 M6%S?M=UUK[DLG=>=<-0@>2\_P`/%AZ8[1]WT5? MQ[8?HWA4!)0`0.V!W=80ZKV@VFH]0%_SA]CS8YGB+KNBV8X3!/A3_@[J3_8L M^DKX3PHYS86@?]?2.`N=^F/$\6[(W,ILYK7BP[.A[&G#[0G&S?1K\,[K$? MN>W@J]]^W.@)4,X`3F#\FH'\FA_PP5-YE9:^3>^6I>CCL1^'I?:Y0+]D[W8W MH/:`0)TX"D`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`;.QSDPM/W9< M]#EQAPQ12'K4FJCK^?&H)MW!FITA!6I[(?YD](.\HCFG.B)%%53#\W2$S]]& M8$P@^9=MWCZRO&Y1&*_OS;KOQ']N*?NC7Y<.5\!M4R8W>SH<(H+[JQ-<0_'- M(>P?.7&/L)WU$&XC,^L.S,`^=OS(4CQ.]!V)P"";L'K![%LI`K2,>$O4,^ MA4S!^:L6?_;\'ORR%TI66Q<,8&/"P)PCVWG+QIK+O%YL3%C5* MT"]@^V>Q*S8C>3J9$[X@B8PWDZP[2&NZX0*-7Q_ MZQ#W9(A#7)8+AN+J35R/O^L;ESES5P57X,`&+8@<]$DOC=[%E#P#Z7EX-_-GR+UT7!*9OEITV>^.@@V;876/BS M`U^CU`2W:`HB0:,=3)8GUJK8]_!W[K[,[VE9+9[MTIO#E1J2_R[JO*]&!)^) MQG5<'[T;L0O-6KJER.FJZ8XV4D1.Z/A*CIYUQ2ST:+ACB7`>A`]X1I=%R7K: M.W\J)S_`'^;8Q^F$Y#^GXBTMH5$-I:O^A9\..IE.:S'/QN]FHW'AS<#TFA.AW8N]`V!3WZ#,,T;<* M>L?BV,@C:<+0CT)_M`QUQ M@W[4[<`TJ<48(N78L+1I)([K.NB7MDYI).LD0RI@S8LLO5PL>7'?9YKA)X(3 MXREPO7&0>^PPNJPKRJ%'Y4UQ5_U->$_%%I]*+0KM:$34KLBM>/TK31E97S1" M:F'HQ.BCT-VI7=_=L81>U%RXES6GF]>."EX8RYR>"+\RR@5A'/KUTI/5^I^_ MB[N#_[ZZ`N]]*PGA\:++7,R:I;S"'2$[/_*U8.>,D5WHHL]D_0AV]JC866[T M$,>QA5\!XUBXB.G6RO:=PK%`4K4IC_*2\>%1(DUU"X\NJ:EK1`JHKK^"J%>E M]4^%$OCXNT>_-FY@G%PO1Y;+V("QH=^$CWZ#M6O!V0CBGL,Q-*7Y:9'?0W+6 M;4:_%55?+2D_$Y=M"Q=/25Q713Z;4K[X3BOX8T4.T0N2DT;\8ZPA^!:;%<>^ M<7(+!L%X;AR&S(O1[ M\7=:T6DMMA%=O55C1(<:$7:KT9D2E(R+-3VR\*\0>RO&C[.L*/NO&/]$2D:& M0RU:CAL'Z#-O]],Z)YN"'^>O%>Q#4.^0`'9QXV[MF.3.`FO_2BX%-.B:R/NKX[3FIQX]5B M.2]NQ2W$5[BB]4^Z8$0#^W-C!39S:MK?6VFONVSQ6Y'_7J2SGRS/I$$N1FN# M6AJ=&IC"P'>A9%QXB-@IPEB_/+-:7B6%W5M2W MU5V='2>RP^*X$/JQ`PC]"/U`6XL'0<97M8*LRR*GZV:F:W)IRIIFIA/"Q!0L MG$E6]=79]'.A.?B;0W2$-MXS]9:5%7CH3YTZLA*_7Q3Y:$&Y^,_9NPXJTCVZ MK!(C1^Q*QC*8OM.*"/5<.KA M.D[G<+=[VNAZC0J@\#"@/Z=CHP__WLS%9'="2IH"$_&J=/;E;\M69^T_-/TA M]N=\(QT)SN'%KOS\@?*$E73"64*_0S^5S0/\S1=+^6IO3>8^$W/D1S;Z;=R@ MF/MK;/69G$/7\M!'DH?E+";OT7&VKB_ILQK M!OS'F).V!J02*2GM/+J!_PMZSV;T?XQ-Z6U%2N$*0M]15HG@-7A-6/V&)C5G M%>M:6#CTZ!^5',*&.6EK0(J0"CWO(?9B*T#OI4T(AZ<_+:!VA9,$-F&OM*`7 M'AI;RH3[4;'RW!`\ZAA_S?=&H&SM0;.<+>J.58LJ`1$_>1N"G:[OXS^RW*^K M>IRGTSGC4)4O`Z+O*/#^56,A#R,V%NS6H0D0-PY4T=`XH[?5I7@BO-Y:ZC03 MTG`C+VR9X4\_G1>\@D)]@/=2_V12L+RZ$:Y_#F?`$\IACMU@=T-S5G!)\*RF M.SB/BFL8VXJH/[7M8UNUIVLNJP!'KP3E!J$#FO&^`L'WM;#:-4F/T.K,_]?WI/,I8W M)X\LGQVB.7"0L_J8A/Z%%C-.EG-0J7@V,]-[)OS/T=F1#-@X@3&D@0SI!WSP M5%XU'F/JW5PP?6?GJ==P',FVW6&(?E.P-LMV^];H7.^06#X9N!S4&1J7$BK8 MG7$-K8@])"[9R5N)C,E=G;P'3Y4<'(T2N6W[FJP/GM0V."(E$I#V(?J*;[ MK^KL%"O=1%PP^0GLU*JY0USN-B`[TX+LP]('L/4EPF!%Z"<$TX(,HQ%AMQJ- M*9GF!>HC-,T+U(6F0O48RN8%P[,RS0M4`66:%V!G9)H7*$7+-"]0%:#1S/VL MN.*H8L)&,U<-0D8SUPSXCS8G;0U()5)&,]>,_EYL2F\K4@J7T5X\EA$UY924-5^-=/(SZ;'*`C0':-@!F0,TW&S,`9H:F,P!&F(VY@`-/2Q, ML>K>O[-E8M4]FZTU($(3JU87FHE5*\/*Q*I5`65BU=@9F5BU4K1,`%15@"8` MBAD0IDUGW]_9BM?]1:S(BB'HZ^*7+06U[F]DL:D2./V[F,Z+NB1Y^DW,^V+. M@#]Y3^'2OBW3BGOO,VH%KH7+,MTC*SARK1[3%:T8VW=VC@3J/K^SW7QG*`<, M/>\ACBT/OPZ[<(>AQ&]:@*(G)PDH?1S#DC"C6^'*MLG/`.')?CE9[B,GTU3U M`Z9/M^]AY5JA'3;ZN'X8/-AVY#L>^KCDJS(I\)7 M)DM:5RP9HINV%1[9X1"8`L\-(1`GW!$#[;`/\!WFW2TA%I:S1=U1K5TE`Q&N MJV=&]0<8"'D8AX'85F"[VS,(=HOXQ!%K@Q-ON\,!D2-612`#C9"^@5B!Y2.+ M<8@O;/D][YY=*]IP_QS?L2+T[OK^A>**S4B>3N:$+T@BEPJ2E9=Y,L0<+OZ+ M^J/E68X3H;)0VSNRG".GW^]L>T_-\^+8C2(7=I>^Y8E5S/85B,EU[J0W+9;% ME/`9[4%4[J:^+>E?-1PXW--=C=JW+NA]N$C3L;T>@];-<'EN.OH:RR^=+QP\ MRNN<-9Q867B.V)O\N#E;/_N%K+^@_]>^]IMX[9__>/QE?69TG9O3"$IV<'[_M6+Z!Q3_%LN+[Y MS9OGNOO]\K9G-"\6+'_MQKN>QM,]7[[YG__8^.P[O_J_7SRSNN*__?N`AW;^ MX_NKZ,5K'>YTTUCN2_8P$-H7.]P&!M4.`Y(IU_!2AUN<0CX>7^V^2?OB*[?Y MW_]IAJCXYW\!4$L#!!0````(`&(Q;$0+BY5#!R0``)4:`@`5`!P`&UL550)``.X,B!3N#(@4W5X"P`!!"4.```$.0$``.T] M:W/CN)'?4Y7_H)M47>6JSN.Q9V>S.[6;E)]SJK)'CN3))O._+C"7AT=UH-!J-?OSTEV]K?[)%),)A\/.;L[?OWDQ0 MX(8>#E8_O_FR.+E87$VG;_[RY]__[J?_.#F9S.>3ZS`(D.^CW>3O+O(1<6(T M>72^A4&XWDVN'-]-?">&T29W./CZY$3HOR?T7V\"7_W]9@$WL?)N^_/?OCQ M_+OSD^\_?/?]R7KUQ@MWDPO6^S0?V,(A,@>A#]_*9"A&]/ MQ'\;DM4I3//^-&_XYO>_FZ2-/WZ+<*W#R_N\^=GIW^_O%NXS6CLG.(AB)W!K M'>E@O*YG/_[XXRG[-6T=X8\1&^4N=!F5)`"<"%O03R=YLQ/ZU/:7- M3QM'/.T+[QQZ_G,1`]/1.6;+6QS`*F''?P@C3*>X\ITHPDN,O./`EQQ[3$0> M'(*.7(P.$\3/*,:NXZM';0IB<(TN_!B1`-A@BWKC`8 MJ-(7Y/WQE`.\`!C0<^A[,,G-KPELO(O`F\&J$BI/X2<41$"IE'2]T>DVFW)D MKYSH^=8/7Z)IX&$"4/=&Z'#$WD!?X\CUPR@AZ!I%+L$;NNMFR\LDP@&*HDLG MPA$P!H&S#<0E_9'2<$,5`5`:%FA%(;OP/+9;';^_9!X.'H6T6B3KM4-VP&)X M%8!X,#?]+5N'?(5VCVY*,%X6!X2ZB",7#\7WCI+JQKFNT.DB@6*>6@"8_?KP]4"[6 M(8GQOYEPOOFV`<7L2/5/,0SC2L%/8>B]8'\X9N!,->I)R)3O@?<\=[)QUS'[ M&O;7CIZJ^:T#OB8)\F9//EXQ+AN0"$?`,C*-UBE8J29/-Z-15.L!W?@[ZBX, M5H^(K.^P\X3]D51)X@-(:S9$;!BY,YZ270WZK MOA3H-;="&E3'A6DN=Y]0N"+.YAF[<[1*+\!9FSNX(]>46W['75_2#`&2D12K MM#*'9E6@5-HTXM#]>DG?;JC*"-I/:ET9Q&318:K!,2SM)]R?%6FCO>8>G`:W M#B9_<_P$99#,F-DM^D0<>OA]B7"PNO0=]RMP)<`0I3\_$.S"#_>AAWIKK$.! M93[EE-X"1X%QY!V9@G/AQGB+X]Y'UQ$S:L&7+4YO':;S?./A.D=1#"P&#,@: MCK2^HEG'E!/[,+PXQ!MHI5MG'1SO:13!]8B]Q$6S)?RRAM6@+8=!6#R=:DSK M[XJ#:4D2TPR*&8>4E,;T"CP+KL(@"+TA&I9> MN:3YQ2&$O<0IE&MR,RG$#^X;=W"_35_('Q!AM*?[+8FS^R^W15]DCYUV:,P/ M[$-?(FH:2B&C6I0381?N<=?83X#38(P1Z-(;*+542P>G8!X"6#XOWGQS_<1# MWBT)UQ4OPF)A%5),,4`*J566UDX?N*A ML<^%V&QYA[;(?S\-@(FCK(4W"^9TP4C&U>#8S!_)O]!Q+>TMU<>-8.+$:DYQZ8!E?/0'HT#>J;F>I# M`%IM6\^13YT!'L.*&!B",CTA4DBO.=J&_A8FID\(``6P)![&A[/#3`KQ2R^! M,68.;0$.R>=P*.?++E,-CN$57`1W0.Q45YLMH?,/E9:LS3`(2\T\//X55R=V M/($`1@1%9B`[%RN"T&`.V?(3#8Q=>7^[ M)LGJFFKI(7/=+&XL%]Z_DBAFZOP06'<#0"G?K]<; M!]>2_K=)3-<(!WB=K.\0546=G9)U[SN]0DJD%HQ'YUM=Q)2FH$L$*T`]#+:8 MFCXO48"6.`;=J]*S+SW4`#$,54;#7`MVQ9_[LU_C)5Q'(V:R8M:^[#'W%E%- MTJ>!0TDNDK#>J-KE%[TH8$:=]7.\PV# MZR"G1.OXP^!2F"6^!*30K."7C.=4+EGK5$ICRYXB]&L"_'&S9:?/,$%C,I.H MQ`KYB#X^_S5Q""C%_JXP"EP[L5-Z)#0VZXVU$B!44B73)*93>G/*PQEA7A\O MZ7TJ=SKNC;CL/&J"8-EMZ#$LR%:$L$8SLG*"S%9&;1ZAC[T!"/"9QM!\WA1TPE;P#DT@1NC:@?C0\E9AT8^=?D'/:4:#C#" M-I2>UQ0"/%+W$^6;IN/L0Q.#Q3H\[L-F,(,(E9S4#^6$6O]/%!K0&F85Q1,-S[1" M7Y$1)%/'V_3>R_JPYD0A!,- MC>+A>WC%66`P?"5G-0/Y8=B[T]R#,WKA_=CL2S"&-:T'*!F9W#+6\PZ(4B,7 MM$6!1[W%TV\I-.K*#*3SG^X!,`)4DM4#&"0`"U"K-C\+`0M)G8NRZ5E1B*43 M/;'*$$ETLG*.WDW=G68&(/V1?_[,YQUXMNUTZN>\\(?_G M-]W[GVK$;HY:?&6WV_-B9F7X/IM;F M0\/S.0Q<+K4Z=%0)(W`9["W\CL&M5OIIZ M:,:@7146-%:R*_?TJS2X!S[`/8(G'XJG0MZ^/7HL'2M0YN?GTGPOI_ZXL.TG MFP!F37,:`0E;X);JJ@>GM$S)CM5%$::(#QO:MJ/O>6=6?`N_0\:8=;'XW MS;@T"V].0RWP%OGQR_P7(HAY377`7*F;T7KF\]MJ@[JTD[0?[PT==,#_0-#& MP;DAH#!=2=Q]97KJP2@MKO7@TRB62H4ML31O[*(#!VEIV20?*];<"U('W2%N M/B#\>6#*K1?9S5J<1C10D8YV@F.TSOLOX5)\8*_))PM%II))2`!D5@OZAW?O MWDQ>$,V5RC[#IPV!FQ3@\O.;\S>3)`+@PDT:)FHJ=LU,5R+[XVM`5D[G*Y`^ M>_<:D.8A=O8:$.MP_RXQ/W\-F`LTCA++][9AN7=B5Y&5-!.6HLHZYFY`OK.5 MO"2#=9S>1(;&I\`2Y]?$]TT*>HGQ=Z\(X[KYHL3QPRO"4>K:4J+^_2M"O=&B M7*+\)WM0YMBRJ@CSC"_E&6W1]4&`9Q<'A!)OBVX237@?;]0O2'%NT?VBA=55 MO7&7M+%(BVNAC>@=JL35(E6M:4MT>"DO<;=(96L3]US;=8FI1:I:RRIS?0Q* M1"W2UV3?>@3'>A5KBU2U8[#FM2J0?V^G!).X<4JXUI:JC9T[G$.%;FZ;)0'L MW/D2=Y9]WZ0293NW?DMZA9= M(/(.9!4U9LM<6:]H9(+*&A=QHS-2OP&U^)P")\^6]$DD6L!95BU%(_(T;>BA MR&>33L!R3!6/4=59BH+:'/I+=M5%::I=Y*=%`WEKS;3XJ3DXH(G99\$U(GC+ M=MPTB.AFI6\-+'T<@LTJ\F.3[:[')\S-ROF5U^\$^&2VR;9DE&8,KV1OOLSSB#?>7^T$SF MYCY:O-BH1I6)!Z;YB64BMZENF.7`U08I\GWJ<`4''W&H7>'"6^,`@[[$-*=F M9I'LK/6>+5)]*R94297?RG?^)O2[\H"53@`R!&@1E%9Z`,C@W7@!M]()0,,% MJ^8FQ-/%K/3;U4S(!NW02@M_J[:[YQDMN`E:Z0TMA;L*FZB5+M6=.$/>-F:E MDW4G6K3=(JUTP&ZXS-MY+('FHR@K"?$[/1/307U(7^B`>NE8_$ M,O3C&'X%K\.&,XO`@B`2`J5AQ,K0"PEL&TS,_<(L-+\N/S@DAGMW=.5L<)R_ M>(_].KC>$/0,Y&7J!-U'L`BS)6PF^)1:1![HU9#J6S'!3TE,W7`>0^I3#(** M>J0P*9Z*(>'CHMI9M%FN.8@P@0O"&:^"U)G#W3T2)X@.Q3MJF*ZNHY M^DT6;_63F4:W'E0P$B=:9=?QJ0?U_X0^"V8ME/8R1"QSPKZ&C\#UH,N'WI%T MZ#W=:Z#=>&331;&CWIKTV!T'.4SVPN0+6EBI[HQ`(SF):Z5%O\MA(D.2_@+; MRCA?4\BX1\'W%EW25).PKQK9[X52\T6(U5FKQ33D?OX<2AGA&$RS(-SZX4LT M#3Q,H)NFM.,$451G2YHIGL9)"#0$7DMM*9&GZXV#"?-G!T*OQ%G1^8W-29&; M"C'@2I!^$;I&Z?^B.W"7(=0X-+,GE6D9\CI;\EY5W,,,@)V[#P5O'O:Q'P/! M7NO3G[)2K"4\^YFNU(ZM)X$JR$`7,ZD&?_LH.Q(DO.:ENNK`Z6:Y!*DY6]Y\ M<]G2S$&TS@+^)N%9Q`7X]AY6!RW$YWZN1Y4*E@#O3D/\OVO_8+CA:).%-8&T M;*I+T-Q'D_M\[1":!H?9?L2^].U=E9P1W)FZ%`+I-L!`,!]D8)&#]+";&7QR ML][XX0ZA+"ZU/;-PIR',P#'/B=0%J6H?,[#(8Z?W0JJE"Q7U&7&@O53)VR2W MBZH=AH2I3$,AHFK7WF;P4)8Y*Q=&W`Q:TNPC-9B6P"`44W7Q@81;["'O`-8]"X\*WQ1'H MM'`SN0Z3IWB9^/DQ(898W$5/$!5+B)79S>H9*`0X-';1$N1#3:N7(&L]:DH% MX=ID+1`TU@'W+P3#S7VYK-IIGN)I%"4@/A'5S@4X2'34^P!XA"FQYA[?0;!9 MF=UK(`)Q3[8R<9)%3O4#$8BKVA0$^LZF^*>>!.IOFRS)9E$`57>5Z55Y9O1# MOUE7$'@)&/[&W8\BV^T,]2W MATB2\BH19(K^+5%%P"4V90]0O:,Z>(%862Y(-;V:_)NL+"*D=(/)I:JWJ8Z0 M>OG#]07J5W=(1P`,M4+Y8900P"]R"=ZD%^P\9].E$^%HMH0#.P(.<#)[;T&V M!5I1SKCP/)QB,@V6(4E70U]03XG3@K(&VX:@':P+MWR%?$ MPF3+:$,UA1IX3W[9^P6UWA\X('3:!!)#F1,K6?!(*>T%#ESR M_96LTE&;>Z1]W'G+CK`[C]N(8^VYX[97EYTTYH6DIS`OS=='GFI6>22,3JQ] MKKT:NRB.WEX M*S)[?I6-BVAERK^N1%"WRWOF]S-4+E/7_3"@^ARM$ETX[5!J:HG23R'8W=+B M77!BY$GA9TM:X(IL&S(ZM/?4DW<@@ZNI#&JEB588Y\[+/>P4@AV_&]'%';7B M\TM(OE+'J]!%43>$&GIJKFEUR$YUIX_VI;3R=BZ->-.:6WGB26/>)#/[7:^M M.+MB)UAAZ@&6^LC9"OB#0^"'9U!.W+R4AJ%8Y)XCWAX*O,JC.K(1PG:(T1W> M'@`8<2"\6(*P_`=RR"UT$)P.?4;4DH^Q$[R?@6<>7Y"_1?IF99Y6\R%GGV M[B/]LF48>H$LWP2IR>(%^V;?=POG_6HHGB;'U`5+A``\D45QW^$E33B3$`IZ M@T-J:X$&DL_';ZH":]XZ?5OPI/S?CTF4$;?4-91:%TU`' MO%\")W>GJ6;5V:N^O@=[2R?]E;FX"U`]53HQHI5:OAP=!&+$2LU=#N,VAK=2 M*9=#7>($M*^.7">%Z3#J/0^&IS',LRFCB`@I:6<7QTOK6I>N+V&J%/%0<J^J+4:ZOE^^$*/C-N0I(G?GASW*S=$3-14.1QS%"?DH+Z=L)FB M"C:9*\2]$S@K5N(4)%H#-S5WT'?M.CCI9*Y@PDY:-;K.RL">]Z;XK+7R-G,4 M.9I$I)4WG+Y,P1>\5MYX>C`$3]I:^=:@@AT$^HR5CPN]A43#3<#*O-O'$Z1% M);`JYD[E=N%=7JP*OE,K/VM:<[\`//OH('E'%V35?H5DD57&^^76-M_(N$Y) ME^;!HS*CH]G15`QK#[F\G(8J+J-Y-L$+-T\^OI=W<\>[D4KTTO-*F^;DK59Z M*2"Z\ITHPDN,O,]AX+:\X'8=1R>VE4,R9W7X4&$4:7R[C*03XSD5^/`_CJ51 MXW;19CKILC@-'?0_@C4B4G_Y[+PUK;2<'$<5/D-;:321(X#TV6.EM>0X)N@D MQVU^.6:1_7'(ZHV%7N+&"\='M#P%X`>HLOEG2WXK)4K/M1,[U]3P@)\2QAB! M]VD34@,$3]EI:*WD/>!3N$4DH)>8S&I*EDZ9F:Q5"T&\6_0$MY32@WG!\]JZCJ5=*J2A?@ M?[G[A,(5<3;/V)VC5A^/:AS;&SQ M"3ZX95$0[L^U/`TFPE^I6,@:S-B.AB/?H9;I+W#=75WZ<`@"6\%P4?KS`\$N M_'`?>LB(T**!4#,N98@,"Z9H9"6(C!!@\E"SI3'BC:,%YCFB"I,+;,0:FD_M MRE[8A_W%(9[!-*?Q%P`J](8MNH1?UK`.M*4Q((/T`*TIBPXR^_BJ@0+E@1;TA3L1K1X^(S??$'$Q+6HUI_I@+D$-Q2K?H[\XA+`*7>;L3=#":"KB MU&SZ@`A;`18E8:]160J??A9Z6KPUB$:SDKK721&)'IA+JGE5$H/0C7]Z"W,DI%(;V. M4?9L3HE5W##I7?7PEEI)Y?+-]1.8\Q8H?U7"5ES`3;IZ%[:[>^30STR(%F:. M-#5T4'J@%2`\YYPP&A3"C3X*\(>*_=>\:44J&W'C*2F+F\Q"R,C MLWFUEZ?MU%4)G(T.JI(`=QY#*>35:!@:7=@1:)GN2N'-E)EBE=VN9)8;0,=% MJ^*T*5^*N:63UE-4#J'2#:;S9K+R`G`D5:0VJI5:_9$$D90$5NKK\B3I=>A; MJ9MW9!=I5<)FI9NKG^;/;K/E'94=[Z?!!JXL60NXM,VI*DXR.Y01S\\<)HZ, M?E7#LQJCSYU[;@(]R-HU2*F8I)>;GQF6DSU`BPV$[U_)[4,:Q_5!!LI_$4-+"EN/C%""1N@\!V"G>M33_. MW%HNP.I41$XPO5+EQ"J/!JUDK>@[5ADSU1)-L])AE=74?,HWB&RKC+'F4[I5 M_;#*P#NTN>`(\(BS#:^9U!SK(+7TLNH4?`Q=; M\7AT]4S]8"V+>?0YIWQBYPKQQ"=D#QU-UPMCQ_=_9#I25KH\,)D=5M"R**&N7>#,HT M1E%@NFGLHLB)3#P#TVSR5#1\!S+9SGJRG%:AJQ;0XZ,DWT^?@M!YN>H)$IL8 MT#X+E4)B<+FC9WXM(V5CN-Z$`35-9JX+H-$@@J(XLP.52J*F4H($I7X5+7N4 MUU*9FS5QW#BA80K)AIHC:P02^5)57O@%7WC_2J(XC1,U``D:0(=3<.B;8^'N MC8V^JPEA+NE_F\1TC7"`U\GZ#E&S5^K2KN7"-MLPXP+BM!=!/%M;)>'66=E3KW\/2IYHQ?)8YFR\1'!)HU]-5913=C_FZK)-E9*U[I5C@2 MK^;.1M1Y[H20B9C4-L5Q:$D-H4__ED6G%7(=:I:<^*YJ1JV'L)7JYM%T:#LP MK+1#'L\50H7&2E.CI#CF57AN.W&MBO%20`^Y<\"J("T57-*BOU@5'B1Y+'+$ MA@3^%AG?C^`#"0+8%[94L184?^X;%:[Q$BB0&5EH\:.LOF`F/JG42&B@_9Q* MC\W&QS1^IFJ7UVQ^5Z;\]2SHD@Y.J43=HP,7^YBM[U59HBQ+[B[*'MUG)*W* M]QZ863A6)2(PC8.CH3:I',AK][8MU?$#&TB/F\"AE0NSI3T.];TQ#,+R&M'Z MO-0LVPVS2C^#L-G7"BBU4T%)@V)!NG?"L74T@S`7B,F+>/\\J&'3C1Y'SJ%8 M4LN`](#(VJ'OT5/0-435MXX?SZ!U_QQ2G8-NQ2ANTAOP;7E/AQTZC&(0I?)$&27?$K=+/2&SF*$)PT=G/ MU-J]_Y!["+Y@$IIN94RZ[B%>[T&AI3FC'3>7+EV$^$%76RZUBL]V*^W)_FF1UK92W+\IC343H\P)8V.>>,UYHGSJA(\1/]V@EUT@+^>G&Y[0-0? MG5N<[T2]=/H4%C#Q*BBU-#8"[FGP0$(71<7E!>[YE9P>LABU#6,$KM5\K$@: MM;U>1F#2`7QC8"ZC.8'Y6?JY94A>'.));YN&$*_1AB`7 MY]NEFF5<'NJF08SPU.4KD#S'3*F#U,H7JAZT:#NZK'R@ZD>/_@>%HS-F%R!<4$7 ME^QFRR\!*2HTP"^Y[FL"N(OD*4*_)J!>W6Q9EF=3Z;I`/J(/B7]-'!(CXN^* MBEC73NP4I&YN9@0B6=[LZ;3%_OGS[PYN7+W#DQ7X0+7]]^?GI MU>3I^O[^Y;_]ZS_]C[_\SU>O7LQF+V[B*,)AB'[ M%S=X$41!!HN]>`BB+\\HQ?_W!?E?_P7\Z3^O9@\OWOWP]L6+599M?GG]^NO7 MKS\DB;]?\0K5?K>_E7#]\N+G']X!:(U?9G$>^;^\>//SVW_Y\[L? MW[WZ^:WW@_O?HS>O?6^^DM>OON3S\W9ETG&!6P^0#T+R_> MO7G[XZLW[U^]?3M_]^Z7=S_]\N;=?S='QYM=$BQ7V8O_[?T?&/SFIUC_PY3_]CQ?EX%^^I4%KPM?W^^%O7__GQXO7VW:OW;W_XEOHO_Y5L^)K-"R;I@RJQB\-=D^&OABJ^'PCN#F7]_RH!%R1[3 MQ5T0P9D&*'R,T^+3N@Y1F@:+`/O]P)=<^Y2(/*($]SP,A0VR%HNC+^F]Y$?)`#U8(2. M5QP,]$V0>F&#1R.MGO+U&B4[8+%@&<'UY"'8U/-`IB%0/,9A MX`4X!<@^IWBZN$VS`&"`/XQ!)ZVP:*31%0J))/.TPG@/SPW.4!".0@7%W4Z! M9WTPY+,%^I,K:(M"X$]R&A]1\@6&/8?X"7MY`C#B=#0B]`#E)!0"`=3/0TP^ MZ!B^X>*")K!MR%<\'C7$VYX"<_(`Q1&A/Q$4MO`?<0)4_X3'PUJPY>DQ!LE[ M&0##3=(49^/QO7!3TUBW)5H3)-`L4TM`LW]^_`-0)NLXR8(_BLOY]ML&!+.> MXI]F&$Y["WZ(8_]K$(['#(RM3OH2%L+WR-\\<[/3GF/U9_B^=N15W6L=\.-2(0>L)R81NL2K%*2)Q^C550;`-WIOZB'.%K.<;)^"-!S$)Y( ME.3NK!'_#TF!I=QU$5>31-;K_AQ`N(BZD,GJE>%_U$&`S1N/3:WS2_H20I/'$: M[S6YG33B!_K&`^BWI8?\$2<%[5_LL<,139OMN.C?F1?>AS2DQ#)61$ MBD)IX($>=Q.$.7`:K'$"N@P&2B_5RL4)F,<`4O?B[3O\$2/R;^)]3.O/NO1)1/[>M+:KAP\6%OIO/#;V^TMLNGC` M6QR^OX^`B=-JA#^-9N3`DHJKQZ&#(@@ZK;U5D`M\NL]!5%J3QPF6D-YH;.P\ M>,K*2+\;E.&&N`H/>1KX15A/',WA?4L7.$F&RQ.:H!B9+O1;#,,J/'>ZF,<9 M"A_SQ%N!U$O4Q?Q M=2!&YYX-K%'$-X>/27Q'ON8ZLG;D:T1Z[Y%I<+T"TN/[J/TQ$WD(0&M]UC,< MDF"`>=RX!L:@S$"(--)KAK=QN(6-B0L!H`"6#,:)X53822-^I1*8!45`6Q3$ MR:=XK.!+E:U&Q_`:%,$=$+N4U:8+F/POC9'%F'$0EMIY?/P;H4[%\P07,$YP MFE5^%.*[74;!'\.?@<'[:Z3%QSSR@P)D-%DF&(\6D"V_T[&4B3$Q#+`R)3-@]+-WG&AG3\;^JZ3`).;W"IZ,,`/>&JRON-@^LHKT3G M^N/@4ILE/D=)+5G!+Q7/Z3RRSJVTYI8]I_CW'/CC=EN\/N,DC[VBAP@S)$(Q*$PP9CK04(G52I)(G[>Z(Y[=,98=\P6!!]:A]T M/!AQV7WT),$6VM`\KLE6I["FTV2)HLI61FP><1CX>W":29V-5'`ZF>(SQ]^R MJ[!W%,$)X7.-H/M\4=L)6\,Y-H&%6;6C\:'DKF,C7X;\@YS23`0WMH8$XS"$ZO9CDT,QJ6$T!ND-AZT$ M&H=]!D(S^F5;\W&I&.^#.BM_V'6U`_EQ#E]I[_%5].?3F"38 MVXR-'CO49#0TN[8SC.XX_"RWZ=BHU^$EXYTN:PL#:(USBOR-QF=:;JS("6XF MQ=WM(L98'W0/&,8F3.U//@%/"/@XYRVQX^CZ](%'?3P3`G>CL5$\]H]E?8>G='KZ$=Q+,$IK&D#0*G(A!)/EE*!8+=Q$MIX51-EK/UB_KL:\1K0.XQCPP%:DTGD&(Y^D691_)4OIZ\]1;O^ZO?_X,$DVW2@``5#@DFGM7V1.Q@GS M(`OR+U#Z7)Q!GKY:(K1Y32[EUSC,TOU?BFOZU9NW55^5?Z[^_'=Q:+<.8.H;@[+AT6V.,0RE%U,.Q1J#>HB`D;Q2I&H":/3B(RX'^JX/Z MBJN8P)3A-FH(%Y,D*%*"BARA9J)A4=6HF;O+)("FQ4W0I6K*0OZOV9@E:V55 M<]"6FVL$*R(35S4F;RI=CHW"\4`C\/)MQCS`!3-,85!5Q!.RS.$P+=(=K671 MJ(7/KJUQ+-_)3]8%*\/?QP&,-=+$Z>Y3!&<@IDS7=%NC0-[8X@)&+L_1=-V MN:9T'?G'\;S=8+.GV8A+AS(I/=TP;N*'B3'0#GCEJ6^#/D];(M&29SS(64-- MP-QHE=8IC[''&H.:VOB[12_!!!/P/R:5--6ILK%&&H)X@X*]V;UV%$E8!V5F MFL&H[`#[&))4ZT8;6+YL()QB`H<921..L+_/N&CX$D!>#SSN_2,QT00^3Y@T MIKUJ,_W'RL_.1$0TPQP&M\H8L&<8P6#O[6Y:YR;?`IXTRA]O%'KRLM[#?W:" M30<:A;>(X>J"M1QD!DY)*=\2N5Y9DI>1W6F0R21I8X(2;[]N%4"C&@M4S5XD M\9KK`-QO&7=YLU[$">#QZ\NW/[S_^YQOGMC^[CK!Q70;'_Z0RP%T9-4E1M%PPD4!69@2BB MMDL'$HBV_184-=N%`0G4I`Q+%&/;Q04)C(6.XQK3=[;+"3)7$><4W]DK)O!C MEYJ(">U45+:U]RU509-CS*)HVOMHJGKWFLB+O%&4D^T5$?O@KI)10&GP_OQH MT#\BA9+%WJ]_R&>A*Y27TND\KP]>PSA^D6%%/7V;L[D9WBZH06 M(W&JK&!8BJ4I'>2HY@D+T5!B5U4]^(:5^L/_KRRPIXBFK/X*(@K]EMV5O:F!^O%P7IV\E4\L1Y-"9 M20_87J52#C-Y"87B;$B!9);8$6+>BO%B,OCQ%V[\VY4Z6A5!DAG\3-&T5S%6 M5Y3:.;D41WOU8#4$1&$5S@+/(#51`F4,(R_D@9G=W%R$^?/V2(/CP-8.@J@**UQ*8@Q M*KQ_?V>Z``;P]#0IV-\OWMU]%Q(>"A(S#6-4`)%.\FP%MPR_#HYHAA48W*=I M+@]]-=H*R*=YEI*2E/#JR8+?G&(&A]H9TQ:XF]3]O"EZLL+`IO9RA)KZ2N:3 M*A\">*O+1K/E#QA>"/E,2\%T\[@I7G&2D\WC)7G1=4RR!0_A=2>88`O\W9=> MURPMQ6$.-NGD>LE)E_362WKK);W5ZO16JZ-BNX)_)2T#MJ/9%?QK+%_HN+/! M>;K.3N(B!*W=/*87)Z%F)Z&:;9CM4VM7*%K":1:"Q'3Q&TH25"KU57KM?<2L MT:=I4=VXS6,.+8NO]0JEV"=L##Q!IX8-[,.Y M?)='Q[S:QLQ7*8G'\R$>,UQF&N,GG&P#CPC;0>Q7K$P&B`(!1M_6<$B+\%8[ M'F=%`(Y+H4.'[^T^)!C^599U?(R30A#.LB1XSC,BFA5@ZQY4@C==&:Z:)Q@Y9WYUV< M?`Q"N!I@7Y:((3UW1$B;=WT_>+DK:(&:K$O<;ZTM89M&&12^#"<_^52P:#:<6PVA(6^9C$H/"3#$8NI/4`+=\+9;<] M`\[C)]"BT\6.S72-BF(LYA^TGG&,^!^UAE5MZ$PD_`HX@XT&K!Z(WJE,B#!S MSB5,^)R[X&@TZFA:W!A=2CWJ)D\(P(7EL[Q_]M=4&091769$^.`S9;_5K,.< M;63O@S5G)?LP)C]."[=XNM=*>&;;'@M9A&^ATG*940WECK5LPUK#(0O6,8'M M/,$HS9-=M\#.&FD5QE8\7//N""XT2I9%DBB4NM$Z4OVU;YESS31(5LTI%1J(F MFAQZ&$^Y5$PN'83N)E\\F1[ MN$F,)\^>YDOHQ-Y5>5$]DM-\L:SQAP6UDB)X*J8J"T2DI+"=8'Q()F*=D-U50Q4\Q93?%T7]H3Q"2ZTA%=ZY$=/ M^7"A@7P/QN`&X[C0&=XF#CEZ"2SN%-_[`JG#@USH"R_!'?))I2XT@.^K%3$S M)UWH_=[[A/G)N"YT?]=SSD<7EL4MX*4,?1VUG8QW>Q^C#!P[QL&I4G!$S[@+ MXZ_I?>3#X^)EA@J9)3@KO&@W0>H)XI%9(PV7&R(N72!B\5W,8V*KB3RXT4". MH9T>YS&A\V,2$^W.O]I]3HF)>PH+VV]>\8G,0+B>1NS+JOP. M,6I)NJ!SB\6D3J MYC&J>(X)+$H-:(Z^X90XW3EP'XXR!&E+;+F/CKLN\<'OGJJG7!5KIX1X[)-\ M>?CVLT0'M05&@GG_#,*!,]E9>IH=?++W@\QPD=#W$*#G("R4>6E^$2QA!X[W M(&5%L)L*4LTY=F!1VUNJT)\.&X_"`I;@1W))]W:$,6%ZB*/E'"=K/E559]O!0R#R;.`-WE^VM]](M!?>]]L0BA\] M%S.#=YGO(Q1*&D,T<5)Y(5;9=L0"?/!IL3FH<]9X94X?<4(C1!_S[!J%81D> MS`15<0D3)]_XXH#_0-+G6AQ8([50^B,.-RL4HHA9LX8YQ`2E0/]A.2U*XT7+ M:<$AH,("=N/7(2?T6,@B?,G]DF8#SI.U@-WX]3M/T4(6XQ4DS%+OQE'+PDYAH$A_BG7C.]K(!RS0A,\,P!OMH\&[(ZY$F M(9['E>MWLD5!2(1$8(XG%.(G[.6)Z%)06<%R#`D3#<>R6,4*3/>N<9P6H;F% M`T)<:4]I"2MPA$L:KN5L1P*0,U`4B6ME4Q9QGY:I-K&(0`? M)V0O0;UVSG@MFD=S>::R!@03];)0FC\JQ'5HXQ..@C@A`8XE2XO>&1TKFN8B M"G*5Q!GY.*GC]H'^[%0]4>5F;\!DCFA MHRGGU31%&WS;@`0Z`0/?Q/ESMLC#O<67#S%_BIE&(G6B/`U.F^$MCK@!D\(I M9G#8U%J=S(O"'V\<^NI]J[R6#\0YPV_,TV>%L5OQ?`RB8)VOVZF&A;VCE1%\J4+-1M,4$TN MYM^%R@TFJ-=9`\OB&A`FZ"4?G>]"40D3%&1F8[M0D,($L60>=Q>J6IB@G=CD MY$)E#,,7'"M%QWBA#4O)II:91JEH;X4V(V\#IU8#I9>]]=E.22_U['$7NL;9 M0,&>^>PN-*V3+L%1TX>IN;M0-%P=U:/P=1>J@ZNCV;()NE`,O`^*+3.D^;K? M0RNFGW0GLO+]UT:&7S M4@+8>[7I)H!4;4'2@][S8M:/Q9A]9&:&C^=FX2A7!>`DL)>4V#_=-@#2S(OX8$2P5YM M6#\1NCIJ_62OV*F?&,N503S2128BDU[)50AU%# M=W`LI9B]4JU>_FDE\%+T[95:]:"O%`-.R6*O\*K_)N:DC-7$^-E>V74$'N$1 MX5RE5BTIII1,YR[7Y M57V5)E6J_<$[K&HQX>7U>,H'$S MSEVIJA'&H\>84EHZ=P\KTE+%STC#\)R[A16IHE+!E%+%T!T,JAN;%G)=I`\K M"^SQ>?.FBL`C&_O9+UX8`Q%^?9DE1:64ZH]QE.%OV6V9$`\:)UZ6`IZ5S"%' MD#XL1)G`7@5H$/;"YYIB;Z^.,PA[H5V!8F_OPRN'_?`V9906]CZ<L7[/@;C;;OM& M\;68CX?@VVPG0Y&U5S$>@*Q<92!*!'M=@@.(P&PC0W&VU^/7`V?IYD44?WM= M?0/.7*)U,:6`Q0I*?PJTR\Y19.7TD;^\IKB"K/"E_&/[;RT"@,J+(Y^6R&V1 MX.O7KS^D&Q"DDWR]6:%D_0.\.:\S]"V.XO7N=4$-4C4%].D\`1DR]9*@@&>Z MV#_+5R@-TNGB$:YN0HT"^\BO-="G4LN>^'Y0XM&@TDL=Y;XF(0`W7\%V&YQG M@9?"M\6O^B48;:*8FG2ZZ4$MM>YYMF#32*^4P(&,M@3R4L$,MOB&:);-4@>\ M8I&*BV@I=G>-(N0'*)HL%O"2DF2:6]!ULQW_"^B88:1)44ZVGBYF>!,GE<.^ MN#6X39?X$\R4"2[2F!Y1DNV$GRUCH&/P_OV=<8@;M6[2JUWS%\%EH["`D3*O MW@K[.7$M5XQ< MEC'4!&W_AI*`'.Q>HRXO^.G7"`3O5;!YQ`E)DD%+'@_)S]=9L+6S5*OQ(JWJ MQ4$.4'-!MU5'4B2!NZ#+]:GYPKD75+6Y,ZB#XH8=EB_RT.I<':*T><.,7&4? M=5FIG&:,$/[!&0?5ACO ML;C!&0I"U^"MCZ4*CVF&QI#T*$92E`F+.XJ^S.'1OL%%T6^V9:5CL"8+.B.( MJ&KF4?KDV5;TSEGC0?S)(&?TBU>:.!RGKN^C'!=TKG1:+ MNMKT(`SH*J>%OB>;2RQE"@^ECT!B*1,69LG(2^9E+C?7'JQJSJ=OKQ)FK/E& ML".5.(B4EN&BR$#QE`J?7=$,$QB4@?V%O@E;";Q]C('FX;T&,BY!FB];A`D) M+S'QS/!1]BMS[N->S[CN%UL/M5E0E?U>>!T613-&HZY0O-`I28Q'59*9J4S8 MQJ31:-LM_)Q*SNDGTE@JO7R,([PK8;O+(U^L>W(&ZZ%JGN4HY,/`&60V0H5> MYNF1F8L;C,*<9`T><@$U1Q/,^OGXTE`[JZ+[S3;NQY'S[^E"V`J_GE1=;5EQ MJXD_[W)S(>VW'\9"Q<:%?%\UM'DOAPNYO?T.F&Z2KV6;'_K\;MT MSFY5:4+)JG=..%#5L.YKL';"B:J!%%RT+)-@+RA,4/#?(2ZX)/(KI;+L&<:O M#L[T&6A;WH2'I.S;^E<<^D5'M6:O([&G3&*BGIBK>+W),YR0<-:G>)%]10D6 MU#O@C]8"S0-Z)F&UV`]0?6Y\:`2C39QU<3BDV=G]>I/$V\)D*#YDT0PM])PN M%H&'[_($+BRX5)J?`Y^LW9-,4)?[75_M.@*89&9:A5&AB*DB4TZR"H\CP406 MEP>C7FTN6$5G*35,R!2K<"`<+RQ3(C/S[#`R5(GE6)8[AE$JFJ)CNMG8"H6; M^Z#'0?>!FP\]D(JV&(\$5L1?<%VW\D\#VWW;]5FG MA;K@^]#,'>V>F1;[.12D`&K]%JBX+@0X],%9I$B[$,G0!V<)9=>%:`9%U*6L M#RZ$,_3$6\;"9CR"H8>16TXCD+K=FT+F6=C`R8T>1[AH\+LO`QX4C?(L+B70 M!CI#T9*T\B[9UX39_HX0`S\$6U(YO0U.0Y9JRDP<-;3'0B:4;0&85[N/Z!]Q M>*MX!&D160:[1/5":&RN%UT^9SB11X^!`N>&4UJJA9WS%T99L%QQ_%=24_3`E:=!B+=J M%.N:8R3=>[U!04*^C^/7OV3`D#`@AT5E9VNA^7U424I#A(,A*YE)QQ>">ON- M])B!>^Y#'/M?`VKO/$K.5US&0ES[O!R#EC1#@S:$A7U4_I2E)MN`%^A$?;%B M3M65`/][\!PKW>J=I3D/]2#$H\"9FL=A;'3BC-UP,Q#D$I!9VS M/\QJ*VB!^C'!VR#.!>+%P0A-N\9^[F6EF')D*6_OSAQIUDDL$L^EW,2="QAL M7O$!Q\L$;5:!AT*A?LH?[S3TID(0]BU#FQ`);"#\\5J^T,^$0?UB$\'=P!BE MM7E&$3,-KUZ7"B0<;S3@H(>QJVE*5K8D&0]!D'`P]#2/-?.&%&0#%UQ-@RFB M*'NXX(;2Q"4"V=:X-^H$5!#?I"Y$H0RE0+?ERH4XD\%4Z+(KNA!THHL(,JQ@ M2_$5"7V)';+7K:2<8=">(K5DC4\VIR(KHZQJ7[4Y`5D1^3ZN=IO3CR71'^1- ML#D#6=_Q*_EL;U$1!'8HHWW!)1O8<9W!=0R$Z0%K_RR6'\DY5S$^A!MT\.HG,AVH^(%,Q9X8S@ M;5F\]B5^^7SBE\?#5%=;&..QHM]=1.8E;D4V;L6(T/#].=LMC$&PHA""71XU M0XK$Q9=DMP'1E`IV#J85*]66?3?P0WR;%K;;;QL@.;8X/Y:>>FT#UB$[34+8 M=[["H+)BN"T]@93*&VI">KK*4_CJ@4V]W_,@+;]!\I\)%NL$W?-LP8:OI_)& M6Z:I7;1NQ[3NCOP7HWD[^\VKC]6_R9,@6I9^D0YXF5-,XL#34/GC3$+;=,%W MYKEU3#*K9]?`22G5[=%:[!1S%'*:%Q_]K#->7S),_R31^=T*H/3+7JM\+;(: M5^_DE/^.%[_5D:Z;(.85>PLM'C:0Y621Y#P;AWW!<;H0YRHNQC-+N.4^N0(` MV[QS\%Z=H2U'B3!B$="%W!DE-'EREPOI,4J(6I#OTL/TQA0FNYYM9\.5.K'M M8U64CE:RTQZ7K]H6:=.CO!K<^R^G/ZB';D-">17V+@>?"`^-/G M,%@6MXXCV*Q+9!*S?AG_R#HN2^<43#%E$@3P!"N^CE'S'Y,B$]EWF:%V1'^M-!CQ%[@S"7Z*" M*>RANN#8!N0A38%I.C]K#G@J*VB!>H:?429H9]7Z7=..69Y$`FYO#S!K+Q3U M$.2:#9F3K,%#SO1Y-,$$_(7^LZC*TN-D&WB@[14N[\/K)"7EFU/V3T*GC-8M M+C3JW*(986DJ$DWT.J'Z MZQCFW3S:NY#+:Y(NF/<5D5<5H(T;^4@!D87^?+MBCS$/?A`:`N]K1G-X9 M7@9E+9IR#'G.6TVIV!-W)C)B)VF`'I$7+`)/V&;]>)P)6\8UL`9\R`DJ4W;2 M+X\@)DC:I;@Y\C#$,JYHZC<4Y!.ZC>?8J]'Y;Q]G4A-":[ M$MSJ'X>05G_^^^>G`]`:/YPT$[;SSF:;6A5NR3.TP:I3CK[#-D<4JN,EEB.- MFU)ZF-*4W__6!W)XL1NWK9V<`M]!V;3F)>Z$:T0&*;96Y83S0P4]AIINWKMQ MPO)H%EQ)LM7OV$(RY[JU$3O18?9`S@K'O=@L&Z-, M6"V/Y+VB1^@BVMDFU*"5NKH$ITGID<0"_F8.-0@S]:-BL_AJ1%E$`C=)$U1UP\+[WX8]]?KK,UI^EJ'[(24DL-:7*0>6N'G.XH*SP) M39E'Q#&O?$GIEF,@;X?N*7?X(FFBB;/@#;0)5<%)#\;4CF/MOK@ZQ97#3I9[!]L>;C.8,-Q8V? MVA7:+8<9?WI/31*VP.)2A9JG+/:^7"&XK$A_'B!953/*#TH0&^0P$H7\%24^ M"=P7F-#:8XQ$[JXW8;S#N.*")Z`Z/J+II[A(:L)^`6\ZCS,4-G^_CM/L4YS] M%\Y(I/LR"O[`?EF?["Y.JC^1<3P+\XF!."LZTY7*245NQ'R%HFGQI?(XSQP\ M)JC_$7T+UOE::'UKCS$")5R:G5"VQFBQF7W*R5KPG)#[]+YX*(,M?@S1$?-T M#M=34Z865::+.Q0D(+!_P=G?4)C#'X#]UG%4[,T"3GJN$4L_T(@4]A3Y5)I# M3,(H=D&T!SD"IZX^9_LFU&1U0=FEXU':=Y\N%IA;#KYKM!%?$8J6(O:GOQN# M3GC[-D=HJ@M%,GN]HNLK7$O%DRDJ$L4=/08T?X-_"KE+.%Z/OP]N.R/!YGQW)50?(Z(^A0L`NR+LRZXXYV&WI`'O*&1,\7H29*0 M>Z,(PP/%O![SB'9%Z8=""93SI@YZN`5N91V-8I?CG` MJ_PB^$0;:*$V))TDT_B1V=I."IZ'96U&J\5A]@+J]Z M]VC;.26)U58$4/;:=K1*2M(MCG5O>)J7E,?ZD[1I:&R`-\VS-$.1#V)DKS=T MT(96?H]>K.$_ANP..FJ^"),,X.G:("%H>JJV@&^I/1"-1 MAI0WRVC@)=/-W@J.&N6&,AXO(AN!R_`YM<)`+,9+%&ZKA)8SL;7,9Y#V^Y3X M@<W]I;$E0>3:G;M4;YG;UU'SI09KD4*5JFJM-(?8E'+KU6>&73H^;"%\AP M`3;Q.8@CH1^;O55FNS!JQYQ0IK,W2+_3751_5@SO(3TRN4*X;B#8<%'2$S24 MB=`GD%6/VXPE`#@WWHAH8"J"GA/Y> M](7]J@:SU2G1OQ>%9'2B:M)$SJ3G-88!I()$'4'26/ MJ2M2LH.!*.2R;?/G^EZ-.Q$5FU/T1K5/N)1]A8#J;K'LGZN6ZD8J`X7%XLW7 MD`59M?-AR2"YR2:BXYK\'LA-A?7YTLVB&11@(P]+%<\X""V.5Q5,, M=]^*=$#'6QS&&P):Q>'B.@T2,R^9XJ+US?1!#6'-Y0<J!:O=04[H9 M7`A)4*:!U&MH/&S`C@`VX4=E_`NYA+%9^#V.0WM954\U-LT^=9M$453Q$PT[ M45J$WF#_%N+2F.-DS:N[/>*&%\W: M)LW:I21-K5FGKFC$/?-.364RV*'E':>S772ZBTYG;WRFQ#.M:KFR3UUJNUU+ M;6CB9<$6T+!5Q6/!7.AWJ9JZQBF\4X(*68D"L+>(\ M48.)3A@+)F'=;^'XL2":PP0UF)HS1H-*5*-<.-Y&-?`P9>XS?/U)X]LLN M=BV\2K0&Z(8#-[5'X>F-B*@,W0@[.4:Q8RQZ5"L=$(#G/M_T,1(,W<5$BM`[4B MRYJV=)Z&^Z25XX_N%.04['XVE&T47C!`6<;NSK]9QSB)'H@KO`RBB/A144@R MKT[RA@T%\?S/:(:)"`4_7\>D=;*7Y2@D9JIW5AP/'SKG[Z7/F\VI7\W#+6WW M&^BQ$'0G0P_4I8V[)633H\8S)&BB,5^7M(G&HK0L9TGLB@]U1$M%G2HJ-E$; M]\O:2R56A5J+H[--4:GI7#`>RVTOG9JN*G>KNHU/IH:7T7BA-\4("5V6.I6H MB:%2Y7<72C'*(8UJ@'2WG)_UM#Y26]VM]&<]K46F2W=K"8Y&=@NL4@X7-'3_ M6+K,S>Z6173FIF*YK]PMO6C])Z$<-:!:L='B*,[#>EZ61Y\V$@Q9ESR M+M_7(6U\9SSL59>Q"-?BQ1V,*G<5L_[<0:]A4R857-'F78)2?M?Q2>&*?[3S MN:U="8)WT+A3RH[4TYY<99Q-+FFJ%GZ8(]%>^8UW-WQA)%KQ903G\G17<0@0 MI[>_YP`F;>=W'RWB9%W0T(36?AVB-*W2;H6J'V.@%HVO8;6XR\-P][>BMG[1 M`H)8SJ)K4FX_(8_,--E;S*:+LJG5O@(4,<@]$@:X"R(4D;)/S6N-I3J>8%<3 MDG8#K4.K)>]8!3-TG^\\0<1!4-@[[V*@'5[@)*DL;93B'>K),,%X?PZH\W<09N%%=[B,\M)U0 MML9H.?MJR7;'URB-P\`G52$G:8HSN.-10OR1CR1891Y?X2=XK.VL5;%J>BQD&^0CNNGE,@=E??P2'?1^Y\BF6)*.6K;308>^+K1ZQ&[1K M.VX$#UKI1&1A/'Q1+;@U*=[>[R$`2ON%C%O^@",/-]U5#*0&K*8+&]`_"&]L M@$E^0TE9C88-*6NDB3N6)2ITBH`=DVS!HQ1Y%'"H)M@"?ZNYN#02S5EF,(D] MC/WT+HG7^[Y\Q;O$EDZYF*FM\KJMYP;4(?IL(I\X3GQQMO'-@JP/+OC M[&&F;TP2X/2J_15W=(GASS"'P:TR!NP99KRL5:^%IJ5.5%"*.]Z<;9EOC6SW M(A&<%8VBLS?D705-SD=%T3058JZU2K`%CKGQ:@1;W-VU"Z.VS89B9"B`_LAY M.KJ@0IM?:Y<%SM"?>I+CD%5V;7:FGI100J^0S;G@I_NZE3P$QB-PK"#9:"9= MF]/)C9+7!F^`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`J*,MA%W=)""/'>3]N7MH4UG'DSGM#/" M13G>PXW<4Y[/GX;"5[(,/Q&'.U8W)"(/E7BLB9,K8^G(1Q]'(!<*F8\]UGQ_ M`J$S4$/F'^?,9SC-0&?(JJ4+_A8PH&BXV7[?`Q\%N:;?6C:Y9&PZDK'I-LT, MO:)UT8V#BU8D_XKG.)G_:B1.XP2:2RL-K5/\,Q_[()>2:Q?=K(@:X;;(UJW< ML1MEZWG.SS"6XA3'H,DN9+,#5U6%/=?4267\^>JJS6$AO=$5ZD?FXS@DY8+O MM.2$Q04YK'CC)3X8H6F%7R;;FM#03D?DN)8$C:^J6,HTSDLV$9I9'L-D>F_SC7221'2^*=Q\9)U:[5.1&:;)&9R+WJ48B3L4)$7[E(\8D7\7 MS%!GV!?-6N#D'P+T'(2`0ST\->)[)^"D-0P4"Y[GB3O>A)7O*D]!@4Q3X)?G M("J^0-""2.@&*;<+2D$`;(/*`Z_(S<&KSTI&,E2)AK<(8'U24_<&;^(T$&=P MB69H\M?MZ52P1!'9U,U02E.UP'E328;-^_H>5.8T*[Y029![K#(:],=WB#KL MPC6T0GZ#MSB,-T4E[#A5)KC,=*WP5F]VS:.>*IGE%C#GJ:82G?`"X0PV`7=- MO_(9:CRC!5S%<^M/HQF!E:0*E:UJDOT_23P?-XM\G#TLH!(#Y@+(SU'\3,H< M$B']/@(I'GZ.(P\P+2X&4/3(]")P5>@U'&T[=VDG68;!>V4, MWMN`05-U/69UN>=`:HWO`DM#,3!50RH4WD09AB./%U(_>%GK:-$0\+031'IM$U1I`"=O`NJ8I$4'*YL0$QF' MZAWU9BR=2SS!!&T_QA'>E6#=Y1$GFK5CL!Y:YEF.0CX,G$&G#N@91;=KFI:U MBO9G'-(S_D$,?I=LSFJV@XSR3YK-^A5;]PR_I8C7.49'2IFF6723LY>Y!-!)%CGS'IX4H$:2^C'Y,J+`N[ M\0!34Q1X=TP!>[,,1J'`^V,*V)MXH,LD3&5;L:&.RF\6*NO$ MA)*(/Z0DL:\\Z2AN!2$#B6.]S*<`F::55'29"ZF`XY)),JC-?'BY`4(-BBJV MN8SKN*PE'?]+263(F&.2J;I@N+>@<>9A' M(=K#&<3#7V*ZK8_I;H@COP79ZHC<:9O>LX-8BTJ6GR%]TI/[=]U)62.(U[TMT)X;(B!D)D7?Q5B\E]XOV>DQYJI=0SPR'*L%_<7\@K M'66@D=Q^(VYK9IZ6TGPMIN9)"'2:KT"BW>`\"SR!Y9LWU$@;D$8EL3(U!-&_ M-`@FSBM37>6[P539:,OAKOW75_!U6MZ7%8O?@IJ0[1[SQ%NANB7>,=,IKF"R MS-8QB.)^`MWS;,&&;^KDC1Z+>SB:^&,,#T86H/`:I:O*J'$(LI8EQ\,KS::+ M-F>S-&EIG"27LX3#6/`>/GOR'"BUFB68W\`+7\%:?3Y+^/X)L[V51UBTB"5X MWBX6F(1`X"-8%?`4+6(+GD6JUGV4X02GV7V:YB!T)^3_B8B]E\B#942E6PF\ M%1:UD@[I(W[&J6G'*7?UPX9:P3 M:4F$1&GQRN+#9:)Y]2HT`L[@AWQ=]*^=+LAC+WE4@[/CR/-X&'PH=8''\O'*\' MHB`$M0)VJ`Q:=W&>".#ACQX%FFF$Y8&A@T>!A?D:'@\:9V]Y*N@MA7>P^!Q& M*YQ(<_@X\'R-%:"I!QNY<>#]Z;QQ6F-,0+EGHGE<">U[41^G'Y(XY0E0G=.T MG/XC3CS8!2U!IYC%.Q1FNT<4^-,(-.@G!(?-XH+N24;H3%YJ[*>D)=0#J--1 MBN\P)M$OF$@H/#)WS#*!R8QHOP+9FOYN##KA-]<<803"4DLF41;+,OBAOK<^ MXFP5^_4_>0C(+V`E?NT!?W"9O\=")O"ES>`8)C10)1O_$F7(*"^CY8:=HQ#6 MDXK]X`TU07/2'&ZZ:%CB!/<1>ZS!UK;]HCEH01F>J%C'9+VS-\%>-_(-?:%& M_[V]-;9TH]\0ARGZ]A82THY^4SNA!+"W0)!N`C25=XJ_O=E-@_$7FE,H!>Q- M6)*.%*.-['E/-+WOSPE=;C0J/5U3F152(=H=P7.L,CH"XAB/2^=F2\F$`K0Z M&BN+R6>RD#300!A19CQ+:$0::/3WNU"44Y5,W49-%U+!=7P@ M?4+P7,C[EJ7-X)`]%Q*[M3-*1\RJ\13N$S"(?#2^"T7[AE-#)>="M5*?S131 M&'?H0D\F)4:1"'%SH7?2<)S;T3`NE/1697\5IY4+E;J5SIP1&.)"Z6WM9\QP MW+G0[DN#>"27G.9"3Z^ADD!G9H$+C;M&(H)">HGQMETGH)(PS9L2X'QDQ,X8 M'VJQ/Q,)4")`B^)\)A*@6H$/BK[[PF!7[@C%]4P$/W'4.T77E`PH5V*I9\I, M\V;KE9EAW' M$_>D9&C<L+`Z%9;0=5(/./7@-S3/!8!SJ+H M93L"I*X/.EVT'%C[8KN@XVJIB*EJ&BJ7O%0`O%0`O%3*N]074[#;C%=Y:LS: M1NK8('C44GA<(L((/JCQFQW\`W\(=UX<+HH$C!#>HQ!%G:W\ M>B[U_>9%GSQ#D1/3HBEQ4;BZ=?F,-MBF.Y(E>G^LU2G9P0]9!;M/%/,Y0V&*#>?P)9^WH-S7+X<4&YYH-CA<"Z14! M,BE(%^1CF40^_`6$JF8TI*19;L@.1NN*L^P#&A:\U$H_*?[7.8@]476K$0"` MT\C_$?%@B\+";;2_ZP910&6C[ZE>_&#H[Z,M$"].=L/`I\N<&'YM5V;_FW$T MNS?-(;GW20KA(D!U",J>V^$[.+X/6E_+8X(W*/"K8%L8/\U6."E_DS>@GP`6 MUZF^;Q8^1]\:/WZ*(Z\DP0F(W0F"ZS3N",PZ`8F[('"=PL0\CA-084,$7VWD MDQ=VLSX-^_+WUO*J/,0H2B?9080'ST,J-<5R3]5YU]*TP4@TW-ER*=1ET-FB M?&:2'E*_`YO):-GQQW:89F\MQCR-9(WLM84M$QB6^1,,74U6"`"$& M>ZLH#N/E[B-*?@^>26GK>8)15O1Z64R\'!AC![=!_!RB-`N\!YQ_P>L`\4VM MVM8V<4:"3V&&"><$T?+XDN,E#_5=S<)>P)<^S^K8:NCSS.T.+*[NPOK>0$/Y M:^POOP116'QT:\$WK'5]LWZM[D>NR91R3JX^:YZYQXN;>M)'3F%[1WJ=Y!FZ M2H92=I#,;+,I6Q?+]18";#967_S.9^)WMKG(G@WD&;W$GF8-RF9OLTZ*Z959 MC7NG>Q@,!XBBWUU!.4VTZK*T2E>7L\W2^I1O-J68BL)]1S*@%8J\`(6-UF0O MK83^>D4*?]U'[8I8K!3`?;GGN'&"EU2W,S)%,G/$V7U^LII=)OX_\C2K6H,< MZ[Z#USPQ9C4,PY"ARUC"4QPXN_P2?5;2$]0=+%'D/Y(K#7F%KH/"]#[R^%:6 MCAF6AW1?B@\YI8AWL:=Y??Q28^CLS0\J-89D[_]+Z:'!'Y$*J?M+)\:U;NN( MPQ-*C=O)+V5:-.FO,[R-PRV@3=@%]-0$^T$V\?V@A-`J71N.98N3C-A(GG`$ M1/T49S@5`'OBF*4:$-*TZCZZ1IL@0X?5#KI&ZZFR&J_718&OV4!-4O<'/&86G)LI]E)+K#YZ=VV^;H'QSILE-CDD<\@W: M?81GB7@32%'0 M$>!@66&XP[3M3[FCQ3KE2SQ/D`^"$'P87.)(SS?%=X<`%L+2''9)5W'H$[D6 M>WD6;#$?V<'+V8E[L[=H\3:5I0:38+D\LJGI6E4;WU;D+=^P)(B\8(-"?J!_ MUQ0M<-TN%B"XP]DK/,>=7].4MSI`X.6M)G'7X?9?2@T?[$R@\LONOF7PN3_`Q,X&6 MF6>DHT2C._0!3!SN$,TPA,$"IVFA`Y/&UGRPV\-,P'K4HO,`2/J[,>B$-T-S MA!&WW0J^\#E.UL73!+L):,D>:P74PF`(WFAG(?_[.TV.S*_Q8QQ$V1/>XN@. M7O_J)6#;\T`_A0GS59RG*/)O2;E\C".![U/?ZB>MI=2AES5B,1EZTQFZ?Y2( M(O>.(?OM$1H$GH8G/@1.RQNB=NQBUG;\4(_-%'_`"Y6'&QDKH3Q'>&M:D6LA] M7D,1_?L[&U#M9M,.APW-%]+H2Z'OHYRB;E_L]S5*DAT(>H4VETX7[]Z\_9?& MR&*,B5#PMC0N\'4R!EH0/E51E1E@)#5EC("]U@Y%A6'"':(0*+G)YNE])-\* M2?W0,RQS#,@[:PARASL,N[);?`SH15G,K)'F(?X"SZ"YQLK,I@TAR*. MS9$B@Y%EWKPV!XLH8*PJ*=H<02(KIS250=D7S'@HB73&MD#.X;.X>XG7'(4V M7F_BB"393Q?S.",YS1E.<)I5O==H7Q_SZ=@?\\@/BF%HLDQP\6#8DXR=),3P M5]0KF$3^)P")_F4._Y4BKR@!(`R;5EUEK,I:G`XS[%J3%:OLV_(,[%9 M-.40<(I)6-$6'Q^5Q_FY>6Y=JK?6+;2E]L-%&A2%$>&S2PDHQ-&7WN`-^;2C MC*^UR$\V(P&PL,]-"C(2\(#=73S(@ MB%I1!K?@QP"NO@P$KD>TX];;%(R^I**=,A6-^T8 M:@F[AJ2^:^2,;<1C'\>QUN*",7DLJG3*5R[8G40@-++CBGNO9:1I$0I1Y.&G%<;90Z54B#IA\8;;`KNX%QE_@N/P&PHXYO1# MN-IUU&_KGF<1-IVUT;KGZ4EV:%\H>V/2?>21^X-9FK)KRAAPU6]&=:WQ/2YR M$T>%<7\)JP-Y,%,+E'=Q&&<[02&[]@#S-47WDF6<"$ISDR'%W=)BW$%QPBYIR05>EQ;ZZL,_>*6-NU;8M6.5 M7L8:-XFWZ@S]P`,()C1DF'<2G1KG#F.)>1^*;H)(R,4V1^4,X().==1^;XR: M>"[Q^#5?3../WXCH\\5A50>*V?RJ]3K(]F;^^DB]0$O'2)ZEN5ZY3#Z7:N.#Y,H MRE%8!`=/H]]6@;>:Q3L49KO[%#B69WI3F'UB:#_#PY?4Y7JGT4#PCYH^_*:#_*:68V.L*%@9X$SJ1H"`CDJMJFVFYZ`D-56/YQ.TANHS M+2\]H&2I4,!_S$CA$J9X(S/-!,WOB/:*0Z*9W4<9BI:DAL$0+?O>)UL0;/B;MGXWP;L/&/2Z2>3/X$I&866,Y7`H M>ZPQJ&G?)]+RB7]=L[ZG2GG"Q)[)!Y ME!76U3PCR@8($T";P"O=`-B_!64DVX%4PNA2""UZ6^KIFP=,VQL+3.I5C0X&)!CF"EJRLW MW+,@M]37[OV^.=3Q]\`9J0N*TDWQ>;-(`&M0^CD@'`W3N3]H;WYI8F9(=`*` MQ//T0-CH\C59PN)+N(M*ZSBYS*-/."N,GTPH9>=JA_0@=FB^0ME]>I<3Y_[5 MKGQJN@"66>*T<$^S%4[(1SH,]L8RVN&?X=*,5/$G"2.H;&@$#E$Z28]5]$-? M.GW(7O*,S9YT&MBDG'8]5C$!/<=%UV,5T[DKC6B5?0P-[\7MF&4(DPV&R^$Q M1""=1?XM?(O%3=+I09*9:15&G7X7F9F7(HRG+,*H"4+2OBS?ES-OA=I\Q-DJ M]ML#_N!^P#T6,E+ZD4C,Q*J"_9N<.+)*[;*TMNS-5""C%9X$#JIJ:QC!,G]. M07(@`/A!O!7T?3H!,7*PL2JH_&:-F9ZM,<28DW2N?NG^((1H%V1&S.EBEQJKCA"K96VT$T2XUD;DOG7YYNR:3!C MU97\;'TYJS]:?;%6ABO83`2JL(40INS\_4@K9#= M9W-F_C!F'QPV8W/^_A#22,7<&T_B'PEY.:>^\0XBHU\1XB1TBO^?SP7_GN;V MFA)O[54->E)"+EF%$N!LY#]AC!/%][RD/XDL2HKZV4B#0YR*E!SG)2=*1-50 MU,]+*NP3M$-I<5YB8)\0($J+\Y(*50I'4!J(O2Y+QD0PV%UBAISDM45,YDH80X+WFQ5VH,)<9YR8E]\FRHS_ULQ$-^WAY% M]ESE0=7BH)0BYR4R2K"S*VU&XJSE4^SKDS[.=Z2';:\9JP^FK!ID-$W&7HVM MUZD>Y9)23.TUZO?!]*A>+$747DM]'T3;!6HIEO8:W?M@>=A.A.)IZC*2>GF. M2H$PV^71BUZ[)2C$Q9,.6$_(ZB%1T*C3V2 MC=0GI@-95X3VSJH8`FR/F5C.ZV!IGS[:O?`NSV!H=?D4&7UUII=Q!$!\CM=X MCK[AE%C(XZA(REH\Q&E:_G2%%W&"X47IMDU.3"?[C&OX=9-4^.D,IQBN MZM4>!$[''-E5-#7/*1CV_^5)D/J!5T3@\)MR<`<;:;D"GU&PC,JTS)VP&AAS MJ`F8:^Z=Y-FJ>#4%M<`X@^V`6UA+BSO<8=AUE0%K7&`/G+89_'&Z(6"UN6"/ M,7IRM]]0$1(!%\XCCLK`87&?&JFINJB9$)'Q!I?_?T\"FJ>;PJ\9+8F<5ES? M=]7US2&VTA(CP5V_-VGKP9&#F#?9!-\^O<@U7O9+:@N0-LMN1V)?L(YDIZ+F;5;B>6KIFV#+Q68-^-(6:V& MH^J*S:I+@&M4)>$J,RY4HY#!4_J:=:'HA`K";&W/>&6)HYISG3(^=;L=B>%G M6$].BAPR3DS[R'(&AS*3FETU6VDME<64[^R-6D3IL+RRF==E]9U.9B M MHV0W77!N+/,NKP,WO`Z_%\="(E'@Z]@LTCU)CZ<*!@C,^=7"\I`'7J&$!AS`4^_^1HR3# M2;B["R(4D6)L-RA#M6%$/,P"^T@5R']_3^[7PAH"GQQ`&P8+4J!]XGG$:YB: M"`V>A&'\%8B%X7*_B?/G;)&'>WB$VI?$1!/*`:7P'KZTZ'Z4XF2+TRL4DC]Q M4)*;:Q]6URLBF/KSN*A"5W-3'R0Y2]F'\PU\444\03\\&],MQ$VDS4I-/4.< ME,.;3X$5::6P+3I.]<*L,=T^W#HL0I*3S>+%>F7IN]QE&55?QV9L159)M37, M"<`J=TQ3%I:15"2-6^VB85Y*AG7A&2TOK&)8,5H:=<`U_O"XY-!JE[ MXXQ-@IK)*50\7#`9GH`>3<')N"'1#I+PM#CC?@8[R--4^(P'(4K;8WL)9_)$ MZ6^B/KT][%.P52=#4.`W]/M,<$4(VRXI_3!6-R M@X8`XE5(&AR>/8:/L``I$6(?ID_!,@H6@4?<"B67D_:C%;@6G]`-SE`0IM-% M]5(_K3#.G.`M6>!&0YAB$^ZK*2%;[YH MQ;$O!V7Q`0U$J'E.)_:0D82`#F-H>XR6L#(0\;(D(&[-(@ZCV($?8"88K04: M6HN,$QLR26_7FS#>8?P19=X*'OVBZG+PG)-#+DZ/,B<#`;T;&`E+K#'8`_H$ M,GI`'N0]5S?YGLCS7B7TT8[,98^5XF/@D6O\_31S#(LW4Q6.D%G`[(D7)'\^ M)/DAW(7>UOS+9[B&TPG)+P-534B1DVQI`0V/V+:\`JI,'F#8H@5M@G)FIH4&N,>T''HI9F M1=KFBBUR=.IC4#$?SJ89:RV&1^-57>0SN9C">BNHL2T=NQP!4)SJ*@Y)/RN2 MBI;MR%@G?(#2H-OJ:;I%"2GTE8+H5GQ7%M.:"ZJMM*US:BD_V.RC$X)K*XVO MJH;%\#X\5^6MG+@XY.`VY_>\8C2")O^98+%YKWN>"=L7"RJ^/Y5KVE)(R7^O<08OO\",.X7L"%>@!U)XHQ7R_ M-V>D9@_F9!TG616^5U7,`QWD-QPL5R"$3[8X07@Z7=S[0)5@$1PW$E=Q M>8ZRHUG_"X/+0,-M_*MN?I:1$,G`QV7=47GGR_`=-//-ONUZH;XW#68,2%6X M8\"Z9GF`&@HITY:L6CT1/BD9'J#G(`Q(>Q1&E1T M"X7`VBOX@#<8%'V/7:M`.-21R>L(14+@`L``00E M#@``!#D!``#476EOXSB:_C[`_`=N9K"H`N+$DN^@JP?.-1,@70D25T_O%!8% M6J(=3LF2EY*3>'[]DM1AW:)D252^=%<2Z;W$Y^'+Z^4O?WO?&.`5$1M;YI<3 MY:Q_`I"I63HVUU].OCWWYL]7=W*`3]IG^G!_U*-O#,#3V=-9*`+_#9XMTZ9/;[;0W(.Y88`G M]I8-GI"-R"O2SSRAAA<10.-MVE].0D%X7Q+CS"+K/+G/P'WX8MW M&T=>>!OXCROG?_QV_ZR]H`WL8=-VH*E%7F3"TEY59K/9.?^K^[2-+VPNY=[2 M>)0$#`293["?>OYC/?:KGJ+V!LK9NZV?_,H4_D(L`SVA%>`V7#C[+?IR8N/- MUD`GWN]>"%JE6V$0/S?1FGY+G6F8,0W*F&GXB_=KWA1/`'ORV]-=ID.S MB"SWI7/72(/]P)IRQ$ST[B!31[IO*'L])UQ<.H\T%\K$6EI$H,%B;I%4Q[FL M%;277.#.[JTAW)ZSIGB.#,?V?\,;9Z^O>$'^B_?K'W--HV!Q*)@?+0-K&-GS MI>T0J#F^-N[CEQ.!%\X#^]DK$0\(LJT=T5"ID+B?IZ05/XPE>VECT%<80R&S M]^WY!&#]RPG6?PS5X6`Z5'[,U.EL,OVA_%!.?CW(`KXP\-T7][^_N';4ZYI# MJ0O=-^^?6LV_.8FV/T@TWT[ZSP('O2?.-8M2S=;I13[CBE@;H;;DZ[>$8W)> M"CWV=HLY)A350P3[C:_#?H1[N#30W-3I;\@.Z3?O6V3:5*5M[S8':'N?K=R[ M->-$MS0JUG0X+1]CF%C34M21,E7'/P:AMF4#3S:@PH$G'?CB@2>_$2BEL42# M7BO=\#J30!ITW243P[!L`)DX2-,XF.UCTR12":^,3\J'J!RUU-HQ)PV\QW") M#>Q0_KO:$4*!3__VE<;)_2&_0RDOKOU.O;2-@EWB8#B=B0`XI`UXZOC?#PH; M@?06$6SI-Z8ND!<^I.Y;W'WHN6\T[;[E0*-]]\>"[EM+`Z_Y`"+5?7FD M5H#K?!;+BV`':&M!H(ZNRJ1MD3?D45/8#-'F.!KW^QEDQ,7YJ58GR*>R@YQN M7'\\L'4)3VD-+@=!B2C(Q,P33;[P*S/K*W+$0)/ZB@34I-DAVJJFDP1L#N(` ME=<-W!SM8K2?)H&X4V!2'VGR#0W#>N/)^,HB0+=V2V>U,U@'YKY"'_FKVA_S MONVOJCH]I4+L+=(<_(J,?1=`F->"TU"8&5-),"2(Y0&:[-;7 MB&91UI;A[\JRG?B\6N'CDK@@S1;!1:_^>#CKCUP>N(*$[-GZ^2LT=OYLL/." MP-*;'[9?$,U2V;XA]I?09`KM@SA1Z/1Q8NW6+_3_T'N29:K^C`S/::FQM!,+ MK`4:,_<,?&/[HVAW1C^50?-9KMAC'["UB-_]L5^'9K'`)YV:^H:=%TS_;"*P M1Y``JL;[%7O%_DB#=7$/INW3"%C3:9>I]Q%%[3&IMFT7T+]S_$>\;[G.HYL'Z=2 MQJ6BW![O<3*#T71GD[FX7>+%#G5`91HZ["W%7=%>#P MIMVMS!%5?2Y@BU-@(-N.=_Y=Y)#T]>:286N:5Q8$FO8*D5OJTCU->!:(;!96 M\9"WO*P.L4^NH<*M=3"<3(4(R5<'6+L!3"%@&ED^V^3HL@I1U1@9$>X*(G,; MCL)87BYUM>0TPU0G@OR'06PY@K M"W!ATI?L:W`N@B3L.N[OATOJP5J3(M,05+ MV;&I,Y=]A'OJAT'[N2=DL".Y_I&=XF2V\%5)V6R178+M:ZP.II-H-NM)YDW, MDWTXH28SG:W5927-Y7G;+@OEL[7Z':&2;>A3$\]O;^>+]*Q6%+/QM%8H6G62 MRQ-:4C4"5!)[4!)Q1*T0'`PIP_YLID9YPA,DE1*.<49IVQDAL!_C403;Q!4D M&\;IZ(B#-L5KB>GTD[6'1N@$6WYZEWBZ_20Z;H+PN$P=#F,X\"5U(G,^RJ]H M3THVV!&F8]S;TWP;?:,J.@6[8 M$N-_^.\?"=LGY.P?Z==BQT!O_F^'^113]E>O1WR["*S%9N'QX'`R"R#K:P9A MU2#0[9Y1#VD'OGK`]?._!Q;4B_2T$DA=BB#?#/7I'MGVYPMV)"0(I1X.)4N, M84BY9-ZH%7PQHJGO&TAF)GZ$DU5/(^B%)O[X%;D3=O>6;7]%SL-J`=^+FZ*0 M%#D\(V*:\)%?51TDZ<0]YQU1X4]',R7\$-G#BDU-2TL/&@N&&@^&>^Q9BP3# MG;[N"!N4:?`9H!>.8D>Q_1NOLE&]M7CO=PO/KE&BU=L&P\&P%)*_N_+EE:MK MP/\$>'/\_\0:]^?<,'0(S-$67A+&H4C6-/-%.WR"]%ML8H>53;@S=;3B/]Q3 MI?1'AWXK=EAN;MO(L6GND#S]>8RD]N?.JI@I.GNCSOJCF3^YYBH"KB:>H1]T M`:X,'+0!5QUP];4]!==\3)1NQJ1H)J_YP+C[X5B%&/H$;;EXA?FI('P(`^3" M)<[_'<,1H0G"RL&4DZN$S4VU\!Z;Z,Y!F^Q*4R5$M)JQB-LEVFE/)HJ2#O(L M5']G.@!7(BUS:2@.:DH<>E7CT%[J4K[!1[.7DM&L-8%Q"ZM["X5\?RW46`[` M=R-X"X=Y%"_TOJQD1<0XT:-I?64Z&[HIRK]N?I_?WWWUB]+[Z\;.08&[+=)? M26[]1&A3WD=Y*JC)[[H?TN!M/?)T2$Q`Z@^!2U'K->'3NMG?7&9YW_+(3B0; MPH&KAXQT'3/IT'"3EX5UB=Q*/G1$9\ZW6V*]PO0/+?9FZP0D9)9@WS@9#89] M;W`4R/62>W;RY1(!7S9X,($OO672J=]CI1,>%Q!-_6Z[#./Z>JCIQ>KP0$\< MKY=`Z/]7%MFP'VZ_/=_=W_PNCW)*X?=`-N+!JYEF0L6,6"VC.]O>9=Q/4/"* M/&))M4>T+YM-E>DP02GQ$D_`%2J+2&KP,$XAK7A8O/#;@*-\-9>]R6NK4$[H M3M&N,MA+X8;LZ-1,"O=88VD-*PN4_[W"#\HC@)`5PBFL.AM.$K#W!/'R5;*P M7MF9.,(;=T8T'ZCLD1KSR/`\DEMQ*P\E*:"->U\S5'_#!K(=RT2/<,_@4@#8 MY./R8)NP173:>S`>I8`W$`=\>;(@?*1C<2"WY)@HG(_T+@YJZ.;W6XAUL-R# MI[L%.\-_B:TUDEB;I!A?*5!/CXR4I8?`ID<:USOS"FZQDY@W*'JZS06%=!.$ M]_%-@JU+AY;%)($[$WBR)*T0U.!8'#(<*]@$6H..B13AK>.;I?G6R_>MM>6, M?!!%5BYR0M$A_.=OC]E2;GW$0,7D]03\EHREG M+U-A>&I.I?U>^Y)=*?U@SK47C%X1^]7#ZHJ.NR$V0Z4Q\I.DDK+D)>'E#!4M MLC[HSY1$@K[U5!WN[&959.%!(YNLT5R=X&Z^%1^*"X/ M*^#I"U?7D3H*:#`VR92@6KOIP.BA&J6D#"TJA+LA=HPI?T8$(_MA%8Q]"B8@ MQ,7(Y\1"&T6GLR:#P3C)AP'FDVAW5;%_'93)9L&:HY')@!*C49;\:@Y)G/@V MP<2/1X%@MTUG/V@">'CO]GI^6"$-A'2(#H4Y)(<)Q6)?,PGR-=EM!@U;FPTB M&H:&=S).E!*K"I5'D!4M%BY.,AE/$VSIZ\S.D.**.\"=;00J3J3="Y0HK;81 M+5'6?0XV-3FCO;BTT=I'E\@")T&6SOM@!<$X0Z,LBN MRALEV3`SF'(F^/^]LQV>"+-K#Z#]PD]%+"SJ`?T9\UL_#^>V%]85?>21C@BP MCO3+/;L4ZLY\\&]NFK-[3OF]3_,ENQ-,RZS*TK3:5I<9FO5%^+S/8.07(#M8 M!#R3W%,];*=O8!6ON!"NP,!*_K-'?=O`Y=Z]]>O.!(%]X&`@^.Z;*&WAHT.1 M5^.1YW>E^;%FUP=_,OCA<+],L<5_R3_.IYW-ZQ=_9C6EW-@O]Z$+T6!@VH7< MI9=VR"*Z>M/"-ZXI`0TL?4+VSF#ZV+4*5R^T\:`[\W=V:]_#ZI^0$.C>JVRM M3?P?9A^K=>/LT_OG8X6VGXX>:;'H7-=T/`MN2`W!COA*W1L]-*Z6[7)P;TVD M8[,W3S6'IZN;_1UQ[6WGIZT&*]$[!$K=ZU]-+U$V]"RMCO?_Y!1+$\W%6S`29-F>PF\W6 ML/8(72(3K;##BH\5M+H:%$BDY..M%TR*ILILZ!7W#9^A8/-BE@GHJ$?[R5*@ M85_Y]).F/526-.9M.28)$J9Y=\[>(FZ$-X\0-@/X=@#/$%Y_42XCMQQ)]6)C)1L[Z!F1 M5ZRA1W[YNS>`8`_PH47QI&`S:N5,+3?BBW#M^UE0T[\<"2Z3'!A8!CS3@&L; M"!GG3C](GU26'W-.D%Q;SPVE%@ZE5QB'5Q2/,"?F)[K!)S;!3%EU99$5PLZ. MQNMS1^:/&V6$C/GCYCYG/3FSOQ1J+]"[&4\]O.U/&6PF(#P5S^$GTV M,@Z94X;?]4#3,!!90S/UW%O:$ZT#,J)>L(L9C575WQ_IO=_V$9GJ9BMALR4= MP#O6!U78AW9@EMK*#PA+.BIE6&%PX4C/&`>E%M@L^7*;*;Z01:+GGOKJM!]` MPY6;,QLAHYAD@WZ'ZE?;!2FSU"RX5`..Y++B,:NKV[/LQ0LB<(MV#M;L.U/+ M[0*SGI;0'6:8(KSZ.V'GH?V^T:*#W9`TMFNJV2XGK\>LQ3-%EF>%G6DM[JGI M[ITR_\XZT=,6`"O*OV:C:;]22:Z.X+L"AYEH;I+B*[@ MUD=#LRB4F\#Q&UM*N;7(%4T1UF@)M9_I*Z<9C\K`<8H=PO7]AN-@#Z`OB4UW MLGU9OJSVQ[3'>Z1$/:*B0$B6)!@?[96:^YVDXC<'-A'\9L6@?OP2I&.';6G. MV/J0]:Q4!(<,$6T:XR&-0QS"O,%S8<"5)A'#E7U*`W%S/HG62*['-5XP$T+L4&U#VH.3M6BM'7T1%,IT`I'=3Q>,B:W_(-NK9V2V>U,^::QHI;IN?E M)5YL>5XKWQKARF1J<*XI@B5?*O#%RB[#5J_'*9UE.8_;G,\2:[#QN2R!:'4- M@4_!]1%7.T)0]K7SI61T!)<)PX0O.9X&I<@*('I0`3P=W0/K<6%(P:WNAP'Z M83C<0M)5Y&8V=%$0IT>Q]CSY"3D[8A:FR/YC,K-CSP;13&LP&L_4M+$M<>5( M'-=6\B2%'SPYDL>SE;Q)@3G)]J;UG#<&B]1T-^QW]7[61MK9VGH]UQ%VNUCZ MCWC/2G_U8TYQHC.LW!IP'?LDR;^WT",FE(H>]U8.MV3XKP/V?KO-^#CS53'S MFVZWF0V#-=AT#Z5DA!N+.%[MHH=5_"[1K!0C_Z4V<[Y<2X37V/LS?V]!2!X[ M(YRX25923E>?F^[!A-B]U^R*B8/?7=A)(-0L(PE;<8CJR=#X91P/J[EI[J#Q M#`UD/YC_?,':RY.UAX:SO[,?X9XEAZF=L_C;K>=SPJ8)W[VNJOV1E^:Y5YA0 M1+GB`9?/JD=Q#YLX"EI.05LR'FE0\X7I(T-12!\0R4OP\HC\&810W_# M.@(VCP5EG3<>"^+%`MNLHBL?3>],'1%`2R5%-==.DO8*KRK?#"8C:OR&^!J0:"7/MM9SCLR0A5)L+4(U46, M1X:I?J9TWJP/P)29U%.!.M,_@50N7;Q9=38K)NZC<"FU5?C4M#(("K$>SQ2+ M](;?/2XM':&ZN+2I"#7#I:7#U`"74G+X"'EG)ODH;V#:D90OG)V%-X[K^/JES21UGKH5#]TO2!V MR`^86VY_E3H=5R?\(K-VM7V/#\A*E_MT`?-WG#GS MWJ#&C\-@>6Z(KA5-!\'T7$V\=KD'6:*^,\MD;=[J2*S5O%AG!^B#4)P(EFLD MOL*O\@'I\!Z;B%?`;J8A'\1_'*(+;!9%VF`X5>MEM>_,!K?&_LAE!Z,+8*[6_B/8KA!5*5"W,7R$&E[A]"HKV<^U"=>X9#8>^PLS M5`3P9,@&W%'>J*6\:0TQ6ALY=YLMQ(3AT3U8G3FZ37^XU?:? M9H$H$\\F(_^@%-]1>A#DG>^7M77V>*_<+;,'?^@@[_;A_F'Q/U^!CFV'X.6. M#_X(7K^D[Q!N#R!Y+2Z*DLRP2(-*+C3:AX)P(YDJ0=FI!O>(L^IOA0V]G,WC M0UDYF&EYJVTWNZW*;IM%UWY&'VJ]K9:]V'$Z'/7#;5;^C9?5W7"3E>?GF\6S M_`:<>^-CTD=Y#;K@E'?DF=:;<\GCR1,EUIH;/8$MQL157`@1LN:^WAEBSCLK MG?!7>JL68NOXL[):>5G2&RO#45IK[PB''^,5I_*K2-.7>R]P7J/*Q$!'&/Z6 M)O?\)H=K;&N&9>](9O'HS.=;QT2*$>(Y[6P8P063Y=WW>I`F$QK'.A>J`YT] MU&@7&SF-+(F/+/_E8>0?R-#=;:[NA2GW"-JH8,6A^,7649-GC?A<^EB)P(<) M]3>.>UQM_?9<-IA<8"T-O(;%*RGM@D^D]2916!@Y M*7!\A=A@F\YO+<+VI!^6*J_1TCG\5#!L*2FE3:"6,TUXW#"=^"4[?`6\``U3 M$5ZQ9TK"/\NM4=5@+-Q;?B#YB1P>##N0)A6OU9IW!+P5@B8%R6^0Z`NJ)6\? M<^29-E$85BR\)-8?^&<@V.N`O2]W3V]E+U1A+UI#1EISB;3[A+,R6O4E-%AQ MJ><7A)Q[IH:F`CD-///Q%MMZE@W"V5%?]4K]>I(`%P5\65(A4(MS:B7GVD)& M49,+@R0W'%W!2^Y&RIP7)&.FW'["\60TS4>-U&V3-3F8BYP.;*XJ;GY%Z)&\ M._(2FC\7>(.NT=:R<4&![(R'6\5-F@6B36HTG@8]C?D3,$'`ER1YLJ$&Q]3` M,2&?VH-(7@N+PB,S!K64UKB$-K8?5H_T`_IE*!XM`VO[W.N"!=YJNU!&L4G" M90Q&P[YW@RD7RC8=;4-B6RZ16[=CRL&QAQ4(BP6N7-F7#=?ML!KYDF&QTFI* MB*,N*!TA&)5Z2&%G8Q/9]EQS+RMG"2W[)T'ZC>E@9_](O_@+M-$CP5I\8:N* MA-;)HI1YHM?OTI&-5UK;EP]""H"O`;@J@*\#<"4MDTIS`5"Z%(`"IFDN"J'E MPJWO)F4%&^N(2.:>2N`^\%#YF$G)X3/-S#]36/Q>FYE]D3'"X\;!9%8,3-G' M"NMU5\UR]U3,W];&`J(M-3(L$`I55X"7,U>;\;1DD)4IL#&:C'.@)76>M@;/ M,E'4A4G:_*96A)=J4[3B*?.51?M#<\V.>(0[_KD3;,69Z__>V0X_0BB8GI23 MV8&TNI3!PD5;)Y/A("?3/BC]__;^M3EN'%D71O\*/IRS=W>$/*N*=9_U2;;L M'NTE6UJRNCMF=YQX@ZI"25Q=(JM)EFS-KW]QX9T@F"1!`.4Y$3-M6R(3F4D\ M#Q*W3%1J%5W&Q8-IA9:-1]\C^JF9G"SQ4^<@?41G,;YCMK\RV]U,$*O&\X;= M$&&?)B"YPENV%H=FTPM$"<&FB+X7]\AB_.XNUTRKF1[#^E`NQE[RS'2$=NWU M?+[LQ90*;0S45V1W?*O,Q]%XAH0Z2C9(MN1+._ MQFX8FS-\437\/7[R?+_%=LNXO4:`/>B\[#]+IH\-NMZTY*SK(\GLM+--/?#R MQV(M6X9M9#CS^>;&=HID3:BW5PS.=J'(:)D)@URL.9R["V+R(\\]?'"CYSOW M3<$D62S2WC!/J"]X8%LZLWF?D"]K%=%F4=JNK?&?`B?U8$J=3E(U.U;@*7Y% M-'<*GR+SW"MH?XI/(49;ZI"CQ"&6A4U2HND10C6[>3P&C6A)B=(F7*X<"^?N MZ2<"=Q^@."N8$Z8K>`UHLW%D6_BT/5;[I;*37<`$7S)CK5K`F6.X1\:7QMW3 M@RW'\!%GRM_N1['Q%8>/@0U63IF9'Z/8>W%CFI,Y7S>EE7_RYNT:![K1I7P, MZ.!6:Z;3=9T+^2KIKSM-J0'23$^KVU4$IP)8S28]"+#0''O&4$(^'D*[WBFOZ=L"S3(A9/$LT`U>%6Z]DTY>L!2&R[<&S*D_P"^D%$YO0 M.^:,1<<7YX;N>"U-]\!K^T7H,>T$+L`'!AD,`.P6!FOSI"T,1OX6OUW[!!0X MBJ^CZ(1WMR']D^;>X*=,HLA[\O&N0R_J(-0PP\$UA?;_Q6(AFZ_P%E':).)M MHML0I:VF1\"2=NWAP)%\E2QQO[P0[T1QL/TS/04?"&.'I M)25+,HO;%MQB&T5V9XXVRNSH72LI-*KJ_>5$CRS>[EGAK^2W?7L<3+A-E`K2 M&)[_.KM,"Z#62,2MO'D::'(%DF?+R9D0&W>3VPBB:!`$EDM2^/;B6/X9AB! MCNN;SGN)8SBH(2"]R(O4V[2YUI$W9'MK79QI2?!5.WC7/L3FKY@-E#(]H%,% M9[:6H=?*LZ3]C)1<@6PQTF"H4NN*+0%(V366X.DN##X%X8M;*\'N1MX6_MGE M8LSB3JH;^&RSX\BF(J0-Q!H1%JU.V1W=WPGSY^/V(_JM6) M[OZ^!0N9C-+E8JLA]"C)NL[+T8J\.[&T8`UJP@=CZJP\3Y7(M8[Y2WE*4ZX!2)5"B M!2)JH$0/5%#$/#]J:U>3)Y+!FXIICXIK_Y;X<_Q.YB7,.3\TKDR3617\(@&DK<`H$6\W1=6V!`,ETMIE-9&BL)I?`2 MD]FU+-:LM20\U$.]2%>;AQIKN.MV4Z'B.R]WS4\>A6;6!-6Q2!^N;/"E46HL M\#3Y!>&?W1<'!K\[KF M(2^I&,QUI$J0>0K]@YY^>W4/=$4\U7Q8W^O2D+W#7@59?BB8NH2NP>-+5?+?K.0M"%;2;:7(_HPZ*B. M4$6,O;S!6$]FGF5,5P5Y#QHK^4DS1UW[KX0#@O!MV*?.Q=C+4IF.T!7$Y7KM MR-+K-L,S:\I6HNKIBSY4-:XO5'%53X@Z_*OM),6,J.0IS' MB8?..\G3R7HQ)7_VH:TS.+S0VQ]]J&OTZ[G?* M(-6#+5@5-$D/AF:D86WL-X8G^["K84^JBAS'<"?/KXOW.*0[@[N";^BAW#/@ MY6Z4UH.R.WC=DCM047K4^`N.K]E-M9OZJ;#N[YN]OR16"GKS?KY>2"J61ZA\ MRX_+1S>CG5GJ<>U(@?UM]QDMNT,D[\8M-X0D[K(-I?>$5?Q:H=$N;UJ"S$0= M<';`Z4HR62IB,A%L'Q;[6"R\`1-R048VW'KT42CXBOY1/-5)V[K'!UHL!#AY M:7S+W'2D225@'.?,UK/UIC+!<#.II& MC;%.Y:OFDYV#S$K-(7H;%`5!M]0])@?H#\'+H^?S/?]B'396>8//DMK2WX-$ M&!BR(7I!1[*9LZG>QBJ(KY0W+#1@.NV]*6=+H@:=V)NGJ<+OII6D6,D22E132,9[= MS.:;236_)X@T#$7SNCQRGN$#J.OWP[Z5,X$K+]H>@N@4@O.%M;QL%M,"C<#) MJ9;KE03&N62+_]JS?8Y4+A9*/?0&#H^+6=3V8A=ND3*FT:T;51J'/'64=Z\ M-5PPMNNJY?#>I2NQVWR<#QX/9.RWD4`&X*R%8/KZW1("$J0>3'8YLF*]^*M' M7%[X]+1,WN4V/KD=NN?`=LS2TC#EP=MISJQZIZ7(4.*4HXD>A;+:&#%5ZK5X MN3;6$)9&IS+N2CU%0G/OE?`6Y0P4/V-$F\=A5N_2,N92`]`6$E/P+2SALYQE MKW=D2/+V'DMO5;KD?ND+[KF7KD3>A?CH>KOD5!1Y_I9TE)#_#M[#->ABEA?' M-Q!:#&BRG%7/4A:Y,U<4%36MI1*A!RI%Z40J]ZX3C;/SEO0UIG3R@#4<:]D' M2LZ*<.>E&5%YHE3FO6WB9K?1BP:)6!^SM)"UIH]Z[H2>G@)^<+\7?OF%?'ON M!@TH:E7A3.F[S2[PEO-F4CTRIY*ULW/@1,_2`[FFY\_42K]%^?A\3-QF]&". M25H8BX1!W^O5O,@H)]LYQ6 M$Q"I)-Y<2\341+F>/TR$K/)+\,OP14][N<-^K&`8R`QCL2_DJYT[^=Z%M.Q$ M_'9'>EY,GJ!)G=@E+PVH:&[[3`FWT2#PQ'<^EZWJ#J7:5#_$%&2/92J>/\FJ M\7YZ184[*LT)U^BB47CDKG$2]"P[>]JWI+!CT M+5-7SII5@J8.<%;K237);>'HLJ$;9JKL*G-!02KB8@T>;1O%WF0-*S.WR]I15[M=UN(7):3PP?7=G>?ZE_L]&=[IL9Z/)`B(WS[CET<N79F6W2.HEI2^^2IB[0,6T, M/;'6WM'FT.>/-W?_N+RY_))>I1H5D!+*T>"8:=$Q24LH:PKE;:&L,72OP2MM M-*7!-4Z7/O.2>0?09S0QW"`J*5!??U\KXD1!8OS+ER",Z4+)AR"JKB=`W]+/ M=&TJ04/L!?512FI)@85MN?@$:]G!)K:G3S%1!G0V4"48?&M++C9`!^#R(NCBT;3-)$)%(,%W@#Y9#R*8!4"?_5#[!YHB[^X'AR5 MHG>MH`N!8L#ENO7:6G3#QZ(O)MH(ZA9LOY@TE'N7A$Y:NU>L.M M]O$3RTRCU_BY@$Z$-IM;F>F*8#G--'E,&]D(4F-V>]=&LH&GAIQ.5IN-TQ:A MU-B&IHVTD&VZV]V1;O2G!!W1=E'L(K388/WWKA#NQ#8]4X)V89O/;O@GCNE\ M["O>GL+&:A+PEZW@&Y%FX,[G+";3G'`N.-L4JLXQ"GK)6D!1UL0%S51[..WH M9>-#0/Y#8/."'FD7WN*0[L*3SX4CNH.1=VDJS?-?<12SC#(7B!5#L(&]AGM1 M3E^Y?)0W8`M]#3?>R;N0[MYC%Q_*2$9.B(T?02\C]ELC:I=D+5?V6''8K*>; M^4P4J.6=7]SO+5Q@4NN3'BQHZ4J46K\XLKY"J.RSF"7M6[\"[LIOU,EW/!7Z`*&LYK\]2 M\'0R7\R7JU[$9^%^@&JW]*'`4?<+U`9[0US3,]P[A_T%.)]TYT2MNP_M"CS0 M7TK/EJL1?":D6=8:?*[164Z$FQJM<^6SI-`A3E)`J(BU;_I"769HH5,]-0PA7XWQ3]=MH+!H@Z`XKM4$1P,756PK!4 MS*E?A9QJR\:Q8J\,)%'UV\I#3K&H]LU<45QJXU8TG%"&\*31VI5"?:/+^(,; MAF^>_R1:O>SVKL8;PR"%H-=JU\ZZ94TN0I_2&W7!$D[_&;ACK-7HA,?H1/WF^3[_UF*:WWAE7;[1\;6$4 M*U]Q^!CHMG/J-'U=DS?C.U%P\8H\W$'VC"S9&G5>BJ+3YQ>];WR$$2@%[I?3 MU:1ME,DW>0HU6/3N]XQK_U)P5M&679S>W;D=J4UN&V^&''UV8QI_OMVQ\14\ M::B^9\7-9B+A4,N*B+9C2#C&VA5YT&-MC<6^(Q8WC/'KA M0ND4_=AHKKD99P-`Y=-+D:?L&?&Y4M?^ELQW(WR%^9^=QI<&$<;'?;%>X*%O M.6D=^GD+*&T"I6W8-/HK\`(+`+[@F)[AY8;^M$OD_$Q^QJ'@]( M'&D1G*7IL;J]:Q[`?5(KT7*!JTTKKN'V5Q^9WK M[3X%X5?25/39(_^)`Q]?;I\]_%JK:`A\R41$+M4(>I9Y-B7\GX?C5"8M[(68 M5)2)1:E<_;&X.C.GALULC\+5V9J3!*MOLR>V1LS6E\Q65V*KMA`>`<9=:_VK"*!NJEU1&ZW4U&0%>X67B[ MO^*+E\)<<)`W=`*M60UH*+AR%FE"C^+]2@*M1)RAS&2J3$A2/Y`"GX`#/+UQJHV<+"D7$R5\CCPQ[ MO#Y&6F4\#DCPG&EA+G[N#OH\DN[HV+%8*JU`=D6B]T/`BC70RZ+1I9\5)[MS MW_B/4YW>@#VEGVP+^*V7XM#3U;/)9K*0LU]6=*^@`+NY'+'%MNS7B1(%EA!6 MYM/*CQI\)V5/VWS7F5\U.%#*OI>'0T!+'B1^VA7V:^/B1NW: MXN-!]"8CZ_Y?22&3W^[3N@"BL8.VG`^>E['\-OX@@68XNZ>VT(N'T]5\4@Y3 M;_/B$>(HC=%)(6"YC,>^HMY"S5I<-+7;11`&UN*G'RCH'<@\%68=XGTCZUX' M-XIN]U_C8/OG5?!2O_$O>5#G*E>M]0XUM=+%+2J#HII)07]P.:;6M(89Y.0& M!1"#M"UH-7:GTCJ6V'@UX027_;L;AB[-)$G^0^NA\A,9OV.:4!_O+E\)!)_P MQ^\XW'H1O@N]VJ[*0&':PXB^FD+#[>5\E+">M"+(AWAYL9!N*[(G!91VQ%4GC M1N5)(\F81V_3MT/L"?3G1LQELBO[LAO1,S2F.8M>GN#HA9UH@#]O"0DP98"S^^5\N9ZU,P`3:07^NQO7"OX1C!L&_1XV-N*^T3B3 MJ"_!JPWSN3?&0SSW7/;3*-FTN#J%9,8J23735Y853`%0%#KZK#?3+*%U(]*2 M[IG_*LIV"7F;9I+5:'%-"PD9=4V/:9)R_SAB_K)K4[0[6I%:[9U"LMX M7?8;BJ^9WN`IZ`+=`-G,IZLV`+E355J\ M:+?X?9I`U;J-+@$T6W>[JHXRPC/!@9@:T).AK_B2:O>$62G32W_WA?BBX=M/[N$N M#)Y">M3=W[$<*E?X2#,[^.+$"1U?UCXUA&H&S5_I+!;I+G\F&J6R&7?PE$&9 M^''3+#1/_$8Q?&J-X2W3NE&L=RK6'U/K*=.Q[$GO=B#K]E5DN9S,.YHAW?UB-9GE6XN^M,83GPV97:#^[1B]T#7[>]QQ$.7S'-<_KI%!-5KZ/H M),LBVEF.9D1W4@[:DQ?K+`\X:R*Y4ITTDI[>3IMA^7YY0RAMR1RNQW,(@_8# MK26`(NX!EMV!.2AB#@I3C]"LP'ON$2]IRCCN>\&A"OWNWE6VR)8T_>ET.+S] MAB-Z>92V\WC`MS2EQ"OI'%[@WX;I<;#;/=O-2+=/?Z5)5N]"CRCI^40[0EO% M-<2FQ9"16S6QK#>N2=##S\YR/=_D"X(9R3"U$-<+I8JA6Y9H)E&-[J]FYZ-O M]WRO-3\:P11$3$.4J5A:8=>_HFB3S^O$?K8^;U_,M,GQO/"Z>.CP4J^?CN1G MV]SOQ*'9-1+R4LC]_F3Z!(PV0BXMKFKXFH:C57F2[=IS9J+-3EL`L\ER/A.0 MCN$LVH.L<3I98R#*DV3-%AJN.DJ[/;+]5OG.I_!9@Q%121%P!KCI9.D(XIA$ MF,%=S.%6U4&KQ2KPJ#[`M"*"^0@<`$S3/;8*820:$>N>,#R.W;GA;?@UIO<< M6$J_.QRRR*>=CAO?-#/6-:D#'2^FJ^+N1P8D(I:&U%QPDN28B.9K*\:'1"5& MUR!V@8ZN#;5:X+VT8>"4NLA]Z_:=37(&V:`5E4#'I#E9Q,+ M`$OF6;D\XZ`:9*``3,DBI#NNA61.]1CHL7%:N>Z13I`A=AH@CR:D-9"&T#56 MD`6=0\.)(GG:)$EP%<"+]ZNE:/Z9$`279?!VA@+CV*6,C\E=!/=`U]XO$ON, M7L-08!J[?9'=K]!B77=.[V%7,Y][C1W2&,>5"4+*;P576,%M@+MILE=,LER/ M"TNS19;60D!U8]]&ZPZC]R?/G-$S- M(6\87*P3J`.]6TS^MEH)ENRXR"0YU;B3<, MYV(C\0GG`QO6\"1($ZWD-;E#-0$\A"XE%];0IR"\"Y/B1OQ\1[:7UO+QH%(, M$@501>CR\6J>%P\J0BMI)L$6/1*5M90>G\K:,D8IH_BB3C/&?0$FGU$<4M]; MB!.'6$A/'7E`1%E=G&AX4B`JD];XF)G@OT/]J:KA87D\F$_K^^T/F?:#F_F$[(_U4#WB+;TA M?3!2SK$-D@USHKY5P=K#H"3U!>B@0OE9@R%-21%H>>;)>C87Q"UISAKCYQ3Z M&U7G/RU&@8.,_I;5SQEEB>W=>S=B-N>- M&!XWNW3=RG`*]I,I5`8^/8>;%V%^<+]?1A&.H_8+U8!W-2.R52'XQ<))?L>^^@=O-C# M/8$H$F`>C0*MP&5GI\ZT%9(%^;;B!D^^J0.#_2!=G#1W<)ZI6"'$ MST0C[Q5?^]O@!7_!\>V>T"3YU^'$M@2"D-+"91R'WN,I9HH'+%>C'Q,'$IV> M4N,DXY;*5C1''0I5AX[+L_DZ/^Z8*X"X!HBH0"F#QB>9%BA1`Q7U(+!"94TR MB)D+84SYD['.;?R,0WHJN>[5GPY!%/U\@7P\DG,HQ=GJG&6>&*/L'.X5Y#%U M3`>#(W!5-6)4_0$LH76^0@1?'06];I:(A3J!#_!."IL.=2Y(5D:M6B!5;K[3 M:/Y/-Q3TEJ%=VH5;8-SL+&73OA/]B#17;+"/O[DAEFY'-CUM8F(G5@5Z7&:S MG,WSI-!<&,^(G(@SMRNIQ+*I*E/W:G;+6\IQ=6*4B44DF'<2H M5-/CET)[':F]CZWV:L0;K*M60`=PE:*U&&%3LN48V0OZ5V0DVH!SEG"",KLTHLY&1PHWW5*I`T,543>LT`,@5EFK:W&/1"$SYJ6VY MIN4]\R-PK@QT1%I.\CI;#;V.#T>F5VP4FBL?@%O--3S^UCLJ8/RM>$KQ^'O[ M>"#,Q9):)H?5'X++[5\G+_+:1[^VE\V-RRV:0:LJ3IPT@04_DW`(_*=WI,N_ MH"!OX&^F1F>51E9YI"`[NY#R$*"">*.#MDK3'='W+1ROM6#(!J)4,'Q#'*68 M4M@E4I8/_I/KA>Q?>5OVJ.3J1Z`3O;PB&3R%J\SS/2,M&(RDY^D$LW M12[J3*Y2BQF3HQ\@EG((^_'9O`8N`@"G@D':7C,8@K-A9T)= MT`]7?LD&UBAI!)Q=.LYRM902!J_V1\4B*M<\4PPP4T(2.LSLS@X#;*U.8EB* MBK3BS"ZU-6RPU1AI"+$HI8NZC\8C"GIH?TO"FTY$47K)"J(H:M2E5]57$DL( M2L7:0A3]S902Q?AF]B"*_K9*B0*GMMI'%"(LRHFBYJ/QB`*RR5!_W`IRZ)39 M9+&:MK&"Z>V%8:9)F<"*K85A]I7G#S;M(#2B20YR]76P?'8U^.0>/@2TGE_E M`E_3QY&^8P+H,H6@>U&+V:*XG9B(1%QF[=*F?L2KLW%JTL9VZ*LSU*D:NN6& M>JFAN-E0;8P``6")%EK]8VAG,2UJN6?YB"Y?Z+R%_YC$)9+3T+B7#*.FREXR MP'56,"VOP]"=:6OOF63:JC+P0PV%#9(:TR;U1.QCVD'F5@F(KE^D=46LH9IA M'W0`U"\$L0X^K-,=F39@*7JAK@ M?6+EK]@!XXXYJ4AG6<_G+7@VF@A6H9%2E)O/^:K0TAKVV_C,(/9E MF5S;76)FXA+%M_M?@F`7?0T.N\L7FISP7R*@0M[0.A%I5`,:8RXWO*Z"V4BZM4^6 M(V:YGQ0-LK21KS1?Q[:CR=_+LH.0KWF!PN#-/=";3O3)5V)0$+ZAH[O]TWUB M,DE?9E:1?UP@FK3M.3A%Z6^B9X^82OZQ9>6*2-\.MAZ[+O;-BY_+>4BTWY13 M[_X2F3'1*)-=8C2CIU#4V^T4NUWIHZ*?>/>C%16+]M/GB%W/K*Y3C?V,)"[M MPS.%^`+N55-Q!LVLF.C1G(VF\ICFB*+8-GC_?KK>Y,CC"3Y3&>8BA]Z69/D\ M7?\-[3"];^KY!"0[_(H/P9%%#$?WC?YI*LGY`.M*6F@]LP'5K9:B&QPWBO&L]LM5TM6S"NP45GA08Q^^<9Z#(@9+" MPW!-)WF7D^'$?&VU4Q@2YOR$:0*-PX/[/='L/?;QWFN$3Q*AAJ"DT%*&J$224>S`NE\)0@`W]$=2A+=_>PI>_V.' M/0XB\I_HG=\*._NZI?II0^J@$ELO:A%.SDF9-2:#!1B,I" M1!BZTGY_4)E=3A^[QD8'I(-12+1ZP>2($H38>_*[CBA-;QD841I4`?.LLUA6 M8,,EVC>BJ+"4CRA81,F7 M_NZ&M-1UX:/E7?T0ERL$79%>KQ:5F1Z3RU84F63K0E>%=C.`,GD6H!/6.05` M!#A$R?D#,L5T23-77L2KAA)D?\)8DBY&_H+NLP92;:!Y!Z:+Q6S#CQA0>0PF M18F(BD1&LL8HM&_:8I_!W#$*K70R*]VJE;_BAU M*MJ7THZEGQI4U&T9)@L@;P;#V^\EJ[6/7DFL?;4695>>YVN.S""_D2RXUG-X)QER3.5-K97%^V$RYY) M9,=`WA6.MJ%WE%SV:7[>&,(*2H`7A)WE4HRJ@C`;<-37-OE0N,WMW8:-FZ:GA8,W[J&H!+BZ[2ZZ8,/+D@XSM)"NQRNMNE$R/- MG:P*D`8_J%E3*LF_\7Q\'>,7\8)2PZ/:5Y/$>D!7)":3#6'5F;!S4&&(2=.] MQJS")C&0Q[:I95E9A6%B)+<8IF==2`Z??%%(XH81(>OP:'5[JGP0:M8(\^A'@G/N]A)@85 M9C>!^,$41O)%E\OO7M.58\&#FI%1;AVV*89SA57!/Z@8@W`88(_3S1Z= M.!!WIBH$!+:;[_T?W#!\XPD!3KYLG:+Q%6.(*.L!75">S=93,392>4F="!M` M,L#$)#^FYV^]HWN@&2X:;#(#%'&_:X:,P!/*)CY-K7S!\>T^K039%/'"7C8Q M20)I!IY);Z:S66'NU(P;1.33'#-I"_KG5",8#B$,+88W7H$9T_HEMW[+#J2A MV?0"42`AG]B[37W`"8;&IN1W:U3<<3";CJ\SPDOS.K@WQZ"CXF;ACM6]?PA= MFK_GRGUK7&0%OV^8E*3*08^,+A?SS;J!ETH[Y+P%E#1!3\;H/NPWFO5B""M1,_!84=^%N'M M*?9><3.!#19G;B8"UA&\]K.>K62XYOT[:PP56C,($4-^6W"$:?BKPH=D M5M3-M7:2PQTF_8^$#4\XJ;_$ZK8\A-[34^W^DBJI5E&%5%7HI'\RFS:M:P@9 M(V\T+]O&RQ@E#=M*'>J\Q>M49QXYYAXALYC"R2A6`4M;+%:<_OB?]`']VOWLOIQ=0G^LJTQB5=%04?.)VE=THJA!) M=@*7BD99DT4J8;]AK:*D61MH9$Q/\?.5;#L.[=VM=_#BMPOTPB7E%:]M.+0\ M&#?-!-+'PV=$'YZOGCX2F?;3!U<4G"5T-5THH0_>[%G11P]/-=`'EW3V]%'& MC0+Z*'C8/'W<-!QW;7O:&.1ONIV?W#CSC=,PJ3!W+E2E:>(S!2VFF<%Q)8S#I\:`(U`& MRL4;9ST7PZ@@=*1#*.UY7T8RER6`^>D&1]'/?R_9N:,^V"4RT4_Y+^+G,#@] M/:/LV`H]EF*D>%/G;MR,PR8_*CM[DNP8L:7>[/"@\&PHZ!43)TPD^D"KBRYF MB\FT<*@DW5'E^R/YH;L,3IF7UTM-L.Q$]F)W/].SXY?E-'U?: MA_,!T+8-S1V[["S?[VT!L+V0[6%R8%>%@[$W_CK, M*[+6!LPJI#)LF%/(%(3&C>O-?#&5S2@.&>YLG4^H2ZAS17DFD4_%+5;U905:G+K0)$K:9-FP6:N(-VM7ZD)]_G+J_KHH.NPB M]=@%"W#ZN4Q_U#,(:>*`J/^W4!HK7>%7?`B._,Q^U'GQ%?*ZJ0@)H!OX3NC: MV2PJP5%!?$(,^@*"UK!(N>U3:VR'!4/*'5!FMEW!`5LJWWC@TP'(M9@'ZJQ1 MF4=27DS^ABW\TJTTU=Q9K-:ME#)J`:[.+-+'PC;B,%EB3*&9+?1@004Q$.Q: MJ:%W#3&UDY]/>(=#]]"M?#;P90-3&;E&X)--DT5UH$X$:Z^K#9V3*#2<%ZGG M\FR8-<"ZJ&AR`'"*4>QY/MTB9G3P!;>"K?*T"72558`?%%S,JW#BDI*AB\@R MC)X!AI4'K#V31,\!&(MF@=U,"!B!'XPB)`BQ]^3W')WD+YO`CU0C8*^;3V:3 M215.7+"]HY,ZP_GHQ.59@2Y0%Q6"K=TI)K&7Z86C=#6-_"-=R?=P!#XWTT62 M`51V4`\Z,"PGBTT%HCDT<518Y:90+31ES0&:L9S"X,M-CXGIAUR@#6#NT>=% MR.[J/"M@WFELM6A0'3CE66VFS5#5,XHV)8X=P])ET=(+Q-JV"GGP\=/Z@;.L MUX?`CSW_1*8&MT?,:[Q&P+WD/A+M0:),37A&CDEU!;09I2AO$>5-6K-]/+:; M2A/2OUL,;@@B.@"_U8%*=UWNW+/[.IV`7=OF@;ML9#9J MWP5N?,<>SNFT@3B=K=:UG6`1S,SN!:NQLIU,+-@/5F-J*V78LR?\&M>R^JEMWL&+";/FM6YP2:6,45?1S_Y@?\N MD86.-)=%X!O.RM'>%473@T;GF,73*_9/&'8;K?*P$0P5-0!WK?FRNC.5"++C MBMD`JZJ`88+L0(>H8XEQ4;/>)"*^DH`07_J[&])4S_-'(!$&T`/1"WS&8+6N M1GM,/-M#8@U8N^NKW`T\H5ML/.-N]PXLPB/8/2912C1*[E"4%M]:OGS36P:P MV*`*_(C/=%:!'\59>M.FO!AM%FXJ++5VF&OIAR)\R?QA!:1^"8.H.4.U\&&3 M`&(:P#<;E\MFW#!19C=3!YC%]E`?:$-YZ@]ZF,'EQCWB?1!B=J^;7^IU#X?@ M&SU79Q602KU/BI_<0U;`YMJ_"X,MCJ)['&'B@6YL8DU!KT0W< M6^<;"0BO?92T@M)F6%!9:,B2`4VE.Y(1SH);9T,[N!2S$)=9@>;BJ:C6,_!- M;YG$:ED5:%\D_ZT>.RI`LW0B<*S#\9U'R@&6LB&35N$N#9@_9>DN?N:#IU4P M%/=,*>H$'K(09.`5_?;W[0%>]X7P]6PBF=I5(&C-TK]:\\OSO3R(M1B(L$T` MF)NL`&>'8<_T6->%]M>U]$\%=-DSJ'4U23[YLPHWT%'+JJ&**`/;)!.]81@; MW3:6YI-Y+<-J&2)V[)H-M?`LQIAZMVN#C"W[:)E.R:E7_^DFB*(/;AB^[8/P MFQONP&N,$@DFD=6L%GCFOYI6-Z8+2,OD(]H`*K5@"?04NP!XV"D>J`7@$6,ZJJ32*R*.B;(%89[/R MNXP7R+=L\:+4I^0(R>RV`@SD+_SP5@FLZ2HF]&.V2#$)'[EJ\$PMLGUI^M?D MR&*IE6RAWQ+,*?0%`V.VCT%S8A9S1]&H<\M:&F=$?\7A8V#.^&G9>HFEQ@@) MAFLI4P$<9@N%I3]+3O,4GZ$KYRNG6:*H-8NH@ID_Y*:J1/>2JU;?)Z;Q@^R=Z9(ZQ MK1S*&`!M(RPE7\!25J/,&[ZR'!>L*(Y[(&0?>C?@%T,!M0: MO.J\D.T4"WDKU8!Q5JH#2I3@/\S4L):LQG!C$B9Q/]`8T97ZP2*"ZHBUCK34 MQ==6D-%OZ>&Z3#EH1Q.\:9(^ZNI`._1\LI'$,YG<'.KF"DXKMIF5G/[-\N.5 MS3U4BLT&WQ@&76$3O?TC%Q\V`ZV"!N!+7HNY:(?@1IZ?3.M`V=>J^OZ;T2I# ML.[5`)*J#Y0F42C+)^&X%UUY>_([3(RY]FE9Y\I7ZORZJ=0*`-W`U:S6Q'V5 M+`L5J"#6`,I;H&>-:1MF,BXH-U[*$YJ,;Q]_1_8!&X6YK;O<5L]'NP9;M69B MZ(#E6E(&J*_L&92KJPQY/23Q\6^6X+G3B-.O!>/#?R^UP0E-%RO1S+S(!?4E MQ4+-LZ9;%SPKNDWQQOAN%%[+L#E0&02Y]NBFO\='#(FN\#'$6R]=O;Q\H5E" M_M4Q^)`)L2,\DF@([-/KQ6JR:8F1BJWP-;E".S8$2JK MD;$\Q+$78A8)0?VC,1[JCY9*Y-/3W;:01/#B>M7`HOUYPV!G2H`S2F\6*QF@ M_^#B+`)L=_,:00G#I-0')D%9ZIUMP,O=9@9I=.NRM:9[,_G[`;>O&75ZU5#O;](' MGL9P,ZVC`F5B]2P$=0*,$I/K0*HN>MB"J+;.VH0TJ9L4K(;O?OW0,] M&/+U&>,XGS`]X._Q>R+O3_&:%O!=_2NP,,6@*>,=9[&9I"NO3#2ZW:-$.&+2 M"XL0Z`_:`&(M:"\',(;A4VL,;ZL0,(;U#M^2+II\N=T&)S)AXPT:7$WMAMW" M(FH'1RFB&;:IA'/OL!X?@Z>VS&_[E/0:?@O`AQ&Y,`7V[O]R>8GSS]G)\ M#AX/;A1[VQM\^A._>*ZL](@BV?II2HWBP/[L.,N5,TUI+&D:Y6VCSY?W_WW] M_I86_D59\Q3P3`%4T@"E*A@K?&+"=]-FW_'&;?)=&UF:<*!3=F"<._!=UOWV MQ(67-SY7\G&[ZIR>38L\]9&5DXMO'@_?$V"PK/R7I6=UE M&>+?SHH")RD+\M^DQ0_X](]8G8J95=H/:]#%*,@:_]O1AAV M7.],JR=T:%.HV%9>?HK0:=9:H:J=.>XLLJ,RKSUE.Q5F!S%D7W%OO.KE+VZ*9$H"5EM.&?P:KF>9] M4>VFY3I54FWD&K&JT+WZV30K*=&);)(T#3E\C"U]F7!8GI7A73U=Q5GPAQPV MO0A$XE[I.EV#2UQ%]W]@=Y/Y&S,M6 M'%UO9Q8V@KY2!D'55*-=FJ#,?3RD500OU2&;_"A3Y1.)H-W# M'0Z]8/>)_*QZRT7^K(9!6:H`=&)$'+"IH(G+0EP88M+TXD>=84X?P\9&":B3 M462T^T$W&OZ)W1"&A?Q)(TC(FH=VE^EF-1?C@(JR`P7]C!)B0&Z4?@34.I:X M_Y<]H*_W<]Q]]'=79'8M^4[EYS3W_%+C\"ZRKO)_PH\?:2:&AOKB>GI]?X.< MK@;I[/'"SE3M[W7;]?7V!R)6\EG8KS7W;=IFAQY0I7+ZNKE^W%EY!Z2\SCY; M[!+5KIJ9IV:6'YZ>"COL2=*/Z)JO)^R$4ZV65[3/[>7Z0,^>+6;S59HY@T@L MI<5)9:)4J.;YO$H+IR8LA";`4&HH6S__Z09'T<]_SPWT)`;JF;'#()=/U@%. M&8,+TM09;\DZH^1P->A%P[P@UJI#E]HL&]@ADYPMI'/91DE"A;EBJJB;:_*$ MLGJK'056FR`2.5Z;Z$3BL5%)Y2;PGQYP^-*=52IOVD(K9;6Z=+E5*Z]0V8@* M-W618@2;V\A%D\W]Z&6(X6W\`C/<*,.(P=M*,0*OF3@A\-$-?<]_BLBDGYW) M:3EZV_BXQI,`33I`Y[F;]339_4\ET66:Y)2:Z4.P2HS+"HS^1.N*_DS#_.`% MHR.Q,J)"_VYRQ[^MQQ5W^:7>L`$N-"WQ%O@I^;,&@<(4@':DQ3*]OB=`"9,T M"D!8+ACOM1-&NMLURQ!RS:&1F78QHFV=P=_=,"=-!SZ.!8`"BPHZ71M]H7>T MM)G81%,L5B("&87E_K"!OZZ\PRFN+6VV/6V0PQ(5H!UJ/DNC:P&+);*LX;$^ MMLF8;$S[.G-9'^.2XXKC6=&#SWIU0`"C[9K--,5I%7*0L5K1*S;PVEUP\+9O M;;=[VMXRR',55:"G?*=K"=]QF1;YR7+>/"VR#UG][,N'*PZ=:FAA$X(Z86>$1$T? M]WN\I9'>A\`GX43D!?Y=Z&UQVJ1H);7U'=WK^&T*08M23>:;9;*"GXE$N4S$ MA,K[T7@+]VJ-G!HU4KY2K]92Q@:?`Q^_T60:J95'9F46P1I;EH?B+UN0!SE' M+35<^^1[X2B^KQ_AE#QHC`2*6H#+TB.Q+]/F=O_Q^_:9^!U396Y]>M7WTM_1/S[^ M=?)>W0.]V,X3\YQ(&')+V)*AKZEJS6"Q.B/I@;J"L]HO9_,B%&FNB;1-!D5T MZ[-+[>Q>&OM+H664-XWRM@W%YCH]5H`ZS6Z#4X]1J$>(C-];ZBDZ8\9YJT;C M>D60*H7_*CQNA%]>CH?@#>.O.'SU:+K9-%M&,9_&%QJ_1#'>77YSPUWT$,0T M"UC^>YIHXTL0_Q/']W@;//FT;&%ZBRM,?D2?FS;U5[U*Z.0NK9:!M^X7V;0B MT0\E"I8RZ)02[61*(JXE8FJ6GV$9`HFFB*B*@2(49'BE1L/[/^D,1=BZ)O\3J M8#V0T>SV*(TDC>GS(]!XFY'02&R]V&AE]*+0Y&U>-XWJCA+E?S!Z5_JM&-/_ MZH>Y2_]M&!U*-%K('?11U:S1I2;0W'QWI-L_DU9I+;[FL_AMKVA?MY/K`UTB MVFP6TWFR@I>Q%16)4IE)G44CI^Z5&CDU:V3+.I]*2_DRP->[.[Y*'Y%8-2)@ M)<1F_#P]$'GY"B#`+^-?5.__A=\JG['Y.4U7UX6-PZ^! M9T$+3_*4R$%,$"*2]%]G'VZ0T]4@'5?O>;+NVWAZ\O`0^PQT;F*/; M4QS%KK_S_*?FCR5[22\.))K`4SJE]6+3/L2$)F,'%XL*G>1H1(^UV%:PT.T072CYY!QQ^<&/\%(3-H5;Y*:V8*#4-[RN+ M10D*3`I*Q9@"0'];G$ZVZ.OMPNY3[N1UHW7U[;O3X\';?CH$;O7&K?@9K?VZ MT'"'6'M6ZM5S0UY\%7:;H`U3C=K]/5N<23' M;LB'C.90O?J:1P^[W/*W3R3P\=S8T'Y$'NWZ18^`9H?7P4OKE?=F)8_J[VG5Q2` MD)3_LU9AO%9H>=QD:@@D]_BH.?;!+\S54-* MBU^FUOJEY;R*#NH((V/>*0R.6#[2%1_1.;X5 MV@7GKYLOT@51]K;IH:RO"0[0!&VCEJ";E,:JJJ%J1JCO.-QZ$68)3Z)[>B?Z MD_``#)EP-FPG.E\ M(R,`(M$>_/-C;#O\U$4^BO`4T&_K)7QL+^`WFA&_J+;UB` M_X(ZT.ZS6L_24F-BB#"9]G!`;Q,E+*#!Q,X\T-O.9B9H-],4%PB`)V.#JF]& MXX-O03IDH@7^+A<;` M7T69%/HEIR@"?HS]'=Y=N3&99(1?\+=[?#RX6TP1=T]SG5T^$;ZA_Q)_.?CK M^FD!K!MPD)D2[TW6*4UPZ8B*9]GS2`.HT`)B3:"L#=VL,9+Q4WN,;R.5D3R0 ME$7XAL*"O2$5&"$W%8EPZJ*=T:S*W>%=(*!N#C2QS?;)]<+?W,,)7T819D=@ MTLJJ;&/?C4XAWMWZ]W2S/_3\)_+`EX`F]N+_I`5CHAO/Q]V#8T; M?4H5AVZSK:?+9-^!-H]8^X@KP,YG%51`J0XT=W.F!7NJJ`Z30X-B@YU^SE4UQ[H*!@N;J*J_VX64)U`;Z;HKW[P2'-[ MN8\'?.T?3RR=GK\EUK)`Z?T;>_W#P8TBZ9']T9HS1X#*;`!?,!6 MSH[>.D7-@ET%/R]IPUT77WY%@DU^S+\^*W$FC5D`!KVOIY<7FJ6/C)L4^\>.P1+8IQL0VNX[PX#- M_OH/#X?$/\]O+)B!C76RE\V`5:(1N"BD:!WT?;%CHDQX$OE9,BBJ,KXVF<_M MM6JL!/3=!EBV>P*&H\!W#B.H>!JC:EP*GC)HOZHGQ!..)RTS\LFBTI]8#U,R=H M)Q:B$N0J6S`:U1H[?D%H5R3U1Q"[/8 M)'I;NW<;@N6.LP7%OWOQ<^V(2U0^XW)?N8:6;'\^A*X?[4F?^H);%_U':-$P M0R@R`XJBY6RZDH[_5!_!:;BH>ARN>H`NW\W.U$)$+WL(R(2C&5WE_O!\]!_H MI^`4_UPX06<;82E&`Z?P_J MBR3)HJQYBMC31*];)ET%%'QR&/R41R@!S=\HERZ#T+T MDC:F-U_4."ZH#ARW>\2E(R:>%YC=L012GT>U6YXJ:ASC'?7?7TO.J*X0SQ)& M=7+CB&ST]=DE?60()S5*L(.9FM0#CK'SU6J^'DI/%RAB6MA`4TK\T<95O!&[ M*4N)(QAO?:AWA5&_^"L.'P,S]DYA1'V1]`#+>+F-[%K86>I!-1R-=SAT#__G M%'K1SMM2IFO.*]S\L';F;=($FBQROIPX*N1YGB+[K;SWW<.U'<0&DA@^Z.M(XU"IFRE5,'6+8M_`%5&)[V,\LMV$(BQ23O9\DDH[B. MWPC()=O+*5UA!":63GXUQ"Y>C&^\5[R[)M-Q_\E[/*2)^+=DCGXZN#'>7;X$ M8>S]2S1;'R!(+V]TU`YZ(&*QS)+SL380:P3EK635-?)V4+$AM6RPX;[P\1-M MJ(4/1G7)G&?7@QNMD0EZ=OD*[/NXSQS&#V)5Z4H"WDVEG:3E5>TXENL#[::K MR6911.ZA$;A<,)H:&[C5VLQW$-VC%[N'I&\B-XH",F!1G'ZC1P:SC63R&^3E M/G%9N^;A"^O-=<`"W&C;,%R@D(_?C]B/\.6>=)I_8C?\1%[H0>]M$BT9F%O4 M!)]:WZS7L!&ZT"!*6D2L243;1+11DQ0POI<8,Y`NNF')_.)G'&*7"C./]T'0 M@([;$%?:SPY?\/?XX1L^O.+/@1\_2U;AAPBUEB.JFH*'QI4S@"9HJX@WBWB[ MY\`4@WR5DL7\?-BA"1K]"4+H0?LY0FGP8'_>,9W,LQMTO:%.FCL;J'=U30KUU9E! MO=#C!T(]]=AY0/V!-*]N6.?2K`8[4Q'Z M_3#`YSX[$\1_"]3U%R++;K1_"\"1ZFJ]'(KU;\'9(+VC8U*<+\X,YWEG'XCR MQ%^68?S]VV?W?X*PM5!5!PEVX+FJ%K2S3M=+V++<^S?$6K"AP-5(;G!R-[QK MTP1[_E/Q7C^CF7,DA]>ZR[- M#B3*5(3?YIK"()HU5IX,\^;,'GP;USG\RDO=9MU9-+1V"&:T_)/_]$;FR-'/ MEK(:A`R`=-?J5&YO;A_^^05E,E$NU%3B+:56K+M`&&8I]J!>$@I0WA1''J/)U88@*7R:2>(IE=,\4.# M/AUZTVI3H8>"R"17E6%V4&)CF1QTVPCC!B6&EJFA:&C8;JA69FB!7XT89.Y1 MR0NM+&`6\YVJ1"Z6LU5E_#<*YA[*EY!K'J4]+'"@[M<)/SG83)?@Y.L8'^A, M/13'[=)'=4Y[!>U#%X:7SFJ>]N]DX8:+,5V==JA-I<4H*\K22CI4::K:9+E) M%"2+>6P]RV4Y;']Q/?\FB*)?_1#3=`)XU_(E02(,H`:B%S@#RFPQJ:"IM`S* MY2/:`*(MH+P)8^E@1G,#2P3S)?#?;=WHF69D90[9I@[!W[?/1`I&!]*&#<#L MTL=%@`5[T"X@1Y?^KK!.'0$K3/>69P7$6Y0$G\Y<+3?M>(_8+E&Q.8M*4FMQ MD=T[0T.A`2,#B#\5S2%/X3]._B[$NUL?_]<=^3ZR^633P_KGE@V:0,L$$"]L MTGSO1!9ZYL(036;T7^A(7M:=WEV-1=/,HD08NF4647EF9Z-*S&/<,)],?_KS MYW:3-$U/6P!4F*K*7*`&S:?(.^#7;GM);>]HQW:+0EW6%]/B+;]^O;[Y^)M5 M>TE*K>2PYR+MVTM2:JI3_*"6[B4!89A3`\1#*AFBE0[,8K_3$LYF,I]-RS@W M"ND>RI?@:QZI/2QPH.[7"4`YV@ROEJ7S_5O_"H?>*X'$*RYDA_Z"X[L0Q^[W MAKD8^'6-4VBH3N"EH>DRJ:"2+X+=TK,2J?!2IG5ZRX++-S,['L5ZGH:5KWT1 M%^R;*QQ^,._JB*A0_=0/_'?XY7@(WK"9XH]]05]< M+>CD5\.,YD7'(/+H*'^[YZ=;VSN+X!TSW%57!-Q5G8F0L'*)M"3M96-Z9,WP M'&HHPR0SDABV8]+<`\7CWOM.@&<^#32H1S9@K,$Y1H`5!+MOWJ'QBZ:_U@F7 MI$UP,M!I6DH^?=/0(-U';Z=-;VW]N=(12EVW:)G)7IHF2K\ZT>J#_#AXR]<0 MOF*@-XOT@/>4]$90*BTO"L#EC7EK$-SQ!YO(3_Q3*9P=;<"#K,N),-+H!*.X M\6M7@L@@M#T$T2G$+36ZNLDP@2R(8M`S.^OI=%6%FB^Z?)RX29[??$.>FN.B):7#.!!K`DXY>E\,ZF`HY2]P726!H56EL[8 M98=KXX*U>+_'6SO&&GFG%`%*XB$EN^B_!*\X]*G0>_SHQI@>U_OP[(9/Y%_; M/ZMX`;VB>Z>]11_@F8R)XRPFR>9[+A$E(EGX4A"J=SM>J873!@LOQ[2P?5%_ M!$/G/.]3_@&?R8>,?FE%8NQYWK-%#*.[=/<]@?3 MMLL/!(WD`"=SP#O1QS?'+5TAG+-,)T'`S=""SH8.GV%09*R)R?3UR]'U0@J, MVWUUF:M08+IAE@=]6^/T&J@2>!MQ.4M.K.>"Z;F8^F)O0;B9*?<8ECMERTV= M`QKEH\[;;=.U>M`1A<5EA"ZN,4(P_C9XP?2`IH<\>?[3[1&'_+[@ M>TRO4//G'MSO)!(A?XEB;]O4&09(U$E$_=6$]N.YLTX&<"Z$'^*CS:&\/90W MB'B+*'F:M8G21@V1EB8O,2+[E<)AA[[&=&IM%._#05'B@(%./!->2-:`U?6D M5*#=K)!H">WNLXTS'4P*29MGPPE]?%3<5S@S,J@@82`7%)UW)E3PV?.#T(O? M2,2#21^,V29]4Z@3@WL)IN^9H$/X\]GPT.65$F4 M:IF(^M7X-5`OJ)2OP9>=R'C]SIR;]BJLJ9,>10@AA( MJ8,^G#D.9I$Q5:3E"&_3T]JYK:8"]/S::ITF-$MH(Y-D_/2M"LN<'I;I17-C M5ZLC3^P*"U!R0UNBYS::Z]K*WC"'EJ(:X'XUF2X:$).*,UJC5I6)8N@`3#2$ M'U$GE&"HYA>+<"2M)BM_QSR6.I5&G4TWDVDKFHS6A%5G9ANB+"CU"NJ0`%09 M+N.:1:"7)Q)8T@"T=6BJ/:P=254-P#5]EFFYUGQRB#))%HQ%@PQS>ABF%RU- MW:P.$Z$C[,`'8,@1/&X4(]UJ<&\FLYD,)1:,,0.-DR#%FI&EN`*^ MW"M[PP1J>M]7G3DSQZD!QZ)+NJI,K,+'NNNW@$XH!)%%5VL%.K5=II6^8A9) MG2^+;E:KA11*QB_(*K.R@B8;ULWEW:X%.B.J.C'([N M7*_QS'#E*1-C&6\:?(!L/JT-7Z274!&&1ZL>=O`DG;1PS9&\2JO76+;-6^L_ MPA&J8+GJ0>G!?3Q4"X.+GS$X&#$%H/4()I/)="4:B)@4Z]U(;#RM!EH%54`]JSY9.UL!&ABHE`BR^1)PF&&L5-_=V'PZD44 M,#\E,GX&183]3>QPYTO%UV-WO'[*S/P9/7(I=L:]8F`U$$3-*48Y`98AL/%Q M$ZS0L^Z?LUC5!UEK,OTIL<[.14Q`SCZI]6KGB?>$O^XQU=\[>&R@_L`*.WRE M=1U^YV4=;M+R%M+90S=)QN:FB+:$RDU=(-X88JVAI#ET M,T[]$/`4=CR?5`E&X!,3+@%.B,?S"U^^ZEQ+1N_\N1JB)K&V6-&XY6]#B-D4=NO"LS7GMX,Q@^PD!HF&,M MY)./OKN-F>:4'OOUJXH,>UBBK!AXJKM:UH]7-!)"TD8655B)_`&.J%2A([-[ M%#:8:0G&Q5VZ`YP%WK((N5>8YIBCUR2[]87">^81FBL#WFV=KEN'Z5RJ\54V M->:R];8TMPAZA0FDE<>7LRZ).I MON=V[`RMTLS#LTU%\`@R$YR6KX`V345>G9T7V[-J4%7J'#:\4IMW!0FTIN(^ MS=#NACZ!NQUKAOU@`<`^R*<6,4+#QL%E_`GO<.@>Z$VV$U'IK611MW[6LPWS M[-%/4>J^A&@S!]YYC92 MNBL+SH4\64TW]?T4,-=DK?+#SZ9V5<9V4'\RUN$@Z![+V%YB))L;[%$)K,A& M0%@UM&"7I3^)"/9:>GK3HA#O2^`G4^S'`TX4__KLAOB]&^'=!S(JDI\DVTA1 MZ[&M0;+-AW3=%`;7HUJN:D>0J^Q1:CDC$-8V8HVC8NN(-F]5^#:BYQBC\.WJ M1^:);4&:A0%9/T0!`K$>/AXS`+O=[[TM#HOM=AAZ1&];$EP)5`-VV)7C+*9M MD50BO@1H*V*FH7:W4)PVNWN%0D.-9RR5"(F,4U1/W+9%.$U.LBB>84S?KUH4EU@9+C\M:*>71M2KL4.*,),"@)L?N M]PODXQ@%^VP%Z+'YT+[A2*.MKP-B"JD#+8(U^<&'$.^\EF33(1G.HL@Y7^*!%KV7YP7WN3`IT1)A!Y1MMFVPSCK]XI`8BK.,5*C*6^[_NY ML_=MPERJ%+0O+AU!IL!F[*%4OK4@[.<`!L9D*2M"%!<)(E$4GW9&SDWW[L>= MX%ERUY@3:?(#MH="Y_1>V'6V*GK;DHFT0#7H8O)T/E\LVF;2]$>\`92W8,54 M>K#E`-[18WFOR?1@\Y.KV>1EO&.',=TX#KW'DZ$*7#W1VS:=;G+3J&03NF3F MODU7";OLD-9>M85F*GI!N]K"62_6K1R3"V>K[G9L;PXSN8U^Y?;;7#R:4BUQ=ZK(%-2IU?U M3BI:]8&735KD1[N9-)2*I3,*[J_#T=(5?\2$XTD%3-IAW$&!@2(=K![WSNYBDX_K#,ZM'QD'V MTRYIY&>TXY<+Z$&_$!^#,*;_.N+0"W;L^@_YN?OT%#*H(/>%?EVZ)!P\'KPG M9@OMQ`>*(Q0':$=T1;M<63ZN_$U[I#"2)Z6<15M`M`E4:,-DV#"2$UCL<%7] MT%9<'^_.#\50HJ._1B*UVMU2V->MOV:>P&HZ`?O98K.:S+/I2!UL@CO9IAEF MF*G-O#*ZJ>VQT#@6\YMNJ75L8:/1.D/TT8A$"6F(O6+'W./CR_$0O&%\S\?K M-/6%)SL2`!=A="[2K!Y@?N3.]#=N[=\JE+B_?L@#`M=>N3UKI@MOB.49`6%`'/F5>%,K-U M5!8DVK-"T-O,.;=3:I(Y?`FZGAQ053^,%"]_P7%22-I_HM6A/[AA^/8I"+^Y MX0X8.\M%F(^CI?K!TW^M)Y68^J>K;!F`3/5)*RAKAI>!9PVAM"73,;8Z-S0S MBADG=)W*J_.$PP\8)8D84)"9?J"F;ZG-;H9<^KMD8M5G\@V7:!;@4#7! M1]-GA<(E`L33]O)-PZ1%=F8_G<5:.%D?QTM.:7?QF+@BNW2,W,0AA>T;RVBA M*VI:>**3ET>:H7`E.JSE%U\P/_LH:`,]9#*;S*>R!?P$LE:LW/^T M)=+TLODHI$$SX$CD+&;SS:8I"/'*]QA+#9@.0938W4Q<>NWN&G\H,;ZRUT'/ M'&T3BZW?F'[T0#U-5_V*T9&TA5Z\`R:O M^C38B9"WIZ?GW]"SNT./&/O((VKF:74?\9/GTTS?]#@]_<%?)S%0T'*ZU\&C@-[69N>C0P=)"D:B/QWLL3]_`'MXDU4+F:E`5.G&8K$O'H*', ME;2*;OD_^&WI;^JE$<88"@486>OIJ"]V& M<#9.:0TLW-V<(OL0&+_4](HF0]DK7)@F+C7JL=%'0DT;1056C41ANEV M$^/,7QO[!W(;5]#T+2D-I93R,M,@OZKFR40!,E-\P;MK-KN^]3]^Q^'6B_#M M_MK_3.;B;TFEY^:%[U["#/)C-TV!/7KJ.'0]I,:-*2GRUM(U#$(%.&F0+E\D MB0)>:+MI07$CM_['=U"-&5-*3!S$FT.W/DH;I)/3:Q^Q-M,R\\96U<=WD-,T MNG)&[-Z/;*#/?DPCHLX>KE=$FSN\]WPOQC>$DW?71!?_B99/X!N1EUO"/R>V MWGGY0K.`_$O"1+TDZ2?,/FJ"Q__I8IYE94P;0JPEE#>5%HPO-(:*K>EFR/$] M,K7*(^#CDAH.&T$*!X'I[T,RJG%3=]V^?W?\)P@\',EI=?O>: ME^"Z2=&ZWM9)->BZ\W0UF8(A_OX-L580:P;]01LR=@5K/'\.S2XH]E^ M?6MHO7I]><&LNR,M!/C'[]O#:>?Y3[\$P>Z;=^C9;^IB[(%X33?P/:)U7N&Q M%>-9*RAMQDJ`#W,&0_@_O(CF,MBRM3!QR3E+<-S8N3L`6>PP"Y&<\\T7]P5? M!2^N5YT-#)%D#YY%ZL'W=];P8;LX9M.FT!^\,3N'[L%N`0[?%]W\8@D5R-#1 M@0T:G6PA(=R1'OCL1CBY]$DH['+W/ZKX%(38>_+1!W:G8?O&<\8?+"C).APF'2BBW:N*5C'OPF"+ MHZPDS:6_*R1G_>R&?WF/`?DF#R%V6>.W^R^!_X]@]_2GYQ_>7H[/A+T^XY=' M'%:ZCWKY^E<\U2D//5GOS#:;5;H.BI+VLP)0[-93,1ORY\O[_[Y^?TNS*:%, M"[I!0O1XARJ:H#^X+N-$'I)E4E-NG(+=R'40NE&O%]NVG$RYDH=U=_?_RWTY M_N<5>I?UO#UQV9=_W$B]HFGE53V5%=9C%3O>3*0G-T+$XMW>U1J[`10"+SQN M5@Z<+'=>C$Y8`+ZC=%D54YH+OR(A;) MW;MQM41-^_/Z(Y]F93J46YMF.[K91"?)I;9+!**02-1^L$65<=.*<(M7S`S)9:5^"8.H MPVX*Z&6M@S)$(W"5V,ULTX0Q)MFB[1+E=MNW2=*EIY8'7K!S;(#@%QSW!:#P M58/P$^D#7I%;+!H'.)K4V5;H#;;9$48L%\C'0OP-MO`5AX^!9ANGS$CZ&2]9 M!3*;B$6&/QFM-#K%$*E@>GTA25+3_%U+3^FEBF+3X/W[C9/M9G`!:4*F<=`? MQ.ZA!1F]S5BR,GZT!9PTX10:(PN=8]"31U--!P) MW6`2)7>NMVOY=.P1`VB@[8*+5SGYM;BDF]#7S?;YS@;P1%!TP9!EK:3;A%XB MRX:.7NPKHLZ=V:LNT/)9B.,>9*.M7;!\K`F=XM1%'WR?"]ZQCNZ M:D>7\6[W=(L^?)4D*FU_TP2JFM6!WX]QG"JZ4JELH9TOOM_N42K9,,P4FH]Q6D]# M^[DT9>95F"$7B(C$Y&J-YD54U28ZLB]HG@!D"*MCO]$=1N-RV49#X1$3D7:' M5??U*J\MF/86@UL(/0TH=??1JIBU;[?W5'\)4%][<-^XOU$QTB@([X*#MWU[ MP-_C]P=9`OR&QTV`LZ(#=-UEO9@OJT#EHM`?5!ABTDRO*PTQ#@)B[2AHZ&!" M1(B,-XJ.>_?;9Y=\/,\]=%LY:G[1!&(:M0%VK_EDL5A5L4.$HDRJ9LM/&7#/X(#/9<<-6P3MCUM M8J5%K`HT=_%ZMIZN\F46+@RETL;>)I2NL:@P;&K(L/;E%176.?VLT[;"(L=4 M:7E%X@Y30RI7Z8$T)WF>_\'$NT^D7DPSUWG1XN^U1XR%QJ$;.1-GL9HE,2)[7?>& M6V^=I[G.1H^$]C;``1J@)Z03=.P\B*O:J`9+M!HNT>IVGY1>HL54/@7AY?:O MDQ=YM)<+2V5W?%D["J&:0><#T\UJEA[I3F33I8VT>ADK04.3IA4:&+/4=3.4 MQS%\:HOA+3PPCO5.R?I@7ZX\1&]T/+B'@!Z_R9JYD#A!#Y=T!79.-)V&8/YI\>MO>@'YMI MIX3D+JR3NVX\TKG#85XS[>X4?W`/A]MC)XA+1%A!0( M@'--W.:_XC!FN8:^!#&.6"U'JJE=;-9.$7)2:W'U>-S&H[9?CT&A+*2TAFUG M(5;PFTQ#\,"[V&0K,DT#[^E8*3*:UA6]2&K;6L!QZGPA9[FD5BUMJ,1V)JO2 MCNL/>5`FZ1LVS@LAS"`GM5;'CD=K`PG-9BH;UE$GF_EJW9?$+"`O%=;+:$F?:QTCZ,X]+8DJDVGK_F%EFORA!][K_B.?#1VSHISYCT^ M)N'R[A['7HAWY+6/+\=#\(;Q@_O]=R]^?N;'-N3=9NS&S3'BR)9!"X`L9IOE MJC[MS;4KK$85;IIE&B*J8GHH,HF8"FJB1$_V?JHI(JJB@JZF:-FJ3U`C]?/_ M!-"QP:KO4!M9POP[Y(N3A1N)7O8=CD0^2_9&7^/3)?)VIN=_A,F'H`)P^B%B M\B&^R3^$YA%*$^$+QC<='>&\1D?(/K4>%7[8D;+3YJFSF$^FU3WS0$#6^U:R M#J1DO9>0M>%->`N_A]G!TX:S`19^%,,CJ46K4EH'"?WCJNJ3$Z2[7_J[SWCG MN1__.GG-]>O:GM8]9C6K`EW=6*^FZ7D((HP5IV/B4";/4+Y-5:9-C9DF9U)5 M]CFI?;2\W@NS#X/LTT))[-6Y&B[*S#<*'ZKFYMBL%0`J$L5[P(T6VX,"40) M+V1CT94;XZGLDU4?U8V#2OO@9*VK90D&N1A$Y:"I010,,8D7:`K\=UL:GQUH M'C@4'#$51V83!V8KIO(-+0A!NED-'"*'&,,&C4RO7XYA\,J"W$AZ`4WVAFZD MB-6`]J[9S"D"A@I#16F&KYJILM`I6^A!+=2*&WD7K,%'XA8C*/+<1^_@Q5YC M&I#B$SI1DC<++KDY=9(EHL++9G*L]=4^+V>&#G(;M/7Q>@F*H8;[,(G< MV-('11EA*3JCB=_:OY'X-3.]7:@+N&K+*CTW4I#(IA5%F8@+-0Z-X::*\<(F MY5%!\O]FDW.QQ0:`).VE#>AJ]I6-D&NII`%^W2((=JU`0?Z$0]%XR8U1K.?Q MV_7E^^N;ZX?KCU_1Y9/VYNKC_=?_C3[^]Z_7#_^T&9>RBAR= MO&8:IU%T>L&[QO4#P9.&T)Q#B11C:P<#[:EDQDX'MS=:R9K9 MY97NS-D2(E8[61-8BBXQC`MQYGS)@V90T2F_.NE$Q/`Z*$9-&M\A\.MC3"'4 M2U+[6SA%$B2);S'?CMX/C]>J+QA%0^>J8*OUJA$5-L5@0^SC13OK$/F[71@! MQE4B3QC&S"?7"]E][KP.6_L7%;UD!CL"3A`GG:@D*)/>-CS%`S M"^--RW*B`0Q)NF`#CIK<809+6[JM2J=,.'PE_XCN,8ET:SE2VI_7BJ`&)<"] M:C5=IN!AHOAB0"(,)=),#3TJC'.*QNUQNA#'):*PV4!]"&KI>&7PR'QB#C>> M_W3Y%&+(AF?C\]IQ(U`"&M0LUI,2;NC>>2[+]%:G$NN<7M;I18VDV]51T^00 M->=&O2?"*W?/;OCB;O$I]K;N(;KVMY*SH_(WM)\?E:H#/GWM3-;)%04N$%4D MTM/OIHZ1*K1P:M+"EM.D"LUT!IBIYU`I"';YP=)VWY@90WUZPSK$.R_^Y&[9 MHFHRQWP?A&'PC5#7!_=(?B/9..X@0NM("]<+O,N:I8*GTED2`B8?I0UDJR=9 M$RAMP]2(/)(7^+H*M]Y-!S<:U0:'5W:>CSJ(IBC@C^R3MLV.W-T[>WDP[^A+ M1>-[O=4KO,J_E*X4B&2UE)I^%M,<(HUO-P(7!]M`VBF,^TV90[#M`C1NY+$,;>O_#. M8+C0$<6%R*&+QVP)(H#']`%O&@X9>IYX7ZQ6+9BTY5B_8IN+<4$ZZ/-C_6]H M1Z39%@!`#OH#733:[]W)Z@9)N M)YDV!`==%`;VV,UD,EW*0P;>:A;$H[Q=5G<^;QDE39L/)D9SE)3.['!4]^!C M-&_Q_+FYV60N],+%T'#DY+-;_B?N-399(O&*5>%)']:11BV=76V84#U?/:$F M,L^'4+G"X.O@T_5LHHQ1>=OGPJA]/*6*4D?TU%B4VL==(D[E2F79T&1,7\4I4RRO:&5&N#W"H7T[GZW31B0I$EW&I M?`F;V?W!`,[$ZMYX4FCDU+"1+3RDT%)GF*5ZR`6&P)P[`/XQLG84^$\/.'PI M,(F&M.Q*/IXWC:U=WC2`%8DZT%7%Y63I5*&3E:4IA,3F!J"QC'92H]_% M?8W6C39`QQ6!K\UC=F'Q@::NZ=P'^%M68)"I`KY%,=],0/AC4JV#7G=;(;!K MMM4\XDK=$X:VW$F*IH>\H7LGD)^ASL]8?(AB*H36.!+NNFK52-HCW0F:R>A MJUPFBC*A^?$;=CKG;WJ92;&9TXJ9N5"42454K`'.46RJ(_ZB;Q<`2[6P"!B( M&6O`/&1BNB'23)Z,0?:&QFF&1`WP=;FL%)`86*,F:FB;6JBRKXJFKQF:).;I MFDT`>E]Q)M'F$UL`Q/,.#0%4DP3#`&M0"]HAUZOY1@:X)`V7S1!4X8$LK5`4 M\_N%GI^DQBM$+[;!LJ5/M\%4YK?1HN/LNCTT:LE?L"$JSK0!'TI?.#-'%A'O M:9*(5RK2@FBXIWD2_LAS8%@2!?^CV-Q?HU6I'&^67_V!*B?"%V=XY*"B\9#D1R3:`C[VHYE<8>N41[@HV> M5C:'_-E2IFW11;T[M@44%=_8@JN[X.!MF^XL2UXPC">N!72_:KV08XE+LP=' M/:QKP)"%@7FYQ[7!IN"*T<+N7_T0NP>ZM/6+ZX&CW&G3"QZ(G(M",6'&"KA@5PLHG(M"3)9`V#D2N5;31W5`8;5"YUM%&=V,[T`85 M;K".+AR80-[(G*6*-_[R'H,K_(H/P1'O'O#VV0\.P=-;\XF>UG<,<(94(6C* M*C(BK=+EOLO[_[Y^?XLRF2@7:NAHCEHK4[J@(@U8V4H7"DUUBJ;N,E-CF*FZ M6`($PR)'M'M()4-<^W=AL,51=(\C3,QZOO1W2>OR"M>=WC?$'"#EP)UNL5XM MLKB#=;IK'R4-H+0%=N*MT(994AG!`5.K'`#BFQ&\X!0'D^N[^__EOAS_\\H: MPNF$ZBKYP-VEDHA:F<8LE73L)+/Y8EKF"J,\T$?[J3;M02#N8T()I;9@4PX^ MPPE'D_0>TD3=Y6>T+L@7&@;7YIW.L[4WGM[%;`[N_D8X4"/TK;(+.DMY8;UJ MJZ(1@XG]R@[+7T?127#A2_*@_A%$H`5T760QV\SGZ4C"/WUR2L`]E,+6E%"V%X:?)"6H@BP_' M9Y>XLO]\LYL$[2#OI%Z'A8YU&D>F#0@G7:X=L\X1G3!M=X)-,\\1/<'C@(\W M=_^XO+G\8M7LLQ?*CU^"(ZT8,Y- M0#$@0Z+D>?VP;%8&2M'KQ6:Q3C&:B$.)/,0%&H.L*NNFYJQK@[,J$YW>)FK" M=SO,"F!O\8H:Y'L'',6DE3OWC:4S)=]6@OOFI[6COE$5\(+/QDE3*&?"4"(- M47&F$*_(LJDIRUK0KL@\IZ=Y>I#>"JL$^[&@`^NEW=\-W3N`9XMQEG!-TU.#6"N^R,4;`M/D=>>\@T MEL%UQYSU=.TT8%AS1;F!-HCQ:N2T]S!#*MCT<8PB]T#S3VV?/?S*$H.-8M4K M#A^#\>R:5@P[2KZ0$:(1'$476CP.L!<`*]&K%==,@[>O\D.8S<^;!SK MWSJ=$=XLIM/)O!'HWXR=V%9B5A/&QS:K(\)[V=8$[Q;;S("[BJ5F:'\S?O:; MER&3G_TN/:/S['>Q86B6'V>SR(8[WX:SW[V-<*!&:#O[+>HLI;/?-5L5#59, M[)<3%7N[_T"K"H8>CFY/<>3M\%7P0E#E;2^/QS!XQ;N/?NS%;Y^"\"'$+LLB M*>:EH4+U#WX#-087=MS,%]DZ&N]^/FN4GW-.FD4!;Q?MDH:1F[2,,&L:[8,0 MQ6GCNH^LZW56B7!XHZR.6.:LI%V4-HS2EA%O&I&V4=:XD7%:J\,<:._Z]6]? M_Y;WK/_[\;?+F^LOY:YE<.171$R%"$'%5U#)NGG)4JJ.'P4';T<34%Y&$8YO MPX]NZ'O^TUWP#8/'OT[NX2'@>3+83V[W)"QZ\(BA'[^3MKT(WX7>%B;HH2+%-SU-#C]IM/ M\/'L':FI]*;E5WK1\IZ6!@@Q,2M7")/.17[$[$C+ZC']&HX[C-.4!8._"CO` M0?URE=U<$#)ZI@RG=W97ENF#4H4H$Q?X-M$I8>RLXB-7R_A@J]^WDM'R#'S; M>7#3[V`V.A4<2\8G.@>-77]'@X[D!KZ[33P:!PBG'CUF'F5/);=$;!K%5-*G M;!A2]MF,+(8'/G[CP]VGD[\3GV)I>5CG\KA0`_`2\VR1AN!43AH$,TFFE\R' M&^;DAKUPP_:MAFE;1I=VL])Z>K,CU,191*AW)`A\<26[O[6'M,N""B=`QP$@P.,2*J5XKVD`XQ!2G8(KY@5$.A`(*12:;"!2_ MX/B#&SW?A<&KM\.[]V^_1GAW[7_R?-??DLG"Y3;V7EFN[X8(IX,`C0$E7"MP MR:5Y>AB#R$94.$JEH_=OB,JG67VR%E#>A)G0HN;.HB>Z;1VX57E%.'"+'&'CP`U`0#^HVSIPWQYQZ`X9N$4" MS$-UO@Q-7C%6R M]?K%.QX#_[_<-_?/4_/>J^`IW9NO=17`%78GLT6R_22^L,J MR+3-O5K?LP%"71?_5O--.Y3,SZ&4FLN&G5LAKLQ.DJ`]$P2P`5.@IG`QB+TM MOL.A%^P>@@=ZC,\F$ MHDRJYBA3I8U3HS:V!*`J#74*AAZYH2S)0B*55D6@-S9EYNJ)4($PS.-5B)?4 M,$22M>%SX,?/T>6>^.XN#':G;4Q(R0N9$Z].(:&JWY^][?.'4Q03P@H_N/X] MCD^AGSPL_-2*1&OG&S5Z0T^8KS?9=#?+P<*;1JQME,A#>>N(-X]8^RA5`!$- M$%3#D/CKR MELQ=%E1,6CGM*OP$1B9*B?[W^!B$,:V,^Q4_B;+F`U[0.35JU`(Z2=BLUILJ M%>324"K.T%1(C7D5K(:Y>?DD,.*"C4Z)6OM@:2XD]XW2$(==ZR43+IKI[17? M$9<+LRO('C<5B@AT`>?^GVW2TLPY-OA-^TP@8A+-!`N#39N:,@TVG`^VKX)[ M5JR=KH(D]AV;[-,Z$DNP51M=FSRB%.P/H4M3(%RY;U'I6O^G(,SO\=,??`C\ M5_(A"0!OCVTP["_4%''TUA@X-*U64V=399>D441;K:7WH#DC"]D\V,_RQA%O MW0P5Z7'6]"R&Q'/48(BB:9#-G"3\!D\YG*#N.78I(3JH5Q MFAS,2C4R'?8%E%#N[7[O;?$G,O_QR"0(7_J[CW^=O"/EI^8C"NTOZ:;,5HV@ M.^6KE;-)*G-PF2@3BHA4E(DU=*)!L:%3TX;*J4JQM4[!VGUFK4NLQ2!KM=`- M&)$9G<"\9&)-X[:\528YG"=Z4N,JAJ!YZ`F"^7J1;.G>5O=SS1W7&VJ/4[8G MW;=E)_C,G/08:A$[X_'33>$((J*@2]=?`C/S,`!0BBLN34XPBNT;[$8X^G2B MW)-F:$NJAEV=FDY&0=\VP0%RE:"];K9*K\CD..*2$1>-LN2*:7DX(MTPN!2: MOBR;?J"2R:C++'])+$^K6%X@=OK*"@3"NK,0E0#O68S4#RY*=($O2EHQ/.JK]P0+"$C_FI\!1BL=N0=4BQZR&+$T^\4K_B=V MP]:P&B[(/N06M`,?ZYTLISW0R]+(O&+$VK(:PWU]DN)X?08X%G3O'EBN>LIN M/),.I0;/F2`K\9QJ!Y["35:KGG@F39T'GGOY),7SZCSP7.W>_?!<\I35>&:U M=)4`NB#)1D3GZH'#RFG?(9K76#X'3/?T2@KJY5F`NM['>Z&ZXBN[8?TM4`/J M5(Z5D$Z4`Z_Z.(M)3T!_"\X#SGT\DH)Y<1Y@KO3L?E`N^LDLD(,H^N"&X=L^ M"+^YX:X=L;47C$"SJ@4XF^!TO:YAD`A#)6FF83;(NBR?1'YREFY+H6V;A?JQ MUM3YQ*`2>D7-(8_&-M[C)\^G1=OR,_(4N<*]^,Y"M!\"Z:HAO%[3=)5<\Y'! M"F7-%&^MT(8TGQ$9UP^M]*+9#RU'2,9U!HB-$,[=\-;@!CUG2_H207[6I)<[ MC<0`X9/K>_]BBN3%*LD_+OW='>EG*9/<[I,4TN[A*_D)YF&,%VW)=R3QS0/^ M'K\G:O[9-*JI;D9GO*%8=^@X/ETOTBBEH`$JJ<`.H165H.=K,S50K@?*%4%_ M4%40T\50Z@2C+F5D=(6C;>@=TPO4[T^1Y^,HND#OWERPXV\YFW\U M?PEI+."6HJXQ/I,1EJ-Y-2ZWV_"$=S>>^^@=6$*^EKU\^4LZ&4BJ"7B>G24H MXFE&$H&H(-'PQKPZ,PO95-S$S.#QX#U9<(8-U!5+*&QWBSE,L5+A$!R5'M2. MG6+KX'GT9CXOX86711\5(JU'T(99LRS`@@DQCP11!ZKW_IK%AGO\%V(>M-,7 MGC73[W,%P-6Q%AM1U\\%F1P@AMCD6`J`>G]JP$#%;F,P^!"\'$/\C/W(>\7Y M.>M/08B])Y\C=?OV$+I^1/.YLY"1_>O``\C=_YRBF,:)7W!\NW]PO\L^N?K& M=`-1N07@XTSS^::(Y)(BQ1L8*-$%I).G1<*'[/`HT\LR#Y>4BWX:\P_[,EG:X"P98A M6:XM.$.M,^^,\S0O9]HV2ALWGKA7L]^<)J8HE7I@3,%R/[C?C2;\50>NKGP" M\+E-;/.K3_0[>/_"NW\$!YJAXA?7\ZD]M_Y73*)`7O,E]"*:O(*EU.,&]HP7 M!C=G`3,-M0%\/G0U7[?R5:X,2K1!5!W.8[<^RC5"B4II;LV$V6R=^6CU,F.W M@BN?J`L39J,3GU?7.]"D=^_V0?@N<@\819D.-M*<*E1#R$_)A_H1*%$?&YXY M$79`YV8RF8[/@NF]>SA?+61/.QMZ5!2VM#K>NL*!Z"/RG=[3$"3KD M8FT"$F"[MMDAQH"3ZU%0[H&&)JW'=Z&OZP850"=PX>+U8E&$6"ZZA#8FW(8C MM&.8SP:VKZ>7%S=\HVN1"=E0.-(*/45'&(=CA]Y<`R?4;R:AVJF$9LM+!F`Y MK.#D?+)>5<"HMZ0F%'X*S)14_K-C^[!3;4V`8XRAZAYOL?=*84[W'`"G5L4O MZ$:34`OPL;?9NC2L%82Q!6SS)[Z'FU=`4)@+,XX;:7>K8:;9#6INMY[B*'9] MNM#R._:>GF.\NWPE$'TBT,3AUHOP7>AM\>]N&+KBJID=)6B_U]I)/7!-\-5J MN4PNM>8-7*!O21/(Y6T@G#2"CK05](TW\S?-=UI'],&TX@.4MH"2)E#:!F*- MH*2543S`2V%^](4+Q*.[@BW\MIA_@3YR-[UWB))A?Z^WN2A.QSIT;UM+@5P;>TB,:XYEBN^"9Z##X'/EJ-/ M+G$00=P3NWAZ^=UKRE\#>5,O&-K4@6Y++%?I7;5$*"V'71"+"G+1'U2R.?0H MM=DIVASWL5DCMJ#=M@(YD,,L1&+;"`1XUQXT=B)\9S&9+N!X-#V>*;8;C,FK MX,7U?)M1*1T*@6XS@\PWMI)PZ>_8S7'W$+6<4)"]H16%C6J`@ZU5CCTNC%U? M2\49/XR@RD2G9*(+-U$?MEH[81E1/M!,'/K[FI01%\^:& M)W4O:XG5@-;7G;/TU[.DI]`I^$LJ"7D^+QFI>8U*A4'3@D&9))HC]6M3##!UF2PI69LLMM86; M0@290>HP<_B%AV/V.4S"L@D/14P*K344D[(+\)^"\!X?R5=]=B-J[?#?F-) M#M&39G"3-@^_/3Y;"?"2BK$`)?TLJJ*#+^7L$F&6`*/:JQH`4?*`22`\!)=\ MBG"9WJ8E(?97]X#SJZ(MWQ,BP0!P`&J!$Q\OUO,*H!X"E(A'F7PVQZ0M%"YW MFP:;.#M(%_M[3UAG+K0"VFDE#1S]$@81>%2NOF82O!5= MX(4'9IMFM.9"$9-J[.R!.EOYAJ4;/9,YGQ^12)'7,[(*>0W=40HUD4\LPQ;+ M`$5=G_QFU_U[UT78@;F:7N`^N5Y(1LL"_I*\;:SGIHU8,U0J6 M.;H\'((HRS2YI0YP)0ZP`+6-'1V(8+$3K4#S74COR,9O=^1KQI?^CMX#.+XT MWTCM(,`DDANU`B^C+*82'*?B$9//3O9E+5@#8D4^J(>ZQ]1Z>MP/R^PVAMW6 M;BU%KMQS:C9.,>D!?NP^X=O]Y=-3R+[O??#F'F@T?>L3RJ`!MGCS%/JN]@U4 MH&+0(VF;R7PV2W91,]%TU,R$HTPZ311(QU36@.:]U%',GEIB=LNVZBBV.Q7; M">F$F<4DBJ"Q`UL]([\XL*U'O*.TM#MMS6S[],)TOIW:Q8G*Z><*O^)#P/B- M;C@]/+OQ=?3IY._P[OW;1S_VXK>V+P\189*,`/I!S]\M9D2%&B>Q#H6/H2>A]J&%D5Q%A+6+F.P$A^,Y]-5CTY*V`9 M;8ZT-5N)JZ<_^G$7S_##6K.9P'KZ!,!A@C[R$!R#!S=\(E$9/?7V/X%'GBV^ M=R1-V\]]=0KISG\5OROGP$^N%WYF6TV_N8>3].1ZMW=-LIU,,>B9S-5TX8BF MBE0VXL(1DS[N>?8NI*;,;`&3F3$;3E[*;&>,];&<]VI/C7^ELC1OOKY.W8Q#FO\#L4"*8<#I*,TE!W52%]M#Y8KX6D5+6 M&LR$?TC",>.F7_XF*TBP M'[,(:;&'PT<@2K;8>+N_<:/X'A^#,";ZN`>>?*U36-9%E%F*!.L)3N`WG:V6 M8H)D;=&_TM90VAP_8<93.UH3QXWF&"$]VN&8+O0XDG>$Y,B]0[<%J'?"U#ML MLX`'A_3,@7WDV)E-&IBQFZ^5T^(]Y@<24\F3647#-FBC)>T:'"-;@R7"!@P M4A0.\)]5&7T#/(;-TN;:-=>8@7I=>,*(=]U\*]ZJF/[ MLV^T/?AQ#?%+1HE,I!%PDK*<.A/AHELBE(/2CH,9P^T4<9%6.SOPSF!C&T]@ MO+%RDKY/\RA^"\+#[INWPRR^BM")7?@G'+!+#GOZXR37><7A8Z#-%5/FB_S$ M#2'9X!2C8\$Y^8F4R-XC*5+"$M-KH^_TL"E++?`A[4ZWOCC55G:R1 M*N#$)O:Q":9[^!8HZ"54BN5,1U2$U_IP!&=8.F'[0=R!K6&ZSMX8Q'1C>4,I MTW5VB1JF(V"V8^NX&UGTY;K4RZJXCA9(#SY^/Y*I>5*&IFEB+'K2`&<)U(#N MTTTW\T5&2T0.77OADM+:4Y'^-;FA]DP+]CS4[#%#&T-MC9_QP$RS9!#?X6!770U6VWF)1KY1IM$?E#()H&> MW1UZ),W2K.DN':^2ILD`EK:-#J1Q=$Q:-\(\FIQ5Y"C6)/H2%'./D%81;99F M9,\;1GG+B#:-TK:-D9HF=_&JVKE[2!<"=*`+Q*O[&>;"X2148*GW29JHA#R(Z.MF:X+UM<&!VJ#M,K2@HY2N.U?6EEF^2/&2@1_.6H?UA.ELO:WU:4E]*7Z_N84>U7]M0)TO8:41]NV"O MFE@XB$F4Z+F'K+)(FC1`.+`W/ZT]?FU4!;J"/%VOLH6W5%BAWDTJ3G.DJE,[J&[N>U+<;EX;9+CXSCU%Y M#5C1H\:PUZVDM^,LUF*<&2[G.M0FIZM-9E`CJ!N`I<1T\5!U M=`W>H.W7;YOA)_63>4`R7:++4_PZCYJH_G)0CFDTTR0]E6+5Q0\$IMO!"X3Q(AZ]; M?,LP0Q14@0Y(R^GLH-M[VB/!AS[`)W)TQOA%#TQ!\_'ZD-V(O_1U+D'D913B./M#;^O?S.Z\RKI[,78KVJG(HQY_M8[NH?+E^#DTR)> M^4("K7CY-3B(DUE!WM./QW:EH/.'R6*Z2*^]I6(1E\O3S^7K+50THK)UPU>U MM5/SUK:A7;7)_-)(4FAG6S#3#V(<7=",>HDW7-:D07Z``[7`&D!_F0F<@RW& MN^@3,?)#<""&!R%MJ_'N1^/S6H/D!B6@<>)Z.LV`QD4A*@N5A)F*AE78YI1L MHST8?3[Y.^_X[(8O+LO6]NGVYO;AGU^*!12,U114\SUY%5!B"*T7X3Z%&/.J M$$FVNA!OL79Q+'%';4RV!T3"7M@,H[IK%$7P>2-T_]GU*WEPR2Q=FJ.BR_OZ M(WJXT@:JZ:79HM6HJ2$D,?Y8]@OXQ)S];5'_6$X0Q"I1 M-A?(,VCGB31"?&!;1W&`"!+7)0K^0MF)'6.A"AJ<*'3G@\*$H:.K3<<"126S M3U'>'@",6Q`IAF(&@&K@878)P7W>H2O[7.;#"]6^X"=GW.BY$G/@[]MG\K:H M&HDMT4>'?M\4D4"].6J4DC7\%?M>$#(.)4'@[3Y]B*:Y[A2W`"7:$LG`U`4O M:JUFRT5[;)-CG+>:C%TT^B:_SYYE3=L1\(SAI@Y4:,A-_>*B,7PEB)18`+2M M!D#6Q3W=&*8U$NK@7'MB(WZ8D*5$O/9IWD3OE6[>LA^_=R.\(Q$>W='E-UQ) M?X"LP0X2;SR:ZJXS^"3`:M,:9B7GD'G&TJQ]-M%BOT),!534`3$E;`K"1G8A M='+&,,X^>&1^.#9I?4R#17F'0N0[=%$F!3QA']W2Y M_%5RFTG^EB%N$:@"GHU,-Q,1920B$96)4J'F*6"HI0S9J6U[:ELHL!6Y@;)_-9-6WBW#\)W M[*=VHAO2W67`;G6F<4S3U83;(YTJ1Q^_XW#K1:!YJ?@]4^@5*0..)I<;8?3, MCP8D4E$FU@*0#K96@$R<"*+H3&[5\Q:L0:.LHS9"L-%5IG&7'#)(E8*,G;57 M#*&MJ@?\).EJ*0):(B^#F`7CX"`36]`E/'AC"\J:NF43P(2.,H0M6J?U-OR* MPU=O*ZVQ('I4+Y9J[4,3A"RF>5I>)H6E-^1RS!9?&&J44S"*3P0329$-!1DD MO:L"#;$75)TQH=+OO:?G.*+K0=FLU69 M(?@R(CW`]/X-YW0/_6?9I6?/WP8O&/U$:]/^;`Z5/6S( M3."Z)Y:,8T(0NX<13%CJ,P&4*[D?%BI]R30EEEFF2H8%`U4M(+PR*)5G1$J2QC*>44V#0U8E/K9'NX84X? MPW3-EV7P*4Z'&]U@*)PYXC!^H]<88C*9^/C7R6/YA-Z_/9"VY;MSJ4,QFQ)E%5-JM5.T^B(QVRV:?=%FM,8A$MIS M*V,GR&-6@?&74#K?D+UD`P29)O"C?0L(^IA,RT#7WGK]@`/*('/$O?<@J`')%H&=*ZVB@=U?RQS`.L M;:DQ;]G#/..<48`8B"U2IUC%$W?!P=N^-1U>Z?RZ#?Q1T0DZEI%^N`9P"9=N M\*#%J/:G/%-`8B;72A`V]%\0($6.L@JPS0VA\]>B9E$]!>!6<'N/]Z7"Y9=LZDN6DYE?TXJ]1 M#_`*YGR3%9-/I+%;YZD\E`HTAC8U)C*8O7=W:$8XTB2>5 M8NI$TT!#IIH-:3G&--`:IYLU>J#<_W9'_!N*ZF/OD^:Z_]=S#M;\/PA>&0WIL\A!$IQ!?/D9Q MZ&Z;-HZ[2M$X]^ZH&GA+9),>6\P:0%D+J-`$RMM`?Z2M&%H2&],7CE)?Z)K1 M]^S^Q4E^'Z=:A_2V[23@R[;@NO,>RW*]!L+9_,[2");SW:73RXL;OM'-I:_X M@+>TE>4P?/F4#H/:WB);D$D/]>(\ZR1L$=:IY>;F>O&CVQ MWT]Y!Z*\KMY>ZQ3%#EVVSUB?%:[MB)[0W6^[+!IL9I-U>LPG^?A&5CZ&&E#L MO1;L1`HZ2*T'JU[DN,>/;BSNE?7?ZU[(*#8.G00OUXMYLLK(7S>TO-A?]ZDN MW>7K$?T-<'(#>#J3#\]N^$3^O?TS,K^J*.KQV;)#S6@C`P7>!D^^1U%QN[]* MRG;>XU?LGW`3`\I>T3F42/2`4O-BLLI`D$FC.>13>2@1J'M33;V1?!/M)0AC M[U]\SD1F%+NL+FV2WC1L-E?;T`3HDJ6QJLU%B@8OJKIW\%S>$+O*]1!\P7$Q MN]<#W;N3)A;L)4?_8-A=22!O3^?S]6R3#IK%9FA_9`W1PN@T!44YI=X?K#ED M+)?@^#Z9"GQRF_KD0>03[A+#*03'=XS3M;,8'/#[LT0A,.CI4$5$]W0ZT*?? M+J,(QU'#'H/\6?V$)58$VL^6R\5TDI)2*@IQ66/O#T@81X514R-&M5&&"LN< M/I9IH@$YA@I0ESA",9QE$^_*,^;@VVEE9>/,5\L::DW-P0>84,6HT:GX`#NJ MB+1@`B[N_0(`&I^('^A<\,X-XS?I)1;!@UHGW=76H;-09^ID4VTF`S$AAJ^C M#+3'Z6:/OBET4VF3)C?[QO&!"'GF=P4[=^,F/`(\90:G1_>-AG+1[?X&4`N\ M^7FM*&Q0`DKUL\U\GH(N%4579F[&K/C=98U8B7WSDH%T@<7&6M^M/;",*)EG MC`,HJ3K^P3UZ-&\+=B-\^WCPGM@\J7FD@TLP!3*Y6N!]B]5D+80=$8^H?)0T M@%@+J-"$%5!4Z84Z.+>)[0^;_=?GUW2'1Z" MKZ21:/_V\>5X"-XP?G"__^[%S\_!84WZQG$^FZ=I, MVAQ%+V^0[F2@$INN)HY!+ MD]?.AU+[>$L9L8[IK;:E>+TN>$* M5)&"]D&(PDR)I$C]*U=#\RUG0^X#D7.B0(V;:2*47`G$M$")&K9%P:,Z41`2 MU[H5@+DCFF3_M=E_IMF['[U!2+S'US&S9AAAXL?G2W]WA5_Q(6"YWY*\,(T+ M4;)WM*X+2A2!KH%MYOFN%Q?',A\5!*;9CTSM<:DRTBD922\T['*!9A?Y`)VP MO*S7YA/KL"2_,`=XTQ9<=3JZ0Q,%S&#H,GWW3K'-4K`9/;S4H[N"L6?\H)-$ M-Y[@N\_G3]ZT!8%<'7C=L?P08`L"N6`+\=?#XCK^BA9_"")QVE0KP%?NJ6#P M%;RD:%F@%*I>?G/#G>R@;^/3^B?N3:I`3YQNR`0MG8A79H-,FK&#P$H,FYHR MK&U-4HEU3L4Z/EEUJ30KKNVV@:HPNY3Z8S2,1]U`'EF$\JA3?UDMYIN)#.;R M_J(7YWU,DP!]9-.Z([V/?><']:@#UB/ST711I]9%(='#>F-F@0;0%9+5?#IO MP(OIY9^A5HE1@INMTA@$2SI8)>YM\L(8PV"R*MN<)5?ZO.&!L*0,L*.L%XO5 MM&$D3.2-F5$6.A#V-TV,;`VF=1H(^]LGQGBR\V(Z7RX$74TC8=TE9H;"V/5\ MO/OHAC[=UKK<$DR>V,6)*[SWMI)+"JTO:ATBV[0!GQR>+S)0<9DH%8H*4E$B MUM38J=1??_\#44#:*_0Q?N:W9)<(7 M)M/PYF+7CEP>\#KYRTJDEA_X%ZXNX@P09!-R:]I!>_!\L5IU0'#E(=*0I5`> MYA`>L3X]A>Q0+G)?:-4\%.(M]EY)_$I!AO9>&,4H8BD27T8EME<+&@> MV#'FDWD:L?+TU)D4Q,282LHRV*)YTM=?CC&=0Z)=*LMD;Y=TJ&+';S)>R;HH M$UXHUG7C^?@ZQB_"*_[-#^M>+VW4!)R6?#9/<]CSGEXJ14?%(29/\U*J(KNF MANR2K[(J,L[I9YR6!=A6.&6+L7)G&!O?I!N!Q2=TCV?=ML:6BTUI'#.[S=?7 M``=F@-;QJGD+KVJEL3Z<['-<^KO+PR'XYA+#VL.UYI=T]_1&3<`ASV*V+G;^ M='N*7DC*15H0T2FR=%Z,#*"AJTD=%L"&6Q/09*AC6K.T;SE/ MA@\IK%/;38,:AF>#4.[029:+B1#%5N"WJQT,N@\44VF]RY&&Y"ZP[6K$$F:$ M";0"@&H11AL*W+4];0ZSW:JE;9S-:C5IP*ZQ,G`J32ONMD9_MP@$HK)O$,/5 MK,UOL>^&7G#K2TJNUQ_2OA9?U0":1V`Q3_,PIB(0D6'H$/,P*Z9ZK6A99Q]D M"L/BK\?`9P4:/#\KULH3IAI/K"2'1KZ^+G2"4EP^?`O:<9D_9`J7F0;P?.V3 MU;P"3"+$,#![FC'5:P8,F3UM8="\]E'\C-''UZ2*R.V1=@",_W>$KK`;/U_0 M37OWT3MX\1MBB59C+\1VP;:&G!ILRQXR$F,FFOSJ1T>\]?8>WDFK.C8_KS/. M;%("?.A^O9E6,%.09;C4HQKKG*)U%V#SM$6@;?VN%(-*/6(&-L]X=SK@V_WE MEI]8N7/?:*%SNINQW88GO+OQ.#UY3774:Y]]@$BMX.NO)W2Z-'/6Z4PP:8VF MWD[;0TF#?*N/-XD*;2+6J`6'=;6YRBFY*A"XBB8MO"4C:I@YK*4FCSXB&(ZD M,E<,]+FBX+F@1:7-&^GA,]"+^H-L@%;0\TVDV?4B#;Q+Z*X!V>`1-?46B_A, MO\5MH;MRLQT59FN*VSN`MA#+0UTV.K,P-NOZ6?E+-C$*TP@Z9UQ.UI,YD$V8 M8(N(I(>A,!(9T=#^_-'#6AAW-%MKG#9*B`111NXET_.:OTY>B'>?/-^+\0V] MM'I-\.P_>326BB(=3(-#2SZ:PH>"=HX0A1S!M$O$7$ MFD1YFX@UBMZ_(=8L8NV:P;E^;PEF-R5OO6OPUB/86R8F.[WAU33;Z?<15`_]BXWZ269-,O'['WM-SC'>7KSATGYAVT>W^>D:Y9#9;:EF<@(9EQ9]=' M@O-T-C@L-.YQGIBCZ&6>#Y25.XQ.VV>!$U-RM2'&')%@10'J6-_+<'1+%-UY MAU-,-/^*MZ>0Q=X?OV\/IQT90XGC/P0OQQ,G[-M]FJ^/]!16F@\8[JIHQ$S\ MJT!S<(4KQQ&M]1]UW;Q;K";3,;G/H@U0$YZMD6`S M[[F'+/7'\TTT013_3=/?3Z.(A;"1RPU M5/3^K?"O#X%/BP*0T)7\+?)V)**E/X:%>,.D&^&X02IW2-HM".K2IE&Q;;JH M6?@WRIM'I?9M">7T^:]&7V+_/9;\=]'+@?J)3`DNQ>PU_`N=*66!H[3A+9P7 M=76-'C:3V4H]?=D3C>EU)..Q#\_D08P\'WURO1#]YAY.C-,:_76/>:6'."CZ M]\S)"Q9^J?D\EI.8H@#+YDBJRY`_FRP7LYZ<:;.:.8!LU&0&O?90V MPTO'L]4&>_9$Q_!%C=9L\`5TRW(,A]1X[2H\/1%?O.)#<&2WV-(C8838=O]S MBF)6$,2"_<=N?"#84>S@SE&H++KV!]_942C8-.GUTAK:V==D&&]D0IK8U+H[ M/6""U."W!M:TTF_=R%2#\^H;H"^)PXAY!"#$39[`C=;=DU+/88VK9&;Q*LN]^J[X6[5/W56C6SQY%KI M)U0=LP8O+X'/JI>SK=7H.HH('5]&/$\-QI_=>/OL^4]T23#T'D_98@`T=E70 M@,$8=KCVT"S,T^5D70EE&?"H`HAIP,\)D/",Z8#<"*5:H%0-5-0CP1JR(:;5 M[$?!L-#HQ\M6/]H6XVIV)D^8PYV5N*[2,VT(7-41F2B`5>1RTX'LRS'PZNWV,?[SWYLJL*B89"TXYJ0J,E9[98"LDF:8Y=GV`-$A+Y MGMVW2-HT3BRZ/97FBG[U(LJK/R42?V9W(W(_&<[@.APO37%@']^:I8PK_!A? M^U$6/_[%_=I!E" M:P<5P0L;Z!]=_XUEQJPYRQ;(]T!( M$P]T=:U9C7_O1MZ6Z'Q%C]=3,SJ10S=I1LBADXK0P6XU%67-$-QY8:TQ MADC:LY`=QO-0XZ;7KQ'?[^+7-FBLP!WE%AQ%CUXD,?Z=79=>>F%(3!_=?6^8 M/O9[O*4+S]F$Y-Z-69US?TLHSVU=[E4BT@R1=-83?+0P+WU69).TO>**`&T2 ME=NTD5'&=562D3MSBFB%X,HC.H11\1HQX91?(\HUGS`]H7Q`7V,W/A'(O'&W M7AZ/!X^?\$Z$/^)]$%JUQ-`??PW\T^]+&2:A9!'U*PY?O2U.B9.>W7JAJR-, M:UK$<9M<"*3V//G>O_".Y]9@9[PZ,)3B]LS0EUHCP+.$]52PXIEMH"3:Y-$2 M.WF9*X1RC>A[N4YIEA1^3-,J\C/H:!YPG5Y>7$)J]((QW8%X)W!KLHQH":F- M@^<&QAOA\YBDPV#?G&(M^G2*3R$6),WI%*,I:<(`Z:G0&WS!?UZ-X0C\I-D3 M(\15$*?8LBVHT^Y+1F4?H]A[8=?N:MD415ZS@$-K)Q9$*R(]VHQ@^QX)+ MLA+7W1@PN)R*[EXED9<2;1FG; MB#2.LM81;]Y&^M#DOGH4478?:R#SGB74,AQG#60ST.EFZ>>7(-A]\PX'V"RA M_+01BBBI`"ZCMIX+PH-4E"V1?G_3:H"$F*8?@\+.)D95W1>6X`0\^-;?,(N7 MKDR_7D\%&6L*'<6^8C8W@L0PTL.%([`NSX.&[H>_9]F^V,WI%_HAB=CR# MC)/8>^IZTJ&?5",@[*4J_*CP3'#>(=ESYVT6SSRDS;)C5$G#%L:RX[M,,"U. ML@*7SRO\E!V(^!FE5T?LO#$Q"&=B.NG_&4Q3#JTM'X1O'TYA2*_S=N46Z>N& M2$2F$_@DX6(AN*"9R4:)<"L909G]PA4Q+MW#T04]+&D+HB'=N`FZK?XRC]$D M]=7E8Q2'[C8&=8+J.\;06%$$GN1AU0#!1"#Z(Q5I!>B&F%D+KN%FFD%;0X=L MAIC(.];@ZJ:A&CGP)=/(NNE6E'HSFZQ7@O-QI3YW8ZH$]PB6RM'58JE1?-4Z M9BO`;@94VQX18;"%T]H+II'5;8UQM1333>NH3=VO%4.C M)3(B`?-7]X"C]V]DLKP[;6.*UBZ)BB`"S"4B`F@'S%\XG:YH\8]:TDQZ/8LU M0;-_)XT@1N#VI,94[H4:I1CW`C0)D')7U,@GM9XUPV:D-`UZT2<6I/WI`'M! M6A^H$\V.]2Q?:#*%[G46JU6`D5B@32OPT+E9",Y3\"2KZ5J2M>>ME#HAORV" MV6V1)-&L1<>KH%U9'$>`G*4XKDB((:&)7W#P%+K'Y[3]`XPOUS@`&&%E3%D07G<`OB"_@3C0; M81`]CSB,W^[(9XPO_=W'OTX>*Q,!6UMH>=U(="'7";R"/!4=VTIE(R:<;6-G MXFU9B%!H?YJUC\F[2(QVH4;K#S)@O5D<8@#AMJJ`F M4Z>HH[]<@Z%(;Z6AU1M6R^5"L/J1-HQ8RY5;ZJ*B8#;%+9J<5N=!6YT&#G(T M>8XQ:$'6NRN:GZ16J+)0G9(E?^>9R&R(@P9SE"@X&N9\LQ'3?Y_<>KOU]$+[T29C419:16*J#@N!SKY.I8-$F:PAE+:%"4\;I0Y]K:HD_ M\`%OZ;UYD8L(F[AVA%X]8"&.P[KZU2P;Y"E%KG

"S:+"ZF&-%$\Z[W$4DP]$!A264>KR MFQON.I6DA`@P-XT$:`>N]K=REJMZ79Z\A:2F#&_#HI([RGT@8%2Q#TQSY=B. M8#Q8GKPUN,*"J5L'I`OF:%#?F0V_ON(G2@SW^$CS)/E/A5#Q_5OR2]A*-ER2 MD3`*K!X\R:!H[SR1A+)V2I.P]V_9`Y:L=8_CEMI^E=0M%W3O"N`7_7%.9W2( M8YEN3E860'%FX9CZ..U8R[Z46<$<%QTYNO) M:E9?5&].`ELL($KYI/!@H@\?05&BT?B'Y@$1E2F_UOGYC/P*C=),.=-,QX_.L1:9$XUV\P7XXX=(T:I.H:-'NX<=<@P M$?1;X--11PIS$X91&7*,`<*6A$S]#0&N10R4;V:%8IC2X+NG"]$%=@6`M&5% M0Z,;Z^L<5/"[QQ8W/KZ5'@2[T<`"B!J@-BR+*/A2%O#88]6"ZLJOOZO\Y%?? MH]M8L??JQ?+K$%J:-,=V2NT`W_=QEH(#>;D^9>#6MR?\7?V'3"V4ZF5\&\3=JPB/9&P;6$"=5_'0O(L4;O[*?1Y2E^#D*ZN_^KO\,ALX;'J/3T M..']C]]QN/62$X[W=$`8$OD-;-2B<'"8)>`\6ZM9EQB1*X5RK1!3*X$V5XS= M?6`19*I;"(\D+@]5.#U]D&6U>WVQ)LJB&,+A&H@L_]8S%O MM^!TC(9_"`;N?')PMA'DPQJ7A2V+6$U[7UA$,O7E+V2B:DMV@+$AKX<_[8]> M#["+:)`UNUA:)LOIYWV:4OXL_^^?;8?I.RDX4SZ@%PZL0_,"_;PB_% MA:>_YO`CBYN6V6YYA;Y,0ID>J*"(U8RD MR:."L]YES['XB8:I$3T0^O[@;O]\1_0-:'Z7-%PEL0']Y>=@ARTIZ:$2N&VL M-O!+&68XJC#YFB3XBV@NB/CM2Q#CW]V0A;E>BP>:$QQ%M#M#F4MH=N0\1;M(N*1G12-29*I-H6#O7#1@-?]'"G66KX MU0^SZWT/[O>D,$MT'QP.GX(PV^&%LD.HNB+%#%3]/*L6:K(0QU_]]\G]^#MWTA`>+G=!B=" M;E=>M#T$T2GLP!7=)1HAB\YJ@H?)Q51P([4PC?%9JHRD092VB/(FK6*+]2)/^_,Z4=VD!'CS M&GL<`*XB+UA`UH*>1UNVFKW05XUB"*1 M/N!>MW`638@J9D.QH)J?:JL;L-;%:E/(DW5>&0H;?68#(N^"@[=]X_]MG>N! MWC6(2:%"'4I.-H*2BTS_L&#>IMQPALO;(TL130Q.&K`)?M*>*L-?LW/,`/!` M9#[]@GWBZ\.EO[O<3];9RBN7 MBQ+!;,VU+!HELDTA4+G=3L'N"_24&$Z74-V2;+.@[-)[RZ@$.\Q>6$:?,5W! M&=0G4AG6@311#+R\-Y_.NV(U0G_P1HR-FV,Y`@I>J0/L0G&ELW<'<]&/9C`= M>CAZ?T=$LF(7[!A("X*;W]"*UT8UP)URMK](=AH9[389`--PJCA_:H9(KZML6J[1A1-K!2O!H]H(Q9-12@122 M(B4YD1ZK]P/8?W[#$:4M?N+W#I,>X\?N4^-ZRRAMZ<:E:@/@!3ZS!,,-N8,* MBF2ITT0IO_A_$W72`_NY0@;9P:AOB-6R?WAV_>0VU*<@W&,OQKMKG]CI!;M.X]TX&A@/ M3D8Q"Y[S:SZ31SQ";A3>MDSN-1741$Q/1!7-[A)FJI('$5=6+6UN^(?P\9-+ M6ND>5EGP/>;T@R2'-9L+[USDOC3.LGKIHCTJ'.\C_I",?"((JYP197=^:0E? M>C&8W0LVA2*86E$_@\X,097:T#9-JZW^CBS2KOFT M<'?_F)Y@1VY<\/6_RUC1B6\]E$ M[SC`]1PKSC?/\@.^@P.,\)/,*S\F9XNI00\K"[[=C\R[]@7W7?7[`9E;66BX M6`+NS_FC1Q@8B9+.>B2Z1O MQQD_N3^_QFX8GY]'%YT]^AX_>;[?XM3S'R<;B%C/."CZHC_H.&??S*J#:C_6 MZ*@J_I[1O!6F!DZ#$RE;!E:UWW'>>Q[U;S7VJG7ZHK?3_]V&9\MFL!W[PX\U MJ/_&+#>V5U5I_H<8G,LVP:\RSN=Z!V"NYX]\)FW(EX#.6WD;/R9CB\E!#RL+ MOMV/S+SVS:FZZO<#RW8WE8K(P2^[_IKM58W[/_KM5_SYCAF6A?I_N<%:C M3J9ZH?@.30E!`YBC5#U$%SXS-1_$[8^G,*V\>/IPG\79%MA)"[?1%SNI&LLRR!QR^3%7?/&UO M\!SN)K=:`8Z@9JNUF@O*;8Q(U4+3,[NGK-;/C`,SAP2\?.'!VX\S0)!HZC$X M"[],&QV#?O)\](;=,/K9^&@Q*KTIN=,-^RH_3"#]6W`@8@YDJD''OL_N=^_E M]*(S&!(K<.ZAM=`J\/G1Y4K958^V$257E$79*%'U!XJVAW\*QJRYF`N9D\XZ M]I:2P>A!>/.'^E'9UO,-LVVBP`_&MMPJO.;,M5_7'9ML>GJ+-M MLY-^)+8MDX%NMBU\J+-GVWLO^O-3B/&U3S"`HUAS9"MK_ER95F(3/,WN>FR> MI5HBJB9*]?S1@EI5WX&1+!7V;D_=Y:7N"MF>WH\6WP((832^;?MB/R;;ZHML M9=1CN)U M8$*NP+DRKM0J,-8GSMAG(VI'M"HK"C\`Z:K[%)65A!^&8$$<,!K%MG^?;B0; M'8\>H\ZIDQ`G_4E_G:_];8C)#Z_]QSA\!7O/@7AY:OK'6C9=/+W:V(9 MO:=4Z=IF=%!,G[M@R\X.,K5M,!`&W^ED,I\N9__/3`V5IKK2`\3))8C;/7^> M!+&)PC3!(LI49O]*E1Z%4T4CVQE\$D6CFY6?I'&8.X/OPH:ZS*N>C_SLMD_$ MO4K^M@U>7LA7BMB='S=S[)XXUDM:12=_1UZ+GS$Z$O\]4VE'HH")L=/H,$"' M3W/?_:RF*3=M)=B'"SZ':<5-QT+FSG*^439=L*#$NUZ_.9G?WK6:X<:.=1-7GAF-:7]8T4VM+-R\-CZHY?\ZS"Z(IM M?++0/+J-W]XY!-UM1H#KX$W49=>O\VFRL&&.0^WR,X0[DU4+>\E3&]Z5!/2@ M[W=6=)F:?05]\"-NCS%ST'H_0LK3P`%:/$<*+/=#'`IC-E"&6GF9)GK ME?)FKMF9L:9B5Y<6>7=RYCQ+2H1C6@DI`C_/6=*B+C(\:PKLB\;-3%VT6(L2 MSY[M!GF5<=R'TD95)DBT4^7YM-ZR]VINFVITR"KENA^.X0I;:"SIT='WI8M@BK/]M/>X#ED^VFU`KJ$M9DL M9FJR_=QFUX,SG5"F5++O?"=_=ELI2HH M%!'BB)7(Q@L%E3BU4F28!S!GQ'EC0%9)2"C].F?.<)7;&^L_F%;_=CP+(8Z1 MV+?U\Y[Y_+QBWSU^<3U:(NM#0")L=QN?W,,H:7H':'*>,WJH>6#.F#J*$ON" M6#O3%Q44/L^0?@M@] ME%=2QHV7Y$V?7PPNM0=*%NOY9#-2`(ZC0F$BIF)UF?*LPV]U[N)3-USK@ZIRK?SL5+NDSNF191:\>G6HX3?X%SI+1/0;C'7GP*\=B4)FKI MC"A-H#[XOLF"UD512VD%=K:AHUW)O:\"4V" M3I6$UO0!SI_0M)S51SKH%I7Z,K14U7I:?C3]GEFR%KDH^E'^,,V>^4<^[U]LY3Z;K=C1[ M/75&9;@1S[L?V9#_T1]U07&88QM6$PM"+]!'[JCW[F&T5-#<4U]C-XSM]=4" MX*OW^,GS_19WG>&X,-ZM`/$W.?-QP,"M`&CKYSEF*#B1[JQ64V4END0CB8E; M`;J'&&7?80Z^&?!O,!@I\^JBPWV+?XMQ2_+3A6$WFF9].OHVW\49EO^$E$62?QC+BE^S"CMG2^0X" M/?8&UY/Y:C+B2##^]JN&\:"W7\<;%`QN:]OBW+9D;_]F`T73QO?8G\NJ0:/# MQH6^=L]U0!F^K#N=+#>;V72T\<7$EL7HXXTZMX\U_%BW4V2I_^&;1/]FHQ5T M6T/O=[5Y)&M:L>/[B<&4I5X!%^K@)WH=6:'`]3ZF=%P\B(EX&K5 MP;PT:].,T?K-?C">E>SIPSZ/GBE,4W&PRRC_XB45"R<1>D47@QJT;A(RQ!H@ M"!>+^;K+LINDJB"ZC%`!R%6R:SFR8W`&H&/YK\S4O=);6=*R, M*O9&Y2H8$QYV#_X:5EY?B9IF$^P_#T2_2W]W1_K0%_<%7P5T#M'WZ'N?IFRZ MF-)#?_!5LL6Z0VV*2+XHPO]+]4%$(40U0E0E]`=7ZO]GZ87ML?W+6.[C7R])%H1#%C=_^>9\G9@DS*)CB[JQKGQ-D=;0-? M-)W-.QRO!W*V,%/[#\K98WZ7+IQ]'HG?1R(2I:S=YXN>)6M+4Y)J(>P.&IP3 M5\/-`I\%<-8SY33=GE;YAV#HD;Y&%W(^AQ3VZME"*2MW_(KV$')U\_!7?X=# MOEO(+*/KZ\3XD@GWU"N7W[UN-3R&M62<8`>I#X>NT[;M5C]2P#1)#Q`P7=@6 M&Z/9,N`14PC]056R:M--GW/YGELWKY@E024(;2>[X9_@S$BM;DF/TP3#6CH/ M4FM2'YJ7W-FH)#4Q=BT\2*#/MT[FVW?UX\X7`N>>&IQ[T=V[9\"-;4!7Q(W2 M3VG/%8:>MA3*M2$'@\SKC?.T8=)IOXFA\<.>?51\X_GX.L8O(\SV98V=:VR<60`N MF#N?C1X>4Z40T^I'")'[N7CT*+G%R6<9*=?`/UJP7/ZHY\^:P3<<)H:]>-)+ MOV,U>;8,6K8#"O+)9-&6GW4HCS+-TK]3W7X$,AW@;<%BZD7BG@-SU:')2>=) MAF),CT>)@D]S]L28WEJKQ](Z>KND]7.ERV:3P%B>+]M.Q@YESOQ*K&!1X`=@ M444?@1%JLAU?\FU4]-L/0ZCM7#`:M[9\L!^&9@MW?@W0K*#U81M-0.6MVVBU2HD_Q,::SD_Z;[71IHC&1MMX4_'A M?_RQ1DUQ2_W:_;`CS.!"B[-5*;^_J<'E7(ICVOT=N^0LOO'V.,U9_.\SRBBH MFVFF"YS]Z,%2Q`WQR=^:,O>C.-/O!MBN'>%NR77EBKOJQ MMBL;,#W:6H_HTZC+5!R54EE^.AT.;[_Q8F4T32A=OO<)-1.RCHB&MV&JWNW^ MGO)XE*SV,5.(RD'XR?/)W(`0>O&67\'(Z-+?_>Z&[%[?`Y7_@+_'[XG:?U:Z MN94J&LF&;(_]\&(2LVFQ+F94RV"^IU:@I&2$E]B!R*^WF24H"!%.686\'S)K MT%.ROLR/D1VI06B?6H3Y]:DEZ.3H9<9A#*+RM?:RSL)--5I:A9B=J$_ MJ&6(F:;Y'.;Y?UVG#-+2U[TNX/)#"9USF@$"H!7)];S;`N#B.$+.U00S]EL]KKX4+NGEQ0W?:(#:Y@0Z,?R5Q[(?H]A[<6,L/-2E M#9:=^G8)I7!G&@%M3%Q+(M(;TL3A_YQ"+]IY6QJF?F;U(9MZ2,M;.F$J5P4Z M-BS73KK]2`6R*2T3B8HRT1]#I6=:3`H!8ED,FBQ4'8VL71F=72NQCH.%6!>U6 M:<6.K,/54-/H"*-XX?6!Z/9,X--%$PAFA.^8P(U($7"ZML7&J6(G*9:4"[0# M/H/-+%:"`AFG'46R;BA$4J-/C*+I%QP\A>[QF82>!PB2:L^;0%%5"?#4?KY9 M51%4E&4'>`99QV]RP&S2CIFFSB;$B]`-1K%RTY;XI?Z@"73<=,P&XBP7JUI0 M9D&&E&'V.-WLT8Z%6F<2@N#&?!*05)7;_0OYT"+Y%EX\1._+7]N5$KYA` MA$`/<$"_RDK:97V)[J43>8@))/R:B#2-DZ%65A`3=+!2.WHDG5&(HR;?&$94 ML@OL'NZ"R*.+$G!D-;]J!F&-^H`OHBXW,P'2,KDH%6P3XM1874=>9ZL-(+"U M\S8@4>XSPXB\<\/8)QW@@WOT8A)X@O'8]*(9-#9H`YZ#S]>UB1+!8BH5)6)M M0J(*B^LX3*7^;Z#)!F#8TF,;0"ASEV$(LK7&Y^"P(^KQ11,X"B7OF@%BLT+@ MV8R3[0D7L5@4G"X#6@1'17;7$5D4_+]AAAL`97L?;L!EB]^,0O/K%OMNZ`60 M=<+2LR:@5U0`'(RM-M,JU%(Y=JP-]K:*`ZG=%NU8$74J(39JIAO%`CN3V_:U M^$,F>C]K&7NHRPB^?FFNG;U:&G\?/4 M'M3:QZNM0U>YYLMUMH%:"YY,]?1!QK#>_A#0>4E4BHMPHTWZNGU3;RIW?:'] M=G3_UFF''7.-H8'V8KI>-L+"@CF%$ON&T M8Z=70[:X%\>A]WB*V1VFX`OQ"TG MD5X86^:!!?5`+3V>7:PXA%3D#-K;O7:P[9<@QE=>M#T$T2ELS,C0_7VCG-F@ M%'@I?YHEH!30(A6.F9^,X9->",>[QDRV MQ4=THRQI%SP\S!?%^3+BKQM+G-K7`GX\7C3?5##\B-\?#D>@C>,WV,?[[V8ID1J_Y`P,69@`M(-?IEJ M*H(2;P/Q1M+T9FDS*&F'930SCCGU[J@D,-G6$6H)(CMU]@;4PMUG+;+90W>D MCSV[$68ISX;T&H$TVW!>5Q':OS?S27>X\T?3]G@>0XMA/]`[#/TL>0Y-QE[+ M,D93%7V]NTO+4%K/!,W@Z$P(#8ZUCA=2%6_WEU&$XUYL4)-A"P=4%0-?PIG- M)E#D9U"_W2/>BH5P'^0(R1!_8?L8W]2]P7@6>LXZ%(LSGO;I*0V2;$&T6#UX M?I(I&-=-^8LM1+<"I]3*2&^+*9OQ=_IWS%*U"")\])./V;$^,N#OL1>?B$X_ M6S_HRS$#)@B)\^VCB4)JPC2YX:Y7CQ,*LH8D1-J!*U8NEVLP1Y12HV9-V4@1 M@UTB#_5/1T83>5K24O)?&1?T=\R&.\;'3VZ,V[>YK4@W:E1?+>?MR!VOD#!8WE3B# M4=YG-]X^([:!3+>4:3CT2H5;B.FV+@X`M-1OMJ*YMM8RH*_495F&[)J"X"Z] M%FX$2O$M6,VT%^;#/`-;RK0=]8U0Z(I]L3-M8P`%$QJ)'$N0/RA`G<\6"R#J MSV$VH\@A0R8SME+`T%B^Q;5J:A[EXK-*2ZSQ2B]H>5A[':`F38"=;KV8D3]F M.0IY5\K[&#]8JKLLCA*K"MR2U&[+:Y$Q:29*PBBQC)'$/8Y(X+^EM7(X"Z3? M;)=\-',55]JPE-<^D;K#V)C.-6I)/EU]3O>87&P2&=VG-F^GFW`C.+>992L-A!S-;,&61, MO;?;4".GJ1,U]'C3=7&H)G^=:*+H5TBNV:;'=2-`H`,X,&SYI#2*8J>31=9UO):3S([+QAL50,^ M;)@5R+J7!!@VS`YR;5HS-3<];@X;77,7.XM5EKV\TI$LR,VLPC8A2*S)R-S2 MX210L2`315EWN2UT!N> M-HB)MTYUPV?.8C)O@`4597Z5=J!I8G2TF&8*(6^2HN@27UB"D_;U7.'S9K'2 M;4ETLUXU#2*\2YE?Z1ULG@PQMJS]RCI>"VJ,KP4?CP>6$=8]I'5KKOU]$+ZX MD"(QP+>U8@JD$CBDF6>G1PJ"\W)%J"#;@C4`];8[-=L+&:V*A9N*GC";Z;); MER[C$^Y`)4?-'MQ#P^&2VJ]U'R)3[&VC%E0)'C6"L+H>P(\^ M72^<^;*(MJ(HD]`;:M+4A$D`3`ZURQ';=4'SY_[-$L@V(Z@,WP9?*()R^$1P M0[PBPW#E&?W@+2L`[`J3VMH#.+N&[,2Q.'S$MP,P.U/EJ7<&8>8WU,<*`FZ,26'%CJ M4?7]0XAW7OS!#<,W,I?\YH:[+`GZQ^]'+V1=_I_8;0!=A_?U8Q*N')2:%\O) MQ$DA^QUQ^:C8`,ISR.=-(-J&;FR/9?W4'NO;N&$L%Z07F\B+VV>6U&F'7_$A M.+)J6S'QS98U'*''S!\X]\=;@S\T$4UWS!=XJ*-+3:P;9^<$6E:(Z\]I7`NN M-0X^,>AD&,P.J1A?W1UFC=/)&EUKM8W=J+@J*S9`<'`,V[LNBWNHSV@?9 MB@+`[[Z9K=>S9!PE$A`7H3O\':+[M**[T2!XB"%.:@C`#CT#5$._SP%+?W<;/^/P,M]E[IP9R[X.!MFZI'PM[5.2!!%(+3>EIC MDHE%1"YB@E$J&>6B$9=M:.12;C8#E,!,HV-9EYY:&M_`[ND/P`AO__84O/[' M#GL<>^0O5WE,:A^SOKO-4"GUBCT\,ATD]9F2EY'_'V]$!BF MO@-3?^P>WM@Q:"\66VAHJ/"C/?D2!$M?QUY($]-'9*X9/P>[RQ<: M`4.^8M.KIG#2H`^PF\TGJ^E"")Q$+J*"$9>,N&@+H*3"Z&2QGPIBR_O!'L6I M"R*C6=G5?]^YS%;:BC5DTH+,1G:1NT&&?8F(95]H8I=`BV&$25'MB"H:)GC$.()3-.49V/EI#OW/2J M*5@UZ`-=WUA/)^+(ER?]3@47`V`K`D(E9L_E@Y&OIKHW(DSE)S2[^M^`N M\/SX*W[%_B?OE28.WA(.^Q#XKSB,O<<#_HI]+PB_!#&.KDZ8O/#P')PBU]]] M])Z>8XQEE[#42==^3"Z=FYL.7\A"$_LK#&^=MJ\?^5.XRPRMJ"^L&GRE$UR5>6DG,7"08(N(-ZX,LK"YIX*B/9 M#.=T=RUM(XF?LE98621S'#J:%Z:V>:&5!D=S!:I M)JF4!PNT5C?UP#`L8AV`MU03SA>:_+IS)-3TED&*:5`)N%"RF,TV*P&U?&'9 MS2T+<5286N<2[::"242%O0EY3#8%$R_993?K0I<62(J(0^8A(XO0I(';_648 MD@_#%OLE*27%S^I<9A8I`-W96#N;=..&)HR[W:."(*/))(>;Y61F!66S&%T$ M_CNW\#-V>,[=)K6PC&>:E/;`TD)RHYM,`.=7WWT)R,C_+[R[PH]Q6IOSX_L#Q8Q!/"'DKCU5]^+\>XKB0=E,V+!4[KCTKH*'19:G"3G%A>"N!1#4>=0 M0Z::#9''E$.MX>4?__;5@EQ:S5#(XL,&:\T,:R'>!D\^98@']_M[[..]%S=% MA$U/:QW(A"J`JVO/EZNT[^>"$,VWD8H:I?OS6KP??>GY`A6VL1,%[]T#&[#< M&&$2$9(@L2DGAB+#2%\.X[%-6U1,RY-_2`S4-S9+@50>E)M]81$'7.$M/*`.P27>_6T\]7W$<\Q3=T>]>_$R>)[^X/,7/04C,P$HXJ+4-6\FH37'P M195):X#4S$H%)1#5`G$U4$&/LZ`GM0XRTB MJFM?9,6'4Q@2$X9&25V%FZ>FCAI#A_O9;+)IXZ2LZ2HG):UKB)7@BY3:G*>LPB6>L(-0$=]G&\]#RF9JW43;2L'#9QPS*93IS<#Z9JKC<(_ M*AS'4W;M_N<4Q3PV/,^I6B^0]>:>,YFJ/3R[\>_!Z;"[?CFZV_CC?H^W]*P# M>>2>?.-N7;!-F'EV:=$0O,.X6,S;^(0VA5A;B#>&LM;8@[0]JPA$I6^;,TQSTB0Q$A*!4BN9=WF%63+5:T;+%.\P4 MIVC*'AN!G2?_J`;FR8__'^KPTD^#E<@^'X!L]IT$S=M)*+N$KCI*C&PV3"MB[ M&F>`((7`DYKY(DF,F8E%N5QV<365C!+1YLXAJ;>\>BKI(S^5Q)\H^YOGP3.M9[!Z"4I[]7EVB090UO"36#WS. M;NDLH#25M(0>@DKM"3.+4J.[A04!J=$QQ&@[,"WO_'"(2UQH'^*O\.ZTE>UV M@5^W!MFY3N`<8^2O4#3GTDV=T!G'^N3PC!N\DME(X[%9 M\.O6(#/7"3I$+#;I3;AV=.;2;<1G3]N3DQD[?K8`_92(>?N9!KCOW>1N;W)= M%`4A^?<>AV&R57T91=CHA=BN71R.W8H_[<,OO1TOR=T`?-D:[*8:P5._P\=5 MEBC!9,*'$4P'#JXMIMN!TVI7AJ.TY#JS&/5W_WUR#][^C1Y83^;&+06R@2\; MP:A,(W#ELNEB4\,HZ9VYY+QD*VR-87H&HV\MR_0B%=&0Q0EL]9Q]"K[QH M>PBB4XAO:**F&+^T#ZA0.=;@5J`<=*Q9K"8K*(3S9M`?-RQE&6W)2CP/]0@0 MVAT\8@?.)7"`0[[)N3:C_X$>X1C8E;@,"U'/%`/W[^6L%^)9(Y:#O;LC>@"] MV1&V8;S4Z?O@._>G&6R''E7@VB<=!$?Q1S_VXK?;;S[I+L_>,-4MF("T>9=)2+-P7D,:QG(,Z-]!+A%^@H-5HO M1_>9Y3Y*0E.73>?S:9+:.&D&X;0=TDL1/\*$OB5-(9>WE3U$[\YML>:3SN,[ M9%IT2-8.8:WT"F7:%$K:RAY"K#4#)Z3'=PKCL!;#+[)_&SEA-I@-_/99%TE,";<5M)2:WF%J;CE%K.36NNAE'1L MJH^JEY#`:*[3$,QO)N9`B8K"E+OB9S3.94H-0R/VS3*MMYL"RTQ:VN%&,'QD M<`CV+(\TI48NT>P5$FD'*DXPZO8;Z>=E\'TY46UN]U?>X40SZ;+ZOK>G.(I= M?^?Y3TW?LJ,4G5CIIAJT(\[7:7'=&E'S)FA=A*21M*)UH1E#D!O1%SRK.YN?U?TTQ7V@Q?/IWC]^0*-Z1"BQ&-@[H-/RV%*&HY& MW"?OT*[9=&TP62/C MW)UER<9>E<"ZNRMF3L\H9CR'*".Y[MYP^'7BL2SK'YVIZ/0ML=ECD]FV,7>) MS/K0=NX[(YP=>C&^W>])P)@<[R\6B_H01(UQ6/N+.MFY51OPU<'E+*5D*I,0 M\)Y-E-/+#^6*9Q\:RH)IH!VU%O/;(+Q@&#_P$NS1KE8";9P+,!`F4OR!&^Q- M/O*>#"S^EHXSS&AZ(R8].D"W.?B-&!^)ZQX;92TPG$M4!7.NDBVV_XM?7?+4 M9S?\$]-\I_>4)26%XZ3/Z]Y&DRD#K9OM+)>KI)C<__WXV^7-]1>4R4-`L``00E#@``!#D!``#MO6ESXSBZ)OI](N8_ MY-1$W)@;<6M)5W6?4QW=,R%OV;['MGQD9=7I_E)!DY"$3HI4<5%:]>L'`'<) M*PD2%,0O56D;`%\\V-[]_>O_>=_Z'_8@BF$8_.V;C]_]\,T'$+BA!X/UW[[Y M_/KM[/7FX>&;__.___M_^^O_^/;;#XO%A]LP"(#O@\.'_W*!#R(G`1^6SGL8 MA-O#AY<(Q"!(G`0-]^$1!E_>G!C\?Q_P?[T/Z%?_=;UX_'#UW<?KWZZ^O;/?_KIS]_^]"?GW[Y]^\']T[<_.U_=N?:[UN(I#1 MYB&R__+AZH>//WW[PX_??ORXO+KZR]6?_O+#U3_KK?^?'[HN$W__V_?<@:_^4]AHT.7W\LFG_\ M_K^>'E_=#=@ZW\(@3IS`;73$@]&Z?OSYYY^_)W_-6L?P+S$9Y3%T"4H2!'Y@ MML`_?5LT^Q;_ZMN/5]_^^/&[]]C[YG_C#_XU"GVP`*L/A(:_)(<=^-LW,=SN M?/!-_KM-!%;H=[L=),A_O,KZ_\_;T$VW>*,%WEV0P.3P$*S":$NH_N8#'O?S MXJ%!?KP#;A*EV]W&B;9DFR7YIOT>-_^>.^+W7>E=H)Z_O:)S`?`WYJM[&*!5 M@H[_$L80?^+&=^(8KB#PVI$O.?:0$WEQ(M!R,10^D&Q``EW'US^U!W0/;L', M3T`4H&VP!YWG'.TJA&^3]&?0!`CI#+H.D]'[6O:)WOCQ)M[/_P:/P0>C!#5G2=T.F)G MHF]A[/IAG$;@%L1N!'?XU,U7UVD,`Q#'UTX,8[0Q:B\]QG"'.0'$-;R"-:9L MYGGDM#I^]YNY/WHT8O6:;K=.=$!;#*X#=#VY#OJHZR(N!5/Q$OK0A2!&E'V. MP7QU%R<0T8!^T0=.6FG1B-&UXV/>Y'4#0$'/+4@"@N+7AIAGN3#XV"+\ M\16T=WRT/_%J/#G1%]3LS0>OP$TC1".(>P.A!2F#((084"_U`3[0(3K#Y(+& MM.WP*>X/#?YGAY@Y?H#"`../&84]^D<8(=2?07^SYGQR^!DCSGL-T8:;Q3%( M^MOWW(^:GG63HS4!@6:>6H*:XOGQCDB9;<,H@7^0R_GN?8<8LY;LGV8:AKT% M/X6A]Q7Z_6T&RJ<&?0D)\]WSF:=^;-AUS'^-SMZB:OB&F-%\`-`Q=]SLF$0WJKK@AT^K9&#.KCHL]<'SZ!86WK'0U=H^B!IE(C56HT'LSI1.G4:2>A^N<:V&\PR M(NXGTZ[THK)0^%3O,ZST)]0_:^)&.WV[=PSN'1C]XO@IR"F9$[5;_"ER\./W M.8;!^MIWW"]H5R(:XNS/+Q%TT1^>0@]TYEC[(FO\R&F5`@>A<>`3F9$SN"2)S_0Z,PJ4&&,L M`L^#FS#(O8GFT=T[B%R(34R9.TS^NN@'H3-%_>)5W#2_.E%$+'$:[S6Y+VF< M'Y(W'I%\FUG(7T!$L,?G+4UR^9?:HNMDVWZV[YF?Z(<^QU@UE%&&N2@GABZ2 MXVZAGZ*=AL88`)?.1.E%+1LO'MW_=0#WGT4;F\+6$P9+]+[%*Q!%W?D)353TC$MU%GT_=\^=KY9AXO@O:>1N M$->+Q7.PQ'KGS,)%YM`3/AVHZ7O_U$RVZ(:&H7^> M'1J#^#?[+U%XCT]SZ5G;\S4B_>V>,;C9(.C!0]`\S)@?0J0UCO4"^-@98!G6 MKH$^D.E(D4:\%F`?^GOT86Q"0%2@+0G[\>%4^)+&^65"8`*)0UL`P^@Y[,OY M4N53O<_P!@F"!P1VQJO-5ZCSO]=:DC;]3%CJR_W/O^;J1)XG=`&#",1);D?! MMMMU`/_H_@QT_KY&+)[2P(.$9&>VC@#HS2%;_D,]SZZ2WVZC='V+N?20N&Z6 M$LO,^U<:)X2=[V/6:@1HW??;+XA5G]<@`"N8(-ZK MUK,K'GJ(Z`>5P69N9';E/X^_?@M72!R-BWDEA./W,Y=2 M+?$YB$K."OTEWW,ZETSX*:VQ96\Q^#U%^^-N3UZ??H+&9#ZB*IR..T]< M]CMZ@F")-+0,2]C*$-9X'JV=(->589U'Z$.O(*<>U%D+!:\Z5_-9@O?DVF_M M13`@?><&:!$O.G9@2SK[!I@;5=O;/I3\:M^3SUS^$9]2#P<8X!A*?W98%PX=>;VL)LP1@\C=L(A;I^%IJV_1Z@C.2.'JZ=@#[0\:FV,\*BS[7]W1+ M/XMJ4_7W5O`_9G2J_:RNS"?[GC;%RV:`*USRJ^.8?#^+K_3M_D7TMV%4$O3/ M]#T]NJM);],4?<[P=/O9SW(?[7OJI7M)?ZM+^X2!:?6SBNP/];]IF;XB`]Q, MBE\?%QA]'>@6-/0-3&E/'F!/<+]E!A M=_'LMY@+"1-<*$<7.>(32ROTV"49]?>`NQP2&FP)H[1 MM`/#;3X4M??0!]$-.@?K,&+O@F:KH6A[2=]\Z-[[H7-\D]/;#$47MK/CAR)( MGITM[413FPU%W2^AC_@E)\H6C;WQCML-1=^OP/?_(PB_!J_`B<,`>"3?4\2D MD]6^?WJ7D8-OCM?#]BWT*?0U_U[24V='9U&3-B=RBX'0/T]XT69!KKS%]SN2 MNN];=P/]DHU=1>%6A:,IJ`@I;\Z',/)`1(K)??SAAV\^H`EDD0R/V5R9!!+J MD%`3`](2]X1AA"CXVS=7WWQ(8S2Y<)>YI)\7/$=<=X7/U80/A^.J9)/6TR=)Y\M,OR0*(\I5I,7U.EKH;V9[I-"3FL@N0XLQ+: M@?/5TGEG;UFE48S,M,PL\N)`G)>\J%5/GQ&CM1'*\\0_=$+K67I,T,7P4V`T M,D>GX-)MM#%.I12HQVV-4+UWH(_?*)QJV*D7[L9Q"M5/`O051S$Q4TJL28VY MF$60Y!$CB<7JV0E)*81ZPD\J`)H&-X%+7LD=_Z]>S3UII&)E3%NNKY%989XX M+TQU&VX=&+"F<-K0"+UL1W,6X9P>IF:0R[#<+7/<3`MW5R7`KA70I2?D/N7O MY#OKHI42),0@C-;2Q.H6>047B$T/4L!_#AB-3=)=YD.L7IOR9)1I%/T#'I]T/9=@RU;VW[5@F5N!3&'I?H<\2 MI,H_FZ#MN/`%VJQ9?24$H8!NJ:YFYH2C;<+H@"ABTEYK8H)&\5$TK9>K<]>! M=YH$1$PVO=L8YR(0)J6[&YX;_V&B-!P'O?+HCT&>?PR#]1)$V\=:G106Y;2F M)FC.]/W9+2WBQ^AMC5%=Z?C%K!>G@PGZ7PH3F5!DH[4T1/'.@87:O30426@' M97J:F5&X0P+>X<5W,@LHNK`)V\CF#;A=3,QA@7.+!L`KTC35;`F(7X1&136[KIV;O8.6=PHN[U1 MZO'+^H#^*22[:FB47HIO@8#[D>IJ=$XDF%U$?=;(#)V2DLM(9!5EZ41&'AG0 MYZ@@BV[[Q`Y&S18G0D#I:/2C78[N\L#PF98*'[L\W.7QD5-:53C9Y>$NCQ,- M"[M!Y[1P(Q97^@X1ROQXX-GG=A^D750 MN#KP2EJS*QRM#40,)7L%D9U,D:K'0ATXGH6].GUV!=%VP4TEPJK"SZ[PVL[X MM??NJR"U\[;K+:WCE59C9*5"V/NH*H0`5AG;*FYV>::HC M6868G:)HEUU'#>JH`+-3&M7$"=99YC8"Z?@%KRY`<8/#*N#L-'MT`8[7NL)M MDC4X)Y/A75^AUT;2.*OCJJ#[E\B!8FN:6S7@U%)RV)KZMMUF8X5BVIKXMOW. MHB?(L37M;;O=1`O0Z9;L=OR7N]"]N,%\4=3!%4!V6D_8'LRGIA,*1V59#F`U M5.3Y+EN3`;?Q*V]R[4W?[8LY;0U?=2HBIQ=6`VC4"I9F6T-@`2ZB%X3&19]/_R*J,,>U;=A^I:L4O_45UB07U%IC"G? MGE*V.K1#YA'93!YY]U]`1)*PLR8@T=/PC+(<\K,TV:!SRTY:R>LQBAF0DAW2 MU.>M1T$YNU"H5!1S&=`>83HW?3(6Y7] M`:#[5CXM"J>[^;DI7G&2G?42X MZR4[3;EHIEPT4RZ:*1?-P+EH1AX`(XH1LJS.5Q\Q0I95]9J,['J-[&KJ(]O= MR^1`DY5^;'0*M]?-H M!0^CW+7E3/GD%MN_6^P$CBFO6.-.09F?WUA`)5Y@'TKQ@BJ+,=D7"+A74;T(RG0(S@Q>E[X]?0]V;;$/'H?S@)SR.` MW4-3347\`9RP,BYS+=>_DH<44O&7[&H*:1Q%4D1$H@,#[+P]#VY!!/?D M97D(8OPHH8L:^W0C$3O!3MW4J4AW-U.;L'!-K[(VI0CX^2Y_>N)KL`JCW(5] MZ;R#^`D&A`]X"-`["V)<$*`Y2N:._`20C.CAO*9QELB"`<^0%)A#N.12!!<- MJ[4YRA'B^8U]#0*P8A9W8K4V5$64;(R,IIP@7O5-1G,S]0C=/-?M*XCVZ(5EB"RR\[(FFR;WAJ M4],TRY$[$DI%KGB,UF8\4'T?5UY"#$CDX"Q#,V\+`X@IPKPW?YM+=C8QKU\! M7&^0$#3;(]+6X#G%;F7S52X:R7IDJXXRHIF>$"?8E,K#C'FN/"E?;0RC;I0" MG5$MO::D?L]V:[8,8JHWG^UF;17,!+R0[>9M%:BX9@#;#=VJ0#6U^-U,W.-/ ML";2I]?18>BO;7>G[`)1J2SOEJAO_"`)M*6-QXXEH-A>/4L!(_:E97O1+`60 MJ'JR;N6RQG]A*^`CH17M5D3+JMTTJ$6M6_DDJW8ITUK5KD32SQE&`5ACMV!K M4*IKIKL5.K)J\[!Y,]LK%2F`I*Z5L[UDD;2]L'E1L8S3ML=0*\&EP_?2]HCK M5OM/WIW)]DK?K>`3V:AMK_O="C0IO-I$[XV?"Q'845D:C-S#,G*"&)T'/)W`(S_YV;GU_I5F:KLJ!SP5L)X^ M-C;<.J`P^CF](+D**VK="#@QN`79_P7.2AH&'A,>GP-$FX]3!/P]]/$AK\3. M5^"F4;U@^"WZ$=T"9'(M]T7GS]F`W7"PF4)L[([5[!=>/I4EJZ-)=E#?K7>B M2NGE[K!=9CZ/]3A:"A7!_)S,;\,N1E>FT_;9SF`!JF1"I+B9D($;-2#[2W#Z:T"UXH7@!XM3'IDCBH4=<#!X"XC(P7_WJ M1(A_(IFVPW6`>=Z'H*BO1\._ZZ"ZY[8,&5@6KO;`P]L8[>$LC&J[\\,#*+SE M7GSG.*-3#Q\8WYPS8T3O,\\_8^942L[C[7@>"Y#YW(#,.@O-G&2&HYPDKALQ`&Z*7A5J.E MM]7"D92.I_-5[2[*;J'[,'J"/CIBZ*LT-D.Z;X^4UF_-=O0R1]!"-1X7U\5I M?!)]IN84S.;CY#L/12LS/ZQTW_XHS:#`A1;NWD'DPK@FQ$B3S!VD/]H[4CT, MO4A:1,^QF^3E&O!A<0)G330KZ.5&_T4/.A89R'.>(;D`NS1R-YA17H`$1N2, M%5(&>O%_A2HPSDNUW8H-N`Q?D20=KP[T33=_\^$ZBTBE;?Y.XQF?$?M0:QC53,J^!#&J MP"LB%;FG@-'8J$?,$>,=RQ34I?:9BNHJ^2&1B[!II9%V1>+T/;NRNH/2>0R; M1I6/IL$G7*B#&](6UJ3]N@-5]MX4SU)6JRQ_O#"SR;Z$VHTVNIG3#2MM9LT8 M:7PSQG^<$T-_7$BA+(5WBX%&-%^BPF!N1K4I"\8:VZPU+#)G'!.S76(OF#0Z MB`4T6DOC%.?R.LQDAGD`,M/H.A@ MG'YR1@LXJPTB,Q-65Z/Y"WE6%G8EVN(V*!WC?K0S%X)WG/Q@HS.ZMC2V/&TJ!5`-F9+E0:("H35Z%C9YY0^5>M82@I M8?G)SK3@4FK;1@8].HX74Y7W1#'NIW#]EI,G<`3&T!MK\^D=J;;1C;:7KRI^PEF MV.RZU76R'#BN2=OV9.<2!U?)?=WV7.9M\>*'*MB>PESN?/8?_&M[UG,=]R## MF:E;`O1SATZ#[WJ[>F^6BIN;:T*P1G.5K' MKEC=JK:=^SD;.A*R7?TW6]!6\W=L5Q+.GN-K)O+4]AISK:_,TO?3]D)R$KM2 M/KM$!=;%"A3RZ1=@MCEQ/+ M2&MI.#TM?M(0B&3S+$-L:@I^?-8)E'".BMSO$UN.9W:!-NS[)A2-H;(+NZ],BW[G.%'!3 M.HK[C64V[)0WK-9&4IBB/3X+//P__,[M'9\\<72O>^Z+W->9A;L`=^ MN".79QBC71%XQ9]>G$/VZX(>:@T!;6./(MWQ62=O+L"]AP'6[1#,205MZAQ8 MK;5"_/-\=??NDB.R0$SV M/*!?5MDY2+%?0\:-G68UU#:L"2S8%=^*6GQ5D3[&O)6&,#''JJK@+7IZ]DY" MPK-B+'@1!ATD+TA68=8XE>YN>&XPSH+I\-5'N&_61N7W,3&+3!):.N\@QKZ# M#+J/6QFBM,&V/""1@$BWV/T=H-W!3B`HU55/BF/:ER+L/!BEZ^.WG\8ZJ`W0 M$\W%,X@6G+J=I;N-8Y\4IOH%(.DU'J'S!GTBU$OO%\X0XYCC`^*R`O0UE4G5 M^XQC%J7>1:[$LL(`(YD?SNQ2W#V(W\<7#^;+LB/>9F/*C]C379$1H'!+U#OT M2=-C&*R7(-JR457M/8X]A%B>'7J#B\OV[AT[GH.B3B.7_6@YF)EY9W9/+E-2 M:Z)I)V478FZAQ9K@HZ-%WT'"7OV5QG@!414D\Y(F-X[O9Y%95%(5AS"Q\K43 MA_8?XO29&@=:2RU(/P%_MW%\)Z#FO:0V,8$4DG]HQHM,>=$P7C``5!A@W/,3 M\`DM!AK1?/']$B<=UI,VP+CGUVX]>0.-:+X4XZ+:/&D#C'M^[=9S;%;87$$? MWX=1/3:K]I0RYB?1T>1\L'7B+2EX`YIJ0J:'X1D4(5YBRLN6)BE>AKE!>[9W MH(^91+0Y7AT?O`(WC7B7@LH((Y\AWD3=9TE&&<5,"Y,_B$GT"#%`\+-U*PTQ MBCFB2QI=R\D!Q\@D2%#$IA6BD92=(7L`0T6]7`"\F&17"7U$?!CA;W%J?#': M:Y$\ZL-3A34$&*_^H5+_7BDN?<)?00##"'N&9UN:]\[H&-'T+JI(SO-8!!Z( MRM`RA#\]:P"O^HNVX4UC4VG5T!V'UA3=:I!Y<0C[F9X-?H80X$].@E^BPWSU MY$1?`''C%[_BRN.,8;;SE3J[HC*$\3DJE'$1]S,]F_RB+PB26:&3+G85VM1& MWQYB1R>T@6_#]"U9I7ZA\653S.YBIOADF>^G,U\@I/C%ZO[ M$*S":)M%T0FVAF1O+;?GTO%#CD6Q_F=-WXO6@%$(GM+`>'$U2TKV_8ID&?2$ MK>H^_TU=.6-&$AVU[(M_@KV#6BW@>I/0BXXSFYF,5!TJGK!98(K')=N?6LD$ MYG)Q#[8G6#*!O#"=J:6IFDQ@+1\9T2[WTW3+\/&GQM-WRAQU%FF03$`MPQ#9 MGX#*!/)\1:7M2:P,7^NTH##[(ET[]4V)+U4O97HU)'::3X!3;RRZI0]30M-M>9:D- M/`W#@.T%E01IN^IA"-C$"O2K0+03B6+ M?@!%%;#_9*`IA6E5H*J(1I<'JD1,>`GEG^V4C7K8G2P` M;?4UTO`:=48$\24X\EWY&$88*ODE>4MRA](PP%:"3\"3%$)TF/JL@M-4* MI&%7*N>BK5"U,X9$S\94R>A:(6IG3?#VV4*92CNY?#V59]Y%;5558%73_%6P M7IBTWA583L:]"M,+$^+[VZQU4"],B.]XM?*3@U56XXN2Y[MN5&Y*T0K3"Q/Q M%5%52:Q>87I1$KUZ9&&9HJWRB+73MT8/8OV'JE3K8*=?CIYU4/%)J3SC+^K- M4D14I2Z%RVN<+3S99;#4:VL?941I,W;:\M+0<=LAHYR%!W0+B,QR'6P6CRK M.[("B)XHN1C(?KNJ@]9"TLM`NPM&+C_+02:=1+."S$Y[K4QVV09P1YE<;0\. MI6>N%470DF#;`IH?+A<;VF$L8;$7%[4,O4>R>K,X?76^[(STZ(15O6!N!92= M6LP.0,GE'*X`M/2E:P\@M4!OA9>=CD]EGEBXA2&\U7F M[4;.9^Z@>;3S6BC&SB)U9`?\FBG\*ZCZUH3]]?LZ3HC?^9+]^OBW#?C`>P(" MKRJX=`)@O`,NSI"[VSC1]CO$&WR?..]A$&X/&8DXDZL?HLL=W(+8C2"A:;XJ M>-)K)X;Q?/527\'`*[6NKV"-,9YY'LSF4L/X&QV)UV<^(FZY09_;@32!;HSN M!';^=4YK$VGMI=,,Y7.0[S>6V=1R`DG,`;<>">69@A+NP2W63-;3`;+*=B@. MHJ7LP(T3.!YT@MEJA;@'['IP%R3H#F&?`$$/(R6O4_SI^6H!=F&4>PZ26X-9 MPIO=P4S1*9+/X<6)D@/WV%(:FJ:WEM@QLJM^_C5`;.<&[EY`A./9G35K_\OWUUE$1U@^9P2% M<]031!Y-SG;97AT@'B??21ZU$BWFC32J*;,HRRTV+QIE7Y;($/8KDE3 M9X>;P>*G`-N^J3HPV"SH1,#;;^G4@ZG05#QM2CZ`QPMGS39J_7=+MUH@.ZW.`Z@"OH MXHCAS-R,L'P)?8CK`LT"[S-.T7`7)Q!!BW[1F\F+[HQ91.!GOK]TU;]$/RV* MG&+C/(5!LHEG*[3>+U'HI6YR][Z#F0OW+?IJL/YU`]W-31HGX19$2!)9`$1- MD#>F34+7T%KFN0#KU,>M#UG"<8;>E=_6Q,T@17TI(6I;3EO?*C4XY<[O<(^2 MZ0OV&A=>H'CUZO4SV?(4X"B=8XT1F19D!JO)RE>@96"3?`VIG$[:+>LER!L*-)EKPS`[?KQO$,3Z'%0!_=[QK`(*'O!1@ M&J:UZISLHZ6B2K%U_Q:J\?OX;QME&O-A`>>$WQ9 MPBU`^QU?!G3_"D'C_CBJ?)ME,0W2K%2S5W_4?8H:U;@_G3J@J?4=C-(LU4T[ M2DG?87GH=KM`/-*PLRBK+'>:037*L-2WW.820YF:A](AD!C*A+0@&5%/OI9G1^AN9'4[&CK79"2`YF\E3RGUV>3U,S*#B$9?H4QQ_94I# M\_3>(!C7B*?,F%K1X]W>^;'JQI5-VD$19`&"#S>O2&+O5-,D=7PV M#8Q&EFE33<_B412CP>\TFGG(A0&==#!;"9;%_S1S6(BY#MM]L>0YKSIRK)O. M]JR1[=#BRA.VIXM4@XSU?-F>&K+=QF*IAJU/`*EJ#.&]:[;?\'*\277XQ)+N M19IVV8BUU9)?I$57$48F9!=DY54[J\>RO>W1M'T=5C:.=L;ZZ<"1:FYM%Z!\ M3E5CM)[:XR(G=DH%_9_:+L5B+-Y\\LX'MM=WT7!J:S:*;K5;SB!_?$\'E@JA MI<5:I"%L86:OP&LC3%P.>.Q:!A\O7:20,A!7<%VZ."%K^:T0NR#!@9E$@&:9 MN:`,%C(0B;;@D!D6QNN[78)4U"MNE"HV$0GGNNDV)=E9ZJ$)Z-\^('LM\.H^ M^9PRRU1+J[;A3=B5LZ"#OP/?^XPV1I17/GS$I9?X7A(2'?5XIX;;78I/!H+J M-5PE7]&9YF2*9;?60DUU[O\>^A[B5;CATYS66JA!=P4.AP`>=,I=Q,:&T]K$ MSB-;98-P>=CNHG!/TIKSMQROAQ8\YZL5=,%]&@4P05=<_7"R815W,H$N\Y:Y M/@@<3V5ZCFI&1$>B.IFLTZCF<<++RL[ET:AG$I.L9\!Z,;E=1C4'O..YZ;%E M>IKU%V-3*.4])NAN+'.%^"6F<^XB.&QW.E!X&([JO(M/R,5BQU5#B!XNV_,$ MMT--G]#6SF)W3I8FS?N2/-SM['/GH[96>/(KVPE'%K7=]:H-7CSYU'8?JS9X M2 M88#OM,STA`N)8F,F,&)/*4N95I0+X@)Y/4Q%M1-Z[F$`8[2!/X6AA^'$>8-C M$.U/D@^J]#0Z([;6K='$*(T+Y^L3DJHBZ/AJH+,[&IW/KV'TY0&+H"Z(U2;$ MZ6DZZ$EPPH]=!T0+:[M\U!8RWMZQ749JBQGOUK9=0&J+V9%2IXTDI*+4.1-6 MZBCWHH%'!._E!#S"/:X(WR2GI@*MJSH9;TJ+@4P\FAPRKP]/SK_"Z,9WXIAC MH%89860SK*A[=K9\PZ+J*".;Z0)@JG`-GKJ2GN3:9=6B;CO:R&9.JH+Y15'Y MES1R-TX,JN(;,^]?:>XZJ`Z$RN#CPN5S#%:I_PA7+).S5%O?N^BEV:2EV&E.+H#C,".?:YGWL-*09#)H4$L2$9L^VLJ%UU)3+\';Z%2F^7L(].RDKM#U9B.&COHH2[-NHSPA1,IQ M5#B`D?EEM2`_@7`=.;L-=!V?*X6SVQNA/D'LRS$]'$T)N[V6'?X9+[!'/L(Y M6Y166K[^3[!W4*LLR!.]&B)!B=O>I$:WA4:LKN%55C?9[J7;4O]6SR>A\"S; M;F_HC*8BRV"[LY:FWJ*(/_AL-T;ORMZ8E6@[1FR.B,H4O)V<[V_ M'`!EMJ"=&;):J;'I\7!B.<]6?E%"2F]Z4L@I\;KE&[,(+E4==[4Z53?9@^@MM&2#R;DLV5KF1-\+P??XZU3X9-3;K;WI3!+84R/`!045ML&2 M8R8KD+-.F.V&'/<6&#("TQ!H(JMPB1'-Y&E[9),\.L>.%K;'+PGM\8U;B0WC M2$+L0$)QFQD,3I3S,I@,2MC]9F?/-.M]$R?_/=D_??&94*+++GH!JV50X97/5T9=O6LT1_,EKY[BY.X!:;6(ZPK"N+[]YW((C! MR"0\"H6S%5J4?P`GND<=U&4AX8@CDP`I]#ZC/;/\"OP]>`J1:-Y"[)49=/PX M:-T$9[3^A-0P957J:#G8>8).(RTM M-.Z2#%T?'%LERMZA+$^RK6+1,`AFKX"MX5^#8)AQ$+9&?`T#(6$^;0WYZAW" M(TG.UN`OO3@>I9)L$^5E12K)2E=4NE7J8`1G/OKN<@,B9P?2!+H<0R:KJ0G& M^CJ-80#B>.;^GL(8DEV-_XF>2:[16-QO++-AF_=9K468%.01,EH M\J?2XI4=5N\VC=";DCG\BOP3:%TFIXN^9\ER8F"W,TEM/>)(F!).T,FL*T9) MG)3?1;.U%M72TO'#@,U%U/^L,S6/9$:>T23BD>9@2I-?`UA;%5*2+%%=>)!` MTE8?ALE#:9P>2M0[R58-J"[0F**HK6K/'MRYCEY_V\\ID]FLH\.7'6Q5"+>" MB,4&VZKR;062O9I;26E"Q'Q=6MBH$*16\;;67MH*P%'.Y>3@B(T!Z7;K1(?Y M:IX@?FEFK)[4C1-O7E,$/J[I^XOCIVA1<0J#AP"1CTEG*"#$_4PH46[SC703 MQDF<5RB&?P#O)0([!WJ(/:O!+:VRZSJJ&21V(;K,XXRH&[)2[/G1VIJ@.DNR MB>^25^`B)B^!(,95?I-#]3-_+BHCF)AA;:?P)T)I:(+>SX&3F<$1UPW>DH_,V':T*F$9F"3]PC=-Z@ M3UY%!OL@W]\$1W1$W3)R/,!GY7@]M!A0%D<-#>*X"`^.+Y9+6:WUH.?[X5?\9-R'T0UZ7M8('?<+-?D( MJZEV.A8@2:-`2$/13%M,%*E>_^0$SIJDVD(W&F%>^[6*]^G:BOS*VR^I* M6XGV[M@N=K?;2`RVSW;W@!87$T>:LMU[0`4M`<]E>W6O=J>0)CK:7L:K[87> M$&ALK]35XIX2ZE9LK3#5\@B*)"Q;ZTKID6=XRMQV9:5LU=!O,]@RBO"5WY/. MGJU1._I:_J'GV)'>N6M\1Z-\KXDX/,_K;$N>.Z_7?6@ MMT07!4P>PS@^L0OQVVJAY-9)'/Q\UA+28HZ?'8S&[V`HS!G!`QW_(8CQ+887 MC1NT36T]TMQ4'3-S;W<)VN/X_L;[G;VJK*:ZZ-C#&%_P:`L+KU@&>2HC:*$Z MT\^Q(6O\7=,7B0:']\EZ`[/!NM7F929]E^PTFGG(Q1V?=#!!/XEV04PF9F9? M0;2'+KH^2"[>X\LM7B):8OJ?N'D?M'["<'`?[WVH\_QZ8;4UA*U%EB3>>;,5 M)K4[DR]ZRG*[G>QL.Q)7^)HX46(+HHH2H>TV.$7@5!FW=J:Y6\ M=D8Z.Z'2()5WL^-E%]]=<(Z(\B(WZ6S/!86WRN`DVJ?VE_7L0Y@HK\"F&&V[ M`;E7*`6Z.MLMSKUBR]25V6Z=[OGP-S1:PQFQQVLG:X2_/X;!>@FB;=V:J$.3 M6*6V*#);+(!/6,;\0P>:>E&BE]G8]BT6-/*URRDBV2?@"@*QT4=]').SK7G* M%`93]$-MHTC/5V4DDS->8-\-(B1)3XW:Q9CW>@U2Z10+$AW',!_ABG`ZF'S= MY->E&7BM?./8[N#>#4CZT;9=VZ:&F?3#;;L#?+>MIO1NVNXJWPY*WN5_.<'H MGZ(PCI/P&21YP=)7QP?Q`K@(#00,^?Y\16^EA8G'XGY=UD?;^=,NQ!(_RR^' MT5J+<\*G<`^B``M[>>`2^H`@Y%+4Q8CA'R]/(>/'.$D;TVN!TM(8Q;D@C57B MA4E!3#R[D\%Y[$&0`D(%.3I\^H\;CX)N=OE#:E/3-",:!#((J[51'3Y_!@T% M/F-CVMXW-=XMGM#5)?8BN2\EC- MC=".WE1PC"4G:HO=W@CUZ5NT(1L= M7S87Y+_;#3CV&W-!A6I:02@ZZO;[1`M90PQ3_?6R7MLL`PA=++7=ST,)&HJ. MQ':'#I&@0H_&4+BXK(\@%4E+#039N]%ZG.AR&8.;ND!4&&[Z5(7><+Y1]FC? M:ZV,U+0[EK>N0>!NMD[TA2O\"[N-0CM_?2C)XBA=A-U&,9=!+0T,3?5]Z(?) M(6#K[YL-]'PSC:$/]IQO-AIH^>:3$_T.WT+V-YL-C.2,SZZ->90%8`'._J8V M-4AS%38&^!I&=OO))C1BFQ"FAFM>K+>8K%;VVGT8>_N?8.^@5NS;M=G`)!\L MRQV=.*:<*\V!>"$1L7J&41(\81-LUAPK` M-+EUVU6&\L`CLSRV@R.(OYI\ET+X:K/:3U?YB+(VFC2*O2>A^N7;B9A:,F>?!C,P:2$9"#;XZD8<34G%TIV2K]#I.*B1,(7MS@\/`.37.:'N M9&\]AR3_(O#(NL5+',!3_SN>V'.8_`,D.`A_'<`_T.Q(YDY2_9#\"K=CF50& M)L(JG*N1LDY97HV-$\S)K<4Z@>;H,8'^D_,.M^F6JRYOMC%")0S$5#;::%$4 M/Z=X+/38XG?E@3#*<`]>?(=>*IO77$]1DE+`F:_N'1AE]4%_1;#)N-]*QZ&KD;=&W@L3G5<$Y;:?_Z?(4X M1\1L9H^'B(JCUD9,IDZPYFVJZN_&J./>:?46FLKUX$0!+GJXR&$G#Q&O=@^S M=1_4_()^Y.XN;GL]9F]T1SIHN'G`J:)TVDCKMY=?.8X?IXW,&+`S*CX'6#@C MB07YH5K,]H;-[U3F;A9%^-P1$00)TV6;7"S)1#0YHWS'\8V@4XIA#)ISDM^. M22;_R<_D`JXW25SQ'"RD>OF6GM,H6CK6RB'&+P+HEP]!R0_B=C&ZO)!$`;#, M-=L[T,<+C/[]$,Q#TV!LO[69Y(EQ@+:YN@UL=B?EQA#4FG;#M M:,<7LJK6S:/PV;/:+T?SRDX$&\3^OW=6Z!73J+2IV81F:;()(ZS?T(V?Q!?/ M$L&A<+,*K=IK]0GU93H.]O6YL^+$2BD<"4M-[4[.)>EFQ\0?'.8E96W]65Q7 M?]7(FZ=)G#@!K@79Z@WM],%1GD>F1%)9I@)/2A?6RZ>,)GXIQ%B9I"^-MGIV M/]D_Q%9P]XYV%XP!6U7";FP&P9(:OF/^23LMR"V_ALM-F,;HW*$=M=S`*`$@ M.%73L]4NBB/HIOH92R3*E+)ZF?1VH-K`&RX.O5Q0MGLKZS':,UQ-NBK);`>? M9KUJ>(9=V&:D

EMY?,O59"]-%.[TUYB*0>K!*N*SNC?`1PT2RD%21V^8XS M39L-=_&Z9='VZX9B1JUC<>3A4MTL=M;&%*'1]*2I3HF=P4I"0V7E@WQJ^:VV M2M^E/\\%G)IINMHY=D9S:3<2TSC"RXNPT(]E[2&\I&`+_4`>B>8%F%<3F"W` M9.@,"U!_G$!M`ZH&5X$+""C2YE"A!7NVV=/VW!0C70B>!=_VY`5ZEV0(HZ3M M61-&>DB8;@>V)VOHX81PPVALS?'0(Y[R84"V)HL8X/+0[P%M?48*_3N='R!2 M`6JG*K1$ZU8P3F)FP-PTF)W^VI! M)F%3E["I(Y:D6I=)Y.Q[75I'BU6+-,FA\K>9P60CU8)-@NX(%HR1A:=:I0N5 MF#OX_[/$MD:6@41EG^Y>.T>7*=IWQZYO+I(4XWW(+R##_B+^&[ M@QU+Q>LQHAEP@^#X?*C,=>?0``BQT=K-_.V,(`QR?F\!_GR"0KF*(TQRKC6,601F0+#+BLP3.+) MJR,K>%\N%"V."*1VL]GNVZ2,GQ0G8+W_49\.J]P+8'+[GWR!C6NC6BEE947U MX1Q\QZELP-U[3ON%W10T'!Q]F?L$(#^\!1Z:.:3 MOL*8OJ+UT2E7?1;':.^0)<='`NO#;^$>>FC3+="L=0L!(;UF.0]\!VE>HY MKDW!!]FNN!WYV@AD`-O#2,]S=4[/CIV^NB-?'0&?;'M4Z\A7AZ[+M#VZ=42+ MTE;T&2Y>UE)SS`O9)1N00->9;#,&;3/G4;7V8Q. M6;T'04(]J[>MJ00'SJ!KZZZ:7!+-+T$O+HG#V*#ZMG*,4VYNQHQF8O',3>`> M3662@@U[*+;9\_-BFY,,8/@Z>PB2"`8Q=,E1T"X!B#]X5A+`Z72RY"T]>1>< M?N?,T3K259:9Z'`JM/XQY'[]S,_QT=P6`,?^P&!]$P;DGDH=OQ<1OP,E9[R7 M0:E])REGFG=:OQN9_^GSQ'0'(]*GG%IO$)Y^Z1P1NP^C%8`)8EGZ1HSVI7-$ MK&DR^Q2%L78E'N=+YXA8+1?](-<;^WMGCEZO'.+I=R:T%+[SV]6YXV6`HY;] M^H1L3U\WN6L[R`CLV;%DA*N>I)4VE&BI[-YU@WS.TUTRN+Y^OC&RF7-XD3Z_ M-"H4%.ZFX;X[9H18Y_J.7`+7CI_E5AX,.3EZ1OF",LUC+#U%'P^I7B+.%.<3 M9889I-7(.$NL*6H0$UBKDG&66'.]FP>!68$"(PB3:FIQG`+O-JWJG)`IQ77_ MYH)4IG)0?2#+_-/TZRTZ^2/M,OP3)TK&[HU7?\O1D9[&]).L(SX>B(MGV*J\C7"%EM:CMA5]' MN$;*9@+;B\".CQV3=_OH5OQUXI?[CF"PO=3K2-DTV45ID37JLL_,T-Y>U5)- MN:2&6:96(435,DW*`G/7G*1/4[58D^I@4'9!$"1F>SWL\:T+)Z2E6HQ)>3#X MPW,2@UZMQJ0F&%3;R3H4?6L"SB?]1::TGY)?M$E^P7#Y;HAK,8_C)S]IFE MR0;=JG\`[S.Z!:/:'?6"./_X^M"85S:M#CDQ.WYT/*[(K2?"2>C:QY?.#+'3 M633K#^M#C/FE\01%MIQ'C2>>4Q/B-[JHY7(9B*2SW[6/K9*\=O[8^>,6?@51 M/JDM9/&;O7[R[#',G+'FJ]-#-P2I`WK"N)]J^1G@0,PU-W]O?2Y]UNZ%?S^)-V*$*'DITO/4^V'MV#V*K3 M44HOLVE/ZS2"=>)*69>:^%R+'JJW!2J4-];?=_UIO$K['%]Q;WT%"S,(UU3^ MMAR2W(8SK1D?;*P>;@KAF:[:]_&^_FO+^N,5CW;+MA8#/=)U. MM!FVUP8^TW7B:<-M#P0?>,E&H"2U/GC-7H`X09@@I$C#J3I@%P=IPS40[GY/T=(]!#'>&7@:\V0#HN7& M"9KY'ICYYTU08"7".*/&T0U$`@]NT9XKZY::`E^..+O6I9FK:7#DCSYO,[;C MV_:J]-FU.L]A'AW63V4FY>]/Z/;X_7.KAR4_O_%=*PJD36LRNC6Q[J3\PBLL M-?CG;<9V?-M>E3[+7$:'>]VGZA!C6Z)CP!4 M:&),"W0JVW7S;[KL5(C&1:%./D\3[S`"Q:#U[E#GM'C*,IGMCE'GM'AJ9C+; M_9_.:>64-&S=/)R4^95QNEJ4@)PZ6V#$IUQT!ETMCA;D[AT3S=+?,1K;=7.P M$!DNRFV6OG-1G[<8R M<5AIE/)2E+';&Z'^[*]<1KI&'.+V]S3PT&4P#\!_8)S9N1K9C<>8J%&F3$^7 MG(SRXY^5/>W$[U>7(>S1;+HU7NG>N^W.#P\`U&X;UNQ5AQG17`D?VWFJS%&, MLE)=WM0Z!\5YIFQ/QB!\H,=MWJ/877W3R):Z0B\]U MU`ET'5S*I:8P:L/+-;!7YH@N,UE.3SBSN;'AO&!&H:W9A#Z:;YPIKV>>!S,2 M'X)5&&T)"2:T-#>^$\=Y\1&NHH+24(MD7M-2W:>^?\A-9F@?D4#)X`;K\J,8 MP3./B@#)^6J!]?J9;32/OWS!F^`>!D[@HKU7OZUI(OX`7S4A$=6F=1RDREI6 M3@_=Z[N,'!R'3L);[T.$77[@R1\KQ`7K)3N*&?SQYQ.(]E"3K@S;[';\O`L# MYFR[C#1I#,T9:6[A'GKHO8@1-?@*N4DC_`S/`N\Y#-SL!^9L);IJ*EJ3/6G$ M!!I&S^#K`NQ\QR4W%KG<9NL(D)]HAU"ENXDU>'+>X3;=4A6[]#9&J(2!F,I& M&RUKGP^)F#(7LSQK`U>$=.R#%&G M+4SN''?S=\+$Y"_A,EP`%\`](&B\S,PE=`+SX/@JW1$P,W.Q=HG/IS)FIC6+$W4A0ALYL\3CR M=2[O5&^AY0;4H1G.'1-91N?^OC,V!&B>"/U\PXA%&CV!(+YNGF+N;N7U,#># M.^49T'N8\0I`4@+>$G6-):^L)K.]21T]6R_;T+GS5JOR:[8S$$0%(L:1K"": MPBUD:L!K?P=L-^5S:ZDT>)F+0*+YD-2Q.-+=50?3SMSK(C2:.L(*#;MBBWIG MK^N8BG0"MEK]!P69:X#L9/!'$O);>-$8JYMP;/52'`[NWO3UMM;9,;HT8S`3 M65O>Q_AC72B^;:W+,_!#W<)3I5-JB>D!E[:*V)H%8KC'08-]V=:$#H-N=3FW M*%MKS`RWW]MX6=I:)F;@NUS1+CQ<41<+4>_L7U.A/TG$G6^:WOSUJU6:A./6 M9X3JM54A.PFGTFX*S2@GIG79VA#)P<"M6?8HS518BB#C:3W*<*:9,8Q:J(@R:+$!A$>+GHA)UT4+78QBL<1GG!4"W M`[EM`^_)"9SL@7@(L+@%]P)*U0<9FV_J"3L]>>=:Z)U[UKZMK<&OWK#`PT?P MV=D";KQ_+Y\REB4LVWO\M3YII^5T8F/Q)DQC)_#N2#)B$-2T@\]A`F+VG2K? MV02RN5J!BVJSC4G6GLKI*27I:76X;/?KG%R,+5$D"-P%E`406^M0#*8-.[JP M)O7BI!$;8[*P#BRG>BB39;[90X&LRHG:7J!PL$U]*GO8ZI,]-+1'PH>M_M2# MWA!"_:2MOLV#HMQ"VSJ/G0 MN1V*4:^MX>Y/T]:T'\R(3:E![3S*@H?85C!V^]%0+Y/`E-I#3Z9+V@?R=6;I MU85]!J$L#V#IMM_;#=O[_$Y2)NT]=>@Y5V`^7K03ICB"&=)M?*NF[P`+M<+ M@#'S?"L5VXM5*UO(SK0:1^\,R%O?FFYQ[\E*+)E4BBT541Q`Z4*(K79'!0E, M2E]GIT9_,HM;8DWDF\6%O'@G2TI67/PU<:+D@L'N*+K::G`QA;V2DM16LXSA MC5_3;;4SR?R<(1R`-7Z-+AWC=A+$E(>FI[V=:TC;.9!-.UN11_GMJF/"F8Q+ MN0LN&>Q6RK-.&68FWE#JB3P2=J8$,UV?2`D5U9189MB;I'&#MTDK,]W@&BW: M4XZ9KH[O'!WLY`1_X4[PIOW3GD'R&,9(0D2-`)(2"488PC3[]GQ%;6$BM4&> M^C8N:!`8S9G-31B-CHE!NQ"ZDH1G;<=`]2WTTX19JXW5V@3E:--F&Q9O70:] MS39&3(G-=[=0_^;`41*ITHV-BJ.,:*8GQ/'.A=H8)HUEHINJSAP<[53;[8@J MT"AN&GO+,;0!C_'B=+(>60>2\@74_YQ=*2V60)LX,V#*K7E0_`4 M!N!0Y5[FSD=Q,$,ET%VQ58WU-[`%'`^MGJ6]KDYF=*%[7D]9,#LRM[9Z@[:!<,V;+^M>0,' MUK>VJ1P8HB6S!SRA1K^-UZ5UC(U8)]W&9U(5IQ$HI2NKXJE2^A6X*:(?)RA\ M=_T4?1/7>[MQ?#?UFVX?)A72,_3`>WCY\&5*I[CNJ'*R2XCFG2$NZAG;A+#< MD?+K`WT`7KV0'K]XA@@^,A(J:!]^/-@(L^L+NQF92\^U<%A9B:K/.)*G`GX.-WI;,\IPZ2(B&JJ',/9K(3SE M0Y.SR3D\O.9&*G-41O]N3P`M84U/'YFJOIQ+U9>\D-_1E<'CV_A]SK(:C(DZ M*_WSVXTJ"4(&S-9,)WVQYV)TE45*V_7+LE+`E(M?`W9L><%V&YLR5%P&T78+ MVE3PR[AR63>';SVV/%FXZ>=RD65R>A$8-?([?.;5VN#E`=>'7A/-V@NA?T0% M@G*!\-6$L*$[Y7&J-J>Y``];S6^[#X^45JSA'4!G2(;CPTP[!MP[,/K%\5/P M!!S\,]F#94FB61R#!&VX1^B\01_-HVP>&W$`P.3$)0W5+%C&/&9[$RK;ZS1& M5UT4$I=M=!YF]\X]6?B@?@4DA,J27*+47JC_O0.4:>= M.X96RF_!'OCA;DL.5*P,N$QWK?3FK$*Y1UU5F.4&,&=`KSA+[@7":&R"[A*_ M[!FJ/:.$+O+<>O-@@6G%";U1@^54OBZCD&;>+T3F0_1X30#]RGR9>C[', MX$IY!E MEFO'1S^"UPT`R:?6.H),6^>K) MB;X`$M-7R13EQVCR%+^#"6Q)'&=&UGT:,!QH!8WU8)DFJ>.S:6`T,JE0[D6& MJRN@NU^-MN;^'\<2R-_(ME8%&$I0;V1(YRF.*Z#M=+8<$FC6VU!A;*>A<`B, M66]>A:V="0"&W+\LW7"%<9L\`9>",=.E0U;Q9+W'UW`X'ZLGK7?]&@I:/6RC M_:Y)0E4Y!UV-=[SM+M!J.GTJYG*ZPHL!DF-$T+]E+\11OY5>FHHVS3QBNQ]_ M+^A=74K`7"_H_7@I,72Z;"V5!,O7@'+;Q[+.UY&(?($LX"U=PVAD9 MJM7&R-VX?*=.VR-P^\59R@75]LP#_4(LZ35K>]B,=I`[A3S8GB"WGRTM'=C0 M+87N!<(KZZ/2*?&N4F[B40:-S7"2:T3U?)4)7)GPQ5*SJ(6/"8-Y&G<)+ZDA MKT-O`4;SS_FZX$_A"^TG<^+;TPMDCQ8$R4R! M'J,/]+`A(*+&%/P*D\W)EHF;>V9Q9'+-Y8!EY`0QNO#C9R"$H(JWA4%`+)%#K%8?#XTR1 MJJU7&/8C)XE\BS0\HMU*E`*T'-YKXD3)M#Y],M<7XU`ROO41,8;=W%6R$W07 M>)>P/EV]_,_3V%",>,_5\`WTF`1W@9M*K$MR!.XKMW[)U$C)Y"=$EFD#' MOW'B3:YI.R99RY#]S2M.YJOFSJ:I6:3G)#G<2'88C=[CIT!^!TJ--I*9WZ)7 M+Z(".9Y]UJ!;!/$CBA56&>O$'&,D\2`_\0(,81Q,E# M'*>(;XWP_S$W6C"U(&7DWDW6ST//\5:CYCZ(_I%O@/0/T M:.#'7G*I.G]FX/E_"D/O*_3];M,K1QEWTOZZM',+8C>"1%07;-/VXXX$C9GXG9&@)?+JXG;ISS\9*W1P M)=,%`DS:2[G1J3_:L#X&5WA4HJW120MM=W$"MUA?A"_2>S_\&C\$_P!.1)7Y MV(U-[,.'P`,K&,`$/")&UD-//;I0E*F@L#QT",`EN$.NH[_&/(#7+CM]5`$?20FH"_D"JK[,(TX]+!;]T+- M/`#RQ%2->Z&%^C*<-NKGV_(HZ$WQ>S3X$K566)%Z\W[H^1HJ4%,V-G+CH-=' M>.,TVIB@LMA$RS!GP@L.%L2?HC!F,1/";EI6_P5$+K:"KI&,L`@/CI\<7ASH MS0,D$;\Z:+%INT#>0+()O?)'U@3D!QCE_)H-_F!N M_A8#F9AO5:"7HA)#8E7M)UX`G_(P6F[8I>.C\:3\&UA-36".Z^C.5S7-&N<^ MHK1H'5=N]^&7\/P20<;W=;$]$K0$_KA==I\C!/8C>0EL1U.@A M87O&:E6(Q2IGVS-)Z#C6;9PE;4\;(8MK9\=,V_-":-^@`J]FVS-`=-V8\K$> MG;+#6O6BZXD'ZI84UIZ=J=&?UO:"MTH;5,)ETO;"M-WQ:GJCV5[11/7(JAB< M;2]4HK37*`YAME<>T;ZW*,;^3O6?K6)1.H>WVE[FN2NO)XQKLKV6GF5Z!G[7VE`[W:[5_@=37AQ<:+$& MPM6!4HXFN/`LV$UGSC*_^'S5\'(H*G$@7+2DR%;5$&=#"A*S3>F/+SG]\46G M"9Z2JPZ>=K//Q(W4BU>4#EAJB)',<00)!AWT.,?H@0SP9O9>HG!W0#^`3_[! M#?T5B5WUT9OJ.X&P.'K+H2XW$<[@*2D8SIN:,E5P1Q]=`HMQF(X$D9>MC^<% MQLIUCO>UM*">@&.=@E@'BV^;#.*ZPEWLMI=W"\]@<5.U M]G:T/`JP!^<7/AMO^PNM6=Y1,@1::U@8%E1#-ILQ6AY>T^W6B0Z(`2K][>>K M99@X?N.^7(;/(&DZXJM9("9=_KGI\EG1&"[Q((V1X(%/W"SPT&^BM!&8(:G> M[_(%H\69:#HZ#0-.!:<&G?]-&N%G*:,/$X!V&OX?YL+WCD],U\5=UPD!E0]= M4M&MSM0_!'L$7A@=NI%?#3,P_=JNS/8W8V^VI2H(]\'#N2Y6T"G]!(O=CL[! MZ7W0."TO$=@YT,NC8%#[>;(!4?8W>:/5`+2<.^JW.=>[=-YK?WP.`S>#8`"P MA22<.\8"[]D!(!91<.X(8P,5B)+#B^^@4QMX^(4EH1`#8,O^]DA0-6_M?PP= M-&1RY.W&\A:1ZC)RB[?=11C&H1/N;GB]'!OU9'B=@D5U(ZARM;=(_Z$DIMOJ M3-$SQC5!VE9W`54$#8NVMOH:C&$9.%*"K4X*8X!=*/[:FNBXY\N;:IOHYMZ` M[7^7B:64=:M3WF.+-JH91:2M69)[WMKT'=PJ+?+E7@]M4A&VT2Y<+,*T;)EV MB7*#9HZ8',8HZ,EMX4OW#)MMPRB!?V3U"@":@7.;=1D0/]3U32GG/]!FS,F9H!W?=9*^ M6Y53M=6RTQ74SD^>K;:;R?5EM+J\?,=CBGI.FC3)JN6="TU=-()]IZ MQ0);/9.TR@A3MNY!(18:8*R]C;5#J28W7+IUYC7=[7R23=GQT26+[M"M@Y!S M`A&Y?84:\WYPXS$$,`B\A;ZB*E0 MR/PJ&JBW:-7\N_,=R:T1K',?5>D@56;_D:Q07%#X#)*'`!T]\,A.NBG??VRS MR\OAMIA7T=,J`]492-92JWDIRAL1:"VN+]N%-IW[[>ANM%WZT@"=@,FQ7?'? M(X(EZS20B:]4%HV="*:K)A#=R1B`*3UT]OQ3>H6V&6E-ME MYOTKC8F>39:55QMSX)F5-'2;3#7,F=/_V]583@6#TA.[K_C$"$>R2D3IE%P# MKIW`>\$/B^,2O#>":(->BERKU7_#;CEV M\M]HB9;L`\POC"#B6CKI!';$;^LU<:)D@E?,KE^*]F#@38QXYFY*A6P;WP7> M><`[E0/HS0ZNA6.=HCN'!U5\SUR2M\$"[$-_C_#`\Y^O;M`D83+S/)A1:=BW MX!:\)16M`J&;T=B$8(M)>0ABO`1H$8L2/PLG`7>K%5H:N`KB\8I412[F%1$Q!.%9'C7YWZ1G3\,RH]Y&>,4UR7?RW MMJ>20)Z*:L,E\S2MV;D)@SV($AQ/\PH"1.QSF(!X-*J= MBI`7!WH/`=K9,'&.2Y.)6FL1#?!A"H/7)'2_O"81_))E*2R\$6F,OZ"'">&R M1A+-RXC9S`RM>&O&$%72;`BQ.W3J'IS!(<.#Q/X!S[%RC<^11(H)9^;9S M)GW-S^H6Q&X$R4,J-9-Z>TVYZ>J,Q8GQN9EJCMZT!SIH;F[,9MJ^7^V.QM;) M7N)EY'A(`$('@PF.='_SQHD:L[1$7XDWH>]A\R!P4RPNLR?;>;AQSKT2*?*W M*:L+'L'U^L1I4=>HVO9M#F_VAD40">H[QV>GCA5UT4)7J7E1>(Z%??10]GN* MQ)@GD&Q"#U<&RGV0<-VE,$Y.?T\WPG8:RL09R'4.5#=<>ALC5&8"/9_*1ALM M>Z)^4%^BT$O=9+YZ=.)D`78A9AQ>'3^3>7!,4BE1T/9$VZ'TS*-YE$D`57$K MX6/_&OK'$?KR_4SL!Y)A!WCQ?11NCVAB[`Y>#T,S6($X)K(\Q8S+;&:"5J(7 MY\1\57\W1AWW9JBW,!+?L4$G?`FB+7EBT=J)&OX4L( M@^059P.XK^PV=-T>DE51A^4F3&,G\.[@>I,`$'`"3?2-;JPVB4!>*S7!FTU-RMM)+%X:*N-675'26I!;;4D M:X=+1HUNJS59%4RN]&5UF4@UD(X$/*M+."H@PS1Y=ZO/>/X`25GANY58/'^0 MV(9^6VLG*FT?-8-5!=EE\^?MK6`5@I?)MFNSI55`7B9C+V>VJU"Z3'Z^FUFF M0N^R&7B.LTD%D?7L.S-:FJ&OMS8`706;FBW(VFS_,GCPC]R0H?,&L.GH*\'` M[T)R9YQ84T^.UVG"*XN1:-KEZE@<.7V4:%Q=)AI-1YT*#;O4`%(V<^YC?2D) MT`3V^2J?GD;C><4=]JW"'&?8T(T310R(1?JQY8>_7U0 M+BP&SFQNGG9>CEY:2_,4?PZ$ZZXFV=ET M9#+]16)KC2^IKJO@1N:HUH\>2UM]]3H#1;V]VKGK_9RA%8`UKB]R]GBI]M6=SX)WH9])"W7HW?"9M(>*VB/N4@/QSJ,5$D1;G=A M@*&;KY;X]CU*_[(`;K@.\+MH).&)ZT:`^%FRY&E>2UVI(,B.2AW_)DP15D<` MT;AN81^]X;'U;&54\87:\#*%+#W[DK\'6*U,4/HKNI/`?+5"QR*_V<@U&,>I M$[@`(\L@7J+C.3\*DF?;5H%)]]LJL\VLCG[2B"7UT;,Z.$HC>)P3W$:V&J\\ MJO4B9+`2EU-+]BD-/$B:.;-U!``10$>3]B^*L+F_6-IG1%+UFR7Z5XS6%-%& MUP.W':6O4I\O:>1NG#CSN9SY9#2(Z_'&`.UZ'$!U"_;`#W=YI!4^QH_0>2,9 M/6F,H_9O7%[!3%U)_7Q$8H@CX_;@=+NYC#_7]Y[(VJCU$]H288+(A8[_$H7H MZH@Q*=BG.+X%.WP]!0G;/"/?V(YP1=R_(]=63(OKPR*DL;6W'E39*VF6%++ M\MKUKQ009$:PSG]S6$09R@EK\TX,BZ[4HUQ@?35AW05KO=RHO?[A4FK)AF.5 MJC[K*R`9&^Q,GVGT,@S7.]H#NZZSFO"*Y_+&,^,M,(+HF21J0&*([D5!T?1"4)Q'W&]%LA$5+Q/WT M))9H'L="V?P0N/CT42LOB;KT05?Y!N27`MO4*]>Q5QJ+*TR=R*.>6JB\#_TP M.7!JS#0;F#@C\V0#HKJJDEDV_.B02'0T7P*LX)_#B%-)B]%>RPZH.*O\#:XA M=J)(KN\,N8Z]T\@LK2KN9-0(*^`AZK("[\VV72$HYE>JQ`!RKX+MAE(-B!V_ M4?:;0"69RJ/22"+>S?;#*`022]YHX47))J`DT.+9:9-N!*<':M_///(?\31WVGU"_T,[`:SEJ?-5N M-_?5[+:["\X5-8XA2\CB66O\;H\:6TJUUI:M#I;*41[2`FK:CH==[F$M"4!^ M`%V$B(9P=I91JAPYRPBX#*]QWB@`]\";![/=+@KWN&0?Q00EUU./Z:S\UB-T M\9N7%5KD$55OJ)D&J4@W7G/-]!3C7CLQ@1Z=4O3.X5_-5S<@2I!@67OX^,0J MCM733(X^_(I>69R%O412@+C\,)KI)_M_QT"OC*B!?Y#S*SN;MH,..+=:?)6& M25%'TS,;WP?1VN'8;XY:Z/DJN1_12Q<$J>.3(*IY\.L&NIM%>'#\Y/`0HQW+ MTLLK]!Z8VL_HX8O*>I/SH"/YI\,9G<_R:ZAS/G@XD\E):A$EY)\1X)O,Q?W& M,AN.)PFCM9[D(4Z\P76-[\.([(+RKLKO,JJY7]QI1&X5DY-()R<1O8D%17/6X1B,O.MW5V22`<,P8<_6.!,VA3V0&9;B8POX/H@SWGFXT&6K[Y=ZPKB>*0,]/C)EJ^^Q#M$2/` M_FCC[R;V[B-`3S4Q/3VQJC&A$`LY?RUDD`ZUZD-C5"<_&^E+[R M_-2+[/9&J,]-BT50>*4S/+%_',]#HN>X9L3+RB/J=4E)VK(A7S=.!&*2M9FA M2*`WU$.#C$9T'"F_CHK-TE>IT4830F3(YQ0/B?5V:9`0;62:8%$#,1,(&^AF M:G/@W2%1)#D@OG@9`2=AJ6V[#ZIE;L]PMPN#_W`.SI>4_<926NGY>HBFB&N= MPM!;AOA2P$EZ0'E=4VD1]1EAPK\IA6%O*0P=7!&KO)X>@MBC,ZAD[:VPU7J/!L;]* MIG7%EU[P#!*B5*-2*=M7.Z5'/B?+C9,\Q/Z)DP'+R:KQ2CZJ<^,"?A;\AN;WFD8VJ2,02U& M,4$]P_338A33`5,U+XC"-X/UW@IZ&9K)#J#+X<5W$!<3>+AD!KE)A)8)F9ZC MFI'0.B'3!KN+[T4R%[WM M"*@6W/:LUB.AG'NOL]MKN8V63H0MVHA1Y12:/VZCY\OA+B0C<_(+G+31\N5* M,F;P/*Q6.K_^'`:H%9)SL)8UEQXX9%";:Z'GGV#OH%;L16@V&$.F;:&O4NE& M?C2Y,I;C1SNSN@O@@1C5>@MM M!(H;4&9[I8!N@"G$B=F:>:';$>WLC&)[_:PVL$IYP=N>@[\-<'*N![;7&>MV M)?+#MROL?IZP:ZN^KU#\:*<;'HE3H34))*.'T5`-L$CU"MK-:#:=)UCB]P=33U55X3C*'&I[?4BT6M&CU<>[\T-*:Q5&=E[<)VGP3G19E\))4E+NU;$X MRK]>[0L[S6,B-)HU`RHT[++92"5&E)-IET?6+4M/D2`!GD!9G MTS/7MTEYQ`6FJW+<]VF"FN:W-$E[4B:E,%++CTER-2]&AM5V8YC(&3G?$2M$ ML"9XQXTE*-"_35FU<&1[CWAF_#J&BH.,>)X/P3W<@W\`)V*E,FTQT+CG&Z:1 MGOF6`XUZODOT53T+7!MIW#/^&NJ9;S&.V=2'+=Z;.I.A>N'9GF]M*$#K^]#V MK&P#8EJ[S3HE<9M0I;^)MJ=Y&Q#4BK&R/>7;4*!VS?(6)HY_+K+Q0X#^"I;. M.XBQCVL88`SFJ\)B3D[/.83ASJ MG&V&%"UMOL9A$&>4U\@L\OLQ.+8N(YK@5%O0BY8-P#6K)$.'`<]D_NBLD^/X M$*#K#JTAF<2;DS5";"ZC2^>=#N%Y')J?V`!N?_FN!8R,![1%]2 M/6&"OB9F5<0LYH=?;9=*=C8ZK^PJ:#DO?F>3\VHWH3.:28L+I94H/UMOI M^H"3>1-V,]"I2/]FT-3`JM#RA(AX;MM-=#W!*L=.V5Z;J:\]*Y"G;*_,JQ[EAAV()G4&&J4XX@V M0L_'JYR:+#"X&!RO,ZZG%+C0AV2'8J^M,"OP]:N#,VLD90*](TJ[C&04_R,R M-SCV\2$H;F/4(`O\^\7QT^S&\_WPJQ.XK,@6#0./$(^[`!T40C5>VG93/QIC M1+.\!5[JDB=5;6:U?B.:S;%,@-'.KGKT\$!<65-ECL+11C1SQC4Y2XY?M,9L MU/!H^0W--[4,22\@VCK8)[21(95^7[<8;T3K_AQBK@D?Q3?U&.9L%DFR02+=I.ZNR?Y]G"/V"W-#X*,-(]0S1>O=*+6*48\5 M2_RDZSG*[WJ>=]LMH'K095_`MAL[)?%3OE9LMVKJV7?UY["=Y?+G#+&`U+/S M+@NSZM%M9YZT$+M.2BW;[9`Z[KH3IL1V*Z,&T*BR6S=KHC6X:9;N)\.B<#=* M:HPFLZ+,_JQKC]L9&"U\A#OKJ"LD+UKH:&F?J=";1`]-UKX*4CO3GNCWL6CC M)GFF/A8WM?P;^-].<(A/=I6A9)0E82<$B9-02O0U$OQ'IZR0XR!H.37:`"9# MD4JTF]YA@N@C5J]1S.13%,8LPP>C\2CH?@A>HM`%<:EQF05>H\RKW(Q$PXQB MKK5C\`RDIW;4:Q0S42!_-#17F:[0YK]QHNBP"J.O3N1)'QO."..8(2YN+CT9 MTG@4=)=JUP:F`KNGZBACF6GQNYR_J^M9T)V5LWNQLIM%+Y\:*69X3:,]P!GO M9JX;I8Z/ECE)HX#\IA`MI(]U^P^,`A]I%TK]/I(,JSN=\T-;#,:%,L(EXN'; M\6Y6[MXCO;<`"3PN+([+;!M&"?R#Z=J@/HA%@>IF,E_*2V"TB!`IQL!VNY4^ M%$6/>"=CUAY$;^%%8=F=3;#="J8/[F,M@.V6+GW(":5WVTU=?9YY:3:W6_C= M)8&<2\BV&\'T`9:K%;O9O<8?GZT/,'TFKG.R7NO#CV@6A[-UC0HNCIVE]#Q1 MDJW;>6A;L/':(\F5^MMY;-N/I[3%8[@$RF=A[)>\-FVO#*,'->H>'2ZYU(B\ M)F:>!S/:'H)5&&VSVVL,NNH16GH8.N$\]NG_3R,8>Y#X(39+-]=UO^S&)G2\ MN1/@39@&272@4LUM:E0O/4N3#3EH]1+'+)5TL_$XZ&X6'192GC>WR!:@)5X3 M(-8A`.((^WH[W13DY<6Y7\_:&,YTXVQA0.[X%X#N?/P`YAHDT3+RNNI",\)U MQ6Y!]O^'`+&!I_:6>[HC1JLA>J*["@WCN8XH=C9;S%72#4:;UPL#:_;XUV`- M@P#]I8K^Q&7]:)BK#V("^T8LL)"UD.VE916H/)7"`BCU-X']YP#)]>$Z@'\0 M3K*PH"TW3O)KF/K>PW:'GK&[U0HQW'`O2&+3ZVB+DO>W-8+22@,T4OX\OR7 M[-H^4@"U92]M3&A;M?I*NZPM5VYKT0CYS::@HK#5 MB;4+6`(]E*VI5Y0.IYR*T58_4ZXZF"\O9Y)U`

^E/]V-2;:B[<5BP2IC]]57`'C!1_2%X#^ MB]N^A#',4_JH3%1MZ-%C\@J2Q`>DIORO,-F@]N@/Q>,!F8&+>K\Q(I0*[JPY M@[P(4M>]HSKXZ''16R)^DND$;+M#3\FK[%X/<4 M?>INC\^E!B]EAB_+C1-O7AR(J[B^.CZ(GR#Z3Q(&8(:6%>RKV=0=6,2=]/@5 M.S#",6*`)+0K$F:3..[X(8Y34GNV_#;5V5AM!!/\[$L4HNV9'%Y\)TAF@7?W M>PI)0/#U88F^S7'ME>DYJAEAJK@NOS(]C?BB-8_CB2+XV`F-U7P$M/.]YZAM M1T"U*)Y1G.;CH%F_LW#:CT2RKEW#+N]'M_0-WL8D MBZ;P_M19-:E+WE:7HQ8O7>7X<+)!;)==1:]G"8T$+VJKCY8R5JJ\L>UZ)Q'# MT'"UI3[0ME]6/+:$AT[Y"%AKHU=%2.K)+-":]A/S2AO2OV$<&'$8*@X?>VDW M$Y5Y$LBSPWF(&M<-`A_@0BO_F3H1(MP_W,/`"5SH^+=.XI3.,_QF)GQH[IP( M^_;&+R`J3 MMEW:U(`9]9*Q7=C4@%O]JNND`#J+=,\:`&-P#YWXOAVQQ>\O#[R2B>D4&Z0* MGW'.V=T`+_7!PT.5>33`#+(/5P?L\^*Z.*#8B(-YF0+U/HQNP_0M6:5^00_7 M9B?1T00#<9K;%6=B+M(T7SL^I_B&7%\K9V7(39U/V\T&VRN\94A20I>GI,TT M&4.-;\[UBKHMYEGK/L*Y\>RC4EW'-R=<516Q0NR(`.GNXYN;P!HOV=GLO&CO MK$!.ENP\OGE5',>)_4YIBK1QQCQ;GJ>+VA@FV6V5N[/.8\MP<+9&E[>[Q^KH MR:%NNR5$[;ZDXR=U1B\;2,X%+;\G2V[_,J*E!D"TSL/9KD(<`$Z6V&:[O]D` MT-:E0_N#HX:[3)N1/FU4DJJ1/N-&E.E4(\MH6>^SI1%)ZHYU[.P.1AP[=*\!PRM$]V=,WA/B-6]8M;4C/)PK@>TW1K%^EW5S M,,*-2#&[^:J.(_G0@76X97OIH2Z-T:L9(W8Y=B.XDZ5.W,O$K8NC4]"6Q?_# M#M][Q\<;E#\?M;Y&9E6KA;T`/A9&<$ELV7E)]C8ULPAL$'EPGZ>7R\B2GYI4 M]S$XIWOLHRR?R?/6?CP3L_\4AMY7Z/N(M`?TS`1KB&2P+$&VW'05!C!:5DIN-LSF9FC' MT1-A)'G,F,U-T/[D1%]`@@7Z5^"F69*BC"X&]9P.HTJ0(;<6TMU-S*W(<8_H MN@5[X(>$LCP!,G>19'J:F1%Q"%]DF8G$/*Q\/R.._6"-85V`'2[6G(LEDI>` M7%\3LT(OGX>+YS0L'0AY@%AM=.JY^TZN[_AU%](2E^U1#2IP28C/MELBU31C MDO>'[39&-=`DGA!;*YRT`TQ2UV)K99-VH/'88ML=S]20DF07;"ULT@XTML1H M:U63=CC)2W>VE[]4PTU%6V1[+4S%UU)6AV][@4PUV#HH9RL@)YE`Q=)2X3:) M!1)6G`JN22C@J=LKG"8Y0%(%6T$V"01*5L@*N+Z%@K$Y\KRBQQ*NH(O9VA-T M)X>^+DIY.6096GFYSN=S&&71N%R7NEN0.-"/YZO<;?YU`T#2V;F6X<0E_;'F M]E3K:\1H5'Q=<%FMS&+A98:]'Z+Q!GY#*G;5R]U$Y>;1V[S#L M.)`G3YJO"H7YBW/`,",2T6^B%%T;BNO7:4@M#LH5!3<;)UB#^"'H/#N-`YM< MYQ"[X\,$/,(].%'(WJ<)SCBVQ3;@S+,_%R^5UEW+)\R>!5G=MK#[`Q*0U9>3U)QH03=SU%>7W@<`Y@8]-;F'K8X*`NGZ\`F$Z\C9;:"[`.LB$Q!I@\C2_(*U_CCEY+4>:SI] M^DY?^P6=3J`J9AI?OTI.0@000JX/]4\JF%1E!M!L'JX#6*%W4*%:;HCIINA# M-)=$`VF+R3E^[O:=XQM+VIY',K,X#9%:\N@^9UT:2;5'2H_^9S`-&U MX29PCUXT1<^^'CXY`@Q/MFUV!?;1A/Z-G.B(SF6?IT'PG0$+-W3N( M7!B#%S15L,"&6T4D^_CP*/&L9M!IY[49>"QXY`\VN4?J9%>U0]"+L\U^UQJ; M#A\Q@A/]T8@BO*4)>W-]H$^NX@$##Q^*9V<+N"5I>_F4$4TM`H MO;S*GD>-C,89TR20AK-3+YO6]F**^M4#QQO+=@3[O"QK9FFV`&B[GQ[[9J7[ M.FJ7N&PW':@"K(=YLCU@HSVJJBRZ[;$'**$F!:5M.W1(W3AKW[&C\2M')`K:YEX(2"T37C)Q6+)"=N$/D(@QO&X MR0&W'4D5V(P@@6'OJ)$9)8PLB"S]C&Q_DX>+OAK-PR6-P^4Z#TB#9,Y-X&S. M7<7!4D']U<'J&US?=@'7&Q7SJ^IX>LRKA-%I\#[WJ>\??D'<(_`P`X1WQ!R7 MZ-TCNK#2(RKD',1C$I(^80)SJ>@%'XU\!P;KNBJK(8X&7C$O"0/NR$@LH$*\#+GC_Q M?[SS9)#?.^-354N.$230@WZ:P'TM+]?=N^NG:"7OT2[&VLTTRQAP\9 M=FD\H@M76G1Q10(\->`I>LFHC69VYK\"_+P#;X88+V<-GE-L@02IC MG^NPOE\GG`F..T2_)RK+MY:64O'FPP'=JA*Y,4F[[ MJZO#_7Z$Y^B,-VA"4A#(.H^ECM+R[U[ M3C>6<%UMYV9;(Z?K[KAIU&L,`Q#'B6=_07_'G1V)QEZ2,?DE(=C9QY5%( M$UUYW"XF#Z[,7.H'5W9-+Y=;DT/('-M6T#=S?T]A#,E>P_^,`#\J2]S/Y%FL M4\5.1\!J/1+*7Z+P/HRVSD.PPO_#OWH.@ZAX$F?>O](XR=(_R.@5=7[!JGNV MBU_%$_#1G8"8O4?HXKSU[)0+C)::@^]=^7+-[H(KXJC9MME7S9\Y#N[R6HIR$,2E;MO1\90IF[CF8N)?BK"Z,S1=%JEU0O.UQV$.'MLJ-E>Y'N+CNDQ11LEQZ8R/)@!D0RA`^#JZ*D2,GNI;-=@RUR8TF?U M[E'"^5Q@9BB9!5ZIAW:AAA+O>G:I%(6"':PV MAHFSJ+@.':8Y#C52JU6M,\^J@$U'7`XIARYCG_6UH`G>R[TM'@+4&DG6[R-Y_BGT".X` M7@\3)YZ+J/04QG$^)5:C?AKY4Y\.&0T7J620^8Z_0W%<,49L?U7@1^CXB MEU044`-!><`S>K`[;R#;[56M\6SQ(-D>D]$:RS87O.V>]*W!5.03;'>?;XVC M^CLSG)O\V.2?U_0M!K^GZ)]W^PY&:TVLPA$Q`IF'V=P(F\,$4H[X<3`IHA5H M'#CVC"]7G_"?J1.A"?B'\F^UN"BCAXM+F;2>0744$T=1<@U:3'`?#U0'' M-+MNF.(PK'$8YKJ0*SHFZB.:N"+X5`KN0,G.)B\!M?G1SWZ+O6'X!OCK]W@Z MN'XT^N'_`E!+`P04````"`!B,6Q$&)FDT7`H``"3[@$`$0`<`'-P<&DM,C`Q M,S$R,S$N>'-D550)``.X,B!3N#(@4W5X"P`!!"4.```$.0$``.U]W7/;N)+O M^U;M_\";A[MSJD9Q[$PRD]3,V9*_,KYK1UY;F3EW7T[!)"3QA@(T(&E;^]=? M-$!2(`%")"4Y8)8O,[&(;G2C?_AJ-!J__OOS,O(>,8M#2GY[=?SZS2L/$Y\& M(9G_]NK+_6A\?W9U]>K?__ZO__+K_QJ-O+L[[YP2@J,(K[U_^#C"#"78FZ)G M2NAR[=W["[Q$/WH/*,:!1XGWC].[:^_D];'G+9)D]?'HZ.GIZ35C0<[DM4^7 M1]YHE%?PAQ3EH_?^]0F71OER1U,2?/3>O#_^YC]^]^>C_ZZ1WZ>?3P MQG\W^H!.COUWQ^CXY.?W"M49PRCA#+V`R_G1.WES_-/HS=O1\?'TY.3CR;N/ M;T[^2RU-5VL6SA>)]X/_-U[XS;L1IWCKW;V^>ZTH_K^]>TIB7GJY0F3MC:/( MNP.JV+O#,6:/.'B=,8U%>WB\D4G\VRNE"9[>OJ9L?L2K.#[ZQ\VU;+=7__HO MGBS[\?F!16&)`G[):=X>A21.$/&Q0A*%Y*N%`CZ#6=1*-)),K.,/'SXS1%:%>5G*'X0I;,/1]!4HS?'H[?'9:IDO<*QD4Q\,=/%JU59_WB%_82E MR]4"L:6`#=`=GY2H"+=1NC2W0I"P(ZCPB!<:\5*8A;Y*NIU.HX$R05*0J0W^ M[DA^5$K[',$)6Y>+Q]A_/:>/1]E'(5\W`8??*A: M8I)<4K8\QS.41ES8OU(4A;,0!Z\\E"0L?$@37"J0DDV1OP.77Q$A-!$CBO@; M?N%`)3.:_,W_SHBS$C;"%>,#)TDZ4&XDJZ?+?LUMLD]3W7.9 M!;`FL\N0\!$Y1-$MC85`9Q&*XPQ?8+0[3O#/A@1V&[[EABL8>3!OD9A&(*(I@9O/L%QDD\&'`?!KQ%?(1-%C@)>0NUMJ:@WF+2GYJ;U/NA),[?!A,W M-O$57]LN\3A*,"-S&Z\=S;C%1]BC\Z\R0J6S)QLZ)G-S<;QGA"^ M,SA#JS"IZX#50G:3O6]N,ECG,[S`).9(\"0VO!^N:1P/7:^Y#>]Y$;R@41C[$8U3AJ?X.3F-J/]5`<$+5FJ'U`?8#Q54\`>.?1:N MA`.)X^@TC4."X_A'OB"+0P$M58H?Q1XJF^#)W+O'K+<QEO3S`?3-_5 M]*J)>+.>KC]A.F=HM0C].SS/EP6B#)>\)1(Z,[<#XVT5&"4L_"C@\;#V-I5Y MLC8Q8>1EH<(!-ITGBZ+Y^2Z#;Q3Y+E&H=X:T)+5KR+4#9KM-*S) MZ!>($;Y*CV\Q$YVSG9'KJ>U&?5\U*LP!TI^8>QEW+,=W.P6[CGZLV!F:>X.;=8`0_BCH&^W:U;^Z,X=/?0TB$9EU'ZX:L[!;_ M1=O^95P]A>U@[QVV_`\[[/#-M':+:N[`._Q(HT=PZ\""7'B6&0["PUNI6!W<::0RW;,G%F@TEW\'^D#S'^*^7_O'AL/U37 M4]N-J3NV"D:>X#08M*M!_S-%+,$L6A??E+#>=M9MR,IN:MV5I1R>XHBKB0.O MJ,DKJO+.48(&&'3NU_X"!VF$)S-P/N3!$_\IPMK7?"K,CB4[S]^[\+<#1G.3 MY55Y5U?\KZ(Z,;%O*LP/6H>YP)E8GSP(XIO$_!25V]&F.>SV$OOC_9!7/X2* M'CS88XKXGKT9R%JRM$-']_Q9`C^\'R3/`0^'CP!I`8BV/.V(T#R']=$@`QZ^ M65A("WCL6(45+6\U%V37$)$!2]\Z5J3-%+27FNS(TORA=7$C`W)>+H"D!4;: M\K2C0?..FH))!B0<+JJDA>6W\;!;6O.16B),!H,?-M2DA=&;\+$;7O.GUH2= M#$9_H?B3%M9OQ=`.`\W7:HQ%&4!PZ/B%%M9OQLEN=LUC6A?+,%C^$$$-+:Q= M3VVWL.:E-`8X#.9]X4B'5OV\`V,[*#3_HS7J80#'0<,?6D"A`1N[X34WHQH* M,=CYA8[06UB\%4.K[7^RWD7>=IP^8*-I)K:BA97CP,DL7TZ+H\#)3#T(A(PD M^2E@=@@X#@*A0?) MS)JZ@,/A2XPGLR*G0".P[96W'6BZTW&WG`D#Q/8',?7P.VM_V8:-0-22V@X3 MS6-I/4,?,'!X#!1C!&1/XD,!'`\\HBC;N-P@]I47$]X*/V5!H3L"R%P0DV)"`J<71$(!ZQS'.&D^!5F9V)&A^6!;(B.O MS).U#=!X&6@84CCOE:,=-.UB1!N`IIP">@#1_D"4;S6#BKW'2\J2+##]XAE" MIW!C&+7A:0>2YO/=`J2B9@U$GEJYE]4^`.D0"]Q/E`9/8=1\V#&06F'Q3G,' MMUC(YE4,MC_`[EFDIVZY.#$2V^W?*OED>0PJBCP[B6 MDQU4._B')5*@RA'4Z2F5#EAIC15Q#RZI7K.[PSXE/F_5[&*ON505+3OQLN-% ME\P`SX;H*I4-484>8YE[N?.=/ M.Y2PL%D/\/N&\%-*'0Z`:B5V"&I^[(-"L'Q/=4!AVV@@N*HG[FVJUS:;!?NT M(+4C1G-BUUXG'0(T#FSY3027\7.-?WHG7G9L:'YI"S;4$+"Z4H,_>K^`*>X6 M9F:>B%#/^!-#L%'^$H=D?AHA_RL?R3F[6'Z^9:'//]S0`&N^ZT-58X79>SWL MN1YFRMW''&E>)H^7">0)B3PATBB3*2OC95)Y0JP!AZ[@T'J.^R)UVA':/.?" MOA$Z'`F_P%0KFW[L)^%CF&@;R0X<[&@RYVQH-JWF,,FK&A!Q0$2([JKYJ%K3 MV]&@.<<[H$%6-&!AWUBXPW'"QV,^9(N"'4>(.BYV7#1^'ZJ,BTUE&42&D>)P MJYVJ99\0"QJ.%UNYV-%A?D2JR8I$!XBH;X#'GN!Q%<IV8.Q<@QU#9B>P MCJ&:$2,7Q>._;(3Q*/-R<<3$(P0J]L`#\/8`O'R)^2=B3-SWM2Q0FU':@6+V M"!N`LEF09A4,Z]#NAO^,$\CS)S.!Y-D#84Y/\[3IQA)5%'1E8X7$SYKWUI:7 M4%Z"R.H#=%B3&`Y`V0=0M`B_+S$$]TE#@)L4Q:$_)L%Y&*5\8.8\.L!HYTKL M(-,7SS[41K@ MX)+1Y=FFP8J!R`+!/5=@AY_FL56`DJ&P#G[*/?-<&&_&I?$4<2H#X6J`7F?H M%6X5-3-JL=B1][-(D`=\KHOBFM>F.R,[E#1W;UTVU](B2E[N@J&JJ%$A')PW M>P)*OD:=S*[Q(X[>7A$^5<19"2[B'71FEDUGS2#3DJ4=/(U3`8\VRVV.'E&S M]]:3=>8<9TK\^>N-K!HJ?`J`/+IN815%TY12A5[RGU M#W#:"YPV*XTHHGZV:)W2!$6W*?,7*,80*(+%ZT;RFJU\B\YDEI MB9&]H#6ERKJD"8AVK,$*K5_T!!TUT))2@/=16T5EHE065)DP,/$IX@RH:XVZ M._Q(HT?>QEP.L#T?ZL-FR9M;4-I1HOFN"\[RXA3@0#`?MFC[L[OYZ95&AF]# M:K>\YC:N?;MEL/R!+7^&&(.7Q*6_=#([>7/\BU)2E&D&A$:<[+C0?,`67.35 MY9Y>/EI`C262[/V?`2K[@8J2'E#L1OFN`7-ED^SZ&J0&F)/PO_6-T,[\[+#1 MO+\VV)1R#TPT'S^YK?C1JFEH.: M?'/J?,[2^3FUSX0U7)BVI+>#0_/5GEF?&!O&D9<`PJ;W7Z8)C!!"V^!BT;L[#!I^1)=>2R1M7I9M9ZHU\LK'I#3&CG%\W+E9>4F'N\4\XX) MJ6<>0XC!/L6$BYY<4J905O&S'Z9V%-F?M:NN5\N1?0^B>N^'0H"_>9D(PK-? M?B!O@%1W2'6&S2[0^*!Y42O0*)A[/V3L_S;8?:]V+_Y9M>-Y.)MA%HOH21$V MFV56N,3@J1:/(*8)9>L[E.#Q:A6%X#]7QXQMP#ETS7;D:9[9"O(V?QI!F,F8 MA7-F4F:Y'3(YO4)0#R3U,E'!KU\>W`84[W5"A'\CLH[/L8Q*X07,^;I;T]L1 MI7E\K=-<5LN_Q5Y>C\#:D+9[=S`TVE!M+6\WMN;&K1A[V"_MWZY%Y-(7P@KO M)?^2#>8:%@ZDFN0Q??HYFSYZWUU[3A;>M-V%JAXF>=V'K0]UM MW_4>P-063)D'ZNH*#DV%)F,"YHW"&9REYL\':'AI2F>'A)Z1(?>(75WQOPK> MPGNVX;YYU>!_D,7A/P\(#D%GWK/X)>&%?GL5A\M5A%]EOR'F`WT)#D]O7U,V M/SK^\.'#D2AUM)*/=X8X/LK9Y@PTZN<'%@GZDS=OWDK\5-HODRKGL&!XQL5: MK<+1R9OCM\/R^CO$@2)E"+>K$/&,4_>BB*7AVYJWG9C`T4YP0& MQ<\+-CW1.T(/.&JH,B]K4/D:./1$VVHW;Z`T)S$H?:LP,NG^ZQ'B7/AR2/S- M_R*$RM+R!ZXZ98E'T!+'*^3;!`])G,"C'J^\F(^A2W2=W12PD,!?HYQN!#^- MCD]&;X]?/\=!)F(;"38MW4Z"G*ZM!"JK=^*O(&E<=TX`E;YK5-T,Q0^".HU' M@,SX"(P_>G/,Y:VM5E2I4LX16@G"(QPE<<%KM.'5OO6#A!T!ER.2+C$+_6:- M4*6"EO@`S7_\?A<1*!EU%(.2S]TD,;;O[H:!7]K:1;"-L?]Z3A^/Q!J%K1N+ M8Z++_]A-D)0Q3'S!\:25)"IA\==HPZ:]+`$.6S=(3@/_V*DA\+._:%U[023^ MM5/](7G$<=):`H4L^_=.4L3)B@&SXS8R%$3B7Z,-N5H_EK="A`"_O=(?1 M',NBZN)Q'/,>GP4'PGSZS^8D);*9C44LXS M3%*@^<1HNLIK#WFMM0T`LH^#)5_M@4!)^(@O,8[/1$]*RHIO*;JSPG*F3S1] M?1%2OT^%*^%89S3.=Y"JKN92/5?S,R5^G7&WE>^YZOG59CB)S!^IF]):J'=@ M<;@^?Y@6$O?DUI#+2='3UAY6@A[!@P_??",5<46RZUGY\%VK_7:*'JE_AQ]0 M8E&V^KT?JLGKOY?@N(")^8IDSA!\S:>JZM/NL4PF5M*]&X.#-DI7-K`8-\)&:]6C#[FSY;( M)FA(T`<0%*I4[CC)'-)&I6M*]LO4UZ$/"(7%JE')TO=^J7831GRSQ<4L!Q17 M%#24ZI>:N=PB!3KO=OXBY.L/^&DR.^/X1"%1%B3&-FC+HA=3GJ9=1;%[+@]< M;"P`8,9'"^I^X4:,U*L:H]/E$C):HRA+,;*ED3KSZL>FH)&>=W@.QV&4K7=H M+#.3GK12<6GJ#L=I!)+(U5X05;N(>&:_4K%>F;@G^#G-:A4DR=QG!2Y%+7,)G6MTY)5/[I'8S4+)3LUDD+= MA[FXN6*W-.$_A2@Z0_'"X(K>F5-?NUT,TTII/-GH+9`@CM:VM513+OUL)>G- MRC.:Q?*,:<+REPC+#P?5-5)C)MG,Q:>M5?:;4[-6GAUYLA(=@LSS,`.[^A:R M/GCL31JI\^XFKWQM_%V>V2KM06'7/&IGB*`@1&0\ MFW&SB(!GL?/43KNV%73IT.L,\<:/*9_Y@5'`=TVK-?\#?XK6/HUF#.,;'*T6 M@!<9\VK0MB,'MYK!L!3*7EN"@_TX*6F\O7`/9D2C&F*K`BE^('"+[URX4;9I M;B3IPXC51)OK\@ZP.4E?`7"#V%VL9T M`M"%^'MJDW8C:!,.WV_K3.&C:9&X)W[NK2-;J]5D%FK"H;>S33KRPVVE#U MX53'H%">'+=ZKUKX0>2G[-!WH^_:WD8=6?:G`2>S3F$86JMUYM.+&(ZS",5Q M<5WB$_P'KDK((?%/#'MQ'(P?N7YS?/$,EW7T8*`=>+ATK%Q68\*$(R*3MQ(Y MN;VH:OP.\?O%8/L">@E3\.]=C-V1VXYF?ZG6*<^Q6PKN:/&7@/*J,CIG,"N10*SYSO$*DP#6^)KS MM3F-4^Y6+C8E]PG?AUVF4;3^@R]I^;R2A29-B+QD#R]23%C>#R"RKRWB*$CN$Q9^E3.,(?AM M6T&7IJ2-J%.&`AB)0%:^N;MEV=)F=6HG`N M&!>YB:BRM36JMY6F%TY#0_1WL5_?I*LW-L`6BKZJ'X,2$,`+;W-M4;Q2MC1I M^+SDMQQ[#-+"N`G/2C31K%QV-\WVNQ(P"&L9A0RE7!N#H+H4,F2E*X@.+,UQ M%9WL1??H7MN/:MERJGX!6E/"J95GD;?L'A.^DX'L9;&FA%Z@)^.?07;S,FQ+ M2?<67W#726SI+Y[]*(5E?Q9,(!.-&/I70XH^./SAD2`XMX`$R^&#H(2L=-I` MN:6<2T,EB*K*R<7^M**57'RV0KVP&WY(-JNHZY"(D:^D85V)DB\E`6_=MS-5 M2<9IY:C`^/6%I0^2CXLUK&72!]%^]7I<\6&8I>+4C^^LUW)0X$L^<94F7_]5 MM&M(TXP7M6\1.VB>05&,CFK5%(ZH^-X.^ MKMI2T*F%56UP2S/K-J3KDWUUE6HM7%_411M/T;-RSTXDZ)$OUG/!\16!"KE:T(<(\5K\:YQ^ MQXL>M%MJ"^V-KS/7XA;BLI3W^-, M0K4Q&A5W:0M??K,HSP)S)=]P4J.(MI;LA=^EK$2Q8,\2/^B]OEEYI[ITC<8`DQ$'#MYC*B M3WSX_[\8,=4E:"GCEO^O%)D=WT&XXB7O63I.[>6<0JE!5)JR1BHIY1Q7:4(: M&4DIYKA"TX5(`[%=I5)!UY5ZHHU4VA1S2Z$$XL.#9_QTAU<1\D49 M$6=2O/Y0TJ\%E50W?R_]8\!I[FN']Y<9$I5;/#2DHU*-V'?>TEC6BR)B8GE6;(K46=LF&FR"G[/24!@_?9\'\8MW26,DZIDL9\('YLU%NV%G50L3HM7!3Y$WW$ MC(CUD7Q#&C;$QN>%MI;LPT`MDF%-Z6>D23]$SCDVQ>>;/#OEI%`&K47GZIQ>6NUE(7B$F.#CA*4OB MBV21(K:L>@G.E#>T*X,^#"(;W4IZ%3]G9S/YXXJ8+1')G,)&&'=BT^.&FLQF M?)'/U-"M[H=.T1/U M&48Q/L?R_UZRB?X$$ M>"*(_9*R)\0">QMLH3Q88,:(N#+?,(+7'-; M!5=<'S*'BZ#Y8T-^NDQ%`H2:P-FN#`XV6^QU"+UEU,=Q;'Z'PQ@)^IF2WVDP M_QJ22(2#+O6@TOVR=['=PIKV&9=5N8-?[O[53_V8"[C41-2" M(@,N#5_=@E?VN!(??*,T@-&F\AY?29OMA?MALTR/&T20S*UVB7$6BFK2UURN M'^-M'@CW.XW@WJ4IHLY6R"5G+'L,#1%+Y9^=ZER0^X_XY4B&_(A_0G*0?FT.3.K=82?5XFR9G*(ID*L1M#6&C[,48:U)*(O?+ MBBIK>=-&H#VM\WVAF])-U.U!C\CWKEGB2`C@*F94OI:`2TZ/(F)=)'R0EK[# MJRR4G6]]$\@GS,GR4/OXS3!8+.5T96_'@=0XV4-O#,I&]4,TN#0'7Z('O M0&^X&1%<5Y";T.K"Q5;(I67,=3A')+CE3;I$/N:4/F]#;CA=H2T%W5**P%`K M>MHE\L6A=7XB421?KB1+:D'3ARG:I,X7DL9PXV3%_T[6,!.%2;;ON96N`]YQ M;]!SN$R76UJF':O=7!0'AT8S94*RMW;)6;G4+A21>)PHZW,(SS?%]6PMZ="N M,C^(X=,,S$0B*T'-_*0/>.UI71H#V[Q`^'T\-MCT7<'^/R'8ZK7`[^1AP%:/ MVWW3=^SVJC,<;30)P=Y>U+'!":3==K)3HV1#,@<5KM/(39'%ZFUS.:MR8%#S M?<>=VC[/HXHWPUOCK"6A4V;+99=7M'27>ET!)Y6HE]Y-L0D*>'$\I2O8'U]3 M(#;H8"OFE$+Y50F3"^0O(,``FD/<*)[2.^QC"&B$1:#86U_\E:)H2N7F+$L# MP,$R#9?PRH"2]")CH3>X94I+!'"P&EQJQ90$X4J<=P+KF0AKE3_^:2Z)_#U8J2 M_T!K]#759#=]=$IXOGP7F?*`/067<4CXH&1*?;.]J#HM?/OL7_D$=T-)LHC' MLP1>,!6WJS=7V^1CN'\N0G]QEO)UP!*S,T3N<)(RDA566V!?'-UL*)G71ST; MB`W*&TLYM2#()55>IJB&^<4ST,"JZM-/X6$A:JJ[6E5N\[AIV]H5+YT3Q`!A-H>I\_"M%2U M6Q*6%CO?-I$JW[!QJ8O]VQ6I7F*J*^!2.$[NJ9E]6E7+!=B'NK^O2)=E==$#NENG!?BVTV5;H<+N-/5ZB*:\L(&\7#L3JZE9_):5!69=V]PP_AAQJFD^J M^L$E!U3EU5AQS)<_M@Y/Z\&17DF5)L5W!N(+7.86@68XB"\971JO"XY)8!IK M6Y'U8O]?HU%AUWM,0LH^\X$G%I?*\D+5M&R[,NI)8\%V0!ZDFFYKU!5H-L^\ M4)??Y.OE=CA=?\)TSM!J$?IW>"XO7F1E0`%3\M_N+$ICGP.Y@+F4RU7"Y]`\ MR8MA]*XIX=8P3A]#.,&)Q:7_4AX1>!E4YDL4/[9I?:OYM+8V7]S?O&4;EY3< MA4T?QOI=--32+.R#F4M'M19]LMC"LCI\"5#)+_$'Q-66DH+LD6IGM*AF].&2$3SW1=Q/#-+=$7.$@CB"21>TTEB;<1 M2\W*.X6K>HFK#^$T*/O"FC5[&4>16TFCG+D-P"5:CM2#7,SQ9'85P%G&+-3S M,M?NKPY=D6L[L8V^9PMXF7;SU(/PFO)]98.F:DKJNO*QEB-WXZ*J=I0F+=*1 MG\/-9'[D=1SGVY<;E/@+/F3`P6C^(&63YMH'7W>;+0\#.%VK3NOMS=*(SEVU M58_4QH6_;J!X0TJ'5<\=J!#%-8ZX6)F_[C2-N0WC6$FWU:0]=F#G;B,9]X$- M6J,1G;MJBQ'N%+)EJL^JC>%,5^8BXY#?E,G"+X22\OK,EF7K/MD[NQ397L>/*!22\G_GQ^YJ"[]XU2ZY M23MKGZ5DVJ0E*%9)>912OC[:1UNWJ:T7KM7.+9%UYOPUIRNBN?SVS_J[`*RF M'8Q]<>A74S8>JH*#!8;M[T!I7ZK;[B8>H*7MU3D4)7D@A>\P>#'S'2A7!S*+ M8+:\$!=%3R5.#M_N#<78.4;C12U2GMK':;*@#"*IQ[$:6*_,1\H5W39-OEL] M)8Q_TX!]*7_YSGT:1>L_Y)B8I6Z<$.7>O?(^B0P=_`01I#@0%Q-X)Z:LR(FN MKG9E*TA$*H&G]7LTUR1S;A>X$;L80K6U17T9MV*OIB@R9$,L_>K229`0;+K@ MX^A*O'>@'X/6EG!+#3;'(F&Y0?[J)P<%KY/:39&SEV_5]!?;,V>T(U,[]3=. MFC&E*RK,8;"2]LDI0SW16QJ2Y!X_8G()27CD'&V^'7">8D@#MZ!IS&?W"['" MPH:1;(],'6NL7$P^=4X7(0-)]21&I@9I1>BHTKEM%#L*"]KTW4;CJ*J?P9?; MU*:UA5U2[@N\M1R(NWJZP4P?G1*^2%J3Y:I4UWVFC[WPLV6"?Z:$X5E*`F"7 M;6EU]J%GMLG(%^5Q[KQKZ(KI1KZC:V6O\"TT@'O@K=5N0.22LO^%'U$4 M$IF?A2_;Y.Y4&W+LQ5P:?'))ZS1P5V1[TSO3XK\>Q?X"+Q'_Y_\'4$L!`AX# M%`````@`8C%L1$M--!SY=@(`J_`B`!$`&````````0```*2!`````'-P<&DM M,C`Q,S$R,S$N>&UL550%``.X,B!3=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`8C%L1`N+E4,')```E1H"`!4`&````````0```*2!1'<"`'-P<&DM,C`Q M,S$R,S%?8V%L+GAM;%54!0`#N#(@4W5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`&(Q;$3`L;-X]5D``'P8!@`5`!@```````$```"D@9J;`@!S<'!I+3(P M,3,Q,C,Q7V1E9BYX;6Q55`4``[@R(%-U>`L``00E#@``!#D!``!02P$"'@,4 M````"`!B,6Q$)V_IPS[S```-S`T`%0`8```````!````I('>]0(`&UL550%``.X,B!3=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`8C%L1+9(;O.G>P``4(\)`!4`&````````0```*2!:^D#`'-P<&DM M,C`Q,S$R,S%?<')E+GAM;%54!0`#N#(@4W5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`&(Q;$08F:31<"@``)/N`0`1`!@```````$```"D@6%E!`!S<'!I M+3(P,3,Q,C,Q+GAS9%54!0`#N#(@4W5X"P`!!"4.```$.0$``%!+!08````` ..!@`&`!H"``` XML 35 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2013
Fair Value Disclosures [Abstract]  
Summary of Asset and Liability Fair Values

The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2 (x)):

 

     December 31, 2013
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 410       $ —        $ 410   

Money market currency funds

     —           100,395         —          100,395   

Mutual funds

     —          3,061         —          3,061   

Deferred compensation investments, including life insurance cash surrender value

     —          5,361         —          5,361   

Equity securities

     3,593         —           —          3,593   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,593       $ 109,227       $ —         $ 112,820   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          3,949         —          3,949   

Deferred development costs

     —          —           17,742         17,742   

Ligand Contingent Consideration

     —          —           4,000         4,000   

Talon CVR

     —          —           4,329         4,329   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 3,949       $ 26,071       $ 30,020   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2012
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 987       $ —        $ 987   

Money market currency funds

        11,698         —          11,698   

Mutual funds

     —          2,323         —          2,323   

Deferred compensation investments, including life insurance cash surrender value

     —          2,881         —          2,881   

Equity securities

     2,480         —          —          2,480   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 2,480       $ 17,889       $ —        $ 20,369   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          2,365         —          2,365   

Deferred development costs

     —          —          12,233         12,233   

Deferred payment contingency

     —          —          2,287         2,287   

Ligand Contingent Consideration

     —          —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 2,365       $ 14,520       $ 16,885   
  

 

 

    

 

 

    

 

 

    

 

 

 

Activity of Level 3 Inputs Measured on Recurring Basis

The following presents a roll forward of our liabilities for which we utilize Level 3 inputs (see Note 2(x)) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “accrued and deferred development costs, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.

  

     Fair Value Measurements  of
Unobservable Inputs (Level 3)
 

Balance at December 31, 2011

   $ —    

Transfers in (out)

     —    

Deferred development costs

     12,233   

Deferred payment contingency

     2,287   
  

 

 

 

Balance at December 31, 2012

     14,520   

Transfers in (out)

     —    

Deferred development costs (see Note 13)

     5,509   

Deferred payment contingency (see Note 13)

     (2,287

Ligand Contingent Consideration (see Note 10(b))

     4,000   

Talon CVR (see Note 10(a))

     4,329   
  

 

 

 

Balance at December 31, 2013

   $ 26,071   
  

 

 

 

XML 36 R79.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Change in Fair Value of Contingent Consideration Related to Acquisition (Detail) (USD $)
In Thousands, unless otherwise specified
10 Months Ended 6 Months Ended
Dec. 31, 2013
Ligand Pharmaceuticals Inc [Member]
Dec. 31, 2013
Talon Therapeutics, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]    
Fair value, Beginning Balance $ 4,700 $ 6,500
Fair value adjustment for year ended December 31, 2013 (700) (2,171)
Fair value, Ending Balance $ 4,000 $ 4,329
XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 R73.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Ending Balance $ 26,071 $ 14,520
Deferred development costs [Member]
   
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Transfers in / (out) of Level 3 5,509 12,233
Deferred payment contingency [Member]
   
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Transfers in / (out) of Level 3 (2,287) 2,287
Ligand Contingent Consideration [Member]
   
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Transfers in / (out) of Level 3 4,000  
Talon CVR [Member]
   
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Transfers in / (out) of Level 3 $ 4,329  
XML 39 R89.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Provision (Benefit) for Income Taxes (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Current:      
Federal $ (8,357) $ 16,222 $ 1,255
State (691) 3,412 2,449
Foreign         
Current, total (9,048) 19,634 3,704
Deferred:      
Federal 36,183 (24,013)  
State (1,637) (9,892)  
Foreign         
Deferred, total 34,546 (33,905)  
Provision (Benefit) for income taxes $ 25,498 $ (14,271) $ 3,704
XML 40 R57.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Additional Information (Detail) (USD $)
12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2013
Plans
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Upon Termination of Employment [Member]
Dec. 31, 2013
In the Event of Optionee's Death, Disability or Retirement [Member]
Dec. 31, 2013
Restricted stock awards [Member]
Dec. 31, 2013
Unvested stock options [Member]
Dec. 31, 2013
Maximum [Member]
Y
Dec. 31, 2013
Minimum [Member]
Y
Dec. 31, 2009
2009 Incentive Award Plan [Member]
Dec. 31, 2013
2009 Incentive Award Plan [Member]
Dec. 31, 2013
2009 Incentive Award Plan [Member]
Maximum [Member]
Dec. 31, 2013
2013 Stock Incentive Plan [Member]
Maximum [Member]
Dec. 31, 2013
Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                            
Common stock authorized for issuance under incentive plan                     10,000,000     5,000,000
Increased number of common stock shares                   2,500,000        
Issuance of common stock                   30.00%        
Incentive awards available for grant                     5,700,000   50,000 10,000,000
Number of stock incentive plans 1                          
Exercise price fair value                       100.00%    
Stock based award vest 8.00% 5.00% 5.00% 25.00%                    
Restricted stock vesting period               10 3          
Restricted stock exercised period       90 days 365 days                  
Percentage of common stock purchase price                           15.00%
Purchase Plan offering period                           6 months
Maximum number of common stock shares available for purchase per participant                           50,000
Maximum number of common stock value available for purchase per participant                           $ 25,000
Increase in number of shares of common stock available for issuance under the purchase plan                           1,000,000
Unrecognized compensation expense           $ 6,500,000 $ 12,400,000              
Weighted average period to recognize compensation expense           2 years 4 months 24 days 2 years 6 months 15 days              
XML 41 R76.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Loans At Acquisition Date [Line Items]  
Net assets acquired $ 33,574
Goodwill 10,526
Talon Therapeutics, Inc. [Member]
 
Loans At Acquisition Date [Line Items]  
Cash and equivalents 131
Inventory 611
Prepaid expenses and other current assets 109
Property and equipment 30
Identifiable intangible assets 44,500
Total assets acquired 45,381
Accounts payable & accrued liabilities 5,231
Deferred tax liability 6,576
Total liabilities assumed 11,807
Net assets acquired 33,574
Goodwill $ 10,526
XML 42 R86.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies - Additional Information (Detail)
In Millions, unless otherwise specified
1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 12 Months Ended 1 Months Ended
May 31, 2006
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Dec. 31, 2013
ZEVALIN [Member]
USD ($)
Apr. 30, 2012
ZEVALIN [Member]
Licensing Agreements [Member]
EUR (€)
Dec. 31, 2013
ZEVALIN [Member]
Licensing Agreements [Member]
Country
Dec. 31, 2013
FOLOTYN [Member]
Sep. 30, 2011
FUSILEV [Member]
USD ($)
Dec. 31, 2013
Minimum [Member]
Dec. 31, 2013
Minimum [Member]
FOLOTYN [Member]
USD ($)
Dec. 31, 2013
Maximum [Member]
Dec. 31, 2013
Maximum [Member]
FOLOTYN [Member]
USD ($)
May 31, 2011
Targent, Inc [Member]
Apr. 30, 2011
Targent, Inc [Member]
Dec. 31, 2011
Targent, Inc [Member]
USD ($)
Dec. 31, 2013
Nippon Kayaku [Member]
USD ($)
Feb. 28, 2010
TopoTarget [Member]
USD ($)
Feb. 14, 2014
TopoTarget [Member]
Subsequent Event [Member]
USD ($)
Dec. 31, 2013
Henderson [Member]
Dec. 31, 2013
Irvine [Member]
Oct. 31, 2008
Allergan [Member]
USD ($)
Long-term Purchase Commitment [Line Items]                                            
Non-cancelable operating lease expiring                                       Apr. 30, 2014 May 31, 2019  
Rental expense   $ 1.2 $ 0.9 $ 0.7                                    
Milestone payments   6.0     5.0                                  
Additional amount paid by RIT to Biogen   5.5                                        
Additional milestone payment upon the achievement of an additional FDA approval milestone   10.0                                        
Minimum number of countries outside U.S. approved ZEVALIN for treatment             40                              
Fees paid to Bayer for acquiring licensing rights           19.0                                
Payment to Merck & Cie for the achievement of FDA approval of FUSILEV 0.1                                          
Amount receivable on approval of oral form of FUSILEV 0.2                                          
Shares of common stock, issued                             0.7              
Capitalization associated with milestone as intangible assets                               6.3            
Common stock issued, shares                           0.6         1.0      
Cash paid for sales milestone achieved                 5.0                   10.0      
Aggregate amount received from first sales milestone                 10.0                          
Percentage of royalty on annual worldwide sales under condition one               8.00%   15.00%   25.00%                    
Percentage of royalty on annual worldwide sales under condition two               9.00%                            
Percentage of royalty on annual worldwide sales under condition three               11.00%                            
Amount of annual worldwide sales on which royalty is payable under condition one                         150.0                  
Amount of annual worldwide sales on which royalty is payable under condition two                     150.0   300.0                  
Amount of annual worldwide sales on which royalty is payable under condition three                     300.0                      
License fees received   3.0                                        
Additional license fees   66.0                                        
Percentage of royalties on net sale of licensed products                   15.00%   25.00%                    
Up-front non-refundable payment                                           41.5
Upfront fee                                 15.0          
Payment related to agreement                                 10.0          
Payment on achievement of commercialization milestones                                 126.0          
Percentage of development cost                                   70.00%        
Percentage of development cost that is funded by TopoTarget for joint development plan                                   30.00%        
Percentage of required payment to be paid for the cost incurred                                   50.00%        
Upfront fee                                   30.0        
Additional payments based on the achievement of certain development                                   313.0        
Shares of common stock, issued                                   1.0        
Notice period for termination of agreement   180 days                                        
Deferrals and contributions   $ 3.9 $ 2.4                                      
XML 43 R81.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Notes - Additional Information (Detail) (USD $)
12 Months Ended 12 Months Ended
Dec. 31, 2011
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
2.75% Convertible Senior Notes Due 2018 [Member]
Dec. 31, 2013
2.75% Convertible Senior Notes Due 2018 [Member]
Minimum [Member]
Dec. 31, 2013
2.75% Convertible Senior Notes Due 2018 [Member]
Maximum [Member]
Debt Disclosure [Line Items]            
Sale of convertible notes, principal amount       $ 120,000,000    
Conversion rate, shares       95    
Conversion rate, price per share       $ 1,000    
Common shares converted value 37,000     11,400,000    
Money conversion price per share       $ 10.53    
Interest rate       2.75%    
Convertible senior notes maturity date       Dec. 15, 2018    
Net proceeds from convertible notes       115,400,000    
Professional fee       4,600,000    
Additional paid in capital   518,144,000 463,710,000 13,100,000    
Strike price per share       $ 14.03    
Common shares sold   64,000 60,000 11,400,000    
Debt convertible trading days         20 days  
Debt convertible consecutive trading days         5 days 30 days
Threshold percentage of conversion price       130.00%    
Convertible senior notes trading price       $ 1,000    
Percentage of product of last reported sale price of common stock       98.00%    
Convertible senior notes conversion description       Prior to June 15, 2018, holders may convert all or a portion of their 2018 Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Notes at any time, regardless of the foregoing circumstances.    
XML 44 R87.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]  
2014 $ 849
2015 950
2016 892
2017 843
2018 868
Operating lease future minimum payments, Total $ 4,402
XML 45 R77.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Amortization Period for such Intangible Assets Acquired (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Talon Therapeutics, Inc. [Member]
 
Acquired Finite-Lived Intangible Assets [Line Items]  
Total identifiable intangible assets $ 44,500
Developed technology - MARQIBO for ALL [Member]
 
Acquired Finite-Lived Intangible Assets [Line Items]  
Amortization Period 13 years
Developed technology - MARQIBO for ALL [Member] | Talon Therapeutics, Inc. [Member]
 
Acquired Finite-Lived Intangible Assets [Line Items]  
Total identifiable intangible assets 26,900
IPR&D - MARQIBO for NHL [Member] | Talon Therapeutics, Inc. [Member]
 
Acquired Finite-Lived Intangible Assets [Line Items]  
Total identifiable intangible assets $ 17,600
XML 46 R71.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Income (Loss) Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 4,486,160      
Preferred Stock [Member]
     
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 40,000      
Common Stock Warrants [Member]
     
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 160,816      
2018 Convertible Notes [Member]
     
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 343,600      
Common stock options [Member]
     
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 2,934,625      
Restricted stock awards [Member]
     
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive excluded from computation of earnings per share amount 1,007,119      
XML 47 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Schedule II - Valuation and Qualifying Accounts
12 Months Ended
Dec. 31, 2013
Valuation And Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts

SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS

Years Ended December 31, 2013, 2012, and 2011

 

Description

   Balance at
Beginning of
Period
     Additions
(Reductions)
     Deductions (1)     Balance at
End of
Period
 
      Additions
(Recovery)
to Bad Debt
Expense or
Deferred
Tax Asset
    Charged
to Other
Accounts
      
     (in thousands)  

Year ended December 31, 2013

            

Allowance for doubtful accounts

   $ 228       $ 11        —         $ (33   $ 206   

Year ended December 31, 2012

            

Allowance for doubtful accounts

   $ 471       $ (128     —         $ (115   $ 228   

Year ended December 31, 2011

            

Allowance for doubtful accounts

   $ 339       $ 139        —         $ (7   $ 471   

 

(1) Deductions represent the actual write-off of accounts receivable balances.
XML 48 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Summary of Other Assets (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]    
Investments in equity securities $ 3,593 $ 2,476
Deposits 190 304
Debt issuance cost 3,432 814
Life insurance cash surrender value 5,361 2,881
Other assets $ 12,576 $ 6,475
XML 49 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Schedule Of Investments [Abstract]      
Cash, equivalents and marketable securities, including long term bank certificates of deposits, and investments, total $ 159.8 $ 143.0  
Securities in continuous unrealized loss position, period Longer than one year    
Depreciation expense 1.2 1.2 0.9
Intangible asset amortization expense $ 21.2 $ 8.8 $ 4.7
XML 50 R75.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Acquisition-Date Fair Value of Consideration Transferred (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Jul. 17, 2013
Business Acquisition [Line Items]    
Total purchase consideration $ 44,100  
Captisol-enabled, propylene glycol-free melphalan rights [Member]
   
Business Acquisition [Line Items]    
Cash consideration 3,000  
Ligand Contingent Consideration 4,700  
Total purchase consideration 7,700  
Talon Therapeutics, Inc. [Member]
   
Business Acquisition [Line Items]    
Cash consideration 11,300  
CVR 6,500 6,500
Spectrum shares of common stock 26,300 26,300
Total purchase consideration $ 44,100  
XML 51 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments

Our future minimum lease payments are as follows:

 

Year ending December 31,    Operating Lease
Minimum
Payments
 

2014

   $ 849   

2015

     950   

2016

     892   

2017

     843   

2018

     868   
  

 

 

 
   $ 4,402   
  

 

 

 

XML 52 R52.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Rebates and Chargebacks [Member]
   
Schedule of Investments [Line Items]    
Balance as of December 31, 2011 $ 26,176 $ 9,064
Allos accruals assumed   2,371
Add: provisions (recovery) 63,609 91,059
Less: credits or actual allowances (55,818) (76,318)
Balance as of December 31, 2012 33,967 26,176
Data and Distribution GPO Fees and Inventory Management Fees [Member]
   
Schedule of Investments [Line Items]    
Balance as of December 31, 2011 14,149 9,808
Allos accruals assumed   182
Add: provisions (recovery) 19,067 32,793
Less: credits or actual allowances (27,843) (28,634)
Balance as of December 31, 2012 5,373 14,149
Prompt Pay Discount [Member]
   
Schedule of Investments [Line Items]    
Balance as of December 31, 2011 1,451 992
Add: provisions (recovery) 183 4,814
Less: credits or actual allowances (1,317) (4,355)
Balance as of December 31, 2012 317 1,451
Returns [Member]
   
Schedule of Investments [Line Items]    
Balance as of December 31, 2011 5,056 4,000
Allos accruals assumed   941
Add: provisions (recovery) (2,034) 159
Less: credits or actual allowances (122) (44)
Balance as of December 31, 2012 $ 2,900 $ 5,056
XML 53 R67.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail)
Dec. 31, 2013
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 28,101,704
Series E Convertible Voting Preferred Stock [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 40,000
2018 Convertible Notes [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 11,400,000
Unvested stock options [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 11,329,218
Exercise of issued warrants [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 445,000
ESPP shares reserved [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 4,540,986
Long-term retention and management incentive plan shares [Member]
 
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]  
Total shares of common stock reserved for future issuances 346,500
XML 54 R61.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Number of Shares, Outstanding, Beginning Balance 10,399,265 10,185,521 8,397,094
Weighted-Average Exercise Price/Share, Outstanding, Beginning Balance $ 6.57 $ 5.46 $ 4.17
Number of Shares, Granted 2,041,300 1,821,915 3,622,150
Number of Shares, Exercised (825,884) (1,287,430) (1,126,257)
Number of Shares, Forfeited (202,882) (316,825) (547,479)
Number of Shares, Expired (82,581) (3,916) (159,987)
Number of Shares, Outstanding, Ending Balance 11,329,218 10,399,265 10,185,521
Number of Shares, Vested (exercisable) - December 31, 2013 7,876,025    
Weighted-Average Exercise Price/Share, Granted $ 8.92 $ 11.57 $ 7.92
Number of Shares, Unvested (unexercisable) - December 31, 2013 3,453,193    
Weighted-Average Exercise Price/Share, Exercised $ 4.40 $ 4.52 $ 4.07
Weighted-Average Exercise Price/Share, Forfeited $ 8.22 $ 7.93 $ 4.81
Weighted-Average Exercise Price/Share, Expired $ 8.91 $ 7.69 $ 5.17
Weighted-Average Exercise Price/Share Outstanding, Ending Balance $ 7.10 $ 6.57 $ 5.46
Weighted-Average Exercise Price/Share, Vested (exercisable) - December 31, 2013 $ 6.11    
Weighted-Average Exercise Price/Share, Unvested (unexercisable) - December 31, 2013 $ 9.38    
Weighted-Average Remaining Contractual Term (Years), Outstanding 7 years    
Weighted-Average Remaining Contractual Term (Years), Vested (exercisable) - December 31, 2013 6 years 2 months 12 days    
Weighted-Average Remaining Contractual Term (Years), Unvested (unexercisable) - December 31, 2013 8 years 10 months 24 days    
Stock options exercised, Intrinsic value $ 3,435 $ 11,500 $ 8,255
Aggregate Intrinsic Value 25,849    
Aggregate Intrinsic Value, Vested (exercisable) - December 31, 2013 24,080    
Aggregate Intrinsic Value, Unvested (unexercisable) - December 31, 2013 $ 1,770    
XML 55 R47.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Components of Intangible Assets (Parenthetical) (Detail) (USD $)
In Thousands, unless otherwise specified
1 Months Ended 12 Months Ended
May 29, 2013
Dec. 31, 2013
Product Rights [Line Items]    
Impairment   $ 1,023
FOLOTYN distribution rights [Member]
   
Product Rights [Line Items]    
Impairment $ 1,023 $ 1,023
XML 56 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies and Use of Estimates
12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies and Use of Estimates
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES

The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, our management evaluates its estimates, including those related to (i) revenue adjustments; (ii) the collectability of customer accounts; (iii) whether the cost of inventories can be recovered; (iv) the value of goodwill and intangible assets; (v) the realization of tax assets and estimates of tax liabilities; (vi) the likelihood of payment and value of contingent liabilities; (vii) the fair value of investments; (viii) assumptions used in reporting stock-based compensation; and (ix) the potential outcome of litigation.

Such estimates are based on our management’s judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may materially differ from management’s estimates. In our judgment, the accounting policies, estimates, and assumptions described below have the potential to significantly impact our preparation of the accompanying Consolidated Financial Statements:

(i) Revenue Recognition

(a) Product Sales: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:

 

  (1) appropriate evidence of a binding arrangement exists with our customer;

 

  (2) price is substantially fixed and determinable;

 

  (3) collection from our customer is reasonably assured;

 

  (4) our customer’s obligation to pay us is not contingent on resale of the product;

 

  (5) we do not have significant obligations for future performance to directly bring about the resale of our product; and

 

  (6) we have a reasonable basis to estimate returns.

Our gross revenue is reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.

Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:

Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.

Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.

Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.

Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

 

Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.

Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.

(b) License Fees: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.

(c) Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.

(ii) Cash and Equivalents

Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.

(iii) Marketable Securities

Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive Income (Loss).

(iv) Accounts Receivable

Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.

(v) Inventories

We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.

(vi) Property and Equipment

Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.

 

(vii) Goodwill and Intangible Assets

Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October 1 each year.

We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

 

  (a) a significant decrease in the market value of an asset;

 

  (b) a significant adverse change in the extent or manner in which an asset is used; or

 

  (c) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.

(viii) Stock-Based Compensation

We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.

We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.

(ix) Foreign Currency Translation

We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).

We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.

(x) Comprehensive Income (Loss)

Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.

(xi) Basic and Diluted Net (Loss) Income per Share

We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.

(xii) Income Taxes

Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in “income tax expense” within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.

(xiii) Research and Development Costs

Research and development costs are expensed as incurred.

(xiv) Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

“Cash and equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.

The fair value of our “drug development liability” and our “deferred payment contingency” within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) internal estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.

“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See Note 10(a) for a discussion of CVRs granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

XML 57 R62.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Summary of Stock Option Grants (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Granted Stock Options Outstanding 11,329,218
Weighted-Average Remaining Contractual Life (Years) 7 years
Weighted-Average Exercise Price $ 7.10
Granted Stock Options Exercisable 7,876,025
Weighted-Average Exercise Price $ 6.11
Exercise Price Range One [Member]
 
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Exercise Price, Range lower limit $ 0.92
Exercise Price, Range upper limit $ 3.15
Granted Stock Options Outstanding 1,192,794
Weighted-Average Remaining Contractual Life (Years) 4 years 6 months
Weighted-Average Exercise Price $ 2.16
Granted Stock Options Exercisable 1,192,794
Weighted-Average Exercise Price $ 2.16
Exercise Price Range Two [Member]
 
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Exercise Price, Range lower limit $ 3.55
Exercise Price, Range upper limit $ 4.95
Granted Stock Options Outstanding 1,924,904
Weighted-Average Remaining Contractual Life (Years) 5 years 10 months 24 days
Weighted-Average Exercise Price $ 4.23
Granted Stock Options Exercisable 1,865,794
Weighted-Average Exercise Price $ 4.23
Exercise Price Range Three [Member]
 
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Exercise Price, Range lower limit $ 5.05
Exercise Price, Range upper limit $ 6.90
Granted Stock Options Outstanding 2,862,699
Weighted-Average Remaining Contractual Life (Years) 5 years 6 months
Weighted-Average Exercise Price $ 6.26
Granted Stock Options Exercisable 2,565,220
Weighted-Average Exercise Price $ 6.19
Exercise Price Range Four [Member]
 
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Exercise Price, Range lower limit $ 7.00
Exercise Price, Range upper limit $ 8.99
Granted Stock Options Outstanding 2,329,167
Weighted-Average Remaining Contractual Life (Years) 8 years 2 months 12 days
Weighted-Average Exercise Price $ 8.17
Granted Stock Options Exercisable 1,147,138
Weighted-Average Exercise Price $ 8.26
Exercise Price Range Five [Member]
 
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]  
Exercise Price, Range lower limit $ 9.00
Exercise Price, Range upper limit $ 16.32
Granted Stock Options Outstanding 3,019,654
Weighted-Average Remaining Contractual Life (Years) 9 years 2 months 12 days
Weighted-Average Exercise Price $ 10.86
Granted Stock Options Exercisable 1,105,079
Weighted-Average Exercise Price $ 11.09
EXCEL 58 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O M=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D=R;W-S=&]?3F5T7U!R;V1U8W1?4V%L97,\ M+W@Z3F%M93X-"B`@("`\>#I7;W)K5]'96]G#I7;W)K M#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M8G-E<75E;G1?179E;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K5\\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K:&]L9&5R#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O M;G9E#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DUU;F1I<&AA#I7;W)K#I7;W)K#I%>&-E;%=O5]O M9E]396QE8W1E9%]1=6%R=&5R;'E?,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D)A;&%N8V5?4VAE971?06-C;W5N=%]$971A:6Q?0SPO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D)A;&%N8V5?4VAE971?06-C M;W5N=%]$971A:6Q?0S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D)A;&%N8V5?4VAE971?06-C;W5N=%]$ M971A:6Q?4S8\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K5]'96]G#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T M;V-K0F%S961?0V]M<&5N#I7;W)K#I%>&-E M;%=O#I%>&-E;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O5]3:&%R97-?;V9?/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]3=6UM87)Y7V]F/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE M;G1S7V%N9%]#;VYT:6YG96YC:65S7S(\+W@Z3F%M93X-"B`@("`\>#I7;W)K M#I7;W)K#I7 M;W)K%]0 M#I7;W)K#I7;W)K#I7;W)K5]O9E]5;G)E8V\\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0 M#I%>&-E;%=O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)U-04$D\'0^)SQS<&%N/CPO'0^)U-014-4 M4E5-(%!(05)-04-%551)0T%,4R!)3D,\'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO2!6;VQU;G1A'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E"!A2!A;F0@ M97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA"!A'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3H\+W-TF5D.R`V-"PQ,#0L,33PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S4L,#`P+#`P,#QS<&%N/CPO M'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XR+#`P,#QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO#H\+W-T'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`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`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO2!E;7!L;WEE92!T M87@@=VET:&AO;&1I;F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!S=&]C:SPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!S=&]C:RP@4VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q M,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C`Y-69A,6-?.#'0O:'1M;#L@8VAA M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPP.38\65E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5D(&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M"!A7)O;&P@86YD(')E;&%T960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA2!O<&5R871I;F<@86-T M:79I=&EE'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C$I/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO&5R8VES92!O9B!C;VUM;VX@6UE;G1S('1O(&%C<75I M6UE;G0@;V8@6UE;G0@;V8@8V%P:71A;"!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-H M86YG92!R871E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/CQB/C$N/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@ M86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/D1%4T-225!424].($]&($)54TE. M15-3+`T*($)!4TE3($]&(%!215-%3E1!5$E/3BP@04Y$($]015)!5$E.1R!3 M14=-14Y4/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M(2TM('AB2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@-G!X)SX-"B`\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CX\8CX\:3XH82D-"B!$97-C#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY3<&5C=')U;0T*(%!H87)M86-E=71I8V%L2UO=VYE9"!S=6)S:61I87)I97,-"B`H)B-X,C`Q0SM3<&5C M=')U;28C>#(P,40[+"!T:&4@)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LL#0H@ M)B-X,C`Q0SMW928C>#(P,40[+"`F(W@R,#%#.V]U#(P,40[+"!O2!C;VUP M86YY('=I=&@@9G5L;'D@:6YT96=R871E9"!C;VUM97)C:6%L#0H@86YD)B-X M03`[9')U9R!D979E;&]P;65N="!O<&5R871I;VYS+"8C>$$P.W=I=&@@82!P M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY792!C=7)R96YT;'D-"B!M87)K970@9F]U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I% M.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>#(P,C([/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX] M,T1L969T/@T*(#QP(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&55-)3$56(&EN M:F5C=&EO;B!F;W(@<&%T:65N=',@:6X@=&AE(%4N4RX@=VET:"!A9'9A;F-E M9`T*(&UE=&%S=&%T:6,@8V]L;W)E8W1A;"!C86YC97(@86YD('1O(&-O=6YT M97)A8W0@8V5R=&%I;B!E9F9E8W1S(&]F#0H@;65T:&]T$$P.SPO<#X-"B`\=&%B;&4@#(P,3D[#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D9/3$]464X@:6YJ96-T:6]N(&9O2!P97)I<&AE6UP:&]M83L@86YD/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@-G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@#(P,3,[;F5G871I=F4@ M86-U=&4@;'EM<&AO8FQA6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY792!A;'-O(&AA=F4@80T*('!I<&5L:6YE(&]F('!R M;V1U8W0@8V%N9&ED871E$$P.W)E9W5L871O'!E"<^#0H@/&9O;G0@6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM M5$]0.B`V<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQI/E!R:6YC:7!L97,-"B!O9B!#;VYS M;VQI9&%T:6]N/"]I/CPO9F]N=#X\+W`^#0H@/'`@#(P,4,[4T5#)B-X,C`Q1#LI+B!4:&5S90T*(&9I M;F%N8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE(&9I;F%N8VEA;"!P;W-I M=&EO;BP@$$P.S$L(#(P,3(L('=E(&%C<75I#(P,4,[06QL M;W,F(W@R,#%$.RD[(&%N9"!O;B!*=6QY)B-X03`[,3"<^#0H@/&9O;G0@#L@5$585"U)3D1%3E0Z(#0E)SX- M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY792!O=VX-"B!F:69T>2UP97)C96YT(&]F(%-P96-T2PF(W@R,#%$.R!A2!R M979E;G5E(&1E2P@=V4@;65E="!T:&4@87!P;&EC86)L92!'04%0#0H@8W)I=&5R:6$@ M87,@:71S("8C>#(P,4,[<')I;6%R>2!B96YE9FEC:6%R>28C>#(P,40[+B!! M0T*(&)E;F5F:6-I87)Y(&]F('1H:7,@=F%R:6%B;&4@ M:6YT97)E2UO=VYE M9"!S=6)S:61I87)Y(&9O"<^#0H@/&9O;G0@&-L=7-I=F5L>2!O;@T*(&1E=F5L;W!I;F<@86YD(&-O M;6UEFEN9R!O;F-O;&]G>2!A;F0@:&5M871O;&]G>2!D'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S M(&%N9"!5'0^)SQS<&%N/CPO2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O M;&EC:65S(&%N9"!5'!E;G-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3=6-H(&5S=&EM871E M#(P,3D[2!M871E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAI*0T*(%)E=F5N=64@4F5C;V=N:71I M;VX\+VD^/"]B/CPO9F]N=#X\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T* M(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C M96QL6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@Q*3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/F%P M<')O<')I871E(&5V:61E;F-E(&]F(&$-"B!B:6YD:6YG(&%R#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T M;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^/&9O;G0@0T*(&9I>&5D(&%N9"!D971E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`V<'@[($U! M4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@S*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/F-O;&QE8W1I;VX@9G)O;2!O M=7(-"B!C=7-T;VUE6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@1D].5"U325I%.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@T*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L M969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/F]U#(P,3D[$$P.SPO<#X-"B`\=&%B;&4@ M$$P.V%N9#PO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@-G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO M<#X-"B`\=&%B;&4@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=7(@9W)O#(P,40[(&EN M('1H92!A8V-O;7!A;GEI;F<@0V]N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/ M=7(@1U1.#0H@97-T:6UA=&5S(')E9'5C92!R979E;G5E(&EN('1H92!S86UE M('!E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/D=O=F5R;FUE;G0-"B!#:&%R9V5B86-K6UE;G0-"B!D:7-C;W5N=',I(&%R92!E6UE;G0@=&5R;7,@ M=&\@97-T:6UA=&4@:71S('9A;'5E+CPO9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQI/E)E8F%T97,\+VD^.@T*(%)E M8F%T97,@87)E(&5S=&EM871E9"!B87-E9"!O;B!T:&4@8W5S=&]M97(F(W@R M,#$Y.W,@86-T=6%L('!U6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R M<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CX\:3Y-961I8V%I9`T*(%)E8F%T97,\+VD^.B!/=7(@<')O9'5C M=',@87)E('-U8FIE8W0@=&\@2!D:7-C;W5N=',@86YD(')E8F%T M97,@87)E('!R;W9I9&5D('1O#0H@<&%R=&EC:7!A=&EN9R!S=&%T92!G;W9E M2!B87-E9"!O M;B!A(&-O;6)I;F%T:6]N(&]F(&UA0T*(&UA;F%G96UE;G0F(W@R,#$Y.W,@:G5D M9VUE;G0@=VET:"!R97-P96-T('1O(&UA;GD@9F%C=&]R6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E M)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CX\:3Y$:7-TF5D('=H;VQE6%L='DL(&]R(&EN(&-E M6UE;G0@;6%Y(&)E('1R:6=G97)E9"!B>2!T M:&4-"B!S=6-C97-S9G5L(&-O;7!L971I;VX@;V8@82!P:&%S92!O9B!D979E M;&]P;65N="P@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAI:2D@ M0V%S:`T*(&%N9"!%<75I=F%L96YT#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#87-H(&%N9`T*(&5Q M=6EV86QE;G1S(&-O;G-I"<^#0H@/&9O;G0@2!S96-UF5D(&=A:6X@*&QO"<^#0H@ M/&9O;G0@#(P,3D[6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\ M:3XH=BD-"B!);G9E;G1O#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!V86QU90T*(&EN=F5N M=&]R>2!A="!T:&4@;&]W97(@;V8@=&AE(&%C='5A;"!C;W-T('1O('!U2P@;W(@=&AE(&UA MF%B;&4@=F%L=64I+B!#;W-T(&ES(&1E=&5R;6EN960@;VX@=&AE(&9I M2!Q=6%N=&ET:65S#0H@:6X@<')O8V5S2!T M;R!R961U8V4@:70@=&\@:71S(&YE=`T*(')E86QI>F%B;&4@=F%L=64N/"]F M;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU,1494.B`R)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@2!O9B!L;VYG+6QI=F5D(&%S#L@34%21TE. M+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`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`\=&%B;&4@#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@ M=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^/&9O;G0@'1E;G0@ M;W(@;6%N;F5R(&EN('=H:6-H(&%N(&%S$$P.SPO<#X-"B`\=&%B;&4@"<^#0H@/&9O;G0@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E=E(')E8V]G;FEZ M90T*('-T;V-K+6)A'!E;G-E(&9O2!A=V%R9"!V M97-T:6YG('!EF5D M(&]N(&$@2!S M=6)J96-T:79E(&%S6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/CQI/BAI>"D-"B!&;W)E:6=N M($-U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E=E('1R86YS;&%T90T* M('1H92!A'!E;G-E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(')E8V]R9`T*(&9O&-H86YG92!R871E('!R979A:6QI;F<@870- M"B!T:&4@9&%T92!O9B!T:&4@=')A;G-A8W1I;VX@=VET:"!R97-U;'1A;G0@ M9V%I;G,@86YD(&QO2!T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!- M05)'24XM5$]0.B`Q.'!X)SX-"B`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`T* M(&%S"!B87-I0T*(&9O'!E8W1E9"!T;R!R979E"!A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&AA=F4-"B!R96-O2!T:&%N(&YO="!T:&%T('1H97-E#0H@9&5F97)R960@ M=&%X(&%S#(P,40[('=I=&AI;B!T:&4-"B!#;VYS M;VQI9&%T960@4W1A=&5M96YT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAX:6EI*0T*(%)E#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY297-E87)C:"!A;F0-"B!D M979E;&]P;65N="!C;W-T"<^#0H@/&9O;G0@#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY792!M96%S=7)E(&9A:7(-"B!V86QU92!B87-E9"!O;B!T:&4@<')I M8V5S('1H870@=V]U;&0@8F4@2!TF4@=&AE('5S92!O9B!O8G-EF4-"B!T:&4@=7-E(&]F('5N;V)S97)V M86)L92!I;G!U=',@=&\@=&AE(&5X=&5N="!P;W-S:6)L92X@1F%I2!T:&%T('!R:6]R:71I>F5S#0H@=&AE(&EN<'5T2!G:79E2!M87)K970@9&%T82X-"B!4:&5S92!I;G!U=',@:6YC;'5D92!Q=6]T960@ M<')I8V5S(&9O0T*(&]B2!T;R!, M979E;"8C>$$P.S,@:6YP=71S+CPO9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>#(P,4,[0V%S:"!A;F0-"B!E<75I M=F%L96YT#(P,40[('=I=&AI;B!O=7(@86-C;VUP86YY:6YG($-O;G-O M;&ED871E9"!"86QA;F-E#0H@4VAE971S(&EN8VQU9&4@8V5R=&EF:6-A=&5S M(&]F(&1E<&]S:70@86YD(&UO;F5Y(&UA#(P,4,[36%R M:V5T86)L90T*('-E8W5R:71I97,F(W@R,#%$.R!C;VYS:7-T(&]F('!U8FQI M8VQY+71R861E9"!E<75I='D@:6YS=')U;65N=',-"B!T:&%T(&%R92!V86QU M960@=71I;&EZ:6YG($QE=F5L(#$@:6YP=71S+CPO9F]N=#X\+W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E1H92!F86ER('9A;'5E M#0H@;V8@;W5R("8C>#(P,4,[9')U9R!D979E;&]P;65N="!L:6%B:6QI='DF M(W@R,#%$.R!A;F0@;W5R#0H@)B-X,C`Q0SMD969E$$P.V5S M=&EM871E'!E8W1E9"!C87-H(&]U=&9L;W=S('1O('1H:7)D('!A M6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P M,4,[06-Q=6ES:71I;VXM6EN9R!#;VYS;VQI9&%T M960@0F%L86YC92!3:&5E=',@2!I;B!C;VYJ=6YC=&EO;B!W:71H M('9A2!A7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VL@6T%B'0^)SQS<&%N/CPO'0^ M)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=) M3BU,1494.B`R)3L@34%21TE.+51/4#H@-G!X)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\ M:3XH82D@0V%S:`T*(&%N9"!%<75I=F%L96YT6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5. M5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q,RP@=V4@:&5L9"!S=6)S=&%N=&EA;&QY(&%L;"!O9B!O=7(@8V%S:"!A M;F0-"B!E<75I=F%L96YT2UR871E M9"!I;G-T2!5+E,N('1R96%S M=7)Y#0H@8FEL;',@;W(@52Y3+B!T2UB86-K960@2!S:6YG;&4@:7-S=65R+B!792!M86EN=&%I;B!C87-H#0H@ M8F%L86YC97,@:6X@97AC97-S(&]F(&9E9&5R86QL>2!I;G-U2!O9B!A(&-O;7!L971E(&QO#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@,'!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/D-A2X@5&AE(&-A#(P,4,[0F%N:R!#1',F(W@R,#%$ M.RD@87!PFEN9R!, M979E;"`R(&EN<'5T"D\+VD^ M*2!B96-A=7-E(&]F(&]U6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1% M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG#0H@:7,@82!S=6UM M87)Y(&]F(&]U#L@34%21TE.+51/4#H@ M,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/E5N6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/D=A:6YS/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/F9A:7(\+V(^/"]F;VYT/CQB6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/E9A;'5E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/DUAF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@ M+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q M,SPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY"86YK(&1E<&]S:71S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C4U+#DQ,3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY-;VYE>2!M87)K970-"B!F=6YDF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P,"PS M.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,#`L M,SDU/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,#`L,SDU/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D)A;FL@0T1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,3`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/DUU='5A;"!F=6YDF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L,#8Q M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#`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`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!C87-H(&%N9"!E M<75I=F%L96YT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$U-BPS,#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/D1E8V5M8F5R)B-X03`[,S$L M#0H@,C`Q,CPO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY"86YK(&1E<&]S:71S/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C$R."PP,#`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$R."PP M,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`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`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A;FL@0T1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY.#<\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CDX-SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/DUU='5A;"!F M=6YDF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(L,S(S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`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`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!C87-H M(&%N9"!E<75I=F%L96YT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$S.2PV.3@\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!F5D M(&QO65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\ M:3XH8BD-"B!02!A;F0@17%U:7!M96YT/"]I/CPO8CX\+V9O;G0^ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!R;W!E M#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M$$P.S,Q M+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C4L,34T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY,86(@86YD(&UE9&EA#0H@97%U:7!M96YT/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@X-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D]F9FEC92!F=7)N:71U MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$L-#DR/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C(L-SDY/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E!R;W!EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+#8P-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXH3&5S6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH.2PP-S`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH-RPS,34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!R;W!E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L-3,U/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$97!R96-I M871I;VX-"B!A;F0@86UOF%T:6]N(&5X<&5N#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q% M1E0Z(#(E.R!-05)'24XM5$]0.B`P<'@G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAC M*0T*($EN=F5N=&]R:65S/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4 M+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DEN=F5N=&]R:65S+`T*(&YE="!C M;VYS:7-T(&]F('1H92!F;VQL;W=I;F#L@34%2 M1TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@2`M+3X- M"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C@X-SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L,S$R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+#,P,CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9I;FES:&5D(&=O;V1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8L,C@Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/DEN=F5N=&]R:65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$S+#4Q.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$T+#0W.#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/CQI/BAD*0T*($EN=&%N9VEB;&4@ M07-S971S(&%N9"!';V]D=VEL;#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G1A;F=I8FQE#0H@87-S M971S(&-O;G-I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X M.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DAIF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E1R86YS M;&%T:6]N/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/D9U;&P\8G(@+SX-"B!! M;6]R=&EZ871I;VX\+V(^/"]F;VYT/CQB6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E!E M$$P.PT*("AY96%RF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E)E;6%I;FEN M9SQB$$P.RAY M96%R6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY-05)124)/#0H@25!2)F%M<#M$/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C$W+#8P,#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY-05)124)/(&1E=F5L;W!E9`T*('1E M8VAN;VQO9WD\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXR-BPY,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B@Q+#$P-SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C0Q+#DP,#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`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`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY:159!3$E.(&UA"U5+E,N/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH-2PS-#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXV.#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D954TE,158@9&5V96QO<&5D#0H@=&5C:&YO;&]G>3PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`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`^#0H@/'`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`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9/ M3$]464X@9&5V96QO<&5D#0H@=&5C:&YO;&]G>3PO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$Q."PT,#`\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@Q,"PU.#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`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`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=) M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A M;"!I;G1A;F=I8FQE#0H@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(X,"PV-C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8X,CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q+#`R,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@ M+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($9/3E0M4TE:13H@,3)P>#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]N($UA M>28C>$$P.S(Y+"`R,#$S+"!W90T*(&%M96YD960@;W5R(&-O;&QA8F]R871I M;VX@86=R965M96YT('=I=&@@375N9&EP:&%R;6$@:6X@;W)D97(@=&\-"B!M M;V1I9GD@=&AE('-C;W!E(&]F('1H96ER(&QI8V5N#(P,3D[ M2P@86YD(')O>6%L='D@ M86YD(&UI;&5S=&]N92!R871E2!A;F0@;6EL97-T M;VYE(')I9VAT6EN9R!#;VYS;VQI M9&%T960-"B!3=&%T96UE;G0@;V8@3W!E#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/DAIF%T:6]N/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DYE=#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@2`M M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY:159!3$E.(&UA"U5 M+E,N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,BPQ.3(\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,S4U/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,BPY.#`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXQ,RPW.3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY&3TQ/5%E.(&1IF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(W+#DP,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(W+#`P-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D9/3$]464X@9&5V96QO M<&5D#0H@=&5C:&YO;&]G>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q."PT,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B@R+#`W-SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W MF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$Q-BPS,C,\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4;W1A;"!I;G1A;F=I8FQE#0H@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(R."PT-C@\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@S-34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T#L@34%21TE.+51/ M4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!415A4+4E.1$5.5#H@-"4G M/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN=&%N9VEB;&4-"B!AF5D(&EN(#(P,3,L(&%N9"`R,#$R+"!A;F0@,C`Q M,0T*('=A2X-"B!%6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.S,Q/"]B/CPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$T M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C(R+#0V.#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P M,34\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M,BPT-C@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$V/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C(R+#0V.#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,3@\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXR,BPS,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXR,#$Y(&%N9`T*('1H97)E869T97(\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY,RPX-C<\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=O;V1W M:6QL(&ES#0H@8V]M<')I#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P$$P M.S,Q+#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I M;B!486)L92!";V1Y("TM/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8W%U:7-I=&EO;B!O M9@T*(%1A;&]N/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$P+#4R-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`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`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C4L,S0V/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXT+#6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D9O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXH,S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAE*2!/=&AE<@T*(&%S#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY/=&AE#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P$$P.S,Q+#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!" M96=I;B!486)L92!";V1Y("TM/@T*(#QT6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G9E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L-3DS/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXR+#@X,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D M>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CX\:3XH9BD-"B!!8V-O=6YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D%C8V]U;G1S#0H@<&%Y86)L M92!A;F0@;W1H97(@86-C6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM M5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD M(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8V-R M=65D(')E8F%T97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR."PX.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$Q+#`R,SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C8W)U960@<')O9'5C=`T*(')O>6%L='D\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY+#0Y.#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#DP,#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8V-R=65D(&1A M=&$@86YD#0H@9&ES=')I8G5T:6]N(&9E97,\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#0S,#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY!8V-R=65D($=03R!A9&UI;FES=')A=&EV90T*(&9E97,\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#,R-SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G9E;G1OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8Q-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!8V-R=65D M(&EN8V]M90T*('1A>&5S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY!;&QO=V%N8V4@9F]R#0H@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU+#`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`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED.R!7 M24142#H@,SEP="<^#0H@/&9O;G0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.V%N9#QB$$P.V%N9#QB3QB MF4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^ M#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T* M(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D M/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D)A;&%N8V4@87,@;V8-"B!$96-E;6)E$$P.S,Q+"`R,#$Q/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CDL,#8T/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/D%L;&]S(&%C8W)U86QS#0H@87-S M=6UE9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(L,S6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ.#(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/D%D9#H@<')O=FES:6]N2D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXY,2PP-3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`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`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQEF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@W-BPS,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,C@L-C,T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D)A;&%N8V4@87,@;V8-"B!$96-E;6)E M$$P.S,Q+"`R,#$R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ-"PQ-#D\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$L-#4Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXU+#`U-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D%D9#H@<')O=FES:6]N2D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXV,RPV,#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Y+#`V-SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH,BPP,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B@R-RPX-#,\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,2PS,3<\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH,3(R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A;&%N8V4@87,@;V8-"B!$96-E;6)E$$P M.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C,S+#DV-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4L,S6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\ M:3XH9RD@3W1H97(-"B!L;VYG+71E"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QLF4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L MF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C8W)U960@97AE8W5T:79E(&1E9F5R6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L.30Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY$969E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-S$\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY"=7-I;F5S3PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C(Y.#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#,U,CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4L.38U M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@ M0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q.'!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C M>$$P.SPO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXT M+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB M/D=23U-3+51/+4Y%5"!04D]$54-4#0H@4T%,15,\+V(^/"]T9#X-"B`\+W1R M/@T*(#PO=&%B;&4^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($1I$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;VUP="!P87D@9&ES8V]U;G1S/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-"PP.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ-#,L-#$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U-"PY.3(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'1A8FQE('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$ M;&5F=#X\8CXU+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX] M,T1L969T/CQB/E!23T150U0@4T%,15,L($Y%5"!"62!'14]'4D%02$E##0H@ M4D5'24].($%.1"!04D]$54-4($Q)3D4\+V(^/"]T9#X-"B`\+W1R/@T*(#PO M=&%B;&4^#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@2!F;W(@=&AE#0H@>65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,Q+#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(T-2PV.3<\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($EN=&5R M;F%T:6]N86PZ/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($5U$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR M+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C0N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#$X,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C(N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O M=&%L($EN=&5R;F%T:6]N86P\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P M+#`Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C,N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*(%!R;V1U8W0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$T,RPT-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#`N M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$P,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-C8S/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1% M6%0M24Y$14Y4.B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R,B!A;&EG M;CTS1&-E;G1E$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P-"PR-3,\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9/3$]464X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-"PS-S`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)28C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%I%5D%,24X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PS M.3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+CD\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(W+#4U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($U!4E%)0D\\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,Q-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+CD\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*(%!R;V1U8W0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$T,RPT-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ,#`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$P,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-C8S/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N M/CPO6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/C(P,#D@4W1O8VL@26YC96YT M:79E#0H@4&QA;CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&AA=F4@;VYE#0H@86-T:79E('-T;V-K:&]L M9&5R+6%P<')O=F5D('-T;V-K+6)A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@;6%X M:6UU;0T*(&YU;6)E$$P.V$@;G5M8F5R(&]F('-H87)E M&5R8VES92!O&5R8VES92DN M/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@ M2!B90T*(&=R86YT960@=6YD97(@=&AE(#(P,#D@4&QA;B!A="!A M;B!E>&5R8VES92!P2!T:&5R96%F=&5R(&]N(&$-"B!S=')A:6=H="UL:6YE(&)A65A&5R8VES960@ M=VET:&EN(#DP(&1A>7,@9G)O;2!T:&4@;&%S="!D871E(&]F(&5M<&QO>6UE M;G0N($EN('1H90T*(&5V96YT(&]F(&%N(&]P=&EO;F5E)B-X,C`Q.3MS(&1E M871H+"!D:7-A8FEL:71Y+"!O&5R8VES M92!P97)I;V0@:7,@,S8U(&1A>7,@9G)O;2!T:&4@;&%S="!D871E(&]F#0H@ M96UP;&]Y;65N="X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@#(P,4,[15-04"8C>#(P,40[*2P-"B!E;&EG:6)L92!E;7!L M;WEE97,@8V%N('!U7)O M;&P-"B!D961U8W1I;VYS+B!4:&4@<'5R8VAA65E#0H@<')I8V4L(&EN(&1E=&5R;6EN:6YG('1H92!V86QU92!O9B!%4U!0 M(&5X<&5N65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P M>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!('1O=&%L(&]F#0H@ M-2XP)B-X03`[;6EL;&EO;B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%R92!A M=71H;W)I>F5D(&9O28C>$$P.S$L(#(P,3`L(&%N9"!E86-H#0H@2F%N M=6%R>28C>$$P.S%S="8C>$$P.W1H97)E869T97(L('1H92!N=6UB97(@;V8@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/E-T;V-K+4)A3PO8CX\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/E=E(&-L87-S:69Y(&]U<@T* M('-T;V-K+6)A'!E;G-E("AI;F-L=7-I=F4@ M;V8@;W5R(#(P,#D@4&QA;BP@15-04"P-"B!A;F0@-#`Q*&LI(&UA=&-H:6YG M*2!I;B!T:&4@86-C;VUP86YY:6YG($-O;G-O;&ED871E9"!3=&%T96UE;G1S M(&]F#0H@3W!E'!E;G-E(&EN8VQU9&5D('=I=&AI;B!O<&5R871I;F<@ M97AP96YS97,-"B!F;W(@>65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3 M25I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L MF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@ M2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/E-E;&QI;F6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXR+#`Q-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L-C(X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY%;7!L;WEE90T*('-T;V-K+6)A'!E;G-E M(&9O65A$$P.S,Q+"`R,#$S M+"`R,#$R+"!A;F0@,C`Q,2!W87,@&5R8VES92!B96AA=FEO65A6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O;G0@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/E1H92!G6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY4:&4@9F%I#L@34%21TE. M+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O M;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY%>'!E8W1E9"!O<'1I;VX@;&EF92`H:6X-"B!Y96%R M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C0N-3`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E)I$$P.RTF(WA!,#LP+C4Q)3PO9F]N=#X\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQF;VYT M('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/C`N.#(E)B-X03`[+28C M>$$P.S(N-"4\+V9O;G0^/"]F;VYT/CPO=&0^#0H@/"]T2`H8RD\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1&-E;G1E$$P.RTF(WA!,#LW,2XU)3PO M9F]N=#X\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8T+C(E)B-X03`[+36QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D1I=FED96YD('EI96QD#0H@*&0I/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E=E:6=H=&5D+6%V97)A M9V4@9W)A;G0M9&%T90T*(&9A:7(@=F%L=64@<&5R('-T;V-K(&]P=&EO;CPO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1C96YT97(^/&9O;G0@#L@34%21TE. M+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P2!T:&4-"B!H:7-T;W)I M8V%L('-T;V-K(&]P=&EO;B!E>&5R8VES92!B96AA=FEO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/BAB*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX] M,T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A2!Y:65L9',@:6X@969F96-T(&1U'!E8W1E9`T*('1E'!E8W1E9"!T97)M+CPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\=&%B;&4@#L@34%2 M1TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\ M8CY3=&]C:R!/<'1I;VX-"B!!8W1I=FET>3PO8CX\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E-T;V-K(&]P=&EO;@T* M(&%C=&EV:71Y(&1U65A"<^#0H@)B-X03`[/"]P M/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E M)R!C96QLF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/DYU;6)E$$P.PT*(&]F/"]B/CPO9F]N=#X\8G(@ M+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,3X\8CY3:&%R97,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E&5R8VES93PO8CX\+V9O;G0^/&)R("\^#0H@ M/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D%G M9W)E9V%T93QB2`M+3X-"B`\='(@8F=C M;VQO6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXX+#,Y-RPP.30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXS+#8R,BPQ-3`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/CF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C0N,#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C@L,C4U/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXT+C@Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X<&ER960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXH,34Y+#DX-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C4N,3<\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"PQ.#4L-3(Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY' M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,2XU-SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY%>&5R8VES960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXH,2PR.#6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXW+CDS/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D5X<&ER960\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,RPY,38\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXW+C8Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D]U='-T86YD:6YG)B-X03`[)B-X,C`Q M-#L-"B!$96-E;6)E$$P.S,Q+"`R,#$R/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8N-3<\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`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`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY% M>&5R8VES960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH.#(U+#@X-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0N-#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C,L-#,U/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX+C(R/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D5X<&ER960\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH.#(L-3@Q/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=71S M=&%N9&EN9R8C>$$P.R8C>#(P,30[#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q M,SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q M+#,R.2PR,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+C`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E9E&5R8VES86)L92DF(WA!,#LF(W@R M,#$T.R!$96-E;6)E$$P.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY5;G9E$$P.R8C>#(P,30[($1E8V5M8F5R)B-X03`[,S$L(#(P,3,\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#0U,RPQ.3,\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX+CD\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@R*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q*3PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E<')E&5R8VES90T*(&%N9"!T:&4@2!T:&4-"B!N=6UB97(@;V8@ M;W!T:6]N&5R8VES960N/"]F;VYT/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@R*3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E M<')E0T*(&]F(#(P,3,@86YD('1H92!S=&]C:R!O<'1I;VX@97AE$$P.S,Q+"`R M,#$S+@T*(%1H92!A;6]U;G0@;V8@:6YT6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/E1H92!F;VQL;W=I;F<-"B!T M86)L92!S=6UM87)I>F5S(&EN9F]R;6%T:6]N('=I=&@@6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C M>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D5X97)C:7-A8FQE/"]B/CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@&5R8VES90T*(%!R:6-E/"]B/CPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D=R86YT M960F(WA!,#M3=&]C:SQBF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E=E:6=H=&5D+3QB6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/D5X97)C:7-E/"]B/CPO9F]N M=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY0F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L&5R M8VES93PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXD,"XY,B`F(W@R,#$S.PT*("8C>$$P.R8C>$$P.S,N,34\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#$Y,BPW M.30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0N-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C(N,38\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,3DR+#6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C(N,38\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD,RXU-2`F(W@R M,#$S.PT*("8C>$$P.R8C>$$P.S0N.34\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#DR-"PY,#0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C4N.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT+C(S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXU+C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C8N,C8\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L-38U+#(R,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0W+C`P("8C M>#(P,3,[#0H@)B-X03`[)B-X03`[."XY.3PO9F]N=#X\+W`^#0H@/"]T9#X- M"B`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M+#$T-RPQ,S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C@N,C8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD.2XP,"`F(W@R,#$S.PT*(#$V+C,R/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXY+C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$P+C@V/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M+#$P-2PP-SD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$Q+C`Y/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q+#,R M.2PR,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!$$P.VUI;&QI;VX@$$P.WEE87)S+CPO9F]N=#X\+W`^#0H@/'`@#L@34%21TE. M+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY2 M97-T#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!('-U;6UA#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/DYU;6)E$$P.V]F/"]B M/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3X\8CY297-T$$P M.T%V97)A9V4\+V(^/"]F;VYT/CQB6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D9A:7(@ M5F%L=64-"B!P97(\8G(@+SX-"B!3:&%R92!A="!'6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY5;G9E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXS-3DL-3`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$R+C0X/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$R M+C,S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C0N-S@\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T M6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXY-3(L-3(U/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,"XQ,3PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=R86YT M960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU M.#8L-C,Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXQ,2XW-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E9EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@T M-S(L,38P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY&;W)F96ET960\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,S(L-#`P/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;G9E$$P M.R8C>#(P,30[#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$L,#,T+#8P-#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY'6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E9EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@U,#$L-C8P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D9OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B@T.2PV,C4\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ,"XV,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY5;G9E$$P.R8C>#(P,30[#0H@1&5C96UB97(F(WA!,#LS,2P@ M,C`Q,SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C$L,#`W+#$Q.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+C`Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E M<')E2!T:&4@;G5M8F5R(&]F('9E"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QLF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@ M5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E'!E;G-E/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C0L,C`R/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\ M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY! M'!E;G-E(')E;&%T960@=&\@:7-S=65D(')E$$P.WEE87)S+CPO9F]N M=#X\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&ES65E2!M871C:&EN9R!O=7(@96UP;&]Y964@8V]N=')I8G5T:6]NF5D(&)E;&]W.CPO9F]N=#X\+W`^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$ M15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QLF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A M9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E-H87)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXY.2PS-3D\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`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`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P2!T:&4@;G5M8F5R(&]F#0H@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3QB'0^)SQS<&%N/CPO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/C6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/E-4 M3T-+2$],1$524R8C>#(P,3D[#0H@15%52519/"]B/CPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\(2TM('AB2`M+3X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R)3L@ M34%21TE.+51/4#H@-G!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\:3Y!=71H;W)I>F5D#0H@ M4W1O8VL\+VD^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX- M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY/;@T*($1E8V5M8F5R)B-X03`[,3,L(#(P,3`L('=E(&9I M;&5D('1H92!#97)T:69I8V%T92!O9B!$97-I9VYA=&EO;B!O9@T*(%)I9VAT MF5D(#$N-28C>$$P.VUI;&QI;VX@F5D(&YU;6)E$$P.W-H87)EF5D+"!O9B!W:&EC:"`Q+C4F(WA!,#MM:6QL M:6]N('-H87)E"<^#0H@/&9O;G0@$$P.S(Y M+"`R,#$P+"!O=7(@0F]A'1E;F0-"B!U;G1I;"!$96-E;6)E$$P.S$S+"`R M,#(P+B!!('-T;V-K:&]L9&5R(')I9VAT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/E5N9&5R('1H92!T97)M&5R8VES M86)L92!U<&]N('1H92!E87)L:65R(&]F(#$P)B-X03`[9&%Y$$P.V)U2!O2!H879E(&YO('-T M;V-K:&]L9&5R7,@ M869T97(@=&AE#0H@&5R8VES86)L92P@96%C:"!R M:6=H="P@;W1H97(@=&AA;B!R:6=H=',@:&5L9"!B>0T*('1H92!P97)S;VX@ M;W(@9W)O=7`@;V8@869F:6QI871E9"!P97)S;VYS('=H;W-E(&%C<75I&5R8VES92!P M0T*('1O(&-E2!A(&YU;6)E&5R8VES92!P"<^#0H@/&9O;G0@#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!397!T96UB97(-"B`R,#`S M+"!W92!R96-E:79E9"!G$$P.VUI;&QI;VX@$$P M.W-H87)E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DEN('1H92!E=F5N M="!W90T*(&%R92!T:&4@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/D-O;6UO M;B!3=&]C:PT*(%)E#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY! M&EM871E;'D@ M,C@N,28C>$$P.VUI;&QI;VX@&5R8VES92!O M9@T*(')I9VATF5D(&)E;&]W.CPO9F]N=#X\+W`^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T], M3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VYV97)S:6]N(&]F(%-E$$P.T4-"B!06QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,"PP,#`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$X($-O;G9E6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXQ,2PT,#`L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@65E#0H@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C$Q+#,R.2PR,3@\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>&5R8VES M92!O9B!IF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0T-2PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY% M4U!0('-H87)EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C,T-BPU,#`\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY4;W1A;"!S:&%R97,@;V8@8V]M;6]N#0H@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXR."PQ,#$L-S`T/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"<^#0H@/&9O M;G0@2!P;&%C96UE;G0@86=E;G1S(&%N9"!C;VYS=6QT M86YT#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!% M;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]U='-T86YD:6YG)B-X03`[)B-X,C`Q-#L-"B!$96-E M;6)E$$P.S,Q+"`R,#$P/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D5X<&ER960\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,RPW-#$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=71S=&%N9&EN9R8C>$$P M.R8C>#(P,30[#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,3PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C0T-2PP,#`\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$N-SD\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M.34L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D=R86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXU,"PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXT-#4L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,#6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$ M)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="`H;&]S2!D:79I9&EN9R!N970@*&QO2!T:&4-"B!W96EG:'1E9"!A=F5R86=E(&YU;6)E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ MF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="`H;&]S M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY7 M96EG:'1E9"!A=F5R86=E('-H87)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV,"PW,CDL,3(X/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXU."PU.#@L.3$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU,RPR-S(L-S8W/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D M/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\ M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E=E:6=H=&5D(&%V M97)A9V4@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="`H;&]SF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY4:&4@9F]L;&]W:6YG#0H@#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E=E:6=H=&5D+3QBF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/CQB/DYE=#QB$$P.U-H87)E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)A M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CDT+#(P,3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$N-C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY$:6QU=&EV92!PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C0P+#`P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY);F-R96UE;G1A;"!C;VUM;VX@&5R8VES92!O9B!I;BUT:&4M;6]N97D@=V%RF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(R-"PT,S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E5N=F5S=&5D M(')E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`S-"PV,#0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CDT+#(P,3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$N-#8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ MF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/DYE="!);F-O;64\8G(@+SX-"B`H;G5M97)A=&]R*3PO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CY996%R($5N9&5D#0H@1&5C96UB97(F M(WA!,#LS,2P@,C`Q,3PO8CX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU,RPR-S(L-S8W/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$ M:6QU=&5D(&YE="!I;F-O;64@<&5R#0H@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1I M;'5T:79E('!R969EF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$:6QU=&EV92!C;VUM;VX@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXT+#$X-2PR,C0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/D-H86YG92!I M;B!C;VUM;VX@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXR-#@L,3DS/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY);F-R96UE;G1A;"!C;VUM;VX@&5R8VES92!O9B!I;BUT:&4M;6]N97D@=V%RF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,"PV-38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E5N=F5S=&5D(')E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,BPX-S0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C0Y+#DS,3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C`N.#8\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I% M.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/=7(@;W5T#L@34%21TE.+51/4#H@,'!X M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%PF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R M/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!" M;V1Y("TM/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$X($-O;G9E6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS M-#,L-C`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`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`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`P-RPQ,3D\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY#;VUM;VX@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$V,"PX,38\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY06QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXT,"PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O M=&%L/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@34%21TE.+51/4#H@ M,'!X)SX-"B`F(WA!,#L\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q M,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C`Y-69A,6-?.#'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@#L@0T],3U(Z(')G8B@P M+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE. M+51/4#H@-G!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5. M5#H@-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O M;G0@F5S(&-E2!F86ER('9A;'5E$$P.SQI/BAX*2D\+VD^.CPO M9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/CQB/DQE=F5L#0H@,3PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4] M,T0Q/CQB/E1O=&%L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/DUO;F5Y(&UA0T*(&9U;F1S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C$P,"PS.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C$P,"PS.34\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/C,L,#8Q/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4L M,S8Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D5Q=6ET>0T*('-E8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C,L-3DS/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C,L-3DS M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@3PO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C$W+#6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C0L,#`P/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E1A;&]N($-64CPO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C,L.30Y/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%=(251%+5-0 M04-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-) M3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#%P>"`G5&EM97,@ M3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!! M0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5. M5#H@,'!X.R`M=V5B:VET+71E>'0MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1EF4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,CPO8CX\+V9O;G0^ M/&)R("\^#0H@/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/DQE=F5L#0H@,CPO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/CQI/D%SF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/CDX-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$Q M+#8Y.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(L,S(S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D1E9F5RF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>#(P M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/C$R+#(S,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/C(L,C@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/DQI9V%N9"!#;VYT:6YG96YT#0H@0V]N MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QTF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$T+#4R,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C$V+#@X-3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@F4],T0R/E=E(&1I9"!N;W0-"B!H879E M(&%N>2!TF4@3&5V96PF(WA!,#LS(&EN<'5T#(P,4,[86-C#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE M9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$54 M5$52+5-004-)3D'0M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6%B;&4L(&%N9"!A8V-R M=65D#0H@;&EA8FEL:71I97,L(&5X8VQU9&EN9R!A8W%U:7-I=&EO;B!R96QA M=&5D(&-O;G1I;F=E;G0@8V]N"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P M#L@ M3$545$52+5-004-)3D#L@+7=E M8FMI="UT97AT+7-TF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D)A;&%N8V4@ M870-"B!$96-E;6)E$$P.S,Q+"`R,#$Q/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/E1R86YS9F5R6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(L,C@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/D)A;&%N8V4@870-"B!$96-E;6)E M$$P.S,Q+"`R,#$R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C$T+#4R,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/D1E9F5R$$P.SQI/DYO=&4-"B`Q,SPO:3XI/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4L-3`Y/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/D1E9F5R6UE;G0-"B!C;VYT:6YG96YC>2`H$$P.S$S/"]I/BD\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P.SQI/DYO M=&4@,3`H8BD\+VD^*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/C(V+#`W,3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#PO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQD:78^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/CQB/D)54TE.15-3 M#0H@0T]-0DE.051)3TY3/"]B/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\(2TM('AB2`M+3X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#9P>"<^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/CQI/E1A;&]N($%C<75I M#L@5$585"U) M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;@T*($IU;'DF(WA!,#LQ-BP@,C`Q M,RP@=V4@96YT97)E9"!I;G1O(&$@4V5C=7)I=&EE#(P,40[*2P@=VAE2P@;VX-"B!*=6QY)B-X03`[,32!A;F0@ M;VYC;VQO9WD@<')O9'5C=',N/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#$R<'@[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@/&9O;G0@&EM871E;'D@)#$N M,PT*(&UI;&QI;VXN(%=E(&AA9"!N;VUI;F%L(&5A6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!4 M86QO;@T*('!U$$P.V%N(&%G9W)E9V%T92!U<&9R;VYT#0H@8V%S:"!A;6]U;G0@;V8@ M)#$Q+C,@;6EL;&EO;BP@*&EI*28C>$$P.VES$$P.W1H92!I#(P,40[*2!I M;FET:6%L;'D@=F%L=65D(&)Y('5S(&%T("0V+C4-"B!M:6QL:6]N+CPO9F]N M=#X\+W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!#5E(@=V%S#0H@=F%L=65D('5S:6YG(&$@=F%L=6%T:6]N(&UO9&5L('1H M870@<')O8F%B:6QI='DM=V5I9VAT'!E8W1E9`T*(&]U=&-O;65S("AR M86YG:6YG(&9R;VT@-3`E('1O(#$P,"4I(&%N9"!D:7-C;W5N=',@=&AO#(P,3,[('-E92!.;W1E(#,@/&D^*'@I/"]I M/BDN(%1H92!#5E(@:&%S(&$@;6%X:6UU;2!P87EO=70@;V8-"B`D,3DU+C`@ M;6EL;&EO;B!I9B!A;&P@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@1D].5"U325I%.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[ M/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!C96QL6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,C([ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1T;W`@86QI9VX],T1L969T/@T*(#QP(&%L:6=N/3-$;&5F=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD-2XP(&UI;&QI;VX@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@;F5T('-A M;&5S(&]F($U!4E%)0D\@:6X-"B!E>&-E65A#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T M;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0Q,"XP(&UI;&QI;VX@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@;F5T('-A M;&5S(&]F($U!4E%)0D\@:6X-"B!E>&-E65A#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T M;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0R-2XP(&UI;&QI;VX@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@;F5T('-A M;&5S(&]F($U!4E%)0D\@:6X-"B!E>&-E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@1D].5"U325I%.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X03`[ M/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA M<'-E)R!C96QL6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,C([ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1T;W`@86QI9VX],T1L969T/@T*(#QP(&%L:6=N/3-$;&5F=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXD-3`N,"!M:6QL:6]N('5P;VX@=&AE(&%C:&EE=F5M96YT(&]F(&YE="!S M86QE2!C86QE;F1A$$P M.SPO<#X-"B`\=&%B;&4@&-E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`V<'@[($U!4D=)3BU43U`Z(#!P>"<^#0H@)B-X M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E)R!C96QL6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P M,C([/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1T;W`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`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-A6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$Q+#,P,#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D-64CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C8L-3`P/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0T+#$P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CX\:3Y&86ER(%9A;'5E($5S=&EM871E(&]F#0H@07-S971S M($%C<75I#L@34%21TE. M+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D-A6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$'!E M;G-EF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C$P.3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E!R;W!EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXT-"PU,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CY4;W1A;"!AF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C0U+#,X,3PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C8V]U;G1S('!A>6%B;&4F(WA!,#LF86UP.PT*(&%C8W)U M960@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXU+#(S,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E9F5R`T*(&QI86)I;&ET>3PO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C8L-3$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C,S+#4W-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@#(P,40[*2!A;F0-"B!-05)124)/ M('1R96%T;65N="!O9B!N;VXM2&]D9VMI;B8C>#(P,3D[6UP:&]M80T* M("@F(W@R,#%#.TY(3"8C>#(P,40[*2!A6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E9A;'5E(&]F M/&)R("\^#0H@26YT86YG:6)L93QB2`M M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C$S)B-X03`[>65A M6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY)4%(F86UP.T0@)B-X,C`Q-#M-05)124)/#0H@9F]R($Y(3#PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C$W+#8P,#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E1O=&%L(&ED96YT:69I86)L90T* M(&EN=&%N9VEB;&4@87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0T+#4P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/"]T$$P.SPO<#X- M"B`\=&%B;&4@6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U) M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F%I2!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D=O;V1W:6QL#0H@<')EF4@9V]O9'=I;&P@87-S;V-I871E9"!W:71H('1H90T*(%1A;&]N(&%C M<75I6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/E-U<'!L96UE;G1A;"!0#L@5$585"U) M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG#0H@=6YA=61I M=&5D('!R;R!F;W)M82!F:6YA;F-I86P@:6YF;W)M871I;VX@:7,@<')E28C M>#(P,3D[65A M0T*(&%S M2!N;W0@8F4-"B!I;F1I M8V%T:79E(&]F('=H870@;W!E28C>$$P.S$L(#(P,3(L(&%N9"!M87D-"B!N;W0@8F4@ M:6YD:6-A=&EV92!O9B!F=71U#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@ M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E!R;R!&;W)M M82!4;W1A;`T*(')E=F5N=65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$U-2PX-30\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@'!E;G-EF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C(P,"PV-3$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(Q,"PT,S,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY0F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@V."PQ-#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXU-RPR-S0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY06QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!R;R!&;W)M82!.970@*&QO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q+C$R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N.#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O M9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#$X<'@G/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/CQI/E1A;&]N($-64B!& M86ER(%9A;'5E(&%S#0H@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,SPO:3X\ M+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E1H92!#5E(@9F%I<@T*('9A;'5E('=I;&P@8V]N=&EN=64@=&\@8F4@979A M;'5A=&5D(&]N(&$@<75A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X M.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/CQB/D9A:7(F(WA!,#M686QU93QB M2`M+3X-"B`\='(@8F=C;VQO28C M>$$P.S$W+`T*(#(P,3,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY&86ER('9A;'5E(&%D:G5S=&UE;G0@9F]R#0H@>65A$$P.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D1E8V5M8F5R)B-X M03`[,S$L#0H@,C`Q,SPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/D]V97)V:65W(&]F($%C<75I#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;@T*($UA&-L=7-I=F4-"B!G;&]B86P@9&5V96QO<&UE;G0@86YD(&-O;6UEF%T:6]N(')I9VAT6QE;F4@9VQY8V]L+69R964@345,4$A!3$%.("@F(W@R,#%#.T,M M10T*($U%3%!(04Q!3B8C>#(P,40[*2!F2UO=VYE9`T*('-U8G-I9&EA2!,:6=A;F0@ M9F]R('5S92!A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&%C8V]U;G1E9`T*(&9O#(P,40[('=I=&AI;B!T:&4@86-C;VUP86YY:6YG($-O;G-O;&ED871E9"!3 M=&%T96UE;G1S(&]F#0H@3W!E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O M;G0@#L@34%21TE.+51/4#H@,'!X)SX- M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D-A6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C,L,#`P/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU, M1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!P M=7)C:&%S90T*(&-O;G-I9&5R871I;VX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A M8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3 M25I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P M>"<^/&9O;G0@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/ M4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!T;W1A M;`T*('!U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q M,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M2`M+3X-"B`\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U) M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!E$$P.U1H92!I M;F-O;64@87!P2!C=7)R96YT(&UA M'!E8W1A=&EO;G,@86)O=70@=&AO&EM871E;'D@,3`@>65A6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!F M86ER('9A;'5E#0H@;V8@=&AE(&-O;G1I;F=E;G0@8V]N2!O9B!S=6-C97-S(&%N9"!T:&4@9&ES8V]U;G1E9"!C87-H M(&9L;W<-"B!M971H;V0@;V8@=&AE(&EN8V]M92!A<'!R;V%C:"`H#(P,3,[('-E92!. M;W1E#0H@,SQI/BAX*3PO:3XI+"!W:&EC:"!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY792!D;R!N;W0-"B!C;VYS:61E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/CQI/DQI9V%N9"!#;VYT:6YG96YT#0H@0V]N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!,:6=A;F0-"B!#;VYT:6YG96YT($-O;G-I9&5R871I;VX@9F%I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X M.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY-87)C:"8C>$$P.S@L#0H@,C`Q,SPO9F]N M=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/D9A:7(@=F%L M=64@861J=7-T;65N="!F;W(-"B!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[ M,S$L(#(P,3,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH-S`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,SPO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E. M1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E=E(&%C<75I$$P.S4L#0H@,C`Q,BP@=VAI8V@@=V%S(&%C8V]U;G1E9"!F M;W(@87,@82!B=7-I;F5S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P M7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/CQB/C$Q+CPO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/CQB/E)%5D],5DE.1R!,24Y%($]�H@0U)%1$E4/"]B M/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[(%=(251%+5-004-%.B!N;W)M86P[(%1% M6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z M(')G8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@ M34%21TE.+51/4#H@-G!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4 M+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^ M#0H@/&9O;G0@2!T97)M:6YA=&5D(&ET(&]N($1E8V5M8F5R)B-X03`[ M,C`L(#(P,3,@:6X@8V]N;F5C=&EO;@T*('=I=&@@=&AE('-A;&4@86YD(&ES M#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#%P>"`G5&EM M97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-) M3D#L@+7=E8FMI="UT97AT+7-T M#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`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`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O M;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA'0^ M)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/D-/3E9%4E1)0DQ%(%-%3DE/4@T*($Y/5$53/"]B/CPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\(2TM('AB2`M M+3X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY/;@T*($1E M8V5M8F5R)B-X03`[,3#(P,40[*2X@5&AE(#(P,3@@0V]N M=F5R=&EB;&4@3F]T97,@87)E(&-O;G9E$$P M.VUI;&QI;VX@8V]M;6]N('-H87)E2!C;VYV97)T960N(%1H M90T*(&EN+71H92UM;VYE>2!C;VYV97)S:6]N('!R:6-E(&ES(&5Q=6EV86QE M;G0@=&\@)#$P+C4S('!E65A6%B;&4@;VX@1&5C96UB97(F(WA!,#LQ-2P@,C`Q M."P@#(P,3D[#0H@;W!T:6]N+CPO9F]N M=#X\+W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]N M#0H@1&5C96UB97(F(WA!,#LR,RP@,C`Q,R!N970@<')O8V5E9',@9G)O;2!T M:&4@2!E;G1E#(P,4,[8F]U9VAT(&-A;&PF(W@R,#%$.R!A M;F0-"B`F(W@R,#%#.W-O;&0@=V%R#(P,40[('1R86YS86-T:6]N M6%L($)A;FL@;V8@0V%N861A#0H@*&-O;&QE8W1I=F5L>2P@ M=&AE("8C>#(P,4,[3F]T92!(961G928C>#(P,40[*2X@5V4@#(P,40[(&EN(&]U6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&5N=&5R960@:6YT;PT*($YO=&4@2&5D M9V4@=')A;G-A8W1I;VYS('1O(')E9'5C92!T:&4@<&]T96YT:6%L(&1I;'5T M:6]N('1O(&]U<@T*(&-O;6UO;B!S=&]C:R!A;F0O;W(@;V9F2!C M87-H('!A>6UE;G1S('1H870@=V4@87)E(')E<75I&-E#(P,4,[8F]U9VAT(&-A;&PF M(W@R,#%$.R!I#(P,4,[ M$$P.S,Q+"`R,#$S+"!T:&4@,C`Q."!#;VYV97)T:6)L92!.;W1E2!U;F1E2!F:7-C86P@<75A2!D=7)I;F<@$$P.S,Q+`T* M(#(P,30L(&EF+"!F;W(@870@;&5A2!O9B!T:&4@:6UM961I871E;'D@<')E8V5D:6YG(&9I M$$P.V1U2!F:79E(&-O M;G-E8W5T:79E('1R861I;F<@9&%Y#0H@<&5R:6]D(&EN('=H:6-H+"!F;W(@ M96%C:"!T2!O9B!T:&%T(&UE87-U2!I;6UE9&EA M=&5L>0T*('!R96-E9&EN9R!T:&4@;6%T=7)I='D@9&%T92P@:&]L9&5R6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[ M($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@5$585"U) M3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!I;FET:6%L;'D-"B!M87D@;VYL M>2!S971T;&4@8V]N=F5R2!P87EI;F<@;W(-"B!D96QI=F5R:6YG+"!A M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&4@8V%R6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@2`M+3X-"B`\='(@8F=C;VQOF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$96-E;6)E$$P.S,Q+"`R,#$S M(&YE=`T*(&-A6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CDQ+#0X M,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!F;VQL;W=I;F<-"B!T86)L92!S M971S(&9O#(P,4,[:6YT M97)E'!E;G-E)B-X,C`Q1#L@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I% M.B`Q,G!X.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@2`M+3X-"B`\='(@8F=C;VQO MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D%M;W)T:7IA=&EO M;B!O9B!D96)T#0H@:7-S=6%N8V4@8V]S=',\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%C M8W)E=&EO;B!O9B!D96)T#0H@9&ES8V]U;G0\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,#$\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N M/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D5F9F5C=&EV92!I M;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXX+C4Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T"<^#0H@)B-X03`[/"]P/@T*(#PO9&EV/CQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4] M,T0R/D%S('1H92!R97-U;'0-"B!O9B!!;&QO$$P.S4L(#(P,3(L('=E(&%SF4],T0R/D]N#0H@36%Y)B-X03`[,CDL M(#(P,3,L('1H92!-=6YD:7!H87)M82!#;VQL86)O#(P,4,[06UE M;F1E9"!-=6YI<&AA3H@*&DI)B-X03`[=&AE('-C;W!E M(&]F('1H90T*(&QI8V5N2P@*&EI*28C>$$P.VUI;&5S M=&]N92!P87EM96YT$$P.W)O>6%L='D@#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%2 M1TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@&-L=61E9"!F6UE;G1S(&]F('5P('1O("0Q-BXP)B-X03`[;6EL;&EO;B!A M;F0-"B!C;VUM97)C:6%L('!R;V=R97-S(&%N9"!S86QE6UE;G1S(&]F('5P('1O#0H@)#$P-RXP)B-X03`[;6EL M;&EO;BP@*&EI:2DF(WA!,#MW92!W:6QL(')E8V5I=F4@=&EE0T*(&]F("0Q,BXS(&UI;&QI M;VX@87,@;V8@4V5P=&5M8F5R(#(P,3(L('5S:6YG('1H92!D:7-C;W5N=&5D M(&-A$$P M.S,Q+"`R,#$S("AI;F-L=7-I=F4@;V8@=&AE("0W+C`@;6EL;&EO;B!P87EM M96YT(&9R;VT-"B!-=6YD:7!H87)M82D@86YD(&ES(&EN8VQU9&5D(&EN(&-U M&EM871E;'D@ M,C`S,2X\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@/&9O;G0@#(P,40[#0H@97AP96YS92!I;B!O=7(@0V]N6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO'0M$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/D-UF4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>#(P,3,[ M/&)R("\^#0H@1D],3U193CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/E1R86YS9F5R(&9R;VT@;&]N9R!T97)M#0H@=&\@8W5RF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M'!E;G-EF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q+#,U-SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C,L,3$Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/BAA*2!&86-I;&ET>2!A;F0-"B!%<75I<&UE;G0@3&5A'!I$$P.S,P+"`R M,#$T+B!790T*(&%L'!I6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]U6UE;G1S(&%R92!A"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=" M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D]P97)A=&EN9R8C>$$P.TQE87-E/&)R("\^ M#0H@36EN:6UU;3QB6UE;G1S/"]B/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$U M/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@Y,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(P,3<\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXX-#,\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M,#$X/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C0L-#`R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/BAB*2!,:6-E;G-I;F<-"B!!9W)E96UE;G1S+"!#;RU$979E M;&]P;65N="!!9W)E96UE;G1S+"!A;F0@36EL97-T;VYE#0H@4&%Y;65N=',\ M+V(^/"]F;VYT/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($U!4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY792!A2!R96%C:`T*(&1E=F5L;W!M96YT(&%N9"!R96=U;&%T;W)Y(&UI;&5S M=&]N97,@6%L=&EE M6UE;G1S(&)A M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\ M:3XH:2D-"B!:159!3$E.(&QI8V5N#(P,40[*2P@:6X-"B!$96-E;6)E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY) M;B!A8V-O&$@0V]R<&]R871I;VXN/"]F;VYT/CPO<#X-"B`\ M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU,1494.B`R M)3L@34%21TE.+51/4#H@,3AP>"<^#0H@/&9O;G0@#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);B!C;VYN96-T:6]N#0H@ M=VET:"!T:&4@:F]I;G0@=F5N='5R92!A6UE;G0@=7!O;B!T:&4@86-H:65V96UE;G0@;V8@86X@861D:71I;VYA;"!& M1$$-"B!A<'!R;W9A;"!M:6QE$$P.U))5"!I M0T*(')O>6%L='D@<&%Y;65N=',@ M9&5T97)M:6YE9"!A'!I2!O9B!A(&)I;W-I;6EL87(@ M<')O9'5C="!I;B!T:&4@52Y3+B!O$$P.S,Q+`T*(#(P M,34N($-4228C>#(P,3D[6UE;G0-"B!O8FQI9V%T:6]N6%L=&EE6UE;G0L('5N9&5R M(&)O=&@@=&AE($-422]":6]G96X-"B!!9W)E96UE;G0@86YD('1H92!A;65N M9&UE;G0@=V5R92!A2!2250@:6X- M"B!C;VYN96-T:6]N('=I=&@@=&AE(&-L;W-I;F<@;V8@=&AE(&IO:6YT('9E M;G1U6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM M5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3XH:6EI*0T*($QI8V5N$$P M.S$L(#(P,3(L('1H6UA;BP@3"Y0+BP@=V4@8V]M<&QE=&5D('1H M92!A8W%U:7-I=&EO;B!O9@T*(&QI8V5N"U54R!2:6=H=',L(&9R;VT@0F%Y97(@4&AA65R+CPO9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&-U0T*(&UA0T*(&%P<')O=F5D(&EN(&UO65R#0H@ M2!P87EM96YT(&]B;&EG871I;VYS('=H:6-H+"!I;@T*('1U M'!I65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!X)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CX\:3XH:78I#0H@06UE;F1E9"!A;F0@4F5S=&%T960@3&EC96YS M92!!9W)E96UE;G0@=VET:"!-97)C:R8C>$$P.R9A;7`[($-I90T*($%'+"!& M55-)3$56/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN($UA>2`R,#`V+"!W90T*(&%M96YD960@86YD M(')E$$P M.R9A;7`[($-I90T*($%'+"!A(%-W:7-S(&-O&-L=7-I=F4-"B!L:6-E;G-E('1O('5S92!R M96=U;&%T;W)Y(&9I;&EN9W,@&-L=7-I=F4@;&EC96YS92!T;R!M86YU9F%C='5R92P@=7-E M+`T*(&%N9"!S96QL($954TE,158@<')O9'5C=',@;W5T6UE M;G0@=7!O;B!A8VAI979E;65N="!O9@T*($9$02!A<'!R;W9A;"!O9B!A;B!O M2UB>2UC;W5N=')Y(&)A6%L M=&EE2!T:6UE(&9O6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAV M*2!!0T*(#(P,3$L('=E(&ES6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/CQB/CQI/BAV:2D-"B!, M:6-E;G-E($%G#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);@T*($1E8V5M8F5R)B-X M03`[,C`P,BP@06QL;W,@96YT97)E9"!I;G1O('1H92!&3TQ/5%E.($QI8V5N M2!O=VYE9"!S=6)S:61I87)Y M(&5F9F5C=&EV90T*(%-E<'1E;6)E$$P.S4L(#(P,3(L('=E(&%R92!B M;W5N9"!B>2!T:&4@1D],3U193B!,:6-E;G-E#0H@06=R965M96YT('5N9&5R M('=H:6-H('=E(&]B=&%I;F5D(&5X8VQU2!F;W(@86QL(&-O;6UEF%T:6]N(&%C=&EV:71I97,N)B-X M03`[26X-"B!A9&1I=&EO;BP@=V4@<&%Y('1H92!L:6-E;G-O6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI/BAV M:6DI#0H@3&EC96YS92!!9W)E96UE;G0@=VET:"!#>61E>"!0:&%R;6%C975T M:6-A;',L($EN8RXL#0H@0V%P=&ES;VPM96YA8FQE9"P@4')O<'EL96YE9VQY M8V]L+69R964@345,4$A!3$%./"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D]N#0H@36%R8V@F(WA!,#LX M+"`R,#$S+"!W92!C;VUP;&5T960@=&AE(&%C<75I2!I;B!A('!I=F]T86P@=')I86P@9F]R('5S92!A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/CQB/CQI/BAV:6EI*0T*($5X8VQU6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DEN($]C=&]B97(- M"B`R,#`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`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY);B!.;W9E;6)E<@T*(#(P,#DL('=E(&5N=&5R M960@:6YT;R!A(&-O;&QA8F]R871I;VX@86=R965M96YT('=I=&@@3FEP<&]N M($MA>6%K=0T*($-O+BP@3%1$+B`H)B-X,C`Q0SM.:7!P;VX@2V%Y86MU)B-X M,C`Q1#LI(&9O&-E<'0@3F]R=&@@86YD M(%-O=71H#0H@2V]R96$@*'1H92`F(W@R,#%#.TYI<'!O;B!+87EA:W4@5&5R M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!U6UE;G1S(&)A6UE M;G0@;V8@)#$P+C`@;6EL;&EO;B!A;F0@)#$R-BXP(&UI;&QI;VX@=7!O;@T* M(&%C:&EE=F5M96YT(&]F(&-E2!A;F0@8V]M;65R M8VEA;&EZ871I;VX@;6EL97-T;VYE2!I M;B!T:&4@;6ED+71E96X@9&EG:71S+CPO9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/D]U6%K=2!P2!H96%L=&@-"B!A=71H;W)I=&EE"<^#0H@/&9O;G0@F4@0D5,14]$05$@:6X@3F]R=&@@06UE M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E5N9&5R#0H@8V]N=&EN=6EN9R!T97)M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E('=I;&P@96%C:`T*('!A>2`U,"4@;V8@=&AE M(&-O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!U$$P M.W-H87)E2!4;W!O5&%R9V5T('5P M('1O#0H@)#,Q,RXP(&UI;&QI;VXN($EN($9E8G)U87)Y(#(P,30L('1H92!F M:7)S="!O9B!T:&5S92!M:6QE6%L=&EE6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E1H92!A9W)E96UE;G0- M"B!W:6QL(&-O;G1I;G5E('5N=&EL('1H92!E>'!I6%L='D@<&%Y;65N=`T*('!E2!W:71H(&-E2!T97)M M:6YA=&4@=&AI2!A;'-O('1E2!I;B!T M:&4@979E;G0@;V8@80T*(&-H86QL96YG92`H=VET:&]U="!4;W!O5&%R9V5T M)B-X,C`Q.3MS(&-O;G-E;G0I(&)Y('5S(&]F('1H92!P871E;G1S#0H@=&AA M="!C;W9E6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+4Q%1E0Z(#(E.R!-05)'24XM M5$]0.B`Q.'!X)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\8CX\:3XH>&DI#0H@0V\M1&5V96QO M<&UE;G0@86YD($-O;6UEF%T:6]N($%G2P@4U!)+3(P,3(\+VD^/"]B M/CPO9F]N=#X\+W`^#0H@/'`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`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!="!E86-H('!E2!P2P@=V4@87)E(&%B;&4@=&\@=&5R;6EN871E#0H@ M=&AE6EN M9R!F;W(@=&AE('-E65T(&)E96X-"B!R M96YD97)E9"!A;F0@;W5R(&9U='5R92!P=7)C:&%S92!O8FQI9V%T:6]N2X\+V9O;G0^/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^ M/&9O;G0@0T*($%G#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!H M879E(&5N=&5R960-"B!I;G1O(&-E&-E960@=&AE:7(@9F%I6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/BAE*2!%;7!L;WEM96YT#0H@ M06=R965M96YT6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&AA=F4@96YT97)E9`T*(&EN=&\@96UP;&]Y M;65N="!A9W)E96UE;G1S('=I=&@@8V5R=&%I;B!O9B!O=7(@;V9F:6-E2!R96%S;VX-"B!O=&AE65E(&9O6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3AP>"<^/&9O M;G0@#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/;@T*(%-E<'1E;6)E$$P.S(L(#(P,3$L('1H92!";V%R9"!O9B!$ M:7)E8W1O2!W:71H('1H90T*(')E<75I2!T;R!M86ME(&%N;G5A;"!E;&5C=&EO;G,@ M=&\@9&5F97(-"B!U<"!T;R!A('-P96-I9FEE9"!A;6]U;G0@;W(@<&5R8V5N M=&%G92!O9B!T:&5I2!T:&4@1$,@4&QA;B!A9&UI;FES=')A=&]R+"!A M;F0@=V4-"B!H879E('1H92!O<'1I;VX@=&\@;6%K92!D:7-C2!C;W5R2!I;F-L=61E('!R;V1U8W0@;&EA8FEL M:71Y+`T*(&EN=&5L;&5C='5A;"!P2P@96UP;&]Y;65N="!M871T M97)S+"!A;F0@;W1H97(@9V5N97)A;`T*(&-L86EM6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@ M,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!M86ME#0H@ M<')O=FES:6]N2!H87,@8F5E;B!I;F-U2!O#(P,4,[04Y$07,F(W@R,#%$.RD@9FEL960@8GD@8V]M<&%N:65S M('-E96MI;F<@=&\@;&%U;F-H(&=E;F5R:6,-"B!F;W)M2!D86UA9V5S+"!C;W-T#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CX\8CX\:3Y&55-)3$56($%.1$$-"B!,:71I9V%T:6]N/"]I/CPO8CX\ M+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D]N#0H@2F%N=6%R>28C>$$P.S(P+"`R,#$R(&%N9"!&96)R=6%R>28C>$$P M.S$W+"`R,#$R+"!R97-P96-T:79E;'DL('=E#0H@9FEL960@B!);F,N(&%N9"!);FYO<&AA6QA;B!E;G1I=&EE0T*('8N(%-P96-T$$P.S$T+`T*(#(P,3,@:6X@56YI M=&5D(%-T871E2!I9&5N=&EC86P@8VQA:6US(&%N9"!A;&QE9V%T:6]N M2!S=&5M(&9R;VT@=&AE#0H@0V]M<&%N>28C>#(P,3D[$$P.S$R+"`R,#$S('!R97-S(')E;&5A28C>#(P,3D[2!S=&]C:RX@ M5&AE(&QA=W-U:71S('-E96L@2!&:6L-"B!V+B!2 M86IE$$P.S$Q+"`R,#$S(&EN#0H@56YI=&5D(%-T871E28C>$$P.S(X M+"`R,#$S.R!#87-E($YU;6)E<@T*(#(Z,C`Q,RUC=BTP,#DT,BU!4$#(P,3D[(&%L;&5G960@<')O9FET28C>$$P.S$U+"`R,#$S+"!T:&4@8V]U6EN9PT*('1H92!A8W1I;VYS M('!E;F1I;F<@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/DAA6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/CQB/BAH*2!314,-"B!3=6)P M;V5N83PO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T* M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]N#0H@07!R:6PF(WA!,#LQ+"`R,#$S+"!W92!R96-E:79E M9"!A('-U8G!O96YA(&9R;VT@=&AE(%-%0R!F;W(-"B!D;V-U;65N=',@<'5R M'1087)T7V(P.35F83%C7S@W,3!?-#$W8U\X83$S7S=D,#@U,F-E,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/C$U+CPO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CX\ M8CY)3D-/344-"B!405A%4SPO8CX\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PO M=&%B;&4^#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@/'`@6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)' M24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA M+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM M/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY5;FET960@4W1A=&5S/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@S,"PT,S<\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@V+#$Y.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B@R+#(S-3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q.3D\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`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`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!415A4 M+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E1H92!P#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P$$P.S,Q+#PO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY3=&%T93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@V.3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXS+#0Q,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494 M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&;W)E:6=N/"]F M;VYT/CPO<#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@Y+#`T.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D1E9F5RF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY&961E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C0L,#$S/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E-T871E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D9O6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXS-"PU-#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@S,RPY,#4\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@"!P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!I;F-O;64@=&%X#0H@<')O=FES:6]N("AB96YE9FET M*2!D:69F97)S(&9R;VT@=&AA="!C;VUP=71E9"!U2!R871E(&%P<&QI960@=&\@:6YC;VUE(&)E9F]R92!T M87AE#L@34%21TE.+51/ M4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1% M4BU#3TQ,05!313H@8V]L;&%P2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(W+#DW-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$X+#(U,#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E-T871E('1A>"P@;F5T(&]F(&9E M9&5R86P-"B!B96YE9FET/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(L-#0R/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#DQ.#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,BPR-30\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH M,BPQ,CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXH,2PT-C0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT M/CPO=&0^#0H@/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]WF4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@T+#$T.#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUM;VX@3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L M,3@V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C@X,#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`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`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY3=&]C:R!B87-E9`T*(&-O;7!E;G-A=&EO;CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E!EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q M+#`X,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L,3$Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR+#`S.3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D1O;65S=&EC(&UA;G5F86-T=7)I;F<-"B!D961U8W1I;VX\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW-C<\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@Q+#(V,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY487@@9&EF9F5R96YT:6%L(&]N(&9OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,3(S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS.#(\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY#:&%N9V4@:6X@=&%X#0H@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B@R.#,\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS,S@\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY686QU871I;VX-"B!A;&QO=V%N8V4\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-BPW,S0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@T M-"PU,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXH,C4L,#@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T"!P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E1H92!!;65R:6-A M;@T*(%1A>'!A>65R(%)E;&EE9B!!8W0@;V8@,C`Q,BP@=VAI8V@@"!C2!F28C M>$$P.S$L(#(P,3(@=&AR;W5G:"!$96-E;6)E$$P.S,Q+"`R,#$S+"!W M87,@;F]T#0H@96YA8W1E9"!I;G1O(&QA=R!U;G1I;"!T:&4@9FER`T*('!R;W9I6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z M(#$R<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#0E)SX- M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY3:6=N:69I8V%N=`T*(&-O;7!O;F5N=',@;V8@;W5R(&1E M9F5R"!AF%T:6]N(&]F('-U8V@- M"B!D969E#L@34%21TE.+51/4#H@,'!X M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C@L,#8V/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXQ+#@T.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E-T;V-K(&)AF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C(L.#DV/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C4X/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXT+#4Y-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E=F5L;W!M96YT#0H@8V]S=',\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXV+#0Y-3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY2971U6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS+#$Q M-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY/=&AEF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8L,#(Q M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L(&1E9F5R"!AF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@Q+#@Q.#PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW M,BPQ,C$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\+W1R/@T*(#QT6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY$969EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D)A$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E<')E8VEA M=&EO;B!A;F0-"B!A;6]R=&EZ871I;VX@9&EF9F5R96YC97,\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C@L,#DV/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M`T*("AL:6%B:6QI M='DI(&%S6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@U+#4P.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\ M+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%2 M1TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4 M:&4@:6YCF%T:6]N(&]F(&]U6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%T#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=V4@:&%D(&9E M9&5R86P@86YD('-T871E(&YE="!O<&5R871I;F<@;&]S2`D,3$W+C0F(WA!,#MM:6QL:6]N(&%N M9`T*("0Q,S(N,"8C>$$P.VUI;&QI;VXL(')E2X@5V4@:&%V M92!A<'!R;WAI;6%T96QY("0T+C$-"B!M:6QL:6]N)B-X03`[;V8@9F]R96EG M;B!L;W-S(&-A2P@=6YL97-S('!R979I;W5S;'D@=71I;&EZ960N#0H@ M070@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@=V4@:&%D(&9E9&5R86P@86YD M('-T871E('1A>"!C2`D-BXY)B-X M03`[;6EL;&EO;B!A;F0@)#(N,B8C>$$P.VUI;&QI;VXL#0H@2!U=&EL:7IE M9"X@5&AE('-T871E(')E"!P;W-I=&EO;G,@86YD M#0H@<')E"!P;W-I=&EO;G,N($]N M;'D@=&%X('!O2!B92!R96-O9VYI>F5D+CPO9F]N=#X\+W`^#0H@/'`@ M#L@ M34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!415A4+4E. M1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!F;VQL;W=I;F<-"B!T86)U;&%R M(')E8V]N8VEL:6%T:6]N('-U;6UA#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T M>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P2`M+3X-"B`\='(@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C4L-#@R/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D%D:G5S=&UE;G1S(')E;&%T960@=&\-"B!P"!P M;W-I=&EO;G,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXH,C`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C4\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY) M;F-R96%S97,@65A6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXR+#4Q-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$96-R96%S97,@ M9'5E('1O#0H@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH,2PR,C<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH-#,T/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E8W)E87-E65A M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L,C$R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D1UF5D('1A>`T*(&)E;F5F:71S('!R:6UA2!R96QA M=&5D('1O(&-R961I=',@0T*("0P+C,@;6EL;&EO;BP@)#4N,B!M:6QL:6]N(&%N9"`D,"XR M(&UI;&QI;VX@;V8@=&AE('1O=&%L#0H@=6YR96-O9VYI>F5D('1A>"!B96YE M9FET$$P.S,Q+"`R,#$S+"`R,#$R(&%N9`T* M(#(P,3$L(')E2P@=V]U;&0@"!R871E(&EF#0H@6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY792!D;R!N;W0-"B!E>'!E8W0@ M;W5R('5N`T*(&5X86UI;F%T:6]N65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY$=7)I;F<@,C`Q,RP-"B!T:&4@26YT97)N86P@4F5V96YU92!397)V M:6-E(&-O;7!L971E9"!A;B!E>&%M:6YA=&EO;B!O9B!O=7(@,C`Q,`T*('1A M>"!R971U"!W87,@<&%I9"!A2!R961U8V5D('1A>"!C2`D,"XX(&UI;&QI;VX@86YD(&YE="!O<&5R871I;F<@;&]S6]V97)S(&)Y#0H@)#$N-B!M:6QL:6]N+CPO9F]N=#X\+W`^#0H@/"]D:78^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU M9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQD:78^#0H@/'1A8FQE M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[ M(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!4 M15A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO#L@34%21TE.+51/4#H@-G!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@2!T:&4@1D1!/"]I/CPO9F]N=#X\+W`^#0H@/'`@#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@28C>$$P.S4L(#(P,30L('=E(')E M8V5I=F5D(&$@8V]M;75N:6-A=&EO;B!F2!R979I97$$P.VUI;&QI;VX@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO2!&:6YA;F-I86P@1&%T83PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78^#0H@/'1A8FQE M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/E-%3$5# M5$5$(%%505)415),60T*($9)3D%.0TE!3"!$051!("A53D%51$E4140I/"]B M/CPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\(2TM('AB2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U! M4D=)3BU43U`Z(#9P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY3 M96QE8W1E9`T*('%U87)T97)L>2!F:6YA;F-I86P@9&%T82`H=6YA=61I=&5D M*2!F;W(@=&AE('EE87(@96YD960-"B!$96-E;6)E$$P.S,Q+"`R,#$S M(&%N9"`R,#$R(&ES('!R97-E;G1E9"!B96QO=SH\+V9O;G0^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X M.R!-05)'24XM5$]0.B`P<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q M-"!A;&EG;CTS1&-E;G1EF4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P M/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O M9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQB/C(P,3,Z/"]B/CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L M(')E=F5N=65S/"]F;VYT/CPO<#X-"B`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`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]P97)A=&EN9R!L;W-S/"]F;VYT/CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@V+#0U-SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q,RPR.#<\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/DYE="!L;W-S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@U+#0S-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@S.2PQ-C8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C`Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@P+C$V/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B@P+C$S/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B@P+C8S/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/DYE="!L;W-S('!E M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C`Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@P+C$S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B@P+C8S/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/CQB/C(P,3(Z/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L(')E M=F5N=65S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4Y M+#@U.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8X+#6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C8Y+#`T,CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/D]P97)A=&EN9R!I;F-O M;64\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`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`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE M="!I;F-O;64@<&5R('-H87)E+`T*(&)A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C`N,3,\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY.970@:6YC;VUE('!E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C`N-S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N,3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L M93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU4 M3U`Z(#$R<'@[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&9O;G0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6EN9R!!8V-O=6YT M'0^ M)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z M(&YO'0M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/ M4#H@,3)P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-TF4],T0R/CQB/EEE87)S($5N9&5D($1E8V5M8F5R)B-X M03`[,S$L(#(P,3,L(#(P,3(L(&%N9`T*(#(P,3$\+V(^/"]F;VYT/CPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%=(251%+5-004-% M.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R<'@@)U1I;65S($YE M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE. M1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@ M,'!X.R`M=V5B:VET+71E>'0M6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M.R!724142#H@,SEP="<^#0H@/&9O;G0@F4],T0Q/CQB/D)A;&%N8V4F(WA!,#MA=#QB$$P.V]F/&)R("\^#0H@4&5R:6]D/"]B/CPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@F4],T0Q/CQB/D%D9&ET:6]NF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@$$P.R@Q*3PO8CX\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.V]R/&)R("\^ M#0H@1&5F97)R960\8G(@+SX-"B!487@@07-S970\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B@S,SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D%L M;&]W86YC92!F;W(@9&]U8G1F=6P-"B!A8V-O=6YTF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C(R.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ MF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`R<'@[(%=(251%+5-004-% M.B!N;W)M86P[($)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,"XU<'0@#L@ M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2\X<'@@)U1I;65S($YE M=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P>#L@3$545$52+5-004-)3D'0M$$P.SPO<#X-"B`\=&%B M;&4@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W M:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/CQB/B@Q*3PO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D1E9'5C=&EO;G,@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q M8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@2UO=VYE9"!S=6)S:61I M87)I97,-"B`H)B-X,C`Q0SM3<&5C=')U;28C>#(P,40[+"!T:&4@)B-X,C`Q M0SM#;VUP86YY)B-X,C`Q1#LL#0H@)B-X,C`Q0SMW928C>#(P,40[+"`F(W@R M,#%#.V]U#(P,40[+"!O2!C;VUP86YY('=I=&@@9G5L;'D@:6YT96=R871E M9"!C;VUM97)C:6%L#0H@86YD)B-X03`[9')U9R!D979E;&]P;65N="!O<&5R M871I;VYS+"8C>$$P.W=I=&@@82!P$$P.SPO<#X-"B`\=&%B;&4@ M3L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@#(P M,3D[6UP:&]M83L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!- M05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@2!P97)I<&AE6UP:&]M83L-"B!A M;F0\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T.R!-05)'24XM5$]0.B`P M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@'!E'0^)SQD M:78^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/CQI M/BAB*2!"87-I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@-G!X M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/E1H90T*(&%C8V]M<&%N M>6EN9R!#;VYS;VQI9&%T960@1FEN86YC:6%L(%-T871E;65N=',@:6X@=&AI M&-H86YG92!#;VUM:7-S:6]N("@F(W@R,#%#.U-%0R8C>#(P M,40[*2X@5&AE2UO=VYE9"X@06QL(&EN M=&5R+6-O;7!A;GD@86-C;W5N=',@86YD('1R86YS86-T:6]N6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/D]N#0H@07!R:6PF(WA!,#LQ+"`R M,#$R+"!W92!A8W%U:7)E9"!T:&4@;&EC96YS:6YG(')I9VAT$$P M.S4L(#(P,3(L('=E(&%C<75I28C>$$P M.S$W+"`R,#$S+"!W92!A8W%U:7)E9"!486QO;@T*(%1H97)A<&5U=&EC#(P,40[*2X@3W5R(&%C8V]M<&%N>6EN M9PT*($-O;G-O;&ED871E9"!&:6YA;F-I86P@4W1A=&5M96YT6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/E9A#(P,4,[=F%R M:6%B;&4@:6YT97)E2`R,#`X+B!#97)T86EN(&]F M(&]U2!A;F0@:&%V92!T:&4@2!O M9B!T:&ES('9A2P@4W!E8W1R=6T@4&AA M2!F;W(@86QL('!E'0^)SQD M:78^#0H@/'`@FEN9R!O;F-O;&]G>2!A;F0- M"B!H96UA=&]L;V=Y(&1R=6<@<')O9'5C=',N($9O65A'0^)SQD M:78^#0H@/'`@2UB87-E9"!P$$P.SPO<#X-"B`\=&%B;&4@ M&ES=',@ M=VET:"!O=7(@8W5S=&]M97([/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@ M/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$ M,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/B@R*3PO=&0^ M#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^<')I8V4@:7,@2!F:7AE9"!A;F0-"B!D971E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI M9VX],T1L969T/B@S*3PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS M1&QE9G0^8V]L;&5C=&EO;B!F$$P.SPO<#X-"B`\=&%B;&4@2!U6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@ M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T M/B@U*3PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^=V4@ M9&\@;F]T(&AA=F4@$$P.SPO M<#X-"B`\=&%B;&4@2!O=7(@9W)O#(P,4,[1U1.)B-X,C`Q1#LI(&5S M=&EM871E#(P,4,[ M4')O9'5C="!S86QE6EN M9R!#;VYS;VQI9&%T960-"B!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,N(%=E M(&1E9F5R(')E=F5N=64@2!D971E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T* M(#QI/E!R;V1U8W0@4F5T=7)N2!P97)M:71T960@=&\@F%T:6]N(')E<75I6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#QI/D=O=F5R M;FUE;G0@0VAA0T*(&)E('-I9VYI9FEC86YT(&QA9R!T:6UE+B!$=64@=&\@97-T:6UA M=&5S(&%N9"!A2!D M:69F97)E;G0@9G)O;2!O=7(@97-T:6UA=&5S+CPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B`\:3Y$:7-C;W5N=',\+VD^.B!$:7-C;W5N=',@ M*&=E;F5R86QL>2!P6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#QI/E)E8F%T97,\+VD^.B!296)A M=&5S(&%R92!E6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`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`@6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4 M.B`T)2<^#0H@0V%S:"!A;F0@97%U:79A;&5N=',@8V]N6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/BAI:6DI($UA M6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M M24Y$14Y4.B`T)2<^#0H@36%R:V5T86)L92!S96-U#(P,4,[=6YR96%L:7IE9"!G86EN M("AL;W-S*2!O;B!S96-U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!! M0T4Z(&YO#L@34%21TE.+51/4#H@ M,3AP>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-TF4] M,T0R/CQB/CQI/BAI=BD-"B!!8V-O=6YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M5TA)5$4M4U!!0T4Z(&YOF4],T0R/D%C8V]U;G1S M#0H@&ES=&EN9PT*(&%C8V]U;G1S(')E8V5I=F%B M;&4N($%C8V]U;G0@8F%L86YC97,@87)E(&-H87)G960@;V9F(&%G86EN&AA=7-T960N/"]F;VYT/CPO<#X-"B`\+V1I=CX\ M2!A="!T:&4@;&]W97(@;V8@=&AE M(&%C='5A;"!C;W-T('1O('!U2P@;W(@=&AE(&UAF%B;&4@=F%L=64I+B!#;W-T(&ES M(&1E=&5R;6EN960@;VX@=&AE(&9I2!Q=6%N M=&ET:65S#0H@:6X@<')O8V5S2!T;R!R961U8V4@:70@=&\@:71S(&YE=`T* M(')E86QI>F%B;&4@=F%L=64N/"]P/@T*(#PO9&EV/CQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M M4U!!0T4Z(&YO#L@34%21TE.+51/ M4#H@,3AP>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-TF4],T0R/CQB/CQI/BAV:2D-"B!02!A;F0@17%U:7!M96YT/"]I M/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R/E!R M;W!E#(P,3D[6EN9R!A;6]U;G0@;6%Y(&YO="!B90T*(')E8V]V97)A8FQE('1H6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1V]O M9'=I;&P@F5D+"!B M=70@:6YS=&5A9"!T97-T960@9F]R#0H@:6UP86ER;65N="!A;FYU86QL>2!U M;FQE2P@;W(@=VAE;F5V97(@979E;G1S M(&]R(&-H86YG97,-"B!I;B!O=7(@8G5S:6YE2!N;W0@8F4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX] M,T1L969T/BAA*3PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE M9G0^82!S:6=N:69I8V%N="!D96-R96%S92!I;B!T:&4@;6%R:V5T#0H@=F%L M=64@;V8@86X@87-S970[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@ M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X- M"B`\='(^#0H@/'1D('=I9'1H/3-$-"4^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/BAB*3PO=&0^#0H@ M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^82!S:6=N:69I8V%N="!A M9'9E'1E;G0@;W(@;6%N;F5R(&EN('=H M:6-H(&%N(&%S$$P.SPO<#X- M"B`\=&%B;&4@F4@65E2!A=V%R9',-"B!W:71H(&UA&-H M86YG92!I;B!E9F9E8W0@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D+B!2979E M;G5E'!E;G-E&-H86YG92!I;B!E9F9E8W0@9'5R:6YG#0H@=&AE('!E&-H86YG92!R871E#0H@<')E=F%I;&EN9R!A="!T:&4@9&%T92!O9B!T M:&4@=')A;G-A8W1I;VX@=VET:"!R97-U;'1A;G0@9V%I;G,@86YD#0H@;&]S M0T*('1R86YS86-T:6]N(&=A:6YS(&%N9"!L;W-S M97,@:&%V92!N;W0@8F5E;B!S:6=N:69I8V%N="!F;W(@86YY#0H@<&5R:6]D M('!R97-E;G1E9"X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M3$5&5#H@,B4[($U!4D=)3BU43U`Z(#$X<'0G/@T*(#QB/CQI/BAX*2!#;VUP M#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%2 M1TE.+4Q%1E0Z(#(T<'@[($U!4D=)3BU43U`Z(#$X<'@[($Q%5%1%4BU34$%# M24Y'.B!N;W)M86P[(%1%6%0M24Y$14Y4.B`P<'@[("UW96)K:70M=&5X="US M=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O;G0@&DI#0H@ M0F%S:6,@86YD($1I;'5T960@3F5T("A,;W-S*2!);F-O;64@<&5R(%-H87)E M/"]I/CPO8CX\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R M/E=E(&-A;&-U;&%T90T*(&)A&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#(E.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3XH>&EI*2!) M;F-O;64@5&%X97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*($1E9F5R"!A"!E9F9E8W1S(&]F('1E;7!O2!D:69F97)E;F-E"!B87-I"!C2!F;W)W87)D"!R871E'!E8W1E9`T*('1O(&)E(&EN(&5F9F5C="!W:&5N M('1H92!D:69F97)E;F-E#(P,40[('=I=&AI;B!T:&4-"B!# M;VYS;VQI9&%T960@4W1A=&5M96YT'0^)SQD:78^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@4F5S96%R8V@@ M86YD(&1E=F5L;W!M96YT(&-O'!E;G-E9"!A'0^)SQD:78^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/CQB/CQI/BAX:78I)B-X03`[1F%I MF4@=F%L=6%T:6]N#0H@=&5C:&YI<75E&EM:7IE('1H92!U'1E;G0@<&]S6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/DQE M=F5L)B-X03`[,3H\+VD^(%%U;W1E9"!P2!T;R!,979E;"8C>$$P.S$@:6YP=71S+CPO M9F]N=#X\+W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/CQI/DQE=F5L)B-X03`[,CH\+VD^($]B6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQI/DQE=F5L)B-X03`[,SH\+VD^(%5N;V)S97)V86)L92!I;G!U M=',@87)E('5S960@=VAE;B!L:71T;&4-"B!O2!G:79E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(W@R,#%#.T-A6EN9R!#;VYS;VQI9&%T960@0F%L86YC90T*(%-H M965T2!M87)K970@9G5N9',@=&AA=`T*(&%R92!V86QU960@=71I;&EZ:6YG($QE M=F5L(#(@:6YP=71S+B`F(W@R,#%#.TUAFEN9R!,979E;"`Q M(&EN<'5T6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1%3E0Z(#0E)SX- M"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY4:&4@9F%I#(P,4,[9&5F97)R960@<&%Y;65N="!C;VYT:6YG96YC>28C>#(P,40[('=I M=&AI;B!O=7(@86-C;VUP86YY:6YG#0H@0V]N0T*(')E M9F5R'!E8W1E9"!P97)I;V0@=&AA="!T M:&4@'!E;F1I='5R97,N(%1H97-E(&EN<'5T2!B87-I6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,3)P>#L@5$585"U)3D1% M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(W@R,#%#.T%C<75I#(P,40[('=I=&AI;@T*(&]U M2!B92!R97%U:7)E9"!T M;R!P87D@:6X@8V]N:G5N8W1I;VX@=VET:"!V87)I;W5S#0H@8G5S:6YE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@ M0FQO8VL@6T%B'0^)SQS<&%N/CPO2!O9B!#87-H(&%N9"!%<75I=F%L96YT M#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@ M,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@2!O9B!O=7(@8V%S:"!A M;F0@97%U:79A;&5N=',@86YD(&UAF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@F4],T0Q/CQB/D=R M;W-S/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0Q/CQB/E5N6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/F9A:7(\+V(^/"]F M;VYT/CQB6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@$$P.V%N9#QB MF4],T0Q M/CQB/DUAF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/CQB/DQO;F<\ M+V(^/"]F;VYT/CQB6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ MF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@2!M87)K970-"B!F=6YDF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C0Q,#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C,L M,#8Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/C$U.2PW-S<\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$U.2PW-S<\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$R M."PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`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`G5&EM97,@ M3F5W(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/CDX-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C(L,S(S/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$T,RPP,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$T M,RPP,#@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\ M8G(@8VQA2!A;F0@17%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E. M1$5.5#H@."4G/@T*(%!R;W!E6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#`V,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`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`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*(%!R;W!E6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P+#8P-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CDL.#8S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQOF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH.2PP-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R M;W!E$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L-3,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-30X/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*(%=O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L,S$R/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L-#$S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,C@Y/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPU,3D\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M'0^)SQD M:78^#0H@/'`@#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA!,#L\+W`^#0H@ M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%PF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N M=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D9O6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D-UF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]LF%T:6]N/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,3X\8CY097)I;V0F(WA!,#L-"B`H>65A65A2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/DU%3%!(04Q!3@T*($E0 M4B9A;7`[1#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXW+#

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`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXR-2PW.3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$Q/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/EI%5D%,24X@;6%R:V5T:6YG(')I9VAT#(P,3,[(%4N4RX\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXT,2PY,#`\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@R,RPT-34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P M,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ."PT-#4\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C$P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C(S+#0Y,#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXQ."PX,CD\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CY&55-)3$56(&1E=F5L;W!E9`T*('1E8VAN;VQO M9WD\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ M-BPW-S@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@T+#@R,3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF M(WA!,#L\+V9O;G0^/"]T9#X-"B`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`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY&3TQ/5%E.(&1I6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR-RPY,#`\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@S+#8V,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@Q M+#`R,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(S+#(Q-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CD\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CY&3TQ/5%E.(&1E=F5L;W!E9`T*('1E8VAN;VQO9WD\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,3@L-#`P/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXH,3`L-3@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`],T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]TF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T"<^ M#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BH\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CY/;B!-87DF(WA!,#LR.2P@,C`Q,RP@=V4-"B!A;65N9&5D(&]U2!W97)E(&5X8VQU9&5D(&9R;VT@375N9&EP:&%R M;6$F(W@R,#$Y.W,@8V]M;65R8VEA;&EZ871I;VX-"B!T97)R:71O6%L='D@ M86YD(&UI;&5S=&]N92!R:6=H=',-"B!C;VYS=&ET=71E9"!A(&-H86YG92!I M;B!T:&4@8V]N=')A8W1U86P@<')O=FES:6]N#(P,40[(&EN('1H92!A8V-O;7!A;GEI M;F<@0V]N"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QLF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,CPO8CX\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/CQB/D%M;W)T:7IA=&EO;CPO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/E1R M86YS;&%T:6]N/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/D%M;W5N=#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A M8FQE($)O9'D@+2T^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/EI%5D%,24X@;6%R:V5T:6YG M(')I9VAT#(P,3,[(%4N4RX\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(S+#0Y,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P+#DT,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D954TE,158@9&5V M96QO<&5D#0H@=&5C:&YO;&]G>3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$V+#6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXR-RPY,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B@X.34\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXR-RPP,#4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&3TQ/ M5%E.(&1E=F5L;W!E9`T*('1E8VAN;VQO9WD\+V9O;G0^/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,3@L-#`P/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXH,BPP-S<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ,38L,S(S/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]TF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,"PR,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`-"B`-"B`\+V1I=CX\'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[ M(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!7 M3U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE M9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,1514 M15(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O;G0@'!E;G-E("AE M>&-L=61I;F<@:6YC2D@9F]R('1H92!F:79E('-U8V-E961I;F<@>65A"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L M;&%P#L@3$545$52+5-004-)3D#L@ M+7=E8FMI="UT97AT+7-T6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED.R!7 M24142#H@.3-P="<^#0H@/&9O;G0@$$P.S,Q/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C(P,30\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/C(R+#0V.#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(R+#0V M.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/C(R+#0V.#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(R M+#0V.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(R+#,Q,SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/C(P-BPP-3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T2!S;W5R8V4I.CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/ M4#H@,'!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($%C<75I$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T* M("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-3(U/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#4R-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#,T-CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#&-H86YG92!T$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@S-SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+#4P M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#(W.3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY/=&AE#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P$$P M.S,Q+#PO8CX\+V9O;G0^/&)R("\^#0H@/&9O;G0@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I M;B!486)L92!";V1Y("TM/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY);G9E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,L-3DS/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`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`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR M+#@X,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\+V1I=CX\6%B;&4@86YD($]T:&5R($%C8W)U960@3V)L:6=A=&EO;G,\+W1D/@T* M("`@("`@("`\=&0@8VQA6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R/D%C8V]U;G1S#0H@<&%Y86)L92!A;F0@;W1H97(@86-C M6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!, M151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B M:VET+71E>'0M$$P.SPO<#X-"B`\ M=&%B;&4@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/C$R+#6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/C,P+#@Q-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C$Q+#`R,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/CDL-#DX/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C4L,#4V/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D%C8W)U960@9&%T82!A;F0-"B!D:7-TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C(L,S(W/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C,L M,#4P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D%C8W)U960@:6YC;VUE#0H@=&%X97,\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C4L,#F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/C$Q+#0T,3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C(L.#$Y/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]TF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/"]T86)L93X-"B`\+V1I=CX\6%B;&4@86YD($]T:&5R($%C8W)U960@3V)L M:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!! M0T4Z(&YOF4],T0R/D%M;W5N=',-"B!P#(P,4,[86-C;W5N=',@<&%Y86)L92!A;F0@;W1H97(@ M86-C6EN9R!#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',-"B!F;W(@1U1.(&5S M=&EM871E#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(#$R<'@@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P M>#L@3$545$52+5-004-)3D#L@ M+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/ M4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@ M;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0MF4],T0Q/CQB/D1EF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.V%N9#QBF4],T0Q/CQB/D1A=&$@ M86YD/&)R("\^#0H@1&ES=')I8G5T:6]N+#QB$$P.T9E M97,L)B-X03`[86YD/&)R("\^#0H@26YV96YT;W)Y/&)R("\^#0H@36%N86=E M;65N=#QBF4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\ M+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$ M-#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C;VQS<&%N M/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/CDL,#8T/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$X,CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/D%D9#H@<')O=FES:6]N2D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C0L.#$T/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B@W-BPS,3@\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$T+#$T M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4L,#4V M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/D%D9#H@<')O=FES:6]N2D\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$X,SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@R M-RPX-#,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/BDF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@2!O9B!/=&AE6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R/D]T:&5R#0H@;&]N9RUT97)M(&QI86)I;&ET:65S(&%R M92!C;VUP6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO M"`G5&EM97,@3F5W(%)O M;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L M.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@"<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.S,Q+#PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q M/CQB/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@&5C=71I=F4-"B!D969E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C,L.30Y/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4W,3PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(Y.#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C4L.38U M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!! M0T4Z(&YO"`G5&EM97,@ M3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@ M;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($1I$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;VUP="!P87D@9&ES M8V]U;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH-"PP.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ-#,L-#$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U-"PY M.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA$$P.S,Q+"`R,#$S+"`R,#$R+"!A;F0@,C`Q M,3H\+W`^#0H@/'`@6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CDS+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDV+C0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.34S/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,3$S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S:6$@ M4&%C:69I8SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+C(\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+C0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X- M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C8\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-#,L M-#$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C(U-"PY.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ M,#`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$P,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4 M.B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R,B!A;&EG;CTS1&-E;G1E M$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($9/3$]464X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XT-"PS-S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N,#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI M9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%I%5D%,24X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PS.3,\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$Q+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(W M+#4U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($U!4E%)0D\\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ+#,Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XP+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*(%!R;V1U8W0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$T,RPT-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#`N,#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$P,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-C8S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU M9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+51/4#H@-G!T.R!415A4+4E.1$5.5#H@."4G/@T*(%-T;V-K+6)A'!E;G-E(&EN8VQU9&5D('=I=&AI;B!O<&5R871I;F<@ M97AP96YS97,-"B!F;W(@>65A$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR+#`Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ+#@T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+#8R.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R M+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"PX.#0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T'0^ M)SQD:78^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H M92!F86ER('9A;'5E#0H@;V8@65A6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0U(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/EEE87(@16YD960-"B!$96-E;6)E$$P.S,Q+#PO8CX\+V9O;G0^/"]T M9#X-"B`\+W1R/@T*(#QTF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X<&5C=&5D(&]P=&EO;B!L:69E("AI;@T*('EE87)S*2`H82D\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C0N.34\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1C96YT97(^/&9O;G0@$$P.RTF(WA!,#LP+CF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G M/C`N,S0E)B-X03`[+28C>$$P.S`N-3$E/"]F;VYT/CPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY6 M;VQA=&EL:71Y("AC*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/CQF;VYT('-T>6QE/3-$)U=(251%+5-0 M04-%.B!N;W=R87`G/C4X+C,E)B-X03`[+28C>$$P.SF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4U+C@E/"]F;VYT/CPO=&0^#0H@/"]T6EE;&0-"B`H9"D\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`E/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`E M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C`E/"]F;VYT/CPO=&0^ M#0H@/"]T2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@&EM=6T-"B!T97)M(&ES(#$P('EE87)S*2X\+V9O;G0^/"]T9#X-"B`\ M+W1R/@T*(#PO=&%B;&4^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ, M05!313H@8V]L;&%P#(P,3D[(&5X<&5C=&5D#0H@=&5R;2DN/"]F;VYT M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BAC*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUE87-U6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/BAD*3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L M969T/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E=E(&1O(&YO="!E>'!E8W0@=&\@9&5C;&%R90T*(&%N M>2!C87-H(&1I=FED96YD#L@0T],3U(Z(')G8B@P M+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE. M+51/4#H@-G!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5. M5#H@-"4[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O M;G0@2!D=7)I;F<@=&AE('EE M87)S(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3,L(#(P,3(L(&%N9`T* M(#(P,3$@:7,@87,@9F]L;&]W6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%2 M1TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E. M1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0Q/CQB/D5X97)C:7-E/"]B/CPO9F]N=#XF(WA!,#L\ M8G(@+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0Q/CQB/E!R:6-E+U-H87)E/"]B/CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/D]U='-T86YD:6YG)B-X03`[)B-X,C`Q-#L-"B!$ M96-E;6)E$$P.S,Q+"`R,#$P/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C@L,SDW+#`Y-#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C0N M,3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1% M6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/D=R86YT960\+V9O;G0^/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$ M,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@&5R8VES960\+V9O;G0^/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C0N,#<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C@L,C4U M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/D9OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C0N.#$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D5X<&ER960\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/"]T$$P.R8C>#(P M,30[#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,3PO9F]N=#X\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$Q M+C4W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@&5R8VES960\+V9O;G0^ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE M/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C0N-3(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/C$Q+#4P,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@'!IF4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@S+#DQ-CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/CF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/D]U='-T86YD:6YG)B-X03`[)B-X,C`Q-#L-"B!$96-E;6)E$$P M.S,Q+"`R,#$R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$P+#,Y.2PR-C4\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C(L,#0Q+#,P,#PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/B@X,C4L.#@T/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B@Q*28C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@R M,#(L.#@R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/CF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C(U+#@T M.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E9E&5R8VES86)L92DF(WA!,#LF(W@R,#$T.R!$ M96-E;6)E$$P.S,Q+"`R,#$S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C8N M,3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C8N,CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/C(T+#`X,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E5N=F5S M=&5D#0H@*'5N97AEF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@ M8V]L;&%P#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@&5R8VES92!P$$P.V)Y('1H92!N=6UB97(@;V8@ M;W!T:6]N6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U4 M4D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!! M0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M MF4],T0R/E)E<')E$$P.SPO:3YD:69F97)E;F-E#0H@8F5T=V5E;B!O=7(@8VQO2!O9B`R,#$S(&%N M9`T*('1H92!S=&]C:R!O<'1I;VX@97AE2!T:&4@;G5M8F5R(&]F(&EN+71H92UM M;VYE>0T*(&]P=&EO;G,@87,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX@ M5&AE(&%M;W5N="!O9B!I;G1R:6YS:6,@=F%L=64-"B!W:6QL(&-H86YG92!B M87-E9"!O;B!T:&4@9F%I2!O9B!3=&]C:R!/<'1I;VX@1W)A;G1S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'@[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)- M.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[ M($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@ M,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.S,Q+"`R,#$S.CPO9F]N=#X\+W`^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P M#L@ M3$545$52+5-004-)3D#L@+7=E M8FMI="UT97AT+7-TF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@"!S;VQI9#L@5TE$5$@Z(#0X<'0G/@T*(#QF;VYT M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/D=R86YT M960F(WA!,#M3=&]C:SQBF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/CQB/E)E;6%I;FEN M9SPO8CX\+V9O;G0^)B-X03`[/&)R("\^#0H@/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/CQB M/D5X97)C:7-E/"]B/CPO9F]N=#X\8G(@+SX-"B`\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0Q/CQB/E!R M:6-E/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/CQB/D=R86YT960\8G(@+SX-"B!3=&]C:SQB M&5R8VES86)L93PO8CX\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE M/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]LF4],T0Q/CQB/D5X97)C:7-E/"]B/CPO9F]N=#X\8G(@ M+SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0Q/CQB/E!R:6-E/"]B/CPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.S,N,34\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/B0S+C4U("8C>#(P,3,[#0H@)B-X03`[)B-X03`[-"XY-3PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/C4N.3PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B0U M+C`U("8C>#(P,3,[#0H@)B-X03`[)B-X03`[-BXY,#PO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C4N-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/B0W+C`P("8C>#(P,3,[#0H@)B-X03`[ M)B-X03`[."XY.3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C@N M,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/B0Y+C`P("8C>#(P,3,[#0H@,38N,S(\+V9O M;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$P+C@V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C$Q+C`Y/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]TF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/C$Q+#,R.2PR,3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/CF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C8N,3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78^#0H@/'`@#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@2!I"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L M;&%P#L@3$545$52+5-004-)3D#L@ M+7=E8FMI="UT97AT+7-TF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.T%V97)A9V4\+V(^/"]F;VYT/CQB6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.S,Q+"`R,#$P/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C,U.2PU,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=) M3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D=R M86YT960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$R M+C,S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE M/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D9OF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/CDN-3<\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/E5N=F5S=&5D)B-X03`[)B-X,C`Q-#L-"B!$96-E M;6)E$$P.S,Q+"`R,#$R/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C$L,#,T+#8P-#PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/E9EF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/CDN-S(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/B@T.2PV,C4\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-% M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z M(&YO"`G5&EM97,@3F5W M(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@"<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$ M,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E(&%L:6=N M/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/BH\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E)E<')E$$P.SQI/FUU M;'1I<&QI960\+VD^)B-X03`[8GD@=&AE(&YU;6)E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N M)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!4 M15A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\+V1I=CX\65E#0H@8V]N=')I8G5T:6]N$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XY.2PS-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C8U+#@X.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Y,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E)R!C96QL6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8L-3`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XT+#$P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B M;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA2!;06)S=')A8W1=/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M34%21TE.+51/4#H@-G!X.R!415A4+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D%S(&]F#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RP@87!P2`R."XQ)B-X03`[;6EL;&EO;B!S:&%R97,@;V8-"B!O=7(@8V]M;6]N('-T M;V-K('=E#L@34%21TE.+51/4#H@ M,'!X)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU# M3TQ,05!313H@8V]L;&%P6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D-O;G9EF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C0P+#`P,#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/C(P,3@@0V]N=F5R=&EB M;&4-"B!.;W1EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$Q+#0P,"PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY%>&5R8VES92!O M9B!I6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D5X97)C M:7-E(&]F(&ES6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D534%`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CXT+#4T,"PY.#8\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,;VYG+71E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L('-H87)EF4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(X+#$P,2PW,#0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`-"B`-"B`\+V1I=CX\'0^)SQD:78^02!S=6UM87)Y(&]F('=A6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#DR)2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L&5R8VES M928C>$$P.U!R:6-E/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\ M(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>#(P,30[($1E8V5M8F5R)B-X03`[,S$L M(#(P,3`\+W`^#0H@/"]T9#X-"B`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`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,RPW-#$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV+C8R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.S,Q+"`R,#$Q/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-#4L,#`P/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C4N,#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XS.34L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4N-#4\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($=R86YT960\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4P+#`P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>#(P,30[($1E8V5M8F5R)B-X03`[,S$L(#(P M,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T-2PP,#`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE&5R8VES86)L928C>$$P.R8C>#(P,30[($1E8V5M8F5R)B-X03`[,S$L(#(P M,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-RPU,#`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R/DYE="`H;&]S2!D:79I9&EN9R!N970@*&QO2!T:&4-"B!W96EG:'1E9"!A=F5R86=E(&YU;6)E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z M(&YO"`G5&EM97,@3F5W M(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M$$P.SPO<#X-"B`\=&%B;&4@"<@8V5L;'-P86-I M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E M;G1EF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@ M,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/CQB M/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/DYE="`H;&]S6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B@V,BPQ,S0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E=E:6=H M=&5D(&%V97)A9V4@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/DYE="`H;&]S6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B@Q+C`R/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C$N-C$\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`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`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4W+#DU.2PW,30\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@ M6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYE="!);F-O M;64\8G(@+SX-"B`H;G5M97)A=&]R*3PO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T2`M+3X-"B`\='(@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(#QB/EEE87(@16YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO8CX\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M."PU.#@L.3$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C8Q M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(R-"PT,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N=F5S M=&5D(')E$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($1I;'5T960@;F5T(&EN8V]M92!P97(@6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XY-"PR,#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV M-"PV,S$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-#8\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.S,Q+"`R,#$Q/"]B/CPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S+#(W M,BPW-C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.30\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1I;'5T:79E M(&-O;6UO;B!S=&]C:R!O<'1I;VYS/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#$X-2PR,C0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($-H86YG92!I;B!C;VUM;VX@2!H860@8F5E;B!I$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT0T* M('=A$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#@W-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP M+C@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/"]T&-L=61E9"!F#L@5$585"U)3D1% M3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)R!S:7IE/3-$,CY/=7(@;W5T#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%PF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB M/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/CQB/C(P M,3$\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@ M16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T* M(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXR,#$X($-O;G9E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-#,L-C`P/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/E)E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXQ+#`P-RPQ,3D\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE M/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]WF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY#;VUM;VX@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$V,"PX,38\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY06QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXT,"PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]WF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@34%21TE.+51/4#H@,'!X)SX-"B`F M(WA!,#L\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W M9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y M-69A,6-?.#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!O9B!!#L@0T],3U(Z(')G8B@P+#`L,"D[($9/ M3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@-G!X M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O;G0@F5S(&-E2!F86ER('9A;'5E$$P.SQI/BAX*2D\+VD^.CPO9F]N=#X\+W`^ M#0H@/'`@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/CQB M/DQE=F5L#0H@,3PO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/CQB/E1O M=&%L/"]B/CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ MF4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/DUO;F5Y(&UA M0T*(&9U;F1S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$P,"PS.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C$P,"PS.34\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C,L,#8Q/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4L,S8Q/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)TU!4D=) M3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D5Q M=6ET>0T*('-E8W5R:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C,L-3DS/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C,L-3DS/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@3PO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$W+#6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/C0L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/E1A;&]N($-64CPO9F]N=#X\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R M/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C,L.30Y/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'@[(%=(251%+5-004-%.B!N;W)M M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@ M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#%P>"`G5&EM97,@3F5W(%)O;6%N M)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M M=V5B:VET+71E>'0MF4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1EF4],T0Q/CQB M/D1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,CPO8CX\+V9O;G0^/&)R("\^#0H@ M/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/DQE=F5L#0H@,CPO8CX\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.S,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/CQI/D%SF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/CDX-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$Q+#8Y.#PO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(L M,S(S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/D1E9F5RF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0Q M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>#(P,30[)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@3PO9F]N=#X\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C$R+#(S,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C(L,C@W/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/DQI9V%N9"!#;VYT:6YG96YT#0H@0V]NF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QTF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$T M+#4R,#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$V+#@X-3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@ M3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@$$P.SQI/DYO=&4@,BAX*3PO:3XI(&EN#0H@9&5T97)M:6YI;F<@<&5R:6]D M+65N9"!V86QU92X@5&AE#(P,40[(&%N9"`F(W@R,#%#.V%C8W)U960@86YD(&1E9F5R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U4 M4D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!! M0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M MF4],T0Q/CQB/D9A:7(F(WA!,#M6 M86QU928C>$$P.TUE87-U$$P.R!O9CPO8CX\+V9O;G0^/&)R M("\^#0H@/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/C$R+#(S,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/E1R86YS9F5R6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/BDF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`S96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/DQI9V%N9"!#;VYT:6YG M96YT#0H@0V]NF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C0L,#`P/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/E1A;&]N($-64@T*("AS964F(WA!,#L\:3Y.;W1E#0H@ M,3`H82D\+VD^*3PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\8G(@8VQA3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q M-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8C`Y-69A,6-?.#'0O:'1M M;#L@8VAA'0^)SQD:78^ M#0H@/'`@F5S('1H92!P=7)C:&%S92!P6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($-A$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$Q+#,P,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!! M0T4Z(&YOF4],T0R/E1H92!F;VQL;W=I;F<-"B!U M;F%U9&ET960@<')O(&9O$$P.S,Q+"`R,#$S(&%N9"`R,#$R M+"!A28C>$$P.S$L(#(P,3(N(%1O(')E9FQE8W0@=&AE#0H@ M8V]M8FEN960@8G5S:6YE2!A;F0@;6%Y(&YO="!B90T* M(&EN9&EC871I=F4@;V8@=VAA="!O<&5R871I;F<@2!T86ME M;B!P;&%C92!O;B!*86YU87)Y)B-X03`[,2P@,C`Q,BP@86YD(&UA>0T*(&YO M="!B92!I;F1I8V%T:79E(&]F(&9U='5R92!O<&5R871I;F<@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E M>'0M$$P.SPO<#X-"B`\=&%B;&4@ M"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q M/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/E!R;R!&;W)M82!4;W1A;`T*(')E=F5N=65S/"]F M;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/C(P,"PV-3$\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C(Q,"PT,S,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4W+#(W-#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B@Q+C$R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C`N.3@\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@#(P M,3,[(&1I;'5T960\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B@Q+C$R/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C`N.#D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\8G(@ M8VQA#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM M97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$545$52+5-004-) M3D'0M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@#(P,40[*2!A;F0-"B!-05)124)/('1R96%T;65N="!O M9B!N;VXM2&]D9VMI;B8C>#(P,3D[6UP:&]M80T*("@F(W@R,#%#.TY( M3"8C>#(P,40[*2!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA) M5$4M4U!!0T4Z(&YO"`G M5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!! M0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0M M$$P.SPO<#X-"B`\=&%B;&4@"<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L0T* M("8C>#(P,30[34%244E"3R!F;W(@04Q,/"]F;VYT/CPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C$S)B-X03`[>65AF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@#(P,30[34%244E" M3PT*(&9O6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B@Q*3PO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/E1O=&%L(&ED96YT:69I86)L90T*(&EN=&%N9VEB;&4@ M87-S971S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ M(#)P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!, M151415(M4U!!0TE.1SH@;F]R;6%L.R!724142#H@,3(T<'@[(%1%6%0M24Y$ M14Y4.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@ M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@3$545$52 M+5-004-)3D#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ M(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R M;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0MF4],T0R/DE04B9A;7`[1"!I2!O9B!!;&QO8V%T:6]N(&]F(%1O=&%L(%!U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@5TA)5$4M4U!!0T4Z(&YOF4],T0R/E1H92!F M;VQL;W=I;F<-"B!T86)L92!S=6UM87)I>F5S('1H92!E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/ M4#H@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@ M,'!X.R`M=V5B:VET+71E>'0M$$P M.SPO<#X-"B`\=&%B;&4@6QE/3-$)TU!4D=)3BU, M1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D-A6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C$S,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E!R97!A:60@97AP96YS97,@86YD#0H@;W1H97(@8W5R6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;BF4],T0R/E!R;W!EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$ M-#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/D%C8V]U;G1S#0H@<&%Y86)L928C>$$P.R9A M;7`[(&%C8W)U960@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/C8L-3"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E1O=&%L(&QI M86)I;&ET:65S#0H@87-S=6UE9#PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]TF4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\8G(@8VQA6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,#`P/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V M<'0[(%1%6%0M24Y$14Y4.B`X)2<^#0H@061J=7-T;65N=',@=&\@0U92(&9A M:7(@=F%L=64@87)E(')E8V]G;FEZ960@=VET:&EN("8C>#(P,4,[8VAA;F=E M#0H@:6X@9F%I6EN9R!#;VYS;VQI9&%T960@4W1A=&5M96YT6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X- M"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/D9A:7(F(WA!,#M686QU93QB6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9A:7(@=F%L=64@861J M=7-T;65N="!F;W(@>65A$$P.S,Q+"`R,#$S M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0L,S(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\+V1I=CX\'0^)SQD:78^#0H@/'`@#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@5TA)5$4M4U!!0T4Z(&YO"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!, M151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B M:VET+71E>'0M$$P.SPO<#X-"B`\ M=&%B;&4@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#8X)2!A;&EG;CTS1&-E;G1EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@$$P.S@L#0H@,C`Q,SPO9F]N=#X\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M$$P.S,Q+`T*(#(P,3,\ M+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C0L,#`P M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/"]T86)L93X-"B`\8G(@8VQA'0^)SQD:78^#0H@/'`@#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@"<^#0H@)B-X03`[/"]P M/@T*(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2 M;VUA;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6EN9R!6 M86QU97,@;V8@,C`Q."!#;VYV97)T:6)L92!.;W1E'0^)SQD:78^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E1H92!C87)R>6EN9PT*('9A;'5E$$P.S,Q M+"`R,#$S#0H@:7,@"<^#0H@)B-X03`[/"]P/@T*(#QT86)L M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E)R!C96QL6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY06QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$R,"PP,#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4 M.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N)R!S:7IE/3-$,CXH3&5SF5D(&1E8G0-"B!D M:7-C;W5N="`H86UOF5D('1H6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C@L-3(P M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/D1E8V5M8F5R)B-X03`[,S$L(#(P,3,@;F5T#0H@8V%R6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@'0^)SQD:78^#0H@/'`@'!E M;G-E)B-X,C`Q1#L@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($%C8W)E=&EO;B!O9B!D96)T(&1I$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($5F9F5C=&EV92!I;G1E"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!% M;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q.'!T.R!-05)'24XM5$]0.B`P M<'0G/@T*("8C>$$P.SPO<#X-"B`\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0@ M0FQO8VL@6T%B'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M>#L@5TA)5$4M4U!!0T4Z(&YO"<^#0H@/&9O;G0@6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO'0M$$P M.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/CQB/D-UF4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@$$P.R8C>#(P,3,[/&)R M("\^#0H@1D],3U193CPO8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU! M4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/E1R86YS9F5R(&9R;VT@;&]N9R!T97)M#0H@=&\@8W5RF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@'!E;G-EF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q+#,U-SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q,S0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/C,L,3$Y/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6UE;G1S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'@[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M M5%)!3E-&3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%2 M1TE.+51/4#H@,3)P>#L@3$545$52+5-004-)3D'0M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@#L@0T],3U(Z(')G M8B@P+#`L,"D[($9/3E0Z(#$R<'@@)U1I;65S($YE=R!2;VUA;B<[($U!4D=) M3BU43U`Z(#!P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$58 M5"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E M>'0M6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.S,Q+#PO8CX\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(P,30\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C@T.3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/CDU,#PO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C@Y,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/C@T,SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C@V.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T MF4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@5TA)5$4M4U!!0T4Z(&YO MF4],T0R/E1H90T*(&-O;7!O;F5N=',@;V8@*&QO M#L@ M0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R<'@@)U1I;65S($YE=R!2;VUA M;B<[($U!4D=)3BU43U`Z(#!P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M M=V5B:VET+71E>'0MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E MF4],T0Q/CQB/D9O$$P.S,Q+#PO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/CQB/C(P M,3,\+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G M8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/C@R+#$V-3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/C4S+#@S-#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/B@V+#$Y.3PO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@R+#(S M-3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/B@Q.3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149& M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B@S-BPV M,S8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N;VYE M.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z M(#%P>"`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,3)P>#L@3$54 M5$52+5-004-)3D#L@+7=E8FMI M="UT97AT+7-T6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X.R!415A4 M+4E.1$5.5#H@-"4G/@T*(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E1H92!P#L@34%21TE.+51/4#H@,'!X)SX-"B`F(WA! M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L M;&%P$$P.S,Q+#PO M8CX\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I M>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@2`M+3X-"B`\='(@8F=C;VQOF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$ M)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CY3=&%T93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@V.3$\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)R!S:7IE/3-$,CXS+#0Q,CPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)TU!4D=)3BU,1494 M.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY&;W)E:6=N/"]F M;VYT/CPO<#X-"B`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`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B@Y+#`T.#PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V M86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/D1E9F5RF4] M,T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)TU!4D=)3BU,1494.B`S96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY&961E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXH,C0L,#$S/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/E-T871E/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(] M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D9O6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$ M,CXS-"PU-#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@S,RPY,#4\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M/&9O;G0@"!P6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/"]T"!02!2871E($%P<&QI960@=&\@26YC M;VUE(&)E9F]R92!487AE'0^)SQD:78^#0H@/'`@F4],T0R/E1H92!I;F-O M;64-"B!T87@@<')O=FES:6]N("AB96YE9FET*2!D:69F97)S(&9R;VT@=&AA M="!C;VUP=71E9"!U2!R871E M(&%P<&QI960@=&\@:6YC;VUE(&)E9F]R92!T87AE#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R M<'@@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#!P>#L@3$545$52 M+5-004-)3D#L@+7=E8FMI="UT M97AT+7-T6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[ M(%=/4D0M4U!!0TE.1SH@,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!4 M15A4+4E.1$5.5#H@,'!X.R`M=V5B:VET+71E>'0MF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]LF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q M96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/E1A>"!P6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B@Q,BPX,C(\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/E-T871E('1A>"P@;F5T(&]F(&9E9&5R86P-"B!B96YE9FET/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@R-#8\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF4],T0R/C,X-3PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B@T+#$T.#PO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/C$L-#DW/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@ M6QE/3-$)TU!4D=)3BU,1494.B`Q96T[ M(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D]F9FEC97)S#0H@8V]M M<&5NF4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C(L,3F4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T* M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;BF4],T0R/C$L-C6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$ M14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S M($YE=R!2;VUA;BF4],T0R/E!EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q+#(V,CPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C,X,CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/E9A;'5A=&EO;@T*(&%L;&]W86YC93PO9F]N=#X\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/B@T-"PU,3D\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/DEN8V]M92!T87@@<')O=FES:6]N#0H@*&)E;F5F:70I/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C,L-S`T/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T M86)L93X-"B`\8G(@8VQA#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(&UE9&EU;2`G5&EM M97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X.R!,151415(M4U!!0TE. M1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW96)K:70M=&5X="US=')O M:V4M=VED=&@Z(#!P>"<^#0H@/&9O;G0@"!AF%T:6]N(&]F('-U8V@-"B!D969E#L@0T],3U(Z(')G8B@P+#`L,"D[($9/3E0Z(#$R<'@@)U1I;65S($YE=R!2 M;VUA;B<[($U!4D=)3BU43U`Z(#!P>#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-T6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S93L@5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@ M,'!X.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X M.R`M=V5B:VET+71E>'0MF4],T0Q/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)TU!4D=)3BU,1494 M.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/DYE="!O<&5R M871I;F<@;&]S0T*(&9OF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$F4],T0R M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C@L M,#8V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@ M/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@ M/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C4X/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C8L-#DU/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)R<@F4],T0R/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C6QE M/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/D]T:&5R+"!N970\+V9O;G0^/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C8L,#(Q M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@T.2PU M.#8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;BF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/BDF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)R<@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/D)AF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/B@Q+#`X,CPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ M$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D M/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$ M)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4] M,T0R/DYE="!D969EF4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4] M,T0R/C,U+#6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)R<@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@2!O9B!5 M;G)E8V]G;FEZ960@5&%X($)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'@[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-&3U)-.B!N M;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L,"D[($9/ M3E0Z(&UE9&EU;2`G5&EM97,@3F5W(%)O;6%N)SL@34%21TE.+51/4#H@,'!X M.R!,151415(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@-"4[("UW M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>"<^#0H@/&9O;G0@F5S(&%C=&EV:71Y(')E;&%T960@=&\@=6YR96-O9VYI>F5D#0H@=&%X(&)E M;F5F:71S.CPO9F]N=#X\+W`^#0H@/'`@"<^#0H@)B-X03`[/"]P/@T* M(#QT86)L92!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA M;B<[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@3$545$52+5-004-)3D#L@+7=E8FMI="UT97AT+7-TF4],T0Q/CQB/C(P,3,\ M+V(^/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@ MF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/C4L-#@R/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B0\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@65AF4] M,T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I M;65S($YE=R!2;VUA;BF4],T0R/B@R,#`\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)R<@65AF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C8T.#PO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ MF4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R/C$L,3(P/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$)TU! M4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;BF4],T0R M/D1E8W)E87-EF4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B8C>#(P,30[)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@F4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)R<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)R<@F4],T0R/C4L-#@R M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)R<@F4],T0R/B8C>$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L M,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T'1087)T7V(P M.35F83%C7S@W,3!?-#$W8U\X83$S7S=D,#@U,F-E,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!396QE8W1E M9"!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@*%1A8FQE#L@ M5$585"U)3D1%3E0Z(#0E)SX-"B`\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY396QE8W1E9`T*('%U87)T M97)L>2!F:6YA;F-I86P@9&%T82`H=6YA=61I=&5D*2!F;W(@=&AE('EE87(@ M96YD960-"B!$96-E;6)E$$P.S,Q+"`R,#$S(&%N9"`R,#$R(&ES('!R M97-E;G1E9"!B96QO=SH\+V9O;G0^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q,G!X.R!-05)'24XM5$]0.B`P M<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P>"!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E MF4],T0Q/B8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(')G8B@P+#`L,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]LF4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!X M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.S,P/"]B/CPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L M,"D@,7!X('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R(&)G M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/CQB/C(P,3,Z/"]B/CPO9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI M9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E1O=&%L(')E=F5N=65S/"]F;VYT M/CPO<#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/D]P97)A=&EN9R!L;W-S/"]F;VYT/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@V+#0U-SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B@Q,RPR.#<\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/DYE="!L;W-S/"]F;VYT M/CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B@U+#0S-3PO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BDF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@S.2PQ-C8\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXI)B-X03`[/"]F;VYT/CPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@P+C`Y/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C$S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C8S/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="!L;W-S('!E6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C`Y M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B@P+C$V/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C$S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B@P+C8S/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#PO='(^#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT M9"!V86QI9VX],T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4],T0R/CQB/C(P,3(Z/"]B/CPO M9F]N=#X\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@F4],T0Q/B8C M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9"!V86QI9VX] M,T1T;W`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1O=&%L(')E=F5N=65S/"]F;VYT/CPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/C4Y+#@U.3PO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/C8X+#6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C8Y+#`T,CPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#PO='(^ M#0H@/'1R(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]P97)A=&EN9R!I;F-O;64\+V9O;G0^/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R M/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`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`^#0H@/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R/DYE="!I;F-O;64@<&5R('-H M87)E+`T*(&)A6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0R/C`N.#`\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N,3,\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)TU!4D=)3BU,1494.B`Q96T[(%1%6%0M24Y$14Y4.B`M,65M M)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CY.970@:6YC;VUE('!E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C`N-S(\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S M:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C>$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B0\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C>$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C`N,3(\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)R!S:7IE/3-$,CXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\+W1R/@T* M(#PO=&%B;&4^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W M9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y M-69A,6-?.#'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^4V5P(#4L#0H)"3(P,3(\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA2!!'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPOF5D(&QO'0^)TQO;F=E'0^)SQS<&%N/CPO'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C(\F%T:6]N(&5X<&5N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!#87-H(&%N9"!%<75I=F%L96YT'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@3&]N9R!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M)FYB'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO2!M87)K970@9G5N M9',@6TUE;6)E'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2P@17-T:6UA=&5D(&9A:7(@5F%L=64\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@06UOF5D($-OF5D($=A:6YS/"]T9#X-"B`@("`@("`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`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8C`Y-69A,6-?.#'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@4&QA;G0@86YD($5Q=6EP M;65N="!;3&EN92!)=&5M2!A;F0@97%U:7!M96YT+"!A="!C M;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$U-#QS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q M,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C`Y-69A,6-?.#'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B M,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA2!;365M8F5R73QB"U5+E,N(%M-96UB97)= M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S2!;365M8F5R73QB M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T M."PY-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!4'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65A'0^)SQS<&%N/CPO65AF%T:6]N(%!E65A'0^)SQS<&%N/CPO'0^)S$Q('EE87)S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S4@>65A'0^)S8@ M>65A'0^)S@@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N($5X<&5N7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q M-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO8C`Y-69A,6-?.#'0O:'1M M;#L@8VAA6%B M;&5S($%N9"!!8V-R=6%L'0^)SQS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO2D\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO2D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS M<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO&5C=71I=F4@9&5F97)R M960@8V]M<&5N"!L:6%B:6QI M=&EE'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS M<&%N/CPO2!D:7-C;W5N=',\+W1D M/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C M93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-? M.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU M9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA6UE;G0@07=A M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S,V-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@ M;G5M8F5R(&]F(&-O;6UO;B!S=&]C:R!S:&%R97,@879A:6QA8FQE(&9O'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@;G5M8F5R M(&]F(&-O;6UO;B!S=&]C:R!V86QU92!A=F%I;&%B;&4@9F]R('!U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPOF4@8V]M M<&5N'0^)SQS<&%N/CPO'0^)S(@>65A7,\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!O9B!3=&]C M:RU"87-E9"!#;VUP96YS871I;VX@17AP96YS92`H1&5T86EL*2`H55-$("0I M/&)R/DEN(%1H;W5S86YD6UE;G0@07=A'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#$R+#'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,"PW-C(\'0^)SQS<&%N/CPO2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE M($ET96US73PO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'!E8W1E9"!O<'1I;VX@;&EF92`H:6X@>65A'0^)S0@>65A&EM=6T\+W1D/@T*("`@("`@ M("`\=&0@8VQA2P@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2P@36%X:6UU;3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q M,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8C`Y-69A,6-?.#'0O:'1M;#L@8VAA M'0^)SQS<&%N M/CPO'!E8W1E9"!O<'1I;VX@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S0@>65A7,\7,\&EM=6T@6TUE;6)E M'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&-E<'0@4VAA6UE;G1S(%M!8G-T'0^)SQS<&%N M/CPO&5R8VES92!0 M&5R8VES86)L92D@+2!$ M96-E;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO&5R8VES92!0&5R8VES92!0&5R M8VES92!0'0^)SQS<&%N/CPO&5R8VES92!07,\'0^)SQS<&%N/CPO'0^)S@@>65A7,\'0^)SQS<&%N M/CPO&5R8VES960L($EN=')I;G-I8R!V86QU93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO&5R8VES M86)L92D@+2!$96-E;6)E3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!O9B!3=&]C M:R!/<'1I;VX@1W)A;G1S("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^ M)SQS<&%N/CPO&5R M8VES92!0&5R8VES92!0'0^)S0@>65A&5R M8VES92!0&5R8VES92!0'0^)S4@>65A7,\ M'0^)SQS<&%N/CPO M&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS M<&%N/CPO'0^)SD@>65A&5R8VES92!0'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE M;G1S(%M!8G-T'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET M96US73PO'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA&EM M=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XU+#`P,"PP,#`\'0^)SQS<&%N/CPOF5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S4L,#`P+#`P,#QS M<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M(%-H87)E&5R8VES92!O9B!2:6=H=',@1W)A;G1E M9"`H1&5T86EL*3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M6UE;G0@07=A'0^)SQS<&%N/CPO M6UE;G0@07=A&5R8VES92!O9B!I2!3:&%R92!"87-E9"!087EM96YT($%W M87)D($]P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO6UE;G0@07=A M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!3:&%R M92!"87-E9"!087EM96YT($%W87)D($]P=&EO;G,@6TQI;F4@271E;7-=/"]S M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO&5R8VES960\+W1D/@T*("`@("`@ M("`\=&0@8VQA'!I'0^)SQS<&%N/CPO&5R8VES92!0&5R8VES92!0&5R8VES M92!O9B!I'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'!I'0^)SQS<&%N/CPO&5R8VES86)L92P@3G5M M8F5R(&]F(%-H87)E3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R&-E<'0@4VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-? M.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8C`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`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO&-L=61E M9"!F'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS M<&%N/CPO&-L=61E9"!F'0^ M)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!&86ER(%9A;'5E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!M87)K970@9G5N9',@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2!M87)K970@9G5N9',@6TUE;6)E M'0^)SQS<&%N/CPO6UE;G0@8V]N=&EN9V5N8WD\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W M9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y M-69A,6-?.#'0O:'1M;#L@8VAA2!O9B!, M979E;"`S($EN<'5T'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^)SQS<&%N/CPO6UE M;G1S(&UE=&AO9',\+W1D/@T*("`@("`@("`\=&0@8VQA&-E65A<@T*#0H@(.*`HB`@("0Q,"XP(&UI;&QI;VX@ M=7!O;B!T:&4@86-H:65V96UE;G0@;V8@;F5T('-A;&5S(&]F($U!4E%)0D\@ M:6X@97AC97-S(&]F("0V,"XP(&UI;&QI;VX@:6X@86YY(&-A;&5N9&%R('EE M87(-"@T*("#B@*(@("`D,C4N,"!M:6QL:6]N('5P;VX@=&AE(&%C:&EE=F5M M96YT(&]F(&YE="!S86QE65A65A&-EF%T:6]N(&9R;VT@=&AE($9$02!R96=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@1F]U'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS M<&%N/CPO6]U="!P97)C96YT86=E(&]N(&YE="!S86QE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M2G5L(#$W+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)U1H92!#5E(@=V%S('9A;'5E M9"!U'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'!E8W1E9"!R871E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XU,"XP,"4\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P M7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O M:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C M93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-? M.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!O9B!!;&QO8V%T:6]N M(&]F(%1O=&%L(%!U'0^)SQS<&%N/CPO3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2!A;F0@97%U:7!M96YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#QS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'10 M87)T7V(P.35F83%C7S@W,3!?-#$W8U\X83$S7S=D,#@U,F-E,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X M-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A M,6-?.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'1087)T7V(P.35F83%C7S@W,3!?-#$W8U\X83$S7S=D,#@U,F-E,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0^4V5P(#4L#0H)"3(P,30\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@;6%X:6UU M;2!I;G1E&EM=6T@86UO=6YT(&]F('5N=7-E9"!L:6YE(&9E93PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)S(P M(&1A>7,\'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO7,\'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!U;F1E2!D=7)I M;F<@7,@ M*'=H971H97(@;W(@;F]T(&-O;G-E8W5T:79E*2!D=7)I;F<@=&AE(#,P(&-O M;G-E8W5T:79E('1R861I;F<@9&%Y('!E2!P97)I;V0@ M:6UM961I871E;'D@9F]L;&]W:6YG(&%N>2!F:79E(&-O;G-E8W5T:79E('1R M861I;F<@9&%Y('!E3L@*#,I('5P;VX@=&AE(&]C8W5R2!I;6UE9&EA=&5L>2!P M2!T:6UE+"!R96=A'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPOF5D(&1E8G0@9&ES8V]U;G0@*&%M;W)T:7IE9"!T:')O M=6=H($1E8V5M8F5R(#(P,3@I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M/B@R."PU,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!-971H;V0@26YV97-T;65N=',@06YD($-O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!D971E6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!!9&IU'0^)SQS<&%N/CPO M2!#=7)R96YT(%M-96UB M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E2!,;VYG(%1E'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X M-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA2`S,2P@,C`P-CQB#(P86,[*3QB M6%K=2!;365M8F5R73QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^07!R(#,P+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^36%Y(#,Q+`T*"0DR,#$Y/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!2250@=&\@0FEO9V5N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@("`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`@("`\=&%B;&4@8VQA6UE;G1S("A$971A:6PI("A54T0@)"D\8G(^26X@5&AO M=7-A;F1S+"!U;FQE6UE;G1S+"!4;W1A;#PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO&5S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,V+#8S-BD\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA&5S M("T@4')O=FES:6]N("A"96YE9FET*2!F;W(@26YC;VUE(%1A>&5S("A$971A M:6PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]B,#DU9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C M93(W-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-? M.#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M&5S("T@26YC;VUE(%1A>"!02!2871E($%P<&QI960@=&\@26YC;VUE(&)E9F]R92!487AE"!$:7-C;&]S=7)E(%M!8G-T'0^)SQS M<&%N/CPO"P@;F5T M(&]F(&9E9&5R86P@8F5N969I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO"!D:69F97)E;G1I86P@;VX@9F]R96EG;B!E87)N:6YG M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU M9F$Q8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#'0O:'1M;#L@8VAA&5S("T@0V]M M<&]N96YT'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO"`H;&EA8FEL:71Y*2!A M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPOF5D+"!W;W5L9"!A9F9E8W0@=&AE(&5F M9F5C=&EV92!T87@@'0^)SQS<&%N/CPO M#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO&5S(%M,:6YE($ET96US73PO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO65A'0^)S(P,C8\'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO69O'!I'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO69O'!I'0^)SQS<&%N/CPO M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\ M=&0@8VQA"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\ M=&0@8VQA"!P;W-I=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!&:6YA M;F-I86P@1&%T82`M(%-U;6UA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES8VQO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6EN9R!!8V-O=6YT'0^)SQS<&%N/CPO M2D@=&\@0F%D($1E8G0@17AP96YS92!O'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]B,#DU9F$Q M8U\X-S$P7S0Q-V-?.&$Q,U\W9#`X-3)C93(W-S0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8C`Y-69A,6-?.#&UL#0I#;VYT96YT+51R86YS M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z M('1E>'0O:'1M;#L@8VAA&UL;G,Z M;STS1")U'10 L87)T7V(P.35F83%C7S@W,3!?-#$W8U\X83$S7S=D,#@U,F-E,C XML 59 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Summary of Cash and Equivalents and Marketable Securities (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Schedule of Investments [Line Items]        
Cash and cash equivalents, Marketable securities, Cost $ 159,777 $ 143,008    
Cash and cash equivalents, Marketable securities, Gross Unrealized Gains          
Cash and cash equivalents, Marketable securities, Gross Unrealized Losses          
Cash and cash equivalents, Marketable securities, Estimated fair Value 159,777 143,008    
Cash and cash equivalents 156,306 139,698 121,202 53,557
Marketable Security, Current 3,471 3,310    
Marketable Security, Long Term          
Money market funds [Member]
       
Schedule of Investments [Line Items]        
Marketable security, Amortized Cost 100,395 11,698    
Marketable security, Estimated fair Value 100,395 11,698    
Cash and cash equivalents 100,395 11,698    
Marketable Security, Long Term         
Bank CDs [Member]
       
Schedule of Investments [Line Items]        
Marketable security, Amortized Cost 410 987    
Marketable security, Gross Unrealized Gains          
Marketable security, Gross Unrealized Losses          
Marketable security, Estimated fair Value 410 987    
Cash and cash equivalents          
Marketable Security, Current 410 987    
Marketable Security, Long Term          
Mutual funds [Member]
       
Schedule of Investments [Line Items]        
Marketable security, Amortized Cost 3,061 2,323    
Marketable security, Gross Unrealized Gains          
Marketable security, Gross Unrealized Losses          
Marketable security, Estimated fair Value 3,061 2,323    
Cash and cash equivalents          
Marketable Security, Current 3,061 2,323    
Marketable Security, Long Term          
Bank Deposits [Member]
       
Schedule of Investments [Line Items]        
Bank deposits, Cost 55,911 128,000    
Bank deposits, Gross Unrealized Gains          
Bank deposits, Gross Unrealized Losses          
Bank deposits, Estimated fair Value 55,911 128,000    
Cash and cash equivalents $ 55,911 $ 128,000    

XML 60 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Sales, Net by Geographic Region and Product Line (Tables)
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Schedule of Product Sales, Net by Geography

The below table presents product sales, net by geography for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

United States

   $ 133,462         93.0   $ 245,697         96.4   $ 180,663         —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

International:

               

Europe

     3,953         2.8     3,113         1.2     —          —  

Asia Pacific

     6,060         4.2     6,182         2.4     —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total International

     10,013         7.0     9,295         3.6     —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         100.0
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 
Schedule of Product Sales, Net by Product Line

The below table presents product sales, net by product line for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

FUSILEV

   $ 68,397         47.7   $ 204,253         80.1   $ 153,110         84.7

FOLOTYN

     44,370         30.9     20,412         8.0     —          —  

ZEVALIN

     29,393         20.5     30,327         11.9     27,553      

MARQIBO

     1,315         0.9     —          —       —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         15.3
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

XML 61 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Gross-to Net Product Sales (Tables)
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Reconciliation of Gross to Net Product Sales

The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:

 

     2013     2012     2011  

Gross product sales

   $ 224,301      $ 383,817      $ 220,670   

Rebates and government chargebacks

     (63,610     (91,059     (22,190

Distribution and data fees and group purchasing organizations fees

     (19,067     (32,793     (11,637

Prompt pay discounts

     (183     (4,814     (4,086

Product returns allowance

     2,034        (159     (2,094
  

 

 

   

 

 

   

 

 

 

Product sales, net

   $ 143,475      $ 254,992      $ 180,663   
  

 

 

   

 

 

   

 

 

 
XML 62 R56.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Product Line (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sales Information [Line Items]      
Product sales, net $ 143,475 $ 254,992 $ 180,663
Percentage of product sales, net 100.00% 100.00% 100.00%
FUSILEV [Member]
     
Sales Information [Line Items]      
Product sales, net 68,397 204,253 153,110
FOLOTYN [Member]
     
Sales Information [Line Items]      
Product sales, net 44,370 20,412  
ZEVALIN [Member]
     
Sales Information [Line Items]      
Product sales, net 29,393 30,327 27,553
MARQIBO [Member]
     
Sales Information [Line Items]      
Product sales, net $ 1,315    
Sales [Member]
     
Sales Information [Line Items]      
Percentage of product sales, net 100.00% 100.00% 15.30%
Sales [Member] | FUSILEV [Member]
     
Sales Information [Line Items]      
Percentage of product sales, net 47.70% 80.10% 84.70%
Sales [Member] | FOLOTYN [Member]
     
Sales Information [Line Items]      
Percentage of product sales, net 30.90% 8.00%   
Sales [Member] | ZEVALIN [Member]
     
Sales Information [Line Items]      
Percentage of product sales, net 20.50% 11.90%  
Sales [Member] | MARQIBO [Member]
     
Sales Information [Line Items]      
Percentage of product sales, net 0.90%      
XML 63 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Schedule of Property and Equipment (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost $ 10,605 $ 9,863
(Less): accumulated depreciation and amortization (9,070) (7,315)
Property and equipment, net 1,535 2,548
Computers and software [Member]
   
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 5,154 4,540
Lab and media equipment [Member]
   
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 1,063 886
Office furniture and equipment [Member]
   
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 1,575 1,492
Leasehold improvements [Member]
   
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 2,813 2,799
Assets held under capital lease obligations [Member]
   
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost   $ 146
XML 64 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2013
Summary of Stock-Based Compensation Expense

Stock-based compensation expense included within operating expenses for years ended December 31, 2013, 2012, and 2011 was as follows:

 

     Year Ended December 31,  
     2013      2012      2011  

Selling, general and administrative

   $ 10,762       $ 13,041       $ 20,609   

Research and development

     2,017         1,843         1,628   
  

 

 

    

 

 

    

 

 

 

Total

   $ 12,779       $ 14,884       $ 22,237   
  

 

 

    

 

 

    

 

 

 
Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model

The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:

 

     Year Ended December 31,
     2013    2012    2011

Expected option life (in years) (a)

   4.95    4.50    4.93

Risk-free interest rate (b)

   0.35% - 0.78%    0.34% - 0.51%    0.82% - 2.4%

Volatility (c)

   58.3% - 71.5%    64.2% -73.6%    55.8%

Dividend yield (d)

   0%    0%    0%

Weighted-average grant-date fair value per stock option

   $4.66    $6.20    $2.65

 

(a) Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
(b) Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
(c) Measured using our historical stock price for a period equal to stock options’ expected term.
(d) We do not expect to declare any cash dividends in the foreseeable future.
Summary of Stock Option Activity

Stock option activity during the years ended December 31, 2013, 2012, and 2011 is as follows:

 

     Number  of
Shares
    Weighted-
Average

Exercise 
Price/Share
     Weighted-
Average
Remaining
Contractual
Term (Years)
     Aggregate
Intrinsic
Value
 

Outstanding — December 31, 2010

     8,397,094      $ 4.17         

Granted

     3,622,150        7.92         

Exercised

     (1,126,257     4.07          $ 8,255 (1) 

Forfeited

     (547,479     4.81         

Expired

     (159,987     5.17         
  

 

 

   

 

 

       

Outstanding — December 31, 2011

     10,185,521      $ 5.46         

Granted

     1,821,915        11.57         

Exercised

     (1,287,430     4.52          $ 11,500 (1) 

Forfeited

     (316,825     7.93         

Expired

     (3,916     7.69         
  

 

 

   

 

 

       

Outstanding — December 31, 2012

     10,399,265      $ 6.57         

Granted

     2,041,300        8.92         

Exercised

     (825,884     4.40          $ 3,435 (1) 

Forfeited

     (202,882     8.22         

Expired

     (82,581     8.91         
  

 

 

   

 

 

       

Outstanding — December 31, 2013

     11,329,218      $ 7.10         7.0       $ 25,849 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Vested (exercisable) — December 31, 2013

     7,876,025      $ 6.11         6.2       $ 24,080 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Unvested (unexercisable) — December 31, 2013

     3,453,193      $ 9.38         8.9       $ 1,770 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

 

(1) Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2) Represents the total difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.
Summary of Stock Option Grants

The following table summarizes information with respect to stock option grants as of December 31, 2013:

 

     Outstanding      Exercisable  

Exercise Price

   Granted Stock
Options
Outstanding
     Weighted-
Average

Remaining 
Contractual
Life (Years)
     Weighted-
Average

Exercise
Price
     Granted
Stock
Options
Exercisable
     Weighted-
Average

Exercise
Price
 

$0.92 –   3.15

     1,192,794         4.5       $ 2.16         1,192,794       $ 2.16   

$3.55 –   4.95

     1,924,904         5.9         4.23         1,865,794         4.23   

$5.05 –   6.90

     2,862,699         5.5         6.26         2,565,220         6.19   

$7.00 –   8.99

     2,329,167         8.2         8.17         1,147,138         8.26   

$9.00 – 16.32

     3,019,654         9.2         10.86         1,105,079         11.09   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
     11,329,218         7.0       $ 7.10         7,876,025       $ 6.11   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Summary of Restricted Stock Activity

A summary of restricted stock activity is as follows:

 

     Number of
Restricted  Stock
Awards
    Weighted Average
Fair Value per
Share at Grant
Date
 

Unvested as of December 31, 2010

     359,500      $ 3.96   

Granted

     1,781,000        12.48   

Vested

     (1,104,025     12.33   

Forfeited

     (83,950     4.78   
  

 

 

   

Unvested — December 31, 2011

     952,525        10.11   

Granted

     586,639        11.76   

Vested

     (472,160     10.26   

Forfeited

     (32,400     9.57   
  

 

 

   

Unvested — December 31, 2012

     1,034,604        11.00   

Granted

     523,800        8.74   

Vested

     (501,660     9.72   

Forfeited

     (49,625     10.60   
  

 

 

   

Unvested — December 31, 2013

     1,007,119      $ 10.09   
  

 

 

   

 

 

 

 

* Represents our stock price on the vesting date multiplied by the number of vested shares.

 

Issued Shares of Common Stock

We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:

 

     2013      2012      2011  

Shares of common stock issued

     99,359         56,254         65,889   

Match contribution value**

   $ 860       $ 691       $ 593   

 

** Represents our stock price on the date of the stock match multiplied by the number of shares of common stock issued.
Restricted stock awards [Member]
 
Fair Value of Restricted Stock Awards
     2013      2012      2011  

Restricted stock expense

   $ 4,202      $ 6,500       $ 4,100   
XML 65 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2013
Equity [Abstract]  
Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted

As of December 31, 2013, approximately 28.1 million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:

 

Conversion of Series E Preferred Stock

     40,000   

2018 Convertible Notes

     11,400,000   

Exercise of issued employee stock options

     11,329,218   

Exercise of issued warrants

     445,000   

ESPP shares reserved

     4,540,986   

Long-term retention and management incentive plan shares

     346,500   
  

 

 

 

Total shares of common stock reserved for future issuances

     28,101,704   
  

 

 

Summary of Warrant Activity
A summary of warrant activity is as follows:

 

     Number of
Shares
    Weighted
Average
Exercise Price
 

Outstanding — December 31, 2010

     4,192,312      $ 6.45   

Expired

     (3,747,312     6.62   
  

 

 

   

 

 

 

Outstanding — December 31, 2011

     445,000      $ 5.04   

Exercised

     (50,000     1.79   
  

 

 

   

 

 

 

Outstanding — December 31, 2012

     395,000      $ 5.45   

Granted

     50,000        7.51   
  

 

 

   

 

 

 

Outstanding — December 31, 2013

     445,000      $ 6.39   
  

 

 

   

 

 

 

Exercisable — December 31, 2013

     407,500      $ 6.29   
  

 

 

   

 

 

XML 66 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business, Basis of Presentation, and Operating Segment
12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Description of Business, Basis of Presentation, and Operating Segment
1. DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT

(a) Description of Business

Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.

We currently market four drugs:

 

   

FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

 

   

ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

 

   

FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

 

   

MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.

We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.

(b) Basis of Presentation

Principles of Consolidation

The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.

On April 1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the “ZEVALIN Rights”); on September 5, 2012, we acquired Allos Therapeutics, Inc. (“Allos”); and on July 17, 2013, we acquired Talon Therapeutics, Inc. (“Talon”). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.

Variable Interest Entity

We own fifty-percent of Spectrum Pharma Canada (a “variable interest entity,” as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its “primary beneficiary”. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.

(c) Operating Segment

We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.

XML 67 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net (Loss) Income Per Share (Tables)
12 Months Ended
Dec. 31, 2013
Earnings Per Share [Abstract]  
Computation of Net (Loss) Income Per Share

Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012      2011  

Net (loss) income

   $ (62,134   $ 94,201       $ 49,931   

Weighted average shares - basic

     60,729,128        58,588,916         53,272,767   

Net (loss) income per share - basic

   $ (1.02   $ 1.61       $ 0.94   

Weighted average shares - diluted

     60,729,128        64,637,256         57,959,714   

Net (loss) income per share - diluted

   $ (1.02   $ 1.46       $ 0.86   

Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share

The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2012

        

Basic net income per share:

   $ 94,201         58,588,916       $ 1.61   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,749,299      

Incremental common stock assumed issued on exercise of in-the-money warrants

        224,437      

Unvested restrictive stock awards

        1,034,604      
  

 

 

    

 

 

    

Diluted net income per share

   $ 94,201         64,637,256       $ 1.46   
  

 

 

    

 

 

    

 

 

 

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2011

        

Basic net income per share:

   $ 49,931         53,272,767       $ 0.94   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,185,224      

Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned

        248,193      

Incremental common stock assumed issued on exercise of in-the-money warrants

        200,656      

Unvested restrictive stock awards

        12,874      
  

 

 

    

 

 

    

Diluted net income per share

   $ 49,931         57,959,714       $ 0.86   
  

 

 

    

 

 

    

 

 

Schedule of Securities Excluded from Calculation of Net (Loss) per Share

Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:

 

     Year Ended December 31,  
     2013      2012      2011  

2018 Convertible Notes

     343,600         —           —     

Common stock options

     2,934,625         —           —     

Restricted stock awards

     1,007,119         —           —     

Common stock warrants

     160,816         —           —     

Preferred stock

     40,000         —           —     
  

 

 

    

 

 

    

 

 

 

Total

     4,486,160         —           —     
  

 

 

    

 

 

    

 

 

 

 

XML 68 R83.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Notes - Components of Total Interest Expense Recognized (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Equity Method Investments And Cost Method Investments [Abstract]  
Contractual coupon interest expense $ 73
Amortization of debt issuance costs 101
Accretion of debt discount 43
Total $ 217
Effective interest rate 8.59%
XML 69 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail)
12 Months Ended
Dec. 31, 2013
Segment
Segment Reporting Information [Line Items]  
Number of reportable operating segment 1
ZEVALIN [Member]
 
Segment Reporting Information [Line Items]  
Acquisition date Apr. 01, 2012
Allos Therapeutics, Inc. [Member]
 
Segment Reporting Information [Line Items]  
Acquisition date Sep. 05, 2012
Talon Therapeutics, Inc. [Member]
 
Segment Reporting Information [Line Items]  
Acquisition date Jul. 17, 2013
Spectrum Pharma Canada [Member]
 
Segment Reporting Information [Line Items]  
Ownership interest, percentage 50.00%
XML 70 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Other Liabilities Disclosure [Abstract]    
Accrued executive deferred compensation $ 3,949 $ 2,366
Deferred rent (non-current portion) 366 571
Business acquisition liability 298 298
Other tax liabilities 1,352 1,132
Other long-term liabilities $ 5,965 $ 4,367
XML 71 R72.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Assets:    
Deferred compensation investments, including life insurance cash surrender value $ 5,361 $ 2,881
Total Assets 112,820 20,369
Liabilities:    
Deferred executive compensation liability 3,949 2,365
Deferred development costs 17,742 12,233
Deferred payment contingency   2,287
Ligand Contingent Consideration 4,000  
Talon CVR 4,329  
Total Liabilities 30,020 16,885
Bank CDs [Member]
   
Assets:    
Marketable securities, fair value 410 987
Money market funds [Member]
   
Assets:    
Marketable securities, fair value 100,395 11,698
Mutual funds [Member]
   
Assets:    
Marketable securities, fair value 3,061 2,323
Equity Securities [Member]
   
Assets:    
Marketable securities, fair value 3,593 2,480
Level 1 [Member]
   
Assets:    
Total Assets 3,593 2,480
Level 1 [Member] | Equity Securities [Member]
   
Assets:    
Marketable securities, fair value 3,593 2,480
Level 2 [Member]
   
Assets:    
Deferred compensation investments, including life insurance cash surrender value 5,361 2,881
Total Assets 109,227 17,889
Liabilities:    
Deferred executive compensation liability 3,949 2,365
Total Liabilities 3,949 2,365
Level 2 [Member] | Bank CDs [Member]
   
Assets:    
Marketable securities, fair value 410 987
Level 2 [Member] | Money market funds [Member]
   
Assets:    
Marketable securities, fair value 100,395 11,698
Level 2 [Member] | Mutual funds [Member]
   
Assets:    
Marketable securities, fair value 3,061 2,323
Level 3 [Member]
   
Liabilities:    
Deferred development costs 17,742 12,233
Deferred payment contingency   2,287
Ligand Contingent Consideration 4,000  
Talon CVR 4,329  
Total Liabilities $ 26,071 $ 14,520
XML 72 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and equivalents $ 156,306 $ 139,698
Marketable securities 3,471 3,310
Accounts receivable, net of allowance for doubtful accounts of $206 and $228, respectively 49,483 92,169
Other receivables 7,539  
Inventories 13,519 14,478
Prepaid expenses and other current assets 3,213 2,745
Deferred tax assets 1,659 12,473
Total current assets 235,190 264,873
Property and equipment, net 1,535 2,548
Intangible assets, net 231,352 200,234
Goodwill 18,501 7,279
Deferred tax assets   23,276
Other assets 12,577 6,745
Total assets 499,155 504,955
Current liabilities:    
Accounts payable and other accrued liabilities 79,837 105,252
Accrued payroll and related expenses 6,872 4,835
Deferred revenue 156 12,300
Drug development liability 3,119 856
Total current liabilities 89,984 123,243
Drug development liability, less current portion 14,623 11,377
Deferred payment contingency   2,287
Acquisition-related contingent obligations 8,329  
Deferred tax liability 7,168  
Other long-term liabilities 5,965 4,367
Revolving line of credit   75,000
Convertible senior notes 91,480  
Total liabilities 217,549 216,274
Commitments and contingencies      
Stockholders' equity:    
Preferred stock      
Common stock, $0.001 par value; 175,000,000 shares authorized; 64,104,173 and 60,026,675 issued and outstanding at December 31, 2013 and 2012, respectively 64 60
Additional paid-in capital 518,144 463,710
Accumulated other comprehensive income 894 273
Accumulated deficit (237,619) (175,485)
Total stockholders' equity 281,606 288,681
Total liabilities and stockholders' equity 499,155 504,955
Series B Junior Participating Preferred Stock [Member]
   
Stockholders' equity:    
Preferred stock      
Series E Convertible Voting Preferred Stock [Member]
   
Stockholders' equity:    
Preferred stock $ 123 $ 123
XML 73 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Components of Inventories, Net (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Inventory Disclosure [Abstract]    
Raw materials $ 1,794 $ 887
Work in process 3,312 7,302
Finished goods 8,413 6,289
Inventories $ 13,519 $ 14,478
XML 74 R96.htm IDEA: XBRL DOCUMENT v2.4.0.8
Schedule II - Valuation and Qualifying Accounts (Detail) (Allowance for Doubtful Accounts [Member], USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Allowance for Doubtful Accounts [Member]
     
Valuation and Qualifying Accounts Disclosure [Line Items]      
Balance at Beginning of Period $ 228 $ 471 $ 339
Additions (Recovery) to Bad Debt Expense or Deferred Tax Asset 11 (128) 139
Charged to Other Accounts         
Deductions (33) (115) (7)
Balance at End of Period $ 206 $ 228 $ 471
XML 75 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Shareholders' Equity (USD $)
In Thousands, except Share data
Total
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Treasury Stock [Member]
Total Stockholders Equity [Member]
Beginning Balance at Dec. 31, 2010   $ 160 $ 51 $ 384,757 $ (92) $ (307,635)   $ 77,241
Beginning Balance, Shares at Dec. 31, 2010   26 51,459,284          
Net income (loss) 49,931         49,931   49,931
Other comprehensive Income (loss), net 49,796       (135)     (135)
Conversion of Series E preferred stock to common stock (37) (37)   37        
Conversion of Series E preferred stock to common stock, Shares   (6) 12,000          
Issuance of common stock to 401(k) plan       593       593
Issuance of common stock to 401(k) plan, Shares     65,889          
Issuance of common stock for ESPP       655       655
Issuance of common stock for ESPP, Shares     100,386          
Adjustments resulting from change in value of warrants recognized in equity       7,392       7,392
Issuance of common stock upon exercise of stock options     1 5,136       5,137
Issuance of common stock upon exercise of stock options, Shares 1,126,257   1,126,257          
Issuance of common stock upon exercise of warrants     4 24,804       24,808
Issuance of common stock upon exercise of warrants, Shares     3,747,312          
Share-based compensation expense and common stock issued (net of forfeitures)     1 21,643       21,644
Share-based compensation expense and common stock issued (net of forfeitures), Shares     998,711          
Purchase of treasury stock             (2,926) (2,926)
Purchase of treasury stock, Shares             363,055  
Issuance of restricted stock for management incentive plan, net of shares repurchased/retired for employee tax withholding     1 (4,033)       (4,032)
Issuance of restricted stock for management incentive plan, net of shares repurchased/retired for employee tax withholding, Shares     426,562          
Fair value of common stock issued to Targent for milestone     1 11,777       11,778
Fair value of common stock issued, Shares     1,311,082          
Ending Balance at Dec. 31, 2011   123 59 452,761 (227) (257,704) (2,926) 192,086
Ending Balance, Shares at Dec. 31, 2011   20 59,247,483       363,055  
Net income (loss) 94,201         94,201   94,201
Other comprehensive Income (loss), net 94,701       500     500
Issuance of common stock to 401(k) plan       691       691
Issuance of common stock to 401(k) plan, Shares     56,254          
Issuance of common stock for ESPP       606       606
Issuance of common stock for ESPP, Shares     54,521          
Issuance of common stock upon exercise of stock options     2 5,815       5,817
Issuance of common stock upon exercise of stock options, Shares 1,287,430   1,287,430          
Issuance of common stock upon exercise of warrants       89       89
Issuance of common stock upon exercise of warrants, Shares     50,000          
Share-based compensation expense and common stock issued (net of forfeitures)       14,193       14,193
Share-based compensation expense and common stock issued (net of forfeitures), Shares     554,239          
Repurchase of shares to satisfy employee tax withholding       (1,434)       (1,434)
Repurchase of shares to satisfy employee tax withholding, Shares     (120,197)          
Dividends paid       (9,011)       (9,011)
Purchase of treasury stock             (9,057) (9,057)
Purchase of treasury stock, Shares             740,000  
Retirement of treasury stock (11,983)   (1)     (11,982) 11,983  
Retirement of treasury stock, Shares     (1,103,055)       (1,103,055)  
Ending Balance at Dec. 31, 2012   123 60 463,710 273 (175,485)   288,681
Ending Balance, Shares at Dec. 31, 2012 60,026,675 20 60,026,675          
Net income (loss) (62,134)         (62,134)   (62,134)
Other comprehensive Income (loss), net (61,513)       621     621
Issuance of common stock to 401(k) plan       860       860
Issuance of common stock to 401(k) plan, Shares     99,359          
Issuance of common stock for ESPP       495       495
Issuance of common stock for ESPP, Shares     74,925          
Issuance of common stock upon exercise of stock options     1 3,576       3,577
Issuance of common stock upon exercise of stock options, Shares 825,884   825,884          
Share-based compensation expense and common stock issued (net of forfeitures)       11,913       11,913
Share-based compensation expense and common stock issued (net of forfeitures), Shares     471,875          
Repurchase of shares to satisfy employee tax withholding       (1,509)       (1,509)
Repurchase of shares to satisfy employee tax withholding, Shares     (159,545)          
Purchase of treasury stock             (1,651) (1,651)
Purchase of treasury stock, Shares             235,000  
Retirement of treasury stock (1,652)     (1,651)     1,651  
Retirement of treasury stock, Shares     (235,000)       (235,000)  
Issuance of common stock for Talon acquisition     3 26,307       26,310
Issuance of common stock for Talon acquisition, Shares     3,000,000          
Issuance of 2018 Convertible Notes       14,443       14,443
Ending Balance at Dec. 31, 2013   $ 123 $ 64 $ 518,144 $ 894 $ (237,619)   $ 281,606
Ending Balance, Shares at Dec. 31, 2013 64,104,173 20 64,104,173          
XML 76 R94.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Events - Additional Information (Detail) (Subsequent Event [Member], TopoTarget [Member], USD $)
In Millions, except Share data, unless otherwise specified
0 Months Ended
Feb. 14, 2014
Subsequent Event [Member] | TopoTarget [Member]
 
Subsequent Event [Line Items]  
Cash paid for sales milestone achieved $ 10.0
Common stock issued, shares 1,000,000
XML 77 R59.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Expected option life (in years) 4 years 11 months 12 days 4 years 6 months 4 years 11 months 5 days
Risk-free interest rate, Minimum 0.35% 0.34% 0.82%
Risk-free interest rate, Maximum 0.78% 0.51% 2.40%
Volatility, Minimum 58.30% 64.20%  
Volatility, Maximum 71.50% 73.60%  
Volatility     55.80%
Dividend yield 0.00% 0.00% 0.00%
Weighted-average grant-date fair value per stock option $ 4.66 $ 6.20 $ 2.65
XML 78 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Notes (Tables)
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Carrying Values of 2018 Convertible Notes

The carrying values of the 2018 Convertible Notes as of December 31, 2013 is summarized as follows:

 

Principal amount

   $ 120,000   

(Less): Unamortized debt discount (amortized through December 2018)

     (28,520
  

 

 

 

December 31, 2013 net carrying amount of 2018 Convertible Notes

   $ 91,480   
  

 

 

Components of Total Interest Expense Recognized

The following table sets forth the components of total “interest expense” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December 31, 2013:

 

Contractual coupon interest expense

   $ 73   

Amortization of debt issuance costs

     43   

Accretion of debt discount

     101   
  

 

 

 

Total

   $ 217   
  

 

 

 

Effective interest rate

     8.59
  

 

 

 

 

XML 79 R65.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Issued Shares of Common Stock (Detail) (401(k) Plan [Member], USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
401(k) Plan [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares of common stock issued 99,359 56,254 65,889
Match contribution value $ 860 $ 691 $ 593
XML 80 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Income Taxes
15. INCOME TAXES

The components of (loss) income before (provision) benefit for income taxes are as follows:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

United States

   $ (30,437   $ 82,165      $ 53,834   

Foreign

     (6,199     (2,235     (199
  

 

 

   

 

 

   

 

 

 

Total

   $ (36,636   $ 79,930      $ 53,635   
  

 

 

   

 

 

   

 

 

 

 

The provision (benefit) for income taxes consist of the following:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

Current:

      

Federal

   $ (8,357   $ 16,222      $ 1,255   

State

     (691     3,412        2,449   

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
   $ (9,048   $ 19,634      $ 3,704   

Deferred:

      

Federal

     36,183        (24,013     —    

State

     (1,637     (9,892     —    

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
     34,546        (33,905     —    

Total income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

 

The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:

 

     2013     2012     2011  

Tax provision (benefit) computed at the federal statutory rate

   $ (12,822   $ 27,975      $ 18,250   

State tax, net of federal benefit

     (246     2,442        2,918   

Expired tax attributes

     —         —         385   

Research credits

     (2,254     (2,129     (1,464

Benefits from credit study

     —         (4,148     —    

Common stock warrant liability

     —         —         1,186   

Transaction costs

     880        1,497        —    

Officers compensation

     2,178        2,908        3,801   

Stock based compensation

     501        134        1,676   

Permanent items and other

     (1,080     2,111        2,039   

Domestic manufacturing deduction

     767        (1,262     —    

Tax differential on foreign earnings

     1,123        382        —    

Change in tax rate

     (283     338        —    

Valuation allowance

     36,734        (44,519     (25,087
  

 

 

   

 

 

   

 

 

 

Income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

 

The American Taxpayer Relief Act of 2012, which reinstated the U.S. federal research and development tax credit retroactively from January 1, 2012 through December 31, 2013, was not enacted into law until the first quarter of 2013. The tax benefit resulting from such reinstatement is reflected in our 2013 tax provision.

 

Significant components of our deferred tax assets as of December 31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.

 

     2013     2012  

Deferred tax assets:

    

Net operating loss carry forwards

   $ 46,482      $ 45,391   

Research credits

     8,066        1,848   

Stock based compensation

     3,486        2,896   

Deferred revenue

     58        4,596   

Development costs

     6,495        5,298   

Returns and allowances

     3,117        7,889   

Other, net

     5,551        6,021   
  

 

 

   

 

 

 

Total deferred tax assets before valuation allowance

     73,255        73,246   

Valuation allowance

     (49,586     (1,818
  

 

 

   

 

 

 

Total deferred tax assets

     23,669        72,121   

Deferred tax liabilities:

    

Basis difference in debt

     (1,082     —    

Depreciation and amortization differences

     (28,096     (36,372
  

 

 

   

 

 

 

Net deferred tax (liability) asset

   $ (5,509   $ 35,749   
  

 

 

   

 

 

 

The increase in the valuation allowance in 2013 was due to uncertainties regarding the realization of deferred tax assets acquired in connection with the Talon acquisition and a change in our overall assessment regarding the realization of our domestic deferred tax assets as a result of larger than expected operating losses sustained in 2013 and an increase in our expected operating loss for 2014. The decrease in the valuation allowance in 2012 was due to a change in our assessment regarding the realization of our domestic deferred tax assets as a result of positive earnings trends in 2010, 2011, and 2012 and operating income recorded in 2011 and 2012.

At December 31, 2013, we had federal and state net operating loss carryforwards of approximately $117.4 million and $132.0 million, respectively. We have approximately $4.1 million of foreign loss carryforwards that will begin to expire in 2028. The federal and state loss carry forwards begin to expire in 2018 and 2014, respectively, unless previously utilized. At December 31, 2013, we had federal and state tax credits of approximately $6.9 million and $2.2 million, respectively. The federal tax credit carryovers begin to expire in 2026 unless previously utilized. The state research and development credits have an indefinite carryover period.

As a result of the prior ownership changes, the utilization of certain net operating loss and research and development tax credit carryforwards including those acquired in connection with the acquisition of Allos and Talon are subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code of 1986 and similar state provisions. Any net operating losses or credits that would expire unutilized as a result of Section 382 and 383 limitations have been removed from the table of deferred tax assets and the accompanying disclosures of net operating loss and research and development carryforwards.

Accounting guidance clarifies the accounting for uncertain tax positions and prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. Additionally, the authoritative guidance addresses the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. Only tax positions that meet the more-likely-than-not recognition threshold at the effective date may be recognized.

 

The following tabular reconciliation summarizes activity related to unrecognized tax benefits:

 

     2013     2012     2011  

Balance at beginning of year

   $ 5,482      $ 3,928      $ 2,803   

Adjustments related to prior year tax positions

     (200     (527     5   

Increases related to current year tax positions

     648        2,515        1,120   

Decreases due to settlements

     (1,227     (434     —    

Decreases related to prior year tax positions

     (2,491     —         —    
  

 

 

   

 

 

   

 

 

 

Balance at end of year

   $ 2,212      $ 5,482      $ 3,928   
  

 

 

   

 

 

   

 

 

 

During 2013, we continue to believe that our tax positions meet the more-likely-than-not standard required under the recognition phase of the authoritative guidance. However, we consider the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.

Approximately $0.3 million, $5.2 million and $0.2 million of the total unrecognized tax benefits as of December 31, 2013, 2012 and 2011, respectively, would reduce our annual effective tax rate if recognized. Additional amounts in the summary rollforward could impact our effective tax rate if we did not maintain a full valuation allowance on our net deferred tax assets.

We do not expect our unrecognized tax benefits to change significantly over the next 12 months. With a few exceptions, we are no longer subject to U.S. federal, state and local income tax examinations for years before 2009. Our policy is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of operations and are not material.

During 2013, the Internal Revenue Service completed an examination of our 2010 tax return. No tax was paid as a result of the examination. As a result of the examination, the Company reduced tax credits carryovers by $0.8 million and net operating loss carryovers by $1.6 million.

XML 81 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
Mundipharma Agreement (Tables)
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Schedule of Drug Development Liability Adjustments

We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.

 

     Year Ended December 31,  
     Drug
Development
Liability,
Current –
FOLOTYN
    Drug
Development
Liability,

Long Term –
FOLOTYN
    Total Drug
Development
Liability –
FOLOTYN
 

Balance at December 31, 2012

   $ 856      $ 11,377      $ 12,233   

Transfer from long term to current

     3,620        (3,620     —    

Amended agreement payment receipt

     —         7,000        7,000   

(Less): Expenses incurred

     (1,357     (134     (1,491
  

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

   $ 3,119      $ 14,623      $ 17,742   

XML 82 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Selected Quarterly Financial Data
12 Months Ended
Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]  
Summary of Selected Quarterly Financial Data
17. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Selected quarterly financial data (unaudited) for the year ended December 31, 2013 and 2012 is presented below:

 

     Quarter Ended (Unaudited)  
     March 31     June 30     September 30     December 31  

2013:

        

Total revenues

   $ 38,667      $ 33,232      $ 42,439      $ 41,516   

Operating loss

   $ (6,457   $ (12,529   $ (13,287   $ (6,512

Net loss

   $ (5,435   $ (9,721   $ (7,812   $ (39,166

Net loss per share, basic

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

Net loss per share, diluted

   $ (0.09   $ (0.16   $ (0.13   $ (0.63

2012:

           

Total revenues

   $ 59,859       $ 68,702       $ 69,042       $ 70,104   

Operating income

   $ 23,596       $ 23,028       $ 23,109       $ 11,041   

Net income

   $ 46,838       $ 18,350       $ 21,524       $ 7,489   

Net income per share, basic

   $ 0.80       $ 0.31       $ 0.37       $ 0.13   

Net income per share, diluted

   $ 0.72       $ 0.29       $ 0.33       $ 0.12   

Net (loss) income per basic and diluted shares are computed independently for each of the quarters presented based on basic and diluted shares outstanding per quarter and, therefore, may not sum to the totals for the year.

XML 83 R68.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]      
Weighted Average Exercise Price, Granted $ 7.51    
Weighted Average Exercise Price, Exercised   $ 1.79  
Weighted Average Exercise Price, Beginning Balance $ 5.45 $ 5.04 $ 6.45
Weighted Average Exercise Price, Expired     $ 6.62
Weighted Average Exercise Price, Ending Balance $ 6.39 $ 5.45 $ 5.04
Weighted Average Exercise Price, Exercisable $ 6.29    
Exercise of issued warrants [Member]
     
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]      
Number of Shares, Outstanding Beginning 395,000 445,000 4,192,312
Number of Shares, Granted 50,000    
Number of Shares, Exercised   (50,000)  
Number of Shares, Expired     (3,747,312)
Number of Shares, Outstanding Ending 445,000 395,000 445,000
Exercisable, Number of Shares Outstanding 407,500    
XML 84 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 85 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Cash Flows From Operating Activities:      
Net (loss) income $ (62,134) $ 94,201 $ 49,931
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:      
Amortization of deferred service revenue (12,400) (12,300) (12,300)
Depreciation and amortization 22,096 12,243 5,650
Stock-based compensation 12,423 14,884 22,237
Change in fair value of common stock warrants issued to non-employees 356   3,488
Accretion of debt discount to interest expense on 2018 Convertible Notes 43    
Amortization of deferred financing costs to interest expense on 2018 Convertible Notes 101    
Bad debt expense (recovery) 127 (128) 245
Loss on disposal of fixed assets   132 38
Non-cash foreign currency exchange loss 1,222 107  
Impairment of FOLOTYN distribution rights 1,023    
Change in fair value of contingent consideration related to acquisition (2,871) 20  
Change in fair value of Allos deferred development costs and deferred payment contingency (2,869)    
Changes in operating assets and liabilities:      
Accounts receivable 42,559 (33,504) (30,897)
Inventories 1,570 3,530 (6,528)
Prepaid expenses and other current assets (359) 9,483 (7,115)
Deferred tax assets 33,252 (34,605)  
Other assets (8,989)    
Accounts payable and other accrued obligations (23,897) 24,038 15,711
Accrued payroll and related expenses 425 (9,726) (1,525)
Drug development liability (5,917) 2,376 3,519
Other long-term liabilities 2,153 1,208 834
Net cash (used in) provided by operating activities (2,086) 71,959 43,288
Cash Flows From Investing Activities:      
Sales and maturities of marketable securities   72,463 18,255
Purchases of marketable securities   (26,430) (17,027)
Purchases of property and equipment (161) (312) (475)
Purchases of available-for-sale securities   (1,712) (164)
Proceeds from sale of available-for-sale securities     157
Acquisition of Allos, net of cash acquired   (133,264)  
Net cash (used in) provided by investing activities (14,330) (114,690) 746
Cash Flows From Financing Activities:      
Proceeds from Mundipharma for FOLOTYN development 7,000    
Proceeds from exercise of stock options 3,576 5,817 5,137
Proceeds from exercise of common stock warrants   89 24,808
Proceeds from sale of common stock under employee stock purchase plan 495 606 655
Payments to acquire treasury stock (1,651) (9,057) (2,926)
Repurchase of restricted stock to satisfy employee tax withholdings at vesting (1,509) (1,434) (4,032)
Payment of stock dividend   (9,011)  
Repayment of capital leases   (9) (31)
Proceeds from revolving line of credit 100,000 125,000  
Repayment of revolving line of credit (175,000) (50,000)  
Proceeds from 2018 convertible Notes 120,000    
Deferred financing costs (4,573)    
Proceeds from sale of common stock warrants related to 2018 Convertible Notes issuance 12,612    
Payment of debt issuance costs   (976)  
Purchase of common stock call options related to 2018 Convertible Notes issuance (25,692)    
Net cash provided by financing activities 35,258 61,025 23,611
Effect of exchange rates on cash and equivalents (2,235) 202  
Net increase (decrease) in cash and equivalents 16,608 18,496 67,645
Cash and equivalents - beginning of year 139,698 121,202 53,557
Cash and equivalents - end of year 156,306 139,698 121,202
Supplemental Disclosure of Cash Flow Information:      
Cash paid for income taxes   17,157 2,042
Cash paid for interest 1,200 495 14
Retirement of treasury shares 1,652 11,983  
Inventory liability assumed in acquisitions   580  
Inventory included in accounts payable   5,000  
Conversion of preferred stock to common stock     37
ZEVALIN Rights [Member]
     
Cash Flows From Investing Activities:      
Acquisition of Allos, net of cash acquired   (25,435)  
C-E MELPHALAN rights [Member]
     
Cash Flows From Investing Activities:      
Acquisition of Allos, net of cash acquired (3,000)    
Talon [Member]
     
Cash Flows From Investing Activities:      
Acquisition of Allos, net of cash acquired (11,169)    
Supplemental Disclosure of Cash Flow Information:      
Common stock issued for acquisition 26,310    
Targent [Member]
     
Supplemental Disclosure of Cash Flow Information:      
Common stock issued for acquisition     $ 11,778
XML 86 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Allowance for doubtful accounts receivable $ 206 $ 228
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 175,000,000 175,000,000
Common stock, shares issued 64,104,173 60,026,675
Common stock, shares outstanding 64,104,173 60,026,675
Series B Junior Participating Preferred Stock [Member]
   
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series E Convertible Voting Preferred Stock [Member]
   
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, stated value $ 10,000 $ 10,000
Preferred stock, shares authorized 2,000 2,000
Preferred stock, shares issued 20 20
Preferred stock, shares outstanding 20 20
Convertible preferred shares 40,000 40,000
Preferred stock, liquidation value $ 240 $ 240
XML 87 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations
12 Months Ended
Dec. 31, 2013
Business Combinations [Abstract]  
Business Combinations
10. BUSINESS COMBINATIONS

(a) Acquisition of Talon Therapeutics, Inc.

Talon Acquisition Overview

On July 16, 2013, we entered into a Securities Purchase Agreement with Talon Therapeutics, Inc. (“Talon”), whereby, on July 17, 2013, we purchased all of its then outstanding shares of common stock. Through the acquisition of Talon, we gained worldwide rights to MARQIBO, an FDA-approved drug that we believe complements our other hematology and oncology products.

Since July 17, 2013, the results of operations of the former Talon business have been included in the accompanying Consolidated Statements of Operations for the year ended December 31, 2013. From July 17, 2013 through December 31, 2013, our revenue derived from the former Talon business was approximately $1.3 million. We had nominal earnings from the Talon business during this period.

The Talon purchase consideration comprised of (i) an aggregate upfront cash amount of $11.3 million, (ii) issuance of 3.0 million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July 17, 2013), and (iii) the issuance of contingent value rights (“CVR”) initially valued by us at $6.5 million.

The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 3 (x)). The CVR has a maximum payout of $195.0 million if all sales and regulatory approval milestones are achieved, as summarized below:

 

   

$5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year

 

   

$10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year

 

   

$25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year

 

   

$50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year

 

   

$100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year

 

   

$5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion

Direct Costs of the Talon Acquisition

Our direct costs of the Talon acquisition included employee severance, banker, legal, and accounting fees which aggregated to $5.7 million. This amount is included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

Consideration Transferred

The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:

 

Cash consideration

   $ 11,300   

CVR

     6,500   

Spectrum shares of common stock

     26,300   
  

 

 

 

Total purchase consideration

   $ 44,100   
  

 

 

 

 

Fair Value Estimate of Assets Acquired and Liabilities Assumed

Under the purchase method of accounting, the total purchase consideration is allocated to Talon net tangible and intangible assets acquired and liabilities assumed based on the estimated fair values as of the acquisition date. The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:

 

Cash and equivalents

   $ 131   

Inventory

     611   

Prepaid expenses and other current assets

     109   

Property and equipment

     30   

Identifiable intangible assets

     44,500   
  

 

 

 

Total assets acquired

     45,381   
  

 

 

 

Accounts payable & accrued liabilities

     5,231   

Deferred tax liability

     6,576   
  

 

 

 

Total liabilities assumed

     11,807   
  

 

 

 

Net assets acquired

   $ 33,574   
  

 

 

 
  
  

 

 

 

Goodwill

   $ 10,526   
  

 

 

 

The acquired intangible assets consisted of developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) as follows in the table below:

 

     Value of
Intangible
Assets
Acquired
     Amortization
Period*
 

Developed technology —MARQIBO for ALL

   $ 26,900         13 years   

IPR&D —MARQIBO for NHL

     17,600              (1)
  

 

 

    

Total identifiable intangible assets

   $ 44,500      
  

 

 

    

 

* Recognized on a straight-line basis.
(1) IPR&D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but rather tested for impairment.

The fair value of the acquired IPR&D technology assets was estimated using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts.

Goodwill

Goodwill presented above of $10.5 million represents the difference of the Talon business purchase price of $44.1 million minus the net assets acquired of $33.6 million. This goodwill includes benefits that we believe will result from combining the operations of Talon with ours, as well as the know-how associated with the MARQIBO compounds for future product development. In accordance with applicable GAAP, we will not amortize goodwill associated with the Talon acquisition, though it will be subjected to annual impairment testing. This goodwill is not deductible for income tax purposes.

 

Supplemental Pro Forma Financial Information

The following unaudited pro forma financial information is presented to reflect the results of the Company’s consolidated operations for the years ended December 31, 2013 and 2012, as if the acquisition of Talon had occurred on January 1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2012, and may not be indicative of future operating results.

 

     Year Ended December 31,  
     2013     2012  

Pro Forma Total revenues

   $ 155,854      $ 267,707   

Pro Forma Total costs and operating expenses

     200,651        210,433   

Pro Forma Net (loss) income

     (68,146     57,274   

Pro Forma Net (loss) income per share – basic

   $ (1.12   $ 0.98   

Pro Forma Net (loss) income per share – diluted

   $ (1.12   $ 0.89   

Talon CVR Fair Value as of December 31, 2013

The CVR fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value
of Talon
CVR
 

July 17, 2013

   $ 6,500   

Fair value adjustment for year ended December 31, 2013

     (2,171
  

 

 

 

December 31, 2013

   $ 4,329   
  

 

 

 

(b) Acquisition of Rights to Captisol-Enabled ® MELPHALAN

Overview of Acquisition of Rights to C-E MELPHALAN

On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled ®, propylene glycol-free MELPHALAN (“C-E MELPHALAN”) from CyDex Pharmaceuticals, Inc. a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”). C-E MELPHALAN is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts up to an aggregate $66.0 million, upon the achievement of certain regulatory milestones and net sales thresholds (“Ligand Contingent Consideration”). We also must pay royalties in the range of 15% to 25% on net sales of licensed products in all territories.

We accounted for the acquisition of these rights as a business combination, using the acquisition method of accounting. This requires that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. Aggregate transaction costs of $15,000 are included in “selling, general and administrative expenses” within the accompanying Consolidated Statements of Operations for the year ended December 31, 2013.

Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items:

 

Cash consideration

   $ 3,000   

Ligand Contingent Consideration

     4,700   
  

 

 

 

Total purchase consideration

   $ 7,700   
  

 

 

 

 

Fair Value Estimate of Asset Acquired and Liability Assumed

The total purchase consideration is allocated to the acquisition of the tangible and intangible assets acquired and liabilities assumed. These amounts are based on their estimated fair values as of the closing date. The allocation of the total purchase price to the net assets acquired is as follows:

 

IPR&D—C-E MELPHALAN rights

   $ 7,700   
  

 

 

 

Acquired IPR&D is an intangible asset that is classified as indefinite-lived until the completion or abandonment of the associated R&D effort, and is subject to impairment testing. C-E MELPHALAN rights will be amortized over an estimated useful life to be determined at the date the project is complete.

We estimated the fair value of the in-process research and development using the income approach. The income approach uses valuation techniques to convert future amounts to a single present amount (discounted). Our measurement is based on the value indicated by current market expectations about those future amounts. The fair value estimate took into account our estimates of future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights, and included estimated cash flows of approximately 10 years and a discount rate of approximately 25%.

The fair value of the contingent consideration liability assumed was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable inputs and are therefore classified as Level 3 inputs – see Note 3(x)), which assumes that FDA approval of C-E MELPHALAN will occur on or about December 31, 2015. Upon receipt of FDA approval, we will be obligated to make a milestone payment of $6.0 million to Ligand.

We do not consider this acquisition to represent a material business combination; accordingly, we have not presented pro forma results of our combined operations that are otherwise required.

Ligand Contingent Consideration Fair Value as of December 31, 2013

The Ligand Contingent Consideration fair value will continue to be evaluated on a quarterly basis. Any changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value of
Ligand
Contingent
Consideration
 

March 8, 2013

   $ 4,700   

Fair value adjustment for year ended December 31, 2013

     (700
  

 

 

 

December 31, 2013

   $ 4,000   
  

 

 

 

(c) Allos Acquisition

We acquired Allos Therapeutics, Inc. (“Allos”) on September 5, 2012, which was accounted for as a business combination. Our total consideration for this acquisition was $205.2 million, through which we acquired FOLOTYN development technology and FOLOTYN distribution rights.

XML 88 R93.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Summary of Unrecognized Tax Benefits (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Income Tax Disclosure [Abstract]      
Balance at beginning of year $ 5,482 $ 3,928 $ 2,803
Adjustments related to prior year tax positions (200) (527) 5
Increases related to current year tax positions 648 2,515 1,120
Decreases due to settlements (1,227) (434)  
Decreases related to prior year tax positions (2,491)    
Balance at end of year $ 2,212 $ 5,482 $ 3,928
XML 89 R91.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Components of Company's Deferred Tax Assets (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Deferred tax assets:    
Net operating loss carry forwards $ 46,482 $ 45,391
Research credits 8,066 1,848
Stock based compensation 3,486 2,896
Deferred revenue 58 4,596
Development costs 6,495 5,298
Returns and allowances 3,117 7,889
Other, net 5,551 6,021
Total deferred tax assets before valuation allowance 73,255 73,246
Valuation allowance (49,586) (1,818)
Total deferred tax assets 23,669 72,121
Deferred tax liabilities:    
Basis difference in debt (1,082)  
Depreciation and amortization differences (28,096) (36,372)
Net deferred tax (liability) asset $ (5,509) $ 35,749
XML 90 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2013
Feb. 28, 2014
Jun. 30, 2013
Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2013    
Document Fiscal Year Focus 2013    
Document Fiscal Period Focus FY    
Trading Symbol SPPI    
Entity Registrant Name SPECTRUM PHARMACEUTICALS INC    
Entity Central Index Key 0000831547    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Accelerated Filer    
Entity Common Stock, Shares Outstanding   65,287,782  
Entity Public Float     $ 449,722,900
XML 91 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Revolving Line of Credit
12 Months Ended
Dec. 31, 2013
Debt Disclosure [Abstract]  
Revolving Line of Credit
11. REVOLVING LINE OF CREDIT

We entered into a credit agreement on September 5, 2012 with Bank of America, N.A, as the administrative agent and Wells Fargo Bank, N.A, as an initial lender, as amended July 16, 2013 (the “Credit Agreement”). The Credit Agreement provided us with a committed $50.0 million revolving line of credit facility (the “Credit Facility”). The Credit Facility was to expire on September 5, 2014, though we repaid it in full, then immediately terminated it on December 20, 2013 in connection with the sale and issuance of our 2018 Convertible Notes.

 

The Credit Facility bore interest, at our election, at a rate equal to the London Interbank Offer Rate (LIBOR), or the base rate, plus an applicable margin (2.75% to 4.25%, dependent on a defined liquidity ratio).

We incurred $1.0 million in related loan costs and fees in securing the Credit Facility, which were capitalized and recognized within “other assets” on our accompanying Consolidated Balance Sheets. This amount was amortized through “interest expense” to the accompanying Consolidated Statements of Operations, using the effective interest method, initially over the term of the Credit Facility, though the remaining unamortized portion was fully expensed in December 2013 when it was repaid and terminated.

An unused line fee was payable quarterly in an amount ranging from 0.375% to 0.625% of the sum of the average daily unused portion of the facilities during any quarter based upon consolidated leverage ratio as at the last test date. A customary fee was also payable to the administrative agent on an annual basis in advance.

We recognized $1.2 million, $0.5 million, and $-0- in 2013, 2012, and 2011, respectively, within “interest expense” for this retired Credit Facility on the accompanying Consolidated Statements of Operations.

XML 92 R80.htm IDEA: XBRL DOCUMENT v2.4.0.8
Revolving Line of Credit - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Debt Disclosure [Abstract]      
Credit agreement revolving line of credit facility $ 50.0    
Credit facility expiry date Sep. 05, 2014    
Credit facility, minimum interest rate 2.75%    
Credit facility, maximum interest rate 4.25%    
Loan costs and fees to be amortized 1.0    
Percentage of maximum amount of unused line fee 0.625%    
Percentage of minimum amount of unused line fee 0.375%    
Interest expense $ 1.2 $ 0.5 $ 0
XML 93 R90.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Income Tax Disclosure [Abstract]      
Tax provision (benefit) computed at the federal statutory rate $ (12,822) $ 27,975 $ 18,250
State tax, net of federal benefit (246) 2,442 2,918
Expired tax attributes     385
Research credits (2,254) (2,129) (1,464)
Benefits from credit study   (4,148)  
Common stock warrant liability     1,186
Transaction costs 880 1,497  
Officers compensation 2,178 2,908 3,801
Stock based compensation 501 134 1,676
Permanent items and other (1,080) 2,111 2,039
Domestic manufacturing deduction 767 (1,262)  
Tax differential on foreign earnings 1,123 382  
Change in tax rate (283) 338  
Valuation allowance 36,734 (44,519) (25,087)
Provision (Benefit) for income taxes $ 25,498 $ (14,271) $ 3,704
XML 94 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Revenues:      
Product sales, net $ 143,475 $ 254,992 $ 180,663
License fees and service revenue 12,379 12,715 12,300
Total revenues 155,854 267,707 192,963
Operating costs and expenses:      
Cost of product sales (excludes amortization of purchased intangible assets) 28,580 46,633 33,838
Selling, general and administrative 99,315 89,922 72,197
Research and development 46,670 41,560 26,662
Amortization and impairment of intangible assets 20,074 8,818 3,720
Total costs and operating expenses 194,639 186,933 136,417
(Loss) income from operations (38,785) 80,774 56,546
Other income (expense):      
Interest expense, net (2,192) (485) 297
Change in fair value of contingent consideration related to acquisition 2,871    
Change in fair value of common stock warrant liability (356)   (3,488)
Other income (expense), net 1,470 (359) 280
Total other income (expense) 2,149 (844) (2,911)
(Loss) income before income taxes (36,636) 79,930 53,635
(Provision) benefit for income taxes (25,498) 14,271 (3,704)
Net (loss) income $ (62,134) $ 94,201 $ 49,931
Net (loss) income per share:      
Basic $ (1.02) $ 1.61 $ 0.94
Diluted $ (1.02) $ 1.46 $ 0.86
Weighted average shares outstanding:      
Basic 60,729,128 58,588,916 53,272,767
Diluted 60,729,128 64,637,256 57,959,714
XML 95 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Product Sales, Net by Geographic Region and Product Line
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Product Sales, Net by Geographic Region and Product Line
5. PRODUCT SALES, NET BY GEOGRAPHIC REGION AND PRODUCT LINE

The below table presents product sales, net by geography for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

United States

   $ 133,462         93.0   $ 245,697         96.4   $ 180,663         —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

International:

               

Europe

     3,953         2.8     3,113         1.2     —          —  

Asia Pacific

     6,060         4.2     6,182         2.4     —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total International

     10,013         7.0     9,295         3.6     —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         100.0
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

The below table presents product sales, net by product line for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012     2011  

FUSILEV

   $ 68,397         47.7   $ 204,253         80.1   $ 153,110         84.7

FOLOTYN

     44,370         30.9     20,412         8.0     —          —  

ZEVALIN

     29,393         20.5     30,327         11.9     27,553      

MARQIBO

     1,315         0.9     —          —       —          —  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Product sales, net

   $ 143,475         100.0   $ 254,992         100.0   $ 180,663         15.3
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

XML 96 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Gross-to Net Product Sales
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Gross-to Net Product Sales
4. GROSS-TO-NET PRODUCT SALES

The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:

 

     2013     2012     2011  

Gross product sales

   $ 224,301      $ 383,817      $ 220,670   

Rebates and government chargebacks

     (63,610     (91,059     (22,190

Distribution and data fees and group purchasing organizations fees

     (19,067     (32,793     (11,637

Prompt pay discounts

     (183     (4,814     (4,086

Product returns allowance

     2,034        (159     (2,094
  

 

 

   

 

 

   

 

 

 

Product sales, net

   $ 143,475      $ 254,992      $ 180,663   
  

 

 

   

 

 

   

 

 

 
XML 97 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Subsequent Event
12 Months Ended
Dec. 31, 2013
Subsequent Events [Abstract]  
Subsequent Event
16. SUBSEQUENT EVENT

BELEODAQ NDA Acceptance by the FDA

On February 5, 2014, we received a communication from the FDA notifying us that our NDA for BELEODAQ (Belinostat) for Injection had been accepted for filing with priority review. As a result of this achievement, pursuant to the TopoTarget agreement (see Note 14(b)(x)), we paid TopoTarget $10.0 million and issued an aggregate 1.0 million shares of our common stock in February 2014.

XML 98 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Notes
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Convertible Senior Notes
12. CONVERTIBLE SENIOR NOTES

On December 17, 2013, we entered into an agreement for the sale of $120.0 million aggregate principal amount of 2.75% Convertible Senior Notes due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal amount of the 2018 Convertible Notes, totaling 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances, as defined in the Indenture. The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year, beginning on June 15, 2014. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option.

On December 23, 2013 net proceeds from the sale of the 2018 Convertible Notes were $115.4 million, after deducting banker and professional fees of $4.6 million. We used a portion of these net proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million, as a reduction to “additional paid-in capital” in our accompanying Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge transaction is not expected to be marked-to-market through earnings or comprehensive income in future reporting periods.

We entered into Note Hedge transactions to reduce the potential dilution to our common stock and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the “bought call” is equal to the conversion price and conversion rate of the 2018 Convertible Notes, matching the 11.4 million common shares the 2018 Convertible Notes may be converted into. The strike price of our “sold warrant” is $14.03 per share of our common stock, and is also for 11.4 million common shares.

As of December 31, 2013, the 2018 Convertible Notes were not convertible. Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter) commencing after March 31, 2014, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the applicable conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of our common stock on such trading day and the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; or (4) at any time we have not received stockholder approval, as that term is defined in the Indenture governing the 2018 Convertible Notes. On and after June 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes at any time, regardless of the foregoing circumstances.

 

We initially may only settle conversions of the 2018 Convertible Notes by delivering shares of our common stock. However, if we obtain stockholder approval in accordance with applicable NASDAQ rules, we may settle conversions of the 2018 Convertible Notes by paying or delivering, as the case may be, cash, shares of common stock, or a combination of cash and shares of common stock, at our election.

The carrying values of the 2018 Convertible Notes as of December 31, 2013 is summarized as follows:

 

Principal amount

   $ 120,000   

(Less): Unamortized debt discount (amortized through December 2018)

     (28,520
  

 

 

 

December 31, 2013 net carrying amount of 2018 Convertible Notes

   $ 91,480   
  

 

 

 

The following table sets forth the components of total “interest expense” recognized in the accompanying Consolidated Statements of Operations for the 2018 Convertible Notes for the year ended December 31, 2013:

 

Contractual coupon interest expense

   $ 73   

Amortization of debt issuance costs

     43   

Accretion of debt discount

     101   
  

 

 

 

Total

   $ 217   
  

 

 

 

Effective interest rate

     8.59
  

 

 

 

 

XML 99 R84.htm IDEA: XBRL DOCUMENT v2.4.0.8
Mundipharma Agreement - Additional Information (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sep. 30, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Company determined development payment $ 194,639,000 $ 186,933,000 $ 136,417,000  
Deferred development cost       12,300,000
Mundipharma [Member]
       
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Company determined development payment 7,000,000      
Development cost liability 17,700,000      
Maximum [Member] | Regulatory [Member]
       
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Potential milestone payments 16,000,000      
Maximum [Member] | Commercial progress and sales-dependent [Member]
       
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Potential milestone payments $ 107,000,000      
XML 100 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net (Loss) Income Per Share
12 Months Ended
Dec. 31, 2013
Earnings Per Share [Abstract]  
Net (Loss) Income Per Share
8. NET (LOSS) INCOME PER SHARE

Net (loss) income per share was computed by dividing net (loss) income by the weighted average number of common shares outstanding for the years ended December 31, 2013, 2012, and 2011:

 

     Year Ended December 31,  
     2013     2012      2011  

Net (loss) income

   $ (62,134   $ 94,201       $ 49,931   

Weighted average shares - basic

     60,729,128        58,588,916         53,272,767   

Net (loss) income per share - basic

   $ (1.02   $ 1.61       $ 0.94   

Weighted average shares - diluted

     60,729,128        64,637,256         57,959,714   

Net (loss) income per share - diluted

   $ (1.02   $ 1.46       $ 0.86   

The following summarizes the amounts used in computing basic and diluted net income per share, for the years ended 2012 and 2011:

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2012

        

Basic net income per share:

   $ 94,201         58,588,916       $ 1.61   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,749,299      

Incremental common stock assumed issued on exercise of in-the-money warrants

        224,437      

Unvested restrictive stock awards

        1,034,604      
  

 

 

    

 

 

    

Diluted net income per share

   $ 94,201         64,637,256       $ 1.46   
  

 

 

    

 

 

    

 

 

 

 

     Net Income
(numerator)
     Weighted-
Average
Shares
Outstanding
(Denominator)
     Net
Income
Per Share
 

Year Ended December 31, 2011

        

Basic net income per share:

   $ 49,931         53,272,767       $ 0.94   
        

 

 

 

Diluted net income per share:

        

Dilutive preferred shares

        40,000      

Dilutive common stock options

        4,185,224      

Change in common stock related to Targent and management incentive plan milestones, as if they had been issued at the beginning of the quarter earned

        248,193      

Incremental common stock assumed issued on exercise of in-the-money warrants

        200,656      

Unvested restrictive stock awards

        12,874      
  

 

 

    

 

 

    

Diluted net income per share

   $ 49,931         57,959,714       $ 0.86   
  

 

 

    

 

 

    

 

 

 

 

Our outstanding securities were excluded from the above calculation of net (loss) per share, using the treasury stock and if-converted method, as applicable, because their impact would have been anti-dilutive due to net (loss) per share in 2013:

 

     Year Ended December 31,  
     2013      2012      2011  

2018 Convertible Notes

     343,600         —           —     

Common stock options

     2,934,625         —           —     

Restricted stock awards

     1,007,119         —           —     

Common stock warrants

     160,816         —           —     

Preferred stock

     40,000         —           —     
  

 

 

    

 

 

    

 

 

 

Total

     4,486,160         —           —     
  

 

 

    

 

 

    

 

 

 

 

XML 101 R60.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected option life 4 years 11 months 12 days 4 years 6 months 4 years 11 months 5 days
Maximum [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected option life 10 years 10 years 10 years
XML 102 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation
12 Months Ended
Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation
6. STOCK-BASED COMPENSATION

2009 Stock Incentive Plan

We have one active stockholder-approved stock-based compensation plan, the 2009 Incentive Award Plan (the “2009 Plan”), which replaced our former stockholder-approved plans. We may grant incentive stock options, non-qualified options, restricted stock awards, and stock appreciation rights under the 2009 Plan.

The maximum number of our common stock available for issuance under the 2009 Plan is 10.0 million shares. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the 2009 Plan increases by the greater of (i) 2.5 million shares or (ii) a number of shares such that the total number of shares of common stock available for issuance under the 2009 Plan shall equal 30% of the then number of shares of common stock issued and outstanding. As of December 31, 2013, 5.7 million shares were available for grant. It is our policy that before stock is issued through the exercise of stock options, we must first receive all required cash payment for such shares (whether through an upfront cash exercise or net-settlement exercise).

Stock-based awards are governed by agreements between us and the recipients. Incentive stock options and nonqualified stock options may be granted under the 2009 Plan at an exercise price of not less than 100% of the closing fair market value of our common stock on the respective date of grant. The grant date is generally the date the award is approved by the Compensation Committee of the Board of Directors, though for aggregate awards of 50,000 or less in each quarter, the grant date is the date the award is approved by our Chief Executive Officer.

Stock-based awards generally vest 25% on the first anniversary of the date of grant, or for new hires, the first anniversary of their initial date of employment. Awards vest monthly thereafter on a straight-line basis over three years. Stock options must be exercised, if at all, no later than 10 years from the date of grant. Upon termination of employment, vested stock options may be exercised within 90 days from the last date of employment. In the event of an optionee’s death, disability, or retirement, the exercise period is 365 days from the last date of employment.

Employee Stock Purchase Plan

Under the terms of our 2009 Employee Stock Purchase Plan (the “ESPP”), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of our common stock on the first or last day of the offering period (whichever is less), minus a 15% discount. We use the Black-Scholes option-pricing model, in combination with the discounted employee price, in determining the value of ESPP expense to be recognized during each offering period. A participant may purchase a maximum of 50,000 shares of common stock during a six-month offering period, not to exceed $25,000 worth of stock on the offering date during each plan year.

A total of 5.0 million shares of common stock are authorized for issuance under the ESPP. Beginning on January 1, 2010, and each January 1st thereafter, the number of shares of common stock available for issuance under the ESPP shall increase by an amount equal to the lesser of (i) 1 million shares or (ii) an amount determined by the ESPP administrator. However, in no event shall the number of shares of common stock available for future sale under the ESPP exceed 10.0 million shares, subject to capitalization adjustments occurring due to dividends, splits, dissolution, liquidation, mergers, or changes in control.

Stock-Based Compensation Expense Summary

We classify our stock-based compensation expense (inclusive of our 2009 Plan, ESPP, and 401(k) matching) in the accompanying Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within operating expenses for years ended December 31, 2013, 2012, and 2011 was as follows:

 

     Year Ended December 31,  
     2013      2012      2011  

Selling, general and administrative

   $ 10,762       $ 13,041       $ 20,609   

Research and development

     2,017         1,843         1,628   
  

 

 

    

 

 

    

 

 

 

Total

   $ 12,779       $ 14,884       $ 22,237   
  

 

 

    

 

 

    

 

 

 

Employee stock-based compensation expense for the years ended December 31, 2013, 2012, and 2011 was recognized (reduced for estimated forfeitures) on a straight-line basis over the vesting period. Forfeitures are estimated at the time of grant and prospectively revised if actual forfeitures differ from those estimates. We estimate forfeitures of stock options using the historical exercise behavior of our employees. For purposes of this estimate, we have applied an estimated forfeiture rate of 8%, 5%, and 5% for the years ended December 31, 2013, 2012, and 2011.

Valuation Assumptions – Restricted Stock and Stock Options

The grant-date fair value per share for restricted stock awards was based upon the closing market price of our common stock on the award grant-date.

The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model. The following assumptions were used to determine fair value for the stock awards granted in the applicable year:

 

     Year Ended December 31,
     2013    2012    2011

Expected option life (in years) (a)

   4.95    4.50    4.93

Risk-free interest rate (b)

   0.35% - 0.78%    0.34% - 0.51%    0.82% - 2.4%

Volatility (c)

   58.3% - 71.5%    64.2% -73.6%    55.8%

Dividend yield (d)

   0%    0%    0%

Weighted-average grant-date fair value per stock option

   $4.66    $6.20    $2.65

 

(a) Determined by the historical stock option exercise behavior of our employees (maximum term is 10 years).
(b) Based upon the U.S. Treasury yields in effect during the period which the options were granted (for a period equaling the stock options’ expected term).
(c) Measured using our historical stock price for a period equal to stock options’ expected term.
(d) We do not expect to declare any cash dividends in the foreseeable future.

 

Stock Option Activity

Stock option activity during the years ended December 31, 2013, 2012, and 2011 is as follows:

 

     Number  of
Shares
    Weighted-
Average

Exercise
Price/Share
     Weighted-
Average
Remaining
Contractual
Term (Years)
     Aggregate
Intrinsic
Value
 

Outstanding — December 31, 2010

     8,397,094      $ 4.17         

Granted

     3,622,150        7.92         

Exercised

     (1,126,257     4.07          $ 8,255 (1) 

Forfeited

     (547,479     4.81         

Expired

     (159,987     5.17         
  

 

 

   

 

 

       

Outstanding — December 31, 2011

     10,185,521      $ 5.46         

Granted

     1,821,915        11.57         

Exercised

     (1,287,430     4.52          $ 11,500 (1) 

Forfeited

     (316,825     7.93         

Expired

     (3,916     7.69         
  

 

 

   

 

 

       

Outstanding — December 31, 2012

     10,399,265      $ 6.57         

Granted

     2,041,300        8.92         

Exercised

     (825,884     4.40          $ 3,435 (1) 

Forfeited

     (202,882     8.22         

Expired

     (82,581     8.91         
  

 

 

   

 

 

       

Outstanding — December 31, 2013

     11,329,218      $ 7.10         7.0       $ 25,849 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Vested (exercisable) — December 31, 2013

     7,876,025      $ 6.11         6.2       $ 24,080 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

Unvested (unexercisable) — December 31, 2013

     3,453,193      $ 9.38         8.9       $ 1,770 (2) 
  

 

 

   

 

 

    

 

 

    

 

 

 

 

(1) Represents the total difference between our closing stock price at the time of exercise and the stock option exercise price, multiplied by the number of options exercised.
(2) Represents the total difference between our closing stock price on the last trading day of 2013 and the stock option exercise price, multiplied by the number of in-the-money options as of December 31, 2013. The amount of intrinsic value will change based on the fair market value of our stock.

The following table summarizes information with respect to stock option grants as of December 31, 2013:

 

     Outstanding      Exercisable  

Exercise Price

   Granted Stock
Options
Outstanding
     Weighted-
Average

Remaining
Contractual
Life (Years)
     Weighted-
Average

Exercise
Price
     Granted
Stock
Options
Exercisable
     Weighted-
Average

Exercise
Price
 

$0.92 –   3.15

     1,192,794         4.5       $ 2.16         1,192,794       $ 2.16   

$3.55 –   4.95

     1,924,904         5.9         4.23         1,865,794         4.23   

$5.05 –   6.90

     2,862,699         5.5         6.26         2,565,220         6.19   

$7.00 –   8.99

     2,329,167         8.2         8.17         1,147,138         8.26   

$9.00 – 16.32

     3,019,654         9.2         10.86         1,105,079         11.09   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
     11,329,218         7.0       $ 7.10         7,876,025       $ 6.11   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

As of December 31, 2013, there was unrecognized compensation expense of $12.4 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.54 years.

 

Restricted Stock Activity

A summary of restricted stock activity is as follows:

 

     Number of
Restricted  Stock
Awards
    Weighted Average
Fair Value per
Share at Grant
Date
 

Unvested as of December 31, 2010

     359,500      $ 3.96   

Granted

     1,781,000        12.48   

Vested

     (1,104,025     12.33   

Forfeited

     (83,950     4.78   
  

 

 

   

Unvested — December 31, 2011

     952,525        10.11   

Granted

     586,639        11.76   

Vested

     (472,160     10.26   

Forfeited

     (32,400     9.57   
  

 

 

   

Unvested — December 31, 2012

     1,034,604        11.00   

Granted

     523,800        8.74   

Vested

     (501,660     9.72   

Forfeited

     (49,625     10.60   
  

 

 

   

Unvested — December 31, 2013

     1,007,119      $ 10.09   
  

 

 

   

 

 

 

 

* Represents our stock price on the vesting date multiplied by the number of vested shares.

 

     2013      2012      2011  

Restricted stock expense

   $ 4,202      $ 6,500       $ 4,100   

As of December 31, 2013, there was approximately $6.5 million of unrecorded expense related to issued restricted stock that will be recognized over an estimated weighted average period of 2.4 years.

401(k) Plan – Stock Matching Contribution

We issued shares of common stock to our employees in connection with our 401(k) program, partially matching our employee contributions, as summarized below:

 

     2013      2012      2011  

Shares of common stock issued

     99,359         56,254         65,889   

Match contribution value**

   $ 860       $ 691       $ 593   

 

** Represents our stock price on the date of the stock match multiplied by the number of shares of common stock issued.
XML 103 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity
12 Months Ended
Dec. 31, 2013
Equity [Abstract]  
Stockholders' Equity
7. STOCKHOLDERS’ EQUITY

Authorized Stock

On December 13, 2010, we filed the Certificate of Designation of Rights, Preferences and Privileges of Series B Junior Participating Preferred Stock with the Delaware Secretary of State which authorized 1.5 million shares to be designated as Series B Junior Participating Preferred Stock. On June 13, 2011, our stockholders approved an amendment to our Certificate of Incorporation to increase the authorized number of shares of our common stock from 100.0 million shares to 175.0 million shares. The amendment was filed with the Delaware Secretary of State on June 24, 2011. As of December 31, 2013, we also had 5.0 million shares of preferred stock authorized, of which 1.5 million shares were designated as Series B Junior Participating Preferred Stock and 2,000 shares were designated as Series E Convertible Voting Preferred Stock.

Stockholder Rights Agreement

On November 29, 2010, our Board of Directors approved a replacement rights agreement, effective December 13, 2010, that replaced the stockholder rights agreement which was originally adopted in 2000. This replacement rights agreement will extend until December 13, 2020. A stockholder rights agreement is designed to deter coercive, unfair, or inadequate takeovers and other abusive tactics that might be used in an attempt to gain control of the Company. A stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire the Company to first negotiate with our Board of Directors.

Under the terms of the new Stockholder Rights Agreement, the rights become exercisable upon the earlier of 10 days after a person or group of affiliated or associated persons has acquired 15% or more of the outstanding shares of our common stock or 10 business days after a tender offer has commenced that would result in a person or group beneficially owning 15% or more of our outstanding common stock. These rights could delay or discourage someone from acquiring our business, even if doing so would benefit our stockholders. We currently have no stockholders who own 15% or more of the outstanding shares of our common stock. Five days after the rights become exercisable, each right, other than rights held by the person or group of affiliated persons whose acquisition of more than 15% of our outstanding common stock caused the rights to become exercisable, will entitle its holder to buy, in lieu of shares of Series B Preferred Stock, a number of shares of our common stock having a market value of twice the exercise price of the rights. After the rights become exercisable, if we are a party to certain merger or business combination transactions or transfers 50% or more of our assets or earnings power (as defined), each right will entitle its holder to buy a number of shares of common stock of the acquiring or surviving entity having a market value of twice the exercise price of the right.

Series E Preferred Stock

In September 2003, we received gross cash proceeds of $20.0 million in exchange for the issuance of 2,000 shares of our Series E Convertible Voting Preferred Stock, convertible into 4.0 million shares of common stock. As of December 31, 2013 and 2012, 20 shares of Series E Preferred Stock were outstanding. No dividends are payable on the Series E Preferred Stock. Pursuant to certain provisions of the Certificate of Designation, Rights and Preferences of the Series E Preferred Stock, we have the option to redeem all of the unconverted Series E Preferred Stock outstanding at the end of a 20-day trading period if, among other things, in that period our common stock trades above $12.00 per share.

In the event we are the subject of any voluntary or involuntary liquidation, dissolution or winding up, before any distribution of our assets shall be made to the common stockholders, the holders of the Series E Preferred Stock shall be entitled to receive a liquidation preference in an amount equal to 120% of the stated value per share plus any declared and unpaid dividends thereon.

Common Stock Reserved for Future Issuance

As of December 31, 2013, approximately 28.1 million shares of our common stock were issuable upon conversion or exercise of rights granted, or to be granted, as summarized below:

 

Conversion of Series E Preferred Stock

     40,000   

2018 Convertible Notes

     11,400,000   

Exercise of issued employee stock options

     11,329,218   

Exercise of issued warrants

     445,000   

ESPP shares reserved

     4,540,986   

Long-term retention and management incentive plan shares

     346,500   
  

 

 

 

Total shares of common stock reserved for future issuances

     28,101,704   
  

 

 

 

Warrant Activity

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through December 2015. A summary of warrant activity is as follows:

 

     Number of
Shares
    Weighted
Average
Exercise Price
 

Outstanding — December 31, 2010

     4,192,312      $ 6.45   

Expired

     (3,747,312     6.62   
  

 

 

   

 

 

 

Outstanding — December 31, 2011

     445,000      $ 5.04   

Exercised

     (50,000     1.79   
  

 

 

   

 

 

 

Outstanding — December 31, 2012

     395,000      $ 5.45   

Granted

     50,000        7.51   
  

 

 

   

 

 

 

Outstanding — December 31, 2013

     445,000      $ 6.39   
  

 

 

   

 

 

 

Exercisable — December 31, 2013

     407,500      $ 6.29   
  

 

 

   

 

 

XML 104 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements
12 Months Ended
Dec. 31, 2013
Fair Value Disclosures [Abstract]  
Fair Value Measurements
9. FAIR VALUE MEASUREMENTS

The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among three fair value measurement categories (as described within Note 2 (x)):

 

     December 31, 2013
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 410       $ —        $ 410   

Money market currency funds

     —           100,395         —          100,395   

Mutual funds

     —          3,061         —          3,061   

Deferred compensation investments, including life insurance cash surrender value

     —          5,361         —          5,361   

Equity securities

     3,593         —           —          3,593   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,593       $ 109,227       $ —         $ 112,820   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          3,949         —          3,949   

Deferred development costs

     —          —           17,742         17,742   

Ligand Contingent Consideration

     —          —           4,000         4,000   

Talon CVR

     —          —           4,329         4,329   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 3,949       $ 26,071       $ 30,020   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2012
Fair Value Measurements
 
     Level 1      Level 2      Level 3      Total  

Assets:

           

Bank CDs

   $ —        $ 987       $ —        $ 987   

Money market currency funds

        11,698         —          11,698   

Mutual funds

     —          2,323         —          2,323   

Deferred compensation investments, including life insurance cash surrender value

     —          2,881         —          2,881   

Equity securities

     2,480         —          —          2,480   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 2,480       $ 17,889       $ —        $ 20,369   
  

 

 

    

 

 

    

 

 

    

 

 

 

Liabilities:

           

Deferred executive compensation liability

     —          2,365         —          2,365   

Deferred development costs

     —          —          12,233         12,233   

Deferred payment contingency

     —          —          2,287         2,287   

Ligand Contingent Consideration

     —          —          —          —    
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ —        $ 2,365       $ 14,520       $ 16,885   
  

 

 

    

 

 

    

 

 

    

 

 

 

We did not have any transfers between Levels 1 and 2 for all periods presented. The following presents a roll forward of our liabilities for which we utilize Level 3 inputs (see Note 2(x)) in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “accrued and deferred development costs, less current portion”. The basis of the Level 3 inputs utilized are discussed in the referenced Notes to these Consolidated Financial Statements for each.

Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition related contingent consideration liabilities, approximate their related fair values due to their short-term nature.

 

     Fair Value Measurements  of
Unobservable Inputs (Level 3)
 

Balance at December 31, 2011

   $ —    

Transfers in (out)

     —    

Deferred development costs

     12,233   

Deferred payment contingency

     2,287   
  

 

 

 

Balance at December 31, 2012

     14,520   

Transfers in (out)

     —    

Deferred development costs (see Note 13)

     5,509   

Deferred payment contingency (see Note 13)

     (2,287

Ligand Contingent Consideration (see Note 10(b))

     4,000   

Talon CVR (see Note 10(a))

     4,329   
  

 

 

 

Balance at December 31, 2013

   $ 26,071   
  

 

 

 

 

XML 105 R64.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Restricted stock expense $ 4,202 $ 6,500 $ 4,100
XML 106 R85.htm IDEA: XBRL DOCUMENT v2.4.0.8
Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Schedule Of Accrued Liabilities [Line Items]  
Beginning Balance $ 856
Amended agreement payment receipt (7,000)
Ending Balance 3,119
FOLOTYN [Member]
 
Schedule Of Accrued Liabilities [Line Items]  
Beginning Balance 12,233
Amended agreement payment receipt 7,000
(Less): Expenses incurred (1,491)
Ending Balance 17,742
FOLOTYN [Member] | Drug Development Liability Current [Member]
 
Schedule Of Accrued Liabilities [Line Items]  
Beginning Balance 856
Transfer from long term to current 3,620
(Less): Expenses incurred (1,357)
Ending Balance 3,119
FOLOTYN [Member] | Drug Development Liability Long Term [Member]
 
Schedule Of Accrued Liabilities [Line Items]  
Beginning Balance 11,377
Transfer from long term to current (3,620)
Amended agreement payment receipt 7,000
(Less): Expenses incurred (134)
Ending Balance $ 14,623
XML 107 R66.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity - Additional Information (Detail) (USD $)
12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Jun. 13, 2011
Maximum [Member]
Jun. 13, 2011
Minimum [Member]
Sep. 30, 2003
Series E Convertible Voting Preferred Stock [Member]
Dec. 31, 2013
Series E Convertible Voting Preferred Stock [Member]
Dec. 31, 2012
Series E Convertible Voting Preferred Stock [Member]
Dec. 31, 2013
Series B Junior Participating Preferred Stock [Member]
Dec. 31, 2012
Series B Junior Participating Preferred Stock [Member]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Options [Line Items]                  
Preferred stock, shares authorized 5,000,000 5,000,000       2,000 2,000 1,500,000 1,500,000
Number of common shares authorized 175,000,000 175,000,000 175,000,000 100,000,000          
New replacement rights agreement extended date December 13, 2020                
Percentage of outstanding shares acquired to exercise preferred share rights 15.00%                
Transfer of assets or earnings power 50.00%                
Preferred stock issued         2,000 20 20 0 0
Preferred stock converted into common stock         4,000,000 40,000 40,000    
Convertible preferred stock outstanding           20 20 0 0
Number of trading days consider for option to redeem preferred stock           20 days      
Dividends payable           $ 0 $ 0    
Common stock trading price per share $ 12.00                
Cash proceeds from exchange of preferred stock         $ 20,000,000        
Percentage of preferred stock liquidation preference common stock 120.00%                
Shares of common stock issuable upon conversion or exercise of rights granted 28,100,000                
Outstanding warrants expire on varying dates December 2015                
XML 108 R63.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]      
Number of Restricted Stock Awards, Unvested, Beginning Balance 1,034,604 952,525 359,500
Number of Restricted Stock Awards, Granted 523,800 586,639 1,781,000
Number of Restricted Stock Awards, Vested (501,660) (472,160) (1,104,025)
Number of Restricted Stock Awards, Forfeited (49,625) (32,400) (83,950)
Number of Restricted Stock Awards, Unvested, Ending Balance 1,007,119 1,034,604 952,525
Weighted Average Fair Value per Share at Grant Date, Beginning Balance $ 11.00 $ 10.11 $ 3.96
Weighted Average Fair Value per Share at Grant Date, Granted $ 8.74 $ 11.76 $ 12.48
Weighted Average Fair Value per Share at Grant Date, Vested $ 9.72 $ 10.26 $ 12.33
Weighted Average Fair Value per Share at Grant Date, Forfeited $ 10.60 $ 9.57 $ 4.78
Weighted Average Fair Value per Share at Grant Date, Ending Balance $ 10.09 $ 11.00 $ 10.11
XML 109 R92.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Additional Information (Detail) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Income Taxes [Line Items]      
Research and development tax credits $ 8,066,000 $ 1,848,000  
Unrecognized tax benefits, if recognized, would affect the effective tax rate 0.3 5,200,000 0.2
Reduction tax credits carryovers 800,000    
Reduction operating loss carryovers 1,600,000    
Examination tax 0    
Federal [Member]
     
Income Taxes [Line Items]      
Net operating loss carryforwards 117,400,000    
Net operating loss carryforwards expiration year 2018    
Research and development tax credits 6,900,000    
Research and development tax credits beginning expiration year 2026    
State [Member]
     
Income Taxes [Line Items]      
Net operating loss carryforwards 132,000,000    
Net operating loss carryforwards expiration year 2014    
Research and development tax credits 2,200,000    
Foreign [Member]
     
Income Taxes [Line Items]      
Net operating loss carryforwards $ 4,100,000    
Net operating loss carryforwards expiration year 2028    
XML 110 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations (Tables)
12 Months Ended
Dec. 31, 2013
Acquisition-Date Fair Value of Consideration Transferred

The Talon acquisition purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based upon their estimated fair value at the acquisition date. The following table summarizes the purchase price:

 

Cash consideration

   $ 11,300   

CVR

     6,500  

Spectrum shares of common stock

     26,300  
  

 

 

 

Total purchase consideration

   $ 44,100  
  

 

 

 
Supplemental Pro Forma Financial Information

The following unaudited pro forma financial information is presented to reflect the results of the Company’s consolidated operations for the years ended December 31, 2013 and 2012, as if the acquisition of Talon had occurred on January 1, 2012. To reflect the combined businesses, adjustments have been made to exclude one-time transaction costs and employee severance costs that were directly associated with the Talon acquisition. These pro forma results have been prepared for informational purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2012, and may not be indicative of future operating results.

 

     Year Ended December 31,  
     2013     2012  

Pro Forma Total revenues

   $ 155,854      $ 267,707   

Pro Forma Total costs and operating expenses

     200,651        210,433   

Pro Forma Net (loss) income

     (68,146     57,274   

Pro Forma Net (loss) income per share – basic

   $ (1.12   $ 0.98   

Pro Forma Net (loss) income per share – diluted

   $ (1.12   $ 0.89   

Amortization Period for such Intangible Assets Acquired

The acquired intangible assets consisted of developed technology and in-process research and development (“IPR&D”) for MARQIBO treatment of acute lymphoblastic leukemia (“ALL”) and MARQIBO treatment of non-Hodgkin’s lymphoma (“NHL”) as follows in the table below:

 

     Value of
Intangible
Assets
Acquired
     Amortization
Period*
 

Developed technology —MARQIBO for ALL

   $ 26,900         13 years   

IPR&D —MARQIBO for NHL

     17,600              (1)
  

 

 

    

Total identifiable intangible assets

   $ 44,500      
  

 

 

    

 

* Recognized on a straight-line basis.
(1) IPR&D is an intangible asset classified as an indefinite-lived until the completion or abandonment of the associated research and development effort, and will be amortized over an estimated useful life to be determined at the date the project is completed. IPR&D is not amortized during this period, but rather tested for impairment.
Summary of Allocation of Total Purchase Price to Net Assets Acquired

The following table summarizes the estimated fair value of the net assets acquired on July 17, 2013:

 

Cash and equivalents

   $ 131   

Inventory

     611   

Prepaid expenses and other current assets

     109   

Property and equipment

     30   

Identifiable intangible assets

     44,500   
  

 

 

 

Total assets acquired

     45,381   
  

 

 

 

Accounts payable & accrued liabilities

     5,231   

Deferred tax liability

     6,576   
  

 

 

 

Total liabilities assumed

     11,807   
  

 

 

 

Net assets acquired

   $ 33,574   
  

 

 

 
  
  

 

 

 

Goodwill

   $ 10,526   
  

 

 

 

Talon Therapeutics, Inc. [Member]
 
Acquisition-Date Fair Value of Consideration Transferred

The acquisition-date fair value of the consideration transferred consisted of the following items:

 

Cash consideration

   $ 3,000   

Ligand Contingent Consideration

     4,700   
  

 

 

 

Total purchase consideration

   $ 7,700   
  

 

 

 
Change in Fair Value of Contingent Consideration Related to Acquisition

Adjustments to CVR fair value are recognized within “change in fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value
of Talon
CVR
 

July 17, 2013

   $ 6,500   

Fair value adjustment for year ended December 31, 2013

     (2,171
  

 

 

 

December 31, 2013

   $ 4,329   
  

 

 

 

 

Melphalan license [Member]
 
Change in Fair Value of Contingent Consideration Related to Acquisition

Adjustments to Ligand Contingent Consideration fair value are recognized within “fair value of contingent consideration related to acquisition” in the accompanying Consolidated Statements of Operations.

 

     Fair Value of
Ligand
Contingent
Consideration
 

March 8, 2013

   $ 4,700   

Fair value adjustment for year ended December 31, 2013

     (700
  

 

 

 

December 31, 2013

   $ 4,000   
  

 

 

 

Summary of Allocation of Total Purchase Price to Net Assets Acquired

The allocation of the total purchase price to the net assets acquired is as follows:

 

IPR&D—C-E MELPHALAN rights

   $ 7,700   
  

 

 

 

XML 111 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Payables And Accruals [Abstract]    
Trade payables $ 12,796 $ 30,814
Accrued rebates 28,893 11,023
Accrued product royalty 9,498 12,275
Allowance for returns 2,900 5,056
Accrued data and distribution fees 2,430 8,449
Accrued GPO administrative fees 2,327 2,650
Inventory management fee 616 3,050
Accrued income taxes 3 2,522
Allowance for chargebacks 5,074 15,153
Accrued drug development costs 6,433 11,441
Other accrued obligations 8,867 2,819
Accounts payable and other accrued obligations $ 79,837 $ 105,252
XML 112 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
12 Months Ended
Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies
14. COMMITMENTS AND CONTINGENCIES

(a) Facility and Equipment Leases

We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring April 30, 2014. We also lease our research and development and administrative facility in Irvine, California under a non-cancelable operating lease expiring May 31, 2019, in addition to several other administrative office leases. Each lease agreement contains certain scheduled rent increases which are accounted for on a straight-line basis. Our total rental expense in 2013, 2012, and 2011 was $1.2 million, $0.9 million, and $0.7 million, respectively.

Our future minimum lease payments are as follows:

 

Year ending December 31,    Operating Lease
Minimum
Payments
 

2014

   $ 849   

2015

     950   

2016

     892   

2017

     843   

2018

     868   
  

 

 

 
   $ 4,402   
  

 

 

 

(b) Licensing Agreements, Co-Development Agreements, and Milestone Payments

We are developing almost all of our drug candidates pursuant to license agreements that provide us with rights in certain territories, among other things, to develop, sublicense, manufacture and sell the drugs. We are generally required to use commercially reasonable efforts to develop the drugs, and are generally responsible for all development, patent filing and maintenance, sales and marketing and liability insurance costs. We are also obligated to make certain milestone payments to the licensors if we successfully reach development and regulatory milestones specified in the license agreements. In addition, we are obligated to pay royalties and, in some cases, milestone payments based on our net sales.

The potential contingent development and regulatory milestone obligations under all of our licensing agreements are generally tied to progress through the various regulatory authorities’ approval process, which approval significantly depends on positive clinical trial results.

Our most significant of these agreements are listed and summarized below:

(i) ZEVALIN licensing and development in the U.S.

In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with Cell Therapeutics, Inc. (“CTI”). Pursuant to the transfer of the ZEVALIN assets from CTI to RIT Oncology LLC (“RIT”), in December 2008, RIT assumed certain agreements with various third parties related to ZEVALIN intellectual property. These agreements relate to the manufacture, use, and sale of ZEVALIN in the U.S.

 

In accordance with the terms of such agreements, RIT is required to meet specified payment obligations including a commercial milestone payment to Corixa Corporation of $5.0 million based on ZEVALIN sales in the U.S., which has not yet been met, as well as U.S. net sales-based royalties of low to mid-single digits to Genentech, Inc. and mid-single digits to Corixa Corporation.

(ii) Asset Purchase Agreement between CTI and Biogen, ZEVALIN U.S.

In connection with the joint venture arrangement with CTI, we entered into an amendment to the original asset purchase agreement between CTI and Biogen, modifying future milestone payments. Pursuant to the terms of the agreement, as amended, (i) upon the achievement of the specified FDA approval milestone, which was achieved in 2009, RIT (as successor to CTI) paid Biogen an additional amount of $5.5 million, (ii) RIT may be required to make an additional $10.0 million milestone payment upon the achievement of an additional FDA approval milestone, and (iii) RIT is required to make yearly royalty payments determined as a mid-single to mid-teen digits percentage of yearly net sales for the preceding year, increasing with the passage of time. The agreement has an indefinite term and is no longer subject to termination; provided, however, that the royalty obligations automatically terminate upon the latest to occur of expiration of the subject patents, the sale by a third party of a biosimilar product in the U.S. or December 31, 2015. CTI’s rights and obligations, including its payment obligations to Biogen for royalties on net sales of ZEVALIN and an additional regulatory milestone payment, under both the CTI/Biogen Agreement and the amendment were assigned to and assumed by RIT in connection with the closing of the joint venture transaction.

(iii) License and Asset Purchase Agreement with Bayer Pharma, ZEVALIN Ex-U.S.

On April 1, 2012, through our subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed the acquisition of licensing rights to market ZEVALIN outside of the U.S., referred to as the ZEVALIN Ex-US Rights, from Bayer Pharma AG, or Bayer.

We currently market ZEVALIN in the U.S. and this agreement expanded our commercial efforts to the rest of the world. ZEVALIN is currently approved in more than 40 countries outside the U.S. for the treatment of B-cell non-Hodgkin lymphoma, including countries in Europe, Latin America and Asia. In consideration for the rights granted under the agreement, concurrent with the closing, we paid Bayer a one-time fee of Euro 19.0 million, and will pay Bayer royalties based on a mid-teen digits percentage of net sales of the licensed products in all territories worldwide except the U.S. Unless earlier terminated, the term of the agreement continues until the expiration of our royalty payment obligations which, in turn, run until the last-to-expire patent covering the sale of a licensed product in the relevant country or 15 years from the date of first commercial sale of the licensed product in such country, whichever is longer.

(iv) Amended and Restated License Agreement with Merck & Cie AG, FUSILEV

In May 2006, we amended and restated a license agreement with Merck & Cie AG, a Swiss corporation, which we assumed in connection with the acquisition of the assets of Targent. Pursuant to the license agreement with Merck & Cie, we obtained the exclusive license to use regulatory filings related to FUSILEV and a non-exclusive license under certain patents and know-how related to FUSILEV to develop, make, use, and sell FUSILEV in the field of oncology in North America. In addition, we have the right of first opportunity to negotiate an exclusive license to manufacture, use, and sell FUSILEV products outside the field of oncology in North America. Also, under the terms of the license agreement, we paid Merck & Cie $0.1 million for the achievement of FDA approval of an injectable form of FUSILEV. Merck & Cie is also eligible to receive a $0.2 million payment upon achievement of FDA approval of an oral form of FUSILEV, in addition to royalties in the mid-single digits based on a percentage of net sales. The term of the license agreement is determined on a product-by-product and country-by-country basis until royalties are no longer owed under the license agreement. The license agreement expires in its entirety after the date that we no longer owe any royalties to Merck & Cie. We have the unilateral right to terminate the license agreement, in its entirety or on a product-by-product or country-by-country basis, at any time for any reason.

(v) Asset Purchase Agreement with Targent, Inc., FUSILEV

In March 2006, we entered into an Asset Purchase Agreement with Targent, Inc. (“Targent”). As part of the consideration for the purchase of certain assets, we agreed to pay milestone payments to Targent upon the achievement of certain regulatory events as well as for certain sales levels for FUSILEV within a calendar year. In connection with the achievement of the FDA approval milestone in April 2011, we issued an aggregate of 0.7 million shares of our common stock to certain of Targent’s stockholders. We capitalized $6.3 million associated with this milestone as an amortizable intangible asset.

 

In addition, in connection with the achievement of the first sales milestone in May 2011, we issued 0.6 million shares of our common stock to certain of Targent’s stockholders. In September 2011, we achieved the second and final sales milestone and paid $5.0 million. We capitalized an aggregate $10.0 million associated with these milestones as amortizable intangible assets.

(vi) License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute, FOLOTYN

In December 2002, Allos entered into the FOLOTYN License Agreement with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. As a result of Allos becoming our wholly owned subsidiary effective September 5, 2012, we are bound by the FOLOTYN License Agreement under which we obtained exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN and its uses. Under the terms of the FOLOTYN License Agreement, we are required to fund all development programs and will have sole responsibility for all commercialization activities. In addition, we pay the licensors royalties based on worldwide graduated annual levels of net sales of FOLOTYN, or sublicense revenues arising from sublicensing the product, if and when such sales or sublicenses occur. Royalties are 8% of annual worldwide sales up to $150.0 million; 9% of annual worldwide sales of $150.0 million through $300.0 million; and 11% of annual worldwide sales in excess of $300.0 million.

(vii) License Agreement with Cydex Pharmaceuticals, Inc., Captisol-enabled, Propyleneglycol-free MELPHALAN

On March 8, 2013, we completed the acquisition of exclusive global development and commercialization rights to C-E MELPHALAN from Ligand (see Note 10(b)). This product candidate is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. We assumed full responsibility for its ongoing clinical and regulatory development program. Under the agreement, we paid Ligand a license fee of $3.0 million on April 1, 2013. We are required to pay Ligand additional amounts of up to $66.0 million, upon achievement of certain regulatory milestones and net sales thresholds, and royalties in the range of 15% to 25% on net sales of licensed products in all territories.

(viii) Exclusive Development and Commercialization Collaboration Agreement with Allergan, APAZIQUONE

In October 2008, we signed an exclusive development and commercialization collaboration agreement with Allergan for APAZIQUONE. Pursuant to the terms of the agreement, Allergan paid us an up-front non-refundable $41.5 million at closing and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones.

On January 29, 2013, we entered into a second amendment to the license, development, supply and distribution agreement with Allergan to amend the agreement and reacquire the rights originally licensed to Allergan in the U.S., Europe, and other territories in exchange for a tiered single-digit royalty on certain products containing APAZIQUONE, and relieved Allergan of its obligations for development, commercialization and other activities. As a result of this amendment to the agreement, Allergan has no remaining obligations to us, and we have no remaining performance obligations to them. However, we are obligated to pay Allergan a tiered single-digit royalty not to exceed mid-single digits based upon the net sales, when and if earned, of certain products containing APAZIQUONE in specified territories. Additionally, we are obligated to pay any royalties or other payments due to certain licensors of underlying intellectual property, as well as to provide indemnification of Allergan for claims arising from the manufacture, development, or commercialization of pharmaceutical products containing APAZIQUONE by us.

(ix) Collaboration Agreement with Nippon Kayaku Co. LTD., APAZIQUONE

In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (“Nippon Kayaku”) for the development and commercialization of APAZIQUONE in Asia, except North and South Korea (the “Nippon Kayaku Territory”). In addition, Nippon Kayaku received exclusive rights to APAZIQUONE for the treatment of non-muscle invasive bladder cancer in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct APAZIQUONE clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of APAZIQUONE in the Nippon Kayaku Territory.

Pursuant to the terms of this agreement, Nippon Kayaku paid Spectrum an upfront fee of $15.0 million and is obligated to make additional payments based on the achievement of certain development, regulatory and commercialization milestones. Under the terms of the agreement, we are entitled to payment of $10.0 million and $126.0 million upon achievement of certain regulatory and commercialization milestones, respectively. Also, Nippon Kayaku has agreed to pay us royalties based on a percentage of net sales of the subject products in the defined territory in the mid-teen digits.

Our license agreement with Nippon Kayaku provides for payments to us upon the achievement of development milestones, such as the completion of clinical trials or regulatory submissions, approvals by health authorities, and commercial launches of drug candidates. Given the challenges inherent in developing and obtaining approval for drug products and in achieving commercial launches, there was substantial uncertainty whether any such milestones would be achieved at the time of execution of such license agreement. We expect to recognize as revenue future payments received from such milestones only if achieved.

(x) Licensing and Collaboration Agreement with TopoTarget, BELEODAQ

In February 2010, we entered into a licensing and collaboration agreement with TopoTarget A/S (“TopoTarget”), as amended in October 2013, for the development and commercialization of BELEODAQ. The agreement provides that we have the exclusive right to make, develop, and commercialize BELEODAQ in North America and India, with an option for China.

Under continuing terms, all development, including studies, will be conducted under a joint development plan. We have final decision-making authority for all developmental activities in North America and India (and China upon exercise of its option). TopoTarget has final decision-making authority for all developmental activities in all other jurisdictions. We are responsible for future costs of the ongoing registrational PTCL trial. We and TopoTarget will conduct future planned clinical trials pursuant to the joint development plan, of which we will fund 70% of the development costs, and TopoTarget will fund 30%.

We will each pay 50% of the costs for chemical, pharmaceutical and other process development related to the manufacturing of the product that are incurred with a mutually agreed upon budget in the joint development plan. We have the right to manufacture clinical and commercial supplies of BELEODAQ. TopoTarget is obligated to purchase its BELEODAQ requirements from us on a cost plus basis.

Pursuant to the terms of this agreement, we paid TopoTarget an upfront fee of $30.0 million in 2010. In addition, on the successful achievement of certain development, regulatory and sales milestones, we are obligated to issue 1.0 million shares of our common stock (subject to certain resale conditions) and pay TopoTarget up to $313.0 million. In February 2014, the first of these milestones was met, resulting in the issuance of 1.0 million shares of our common stock and the payment of $10.0 million to TopoTarget (see Note 17). We will pay TopoTarget future royalties in the mid-teen digits based on net sales of BELEODAQ in the defined territory.

The agreement will continue until the expiration of the last royalty payment period in the last country in the defined territory with certain provisions surviving, unless earlier terminated in accordance with its terms. We may terminate this agreement with 180 days notice to TopoTarget. We may also terminate immediately upon a prohibition on the use of the subject product or clinical hold by the FDA. TopoTarget may also terminate immediately in the event of a challenge (without TopoTarget’s consent) by us of the patents that cover the product.

(xi) Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Company, SPI-2012

In late January 2012, we entered into a co-development and commercialization agreement with Hanmi Pharmaceutical Company, (“Hanmi”), for SPI-2012, formerly known as “LAPS-GCSF”, a drug for the treatment of chemotherapy induced neutropenia based on Hanmi’s proprietary LAPSCOVERY™ Technology. In consideration for the rights granted to us under the co-development and commercialization agreement with Hanmi, we paid Hanmi a fee which is included in “research and development expense” in the accompanying Consolidated Statements of Operations because the technology has not yet achieved regulatory approval. Under the terms of the agreement, we will share the costs and expenses of the study with Hanmi, although we will have primary responsibility for them. If SPI-2012 is ultimately commercialized by us, we will have worldwide rights except for Korea, China and Japan upon payment of fees and milestone payments related to further development, regulatory approvals and sales targets.

(c) Service Agreements

In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers, and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients.

At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. We are in a position to accelerate, slow-down or discontinue any or all of the projects that we are working on at any given point in time. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered and our future purchase obligations would reduce accordingly.

(d) Supply Agreements

We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements, and the contracted prices do not exceed their fair market value.

(e) Employment Agreements

We have entered into employment agreements with certain of our officers and other “key employees” under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

(f) Deferred Compensation Plan

On September 2, 2011, the Board of Directors approved the Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”). The DC Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is administered by the Compensation Committee of our Board of Directors. The DC Plan is intended to be an unfunded plan which is maintained primarily to provide deferred compensation benefits for a select group of our employees, as selected by the DC Plan administrator (the “DC Participants”). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, as established by the DC Plan administrator, and we have the option to make discretionary contributions. At December 31, 2013 and 2012, DC Plan deferrals and contributions totaling $3.9 million and $2.4 million, respectively, are included as a liability in the accompanying Consolidated Balance Sheets.

(g) Litigation

We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims.

We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.

We are presently responding to Abbreviated New Drug Applications (“ANDAs”) filed by companies seeking to launch generic forms of FUSILEV and to certain shareholder suits that purportedly stem from our March 12, 2013 press release, in which we announced anticipated changes in customer ordering patterns of FUSILEV. These complaints allege that, as a result of the March 12, 2013 press release, our stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of our stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.

 

FUSILEV ANDA Litigation

On January 20, 2012 and February 17, 2012, respectively, we filed suit against Sandoz Inc. and Innopharma Inc, respectively following Paragraph IV certifications in connection with their filing separate ANDAs, to manufacture a generic version of FUSILEV. We filed the lawsuits in the U.S. District Court for the Districts of Nevada and Delaware seeking to enjoin the approval of their ANDAs plus recovery of our fees and costs incurred in such matters. On December 9, 2013, three Mylan entities collaborating with Innopharma were joined to Innopharma case. While we believe our patent rights are strong, the ultimate outcome of these cases is uncertain.

Shareholder Litigation

John Perry v. Spectrum Pharmaceuticals, Inc. et al. (Filed March 14, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00433-LDG-CWH. This putative consolidated class action raises substantially identical claims and allegations against defendants Spectrum Pharmaceuticals, Inc., Dr. Rajesh C. Shrotriya, Brett L. Scott, and Joseph Kenneth Keller. The alleged class period is August 8, 2012 to March 12, 2013. The lawsuits allege a violation of Section 10(b) of the Securities Exchange Act of 1934 against all defendants and control person liability, as a violation of Section 20(b) of the Securities Exchange Act of 1934, against the individual defendants. The claims purportedly stem from the Company’s March 12, 2013 press release, in which it announced that it anticipated a change in ordering patterns of FUSILEV. The complaints allege that, as a result of the March 12, 2013 press release, the Company’s stock price declined. The complaints further allege that during the putative class period certain defendants made misleadingly optimistic statements about FUSILEV sales, which inflated the trading price of Company stock. The lawsuits seek relief in the form of monetary damages, costs and fees, and any other equitable or injunctive relief that the court deems appropriate.

Timothy Fik v. Rajesh C. Shrotriya, et al. (Filed April 11, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00624-JCM-CWH); Christopher J. Watkins v. Rajesh C. Shrotriya, et al. (Filed April 22, 2013 in United States District Court, District of Nevada; Case Number 2:2013-cv-00684-JCM-VCF); and Stefan Muenchhagen v. Rajesh C. Shrotriya, et al. (Filed May 28, 2013; Case Number 2:2013-cv-00942-APG-PAL). These derivative complaints are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum against certain current and former directors and officers. The complaints generally allege breaches of fiduciary based on conduct relating to the events alleged in the consolidated Perry action. The complaints seek compensatory damages, corporate governance reforms, restitution and disgorgement of defendants’ alleged profits, and costs and fees. On May 15, 2013, the court entered a consolidation order staying the actions pending resolution of the federal securities class action.

Hardik Kakadia v. Rajesh C. Shrotriya, et al. (Filed April 23, 2013 in the Eighth Judicial District Court of the State of Nevada in and for Clark County; Case Number A-13-680643-B); and Joel Besner v. Rajesh C. Shrotriya, et al. (Filed May 31, 2013; Case Number A-13-682668-C) (collectively the “State Derivative Actions”). These consolidated State Derivative Actions are brought by the respective purported shareholders on behalf of nominal plaintiff Spectrum Pharmaceuticals, Inc. and are substantially similar to the consolidated federal derivative actions.

(h) SEC Subpoena

On April 1, 2013, we received a subpoena from the SEC for documents pursuant to a formal order of investigation. The subpoena followed our March 12, 2013 announcement that we anticipated a change in customer ordering patterns of FUSILEV. We continue to cooperate with this SEC investigation, though we cannot predict its outcome, or the timing of resolution.

XML 113 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business, Basis of Presentation, and Operating Segment (Policies)
12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Description of Business

(a) Description of Business

Spectrum Pharmaceuticals, Inc. and its wholly-owned subsidiaries (“Spectrum”, the “Company”, “we”, “our”, or “us”), is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in oncology and hematology. Our strategy is comprised of acquiring, developing, and marketing a diverse pipeline of late-stage clinical and commercial products.

We currently market four drugs:

 

    FUSILEV injection for patients in the U.S. with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy;

 

    ZEVALIN injection for patients in the U.S. and various international markets with follicular non-Hodgkin’s lymphoma;

 

    FOLOTYN injection for patients in the U.S. with relapsed or refractory peripheral T-cell lymphoma; and

 

    MARQIBO injection for patients in the U.S. with Philadelphia chromosome–negative acute lymphoblastic leukemia.

We also have a pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. We have assembled an integrated in-house scientific team, including formulation development, clinical development, medical research, regulatory affairs, biostatistics and data management, and have established a commercial infrastructure for the marketing of our drug products. We also leverage the expertise of our worldwide partners to assist in the execution of our business strategies.

Basis of Presentation

(b) Basis of Presentation

Principles of Consolidation

The accompanying Consolidated Financial Statements in this Annual Report on Form 10-K have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among the consolidated entities have been eliminated in consolidation.

On April 1, 2012, we acquired the licensing rights outside of the U.S. to market ZEVALIN (the “ZEVALIN Rights”); on September 5, 2012, we acquired Allos Therapeutics, Inc. (“Allos”); and on July 17, 2013, we acquired Talon Therapeutics, Inc. (“Talon”). Our accompanying Consolidated Financial Statements include the assets acquired and liabilities assumed in connection with these acquisitions, in addition to the operating results and cash flows, beginning with the corresponding acquisition date for each acquisition.

Variable Interest Entity

We own fifty-percent of Spectrum Pharma Canada (a “variable interest entity,” as defined under applicable GAAP), which was organized in Quebec, Canada in January 2008. Certain of our drug clinical studies are conducted through this entity. We are obligated to fund all costs of this entity and have the sole rights to any revenue derived from its operations. Since we carry the full risks and rewards of this entity, we meet the applicable GAAP criteria as its “primary beneficiary”. As the primary beneficiary of this variable interest entity, Spectrum Pharma Canada’s balance sheets and statements of operations are included in our Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.

Operating Segment

(c) Operating Segment

We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the years ended December 31, 2013, 2012, and 2011, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our long-lived assets are located in the U.S.

Revenue Recognition

(i) Revenue Recognition

(a) Product Sales: We sell our products to wholesalers and distributors. Our wholesalers and distributors purchase our products and sell the products directly to end-users, such as clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized upon shipment of product when title and risk of loss have transferred to our customer, and the following additional criteria are met:

 

  (1) appropriate evidence of a binding arrangement exists with our customer;

 

  (2) price is substantially fixed and determinable;

 

  (3) collection from our customer is reasonably assured;

 

  (4) our customer’s obligation to pay us is not contingent on resale of the product;

 

  (5) we do not have significant obligations for future performance to directly bring about the resale of our product; and

 

  (6) we have a reasonable basis to estimate returns.

Our gross revenue is reduced by our gross-to-net (“GTN”) estimates, resulting in our reported “Product sales, net” in the accompanying Consolidated Statements of Operations. We defer revenue recognition in full if/when these estimates are not reasonably determinable at the time of sale.

Our GTN estimates reduce revenue in the same period that the related sale is recorded and include the following major categories:

Product Returns Allowances: Our FUSILEV customers are typically permitted to return products within six months after its expiration date, subject to certain restocking fees and preauthorization requirements. We estimate potential returns, based on several factors, including historical rates of return, customer and end-user ordering patterns, inventory held by distributors, and sell through data of distributor sales to end users. In general, returned product is not resold.

Government Chargebacks: Our products are subject to certain pricing limits under federal government programs. Qualifying entities purchase products through our distributors at the discounted price. Our distributors charge the difference between the list price and discounted price back to us, for which there may be significant lag time. Due to estimates and assumptions inherent in determining the amount and extent of government chargebacks we will incur, which take in account our estimates of which sales will be subject to government chargebacks and the amount of such chargebacks, the actual amount of government chargeback claims may be materially different from our estimates.

Discounts: Discounts (generally prompt payment discounts) are estimated at each reporting period. We review the terms of the contracts, specifically price and discount structures, and applicable payment terms to estimate its value.

Rebates: Rebates are estimated based on the customer’s actual purchase level during the rebate purchase period, and the corresponding contractual rebate tier we expect the customer to achieve.

 

Medicaid Rebates: Our products are subject to state government-managed Medicaid programs whereby discounts and rebates are provided to participating state governments. Our calculations related to these rebate accruals require estimates, including estimates of customer mix primarily based on a combination of market and clinical research, to determine which sales will be subject to rebates and the amount of such rebates. Our estimate of utilization is based on historical claims and forecasting techniques, and supplemented by management’s judgment with respect to many factors, including changes in sales trends, an evaluation of current laws and regulations and product pricing. Due to estimates and assumptions inherent in determining the amount of our product sales subject to Medicaid rebates, and the time lag to receive these rebate notices (generally several months after the sale is made), the actual amount of these claims may be materially different from our estimates. As a result, adjustments may be recorded over several periods after the initial sale is recorded.

Distribution and Data Fees: Distribution and data fees are paid to authorized wholesalers and specialty distributors of FUSILEV and FOLOTYN as a percentage of products sold. The services provided include contract administration, inventory management, product sales reporting by customer, returns processing. We estimate these fees based on a percentage of FUSILEV and FOLOTYN revenues that are governed by distribution agreements.

(b) License Fees: We recognize license fees based on the terms of each contractual agreement. In general, this results in periodic revenue recognition as the third-party licensee has sales for which we are entitled to a royalty, or in certain cases, a lump-sum license fee in which revenue is recognized in that period.

(c) Service Revenue: We receive fees under certain arrangements for our research and development services. These services are generally undertaken in connection with a collaboration agreement with another pharmaceutical company. Payment may be triggered by the successful completion of a phase of development, results from a clinical trial, acceptance of an NDA or an equivalent filing, and/or regulatory approval. We recognize revenue when the corresponding milestone is achieved, or the revenue is otherwise earned through our on-going activities.

Cash and Equivalents

(ii) Cash and Equivalents

Cash and equivalents consist of highly liquid investments with original maturities of three months or less from the original purchase date.

Marketable Securities

(iii) Marketable Securities

Marketable securities are equity securities. These are classified as available-for-sale, with any unrealized change in value reflected in “unrealized gain (loss) on securities” on the accompanying Consolidated Statements of Comprehensive Income (Loss).

Accounts Receivable

(iv) Accounts Receivable

Accounts receivable are recorded at the invoiced amount, and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.

Inventories

(v) Inventories

We value inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory (i.e., net realizable value). Cost is determined on the first-in, first-out method (FIFO). We regularly review inventory quantities in process and on hand, and when appropriate, record a provision for obsolete and excess inventory to reduce it to its net realizable value.

Prooperty and Equipment

(vi) Property and Equipment

Property and equipment are stated at cost and depreciated on a straight-line basis over its estimated useful lives. In the case of leasehold improvements, depreciation is over the shorter of the estimated useful life or remaining term of the lease. We evaluate the recoverability of long-lived assets (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.

Goodwill and Intangible Assets

(vii) Goodwill and Intangible Assets

Goodwill represents the excess of acquisition cost over the fair value of the net assets of the acquired businesses. Goodwill has an indefinite useful life and is not amortized, but instead tested for impairment annually unless there are interim impairment indicators. We perform our annual evaluation as of October 1 each year.

We evaluate the recoverability of indefinite and definite lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following:

 

  (a) a significant decrease in the market value of an asset;

 

  (b) a significant adverse change in the extent or manner in which an asset is used; or

 

  (c) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset.
Stock-Based Compensation

(viii) Stock-Based Compensation

We recognize stock-based compensation expense for employees and directors over the equity award vesting period, based on its fair value at the date of grant. The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized is net of an estimated forfeiture rate, which is updated as appropriate.

We use the Black-Scholes option pricing model to determine the fair value of stock option grants with service conditions for vesting and the Monte Carlo valuation model to value certain equity awards with market conditions and service conditions for vesting. These models require the use of highly subjective assumptions, including the probability of the achievement of certain market capitalization levels.

Foreign Currency Translation

(ix) Foreign Currency Translation

We translate the assets and liabilities of our foreign subsidiaries stated in local functional currencies to U.S. dollars at the rates of exchange in effect at the end of the period. Revenues and expenses are translated using rates of exchange in effect during the period. Gains and losses from the translation of financial statements denominated in foreign currencies are included as a separate component of accumulated other comprehensive income (loss) in the statement of comprehensive income (loss).

We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any period presented.

Comprehensive Income (Loss)

(x) Comprehensive Income (Loss)

Comprehensive income (loss) is calculated in accordance with authoritative guidance which requires the disclosure of all components of comprehensive income, including net income (loss) and changes in equity during a period from transactions and other events and circumstances generated from non-owner sources.

Basic and Diluted Net Income (Loss) per Share

(xi) Basic and Diluted Net (Loss) Income per Share

We calculate basic and diluted net (loss) income per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.

Income Taxes

(xii) Income Taxes

Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

We have recorded a valuation allowance to reduce our net deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance of our deferred tax assets would increase net income in the period such determination was made. In the event that we were assessed interest and/or penalties from taxing authorities, such amounts would be included in “income tax expense” within the Consolidated Statements of Operations and Comprehensive Income (Loss) in the period the notice was received.

Research and Development Costs

(xiii) Research and Development Costs

Research and development costs are expensed as incurred.

Fair Value Measurements

(xiv) Fair Value Measurements

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

“Cash and equivalents” within our accompanying Consolidated Balance Sheets include certificates of deposit and money market funds that are valued utilizing Level 2 inputs. “Marketable securities” consist of publicly-traded equity instruments that are valued utilizing Level 1 inputs.

The fair value of our “drug development liability” and our “deferred payment contingency” within our accompanying Consolidated Balance Sheets was valued using a model commonly referred to as the discounted income approach model. The unobservable inputs (i.e., Level 3 inputs) in this valuation model that have the most significant effect on these liabilities include (i) internal estimates of research and development personnel costs needed to perform the research and development services, (ii) estimates of expected cash outflows to third parties for services and supplies over the expected period that the services will be performed, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed for reasonableness by management on at least on a quarterly basis.

“Acquisition-related contingent obligations” within our accompanying Consolidated Balance Sheets represent future amounts we may be required to pay in conjunction with various business combinations. See Note 10(a) for a discussion of CVRs granted as part of our acquisition of Talon, and Note 10(b) for the fair value of the liability associated with FDA approval of C-E MELPHALAN. These liabilities are valued using Level 3 inputs and include probabilities and assumptions related to the timing and likelihood of achievement of regulatory and sales milestones.

XML 114 R95.htm IDEA: XBRL DOCUMENT v2.4.0.8
Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 41,516 $ 42,439 $ 33,232 $ 38,667 $ 70,104 $ 69,042 $ 68,702 $ 59,859 $ 155,854 $ 267,707 $ 192,963
Operating income (loss) (6,512) (13,287) (12,529) (6,457) 11,041 23,109 23,028 23,596 (38,785) 80,774 56,546
Net income $ (39,166) $ (7,812) $ (9,721) $ (5,435) $ 7,489 $ 21,524 $ 18,350 $ 46,838 $ (62,134) $ 94,201 $ 49,931
Net Income Per Share, Basic $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.13 $ 0.37 $ 0.31 $ 0.80 $ (1.02) $ 1.61 $ 0.94
Net Income Per Share, Diluted $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.12 $ 0.33 $ 0.29 $ 0.72 $ (1.02) $ 1.46 $ 0.86
XML 115 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail - Schedule of Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Goodwill [Line Items]    
Foreign exchange translation effects $ 104 $ (37)
Goodwill 18,501 7,279
ZEVALIN Rights [Member]
   
Goodwill [Line Items]    
Acquisition 2,525 2,525
Allos Therapeutics, Inc. [Member]
   
Goodwill [Line Items]    
Acquisition 5,346 4,791
Talon [Member]
   
Goodwill [Line Items]    
Acquisition $ 10,526  
XML 116 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail)
12 Months Ended
Dec. 31, 2013
Regulatory Assets [Abstract]  
Number of months customers are allowed to return products 6 months
Cash and equivalents maturities period 3 months
XML 117 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Comprehensive Income (Loss) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Statement Of Partners Capital [Abstract]      
Net (loss) income $ (62,134) $ 94,201 $ 49,931
Other comprehensive (loss) income, net of tax:      
Unrealized gain (loss) on available-for-sale securities 1,110 797 (135)
Income tax on unrealized gain on available-for-sale securities (420) (213)  
Foreign currency translation adjustments (69) (84)  
Other comprehensive income (loss), net 621 500 (135)
Total comprehensive (loss) income $ (61,513) $ 94,701 $ 49,796
XML 118 R88.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Income Tax Disclosure [Abstract]      
United States $ (30,437) $ 82,165 $ 53,834
Foreign (6,199) (2,235) (199)
(Loss) income before income taxes $ (36,636) $ 79,930 $ 53,635
XML 119 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Balance Sheet Account Detail
3. BALANCE SHEET ACCOUNT DETAIL

(a) Cash and Equivalents and Marketable Securities

As of December 31, 2013, we held substantially all of our cash and equivalents, and marketable securities at major financial institutions.

Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, with limitations on investing in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation (FDIC) and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks on our portfolio by investing in highly liquid, highly rated instruments and do not invest in long-term maturity instruments.

 

Cash and equivalents and marketable securities, including long term bank certificates of deposits, and investments totaled $159.8 million and $143.0 million as of December 31, 2013 and 2012, respectively. The carrying amount of our money market funds and bank certificate of deposits (“Bank CDs”) approximates its fair value (utilizing Level 2 inputs – see Note 2(x)) because of our ability to immediately convert these instruments into cash with minimal change in value.

The following is a summary of our cash and equivalents and marketable securities:

 

     Cost      Gross
Unrealized
Gains
     Gross
Unrealized
Losses
     Estimated
fair
Value
     Cash and
equivalents
     Marketable Securities  
                  Current      Long
Term
 

December 31, 2013

                    

Bank deposits

   $ 55,911       $ —         $ —         $ 55,911       $ 55,911       $ —         $ —     

Money market funds

     100,395               100,395         100,395         

Bank CDs

     410         —           —           410         —           410         —     

Mutual funds

     3,061         —           —           3,061         —           3,061         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 159,777       $ —         $ —         $ 159,777       $ 156,306       $ 3,471       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

December 31, 2012

                    

Bank deposits

   $ 128,000       $ —         $ —         $ 128,000       $ 128,000       $ —         $ —     

Money market funds

     11,698               11,698         11,698         

Bank CDs

     987         —           —           987         —           987         —     

Mutual funds

     2,323         —           —           2,323         —           2,323         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 143,008       $ —         $ —         $ 143,008       $ 139,698       $ 3,310       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

As of December 31, 2013, none of these securities had been in a continuous unrealized loss position longer than one year.

(b) Property and Equipment

Property and equipment consist of the following:

 

     December 31,  
     2013     2012  

Computers and software

   $ 5,154      $ 4,540   

Lab and media equipment

     1,063        886   

Office furniture and equipment

     1,575        1,492   

Leasehold improvements

     2,813        2,799   

Assets held under capital lease obligations

     —          146   
  

 

 

   

 

 

 

Property and equipment, at cost

     10,605        9,863   

(Less): accumulated depreciation and amortization

     (9,070     (7,315
  

 

 

   

 

 

 

Property and equipment, net

   $ 1,535      $ 2,548   
  

 

 

   

 

 

 

Depreciation and amortization expense for property and equipment (including leasehold improvements) for the years ended December 31, 2013, 2012, and 2011 was $1.2 million, $1.2 million, and $0.9 million, respectively.

 

(c) Inventories

Inventories, net consist of the following:

 

     December 31,  
     2013      2012  

Raw materials

   $ 1,794       $ 887   

Work in process

     3,312         7,302   

Finished goods

     8,413         6,289   
  

 

 

    

 

 

 

Inventories

   $ 13,519       $ 14,478   
  

 

 

    

 

 

 

(d) Intangible Assets and Goodwill

Intangible assets consist of the following:

 

            December 31, 2013  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
     Impairment     Net Amount      Full
Amortization

Period  (years)
     Remaining
Amortization
Period (years)
 

MARQIBO IPR&D

   $ 17,600       $ —        $ —         $ —        $ 17,600         n/a         n/a   

MELPHALAN IPR&D

     7,700         —          —           —          7,700         n/a         n/a   

MARQIBO developed technology

     26,900         (1,107     —           —          25,793         11         11   

ZEVALIN marketing rights – U.S.

     41,900         (23,455     —           —          18,445         10         5   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (5,343     682         —          18,829         8         6   

FUSILEV developed technology

     16,778         (4,821     —           —          11,957         11         8   

FOLOTYN distribution rights*

     27,900         (3,662     —           (1,023     23,215         10         9   

FOLOTYN developed technology

     118,400         (10,587     —           —          107,813         13         12   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

Total intangible assets

   $ 280,668       $ (48,975   $ 682       $ (1,023   $ 231,352         
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

 

* On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the “amortization and impairment of intangible assets” in the accompanying Consolidated Statement of Operations for the year ended December 31, 2013.

 

     December 31, 2012  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
    Net
Amount
 

ZEVALIN marketing rights – U.S.

   $ 41,900       $ (19,735   $ —        $ 22,165   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (2,192     (355     20,943   

FUSILEV developed technology

     16,778         (2,980     —          13,798   

FOLOTYN distribution rights

     27,900         (895     —          27,005   

FOLOTYN developed technology

     118,400         (2,077     —          116,323   
  

 

 

    

 

 

   

 

 

   

 

 

 

Total intangible assets

   $ 228,468       $ (27,879   $ (355   $ 200,234   
  

 

 

    

 

 

   

 

 

   

 

 

 

 

Intangible asset amortization expense recognized in 2013, and 2012, and 2011 was $21.2 million, $8.8 million, and $4.7 million, respectively. Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:

 

Years Ending December 31

      

2014

   $ 22,468   

2015

     22,468   

2016

     22,468   

2017

     22,468   

2018

     22,313   

2019 and thereafter

     93,867   
  

 

 

 
   $ 206,052   
  

 

 

 

Goodwill is comprised of the following (by source):

 

     December 31,
2013
     December 31,
2012
 

Acquisition of Talon

   $ 10,526         —     

Acquisition of ZEVALIN Rights

     2,525       $ 2,525   

Acquisition of Allos

     5,346         4,791   

Foreign exchange translation effects

     104         (37
  

 

 

    

 

 

 
   $ 18,501       $ 7,279   
  

 

 

    

 

 

 

(e) Other assets

Other assets are comprised of the following:

 

     December 31,
2013
     December 31,
2012
 

Investments in equity securities

   $ 3,593       $ 2,476   

Deposits

     190         304   

Debt issuance cost

     3,432         814   

Life insurance cash surrender value

     5,361         2,881   
  

 

 

    

 

 

 
   $ 12,576       $ 6,475   
  

 

 

    

 

 

 

(f) Accounts payable and other accrued obligations

Accounts payable and other accrued obligations are comprised of the following:

 

     December 31,  
     2013      2012  

Trade payables

   $ 12,796       $ 30,814   

Accrued rebates

     28,893         11,023   

Accrued product royalty

     9,498         12,275   

Allowance for returns

     2,900         5,056   

Accrued data and distribution fees

     2,430         8,449   

Accrued GPO administrative fees

     2,327         2,650   

Inventory management fee

     616         3,050   

Accrued income taxes

     3         2,522   

Allowance for chargebacks

     5,074         15,153   

Accrued drug development costs

     6,433         11,441   

Other accrued obligations

     8,867         2,819   
  

 

 

    

 

 

 
   $ 79,837       $ 105,252   
  

 

 

    

 

 

 

 

Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

 

Description

   Rebates and
Chargebacks
    Data and
Distribution,
GPO Fees, and
Inventory
Management
Fees
    Prompt
Pay
Discount
    Returns  

Balance as of December 31, 2011

   $ 9,064      $ 9,808      $ 992      $ 4,000   

Allos accruals assumed

     2,371        182        —          941   

Add: provisions (recovery)

     91,059        32,793        4,814        159   

Less: credits or actual allowances

     (76,318     (28,634     (4,355     (44
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2012

     26,176        14,149        1,451        5,056   

Add: provisions (recovery)

     63,609        19,067        183        (2,034

Less: credits or actual allowances

     (55,818     (27,843     (1,317     (122
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2013

   $ 33,967      $ 5,373      $ 317      $ 2,900   
  

 

 

   

 

 

   

 

 

   

 

 

 

(g) Other long-term liabilities

Other long-term liabilities are comprised of the following:

 

     December 31,  
     2013      2012  

Accrued executive deferred compensation

   $ 3,949       $ 2,366   

Deferred rent (non-current portion)

     366         571   

Business acquisition liability

     298         298   

Other tax liabilities

     1,352         1,132   
  

 

 

    

 

 

 
   $ 5,965       $ 4,367   
  

 

 

    

 

 

 

 

XML 120 R58.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense $ 12,779 $ 14,884 $ 22,237
Selling, general and administrative [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense 10,762 13,041 20,609
Research and development [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total share-based compensation expense $ 2,017 $ 1,843 $ 1,628
XML 121 R82.htm IDEA: XBRL DOCUMENT v2.4.0.8
Convertible Senior Notes - Carrying Values of 2018 Convertible Notes (Detail) (2018 Convertible Notes [Member], USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
2018 Convertible Notes [Member]
 
Debt Instrument [Line Items]  
Principal amount $ 120,000
(Less): Unamortized debt discount (amortized through December 2018) (28,520)
December 31, 2013 net carrying amount of 2018 Convertible Notes $ 91,480
XML 122 R69.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Earnings Per Share [Abstract]                      
Net (loss) income                 $ (62,134) $ 94,201 $ 49,931
Weighted average shares - basic                 60,729,128 58,588,916 53,272,767
Net (loss) income per share - basic $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.13 $ 0.37 $ 0.31 $ 0.80 $ (1.02) $ 1.61 $ 0.94
Weighted average shares - diluted                 60,729,128 64,637,256 57,959,714
Net (loss) income per share - diluted $ (0.63) $ (0.13) $ (0.16) $ (0.09) $ 0.12 $ 0.33 $ 0.29 $ 0.72 $ (1.02) $ 1.46 $ 0.86
XML 123 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Balance Sheet Account Detail (Tables)
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Summary of Cash and Equivalents and Marketable Securities

The following is a summary of our cash and equivalents and marketable securities:

 

     Cost      Gross
Unrealized
Gains
     Gross
Unrealized
Losses
     Estimated
fair
Value
     Cash and
equivalents
     Marketable Securities  
                  Current      Long
Term
 

December 31, 2013

                    

Bank deposits

   $ 55,911       $ —         $ —         $ 55,911       $ 55,911       $ —         $ —     

Money market funds

     100,395               100,395         100,395         

Bank CDs

     410         —           —           410         —           410         —     

Mutual funds

     3,061         —           —           3,061         —           3,061         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 159,777       $ —         $ —         $ 159,777       $ 156,306       $ 3,471       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

December 31, 2012

                    

Bank deposits

   $ 128,000       $ —         $ —         $ 128,000       $ 128,000       $ —         $ —     

Money market funds

     11,698               11,698         11,698         

Bank CDs

     987         —           —           987         —           987         —     

Mutual funds

     2,323         —           —           2,323         —           2,323         —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total cash and equivalents and marketable securities

   $ 143,008       $ —         $ —         $ 143,008       $ 139,698       $ 3,310       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Schedule of Property and Equipment

Property and equipment consist of the following:

 

     December 31,  
     2013     2012  

Computers and software

   $ 5,154      $ 4,540   

Lab and media equipment

     1,063        886   

Office furniture and equipment

     1,575        1,492   

Leasehold improvements

     2,813        2,799   

Assets held under capital lease obligations

     —         146   
  

 

 

   

 

 

 

Property and equipment, at cost

     10,605        9,863   

(Less): accumulated depreciation and amortization

     (9,070     (7,315
  

 

 

   

 

 

 

Property and equipment, net

   $ 1,535      $ 2,548   
  

 

 

   

 

 

 
Components of Inventories, Net

Inventories, net consist of the following:

 

     December 31,  
     2013      2012  

Raw materials

   $ 1,794       $ 887   

Work in process

     3,312         7,302   

Finished goods

     8,413         6,289   
  

 

 

    

 

 

 

Inventories

   $ 13,519       $ 14,478   
  

 

 

    

 

 

 
Components of Intangible Assets

Intangible assets consist of the following:

 

            December 31, 2013  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
     Impairment     Net Amount      Full
Amortization

Period  (years)
     Remaining
Amortization
Period (years)
 

MARQIBO IPR&D

   $ 17,600       $ —        $ —         $ —        $ 17,600         n/a         n/a   

MELPHALAN IPR&D

     7,700         —          —           —          7,700         n/a         n/a   

MARQIBO developed technology

     26,900         (1,107     —           —          25,793         11         11   

ZEVALIN marketing rights – U.S.

     41,900         (23,455     —           —          18,445         10         5   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (5,343     682         —          18,829         8         6   

FUSILEV developed technology

     16,778         (4,821     —           —          11,957         11         8   

FOLOTYN distribution rights*

     27,900         (3,662     —           (1,023     23,215         10         9   

FOLOTYN developed technology

     118,400         (10,587     —           —          107,813         13         12   
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

Total intangible assets

   $ 280,668       $ (48,975   $ 682       $ (1,023   $ 231,352         
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

       

 

* On May 29, 2013, we amended our collaboration agreement with Mundipharma in order to modify the scope of their licensed territories and the respective development obligations. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and royalty and milestone rates were modified. The modification of our associated royalty and milestone rights constituted a change in the contractual provisions under which we measured our original acquired intangible asset (i.e., the FOLOTYN distribution rights). We determined that an impairment of the FOLOTYN distribution rights of $1.0 million resulted from the amendment and is recorded in the “amortization and impairment of intangible assets” in the accompanying Consolidated Statement of Operations for the year ended December 31, 2013.

 

     December 31, 2012  
     Historical
Cost
     Accumulated
Amortization
    Foreign
Currency
Translation
    Net
Amount
 

ZEVALIN marketing rights – U.S.

   $ 41,900       $ (19,735   $ —        $ 22,165   

ZEVALIN marketing rights – Ex-U.S.

     23,490         (2,192     (355     20,943   

FUSILEV developed technology

     16,778         (2,980     —          13,798   

FOLOTYN distribution rights

     27,900         (895     —          27,005   

FOLOTYN developed technology

     118,400         (2,077     —          116,323   
  

 

 

    

 

 

   

 

 

   

 

 

 

Total intangible assets

   $ 228,468       $ (27,879   $ (355   $ 200,234   
  

 

 

    

 

 

   

 

 

   

 

 

Estimated Intangible Asset Amortization Expense

Estimated intangible asset amortization expense (excluding incremental amortization from the reclassification of IPR&D to developed technology) for the five succeeding years and thereafter is as follows:

 

Years Ending December 31

      

2014

   $ 22,468   

2015

     22,468   

2016

     22,468   

2017

     22,468   

2018

     22,313   

2019 and thereafter

     93,867   
  

 

 

 
   $ 206,052   
  

 

 

 

Schedule of Goodwill

Goodwill is comprised of the following (by source):

 

     December 31,
2013
     December 31,
2012
 

Acquisition of Talon

   $ 10,526         —     

Acquisition of ZEVALIN Rights

     2,525       $ 2,525   

Acquisition of Allos

     5,346         4,791   

Foreign exchange translation effects

     104         (37
  

 

 

    

 

 

 
   $ 18,501       $ 7,279   
  

 

 

    

 

 

 
Summaey of Other Assets

Other assets are comprised of the following:

 

     December 31,
2013
     December 31,
2012
 

Investments in equity securities

   $ 3,593       $ 2,476   

Deposits

     190         304   

Debt issuance cost

     3,432         814   

Life insurance cash surrender value

     5,361         2,881   
  

 

 

    

 

 

 
   $ 12,576       $ 6,475   
  

 

 

    

 

 

Schedule of Accounts Payable and Other Accrued Obligations

Accounts payable and other accrued obligations are comprised of the following:

 

     December 31,  
     2013      2012  

Trade payables

   $ 12,796       $ 30,814   

Accrued rebates

     28,893         11,023   

Accrued product royalty

     9,498         12,275   

Allowance for returns

     2,900         5,056   

Accrued data and distribution fees

     2,430         8,449   

Accrued GPO administrative fees

     2,327         2,650   

Inventory management fee

     616         3,050   

Accrued income taxes

     3         2,522   

Allowance for chargebacks

     5,074         15,153   

Accrued drug development costs

     6,433         11,441   

Other accrued obligations

     8,867         2,819   
  

 

 

    

 

 

 
   $ 79,837       $ 105,252   
  

 

 

    

 

 

 
Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations

Amounts presented within “accounts payable and other accrued obligations” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

 

Description

   Rebates and
Chargebacks
    Data and
Distribution,
GPO Fees, and
Inventory
Management
Fees
    Prompt
Pay
Discount
    Returns  

Balance as of December 31, 2011

   $ 9,064      $ 9,808      $ 992      $ 4,000   

Allos accruals assumed

     2,371        182        —          941   

Add: provisions (recovery)

     91,059        32,793        4,814        159   

Less: credits or actual allowances

     (76,318     (28,634     (4,355     (44
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2012

     26,176        14,149        1,451        5,056   

Add: provisions (recovery)

     63,609        19,067        183        (2,034

Less: credits or actual allowances

     (55,818     (27,843     (1,317     (122
  

 

 

   

 

 

   

 

 

   

 

 

 

Balance as of December 31, 2013

   $ 33,967      $ 5,373      $ 317      $ 2,900   
  

 

 

   

 

 

   

 

 

   

 

 

 

Summary of Other Long-Term Liabilities

Other long-term liabilities are comprised of the following:

 

     December 31,  
     2013      2012  

Accrued executive deferred compensation

   $ 3,949       $ 2,366   

Deferred rent (non-current portion)

     366         571   

Business acquisition liability

     298         298   

Other tax liabilities

     1,352         1,132   
  

 

 

    

 

 

 
   $ 5,965       $ 4,367   
  

 

 

    

 

 

 

 

XML 124 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 345 587 1 false 122 0 false 9 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.spectrumpharm.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfPartnersCapital Consolidated Statements of Comprehensive Income (Loss) false false R6.htm 107 - Statement - Consolidated Statements of Shareholders' Equity Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statements of Shareholders' Equity false false R7.htm 108 - Statement - Consolidated Statements of Cash Flows Sheet http://www.spectrumpharm.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R8.htm 109 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Description of Business, Basis of Presentation, and Operating Segment false false R9.htm 110 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies and Use of Estimates false false R10.htm 111 - Disclosure - Balance Sheet Account Detail Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsDetailsOfBalanceSheetDisclosureTextBlock Balance Sheet Account Detail false false R11.htm 112 - Disclosure - Gross-to Net Product Sales Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsGrossToNetProductSalesDisclosureTextBlock Gross-to Net Product Sales false false R12.htm 113 - Disclosure - Product Sales, Net by Geographic Region and Product Line Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsProductSalesNetByGeographicRegionAndProductLineTextBlock Product Sales, Net by Geographic Region and Product Line false false R13.htm 114 - Disclosure - Stock-Based Compensation Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R14.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R15.htm 116 - Disclosure - Net (Loss) Income Per Share Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net (Loss) Income Per Share false false R16.htm 117 - Disclosure - Fair Value Measurements Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements false false R17.htm 118 - Disclosure - Business Combinations Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Business Combinations false false R18.htm 119 - Disclosure - Revolving Line of Credit Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock Revolving Line of Credit false false R19.htm 120 - Disclosure - Convertible Senior Notes Notes http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsConvertibleSeniorNotesTextBlock Convertible Senior Notes false false R20.htm 121 - Disclosure - Mundipharma Agreement Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsAgreementsTextBlock Mundipharma Agreement false false R21.htm 122 - Disclosure - Commitments and Contingencies Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R22.htm 123 - Disclosure - Income Taxes Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R23.htm 124 - Disclosure - Subsequent Event Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Event false false R24.htm 125 - Disclosure - Summary of Selected Quarterly Financial Data Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlock Summary of Selected Quarterly Financial Data false false R25.htm 126 - Disclosure - Schedule II - Valuation and Qualifying Accounts Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock Schedule II - Valuation and Qualifying Accounts false false R26.htm 127 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Policies) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Description of Business, Basis of Presentation, and Operating Segment (Policies) false false R27.htm 128 - Disclosure - Balance Sheet Account Detail (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsDetailsOfBalanceSheetDisclosureTextBlockTables Balance Sheet Account Detail (Tables) false false R28.htm 129 - Disclosure - Gross-to Net Product Sales (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsGrossToNetProductSalesDisclosureTextBlockTables Gross-to Net Product Sales (Tables) false false R29.htm 130 - Disclosure - Product Sales, Net by Geographic Region and Product Line (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsProductSalesNetByGeographicRegionAndProductLineTextBlockTables Product Sales, Net by Geographic Region and Product Line (Tables) false false R30.htm 131 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R31.htm 132 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R32.htm 133 - Disclosure - Net (Loss) Income Per Share (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Net (Loss) Income Per Share (Tables) false false R33.htm 134 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) false false R34.htm 135 - Disclosure - Business Combinations (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Business Combinations (Tables) false false R35.htm 136 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsConvertibleSeniorNotesTextBlockTables Convertible Senior Notes (Tables) false false R36.htm 137 - Disclosure - Mundipharma Agreement (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsAgreementsTextBlockTables Mundipharma Agreement (Tables) false false R37.htm 138 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) false false R38.htm 139 - Disclosure - Income Taxes (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables Income Taxes (Tables) false false R39.htm 140 - Disclosure - Summary of Selected Quarterly Financial Data (Tables) Sheet http://www.spectrumpharm.com/taxonomy/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables Summary of Selected Quarterly Financial Data (Tables) false false R40.htm 141 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndOperatingSegmentAdditionalInformation Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail) false false R41.htm 142 - Disclosure - Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndUseOfEstimatesAdditionalInformation Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail) false false R42.htm 143 - Disclosure - Balance Sheet Account Detail - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailAdditionalInformation Balance Sheet Account Detail - Additional Information (Detail) false false R43.htm 144 - Disclosure - Balance Sheet Account Detail - Summary of Cash and Equivalents and Marketable Securities (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailSummaryOfCashAndEquivalentsAndMarketableSecurities Balance Sheet Account Detail - Summary of Cash and Equivalents and Marketable Securities (Detail) false false R44.htm 145 - Disclosure - Balance Sheet Account Detail - Schedule of Property and Equipment (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailScheduleOfPropertyAndEquipment Balance Sheet Account Detail - Schedule of Property and Equipment (Detail) false false R45.htm 146 - Disclosure - Balance Sheet Account Detail - Components of Inventories, Net (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailComponentsOfInventoriesNet Balance Sheet Account Detail - Components of Inventories, Net (Detail) false false R46.htm 147 - Disclosure - Balance Sheet Account Detail - Components of Intangible Assets (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailComponentsOfIntangibleAssets Balance Sheet Account Detail - Components of Intangible Assets (Detail) false false R47.htm 148 - Disclosure - Balance Sheet Account Detail - Components of Intangible Assets (Parenthetical) (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailComponentsOfIntangibleAssetsParenthetical Balance Sheet Account Detail - Components of Intangible Assets (Parenthetical) (Detail) false false R48.htm 149 - Disclosure - Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailEstimatedIntangibleAssetAmortizationExpense Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) false false R49.htm 150 - Disclosure - Balance Sheet Account Detail - Schedule of Goodwill (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailScheduleOfGoodwill Balance Sheet Account Detail - Schedule of Goodwill (Detail) false false R50.htm 151 - Disclosure - Balance Sheet Account Detail - Summary of Other Assets (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailSummaryOfOtherAssets Balance Sheet Account Detail - Summary of Other Assets (Detail) false false R51.htm 152 - Disclosure - Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailScheduleOfAccountsPayableAndOtherAccruedObligations Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Obligations (Detail) false false R52.htm 153 - Disclosure - Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailScheduleOfAmountsPresentedInAccountsPayableAndOtherAccruedObligations Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations (Detail) false false R53.htm 154 - Disclosure - Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBalanceSheetAccountDetailSummaryOfOtherLongTermLiabilities Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) false false R54.htm 155 - Disclosure - Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureGrosstoNetProductSalesReconciliationOfGrosstoNetProductSales Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) false false R55.htm 156 - Disclosure - Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Geography (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureProductSalesNetByGeographicRegionAndProductLineScheduleOfProductSalesNetByGeography Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Geography (Detail) false false R56.htm 157 - Disclosure - Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Product Line (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureProductSalesNetByGeographicRegionAndProductLineScheduleOfProductSalesNetByProductLine Product Sales, Net by Geographic Region and Product Line - Schedule of Product Sales, Net by Product Line (Detail) false false R57.htm 158 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R58.htm 159 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpense Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) false false R59.htm 160 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedUsingBlackScholesOptionPricingModel Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Detail) false false R60.htm 161 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedUsingBlackScholesOptionPricingModelParenthetical Stock-Based Compensation - Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model (Parenthetical) (Detail) false false R61.htm 162 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivity Stock-Based Compensation - Summary of Stock Option Activity (Detail) false false R62.htm 163 - Disclosure - Stock-Based Compensation - Summary of Stock Option Grants (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionGrants Stock-Based Compensation - Summary of Stock Option Grants (Detail) false false R63.htm 164 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRestrictedStockActivity Stock-Based Compensation - Summary of Restricted Stock Activity (Detail) false false R64.htm 165 - Disclosure - Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationFairValueOfRestrictedStockAwards Stock-Based Compensation - Fair Value of Restricted Stock Awards (Detail) false false R65.htm 166 - Disclosure - Stock-Based Compensation - Issued Shares of Common Stock (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockBasedCompensationIssuedSharesOfCommonStock Stock-Based Compensation - Issued Shares of Common Stock (Detail) false false R66.htm 167 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R67.htm 168 - Disclosure - Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockholdersEquitySharesOfCommonStockIssuableOnConversionOrExerciseOfRightsGranted Stockholders' Equity - Shares of Common Stock Issuable on Conversion or Exercise of Rights Granted (Detail) false false R68.htm 169 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivity Stockholders' Equity - Summary of Warrant Activity (Detail) false false R69.htm 170 - Disclosure - Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureNetLossIncomePerShareComputationOfNetLossIncomePerShare Net (Loss) Income Per Share - Computation of Net (Loss) Income Per Share (Detail) false false R70.htm 171 - Disclosure - Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureNetLossIncomePerShareScheduleOfAmountsUsedInComputingBasicAndDilutedNetIncomePerShare Net (Loss) Income Per Share - Schedule of Amounts Used in Computing Basic and Diluted Net Income Per Share (Detail) false false R71.htm 172 - Disclosure - Net Income (Loss) Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfSecuritiesExcludedFromCalculationOfNetLossPerShare Net Income (Loss) Per Share - Schedule of Securities Excluded from Calculation of Net (Loss) per Share (Detail) false false R72.htm 173 - Disclosure - Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAssetAndLiabilityFairValues Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) false false R73.htm 174 - Disclosure - Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureFairValueMeasurementsActivityOfLevel3InputsMeasuredOnRecurringBasis Fair Value Measurements - Activity of Level 3 Inputs Measured on Recurring Basis (Detail) false false R74.htm 175 - Disclosure - Business Combinations - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformation Business Combinations - Additional Information (Detail) false false R75.htm 176 - Disclosure - Business Combinations - Acquisition-Date Fair Value of Consideration Transferred (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsAcquisitionDateFairValueOfConsiderationTransferred Business Combinations - Acquisition-Date Fair Value of Consideration Transferred (Detail) false false R76.htm 177 - Disclosure - Business Combinations - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsSummaryOfAllocationOfTotalPurchasePriceToNetAssetsAcquired Business Combinations - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) false false R77.htm 178 - Disclosure - Business Combinations - Amortization Period for such Intangible Assets Acquired (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsAmortizationPeriodForSuchIntangibleAssetsAcquired Business Combinations - Amortization Period for such Intangible Assets Acquired (Detail) false false R78.htm 179 - Disclosure - Business Combinations - Supplemental Pro Forma Financial Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsSupplementalProFormaFinancialInformation Business Combinations - Supplemental Pro Forma Financial Information (Detail) false false R79.htm 180 - Disclosure - Business Combinations - Change in Fair Value of Contingent Consideration Related to Acquisition (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureBusinessCombinationsChangeInFairValueOfContingentConsiderationRelatedToAcquisition Business Combinations - Change in Fair Value of Contingent Consideration Related to Acquisition (Detail) false false R80.htm 181 - Disclosure - Revolving Line of Credit - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureRevolvingLineOfCreditAdditionalInformation Revolving Line of Credit - Additional Information (Detail) false false R81.htm 182 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://www.spectrumpharm.com/taxonomy/role/DisclosureConvertibleSeniorNotesAdditionalInformation Convertible Senior Notes - Additional Information (Detail) false false R82.htm 183 - Disclosure - Convertible Senior Notes - Carrying Values of 2018 Convertible Notes (Detail) Notes http://www.spectrumpharm.com/taxonomy/role/DisclosureConvertibleSeniorNotesCarryingValuesOf2018ConvertibleNotes Convertible Senior Notes - Carrying Values of 2018 Convertible Notes (Detail) false false R83.htm 184 - Disclosure - Convertible Senior Notes - Components of Total Interest Expense Recognized (Detail) Notes http://www.spectrumpharm.com/taxonomy/role/DisclosureConvertibleSeniorNotesComponentsOfTotalInterestExpenseRecognized Convertible Senior Notes - Components of Total Interest Expense Recognized (Detail) false false R84.htm 185 - Disclosure - Mundipharma Agreement - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureMundipharmaAgreementAdditionalInformation Mundipharma Agreement - Additional Information (Detail) false false R85.htm 186 - Disclosure - Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureMundipharmaAgreementScheduleOfDrugDevelopmentLiabilityAdjustments Mundipharma Agreement - Schedule of Drug Development Liability Adjustments (Detail) false false R86.htm 187 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R87.htm 188 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePayments Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) false false R88.htm 189 - Disclosure - Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossIncomeBeforeProvisionBenefitForIncomeTaxes Income Taxes - Components of (Loss) Income before (Provision) Benefit for Income Taxes (Detail) false false R89.htm 190 - Disclosure - Income Taxes - Provision (Benefit) for Income Taxes (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesProvisionBenefitForIncomeTaxes Income Taxes - Provision (Benefit) for Income Taxes (Detail) false false R90.htm 191 - Disclosure - Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesIncomeTaxProvisionBenefitDiffersFromComputedUsingFederalStatutoryRateAppliedToIncomeBeforeTaxes Income Taxes - Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes (Detail) false false R91.htm 192 - Disclosure - Income Taxes - Components of Company's Deferred Tax Assets (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfCompanysDeferredTaxAssets Income Taxes - Components of Company's Deferred Tax Assets (Detail) false false R92.htm 193 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R93.htm 194 - Disclosure - Income Taxes - Summary of Unrecognized Tax Benefits (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfUnrecognizedTaxBenefits Income Taxes - Summary of Unrecognized Tax Benefits (Detail) false false R94.htm 195 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation Subsequent Events - Additional Information (Detail) false false R95.htm 196 - Disclosure - Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataSummaryOfSelectedQuarterlyFinancialData Selected Quarterly Financial Data - Summary of Selected Quarterly Financial Data (Detail) false false R96.htm 197 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail) Sheet http://www.spectrumpharm.com/taxonomy/role/DisclosureScheduleIIValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts (Detail) false false All Reports Book All Reports Element sppi_BusinessAcquisitionAcquiredEntityPurchasePrice had a mix of decimals attribute values: -5 -3. Element sppi_BusinessAcquisitionCostOfAcquiredEntityContingentValueRight had a mix of decimals attribute values: -5 -3. Element us-gaap_AdditionalPaidInCapital had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned had a mix of decimals attribute values: -5 -3. Element us-gaap_CommonStockSharesAuthorized had a mix of decimals attribute values: -5 0. Element us-gaap_CommonStockValue had a mix of decimals attribute values: -5 -3. Element us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion had a mix of decimals attribute values: -5 0. Element us-gaap_CostsAndExpenses had a mix of decimals attribute values: -5 -3. Element us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch had a mix of decimals attribute values: -5 -3. 'Shares' elements on report '158 - Disclosure - Stock-Based Compensation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '175 - Disclosure - Business Combinations - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '182 - Disclosure - Convertible Senior Notes - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '185 - Disclosure - Mundipharma Agreement - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '193 - Disclosure - Income Taxes - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Sep. 30, 2003' Process Flow-Through: 105 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2012' Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Income (Loss) Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2012' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2012' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2012' Process Flow-Through: 108 - Statement - Consolidated Statements of Cash Flows sppi-20131231.xml sppi-20131231.xsd sppi-20131231_cal.xml sppi-20131231_def.xml sppi-20131231_lab.xml sppi-20131231_pre.xml true true XML 125 R74.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations - Additional Information (Detail) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
1 Months Ended 6 Months Ended 12 Months Ended
Jul. 17, 2013
Dec. 31, 2013
Dec. 31, 2013
Business Acquisition [Line Items]      
Milestone payments methods If all sales and regulatory approval milestones are achieved, as summarized below: • $5.0 million upon the achievement of net sales of MARQIBO in excess of $30.0 million in any calendar year • $10.0 million upon the achievement of net sales of MARQIBO in excess of $60.0 million in any calendar year • $25.0 million upon the achievement of net sales of MARQIBO in excess of $100.0 million in any calendar year • $50.0 million upon the achievement of net sales of MARQIBO in excess of $200.0 million in any calendar year • $100.0 million upon the achievement of net sales of MARQIBO in excess of $400.0 million in any calendar year • $5.0 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion    
Milestone net sales achievement     $ 6,000,000
Direct costs of acquisition   5,700,000 5,700,000
Goodwill   10,526,000 10,526,000
Net assets acquired   33,574,000 33,574,000
Total purchase consideration   44,100,000 44,100,000
License fees received     3,000,000
Aggregate transaction costs expensed     15,000
Milestone Payments [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 5,000,000   66,000,000
Milestone net sales achievement 30,000,000    
Milestone Payment One [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 10,000,000    
Milestone net sales achievement 60,000,000    
Milestone Payment Two [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 25,000,000    
Milestone net sales achievement 100,000,000    
Milestone Payment Three [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 50,000,000    
Milestone net sales achievement 200,000,000    
Milestone Payment Four [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 100,000,000    
Milestone net sales achievement 400,000,000    
Menadione Topical Lotion [Member]
     
Business Acquisition [Line Items]      
Milestone net sales achievement 5,000,000    
Minimum [Member]
     
Business Acquisition [Line Items]      
Royalties payout percentage on net sales of licensed products   15.00% 15.00%
Maximum [Member]
     
Business Acquisition [Line Items]      
Royalties payout percentage on net sales of licensed products   25.00% 25.00%
Talon Therapeutics, Inc. [Member]
     
Business Acquisition [Line Items]      
Securities purchase agreement date     Jul. 16, 2013
Additional shares business acquisition date     Jul. 17, 2013
Revenue derived from the former business   1,300,000  
Cash consideration     11,300,000
Shares issued in acquisition 3.0    
Common stock value, per share     $ 8.77
Common stock value assigned 26,300,000 26,300,000 26,300,000
Estimated fair value of acquisition 6,500,000 6,500,000 6,500,000
Contingent value rights future cash payments 195,000,000    
Contingent value rights valuation description The CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100%) and discounts those amounts to their present value, using a discount rate of 25% (these represent unobservable inputs and are therefore classified as Level 3 inputs - see Note 3 (x)).    
Contingent value rights discount rate 25.00%    
Goodwill   10,526,000 10,526,000
Net assets acquired   33,574,000 33,574,000
Total purchase consideration   44,100,000 44,100,000
Talon Therapeutics, Inc. [Member] | Minimum [Member]
     
Business Acquisition [Line Items]      
Contingent value rights expected rate 50.00%    
Talon Therapeutics, Inc. [Member] | Maximum [Member]
     
Business Acquisition [Line Items]      
Contingent value rights expected rate 100.00%    
Allos Therapeutics, Inc. [Member]
     
Business Acquisition [Line Items]      
Total purchase consideration   $ 205,200,000 $ 205,200,000
In-process research and development [Member]
     
Business Acquisition [Line Items]      
Estimated cash flow period     10 years
Estimated cash flow discount rate   25.00% 25.00%
XML 126 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2013
Income Tax Disclosure [Abstract]  
Components of (Loss) Income before (Provision) Benefit for Income Taxes

The components of (loss) income before (provision) benefit for income taxes are as follows:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

United States

   $ (30,437   $ 82,165      $ 53,834   

Foreign

     (6,199     (2,235     (199
  

 

 

   

 

 

   

 

 

 

Total

   $ (36,636   $ 79,930      $ 53,635   
  

 

 

   

 

 

   

 

 

 

 

Provision (Benefit) for Income Taxes

The provision (benefit) for income taxes consist of the following:

 

     For the Years Ended
December 31,
 
     2013     2012     2011  

Current:

      

Federal

   $ (8,357   $ 16,222      $ 1,255   

State

     (691     3,412        2,449   

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
   $ (9,048   $ 19,634      $ 3,704   

Deferred:

      

Federal

     36,183        (24,013     —    

State

     (1,637     (9,892     —    

Foreign

     —         —         —    
  

 

 

   

 

 

   

 

 

 
     34,546        (33,905     —    

Total income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

Income Tax Provision (Benefit) Differs from Computed Using Federal Statutory Rate Applied to Income before Taxes

The income tax provision (benefit) differs from that computed using the federal statutory rate applied to income before taxes as follows:

 

     2013     2012     2011  

Tax provision (benefit) computed at the federal statutory rate

   $ (12,822   $ 27,975      $ 18,250   

State tax, net of federal benefit

     (246     2,442        2,918   

Expired tax attributes

     —         —         385   

Research credits

     (2,254     (2,129     (1,464

Benefits from credit study

     —         (4,148     —    

Common stock warrant liability

     —         —         1,186   

Transaction costs

     880        1,497        —    

Officers compensation

     2,178        2,908        3,801   

Stock based compensation

     501        134        1,676   

Permanent items and other

     (1,080     2,111        2,039   

Domestic manufacturing deduction

     767        (1,262     —    

Tax differential on foreign earnings

     1,123        382        —    

Change in tax rate

     (283     338        —    

Valuation allowance

     36,734        (44,519     (25,087
  

 

 

   

 

 

   

 

 

 

Income tax provision (benefit)

   $ 25,498      $ (14,271   $ 3,704   
  

 

 

   

 

 

   

 

 

 

Components of Company's Deferred Tax Assets

Significant components of our deferred tax assets as of December 31, 2013 and 2012 are shown below. A valuation allowance has been recognized to offset the net deferred tax assets as realization of such deferred tax assets no longer meets the “more-likely-than-not” threshold under GAAP.

 

     2013     2012  

Deferred tax assets:

    

Net operating loss carry forwards

   $ 46,482      $ 45,391   

Research credits

     8,066        1,848   

Stock based compensation

     3,486        2,896   

Deferred revenue

     58        4,596   

Development costs

     6,495        5,298   

Returns and allowances

     3,117        7,889   

Other, net

     5,551        6,021   
  

 

 

   

 

 

 

Total deferred tax assets before valuation allowance

     73,255        73,246   

Valuation allowance

     (49,586     (1,818
  

 

 

   

 

 

 

Total deferred tax assets

     23,669        72,121   

Deferred tax liabilities:

    

Basis difference in debt

     (1,082     —    

Depreciation and amortization differences

     (28,096     (36,372
  

 

 

   

 

 

 

Net deferred tax (liability) asset

   $ (5,509   $ 35,749   
  

 

 

   

 

 

 

Summary of Unrecognized Tax Benefits

The following tabular reconciliation summarizes activity related to unrecognized tax benefits:

 

     2013     2012     2011  

Balance at beginning of year

   $ 5,482      $ 3,928      $ 2,803   

Adjustments related to prior year tax positions

     (200     (527     5   

Increases related to current year tax positions

     648        2,515        1,120   

Decreases due to settlements

     (1,227     (434     —    

Decreases related to prior year tax positions

     (2,491     —         —    
  

 

 

   

 

 

   

 

 

 

Balance at end of year

   $ 2,212      $ 5,482      $ 3,928   
  

 

 

   

 

 

   

 

 

 

XML 127 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Mundipharma Agreement
12 Months Ended
Dec. 31, 2013
Text Block [Abstract]  
Mundipharma Agreement
13. MUNDIPHARMA AGREEMENT

As the result of Allos becoming our wholly-owned subsidiary, effective September 5, 2012, we assumed obligations under a strategic collaboration agreement with Mundipharma (the “Mundipharma Collaboration Agreement”). Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the “Mundipharma Territories”).

On May 29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the “Amended Munipharma Collaboration Agreement”), in order to modify: (i) the scope of the licensed territory, (ii) milestone payments, (iii) royalty rates, and (iv) development obligations. In connection with the Amended Munipharma Collaboration Agreement, we received a one-time $7.0 million payment from Mundipharma for certain research and development activities to be performed by us.

As a result, (i) Europe and Turkey were excluded from Mundipharma’s commercialization territory, (ii) we may now receive potential regulatory milestone payments of up to $16.0 million and commercial progress and sales-dependent milestone payments of up to $107.0 million, (iii) we will receive tiered double- digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories, and (iv) we and Mundipharma will bear our own FOLOTYN development costs. We recorded the fair value of the related drug development liability of $12.3 million as of September 2012, using the discounted cash flow method of the income approach. The fair value of this liability was determined to be $17.7 million as of December 31, 2013 (inclusive of the $7.0 million payment from Mundipharma) and is included in current and long-term “drug development liability” within the accompanying Consolidated Balance Sheets. This value includes our assumptions about personnel needed to perform these research and development activities, third party costs for projected clinical trial enrollment, and patient treatment-related follow up through approximately 2031.

We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our Consolidated Statements of Operations.

 

     Year Ended December 31,  
     Drug
Development
Liability,
Current –
FOLOTYN
    Drug
Development
Liability,

Long Term –
FOLOTYN
    Total Drug
Development
Liability –
FOLOTYN
 

Balance at December 31, 2012

   $ 856      $ 11,377      $ 12,233   

Transfer from long term to current

     3,620        (3,620     —    

Amended agreement payment receipt

     —         7,000        7,000   

(Less): Expenses incurred

     (1,357     (134     (1,491
  

 

 

   

 

 

   

 

 

 

Balance at December 31, 2013

   $ 3,119      $ 14,623      $ 17,742